<SEC-DOCUMENT>0000950170-24-036729.txt : 20240327
<SEC-HEADER>0000950170-24-036729.hdr.sgml : 20240327
<ACCEPTANCE-DATETIME>20240326203525
ACCESSION NUMBER:		0000950170-24-036729
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		105
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240327
DATE AS OF CHANGE:		20240326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001831828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				812744449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40407
		FILM NUMBER:		24785485

	BUSINESS ADDRESS:	
		STREET 1:		8000 MARINA BOULEVARD, SUITE 120
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		650-770-0077

	MAIL ADDRESS:	
		STREET 1:		8000 MARINA BOULEVARD, SUITE 120
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vera-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-26T14:42:06.9532+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:vera="http://veratx.com/20231231" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_ccf892e2-cc65-4d06-90ab-1234329305b6" name="dei:AmendmentFlag" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c">false</ix:nonNumeric><ix:nonNumeric id="F_889c5f43-63dc-4264-9bdc-f5352440eef2" name="dei:EntityCentralIndexKey" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c">0001831828</ix:nonNumeric><ix:nonNumeric id="F_91a574f5-f528-4208-af93-dbe15c2bf248" name="ecd:TrdArrDuration" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" format="ixt-sec:durday">436</ix:nonNumeric><ix:nonNumeric id="F_73d24ba4-af5c-42e1-9de1-9b315e3db229" name="dei:DocumentFiscalPeriodFocus" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c">FY</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vera-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="C_b150cadf-6fed-4382-b18e-37a4483af270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_539e555a-bda4-46de-a744-e41a88c96a83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97937f19-9b0a-4f85-bf7b-949364d71662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45e8c8b4-f505-443e-882c-c062f4a6a499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d99a19d8-325e-4a9a-aacd-082609a73db3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyThreeTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba1ed2ab-29c6-4f44-8a57-210882c88795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">vera:CeliaLinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5886db7b-8ba3-408a-b5d3-cf86749ed8e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6af2ee58-50ae-4209-960f-c26d33ada18c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6fea3c9-4692-4fad-ad2a-ff7a304239a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyThreeTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3deb204-a947-4aea-a198-2bd978183c67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-31</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c1ed1eb-4ad3-48de-bbf2-10a461092b17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_656df8a2-b22a-4441-86ea-edc39b8cabaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">vera:TaxYear2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee626bdd-f836-4146-83f9-c629e739a018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6f5b77a-d7c2-44e0-9317-e969b8465d61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06c1a6f1-5730-4884-a735-4b4f7cac06bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_656af685-44e8-4daf-aeaf-64e77e34538a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed279c02-7bf7-4e6e-932b-ec6e10a522e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7049dbef-cfb0-4b5b-aeab-21592adc5141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27ff2e6e-72bd-4173-93c6-978428eecba6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyThreeTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4204b6de-68e6-4940-9da6-ada3032391f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88fbad11-b4e4-408e-a5f8-605f139b9287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-31</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c317a6f-636d-4344-a7db-5f93a49f62a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fad68b53-11d9-436b-9004-a5b8faf94415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-14</xbrli:startDate><xbrli:endDate>2022-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_644f1830-26e7-4980-866c-9c896b77aefd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ac3dbbb-9f62-4b97-afd2-60e8f5b19158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ba166aa-651f-42ca-a136-020ed2b46e9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a795fca-1ad9-451e-9a6e-1d3d138b141b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">vera:LoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83dcf10b-9a2d-456b-b6d7-c0671495052f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_652b7128-53c0-4531-a4b7-ce80609438f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d9746ec-02a4-4faa-807d-24788184f0f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_106b349b-6afb-4176-a3b0-f3279ad1790b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12676876-59e5-4f18-b296-25ca0885c06f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cade7871-7cd4-4bc1-8f5e-7e8350a76e16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39cdc351-ad9a-4bdc-9a2f-e68f40e8b2b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e0be373-0021-42a8-b661-4dcf7ed20677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b73d9107-896f-43a1-9a6e-d51d7847b59f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d83a4fc8-8999-4dbb-8d15-fe08a22689c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a88ca419-8f83-4779-954c-2d82558cf7e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98c19bb9-6dc0-4e42-9491-940aabbbe506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c7489d8-52e2-4215-8365-cea7bd8503e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a335021c-fe71-40a4-b161-f8c7dade5c43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3e496cc-f877-412e-b2d0-1b4233183c32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vera:CowenAndCompanyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:TwoThousandTwentyTwoAtmFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d97919f2-efef-4f37-8154-249dcc9ce087"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">vera:LoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e95c3e40-5150-4128-b63f-a06464bb547b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f304eef-dfa2-48ba-a1fb-90a97b78c719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyTwoElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e13a118-4107-4dfb-bab4-6714cdfa6f1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43178910-84ec-42e6-9755-a7c57bb14391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa03b9e4-2af3-40b2-8a5a-57a770a088a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">vera:LondonInterbankOfferedRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyOneTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b708e8c-5665-48f7-9c36-8c9a842be8a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df5e40de-de67-4c81-87ff-65f4bafe12aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80f2efae-f54f-4396-a49d-51ff68d5fa88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_763f4bc0-e8d2-4dff-a69a-bf5d94bdc0c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_88d87548-c2bd-4d90-827b-1b12287efa7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_866552c5-4fd9-48eb-ba57-9fc63a8df408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-14</xbrli:startDate><xbrli:endDate>2022-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ee2de34-00df-4708-bfcd-a29d841f802c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a52fd0c-ea66-4e45-91f2-1ab3d98bfe72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:ClassACommonStockIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75cc6cdb-a496-4205-b05d-09f40af83bb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3ba2032-8472-4a06-af17-769f411f1c3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83acb7dc-4dff-4e8f-926f-7ad1a9c65845"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f419ef0f-acae-4639-b7c3-1c50d6d17329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vera:CowenAndCompanyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:TwoThousandTwentyTwoAtmFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6eaa2abb-9090-46f3-9dcd-75944c3a5636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8590b670-5825-42b7-a28a-b57150a094ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55828b2f-49ab-4655-b54a-8c64b655d49b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9205105-dc48-4b1b-8905-ca16af40dfee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24a4e735-d3db-4c23-bb5e-9ca013ac3681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4135b425-1776-49c1-98fa-141157b08b6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49967e2d-722f-4392-96f6-1a63849048ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">vera:CeliaLinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c194f4a2-535c-4148-b525-7d7cf987efe3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ea44b8b-7856-4f7e-9da8-750bd3da72e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b12037ba-e589-4ed7-b30f-5ff359e4b80b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AmplyxAndNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c8b4716-9f64-4262-a82a-7d6247559af1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9deafbe4-5698-4e04-a2fb-fc9f4ae865ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4034580-fe87-43d7-b8fa-5582e2ab5313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e02b6343-2192-4292-8c98-078fac080977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_778ecdc2-82e7-487e-8f23-1ed776e1936e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8be84990-aa18-4a2e-8a74-e8d386ecfe3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddb29d7c-a69c-4f1e-9ea5-993bbfcc10d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">vera:TaxYear2036Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8436e431-af1b-457d-91b5-f52f9019d971"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b426fd92-70e4-4d90-867a-c0ba79af8b53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45df6405-1d04-4fca-8db5-99ee7b1dd71e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9972233c-cff0-41a9-9e4e-78f8ec9718ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfc189ab-bacf-4a05-9ffd-a7ef871b7cc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5dc0b4e6-1ca3-4772-bc5f-e4b2611208cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91729747-ed44-43ba-b06c-0ca33c08ecef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3bd84b09-3c01-4501-bfd7-f6e21766d9ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f5962f0-d8e3-4966-ae7c-c8b41d160a04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41942c9c-8370-420a-b267-bd2d98ddef61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ce276b6-c154-43a1-9f92-2f2097479a87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c93b8c94-7f03-454e-b44d-c951c33fb0a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-06</xbrli:startDate><xbrli:endDate>2023-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33e49389-84fd-47c2-a929-1bc794eb3c19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64111eab-3827-4866-aa3a-fc5810fb7d15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddc80ff3-7e9a-4f5e-8fc8-162ee5659dda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aac5b93f-8d14-44a8-81ce-17fdcee51c82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76b7492e-4260-4f67-8590-2c3713b1204a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edca4e98-4e0f-44a2-ace4-368b647169df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">vera:LoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b83fa9a-deb4-4a21-b9ff-0b9830dba0d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_299bd9f5-1494-45ab-a9b2-e9efcfe185b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28836329-d13e-4a50-b307-58f77fac513d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2f7961f-3a91-49fc-8d5c-eadda8e3cd86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27a18667-bb0a-48ea-8694-1c1986159e16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_113d6c08-ba78-41b5-9746-69bcf0dfe625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b5a8210-e301-4c4e-b003-8559739c8a43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67ddbf76-c9a0-4921-9378-a929a1fa7f5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89a4ab10-0f5d-46b6-bb03-b0eae339e011"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AmplyxAndNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ed90599-4b8c-4161-b826-92693ffe24bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_883d50e8-64b0-42ff-91c1-09162e80e0ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_94d2afc6-a122-4a1e-804c-c6fd42dafadc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0446608-4adf-4b9a-a12b-80d69068a5b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vera:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caf5dab2-ce38-4cdf-9364-9103e398ebaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f7c27af-2605-4301-ae0d-b823d5c17fb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyTwoElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c78fe3f-f7cb-44db-809e-efe584139ec5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">vera:LondonInterbankOfferedRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyOneTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28a77420-c2ea-47f5-a8d9-5ab260bf4726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_627daa2d-be5a-4f02-9196-f41419329d3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d2f152f-37d4-4884-be62-4c29d7144c37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9b98e83-50fd-4219-bcaa-dce9a91dd403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_104cfa0f-5c0c-42af-a707-85e7636b50f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce9554a4-9d43-44af-976d-e2f6d319f429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyTwoElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9beda916-eeba-458d-97e7-f73f38603c69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:ClassACommonStockIssuedAndOutstandingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9ecbd41-6232-4712-8087-88a53aeacf61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e154e33-2372-4217-add2-91f0995fc280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15d01a5a-3d63-4633-9f8b-b5972d8790e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae34e80b-e684-4ceb-8100-75a5ed7d4c34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:EmployeeStockPurchasePlanEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be8fb598-3863-42c0-ae6e-183bbd558432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d1e9814-ee09-45d4-9d31-1141dbaf3188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f6268ee-8510-4770-a4af-2174ce8766bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe9431d7-e239-4190-9590-1758494ffd28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc44f825-ebce-4f12-ad2f-3c428d8aa752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ffca1f3-be18-4f89-a42d-d60b717612a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vera:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36414961-ec1c-41e6-866e-dc6627ebdbe7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e56d451-bf45-4d4d-ad5b-7a10597988a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c6e0d65-dc7d-4088-be4a-b8a144d6a7dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">vera:LondonInterbankOfferedRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyOneTwelveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0d79c47-62a3-4c6c-977a-e3a7e09cdea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a437c869-1510-4704-bfa5-0c8b5fb1e04f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8211428a-3da0-4229-b27d-cbfee378013c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b5bdaed-6212-482b-968a-c7919dfb3d46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b5b601c-cee7-4811-bef5-aa093f9e6050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfSpecifiedCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7402c574-533f-4f99-9103-cfb6bfdbe42f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd7aa2da-6cbb-441f-945f-fb8ccbd69234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831828</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a640b435-6c35-4471-99b9-67265e6c5a22" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_0892ac04-799e-4a6a-b237-002187e9d87f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffda962f-9677-449a-84b9-c3faa7a8f058" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_350db3a7-4f48-43bc-a55e-518b93cd904a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f7633ff-0d4f-4e3b-a661-014ec32e1dc9" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2023</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_8e36a540-d4b1-49d9-b18b-5e1b28e77a8a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission file number </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed9791b9-6fac-4767-8961-754cbff299e6" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-40407</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:20pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82f340c4-8482-4a36-81e1-d626f99e6a72" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:20pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_43bde9a4-9572-49d4-9812-4822479c6065" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a89c447f-3681-4fe6-a662-455d904391c3" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-2744449</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_9b8efa79-8800-4f7c-b45c-8399ee919df4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8000 Marina Boulevard</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_a9eabc00-62d1-46ec-ba0d-4536a2132e4c" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 120</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_4b207383-f0e6-46db-ad90-a7bbd68246a8" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Brisbane</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_908d12e7-2c91-4fbb-bf48-5e2148c51b55" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0031c51b-5b66-4b16-9f06-19a9887373cd" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94005</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6601dc59-eeb3-493a-805c-b7b3a5354723" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1385a9c0-dc9f-4b02-8289-a475f3b0c3bc" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">770-0077</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8.5pt;min-width:fit-content;">     </span><span style="font-size:8.5pt;"><ix:nonNumeric id="F_3d3ed0f0-563b-4e8d-996a-49333bbc4c88" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_5a434bf0-d413-42a5-be9c-6cbbc345e0b3" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">VERA</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8.5pt;"><ix:nonNumeric id="F_6ecfb3ee-3d7d-4746-8406-504e2f614f6e" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61015ac9-dc41-43aa-acc4-9e558a2edff5" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityWellKnownSeasonedIssuer"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;     </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c885ebeb-8a83-4cdb-95b5-6f9ef4a5fa52" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityVoluntaryFilers"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66e9df16-bcd9-43bf-ba6a-fa98923648ad" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityCurrentReportingStatus"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e480967-9fe1-4312-b408-c311d8a52065" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityInteractiveDataCurrent"><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9746;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.824%;"/>
    <td style="width:1%;"/>
    <td style="width:55.831%;"/>
    <td style="width:1.02%;"/>
    <td style="width:20.044%;"/>
    <td style="width:1%;"/>
    <td style="width:2.28%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_8e20d37a-8e51-4e3f-b830-1151fba1e642" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_3f118c02-0394-4211-b465-c039b060c755" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntitySmallBusiness" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_2de41b35-40f3-40ca-b119-e875fc9cc5b6" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64d6c4cf-67ea-4e5d-8183-0d350d432401" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8f5d0bc-95ba-4ffb-82fd-18a01bdda0ac" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.  </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f6a47d0-135f-4ed0-9e16-1871f2e3e657" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).  &#9744;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Yes</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> &#9744;     </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_98163537-6968-404a-a258-10de9a252785" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">The aggregate market value of the Registrant&#8217;s Class A common stock held by non-affiliates of the Registrant as of June 30, 2023, the last business day of the Registrant&#8217;s most recently completed second fiscal quarter, was approximately $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24609b0b-eb0e-4436-abfa-b8570851f906" contextRef="C_9deafbe4-5698-4e04-a2fb-fc9f4ae865ad" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">449.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> million based on the closing price of the Registrant&#8217;s Class A common stock on the Nasdaq Global Select Market of $16.05 per share.</span></p>
  <p style="font-size:10pt;margin-top:7pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of March 20, 2024</span><span style="color:#404040;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">the registra</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">nt had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f182822-9332-4798-be5b-c7c109fd9c58" contextRef="C_9c7489d8-52e2-4215-8365-cea7bd8503e3" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">54,452,029</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> common stock, $0.001 par value per share, and</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06cf0e95-2017-4035-9712-203f469c9ee6" contextRef="C_83dcf10b-9a2d-456b-b6d7-c0671495052f" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> shares of</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> Class B common stock, $0.001 par value per share, outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2d67f6f-2db9-4024-8932-32f0e456da85" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><ix:exclude><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
     <hr style="page-break-after:always;"/><div style="min-height:0.5in;"></div></ix:exclude><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:82%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#special_note_forward_looking_statements"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ii</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#summary_of_risks_business"><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">iv</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Business</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item IC.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#itemic_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cybersecurity</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Properties</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_reserved"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Reserved</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 8.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">128</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART III</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 10.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 11.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 12.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 13.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 14.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART IV</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 15.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibit and Financial Statement Schedules</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 16.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="special_note_forward_looking_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report on Form 10-K (the Annual Report) may contain &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate&#8221; or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of developing our product candidates and conducting nonclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and costs involved in obtaining and maintaining regulatory approval of our product candidates and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations for our product candidates for various diseases;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and our ability to grow a sales team;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to license additional intellectual property relating to any future product candidates and to comply with our existing license agreements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of unfavorable geopolitical and macroeconomic conditions on our business and operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our strategic plans for our business and current product candidates or any other product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the market opportunity for our product candidates in each of the diseases we target;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reliance on third parties to conduct nonclinical research activities, and for the manufacture of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our estimates of the number of patients in potential commercial markets who suffer from the diseases we target and the number of subjects that will enroll in our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress and focus of our current and future clinical trials, and the reporting of data from those trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to advance product candidates into and successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability of our clinical trials to demonstrate the safety and efficacy of our product candidates, and other positive results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competing therapies that are or may become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments relating to our competitors and our industry, including competing product candidates and therapies;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans relating to the further development and manufacturing of our product candidates, including additional indications that we may pursue;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">existing regulations and regulatory developments in the United States and other jurisdictions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our potential and ability to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the rate and degree of market acceptance of our product candidates, as well as the pricing and reimbursement of our product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our plans and ability to obtain and protect intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights, including atacicept, MAU868 and any other product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (JOBS Act) and as a smaller reporting company under the </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Exchange Act of 1934, as amended (Exchange Act)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. You should be aware that the occurrence of any of the events discussed under Part I, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Annual Report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cautionary statements made in this Annual Report are intended to be applicable to all related forward-looking statements wherever they may appear in this Annual Report. We urge you not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. Except as required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="summary_of_risks_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An investment in shares of our Class A common stock involves a high degree of risk. Below is a list of some of the material risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part I, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report.</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not completed any clinical trials for our lead product candidate, atacicept, and have no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long-term.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are substantially dependent on the success of our product candidates, atacicept and MAU868, which are currently in the clinical development stage. If we are unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Enrollment and retention of participants in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with immunoglobulin A nephropathy (IgAN), the availability of competitive products, and significant competition for recruiting participants in clinical trials.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The incidence and prevalence for target patient populations of atacicept in specific indications are based on estimates and third-party sources. If the market opportunities for atacicept, MAU868 or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim, initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than us.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if any product candidate we develop receives regulatory approval, it could be subject to significant post-marketing regulatory requirements and will be subject to continued regulatory oversight.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biosimilars to our product candidates may provide competition sooner than anticipated.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iv</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unfavorable geopolitical and global economic conditions could adversely affect our business, financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees and key consultants.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis International Pharmaceutical AG (Novartis) related to MAU868, we could lose the ability to continue the development and commercialization of atacicept or MAU868, respectively.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be required to make significant payments under our license agreements related to atacicept and MAU868.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on atacicept, MAU868 or any future product candidates we may develop for an adequate amount of time.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations (CROs), to conduct certain aspects of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize atacicept, MAU868 or future product candidates we may develop and our business, financial condition, results of operations and prospects could be significantly harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our product for patients, if approved, could be delayed or prevented.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price of our common stock may be volatile, and you could lose all or part of your investment.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our outstanding voting stock and will be able to exert significant control over matters subject to stockholder approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention. </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">v</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 1. Business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. IgA nephropathy (IgAN) is a B cell disorder with a kidney pathology. Our lead product candidate, atacicept, is an at home, self-administered transmembrane activator and CAML interactor (TACI)-Fc fusion protein that blocks both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) with best-in-class potential for the treatment of IgAN. The Phase 2b ORIGIN clinical trial evaluating the safety and efficacy of atacicept in participants with IgAN reported positive results at three timepoints: 24-week topline results in January 2023, 36-week results in June 2023, and 72-week results in January 2024. The trial remained blinded through 36 weeks, after which all participants were eligible for the open label extension portion of the study and received atacicept 150 mg through 96 weeks. At 24 and 36 weeks, respectively, atacicept met its primary endpoint with statistically significant reductions in urine protein creatinine ratio (UPCR) on atacicept 150 mg, and stable estimated glomerular filtration rate (eGFR) was observed for participants on atacicept, with clinically meaningful and statistically significant difference versus placebo. Participants treated with atacicept demonstrated reductions in galactose-deficient IgA1 (Gd-IgA1), the autoantigen produced by B cells in patients with IgAN, and a reduction in hematuria. The improvements in Gd-IgA1, hematuria, UPCR and eGFR represent the quartet of findings consistent with IgAN disease modification. The 72-week open label extension results showed consistent and sustained reductions in Gd-IgA1, hematuria, UPCR and continued eGFR stabilization. Additionally, atacicept&#8217;s safety profile was comparable to placebo. We advanced atacicept 150 mg in a pivotal Phase 3 clinical trial in IgAN in the second quarter of 2023. We believe that atacicept has pipeline in a molecule potential, with potential application in additional indications including systemic lupus erythematosus (SLE) and lupus nephritis (LN), a severe renal manifestation of SLE. We have designed and are poised to conduct a Phase 3 clinical trial of atacicept in LN, based on feedback from the FDA&#8217;s review of clinical results in a Phase 2 clinical trial of atacicept in SLE patients with high disease activity (HDA). We also hold worldwide, exclusive development and commercial rights to MAU868, a potentially first-in-class monoclonal antibody to treat reactivated BK virus (BKV) infections, for which we completed a Phase 2 clinical trial in 2022. In January 2023, we delayed enrollment in the pivotal Phase 3 trial for LN and commitment of resources to the MAU868 program. We believe that our current pipeline programs leverage the deep expertise of our team and have strong potential commercial synergies. We hold global developmental and commercial rights to all of our pipeline molecules.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept in IgAN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IgAN is a serious and progressive autoimmune disease of the kidney that is driven by the production of Gd-IgA1, which is associated with increased risk of kidney-related morbidity and mortality. We estimate there will be approximately 157,000 biopsy-confirmed IgAN patients in the United States, 136,000 in Europe, and 130,000 in Japan, at estimated peak year of sales. Up to 50% of patients diagnosed with IgAN develop end-stage renal disease (ESRD) within 20 years from initial diagnosis, requiring dialysis or kidney transplant. ESRD causes considerable morbidity and impact on patients&#8217; lives and represents a significant health economic burden, which was estimated to be $49.2 billion in the United States in 2018. Despite this high level of morbidity, only two treatments have been approved for this indication: TARPEYO (budesonide, developed by Calliditas Therapeutics AB), a reformulated steroid, and FILSPARI (sparsentan, developed by Travere Therapeutics), a dual endothelin angiotensin receptor antagonist. Neither of these agents are disease-modifying treatments in IgAN. The current standard of care continues to consist of off-label use of renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), and, in some patients, sodium-glucose cotransporter-2 (SGLT2) inhibitors. We estimate the global market opportunity for novel, disease-modifying therapeutics in IgAN is approximately $6.0 billion to $10.0 billion annually, based on the disease prevalence and the segment of IgAN patients at high risk of progressing to ESRD.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept is a TACI-Fc fusion protein self-administered at home as a subcutaneous injection once weekly that blocks both BAFF and APRIL, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. We believe that atacicept&#8217;s mechanism has the potential to generate clinical success by measures designed to assess efficacy in IgAN and other immunologic diseases. BAFF inhibition has been clinically and commercially validated through the approval of Benlysta (belimumab) in both SLE and LN. Preclinical and clinical evidence support that atacicept&#8217;s mechanism of dual inhibition of BAFF and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone. Atacicept has the potential to be the first disease-modifying therapy for IgAN due to its ability to modulate B cell and plasma cell activity, with reductions in Gd-IgA1, hematuria, and proteinuria &#8211; and stabilization of eGFR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have worldwide, exclusive rights to atacicept from Ares, an affiliate of Merck KGaA, Darmstadt, Germany, pursuant to the Ares Agreement, which advanced atacicept in randomized, double-blind, placebo-controlled clinical trials for several autoimmune diseases in over 1,500 patients, in which it was well tolerated. In IgAN, Merck KGaA, Darmstadt, Germany, conducted a randomized, double-blind, placebo-controlled Phase 2a trial known as JANUS. Results from the JANUS trial showed a dose-dependent effect of atacicept 25 mg and 75 mg weekly on serum Gd-IgA1, proteinuria, and key biomarkers, including serum Ig levels. As reported at the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">American Society of Nephrology (ASN) Kidney Week conference in 2022, atacicept is also the first therapeutic candidate in IgAN to show reduction in all first three hits of disease pathogenesis&#8212;serum Gd-IgA1, anti-Gd-IgA1 autoantibody, and immune complex levels.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are conducting a multinational, randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which we refer to as ORIGIN 3, and completing the open label extension of our Phase 2b clinical trial in IgAN, which we refer to as ORIGIN 2b. The ORIGIN 3 trial is evaluating atacicept 150 mg by weekly subcutaneous injection at home versus placebo through 104 weeks. The primary endpoint is reduction in UPCR in a 24-hour urine collection versus placebo at 36 weeks to support potential accelerated approval. A significant reduction in proteinuria, as measured by UPCR in a 24-hour urine collection, is associated with improved renal outcomes in patients with IgAN. UPCR is a surrogate endpoint accepted by the FDA for primary glomerular diseases associated with significant proteinuria, including IgAN. Given the FDA&#8217;s recent approvals of TARPEYO and FILSPARI, we believe the use of proteinuria as a surrogate endpoint for accelerated approval has been validated. The key secondary endpoint is eGFR change up to week 104.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ORIGIN 2b trial evaluated three subcutaneous weekly doses of atacicept (25 mg, 75 mg and 150 mg) and their impact on the reduction of proteinuria as measured by UPCR as the primary endpoint, with secondary endpoints including the difference in kidney function between treated and placebo participants as measured by eGFR and reduction in Gd-IgA1. We completed enrollment of the Phase 2b ORIGIN trial in mid-2022, enrolling a total of 116 participants at multiple global sites. In January 2023, we announced that atacicept met the primary endpoint: the pooled 75 mg and 150 mg arms achieved a statistically significant reduction in proteinuria versus placebo at 24 weeks. In June 2023, we announced positive results at 36 weeks in a late-breaking presentation at the European Renal Association (ERA) Conference. In a prespecified per-protocol (PP) analysis in which a blinded third-party CRO identified and excluded participants with protocol deviations, atacicept 150 mg achieved a 43% mean reduction in proteinuria versus placebo, and a 35% mean reduction in proteinuria versus placebo in the intent-to-treat (ITT) population. Stable eGFR was observed for participants on atacicept 150 mg at 36 weeks, with an 11% mean eGFR change versus placebo, approximating to an absolute difference of 5.8 mL/min/1.73m2. Atacicept 150 mg reduced Gd-IgA1 64% from baseline. Hematuria was resolved in 80% of participants receiving atacicept 150 mg compared to 5% of those receiving placebo. Furthermore, Atacicept was well tolerated, and its safety profile in IgAN was comparable to placebo. The ORIGIN 2b trial remained blinded through 36 weeks, after which all participants were eligible to roll onto the open label portion of the trial and receive atacicept 150 mg once weekly through 96 weeks, allowing for the evaluation of long-term safety and durability of response of atacicept in IgAN. In January 2024, we announced positive results at 72 weeks at an R&amp;D Day. Through 72 weeks, atacicept showed consistent and sustained UPCR reduction and eGFR stabilization. Atacicept also achieved consistent and sustained Gd-IgA1 reduction and reductions in percentage of participants with hematuria through 72 weeks. The open label extension adverse events profile was consistent with the randomized period. In aggregate, we believe these data provide evidence of long-term, comprehensive IgAN disease modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate full enrollment for the primary endpoint of ORIGIN 3 in the second half of 2024. With Phase 3 topline results expected in the first half of 2025, if positive, we expect to submit a biologics license application (BLA) for atacicept in IgAN to the FDA in the second half of 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beyond our lead indication in IgA nephropathy, we have several late-stage opportunities for potential patient benefit &#8211; consisting of both indication expansion opportunities for atacicept, and the development of MAU868 for BK viremia among kidney transplant recipients. We are currently evaluating these opportunities for future development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For atacicept, we plan to evaluate the possibility of extended dosing intervals as part of our life cycle management strategy. There are also multiple indications in which blocking BAFF and APRIL may offer therapeutic benefit and offer an attractive commercial opportunity. Indications in which atacicept is Phase 3 ready based on feedback from regulators include LN and SLE. We have designed a Phase 3 clinical trial in LN. We believe that atacicept also has potential to initiate Phase 3 clinical trials in Sjogren&#8217;s syndrome, myasthenia gravis, and membranous nephropathy, pending alignment with regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regarding MAU868 for BK viremia among kidney transplant recipients, at ASN 2022, final results from the Phase 2 clinical trial of MAU868 versus placebo showed that MAU868 was well tolerated and demonstrated clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia. Following feedback from the FDA on the Phase 2 clinical trial, we are evaluating strategies for continued development, including a potential next clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept in LN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on feedback from the FDA&#8217;s review of clinical results in a Phase 2 clinical trial of atacicept in HDA SLE patients, we have designed a Phase 3 clinical trial of atacicept as a potential treatment for patients with LN. We estimate that there will be approximately 120,000 LN patients in the United States, 70,000 in Europe , and 21,000 in Japan, at estimated peak year of sales. We estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0 billion, $600 million and $200 million in United States, Europe and Japan, respectively. Significant unmet need for improved efficacy persists for these patients despite the recent approval of the first two LN-specific therapies. Fewer than half of patients treated for LN have a complete response to therapy, and among patients</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">without a complete response, over half will have non-functioning kidneys within five years. Benlysta (belimumab), a BAFF-only inhibitor, is one of the two therapies approved for patients with LN. Both BAFF and APRIL levels are increased in patients with SLE, suggesting that dual inhibition by atacicept may be more potent than blocking BAFF alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously initiated a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the APRIL-LN trial, evaluating the efficacy and safety of atacicept 150 mg twice weekly for four weeks&#8212;then weekly&#8212;in participants with active LN. However, this trial was terminated early due to three participants developing hypogammaglobulinemia with induction therapy (mycophenolate mofetil (MMF) and corticosteroids (CS)) which continued to worsen when initiating atacicept and subsequently two participants developed pneumonia. In prior Phase 2 clinical trials of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint in the broader SLE study population, atacicept achieved positive clinical data on multiple measures within the pre-specified patient segment with HDA (defined as Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K] &#8805;10 at screening), including reduction of renal flares, which we believe supports atacicept&#8217;s applicability in LN. Because both preclinical and clinical evidence suggest atacicept&#8217;s dual inhibition of BAFF and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone, we believe there is a strong rationale to conduct a clinical trial of atacicept in LN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our currently designed Phase 3, randomized, parallel-group, double-blind, placebo-controlled, multicenter, multinational study plans to evaluate the efficacy and safety of atacicept vs placebo in participants with LN. The clinical trial consists of a 104-week double blind treatment period, followed by a 52-week open label treatment period and a 26-week safety follow-up period. The trial will assess once weekly subcutaneous injections of 150 mg atacicept versus placebo. The primary endpoint is complete renal response at 52 weeks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MAU868 in BK viremia among kidney transplant recipients</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have exclusive worldwide rights, pursuant to the Novartis license, to MAU868, which is a potential treatment for reactivated BK infection in kidney transplant recipients. While up to 90% of healthy adults have been infected with BKV at some point in their lives, it remains latent except in severely immunocompromised populations such as kidney transplant recipients. BKV is a polyoma virus that can cause BKV nephropathy (BKVN), a condition in which BK infection, typically first identified as BK viremia, triggers inflammation, which then progresses to fibrosis and tubular injury; BKVN is a leading cause of allograft loss. Currently, there are no approved treatment options for BK viremia or BKVN. We estimate that approximately 80,000 kidney transplants are conducted globally each year, with approximately 20,000 in the United States, 20,000 in Europe, 1,500 in Japan, and 10,000 in China. Approximately 15% of kidney transplant recipients develop BK viremia; 3&#8211;4% of kidney transplant recipients develop BKVN. We estimate the market for a novel agent to treat reactivated BK infection in kidney transplant recipients to be a large commercial opportunity worldwide. We believe that MAU868 has the potential to become standard of care for the treatment of reactivated BK infection in order to prevent devastating consequences following kidney transplantation such as BKVN and graft loss.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business principles and strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our goal is to develop and commercialize transformative treatments for patients suffering from severe immunological diseases. We believe the successful translation of biomedical science into innovative therapeutic products for patients with immunological diseases will enable outsized growth over the next decade and beyond. Specifically, our strategy is based on the following business principles:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Develop disease-modifying medicines to improve patients&#8217; lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Our team seeks to bring transformative medical products to patients with severe immunological diseases, who often receive steroids for treatment. The non-specific immunologic effect of steroids, with known acute and chronic side effects, presents an important opportunity for innovation. We aim to develop and commercialize disease-modifying drugs that target the source of disease, minimize side effects, and have high potential to meaningfully change standard medical care and improve patients&#8217; lives.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establish clear line-of-sight to successful products. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We apply our deep drug development experience, scientific rigor, and disciplined decision making to establish clear line-of-sight along the full spectrum of drug development. We pursue biologic targets, product candidates, and disease indications with a de-risked profile and capital-efficient development pathway, and optimize for high probability of clinical, regulatory, and commercial success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Build a leading biotech company that delivers innovative medicines to patients. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our team&#8217;s expertise and our business culture are fundamental to our success. Our Research and Development team is led by experienced drug development executives with proven track records in clinical and commercial development who have led or been involved in the approvals of more than 15 medicines from leading companies, including Gilead Sciences and Amgen. We leverage our team&#8217;s know-how with additional outsourced resources and enable focused clinical development of our product candidates with the goal of improving patients&#8217; lives.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These principles have guided us to the successful in-licensing of atacicept from Ares and obtaining the rights to MAU868 from Amplyx, in each case with worldwide rights for development and commercialization in all indications. We take a gated-capital raise</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approach and scale product candidate investment and exposure in close step with key development milestones to ensure high return on development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The near- and long-term objectives to achieve our goal include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Complete global development of atacicept in IgAN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We reported positive 72-week results from the open label extension of the ORIGIN Phase 2b clinical trial in January 2024, and we will report 96-week results in the second half of 2024. Our global pivotal Phase 3 clinical trial is currently ongoing and we expect to complete enrollment for the primary endpoint in the second half of 2024.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Build and scale organizational capabilities to support commercialization of atacicept.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Under the leadership of our experienced management team, we have begun building a specialized commercial organization with deep launch experience in nephrology, B cell, and autoimmune therapeutics, to launch atacicept in the United States and other key markets, if approved.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Explore additional disease areas where atacicept holds significant therapeutic promise. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By targeting BAFF and APRIL, atacicept&#8217;s ability to reduce disease-causing autoantibodies may provide clinical benefit. We intend to explore additional immunologic diseases where BAFF and APRIL are abnormally elevated, or where autoantibodies play an important role. We have designed a global Phase 3 clinical trial of atacicept as a potential treatment for patients with LN, a frequent and devastating complication of SLE.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identify next clinical trial for MAU868 in BK viremia in kidney transplant recipients and align with regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We reported final results from our Phase 2 clinical trial in kidney transplant recipients in 2022. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expand our pipeline by acquiring or in-licensing product candidates for immunologic diseases with unmet needs. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe our expertise and track record will enable us to identify and acquire or in-license additional product candidates that represent opportunities to expand the potential value of our pipeline. We will leverage our lean clinical development operation to bring to market additional product candidates to address kidney and immunologic diseases.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept in IgAN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We are developing atacicept as a potential treatment for patients with IgAN, a serious and progressive autoimmune disease of the kidney with a high unmet medical need and limited treatment options available. Up to 50% of confirmed IgAN patients progress to ESRD, requiring dialysis or kidney transplant. ESRD causes significant morbidity and impact on patients&#8217; lives and represents a significant health economic burden estimated to be over $40 billion annually in the United States. Despite this high level of morbidity, the current standard of care consists of off-label use of RAAS inhibitors, including ACE inhibitors and ARBs, increasingly includes the use of SGLT2 inhibitors, and potentially includes steroids. IgAN is driven by the production of pathogenic Gd-IgA1, and patients with elevated Gd-IgA1 are at increased risk of kidney-related morbidity and mortality. We reported positive topline 24-week results in January 2023, 36-week results in June 2023, and 72-week results in January 2024 from the Phase 2b ORIGIN trial. We initiated a pivotal Phase 3 clinical trial in the second quarter of 2023, which we refer to as ORIGIN 3, that is currently ongoing. We believe that atacicept has the potential to be the best-in-class and the leading B cell-targeted therapy for IgAN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pathophysiology of IgAN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IgA antibody plays a key role in the immune system by protecting the body from foreign substances such as bacteria and viruses. Patients with IgAN produce elevated levels of Gd-IgA1. This abnormal glycosylation pattern of IgA1 is of central importance to the disease etiology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As shown in Figure 1 below, a multi-step process leads to the ultimate development of progressive renal injury.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 1: IgAN pathophysiology</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_0.jpg" alt="img76291469_0.jpg" style="width:730px;height:264px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">B cells, which mature into plasma cells, are abnormally primed in the Peyer&#8217;s patch region of the ileum of the intestines, potentially due to a combination of genetic predisposition and environmental, bacterial or dietary factors. BAFF and APRIL are upregulated, leading to B cell maturation and survival, and antibody class switching, a mechanism that changes cells&#8217; production from one immunoglobulin to another, causing an increase in the production of immunogenic Gd-IgA1.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Gd-IgA1 antibodies are immunogenic when found in the systemic circulation, and are recognized as an autoantigen by autoantibodies, or antibodies created by the body in response to a constituent of its own tissue. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gd-IgA1 and anti-Gd-IgA1 autoantibodies combine to form pathogenic immune complexes, or clusters of antibodies.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pathogenic immune complexes are deposited and become trapped in the kidney&#8217;s glomeruli.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This initiates an inflammatory response that damages the membranes. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the glomeruli are destroyed, the kidney&#8217;s ability to remove waste products from the blood is reduced, and protein and blood leak into the urine. This can result in potentially life-threatening complications that lead to the need for dialysis or kidney transplant in many patients. </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Gd-IgA1 is central to the pathogenesis of IgAN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gd-IgA1 is a subclass of IgA antibodies that lack units of galactose, a type of sugar, at the O-linked glycans of their hinge region. The hinge region is a stretch of amino acids in the IgA antibody. Circulating Gd-IgA1 antibodies have been shown to be the target of autoantigens for IgG antibodies with specificity for the hinge region.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A histopathological hallmark of IgAN is deposition of Gd-IgA1 in the glomerular mesangium, either alone or in combination with IgG and/or IgM. Sampling of the serum of patients with IgAN has confirmed the presence of elevated levels of circulating immune complexes containing Gd-IgA1.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials of patients with IgAN have correlated higher serum levels of Gd-IgA1 with greater severity of IgAN disease, suggesting that reduction in serum Gd-IgA1 may slow disease progression. Compared with healthy subjects, patients with IgAN have an increased proportion of Gd-IgA1 O-glycoforms in the serum. As published in Kidney International, in a prospective study of 275 patients with IgAN, higher serum levels of aberrantly glycosylated IgA1 demonstrated correlation with a higher likelihood of developing progressive renal failure, as shown in Figure 2 below. A separate clinical trial of patients with IgAN of varying severity found that higher titers of autoantibodies specific for Gd-IgA1 corresponded to both absolute renal risk score and risk of ESRD or death.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 2: Renal survival by serum Gd-IgA1 quartiles in IgAN patients</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_1.jpg" alt="img76291469_1.jpg" style="width:379px;height:371px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, high serum APRIL levels correlate with increased expression of serum Gd-IgA1 in IgAN patients and high serum BAFF levels are associated with more severe clinical features, as well as more severe histopathological features. For these reasons, we believe a fusion protein that blocks both BAFF and APRIL, which has the potential to reduce serum Gd-IgA1, would address the upstream source of IgAN, and represent the first disease-modifying approach for IgAN.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disease burden, diagnosis, and predictors of disease progression</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IgAN is a rare disease in the United States and Europe and is also the predominant cause of primary glomerulonephritis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients with IgAN are diagnosed throughout life, but most commonly in the second and third decades. There are three common ways in which patients present:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40&#8211;50% present with one or more episodes of gross (visible) hematuria, often linked to an upper respiratory tract infection.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30&#8211;40% present with microscopic hematuria and mild proteinuria, which is detected in a routine physical or during chronic kidney disease evaluation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Less than 10% present with either nephrotic syndrome or an acute, rapidly progressive glomerulonephritis with symptoms including edema, hypertension, renal insufficiency, and hematuria.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once IgAN is suspected based on clinical history and laboratory data, kidney biopsy, which is the gold standard for IgAN diagnosis, is performed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IgAN market opportunity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate there will be approximately 157,000 biopsy-confirmed IgAN patients in the United States, 136,000 in Europe, and 130,000 in Japan, at estimated peak year of sales, and that growth in the diagnosed prevalent population is due to overall population growth.  Underlying genetic differences may contribute to the significantly higher rate in Japan. As therapies become commercially available, however, an increase in diagnosis rate or longer time to progression, due to better treatments, may increase the diagnosed population over time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 3: Estimated IgAN epidemiology at estimated peak year of sales</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_2.jpg" alt="img76291469_2.jpg" style="width:458px;height:395px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current standard of care for IgAN patients</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the high unmet medical need in IgAN, there are limited treatment options available. The following two general approaches are typically employed for the treatment of patients with IgAN:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-specific measures to slow progression, including RAAS inhibitors (including ACE inhibitors or ARBs) and SGLT2 inhibitors.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Steroids with or without other immunosuppressive agents to non-specifically reduce inflammation as a result of immune complex deposition in the glomeruli.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Treatment is selected based on perceived risk of progressive kidney disease, and clinical measures such as hematuria, proteinuria, and eGFR are used to monitor patients while on treatment. The current standard of care is seen as insufficient by physicians and patients; these treatment approaches have limited clinical efficacy and are not well tolerated. Approximately 50% of patients fail to achieve controlled UPCR on ACE inhibitors, ARBS, or steroids. The use of steroids may cause significant side effects, including serious infections, high blood pressure, weight gain, diabetes, and osteoporosis. As such, there is a high unmet medical need for targeted therapies that impact the underlying disease pathophysiology and more tolerable, steroid-sparing treatment options for IgAN patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging therapies in development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are two agents approved for the treatment of IgAN and there are several treatments in clinical development. The multistep IgAN pathogenesis hypothesis offers potential target points and approaches for therapeutic intervention. Most therapeutic candidates in clinical development have employed various approaches to target inflammation and the downstream effects. Atacicept is the first agent in development for IgAN that has demonstrated a 64% reduction of Gd-IgA1, the upstream source of IgAN pathogenesis, after 36 weeks of treatment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These agents can be grouped mechanistically into the following categories: glucocorticoid receptor agonists, endothelin receptor antagonists (ERAs), complement inhibitors, B cell modulators, and a variety of other approaches that are earlier in development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Glucocorticoid receptor agonists</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Glucocorticoid receptor agonists are a well-known class of molecules that have broad anti-inflammatory effects, and well-established acute and chronic side effects. Though reduction in the risk of eGFR decline was shown in clinical trials, there is no consensus on whether glucocorticoids may improve renal survival. The glucocorticoid budesonide has been reformulated to concentrate steroid effects locally on the gut mucosa, theoretically suppressing the abnormal B cell activity and reducing systemic steroid toxicity. Reformulated budesonide is currently approved by the FDA and European Commission for reducing the loss of kidney function in adults with IgAN who are at risk for disease progression, though systemic steroid side effects have been observed in clinical trials.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ERAs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Aberrant endothelin signaling is implicated in structural podocyte changes and increased mesangial proliferation in chronic kidney diseases, including IgAN. ERAs block endothelin-induced cell proliferation and hence may reduce renal perfusion pressure and proteinuria. Since this mechanism of action works downstream of disease-related immune activities, it is not expected to reduce Gd-IgA1 or the resulting immune complexes that cause the disease. ERAs have previously been approved for the treatment of pulmonary arterial hypertension and erectile dysfunction and make use of a vasodilatory effect. One ERA that is currently approved by the FDA has a boxed warning for hepatotoxicity and embryo-fetal toxicity and a REMS for liver toxicity, and another ERA is completing Phase 3 development. ERAs have been associated with edema, significant liver toxicity and increased risk of heart failure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Complement inhibitors</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Increased complement activation is commonly observed in patients with IgAN. It is hypothesized that immune-complex deposition in glomeruli may contribute to complement activation, though the exact mechanism is not well understood. Several agents that inhibit complement activation are in clinical development for IgAN. Modest reduction of proteinuria has been observed in early clinical trials. As complement inhibition works downstream of immune complex formation, these agents are not expected to impact the upstream cause of disease and reduce Gd-IgA1 or the resulting immune complexes that cause inflammation and complement activation in the kidney.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">B cell modulators</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. B cell modulators, including atacicept, are an important category of emerging therapies for IgAN. The disease-causing Gd-IgA1 is predominantly produced by B cells and plasma cells. Therefore, control of B cell activation may reduce production of Gd-IgA1 and the downstream formation of autoantibodies and immune complexes. Preclinical models have shown that dual inhibition of BAFF and APRIL offers improved suppression of B cell activities over blocking BAFF or APRIL alone. Atacicept blocks both BAFF and APRIL and has shown substantial reduction (64% at 36 weeks) in Gd-IgA1. We believe that dual inhibition may also confer a potential dosing advantage versus APRIL-only inhibition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our solution: Atacicept</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept is a fusion protein that blocks both BAFF and APRIL, which play key roles in the upstream pathway that causes IgAN, and is dosed once weekly via a 1-mL subcutaneous injection, self-administered at home. As a result, we believe atacicept has the potential to be the first disease-modifying therapy for IgAN. Through an integrated analysis of randomized, double-blind, placebo-controlled clinical trials in multiple autoimmune diseases with over 1,500 participants to date, atacicept has a well-characterized clinical safety profile. In a Phase 2a clinical trial in participants with IgAN, atacicept substantially reduced Gd-IgA1 and demonstrated a clinically meaningful reduction in proteinuria and stable eGFR parameters at week 24. We completed enrollment of participants in the Phase 2b ORIGIN trial in 2022, and we reported positive results at 24 weeks in January 2023, 36 weeks in June 2023, and 72 weeks in January 2024.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our approach to IgAN: Reducing Gd-IgA1, the source of autoantibodies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept is a fully humanized fusion protein that is designed to modulate the B cell and plasma cell pathway, which has well characterized implications in immunologic diseases. Specifically, as shown in Figure 4 below, atacicept contains the soluble extracellular domain of the TACI receptor fused with the inactivated Fc domain of IgG1. TACI is a native receptor for BAFF and APRIL, members of the tumor necrosis factor family that promote B cell survival and autoantibody production associated with IgAN and other immunologic diseases. Dual blockade of BAFF and APRIL by TACI has been shown to be more potent than blocking BAFF alone or APRIL alone and has the benefit of targeting long-lived plasma cells, in addition to B cells, thus reducing production of Gd-IgA1 and its autoantibodies. Therefore, atacicept is designed to modulate B cell and plasma cell activity by binding both BAFF and APRIL, and follows a long history of impactful agents that are logically designed Fc fusion proteins. This mechanism acts directly on the source of IgAN, which we believe will significantly mitigate the downstream effects of the disease.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 4: Atacicept is the result of rational drug design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_3.jpg" alt="img76291469_3.jpg" style="width:730px;height:230px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept&#8217;s specific actions on IgAN disease pathogenesis are shown in Figure 5 below.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 5: Atacicept impact on IgAN pathogenesis</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_4.jpg" alt="img76291469_4.jpg" style="width:730px;height:264px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept inhibits BAFF and APRIL, leading to decreased Gd-IgA1 production by B cells.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This leads to a reduction in the autoantibodies that bind to Gd-IgA1.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Therefore, formation of pathogenic immune complexes is greatly reduced.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(4)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This, in turn, reduces immune complex deposition in glomeruli.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(5)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Glomerular inflammation is reduced.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(6)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ultimately, progressive renal injury is attenuated, with reductions in hematuria and proteinuria, and stabilization of eGFR, which we believe will significantly lower the morbidity and mortality associated with IgAN.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept&#8217;s disease-modifying mechanism addresses the upstream processes that cause IgAN, while most other molecules in development act downstream. Therefore, we believe that the clinical outcomes of atacicept, measured by endpoints designed to assess efficacy and durability, will be favorable over competitors, with a demonstrated tolerability profile. Once weekly 1 mL subcutaneous dosing also provides an attractive target product profile for patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept in IgAN: clinical development</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept was the subject of a collaboration agreement between Ares and ZymoGenetics, Inc. in 2001, and was licensed on an exclusive basis to Ares in 2008. It was advanced by Merck KGaA, Darmstadt, Germany, in clinical trials for several autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis, SLE, and IgAN, and in totality studied in double-blind placebo-controlled clinical trials in over 1,500 participants to date. Safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of the weekly 25 mg, 75 mg and 150 mg doses administered subcutaneously have been studied.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept is being studied in the Phase 2b ORIGIN clinical trial, a multinational, 36-week randomized, placebo-controlled, double-blind trial, with a 60-week open label extension (Figure 6). The ORIGIN Phase 2b trial was designed to evaluate the efficacy and safety of atacicept in participants with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite being on a stable prescribed regimen of a RAAS inhibitor for at least 12 weeks that is at the maximum labeled or tolerated dose. The clinical trial consisted of a 36-week double-blind treatment period, followed by a 60-week open-label treatment period &#8212; which is currently ongoing &#8212; and a 26-week safety follow-up period. The trial assessed three doses (25 mg, 75 mg and 150 mg) of once weekly 1-mL subcutaneous injections of atacicept versus placebo on impact of renal function as measured by proteinuria. The primary endpoint was change from baseline in UPCR at 24 weeks based on 24-hour urine collection, with a secondary endpoint of UPCR at 36 weeks. Other endpoints include change from baseline in UPCR at 12, 48, and 96 weeks, change from baseline in eGFR at 12, 24, 36, 48, and 96 weeks, change from baseline in IgA, IgG, IgM, and Gd-IgA1 levels at 12, 24, 36, 48, and 96 weeks, number of participants with adverse events during the double-blind treatment period through 36 weeks, and the serum concentration of atacicept through study completion.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 6: Phase 2b ORIGIN trial design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><img src="img76291469_5.jpg" alt="img76291469_5.jpg" style="width:672px;height:207px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera reported positive results from the randomized phase of the Phase 2b ORIGIN clinical trial, which showed the following at 36 weeks:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Gd-IgA1 reduction of 64% from baseline with atacicept 150 mg.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hematuria resolution in 80% of participants on atacicept 150 mg versus 5% on placebo.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In a PP analysis, a blinded third-party CRO identified participants with protocol deviations that potentially confounded proteinuria measure. In the PP population excluding these participants, atacicept 150 mg achieved a 43% mean reduction in proteinuria versus placebo (p&lt;0.05); in the ITT population, atacicept 150 mg achieved a 35% delta versus placebo.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stable eGFR observed for participants on atacicept, with clinically meaningful and statistically significant difference versus placebo.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Clinical safety profile similar between atacicept and placebo.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, Vera reported positive results from the open label phase of the Ph2b ORIGIN clinical trial at 72 weeks, which demonstrated consistent and sustained reductions in Gd-IgA1, hematuria and UPCR and consistent and stable eGFR (Figure 7 below). In aggregate, we believe these data provide evidence of long-term, comprehensive IgAN disease modification.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 7: Phase 2b ORIGIN clinical trial 72-week results with atacicept</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_6.jpg" alt="img76291469_6.jpg" style="width:731px;height:242px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We initiated our ORIGIN 3 Phase 3 clinical trial in June 2023. We are using the same formulation as the Phase 2b trial, and have incorporated learnings from Phase 2b subgroup analyses into the design of our Phase 3 trial that aims to accurately assess treatment efficacy while minimizing potential confounders for proteinuria measure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept safety and tolerability profile</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the randomized phase of the ORIGIN Phase 2b clinical trial, the clinical safety profile was similar between atacicept and placebo &#8211; and in the week 72 results, the safety profile observed was consistent with that of the randomized phase (Figure 8 below).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 8: Phase 2b ORIGIN clinical trial adverse events profile</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_7.jpg" alt="img76291469_7.jpg" style="width:731px;height:310px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An integrated safety analysis of clinical trials in multiple indications with over 1,500 participants in a number of indications, atacicept was well tolerated, shown in Figure 9 below. Serious treatment-emergent adverse events (TEAEs) reported in the highest proportions were those in infections and infestations (placebo 3.9% versus atacicept 4.4%), musculoskeletal and connective tissue disorders (placebo 1.9% versus atacicept 1.3%), and nervous system disorders (placebo 2.1% versus atacicept 1.2%). The most frequently reported TEAE was pneumonia (placebo 1.2% versus atacicept 1.3%). We believe that this large and established data set is a competitive advantage for atacicept versus other approved and emerging therapies in development, many of which lack extensive safety data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 9: Integrated safety analysis: Summary of treatment-emergent adverse events &gt; 5% in any arm, by dose</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_8.jpg" alt="img76291469_8.jpg" style="width:730px;height:205px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The safety profile of atacicept 25 mg, 75 mg and 150 mg has been characterized in healthy subjects and patients with RA, multiple sclerosis, optic neuritis, SLE, and B cell malignancies, and is considered acceptable in IgAN. Over 1,940 individuals have been enrolled in 22 clinical trials, of which over 1,425 individuals have received at least one dose of atacicept. In the three Phase 2/3 clinical trials, 590 participants with SLE and 11 participants with IgAN have received at least one dose of atacicept.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe the benefit-risk balance of atacicept to be favorable for further development in IgAN and certain additional autoimmune diseases, and we intend to explore additional immunologic diseases where BAFF and APRIL are abnormally elevated, or where autoantibodies play an important role.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">UPCR is an accepted surrogate primary endpoint for clinical trials in IgAN, which potentially allows for a faster path to commercialization than rate of change/slope in eGFR, which is measured after two years. The recommendation for usage of this surrogate endpoint was put forward by the ASN, partnering with the FDA under the auspices of the Kidney Health Initiative, and the European Medicines Agency (EMA), and has now been implemented in five Phase 3 clinical trials in IgAN and in the two FDA approvals granted. Accelerated and/or conditional approval may be granted on the UPCR endpoint, with full approval to be granted upon longer-term data demonstrating stabilization of eGFR with treatment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ongoing Phase 3 ORIGIN 3 clinical trial</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We advanced atacicept 150 mg into a pivotal Phase 3 trial in IgAN in the second quarter of 2023, using the same formulation from the Phase 2b trial and learnings from the Phase 2b subgroup analyses to reduce risk in the design of a Phase 3 trial that aims to accurately assess treatment efficacy while minimizing potential confounders for proteinuria measure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 10: Phase 3 ORIGIN 3 trial design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_9.jpg" alt="img76291469_9.jpg" style="width:693px;height:119px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORIGIN 3 is a Phase 3 global, multicenter, 104-week randomized, placebo-controlled, double-blind trial, with a 52-week open label extension and a 26-week safety follow-up period (Figure 10), in participants with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression despite being on a stable prescribed regimen of renin-angiotensin system inhibitors (ACE inhibitors or ARBs) for at least 12 weeks that is the maximum labeled or tolerated dose. The clinical trial consists of a 104-week double-blind treatment period which is currently ongoing, followed by a 52-week open-label treatment period and a 26-week safety follow-up period. The trial will assess once weekly 1-mL subcutaneous injections of atacicept 150 mg versus placebo on impact of renal function as measured by proteinuria and eGFR. The primary endpoint is change from baseline in UPCR at 36 weeks based on 24-hour urine collection and the key secondary endpoint is eGFR up to 104 weeks. Additional secondary endpoints are change in Gd-IgA1, change in eGFR up to 52 weeks, and time from randomization to first occurrence of composite kidney failure endpoint event.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">With the ongoing data from the Phase 2b trial expected through 2024 and Phase 3 topline results expected in the first half of 2025, if positive, we expect to submit a BLA for atacicept in IgAN to the FDA in the second half of 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept in LN: A severe renal manifestation of SLE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on discussions with the FDA following the review of Phase 2 data in SLE, we have designed a Phase 3 clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that there will be approximately 120,000 LN patients in the United States, 70,000 in Europe, and 21,000 in Japan, at estimated peak year of sales. Significant unmet need for improved efficacy persists for these patients despite the recent approval of the first two LN-specific therapies. Fewer than half of patients treated for LN have a complete response to therapy, and among patients without a complete response, over half will have non-functioning kidneys within five years. Benlysta (belimumab), a BAFF-only inhibitor, is one of the two therapies approved for patients with LN. Both BAFF and APRIL levels are increased in patients with SLE, suggesting that dual inhibition by atacicept may be more potent than blocking BAFF alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously initiated a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the APRIL-LN trial, aimed to evaluate the efficacy and safety of atacicept at 150 mg twice weekly for four weeks&#8212;then weekly&#8212;in patients with active LN. However, this trial was terminated early due to three participants developing hypogammaglobulinemia with induction therapy (MMF and CS) which continued to worsen when initiating atacicept and subsequently two participants developed pneumonia. In prior Phase 2 clinical trials of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint of improved SLE responder index 4 (SRI-4) at week 24, in the broader SLE study population, atacicept achieved positive clinical data on multiple measures within the prespecified HDA patient segment, including reduction of renal flares, which we believe supports atacicept&#8217;s applicability in LN. Because both preclinical and clinical evidence suggests atacicept&#8217;s dual inhibition of BAFF and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone, we believe there is a strong rationale to conduct a clinical trial of atacicept in LN.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pathophysiology of LN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LN is a severe renal manifestation of SLE (also referred to as lupus). SLE is a chronic and disabling autoimmune disease in which the body&#8217;s own immune system attacks itself. SLE predominantly affects women and is more prevalent in women of color. When LN is diagnosed in a patient, mortality risk dramatically increases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LN pathogenesis involves a variety of disease-causing mechanisms, including the formation of immune deposits within the kidneys that are primarily due to anti-double stranded DNA (anti-dsDNA) antibodies, which atacicept has been shown to reduce in a dose-dependent manner. However, there are also instances in which induction of LN by anti-dsDNA may not require immune complex formation&#8212; autoreactive plasma cells in the kidney may be another cause of nephritis. Certain genes and genetic factors may also predispose patients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LN disease burden and diagnosis</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LN has a strong influence on morbidity and mortality within SLE, with up to 26% of patients progressing to ESRD within 15 to 20 years from initial diagnosis. LN is characterized by abnormal proteinuria, hematuria, and impaired kidney function.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diagnosed SLE patients are routinely monitored by rheumatologists, who will refer to nephrologists upon suspicion of renal manifestations. In the United States and Europe, LN patients without a prior SLE diagnosis will typically first present to a primary care physician (U.S.) or internist (EU) with hematuria or proteinuria before ultimate referral to a nephrologist. For confirmatory diagnosis, nephrologists perform renal biopsy&#8212;of which the results are analyzed to determine histologic class and relevant treatment course.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">LN patients are segmented in Classes I&#8211;VI based on histopathology and degree of renal impairment, and this classification drives treatment decisions. Class I, or Minimal mesangial LN, is rarely diagnosed as these patients have normal urinalysis and therefore biopsy is not typically performed. Class II, Mesangial proliferative LN, refers to microscopic hematuria and/or proteinuria. Patients with Class III, or Focal LN, tend to have both hematuria and proteinuria, and may have hypertension, decreased eGFR, and nephrotic syndrome. Class IV, or Diffuse LN, is the most commonly diagnosed and severe form of LN, with patients exhibiting hematuria, proteinuria, nephrotic syndrome, hypertension, and decreased eGFR. Patients with Class V, or lupus membranous nephropathy, tend to have nephrotic syndrome, and may have microscopic hematuria and hypertension, but normal UPCR. Class VI, or advanced sclerosing LN, refers to a slow progression of kidney dysfunction correlated with proteinuria.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As shown in Figure 11 below, LN typically develops early in the disease course, though the rate of SLE patients who develop LN increases over time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 11: LN progression</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_10.jpg" alt="img76291469_10.jpg" style="width:576px;height:146px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">LN market opportunity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">According to the Centers for Disease Control and Prevention, there are approximately 322,000 people living with SLE in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approximately half of individuals living with SLE develop LN within 15 years of their initial diagnosis, as shown in Figure 11 above.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate that there will be approximately 120,000 LN patients in the United States, 70,000 in Europe, and 21,000 in Japan, at estimated peak year of sales. In the United States, higher prevalence rates occur in the heterogeneous population, as both SLE and LN occur more frequently among non-White patients&#8212;with the highest frequency of LN occurring in Black and Hispanic populations after adjustment for socioeconomic factors. In all three geographies, women account for the majority of LN cases.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on primary market research with physicians and payors and extensive secondary research, we estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0 billion, $600 million and $200 million in United States, Europe and Japan, respectively.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current standard of care for LN patients</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Current LN treatment is largely cyclical, with induction versus maintenance therapy dictated by the severity of disease and frequency of flares. Treatment is driven by histologic class and can be influenced by the treatments that the patient has been on since SLE diagnosis. Class I and II LN do not generally need LN-specific treatment. Within Class III&#8211;V, patients tend to receive induction therapy for approximately one year to achieve complete or partial remission. Induction therapy for Class III&#8211;IV patients include several immunosuppressive agents, such as MMF &#177; CS or cyclophosphamide (CYC) &#177; CS in the first line of treatment, switching to either CYC or MMF in the second line, whichever was not administered first line. Third line induction therapy has generally consisted of rituximab for Class III&#8211;V patients. For induction therapy of Class V LN patients, patients typically receive MMF &#177; steroids in the first line, a calcineurin inhibitor in the second line, and rituximab for third line. Maintenance therapy, which typically consists of MMF, azathioprine (AZA), or hydroxychloroquine (HCQ), is typically prescribed to well controlled patients after any line of induction to reduce flares. Immunosuppressive therapy is unlikely to be beneficial for Class VI, or advanced sclerosing LN.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients on maintenance still experience flares approximately every year, resulting in cycling back to induction therapy. Many of the therapies used in the treatment paradigm today have limited efficacy and poor tolerability profiles&#8212;and therefore there is significant unmet need for safe and specific therapies that have a direct impact on LN disease activity without a high risk of infection.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently approved and emerging therapies in development</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until relatively recently, there were no approved therapies for the treatment of LN. In December 2020, the FDA approved Benlysta (belimumab), an anti-BAFF antibody, for treatment of adult patients with active LN who are receiving standard therapy. In January 2021, the FDA approved Lupkynis (voclosporin), a calcineurin inhibitor, to be used in combination with a background immunosuppressive therapy regimen for adult patients with active LN. Clinical guidelines on how these two medicines may be incorporated into standard of care remain to be updated. In addition to Benlysta (belimumab) and Lupkynis (voclosporin), there are several other cytokine inhibitors and complement inhibitors in development for LN.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">B cell Modulators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Benlysta (belimumab) is an anti-BAFF antibody, belonging to the class of B cell modulators. Within the B cell modulator class, there is a desire for different mechanisms to target the complex pathophysiology of LN. The results shared to date for these agents reveal statistically significant efficacy, but complete response rates are only achieved in fewer than 50% of the patients studied. Other B cell modulatory approaches under late-stage investigation include blocking the BAFF receptor and binding CD20.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Calcineurin Inhibition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Lupkynis (voclosporin) is a calcineurin inhibitor, a mechanism which has been commonly used in generic form as induction therapy for Class V patients. Calcineurin inhibition has been shown to reduce cytokine activation of T-cells and protect against proteinuria, however it may pose serious infection risks and nephrotoxicity is a known class effect.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cytokine Inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The other cytokine inhibitors under investigation offer blockade of key pro-inflammatory cytokines (Type 1 IFNs, IL17A, IL23) involved in the pathogenesis of LN.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Complement Pathway Inhibitors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Complement pathway inhibitors are also early in their development, but unlikely to be disease-modifying, since complement activation is one result of the inflammation caused by immune-complex deposition in the kidneys, downstream of key steps in disease pathophysiology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our solution: Atacicept</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Targeting both BAFF and APRIL is key to reduce autoantibodies produced by B cells and plasma cells in LN. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Autoantibodies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">play a large role in the pathogenesis of LN. Autoantibodies target tissue or form immune complexes, leading to tissue and organ damage. Both short-lived and long-lived plasma cells are responsible for generating high levels of autoantibodies in LN.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-lived plasma blasts are the main B cell effector subset dependent on activation of various B cell receptors such as TACI, B cell maturation agent (BCMA) and BAFF. Therefore, B cell blocking agents such as Rituxan (rituximab; anti-CD20) and Benlysta (belimumab; anti-BAFF) can reduce short-lived plasma cells and the resulting autoantibody production.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Long-lived plasma cells are in bone marrow and inflammatory tissue niches, and form antibodies in the absence of B cell activation. Inflammatory tissue has high levels of BAFF and APRIL, which serve to maintain long-lived plasma cells. Inhibiting APRIL blocks long-lived nonproliferating plasma cell activities to further reduce autoantibody formations in LN.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept contains the soluble TACI receptor that binds to the cytokines BAFF and APRIL and prevents their interaction with TACI, BCMA and BAFF receptors (BAFF-R is also known as B cell activating factor receptor or BAFF-R). Atacicept thus inhibits survival of immature and mature B cells and antibody-producing plasma cells and prevents immunoglobulin class switching. In contrast to a range of available biologics directed at B cells only, we believe atacicept has a prompt and marked effect on antibody production by inhibiting both short-lived and long-lived plasma cells.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical evidence indicates that dual inhibition of BAFF and APRIL is superior to either BAFF or APRIL alone. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Animal models</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of kidney disease have confirmed that atacicept reduces plasma cell numbers and reduces autoantibodies more effectively than BAFF and APRIL antibodies given individually. In a mouse model of collagen-induced arthritis, soluble atacicept inhibited development of collagen-specific antibodies and reduced the incidence of the disease better than BAFF agents alone. In a mouse model of SLE, soluble atacicept decreased the number of B cells, increased survival time and reduced severity of disease symptoms. Furthermore, in a mouse model of SLE, atacicept administered after onset of autoimmunity decreased the number of bone marrow plasma cells and slowed down further formation of autoantibodies. Atacicept prevented renal damage during a 12-week treatment period regardless of autoantibody levels, while the BAFF-only inhibitor did not. Atacicept also decreased established plasma cells in an immunization model better than single inhibitors of BAFF or APRIL.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In patients with active SLE, targeting BAFF and APRIL with atacicept appears to have improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to BAFF alone (Benlysta (belimumab)). While atacicept and Benlysta (belimumab) have not been studied head-to-head in clinical trials, each has been studied in similar populations of patients with SLE, and results of a Phase 2 clinical trial of 150 mg of atacicept compared favorably to published reports on changes in SLE responder index (SRI-4) of belimumab. In a Phase 2 clinical trial of atacicept, the magnitude of efficacy as measured by the difference between treatment and placebo in SRI-4 at 24 weeks was approximately 39% (25% placebo, 64% atacicept 75 mg, 65% atacicept 150 mg, both p=0.005). For Benlysta (belimumab), in a Phase 3 clinical trial of SLE patients, a published analysis of participants with HDA and serologically active disease, clinical efficacy for Benlysta (belimumab) 10 mg/kg showed a difference between treatment and placebo in SRI-4 at 24 weeks of approximately 12%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 12: Evidence for atacicept performance in SLE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_11.jpg" alt="img76291469_11.jpg" style="width:693px;height:323px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept consistently demonstrated improved clinical outcomes, measured by endpoints designed to assess efficacy, versus placebo in SLE patients with HDA (SLEDAI-2K &#8805;10) across additional clinical measures, and consistently across all SRI cut-offs, as well as using the separate clinical assessment, British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA). In the HDA population in ADDRESS II, the BICLA delta at week 24 was 20% (atacicept 150 mg 49%, placebo 29.2%, p=0.035), which compares very favorably to BICLA data from other late-stage SLE clinical trials, such as anifrolumab (week 24 BICLA in 16%). We believe that based on these results, an improved clinical benefit may be observed in patients with LN.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Prior clinical development of atacicept in LN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Merck KGaA, Darmstadt, Germany conducted a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the APRIL-LN trial, aimed to evaluate the efficacy and safety of atacicept in patients with active LN. As per trial protocol, participants initiated high-dose CS (the lesser of 0.8 mg/kg/day or 60 mg/day prednisone) and MMF (1 g daily, increased by 1 g/day each week to 3 g daily) at the time of screening (day -14). From day 1, atacicept (150 mg, subcutaneously, twice weekly for four weeks, then weekly) was initiated with MMF along with a tapered dose of CS.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Four of the six enrolled LN patients developed decreases in serum IgG levels following the initiation of MMF and CS in the setting of significant proteinuria, which are contributing factors of hypogammaglobulinemia. After initiation of atacicept, serum IgG levels further declined; two participants developed severe hypogammaglobulinemia, defined as IgG &lt;3 g/L, and pneumonia. These two participants recovered after treatment discontinuation and received antibiotics therapy. This trial was terminated. Based on the detailed assessment of results from this trial, plans to develop atacicept for the treatment of LN will explore alternatives to the induction regimen studied previously, including not dosing atacicept 150 mg twice weekly; clearly defining the dosing regimen for CS and MMF; and closely monitoring immunoglobulin levels during induction therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of safety and efficacy profile of atacicept in SLE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept 75 mg and 150 mg, dosed once per week with subcutaneous auto-injection, have demonstrated improved clinical outcomes, measured by endpoints designed to assess efficacy, in patients with SLE in the Phase 2 APRIL-SLE and ADDRESS II trials. In these trials, autoantibody titers were significantly reduced, and prespecified and post hoc analyses revealed prevention of flare and reduction of active disease with atacicept treatment, despite the fact that the primary endpoints in these trials were not met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In ADDRESS II, SLE patients with HDA (SLEDAI-2K &#8805;10) had an increase in SRI-6 response, attainment of low disease activity (LDA), or SLEDAI-2K &#8804;2, and a reduction of the risk of a first new severe flare (defined by SLEDAI Flare Index [SFI] or by BILAG A) when treated with atacicept 150 mg. Furthermore, the 024 long-term extension (LTE) trial showed durability of these effects through a median duration of treatment of 96 weeks.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following the release of the HDA data, Merck KGaA, Darmstadt, Germany pursued the planning and initiation of a global Phase 3 registrational program for atacicept 150 mg once per week in SLE. This program, including two large Phase 3 randomized placebo-controlled trials of atacicept 150 mg compared to placebo, were reviewed by FDA via end-of-phase-2 communication and scientific advice communication with EMA, prior to Merck KGaA, Darmstadt, Germany terminating the SLE program and the IgAN program for business strategy reasons.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2 clinical trial in patients with SLE for 24 weeks</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ADDRESS II, a Phase 2b SLE trial of 306 participants, evaluated the efficacy and safety of atacicept at two subcutaneous doses (150 mg and 75 mg) versus placebo over the course of 24 weeks, with an LTE arm continuing an additional 96 weeks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept demonstrated consistent reductions in IgG, IgA, and IgM serum levels, and reductions in anti-dsDNA antibodies, as well as improvements in serum C3 and C4 levels, as shown in Figure 13 below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 13: Atacicept impact on key biomarkers in the phase 2 ADDRESS II trial</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_12.jpg" alt="img76291469_12.jpg" style="width:730px;height:328px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Though atacicept missed its primary endpoint of SRI-6 reduction versus placebo in all comers, in a prespecified analysis of HDA patients, which comprised approximately half of those enrolled, atacicept 150 mg showed improved clinical outcomes, measured by multiple endpoints designed to assess efficacy, including a 26% improvement (p=0.005) in SRI-6 versus placebo, flare risk reduction, and serologic marker normalization. SRI-6 response is defined as &#8805;6-point reduction in the SELENA-SLEDAI score, no new BILAG A organ domain score or two new BILAG B organ domain scores, and no worsening (&lt;0.30-point increase) in Physician&#8217;s Global Assessment score. Also, among this HDA patient segment, significantly more participants on the atacicept 150 mg arm reached LDA, as measured by SLEDAI-2K &#8804;2, as shown in Figure 14 below.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 14: SRI-6 response and LDA attainment among HDA patients in the phase 2 ADDRESS II trial</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_13.jpg" alt="img76291469_13.jpg" style="width:672px;height:203px;"/>&#160;</p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, Figure 15 below demonstrates the durable clinical outcomes observed in the HDA segment: more participants reached LDA by multiple measures at both week 24 and week 48. Significantly more participants treated with atacicept 150 mg once weekly versus placebo demonstrated clinical improvement (as shown by SRI-6), achieved LDA, and remission.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 15: Durable clinical outcomes observed in HDA patients in the phase 2 ADDRESS II trial</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_14.jpg" alt="img76291469_14.jpg" style="width:672px;height:459px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that the clinical outcomes, measured by multiple endpoints designed to assess efficacy within the HDA segment of the SLE population in the ADDRESS II trial&#8212;and a favorable tolerability profile observed in ADDRESS II, as well as the integrated safety analysis in over 1,500 participants&#8212;provide the foundation of our rationale for developing atacicept further in LN, a severe renal manifestation of SLE.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 3 clinical trial design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our currently designed Phase 3, randomized, parallel-group, double-blind, placebo-controlled, multicenter, multinational study will evaluate the efficacy and safety of atacicept vs placebo in patients with LN. The clinical trial consists of a 104-week double blind treatment period, followed by a 52-week open label treatment period and a 26-week safety follow-up period. The trial, as shown in Figure 16 below, will assess atacicept 150 mg once weekly subcutaneous injections versus placebo. The primary endpoint is complete renal response at 52 weeks.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 16: Phase 3 clinical trial design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_15.jpg" alt="img76291469_15.jpg" style="width:726px;height:161px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAU868 in reactivated BK infection among kidney transplant recipients</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have exclusive worldwide rights, pursuant to the Novartis license, to MAU868, which is a potential treatment for reactivated BK infection in kidney transplant recipients. While up to 90% of healthy adults have been infected with BKV at some point in their lives, it remains latent in everyone except severely immunocompromised populations such as kidney transplant recipients. There are approximately 80,000 kidney transplants annually worldwide, with approximately 20,000 in the United States. Approximately 225,000 kidney allograft recipients are living in the United States. Waitlists to receive kidneys are long: approximately 3&#8211;5 years and 75,000 people long in the United States. Up to 12% of transplants per year are re-transplants, which further limits organ availability for new patients. BKV is a polyoma virus that is tropic to the kidney and bladder tissue and can reactivate with the immunosuppression required for kidney transplant. This reactivation can cause BKVN, a condition in which BK infection, typically first identified as BK viremia, triggers inflammation, which then progresses to renal fibrosis and tubular injury; as shown in Figure 17, BKVN is a leading cause of allograft loss, a devastating outcome for kidney transplant recipients.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 17: Graft survival (%) in kidney transplant patients is worse with BKVN</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_16.jpg" alt="img76291469_16.jpg" style="width:384px;height:223px;"/>&#160;</p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, there are no approved treatment options for BK viremia or BKVN. We shared full Cohort 1 and Cohort 2 results in 2022 from the Phase 2 trial conducted by Amplyx. Following feedback from the FDA on the Phase 2 clinical trial, we are evaluating strategies for continued clinical development, including a potential next clinical trial. We believe that MAU868 has the potential to become standard of care for the treatment of BK viremia in order to prevent devastating consequences such as BKVN.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pathophysiology of BK virus in kidney transplant</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BKV has a worldwide seroprevalence of up to 90%. Primary BK infection is typically acquired during childhood, after which the virus establishes lifelong infection in the kidney and bladder tissue. Most people do not experience any known adverse effects from either primary or persistent infection. Control of infection is dependent on CD4+ and CD8+ T cell immunity, which can be displaced by immunosuppressants. In the setting of kidney transplant and related immunosuppression, latent virus can be reactivated or new virus can be transmitted via the donor kidney. BKV reactivation is marked first by viruria&#8212;or detection of virus in the urine, and then viremia&#8212;detection of viral DNA in the blood, and most commonly occurs within the first year of transplant.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Viremia typically occurs in 15% of kidney transplant recipients, after which BKVN may occur. Approximately 3-4% of kidney transplant recipients develop BKVN.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BKVN disease burden and diagnosis</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BKVN may lead to allograft injury and in some cases, allograft loss. Up to 24&#8211;60% of all graft losses are due to BKV-associated disease. The average cost of a kidney transplant in the United States is over $440,000. Pre-transplant, recipients are typically on dialysis, for which the cost is approximately $90,000 per year; there is an approximate 450% increase in annual medical cost to treat transplant recipients who experience graft loss.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Most institutions monitor for BK in both the urine, through PCR and urinalysis, and plasma, via PCR. It is common practice to screen kidney transplant recipients for BK viremia via PCR test monthly in the first six months post-transplant and then every three months until two years post-transplant, after which patients are typically screened annually. Also, at any sign of allograft dysfunction, physicians will test for BK viremia. Viral load levels &gt;1000 copies/mL are considered positive for BK viremia, and levels &gt;10,000 copies/mL are considered presumptive BKVN. Kidney allograft biopsy is considered the gold standard for diagnosing BKVN. Late diagnosis of BKV can lead to irreversible renal function decline and poor treatment outcomes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Kidney transplant market opportunity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An estimated 80,000 kidney transplants are conducted globally each year, with approximately 20,000 in the United States, 20,000 in Europe, 1,500 in Japan, and 10,000 in China. Approximately 225,000 kidney allograft recipients are living in the United States. Waitlists to receive kidneys are long: 3&#8211;5 years and 75,000 people deep in the United States. Up to 12% of transplants per year are re-transplants, which further limits organ availability for new patients. Approximately 15% of kidney transplant recipients develop BK viremia. Patients can be risk stratified for BK viremia based on the degree of immunosuppression employed, which is related to the degree of human leukocyte antigen (HLA) match between the graft and recipient; the greater the mismatch, the more intense immunosuppression required, which increases the risk of BKV reactivation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate the market for a novel agent to treat reactivated BK infection in kidney transplant recipients to be a large commercial opportunity. We believe that MAU868 has the potential to become standard of care for the treatment of reactivated BK infection in order to prevent devastating consequences following kidney transplantation such as BKVN and graft loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current standard of care for kidney transplant patients with BK viremia</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Currently, there is no approved treatment specific to BKV. Upon detection of BK viremia, physicians&#8217; first line of defense is to reduce immunosuppression with the goal of restoring CD4+ and CD8+ T cell immunity without causing acute rejection. Initial modification will typically consist of lowering MMF by 50% followed by a reduction in tacrolimus by 50%. If no improvement is observed, use of MMF and tacrolimus will be stopped and dose of prednisone will be increased. Other agents such as intravenous immunoglobulin (IVIG), leflunomide, and cidofovir, are occasionally used&#8212;but all have limited data and both leflunomide and cidofovir have serious safety concerns. After development of BKVN, patients have limited options and may continue to receive antivirals or IVIG. Physicians are not satisfied with current treatment options for BKV and highlight that there is a significant unmet need for a viable therapy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Emerging therapies in development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the high level of unmet need in treating BK viremia and preventing devastating consequences, there is limited development in the space. Allovir&#8217;s posoleucel (formerly known as ALVR-105 and Viralym-M), a multi-virus specific T-cell therapy, has paused in its development following a Phase 2 clinical trial. While this approach may have the potential to treat BKV and other opportunistic infections, logistics and distribution are likely to render this approach less feasible than a monoclonal antibody, for instance. Therefore, posoleucel may be reserved for second line of therapy and/or treatment of presumptive BKVN rather than BK viremia. Memo Therapeutics is also developing a BKV neutralizing monoclonal antibody, though limited supporting data is available.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our solution: MAU868 / scientific rationale</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAU868 is a human monoclonal antibody (IgG1/l isotype subclass) directed against the major viral capsid protein of BKV, VP1, which is essential for binding to and infection of new cells, as shown in Figure 18. MAU868 neutralizes all four serotypes of BKV at sub-nanomolar concentrations and has a high barrier to resistance in vitro (resistant isolates of BKV were not selected in vitro at any of the concentrations of MAU868 investigated). MAU868 is being developed for the treatment of BKV disease in kidney transplant recipients (BKV nephropathy) and being considered for hematopoietic stem cell transplant (HSCT) recipients (BKV-associated hemorrhagic cystitis). MAU868 also has neutralizing activity in vitro against the closely related JC virus, the cause of progressive multifocal leukoencephalopathy.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 18: MAU868 blocks BK virion binding</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_17.jpg" alt="img76291469_17.jpg" style="width:627px;height:497px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development of MAU868</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 1</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A first-in-human, randomized, blinded, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics of MAU868 following IV or SC administration to healthy adult subjects was performed. Administration of up to 100 mg/kg MAU868 IV and 3 mg/kg MAU868 SC were well tolerated. No deaths or serious adverse events were reported, and there were no adverse events that led to the discontinuation of the drug or the study.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Phase 2</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We completed a Phase 2 randomized, double-blind, placebo-controlled clinical trial designed to assess the safety, tolerability, and efficacy of MAU868 for the treatment of allograft-threatening BKV infection in kidney (or kidney-pancreas) transplant recipients in 2022. Two sequential cohorts enrolled a total of 28 participants with BK viremia. As shown in Figure 19, each cohort was designed to randomize approximately 12 participants (8 to MAU868 and 4 to placebo), for which Cohort 1 (1350 mg IV approximately every 28 days for a total of 4 doses) and Cohort 2 (6750 mg IV on Day 1, 1350 mg IV every 28 days for 3 additional doses) have completed dosing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The primary objective of the clinical trial was to assess the safety and tolerability of MAU868, with secondary objectives to assess the impact of MAU868 on BKV related outcomes. MAU868 has been shown in an interim analysis of week 12 data from Cohorts 1 and 2 to be well-tolerated and showed a greater proportion of participants with decrease in BK plasma viral load versus placebo.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At ASN 2022, final results from the Phase 2 clinical trial of MAU868 versus placebo showed that MAU868 was well tolerated and demonstrated clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Figure 19: MAU868 phase 2 clinical trial design</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img76291469_18.jpg" alt="img76291469_18.jpg" style="width:731px;height:155px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future clinical trials</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following feedback from the FDA on the Phase 2 clinical trial, we are evaluating strategies for continued development, including a potential next clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exclusive license agreement with Ares Trading S.A.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 29, 2020, we entered into the Ares Agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, pursuant to which Ares granted us an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept or any other compound that is covered by a claim of such licensed patents. Pursuant to the Ares Agreement, Ares also transferred inventory of licensed product to us for use in our clinical development of atacicept.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Per the Ares Agreement, we have obligations to use commercially reasonable efforts to develop at least one licensed product, to launch at least one licensed product in a major market country within a specified time frame after receiving marketing approval for such product and to maintain sufficient resources to manufacture and supply licensed products to meet the market demand in each country for which a licensed product has received marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration for the rights granted under the Ares Agreement, we issued 22,171,553 shares of our Series C redeemable convertible preferred stock to Ares at the time of the initial closing of our Series C redeemable convertible preferred stock financing in October 2020, representing ownership of approximately 10% on a fully diluted basis. As additional consideration under the Ares Agreement, we paid Ares $25.0 million upon delivery and initiation of the transfer of specified information and supply of drug product and drug substance and we are required to pay Ares aggregate milestone payments of up to $ 176.5 million upon the achievement of specified BLA filing or regulatory approvals in the United States, Europe and Japan (the first of which consists of a $15.0 million payment upon filing of the BLA), and aggregate milestone payments of up to $515.0 million upon the achievement of specified commercial milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay tiered royalties of low double-digit to mid-teen percentages on annual net sales of the products covered by the license. Our obligation to pay royalties will expire on a licensed product-by-licensed product and country-by-country basis until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii) the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii) expiration of all applicable regulatory exclusivity periods in such country with respect to such licensed product. In the event we sublicense our rights under the Ares Agreement, we are obligated to pay Ares a percentage ranging from the mid single-digit to the low double-digits of specified sublicensing income received.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the Ares Agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the expiration of our obligation to pay royalties to Ares with respect to such licensed product in such country. We have the right to terminate the Ares Agreement at will upon a specified notice period, provided that such termination is not within two years of the effective date of the Ares Agreement. Ares has the right to terminate the Ares Agreement in the event we challenge the validity of the licensed patents. Additionally, either party can terminate the Ares Agreement for the other party&#8217;s uncured material breach or bankruptcy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Asset purchase agreement with Amplyx and exclusive license with Novartis</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 16, 2021, we entered into an asset purchase agreement (the Amplyx Agreement) with Amplyx, a wholly-owned subsidiary of Pfizer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Amplyx Agreement, we acquired all of Amplyx&#8217;s right, title and interest in and to certain assets of Amplyx related to MAU868, a monoclonal antibody that was under development by Amplyx for the treatment of BKV infections (the Purchased Assets). The Purchased Assets include an investigational new drug application filed with the U.S. Food and Drug Administration, patents, contracts, including the Novartis License, chemical and biological materials, and development and regulatory files, documentation, data, results and other electronic records related to MAU868. We also assumed certain liabilities of Amplyx arising out of the Purchased Assets. We and Amplyx have made customary representations and warranties and agreed to customary</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">covenants in the Amplyx Agreement. Subject to certain limitations, each of we and Amplyx has also agreed to indemnify the other for breaches of representations and warranties and other specified matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In partial consideration for the Asset Acquisition, we made an upfront initial payment of $5.0 million to Amplyx. In addition, we are also obligated to make certain milestone payments to Amplyx in an aggregate amount of up to $7.0 million based on certain regulatory milestones. Further, we are required to pay Amplyx low single digit percentage royalties based on net sales on a country-by-country and product-by-product basis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAU868 is subject to the Novartis License, which was assigned to us by Amplyx. Pursuant to the terms of the Novartis License, we obtained a worldwide, exclusive license from Novartis to develop, manufacture and commercialize MAU868, subject to certain retained rights for research and development by Novartis, provided that Novartis may not develop or sell products incorporating monoclonal antibody targeting BKV and treating BKV disease within a certain period. We will be solely responsible for all research, development, regulatory, manufacturing and commercialization activities of MAU868. Pursuant to the Novartis License, we are obligated to make certain milestone payments to Novartis in an aggregate amount of up to $69.0 million based on certain clinical development, regulatory and sales milestones. Further, we are required to pay Novartis mid- to high-single digit percentage royalties based on net sales on a country-by-country and product-by-product basis. Unless terminated earlier, the Novartis License will remain in effect with respect to each MAU868 product until the expiration of the royalty term for such product. We may terminate the Novartis License for convenience with 60 days&#8217; prior written notice. We or Novartis may terminate the Novartis License for the other party&#8217;s uncured material breach. Novartis may terminate the Novartis License for our insolvency. Upon termination, any license granted by Novartis to us will terminate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part upon our ability to protect our core technology and intellectual property. To protect our intellectual property rights, we rely on patents, trademarks, copyrights and trade secret laws, confidentiality procedures, and employee disclosure and invention assignment agreements. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States and internationally for our product candidate, and other inventions that are important to our business. For our product candidates, we generally intend to pursue patent protection covering compositions of matter, including new formulations, methods of making and methods of use. As we continue the development of our product candidates, we intend to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through claims covering additional methods of use.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we have licensed, including pursuant to sublicenses, from Ares, an affiliate of Merck KGaA, Darmstadt, Germany, a patent portfolio related to atacicept that contains approximately six issued U.S. patents, as well as certain foreign counterparts of a subset of these patents in foreign countries, including Australia, Brazil, Canada, China, Hong Kong, Israel, India, Japan, Mexico, Singapore, South Korea, South Africa, and countries within the European Patent Convention and the Eurasian Patent Organization. The issued patents include claims covering methods of purifying atacicept, formulations and various methods of treatment, and are expected to expire between 2027 and 2029, without considering any patent term extension.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is also a pending U.S. application as well as certain foreign counterparts directed to treatment of IgAN and proteinuria. The 20-year expiration date for patents that issue in this family is expected to be in 2041.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because atacicept is a biologic, marketing approval would also provide 12 years of market exclusivity from the approval date of a BLA in the United States. We are currently seeking orphan drug designation for atacicept in IgAN from the FDA and EMA, which, if secured, would provide seven and ten years, in the United States and European Union, respectively, of regulatory exclusivity protection from the approval date.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our patent portfolio licensed from Novartis and covering MAU868 includes three issued U.S. patents with claims covering the composition of matter of MAU868, and methods of neutralizing BKV or JC virus as well as methods of treating or reducing the likelihood of BKV or JC virus associated disorders. Corresponding foreign counterparts are granted in countries within the European Patent Convention, Australia, China, Japan, India, Israel, Mexico, Macau and Taiwan, and pending in Canada. The 20-year expiration date for patents in this family is in 2036.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, an application co-owned with and licensed from Novartis that is directed to dosing regimens for MAU868 is pending as a U.S. application as well as certain foreign counterparts. The 20-year expiration date for patents in this family is in 2041.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patents, we may rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how can be difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-solicitation, confidentiality, and invention assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">guarantee, however, that we have executed such agreements with all applicable counterparties, such agreements will not be breached, or that these agreements will afford us adequate protection of our intellectual property and proprietary rights. For more information, see &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, we seek trademark protection in the United States and internationally where available and when we deem appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing and supply</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We manage a number of external CMOs to develop and manufacture our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept is a fully humanized fusion protein that impacts the B cell pathway, which has well characterized implications in immunologic diseases. The human IgG1-Fc was modified to reduce the Fc binding to the C1q component of complement and the interaction with Fc receptors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Atacicept is manufactured following cGMPs using a process that is similar to that used routinely for production of monoclonal antibodies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The atacicept drug product is available as a ready-to-use injection solution in a prefilled syringe (PFS) at strengths of 25 mg/mL, 75 mg/mL, or 150 mg/mL of trial drug. Each atacicept PFS is designed to deliver a 1 mL solution of drug product. All formulation components are pharmacopeia grade. An atacicept prefilled syringe/autoinjector combination is in late-stage development and will be introduced into future clinical trials when appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Ares Agreement includes the transfer of all existing inventory of atacicept drug substance and drug product, for our use in planned and future clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We acquired approximately 35,000 PFS of atacicept, representing all three strengths, 25 mg, 75 mg and 150 mg, of atacicept and approximately 25,000 PFS of placebo, as part of the Ares Agreement. This drug product was used to initiate the Phase 2b ORIGIN trial. Additionally, we acquired 6 kg of atacicept drug substance which has subsequently been converted into drug product to supply both the ongoing Phase 2b ORIGIN trial and to support our future clinical trials through the first quarter of 2026.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MAU868 is an IgG1 monoclonal antibody that binds to BKV protein VP1. It is manufactured according to cGMP using a high expression CHO cell and a standard antibody manufacturing process that is completely free from animal or human derived raw materials. The MAU868 manufacturing supply chain is fully established using contract manufacturing organizations with contracts that are assignable to Vera Therapeutics</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fully formulated MAU868 drug product is provided as a 3 mL fill in a 6 mL vial which can be combined with multiple vials to prepare infusions at different dosage strengths for use in clinical trials. The drug product formulation is composed of MAU868 as the active substance, a buffering agent, and both a sugar and a surfactant as stabilizing agents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Amplyx Agreement includes the transfer of all existing inventory and work-in-process of MAU868 drug product for use in clinical trials. This includes 2,777 unlabeled vials and work-in-process expected to yield approximately 5,300 vials with release targeted for March 2022. These materials will support both the completion of the ongoing Phase 2 clinical trial and initiation of a future clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commercialization plans</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate the market opportunity for novel therapeutics in IgAN to be approximately 157,000 patients in the United States, 136,000 patients in Europe and 130,000 in Japan, at estimated peak year of sales, based on our assumptions, secondary research, and primary market research with physicians and payors. In order to capitalize on this opportunity, we plan to build a specialty commercial infrastructure focused on IgAN, engaging treating physicians, including nephrologists, educating and engaging patients, and ensuring market access for patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For novel therapeutics in LN, we estimate the market opportunity will be approximately 120,000 LN patients in the United States, 70,000 in Europe, and 21,000 in Japan, at estimated peak year of sales. If we receive regulatory approval for atacicept in both IgAN and LN, we plan to assess call point overlap for the two indications and selectively build out our future commercial infrastructure to address any gaps to optimize our coverage of LN treating physicians. We also plan to build out LN-specific patient and market access programs, leveraging synergies where possible.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through the Ares Agreement, we were granted worldwide rights to the development and commercialization of atacicept in all indications. We intend to commercialize atacicept ourselves in the United States and other key markets, if approved. Within certain ex-U.S. markets, we may consider strategic collaborations to facilitate commercialization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MAU868</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to develop MAU868 for the treatment of BK viremia in kidney transplant as an initial indication, which we believe has strong potential commercial synergies with our plans for atacicept. We believe that the prescribing physicians for MAU868 in renal transplant, if approved, will be a subset of the IgAN treating physicians, and plan to conduct an assessment of call point overlap. The launch of this indication, if prior to the atacicept launch, would require a smaller specialty commercial infrastructure build focused on educating and engaging treating physicians, including transplant nephrologists, partnering with kidney transplant organizations, and ensuring market access for patients. If prior to the atacicept launch, we would plan to leverage this infrastructure for eventual atacicept sales and marketing activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Through the Amplyx Agreement, we obtained worldwide rights to the development and commercialization of MAU868 in all indications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similar to our plans with atacicept, we intend to commercialize MAU868 ourselves in the United States and other key markets, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also may consider strategic collaborations to facilitate commercialization in certain ex-U.S. markets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. This is also true for the development and commercialization of treatments for immunologic diseases. Though we believe that our focus, experienced team, scientific knowledge, and intellectual property provide us with competitive advantages, we face competition from a number of sources, including large and small biopharmaceutical companies, universities, and other research institutions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. Many of our competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidates or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept in IgAN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite a high level of morbidity for IgAN, the current standard of care consists of off-label use of RAAS inhibitors, including ACE inhibitors and ARBs, and potentially steroids. Atacicept, if and when approved and successfully commercialized, may compete with these existing approaches and with any new therapies that may become available in the future. SGLT2 inhibitors, including AstraZeneca plc&#8217;s (AstraZeneca) Farxiga, which is approved for chronic kidney disease, are becoming the standard-of-care in some geographies including the United States. Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the reformulated steroid from Calliditas Therapeutics AB, and endothelin and angiotensin II receptor antagonist from Travere Therapeutics, Inc.; programs in Phase 3 clinical development: Otsuka Pharmaceutical Co., Ltd., Novartis, Alnylam Pharmaceuticals Inc., and Roche/Ionis; and the following companies with programs in Phase 2 of clinical development: Reata Pharmaceuticals, Inc., , AstraZeneca, HI-Bio, Inc., Eladon Pharmaceuticals, and DiaMedica Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Atacicept in LN</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In LN, prior to December 2020, there had been no approved therapies, and the standard-of-care has consisted of a number of non-specific therapies, including MMF, steroids, CYC, rituximab, calcineurin inhibitors, AZA, and HCQ, dependent on class of disease and whether a patient was cycling through the induction or maintenance phase of therapy. Paradigms are evolving with the FDA approvals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of GlaxoSmithKline plc&#8217;s Benlysta (belimumab) and Aurinia Pharmaceuticals Inc.&#8217;s Lupkynis (voclosporin), both of which we consider to be direct competitors. Our competitors include: Roche Holding AG, Novartis Pharmaceuticals Corporation, and AstraZeneca, each of which have programs in Phase 3 clinical development; and BeiGene Ltd., Janssen Pharmaceuticals, Inc., AstraZeneca, Alexion Pharmaceuticals Inc. (Alexion), Omeros Corporation, Kezar Life Science Inc., Bristol Myers Squibb, Boehringer, Amgen Inc., and Novartis Pharmaceuticals Corporation, each of which have programs in Phase 2 clinical development.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">MAU868</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are currently no anti-BKV therapies approved, either in the kidney transplant or HSCT setting. The standard of care in both settings is to reduce immunosuppression as a first line, and potentially to offer IVIG in kidney transplant recipients or antivirals with limited clinical evidence, including leflunomide and cidofovir, in either setting. There are few industry-sponsored programs in development for these indications; we consider our most direct competitors to be Allovir&#8217;s multi-virus specific T-cell therapy, posoleucel, which is currently paused after a Phase 2 clinical trial for BK viremia in kidney transplant recipients, and Memo Therapeutics AG&#8217;s AntiBKV, a neutralizing monoclonal antibody in a Phase 2/3 clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, such as our investigational medicines and any future investigational medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory approval in the United States</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (FDCA), and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post- approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of a new drug application (NDA). Biological products are approved, or licensed, for marketing under provisions of the Public Health Service Act (PHSA) via a BLA. The application process and requirements for approval of BLAs for originator biological products are similar to those for NDAs for new chemical entities, and biologics are associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United States. The process generally involves the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practices (GLP) requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the FDA of an Investigational New Drug Application (IND), which must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval of the protocol and related documents by an IRB or independent ethics committee at each clinical trial site before each clinical trial may be commenced;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well controlled human clinical trials in accordance with applicable IND regulations, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of and submission to the FDA of a BLA for marketing approval that includes sufficient evidence of establishing the safety, purity, and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">payment of any user fees for FDA review of the BLA;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with current cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, strength, quality and purity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the BLA to assure compliance with GCPs and integrity of the clinical data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with any post-approval requirements, including a REMS, where applicable, and post- approval studies required by the FDA as a condition of approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical studies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate in the United States, an IND must be submitted to the FDA and the FDA must allow the IND to proceed. An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA allowance that such investigational product may be administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment and administration. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND sponsor must also submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. Some long-term preclinical testing may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trials</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee (DSMB). This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well- designed and well-conducted foreign clinical trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product candidate, and, if possible, early evidence of effectiveness.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These Phases may overlap or be combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A single Phase 3 or Phase 2 trial with other confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally subject to the requirement of additional post-approval studies).</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, FDA may require, or firms may voluntarily pursue, post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including non-compliance with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">FDA review processes</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as part of a BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act (PDUFA), each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. The applicant under an approved BLA is also subject to an annual program fee.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review to determine if it is substantially complete before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, for its intended use, and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and potency.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA for a new molecular entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be extended by FDA requests for additional information or clarification.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before approving a BLA, the FDA will conduct a pre -approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. Additionally, the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the FDA evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter generally outlines the deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Furthermore, as a condition of BLA approval, the FDA may require a REMS to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#8217;s safe use (ETASU). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan drug designation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Orphan drug exclusivity may be lost if the FDA later determines that the request for designation was materially defective. Further, competitors may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for off-label uses, the competitor&#8217;s product could be used for the orphan indication despite another product&#8217;s orphan exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Expedited development and review programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#8217;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s BLA before the application is complete. This &#8220;rolling review&#8221; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#8217;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and taking other steps to design the clinical trials in an efficient manner.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review. Under priority review, the FDA&#8217;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. Priority review designation does not change the standard for approval or the quality of evidence necessary to support approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accelerated approval may be granted for products that are intended to treat a serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Use of the accelerated approval pathway entails submission of a BLA with the surrogate or intermediate clinical endpoint data while continuing to conduct the trial(s) to completion and is contingent on a sponsor&#8217;s agreement to complete and/or conduct additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional controls for biologics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Combination products</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A combination product is a product comprised of two or more regulated components, e.g., drug and medical device, that are physically combined and produced as a single entity, packaged together in a single package, or packaged separately but intended to be labeled for use together. Atacicept in a prefilled autoinjector would be such a combination of therapeutic and delivery device.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA is divided into various branches, or Centers, by product type. Different Centers typically review drug, biologic, or device applications. In order to review an application for a combination product, FDA must decide which Center should be responsible for the review. FDA regulations require that FDA determine the combination product&#8217;s primary mode of action (PMOA), which is the single mode of a combination product that provides the most important therapeutic action of the combination product. The Center that regulates that portion of the product that generates the PMOA becomes the lead evaluator. If there are two independent modes of action, neither of which is subordinate to the other, FDA makes a determination as to which Center to assign the product based on consistency with other combination products raising similar types of safety and effectiveness questions or to the Center with the most expertise in evaluating the most significant safety and effectiveness questions raised by the combination product. When evaluating an application, a lead Center may consult other Centers but still retain complete reviewing authority, or it may collaborate with another Center, by which the Center assigns review of a specific section of the application to another Center, delegating its review authority for that section. Typically, FDA requires a single marketing application submitted to the Center selected to be the lead evaluator, although the agency has the discretion to require separate applications to more than one Center. We believe that our prefilled autoinjector would have a biologic PMOA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Best Pharmaceuticals for Children Act (BPCA) provides a six-month extension of any exclusivity&#8212;patent or non-patent&#8212;for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new biologic in the pediatric population may produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-approval requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. Although physicians may prescribe products for off-label uses as the FDA and other regulatory authorities do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Adverse event reporting and submission of periodic safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#8217;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning or other enforcement-related letters or holds on post-approval clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. marketing exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The BPCIA created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulatory approval in the European Union</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally authorized medicinal products. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of medicines by working through a network of about 4,500 experts throughout the European Union, nominated by the Member States. The EMA draws on resources of over 40 national competent authorities of European Union Member States.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally involves satisfactorily completing each of the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory Practice regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission of a single clinical trial application (CTA) through the Clinical Trials Information System (CTIS) to the relevant national authorities of EU Member States in which a clinical trial is planned to be conducted, which must be approved by such national authorities and the subject of a positive opinion from at least one independent ethics committee before the trial may begin in each country where the clinical trial is planned;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">submission to the relevant competent authorities of a marketing authorization application (MAA) which includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">satisfactory completion of an inspection by the relevant competent national authorities of EU Member States of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical studies</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant international, E.U. and national legislation, regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical trials</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Economic Area (EEA), comprising the European Union Member States plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after a related marketing authorization (MA), has been granted. To obtain an MA for a product in the EEA, an applicant must submit a MAA under one of four procedures: the centralized authorization procedure, administer by the EMA, or one of the procedures administered by the competent authorities of EEA countries, the mutual recognition procedure, the decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized procedure, only this procedure will be described here.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The centralized procedure provides for the grant of a single MA by the European Commission that is valid throughout the EEA. Pursuant to Regulation (EC) No 726/2004, certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization procedure for marketing authorization. The centralized procedure is also mandatory for orphan medicinal products, advanced-therapy medicinal products (i.e., gene-therapy, somatic cell therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, and indicated for the treatment of other diseases, or for products that are highly innovative or for which a centralized process is in the interest of patients, authorization through the centralized procedure is optional on related approval</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (CHMP) serves as the scientific committee that renders opinions about the safety, efficacy and quality of human medicinal products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#8217;s national drug authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a further member of the CHMP acting as a Co-Rapporteur. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#8217;s opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. The European Commission&#8217;s decision is issued within 67 days of receipt of the CHMP&#8217;s opinion. If the opinion is negative, information is given as to the grounds on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which this conclusion was reached. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Review and approval</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Authorization to market a product in the EEA, comprising the European Union Member States plus Norway, Iceland and Liechtenstein, proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized procedure, only this procedure will be described here.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization procedure for marketing authorization. The centralized procedure is also mandatory for orphan medicinal products, advanced-therapy medicinal products (i.e. gene-therapy, somatic cell -therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid throughout the EEA. The other European Economic Area Member States (namely Norway, Iceland and Liechtenstein) are also obligated to recognize the European Commission decision. The EMA and the European Commission administer the centralized authorization procedure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (CHMP) serves as the scientific committee that renders opinions about the safety, efficacy and quality of human medicinal products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#8217;s national drug authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a further member of the CHMP acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout its life cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data. Clock stops may extend the timeframe of evaluation of a marketing authorization application considerably beyond 210 days. The process is complex and involves extensive consultation with the regulatory authorities of Member States and a number of experts. Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#8217;s opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. The European Commission&#8217;s decision is issued within 67 days of receipt of the CHMP&#8217;s recommendation. If the opinion is negative, information is given as to the grounds on which this conclusion was reached</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized MAs (under the Northern Irish Protocol, centralized MAs will continue to be recognized in Northern Ireland). All medicinal products with a current centralized MA were automatically converted to Great Britain MAs on January 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Alternative approvals, accelerated assessment and PRIME</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, in accordance with Article 14(7) of Regulation (EC) 726/2004, a &#8220;conditional&#8221; marketing authorization may be granted in cases where all the required safety and efficacy data are not yet available. The European Commission may grant a conditional marketing authorization for a medicinal product if it is demonstrated that all of the following criteria are met: (i) the benefit-risk balance of the medicinal product is positive; (ii) it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii) the medicinal product fulfils an unmet medical need; and (iv) the benefit of the immediate availability to patients of the medicinal product is greater than the risk inherent in the fact that additional data are still required. The conditional marketing authorization is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and must be renewed annually until all related conditions have been fulfilled. Once any pending studies are provided, the conditional marketing authorization can be converted into a traditional marketing authorization. However, if the conditions are not fulfilled within the timeframe set by the EMA and approved by the European Commission, the marketing authorization will cease to be renewed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A marketing authorization may also be granted &#8220;under exceptional circumstances&#8221; where the applicant can show that it is unable to provide comprehensive data on efficacy and safety under normal conditions of use even after the product has been authorized and subject to specific procedures being introduced. These circumstances may arise in particular when the intended indications are very rare and, in the state of scientific knowledge at that time, it is not possible to provide comprehensive information, or when generating data</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may be contrary to generally accepted ethical principles. Like a conditional marketing authorization, a marketing authorization granted in exceptional circumstances is reserved to medicinal products intended to be authorized for treatment of rare diseases or unmet medical needs for which the applicant does not hold a complete data set that is required for the grant of a standard marketing authorization. However, unlike the conditional marketing authorization, an applicant for authorization in exceptional circumstances is not subsequently required to provide the missing data. Although the marketing authorization &#8220;under exceptional circumstances&#8221; is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually, and the marketing authorization will be withdrawn if the risk-benefit ratio is no longer favorable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accelerated assessment may be granted by the CHMP in exceptional cases, when an application is submitted for a marketing authorization in respect of a drug for human use targeting an unmet medical need which is expected to be  of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In these circumstances, the applicant may request an accelerated assessment procedure pursuant to Article 14(9) of Regulation (EC) 726/2004, which must be substantiated. If the CHMP accepts the request for accelerated assessment, the time limit of 210 days for the CHMP&#8217;s opinion is reduced to 150 days excluding clock stops. The CHMP may, however, revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. We believe that some of the disease indications in which our product candidates are currently being or may be developed in the future may qualify for this provision, in which case, we intend to submit related applications for accelerated assessment as appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Innovative products that target an unmet medical need and are expected to be of major public health interest may be eligible for a number of expedited development and review programs, such as the Priority Medicines scheme (PRIME), which provides incentives similar to the breakthrough therapy designation in the U.S. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicinal products that target unmet medical needs. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the EU or, if there is, the new medicinal product will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Validity of marketing authorizations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A marketing authorization is initially valid for five years and may then be renewed on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the national competent authority of the authorizing Member State (where the centralized procedure is not used). To this end, the marketing authorization holder shall provide the EMA or the competent authority with a consolidated version of the Common Technical Document providing up-to-date data in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before expiry of the initial five year period. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the European Commission or the relevant national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Once subsequently definitively renewed, the MA shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the drug on the EEA market (if the centralized procedure is used) or on the market of the authorizing Member State (if the centralized procedure is not used) within three years after authorization shall cease to be valid (the so-called sunset clause).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pediatric development</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, Regulation (EC) No 1901/2006 provides that all MAAs for new medicinal products have to include the results of trials conducted in the pediatric population, in compliance with a pediatric investigation plan (PIP), agreed with the EMA&#8217;s Pediatric Committee (PDCO). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures provided in the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these data are not needed or appropriate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing authorization</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is obtained in all EU Member States and study results are included in the product information, even when negative, the product is eligible for a six-month extension to the Supplementary Protection Certificate (SPC), if any is in effect at the time of authorization or, in the case of orphan medicinal products, a two-year extension of orphan market exclusivity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing regulation in the EU</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to a marketing authorization, various other requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization and import of medicinal products into the EU requires a manufacturing authorization allowing for import.  The manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">distribution of medicinal products within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of EU Member States. Marketing authorization holders and/or manufacturing and import authorization, or marketing authorization holders and/or distribution authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU Member States&#8217; requirements applicable to the manufacturing of medicinal products.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data and market exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU provides opportunities for data and market exclusivity related to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing authorization</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s. Upon receiving a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> marketing authorization</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, innovative medicinal products are generally entitled to receive eight years of data exclusivity and 10 years of market exclusivity. Data exclusivity, if granted, prevents  regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar MAA can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the EU until 10 years have elapsed from the initial marketing authorization of the reference product in the EU. The overall ten-year period may, occasionally, be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for marketing authorization. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Orphan drug designation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EC) 141/2000, as implemented by Regulation (EC) 847/2000 states that a drug can be designated as an orphan drug if its sponsor can establish (i) that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii) either such condition affects not more than five in 10,000 persons in the European Union when the application is made, or, without incentives, it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment in its development; and (iii) that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EC) 847/2000 sets out provisions for the implementation of the criteria for the designation of orphan drugs. An application for designation as an orphan product can be made any time prior to the submission of an MAA. A marketing authorization for an orphan medicinal product may only include indications designated as orphan. For non-orphan indications treated with the same active pharmaceutical ingredient, a separate marketing authorization has to be sought. Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure.. Marketing authorization for an orphan drug leads to a 10-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity. In addition, a marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10 year period of market exclusivity on an individual basis in very select cases, such as with consent from the marketing authorization holder, if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities of the authorized product or if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-authorization requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Where an MA is granted in relation to a medicinal product in the EU, the holder of the MA is required to comply with a range of regulatory requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the individual EU Member States. The holder of an MA must</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (PSURs)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All new MAAs must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. Such risk- minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States&#8217; laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (SmPC), which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Combination products</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The EU regulates medical devices and medicinal products separately, and through different legislative instruments. Products that are a combination of a medicinal product and a medical device may be regulated as either a medicinal product, a medical device or, subject to certain requirements, on the basis of both sets of rules. The applicable requirements governing placing a drug-device combination on the EU market will vary depending on the type of drug-device combination product and on which of the components of the combination has the primary mode of action. Drug-device combination products that form a single integral product that is not reusable and for which the action of the medicinal product is principal to that of the medical device are governed by the regulatory framework applicable to medicinal products. However, the General Safety and Performance Requirements (GSPRs) of Annex I to </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulation (EU) 2017/745 on Medical Devices (MDR)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> will be applicable to the safety and performance of the medical device part of the product in the context of its use with the medicinal product. Drug-device combination products that form a single integral product that is not reusable and for which the action of the medicinal products is ancillary to that of the medical device are governed by the regulatory framework applicable to</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> medical devices in accordance with the MDR. Where a medical device incorporates a medicinal product as an integral part as a single use drug delivery system, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">which is intended exclusively for use in the given combination and which is not reusable, </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is regulated as a medicinal product. In this case, the relevant GSPRs of the MDR will apply to the safety and performance of the device element. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By contrast, drug-device combination products which do not form a single integral product will be regulated separately. This may include, for example a drug-device combination product where a medical device and a medicinal product are co-packaged and the medical device is intended solely to be used for the administration of the co-packaged medicinal product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Brexit</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The United Kingdom&#8217;s (UK) withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has changed the regulatory relationship between the UK and the EU. The MHRA is now the UK&#8217;s standalone regulator for medicinal products and medical devices. Great Britain (England, Scotland and Wales) is now a third country to the EU. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules for now</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The UK regulatory framework in relation to clinical trials is governed by the </span><span style="color:#040c28;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">derived from the Clinical Trials Directive (EU) 2001/20 (CTD), as implemented into UK national law through secondary legislation. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials, and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the EU Clinical Trials Regulation (CTR). In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketing authorizations in the UK are governed by the </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Human Medicines Regulations (SI 2012/1916), as amended. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since January 1, 2021, an applicant for the EU centralized procedure marketing authorization can no longer be established in the UK. As a result, since this date, companies established in the UK cannot use the EU centralized procedure and instead must follow one of the UK national authorization procedures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or one of the remaining post-Brexit international cooperation procedures</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to obtain a marketing authorization to market products in the UK. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ll existing EU marketing authorizations for centrally authorized products were automatically converted or grandfathered into UK marketing authorization, effective in Great Britain only, free of charge on January 1,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2021, unless the marketing authorization holder opted-out of this possibility. Northern Ireland currently remains within the scope of EU authorizations in relation to centrally authorized medicinal products. Accordingly, u</span><span style="color:#0b0c0c;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ntil the Windsor Framework is implemented in Northern Ireland on January 1, 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The MHRA has also introduced changes to national marketing authorization procedures. This includes introduction of procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling review procedure and the International Recognition Procedure. Since January 1, 2024, the MHRA may rely on the International Recognition Procedure (IRP) when reviewing certain types of marketing authorization applications. This procedure is available for applicants for marketing authorization who have already received an authorization for the same product from a reference regulator. These include the FDA, the EMA, and national competent authorities of individual EEA countries. A positive opinion from the EMA and CHMP, or a positive end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU, but have been tailored for the market. This includes the criterion that prevalence of the condition in Great Britain, rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in Great Britain.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">European and United Kingdom data collection and processing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The collection, receipt, storage, generation, transfer, access, protection, securing, disposal, transmittal, sharing, use, disclosure and other processing (commonly referred to as processing) of health-related and other personal data about clinical trials participants and other individuals in Europe is governed by the European Union&#8217;s General Data Protection Regulation (EU GDPR), and in the UK, is governed by the European Union (Withdrawal) Act 2018 and the UK Data Protection Act 2018 (UK GDPR). The EU GDPR and UK GDPR require companies to, among other things, give detailed disclosures about how they are processing personal data; ensure any consents relied on to process personal data (including special categories of personal data, such as health information) meet the strict EU GDPR requirements; contractually impose data protection measures on vendors entrusted with personal data; maintain adequate data security measures; notify regulators and affected individuals of certain data breaches; meet extensive privacy governance and documentation requirements; honor individuals&#8217; data protection rights, including their rights to access, correct and delete their personal data; and refrain from transferring personal data from Europe or the UK to most other countries unless specific safeguards can be implemented. Companies that violate the EU GDPR or UK GDPR can face private litigation, prohibitions on data processing and heavy fines. Complying with the EU GDPR and UK GDPR may be costly and require us to limit our activities in Europe. If our efforts to comply are not successful, we may face litigation, reputational harm, significant penalties and other liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Marketing</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Much like the Anti-Kickback Statute prohibition in the United States, as described below, the provision of benefits or advantages to physicians and other health care professionals to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the E.U. Interactions between pharmaceutical companies and health care professionals are governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Infringement of related laws could result in substantial fines and imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the European Union Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">International regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other healthcare laws and regulations and legislative reform</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare laws and regulations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our products. The healthcare laws that may affect our ability to operate include, but are not limited to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, Affordable Care Act), to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private citizens through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have been prosecuted under the False Claims Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their implementing regulations, which impose privacy, security and data breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates and subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act, which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services (CMS) information related to payments and other transfers of value provided to physicians (defined to </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare professionals; state and foreign laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state and foreign laws that require the posting of information relating to clinical trials and their outcomes; and other federal, state and foreign laws that govern the privacy and security of health information or personal data in certain circumstances, including state health information privacy and data breach notification laws which govern the processing of health-related and other personal data, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, or comparable foreign programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, if any of the physicians or other healthcare professionals or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Legislative reform</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. The Affordable Care Act, among other things, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs; required collection of rebates for drugs paid by Medicaid managed care organizations; required manufacturers to participate in a coverage gap discount program, under which they must agree to offer point-of-sale discounts (increased to 70 percent, effective as of January 1, 2019) off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected expanded the types of entities eligible for the 340B drug discount program; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act as well as efforts to repeal or replace certain aspects of the Affordable Care Act. For example, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Affordable Care Act. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect through 2032, absent additional congressional action. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient assistance programs and reform government program reimbursement methodologies for drug products. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services (HHS) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; for such drugs and biologics under the law, and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations, financial condition and prospects. However, we expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Environmental, health and safety laws and regulations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product candidates use PBDs, which are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">highly potent cytotoxins that require special handling by our and our contractors&#8217; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pharmaceutical coverage, pricing and reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third- party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost- effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability. Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, which decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow the CMS&#8217;s decisions regarding coverage and reimbursement. It is difficult to predict what third-party payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#8217;s determination to provide coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. Therefore, it is possible that any of our product candidates, even if approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reimbursement authorities in Europe may be more restrictive than payors in the United States. In Europe, pricing and reimbursement schemes vary widely from country to country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. In addition, the European Union provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union Member States may approve a specific price for a product, may adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for product but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. In addition, some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reference pricing used by various European Union Member States and parallel distribution, or arbitrage between low-priced and high-priced Member States, can further reduce prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">healthcare costs in general, and prescription products in particular, has become increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employees and human capital resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had a total of 51 full-time employees. We employ physicians, professionals in research and development, clinical, regulatory, manufacturing, marketing, finance and legal and other functions that are important to our business. We are not a party to any collective bargaining agreements. We use temporary workers such as consultants and advisors in certain instances when we think it is in the best interests of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attracting, developing, and retaining highly qualified individuals are key to our success. To do so, we believe we offer competitive compensation packages&#8212;inclusive of base salary, bonus, and equity, and benefits. We also sought to establish a values-based culture centered around our core values of collaboration, accountability, and empathy for patients to enhance the working environment for our current employees and to attract our desired candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Facilities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are occupying 9,885 square feet of office space at 8000 Marina Boulevard in Brisbane, California though November 2024. We also have leased 24,606 square feet of office and lab space at 170 Harbor Way in South San Francisco, California. This space is currently subleased through the term of the lease, ending September 2025.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We were incorporated as a Delaware corporation in May 2016. Our principal executive offices are located at 8000 Marina Boulevard, Suite 120, Brisbane, California 94005.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1A. Risk Factors.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">An investment in shares of our Class A common stock (common stock) involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;  before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the risks described below could harm our business, financial condition, results of operations, growth prospects, and/or stock price or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our financial position and need for additional capital</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have not completed any clinical trials for our lead product candidate, atacicept, and have no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a late clinical-stage biotechnology company and we have no products approved for commercial sale, have not generated any revenue from product sales and have incurred losses since inception. To date, we have devoted substantially all of our resources to our research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. We have not yet demonstrated our ability to successfully complete any clinical trials with respect to our product candidates, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult to accurately predict our future success or viability than it could be if we had a longer operating history.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by late-stage biotechnology companies in rapidly evolving fields. We may face difficulty transitioning from a company with a research focus to a company capable of successfully executing drug development activities and supporting commercial operations. If we do not adequately address these risks and difficulties or successfully make such a transition, our business, financial condition, results of operations and prospects will be significantly harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing treatments for immunological and inflammatory diseases, including conducting nonclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses will increase in connection with our ongoing activities, particularly as we continue to conduct clinical trials of, and seek marketing approval for, our product candidates. We anticipate incurring significant costs associated with the development of our product candidates. Our expenses could increase beyond expectations if we are required by the FDA, or any comparable foreign regulatory authority to perform clinical trials or nonclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for atacicept or MAU868, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. We also will continue to incur costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had $160.7 million in cash, cash equivalents and marketable securities. In December 2021, the Company entered into a non-revolving loan and security agreement (the Loan Agreement) with borrowing capacity of up to $50.0 million. At the closing of the Loan Agreement in December 2021, $5.0 million was funded, and an additional $20.0 million was funded in November 2022. In December 2023, the Company borrowed the remaining $25.0 million from the Loan Agreement. As of December 31, 2023, the Company&#8217;s outstanding borrowing under the Loan Agreement was $50.0 million. We expect that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations and capital expenditure requirements for at least the next 12 months from the date of this Annual Report. Our estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic nature of our business and the macroeconomic and geopolitical environment generally. We anticipate that our expenses will increase substantially if, and as, we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our ongoing and planned research and development of atacicept for the treatment of IgAN and LN;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiate or continue nonclinical studies and clinical trials for atacicept, MAU868 and any additional product candidates that we may pursue in the future;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our research and development of MAU868 for the treatment of BK viremia in kidney transplant recipients and other indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity requirements for clinical trials and potential commercialization;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets, and know-how;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acquire, develop or in-license other product candidates and technologies and further expand our clinical product pipeline;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract, develop and retain additional clinical, scientific, quality control, and manufacturing management and administrative personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Advancing the development of atacicept, MAU868 and any future product candidates we may develop will require a significant amount of capital. Our working capital and available credit will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates through approval and commercial launch.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, we delayed enrollment in the pivotal Phase 3 trial for LN and commitment of resources to the MAU868 program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. Adequate additional financing may not be available to us on acceptable terms, or at all. Adverse geopolitical and macroeconomic developments, such as the recent and potential future disruptions in access to bank deposits and lending commitments due to bank failures, ongoing military conflicts, related sanctions, actual and anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, could affect our ability to access capital as and when needed. Our failure to raise capital as and when needed, or on acceptable terms, would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long-term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred net losses in each reporting period since the commencement of our operations and have not generated any revenue from product sales to date. We had net losses of $96.0 million and $89.1 million for the years ended December 31, 2023 and 2022, respectively. We had an accumulated deficit of $309.1 million as of December 31, 2023. Our losses have resulted principally from expenses incurred in research and development and from management and administrative costs and other expenses that we have incurred while building our business infrastructure, a significant portion of which were incurred resulting from our efforts to develop gamma-PNA chemistry and triplex gene editing for therapeutic use, which we discontinued in September 2020. Our product candidates are in clinical development. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing our product candidates in one or more indications, we expect that we will continue to incur substantial research and development and other expenses as we continue the clinical development programs for our product candidates in other indications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur increased expenses and operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval for our product candidates. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital. In any particular period, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses and negative cash flows from operations. As a development stage company, we expect to incur significant and increasing losses until regulatory approval is granted for our product candidates. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long-term.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never be profitable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, atacicept, MAU868 and any future product candidates we may develop. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate revenue from product sales depends heavily on our and our current and potential future collaborators&#8217; success in:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completing clinical development of product candidates and programs and identifying and developing new product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seeking and obtaining marketing approvals for any product candidates that we develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">launching and commercializing product candidates for which we obtain marketing approval by establishing a sales force, marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">achieving adequate access and reimbursement by government and third-party payors for product candidates that we develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and the market demand for product candidates that we develop, if approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining market acceptance of product candidates that we develop as viable treatment options;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any competing technological and market developments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining our rights under our existing license agreement with Ares, Novartis and any similar agreements we may enter into in the future;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations in such collaborations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">defending against third-party interference, infringement or other intellectual property-related claims, if any; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attracting, developing and retaining qualified personnel.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if atacicept, MAU868, or any future product candidate that we may develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to perform clinical trials or nonclinical studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not be able to reach or sustain profitability, and may need to obtain additional funding to continue operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Loan Agreement provides us with up to $50.0 million of borrowing capacity. At the closing of the Loan Agreement in December 2021, $5.0 million was funded and an additional $20.0 million was funded in November 2022. In December 2023, the Company borrowed the remaining $25.0 million from the Loan Agreement. As of December 31, 2023, the Company&#8217;s outstanding borrowing under the Loan Agreement was $50.0 million. Our overall leverage and certain obligations and affirmative and negative covenants contained in the related documentation could adversely affect our financial health and business and future operations by limiting our ability to, among other things, satisfy our obligations under the Loan Agreement, refinance our debt on terms acceptable to us or at all, plan for and adjust to changing business, industry and market conditions, use our available cash flow to fund future acquisitions and make dividend payments, and obtain additional financing for working capital, to fund growth or for general corporate purposes, even when necessary to maintain adequate liquidity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we default under the Loan Agreement, Oxford may accelerate all of our repayment obligations and exercise all of their rights and remedies under the Loan Agreement and applicable law, potentially requiring us to renegotiate our agreement on terms less favorable to us. Further, if we are liquidated, the lenders&#8217; right to repayment would be senior to the rights of the holders of our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">common stock to receive any proceeds from the liquidation. Oxford could declare a default upon the occurrence of customary events of default, including events that they interpret as a material adverse change as delineated in the Loan Agreement, payment defaults or breaches of certain affirmative or negative covenants, thereby requiring us to repay the loan immediately. Any declaration by the lender of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. Additionally, if we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to the discovery, development and commercialization of our product candidates</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are substantially dependent on the success of our product candidates, atacicept and MAU868, which are currently in the clinical development stage. If we are unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future success is heavily dependent on our ability to timely complete clinical trials, obtain marketing approval for and successfully commercialize our product candidates. We expect that a substantial portion of our efforts and expenses over the next several years will be devoted to the development of atacicept in our ongoing clinical trials of atacicept in patients with IgAN and LN, as well as our efforts to evaluate atacicept in MAU868 in kidney transplant recipients. In the near-term, we plan to prioritize and focus our current resources on our pivotal Phase 3 trial of atacicept in IgAN. As a result, we are delaying enrollment in the pivotal Phase 3 trial for LN and any commitment of resources to the MAU868 program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to invest significant efforts and financial resources in the research and development of our product candidates, which will require additional clinical development, evaluation of clinical, nonclinical and manufacturing activities, marketing approval from regulatory authorities, and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to market or promote our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. Should our planned clinical development of atacicept in patients with IgAN and LN or MAU868 in kidney transplant recipients fail to be completed in a timely manner or at all, we will need to rely on clinical development of atacicept or MAU868 in additional indications, which will require more time and resources to obtain regulatory approval and proceed with commercialization, and may ultimately be unsuccessful. We cannot assure you that our planned clinical development programs for our product candidates will be completed in a timely manner, or at all, or that we will be able to obtain approval for atacicept or MAU868 from the FDA or comparable foreign regulatory authorities. If we are unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development. We have never completed a clinical trial or submitted a BLA to the FDA or similar drug approval filings to comparable foreign authorities. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business, financial condition, results of operations and prospects will be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of nonclinical studies and early clinical trials may not be predictive of the results of subsequent clinical trials. We have a limited operating history and to date have not demonstrated our ability to complete large scale clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through nonclinical studies and initial clinical trials. For example, atacicept has been the subject of clinical trials by prior sponsors, including a Phase 2 trial in SLE, that missed its primary endpoint in the overall study population. In the future, clinical trial failures may result from a multitude of factors including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we or any potential future collaborator may decide, or regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Any future delays or abandonment could harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our clinical trials are completed as planned, we cannot be certain that their results will support our proposed indications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future clinical trials may not be successful. If any product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business, financial condition, results of operations and prospects may be significantly harmed. In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and the dropout rate among clinical trial participants. Patients treated with</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not know whether our clinical trials will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. If we are unable to bring our product candidates to market, our ability to create long-term shareholder value will be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in nonclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit an application seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured, the terms of such approval may limit the scope and use, which may also limit commercial potential. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of a product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in clinical trials of our product candidates. Our planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of participants, or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including delays related to:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining approval from one or more institutional review boards (IRBs) or positive Ethics Committee opinions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">IRBs refusing to approve or Ethics Committees issuing negative opinions, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to clinical trial protocol;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">study conduct issues, which could confound the clinical endpoints and/or data;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing sufficient quantities of clinical trial material to supply the clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrollment due to low prevalence or incidence rates of subjects with the applicable disease;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrollment due to a shift in our prioritization and dedication of resources towards other product candidates or indications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjects choosing an alternative treatment or participating in competing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">lack of adequate funding to continue the clinical trial;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjects experiencing severe or unexpected drug-related adverse effects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities imposing a clinical hold;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shutdowns, either temporarily or permanently, of any facility manufacturing our product candidates or any of their components, including by order from the FDA or comparable foreign regulatory authorities due to violations of current good manufacturing practice (cGMP), regulations or other applicable requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we experience delays in the completion of, or termination of, any clinical trial, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down development and approval processes and jeopardize our ability to commence product sales and generate revenues.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any delays in our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize atacicept, MAU868 or any other product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of atacicept, MAU868 or other product candidates could be significantly reduced. Any of these occurrences may significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Enrollment and retention of participants in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with IgAN, the availability of competitive products, and significant competition for recruiting participants in clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of participants to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of participants to complete any of our trials. In particular, as a result of the inherent difficulties in diagnosing IgAN, the availability of competitive products such as TARPEYO and FILSPARI, and the significant competition for recruiting the limited number of patients who have the diseases for which our product candidates are being developed, there may be delays in enrolling the participants we need to complete clinical trials on a timely basis, or at all. Although we have engaged certain third-party investigators to assist with participant enrollment, there can be no assurance that we will be able to maintain our relationships with such third parties or that such third parties will be successful in helping us identify patients.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Factors that may generally affect participant enrollment include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size and nature of the patient population;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and location of clinical sites we enroll;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competition with other companies for clinical sites or patients;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the drug background and clinical experience (e.g., safety profile, risk/benefit assessment, mechanism of action, known proof of concept);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the eligibility and exclusion criteria for the trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the clinical trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to obtain and maintain participant consents;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risk that enrolled participants will drop out before completion;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a shift in our prioritization and dedication of resources towards other product candidates or indications; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if any significant adverse events or other side effects are observed in any of our future clinical trials or other sponsor development programs of similar mechanism of action that may result in a drug class effect, it may make it more difficult for us to recruit patients to our clinical trials and participants may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. Our inability to enroll a sufficient number of participants for our clinical trials would result in significant delays, which would increase our costs and have an adverse effect on our company.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited financial and human resources, which has in the past and may in the future cause us to make prioritization and resource allocation decisions. For example, in January 2023, we announced our plan to prioritize and focus our current resources on the advancement of our pivotal Phase 3 trial of atacicept in IgAN. As a result, we delayed enrollment in the pivotal Phase 3 trial for LN and any commitment of resources to the MAU868 program. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may develop atacicept, MAU868 and potentially future product candidates, in combination with other therapies, which exposes us to additional risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may develop atacicept, MAU868 and future product candidates in combination with one or more currently approved therapies. Even if atacicept, MAU868 or any product candidate we develop, were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke or modify approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also evaluate atacicept, MAU868 or any other future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell atacicept, MAU868 or any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with atacicept, MAU868 or any other product candidate we develop, we may be unable to obtain approval of or market atacicept, MAU868 or any other product candidate we develop.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The incidence and prevalence for target patient populations of our product candidates in specific indications are based on estimates and third-party sources. If the market opportunities for atacicept, MAU868 or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy, including acquiring or in-licensing product candidates and determining indications on which to focus in nonclinical or clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The incidence and prevalence for target patient populations of our product candidates in specific indications are based on estimates and third-party sources. These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, acceptance of our drugs by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to. If the market opportunities for atacicept, MAU868, or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve and sustain profitability might be materially and adversely affected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, initial, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary or top-line data from our nonclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more participant data become available or as participants from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of our particular program, the approvability or commercialization of our particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition, which may result in others discovering, developing or commercializing products before or more successfully than us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our competitors include multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. The current standard-of-care for IgAN consists of treatment with off-label use of RAAS inhibitors,  including ACE inhibitors and ARBs, to control blood pressure, or steroids with or without other immunosuppressive agents to non-specifically reduce inflammation. SGLT2 inhibitors, including AstraZeneca&#8217;s Farxiga, which is approved for chronic kidney disease, is becoming the standard-of-care in some geographies including the United States. Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the reformulated steroid from Calliditas Therapeutics AB, and endothelin and angiotensin II receptor antagonist from Travere Therapeutics, Inc.; programs in Phase 3 clinical development: Otsuka Pharmaceutical Co, Ltd., Novartis, Alnylam Pharmaceuticals Inc. and Roche/Ionis; and the following companies with programs in Phase 2 of clinical development: Reata Pharmaceuticals, Inc., AstraZeneca, HI-Bio. Inc., Eladon Pharmaceuticals and DiaMedica Therapeutics, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In LN, prior to December 2020, there had been no approved therapies, and the standard-of-care has consisted of a number of non-specific therapies, including MMF, steroids, cyclophosphamide, rituximab, calcineurin inhibitors, azathioprine, and hydroxychloroquine, dependent on class of disease and whether a patient was cycling through the induction or maintenance phase of therapy. Paradigms are evolving with the FDA approvals of GlaxoSmithKline plc&#8217;s Benlysta (belimumab) and Aurinia Pharmaceuticals Inc.&#8217;s Lupkynis (voclosporin), both of which we consider to be direct competitors. Our competitors include: Roche Holding AG, Novartis Pharmaceuticals Corporation, and AstraZeneca, each of which have programs in Phase 3 clinical development; and BeiGene Ltd., Janssen Pharmaceuticals, Inc., AstraZeneca, Alexion, Omeros Corporation, Kezar Life Science Inc., Bristol Myers Squibb, Boehringer, Amgen Inc. and Novartis, each of which have programs in Phase 2 clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the kidney transplant or HSCT setting, there are currently no anti-BKV therapies approved. The standard of care in both settings is to reduce immunosuppression as a first line, and potentially to offer intravenous immune globulin (IVIG) in kidney transplant recipients or antivirals with limited clinical evidence, including leflunomide and cidofovir, in either setting. There are few industry sponsored programs in development for these indications; for example, Memo Therapeutics AG&#8217;s MTX-005, a monoclonal antibody targeting BKV is in Phase 1 clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our competitors have significantly greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">products and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA or comparable approval for superior products. Many of our competitors have established distribution channels for the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidates or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and participant registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As our product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, and manufacturing sites are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to regulatory approval and other legal compliance matters</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition, results of operations and prospects will be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities typically takes many years following the commencement of clinical trials. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applications for atacicept or MAU868 could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may determine that our product candidate is not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval, resulting in a restrictive label and limiting commercial use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials may not be sufficient to support the submission of a BLA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that the risk-benefit ratio for our proposed indication is acceptable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, even if we obtain approval of our product candidates for a lead indication, regulatory authorities may not approve them for other indications, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy (REMS). Certain regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or may approve them with a label that does not include the labeling claims necessary or desirable for successful commercialization of our product candidates. In addition, if we are unable to obtain regulatory approval, or if regulatory approval results in a limited label, our business, financial condition, results of operation and prospects will be significantly harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our product candidates would depend on a number of factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing of market introduction of the product candidate as well as competitive products, such as TARPEYO and FILSPARI;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the clinical indications for which the product candidate is approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on use, such as boxed warnings or contraindications in labeling, or a REMS or comparable foreign restriction, if any, which may not be required of alternative treatments and competitor products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential and perceived advantages of product candidates over alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of treatment in relation to alternative treatments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our pricing and the availability of coverage and adequate reimbursement by third-party payors, including government authorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of atacicept or MAU868 for use as a combination therapy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relative convenience and ease of administration;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effectiveness of sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inclusion or exclusion of our product candidates from treatment guidelines established by various physician groups;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable publicity relating to our product candidates or similar approved products or product candidates in development by third parties; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval of other new therapies for the same indications.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and accessible to patients. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare professionals, government agencies, regulatory authorities or private insurers will determine that our product is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from such product candidate and may not be able to achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our product, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our product or more serious enforcement action, limitations on the approved indications for which it may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our product, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any product candidate, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with the use of atacicept, MAU868 or any future product candidates we may develop. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. For example, Merck KGaA, Darmstadt, Germany previously conducted APRIL-LN, a study aimed to evaluate the efficacy and safety of atacicept in patients with active LN, receiving newly initiated CS and MMF. Two weeks before the initiation of atacicept, significant decreases in immunoglobulin G (IgG) levels began unexpectedly with initiation of MMF and high-dose CS, and persisted upon initiation of atacicept, which led to trial termination. The drug-related side effects could affect participant recruitment or the ability of enrolled participants to complete the trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If product candidates we develop are associated with undesirable side effects or have unexpected characteristics in nonclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect participant recruitment or the ability of enrolled subjects to complete a trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participants in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our nonclinical studies or previous clinical trials. Our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory authorities. In addition, if atacicept, MAU868 or any future product candidates we may develop, are used in combination with other therapies, atacicept, MAU868 or any future product candidates we may develop may exacerbate adverse events associated with the therapy and it may not be possible to determine whether it was caused by our product or the one with which it was combined. Patients treated with our product candidates may also be undergoing surgical, radiation, chemotherapy or other treatments, which can cause side effects or adverse events that are unrelated to our product candidates, but may still impact the success of our clinical trials. The inclusion of patients with advanced disease in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting participants to the clinical trials, participants may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB or Ethics Committee may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, toxicities associated with our products not seen during clinical testing may also develop after any approval, if obtained, and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on nonclinical studies or early-stage clinical trials.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval in other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or other foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the marketing approval of the product candidate in their countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our product is also subject to approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if any product candidate we develop receives regulatory approval, it could be subject to significant post-marketing regulatory requirements and will be subject to continued regulatory oversight.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the marketed product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve atacicept or MAU868, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or applicable foreign regulatory authorities approve atacicept, MAU868 or any product candidate we develop in the future, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> delays in or the rejection of product approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the products, manufacturers or manufacturing process;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">warning letters;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">civil and criminal penalties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension, variation or withdrawal of regulatory approvals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizures, detentions or import bans;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">voluntary or mandatory product recalls and publicity requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">total or partial suspension of production; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">imposition of restrictions on operations, including costly new manufacturing requirements.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any event or penalty described above may inhibit our ability to commercialize atacicept, MAU868, or any product candidate we may develop in the future, and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of atacicept, MAU868 or any product candidate we may develop in the future. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not be able to achieve or sustain profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If these actions impose constraints on FDA&#8217;s or foreign regulatory authorities&#8217; ability to engage in oversight and implementation activities in the normal course, it may significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are currently seeking orphan drug designation for atacicept for the treatment of IgAN, but even if designated we may not ultimately realize the potential benefits of orphan drug designation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently seeking orphan drug designation from the FDA for atacicept for the treatment of IgAN. We are required to provide evidence that IgAN meets the orphan criteria as specified by the FDA and the EU. Under the Orphan Drug Act, the FDA may designate a drug product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States but where there is no reasonable expectation to recover the costs of developing and marketing a treatment drug in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. However, orphan drug designation neither shortens the development time nor regulatory review time of a product candidate nor gives the candidate any advantage in the regulatory review or approval process.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. Even if we obtain orphan drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective, or makes a major contribution to patient care.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, in the EU, a medicinal product may receive orphan designation under Article 3 of Regulation (EC) 141/2000. This applies to products that are intended for a life-threatening or chronically debilitating condition and either (1) such condition affects no more than five in 10,000 persons in the EU when the application is made, or (2) the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment in its development. Moreover, in order to obtain orphan designation in the EU it is necessary to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal product designation entitles an applicant to incentives such fee reductions or fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Marketing authorization for an orphan drug leads to a 10-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years.  A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity. In addition, a marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10 year period of market exclusivity on an individual basis in very select cases, such as with consent from the marketing authorization holder, if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities of the authorized product or if the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do not receive or maintain orphan drug designation for atacicept for the treatment of IgAN, it could limit our ability to realize revenues.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even though MAU868 has Fast Track designation from FDA for the prevention of BK viremia in renal transplant and hematopoietic stem cell transplant, it may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that MAU868 will receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a drug or biologic is intended for the treatment of a serious or life-threatening condition or disease, and nonclinical or clinical data demonstrate the potential to address an unmet medical need, the product may qualify for FDA Fast Track designation, for which sponsors must apply. The FDA has broad discretion whether or not to grant this designation. Although we have received Fast Track designation for the investigation of MAU868 for the prevention of BK viremia in renal transplant and hematopoietic stem cell transplant recipients, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional nonclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA or comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or comparable foreign regulatory authorities may seek to withdraw any accelerated approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future seek an accelerated approval for atacicept, MAU868 or future product candidates we may develop. For example, if the results from our Phase 3 trial of atacicept in patients with IgAN are positive, we may seek accelerated approval with the FDA based on this trial, which we may not be granted. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. For example, UPCR is an accepted surrogate primary endpoint for clinical trials in IgAN, which could allow for a faster path to commercialization than rate of change/slope in eGFR. We may seek accelerated approval based on the UPCR endpoint. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Use of the accelerated approval pathway would entail submission of a BLA under Subpart E of the FDA regulations with week 36 UPCR surrogate endpoint data while completing the Phase 3 trial to collect eGFR data to demonstrate improvement in kidney function. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to complete ongoing trials and/or conduct, in a diligent manner, additional post-approval confirmatory studies to verity and describe the drug&#8217;s clinical benefit and to report regulatory to the FDA on progress on such trials. Additionally, unless and until converted to full approval at the time of satisfying the conditions of any accelerated approval letter, the sponsor must submit any promotional materials for the accelerated approval drug to FDA at least 30 days prior to use. Third-party payors may refuse to provide coverage or reimbursement for the drug until the confirmatory studies are complete. Additionally, if such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to seeking accelerated approval for atacicept or MAU868, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA, for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for atacicept, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for atacicept or MAU868 would result in a longer time period to commercialization of such product candidate, could increase the cost of development of atacicept or MAU868 and could harm our competitive position in the marketplace.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Biosimilars to our product candidates may provide competition sooner than anticipated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the Affordable Care Act), signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the European Union, upon receiving a marketing authorization, innovative medicinal products are generally entitled to receive eight years of data exclusivity and ten years of market exclusivity. Data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the European Union until ten years have elapsed from the initial marketing authorization of the reference product in the European Union. The overall ten-year period may, occasionally, be extended for a further year to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be a new chemical/biological entity, and products may not qualify for data exclusivity. In the EU, there is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not meet the definition of a generic medicinal product. For such products, the results of appropriate preclinical or clinical trials must be provided in support of an application for marketing authorization. Guidelines from the EMA detail the type of quantity of supplementary data to be provided for different types of biological product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any approved products are subject to biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial opportunity will be limited.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any product candidate we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to seek approval to market atacicept and MAU868 in both the United States, in the EU and in certain foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for atacicept or MAU868, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of atacicept or MAU868. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of a product candidate will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for the product candidate and may be affected by existing and future healthcare reform measures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. If we obtain marketing approval of a product candidate, sales of such product will depend substantially, both in the United States and internationally, on the extent to which the costs of the product will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only at inadequate levels, we may not be able to successfully commercialize any product candidates we develop. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare &amp; Medicaid Services (CMS) an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our product to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Governmental payors, as well as other third-party payors, including pharmacy benefit managers, have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our product. Nonetheless, atacicept, MAU868 or any future product candidates we may develop may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as atacicept, MAU868 or any future product candidates we may develop. In many countries, particularly the countries of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical study that compares the cost-effectiveness of atacicept, MAU868 or any future product candidates we may develop to other available therapies. The Health Technology Assessment (HTA) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. In December 2021, Regulation No 2021/2282 on HTA, amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 will apply as of January 2025. It is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for product candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for atacicept, MAU868 or any future product candidates we may develop. Accordingly, in markets outside the United States, the reimbursement for any product that we commercialize may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates that we commercialize from third-party payors, the adoption of those products and potential sales revenue would be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for a product for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may face difficulties from changes to current regulations and future legislation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of atacicept, MAU868 or any future product candidates we may develop. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not be able to achieve or sustain profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, the Affordable Care Act was passed in March 2010, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period coverage through the Affordable Care Act marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or congressional challenges in the future. It is also unclear how any healthcare reform measures of the Biden administration will affect the Affordable Care Act and our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, the Infrastructure Investments and Jobs Act and the Consolidated Appropriations Act of 2023, will remain in effect until 2032, unless additional congressional action is taken. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have an adverse effect on customers for our product candidates, if approved, and, accordingly, our financial operations. In addition, Congress is considering additional health reform measures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although the Medicare drug price negation program is currently subject to legal challenges. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has issued and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. On February 14, 2023, in response to the Biden administration&#8217;s October 2022 executive order, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement-constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that the Affordable Care Act, the IRA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, achieve and sustain profitability or commercialize atacicept, MAU868 or any future product candidates we may develop.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of any product candidates we develop, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, FDA and comparable foreign regulations and guidance may be revised or reinterpreted by the competent authorities in ways that may significantly affect our business and our products. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen review times for atacicept, MAU868 or future product candidates we may develop. We cannot determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could, among other things, require:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional clinical trials to be conducted prior to obtaining approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes to manufacturing methods;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recalls, replacements, or discontinuance of one or more of our products; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional recordkeeping.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. As an example, the regulatory landscape related to clinical trials in the EU has evolved. The CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment by all EU Member States concerned, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the clinical trial approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. For clinical trials in relation to which application for approval was made on the basis of the Clinical Trials Directive before January 31, 2023, the Clinical Trials Directive will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans. In light of the entry into application of the CTR on January 31, 2022, we may be required to transition clinical trials for which we have obtained regulatory approvals in accordance with the CTD to the regulatory framework of the CTR. Transition of clinical trials governed by the CTD to the CTR will be required for clinical trials which will have at least one site active in the E.U. on January 30, 2025. A transitioning application would need to be submitted to the competent authorities of E.U. Member States through the Clinical Trials Information Systems and related regulatory approval obtained to continue the clinical trial past January 30, 2025. This would require financial, technical and human resources. If we are unable to transition our clinical trials in time, the conduct of those clinical trials may be negatively impacted. It is currently unclear to what extent the UK will seek to align its regulations with the EU in the future. The UK regulatory framework in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January 17, 2022, the UK  MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. Failure of the UK to closely align its regulations with the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization for the Company's product candidates on the basis of clinical trials conducted in the United Kingdom.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of atacicept, MAU868 or future product candidates we may develop, and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future business activities may be subject to federal, state and foreign healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare professionals and third-party payors play a primary role in the recommendation and prescription of our product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our product for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their implementing regulations, also imposes obligations, including mandatory contractual terms, upon certain covered </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some state and foreign laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare professionals or marketing expenditures. Some state and foreign laws require biotechnology companies to report information on the pricing of certain drug products. Some state and local laws require the registration of pharmaceutical sales representatives.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians and other healthcare professionals to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. Interactions between pharmaceutical companies and health care professionals are governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. Infringement of related laws could result in substantial fines and imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians and other healthcare professionals in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians and other healthcare professionals may require prior notification or approval by the physician&#8217;s or other health care professional&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, or comparable foreign programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare professionals or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">confidential business information, trade secrets, intellectual property, information we collect about trial participants in connection with clinical trials, and sensitive third-party information (collectively, sensitive information). Our data processing activities subject us to numerous obligations relating to data privacy and security, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual obligations and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations and industry standards govern data privacy and security. For example, the EU GDPR and UK GDPR (collectively, GDPR), Canada&#8217;s Personal Information Protection and Electronic Documents Act (PIPEDA), Australia&#8217;s Privacy Act, India&#8217;s Information Technology Act, and South Korea&#8217;s Personal Information Protection Act impose strict requirements for processing of personal data, including clinical trials participants and other individuals. For instance, companies that violate the GDPR can face private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests, temporary or definitive prohibitions on data processing and other corrective actions, fines of up to the greater of 20 million Euros under the EU GDPR / 17.5 million pounds under the UK GDPR, or 4% of their worldwide annual revenue, whichever is higher.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries.  In particular, the EEA and the UK have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate.  Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA standard contractual clauses, the UK&#8217;s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework). These mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States.  If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as the EEA and/or UK) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.  Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of the EEA for allegedly violating the EU GDPR&#8217;s cross-border data transfer limitations. Additionally, companies that transfer personal data out of the EEA and/or UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators individual litigants and activist groups.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States federal, state and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g. Section 5 of the Federal Trade Commission Act), other similar laws (e.g. wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security and transmission of individually identifiable health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, in the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act (CPRA,=), (collectively, the CCPA), applies to personal data of consumers, business representatives, and employees who are California residents, and requires covered businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA also provides for fines of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our employees and personnel use generative artificial intelligence (AI) technologies to perform their work, and the disclosure and use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Our use of this technology could result in additional compliance costs, regulatory investigations and actions, and lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to data privacy and security laws, we are contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future.  We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security.  If these policies, materials, or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. All of these evolving compliance and operational requirements impose significant costs that are likely to increase over time, may require us to modify our information processing practices and policies, divert resources from other initiatives and projects, including increased costs related to insurance, cybersecurity and information technology, and could restrict the way products and services involving data are offered, all of which could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our effort to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third-party partners (such as contract research organizations and clinical trial sites) may fail (or be perceived to have failed) to comply with such obligations, which could negatively impact our business operations. If we or our third-party partners fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands.  Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process sensitive information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits companies and their employees and third-party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our product in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our product and activities may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our product, or our failure to obtain any required import or export authorization for our product, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product may create delays in the introduction of our product in international markets or, in some cases, prevent the export of our product to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or product targeted by such regulations, could result in decreased use of our product by, or in our decreased ability to export our product to existing or potential customers with international operations. Any decreased use of our product or limitation on our ability to export or sell access to our product would likely significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to various laws relating to foreign investment and the export of certain technologies, and our failure to comply with these laws or adequately monitor the compliance of our suppliers and others we do business with could subject us to substantial fines, penalties and even injunctions, the imposition of which on us could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to U.S. laws that regulate foreign investments in U.S. businesses and access by foreign persons to technology developed and produced in the United States. These laws include Section 721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31 C.F.R. Parts 800 and 801, as amended, administered by the Committee on Foreign Investment in the United States; and the Export Control Reform Act of 2018, which is being implemented in part through Commerce Department rulemakings to impose new export control restrictions on &#8220;emerging and foundational technologies&#8221; yet to be fully identified. Application of these laws, including as they are implemented through regulations being developed, may negatively impact our business in various ways, including by restricting our access to capital and markets; limiting the collaborations we may pursue; regulating the export our products, services, and technology from the United States and abroad; increasing our costs and the time necessary to obtain required authorizations and to ensure compliance; and threatening monetary fines and other penalties if we do not.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to employee matters, managing our growth and other risks related to our business</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable geopolitical and global economic conditions could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy, the global financial markets, and adverse geopolitical and macroeconomic developments. U.S. and global market and economic conditions have been, and continue to be, volatile due to many factors, including recent and potential future disruptions in access to bank deposits and lending commitments due to bank failures, supply chain challenges, ongoing military conflicts, related sanctions, changes in U.S.-China relations, increasing inflation rates and the responses by central banking authorities to control such inflation, among others. General business and economic conditions that could affect our business, financial condition or results of operations include fluctuations in economic growth, debt and equity capital markets, bank failures, liquidity of the global financial markets, the availability and cost of credit, investor and consumer confidence, and the strength of the economies in which we, our manufacturers and our suppliers operate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A severe or prolonged global economic downturn could result in a variety of risks to our business. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise raise capital on acceptable terms, if at all. In addition, the U.S. Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation, which, coupled with reduced government spending and volatility in financial markets may have the effect of further increasing economic uncertainty and heightening these risks. Recent bank failures have caused significant disruption in certain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">companies&#8217; access to bank deposits and lending commitments and may continue to do so. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In response to the invasion of Ukraine by Russia, the United States, United Kingdom and EU, along with others, imposed significant new sanctions and export controls against Russia, Russian banks and certain Russian individuals and may implement additional sanctions or take further punitive actions in the future. The full economic and social impact of the sanctions imposed on Russia (as well as possible future punitive measures that may be implemented), as well as the counter-measures imposed by Russia, in addition to the ongoing military conflict between Ukraine and Russia, which could conceivably expand into the surrounding region, remains uncertain; however, both the conflict and related sanctions have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability, supply chain continuity and reduced access to liquidity in both Europe and globally, and has introduced significant uncertainty into global markets. As a result, our business and results of operations, including conduct of global clinical trials with sites in eastern Europe and western Asia, may be adversely affected by the ongoing conflict between Ukraine and Russia and related sanctions, particularly to the extent it escalates to involve additional countries, further economic sanctions or wider military conflict.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tensions between the United States and China have increased over the past few years as a result of disputes in areas including trade policy, intellectual property, cybersecurity and data privacy, as well as due to geopolitical conflicts such as the war between Ukraine and Russia. We conduct manufacturing and clinical development activities in China. Any unfavorable government policies on cross-border relations or international trade, changes to law, executive orders, tariffs, treaties or trade agreements, or deterioration in U.S.-China relations or international trade may adversely affect the import or export of our drug candidates and materials required for manufacturing or otherwise delay our product development activities, which could in turn have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees and key consultants.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, as well as the other members of our scientific and clinical teams, including certain key consultants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, although we have employment offer letters with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for all of our executives or employees. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize atacicept, MAU868 or any other product candidate will be limited and the potential for successfully growing our business will be harmed.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market atacicept, MAU868 or any product candidate we may develop in the future, we may not be able to successfully sell or market atacicept, MAU868 or any future product candidate we may develop in the future that obtained regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market atacicept, MAU868 or any future product candidate we may develop. We may not be successful in accomplishing these required tasks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize atacicept, MAU868 or any product candidate we may develop in the future will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of atacicept, MAU868 or any product candidate we may develop in the future that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize atacicept, MAU868 or any product candidate we may develop in the future which may receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an organization, we have never commercialized a product candidate, and we currently have limited marketing and no sales force, market access or distribution capabilities. To achieve commercial success for a product candidate, which we may license to others, we will rely on the assistance and guidance of those collaborators. For any product candidates for which we retain commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an organization, we have never commercialized a product candidate. Factors that may affect our ability to commercialize our current or any future product candidate we may develop, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or educating adequate numbers of physicians on the benefits of our current or any future product candidates we may develop and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of atacicept, MAU868 or any future product candidate we may develop. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our current or any future product candidate we may develop, we may not generate revenues from such product candidate or be able to achieve or sustain profitability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had 51 full-time employees, including 34 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, and as we continue to operate as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory authorities&#8217; review process for atacicept, MAU868 and any other future product candidates we may develop, while complying with any contractual obligations to contractors and other third parties we may have; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we plan to conduct multiple clinical trials of atacicept for several different indications concurrently, as well as MAU868 for the treatment of BKV disease in kidney transplant recipients. Given the small size of our organization, we may encounter difficulties managing multiple clinical trials at the same time, which could negatively affect our ability to manage growth of our organization, particularly as we take on additional responsibility associated with being a public company. Our future financial performance and our ability to successfully develop and, if approved, commercialize, atacicept, MAU868 and any other future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of atacicept, MAU868 and any other future product candidates we may develop or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize atacicept, MAU868</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and any other future product candidates we may develop and, accordingly, may not achieve our research, development and commercialization goals.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters is located in Brisbane, California, in a region which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant portion of our research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have an adverse effect on our ability to conduct our clinical trials, our development plans and business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (Tax Act) and the Coronavirus Aid, Relief and Economic Security Act of 2020 (CARES Act) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. More recently, the Inflation Reduction Act of 2022 was enacted which includes provisions that will affect the U.S. federal income taxation of corporations, including imposing a minimum tax on the book income of certain large corporations and an excise tax on certain corporate stock repurchases that would be imposed on the corporation repurchasing such stock. In addition, it is uncertain if and to what extent various states will conform to such legislation or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future U.S. tax expense. Among the changes made by the Tax Act was a reduction of the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#8220;orphan drugs&#8221;. We continue to examine the impact this tax reform legislation may have on our business. We urge investors to consult with their legal and tax advisers regarding the implications of the Tax Act and other past and potential future changes in U.S. tax laws on an investment in our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred losses during our history, we expect to continue to incur significant losses for the foreseeable future, and we may never achieve profitability. As of December 31, 2023, we had federal and state net operating loss (NOL) carryforwards of $118.9 million and $35.7 million, respectively, that will begin expiring in the year 2032 and 2036, respectively, if not utilized. We also have $109.0 million of federal NOL carryforwards as of December 31, 2023, that do not expire as a result of recent tax law changes. Our NOL carryforwards are subject to review and possible adjustment by the U.S. and state tax authorities. Our NOL carryforwards could expire unused and be unavailable to offset future taxable income because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. NOLs arising in tax years beginning after December 31, 2017, and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss, and NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of current year taxable income. At the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. It is generally uncertain if and to what extent various states will conform to federal tax laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a cumulative change in our ownership by &#8220;5-percent shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period), the corporation&#8217;s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the ownership. Our ability to utilize those NOLs could be limited by an &#8220;ownership change&#8221; as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have an adverse effect on our cash flows and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">A variety of risks associated with marketing our current or any future product candidate we may develop internationally could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to seek regulatory approval of our current or any future product candidates we may develop outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">differing regulatory requirements and reimbursement regimes in foreign countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential liability under the FCPA or comparable foreign regulations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These and other risks associated with our international operations may significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our intellectual property</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our and our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for atacicept, MAU868, and any future product candidates that we may develop and technologies related to their various uses. We generally seek to protect our proprietary position by, among other things, filing patent applications in the United States and abroad related to our proprietary technologies, and their manufacture and uses that are important to our business, as well as inventions and improvements that are important to the development and implementation of our business. Our owned and in-licensed patents and patent applications in both United States and certain foreign jurisdictions relate to atacicept, MAU868, and other products. There can be no assurance that the claims of our owned or in-licensed patents, or any patent application that issues as a patent, will exclude others from making, using or selling our product candidates or any future product candidates or products that are substantially similar to our product candidates or any future product candidates. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position. We may seek to protect our proprietary position by acquiring or in-licensing additional relevant issued patents or pending applications from third parties. If we or our potential licensors, licensees or collaborators are unable to obtain or maintain patent protection with respect to atacicept, MAU868, and our other products, proprietary technologies and their uses, our business, financial condition, results of operations and prospects could be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our owned or in-licensed patent applications or our current or future licensors&#8217;, licensees&#8217; or collaborators&#8217; patent applications will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around or invalidated by third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, in the future, some of our owned or in-licensed patents and patent applications may be co-owned with third parties. If we are unable to obtain exclusive licenses to any such co-owners&#8217; interest in such patents or patent applications, then such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. Thus, the degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to atacicept, MAU868, or any future product candidates we may develop could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot be certain that the claims in our U.S. pending patent applications and corresponding international applications will be considered patentable by the United States Patent and Trademark Office (USPTO) courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patent(s) will not be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting atacicept, MAU868, or any future product candidates we may develop by obtaining and defending patents. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications must be filed in advance of certain events (e.g., third-party filings, certain sales or offers for sale, or other activities that might be legally deemed to be public disclosures) and we might not be aware of such events or otherwise might not succeed in filing applications before they occur;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patent applications may not result in any patents being issued;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is also expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection, for example, if patentable aspects are publicly disclosed, by us or a third party, such as by public use, sale or offer for sale, or publication.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Further, although we require our employees, commercial contractors, and certain consultants and investigators to enter into invention assignment agreements that grant us ownership of any discoveries or inventions made by them while in our employ, we cannot guarantee that we have entered into such agreements with each party, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach such agreements and claim ownership in intellectual property that we believe is owned or in-licensed by us. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or any licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Should any of the above events occur, it could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we breach our license agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis related to MAU868, we could lose the ability to continue the development and commercialization of atacicept or MAU868, respectively.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on patents, know-how and proprietary technology licensed or sublicensed to us from Ares and Novartis. Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our and our licensor&#8217;s proprietary technologies without infringing the proprietary rights of third parties. Either Ares or Novartis may have the right to terminate the applicable license agreement in full in the event we materially breach or default in the performance of any of the obligations under the applicable license agreement. A termination of either license agreement could result in the loss of significant rights and could harm our ability to commercialize our product candidates. Additionally, certain patents, know-how and proprietary technology of third parties, including certain composition of matter patents, are sublicensed to us and in the event the applicable license agreement terminates, expires or is in dispute, it could result in the loss of significant rights and could harm our ability to commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may also arise between us and Ares, an affiliate of Merck KGaA, Darmstadt, Germany, Novartis, or any future potential licensors, regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates and what activities satisfy those diligence obligations; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we acquired worldwide, exclusive rights to atacicept pursuant to the Ares Agreement, and worldwide, exclusive rights to develop, manufacture and commercialize MAU868 pursuant to the Amplyx Agreement, pursuant to which we acquired Amplyx&#8217;s right, title and interest in the license agreement between Amplyx and Novartis related to MAU868 (the Novartis Agreement). The Ares Agreement and Novartis Agreement are complex, and certain provisions may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our financial or other obligations under such agreement, either of which could have an adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangement on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have an adverse effect on our business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be required to make significant payments under our license agreements related to atacicept and MAU868.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Ares Agreement, in consideration for the license, we issued shares of our Series C redeemable convertible preferred stock to Ares at the time of the initial closing of our Series C redeemable convertible preferred stock financing, which automatically converted into 1,913,501 shares of our common stock upon the closing of our IPO. As additional consideration for the license, we paid Ares $25.0 million upon delivery and initiation of the transfer of specified information and materials and we are required to pay Ares aggregate milestone payments of up to $176.5 million upon the achievement of specified BLA filing or regulatory approval and aggregate milestone payments of up to $515.0 million upon the achievement of specified commercial milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay tiered royalties of low double-digit to mid-teen percentages on annual net sales of the products covered by the license. In the event we sublicense our rights under the Ares Agreement, we are obligated to pay Ares a percentage ranging from the mid-single-digit to the low double-digits of specified sublicensing income received.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Amplyx Agreement, we made an upfront initial payment of $5.0 million. We are also obligated to make certain milestone payments to Amplyx in an aggregate amount of up to $7.0 million based on the achievement of certain regulatory milestones. Further, we are required to pay Amplyx low single digit percentage royalties on net sales of MAU868 on a country-by-country and product-by-product basis. In addition, pursuant to the Novartis Agreement, we are obligated to make certain milestone payments to Novartis in an aggregate amount of up to $62.0 million based on the achievement of certain clinical development, regulatory and sales milestones. Further, we are required to pay Novartis mid-to high-single digit percentage royalties based on net sales of MAU868 on a country-by-country and product-by-product basis. If milestone or other non-royalty obligations become due,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not have sufficient funds available to meet our obligations, which will adversely affect our business operations and financial condition.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent positions of biotechnology companies generally are highly uncertain, involve complex legal and factual questions for which important legal principles remain unsolved and have been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect atacicept or MAU868 or which effectively prevent others from commercializing competitive technologies and product candidates. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted after issuance. Legal standards relating to valid and enforceable claim scope are unsettled in the United States and elsewhere and disputes challenging or re-defining scope are common in the biopharmaceutical industry. Even if patent applications we own or in-license currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or in-license may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether atacicept, or MAU868, or any future product candidates we may develop will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process by which patent applications are examined and considered for issuance as patents involves consideration by the relevant patent office of &#8220;prior art&#8221; relative to the invented technology. Different countries have different rules about what information or events can be considered &#8220;prior art,&#8221; and different requirements regarding when a patent application must be filed relative to any particular piece of potential prior art. Moreover, legal decisions can re-interpret or change whether particular information or events are considered to be &#8220;prior art.&#8221; Still further, in the United States, patent applicants are required to notify the USPTO of any material &#8220;prior art&#8221; of which they are aware for the patent examiner to consider in addition to independent searches that the patent examiner is required to do. Also, in the United States and certain other jurisdictions, third parties are entitled to submit prior art to patent offices for consideration during examination.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be aware of certain relevant prior art, may fail to identify or timely cite certain prior art, or may not be able to convince a patent examiner that our patent(s) should issue in light of the art. Also, we cannot be certain that all relevant art will be or was identified during examination of a patent application so that, even if a patent issues, it may be susceptible to challenge that it is not valid over art that was not considered during its examination.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to a third-party pre-issuance submission of prior art to the USPTO or other jurisdictions, or become involved in post-grant challenges such as opposition, derivation, revocation, reexamination, post-grant review (PGR) and inter partes review (IPR), or other similar proceedings, or in litigation, challenging our patent rights, including by challenging the validity or the claim of priority of our patents. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize atacicept, MAU868, or any future product candidates we may develop and compete directly with us, without payment to us. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of atacicept, MAU868, or any future product candidates we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, including art of which we were unaware, and art which was not raised during prosecution of any of our patents or patent applications. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates that we may develop. Such a loss of patent protection would significantly impact our business, financial condition, results of operations and prospects. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates or could embolden competitors to launch products or take other steps that could disadvantage us in the marketplace or draw us into additional expensive and time consuming disputes. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not be able to detect infringement of our issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to develop products that are similar to atacicept, MAU868, or any future product candidates we may develop, but that are not covered by the claims of the patents that we may in-license in the future or own;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell atacicept, MAU868, or any future product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our current or future collaborators or license partners, might not have been the first to make the inventions covered by the issued patents or patent applications that we may in-license in the future or own;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we, or our current or future collaborators or license partners, might be found not have been the first to file patent applications covering certain of our or their inventions;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that the pending patent applications we may in-license in the future or own will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our patents, or parts of our patents, for which we are not aware;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">issued patents may not have sufficient term or geographic scope to provide meaningful protection;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets, and a third party may subsequently file a patent covering such intellectual property.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise violating the patents and other proprietary rights of third parties. Claims by third parties that we infringe, misappropriate or otherwise violate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on avoiding infringement, misappropriation or other violations of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. A finding by a court or administrative body that we infringe the claims of issued patents owned by third parties could preclude us from commercializing atacicept, MAU868, or any future product candidates we may develop.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import atacicept, MAU868, or any future product candidates we may develop and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, and proceedings, such as oppositions, reexaminations, IPR proceedings and PGR proceedings, before the USPTO and/or corresponding foreign patent offices. In addition, many companies in intellectual property-dependent industries, including the biotechnology industry, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous third-party U.S. and foreign issued patents and pending patent applications may exist in the fields in which we are developing atacicept, MAU868, or any future product candidates we may develop. There may be third-party patents or patent applications with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of atacicept, MAU868, or any future product candidates we may develop.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may be unable to develop, manufacture, market, sell and commercialize products or services or perform research and development or other activities covered by these patents. In the event that any of these patents were to issue and be asserted against us, we believe that we would have defenses against any such assertion, including that such patents are not valid. However, if such defenses to such assertion were unsuccessful, we could be liable for damages, which could be significant and include treble damages and attorneys&#8217; fees if we are found to willfully infringe such patents. We could also be required to obtain a license to such patents, which may not be available on commercially reasonable terms or at all. If we are unable to obtain such a license, we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As the biotechnology industry expands and more patents are issued, the risk increases that atacicept, MAU868, or any future product candidates we may develop, may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents that may be infringed by commercialization of atacicept, MAU868, or any future product candidates we may develop, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that atacicept, MAU868, or any future product candidates we may develop may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Still further, we cannot rely on our experience that third parties have not so far alleged that we infringe their patent rights, as provisions of U.S. patent laws provide a safe harbor from patent infringement for therapeutic products under clinical development.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any claims of patent infringement, misappropriation or other violations asserted by third parties would be time consuming and could:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">result in costly litigation that may cause negative publicity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">divert the time and attention of our technical personnel and management;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cause development delays;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prevent us from commercializing atacicept, MAU868, or any future product candidates we may develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subject us to significant liability to third parties; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any patent-related legal action against us claiming damages or seeking to enjoin commercial activities relating to our products, or processes could subject us to significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market atacicept, MAU868, or any future product candidates we may develop. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or a future strategic partner were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign atacicept, MAU868, or any future product candidates we may develop processes to avoid infringement, if necessary.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing atacicept, MAU868, or any future product candidates we may develop, which could significantly harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing atacicept, MAU868, and future product candidates and technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have an adverse effect on our ability to raise additional funds or otherwise significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights from third parties that we identify as necessary for future product candidates we may develop through acquisitions and in-licenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we may have in-licensed patents that cover atacicept and MAU868, it is possible that third parties may have blocking patents that prevent us from marketing, manufacturing or commercializing our patented products and practicing our in-licensed patented technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unsuccessful in acquiring or in-licensing compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for practicing inventions claimed by our patents, including the manufacture, sale and use of atacicept, MAU868, and any future product candidates we may develop. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors or other third parties may infringe, misappropriate or otherwise violate our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement or other intellectual property claims, which can be expensive and time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we may in-license in the future or own is not valid, is unenforceable, and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our owned or in-licensed patents do not cover the technology in question. If we or any of our potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at atacicept, MAU868, or any future product candidates we may develop, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement, or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have an adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring atacicept, MAU868, or any future product candidates to market. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our patents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Our ability to obtain patents is highly uncertain because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States. Furthermore, the specific content of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the United States has enacted and implemented wide-ranging patent reform legislation and the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For example, recent decisions raise questions regarding the award of patent term adjustment (&#8220;PTA&#8221;) for patents in families where related patents have issued without PTA. Thus, it cannot be said with certainty how PTA will or will not be viewed in the future and whether patent expiration dates may be impacted.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> An inability to obtain, enforce, and defend patents covering our proprietary technologies (including atacicept and MAU868) would adversely affect our business prospects and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States and Europe. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement, in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system took effect on June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC and remaining as national</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that we do not transfer or perfect ownership of all patents, patent applications or other intellectual property. This possibility includes the risk that we do not identify all inventors, or identify incorrect inventors, which may lead to claims disputing inventorship or ownership of our patents, patent applications or other intellectual property by former employees or other third parties. There is also a risk that we do not establish an unbroken chain of title from inventors to us. Errors in inventorship or ownership can sometimes also impact priority claims. If we were to lose ability to claim priority for certain patent filings, intervening art or other events may preclude us from issuing patents.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could significantly harm our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on atacicept, MAU868, or any future product candidates we may develop for an adequate amount of time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. Various extensions may be available, but there can be no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. There is a risk that we may take action that detracts from any accrued patent term adjustment. Even if patents covering atacicept, MAU868, or any future product candidates we may develop are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our earliest in-licensed patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, financial condition, prospects and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar non-United States legislation for extending the term of patents covering each of our product candidates, our business may be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent may be extended per approved drug product, and only those claims covering the approved drug product, a method for using it, or a method for manufacturing it may be extended. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be impacted and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the United States. Consequently, we will not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These infringing products may compete with atacicept, MAU868, or any future product candidates we may develop, without any available recourse.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to biopharmaceuticals. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. Because the legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceutical products, it could be difficult for us to stop the infringement, misappropriation or violation of our patents or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our intellectual property and other proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly, could put our patent applications or the patent applications of our licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Russian and Eurasian patents. Recent Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, recordation of licenses with respect to exclusively licensed patent rights outside of the United States is potentially costly and we might fail to record such rights timely. If we fail to timely record our patent rights, third parties may try to seek licenses from the patent owners, or we may not be able to recover full damages for patent infringement in jurisdictions where we have no such recordations, any of which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or patent applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, potential competitors might be able to enter the market with similar or identical products or technology, which could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations and prospects could be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business, financial condition, results of operations and prospects may be significantly harmed. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any proprietary name we propose to use with our current or future products in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business, financial condition, results of operations, prospects and competitive position would be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology or processes. Further, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, or claim ownership in intellectual property that we believe is owned or in-licensed by us. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. Any of the foregoing could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have entered into and may enter in the future into non-disclosure and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential partners, lessees of shared multi-company property and other third parties. Many of our employees and consultants were previously employed at, may have previously provided or may be currently providing consulting services to, other biotechnology companies, including our competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents or patent applications. Defense of such matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing atacicept, MAU868, or any future product candidates or technologies we may develop. Failure to defend against any such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, and cause us to lose valuable intellectual property rights or personnel, which could significantly harm our business, financial condition, results of operations and prospects. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from the initiation and continuation of any litigation could have an adverse effect on our ability to raise additional funds or otherwise significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may enter into license agreements in the future with others to advance our research or allow commercialization of our product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in our licenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to comply with our obligations under any such license agreements, including obligations to make various milestone payments and royalty payments and other obligations, the licensor may have the right to terminate the license. If these agreements are terminated, we could lose intellectual property rights that are important to our business, be liable for any damages to such licensors or be prevented from developing and commercializing our product candidates, and competitors could have the freedom to seek regulatory approval of, and to market, products identical to ours. Termination of these agreements or reduction or elimination of our rights under these agreements may also result in our being required to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, or impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business, including the payment of all applicable fees for patents covering our product candidates. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject of such licensed rights could be adversely affected. Further, we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control the prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by the actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may need to obtain additional licenses from existing licensors and others to advance our research or allow commercialization of product candidates we develop. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could significantly harm our business, financial condition, results of operations and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes may arise between us and our past, current or future licensors regarding intellectual property subject to a license agreement, including:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patents and other rights to third parties;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to transfer or assign the license;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could significantly harm our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could significantly harm our business, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could significantly harm our competitive position, business, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property discovered through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may develop, acquire, or license intellectual property rights that have been generated through the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as march-in rights). If the U.S. government exercised its march-in rights in our future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to our dependence on third parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize atacicept, MAU868 or future product candidates we may develop and our business, financial condition, results of operations and prospects could be significantly harmed.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our nonclinical studies and clinical trials and to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for atacicept and MAU868 in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Failure to comply and maintain adequate documentation with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to atacicept or MAU868 and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of atacicept or MAU868, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize atacicept or MAU868. As a result, our results of operations and the commercial prospects for atacicept and MAU868 would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely, and our business, financial condition, results of operations and prospects could be significantly harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. In addition, our CROs could fail to perform, we could terminate their agreements or they could go out of business. If our relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding CROs involves substantial cost and requires management time and focus, and could delay development and commercialization of atacicept, MAU868 or any future product candidate we may develop. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. There can be no assurance that we will not encounter challenges or delays with CROs in the future or that these delays or challenges will not significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining the rights to MAU868 from Amplyx, third parties had been responsible for all development activities. Although we believe the historical development activities were conducted in accordance with applicable rules and regulations in material respects, we cannot assure you that we will not discover inaccuracies or noncompliance in prior development activities that have an adverse effect on the future development of MAU868. For example, a regulatory authority may choose to inspect an investigational site and/or vendor such as a CRO for an MAU868 study that was previously conducted by Amplyx. Findings from such inspections could have an impact on the review of any future marketing applications by the FDA or foreign regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our acquisition of MAU868, we have assumed the responsibility for ongoing clinical studies with MAU868, including related expenses and manufacturing and regulatory activities, which were previously managed and funded by Amplyx. This includes responsibility for the Phase 2 clinical trial of MAU868 for the treatment of BKV infection in kidney transplant recipients previously conducted by Amplyx. Any adverse events or reactions experienced by subjects in the trial may be attributed to MAU868 and may limit our ability to obtain regulatory approval with labeling that we consider desirable, or at all.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We contract with third parties for the manufacture of atacicept and MAU868 drug products for our ongoing clinical trials, and expect to continue to do so for additional clinical trials of our product candidates and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of atacicept, MAU868 or other product candidates necessary for the development or commercialization of atacicept, MAU868 or such other product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for clinical trials under the guidance of members of our organization. We do not have long-term commercial supply agreements for atacicept or MAU868. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to rely on third-party manufacturers for the commercial supply of our product candidates, if we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the breach by the third-party contractors of our agreements with them;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of third-party contractors to comply with applicable regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the failure of the third party to manufacture our product candidates according to our specifications;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disruptions resulting from the effect of public health pandemics or epidemics; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the misappropriation of our proprietary information, including our trade secrets and know-how.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited control over the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or other regulatory authorities, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. We, or our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMP. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or other drugs necessary for the development or commercialization of our product candidates and significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or other drugs necessary for the development or commercialization of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our product for patients, if approved, could be delayed or prevented.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide nonclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and significantly harm our business, financial condition, results of operations and prospects. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the assumption of contingent liabilities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the issuance of our equity securities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing programs and initiatives in pursuing such a strategic merger or acquisition;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and marketing approvals; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we undertake acquisitions or pursue partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may enter into collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of atacicept or MAU868.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may partner with third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any future collaboration arrangements would likely include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we decide to establish collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our drug development programs and the potential commercialization of our current or any future product candidates we may develop will require substantial additional cash to fund expenses. We may continue to seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we seek collaborations in the future, we will face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidates. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If and when we seek to enter into additional collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks related to ownership of our common stock</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common stock may be volatile, and you could lose all or part of your investment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock has been, and is likely to be, highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. For example, the closing price of our common stock from January 1, 2023 to March 20, 2024, has ranged from a low of $5.41 to a high of $49.14. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, these factors include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing and results of nonclinical studies and clinical trials of our current or any future product candidates we may develop or those of our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory actions with respect to our product candidate or our competitors&#8217; products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the success of competitive products or announcements by potential competitors of their product development efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments associated with our license with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, including any termination or other change in our relationship with Ares or Merck KGaA, Darmstadt, Germany;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments associated with our license with Novartis, including any termination or other change in our relationship with Novartis or Amplyx;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in our growth rate relative to our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of our efforts to in-license or acquire additional product candidates or products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sector;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the public release of clinical trial data from companies perceived by investors to be comparable to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcement or expectation of additional financing efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our securities by us, our insiders or our other stockholders; and </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">general </span><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">eopolitical, macroeconomic, industry and market conditions, including the recent and potential future disruptions in access to bank deposits and lending commitments due to bank failures, ongoing military conflicts, related sanctions, economic slowdowns, recessions, inflation, rising interest rates, and tightening of credit markets.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the trading prices for common stock of other biotechnology companies have been highly volatile as a result of factors unrelated to the specific company or its technology. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act of 2002 (Section 404) requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public accounting firm, to the extent we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and are not a non-accelerated filer. We do not expect our independent registered public accounting firm to attest to our management report on internal control over financial reporting for so long as we are an emerging growth company.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have in the past and may in the future identify material weaknesses in our internal control over financial reporting. If we identify any such material weaknesses, if we are unable to comply with the requirements of Section 404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could require additional financial and management resources.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our outstanding voting stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding capital stock, beneficially own a significant percentage of our outstanding voting stock. Therefore, these stockholders are able to significantly influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their shares, and might affect the prevailing market price for our common stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our common stock price could decline as a result of sales of a large number of shares of common stock in the future or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, there were 44,452,161 shares of Class A common stock outstanding and held of record by 23 stockholders. The number of record holders of our common stock does not include DTC participants or beneficial owners holding shares through nominee names. Subsequent to our follow-on public offering in February 2024, the resale of shares of common stock held by our officers and directors is currently prohibited or otherwise restricted until April 1, 2024, as a result of lock-up agreements entered into by our officers and directors with the underwriters in connection with such offering. The representatives of the underwriters may release some or all of the shares of common stock subject to lock-up agreements at any time in their sole discretion and without notice, which would allow for earlier sales of shares in the public market.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, certain holders of our common stock have rights, subject to certain conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We have also registered all shares of common stock that we may issue under our equity compensation plans. Such shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to atacicept, MAU868 or future product candidates we may develop on unfavorable terms to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. For example, since our initial public offering, we have completed three follow-on public offerings of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to atacicept, MAU868 or future product candidates we may develop, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; and a &#8220;smaller reporting company&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.235 billion in annual revenue; (2) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) December 31, 2026. Based on our current public float, we anticipate that when we re-evaluate our filer status on June 30, 2024, we will determine that we qualify as a &#8220;large accelerated filer&#8221; for the year ending December 31, 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have taken advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 404 we will be required to furnish a report by our management on our internal control over financial reporting, including, if required by our filing status, an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company or a non-accelerated filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we are also a &#8220;smaller reporting company,&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. Based on our current public float, we anticipate that when we re-evaluate our smaller reporting company status on June 30, 2024, we will determine that we no longer qualify a smaller reporting company for the year ending December 31, 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investors may find our common stock less attractive as a result of our reliance on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the Loan Agreement restrict our ability to declare and pay dividends without the prior written consent of Oxford. Any return to stockholders will therefore be limited to any appreciation in the value of our common stock, which is not certain.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a classified board of directors such that not all members of the board are elected at one time;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">limit the manner in which stockholders can remove directors from the board;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit our stockholders from calling a special meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit cumulative voting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our amended and restated certificate of incorporations or amended and restated bylaws.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (DGCL), which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any derivative claim or cause of action brought on our behalf;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our bylaws (as each may be amended from time to time);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any claim or cause of action against us or any of our current or former directors, officers, or other employees governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">United States will be the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying such offering. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General risk factors</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our information technology systems, or those of any of our third-party partners (such as contract research organizations and clinical trial sites), or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; additional costs; loss of revenue or profits; and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we and our third-party partners (such as contract research organizations and clinical trial sites) process sensitive information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result, we and our third-party partners are vulnerable to a variety of evolving threats that could cause security incidents. Cyberattacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive information and information technology systems, and those of our third-party partners.  These threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and our third-party partners (such as contract research organizations and clinical trial sites) may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and our third-party partners may also be subject to a variety of evolving threats, including but not limited to errors or malfeasance by personnel, malware (including as a result of advanced persistent threat intrusions), malicious code (such as viruses and worms), software vulnerabilities, hacking, denial of service attacks, credential stuffing, social-engineering attacks (including deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods and other similar threats.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive information and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Remote work has become more common and has increased risks to our information technology systems and sensitive information, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.  Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our reliance upon third-party partners and technologies to operate critical business systems and to process sensitive information could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party partners in a variety of contexts, including, without limitation, third-party providers of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cloud-based infrastructure, encryption and authentication technology, employee email, content delivery to customers, and other functions. We also rely on third-party partners to provide other products, services, parts, or otherwise to operate our business.  Our ability to monitor these third parties&#8217; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> If our third-party partners experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party partners fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps to detect, mitigate, and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of our third-party partners). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third-party partners. A security incident or other interruption could disrupt our ability (and that of our third-party partners (such as contract research organizations and clinical trial sites)) to provide our products or services. We may expend significant resources or modify our business activities (including our clinical trial activities) in an effort to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators and investors, of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we or our third-party partners (such as contract research organizations and clinical trial sites) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing information (including personal data); substantial remediation costs; litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be certain that our insurance coverage will be adequate or sufficient to protect us from or mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available to us on economically reasonable terms, or at all, or that such coverage will pay future claims.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, disclosed or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s or vendors&#8217; use of generative AI technologies.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">again in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance activities. See the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212; Recent accounting pronouncements.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The requirements of being a public company may strain our resources, result in more litigation and divert management&#8217;s attention.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act the listing requirements of the Nasdaq Stock Market LLC and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could significantly harm our business, financial condition, results of operations and prospects. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial condition, results of operations and prospects may be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By disclosing information in SEC filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to securities litigation, which is expensive and could divert management attention.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation and shareholder derivative actions. We may be the target of these types of litigation and claims in the future. These claims and litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock is influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If few securities or industry analysts commence coverage of us, the stock price would be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="itemic_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 1C. Cybersecurity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk management and strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical computer networks, third-party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and sensitive personal data, including of our employees, consultants and clinical trial participants (Information Systems and Data).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Chief Financial Officer, Chief Business Officer, Chief Accounting Officer, and Head of Legal form our Cybersecurity Risk Management Committee and help identify, assess and manage the Company&#8217;s cybersecurity threats and risks. This Cybersecurity Risk Management Committee, which reports to our overall risk management committee, identifies and assesses risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods including, for example: manual and automated tools in certain environments and systems, subscribing to reports and services that identify certain cybersecurity threats, conducting scans of certain threat environments, analyzing reports of certain threats and actors, evaluating certain cybersecurity threats reported to us, and conducting internal and external audits of certain environments and systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending on the environment and system, we implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity threats to our Information Systems and Data, including, for example: incident response plan; incident detection and response tools; risk assessments of certain environments and systems; encryption of certain data; network security for certain environments and systems; access controls for certain environments and systems; data segregation of certain data; access controls; physical security; asset management; third-party systems monitoring; employee cybersecurity training; and cybersecurity insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our assessment and management of material risks from cybersecurity threats are integrated into the Company&#8217;s overall risk management processes. For example, our Cyber Security Risk Management Committee evaluates material risks from cybersecurity threats against our overall business objectives and reports to the audit committee of the board of directors, which evaluates our overall enterprise risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example professional services firms, such as legal counsel, threat intelligence service providers, and cybersecurity software providers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use third-party service providers to perform a variety of functions throughout our business, such as software application providers, hosting companies, contract research organizations, and contract manufacturing organizations. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a description of the risks from cybersecurity threats that may materially affect the Company and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report, including the section titled &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risk Factors&#8212;General risk factors&#8212;If our information technology systems or data, or those of any of our third-party partners (such as contract research organizations and clinical trial sites), or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; additional costs; loss of revenue or profits; and other adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governance</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our board of directors addresses the Company&#8217;s cybersecurity risk management as part of its general oversight function. The board of directors&#8217; audit committee is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of mitigation of risks from cybersecurity threats.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Chief Business Officer, Chief Accounting Officer, and Head of Legal, working closely with our third-party information technology team; the senior staff members of our third-party information technology team have been in business providing services to similarly situated companies in our industry for more than 27 years, including extensive experience addressing complex information technology and cybersecurity matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In particular, the Chief Business Officer is responsible for hiring appropriate personnel and third-party vendors, communicating key priorities to relevant personnel, and, in concert with members of the Cybersecurity Risk Management Committee, helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy. Our Chief Business Officer, Chief Accounting Officer, and Head of Legal, in consultation with our third-party information technology team, is responsible for maintaining cybersecurity-related budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our incident response plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the Cybersecurity Risk Management Committee. This group works with the Company&#8217;s incident response team to help the Company mitigate and remediate cybersecurity incidents of which they are notified. In addition, the Company&#8217;s incident response plan includes reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The audit committee receives regular reports concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, including during audit committee meetings and other periodic updates. These reports are provided by members of the Company&#8217;s management team responsible for such reporting, including the Cybersecurity Risk Management Committee. The audit committee also receives various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Properties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate headquarters are located in Brisbane, California.  We occupy approximately 9,885 square feet of office space for our corporate headquarters under a lease that expires in November 2024.  We believe our existing leased facility is in good condition and suitable for the conduct of our current business.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Legal Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. We are not currently a party to any material legal proceedings. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_market_for_registrants_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Class A common stock has traded on the Nasdaq Global Select Market under the symbol &#8220;VERA&#8221; since May 14, 2021.  Prior to that, there was no public market for our stock.  Our Class B common stock is not listed on any stock exchange nor traded on any public market.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 20, 2024, there were approximately 21 stockholders of record of our Class A common stock.  The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dividend Policy</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never declared or paid any cash dividends on our common or capital stock.  We intend to retain any future earnings for the long-term growth of the business and do not expect to pay cash dividends in the foreseeable future. In addition, the terms of the Loan Agreement with Oxford restrict our ability to declare and pay dividends without the prior written consent of Oxford.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">See Item 12 of Part III of this Annual Report for information about our equity compensation plans which is incorporated by reference herein.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, all of the net proceeds from our initial public offering have been applied as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on May 17, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Parties</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_reserved"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. Res</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">erved.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7_managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:5.067%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and the related notes included elsewhere in this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In addition to historical financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, beliefs and expectations, and involve risks and uncertainties. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report, particularly in the sections titled &#8220;Special Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. IgAN is a B cell disorder with a kidney pathology. Our lead product candidate, atacicept, is an at home, self-administered TACI-Fc fusion protein that blocks both BAFF and APRIL with best-in-class potential for the treatment of IgAN. The Phase 2b ORIGIN clinical trial evaluating the safety and efficacy of atacicept in participants with IgAN reported positive results at three timepoints: 24-week topline results in January 2023, 36-week results in June 2023, and 72-week results in January 2024. The trial remained blinded through 36 weeks, after which all participants were eligible for the open label extension portion of the study and received atacicept 150 mg through 96 weeks. At 24 and 36 weeks, respectively, atacicept met its primary endpoint with statistically significant reductions in UPCR on atacicept 150 mg, and stable eGFR was observed for participants on atacicept, with clinically meaningful and statistically significant difference versus placebo. Participants treated with atacicept demonstrated reductions in Gd-IgA1, the autoantigen produced by B cells in patients with IgAN, and a reduction in hematuria. The improvements in Gd-IgA1, hematuria, UPCR and eGFR represent the quartet of findings consistent with IgAN disease modification. The 72-week open label extension results showed consistent and sustained reductions in Gd-IgA1, hematuria, UPCR and continued eGFR stabilization. Additionally, atacicept&#8217;s safety profile was comparable to placebo. We advanced atacicept 150 mg in a pivotal Phase 3 clinical trial in IgAN in the second quarter of 2023. We believe that atacicept has pipeline in a molecule potential, with potential application in additional indications including SLE and LN, a severe renal manifestation of SLE. We have designed and are poised to conduct a Phase 3 clinical trial of atacicept in LN, based on feedback from the FDA&#8217;s review of clinical results in a Phase 2 clinical trial of atacicept in SLE patients with HDA. We also hold worldwide, exclusive development and commercial rights to MAU868, a potentially first-in-class monoclonal antibody to treat reactivated BKV infections, for which we completed a Phase 2 clinical trial in 2022. In January 2023, we delayed enrollment in the pivotal Phase 3 trial for LN and commitment of resources to the MAU868 program. We believe that our current pipeline programs leverage the deep expertise of our team and have strong potential commercial synergies. We hold global developmental and commercial rights to all of our pipeline molecule.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to our research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales. Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful development and eventual commercialization of one or more of our product candidates, which we expect will take a number of years. We also do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for nonclinical and clinical testing, as well as for commercial manufacturing if any of our product candidates obtain marketing approval. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also enabling us to focus our expertise and resources on the development of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have funded our operations primarily through proceeds from the sale of shares of our common stock, redeemable convertible preferred stock, debt financing and convertible promissory notes. As of December 31, 2023, we had $160.7 million in cash, cash equivalents and marketable securities, compared to $114.7 million as of December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses since the commencement of our operations. Our net losses were $96.0 million and $89.1 million for the years ended December 31, 2023 and 2022, respectively, and we expect to incur significant and increasing losses for the foreseeable future as we continue to advance our product candidates, atacicept and MAU868, to commercialization. Our net losses may fluctuate significantly from period to period, depending on the timing of expenditures on our research and development activities. As of December 31, 2023, we had an accumulated deficit of $309.1 million, compared to $213.1 million as of December 31, 2022. Our primary use of cash is to fund operating expenses, which consist of research and development expenditures and general and administrative expenditures. Cash used to fund operating expenses depends on the timing of when we pay these expenses, as reflected in the changes in our working capital balances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to continue to incur net operating losses for at least the next several years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and capital requirements will increase significantly in connection with our ongoing activities as we:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue our ongoing and planned development of our product candidates, atacicept for the treatment of IgAN and LN, and MAU868 for the treatment of BK viremia;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conduct clinical trials and nonclinical studies for atacicept and MAU868;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity requirements for clinical trials and potential commercialization;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related additional commercial manufacturing costs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and know-how;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">attract, hire and retain additional clinical, scientific, quality control, and manufacturing management and administrative personnel; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">add clinical, operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> We will require substantial additional funding to develop our product candidates and support our continuing operations. Until such time that we can generate significant revenue from product sales or other sources, if ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaborations, strategic partnerships, or marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to have to delay, reduce or eliminate our product development or future commercialization efforts. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts. We cannot provide assurance that we will ever be profitable or generate positive cash flow from operating activities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Geopolitical and Macroeconomic Developments</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Due to geopolitical and macroeconomic events, including ongoing military conflicts, inflation and the actions taken by governments to address inflation and lingering effects of the COVID-19 pandemic,  the U.S. and global financial markets experienced volatility, which has led to disruptions to trade, commerce, pricing stability, credit availability and supply chain continuity globally. As a result of these factors and other geopolitical and macroeconomic developments described in this Annual Report, our business and results of operations may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we did not see a significant financial impact to our business operations as a result of recent geopolitical and macroeconomic developments during the year ended December 31, 2023, there may be potential impacts to our business in the future that are highly uncertain and difficult to predict such as disruptions or restrictions in our supply chain, disruption or restrictions on our employees&#8217; ability to travel, disruptions to or delays in ongoing non-clinical trials, clinical trials, third-party manufacturing supply and other operations, adverse geopolitical and macroeconomic concerns, interruptions or delays in the operations of the FDA or other regulatory authorities, continued increases in inflation and interest rates, or changes in availability and cost of credit and our ability to raise capital and conduct business development activities. The ultimate impact of these geopolitical and macroeconomic developments, as well as any lasting effects on our business, is highly uncertain and subject to continued change, and we recognize that macroeconomic and geopolitical factors may continue to present unique challenges for us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that our existing cash, cash equivalents and marketable securities held as of December 31, 2023, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of this Annual Report. However, should adverse geopolitical and macroeconomic events, such as ongoing military conflicts, related sanctions, any recession or depression associated with those events or other events described herein, continue for a prolonged period, our results of operations,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">financial condition, liquidity and cash flows could be materially impacted as a result of a lower likelihood of effectively and efficiently developing and successfully commercializing our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2023 and 2022</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2023 and 2022.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.7%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:11.360000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:11.360000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.46%;"/>
    <td style="width:1%;"/>
    <td style="width:11.360000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.84%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CHANGE</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(dollars in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AMOUNT</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,993</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,787</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,910</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,877</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,012</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,903</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,109</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(102,012</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(90,903</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(11,109</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,979</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,750</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,229</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">356</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,786</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(992</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,794</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">282</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,877</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,899</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of non-marketable equity securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(47</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(809</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">762</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(94</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,848</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,175</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(95,989</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(89,055</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,934</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Not meaningful</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses represent a substantial portion of our operating expenses. Our research and development expenses consist primarily of direct and indirect expenses incurred in connection with the research and development of our product candidates. Direct expenses include costs incurred under agreements with third parties, including contract research organizations, contract drug manufacturing organizations and consultants directly related to our research and development of product candidates, and license and milestone fees incurred as a result of our contractual obligations for our development candidates. Indirect expenses include employee compensation and other personnel-related expenses, including stock-based compensation, facilities and depreciation related to buildings and equipment used by research and development personnel and activities and other expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses are recorded as expense in the period in which the related activities occurred, and payments we make prior to the receipt of goods or services to be used in research and development efforts are deferred as prepaid expenses until the goods or services are received and used. We accrue expenses for contract research and development as the related services are performed by monitoring the status of specified activities and billings received from our external service providers. These expenses are accrued based on estimates and are adjusted as actual expenses become known. The cost incurred in obtaining technology licenses, including initial and subsequent milestone payments incurred under our licensing agreements, are recorded as expense in the period in which they are incurred, as the licensed technology, method or process has no alternative future uses other than for our research and development activities. Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses incurred during the respective periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.37%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.182%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.942%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.662%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CHANGE</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(dollars in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AMOUNT</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Direct research and development expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract drug manufacturing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,049</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,587</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical trial expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,611</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,534</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(923</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Consulting and professional services</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,648</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,431</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">License and milestone obligations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,661</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,661</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indirect research and development expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation and related benefits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,623</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,987</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,636</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Facilities and other</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">793</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">501</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,993</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,232</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses increased by $9.2 million, or 13%, to $78.2 million in the year ended December 31, 2023, from $69.0 million in the year ended December 31, 2022. The increase was primarily due to progressing clinical development of atacicept in IgAN, including expenses incurred related to manufacturing drug supply for clinical trials. Contract drug manufacturing expenses increased by $7.5 million primarily due to production of atacicept drug supply for our ORIGIN 3 clinical trial and development of an atacicept auto-injector combination product. Compensation and related benefits for research and development employees, including stock-based compensation, increased by $5.6 million due to growth in research and development headcount. In 2022, we recorded license and milestone expense of $3.7 million as a result of an amendment to the Novartis License that was assigned to us in connection with our purchase of MAU868 and certain related assets from Amplyx. Clinical trial expenses decreased by $0.9 million due to a decrease in expenses for the COMPASS trial in 2023 following our announcement to delay enrollment in this trial to prioritize and focus resources on our ORIGIN 3 clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our research and development expenses to increase in future periods as we continue to support our ongoing ORIGIN 3 Phase 3 clinical trial and prepare to seek regulatory approval of atacicept in IgAN, and if we resume development of other indications or  product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of compensation and personnel-related expenses, including stock-based compensation, for our personnel in executive management, legal, finance, human resources, and other administrative functions. General and administrative expenses also include professional fees paid for accounting, auditing, legal, tax and consulting services, and other general overhead costs to support our operations. General and administrative expenses are recorded as expense in the period in which incurred, and payments we make prior to the receipt of goods or services to be used for general and administrative purposes efforts are deferred as prepaid expenses until the goods or services are received and used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CHANGE</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(dollars in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AMOUNT</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,787</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,910</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,877</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses increased by $1.9 million, or 9%, to $23.8 million in the year ended December 31, 2023, from $21.9 million in the year ended December 31, 2022, due primarily to an increase of $4.6 million of payroll and related expenses, including stock-based compensation, as a result of increased general and administrative employee headcount, partially offset by a decrease of $1.2 million in legal expenses, a decrease of $0.9 million in insurance premium expenses, and a decrease of $0.6 million in recruiting and placement fees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.66%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.940000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.66%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">CHANGE</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(dollars in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AMOUNT</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">%</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,848</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,175</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net, increased by $4.2 million, or 226%, to $6.0 million in the year ended December 31, 2023, from $1.8 million in the year ended December 31, 2022, primarily due to an increase of $6.2 million in interest income from investments in marketable securities. In addition, other expense recognized due to the change in fair value of non-marketable equity securities was $0.8 million lower in the current year. The increase in interest income was partially offset by a $2.8 million increase in interest expense from the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Oxford Loan Agreement, under which an additional $20.0 million and $25.0 million was funded in November 2022 and December 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have funded our operations primarily through proceeds from the sale of shares of our common stock, redeemable convertible preferred stock, debt financing and convertible notes. From our inception through December 31, 2023, we have raised aggregate net cash proceeds of approximately $427.3 million from the issuance and sale of redeemable convertible preferred stock, convertible notes and common stock, and proceeds from our Loan Agreement with Oxford. Since the date of our incorporation, we have not generated any revenue from product sales and have incurred substantial operating losses and negative cash flows from operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2024, we completed a follow-on public offering and issued 9,274,194 shares of common stock for net proceeds of approximately $269.6 million, after deducting underwriting discounts and commissions and offering related expenses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We use our cash to fund operations, primarily to fund our research and development efforts, clinical trials, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. Cash used to fund operating expenses is affected by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid assets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that we will continue to incur net losses for the foreseeable future as we continue research and development activities of atacicept and MAU868, hire additional staff, including clinical, operational, administrative and management personnel, and incur additional expenses associated with operating as a public company. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our clinical development activities and our product candidate portfolio. We expect that our research and development and general and administrative costs will increase substantially in connection with conducting additional clinical trials and clinical trials for our research programs and product candidates, contracting with third parties to support nonclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had cash, cash equivalents and marketable securities of $160.7 million, as compared to $114.7 million as of December 31, 2022. We believe, based on our current operating plan, that our cash, cash equivalents and marketable securities as of December 31, 2023, and the net proceeds from our February 2024 follow-on public offering, will be sufficient to fund our operations and capital expenditure requirements for at least 12 months subsequent to the issuance date of the financial statements appearing elsewhere in this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended<br/>December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(dollars in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(92,181</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(67,596</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(39,431</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(70,552</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">133,541</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101,933</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and<br/>&#160;&#160;&#160;restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,929</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(36,215</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, we used $92.2 million of cash in operating activities, attributable to a net loss of $96.0 million, partially offset by non-cash charges of $9.7 million and a net change in our net operating assets and liabilities of $5.9 million. Non-cash charges primarily consisted of $11.5 million of stock-based compensation, $4.1 million of depreciation, amortization and accretion, and a $2.2 million reduction in the carrying amount of operating lease right-of-use assets. The change in our net operating assets and liabilities was primarily due to a decrease of $2.6 million in operating lease liabilities, a decrease of $2.2 million in accrued and other current liabilities and a decrease of $0.9 million in accounts payable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, we used $67.6 million of cash in operating activities, attributable to a net loss of $89.1 million, partially offset by non-cash charges of $14.7 million and a net change in our net operating assets and liabilities of $6.7 million. Non-cash charges primarily consisted of $8.9 million of non-cash stock based compensation expense, $0.8 million of depreciation, amortization, and accretion, $2.3 million reduction in the carrying amount of operating lease right-of-use assets, and $3.7 million of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">102</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">non-cash license and milestone expenses. The change in our net operating assets and liabilities was primarily due to a $8.2 million increase in prepaid expenses and other current assets, and a $2.6 million decrease in operating lease liabilities, partially offset by a $10.6 million increase in accounts payable, a $7.0 million increase in accrued and other current liabilities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, our investing activities used $39.4 million of cash, primarily resulting from the purchase of short-term marketable securities, less sales and maturities of short-term marketable securities during the year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, our investing activities used $70.6 million of cash, primarily resulting from the purchase of short-term marketable securities, less maturities of short-term marketable securities during the year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, our financing activities provided $133.5 million of cash resulting from $115.0 million gross proceeds received from our February 2023 follow-on offering, $24.7 million of net cash proceeds from the issuance of debt to Oxford and $1.1 million proceeds from exercise of stock options and issuance of shares under our employee stock purchase plan, less $7.3 million offering costs related to our follow-on offering, including underwriting discounts and commissions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2022, our financing activities provided $101.9 million of cash resulting from $86.1 million gross proceeds received from our February 2022 follow-on offering, $19.8 million of net cash proceeds from the issuance of debt to Oxford and $2.1 million proceeds from exercise of stock options and issuance of shares under our employee stock purchase plan, less $6.2 million offering costs related to our follow-on offering, including underwriting discounts and commissions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contractual Obligations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into agreements in the normal course of business with various third parties for preclinical, clinical and other services. These contracts are generally cancellable without material penalty upon written notice.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operating lease obligations reflect our lease obligations for our office space in Brisbane, California, and our office and life science research space in South San Francisco, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, we entered into a  lease agreement for our headquarters office space in Brisbane, California, which was amended in July 2022 to add approximately 5,000 square feet of office space in the same building adjacent to this location. The term of the lease amendment is 27 months from September 2022, and the base rent is approximately $0.3 million for the first 12 months with scheduled annual 3% increases. The lease includes renewal options.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Loan and security agreement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 17, 2021, we entered into the Loan Agreement with Oxford, a Delaware limited liability company, as lender (Lender) and collateral agent. The Loan Agreement provides for a term loan (the Loan) in an aggregate maximum principal amount of $50.0 million, of which $5.0 million was funded on December 17, 2021, $20.0 million was funded on November 4, 2022, and the remaining $25.0 million was funded on December 22, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2023, we opted to extend the final maturity date of the Loan from December 2026, to December 2027, based on positive Phase 2b clinical trial data of atacicept in IgAN, as provided in the Loan Agreement. We are required to make monthly interest-only payments for 60 months followed by full amortization through maturity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initially, through December 30, 2021, the Loan incurred interest at a per annum rate of 8.254%. Thereafter, the Loan bears interest at a floating per annum rate (based on the actual number of days elapsed divided by a year of 360 days) equal to the greater of (i) 8.25% and (ii) the sum of (a) 1-Month CME Term SOFR as reported by CME Group Benchmark Administration Limited on the last business day of the month that immediately precedes the month in which the interest will accrue, and (b) 8.25%.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are permitted to prepay the Loan in full or in part at any time upon 10 business days&#8217; written notice to the Lender, subject to the applicable Prepayment Fee (as defined below). Upon the earliest to occur of the maturity date, acceleration of the Loan or prepayment of the Loan, we are required to make a final payment equal to 7.0% of the aggregate principal amount of the Loan (the Final Fee). Any prepayments of the Loan, whether mandatory or voluntary, must include an amount equal to the sum of (a) the portion of the outstanding principal of the Loan being prepaid plus accrued and unpaid interest thereon through the prepayment date, (b) the Final Fee, (c) the Lender&#8217;s expenses and all other obligations that are due and payable to the Lender, and (d) a prepayment fee of (i) 3.0% of the portion of the Loan being prepaid if the repayment is on or before the first anniversary of the funding date of such term loan or (ii) 2.0% of the portion of the Loan being prepaid if the repayment is after the first anniversary of the funding date but on or before the second anniversary of the funding date of such term loan (the Prepayment Fee). There is no Prepayment Fee for any prepayments occurring after the second anniversary of the funding date of such term loan.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">103</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our obligations under the Loan Agreement are secured by a security interest in all of our assets, other than our intellectual property, which is subject to a negative pledge. The Loan Agreement does not contain any financial related covenants. Included in the Loan Agreement are customary representations and covenants that, subject to exceptions, restrict our ability to, among other things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to our existing business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Upon the occurrence of an event of default, a default interest rate of an additional 5.0% may be applied to the outstanding loan balances, and the Lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Events of default under the Loan Agreement include customary events of default, including, but not limited to: (i) failure to (a) make any payment of principal or interest on its due date, or (b) pay any other obligations within three business days after such obligations are due and payable; (ii) failure to perform any obligation under specified covenants; (iii) the occurrence of a material adverse change; (iv) we or any of our subsidiaries being or becoming insolvent, beginning an insolvency proceeding, or becoming subject to an insolvency proceeding that is not dismissed or stayed within 45 days; (v) a default under any agreement with a third party resulting in a right by such third party to accelerate the maturity of any indebtedness in an amount in excess of $500,000 or that could reasonably be expected to have a material adverse change; (vi) the rendering of judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least $500,000 that remain unsatisfied, unvacated, or unstayed for a period of 10 days after the entry thereof; (vii) revocation, rescission, suspension or adverse modification of any governmental approval, or non-renewal of a governmental approval in the ordinary course for a full term, that could reasonably be expected to result in a material adverse change; and (viii) failure of a lien created under the Loan Agreement or any other loan document to constitute a valid and perfected lien on any of the collateral purported to be secured thereby, subject to no prior or equal lien, other than permitted liens.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">At-the-Market Offering</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, we entered into a sales agreement with Cowen and Company LLC (Cowen) as sales agent, pursuant to which we may issue and sell shares of our common stock for an aggregate maximum offering price of $150.0 million under an at-the-market offering program (ATM). We will pay Cowen up to 3.0% of gross proceeds of the common stock sold through the ATM. Effective January 29, 2024, we suspended and terminated the prospectus related to the sale of common stock under the ATM. As a result, we will not make any sales of common stock pursuant to the ATM unless and until a new prospectus, prospectus supplement or registration statement is filed.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will remain an emerging growth company under the JOBS Act until the earliest of (i) the last day of our first fiscal year in which we have total annual gross revenue of $1.235 billion or more, (ii) the date on which we have issued more than $1.0 billion of non-convertible debt instruments during the previous three fiscal years, (iii) the date on which we are deemed a &#8220;large accelerated filer&#8221; under the rules of the SEC with at least $700.0 million of outstanding equity securities held by non-affiliates, or (iv) December 31, 2026. Based on our current public float, we anticipate that when we reevaluate our filer status on June 30, 2024, we will determine that we qualify as a &#8220;large accelerated filer&#8221; for the year ending December 31, 2025.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting policies and estimates are most important to understanding and evaluating our reported financial results.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">104</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and development contract costs, and related prepaid and accrued balances</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into various research and development and other agreements with commercial firms, researchers and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. We record accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the prepaid and accrued balances at the end of any reporting period. Actual results could differ materially from our estimates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not required.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 8. Financial Statements and Supplementary Data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">105</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Index to Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Years ended December 31, 2023 and 2022</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93%;"/>
    <td style="width:7%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p><p style="padding-bottom:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.75pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_public_accounting_firm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Report of Independent Registered Public Accounting Firm     (PCAOB ID: </span><span><ix:nonNumeric id="F_ac88040d-5da1-4c49-8791-b6d9edebfd73" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">185</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">)</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">107</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial Statements:</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_of_operations"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_of_redeemable"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Stockholders&#8217; Equity</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:36pt;vertical-align:top;"><p style="margin-left:24pt;text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_unaudited_condensed_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">106</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_public_accounting_firm"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the Stockholders and the Board of Directors<br/>Vera Therapeutics, Inc.:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have audited the accompanying balance sheets of Vera Therapeutics, Inc. (the Company) as of December 31, 2023 and December 31, 2022, the related statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and December 31, 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:49.867%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5e51085-e58f-40ef-b016-19a57e3a9655" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2018.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27a859f0-ffbe-4ea8-9677-0d5e6d271d59" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">San Francisco, California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/>March 26, 2024</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">107</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd9e5c4-9216-4288-ad02-9e61024b7bec" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,681</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a88eccf-2f68-4d26-ad44-196593ca14e0" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df510b84-d111-44d7-b910-441e1bd5fb54" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,035</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86d31e56-ed3d-4b84-b0a5-e0ef52e3872b" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other assets, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bb52a63-9750-4273-86bd-ac9fc261b968" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc5045d0-0471-4515-97ff-d2fdfe309432" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,045</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_389885c3-4ff9-4bf7-8139-34df3e771c33" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,023</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91258019-d654-4d0b-b717-1d3ffa5400b6" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">125,698</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_682d1b0e-38a0-4ec0-83c8-eae523a8baa6" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88a85bf6-c083-4b52-b2a7-3a6a3e7cf5da" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfc822cb-cf6b-44fa-ad67-54c94fa58983" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_254a42aa-79e1-41e6-b35d-752a5fc361a0" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7202e4ba-8fcf-4117-8978-966263a3b965" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43a2df3d-18be-477a-a635-adc27b651a59" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,173</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other assets, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0de31780-88d6-4be2-9547-0f2a6380f18d" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">471</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca400b9a-9bac-4a6b-be2e-24284480a4b4" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">162</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-marketable equity securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5c7c4dd-4f37-45ab-865f-98b05c692477" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7528db6-38e6-4eed-a06c-1dc9f646af4c" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:MarketableSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b04a008-a148-482f-960d-7b08afefcf8d" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e005dc3-6d13-4990-84b0-e48a88215faf" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1c93f03-7324-4660-900c-34eb3babd4f2" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79182f78-b43e-4f19-a2bb-fd05e02d5170" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,991</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4b99b41-811f-4c75-a323-47954bf94052" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,436</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffa8cbe2-dcba-4be7-bd60-80689107c1c0" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e03fdd3d-5691-4746-8f92-658901242c91" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eaf9d03b-eb11-4847-a678-d0d648d9615e" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,964</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_369884c7-d00e-44be-8cda-3475673407f0" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,303</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac58032b-af2f-4a3a-8a5e-e0c1c2936e84" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,600</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81c6a8fd-b323-4195-bda0-38b5bd2fedba" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,877</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0fdbd19-9e60-4a1c-b35a-0945f88f8280" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,810</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_748568d1-3a0f-43a3-8dd8-cc6ffd81ec37" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,395</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f066a50c-d3df-4cbd-984b-a44852d32424" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other liabilities, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e598d5f-0716-4840-8e34-abcda95b970e" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9c6c665-e935-4baa-8cf0-0d73a4cd1b80" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2a65f0c-853f-49ed-8089-04f747dc80ee" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,861</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e415532-4899-419e-a7bc-6c6a5e266b9f" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74dca446-ef3b-490e-9302-15839d17b2a2" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_78f06f87-456a-48b5-a597-84d825ef1c24" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d56a3d58-799d-426c-94cc-319775225859" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_07ec2406-7aa3-4c70-8196-c845ee8ba859" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;authorized<br/>&#160;&#160;&#160;as of December 31, 2023 and December 31, 2022; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9be670b4-5f70-4eb7-aa74-a789cb8e32dc" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f2a20967-c050-48c6-98b8-be6b2a2e67f2" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a8c6c226-ffe8-492e-bdca-79473a862148" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d62eb141-96e3-4111-9d6d-75ccfddc8ed1" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued<br/>&#160;&#160;&#160;and outstanding as of December 31, 2023 and December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56dfc381-5bf6-4372-a6cc-10aac47e0ef1" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1570f6f4-0813-4981-aded-e7a8ef423ab5" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3da5843d-8147-4a1c-bfce-ffc5403bee0f" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_80b7f455-bab7-4542-bee0-69513d668ec2" contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46a2764f-9571-42de-b455-bac9aa982f33" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0b77163d-bf7f-4a89-94f3-b5a3c32fc02d" contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;authorized as of December 31, 2023 and December 31, 2022;<br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2c3d8c1-4e80-42c0-af85-5bc0a603dff5" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1b805e70-6e3b-4af3-9723-e2ad3f72a6fb" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,452,161</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and  </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05641d71-b973-49cd-a5e8-4da117712a3d" contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_2685bf58-808e-4bbf-83e8-a21a2f2165f3" contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,800,861</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of <br/>&#160;December 31, 2023 and December 31, 2022, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_455b089a-0638-431a-84b8-81ef664f1ba0" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a21b380c-71c8-45b7-9646-cf85d1c83126" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f89adb8-4734-444b-9719-c69b173b6630" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410,492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f21c5217-c3f1-4518-bd80-e13c8e7c3ad5" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive gain (loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c8d651c-152c-44e1-a28b-483bba2d0509" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23ec1dd3-5898-4aa5-bb85-88b8fa5b0c5f" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c52257ed-e934-44d1-8ce7-07b070fc372a" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">309,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aa99605-23f0-4000-b5f0-2d69cf215bfb" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">213,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e44f3856-68f2-4d73-80e9-3e774e1cf804" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b0b7aa2-cabd-4359-9e97-37387a5f3542" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_956ab0c9-ad15-4cb9-95f5-df41a484f642" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175,546</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fd75d54-8419-4d76-ac55-68d0fcc10158" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">108</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_of_operations"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">perations and Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="range_a1_e18">&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07568bfe-90c2-40e9-a537-5b9eee49b7bc" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,225</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c0efb2c-336a-41fa-9008-f3892c7898c1" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,993</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447b60ea-ca8f-45de-8861-19c22cb93de1" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,787</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15124c16-4bc8-4996-b89e-f53169cc4f44" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa84d02f-7d0c-446a-a5ff-91761b8cbe91" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dae34db1-53d1-4469-a612-e62f9ea4a3d4" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77a019ed-b942-4cdb-ab03-38453c5923ea" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">102,012</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbfb097d-26ff-4d65-9829-ceddf3ac2e4f" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90,903</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2e13362-2899-4bed-8b72-91fdc4c69c4f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,979</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f84c7671-93a5-4af7-9106-89a628b9edfd" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df5b999a-bab5-4d51-a848-c6a308030277" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,786</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22e58e95-f4c5-4919-ad9b-67ea00c84691" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">992</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ee506d6-c87b-466b-9923-0e474e5276c9" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,877</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4eb1ecf1-4e08-46d0-9595-792582fdb3e7" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of non-marketable equity securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11b3dad6-ba25-431d-be39-6929a3fef76b" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01a9dabe-a3c2-4816-907e-15a97985d0ef" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:EquitySecuritiesFvNiGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total other income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0dfa8b5-3aed-4f20-a27a-a7a6c5d011b5" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,023</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1eca33b-4a99-4522-a0ed-792ee5871dcc" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,848</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e094441b-9b50-4cec-ae81-8198750d0e65" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd75645c-5c52-41ea-b1a9-89a2249a90f7" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,055</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b705d00b-49d3-4224-9896-d420d42094ed" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_285f6ab5-036d-4949-9cbb-3f30d54fe72e" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eea46298-25c4-461c-a203-fcf5de407c4d" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdad4a17-9642-453a-9b8a-111ac4d0f4d4" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in unrealized gain (loss) on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00ee5306-37b4-472a-bc6c-656d85e26c8b" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cf15789-bf37-4dbc-95d4-512d064d5e62" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e1b6aaf-96f3-4d21-9d8f-a0d84bc632db" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,739</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70fed9d9-c1bf-4e2c-b3d8-0752018851cb" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,280</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ee0d97e-61c4-4434-8741-a21aa24afa1f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a83bd7d7-e67e-4b60-86fc-5b88472a6c21" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.25</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f73cf1f-5245-4b2c-9c4e-df8d48dab030" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0e50a5ed-bc29-4503-8f8f-c755e415dbb2" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">3.35</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares used in computing net loss per share<br/>&#160;&#160;&#160;attributable to common stockholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f8e59d9-4ddd-4272-8a74-0ef4a60ec237" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_34c3f15a-55c9-4676-ba64-b4403bfbb424" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">42,707,072</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e467ea2-824b-4074-9079-ad50a6974bf0" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a98527ce-c53e-47f6-844a-142feb96555d" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">26,570,676</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">109</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_of_redeemable"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Statements of</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="range_a1_s13">&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.148%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.483%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:6.563%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.843%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:6.483%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.323%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:6.903%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:7.323%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:6.803%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Class A Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Class B Common<br/>Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-in</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Other</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Comprehensive Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2021</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_30918cc3-fd9b-44cf-b829-680d0423e12d" contextRef="C_e02b6343-2192-4292-8c98-078fac080977" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,968,376</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_eeeb673b-b48e-4cc6-a38a-0c487d63385b" contextRef="C_644f1830-26e7-4980-866c-9c896b77aefd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_27494326-4e32-4035-b563-5410486be3ea" contextRef="C_8211428a-3da0-4229-b27d-cbfee378013c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">309,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_7c46c62e-e9b8-48a2-a2fc-8ffbf16521fb" contextRef="C_39cdc351-ad9a-4bdc-9a2f-e68f40e8b2b8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_89bb8742-60f8-4a2c-9e0e-600cabaa0edb" contextRef="C_3b708e8c-5665-48f7-9c36-8c9a842be8a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">124,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_bb636c61-b0c2-4743-91e3-1cb1599e89db" contextRef="C_5ed90599-4b8c-4161-b826-92693ffe24bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6958400-33be-4b8d-98a4-ddb0c27b02b8" contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,742,026</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9d3cd91-c90e-439f-b3c7-6f96fa411d0f" contextRef="C_caf5dab2-ce38-4cdf-9364-9103e398ebaa" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb30579e-eba0-42b5-a3b5-a14c8ee46c5a" contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,028</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f79c6c2b-8f42-4e54-a1a9-d80ff06a4460" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,034</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock upon exercise of options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b0000a7-bfcb-434a-b93f-fa007cb0e108" contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">405,140</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee1f8257-3e14-4e51-9275-7a5d94b29b4c" contextRef="C_caf5dab2-ce38-4cdf-9364-9103e398ebaa" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c427707c-77fc-49f5-8a8c-f7c4c6d2fae0" contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,791</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b100d443-e137-4beb-b221-a6e9d0ae4a15" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,792</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock pursuant to employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4998d8c-78f9-4720-814d-dc665b649e6f" contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,328</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b46165c3-37cb-48a2-b344-61b6ec813a47" contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5095082b-b254-4a05-aac3-5d950b4344de" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock upon vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a5f5a18-1fb7-45bc-a645-cec977c860d0" contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">77,719</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Conversion of Class B common stock into Class A common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c4ed986-9b04-42d7-a64d-137437b8ca2b" contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">309,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2da0ac64-c334-40b3-a376-00653453bdb1" contextRef="C_aac5b93f-8d14-44a8-81ce-17fdcee51c82" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" sign="-" format="ixt:num-dot-decimal">309,238</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock for payment of licensing fees, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb7dd076-1716-4a85-9c9a-796312f627a2" contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61" name="vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">283,034</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58c795b5-c5c9-4555-9b2f-a25e768165b5" contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6" name="vera:StockIssuedDuringPeriodValueLicensingPaymentsInEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a81a8a3-f2d6-4749-bb42-fa6b2337491b" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:StockIssuedDuringPeriodValueLicensingPaymentsInEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3374b6ff-ff62-49b5-a810-8cd05f53d754" contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,887</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d37eff7-3b38-4b50-942a-10af3893cb79" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,887</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6b6861d-1cc6-466f-acf5-a8b9a0ebcb5f" contextRef="C_67ddbf76-c9a0-4921-9378-a929a1fa7f5b" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f234ac92-b417-49e6-bd9f-22f290e39ca5" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab719833-a8d4-4b23-8b8f-73cc26f7ae0b" contextRef="C_45e8c8b4-f505-443e-882c-c062f4a6a499" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e222870-6914-46b5-b9ec-b14a5cfef3f0" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8e89c0b2-480b-41cb-b4e6-66c42a22bd33" contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">27,800,861</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_e525f961-d2d1-4cb0-8fca-249620a4fa36" contextRef="C_883d50e8-64b0-42ff-91c1-09162e80e0ef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_7b517f57-d0d3-4d46-b004-251f1313db34" contextRef="C_ed279c02-7bf7-4e6e-932b-ec6e10a522e9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">290,216</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_71c146b2-262a-4bdc-921f-72fc7dc6ac77" contextRef="C_e6f5b77a-d7c2-44e0-9317-e969b8465d61" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_e38c1345-cafa-45bd-be87-1580ab505315" contextRef="C_28836329-d13e-4a50-b307-58f77fac513d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">213,112</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_e8f99a54-759d-4b28-93bf-60ff6c54fb96" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,908</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock from underwritten follow-on offering, net of offering costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f9bc083-0c9d-4687-acce-e40603731ee3" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,428,572</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_facb44a1-0396-4c46-b407-79db8b6ce8a5" contextRef="C_15d01a5a-3d63-4633-9f8b-b5972d8790e7" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ce9b1fd-74b1-4b70-88dd-4cabf7b9cc48" contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe0836a5-c771-4d81-9ccb-cbe9cfea5e78" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock upon exercise of options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a434daf8-4f02-4ec7-b724-14cbaf8c31a3" contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">111,927</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b00401b3-5e58-45b8-865f-dec5bbfa4ae2" contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">781</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c0a5af7-508d-4e2c-9bbe-6210ee4dec49" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">781</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock upon vesting of restricted stock units</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93f86380-8043-4358-a0fd-1d09624079e3" contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">66,321</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock pursuant to employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc069f43-e804-4c30-838c-b98bb6e745fd" contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,480</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb66414d-3985-407e-b930-3c6d3c5d1765" contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a200476c-afbe-483c-beef-2160a8e8f9b0" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e8f4583-15b9-4430-92f6-e0c216c35df0" contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb7713f7-6804-4717-96f7-6f99a18a6eed" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d863d8a-471f-48f5-a5b5-a7dcd43f2877" contextRef="C_cfc189ab-bacf-4a05-9ffd-a7ef871b7cc4" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0228bbb7-75c7-4ded-a1a9-e68d1d52ec65" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_32fca3e6-ba81-4983-8d79-6099841b6f9a" contextRef="C_98c19bb9-6dc0-4e42-9491-940aabbbe506" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4439e1d7-f0a5-472d-9f22-7c9cb8c68e85" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f529f1e7-4c1d-423b-b238-5ea50e1c48da" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">44,452,161</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_b797f4bf-e05c-4487-b3db-e07a4534a2c0" contextRef="C_539e555a-bda4-46de-a744-e41a88c96a83" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4c51c627-4c2a-4215-a20c-a6d94c524fd5" contextRef="C_ba1ed2ab-29c6-4f44-8a57-210882c88795" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410,492</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_55146b34-7023-4c83-a0ab-85ae4c765195" contextRef="C_a88ca419-8f83-4779-954c-2d82558cf7e7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_500ef725-7601-4cc2-a072-772929a501cc" contextRef="C_28a77420-c2ea-47f5-a8d9-5ab260bf4726" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">309,102</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9ea3b4ab-cb9c-407c-9ef6-1af1218305cf" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,685</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">110</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ements of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1c03544-a706-4a43-9230-1ff91bced7c9" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a756b56-7925-4065-8881-9a1ef48bfd89" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation, amortization and accretion</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee79ba49-6eb4-4e32-9da2-c722a62bbc6b" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DepreciationAmortizationAndAccretionNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,086</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afc4662f-8b13-46c1-abed-bc551e1a8a17" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:DepreciationAmortizationAndAccretionNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">846</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reduction in the carrying amount of operating lease right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10c9a97b-dbd5-415e-aa57-420f6364211c" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,224</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_457100eb-cd78-44be-9ebe-2c00f21b5346" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,271</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_402d7a12-3ce3-4fd7-9b9a-2d74f6ceca1a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_37a9900d-ac2a-455d-910c-ae14b87775d8" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,887</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock for licensing payment, net of costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbdf3eb9-ef4a-40ed-ac87-14aad6f0ba68" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:IssuanceOfCommonStockForLicensingPaymentNetOfCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cfa00a3-720d-4190-8af4-1886a1f570d1" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:IssuanceOfCommonStockForLicensingPaymentNetOfCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,592</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of non-marketable equity securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_129ceffc-9dae-41d8-b495-3c861c788c56" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">47</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e97284e-f873-40e7-8784-cef8c659ef29" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">809</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expense and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83b0fde0-97ad-47b9-89fa-84cd9e512629" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">173</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5714fb0-2935-416f-9859-31d5dfc27465" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,182</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43fbfd18-c791-46f7-8b02-84914d77762e" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">309</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac3854de-345d-4182-9ad2-a589149b8213" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4014b648-9988-433a-acc8-c5532b8a8f30" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">873</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18b81df4-1e24-4f7c-9d09-1634df87c2b7" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58f42eb3-0109-40c6-a326-08e69a647a0d" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35ea50fc-378a-438b-bc53-0b23d271b882" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,036</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9cbe5f06-4360-45cc-845c-c5d1c97611cc" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,645</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c96e9e62-f4b1-42ec-b1b1-2103cb2e569a" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,602</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7263c2a4-0747-4d50-9ad6-ac310811df18" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,181</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a9af986-0354-46ea-8706-20e510f1a35b" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">67,596</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d9468dd-d33c-4013-9c52-8559508485ad" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43eb23f9-cebf-43f3-95d9-4f22ff7eeb35" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeb48b86-9c02-496b-a84d-e6786bf817f8" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">224,930</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a234c64b-b52f-4d35-9405-4d31038033d2" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148,490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd1d0b98-264f-4d05-834b-6f0110f2daf2" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09a862ae-6f4f-41c9-96c1-73386d6183c4" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a52d2dda-20f1-42a8-92a0-7803802aba73" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,543</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6850c59-463f-4099-93b9-0279f469b8f3" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:ProceedsFromSaleOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8bd48052-c905-421c-99c3-cbe8eb325085" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">39,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f194ab07-0711-42fd-88cf-36aa22845ed3" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options and employee stock purchase plan</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2654560a-8f8d-4a46-a6cb-aceebd64f214" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e834bd46-47a9-4211-9fd7-4444eda0b95e" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,083</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from borrowings, net of costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7db57ac1-69a0-4a39-99bf-7b205f408ff5" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:ProceedsFromBorrowingsNetOfCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,741</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_957f32a7-3cec-4f50-96db-9211b672cb9a" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:ProceedsFromBorrowingsNetOfCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,816</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from issuance of Class A common stock in follow-on offering</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18d3a8f7-3bf6-4de7-9492-bd07a0eb846a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:ProceedsFromIssuanceOfCommonStockFollowOnOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c110ab00-1240-49bb-90d7-3b7bd153258d" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:ProceedsFromIssuanceOfCommonStockFollowOnOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,131</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of costs and underwriting discounts and commissions related to follow-on offering</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf8679ab-ff34-42cc-a658-58f90e226f63" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:PaymentsOfStockIssuanceCostsOnFollowOnOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,256</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f2b770f-4971-4c8b-b4ec-2f4f38e1a89f" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:PaymentsOfStockIssuanceCostsOnFollowOnOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,097</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b67507fc-c84d-4518-ab87-484e1d502846" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,541</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7e34e70-63bc-4f10-bda2-6a01797a3dc3" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01672a41-6514-4b8c-98b9-c0b41b0e1fd4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c735286c-986f-4089-865c-efa6382158dd" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,215</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_101785a8-7fda-4767-975f-0ccffb00197f" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_facb835d-212c-47de-a77c-85db3b623c21" contextRef="C_5ed90599-4b8c-4161-b826-92693ffe24bd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,967</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of year</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c22652a-4164-43b3-90ae-353b162d0353" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,681</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec55d594-0bbe-4907-9bc8-687c88a8ea09" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reconciliation of cash and cash equivalents and restricted cash to the<br/>&#160;&#160;&#160;balance sheets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_edb23367-989e-4b47-a2a5-eadf46db72eb" contextRef="C_80f2efae-f54f-4396-a49d-51ff68d5fa88" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,681</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d15beecd-b507-484f-a791-56e0f5a16ef3" contextRef="C_88d87548-c2bd-4d90-827b-1b12287efa7b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,459</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00a9c25c-e239-48ba-8389-078aa5ce016d" contextRef="C_f0446608-4adf-4b9a-a12b-80d69068a5b3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d76040b4-3af8-450f-985e-0ac28473fb6a" contextRef="C_1ffca1f3-be18-4f89-a42d-d60b717612a9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash and cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55f98f6c-a706-4d80-a6e7-4e9776ca8379" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,681</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b6c900f-fec1-44df-88c3-27a97f9f1840" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,752</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental disclosure of cash flow information</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff75e03d-1012-481e-8ba3-e8b76779e60f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c308643c-4699-4ab8-bcc5-b7126e2ce584" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">895</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for operating leases</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49e23c1a-7aa4-4e1d-a113-e0d0904c3a23" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16bf0bdc-3703-4762-be40-adbba54a60a1" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,734</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of Class A common stock in payment of licensing fees</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1e977ba-245a-4c76-b8f5-dad6a3ad295f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_75cb2101-8afe-4f7c-a4f7-b28a23cb3048" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">111</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_unaudited_condensed_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a7ae46d-7af5-4ecd-9477-4b50ac5b08c3" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:NatureOfOperations" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware.  The Company&#8217;s headquarters and operations are located in Brisbane, California. The Company operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 13, 2021, the Company&#8217;s registration statement on Form S-1 for its initial public offering (the IPO) was declared effective by the Securities and Exchange Commission (the SEC), and the shares of its Class A common stock commenced trading on the Nasdaq Global Select Market on May 14, 2021. The IPO closed on May 18, 2021. Prior to the completion of the IPO, all shares of redeemable convertible preferred stock then outstanding were converted into shares of Class A and Class B common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">S</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ince inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. The Company has incurred recurring net operating losses and has not generated positive cash flow from operations since its inception, and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_161a21cd-ad06-4091-950b-280a17e1e307" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">309.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as of December 31, 2023. The Company had cash, cash equivalents and marketable securities of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99d32a74-1995-4b1d-89ea-7514e9d59070" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:CashAndCashEquivalentsAndMarketableSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">160.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as of December 31, 2023. The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management believes that the Company&#8217;s cash, cash equivalents and marketable securities as of December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months subsequent to the issuance date of these financial statements. The Company intends to raise additional capital through public or private equity offerings or debt financing or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives. If the Company fails to obtain necessary capital when needed on acceptable terms, or at all, it could force the Company to delay, limit, reduce or terminate its product development programs, commercialization efforts or other operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c1fa952-f638-4d64-b8b3-2b9fd9218ab2" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6617a6d8-a140-4e80-8b5a-ed91c13e13af" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the SEC regarding financial reporting. The U.S. dollar is the Company&#8217;s functional and reporting currency.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34b9237d-e0c5-45ed-8d53-ebbb7362623e" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:EmergingGrowthCompanyStatusPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afc7e2da-f586-4f5e-b76a-1848121e38e7" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the research contract costs and accruals, stock-based compensation expense, and the valuation allowance for deferred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">112</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ab9eed4-6bd4-4acf-b410-a3a487541315" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s current and potential future product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b864c9c8-883c-44ab-b3d0-fe22ef8d4792" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d45a6b03-1634-4a1c-9595-263c9371f0d1" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash represents cash held by a financial institution as collateral for a letter of credit securing its operating lease for office and laboratory space, which is classified as a non-current asset on the balance sheets based on the maturity of the lease.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f208aa4-0321-4fd0-bc21-c2d343d9f64f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company holds investments in marketable securities, consisting of U.S. government securities. Marketable debt securities with stated maturities of three months or less from the date of purchase are classified as cash equivalents and those with stated maturities of greater than three months as marketable securities on the balance sheet. The Company determines the appropriate classification of marketable debt securities at the time of purchase. The Company has the ability, if necessary, to liquidate its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying balance sheets. All marketable debt securities are classified as available-for-sale and are reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss within stockholders&#8217; equity. Interest, amortization and accretion of purchase premiums and discounts on marketable debt securities are included in other income (expense), net, in the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of available-for-sale marketable securities sold is based on the specific identification method. Realized gains and losses on the sale of available-for-sale marketable securities are recorded in other income, net in the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company regularly reviews all of the marketable securities for decline in fair value to determine whether unrealized losses have resulted from credit loss or other factors. The review includes considerations for the cause of the impairment but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers. A decline of fair value below cost basis is considered an other-than-temporary impairment if the Company has the intent to sell the security or it is more likely than not that the company will be required to sell the security before recovery of the entire cost basis. Regardless of the Company&#8217;s intent or requirement to sell the security, an impairment is considered other-than-temporary if the Company does not expect to recover the entire cost basis. In those instances, an impairment charge equal to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">113</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difference </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">between fair value and the cost basis is recorded in other income (expense), on the statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec8b19e9-84cf-45b7-b992-4436aeaaa875" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2aed0c9e-099a-40c7-a3ff-ad8d1a5014b4" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ImpairmentOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment loss was recognized for the fiscal years ended December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amortized or accreted cost basis of the marketable securities approximates its fair value.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_750083e0-ac31-4bdb-8d92-00e900657d99" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:DeferredOfferingCostsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred offering costs consisting of legal, accounting and filing fees relating to equity offerings. Deferred offering costs are included in other long-term assets on the Company&#8217;s balance sheets. Upon completion of the offering, these amounts are offset against the proceeds of the offering.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b62ee3ff-e676-4b08-851b-807686763215" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space under operating leases and determines if the arrangement is a lease at inception. These leases contain lease and non-lease components. Non-lease components include payments for maintenance, utilities, real estate taxes, and management fees. The lease and non-lease components are combined and accounted as a single lease component. Payments made under operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis over the term of the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is a hypothetical rate based on the Company&#8217;s understanding of what the credit rating would be in a similar economic environment. Operating leases are included in operating lease right-of-use assets and operating lease liabilities, current and non-current, on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases may include one or more options to renew. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured. The lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6882f9dc-a842-4ebb-bfcf-31aefaa5c6aa" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bd3c13c-107c-40ee-bc4e-3f7544aa4b55" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements are classified and disclosed in one of the following three categories:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; Quoted unadjusted prices for identical instruments in active markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed in the financial statements on a recurring basis.  The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, prepaid expenses and other current assets, non-marketable equity securities, accounts payable and accrued expenses and long-term debt.  Cash, restricted cash, and marketable securities and non-marketable securities are reported at their respective fair values on the Company&#8217;s balance sheets.  The remaining financial instruments are reported on the Company&#8217;s balance sheets at cost, which approximate their fair value due to their short-term nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments that are actively traded. The pricing information for the Company&#8217;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">114</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s non-marketable equity securities (see Note 5) are measured at fair value using an option pricing valuation methodology. The option pricing methodology relies on risk-neutral valuation which calculates the value of an asset by discounting the expected value of its future payoffs at the risk-free rate of return. The fair value of the non-marketable equity securities is derived from quoted prices for similar instruments and observable inputs in active markets. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December 31, 2023, and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42ba38c1-f24f-4f59-a57e-17c0e83679ee" contextRef="C_763f4bc0-e8d2-4dff-a69a-bf5d94bdc0c9" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">44.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce2054b2-f69d-415e-83df-8379d6aa1ba7" contextRef="C_0c317a6f-636d-4344-a7db-5f93a49f62a8" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in money market funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c156bf53-654d-4598-ac91-6e6613aebc01" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss consists of two components: net loss and other comprehensive loss. Other comprehensive loss refers to unrealized gains and losses that are recorded as an element of stockholders&#8217; equity and are excluded from net loss. For the year ended December 31, 2023, other comprehensive loss consists of unrealized gains and losses on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11e5e162-0548-4f1d-9eeb-56e0dbe6069b" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of employees&#8217; salaries and related benefits, including stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support the Company&#8217;s operations that are directly attributable to the Company&#8217;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred in obtaining technology licenses including upfront and milestone payments incurred under the Company&#8217;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#8217;s research and development activities. Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81623283-a923-4b65-abea-706e35d740ba" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:ResearchContractsCostsAndAccrualsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research Contract Costs and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_19a00af6-0424-4eea-a1ce-40a0ada79a8f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#8217;s employees, nonemployee directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgments about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#8217;s Class A common stock on the date of the grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all stock options granted, the Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#8220;plain vanilla&#8221; stock option awards, as the Company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. The estimate of expected volatility is based on comparative companies&#8217; volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company determines the fair value of its Class A common stock using the market closing price on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">115</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_caf7468a-5707-4a39-8d45-86d7ffd09d03" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect tax rates expected to be in effect for the years in which the differences are expected to be reversed. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8dd51fab-69d8-49d5-b48b-680bc4dc0e99" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_8dd51fab-69d8-49d5-b48b-680bc4dc0e99_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_8dd51fab-69d8-49d5-b48b-680bc4dc0e99_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive shares are not assumed to have been issued if their effect is anti-dilutive.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_663f5c7f-f08e-4227-ab14-1e3f1239fabc" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies the guidance in Topic 210, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material impact on its financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company&#8217;s financial statements upon adoption.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a19f464-8865-4fd2-9505-2929c00c3964" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:OtherFinancialStatementInformationTextBlock" escape="true" continuedAt="F_3a19f464-8865-4fd2-9505-2929c00c3964_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. OTHER FINANCIAL STATEMENT INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d9716a2-592b-4641-8475-f4a166a312d5" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid clinical trial and drug manufacturing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ce95763-c4f3-44b8-8ef2-e80b2cb9c1fc" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:PrepaidClinicalTrialAndDrugManufacturingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2ce4627b-5233-46d9-a108-a10a41490bac" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:PrepaidClinicalTrialAndDrugManufacturingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,487</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab6cd07e-2e36-43f3-8b19-a841508e4cbe" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">597</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6942faea-4ff5-4147-8d93-825ca1838397" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid equity financing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53ff6ff3-d0a2-4f35-8fd2-74a4f97fa887" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:PrepaidEquityFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">410</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff77f860-7af2-41ed-9133-37f5dfcb8c8f" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:PrepaidEquityFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98e60549-8e19-47b7-a193-3fd45c5cfd43" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8feaf5e1-4d42-404c-adcf-006c1fa87810" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">247</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid software costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcf4e55f-9b3e-48cf-84cc-b00b6675825e" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:PrepaidSoftwareCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94a352ab-ab5a-4906-8c3b-f11463489bf4" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:PrepaidSoftwareCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid recruiting fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9172d596-e50c-4612-925f-a693a643d6ad" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:PrepaidRecruitingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">109</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_934d0a40-0bdf-47ee-ba0d-a803db2eb4b1" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:PrepaidRecruitingFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_548f82ac-65e4-420b-9e83-b5b1fdb3079c" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b5f88010-f6d7-4694-89b2-ab496e7c95e9" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e5d00c9-6da5-43e2-8b90-a7f8bc0d34af" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,307</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_823081de-f65b-4dbc-8219-dab3fdc2c4be" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2542f035-0eed-42dc-baa1-1f42149e715a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">116</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f9816849-3c4c-4e35-9c9c-8d645a6eeef7" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,932</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9c559dc-4465-4579-9f17-0be519d5dec8" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,217</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical and drug manufacturing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3bab69c-a485-44b3-8319-8625bbad535d" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:AccruedClinicalAndDrugManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,213</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f61d6287-79f7-4225-93b7-8899aac0c85f" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:AccruedClinicalAndDrugManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,334</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5a687bab-921b-44fe-9e3a-5689690d58d7" contextRef="C_ddc80ff3-7e9a-4f5e-8fc8-162ee5659dda" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,926</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aa8e46b-eb08-40b8-a12e-ceaac9f4366d" contextRef="C_12676876-59e5-4f18-b296-25ca0885c06f" name="us-gaap:OtherLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,780</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_61d40d97-9ce5-466c-806c-ee8243a8bbb8" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73a165d2-64c6-475f-9a3b-b2e0a85f2f63" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">338</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45de3c3c-ac76-4d04-8a23-92e244cc8349" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">619</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_459694a0-58a8-49a0-a777-bf192014b4c2" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_936b0018-10ec-49cf-b86f-bc5404e208f8" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,749</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92fe98dc-4cd7-4b56-929b-ff42f0d71f63" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,964</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:continuation id="F_3a19f464-8865-4fd2-9505-2929c00c3964_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related party payable represents amounts due to Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to manufacturing technology and know-how transfer services performed for atacicept pursuant to the license agreement between the Company and Ares (see Note 11).</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23fdac9f-ff36-453e-8868-05b32155b1e1" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. CASH EQUIVALENTS AND MARKETABLE SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are classified within Level 1 in the fair value hierarchy because the Company uses quoted market prices to the extent available or alternative pricing sources to determine fair value. Marketable debt securities are classified as Level 2 because they are valued using fair value from an independent pricing service, which may use quoted market prices for identical or comparable instruments or valuations using observable market data. The Company&#8217;s debt securities are accounted for as available-for-sale securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrealized gains and losses are reported as a component of other comprehensive loss. Fair value of the debt securities were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fda95489-5659-47df-aa41-c04af8dc94c6" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">115.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1369714-bfef-48d7-add3-a1a0af39f15b" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and December 31, 2022, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da7b905e-1275-4a64-b6e6-f11cc5dd62a4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:33.647%;"/>
        <td style="width:1.4%;"/>
        <td style="width:12.623%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1%;"/>
        <td style="width:1.4%;"/>
        <td style="width:1%;"/>
        <td style="width:9.682%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c3d16dd-064a-4efb-9016-4614b678165b" contextRef="C_7049dbef-cfb0-4b5b-aeab-21592adc5141" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,650</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d1af2fa-1c67-4083-b061-df5fc476ff2b" contextRef="C_6eaa2abb-9090-46f3-9dcd-75944c3a5636" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_865bf027-4e73-47f3-9daf-6b03516f99a2" contextRef="C_6eaa2abb-9090-46f3-9dcd-75944c3a5636" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ad5a296-2979-4aa3-acf6-b279f7885777" contextRef="C_7049dbef-cfb0-4b5b-aeab-21592adc5141" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,650</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb589d33-3914-4eb2-a65b-90b6a0dc2533" contextRef="C_2f5962f0-d8e3-4966-ae7c-c8b41d160a04" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,619</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afe047a1-0905-433b-9ddf-c22dd1317bfb" contextRef="C_27a18667-bb0a-48ea-8694-1c1986159e16" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c3f69c0-abd8-48d8-9076-e7f115d1cbf2" contextRef="C_27a18667-bb0a-48ea-8694-1c1986159e16" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99fece51-f7f6-481c-9c6d-a079b9df3529" contextRef="C_2f5962f0-d8e3-4966-ae7c-c8b41d160a04" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,683</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f13d3459-830c-4967-a688-7c4cbbe33b20" contextRef="C_a437c869-1510-4704-bfa5-0c8b5fb1e04f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,665</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f1b8bc9-f57b-481b-97cb-7f66aa2c5f93" contextRef="C_91729747-ed44-43ba-b06c-0ca33c08ecef" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e78ddaf-3da2-4a1b-b8c7-b1d05de0ead4" contextRef="C_91729747-ed44-43ba-b06c-0ca33c08ecef" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_429d4741-b737-4b36-bbfa-7aa11f9212d7" contextRef="C_a437c869-1510-4704-bfa5-0c8b5fb1e04f" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,658</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b7708dd-d288-4bd8-b9f3-d6bee3dda4fb" contextRef="C_4c8b4716-9f64-4262-a82a-7d6247559af1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,500</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_532e4288-d371-4b2d-b380-aa2c85652541" contextRef="C_ee626bdd-f836-4146-83f9-c629e739a018" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35c2d102-4696-4dfa-b47f-f15ba9a37d9f" contextRef="C_ee626bdd-f836-4146-83f9-c629e739a018" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e0f30ee-94de-4e7b-9ee7-0850094e1b1d" contextRef="C_4c8b4716-9f64-4262-a82a-7d6247559af1" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,694</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6f4b438-93d4-46b8-9a1f-c66bd4db2588" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,434</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ab6031b-1e77-4b16-a89c-24b502ac1541" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ce45c5c-1f7c-4e8b-a07b-e94525e11790" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ace1d4f-8808-4804-89c5-9a21adeae195" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,685</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c986f10a-270c-42ef-9006-5170a66c7c1f" contextRef="C_c194f4a2-535c-4148-b525-7d7cf987efe3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4e04748-51d0-4515-9e4c-2fea9d691e45" contextRef="C_8436e431-af1b-457d-91b5-f52f9019d971" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c88157a-3eb4-4994-8146-c986fb5b2456" contextRef="C_8436e431-af1b-457d-91b5-f52f9019d971" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cb6b4c8-7523-4163-87c5-7fbd01841657" contextRef="C_c194f4a2-535c-4148-b525-7d7cf987efe3" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,495</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a84a3a6-bdd4-4dac-9afb-4f2584ee7f4b" contextRef="C_3ce276b6-c154-43a1-9f92-2f2097479a87" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,418</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14291c63-1978-41a8-ac2d-6274d503338c" contextRef="C_5ea44b8b-7856-4f7e-9da8-750bd3da72e0" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9479f1a-ecaa-4b4b-9ad0-2aa8a53c4615" contextRef="C_5ea44b8b-7856-4f7e-9da8-750bd3da72e0" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e40c0ad9-65f8-48ea-994d-02d7fd968e00" contextRef="C_3ce276b6-c154-43a1-9f92-2f2097479a87" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,194</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_265d697b-30b1-453c-ac5e-0f9c5673d5da" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,913</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b2c5852-7f0e-4405-8a09-f2bb18831be1" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9f52a5b-0b9b-4d39-8bf6-26ee3b4d1145" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8140ded-744f-4963-84fb-17bb70669ed3" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:CashEquivalentAndMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable debt securities that had been in unrealized loss positions as of December 31, 2023 and December 31, 2022 were in an unrealized loss position for less than 12 months. Unrealized losses from marketable debt securities are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on evaluation of available evidence.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_a0ff302c-144d-4a6f-8f1c-426777100f76" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:75.975%;"/>
        <td style="width:2.3%;"/>
        <td style="width:1%;"/>
        <td style="width:19.724%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due within one year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20122ad6-8cf6-44b5-9593-8c1c38fe3e05" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,845</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due after one year to two years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63ba7bff-49d4-4116-9cb3-e958e0e9f458" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb26ed4d-71dc-4e6a-96cf-582c34a6dd8b" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,035</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">117</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_12a35b58-3bff-4310-90a8-36149d453517" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. NON-MARKETABLE EQUITY SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value of non-marketable equity securities is determined using alternative pricing sources and models utilizing market observable inputs. The Company reports the restricted equity securities as non-marketable equity securities on the balance sheet and determines current or non-current classification based on the expected duration of the restriction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value is measured as the total initial cost, less the cumulative net unrealized loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe2c2822-7592-4bac-b162-183a5a6b5204" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock" escape="true" continuedAt="F_fe2c2822-7592-4bac-b162-183a5a6b5204_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the value of non-marketable equity securities using the measurement alternative </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_fe2c2822-7592-4bac-b162-183a5a6b5204_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:62%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:16.52%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:15.48%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Initial cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36e3ed46-de76-470c-9f06-c231483c4d77" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2c3b7ee-3ca5-4515-9136-74491729e245" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,759</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative net fair value loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3aa17ed4-6871-4d60-88c9-9b65db4d212d" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,748</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b7d75e7-2070-43c5-916c-5708737e9cd6" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,701</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrying value of non-marketable equity securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00ba5bd0-363a-4923-bc69-ceeddee09aa9" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:NonmarketableEquitySecuritiesCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fd0c14e-8636-4eff-82a5-21d0f7286272" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:NonmarketableEquitySecuritiesCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce901a87-933c-484b-82b2-88a9ed6320e3" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. LEASES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3fc4209c-3653-4eb7-891d-66e3ba266cb2" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net lease cost recognized for 2023 is summarized as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.532%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:15.603%;"/>
        <td style="width:1%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:15.143%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10944205-2593-436f-bb39-8b4e9839cc97" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,577</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf9d5a0b-f2ca-4e2f-ae2f-9de9426850a5" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,378</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10fec6f2-1e01-422d-9bd9-55aa1db14a71" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ae7b7b0-a302-4e5e-9521-6a9d4bf96f07" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,928</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_35ca71c2-d314-41cf-872d-b13445b5ae36" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2582425e-c251-4d8d-8f43-a1908112395d" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_afe1e361-b5b1-4b53-8194-97f13038554f" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of the lease liabilities based on minimum lease commitment amount are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60da932a-1868-43f4-9d22-5c78aea715af" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,022</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e221dba-fa42-4ea8-ba63-fe5bb4221603" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_511b13a4-4526-43bb-9b4f-1002bd4903a6" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c56d8fb0-a7ca-42a0-859f-0a9e7495fd13" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_796476f8-8147-4aac-92b2-971cce498e58" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ad88924-d5db-47ac-be9b-4435873392c5" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,071</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ba95671-5053-47d5-96ed-c0147cf15d72" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b0a0bff-be1f-4b0a-8707-a5914715531b" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,436</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57562bf3-dd65-4442-abbe-def0ba816460" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,395</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, the Company entered into a non-cancellable sublease agreement for the leased facilities in South San Francisco, California, which ends concurrently with the original lease in September 2025.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_15fb2b98-4d9f-4f49-98b6-3e78eb66e814" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, under the terms of the sublease agreement, the Company is entitled to receive future annual sublease payments as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:69.5%;"/>
        <td style="width:3.38%;"/>
        <td style="width:1%;"/>
        <td style="width:25.119999999999997%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e347691d-74ac-43c6-a944-c5b1a66ecf71" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,954</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e1adeae-31f2-4305-80c9-57a9f9e41978" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,496</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total sublease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_066c1e76-6e10-4d65-a68b-eb14f5184290" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,450</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The subtenant of the leased facilities in South San Francisco, California, has disclosed in public filings that there is substantial doubt regarding its ability to continue as a going concern. As tenant, the Company remains responsible for minimum lease commitments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fa0d973-c93b-4f53-9c1a-e193b9c33af2" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, on the South San Francisco facilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into a lease agreement that was amended in July 2022 for its headquarters office space in Brisbane, California. The lease term is through November 2024 with renewal options for the Company.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">118</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had not executed any finance leases that were yet to commence. As of December 31, 2023, the weighted-average remaining operating lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74f8ae50-d9b1-43ea-863d-7ee4ffc91ca8" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted-average discount rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27eccf8a-9f5a-4a7d-bf3c-f8486cd52b58" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for operating leases recognized in the financial statements.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f051488d-5ddd-42a4-b687-75a2d469b724" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:LongTermDebtTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. NOTE PAYABLE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e02275d-124e-4e53-ad03-f04c6c2ff9ea" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfDebtTableTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note payable consists of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">($ in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:26.985%;"/>
        <td style="width:2.16%;"/>
        <td style="width:12.062%;"/>
        <td style="width:2.16%;"/>
        <td style="width:14.923%;"/>
        <td style="width:2.16%;"/>
        <td style="width:1%;"/>
        <td style="width:8.062000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:2.16%;"/>
        <td style="width:14.923%;"/>
        <td style="width:2.16%;"/>
        <td style="width:1%;"/>
        <td style="width:8.242%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective Interest Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective Interest Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2021-12</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_19440935-5089-421e-aa42-43ad028fe500" contextRef="C_0c6e0d65-dc7d-4088-be4a-b8a144d6a7dc" name="vera:CollateralizedDebtInstrumentMaturityDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_834f8427-579b-4e98-8406-92f60ce541b0" contextRef="C_aa03b9e4-2af3-40b2-8a5a-57a770a088a6" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">14.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18042c96-d4cd-4756-8ea0-6abe512d613c" contextRef="C_aa03b9e4-2af3-40b2-8a5a-57a770a088a6" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7950f382-c3d3-4319-8406-128ffc437dbe" contextRef="C_2c78fe3f-f7cb-44db-809e-efe584139ec5" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">13.57</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27237736-f783-4a02-ab5a-1fc57214d1be" contextRef="C_2c78fe3f-f7cb-44db-809e-efe584139ec5" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2022-11</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7c2548ed-1e0e-40eb-b864-c323c764afee" contextRef="C_5f7c27af-2605-4301-ae0d-b823d5c17fb3" name="vera:CollateralizedDebtInstrumentMaturityDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c454b453-53cd-4a98-b49c-630a48b75b1b" contextRef="C_9f304eef-dfa2-48ba-a1fb-90a97b78c719" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">14.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7fc5b67-15e1-40c5-9e04-52f18a78e0b9" contextRef="C_9f304eef-dfa2-48ba-a1fb-90a97b78c719" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8956f6c3-5b97-4dd1-8043-4bc820d17bf3" contextRef="C_ce9554a4-9d43-44af-976d-e2f6d319f429" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">13.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b307315d-b4ad-486e-ad08-aee8173d4496" contextRef="C_ce9554a4-9d43-44af-976d-e2f6d319f429" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2023-12</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_02c847b4-9a50-4bfb-aa0c-f967619030dc" contextRef="C_d99a19d8-325e-4a9a-aacd-082609a73db3" name="vera:CollateralizedDebtInstrumentMaturityDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></ix:nonNumeric></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6abe1734-3666-450c-9066-7dfefbb424dd" contextRef="C_a6fea3c9-4692-4fad-ad2a-ff7a304239a9" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">15.37</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7b5a1a0-c169-4668-bdd2-1dc275d532ad" contextRef="C_a6fea3c9-4692-4fad-ad2a-ff7a304239a9" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_817b5301-f4ff-4bf6-8b3b-90a8b26a051b" contextRef="C_27ff2e6e-72bd-4173-93c6-978428eecba6" name="us-gaap:SecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total borrowings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e75dbe1-03d1-4d40-a387-a405775592d5" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b8e7fd7-f390-4ee7-a6b6-5566363888a2" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f608881-d8f6-49e8-80ca-a18ae14691e3" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cba08b2-51d8-4608-a659-307052015172" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:UnamortizedDebtIssuanceExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_294ef806-5792-4ce7-a290-b3c899a83857" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,877</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81b73d34-a725-4878-8fe4-9a48c2575392" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,810</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amount of debt approximates fair value due to its variable interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company entered into a non-revolving loan and security agreement (the Loan Agreement) with borrowing capacity of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a947a526-136c-4862-8f6a-ab054739ddce" contextRef="C_d97919f2-efef-4f37-8154-249dcc9ce087" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was scheduled to expire in December 2022.  In November 2022, the Company entered into an amendment of the Loan Agreement.  Among other changes, the amendment extended the scheduled expiration of the Loan Agreement to December 2023 and modified the reference rate from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financial Rate (SOFR).  In conjunction with the amendment, the Company borrowed an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96888a64-6246-4282-a650-acf947961d95" contextRef="C_d97919f2-efef-4f37-8154-249dcc9ce087" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Loan Agreement. In December 2023, the Company borrowed the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49b75612-9ad2-454a-b23e-de5c6474d037" contextRef="C_edca4e98-4e0f-44a2-ace4-368b647169df" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Loan Agreement. As of December 31, 2023, the Company&#8217;s outstanding borrowing under the Loan Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b4b6beb-3633-48aa-be76-8078c2a5ef15" contextRef="C_edca4e98-4e0f-44a2-ace4-368b647169df" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In March 2023, upon achievement of a clinical data milestone, the Company elected to exercise a borrower option to extend the maturity of the outstanding loan by 12 months, from December 2026 to December 2027. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38d8a9bc-575e-4247-8ecb-7747fa7af0a5" contextRef="C_0a795fca-1ad9-451e-9a6e-1d3d138b141b" name="us-gaap:LineOfCreditFacilityFrequencyOfPayments"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The interest-only payment period was also extended by 12 months to December 2026.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company is permitted to prepay the loan, subject to certain conditions. Upon the maturity date or prepayment of the loan, the Company is required to make a final payment equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80b4ffb5-c60c-4611-a987-5644822c3016" contextRef="C_edca4e98-4e0f-44a2-ace4-368b647169df" name="vera:LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The variable interest rate on the drawn amount is adjusted SOFR plus 825 basis points, subject to a per annum floor rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbc9837d-e50d-4bb5-ba4f-db243715340e" contextRef="C_e95c3e40-5150-4128-b63f-a06464bb547b" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">8.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.  The Loan Agreement contains a subjective acceleration clause in the case of an event of default. If such a matter occurs and is continuing, the lender may legally demand the outstanding principal and interest immediately due and payable. There are no financial covenants associated with the Loan Agreement and the loan is secured by the Company&#8217;s assets. The Loan Agreement is available for working capital, capital expenditures, and other general corporate purposes.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3eb74c76-4bf0-4a4d-9406-9340124a7d1c" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principal installments due on the notes are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"/>
        <td style="width:1.94%;"/>
        <td style="width:1%;"/>
        <td style="width:15.823%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a84b18f1-5ab7-462b-9d99-70162018ce95" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e00a606e-1e55-40a0-80f8-dc099aa03332" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9763371c-8cf9-4f00-8c45-02916a46ea3a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. COMMON STOCK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6907a71b-c380-4f06-afec-7040241148a3" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0686d66b-4f01-452e-b44a-2f4deed41d25" contextRef="C_7402c574-533f-4f99-9103-cfb6bfdbe42f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,600,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock, each with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34406778-529f-4209-a0bb-a154052ccd42" contextRef="C_7402c574-533f-4f99-9103-cfb6bfdbe42f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_fdf2c660-75ff-431d-9636-93abbaed6718" contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Each share of Class A common stock entitles the holder to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_155a08be-eb37-4d82-8c9e-6d2b00907988" contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d" name="us-gaap:CommonStockConversionBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Class B common stock is non-voting. Class A common stockholders and holders of Class B common stock are entitled to receive dividends, as may be declared by the board of directors. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa6b0096-170a-4290-a46a-530c6dd075eb" contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d" name="us-gaap:DividendsCash" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cfbeeb2a-ae63-41be-886b-e24fdb4123b6" contextRef="C_3bd84b09-3c01-4501-bfd7-f6e21766d9ca" name="us-gaap:DividendsCash" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends have been declared or paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company completed a follow-on public offering pursuant to which the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7e72f1-fdb8-42f8-9429-e30c290e0aa8" contextRef="C_866552c5-4fd9-48eb-ba57-9fc63a8df408" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">5,742,026</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Class A common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7d81fde-1633-45af-8964-37814e9e86d4" contextRef="C_fe9431d7-e239-4190-9590-1758494ffd28" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5633a347-b60b-4fbc-9537-529ff24adf68" contextRef="C_fad68b53-11d9-436b-9004-a5b8faf94415" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">748,959</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">119</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44659264-e0d9-4f6d-b3c8-e64368a9902b" contextRef="C_43178910-84ec-42e6-9755-a7c57bb14391" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">210,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d04065c2-396a-49c0-8a8f-28d58c687968" contextRef="C_8be84990-aa18-4a2e-8a74-e8d386ecfe3d" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">210,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock. In September 2022, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da474c42-6b03-4a24-9d52-11cafcea6f64" contextRef="C_1d2f152f-37d4-4884-be62-4c29d7144c37" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,238</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b168f3e-9f7a-476a-9f45-fab2d7f652bd" contextRef="C_e4034580-fe87-43d7-b8fa-5582e2ab5313" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">99,238</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock. The shares of Class B common stock that were converted into shares of Class A common stock have been retired and cancelled, and therefore will not be available for reissuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-265408) with the Securities and Exchange Commission, which permits the offering, issuance, and sale of up to a maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b6838b73-63de-4e04-b29b-2e63dc078019" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, preferred stock, debt securities and warrants. Up to a maximum of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4de7fa1-9263-4b88-b3eb-08b263470dfe" contextRef="C_f419ef0f-acae-4639-b7c3-1c50d6d17329" name="vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8feabc36-5fa4-44b7-87bb-36b34f9f49cf" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">400.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million may be issued and sold pursuant to an at-the-market financing facility under a sales agreement dated June 3, 2022, between the Company and Cowen and Company, LLC (Sales Agreement). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ed78bc2-41e2-480d-81e3-9fd821501227" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:AvailableForIssuanceAndSaleUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million remains available for issuance and sale under the Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b4cd367-1f05-4b84-9d1b-666666a6cc67" contextRef="C_104cfa0f-5c0c-42af-a707-85e7636b50f5" name="vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">283,034</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock to Novartis Pharma AG pursuant to an amendment to a license agreement between the two parties (see Note 11).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company completed a follow-on public offering pursuant to which the Company issued and sold  </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca287270-92cf-41d2-8c3f-88621e2f91af" contextRef="C_45df6405-1d04-4fca-8db5-99ee7b1dd71e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,428,572</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Class A common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_648e810b-2187-44da-bd2b-87735345eb0a" contextRef="C_a9205105-dc48-4b1b-8905-ca16af40dfee" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_541fba3f-5d71-4190-a322-054d064b810e" contextRef="C_c93b8c94-7f03-454e-b44d-c951c33fb0a3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,142,857</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_4b56ef34-3afd-4eda-8a03-b78782f415d0" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. STOCK COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan (ESPP) and the 2021 Equity Incentive Plan (2021 EIP), each of which became effective in connection with the IPO. The Company has reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a03497f7-5d48-4bdc-9afe-21b713fb38b6" contextRef="C_ae34e80b-e684-4ceb-8100-75a5ed7d4c34" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">707,942</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d81b95-71a8-4aa8-9d32-a9f648d65864" contextRef="C_106b349b-6afb-4176-a3b0-f3279ad1790b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">4,650,796</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock for issuance under the ESPP and 2021 EIP, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may not grant any additional awards under the 2017 Equity Incentive Plan (2017 EIP). The 2017 EIP will continue to govern outstanding equity awards granted thereunder. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a868059f-5a1b-4194-b4c8-7efab8c2b62c" contextRef="C_b73d9107-896f-43a1-9a6e-d51d7847b59f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">288,775</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2021 EIP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2017 EIP and 2021 EIP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_446db923-88bd-4503-ae03-a19f8737a101" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2017 EIP and 2021 EIP was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.638%;"/>
        <td style="width:1.341%;"/>
        <td style="width:1%;"/>
        <td style="width:9.664%;"/>
        <td style="width:1%;"/>
        <td style="width:1.821%;"/>
        <td style="width:1%;"/>
        <td style="width:8.743%;"/>
        <td style="width:1%;"/>
        <td style="width:1.341%;"/>
        <td style="width:1%;"/>
        <td style="width:12.845%;"/>
        <td style="width:1%;"/>
        <td style="width:1.341%;"/>
        <td style="width:1%;"/>
        <td style="width:10.264%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUMBER OF<br/>OPTIONS</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE PER<br/>SHARE</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>LIFE (YEARS)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE (000s)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbdbb465-7125-42d8-9315-825def1dc24a" contextRef="C_4135b425-1776-49c1-98fa-141157b08b6f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,821,787</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce97ae30-35f2-4347-9be0-ba5662eacc22" contextRef="C_4135b425-1776-49c1-98fa-141157b08b6f" name="vera:ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.30</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_1af44e14-a067-461c-8109-711b0724961f" contextRef="C_76b7492e-4260-4f67-8590-2c3713b1204a" name="vera:ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.51</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f33f7eba-a1f6-45df-8106-398b0a249fc0" contextRef="C_4135b425-1776-49c1-98fa-141157b08b6f" name="vera:ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,872</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1abcb711-e45a-414d-ae85-5e2f72dfcbba" contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,291,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f891993-e0ed-4c5e-b64d-6b60f98004ca" contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">111,927</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled and forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b92bb00-f21b-4d60-a7a8-554712834008" contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">238,624</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d009746b-fc6e-4256-bd22-90c1a7c068fe" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,762,236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_481ddc91-807e-4291-ad16-20e85d87b735" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="vera:ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d0640a75-0251-4bd1-a3da-ef7f20eb7765" contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa" name="vera:ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18b8d27a-e640-4cf9-ad48-8c17a6b9f84d" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="vera:ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfea28fa-34c8-400b-a892-df24f7f908ae" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,611,696</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7897c37e-bb6f-43ec-94de-1c58e059b59e" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_e273974d-56ec-4736-bc67-a65d5841d38b" contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8047a6a6-ab7c-43a0-9881-8dc91b606c8f" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,112</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64c783c1-ec9a-4ec8-88c0-c104280f8a64" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,762,236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19da75bf-e4d3-4c77-acab-8e6cb4dc366e" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3e0960bf-f631-4a5f-8e19-8dcd3066dcce" contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba5e14aa-665f-49ee-bc77-180f1213b867" contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06028e3b-119c-448d-ad89-3f73f0c894bb" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022, was</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bb58020-0e55-4572-9642-ee128e6ca3be" contextRef="C_2ee2de34-00df-4708-bfcd-a29d841f802c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.92</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_018d57dc-456b-4376-a435-06ed8f951824" contextRef="C_33e49389-84fd-47c2-a929-1bc794eb3c19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">13.63</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ESPP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP enables eligible employees to purchase shares of the Company&#8217;s Class A common stock at the end of each offering period at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39b9e1ac-f0bf-4dbb-81cc-6ab92f97f336" contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the shares on the first trading day or the last trading day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adf254e2-f5bb-463c-b85d-ebb27f3a6b53" contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a" name="vera:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d64db7c-bfa5-4e72-88c0-7fac3a8ff24e" contextRef="C_f0d79c47-62a3-4c6c-977a-e3a7e09cdea5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first day of each fiscal year, beginning on January 1, 2022, by a number equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cf1f9d2-15d3-40a5-aeb5-3543e49f160b" contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a" name="vera:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">440,502</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_727e7a5e-3e99-41f3-9497-13af33840773" contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a" name="vera:PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the total number of shares of the Company&#8217;s capital stock (including all classes of the Company&#8217;s common stock) outstanding on the last day of the calendar month prior to the date of the increase, or such lower number of shares (including no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">120</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approved by the Company&#8217;s board of directors. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6354a920-f567-4a57-8f0b-2bfaf0a42137" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">59,808</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued pursuant to the ESPP. The ESPP generally provides for six-month consecutive offering periods beginning on September 14, 2021. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. Stock-based compensation expense for the year ended December 31, 2023, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40ebacfc-5bba-4e51-8a84-e53398b4f7ff" contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9196806f-5640-475b-9377-4b7b51b7787c" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the stock-based compensation expense for stock options, restricted stock awards, and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company&#8217;s statements of operations and comprehensive loss for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years ended December 31, 2023 and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_503c604b-6e45-48be-9f88-3748d5b798f8" contextRef="C_9972233c-cff0-41a9-9e4e-78f8ec9718ca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,845</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b85b647d-c191-401e-b1a4-611996746519" contextRef="C_5e154e33-2372-4217-add2-91f0995fc280" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,592</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53886819-01bb-4a0d-8431-32f498d3dc52" contextRef="C_c2f7961f-3a91-49fc-8d5c-eadda8e3cd86" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1fc00c2-e906-48cb-91e2-f96c572da22b" contextRef="C_1d9746ec-02a4-4faa-807d-24788184f0f8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,295</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff98f3d0-5b0c-473e-bf6c-0a6a2e55bb18" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e60302c-36b3-46da-be19-2a287874023a" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,887</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83643e3e-eec8-4e4a-8f8e-f85f25153083" contextRef="C_dc44f825-ebce-4f12-ad2f-3c428d8aa752" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,494</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1977f64-4179-4dbc-b969-3e86bf406d6a" contextRef="C_83acb7dc-4dff-4e8f-926f-7ad1a9c65845" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,975</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonemployees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5412eacf-cad0-444f-af51-5c8f7cef53e0" contextRef="C_55828b2f-49ab-4655-b54a-8c64b655d49b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">999</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63c9c690-c072-46dd-81fc-f7185d6c3e14" contextRef="C_113d6c08-ba78-41b5-9746-69bcf0dfe625" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,912</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ee8e440-54ff-428d-a84c-e92cf7f70724" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,493</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8f8d84f-f409-4ae7-b45b-133b85a39444" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,887</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4cf06714-b931-44b4-939d-abd439f1cd24" contextRef="C_df5e40de-de67-4c81-87ff-65f4bafe12aa" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of unrecognized stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ade7cd62-18ec-428e-895c-0490e7523520" contextRef="C_b426fd92-70e4-4d90-867a-c0ba79af8b53" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d25d3d7e-7808-4c93-a042-9d5490f6695a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.049%;"/>
        <td style="width:1.8%;"/>
        <td style="width:21.676%;"/>
        <td style="width:1.8%;"/>
        <td style="width:21.676%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7f5e35f9-de56-4d63-95d2-ed34e612ceb6" contextRef="C_06c1a6f1-5730-4884-a735-4b4f7cac06bf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_772d5f71-0026-4d67-b085-f4d580512989" contextRef="C_6f6268ee-8510-4770-a4af-2174ce8766bc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c6f6e618-d8d6-40e4-91a8-f4c2d8fb094b" contextRef="C_cd7aa2da-6cbb-441f-945f-fb8ccbd69234" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_f568aa1b-78c6-4e3e-9633-f3979c0ebbfe" contextRef="C_8c1ed1eb-4ad3-48de-bbf2-10a461092b17" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e1aa8b7-680c-4c16-8f96-859a86d40d71" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">79.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a4a846e-e7cb-4437-9b1b-51a35aeeb0e8" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">80.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15ed519b-2b28-4358-b30d-5a69177334c6" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">75.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b0207be-be2d-4ff7-bb6a-e83411d66567" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">77.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5080289-1d69-4409-ada2-83133020c812" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a208c8c-dca6-4309-8db9-4c70241a5e75" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6efa3c56-1b6a-4656-81af-8782050512ed" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.76</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d828a6f-fcbf-4b92-b55f-26c4754289d0" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants restricted stock units (RSU) pursuant to the 2021 EIP and satisfies such grants through the issuance of the Company&#8217;s Class A common stock. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55b9b727-8a2d-43d5-aaec-192a41a89e34" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true" continuedAt="F_55b9b727-8a2d-43d5-aaec-192a41a89e34_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows RSU activity for the period ending </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_55b9b727-8a2d-43d5-aaec-192a41a89e34_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.19%;"/>
        <td style="width:1.72%;"/>
        <td style="width:1%;"/>
        <td style="width:18.544%;"/>
        <td style="width:1%;"/>
        <td style="width:2%;"/>
        <td style="width:1%;"/>
        <td style="width:23.544999999999998%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUMBER OF<br/>SHARES</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>GRANT DATE <br/>FAIR VALUE <br/>PER SHARE</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81e9e0ca-abda-4b6e-80fa-ae877717dffc" contextRef="C_8590b670-5825-42b7-a28a-b57150a094ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">204,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53091cad-1ab9-40e5-b023-ac481daf4c57" contextRef="C_8590b670-5825-42b7-a28a-b57150a094ad" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.37</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a14c69ce-eee5-4eca-a7cc-1d2408f07859" contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e51ae2f-c69d-4d9c-839b-392479d56b61" contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce74bced-a3eb-4218-9af8-5e09c9adafaf" contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">66,321</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44e22d07-b789-450a-944e-1b5eca1a2791" contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled and forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7859a292-e138-441f-b4fd-ee96313bcc91" contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b891c72-fcc2-4410-aaa4-1dd55e7fa163" contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.60</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d2e45f90-7772-47e0-b514-f6cb3b24dfcd" contextRef="C_c9b98e83-50fd-4219-bcaa-dce9a91dd403" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">131,679</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5e5292f-ee20-446f-904e-b9b14991d680" contextRef="C_c9b98e83-50fd-4219-bcaa-dce9a91dd403" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.36</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the Company recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a75712c-4d11-457c-a887-868cecbd2cb6" contextRef="C_5886db7b-8ba3-408a-b5d3-cf86749ed8e2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f stock-based compensation for RSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd1f2a62-bb62-4275-8ef4-8a214762f9ef" contextRef="C_b150cadf-6fed-4382-b18e-37a4483af270" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8887b73-e481-4864-818a-bfac6cee20c0" contextRef="C_652b7128-53c0-4531-a4b7-ce80609438f6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">121</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a521c5e-3cca-4894-b4b4-ecdb8f7ad96c" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. EMPLOYEE BENEFIT PLANS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. The Company contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da9029c7-d4c8-40c9-9fe9-0459f42e3445" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26805581-a218-4139-a80c-bdb4aae48fda" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the plan for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7138a32e-0262-4796-8917-91fbd8858405" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="vera:LicenseAndCollaborationsTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. LICENSES AND COLLABORATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ares Trading S.A.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company entered into a license agreement with Ares (the Ares Agreement), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the Ares Agreement, the Company paid a non-refundable license issue fee to Ares in the form of shares of redeemable convertible preferred stock valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90a22db8-8849-47c9-8ccd-cc8b19bc60db" contextRef="C_f3deb204-a947-4aea-a198-2bd978183c67" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, resulting in Ares becoming a related party to the Company. The redeemable convertible preferred stock subsequently converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c7547ff-51fd-4bac-b7af-aed3a559d129" contextRef="C_88fbad11-b4e4-408e-a5f8-605f139b9287" name="us-gaap:ConversionOfStockSharesIssued1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,913,501</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock in connection with the IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, the Company paid Ares a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4919b824-8694-4cd1-a619-5d9caea80b4a" contextRef="C_6af2ee58-50ae-4209-960f-c26d33ada18c" name="vera:MilestonePaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon delivery and initiation of the transfer of specified information and materials. The Company is obligated to pay Ares aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cdbb831-bb9a-48eb-894c-6c7b44c2e717" contextRef="C_5e13a118-4107-4dfb-bab4-6714cdfa6f1f" name="vera:MilestonePaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">176.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified BLA filing or regulatory approval milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae15455c-5e30-4edb-9016-af4c49bf3123" contextRef="C_5b5b601c-cee7-4811-bef5-aa093f9e6050" name="vera:MilestonePaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">515.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified commercial milestones. The non-refundable license issue fee and milestone payment were recorded to research and development expense in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the effective date of the Ares Agreement, Ares is performing manufacturing technology and know-how transfer to the Company. The Company recorded related party expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2886d594-a4e6-4be3-b533-750879e78d31" contextRef="C_8ac3dbbb-9f62-4b97-afd2-60e8f5b19158" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c268ea49-be8a-47f2-a452-f980805cff13" contextRef="C_3b83fa9a-deb4-4a21-b9ff-0b9830dba0d1" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Ares for these services during the years ended December 31, 2023 and 2022, respectively. These amounts are included in research and development expenses on the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered royalties of low double-digit to mid-teen percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed product-by-licensed product and country-by-country basis from the first commercial sale of a product in a country until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii) the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to sublicense its rights under the Ares Agreement, the Company would be obligated to pay Ares a percentage ranging from the mid-single-digit to the low double-digits of specified sublicensing income received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amplyx Pharmaceuticals, Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In December 2021, the Company entered into an asset purchase agreement (the Amplyx Agreement) with Amplyx Pharmaceuticals, Inc. (Amplyx), a wholly owned subsidiary of Pfizer Inc. Pursuant to the terms of the Amplyx Agreement, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e646b28-cb48-4ada-9e17-61079a6ebc72" contextRef="C_8b5bdaed-6212-482b-968a-c7919dfb3d46" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Amplyx to purchase assets relating to an anti-BKV monoclonal antibody referred to as MAU868 for the treatment of BKV infection pursuant to a License Agreement between Amplyx and Novartis International Pharmaceutical AG (Novartis). In addition, the Company recognized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f56b315-15cf-4092-8656-266510b5b6c3" contextRef="C_9d1e9814-ee09-45d4-9d31-1141dbaf3188" name="vera:MilestonePaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million contingent milestone obligation as an assumed liability related to the asset purchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The acquisition cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8afb0c7-90dd-4b1a-906f-ca4ba7950334" contextRef="C_8b5bdaed-6212-482b-968a-c7919dfb3d46" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as research and development expense in the statement of operations and comprehensive loss on the acquisition date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Amplyx asset purchase, Amplyx assigned the Exclusive License Agreement between Amplyx and Novartis (the Novartis License) and Manufacturing and Supply Agreements to the Company.  Under the Novartis License, the Company has exclusive worldwide rights from Novartis to develop, manufacture and commercialize MAU868. The Company will be solely responsible for all research, development, regulatory, manufacturing and commercialization activities of MAU868.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Amplyx Agreement, the Company is obligated to make future milestone payments to Amplyx and Novartis upon the achievement of specified development, regulatory and commercial milestones. In September 2022, the Company and Novartis entered into an amendment to the Novartis License to modify the terms of future milestone payments. Pursuant to this amendment, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db824f9c-0f30-4163-8cc2-025a9e1826a3" contextRef="C_104cfa0f-5c0c-42af-a707-85e7636b50f5" name="vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">283,034</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock to Novartis in exchange for a reduction of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ab58cf7-79bc-402a-a16b-ced5ad043f34" contextRef="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c" name="vera:ReductionInContingentFutureDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contingent future development milestones, including the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd43e11e-fa42-49e8-9db5-cecfa2b3e456" contextRef="C_8b5bdaed-6212-482b-968a-c7919dfb3d46" name="vera:ContingentMilestoneObligationAccrued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million contingent milestone obligation accrued by the Company in December 2021. The value of the shares issued was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e79efa4-4b98-4044-8c88-f8bffc78b13c" contextRef="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c" name="vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on the closing market value of the Company&#8217;s Class A common stock as of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">122</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date of the amendment, and as a result of the amendment the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8a4f772-a688-4906-bc66-ed60e789dde6" contextRef="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of research and development expense in the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company is obligated to make future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b29e654c-861c-41cc-bf41-ad2840c41dc0" contextRef="C_89a4ab10-0f5d-46b6-bb03-b0eae339e011" name="vera:MilestonePaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ec68d7a-73eb-46ae-bf15-46c805cc24da" contextRef="C_b12037ba-e589-4ed7-b30f-5ff359e4b80b" name="vera:MilestonePaymentsPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Amplyx and Novartis, respectively, contingent upon the achievement of specified development, regulatory and commercial milestones. In the event that MAU868 is commercialized, the Company will be obligated to pay royalties to Amplyx and Novartis based on net sales by country and by product.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_10b9e67c-1bd6-4670-89c1-00da109ba68b" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. INCOME TAXES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59f94d3e-b8f2-4366-ae1c-62d39bc83077" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For financial reporting purposes, income (loss) before provision for income taxes, includes the following components </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
        <td style="width:1.62%;"/>
        <td style="width:1%;"/>
        <td style="width:12.883000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a454a3c8-156e-4d93-825d-212fd2fcfa46" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,989</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e2f2d15-0e5e-4d47-a008-7ff9f7773e26" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14e8caeb-fd6f-46c6-987e-58a1cd31e10b" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8678e79a-532e-4484-a45d-291115448d99" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60bf09e4-3615-41e9-92a6-c5174a2da4a4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">95,989</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b234cc87-712d-41a5-9656-f16a239fca36" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">89,055</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provision for Income Taxes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be20afd7-457f-4b20-b2fe-f59fa965ae55" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for income taxes consisted of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.59%;"/>
        <td style="width:2.38%;"/>
        <td style="width:1%;"/>
        <td style="width:19.823999999999998%;"/>
        <td style="width:1%;"/>
        <td style="width:2.38%;"/>
        <td style="width:1%;"/>
        <td style="width:19.823999999999998%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_473c74b8-83b2-4178-9fc0-ccef86c8d9f7" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6be9d1fc-7cb9-4b22-b691-051673a8ebf0" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d87b44e2-27b1-46a7-94cb-09e34a7bdd05" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a4c0338-e540-4084-b381-716d2ab63c38" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b60d454-96fe-4f8d-babd-6d2d043d2bda" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_663ac063-99b2-4d9f-9b9f-789a2c6fb23e" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_73211efb-88bd-422e-9199-e8d45887ad03" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7780dfba-c387-4b71-bc7f-d8e3415409e6" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5ad2101-f001-4aac-9ba0-10ef82117ae4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52b86013-1cc6-4d75-bbb1-283874f992e4" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cc0a4dc-dafd-4cad-a79a-93af25413e3d" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes computed using the U.S. statutory federal income tax rate compared to the income tax provision included in the statement of operations and comprehensive loss is as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.98%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.459999999999997%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:19.36%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax on U.S. statutory rate on income before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9bd4a3d-9222-4471-9773-d29607b76c3d" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20,158</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3800540-669c-4c29-b859-08f2d5cd888c" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,702</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b7db8e7-d3e5-4da0-80fa-31a1d59a8aac" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">489</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6daf6ae7-54da-42e2-b8e5-26844da5ac8a" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,583</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91bdd744-d71d-4f08-9e6e-aa1f00419f22" contextRef="C_cade7871-7cd4-4bc1-8f5e-7e8350a76e16" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">490</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c07c3e3b-dbd5-4c4f-a237-d622101a43b5" contextRef="C_64111eab-3827-4866-aa3a-fc5810fb7d15" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,582</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09d42ccd-d93c-457f-a896-7a45014e8a24" contextRef="C_778ecdc2-82e7-487e-8f23-1ed776e1936e" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,250</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb1dec62-6023-4536-8aa4-6900b13f9726" contextRef="C_94d2afc6-a122-4a1e-804c-c6fd42dafadc" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,643</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd74061d-8f73-41bb-8594-6e2f055e662e" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,598</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c89fc6eb-7728-40fc-b512-3859b6905c95" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxReconciliationTaxCredits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">710</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58f96198-052a-4c60-9886-d2da499cdd26" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_822c0490-d376-4f67-8ca3-07af7a6a0a87" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">231</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c63b7c49-69d7-4438-8070-865361ecb58e" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2b3dedd-6608-400c-9b87-0307c83e008a" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Tax Assets and Liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities are determined based on the differences between financial reporting and income tax bases of assets and liabilities, as well as net operating loss carryforwards and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00d6e265-7142-4470-af7e-726ebb1d24e3" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_00d6e265-7142-4470-af7e-726ebb1d24e3_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s net deferred tax assets and liabilities are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:continuation id="F_00d6e265-7142-4470-af7e-726ebb1d24e3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">123</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.151%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.224%;"/>
        <td style="width:1%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.224%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state NOL carryforward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd72337a-90ff-4ff0-a60f-820f107d9e03" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,539</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_658189e4-9390-4a62-85ac-d2a50f5f6b83" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,945</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and other credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6032db9-1de9-42b1-ae8a-12891db7931d" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,051</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67179538-a9b5-43e3-b252-bc8b2354d36d" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,762</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df682965-279c-42fd-aeef-bf44622f458e" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,264</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3aa2fbc9-07f2-45ef-8510-73cef045f8cb" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,731</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_86028361-1df5-4568-85b1-024b5439a184" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec1994ce-1a51-4739-a6eb-67c5c5134982" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f524856b-c406-4155-ba8b-1e19bfdd0e20" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96b03e42-dbe2-4524-b001-9744055951f6" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">519</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0f5d282-1d7d-438a-a068-24672dcf2c6a" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,978</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4af81ce4-5881-4dec-88f0-8c0ac5547e29" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other intangibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8831685b-69d7-4d41-ad16-626ed689689b" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,313</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9577762d-9464-4341-8d4c-840396086c81" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,583</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other DTA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c00b8d7-fe54-4318-bcab-d89cac98e898" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">384</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57c58819-9ca2-4e3a-aac0-53e6c2a24b43" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">402</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab7191b8-a689-44bb-aceb-3a9f5b5255e5" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">804</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77853698-82a2-4b9b-bc8a-e64fbc81612b" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:DeferredTaxAssetsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,360</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross DTA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03d0279f-0965-4bab-a06f-5fe1ad600b2f" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,091</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec3d6e6a-efea-4164-96a3-6db2aa45474e" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,734</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_481eef39-036f-45b8-9f98-276f47651d5a" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">71,372</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_12741ee0-0292-49f3-a56f-6ceede718863" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0754491b-909e-4fa8-a7ee-1ff4518bb101" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba4fe011-9c86-4006-bd0b-8be47b30aaab" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,086</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d71ab86e-c72e-43fb-a778-467496378b22" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="vera:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">619</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_167d432b-d596-4211-8028-af7a889ec402" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="vera:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,086</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other DTL</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87e3869c-0a3b-4277-ad5b-690c6ee183ee" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76607bcb-22af-4ce1-9018-cba3c1ca80b1" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross DTL</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6ab9e45-6774-415a-b651-41c17d9ddba5" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab61c124-fb0f-47e7-84a9-e6e027a4717c" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,086</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5230020d-4a8a-43e0-931f-339b387ade1f" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d443680-b573-41a9-941f-dbd788c54383" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has federal and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e83c2586-8825-4036-868d-75b883f7d7b5" contextRef="C_6b5a8210-e301-4c4e-b003-8559739c8a43" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">118.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ebd7dd5-2d79-4cc1-9541-b5b800b439e4" contextRef="C_24a4e735-d3db-4c23-bb5e-9ca013ac3681" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7578b5f-c1e1-4234-ad62-fc1180c0732b" contextRef="C_656df8a2-b22a-4441-86ea-edc39b8cabaf" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal net operating loss carryforwards and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_09b2337a-4f9b-46af-b757-1ed096817393" contextRef="C_ddb29d7c-a69c-4f1e-9ea5-993bbfcc10d6" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of state net operating carryforwards will begin expiring in the year </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35e2af96-4ee1-4446-af0b-c5801e390aec" contextRef="C_778ecdc2-82e7-487e-8f23-1ed776e1936e" name="vera:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2032</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14035370-f4f4-4dcd-89c5-41ed4599da10" contextRef="C_cade7871-7cd4-4bc1-8f5e-7e8350a76e16" name="vera:OperatingLossCarryforwardsExpirationYear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, if not utilized. The Company also has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1057e7fc-37f6-478c-b1ec-b701f7174306" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">109.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal net operating loss carryforwards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that does not expire as a result of recent tax law changes. The Company has $5</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f9b55b6-3c40-41b7-99ee-91a1583bdacd" contextRef="C_2e56d451-bf45-4d4d-ad5b-7a10597988a0" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal research and development tax credit carryforwards, which begin to expire in the year 2037. The Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e0eb0f7-4198-4330-822f-0a2af860e57e" contextRef="C_e3ba2032-8472-4a06-af17-769f411f1c3b" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of state research and development tax credit carryforwards, which have no expiration date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the federal and state net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed an analysis to determine if such ownership changes have occurred. An analysis will be performed prior to recognizing the benefits of any losses or credits in the financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence including a history of operating losses, management has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a1de001-2d27-4f0e-ab01-d3c20b4bfd5b" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3ae8b2a-42ed-497d-a4ed-3ac7cee99dbe" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and 2022 has been established to offset the deferred tax assets as realization of such assets is uncertain.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncertain Tax Benefits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa65c08e-0f3d-47e6-a25b-5c7cd011aad5" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the following activity relating to the gross amount of unrecognized tax benefits </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.151%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.224%;"/>
        <td style="width:1%;"/>
        <td style="width:2.2%;"/>
        <td style="width:1%;"/>
        <td style="width:18.224%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10b57d5c-7214-42ef-b2f2-5c9d2ca54063" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a1b7048-f45d-4900-9e3c-08960199b91d" contextRef="C_5ed90599-4b8c-4161-b826-92693ffe24bd" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">668</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_443d74f6-f204-450e-aada-3912cb1cfbb4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8d55c30-5da0-4196-b244-d049df512a2b" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e444562-ba16-4385-bbce-42e93319dbeb" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_418293a5-4555-47f8-809d-3887bdfcb75f" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11470b04-a492-4c77-9f44-481fa887e6bd" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">572</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64e0aaee-3778-472e-b54d-b65112a05402" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">265</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a52d649-b350-4393-89fd-35abad016588" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,513</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_033941f7-0d5a-455d-a8fe-3df872c395f5" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">941</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. None of these uncertain tax positions will impact the Company&#8217;s effective tax rate if assessed. The Company&#8217;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fad7ab4-34a1-4b8a-90a4-78b542b13412" contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ff5620de-ec80-49e4-a8be-c3bc26d83076" contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or penalty accruals associated with uncertain tax benefits in its balance sheet and statement of operations for the years ended December 31, 2023 and 2022. The Company files income tax returns in the U.S. and California. The Company is not currently under examination by any major tax jurisdictions nor has it been in the past. Because of net operating losses and research credit carryovers, substantially all of our tax years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">124</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">remain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">open to examination. Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a88832c7-153a-45c5-be6d-c35b8c0547d0" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that there are no actions pending which would have a material adverse effect on its results of operations, financial condition, or cash flows.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company did not have any material indemnification claims that were probable or reasonably possible, and consequently no related liabilities have been recorded.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including severance and accelerated vesting of equity incentives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development and Manufacturing Services Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into development and manufacturing contracts with vendors in the conduct of our business. Contracts with these vendors may be terminated at the Company&#8217;s option, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would be obligated to pay for the products or services that had been provided or received at the time the termination became effective,  and potentially additional compensation based upon lead time remaining between the date of notice of cancellation and the scheduled manufacturing run.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fae65d4b-d708-4b3e-b391-07e82d7dda29" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bce71323-2c74-4612-9650-1bd97b49c47c" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.26%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.26%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acde5451-74a1-437c-89bf-3f54e0577f9e" contextRef="C_4a52fd0c-ea66-4e45-91f2-1ab3d98bfe72" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,762,236</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_135a2a27-f1c8-49fe-adf3-06998b25d8c3" contextRef="C_9beda916-eeba-458d-97e7-f73f38603c69" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,821,787</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_034d435f-5dbb-494a-8058-e20251f069c8" contextRef="C_36414961-ec1c-41e6-866e-dc6627ebdbe7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">131,679</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72ad5b9a-9903-47ae-8261-f535be974a87" contextRef="C_75cc6cdb-a496-4205-b05d-09f40af83bb9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">204,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0688afa-6b50-4630-aa18-06ea9d0fcd26" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,893,915</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9eea9aac-5bf1-4b24-b0e6-3c24f8b23078" contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,025,787</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fa6666a-0e71-4a58-800c-53df180dd7b4" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. RELATED PARTY TRANSACTIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. Related party transactions and balances in the current periods presented are described in Note 3 and Note 11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f739bf9-5914-4021-b503-1567fb39c63a" contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. SUBSEQUENT EVENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 29, 2024, the Company suspended and terminated the prospectus (the ATM Prospectus) related to the sale of its Class A co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mmon stock in an &#8220;at-the-market&#8221; offering pursuant to the terms of the Sales Agreement (see Note 8). As a result, the Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. Deferred costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_024544fe-84c7-4642-9310-1781aa51ee4c" contextRef="C_b3e496cc-f877-412e-b2d0-1b4233183c32" name="vera:WriteOffOfDeferredCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recognized as general and administrative expense upon termination of the ATM Prospectus.</span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">125</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 1, 2024, the Company completed a follow-on public offering pursuant to which the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e62b858a-2318-4bb2-9af0-787e6c79cce4" contextRef="C_be8fb598-3863-42c0-ae6e-183bbd558432" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">9,274,194</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Class A common stock at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ab0365f-3c67-4cb8-87be-e10c825817c5" contextRef="C_299bd9f5-1494-45ab-a9b2-e9efcfe185b5" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">31.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d187f12d-5a24-45da-9fa4-e10c180acb0e" contextRef="C_d83a4fc8-8999-4dbb-8d15-fe08a22689c1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,209,677</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock. The Company received total net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36154202-e3a3-43f7-93b9-42efe8737672" contextRef="C_7e0be373-0021-42a8-b661-4dcf7ed20677" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">269.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78b0df87-029a-4661-8448-27da998325c3" contextRef="C_7e0be373-0021-42a8-b661-4dcf7ed20677" name="us-gaap:PaymentsForUnderwritingExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and offering costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd20f023-6774-409a-a9a9-cf65b8c8a321" contextRef="C_7e0be373-0021-42a8-b661-4dcf7ed20677" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">126</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 9A. Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of December 31, 2023, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f). We maintain internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, in designing and evaluating the disclosure controls and procedures, management recognizes that any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the criteria set forth in &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this assessment, our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting due to an exemption established by the JOBS Act for &#8220;emerging growth companies&#8221; and because we qualify as a &#8220;non-accelerated filer&#8221; (i.e., we do not qualify as either an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act).</span></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#333333;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">              </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) during the quarter ended December 31, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9B. Oth</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">er Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Arrangements</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">127</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2a426196-484e-45e8-b04f-08cc2ed14aca" contextRef="C_5dc0b4e6-1ca3-4772-bc5f-e4b2611208cb" name="ecd:MtrlTermsOfTrdArrTextBlock" escape="true"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the quarter ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company&#8217;s securities set forth in the table below.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:21.12%;"/>
      <td style="width:10%;"/>
      <td style="width:13.84%;"/>
      <td style="width:9.22%;"/>
      <td style="width:9.22%;"/>
      <td style="width:10.74%;"/>
      <td style="width:25.86%;"/>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Position</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Action</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adoption/ Termination</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rule 10b5-1*</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rule 10b5-1**</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Shares of Class A Common Stock to be Sold</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Date</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_8d602f56-894c-4d38-a5fc-9e86f3510aa7" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="ecd:TrdArrIndName"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Celia Lin</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_3952a794-cfed-44e3-ac2b-f9d933761b7e" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="ecd:TrdArrIndTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Medical Officer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">***</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_c694922e-70e4-44b3-a102-ca2fbd7d1ad7" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adoption</span></ix:nonNumeric></span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_681b238b-a5af-42f1-9bdc-3f400f5eeb6d" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="ecd:TrdArrAdoptionDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 10, 2023</span></ix:nonNumeric></span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71d01983-f901-4660-89b9-e067dfbb3828" contextRef="C_49967e2d-722f-4392-96f6-1a63849048ac" name="ecd:TrdArrSecuritiesAggAvailAmt" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">134,401</ix:nonFraction></span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_38bbc43c-0aef-4ba8-a921-1064ab768160" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="vera:TrdArrExpirationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 19, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">****</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">** &#8220;</span><span><ix:nonNumeric id="F_e767a0b5-acb9-4169-9405-b06191a34cb0" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">n-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">***Dr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;min-width:fit-content;">. Lin separated from Vera effective January 3, 2024.</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">****In connection with her separation from Vera, Dr. Lin terminated this 10b5-1 Plan effective </span><span><ix:nonNumeric id="F_5ee51d4a-7c7d-48ae-bdf3-98e16a559308" contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0" name="ecd:TrdArrTerminationDate"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 19, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">128</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_10_directors_executive_officers"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 10. Directors, Executive Officers and Corporate Governance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item will be contained under the captions &#8220;Proposal 1 &#8211; Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; &#8220;Executive Officers,&#8221; and &#8220;Delinquent Section 16(a) Reports,&#8221; if any, in our definitive proxy statement to be filed with the Securities and Exchange Commission in connection with our 2024 Annual Meeting of Stockholders (&#8220;Definitive Proxy Statement&#8221;), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2023 and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Code of Business Conduct and Ethics</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain a Code of Business Conduct and Ethics (Code of Conduct) that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Conduct is posted on our website at www.veratx.com. If we make any substantive amendments to the Code of Conduct or grant any waiver from a provision of the Code of Conduct to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 11. Executive Compensation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item will be set forth under the caption &#8220;Executive Compensation&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_12_security_ownership"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item will be set forth under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_13_certain_relationships"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 13. Certain Relationships and Related Transactions, and Director Independence.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item will be set forth under the captions &#8220;Transactions With Related Persons and Indemnification&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_14_principal_accounting_fees"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ite</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">m 14. Principal Accountant Fees and Services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information required by this item will be set forth under the caption &#8220;Proposal 2 &#8211; Ratification of Selection of Independent Registered Public Accounting Firm&#8221; in our Definitive Proxy Statement and is incorporated herein by reference.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">129</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_15_exhibits_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">em 15. Exhibit and Financial Statement Schedules.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have filed the following documents as part of this Annual Report.</span></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial statements filed as part of this Annual Report are included in Part III, Item 8 of this Annual Report.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statement Schedules:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All schedules have been omitted because they are not required, not applicable, not present in amounts sufficient to require submission of the schedule, or the required information is otherwise included.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibits:</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this Annual Report.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 16. Fo</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">rm 10-K Summary.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT INDEX</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.5pt;vertical-align:top;"><p style="text-indent:-7.5pt;padding-left:7.5pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312522167319/d361240dex12.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Sales Agreement, by and between the Registrant and Cowen and Company, LLC, dated June 3, 2022 (incorporated by reference to Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form S-3, filed with the SEC on June 3, 2022).<br/><br/></span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.5pt;vertical-align:top;"><p style="text-indent:-7.5pt;padding-left:7.5pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.5pt;vertical-align:top;"><p style="text-indent:-7.5pt;padding-left:7.5pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1&#x5E;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312522029746/d210084dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Asset Purchase Agreement between the Registrant and Amplyx Pharmaceuticals, Inc. dated December 16, 2021 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on February 7, 2022).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521165336/d141137dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 18, 2021).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521165336/d141137dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on May 18, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex41.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Class  A Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended, filed with the SEC on May 10, 2021).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521129272/d96328dex42.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amended and Restated Investors&#8217; Rights Agreement, by and among the Registrant and certain of its stockholders, dated October 29, 2020 (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended, filed with the SEC on April 23, 2021).</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex4_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Description of Common Stock of the Registrant</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:3.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:3.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.1</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521129272/d96328dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on April 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521129272/d96328dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statements on Form S-1, filed with the SEC on April 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex103.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex104.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex105.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex106.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">130</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11%;"/>
    <td style="width:1%;"/>
    <td style="width:88%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.7&#134;*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc. 2024 Inducement Plan.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.8&#134;*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex10_8.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Vera Therapeutics, Inc. 2024 Inducement Plan.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9&#134;*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex10_9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Restricted Stock Unit Grant Notice and Award Agreement under the Vera Therapeutics, Inc. 2024 Inducement Plan.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000095017023010288/vera-ex10_7.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc. 2021 Non-employee Director Compensation Policy, as amended on March 28, 2023 (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 28, 2023).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.11&#134;*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex10_11.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc. Non-employee Director Compensation Policy, as amended December 6, 2023.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.12</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex108.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Form of Indemnification Agreement by and between the Registrant and its directors and executive officers (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1, file with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.13</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;&#165;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521155556/d96328dex109.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Offer Letter by and between the Registrant and Marshall Fordyce, M.D., dated May 7, 2021 (incorporated by reference to Exhibit 10.9 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.14</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;&#165;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex10_14.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Separation Agreement by and between the Registrant and Celia Lin, M.D., dated January 3, 2024.</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">10.15</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;&#165;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521215234/d185242dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Offer Letter, by and between the Registrant and Sean P. Grant, dated May 30, 2021 (incorporated by reference to Exhibit 10.1 the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on July 14, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.16&#x5E;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312521129272/d96328dex1015.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement by and between the Registrant and Ares Trading S.A., dated as of October 29, 2020 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on April 23, 2021).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.17&#165;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312522029746/d210084dex1014.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Loan and Security Agreement between the Registrant and Oxford Finance LLC, dated December 17, 2021 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on February 7, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.18&#165;&#x5E;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312522029746/d210084dex1016.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">License Agreement between Novartis International Pharmaceuticals AG and Amplyx Pharmaceuticals, Inc. dated August 26, 2019 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on February 7, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.19&#x5E;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312522029746/d210084dex1017.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment No. 1 to License Agreement between Novartis International Pharmaceutics AG and Amplyx Pharmaceuticals, Inc. dated September 24, 2019 (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1, filed with the SEC on February 7, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.20&#x5E;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000119312522241970/d265248dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amendment to License Agreement, by and between the Registrant and Novartis Pharma AG, dated September 9, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed with the SEC on September 9, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.21&#165;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1831828/000095017022023932/vera-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">First Amendment to Loan and Security Agreement, by and between the Registrant and Oxford Finance, LLC, dated November 4, 2022 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on November 9, 2022).</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23.1*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24.1*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Power of Attorney (included on signature page).</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*#</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.2*#</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex32_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97.1*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="vera-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Vera Therapeutics, Inc. Incentive Compensation Recoupment Policy</span></a></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
   </tr>
   <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:middle;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:10.8pt;vertical-align:middle;"><p style="margin-left:10.8pt;text-indent:0;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:7.2pt;vertical-align:top;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104*</span></p></td>
    <td style="text-indent:10.8pt;vertical-align:top;"><p style="margin-left:10.8pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#134; Indicates management contract or compensatory plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#165; Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x5E; Pursuant to Item 601(b)(10) of Regulation S-K, certain portions of this exhibit (indicated by asterisks) have been omitted.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"># The information in Exhibits 32.1 and 32.2 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">131</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (including this Annual Report on Form 10-K), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">132</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signature"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TURES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:42.42%;"/>
    <td style="width:11.44%;"/>
    <td style="width:3.72%;"/>
    <td style="width:42.42%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vera Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 26, 2024</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:top;"><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Marshall Fordyce</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marshall Fordyce, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer and President</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.98%;"/>
    <td style="width:1.04%;"/>
    <td style="width:43.3%;"/>
    <td style="width:1.04%;"/>
    <td style="width:21.64%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Marshall Fordyce</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marshall Fordyce, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sean Grant</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sean Grant</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Joseph Young</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Senior Vice President, Finance and Chief Accounting Officer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Joseph Young</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Accounting Officer)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Morrissey</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chairman of the Board</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Michael Morrissey, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Andrew Cheng</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Andrew Cheng, M.D., Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Patrick Enright</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Patrick Enright</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Kimball Hall</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Kimball Hall</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Maha Katabi</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maha Katabi, Ph.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Scott Morrison</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Scott Morrison</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Beth Seidenberg</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;March 26, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Beth Seidenberg, M.D.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">133</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>vera-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 4.3</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DESCRIPTION OF COMMON STOCK</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following description summarizes the terms of the Class A common stock and Class B common stock of Vera Therapeutics, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this &#x201c;Description of Common Stock,&#x201d; you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, which are included as exhibits to our Annual Report on Form 10-K, and to the applicable provisions of the Delaware General Corporation Law. Our amended and restated certificate of incorporation authorizes us to issue 500,000,000 shares of Class A common stock, par value $0.001 per share, 14,600,000 shares of Class B common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. Our board of directors is authorized, without stockholder approval except as required by the listing standards of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock. In addition, under our amended and restated certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding and not by more than the number of remaining authorized but designated shares of preferred stock. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the Class A common stock and Class B common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our Class A common stock and Class B common stock and may adversely affect the market price of our Class A common stock and the voting and other rights of the holders of our Class A common stock and Class B common stock.</font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Voting Rights and Conversion Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of our Class A common stock are entitled to one vote per share of Class A common stock on any matter that is submitted to a vote of our stockholders and holders of our Class B common stock are not entitled to any votes per share of Class B common stock, including for the election of directors. Additionally, holders of our Class A common stock have no conversion rights, while holders of our Class B common stock shall have the right to convert each share of our Class B common stock into one share of Class A common stock at such holder&#x2019;s election, provided that as a result of such conversion, such holder would not beneficially own in excess of 9.9% of any class of our securities registered under the Securities Exchange Act of 1934, as amended (Exchange Act), unless otherwise as expressly provided for in our amended and restated certificate of incorporation. However, this ownership limitation may be increased to any other percentage designated by such holder of Class B common stock upon 61 days&#x2019; notice to us or decreased at any time. Holders of our Class B common stock are also permitted to make certain transfers of Class B common stock to non-affiliates upon which, such transferred shares could be immediately converted into shares of our Class A common stock.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation does not provide for cumulative voting for the election of directors for our Class A common stock. Our amended and restated certificate of incorporation establishes a classified board of directors that is divided into three classes with staggered three-year terms. Only the directors in one class are subject to election by a plurality of the votes cast at each annual meeting of our stockholders holding shares of Class A common stock, with the directors in the other classes continuing for the remainder of their respective three-year terms. The affirmative vote of holders of at least 662&#x2044;3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of directors, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Economic Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law, and other than the voting rights and conversion rights stated above, all shares of Class A common</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">stock and Class B common stock have the same rights and privileges and rank equally, share ratably, and are identical in all respects for all matters, including those described below.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Dividends</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our Class A common stock and Class B common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On our liquidation, dissolution, or winding-up, the holders of our Class A common stock and Class B common stock will be entitled to share equally, identically and ratably in all assets remaining after the payment of any liabilities, liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any outstanding preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of such affected class, voting separately as a class.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">No Preemptive or Similar Rights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The holders of shares of our Class A common stock and Class B common stock are not entitled to preemptive rights, and are not subject to redemption or sinking fund provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-Takeover Provisions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws, which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Certificate of Incorporation and Bylaws</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of Class A common stock are able to elect all of our directors. Our amended and restated certificate of incorporation and our amended and restated bylaws provide that stockholders may only take action at a duly called meeting of stockholders. A special meeting of stockholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes with staggered three-year terms.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing provisions will make it more difficult for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 203 of the Delaware General Corporation Law</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to Section 203 of the Delaware General Corporation Law (DGCL), which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, subject to certain exceptions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Choice of Forum</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal district court for the District of Delaware) and any appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i) any derivative claim or cause of action brought on our behalf; (ii) any claim or cause of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii) any claim or cause of action against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws (as each may be amended from time to time); (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (v) any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any claim or cause of action against us or any of our current or former directors, officers, or other employees governed by the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#x2019;s having personal jurisdiction over the indispensable parties named as defendants. This choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act of 1933, as amended (Securities Act), the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America are the exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. Additionally, our amended and restated certificate of incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>vera-ex10_7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html>
 <head>
  <title>EX-10.7</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.176%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">INDUCEMENT PLAN</font></p>
  <p style="font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:29.893%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:30.056%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc. 2024 Inducement Plan</font></p>
  <p style="font-size:10pt;margin-top:1.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:2.36%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.528%;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adopted by the Board of Directors: February 2, 2024</font></p>
  <p style="font-size:10pt;margin-top:2.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__general_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__eligible_award_recipients___the_only"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Eligible Award Recipients. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person who previously served as an Employee or Director will not be eligible to receive Awards under the Plan, other than following a </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">bona fide </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">period of non-employment. Persons eligible to receive grants of Awards under this Plan are referred to in this Plan as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eligible Employees</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; These Awards must be approved by either a majority of the Company&#x2019;s &#x201c;Independent Directors&#x201d; (as such term is defined in Nasdaq Marketplace Rule 5605(a)(2)) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent Directors</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or the Company&#x2019;s compensation committee, provided such committee is comprised solely of Independent Directors of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Independent Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in order to comply with the exemption from the stockholder approval requirement for &#x201c;inducement grants&#x201d; provided under Rule 5635(c)(4) of the Nasdaq Marketplace Rules. Nasdaq Marketplace Rule 5635(c)(4) and the related guidance under Nasdaq IM 5635-1 (together with any analogous rules or guidance effective after the date hereof, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inducement Award Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:11.95pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__plan_purpose___the_company__by_means"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan Purpose. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company, by means of the Plan, intends to provide (i) an inducement material for certain individuals to enter into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules, (ii) incentives for Eligible Employees to exert maximum efforts for the success of the Company and any Affiliate and (iii) a means by which Eligible Employees may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__available_awards___the_plan_provides"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Available Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Plan provides for the grant of the following Awards: (i) Nonstatutory Stock Options; (ii) SARs; (iii) Restricted Stock Awards; (iv) RSU Awards; (v) Performance Awards; and (vi) Other Awards.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;" id="xd__effective_date___the_plan_will_come_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Plan will come into existence on the Effective Date.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__shares_subject_to_the_plan_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Shares Subject to the Plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__share_reserve___subject_to_adjustmen"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Share Reserve. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to adjustment in accordance with Section 2(b) and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 500,000 shares of Common Stock.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:4.45pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;" id="xb__share_reserve_operation_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Share Reserve Operation.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__limit_applies_to_common_stock_issued"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limit Applies to Common Stock Issued Pursuant to Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:1.731%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.25pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__actions_that_do_not_constitute_issu"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued; (2) the settlement of any portion of an Award in cash (</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Participant receives cash rather than Common Stock);</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award.</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__reversion_of_previously_issued_sha"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reversion of Previously Issued Shares of Common Stock to Share Reserve. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2) any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__eligibility_and_limitations_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Eligibility and Limitations.</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__eligible_award_recipients___awards_m"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Eligible Award Recipients. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Awards may only be granted to persons who are Eligible Employees described in Section 1(a) of the Plan, where the Award is an inducement material to the individual&#x2019;s entering into employment with the Company or an Affiliate within the meaning of Rule 5635(c)(4) of the Nasdaq Marketplace Rules or is otherwise permitted pursuant to Rule 5635(c) of the Nasdaq Marketplace Rules.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__limitations_on_nonstatutory_stock_op"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limitations on Nonstatutory Stock Options and SARs. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nonstatutory Stock Options and SARs may not be granted to Employees unless the stock underlying such Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A or unless such Awards otherwise comply with the requirements of Section 409A.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__approval_requirements___all_awards_m"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Approval Requirements. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Awards must be granted either by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__options_and_stock_appreciation_rights"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Options and Stock Appreciation Rights.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Option and SAR will have such terms and conditions as determined by the Board. All Options will be Nonstatutory Stock Options. Each SAR will be denominated in shares of Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font></p>
  <div style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__term___no_option_or_sar_will_be_exer"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__exercise_or_strike_price___the_exerc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise or Strike Price. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Section 409A of the Code.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__exercise_procedure_and_payment_of_ex"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Procedure and Payment of Exercise Price for Options. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement:</font></div></div>
  <div style="margin-left:15.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__by_cash_or_check__bank_draft_or_mone"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by cash or check, bank draft or money order payable to the Company;</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__pursuant_to_a__cashless_exercise__p"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">pursuant to a &#x201c;cashless exercise&#x201d; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds;</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__by_delivery_to_the_company__either"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares are endorsed or accompanied by an executed assignment separate from</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">certificate, and (5) such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__by_a__net_exercise__arrangement_pur"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(v)</font><div style="width:100%;display:inline;" id="xv__in_any_other_form_of_consideration_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd__exercise_procedure_and_payment_of_ap"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Procedure and Payment of Appreciation Distribution for SARs. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) the aggregate Fair Market Value on the date of exercise of a number of shares of Common Stock equal to the number of Common Stock equivalents that are vested and being exercised under such SAR, over (ii) the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of Common Stock or cash (or any combination of Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(e)</font><div style="width:100%;display:inline;" id="xe__transferability___options_and_sars_m"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transferability. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Options and SARs may not be transferred to third party financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration:</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__restrictions_on_transfer___an_option"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on Transfer. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#x2019;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__domestic_relations_orders___notwith"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Domestic Relations Orders. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(f)</font><div style="width:100%;display:inline;" id="xf__vesting___the_board_may_impose_such_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board. Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#x2019;s Continuous Service.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(g)</font><div style="width:100%;display:inline;" id="xg__termination_of_continuous_service_fo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Continuous Service for Cause. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service is terminated for Cause, the Participant&#x2019;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.3pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(h)</font><div style="width:100%;display:inline;" id="xh__post_termination_exercise_period_fol"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to Section 4(i), if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise his or her Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__three_months_following_the_date_of_s"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#x2019;s Disability or death);</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__12_months_following_the_date_of_suc"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12 months following the date of such termination if such termination is due to the Participant&#x2019;s Disability;</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__18_months_following_the_date_of_su"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18 months following the date of such termination if such termination is due to the Participant&#x2019;s death; or</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__18_months_following_the_date_of_the"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18 months following the date of the Participant&#x2019;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i) or (ii) above).</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="following_the_date_of_such_termination__"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(i)</font><div style="width:100%;display:inline;" id="xi__restrictions_on_exercise__extension_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on Exercise; Extension of Exercisability. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i) the exercise of the Participant&#x2019;s</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#x2019;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)).</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(j)</font><div style="width:100%;display:inline;" id="xj__non_exempt_employees___no_option_or_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Exempt Employees. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such Participant&#x2019;s death or Disability, (ii) a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii) a Change in Control, or (iv) such Participant&#x2019;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#x2019;s then current employment policies and guidelines). This Section 4(j) is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(k)</font><div style="width:100%;display:inline;" id="xk__whole_shares___options_and_sars_may_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Whole Shares. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Options and SARs may be exercised only with respect to whole shares of Common Stock or their equivalents.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__awards_other_than_options_and_stock_a"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Awards Other Than Options and Stock Appreciation Rights.</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__restricted_stock_awards_and_rsu_awar"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Awards and RSU Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:</font></div></div>
  <div style="margin-left:15.065%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;" id="xi__form_of_award_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form of Award.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;" id="x1__restricted_stock_awards__to_the_exte"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Awards: To the extent consistent with the Company&#x2019;s Bylaws, at the Board&#x2019;s election, shares of Common Stock subject to a Restricted Stock Award may be (i) held in book entry form subject to the Company&#x2019;s instructions until such shares become vested or any other restrictions lapse, or (ii) evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;" id="x2__rsu_awards__an_rsu_award_represents_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RSU Awards: An RSU Award represents a Participant&#x2019;s right to be issued on a future date the number of shares of Common Stock that is equal to the number of</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#x2019;s unfunded obligation, if any, to issue shares of Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award).</font></p>
  <div style="margin-left:15.065%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__consideration_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consideration.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;" id="x1__restricted_stock_awards__a_restricte"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Awards: A Restricted Stock Award may be granted in consideration for (A) cash or check, bank draft or money order payable to the Company, (B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future services) as a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may determine and permissible under Applicable Law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;" id="x2__rsu_awards__unless_otherwise_determi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RSU Awards: Unless otherwise determined by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee at the time of grant, an RSU Award will be granted in consideration for the Participant&#x2019;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of Common Stock pursuant to the RSU Award. If, at the time of grant, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee determines that any consideration must be paid by the Participant (in a form other than the Participant&#x2019;s services to the Company or an Affiliate) upon the issuance of any shares of Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may determine and permissible under Applicable Law.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__vesting___the_board_may_impose_suc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#x2019;s Continuous Service.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__termination_of_continuous_service__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Continuous Service. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#x2019;s Continuous Service terminates for any reason, (i) the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant under his or her Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and the Participant will have no further right, title or interest in the Restricted Stock Award, the shares of Common Stock subject to the Restricted Stock Award, or any consideration in respect of the Restricted Stock Award and (ii) any portion of his or her RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the RSU Award, the shares of Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award.</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(v)</font><div style="width:100%;display:inline;" id="xv__dividends_and_dividend_equivalents__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dividends and Dividend Equivalents. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(vi)</font><div style="width:100%;display:inline;" id="xvi__settlement_of_rsu_awards___an_rsu_a"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Settlement of RSU Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. An RSU Award may be settled by the issuance of shares of Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__performance_awards___with_respect_to"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__other_awards___other_forms_of_awards"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Other forms of Awards valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof, may be granted either alone or in addition to Awards provided for under Section 4 and the preceding provisions of this Section 5. Subject to the provisions of the Plan, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__adjustments_upon_changes_in_common_st"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments upon Changes in Common Stock; Other Corporate Events.</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__capitalization_adjustments___in_the_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Capitalization Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the class(es) and maximum number of shares of Common Stock subject to the Plan and; (ii) the class(es) and number of securities and exercise price, strike price or purchase price of Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this Section.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__dissolution_or_liquidation___except_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#x2019;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of Common Stock subject to the</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service, provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__corporate_transaction___the_followin"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Corporate Transaction. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following provisions will apply to Awards in the event of a Corporate Transaction unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__awards_may_be_assumed___in_the_event"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Awards May Be Assumed. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Corporate Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#x2019;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#x2019;s parent company, if any), in connection with such Corporate Transaction. A surviving corporation or acquiring corporation (or its parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume, continue or substitute the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__awards_held_by_current_participants"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Awards Held by Current Participants. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Current Participants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) as the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective time of the Corporate Transaction), and such Awards will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and that have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of the Corporate Transaction in which the Awards are not assumed, continued or substituted in accordance with Section 6(c)(i). With respect to the vesting of Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and are settled in the form of a cash payment, such cash payment will be made no later than 30 days following the</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">occurrence of the Corporate Transaction or such later date as required to comply with Section 409A of the Code.</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__awards_held_by_persons_other_than_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Awards Held by Persons other than Current Participants. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Corporate Transaction in which the surviving corporation or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__payment_for_awards_in_lieu_of_exerc"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment for Awards in Lieu of Exercise. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection with such exercise.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd__appointment_of_stockholder_represent"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Appointment of Stockholder Representative. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#x2019;s behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(e)</font><div style="width:100%;display:inline;" id="xe__no_restriction_on_right_to_undertake"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Restriction on Right to Undertake Transactions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#x2019;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__administration_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration.</font></div></div>
  <p style="font-size:10pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__administration_by_board___the_board_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration by Board. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board will administer the Plan; provided however, that Awards may only be granted by either (i) a majority of the Company&#x2019;s Independent Directors or (ii) the Independent Compensation Committee. Subject to those constraints and the other constraints of the Inducement Award Rules, the Board may delegate some of its powers of administration of the Plan to a Committee or Committees, as provided in subsection (c) below.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__powers_of_board___the_board_will_hav"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Powers of Board. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan and Inducement Award Rules:</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__to_determine_from_time_to_time__1__w"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To determine from time to time (1) which of the persons eligible under the </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:1.731%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan will be granted Awards; (2) when and how each Award will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of Common Stock or other payment pursuant to an Award; (5) the number of shares of Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment; provided, however, that Awards may only be granted by either (i) a majority of the Company&#x2019;s Independent Directors or (ii) the Independent Compensation Committee.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__to_construe_and_interpret_the_plan_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.</font></div></div>
  <div style="margin-left:15.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__to_settle_all_controversies_regard"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To settle all controversies regarding the Plan and Awards granted under it.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__to_accelerate_the_time_at_which_an_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(v)</font><div style="width:100%;display:inline;" id="xv__to_prohibit_the_exercise_of_any_opti"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of Common Stock or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(vi)</font><div style="width:100%;display:inline;" id="xvi__to_suspend_or_terminate_the_plan_at"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(vii)</font><div style="width:100%;display:inline;" id="xvii__to_amend_the_plan_in_any_respect_t"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To amend the Plan in any respect the Board deems necessary or advisable; provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div></div>
  <div style="margin-left:15.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(viii)</font><div style="width:100%;display:inline;" id="xviii__to_submit_any_amendment_to_the_pl"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To submit any amendment to the Plan for stockholder approval.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ix)</font><div style="width:100%;display:inline;" id="xix__to_approve_forms_of_award_agreement"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, that, a Participant&#x2019;s rights under any Award will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and (2) such Participant consents in writing.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(x)</font><div style="width:100%;display:inline;" id="xx__generally__to_exercise_such_powers_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:1.731%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">conflict with the provisions of the Plan or Awards.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(xi)</font><div style="width:100%;display:inline;" id="xxi__to_adopt_such_procedures_and_sub_pl"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Eligible Employees who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction).</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;" id="xc__delegation_to_committee_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Delegation to Committee.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:11.75pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__general___subject_to_the_terms_of_se"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to the terms of Section 3(b), the Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with the Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__rule_16b_3_compliance___to_the_exte"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 16b-3 Compliance. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act that is available under Rule 16b-3 of the Exchange Act, the Award will be granted by a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) of the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by a Committee meeting such requirements to the extent necessary for such exemption to remain available.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd__effect_of_board_s_decision___all_det"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Board&#x2019;s Decision. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(e)</font><div style="width:100%;display:inline;" id="xe__cancellation_and_re_grant_of_awards_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cancellation and Re-Grant of Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Neither the Board nor any Committee will have the authority to: (i) reduce the exercise price or strike price of any outstanding Option or SAR, or (ii) cancel any outstanding Options or SARs that have an exercise price or strike price greater than the current Fair Market Value in exchange for cash or other Awards, unless the stockholders of the Company have approved such an action within twelve months prior to such an event.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__tax_withholding"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__withholding_authorization___as_a_con"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Authorization. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of Common Stock subject to an Award, unless and until such obligations are satisfied.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__satisfaction_of_withholding_obligati"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Satisfaction of Withholding Obligation. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; (v) by allowing a Participant to effectuate a &#x201c;cashless exercise&#x201d; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__no_obligation_to_notify_or_minimize_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Obligation to Notify or Minimize Taxes; No Liability to Claims. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii) acknowledges that such Participant was advised to consult with his or her own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least equal to the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#x201c;fair market value&#x201d; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd__withholding_indemnification___as_a_c"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Indemnification. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#x2019;s and/or its Affiliate&#x2019;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x__miscellaneous_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Miscellaneous.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__source_of_shares___the_stock_issuabl"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Source of Shares. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__use_of_proceeds_from_sales_of_common"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Use of Proceeds from Sales of Common Stock. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute general funds of the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__corporate_action_constituting_grant_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Corporate Action Constituting Grant of Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd__stockholder_rights___no_participant_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records of the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(e)</font><div style="width:100%;display:inline;" id="xe__no_employment_or_other_service_right"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Employment or Other Service Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant&#x2019;s agreement with the Company or an Affiliate, or (iii) the service of a Director</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(f)</font><div style="width:100%;display:inline;" id="xf__change_in_time_commitment___in_the_e"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Time Commitment. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event a Participant&#x2019;s regular level of time commitment in the performance of his or her services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i) make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(g)</font><div style="width:100%;display:inline;" id="xg__execution_of_additional_documents___"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Execution of Additional Documents. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#x2019;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator&#x2019;s request.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(h)</font><div style="width:100%;display:inline;" id="xh__electronic_delivery_and_participatio"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electronic Delivery and Participation. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any reference herein or in an Award Agreement to a &#x201c;written&#x201d; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#x2019;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(i)</font><div style="width:100%;display:inline;" id="xi__clawback_recovery___all_awards_grant"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Clawback/Recovery. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#x2019;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause.  No recovery of compensation under such a clawback</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">policy will be an event giving rise to a Participant&#x2019;s right to voluntarily terminate employment upon a &#x201c;resignation for good reason,&#x201d; or for a &#x201c;constructive termination&#x201d; or any similar term under any plan of or agreement with the Company.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(j)</font><div style="width:100%;display:inline;" id="xj__securities_law_compliance___a_partic"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Law Compliance. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(k)</font><div style="width:100%;display:inline;" id="xk__transfer_or_assignment_of_awards__is"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transfer or Assignment of Awards; Issued Shares. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(l)</font><div style="width:100%;display:inline;" id="xl__effect_on_other_employee_benefit_pla"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect on Other Employee Benefit Plans. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#x2019;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#x2019;s or any Affiliate&#x2019;s employee benefit plans.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(m)</font><div style="width:100%;display:inline;" id="xm__deferrals___to_the_extent_permitted_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Deferrals. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section 409A.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(n)</font><div style="width:100%;display:inline;" id="xn__section_409a___unless_otherwise_expr"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not so exempt, in compliance with the requirements of Section 409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#x201c;deferred compensation&#x201d; under Section 409A is a &#x201c;specified employee&#x201d; for purposes of Section 409A, no distribution or payment of any amount that is due because of a &#x201c;separation from service&#x201d; (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#x2019;s &#x201c;separation from service&#x201d;</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or, if earlier, the date of the Participant&#x2019;s death, unless such distribution or payment can be made in a manner that complies with Section 409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(o)</font><div style="width:100%;display:inline;" id="xo__choice_of_law___this_plan_and_any_co"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HOICE OF </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">L</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">AW</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x0__covenants_of_the_company_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covenants of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;" id="the_company_will_seek_to_obtain_from_eac"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:12.3pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;" id="x1__additional_rules_for_awards_subject_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Rules for Awards Subject to Section 409A.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(a)</font><div style="width:100%;display:inline;" id="xa__application___unless_the_provisions_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Application. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless the provisions of this Section of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this Section shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non- Exempt Award.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb__non_exempt_awards_subject_to_non_exe"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Exempt Awards Subject to Non-Exempt Severance Arrangements. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent a Non-Exempt Award is subject to Section 409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__if_the_non_exempt_award_vests_in_the"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Non-Exempt Award vests in the ordinary course during the Participant&#x2019;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">st</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> of the calendar year that includes the applicable vesting date, or (ii) the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> day that follows the applicable vesting date.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__if_vesting_of_the_non_exempt_award_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If vesting of the Non-Exempt Award accelerates under the terms of a Non- Exempt Severance Arrangement in connection with the Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant&#x2019;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> day that follows the date of the Participant&#x2019;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of such Participant&#x2019;s Separation from Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__if_vesting_of_a_non_exempt_award_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If vesting of a Non-Exempt Award accelerates under the terms of a Non- Exempt Severance Arrangement in connection with a Participant&#x2019;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#x2019;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.25pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc__treatment_of_non_exempt_awards_upon_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Treatment of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions of this subsection (c)shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non- Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:11.8pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__vested_non_exempt_awards___the_follo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vested Non-Exempt Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;" id="x1__if_the_corporate_transaction_is_also"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award. Upon the Section 409A Change in Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section 409A Change in Control.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;" id="x2__if_the_corporate_transaction_is_not_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non- Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__unvested_non_exempt_awards___the_fo"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unvested Non-Exempt Awards. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to subsection (d) of this Section.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;" id="x1__in_the_event_of_a_corporate_transact"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event of a Corporate Transaction, the Acquiring Entity shall </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:0.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">assume, continue or substitute any Unvested Non-Exempt Award. Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#x2019;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;" id="x2__if_the_acquiring_entity_will_not_ass"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in Section 11(d)(ii) below. In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate Transaction.</font></div></div>
  <div style="margin-left:0.935%;text-indent:20.408%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.747337606621915%;text-indent:0;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;" id="x3__the_foregoing_treatment_shall_apply_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section 409A Change in Control.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd__if_the_rsu_award_is_a_non_exempt_awa"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(d)shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__any_exercise_by_the_board_of_discret"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Any exercise by the Board of discretion to accelerate the vesting of a Non- Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section 409A.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__the_company_explicitly_reserves_the"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A- 3(j)(4)(ix).</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__to_the_extent_the_terms_of_any_non"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section 409A Change in Control. To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a &#x201c;separation from service&#x201d; such Participant is subject to the </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:1.731%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;" id="xiv__the_provisions_in_this_section_11_d"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">distribution limitations contained in Section 409A applicable to &#x201c;specified employees,&#x201d; as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#x2019;s Separation From Service, or, if earlier, the date of the Participant&#x2019;s death that occurs within such six month period.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="x2__severability_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The provisions in this Section 11(d) for delivery of the shares in respect of the settlement of an RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.</font></div></div>
  <div style="margin-left:0.935%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Severability.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;" id="x3__termination_of_the_plan_"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of the Plan.</font></div></div>
  <p style="font-size:10pt;margin-top:0.85pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.795%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:1.167%;text-align:justify;" id="x4___definitions_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Board may suspend or terminate the Plan at any time. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:0.935%;display:flex;margin-top:12.25pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:6.729924796850553%;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions.</font></div></div>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As used in the Plan, the following definitions apply to the capitalized terms indicated</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">below:</font></p>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;" id="xa___acquiring_entity__means_the_survivi"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Acquiring Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the surviving or acquiring corporation (or its parent</font></div></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">company) in connection with a Corporate Transaction.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(b)</font><div style="width:100%;display:inline;" id="xb___affiliate__means__at_the_time_of_de"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Affiliate</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(c)</font><div style="width:100%;display:inline;" id="xc___applicable_law__means_the_code_and_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Applicable Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Code and any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority).</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(d)</font><div style="width:100%;display:inline;" id="xd___award__means_any_right_to_receive_c"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any right to receive Common Stock, cash or other property granted under the Plan (including a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award).</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(e)</font><div style="width:100%;display:inline;" id="xe___award_agreement__means_a_written_or"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a Participant evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided, including through </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:0.935%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">electronic means, to a Participant along with the Grant Notice.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(f)</font><div style="width:100%;display:inline;" id="xf___board__means_the_board_of_directors"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(g)</font><div style="width:100%;display:inline;" id="xg___capitalization_adjustment__means_an"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Capitalization Adjustment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:0.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(h)</font><div style="width:100%;display:inline;" id="xh___cause__has_the_meaning_ascribed_to_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; has the meaning ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) the Participant&#x2019;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii) the Participant&#x2019;s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Participant&#x2019;s failure to perform the Participant&#x2019;s assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv) the Participant&#x2019;s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or(v) the Participant&#x2019;s material violation of any provision of any agreement(s) between the Participant and the Company relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#x2019;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#x2019;s chief executive officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(i)</font><div style="width:100%;display:inline;" id="xi___change_in_control__or__change_of_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Change of Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__any_exchange_act_person_becomes_the_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur</font></div></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(A) on account of the acquisition of securities of the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#x2019;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because the level of Ownership held by any Exchange Act Person (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subject Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__there_is_consummated_a_merger__cons"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A) outstanding voting securities representingmore than 50% of the combined outstanding voting power of the Acquiring Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting power of the parent of the Acquiring Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__there_is_consummated_a_sale__lease"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__individuals_who__on_the_date_the_pl"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">individuals who, on the date the Plan is adopted by the Board, are members of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incumbent Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the payment not to violate Section 409A of the Code.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(j)</font><div style="width:100%;display:inline;" id="xj___code__means_the_internal_revenue_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(k)</font><div style="width:100%;display:inline;" id="xk___committee__means_a_committee_of_one"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a committee of one or more Independent Directors to whom authority has been delegated by the Board or in accordance with Section 7(c) of the Plan.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;" id="xl___common_stock__means_the_class_a_com"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Class A Common Stock of the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(m)</font><div style="width:100%;display:inline;" id="xm___company__means_vera_therapeutics__i"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Vera Therapeutics, Inc., a Delaware corporation.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(n)</font><div style="width:100%;display:inline;" id="xn___consultant__means_any_person__inclu"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#x201c;Consultant&#x201d; for purposes of the Plan. Notwithstandingthe foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#x2019;s securities to such person. Consultants are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(o)</font><div style="width:100%;display:inline;" id="xo___continuous_service__means_that_the_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Continuous Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that the Participant&#x2019;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#x2019;s service with the Company or an Affiliate, will not terminate a Participant&#x2019;s Continuous Service; provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#x2019;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive officer of the Company, in that party&#x2019;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Company or an Affiliate, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#x2019;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#x201c;separation from service&#x201d; as defined under Treasury Regulation Section 1.409A-1(h) (without regard to any alternative definition thereunder).</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.1pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(p)</font><div style="width:100%;display:inline;" id="xp___corporate_transaction__means_the_co"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Corporate Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events:</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__a_sale_or_other_disposition_of_all_o"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries;</font></div></div>
  <div style="margin-left:15.065%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;" id="xii__a_sale_or_other_disposition_of_at_l"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a sale or other disposition of at least 50% of the outstanding securities of</font></div></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Company;</font></p>
  <div style="margin-left:15.065%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.849531995055041%;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;" id="xiii__a_merger__consolidation_or_similar"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a merger, consolidation or similar transaction following which the</font></div></div>
  <p style="margin-left:1.773%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company is not the surviving corporation; or</font></p>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iv)</font><div style="width:100%;display:inline;" id="xiv__a_merger__consolidation_or_similar_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing or any other provision of this Plan, (A) the term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Corporate Transaction (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.139%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(C) with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event described in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the payment not to violate Section 409A of the Code.</font></p>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(q)</font><div style="width:100%;display:inline;" id="xq___director__means_a_member_of_the_boa"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a member of the Board. Directors are not eligible to receive Awards under the Plan with respect to their service in such capacity.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(r)</font><div style="width:100%;display:inline;" id="xr___determine__or__determined__means_as"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">determine</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">determined</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means as determined by the Board or the Committee (or its designee) in its sole discretion.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(s)</font><div style="width:100%;display:inline;" id="xs___disability__means__with_respect_to_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(t)</font><div style="width:100%;display:inline;" id="xt___effective_date__means_february_1__2"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means February 1, 2024.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(u)</font><div style="width:100%;display:inline;" id="xu___employee__means_any_person_employed"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#x201c;Employee&#x201d; for purposes of the Plan.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(v)</font><div style="width:100%;display:inline;" id="xv___employer__means_the_company_or_the_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Employer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company or the Affiliate of the Company that employs the Participant.</font></div></div>
  <div style="margin-left:7.602%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:7.2155241455442765%;display:inline-flex;justify-content:flex-start;">(w)</font><div style="width:100%;display:inline;" id="xw___entity__means_a_corporation__partne"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a corporation, partnership, limited liability company or other entity.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(x)</font><div style="width:100%;display:inline;" id="xx___exchange_act__means_the_securities_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.803%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(y)</font><div style="width:100%;display:inline;" id="xy___exchange_act_person__means_any_natu"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act), except that &#x201c;Exchange Act Person&#x201d; will not include (i) the Company or any Subsidiary of the Company, (ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or &#x201c;group&#x201d; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that,</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#x2019;s then outstanding securities.</font></p>
  <div style="margin-left:0.935%;text-indent:6.812%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.4788270327562714%;">(z)</font><div style="width:100%;display:inline;" id="xz___fair_market_value__means__as_of_any"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows:</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(i)</font><div style="width:100%;display:inline;" id="xi__if_the_common_stock_is_listed_on_any"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.717%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.065%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(ii)</font><div style="width:100%;display:inline;" id="xii__if_there_is_no_closing_sales_price_"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</font></div></div>
  <div style="margin-left:1.731%;text-indent:13.736%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.204%;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.1230601715698745%;">(iii)</font><div style="width:100%;display:inline;" id="xiii__in_the_absence_of_such_markets_for"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.</font></div></div>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xaa___governmental_body__means_any___a__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(aa) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Governmental Body</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or regulatory body, or quasi- governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any tax authority) or other body exercising similar powers or authority; or (d) self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;" id="xbb___grant_notice__means_the_notice_pro"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(bb) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xcc___materially_impair__means_any_amend"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(cc) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Materially Impair</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any amendment to the terms of the Award that materially adversely affects the Participant&#x2019;s rights under the Award. A Participant&#x2019;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not materially impair the Participant&#x2019;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#x2019;s rights under the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised; (ii) to clarify the manner of exemption from, or to bring the Award into compliance</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with or qualify it for an exemption from, Section 409A; or (iii) to comply with other Applicable Laws.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;" id="xdd___non_employee_director__means_a_dir"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(dd) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Employee Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Regulation S-K</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii) is otherwise considered a &#x201c;non-employee director&#x201d; for purposes of Rule 16b-3.</font></p>
  <p style="margin-left:0.92%;text-indent:6.792%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.12%;text-align:justify;" id="xee___non_exempt_award__means_any_award_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ee)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii) the terms of any Non-Exempt Severance Arrangement.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xff___non_exempt_severance_arrangement__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ff)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Exempt Severance Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#x2019;s termination of employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder)) (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Separation from Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and such severance benefit does not satisfy the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xgg___nonstatutory_stock_option__means_a"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(gg)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nonstatutory Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any option granted pursuant to Section 4 of the Plan that does not qualify as an &#x201c;incentive stock option&#x201d; within the meaning of Section 422 of the Code.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xhh___officer__means_a_person_who_is_an_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(hh)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:left;" id="xii___option__means_a_nonstatutory_stock"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;" id="xjj___option_agreement__means_a_written_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(jj) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided, including through electronic means, to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;" id="xkk___optionholder__means_a_person_to_wh"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(kk)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Optionholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;" id="xll___other_award__means_an_award_valued"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ll) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) that is not a Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance Award.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;" id="xmm___other_award_agreement__means_a_wri"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(mm) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xnn___own____owned____owner___or__owners"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(nn)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Own,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Owned,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Owner,</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ownership</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means that a person or Entity will be deemed to &#x201c;Own,&#x201d; to have &#x201c;Owned,&#x201d; to be the &#x201c;Owner&#x201d; of, or to have acquired &#x201c;Ownership&#x201d; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;" id="xoo___participant__means_an_eligible_emp"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(oo)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Eligible Employee to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;" id="xpp___performance_award__means_an_award_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(pp)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant to such terms as are approved by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;" id="xqq___performance_criteria__means_one_or"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(qq) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Criteria</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means one or more criteria that a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; relative stockholder return; return on equity or average stockholder&#x2019;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#x2019; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; financing; regulatory milestones; stockholder liquidity; corporate governance and compliance; intellectual property; personnel</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">matters; progress of internal research; progress of partnered programs; partner satisfaction; budget management; partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; implementation or completion of projects or processes; employee retention; number of users, including unique users; strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property); establishing relationships with respect to the marketing, distribution and sale of the Company&#x2019;s products; supply chain achievements; co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Company&#x2019;s Independent Directors or the Independent Compensation Committee whether or not listed herein.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.046%;text-align:justify;" id="xrr___performance_goals__means__for_a_pe"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(rr) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Goals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, for a Performance Period, one or more goals established by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee (i) in the Award Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments to corporate tax rates; (5) to exclude the effects of items that are &#x201c;unusual&#x201d; in nature or occur &#x201c;infrequently&#x201d; as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company&#x2019;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. In addition, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee may establish or provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting forth the Performance Goals at the time the Performance Goals are established. In addition, a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="margin-left:1pt;font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.7</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Award.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;" id="xss___performance_period__means_the_peri"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ss) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period of time selected by a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#x2019;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of a majority of the Company&#x2019;s Independent Directors or the Independent Compensation Committee.</font></p>
  <p style="margin-left:0.92%;text-indent:6.79%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.093%;text-align:justify;" id="xtt___plan__means_this_vera_therapeutics"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(tt)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this Vera Therapeutics, Inc. 2021 Inducement Plan, as amended from time to time.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xuu___plan_administrator__means_the_pers"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(uu) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan and the Company&#x2019;s other equity incentive programs.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;" id="xvv___post_termination_exercise_period__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(vv) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Post-Termination Exercise Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period following termination of a Participant&#x2019;s Continuous Service within which an Option or SAR is exercisable, as specified in Section 4(h).</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xww___restricted_stock_award__or__rsa__m"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ww) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSA</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;" id="xxx___restricted_stock_award_agreement__"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(xx) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;" id="xyy___rsu_award__or__rsu__means_an_award"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(yy)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award of restricted stock units representing the right to receive an issuance of shares of Common Stock which is granted pursuant to the terms and conditions of Section 5(a).</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:justify;" id="xzz___rsu_award_agreement__means_a_writt"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(zz) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="margin-left:0.92%;text-indent:6.788%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.065%;text-align:left;" id="xaaa___rule_16b_3__means_rule_16b_3_prom"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(aaa)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="xbbb___rule_405__means_rule_405_promulga"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(bbb) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 405</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Rule 405 promulgated under the Securities Act.</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;text-indent:6.793%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.13%;text-align:justify;" id="xccc___section_409a__means_section_409a_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ccc) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Section 409A of the Code and the regulations and other guidance thereunder.</font></p>
  <p style="margin-left:0.92%;text-indent:6.786%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.037%;text-align:justify;" id="xddd___section_409a_change_in_control__m"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ddd) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Section 409A Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#x2019;s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A- 3(i)(5) (without regard to any alternative definition thereunder).</font></p>
  <p style="margin-left:7.587%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="xeee___securities_act__means_the_securit"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(eee)	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.083%;text-align:justify;" id="xfff___share_reserve__means_the_number_o"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(fff)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the number of shares available for issuance under the Plan as set forth in Section 2(a).</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;" id="xggg___stock_appreciation_right__or__sar"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ggg) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SAR</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section 4.</font></p>
  <p style="margin-left:0.92%;text-indent:6.789%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;" id="xhhh___sar_agreement__means_a_written_or"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(hhh) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SAR Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a written or electronic agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan.</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.056%;text-align:justify;" id="xiii___subsidiary__means__with_respect_t"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(iii)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(ii) any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;" id="xjjj___trading_policy__means_the_company"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(jjj)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s policy permitting certain individuals to sell Company shares only during certain &#x201c;window&#x201d; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.102%;text-align:justify;" id="xkkk___unvested_non_exempt_award__means_"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(kkk) </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unvested Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction.</font></p>
  <p style="margin-left:0.92%;text-indent:6.791%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.111%;text-align:justify;" id="xlll___vested_non_exempt_award__means_th"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(lll)  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Vested Non-Exempt Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction.</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>vera-ex10_8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<html>
 <head>
  <title>EX-10.8</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.8</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">STOCK OPTION GRANT NOTICE<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(2024 INDUCEMENT PLAN)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), pursuant to its 2024 Inducement Plan (as may be amended and/or restated as of the Date of Grant set forth below, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has granted to Optionholder an Option to purchase the number of shares of the Common Stock set forth below (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as an inducement material to you entering into employment with the Company in compliance with Nasdaq Listing Rule 5635(c)(4).  The Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and in the Plan, the Option Agreement, and the Notice of Exercise, all of which are attached to this Grant Notice and incorporated into this Grant Notice in their entirety.  Capitalized terms not explicitly defined in this Grant Notice but defined in the Plan or the Option Agreement shall have the meanings set forth in the Plan or the Option Agreement, as applicable. If the Company uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank or the information is otherwise provided in a different format electronically, the blank fields and other information (such as exercise schedule and type of grant) shall be deemed to come from the electronic capitalization system and is considered part of this Grant Notice.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:94.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.72%;"></td>
    <td style="width:60.28%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Optionholder:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date of Grant:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vesting Commencement Date:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of Shares of Common Stock Subject to Option:</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise Price (Per Share):</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total Exercise Price:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expiration Date:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">[&#x25cf;]</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise Schedule:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Same as Vesting Schedule</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Type of Grant:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonstatutory Stock Option</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-20%;padding-left:16.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	[</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Sample of standard vesting:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  12/48ths of the total shares will vest on the first anniversary of the Vesting Commencement Date, and 1/48th of the total shares will vest each month thereafter on the same day of the month as the Vesting Commencement Date (or if there is no corresponding day, on the last day of the month), subject to Optionholder&#x2019;s Continuous Service through each such date.]</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Optionholder Acknowledgements:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  By Optionholder&#x2019;s signature below or by electronic acceptance or authentication in a form authorized by the Company, Optionholder understands and agrees that the Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Option Agreement and the Notice of Exercise, all of which are made a part of this document.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By accepting this Option, Optionholder consents to receive this Grant Notice, the Option Agreement, the Plan, and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.  Optionholder represents that he or she has read and is familiar with the provisions of the Plan and the Option Agreement.  Optionholder acknowledges and agrees that this Grant Notice and the Option Agreement may not be modified, amended or revised except in writing signed by Optionholder and a duly authorized officer of the Company.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Optionholder further acknowledges that in the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise and the terms of the Plan, the terms of the Plan shall</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.8</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">control.  Optionholder further acknowledges that the Option Agreement sets forth the entire understanding between Optionholder and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i) any other equity award concurrently granted to Optionholder; and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and Optionholder in each case that specifies the terms that should govern this Option.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Optionholder further acknowledges that this Grant Notice has been prepared on behalf of the Company by Cooley LLP, counsel to the Company and that Cooley LLP does not represent, and is not acting on behalf of, Optionholder in any capacity. Optionholder has been provided with an opportunity to consult with Optionholder&#x2019;s own counsel with respect to this Grant Notice.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Grant Notice may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.833%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.762%;"></td>
    <td style="width:41.748%;"></td>
    <td style="width:2.921%;"></td>
    <td style="width:7.762%;"></td>
    <td style="width:39.808%;"></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vera Therapeutics, Inc.</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Optionholder:</font></p><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Signature)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Signature)</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Email:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:justify;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-18.805%;padding-left:15.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-18.805%;padding-left:15.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Attachments</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:  Option Agreement, 2024 Inducement Plan and Notice of Exercise</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT 10.8</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ATTACHMENT I</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OPTION AGREEMENT</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">INDUCEMENT AWARD UNDER THE 2024 INDUCEMENT PLAN</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"><br><br></font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">OPTION AGREEMENT<br>(NONSTATUTORY STOCK OPTION)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to your Stock Option Grant Notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and this Option Agreement, Vera Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has granted you an Option award under its 2024 Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to purchase the number of shares of the Company&#x2019;s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">as an inducement material to you entering into employment with the Company in compliance with Nasdaq Listing Rule 5635(c)(4).  The Option is granted to you effective as of the date of grant set forth in the Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Date of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The details of your Option, in addition to those set forth in the Grant Notice and the Plan, are as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Vesting</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Your Option will vest as provided in your Grant Notice, subject to the provisions contained herein and the terms of the Plan.  Vesting will cease upon the termination of your Continuous Service.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares and Exercise Price</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  The number of shares of Common Stock subject to your Option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise Restriction for Non-Exempt Employees</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Non-Exempt Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and except as otherwise provided in the Plan, you may not exercise your Option until you have completed at least six months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six months. Consistent with the provisions of the Worker Economic Opportunity Act, you may exercise your Option as to any vested portion prior to such six month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your Option is not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your &#x201c;retirement&#x201d; (as defined in the Company&#x2019;s benefit plans).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise prior to Vesting (&#x201c;Early Exercise&#x201d;)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If permitted in your Grant Notice (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, the &#x201c;Exercise Schedule&#x201d; indicates &#x201c;Early Exercise Permitted&#x201d;) and subject to the provisions of your Option, you may elect at any time that is both (i) during the period of your Continuous Service and (ii) during the term of your Option, to exercise all or part of your Option, including the unvested portion of your Option; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a partial exercise of your Option will be deemed to cover first vested shares of Common Stock and then the earliest vesting installment of unvested shares of Common Stock;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">any shares of Common Stock so purchased from installments that have not vested as of the date of exercise will be subject to the purchase Option in favor of the Company as described in the Company&#x2019;s form of Early Exercise Stock Purchase Agreement; and</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">you will enter into the Company&#x2019;s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will result in the same vesting as if no early exercise had occurred.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Method of Payment</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  You must pay the full amount of the exercise price for the shares you wish to exercise.  The permitted methods of payment are as follows:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">by cash, check, bank draft, electronic funds transfer or money order payable to the Company;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">subject to Company and/or Board consent at the time of exercise and provided that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds.  This manner of payment is also known as a &#x201c;broker-assisted exercise&#x201d;, &#x201c;same day sale&#x201d;, or &#x201c;sell to cover&#x201d;;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">subject to Company and/or Board consent at the time of exercise and provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise.  &#x201c;Delivery&#x201d; for these purposes, in the sole discretion of the Company at the time you exercise your Option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company.  You may not exercise your Option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#x2019;s stock;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">subject to Company and/or Board consent at the time of exercise, and provided that the Option is a Nonstatutory Stock Option, by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of the Option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price plus, to the extent permitted by the Company and/or Board at the time of exercise, the aggregate withholding obligations in respect of the Option exercise; provided, further that you must pay any remaining balance of the aggregate exercise price not satisfied by the &#x201c;net exercise&#x201d; in cash or other permitted form of payment.  Shares of Common Stock will no longer be subject to the Option and will not be exercisable thereafter to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &#x201c;net exercise,&#x201d; (B) shares are delivered to you as a result of such exercise, and (C) shares are withheld to satisfy tax withholding obligations;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">subject to the consent of the Company and/or Board at the time of exercise, according to a deferred payment or similar arrangement with you; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that interest will compound at least annually and will be charged at the minimum rate of interest necessary to avoid (A) the imputation of interest income to the Company and compensation income to the Optionholder under any applicable provisions of the Code, and (B) the classification of the Option as a liability for financial accounting purposes; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">in any other form of legal consideration that may be acceptable to the Board.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Whole Shares</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  You may exercise your Option only for whole shares of Common Stock.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Securities Law Compliance</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  In no event may you exercise your Option unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act.  The exercise of your Option also must comply with all other applicable laws and regulations governing your Option, and you may not exercise your Option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Term</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  You may not exercise your Option before the Date of Grant or after the expiration of the Option&#x2019;s term.  Except as set forth in your Grant Notice, the term of your Option expires, subject to the provisions of Section 4(h) of the Plan, upon the earliest of the following:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">immediately upon the termination of your Continuous Service for Cause;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">three months after the termination of your Continuous Service for any reason other than Cause,</font><font style="color:#0070c0;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">your Disability or your death (except as otherwise provided in Section 8(d) below); </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">that if during any part of such three month period your Option is not exercisable solely because of the condition set forth in the section above relating to &#x201c;Securities Law Compliance,&#x201d; your Option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three months after the termination of your Continuous Service; </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided further,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> that if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six months after the Date of Grant, and (iii) you have vested in a portion of your Option at the time of your termination of Continuous Service, your Option will not expire until the earlier of (x) the later of (A) the date that is seven months after the Date of Grant, and (B) the date that is three months after the termination of your Continuous Service, and (y) the Expiration Date;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">12 months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(d) below);</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">18 months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Expiration Date indicated in your Grant Notice; or</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the day before the 10th anniversary of the Date of Grant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exercise</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You may exercise the vested portion of your Option (and the unvested portion of your Option if your Grant Notice so permits) during its term by delivering a Notice of Exercise (in a form designated by the Company) together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours.  If required by the Company, your exercise may be made contingent on your execution of any additional documents specified by the Company (including, without limitation, any voting agreement or other agreement between the Company and some or all of its stockholders).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By exercising your Option you agree that, as a condition to any exercise of your Option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">By exercising your Option you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lock-Up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;); </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">provided, however</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period.  You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.  In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period.  You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 9(c).  The underwriters of the Company&#x2019;s stock are intended third party beneficiaries of this Section 9(c) and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transferability</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Except as otherwise provided in this Section 10, your Option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Certain Trusts</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon receiving written permission from the Board or its duly authorized designee, you may transfer your Option to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the Option is held in the trust.  You and the trustee must enter into transfer and other agreements required by the Company.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Domestic Relations Orders</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your Option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.  You are encouraged to discuss the proposed terms of any division of this Option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Beneficiary Designation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this Option and receive the Common Stock or other consideration resulting from such exercise.  In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this Option and receive, on behalf of your estate, the Common Stock or other consideration resulting from such exercise.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Option not a Service Contract</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Your Option is not an employment or service contract, and nothing in your Option will be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment.  In addition, nothing in your Option will obligate the Company or an Affiliate, their respective </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">At the time you exercise your Option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#x201c;same day sale&#x201d; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your Option.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Upon your request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your Option a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your Option as a liability for financial accounting purposes).  If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your Option, share withholding pursuant to the preceding sentence will not be permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of your Option.  Notwithstanding the filing of such election, shares of Common Stock will be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of your Option that are otherwise issuable to you upon such exercise.  Any adverse consequences to you arising in connection with such share withholding procedure will be your sole responsibility.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You may not exercise your Option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.  Accordingly, you may not be able to exercise your Option when desired even though your Option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your Option or your other compensation. In particular, you acknowledge that this Option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#x201c;fair market value&#x201d; per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the Option. Because the Common Stock is not traded on an established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined by the Board is less than the &#x201c;fair market value&#x201d; as subsequently determined by the Internal Revenue Service.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notices</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Any notices provided for in your Option or the Plan will be given in writing (including electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.  The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this Option by electronic means or to request your consent to participate in the Plan by electronic means.  By accepting this Option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Plan Document</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Your Option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  If there is any conflict between the provisions of your Option and those of the Plan, the provisions of the Plan will control.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ATTACHMENT II</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT PLAN</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">ATTACHMENT III</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">NOTICE OF EXERCISE</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.<br>NOTICE OF EXERCISE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This constitutes notice to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for the price set forth below.  Capitalized terms not explicitly defined in this Notice of Exercise but defined in the Stock Option Grant Notice, Option Agreement or 2024 Inducement Plan, as may be amended from time to time, (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall have the meanings set forth in the Stock Option Grant Notice, Stock Option Agreement and Plan.  Use of certain payment methods is subject to Company and/or Board consent and certain additional requirements set forth in the Option Agreement and the Plan.  If the Company uses an electronic capitalization table system (such as Carta or Shareworks) and the fields below are blank, the blank fields shall be deemed to come from the electronic capitalization system and is considered part of this Notice of Exercise.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:57.84%;"></td>
    <td style="width:42.16%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Option Information</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Type of Option:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonstatutory</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock Option dated:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of Shares as to which Option is exercised:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Certificates to be issued in name of:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Exercise Information</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date of Exercise:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total exercise price:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:27pt;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="margin-left:27pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:27pt;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="margin-left:27pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Regulation T Program (cashless exercise):</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:27pt;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="margin-left:27pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Value of _________ Shares delivered with this notice:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:27pt;padding-left:0.075in;vertical-align:bottom;padding-right:0.075in;"><p style="margin-left:27pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Value of _________ Shares pursuant to net exercise:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By this exercise, I agree (i) to provide such additional documents as you may require pursuant to the terms of the Plan, Stock Option Grant Notice and the Option Agreement, and (ii) to provide for the payment by me to you (in the manner designated by you) of your withholding obligation, if any, relating to the exercise of this Option.  I further agree that this Notice of Exercise may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company will request to facilitate compliance with applicable FINRA rules) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lock-Up Period</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.  In order to enforce the foregoing covenant, the Company may impose stop&#x2011;transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:18pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Very truly yours,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">____________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                                                                                                                                               (Signature)</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">____________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                                                                                                                                       Name (Please Print)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Address of Record: ____________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">____________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">____________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Email: ____________________________________</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>5
<FILENAME>vera-ex10_9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<html>
 <head>
  <title>EX-10.9</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 10.9</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT GRANT NOTICE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has awarded to you (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) the number of restricted stock units specified, and on the terms set forth, below in consideration of your future services (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Your RSU Award is subject to all of the terms and conditions as set forth herein, in the Company&#x2019;s 2024</font><font style="color:#4f81bd;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), which are attached hereto and incorporated herein in their entirety.  Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participant:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting Commencement Date:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Number of Restricted Stock Units:	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">	</font></p>
  <p style="margin-left:0.173%;text-indent:-19.792%;padding-left:16.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.173%;text-indent:-19.792%;padding-left:16.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.173%;text-indent:-19.792%;padding-left:16.493%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 	[</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">____________]</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, vesting shall terminate upon the Participant&#x2019;s termination of Continuous Service.</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </font></p>
  <p style="text-indent:-20.968%;padding-left:17.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-20%;padding-left:16.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance Schedule:	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One share of Common Stock will be issued for each restricted stock unit that vests at the time set forth in Section 5 of the Agreement.</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participant Acknowledgements:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RSU Award is governed by this RSU Award Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and the provisions of the Plan and the Agreement, all of which are made a part of this document.  Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company.  </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.  In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.  </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of: (i) any other equity award concurrently granted to you; and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this RSU Award.</font></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:18pt;text-align:left;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc.	Participant:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	Signature	Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Title: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	Date: </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:-18.805%;padding-left:15.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 10.9</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Attachments</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">	Award Agreement (RSU Award), 2024</font><font style="color:#4f81bd;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inducement Plan</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">AWARD AGREEMENT (RSU AWARD)</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As reflected by your Restricted Stock Unit Grant Notice (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Grant Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), Vera Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) has granted you an RSU Award under the Company&#x2019;s 2024 Inducement Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) for the number of restricted stock units as indicated in your Grant Notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU Award</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  This RSU Award is granted in compliance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to you entering into employment with the Company.  The terms of your RSU Award as specified in this Award Agreement for your RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Grant Notice constitute your &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;.  Defined terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The general terms applicable to your RSU Award are as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">1.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Governing Plan Document.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Your RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in: </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 6 of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 9(e) of the Plan regarding the Company&#x2019;s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award; and </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Section 8(c) of the Plan regarding the tax consequences of your RSU Award.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">2.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Grant of the RSU Award.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This RSU Award represents your right to be issued on a future date the number of shares of the Company&#x2019;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of Section 3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your RSU Award.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">3.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Dividends.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">4.</font><div style="width:100%;display:inline;" id="ole_link5"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Withholding Obligations.</font><font id="ole_link6"></font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As further provided in Section 8 of the Plan, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">obligations, if any, which arise in connection with your RSU Award (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Withholding Obligation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in accordance with the withholding procedures established by the Company.  </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Unless the Withholding Obligation is satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award.  In the event the Withholding Obligation of the Company arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">5.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date of Issuance.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and will be construed and administered in such a manner.  Subject to the satisfaction of the Withholding Obligation, if any, in the event one or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 above, and subject to any different provisions in the Grant Notice).  Each issuance date determined by this paragraph is referred to as an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Original Issuance Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.&#x201d; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day.  In addition, if:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">the Original Issuance Date does not occur (1) during an &#x201c;open window period&#x201d; applicable to you, as determined by the Company in accordance with the Company&#x2019;s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance with the Company&#x2019;s policies (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">10b5-1 Arrangement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;)), </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">and</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.667%;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">either (1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date, to you under this Award, and (B) not to permit you to enter into a &#x201c;same day sale&#x201d; commitment with a broker-dealer (including but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding Obligation in cash, </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">then</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#x2019;s Common Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">if and only if</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to a &#x201c;substantial risk of forfeiture&#x201d; within the meaning of Treasury Regulations Section 1.409A-1(d).</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.8%;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent the RSU Award is a Non-Exempt Award, the provisions of Section 11 of the Plan shall apply.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">6.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Transferability.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.  </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">7.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Corporate Transaction.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">8.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">No Liability for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">9.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">.  If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">10.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Other Documents.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.  In addition, you acknowledge receipt of the Company&#x2019;s Trading Policy.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:2.4%;">11.</font><div style="width:100%;display:inline;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Questions. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>6
<FILENAME>vera-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10.11</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> 10.11</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Employee Director Compensation Policy</font><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amended and Restated Effective January 1, 2024</font></p>
  <p style="padding-bottom:9pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;border-bottom:0.5pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Each member of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Vera Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eligible Director</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will receive the compensation described in this Non-Employee Director Compensation Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be.  This Policy shall be effective as of the date set forth above (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Cash Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred.  If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, his or her first quarterly installment will be pro-rated based on days served in the applicable quarter. All annual cash fees are vested upon payment.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Board Service Retainer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a.	All Eligible Directors: $40,000</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">b.	Non-executive chairperson of the Board: $70,000 (inclusive of Annual Board 	Service Retainer)</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Committee Member (non-Chair) Service Retainer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a.	Member of the Audit Committee: $10,000</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">b.	Member of the Compensation Committee: $6,000</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">c.	Member of the Nominating and Corporate Governance Committee: $5,000</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Committee Chair Service Retainer (inclusive of Committee Member Service Retainer)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">a.	Chairperson of the Audit Committee: $20,000</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">b.	Chairperson of the Compensation Committee: $12,000</font></p>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">c.	Chairperson of the Nominating and Corporate Governance Committee: $10,000</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company will also reimburse each of the Eligible Directors for his or her travel expenses incurred in connection with his or her attendance at Board and committee meetings. Such reimbursements shall be paid on the same date as the annual cash fees are paid.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Equity Compensation</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	The equity compensation set forth below will be granted under the Company&#x2019;s 2021 Equity Incentive Plan, as the same may be amended or restated from time to time (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Capitalized terms used below not otherwise defined in this Policy shall have the meanings given to them in the Plan All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock on the date of grant, a term of 10 years from the date of grant (subject to earlier termination in connection with a</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">termination of service as provided in the Plan), and subject to all the terms, conditions and limits set forth in the Plan and the applicable award agreement. For the avoidance of doubt, the share numbers in this Policy shall be subject to adjustment as provided in the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Initial Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">: For each Eligible Director who is first elected or appointed to the Board following the Effective Date, on the date of such Eligible Director&#x2019;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase 40,000 shares (as adjusted for stock splits, combinations and the like) of the Company&#x2019;s common stock.  The shares subject to each such stock option will vest monthly over a three-year period, subject to the Eligible Director&#x2019;s Continuous Service on each vesting date, and will vest in full upon a Change in Control, subject to the Eligible Director&#x2019;s Continuous Service through such date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Annual Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">: On the date of each annual stockholders meeting of the Company, each Eligible Director who continues to serve as a member of the Board through and following such stockholders meeting (and who joined the Board no later than February 28 of the year in which the stockholders meeting is held) will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase 20,000 shares (as adjusted for stock splits, combinations and the like) of the Company&#x2019;s common stock (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Annual Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The shares subject to each such stock option will vest on the earlier of (a) the first anniversary of the date of grant and (b) the date of the Company&#x2019;s next annual stockholders meeting, subject to the Eligible Director&#x2019;s Continuous Service through such date. Such option will vest in full upon a Change in Control, subject to the Eligible Director&#x2019;s Continuous Service through such date.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Compensation Limits</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">	Notwithstanding anything to the contrary in this Policy, all compensation payable under this Policy will be subject to any limits on the maximum amount of Eligible Director compensation set forth in the Plan, as in effect from time to time.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Approved by the Board of Directors:  May 7, 2021</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Most Recently Amended by the Compensation Committee of the Board:  December 6, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>7
<FILENAME>vera-ex10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html>
 <head>
  <title>EX-10.14</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">January 3, 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Celia Lin, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Via Email</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Dear Celia:</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">This letter sets forth the substance of the separation agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) that Vera Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) is offering to you to aid in your employment transition. By executing and delivering this Agreement, you and the Company agree as follows:</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">1. S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">EPARATION</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. Your last day of employment with the Company will be January 3, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Separation Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">2. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">CCRUED </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ALARY AND </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">AID </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">IME </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">FF</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. On the Separation Date, the Company will pay you all accrued salary and all accrued and, if applicable, any unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings. You are entitled to this payment regardless of whether or not you sign this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">3. S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">EVERANCE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ENEFITS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of your offer letter agreement with the Company dated May 7, 2021 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Offer Letter</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), if you timely sign this Agreement, allow it to become effective, and comply with your obligations under it (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Severance Preconditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company will provide you with the following severance benefits (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Severance Benefits</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;):</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(a) Severance Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. The Company will pay you, as severance, an amount equivalent to nine months of your base salary in effect as of the Separation Date, subject to standard payroll deductions and withholdings. This amount will be paid to you in a lump sum severance payment (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Severance Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Severance Pay will be paid to you within two of the Company&#x2019;s regularly scheduled payroll dates after the Effective Date (as defined below).</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Bonus</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. You acknowledge that as of the Separation Date, you will not have earned and will not be entitled to any 2023 bonus payment. As an additional severance benefit, the Company will pay you the cash equivalent of your 2023 target bonus that you could have earned had you met the conditions for earning it, as calculated at the sole discretion of the Company, subject to standard payroll deductions and withholdings. This amount will be paid out to you by no later than March 15, 2024, in accordance with the Company&#x2019;s regular bonus payout schedule.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(c) Health Insurance</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#x2019;s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense following the Separation Date. Later, you may be able to convert to an individual policy through the provider of the Company&#x2019;s health insurance, if you wish. You will be provided with a separate notice describing your rights and obligations under COBRA and a form for electing COBRA coverage. As an additional severance benefit, provided that you timely elect continued coverage under COBRA, then the Company shall reimburse you or pay directly (at the Company&#x2019;s discretion) for the COBRA premiums to continue your health insurance coverage (including coverage for eligible dependents, if applicable) through the period (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">COBRA Premium Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) starting on the Separation Date and ending on the earliest to occur of: (i) nine months after the Separation Date; (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">eligible for COBRA coverage for any reason. You must timely pay your premiums, and then provide documentation to the Company, to obtain reimbursement for your COBRA premiums under this Section 3(c). In the event you become covered under another employer&#x2019;s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately notify the Company in writing. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without a substantial risk of violating applicable law, then the Company instead shall pay you a fully taxable cash payment equal to the remaining COBRA premiums due under this Section, subject to applicable tax withholdings, which you may, but are not obligated to, use toward the cost of COBRA premiums.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">4. E</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">QUITY </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">WARDS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of your equity award agreement(s) and the applicable plan documents, vesting of your equity awards will cease as of the Separation Date. Your right to exercise any vested shares, and all other rights and obligations with respect to your equity award(s), will be as set forth in the applicable award agreement, grant notice and applicable plan documents.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">5. C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ONSULTING </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ERIOD</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Beginning on January 3, 2024, the Company will engage you as a consultant on the terms set forth herein.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Term. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">If: (i) you timely sign, date, and return this Agreement to the Company and allow all of the releases contained herein to become effective; and (ii) you comply with all of your obligations to the Company hereunder (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Preconditions</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), then the Company will continue your engagement as a consultant through July 3, 2024, unless terminated earlier pursuant to the terms set forth below or extended by mutual written agreement. If you do not timely execute and return this Agreement, or you revoke your signature after you sign it, or you otherwise do not satisfy the Preconditions, then your consulting engagement will end immediately upon the failure of any of the Preconditions (as determined by the Company in its discretion). The Company is under no legal obligation to retain your services as a consultant after the Separation Date and therefore this Consulting Period constitutes consideration for your obligations as specified herein. The full term of your consulting engagement as described in this Section 3 will be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Consulting Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Consulting Services. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">During the Consulting Period, you will provide consulting services as may be requested by the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Consulting Services</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). You will exercise the highest degree of professionalism and utilize your expertise and creative talents in performing these services. You will make yourself available to perform such Consulting Services throughout the Consulting Period, on an as-needed basis, up to a maximum of 10 hours per week. The Consulting Services will constitute a permanent reduction in your services to the Company to not more than 20% of the average level of bona fide services you provided to the Company during the 36-month period immediately preceding the Separation Date (or such lesser period of time you have been with the Company), such that any such Consulting Services shall be deemed a &#x201c;separation from service&#x201d; under Section 409A (as defined below). You will not be required to report to the Company&#x2019;s offices during the Consulting Period, except as specifically requested by the Company. When providing such services, you shall abide by the Company&#x2019;s policies and procedures.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(c) Consulting Fees. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">During the Consulting Period, you will receive consulting fees at a rate of $400 per hour (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Consulting Fees</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). The Consulting Fees will be paid within 30 days of receipt by Company of each invoice for Consulting Services, which you shall submit monthly. You shall seek advance written approval prior to incurring any expenses for which you will seek reimbursement in connection with your duties during the Consulting Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(d) Independent Contractor Relationship. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">During the Consulting Period, your relationship with the Company will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship after the Separation Date. Except as expressly provided in this Agreement, you will not be entitled to, and will not receive, any benefits which the Company may make available to its employees, including but not limited to, group health or life insurance, profit-sharing or retirement benefits.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(e) Taxes and Withholding. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">As an independent contractor, the Company will not withhold from the Consulting Fees any amount for taxes, social security or other payroll deductions. The Company will issue you a Form 1099 with respect to your Consulting Fees. You acknowledge that you will be entirely responsible for payment of any such taxes, and you hereby indemnify, defend and save harmless the Company, and its officers and directors in their individual capacity, from any liability for any taxes, penalties or interest that may be assessed by any taxing authority with respect to all compensation you receive under this Agreement, with the exception of the employer&#x2019;s share of social security, if any.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(f) Limitations on Authority. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">During the Consulting Period, you will have no responsibilities or authority as a consultant to the Company other than as provided above. You will have no authority to bind the Company to any contractual obligations, whether written, oral or implied, except with the prior written authorization of an officer of the Company. You will not represent or purport to represent the Company in any manner whatsoever to any third party unless authorized in advance by the Company, in writing, to do so.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(g) Confidential Information and Inventions. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">During the Consulting Period and thereafter, you will not use or disclose, in any manner that is not authorized by the Company or essential to your performance of specifically requested Consulting Services, any confidential or proprietary information or materials of the Company that you obtain or develop in the course of performing the Consulting Services. Any and all work product you create in the course of performing the Consulting Services will be the sole and exclusive property of the Company. You hereby assign to the Company all right, title, and interest in all inventions, techniques, processes, materials, and other intellectual property developed in the course of performing the Consulting Services. You further acknowledge and reaffirm your continuing obligations, both during the Consulting Period and thereafter (as applicable), under the Employee Confidential Information and Inventions Assignment Agreement entered into between you and the Company, a copy of which is attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">and incorporated herein by reference.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(h) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Other Work Activities. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Throughout the Consulting Period, you shall have the right to engage in employment, consulting, or other work relationships in addition to your work for the Company. In order to protect the trade secrets and confidential and proprietary information of the Company, during the Consulting Period, you will notify the Company in writing, and obtain the Company&#x2019;s written consent, before you obtain employment with, or perform competitive work for, any business entity that is competitive with the Company, or engage in any other work activity, or preparation for work activity, competitive with the Company.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(i) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Termination of Consulting Period. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">The Consulting Period will end on the earliest to occur of: (i) July 3, 2024, unless the Consulting Period is extended as agreed upon in a writing signed by both you and an authorized representative of the Company; (ii) 10 days after you provide written notice that you are terminating the Consulting Period for any reason; (iii) 10 days after the Company provides you with written notice that it is terminating the Consulting Period for any reason; or (iv)</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">immediately upon the Company&#x2019;s written notice to you that you have breached your obligations hereunder or have breached any of your obligations under your Employee Confidential Information and Inventions Assignment Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">6. O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">THER </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">OMPENSATION OR </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ENEFITS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits before or after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested stock options. You further acknowledge that the offer of benefits herein satisfies and exceeds any severance or other benefits you may be eligible for or entitled to receive under the Offer Letter and any other agreement, plan or policy, and that upon your execution of this Agreement, any and all of the Company&#x2019;s obligations to provide you any severance or other separation benefits under the Offer Letter and any other agreement, plan or policy is hereby waived and extinguished.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">7. E</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">XPENSE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">EIMBURSEMENTS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Within ten days after the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for these expenses pursuant to its regular business practice.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">8. R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ELEASE OF </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">LAIMS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.05pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(a) General Release of Claims</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown, arising from or in any way related to events, acts, conduct, or omissions occurring at any time prior to and including the date you sign this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.05pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(b) Scope of Release</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. This general release includes, but is not limited to: (i) all claims arising from or in any way related to your employment with the Company or the termination of that employment; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, equity awards, or any other ownership, equity, or profits interests in the Company; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#x2019; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the California Labor Code (as amended), the California Family Rights Act, the Age Discrimination in Employment Act (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">ADEA</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the California Fair Employment and Housing Act (as amended). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You acknowledge that you have been advised, pursuant to California Government Code Section 12964.5(b)(4), that you have the right to consult an attorney regarding this Agreement and that you were given a reasonable time period of not less than five business days in which to do so. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">In the event you sign this Agreement prior to the end of the reasonable time period provided by the Company, your decision to accept such shortening of time is knowing and voluntary and is not induced by the Company through fraud, misrepresentation, or a threat to withdraw or alter the offer</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:13.05pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">prior to the expiration of the reasonable time period, or by providing different terms to employees who sign such an agreement prior to the expiration of the time period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">(c) ADEA Release. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you have under the ADEA, and that the consideration given for the waiver and releases you have given in this Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised, as required by the ADEA, that: (i) your waiver and release does not apply to any rights or claims arising after the date you sign this Agreement; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so); (iii) you have 21 days to consider this Agreement (although you may choose voluntarily to sign it sooner); (iv) you have seven days following the date you sign this Agreement to revoke this Agreement (in a written revocation sent to the Company); and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after you sign this Agreement provided that you do not revoke it (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(d) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Section 1542 Waiver. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">In giving the release herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows: </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#x201d; </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect with respect to your release of claims herein, including but not limited to your release of unknown claims.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(e) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Exceptions</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. Notwithstanding the foregoing, you are not releasing the Company hereby from: (i) any obligation to indemnify you pursuant to the Articles and Bylaws of the Company, any valid fully executed indemnification agreement with the Company, applicable law, or applicable directors and officers liability insurance; (ii) any claims that cannot be waived by law; or (iii) any claims for breach of this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(f) </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Protected Rights. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Civil Rights Department, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Government Agencies</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement. Nothing in this Agreement (i) prevents you from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful; or (ii) waives any rights you may have under Section 7 of the National Labor Relations Act (subject to the release of claims set forth herein).</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ETURN OF </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">OMPANY </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ROPERTY</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. Within five days after the Separation Date, or as otherwise agreed by the parties, you will return to the Company all Company documents (and all</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">copies thereof) and other Company property in your possession or control, including, but not limited to, Company files, notes, account and device login and password information, product and services information, drawings, records, plans, forecasts, reports, studies, analyses, proposals, agreements, drafts, financial and operational information, research and development information, sales and marketing information, customer lists, prospect information, pipeline reports, sales reports, personnel information, specifications, code, software, databases, computer-recorded information, tangible property and equipment (including, but not limited to, computing and electronic devices, mobile telephones, servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any proprietary or confidential information of the Company (and all reproductions or embodiments thereof in whole or in part). You will make a diligent search to locate any such documents, property and information by the close of business on the Separation Date or as soon as possible thereafter. If you have used any personally owned computer or other electronic device, server, or e-mail system to receive, store, review, prepare or transmit any Company confidential or proprietary data, materials or information, within five days after the Separation Date, you shall provide the Company with a computer-useable copy of such information and then permanently delete and expunge such Company confidential or proprietary information from those systems; and you will provide the Company access to your system as requested to verify that the necessary copying and/or deletion is completed. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Your timely compliance with this paragraph is a condition to your receipt of the Severance Benefits provided under this Agreement.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">10. C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ONFIDENTIAL </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">NFORMATION </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">BLIGATIONS</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. You acknowledge and reaffirm your continuing obligations under your Employee Confidential Information and Inventions Assignment Agreement, a copy of which is attached hereto as Exhibit A and incorporated herein by reference.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">11. N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ON</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">DISPARAGEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Except to the extent permitted by the &#x201c;Protected Rights&#x201d; Section above, you agree not to disparage the Company, its officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to its or their business, business reputation, or personal reputation; provided that you may respond accurately and fully to any request for information if required by legal process or in connection with a government investigation. In addition, nothing in this provision or this Agreement prohibits or restrains you from making disclosures protected under the whistleblower provisions of federal or state law or from exercising your rights to engage in protected speech under Section 7 of the National Labor Relations Act, if applicable.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">12. N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">O </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">V</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">OLUNTARY </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">DVERSE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">CTION</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. You will not voluntarily (except in response to legal compulsion or as permitted under the section of this Agreement entitled &#x201c;Protected Rights&#x201d;) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">13. C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">OOPERATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You will cooperate fully with the Company in connection with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by the Company. Such cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages) and will make reasonable efforts to accommodate your scheduling needs.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">14. N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">O </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">DMISSIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">The promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">15. S</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ECTION </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">409A. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">All payments and benefits provided under this Agreement are intended to satisfy the requirements for an exemption from application of Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and other guidance thereunder and any state law of similar effect (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to the maximum extent that an exemption is available and any ambiguities herein shall be interpreted accordingly; provided, however, that to the extent such an exemption is not available, such payments and benefits are intended to comply with the requirements of Section 409A to the extent necessary to avoid adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly. For purposes of Section 409A, any installment payments provided under this Agreement will each be treated as a separate payment. Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under the this Agreement is determined to be subject to (and not exempt from) Section 409A, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the expenses eligible for reimbursement or in kind benefits to be provided in any other calendar year, in no event shall any expenses be reimbursed after the last day of the calendar year following the calendar year in which you incurred such expenses, and in no event will any right to reimbursement or the provision of any in-kind benefit be subject to liquidation or exchange for another benefit. To the extent required under Section 409A, any payments to be made under this Agreement in connection with a termination of employment will only be made if such termination constitutes a &#x201c;separation from service&#x201d; under Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">16. R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">EPRESENTATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">You hereby represent that you have: been paid all compensation owed and for all hours worked; received all leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise; and not suffered any on-the-job injury for which you have not already filed a workers&#x2019; compensation claim.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">17. M</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">ISCELLANEOUS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">This Agreement constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the State of California without regard to conflict of laws principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any successive breach. This Agreement may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">If this Agreement is acceptable to you, please sign below and return the original to me. You have 21 calendar days to decide whether to accept this Agreement, and the Company&#x2019;s offer contained herein will automatically expire if you do not sign and return it within that timeframe.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">We wish you the best in your future endeavors.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Sincerely,</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Marshall W. Fordyce, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Chief Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">I </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">HAVE READ</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">UNDERSTAND AND AGREE FULLY TO THE FOREGOING </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;min-width:fit-content;">GREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Celia Lin, M.D.</font><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">Date</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 10.14</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;">EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS AGREEMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>vera-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 23.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">We consent to the incorporation by reference in the registration statements (No. 333-265408) on Form S-3 and (Nos. 333-263899 and 333-256269) on Form S-8 of our report dated March 26, 2024, with respect to the financial statements of Vera Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">San Francisco, California<br>March 26, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>vera-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 31.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Marshall Fordyce, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Vera Therapeutics, Inc.; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability to financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.42%;"></td>
    <td style="width:12.12%;"></td>
    <td style="width:3.04%;"></td>
    <td style="width:42.42%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 26, 2024</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Marshall Fordyce</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marshall Fordyce, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>vera-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 31.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Sean Grant, certify that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Vera Therapeutics, Inc.; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability to financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></div></div>
  <div style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div style="margin-left:5.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:5.065%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:5.343052449470442%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42%;"></td>
    <td style="width:13%;"></td>
    <td style="width:3%;"></td>
    <td style="width:42%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 26, 2024</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sean Grant</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sean Grant</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>vera-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 32.1</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Vera Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42%;"></td>
    <td style="width:13%;"></td>
    <td style="width:3%;"></td>
    <td style="width:42%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 26, 2024</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">/s/ Marshall Fordyce</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Marshall Fordyce, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>vera-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 32.2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Annual Report of Vera Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and </font></div></div>
  <div style="margin-left:4.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.759107549327096%;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42%;"></td>
    <td style="width:13%;"></td>
    <td style="width:3%;"></td>
    <td style="width:42%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: March 26, 2024</font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">/s/ Sean Grant</font></p><p style="border-top:1pt solid;padding-top:1pt;font-size:10pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sean Grant</font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>13
<FILENAME>vera-ex97_1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html>
 <head>
  <title>EX-97.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">VERA THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">NCENTIVE </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OMPENSATION </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ECOUPMENT </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">P</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OLICY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">As adopted on November 6, 2023</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">1. INTRODUCTION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Compensation Committee (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) of Vera Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) providing for the Company&#x2019;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rule 10D-1</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and Nasdaq Listing Rule 5608 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Listing Standards</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">2. EFFECTIVE DATE</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Incentive Compensation is deemed &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">received</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; in the Company&#x2019;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">3. DEFINITIONS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Restatement Date</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Compensation Committee or, in the absence of such committee, the Board.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Covered Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means each current and former Executive Officer.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Nasdaq Stock Market.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 97.1</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Executive Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Company&#x2019;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#x2019;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Financial Reporting Measures</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#x2019;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TSR</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). A measure need not be presented in the Company&#x2019;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Lookback Period</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#x2019;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recoverable Incentive Compensation</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">i.e.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.85pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">4. RECOUPMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.85pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(a) Applicability of Policy. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(b) Recoupment Generally. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the provisions of this Policy, if there is an</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#x2019;s obligation to</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(c) Impracticability of Recovery. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Recoupment may be determined to be impracticable if, and only if:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(ii) recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(d) Sources of Recoupment. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(e) No Indemnification of Covered Officers. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#x2019;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(f) Indemnification of Administrator. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12.1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(g) No &#x201c;Good Reason&#x201d; for Covered Officers. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#x201c;good reason&#x201d; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">5. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">DMINISTRATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#x2019;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">6. SEVERABILITY</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">7. N</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">O </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">I</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">MPAIRMENT OF </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">O</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">THER </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">EMEDIES</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#x2019;s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Company&#x2019;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;">287688418 v2 8</font><font style="color:#000000;white-space:pre-wrap;font-size:7pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="font-variant:small-caps;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 97.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">8. A</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">MENDMENT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">; T</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ERMINATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">9. SUCCESSORS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">10. R</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">EQUIRED </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">F</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">ILINGS</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img76291469_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Z".@# 2(  A$! Q$!_\0
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MT1^I_*C[1'ZG\JJ44!<M_:(_4_E1]HC]3^55** N6_M$?J?RH^T1^I_*JE%
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MHC]3^5'VB/U/Y54HH"Y;^T1^I_*C[1'ZG\JJ44!<M_:(_4_E1]HC]3^55**
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MB]XSCR4C,I;M@#--H2=R7>HZLOYTH((R""/:OEV^$VJ"^UV7[LMT0<CG<V6
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M@#LZ*:[I$F^1T1/[SL /S--BGAGSY,T4N.OEN&Q^5 $E%->1(D+R.B(.K.P
M'XFFK<0/&94N(6C7JZR J/J<XH DHID4T4ZEH98Y5'4QN& _*GT %%%1/=6T
M;['NH$?^ZTJ@_EF@"6BCMGL:B^U6WG>3]I@\W./+\Q=V?3&<T 2T5&;FW$OE
M&XA$G]PR+N_+.:DH *0LHZL!]33)9X("!-/%$3T$D@4G\Z\3^, #>,K(\$&Q
MCP>O_+1Z$#/<**AL_P#CQMO^N*?^@BIJ %'4?6K5Q_JOQJJ.H^M6KC_5?C0,
MJ4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(2 ,D@?6E!!&00?I7 _&#!\#Q]Q]NB_]!>I_A.,>!8<?\]Y/YT =O13)9H8
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MM=:M\0_[4MX3';1R2SRE?NH&)(7/XXKW>AC1XA\9I7/BBTC.=B609?J7;/\
M(5Z]X?C2'PUI4<8 06D6,>Z@G]2:X;XM>&;C4[&WU>SC,LEHI29%&28R<Y ]
MC_.JGA#XHZ79>'[>PUCSH[BU7RU=(RXD4=.G0]J.@=3T^6SM)WWS6EO*_3=)
M$K'\R*\Y^+/B:[TNVM=(T^5X7N5+S/&<'8. H/;)_E7+7GBOQ#XQ\8>1H-Y?
MVD$K!(X8IF4*HZNP!P/4UJ?&'2+B.;3-2"O+ L/V>20Y.&!R,GWYYHL#9EWG
M@C1K;PH=4C\36\FLK$)6B6YCYSU0<[LC^8KMOA?XDNM<T"ZM+V0RW%CA1(W+
M,C [<^XP1^%<3*GPVCT,7:?;9K[RQ_HGF,I+]QNQ@#KS79_"^VLFTJ_U&QTN
M>PCG(C'FW)E$@4'D?*.A8BA@MSC?@Y_R-\G_ %Z-_2FZU_R6O_N(Q?TIWP<_
MY&^3_KT;^E-UK_DM?_<1B_I3%T/=SU-<#\7_ /D2E_Z^HZ[X]37 _%__ )$I
M?^OJ.I13V//VTK[9\'[?4$7,EE?R;CC^!S@_KM_.NBU'Q3O^"MN-_P#I$^+!
MLGGY>O\ XX ?QK2^'>G)JWPMN]/?I</-&/8GH?P.#7E>G6E[J6I6?A_+!6N\
M>61]USA6)_ 51)TVN:2=*^$VB%QB6[NVN'_%>!^0_6N_^&?G_P#"L[?[-L^T
M;KCRM_W=V]L9]LUF?&*)(/"NEPQ#$<=QL0>@"8%'A::\M_@E--8;OM*)<%"G
M4?O&R1[@9-(?4YF/PQIR:O=2^/?$5J7/(2WN6E?>3SNPORX]*7X=ZI+IOQ!_
MLK3[][G2IW=%W$[74#*L >AJCX#G\(1F^F\4!7GX,7G*S*1SNP!U;IUJ/PG+
M!/\ %?3YK6#[/;27;M#$%V[4V-CBF(N?$SPG9>'+JUN[269Y-0DF>428P"-I
MXQ_O&NT^'?@;3M/33/$L4\[7<MN24;&SYA@^]9GQKB9K31I@/D1YE)]R$Q_Z
M":W/A]XOTB^TO2M#BFD_M&* AHC&V,+DD[L8Z>]+H/J>?Z BCXVQG:,_;YN<
M?[#UU'QJ56TK2L@']^_4?[-<C/=?\(O\6I+V^C<1P7CR-@9)1@1N'KPV:O\
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M1+VXC4'RFCFV#Y5D(4X^G7\JM)\1=%'P\73D>8ZE]C^S"W$3=<8SNQC&.>M
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MGX<>,XET^]DD6,),I/REU/56 X/<5ZW\0/$,WASPK+<VIVW<S"&%O[I/4_@
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MKZ&I,:"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4W^N;ZU+:]&_"HIO]<WUH&,HHHH$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!%<6UO>0-!<P1SQ-U21 P/X&L&7P#X4F<O)H5L6/H77] U
M='10!D6/A;0--D62STBTB=?NMY>XCZ$YQ4NK^'])UY8EU6QCNA$28P[,-I/7
MH16E10!!96=MIUE#9V<0AMH%V1QJ20H].>:S-0\(>'=5G,]]H]M+*3DO@J2?
M?:1FMJB@"GIVDZ=I$)BTZRAM4/41K@GZGJ?QJOJ_AS1]>:)M5L([HQ B,NS#
M;GKT(K4HH KI86L>G+IZ0*+-8A"(LG 0#&WUZ51TCPSHF@2RRZ5IT5K)*H1V
M1F.Y0<@<DUK44 8VJ>$]!UJ[%UJ6F17,X4)O=F!P.@X(K9[8[444 8%SX(\+
MWDYGGT2U:0G)*AER?HI K7LK"STVW%O8VT5O"#G9$N!GU]ZL44 8P\)Z -8&
MKC3(O[0$GFB?<V=_KC./TK9HHH QM0\(^'M5NOM5]I%M-.3DR$%23[X(S^-,
MO/!OAR_,/VK1[9_(39$!N4*N<X 4BMRB@"CJ6C:=K%BMEJ-HEQ;(RLL;$@ @
M8!X(/0FG:;I5CHUF+33K9;>W!+"-22,GKU)JY10!D:GX6T+69?-U'2K>XE/5
MR"K'ZE2":GTS0M*T52NFZ?!:[A@E%^8CW)YK0HH H:MHFF:[;QP:I9I=11OY
MB*Y(PV",\$=B:FT[3[32;*.ST^!;>WC^Y&I) _/-6:* ,;3O"6@:1??;=/TN
M*WN<$>8K,3@]>I(J_?Z;8ZK;_9[^TAN8LY"RKG!]CU'X5:HH PK/P7X9T^<3
MVNBVJ2@Y#$%\'_@1(K,^*) ^'FI$D ;H>O\ UU2NPIKQI*A21%=3U5U!!_ T
M >6?"S2-+USPA>0ZC9PW<:W>5#C[OR]B.17HFE:#I.B(RZ9I\%KNX8H#D_4G
M)J]'%%"I6**.,'DA%"C]*?0!EZOX<T?7S"=5L([HPAA'O9AMSC/0CT'Y5<CL
M;6'3Q81PJMH(S$(@3C81C'KTJQ10!DZ3X7T309GETK3HK621=C,C,<CTY)IG
M_")Z!_; U?\ LR+^T!)YHGW-G?ZXSC]*V:* &R1I+$\<B[D=2K*>X(P167I7
MA?0]#N'GTO38K661=C,C,<C.<<DUK44 9NJ^'](UP(-3T^&ZV<*7!!'X@@T:
M?X>TC2K6:VL-/BMX9UVRJF?G&,<DG/0UI44 9.D^&-$T*>2;2].BM9)%V.R,
MQR,YQR31J?A?0M:E\W4=+M[B3^^058_4@@FM:B@#.TS0=)T4,--TZ"UW#!9%
M^8CZGFM&BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I
M;?\ UH^E15+;_P"M'TH MT444B@JI<?ZT_2K=5+C_6GZ4"9%1113$%%%% !1
M110 4444 8OB;Q/8>%M-^UWI+,Y*PPI]Z1O;V]37G(^)_BR_5[K3M A:S0G<
M?*DDQ_P($#]*Q_B;=RZKX_-B&PD CMXP>@)P2?S->X:=90:7I]O96J!(($"*
MH&.G?ZFF+<XWP7\2+?Q-=#3[NW%I?D$H%;*2XZX]#[50\>>/M7\,>(8K"QAL
MWA:%9"9HV9LDD=F'I5^/X7V,'B@:[!J=Q%(MS]H6!8EV ]USUQU_.N'^+W_(
MZ0?]>J?^A-0#O8]OB8O#&YZLH)Q[BGUS'BOQ7%X0\-07K1"::7;%!&S8#-MS
MR?0 9KBH_&OC^70SXA2QL&TD<\1\[<XSUSC/>E8=SURBN;\(>+H?%&A/?O$+
M>6 E;A,Y"D#.0?0BN/A\?^*?%.IW%MX3TZU6&$;M]Q\Q*YP"<],^E%@N>J45
MP'A/QEX@O->;1O$&CR12Y95N8H&5 RC."<8P0.#FH/$'Q U3_A)SX=\-6,4]
MXK>6TDW(+XR0!Z#U/I18+GHU%>8V_C/QGH^N0V/B+11/#(5W2V=NQV@G&05R
M#CN#7IW7D=* "O,=>^*[QZHVG>'M/%[(KE/-?)#L.RJ.2/?->E3HTMM-&IPS
MQLH/H2"*^=_#>IS> ?&!EU*Q=Y85:&1#P^#CYE)^E-"9U[_$[Q3HUS&->T".
M*-SPOEO"Q'?!8D&O3]'U:UUS2H-1LG+03+D9X*GN#[BN,N_%?@?QO81Z=J-W
M+ ID#JLN8F5AZ-R.]:MUIQ\'>!+W_A%VRT.;I//;S@V<;L=,C XH ZRBN%^&
MWC&_\507Z:FT!N+=E*>3'L^0CN/J#7+>)OBCKMAXDO[73&M/L5O+Y:[X-QXX
M/.>Y!I6"Y['45U(\-G/+& 72-F4$9R0,BL35/$8M/ DGB"';O-HLL8(R-[ <
M8^N?RK%^'_B77O$6DZCJ.J/;^7$=D'E0[,L!DGKR.@_"@9!X(\8^(=?UR2TU
M6PAM[=86<.D#H2P(XRS$=ZZ+7?&>B>';A;6]N2;M]NVWC7<^&/!/H/K7%^#?
M'WB;Q)J-]9SM:R-':/+"J0[29!C;GGIS7 >+)]?G\3I+K\$<6J[(L(B@#&?E
MX!/>G85SZ14[E!]1FEKD?"-_XJ:*^E\66\%K;PQHT#J@48^;<3@GH M<LWQ%
M\2^(M7EL_"6FPF.-2P:9-[%1W.2 ,]A2L.YZO7FS>/\ 5Q\1_P#A'O)L_L?V
MWR-WEMYFW/KNQG\*G\#_ !$N-=U1]&UBV2"_ ;8\8P&*_>4CL:X+6+[^S/BW
M=7HA><P:@7$2=7(/ 'UIV$V>_P!4=9NI['1+V[MD#SPPL\:$$AF X&!R:\PU
M7Q]XZT&XAN-5T>VM[2<_NXFCZ]\;P>N*]"A\0+J/@N77K ;#]CDGC5QG8ZJ3
M@^N"*0[F#X#\5Z[XBN[R+5[&*W2*-6C*0NF23@_>)KN:\]^&_C36O%=]>PZK
M) R0QJR>5%LY)QZU@S?%#7;+Q9>6,D,%U:Q3R11010XD<@X4;LT["N>P45X[
MJ/Q%\;Z'J$1U?2;>VAD^98'BQN7OAP37IMOX@LIO#*:^[&*S-OY[;NJC'(]S
MGBE8=S5HKR.V^(7C+Q)J4R^'-*@-O%R4>/<0O;<Q( )]JKS_ !1\2'7K:Q-K
M;V3"1(;F&2'<P?.&P<\"G85SV2BBBD,**** "BBB@ HHHH 4=1]:M7'^J_&J
MHZCZU:N/]5^- RI1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+>[M1^ZE*Y4C&""/0XKF;7X7ZW)I[:?J?B/S+&-&\BVB9RF_!V[LC@ \\9H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!8M>C?A44W^N;ZU+:]&_"HIO]<WUH
M&1NRHC.QPJC)/M66OB/3'4,LTQ4C((MI<$?]\U?N_P#CSG_ZYM_*N-L/^0=:
M_P#7%/Y"L*U9T^AU8;#JMN['2?\ "0Z;_P ])_\ P%E_^)H_X2'3?^>D_P#X
M"R__ !-8=%<_UQ]CK_LZ/\QN?\)#IO\ STG_ / 67_XFC_A(=-_YZ3_^ LO_
M ,36'11]<?8/[.C_ #&Y_P )#IO_ #TG_P# 67_XFC_A(=-_YZ3_ /@++_\
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MD.F_\])__ 67_P")H_X2'3?^>D__ ("R_P#Q-8=%'UQ]@_LZ/\QN?\)#IO\
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M7****H@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HI&8(I9B%4#))/ %<+X@\4O>,UGI[%8#\K
M2#[TGL/;^=1.:BKLWH8>=:5HFQK/BVWL-T%GMN+@<$_P(?ZFN2":MXBN2[,\
MN/XF.$7_ #[5IZ/X7W!;C4 0.JP]S]?\*Z5Y8+.(( J@#Y445S2E*6YZM.-.
MA[M)7EW,6R\)VL(#73F=_P"Z.%_^O6TBVMD@5%CB4=E&*H37TLF0IV+[=:JD
MY.34FOL9SUJ,U7U&$'Y0S?I41U,]HA^)K/JA=ZM!;$HO[R0=EZ#\:+FBP\.Q
MN_VF_P#SS7]:<-3/\40_ URPN-6N_P#51>6IZ'&/U-.-AK!&6GV_\"Q4\Z&Z
M%/JCK$U&$_>#+^M2.MK>QE'6.93U##-<:8]9@Y#"0>G!_P#KT^#6BD@2[B,3
M#^(?X4U-,AX:.\6:M]X3M9LM:.8'_NGYE/\ A6%C5O#ESN1GBR?O+RC_ -/S
MKIK;4GVA@PEC/?/]:T4D@O(BA574CYD<9I^:(<JD%::YD5=&\66VH%8+H+;W
M)X!S\C_0]C[5T5<#K'A<H&GT\$KU:$G)'T]?I3_#_BI[1EL]08M!]U9#]Z/V
M/J/Y5M"KTD<=?!QFO:4/N.[HI%8,H92&4C((/!%+70>6%%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVDY[@U%6CJ"9C1QU!Q3;:R&-\P^B_P"-9RHOG<8FD:Z]FI2*%%6KZ)8I5V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH 4=1]:M7'^J_&JHZCZU:N/]5^- RI1110(****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /-_%/Q U#1/%XT^*"#['$4\S>IW.
M#U.<\>U>C@AE##H1FO&?BU:^5XG@N/\ GO;*?^^217JOA^Z^W>'=.N<Y,ENC
M'G/.!FN2A4DZLX2>Q]#FF$HQP&&Q%*-KJS\W_5Q;W2DGR\.$D].S5G6L]Q87
M(B<$*3AE;I]:Z*FAD8G#*Q'7!!Q7!B<GIRKJO0E[.?EL_EI_6YY5/%R4'":Y
MD,6Y@9B%FC)'8-4H(/0YK.;3+&8DHV"?[KC'Y4J:7Y,3K%<RJ6Z>@K>&(QM_
M>IJ2[QE_F1*G1Z2:?FC0HK*^QZG%_J[H-]3_ (U?MOM B N-F_U6ML/BYU9<
MDZ4HOSM;[T14I**NI)DU%%%=IB%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!8M>C?A44W^N;ZU+:]&_"HIO]<WUH&5KO_CSG_ZYM_*N-L/^0?:_
M]<D_D*[*[_X\Y_\ KFW\JX[3SML+1AVB0_H*XL7T/2R_K_78NFUG SY35+9L
M8KC:X*[ACFM!'$B*XZ,,U3U2YC@M2K8+M]U?ZTO8J'OQ9NJTJCY&MQU[J,5F
MN/O2'HH_K7*:EJF',L[;I#]U!4&H7_D G.Z9N@]*SK2PFU!S+(Y5">7/4_2B
M4W(ZZ5"--79&\UQJ$ZQY^\>%'05KVND00 -(/-?WZ#\*H7%H^DSQ7$;^8N>X
MQ^%3RZZOE_N83O\ ]H\"I5EN:2YI?#L;'RHO95'X5GWFJ6Z0ND;B1R, #I^=
M8<]U/<G,LA;V[?E4-#GV"-'N7+'4)+'< H=&ZJ3CFKAUY^UNO_?7_P!:L>BI
MNS1PBW=FRNO?WK?\G_\ K5!?ZK]KA\I(RJDY))K-HI\S$J<4[HZ?3&B:QB$6
M.!\P[Y[TZYT^VN<ETP_]Y>#7,)(\3;HV*MZ@UJVFMLN$N1N']\=?Q%-26S,Y
M4Y)WB0SV-UI[>;$Q9!_$O;ZBK=CJ@D8*YV2]B.AK5CD2:,/&P=#W%<M>B);V
M40XV!N,4-6'"7/HST/3-129%@DPL@''HU7;I_+MW/<C KSW3M1.5BE;!_@?-
M==87)OG6&XD)*C./6K4WR\J.2KAU&7/T&45KK:P+TC'XU2ODC290@ ..0*PG
M0<(W;*A7C.7*D5:***P-PJ5;:9QD1MCWJS80!LRL,X.%J_732P_,KR.6KB>5
M\L3&>"6,9:-@/7%1UNU7FM(Y1D#:WJ*J>&_E8H8K^9&513Y8GA?:X^A]:97*
MTT[,ZTTU=!1112 **** "BBB@ HHHH **** "BBB@#7\-_\ 'M>_]?1_]%I6
MS6-X;_X]KW_KZ/\ Z+2MFO8I_ O1'SE;^)+U?YA1115F85!=6L=W&%?*LIW)
M(O#(WJ#4]% %.UNG\[[)= +<@94CA95_O+_4=JN5#=6L=Y#Y<F00=R.IPR-V
M(/K4-K<RK*+2\VBX RC@868>H]_44 7**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "@=:*J:K<?9=(NY_[D3?KQ_6DW;4J,>9
MI+J< ['7/%;,<F-Y>_9%[?D*[&\D\JV;'!;Y17+>#X-]Y<3D9V(%!]R?_K5O
MZF^71/09-<2?4]Z44ZL8+9%&BBB@ZPHHHH #P,UE: V;F]F'WF&T?B:TIFV0
MNWHI-9WAX;+>1^Y<?H*SJ.R%+X6= RB21(0<1Q#YC_.D(:\GPG"+T]A3!N*B
M%.7<Y8TZ20*GV>#D'[S#^(UE?N<]GT_KS%GG54\B#A!U/]ZB&V4)YUP=J=AW
M-.6**T >?YI.R#M]:9B>^DS_  C\A3ZZ[]A=--NXDTSW+A$7"CA5%2D+91]C
M.P_[YH:6*T4K#AY>[^E,AMS+F:=BL?4D]31K?S#2W9?F)"FU#<2<@?=!_B-4
M=0;R],GF?JP('O5\[KR8*@VQKT] *P_$ET)&BLX>F< >W_ZZ$KFD+N0:(A73
MP3_$Q-:-1V\(@MXXA_",5)6YL%/BE:&0.O4?K3**8FKZ,V)8H-1LFCD&Z.08
M(]#_ (UQ<$USX8USG+*.& Z2(:Z6RN/)EVL?D;K[>].U_2QJ5B2@_P!(BRT9
M]?44>:.2RIR<)?"SHH)X[F".>%@T<BAE([BI*X?P;JYAF.F3MA'),.>S=U_'
M^==Q77"7,KGCXBBZ-1Q844459@%%%% !4MO_ *T?2HJEM_\ 6CZ4 6Z***10
M54N/]:?I5NJEQ_K3]*!,BHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** %'4?6K5Q_JOQJJ.H^M6KC_ %7X
MT#*E%%% @HHHH **** "BBB@ HHHH **** "DR-VW(SUQ7+>,?&MKX8M_)CV
MS:C(O[N+/"?[3?X=Z\]\&6NN^)/%Z:RT\FV&0//<,>,?W!]1QBN:IB5&:IQ5
MV>UA,FJ5L-/%59<D$M&^K_KK]Q[97GGQ<@N'T.RN(W?R8YB)%'3)'!/\J]#K
M#\8:?_:GA+4;8+N<1&1!_M+S5UX<].2.7*JZP^-I5'LFOQT,KX::HVI>$DBD
M8M):2&$DGG'4?H:[&O)_A+)=6UU=+)!*ME=*!',5(0R+_"#ZD$_E7JLLL<$+
MRRNJ1HI9G8X"@=S4X6?-239T9[AU1S"I&&S=U\_^#<KZEJ5II&GRWU[*(X(A
MDGJ3Z #N:H^'O$^F^)K>66P,H,3!7CE4*PST/!/%>2>,/$UUXPUN.QL%=K1)
M-EO$.LC=-Q^OZ"O4O!OA>/POI B8A[R;#7#CIG^Z/85%.O*K5M#X4=&+RJC@
ML"IXAOVTMEV7G_6^G<Z*BBBNL^?"O-_#2/X?^*&J:0%86UZK2Q\8 _B&/8?,
MM>D5R_C+5(O#R:?K)MC*\4_E,5Z^6P.X9_Q[UA62TFWL>GEM23<\,HW]HK6\
M]T_O,]-$O-+^*(U* #[!J"/O/7#8!(]N>1^-=Q7&^/KJY;P=;ZKI<I7R9HKE
M74 D*00#_P"/8_&NBT/4EU?0[/4%Q^_B#,!V;N/SS13<8S<%Z_>5C55K8>GB
M9]/<?>\=K_+\BAXM\+Q>*M,CM7N6MWBD\R-PNX9QCD=Z\TOOA5K]H2UI);W:
MCIL?8WY'C]:]JHI5<+3JN\MR\!GF,P,/9TFG'LU_3_$\P\ 6>IZ5K4MGXA74
M+>"2/;"7D;R2^>A(XR>W->C7^G210B:":9UB._:S9=3ZJQ[X['(-6'19$*.H
M96&"",@U1NM/GDLI;>SU.ZLRZD*5*N%/_ @3CV!'M3A2]G'E6I.)S#ZY7]K-
M*+=K]O7NOQ,3QA?^(X-*L[W3((+@VTHFD:,'<R[2,;/3YN<'/2M;0M<@UO3H
M9UVPW)7][;,WSQ,."".O_P!8BN5T/4M2\%PO9>*YR;(OML[I<R GNI(Y Q@C
M/O3_ !5X5N=1NHO$WAN[(U!5#8C;B90."I]<<8Z$?KFIR7OQ^:_K^F=4\-1E
M;#U6DM>6HMGY/IZ_ROH=W17+>#?%K>(H9K6\@-OJ=J!YR8P&[9 [>XKJ:Z(3
M4X\T3QL3AJF&JNE55F@HHHJS **** "BBB@ HHHH **** "BE )Z"DH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUAJC*42T$AB^:=_,?^XI_F:?NN+E=L:;(NP' JO'<P+]TP*?[TC@TZ2_M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** .:\2>%[?Q3J^EV]R[+# 'DF"G!9>
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MB7_KH"G\Q6I#<0W*;X)HY4/\2,"/TH"Z)**** "BBB@ HHHH **** "BBB@
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M=I89JHQ=&D];V,JM>.8XV#Y%!-I.VV^Y2^'UVDOAFZU6:UBMVEN)999(UQO
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M:[BNDW1D^X(Y%4QK-L_$D3CZ@&K\,D4L0:$J4_V>U=>7XB56I98A5%VY;/\
M/]#*O!1CK3<7ZZ#V94&6( )QS2UDJ[7^K H3Y,!SQW_R:MR7H%\EJBY8GYF]
M!712S&G-.;TCS<L7_,_+YD2P\E9+>UWY%NBBBO1.<*.@S1T&:S]2N3]F$<!#
MM*=ORG/%<^*Q,</2E4ET6W?^F:4Z;J244,18M3O#-\VR'  /1NM)J(DN[V.S
M7(0?,YJ7Y=+TWMO_ )L:=I<<BVQDE8EY3NY]*\54?:VPM3XY^]4:[=%^2^5^
MIU\_+>K'9:1_S+B(J(J*,*HP!2T45]"DDK(X=PHHHIB"BBB@"Q:]&_"HIO\
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MN=7:,9/U:6GXFMXZUNUTO3HK2XB:8W\HBV#^Z&4L3R#TX'O73(JJBJH 4#
M'05YUXM5]5^)N@:<%;9 %E;(X/)<_HH%>C' !)X YHIR<IR?1:!C*,:.%H17
MQ23D_F[+\$%%<Q'\0O#$ER\']H["AQO>,A3]#6Y::KIU^H:TO[:8'ILE&3^'
M6M(U(2V9RU<'B**O4IM>J9YG\6M#*7-MK4*_+(/)FP/XA]T_EQ^ KK?A]K9U
MCPQ$DIS<V?[F0'J0/NG\OY5NZE MU:$>6DYAE28Q'!W%6!QC\*FN+*!X_P"U
M-.1!<%-Q**!YRCG:?Z>AK!4N2LYIZ/H>G4S!8C+X86I'WHO27;LG\OR1/2C&
M1GIWJ.&59X8YD.4=0P/L:?74>(U;1G@NG@ZU\3HV/S>9?E_J%)/]*]Z/6N:T
MKP+I&CZY)JUOYQF8L41V!6,GKBNEKFPU&5-/FW;/:SO,*6,J4_8WY8Q2U[_U
M8*YI_ FA/KRZP+=EG5Q)Y:MB,OUW8]<\^E=+16\H1E\2/*HXBK0O[*35U9V[
M!6+JWBS1M#OH;/4+L132@$#:3M!Z$D=!6U7%>.? G_"2,+^RE$>H1ILV.?EE
M Z#/8U%9S4+TU=G1EU/"U*ZABI.,'U7?I\CLHI8YXDEB=9(W&5=3D$>QI]>#
MZ%XHUKP3?M97,,A@5OWMI-QCW7T/Z&O9-%\0Z;KUFEQ9SCYN#')\KJ?3!Z_A
M44,3&KIL^QUYGDU; OG7O4WM)?KV_(U**7%)70>,<]XVT;^W/"UU;H,SQ#SH
MO]Y><?B,UP'PGUK[-JUQI$KXCNEWQ@G^->WXC^5>PUX]J'@W6=.\?QSZ3:R&
MV:X$T4R_=0$Y8$]L<_A7%B(2C4C5BO)GTV35Z5;!UL!7DDFN:+??^K/[SV"B
MCZ]:*[3YD**** "BBB@ !P0:X?PW:Z?HGCW6]/CNV::Y59DB*\#JS#/J,_E7
M<5YOXGQI/Q4T34>0ERJH^.YY3^HKGKOEY9]G^>AZV51=7VN'O;F@_FX^\OR-
M""[L=)^*ES8QV12348%9IMW'F89R0/0\#ZCWKN*\\\>VLUGXO\.ZQ;Q.Y$JP
MOL7/1P0#]=Q'X5Z(1S3HMJ4HOH_S%F,8RI4*\7\4;/7K'3\K"4445N>4%$'_
M !^_]L_ZT40_\?O_ &S_ *T 27,#$^=$,R 8*_WQZ?6H4=74,IX-7ZIW,1A<
MSQ@E#_K%'_H0H 2B@$$ @Y!Y!HH **** "BBB@ HHHH **** "BBB@ HHHH
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MM=07<*RV\@=&&>.H]B.QJ:NS<^>::=F)12T4"$HI:R-4\4:+HP/VW484<?\
M+-3N?\AS2E)15VS2E2J59<M.+;\M1=;\/Z?KB1-=6\3SP,'BD9>00<X/JIQ@
MBKXN--DA\J]@AMF VLLH"K_P%NA'TY]A7'6/Q'TW6=<ATRW9K.&3(^USX&3V
M"CH"?4_E79G3[ IN:ZF)Z[_M;=?7&=OZ8K&,H3;E ]"M0Q.&4:6)375+M?\
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M5;E;7S-99K5J<WM8QE?2_*KKT:6Y0DTG.)K2\E5L97<V]"/Y\^H-,L9[:_\
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M.R.QNYD?\3T=9RW_  /--,&L2\/,%!Z_,*V:*7*A&7;Z-&K^9<N9G].U:8
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M%=D %     P .U86J^)[/PW>V]IK5P%^T F*9%XP,9W@=.O4<?E6K8ZA9ZE
M)K&ZAN(_[T3AL?7TJZ:IQ;C'<Y<9+%U8QJU[N-K)ZVMMH_SZ]RS2BDI16IP#
M9(TEB>*1=R.I5@>X/!KC/#O@R3P[XCNH[75;E-/N(C)%"NW[P(R&R". 1@C!
M/X5VM0W-N9T78YCE1@T;CL?\#T-1."DU+JCKP^*J48RII^[+?KZ/Y%*+[;97
MK0@Q%I,LH.523'4CKM;U'(/7CFN<^(&AZGXJTRW@L],C6>&3=YDLR@XQ@A<'
MOQUQTJ+4?B/I\5W!87]K<6^H6]VJS* -@&<%@WH0<_0UW8((!!R#R".]9>Y5
MBX7T.UO$Y?4IXAPL^E]G]SU5G_2/G\Z1XV\.Y:.+4[=$[PNQ3]#BN]^&WB#Q
M%J]S>0:MOEMXD!6:2,(5;/W> ,UZ(#1FIIX7V<DXR=NQT8S/5C*,J=6C'F?V
MENOZ]0HHHKJ/GPI:** "BBB@"M>:E8Z?Y?VR\@M_,.U/-<+N/M5H'(R.17F'
MQ<\/W-U;V^MP%G2V3RIHQSM4G(8?B<'\*N?"_P 6_P!J:>-&O),WEJO[IF/^
MLC';ZC^5<ZKVK>SDK=CV995S9>L;1ES6^)=OZ_6YZ'4%W9VVH6LEK=P)/!(,
M-&XR#4]%=#U/'BW%W3U..T3X<:5H7B'^U;::=@F?*A?&(R??J:[*BBHA",%:
M*L;XG%5L3)3K2YFE;7L%5=2O4T[2[J]?&V")I"#WP.E6JXOXI:D+#P9-"& D
MNY%B ]NI_E^M%2?)!R[%8+#_ %C$PH_S-+_,J>#?&">)M+M]$\J07B)BY?'R
M>4I&3GU.0N/?-=AJ-M>;)KG2Y(X[XI@+*,QR8Z!@"/SKS_X-:=LL-1U)EYED
M6%"?11DX_%A^5>H5CA^:=).1Z&<^SP^/G"@M$_75ZOY=+>1X-X8\7W_A3Q1=
MQZLKB&XG/VR(CF-\\N![?J*]VAFCN(4FA=9(I%#(ZG(8'H17!?$;P-_;EL=4
MTV(?VC$/G1?^6Z__ !0_6G_"N'6[;1+FWU6&6*VCD'V59E(89SN&#SCICZFL
MZ'/2J>REJNC.W-/JN.PJQ])J,U92C^&G];>AWM+24M=I\P%%%% !2TE+0,*K
MW-N9 )(\"91Q_M#T-6**!%".02IN&1S@@]0?0TZENH61S<0KEL?O$'\0]?J*
M:KJZAE.5/(-,0M%+10 E%+10 E%+10 E%+10!C>)]>7PWH<NHM"9BI"K&#C)
M)[GL*I^$/%]MXKM)&6,6]W"?WD!;/'9@>XK;U"PMM4L)K*[C$D$R[64_S'N.
MM>%7=OJ?P]\7*T3-^[.Z-_X9HSV/\C[UR5ZLZ4U+[)]#E6!PV/P\Z"TK+5.^
MZ[?UZGOU>3ZSX)UN?XA&^M;<-:2W"SB<,-J#@G/H<Y^M>DZ+K%KKNE0ZA:-F
M.0<J3RC=U/TK0K6I3C6BK^IP8/&U\MJS45JTXM,#RQ-,DC66-HVY5A@T^BM9
M)233V/.6FQDZ2[1R36<G5#D?UI]G"UE?RQ%@(I1F,9ZTNHRM9W$-RB+@_+(<
M=1Q_A3=7C+0Q7<1YC(.?8]*^;LL/3<5[TJ#NNGNO\]/Q1Z%_:2OLI_FO^":=
M%1V\PG@25>C#-8OC#Q%)X9T,WT5MY\AD$:AB=JY[G%?0^U@Z?M$]+7.6CAZE
M:JJ,%[S=C>HKB?"_Q(T_7&6UOPEC>DX4%OW<GT)Z'V-=O3IU(U%>++Q6#KX2
MI[.O&S_K;N>:?&$'^S-,.>/.8?I6[\-&+>!;/)Z22C_QZJ7Q/TN]U?3M.MM/
MMGN)Q.[;$Z[0O)J3X>W L/ T:SJRRQW$J&-A@[L],=JX9U(TL1*I4=HI;_<>
M]4:J9%3IQUDI[=?M'7W-W#:*#*W7H!U-5K*#S;N2^W95\A >N*RD2?5+PDGK
MU/917100I;PK$@^5:X<%B*F95_:RC:E!^[W;[_UL>+6A'#PY4_>>_H9Z1/-K
MDDCJ0L0X_+BM.L%;N:/66W.<&38P[8Z5OUOD]:G457DO?G=[^?\ P",5"47&
M_9"44M%>P<@E49[Z)]4ATF*Z2.[D0R, 061!Z ]SGBN>\:^.8/#4)M;7;-J;
MK\J'D1#^\WOZ"O.O"OAK5?%^L-J-Q/-' 'W37>2&8^BGU_E7)5Q%IJG!79[^
M R?GP\L7B9<D$M+J]WZ=OS/;)XM*LE*"VBN+AQM"$"21_J3DX^O%<GIOPVTJ
MWU+^TKTFYG:0R^1M A0GG;CG('0?3I766-A:Z;;);VL01% &<Y9OJ3R3]:LU
MLZ496<EL>=''UJ*E&C-I/=]7_E]_S*%IHVEV$ADL].M8)"<EXXE!_/%7J6BM
M$DMCDG.4W>3N_,2L_7KMK#P]J-TC%7BMI&4CLVTX_7%:-<O\0[G[-X&U$C[T
M@2,?BPS^F:FI+E@WY&^"I>UQ-.GWDE^)PWPCEN9/$%_F5S$;<O("Q(9MPP3[
M]>:]@KR_X.VQ":M<D8YCC'ZD_P!*]1K#!*U%'J<2S4LRFETLOP0E%,FGBMH6
MFGE2*)?O/(P51^)HAFBN(EE@E26-AE71@P/T(KIN>'RNU^@^BEHIDB44M% $
M]M_%^%12_P"M;ZU+;?Q?A44O^M;ZT#()_P#CWD_W3_*L#2_^019?]>\?_H(K
MH)_]1)_NG^5<_I?_ ""++_KWC_\ 0131U88L2QK-$T;C*L,&N2U+3\%[>7MR
MK?UKL*J:A9"[AXP)%^Z?Z5G5I\RTW/1HU.1Z['G,<DVG7?HPX([,*V'UJV^S
MEEW%R/N$=Z6]L1<*4<;)5X!/:L"6)X9"DBX8?K7#=H[^6,]66(=.NKB+S8X_
ME/3)QGZ56=&C<HZE6'4&NCTR\BGMDB! D10"OKCN*GN;."[ \U,D=&'!I\MU
MH3[5IV:.3HS72KI%DI_U;-_O-FK,=K;Q?<A0?A1R,;K+H<HL<C=(V/T%#1R+
M]Z-A]1789VCK@4@97X#!O;.:?(3[;R.-S175RV-K/]^%<^H&#5"70HSS#,R^
MS#-2XLI58O<PZ*U1H4^>98\>N#5^VTFV@7YU\U^Y;I^5"BQNK%&)86RW5VL;
M'"XR<=ZZA52&,  *BC\ *P=3A6PO(Y+8^62,X'8U6GO[JZ01N^0?X5&,TT^4
MF47.S6Q/J6HFZ?RHL^4#_P!]&K>G67V=/,<?O&'Y"H[#3_*Q-,/G[+_=K2((
MY(/-'FRG9*R+%BK->Q!?O9X^M=)<-<*F8U4^I')KG+"01WT+'H&KJZT@KIJY
MP8J5I)V,5Y'D/SL3]:95W4-@=   V,DBJGEN(]^T[#WKDG%J36YT4Y)Q3V&T
M4 $D =3Q5R6P9(]R,68=1_A2C"4DVARJ1BTGU*=*01U!%2VT?FW"J>@Y-:5Q
M")XBO<?=/I5PHN<6T9U*RA)19!I[DQ,I_A/%27QQ:MCN0*98*520$8(;!%/O
M5+VQ"\G<,5TQO['Y'+*WM_F9B1O(2$4MCTII!!P1@BMBWA$$04=>I/O5*_CV
MRAQT;K]:YYT'&',=$*ZG/E*E.1VC<,IP15NVL@Z[Y<@'H!5:>+R9F3.0.E0Z
M<HI29HJD92<4:T3^9$KCN*?4-J-MK&/:BXN5MU'&6/05Z"E:*E(\YPO-QB35
M#-<QPCYFRW]T5G274TG!; ]%XJ&N>>)_E1TPPO\ ,Q\LK32%V[]O2F445R-M
MN[.Q))604444@-?PW_Q[7O\ U]'_ -%I6U6-X;_X]KW_ *^C_P"BTK:KV*?P
M+T1\[6_B2]7^8E%+15F0E%+10 E%+10 E8?BK6UT32'=& N9<I%[>K?A6[7B
M'Q%U_P#M#4Y(XG_=+^ZC_P!T=3^)I.2BG)FE*DZLU3CNSC=1O&O;MI,DJ.%S
M_.JE%%>=*3D[L^NITXTX*$=D%%%%26136Z3#GANQK.EB>)L,/H?6M:M#3M)-
M_P#/,,6XZ_[7TIIDR2,G2-&EU2;/*6ZGYY/Z#WKTS0O#JM"HC3R;13U'5_\
M/K5G1- 5HXWDC$=LH^2,#&[_ .M75 !5"J  !@ =JB4^B,)2MHAL,,=O$(XD
M"(.@%.8A5)8@ #G-+7*^(-6,TK6,$FV)1^^D'\JA*[,V[:L+_56NI&M[5REB
MI_>2_P"'M59]?L=,B\NWP!W.>6^M<=JNO$8M;4'&<!5ZDU7MM&FFQ+?2L%//
MEH>1]370J:MJ<KJSF^6FCK&\;1@_>I!XWC_OBL^WTNQB V6T9]R,DU;_ +/L
MY!A[6$C_ '11RP*]G5[FG9^+X96 9A6C+XFMTBSO%<A<^&[*3YK<O;/VV'(_
M(USEYINL0726NPRB0X21/NGZ^GXT>RBS.4JL%JKG97_C15R%:L8^,IW;Y0[#
MV!-26'ARUME5[G_2)^Y;[H/L*UE1(QA$51_LC%.T%LC2-"K+63L4+?QG(A_>
M!A_O BNAT[Q7#<$ L.:S'1).'16'^T :S+G186/F6A^SS#GC[I^HJ6HLMT:L
M-8NYZ;;W23H&4@U8KSC0==EMI_LMUE)%."#7?VUPL\88'-8SARL=.HI(DFAC
MN(C%*@=#U!K&/GZ#+D;I;!SR.\9K=I'19$9'4,K#!![U*9JF9&J:?'J5L+RU
M(,@7((_C'^->=ZAINV_AGB7"/(H=0.ASUKOU+Z#>JA8M83-P3_RS-5->T]89
M1=1 >5*>0.@;_P"O6D7T-(2MH8U8'B)OWL"_[)/ZUOUS6O/NU +_ '4%6:1W
M,NBBBD:&UX:U>72]2B>-]K!PR'T;T^AZ5]#:7J$6JZ=#>0GY9!R/[I[C\*^7
M^AS7KOPQU_>S6$K\3#*Y[2 <_F/Y5V8>=UROH>!FN'Y9*M'9[^IZ=12T5T'D
MB44M% "44M% "44M% "44M% "44M% "44M% "44M)G R>E %>^LX]0L9K60?
M+*I'T/8UP'ARX?3]:>RFR!(3&P/9AT_K7H$E];1?>E4GT'-<)KT(.OF^MFV!
MBL@W#^(=?Y5SUK:-'JX!2:E3:T?YG1:E'E%D Y'!^E9M77O9+JW(2 L''! )
MJALN/^?>3_O@UB>A034;2+^A2^7=RPGHZY'U%=!6'I%C,L_VF52@ PH/4UM5
MM"]CBQ;BZET.HIM%6<Q'=74=I TLAZ=!ZGTKF)[B6^F\R4\=E'05/JD[7-^8
M\_)'\H'\S4'2L)RN['J8>BJ<>9[L  !@4445)T!112.ZHA=V"J!DDT #,J*6
M8@*.23VK'FU"XO)OL]@IQW?O_P#6I";G7;O[-:@K IRS'ICU/^%=':06NEQ"
M&U3S9?XG]342=B)SY=%JS+M/"Q9?,NG)8\G)P/\ &KPT/38QAFB!^F?ZU<:W
MN9_FFD"+[GI3#;6Z_>N1^ J'?L8^T;WE]QG3Z#ITPPDJ(?4$BLR?3K[2#YUL
M_FP]\<C\171&&V[7)_%:88,9\N5'^AP?UI<S1<9M=?O1FV.H17J<?+(!\R'^
ME:NGMBZ ]017.ZE9M9S"]MAM*GYUQTK8TFZ6Y:"9>,G!'H:UC*Y=17@R+QE'
MFTM9,=)"I^A%=+X?E\[P_8OG)\H _45A^*TW:*6_NR*:T?![[_#<'^R[C]:W
MI?&>9B5?#)]F;M2P?ZW\*CJ2#_6_A72>66J***0PJK/_ *W\*M55G_UOX4"9
M'1113$%%%% !1110 5R_CBTDFTFWNXU+"SF\QP.NTC!/X5U%(0&!! ((P01P
M:SJTU4@X/J:4YNG-270\?O65X8&4@J9D((^M6ZWO%/A2RM=/EU+3XI8WBD65
MX(V^0KGYB%[>M8"L'4,IRI&01WKY;$X:6'ERR/H*%:-:/-$BO/\ CRG_ -PT
MWS1%9HV,DJ JCJQ[ 4MWN:W:*-2TLO[N-1U9CP!7?:/X2T[2GCG*R3W2J,/,
MVX(?]D=JO"826(VT2(Q&)C1WW+GAZRDT[P_8VDPQ+''\X]"221^M:=%%?41B
MHQ45T/ E+F;;"BBBJ)//-6_Y#%Y_UU:NK\-?\@9/]]JY75O^0S>?]=6KJO#7
M_(&3_?:O"P'^]2^?YGK8O_=X_+\C8HHHKW3R0HHHH **** "BBB@#"7_ )&,
M_P"__2IKO-QJ2PY^4$#_ !J%?^1D/^__ $J?_F-_\"/\JY*'VO5FF+^PO)&H
MJJBA5  '04ZBBNLS"DXI:* .6^(&G&_\,/*@S):N)1C^[T/]*\>KZ(=%D1D=
M0R,"&4]P:\0\3Z(^A:U-;[3Y#'?"Q[J?\.E?39%B4XN@]]U^IX>:T'S*JO1F
M-1117T)XXH)4Y!(/J*=YTO\ SUD_[Z-,HHL I)8Y))/J32444 %%%*JL[!5!
M9F. !U)H ZWX=::;SQ,MR1^[M$,A/^UT%>PUS?A#13H6AQQM&OVF;]Y,2><G
MH/PK?WR?W5_.OB,SQ*Q&(<H[+1'U.!H>QHI/=ZDU%0^9)_<7_OJCS9?[B?\
M?5>>=A/3A5;SIO\ GFG_ 'U1YT__ #SC_P"^C0!9%+5>*>1IA&Z*,@D$'-6!
M2 4=:@NKDH?*A :4^O1!ZFDN+@JPBBP93Z]%'J:<85@@(&2Q.68]6/K0!6CC
M$8/)9B<LQZL:DHHIB"N9U_QUHN@;HY)_M%T/^6$&&(/N>@JE\1H=?GTFWCT0
M3F-G(N! <.1VZ<XZ]*X_0/A3?WA6?6)?L<)Y\I>9#_05R5JU7FY*<?F?09=E
M^!=!8K&54E_*M]/Q_#YG<^#->/BF*ZU:_,$$-O)MAMPW"<9+L3U//'0=:W+B
MZDU"]MUME_=@DQ,XX8XP7]=H!P/4MZ<U7TGPOHNBPJEEI\(8<^:ZAW)]=Q_I
M27OB#2M$UISJ=XEN6M R;_X@&;('O6D5*,%[1G)5E2KXB7U6#MT5NGHK_P!?
M>9EYX0@N/'5KJ=W=377E6_F".7& ZL N,  #DG'J*ZNL[2+Q=6MAJZHRBZ'[
MH,.1$"=OYY)_'VK1JZ<8I7774YL76JSDJ=1_ K>E@I:2EK0Y JIJ6IVFDVAN
M;R98XP<+D\L>P [FL#QAXWM/"T0A$9GOY%W1Q=%4>K'^E>41P^(_B%K&XEIB
M#RQ^6*$?R'\S7+6Q*@^2"O(][+<CGB(?6,1+DI+J^OI_G]USWM-/>X02WLC*
MQ&?+B;:$_P"!#DG\<>U<QXD3Q#)+'#X2NGVJ2MS)-(KJ#V 9\G/KCBM#0?#*
MZ3IR07=]=:A+CYFGF8H/8+G&/KFMQ45$"(H55& JC  K3D<XZZ?F<*Q$,/5O
M"TTMKKW?N.(O?#7B_5+"SCG\3+!*BD3B!"@/XJ1N_(53M?A:XNH[B^\0W<[(
MP;Y%*'CW+$_C7HM%)X:FW=Z_-FD<YQ<(\E-J*\HQ6_R.<U+P-H6K-$UW!-(T
M0P&-PY)'N2<FG6?@;PU8.CPZ5"70@JTF7(([_,370T5?LJ=[\J.;Z_BN3D]I
M*W:[(/L-H9S-]E@\T]7\L9/XTP:;;J,1&:%>NV&9D7/T!Q5NBJY4<ZJ36S9P
M/B+X7VFL3O=V^I745RW7[0YF4_B3N'YFN#O? _BSPW-]HM8Y9%0Y$]BY)^N!
MAA^5>]45S5,'3F[K1GMX3B+&8>/))J<>S_S_ ,[G/>"9]9N/#4+ZXDBW>X@&
M5<.R=B1ZUT5)2UTPCRQ2N>/7JJK5E445&[O9;(****HQ/(OB[H7E7=MK<,?R
M3#RIR!_$/NG\1_*NR^'FN_VYX5A\QBUS:_N)<]3@<'\L5M:[HT&OZ-<:;<':
MDJ\.!DHPZ&L3P/X,;PE%=F6\%Q+<%0=BD*H&<=>_-<BI2A7YH[/<^@J8^AB,
MI5"J_P!Y3?N^:_X;\D=;11174?/A117/>+/%UCX5L=\Q$MY(/W-N#RWN?04I
M245S2V-:%"I7J*E25Y,Z'BEKPSPQ>>)O%7C6'4([F;]W*'F<$B..//*XZ<CC
M%>YGK65"M[5-I61VYGESP$XTY34I-7=NGD%%-=TCC:21@J*"69C@ >M8/_"=
M>%]Q']M6W'N<?RK24XQW=CCI8>K5O[.+E;LFS>EBCGA>&5%>-U*NK#(8'J*\
MB7X;:Q9>,)7T6[@MXK?$]M+,YR03]W@$\=#[5Z%%XT\-SRI%%K%N\CD*J*22
MQ/0 8JQ<W8\U+E(;F"6($;Y86"%3U#8K&K"G5L[['IX'$8S .45%I35K-:?<
M_N^9;L[N20+#=Q>1>! 7CSE3ZE3W'Z^M6ZP==U5AH<UW;V5S)=P+YL(C3>"P
M]".H/0^V:J>%O'6G^(X)1(/L5W!CS8IG 'U4GK6BJQ4N5O4Y)8*M.DZ\(^ZG
M9^7ZV.JHH'(R.AHK0X0KE/'7A"7Q;8VL<%TD$MNY8;U)5@1ST^E=72U,X*<>
M66QOAL34PU55J3M)&1X9T-/#F@6VF))YAB!+R8QN8G)/ZUKT44XQ459$5:LJ
MLW4F[MN["BBBF9A2T44 %%%% PI:2EH$%%%% PJC/%]F<S(/W+'+J!]T_P![
MZ>M7J, C!&0?6@3*7%+4;Q_8Y G_ "P<X0_W3_=/MZ?E4E,04444 %%%% !1
M17 ^*_B2?#VM2:;;Z<L[1 ;WDD*\D9X %9U*L::YI,Z\'@J^,J>SH1N]^WYG
M?5B^(]!LM<M(3=V_G&UD$JJ.K =5^A':O.V^,.H'[NEVP^LC&N_\):G-XIT1
M-0:]CCD+$/!;J/W1!X#$YSQ@]NM91KTJWN+4]"KE6.RZV(J>[9[W_P C1L]#
MT^V@-QH216GF@-LC&(G_ -Y>Q]QS_*I[6Y6YC) VR(Q21,Y*,."#52>VFTR3
M[0]UY<+M^\ECPB@DX!93D=>XQUYKF[SP3J/_  DG]NZ5KSQS3.'F6895P.@^
M7@KVP:J\H_#$P5.E7;=:K;LVF[OLW^OX:G;45P ^(T^EZI)9>)-(DL@&PLL6
M67'K@]1]/6NUT_4K+5;47-A<QW$).-R'.#Z'T-7"K">B>IAB<!B,,E*I'W7L
MUJG\UH.O+<75J\7&2/E/O4=E&S:?Y-P.1E"#Z5<HK*6%A*O[;K;E?9KS.956
MH<GG<AMH%MH1$IRH)(_$T7-M!>6[V]S"DT,@PR.N014U%;0IQA!0BM%H3SRY
MN:^IY+XI^%LD.^\\/[I$ZM:,<L/]P]_H>?K6W\,7UV\T6Y\Z]1X[6;R$M[F,
MEUP <;LY YQR#C%=_55HC:73WMM$&>0 3HO!D Z'_>&3]1QZ5@L-&$^>&GD>
MW/.JV)PKPV(2D]+2>_S]>^_<;;7"G5XFD4Q2&-H6C;JK9R/J"!P>]4-2TQGU
MV1;<!4EC$KCH Q)!/XXI+K5](U'Q!;Z?%=8O61A)$,JZ;1N7KT8'I^-8C:MK
M>G_$J&SOQY]C>0B*"1(]HXRP)_V@<@UCC*%+$TO95=8MK8BA0JIMPT:@W9]4
MGT[]3L+:VCM81'&/J>Y-3T45VTZ<:<5""LD>/*3D[O<YS5D,>HLP_B 85T$;
MB2-7'1@#5'4M/>\9'C90RC!!]*N6\1AMXXB<E5 S7C9?A:V'QU=N/N2U3_KU
M9UUZD9T8:ZHEHHJC97C75S<<?NTP%_6O5J8B%.I"G+>5[?)7.6,'*+DMD<EK
M/PUMM9\3OJDM\ZV\I#30!.20 ,!L\ X]*[6UM;>RM8[:UB2*"-=J(@P *2*Z
MCFN9(4.3&.3[U/10]D[SI=6_^"=6)QF)K0A2K2NHK1!1116YQ!1110 52N+"
MWU>\BMKF)9+>V99V5APS\A0?IR?RJ[7%^&/%&I:]X@UDV-K&NGJ55)Y<_*0,
M=!U)ZXXQ^-95))-1?4[<)0J3C.M#106^V[M]^YT[R6]OJ=]-\D:!8HV8#&7&
MXX]SAE_.N<\7^./^$:@B$6G3RS3@F-ID,<8QZYY)]N*Z/3([6)9KR692(I'0
M/(PX;/SL?1B<_A@5AZI8:=XRU:#[<9#9VV3!"#M$Q/5B>N..!6%>NH)1YDI2
M=D=>%A0]OSXB+E"*U^2T7],\IDG\4^/KW:!-<JI^ZHV0Q?T'X\UZ_P"#?#\O
MAK0%L9[@32M(96*YVJ2 ,#\JVK6TM[&W2WM8$AA3A4C7 %2DA06/0#)JJ.'5
M-\\G=FF99S+%TUAZ4%"FMDOZ_+\1-Z;]FY=W7&>:=7-6Q:[U97!.2^[/M72U
MSY;F#QT9S4;).R\SS,10]BTKZV"BBBO2.8GMOXOPJ*7_ %K?6I;;^+\*CE_U
MK?6@9!-_J)/]T_RKG]+_ .019?\ 7O'_ .@BN@F_U$G^Z?Y5S^E_\@BR_P"O
M>/\ ]!%-'5ABW1113.LS]1TX70\R/ E _P"^JYNZM%F!BF0AA^8-=I56[L8K
MM?F&UQT<5A4I<VJ-Z5;ET9YU<6,UHV]<LH/#KVJW::TZ82Y&]?[XZC_&MZYT
M^>V)W)N3^\O(K)GTV"<[@-C>J_X5RN+BSM4HS6IH0W,-PN8I%;V!Y%2US4FF
M7,+;HCOQT*G!I%O[^W.UG?CLZYHYNY#I=F7+ZVNS,SG=(A/!7L/I5,1S;OE1
M\^P-3+KMR.J1M^&*=_;TW_/%/S-*Z'R2-2P%P(/](SG/RYZX]ZM5@-KMQCB.
M,?7FH7U6]FX5\?[BT^9$^RDSHI9HX5W2.JCW-9=SK:+E;=-Q_O-T_*LY;*\N
M6W,K<_Q.:O0:1&I'FDR-_='2E=O8M4XK<S\7.H3ECEV[D]!6_I.A,QW 9/>1
MAP/I6MI^C856F78@Z1CC/UK;5510J@!1T K>G0OK(QJXBVD2I;:;;VX!V[W_
M +S<U::-'4JR*5/8BG45TJ*2LCC<FW=G-ZC:BTN<)]QAN7VK7T_4HYH LK!9
M$&#GO63JLXFO6"G*H-OX]ZIABI!4X([UQR?+)\IUNG[2"4CHDB-Y.TK<1Y_/
MVJ^45HRA'RD8Q7/6NKRVZ[2@=:LG7^.+?G_>I4W&*UW9A5HU6]-EL68K4QWJ
MJW*CY@?6M&N<EUB=Y ZJ%(&!4$NHW<WWIF ]%XH@U!-)%3H5*C3DS?>2WM;D
MLS!2R\^U,?5[-/\ EH6_W17+2SQQ?-+(!_O'FJ4FKP+PBL_TX%'.UL:+")[M
MLZG^V42=W5&*MVHDUP-MVQ%<'/)S7'/K,G\,2#ZG-1_VK='H$_[Y-1S.UKFO
MU:&]CN5UZ(_>A8?0T_\ M2UN)(U<[5!R2U<(-5NEZJG_ 'R:>FLO_'$I_P!T
MT^=O1LGZI!:I'I2.DBY1E8>H.:J7<)ENHP/XAS7&0:S"&R'DA;U__56M:ZO*
M'$JR+-VR3GBJG-35F8K#2IN\6=3PJ^@ K/$$EW*TC?*AZ$^E-@U>"X=4<>7G
MKN-:8((!'3MBK:C4]$<WOT=UJS&GA,$NPG/&<U'5F^.;HCV%-%G.4+;,#K@G
MFN*4'S-11W1FN1.3(****S- HHHH V/#?_'M>_\ 7T?_ $6E;58OAK_CVO?^
MOH_^BTK:KV*?P+T1\[6_B2]7^844459D%%%% !1110!@^+M5.E:#*\;;9IOW
M2'TSU/X#-?/-[<FZNGD_AZ+]*],^*>L9N19HW$*;>/[[<G\ABO*ZYL3+:)[6
M44?BJOT7ZA1117(>V%%%:>EZ8;MA+*"( ?\ OJ@3=@TS2VNR)905@'_CU>A:
M+H8*I/<1A8A_JXL=?<^U.T311M2XN$ 0?ZN+'ZFNCJ)2Z(PG.^B"BBCZ\"LS
M(S-;OS9V>R(_OY?E0#J/>O.?$%V+&W\A6RYY<^IKLI)/MM[<W[?ZJ+]W%G^?
M^?6O,M?E-UJ8CS]YP/UKII1U.;%2:7*B?1++"_;)AF1_N9_A%;Z56C4*H5>@
M&!63XAOI(DCLX6*F4;G8=<=,5>LF=#Y</2]#1N=?L+!RGF&4CJD0SC\>E$/C
M#36(#K/&/5D!'Z$UDZ3X=>]4$"KE_P"$9;>,L%)'IBJ]Q:'"Z]9ZI:'36M]:
MWT7F6LZ2J.NT\CZCM4IKS..2ZT>]$T#%&'4=F'H?45Z#IM_'J=A%=1C ;AE_
MND=12E&QT8>O[31[D\LB0Q/)(P5$!9B>PKDY_&3>:PM[0-&#PSMR?RKH-9@D
MN-&NXHOOE,CWP<_TKB].M([A<'K1!*UV3BJM2#48:&]I_BNVNI!%=)]F<\!B
M<J?Q[5T'49'2O/=1T_R"2.E:OA75W\S^S9V)!!,+$]/]FB4%:Z##XN3ER5/O
M-W5+(SQ">$8N(N5(_B'I6[X4U?SX51FYJE63;.VF:^57B.7YU_K^M1;F5C6O
M'DDJB^9ZLIW#-+56QE\VW4^U6JYF:)W1%<V\=W;O#*,JP_+WKE;RXFAM#IL^
M2T,F0WJN.*ZMYD3J17+:]<)/?KLQ\J $^IZU4"H/6QEUR.IR^;J,[=MV!^%=
M=7%W4;0W<L;=0YK4Z(D5%%%(L*U= OY++44,;E&+ JP/1AT-95*K%'#+P0<B
MKA+EDF8UZ2K4W3?4^E]%U;^T[*&24*LSH'XZ./4?CU':M2N ^']ZFJZ/)9M(
M4EA(G@<=4SP<>V>WI7;6MRTI:&90ES']]1T([,/8UZ)\A9K1[EFBBB@ HHHH
M **** "BBB@ HHIKR+&A=V"J.YH&M1U137$5N,R.![=S5"2_FN7\JT1O]['/
M_P!:IK?1LGS+MRS'JH/\S4<U]CH5%15ZKMY=2!]3EF;9:PDGU(R?RIRZ9>W1
MW7$VP>A.?TK9CBCA3;&@5?0"GT<M]P]NH_PU;\S-BT6U3E]TA]S@?I46IZ?:
MK#&ZV\8*MC.T5KU5U$9LG/H0:'%6%&K-S5V1V1!M4X P,4QN&(]Z;IS9MV'H
MU.E_UAJ#9?$Q,T9I**"Q<T9I** .:U",P:E(3]USN!^M1UT%Y9QWD05^&'W6
M':L9]*O(CA ''JIK&46F>G1KQE%)NS1!2%@.I%6TT>Z?_6,J#W.?Y58&C6\*
M-)<3MM49; P *7*RG7IKJ9+SQQH68X4=360SRZU=>3&3';+RQ_K]?:B9FUF]
M*6ZF*S0]2<DCU/O6[9VR6L02+9&H_B;K64IVT1I*5D3VMK':VHA3$$'4D_??
MW-2"X"?):Q<_WB,DTS=;*<G?,_OP*D$]RPVPP[!_LK47.9KN-^RW4QS(<?[Q
MH-D%^_/&M(;:[E^\&/U-)]@N/[@_.E;R'S?WD@-K'VN8OSIIM6_@DC?_ '6I
MWV&X_NC\Z8;28?P9^AI->0U+^\12Q$AHY5.",$'TK'T9FL]7:S8Y&[*_4?\
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M2*TMHU*]7VC<Q]2:T*^:Q=6C4FO80Y4OQ\SV\-3JPB_:RNV%%%%<ATA1110
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MFW/D0I][W]J]&T/1E94N)T B'^KCQU]S[5G^'M(21TBQ^XA&7/\ >-=J  ,
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MO'\Z3)]3^=6C?2?W(Q_P&FF\E/\ ='T44K+N.\NQ!N;^\?SK%UOB:T(ZY/\
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M$FNLFY/\=/P,+P[8:QH>E)9W4T%^RLS&4,5<DG/)/7ZU7\6V7B36=&FL=/\
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M! )ZD9Z&O-S3#8C$45##SY7?S6GJB*=6$:EYJZ.BO]/M])U.[TVVE\R.VD*
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M_CVO?^OH_P#HM*VJ]:G\"]$?/UOXDO5_F%%%%69A1110 5R'Q!E_XE]C:_\
M/:XSCZ#_ .O77UPGC>3S->TVW[)&7/U)/^ HVU!*[2[F93)(8Y1^\16^HI]%
M<I[2=MBC)I<+<HS(?SK.N[(6SJSE'8]#CD5OUE:AF2_BC^@_,UG-)*YTT:DG
M*S9T6C6WV738P1AY/G;\:OT!0H"CH!@45QMW-7J%%%%(05CK^]\5,>T4./\
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M2#_6_A74>46J***0PJM/_K?PJS5:?_6?A0#(J*6BF2)12T4 )12T4 )12T4
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MZMBZR1N'1AU!%1W_ (M\3:UIQTV9(8T<;99(D(9QZ'GC\*]:O?[-O<^8C_\
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M]%%%=9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>QNC%("$8[67T/K703EEMY"@RP4XQZU5U"TA,4ESY>9D7((/I3X;E[G3&G7
MDVGIZBN+ 4YX)3P=2=]'*-M[=?GY'B5I1K<M6*\GZF?HT!:Y,I!VH.#[UNU1
MTJ4RV*Y.2AVU>KKR>A"C@X<CO?7[_P"K&6*FY57?IH+2TE+7J'.+2TE+2 *6
MD%** )$[TA^\:5.](?O&@8C<J?I4$2KY:\#H*G;A3]*@A8>6@]A05$F &.E1
MW2V[6D@N0ODX^;-.>1(8FDD8*J\DFL.YNGO) S?+&OW$_J?>FD5&#F[(II:6
MY!S A&3M+*,X[9]Z4V5J>MO%_P!\U(TJIU-1&ZBP?F%.R/03:5KF'XBLK$6+
MYAC''85X#K"6D.N1-(FZW693(H[J#S^E>L^.M9,$#*C5X\+6759GE=]D><9Q
MDFLJKA"+<M$3"C6Q554J*YI'MFN:YX>?PE<N]W:RV<MNRQ1JP.XD<!1ZYQ]*
M\,L;!KA2127^DO:1>=&_F(/O<8(IVGWLELH)!56Z$C@UY>58&GA*<O93<KLT
MQ]*M2JJGB8<K2&20FSO8]\CI%O42%3@[<\_IFO>M1M- ?PE*)4MAI@MRP< 8
M QP0?7^M>%:A<1W SG)K.4S2*MLC2,F<K'N)&?ITIYCEKQDH2Y^7E?\ 7S,*
M6(<+P2NGT-CP_(?M"C/6NGU/PW<7T'F*A(QU-<C!!>Z>1,8B%')P<XKO_#7B
M-)HA',01[UZ<7&>J=PE2J4?<JP<7YJQQ6H'6;>S^P3ZA=-:+P(#*=GY5A[<5
MW7C"Y@D<^6!SZ4ZV^%>L76CI??:+=)W3S$MFSN((R 3T!K"MB,-A$O:-1N_Q
M_KJ8>SG4=HZV,2S?5]9CCM)[^ZGMU(VQ/*2H_"O6?!GALV:*[KS7GW@N18K\
M12KAU;:P/8CJ*]YTT(;9"H'2NF$(Q5HJQI25]6/>QBD0!E!JA>Z7;06DL@09
MQ@?CQ6U6=K3;;)5_O.*<W:+9U0BG)(X75%2,QQ*,8&XULZ;#Y%A$O=AN/XUA
MWY\W4F7W"UTX7: H[<5PQW/0J:12,G6;TQ*+>-L,PRQ'IZ5A5/>RF:]E<_WL
M#Z5!4-W9K"/*A:6DI:!L44M%**9+#%+12T$W$I,4ZDH"XVD-.-(:"D-IIIU(
M:12$K8T*;#RP'H1N%8]2VUPUK<),HR5[>HH3LQ35U8Z#5H?.L'/=/F%5=&F/
MD%>\;<?2H[O65FMFBBC92XP2QZ5#H[8N'3L5S5-ILB$6HV9Z);PPO:QMY:G<
M,Y(ID]E$$9URA SUXJ'3;I18H&#$J.PS4<]R\YQ]U?[M.4J:@KK4X(PJ>T=G
MH:/AK_CVO?\ KZ/_ *+CK;K$\-?\>U[_ -?1_P#1<=;==E/X%Z(\FM_$EZO\
MPHHHJS,**** "O'?BPF-5=CT*1G],5[%7DOQDMB464?Q6X/Y/_A4R5XOT-:$
MN6M!^:/';BZ+Y2,X7N?6JHX.1P:**X#ZENYKV/B.^L\([^?&/X9.H^AKH[+Q
M)876%=S!(>-LG3\^E<+118#W?P[>!X&M'/S1_,ON*W*\H\*ZXTJ1J7 N[?U_
MC6O3K&]COK<2Q\'HR]U-83C9W,Y+J6:***@@*R-?0K!!=J.8) 3]*UZBN8%N
M;:2%NCJ133LQK<<KB6)9%Y##(KA/&EF7B9L5U.A3EK1[23B6W;:0?3M5?Q!9
M?:;1N.U7!\LC*M&\6CRCPZ^RXN8#U.&'\JZ9!D8-<E=))I.JK.%.%;YAZCN*
MZJVFCN(4EB8,C#((KIFM;DX2:<.1[HY2:*XT.]/RMY1.8W'0C_&M!?%LXCVA
MS72A5=2K*&4]01D&G)866<_8[?/KY2_X4^9/=&4L*T_<EH<5+>ZAJTFR"*24
MGT''YUK:1X5\N5;G4"'<'*Q#D ^_K74@#:%0!4'8#%!I.>ED53PL4^:3N--<
M]KGB$Z;<I;V\:2R#F3=G '8<=ZV-0NQ8V$]R<$HO /<]!7+:1I#:I*993N=S
MEB>YI12W9>(JRC:$-V7;;Q;;. +BWEB/JOS#_&K\6OZ7+TNT4_[8*_SJ9O!:
M[,@"LNX\'NK' H]QF2KUX[JYM+>6SC*W$3#U#BF/J%E%_K+N!?K(!7-S>&&B
M4DBN?O+7R'(IJ"?4)8Z<5K$](M[F&ZB\R"5)$SC<IR*E[<#)]*XSP:\@O;B,
M$^48PQ';.>/ZUV=1*/*['90J^U@I&)'XGLFF:*6.>%E)4[ER ?PK7AFBN(Q)
M#(KH>A4YKG[;25O]:N\#Y3(<5MMH<FCQFXC) ) V=F-.2CT,*5>IS6DKHMQR
M-%(LB'#+T-8?B"4B"*,GEG+&MME9&VNI5NX/45F:U:B>R,@'SQ<CZ=Z@[HVO
M<YBBBBD:A1110 5[7\*D*V%T?]B(?H?\:\4QG@=:]X^&L!BT2X<_Q2A1^"BN
MK#=3Q<X>D%YL[6BBBNH\4***CGD\N!W]!Q0"5W8I$?:]1"]47^0J[C[&V5'^
MCD\C_GF?4>W\JBTN+;$TIZL<"K_48-3'N:UGKRK9!U&1158?Z(P4_P#'N3P?
M^>9]/I_*K)( )/ %,R(YIE@B+MVZ#UK,CB>^F,TQ^3L/Z4YRU_=8Y$2U> "@
M # '05/Q&[?LE9;O\       %+115F 5F:YJ\>D6)DX,S\1IZGU^@J?4M2M]
M*LVN;AL <*HZN?05YW)-=>(=3::4D+WQT1?05G4GRZ+<Z</0YWS2V1/I%J][
M>->W!+*&W9/\35NW4^U-@/S-U^E1*8[2W"H,*HPHJFTA=BS'DUSGHQ]^7,]D
M2 TC98A1U)IH-2VHWW2YZ+S2.GFLKFQ& B*HZ 8JKJ,I$:Q@_>.34X:LZZ?S
M+HCLO%7+8YZ*O.[&J,"E(R*;FES69UW+VGW)_P!0YY'W3_2M#-8!R"'4X(J/
M4M;F.RULQB=A\[#L?05:E9:F%2E>5XF]/=6]NN9YHXP?[[ 9K OM2TI<M!*Q
M?^ZBG'ZU4CT?S#YEW,[R'J ?ZU<ATVR0_P"K3/\ M@FLI5DRX04-;F:=;).(
M[=F/;)H^W:G+_J[3:/78?ZUT<*+&,1-;+[;<58 NQ]QHC],5/,V4ZUNARF-;
M;T7_ +YI#)K,/+1AQZ  _P N:ZMI;Q/OPJP^E1>?;RG$T&P^JTG)]P55OI]Q
MSUOK,;-LN4,3],]O_K5IJP90RD$'H13[[1X+J(NH$B_WU^\M8*23Z-<B*4E[
M9CP?ZBJ4NC-8R4MC<HI%974,I!4C(([TM6,*U--7$#-_>:LNMJ$""T4GC:N3
M_.A'/B7[ENYR5XO]H^-(X1T\U$_ <UZ.>M>>^$4-]XF>Z89"*\I]B>G\Z]"K
MHH+1L\W,':<8=D%20_ZS\*CJ2'_6?A6QYY9HHHI#"JTW^L_"K-5IO]9^% ,C
MHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBEH XC4/^0E<_]=#72Z%_
MR"H_JW\ZYK4/^0E<_P#70UTNA?\ (*C^K?SK*'Q'%0_B,T:***U.T**** "B
MBB@ HHHH P5_Y&0_[_\ 2K'_ #&_^!'^50+_ ,C(?]_^E3_\QO\ X%_2N3#_
M &O4O%_8^1K4445UD!110< 9/04 %1SSPVT1EGE2*,=6=L"N3U[QU;V1>VTT
M+/..#(?N*?ZUP%_J=YJ<QEO+AY6[ G@?0=JZ*>'E+5Z&4JJ6QZ-?^/=)M"5M
MQ+=N/[@VK^9_PKG[GXBZC(2+:UMX5[%LL:XZBNF.'IKH8NK)F_+XTU^4_P#'
M[L_ZYH!4/_"6:]G/]J3_ *5C45I[.'8GFEW-Z+QGK\1_X_M_^^@-:=M\1-2C
M(^TVUO,.Y *G]*XZBDZ4'T!3DNIZA8>/M)NB%N5EM&/]\;E_,?X5TT%Q!=1"
M6WF26,]&1LBO":LV6HW>G3"6TN'B8?W3P?J.]8SPJ?PFD:SZGN-%<;H/CN"[
M*6^IA8)CP)1PC?7TKL@00",$'D$&N.<)0=F;QDI;!1114E!1110 A=595+ ,
MW0>M+4;1)-<*CC(*'\* 6BD$4O)/W'[-_P#7H$2CJ*L3_P"K_&JXZBK$_P#J
M_P :!E:BBB@ HHHH 6BBB@ HHHH 6BBB@ HHJ&[8K9SLIPPC8@_A45)\D')]
M!Q5VD3T5@Z#(QN)4+$J5SC/?-;U<N7XU8V@JR5K]#6O1]C/DO<****[3$*6B
MB@ HHHH ****0"T444P"N67YM>'O<9_\>KJ:YRWM9O[=YC;Y9-Y..,>M?/9[
M"4Y4%%7]X[L$TE-OL='12,RHI9R%4=236)?:YUCM/H9#_2O4QF/H8.'-5?HN
MK.>C0G5=HHW,C.,C/I2US^D6ETUTMVY94YR6/+5T%++\7/%TO:R@XZZ7ZKN%
M>DJ4N5.X4445VF(4M)2T %%%%, I:2N:U.:YM=7,F]N,,G/&WTKS\QQZP5-5
M)1NF[>GF;T*+K2<4['344R&59X4E0_*XR*?7=&2DE);,Q:L[,***6F(****
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MFMQ5'[I=+A5)/0#-9@8LQ8]2:L7,FV ^_%5%/%$@HZ*Y,#2YJ,&G U)O<?G
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M'JQ^FNSZO"['+,^2:ZRN2TK_ )"EO_O5UM47(YG71C43[H*S*T]=_P"0C_P
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MSK?PWZ'-NRH&9B HY)]!6?MN-2B)W^1;., !<LX]3GI4VK$C3;@C^[C]:M*
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MX>.L^=G?TKR\3D]*M7IUDVN7HNNMS>KCL55O[9\S?<R/"UM)+;LN#D<BO0-
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M&G,WWYR1],U8BT^!#D@N?]KI4\A:2(FEN=1.R,;(>YK1MK>.VCV(/J3U-"X
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M'E*%.<UML:;W$**6>154=S6'?ZVTF8[7*KT+]S]*DN2VL9CML!83R6. Q/\
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M2#^*HY/]8U %/4F5-*O'8X58')/H-IKR&35IFMHX(1Y:J@4MW/&/PKUK6_\
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MHHHK,T"BBB@ HHHH **** -KPS_QZWO_ %]'_P!%QUMUB>&?^/6]_P"OH_\
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M2KD _B;\!5V*<K*YH6Z[?F;KV'I5?4=1V@P1-\Q^\1V]JKWFH>0OEQG]X?\
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MSQQ!9&!SD]^3UJW115&Z5E8****!A1110 4444 %%%% !1110 4444 %%%%
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M)Z(.@J[BBO1I8*HJGM:U5R?;:/W+]682JQY>6$4OQ84445Z!@%%%% !1110
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MWGA.6.)I.]M6M5\O^"3#"JK=TY+Y[G445S\>O3K_ *R)'^G!K;MYEN+=)E!
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MV%-?I3J8_44 A0, 4M%%,04444 %%%% !3)88IX7AFC22)QM='&58>A%/HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?M5Z""*VA6&% D:C@"EAACMX4AA14C0855Z"GT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 @ZTM(!S2T@"D/44M(1S3 6BBB@ HHHH **
M** "BBB@ HHHH *.1110!FWWA[1=39GO](L+EVZO-;(S'\2,UA2_"SP1.Y9_
M#MN"?[DDB_H&KKZ*0[LXE?A'X'5MW]BY'H;B3'_H56X/AIX,MF#1^'[;(_ON
M[_H6-=7119!S,I6>CZ9IQ!L=-L[9@,;H8%0_F!5VBB@04444P"BBB@ HHHH
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MO';1!$'U/<U+0D#?1!5NQM1/<)YAQ%GGWJ:PTM[K$DF4B_5JVY+:(6S1I&H
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M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6GQ??_
M  J.GQ??_"@">BBB@85#+]_\*FJ&7[_X4 ,HHHIB"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #O4TOW/QJ'O4
MTOW/QI 0T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,WX(Y+^QM8_Y]K7_P "3_\ $4?V-K'_ #[6O_@2?_B*ZVBCZM2[?F'URO\
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MMA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %/B^_^%,I\7W_ ,*0$U%%% PJ
M&7[_ .%35#)]_P#"@!E%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 =ZFE^Y^-0]ZFE^Y^-("&BBBF 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $L7>F/]\T^+O3'^^:0#:***8!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4^+[_X4RGQ_?_"D!-1110,*AD^_4U0R??H 91113$%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4  ZU-+]S\:A'6II?N?C2 AHHHI@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+%WIC
M_?-/B[TQ_OFD VBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %/C^_3*?']^D!-11
M10,*AD^_4U0R??H ;1244"%HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %[U+)]S\:B'6I9
M/N4 144E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T
M4E% "T4E% $L7>F/]\T^+O3'^^: $HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %IT?WZ93X_OT 34444#"
MH9/OU-4,GWZ &T444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **Y;5_'%AITC06R&[F4X.TX0'Z]
M_P *P#\1-2WY6TM0OH0Q/YYIV ](HKC--^(-K,XCU"W-N3QYB'<OXCJ/UKL(
MY(YHUDB=71AE64Y!% #Z***0!1110 4444 %%%% !1110 4444 %%%% !111
M0 #K4LGW*B'6I9/N4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45B:_
MXDM="BVL/-N6&4A!_4^@K@;WQEK5XY*W1MT[)"-N/QZT[ >LT5X[#XGUN!PR
MZE<,1VD;>/R-=;H7CI+F1;;5%2)SPLR\*3[CM18#M:***0!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%<[XA\66VBDP1J)[S_GF#PO\ O'^E,#HJ*\CN_%^M
MW;D_;&A7LL(V@?CUJ*#Q1K=NP9=2G;':1MX_7-%@/8:*XK0O'<=S(MMJBI"Y
MX69?ND^X[5VM !1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH DB[TU_OFG1=Z:_P!\T -HHHH **** "BBB@ HHHH **** "C!/K7&
M>(_&PLIGL]-"R3H</*PRJGT'J:X>ZUC4;URUQ>SR9[%S@?ATIV ]KP1V-%>(
MV^IWUHP:WO)XR/[KD5V.@>.I&F6VU;:58@+.HQ@_[0_K18#O:*0$, 000>01
M2T@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **I:IJEMI%DUU=-A1P%'5CZ"O-
MM4\9ZIJ#L(93:09X2(X;'NW6G8#U;!]#17AK7=RS[VN)2WJ7.:U-.\5:OIS#
M9=--&/\ EG,=P_Q'X46 ]>HK(T'Q!:Z];%HAY<Z8\R(GD>X]16O0 4444@"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJO?7MOIUG)=7+A(HQD
MGU]A[T 6*,'T->8:OXXU"]D9+)C:6^>-OWS]3V_"N=>\NI7WR7$K-ZLY)IV
M]QHKQVP\2:MIS@PWDC(/^6<AW*?P->A^'/$]OKL9C91%=H,M'G@^ZT6 WZ**
M*0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z/[
M]-IT?WZ )J***!A44GWZEJ*3[] #****8@HHHH **** "BBB@ HHHH ****
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M?XT 7**I?VSI7_03LO\ P(3_ !H_MG2O^@G9?^!"?XT 7:*I?VSI7_03LO\
MP(3_ !H_MG2O^@G9?^!"?XT 7:*I?VSI7_03LO\ P(3_ !H_MG2O^@G9?^!"
M?XT 7:*I?VSI7_03LO\ P(3_ !H_MG2O^@G9?^!"?XT 7:*I?VSI7_03LO\
MP(3_ !H_MG2O^@G9?^!"?XT 7:*I?VSI7_03LO\ P(3_ !H_MG2O^@G9?^!"
M?XT 7:*I?VSI7_03LO\ P(3_ !H_MG2O^@G9?^!"?XT 7:*I?VSI7_03LO\
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M^YIB*_BKPCIFBZ&UW:F<RB15^>3(P3SQBN&KTKQ3(\OPZLY)&+.R6[,Q/))
MR:\UH0STSP'JKWNF26<S;I+4@*2>2AZ?ER*ZRO,O 5RMMJURT@E*&#'[N)Y#
MG<,<*#[UZ!_:MK_<N_\ P"F_^(I,"[15+^U;7^Y=_P#@%-_\11_:MK_<N_\
MP"F_^(H NT52_M6U_N7?_@%-_P#$4?VK:_W+O_P"F_\ B* +M%4O[5M?[EW_
M . 4W_Q%']JVO]R[_P# *;_XB@"[15+^U;7^Y=_^ 4W_ ,11_:MK_<N__ *;
M_P"(H NT52_M6U_N7?\ X!3?_$4?VK:_W+O_ , IO_B* +M%4O[5M?[EW_X!
M3?\ Q%']K68^\TZ#UDMI$'YE10!=HJ*"Y@NDWP31RKZHP.*EH **** "BBB@
M HHJ*XNK>U4-<3QQ ]-[ 9^GK0!+15'^U[,_=,[^Z6TK#]%I?[5M?[EW_P"
M4W_Q% %VBJ7]JVO]R[_\ IO_ (BC^U;7^Y=_^ 4W_P 10!=HJE_:MK_<N_\
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M76A10!G_ -BVG]^\_P# V;_XNC^Q;3^_>?\ @;-_\76A10!G_P!BVG]^\_\
M V;_ .+H_L6T_OWG_@;-_P#%UH44 9_]BVG]^\_\#9O_ (NC^Q;3^_>?^!LW
M_P 76A10!G_V+:?W[S_P-F_^+H_L6T_OWG_@;-_\76A10!G_ -BVG]^\_P#
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M%M/[]Y_X&S?_ !=:%% &?_8MI_?O/_ V;_XNC^Q;3^_>?^!LW_Q=:%% &?\
MV+:?W[S_ ,#9O_BZ/[%M/[]Y_P"!LW_Q=:%% &?_ &+:?W[S_P #9O\ XNC^
MQ;3^_>?^!LW_ ,76A10!G_V+:?W[S_P-F_\ BZ/[%M/[]Y_X&S?_ !=:%% &
M?_8MI_?O/_ V;_XNC^Q;3^_>?^!LW_Q=:%% &?\ V+:?W[S_ ,#9O_BZ#HUJ
M>LE[_P"!TW_Q=:%% &?_ &+:?W[S_P #9O\ XNC^Q;3^_>?^!LW_ ,76A10!
MG_V+:?W[S_P-F_\ BZ/[%M/[]Y_X&S?_ !=:%% &?_8MI_?O/_ V;_XNC^Q;
M3^_>?^!LW_Q=:%% &?\ V+:?W[S_ ,#9O_BZ/[%M/[]Y_P"!LW_Q=:%% &<=
M)"\P7MY$?>7S!_X_FHV.HV?,L:7D0ZM NUQ_P$DY_ Y]JU:* *5M=0W<7F0.
M'4'![%3Z$=C4U5KW3V>4WEFRQ7@&,G[LH_NL/Z]12V=VEY"752CJ2DD;=48=
M0:!%BBBHKBXCM;=YI20BCL,DGL![D\4 -N;J&SB\R9L G"@#)8]@!W-0+!?W
MV&F<V4)Z1QD&4_4]%^@R?>I+"SD>3[=>J/M+#Y(\Y$"^@]_4UHT#*46D6,3;
M_LZR2?\ /28F1OS;)JVJ(HPJJ!Z 4ZB@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/
M048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3
M ]!1@>@I:* $P/05C^*=/.H^';J"-<R!=Z =R.:V:* /G_IUKT_P-H5I;Z3#
MJNSS;N=206_@&2,#\NM8WC#PA+;SR:CIT1>W?YI8E&2A[D#TKD$O;N)!''=W
M,:KP%65E _ &JW$>@:YX8\0Z_=^9/=6D<*_ZJ$.V%'Y<GWKSZ[MGL[R>VD(+
MPR-&Q'0D'%/_ +1O_P#G_N_^_P"_^-7=&T&_U^[Q"K>7G,D[YP/7GN: .E^&
M^GLUQ=:@ZG8JB)#ZGJ:]$P/055TW3K?2K"*SMEQ'&/Q)[DU;J6,3 ]!1@>@I
M:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z
M"EHH 3 ]!1@>@I:* $P/04UXHY!AXT8>C*#3Z* *#Z-9EB\"-:N?XK=MGY@<
M'\0:@>6\TX9N@+FV'6>-<.@]67O]1^0K6HH JQR)+&LD;*Z,,JRG((I]9T\/
M]D3&YA'^A.<SQCI$?[ZCT]1^-:(((R.10(*3H,FEK/93JUR\ W"QA;$K X\Y
MQ_ /]D=_4\4 "W=Q?L5TY4\H'!NI!E<]]H_B_0>]3+HUNV#=O+>-W\]LK_WP
M/E_2M!55%"JH50,  8 %+0,CC@AA&(XHT [*H%/P/04M% "8'H*,#T%+10 F
M!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10!SGC72VU'P](8EW2P$2J!W Z_
MI_*O(NU?0!&1@]*\X\4^"9HYY+[2H_,B8Y>W7JON/44TQ,6U\%:=JV@176F7
MLGVMD4GS&!0-_$" ,CO6_;HGA;P@\&K7*3$*X"Y)#9Z(,UY6LMS9R,B2S6[Y
M^958H?Q%-EGEG8&::25AP#(Y8_K3L SO7??#C3&WW.IR+A<>5'GOW)K#T#PA
M?ZQ*KS1O;6G4R.,%AZ**]8M+2"QM8[:WC"11C"J*&P1+@>@HP/04M%2,3 ]!
M1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!2-&CC#(K#T(S3J* *$FCV+L
M7CA\B3^_;L8S^.WK^.:@<7VG@E\WML.K  2J/<#AOPP?:M:B@"I#-%<PK-"Z
MO&XRK+T-251O(&T^9K^U0M&QS<PKW']]1_>'?U%7$=9(UD1@R, 58="#0(=1
M16?<;]1NFL(R5@0 W3@X)!Z(/<]_;ZT +]JGOI6BT\((T.'N7&5!]%'\1_2I
MXM'M5823J;J8'/F3_,0?8=%_ "KL<:0QK'&H1%&%4#  IU P  Z4444 %%%%
M !1110 4444 %%%% !1110 5S?C;27U/06:%=TUNWFJ.Y'<?E_*NDHH \ 1M
MKJXYVD'\J[=?B5<A0/[,A.!C_6G_  JUXF\"O-,][I 7<YR]N3@9]5_PK@[F
MSNK-RES;RPL/[Z$56XCUS6_$(TS04OXDBFD;9F/?_>_PKQ^5_,EDD(P78MCT
MR<TL%M)<.!;P/*QZ"-"Q_2NS\.^ [B>9+G5E\J%2&$&?F?Z^@HV U_AYI36N
MFRW\JX>Y("9Z[!W_ !/\J[.D1%C1410JJ, #H!2U(PHHHH **** "BBB@ HH
MHH **** "BBB@"I<Z99W3;Y(%$O:5/E<?\"'-5)/MFF#?(6O+4=6"_O8QZD#
MAA],'ZUK44 58Y$FB66)U=&&59>013ZS[B+^R;@W,0 LI6_?I_SS8_QCV]?S
M]:T*!!4<\\5M"TTSA(U&2QIY(4%F(  R2>PJC9Q'49UU"=?W"\VL1[?]-"/4
M]O04 "1WNHC<S-9VQZ*!^]<>_P#<_G]*N6VG6=HQ:&W19#UD(W.?JQY-6J*!
MA1110 4444 %%%% !1110 4444 %%%% !1110!X]XPTIM+U^;"XAG)EC/;GJ
M/P-0^&CI!U3RM9C#6\B[5=G90C>^#WKU;6M%M=<L3;7((/5)!U0^HKRS5O">
MJZ3(VZW:>#/RRP@MD>XZBJN([*U\)Z38ZXFJPZ@B6T9WI#N! ./[Q/3O7*^-
M-;AUG5D%JP>WMU**_P#?)ZD>W KFBBJVTH WH1S6IIOA_5-5D"VMI)M/_+20
M%5'XF@"OI>GRZKJ4%E$,F1L$^B]S^5>Y0Q+!!'$@PB*% ]A6+X;\,V^@6Y.[
MS;J0?O)2/T'H*W:38(****0PHHHH **** "BBB@ HHHH **** "H+FRM;M0M
MQ;QR@=-R@D?0]JGHH RWLKNR^:RD,\0ZV\[9(_W7//X'/U%2VEW%>1%X\@J=
MKHPPR'T([5?K.O[*3S1?6:C[4@PR]!,G]T^_H>U %JBHK>XCNK>.>(DHXR,C
M!'L?>I:!!5!KN:ZG>WT]48H<23N#L0^@_O'V_6ENFEN[G^S[=B@P&N)1U1#T
M4?[1_0<^E:,,,=O"D,*!(T&%4= * *<>CVQ827>;R;KNGY /LO0?@*O@!0
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MT6:26"*3RF9XF3YL ]#]:W: "BL'Q5XQT;P98PWNM3R0P32^4A2(OEL$]![
MUK6-Y#J.GVU];,6@N8EFC)&"58 C@].#0!8HHIDLBPQ/*YPJ*6/T% #Z:R*_
MWE#?49K&\+^+-(\8::^H:--)+;I(8BSQE#N !Z'ZUMT -6-$^ZBK]!BG444
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MO+B0);PQF623J%4#)/'M7B'CWQ9\+M6\$W^F6#6K7D4)^Q>382*%D'W=KA
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M+=>#),X49].>_M7D?A+_ ).7\5_]@]O_ $*"L3QGK^A7_P <&M?%\Y70]'A
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M]=WOG->7_!C3I-(^*7B[3I9GF-M'Y0D=MS,HD 7)]<8H ]YK-U'_ )".E?\
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MV^FNZ1QM)(RJB@EF8X  [FG5YM\<]6NM*^&ER+5RC7<Z6SL#@[#DD?CMQ^-
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MNRODAC:[OMTLLQ7YB,D*N?0 4 ='X4^(?ASQDTD6E7;"ZB&7MITV2*/7'?\
M#-;&M:[I?AW3GO\ 5[V*TMEXWR'J?0#J3["O'_BK%#X:^*O@W7M-C$%W=2M'
M<&/Y?-560<XZY#D'VQZ4_P ;6Y\6?'K0O#FH$/I=I +@P$G;(<%CD>^ /I0!
MTT'QQ\&2S*LDM_;V[L56ZFM6$3$>A&3^E>A6EW;WUK%=6D\<]O*NY)(V#*P]
M01574-$TW5-)ETN[LH9+.6,QM$4  &.WICL1TKR?X%W%U GBGPN]R[P:;=E+
M=S_#DLK?JH./K0!V&N?%GPKH>IOIK3W-]>QDB2&QA,I3'7)Z5I>%?'WAWQEY
MJ:1>[[B)=TEO*A21!G&2#UY],UY#X9U36?@]=ZM:Z_X5O+VTN;DS?VG:C=D=
M!SC!SUP2",FNY\$ZO\/?%GB^XU_1(Y(/$;18FCF9XW*8"GY-VP]!G&>>: -7
M^U?")^*7]E?V9_Q4OD^;]J\@?=V_W\YZ<=*\Z^)WQ/\ ,US1;/3'UFSAM;\B
M^0PF,7"JZ<+S\_1N..OO6H/^3I!_V#S_ .BS3OC< /$7@/@?\A+_ -GBH ](
M\+>*K+Q;837EE;7L"12^4RW</E,3@'(&>G/6MVD  Z "EH *S9_^1AMO^O27
M_P!#CK2K-G_Y&&V_Z])?_0XZ $L?^0UJ?TA_]!-:=9EC_P AK4_I#_Z":TZ
M"BBB@ HHHH **** "BBB@ K"\6^+--\&:-_:NJ"<VWFK%^X3<VXYQQD<<5NU
MY9^T#_R3)O\ K]A_]FH V[SXL^%+/7K/1?M4T]]=21Q;(8]PC9R  YS@'D9Q
MG%;GB;QAH7A"T2XUJ_2W$F?+C^\\F.NU1R?KTK-\!>%='T7PEIHMK*$S2P)-
M-.Z R22$ EB>N<_E7E.K>(;:/]H#4KS5M)U'5HM+A6*SM[* 3&,[5.XJ2!U9
MCGU(H ]'TOXP>%-2U*&PDDO-/FG($)O[<Q+)GI@]/SQ78ZIJMCHNFS:CJ5U'
M;6D*[I)9#P!_4^PZUXK\1O&%GXT\(7&F0>"_$JWP*O:S3Z> (V!&3D,2.,CI
M5[Q7X<\2>,?@?X?CMX99-3M1%-<6TIVO*%1E/!QEN0<'W[T ;Z_''P<9%+-J
M*6K.4%XUHWDD_7K^E=K)XATU?#4OB"&X%QIT=NUSYD/S;D4$G ]>.E>3I\6]
M"_LD>'O&?A+4-)1X?(FC\C,07&.!\K*/H#CUKJGMO#EM\%]87PHRMI#:?<O%
MME9\$HVX98D@Y['I0!U'A;Q1I_B_0X]7TP3"UD=D'G)M;*G!XR:JZKXXTG1_
M%>F^&[H7/V_4,>24C!3DD<G/'3TKE_@-_P DKL_^OB;_ -#K!\??\E_\%?1?
M_0FH E_: _X]?"__ &$#_P"RUT'Q3\=Q^&=#O=.@74H]2FM#);W5O!F.,YP,
MOGCI7/\ [0'_ !Z^%_\ L('_ -EKMOB@!_PK#Q"<#/V-OZ4 <W\(_'MMJVA:
M5H<\>J2ZD(7>6ZGA)B<AB3^\)YZUN^&-4\(W_C;7;;1],\C6K)GCO;@P!=Y+
M_-AL\Y9<T?"(#_A5>@' SY#?^AM7&_"__DLWQ!_Z^&_]&M0!W^H_$#0=)\5_
M\(]?32P70MC=-*Z@1+& 226SZ*>U8"?'+P0VH+;-=W4<;'"W4ELPB;W!ZX_"
MN1\5:)::_P#M*:78WT:RVWV-)7C;D/L#M@^HXKT3XF:/I]]\-]9CGM(BL%JT
ML6$ ,;*,@CTZ?E0!U\,T5Q DT,B212*&1T.0P/0@]Q7$ZU\6O"NC:J^F>?<W
M]Y&2)8K" S&,CKDCCCVS7-^#-7O+']FTZE%*?M5M8W7E.>=NUY OY #\JT/@
M9H]I9?#FUU!$5KJ_D>6>4@%B0Q4 GT&/U- &B/C!X1D;3$M[N>XEU"X^S)%'
M%\\4F5&)%)!7EAZ]Z[RO#?BSHMA9_%#P/JEM#'%<W>H1)/L &_9+'AC[\XS[
M5[E0!A^+[S2-/\*WUWKUM]ITR%0T\7EA]PW #@]>2*7PQ=:1-X3LKW1;7[-I
M<D/G0Q! FU3D]!T[UB?%W_DE6O\ _7!?_0UI_P .O^22:)_V#Q_(T 4H/C+X
M/FT'^UVNKB*)IVMXX'A_?2N "=J@G(^8<U=\+?%+PMXNO38Z?=R17O.VWN8_
M+=L=<=0?IG->?_LYZ#8MH>I:W+ DEX;G[.CNN3&H4$X],EAGZ"I?B_8V^G_$
M+P5JMG&L%Y->I%)+&-I=0ZXSCKP2/I0![=1110 4444 %%%% &=K/_'M;_\
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MFC?\>/\ V\3_ /HYZ7P__P @2W_X%_Z$:31O^/'_ +>)_P#T<]+H'_($M_\
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M/:E)-H/BW1[4W4^B7 EE@0$L4#!P0/0%3GZ^U>KQ11P1B.*-(T'14& /PI]
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M(YS"49PQ. #GCZUU;HLB,CJ&5A@JPR"*9!;06J%+>".%"<[8T"C/X4 ?/_\
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M=7_UNF_]?B_^@M0 7O\ Q_:7_P!?3?\ HF2M*LV]_P"/[2_^OIO_ $3)6E0
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MG4*)KBWV);$GDDG@GK[5ZW10!YUXRM=3LO@9J=OK-Z;S4EL?](GP!N<L"<8
M&!G'X5R'PW\::GX0\"Z=!K&A:A>:9*IDL[VQ3S0%).4=>H(.:].^(6F7FL^
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M7RC'>1[&)P#D>HYZUT5%% !6;/\ \C#;?]>DO_H<=:59L_\ R,-M_P!>DO\
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M^C18Q??;4$38&-Y7.?>M/X7>!+WPA9:A>:Q<QW&KZI-YUP8Q\J<DX![Y))-
M'/7EI=']IBQNA;3FW%B09A&=@/EMQNQBO3]>TF+7M O])G)6.\@>%B.V1C-:
M-% 'BOA+Q7K/PUTL>&/$_A[49HK1F%I>V,)ECD3.<<>Y/]>E;WAG5O&?BWQR
M-6>VO-%\*00X2TN44/<O@X)R,CDYX./E [FO3** /*?$?B'QIX+\>W&HSVEY
MK/A.XC^2&UB4M;M@>@SG(/4X(-<KXM:_^,&KZ/;Z/X7O["*VGS<:G=Q"-E0X
MR >^.3CUKZ HH \U^(5UXWT#6=(UGP\)[_1H%"7^G1(I9L$DMTW<J<<="H]:
MY+QKXNN/B5X>.@Z/X*U1[V5T(FNX JV_/)#=CV^F:]WHH \D\=^'KO1_@#'H
M:K)=75M%!&PB0L20XS@#L*[SP+&\/P_\.1RHR2)IENK*PP5(C7((K?HH ^<_
MB+H^O>%_'FK+X=LY9+7Q/;>5)Y2$A'9@&Y XYYY_O&O=/"F@P>&/"^GZ/  %
MMH0K$?Q/U8_B2:V** /'M:T_6_A[\3+[Q=INDSZKHNJQXO(+5<R0L,9('?D9
MS_M$4[6_'WB;Q?'!I7@;1M4LKB213-J-W;B-(5[CY@?S_*O7Z* (+*&:WL;>
M&XG:XF2-5DF8 %V Y/&!S4]%% !1110 4444 %9NK_>T_P#Z_$_D:TJS=7^]
MI_\ U^)_(T :5%%% !6;9?\ (;U3_ME_Z#6E6;9?\AO5/^V7_H- &E1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M7#:CX[N;+XLZ9X-6QB>WO+8SM<ER&4XD. .G\ _.@#N:*** "B@D $DX JEI
M^KZ=JIG_ +/O8+KR'V2F%PP5NN,B@"[1110 4444 %%<1-XZN8OBW;^#!91&
MWEM?M!N=YW [6.,=.U=O0 4444 %%%% !1110 4444 %%%% !117#>%_&.OZ
MUXUU;1]0\.O8Z?:"4P7I#XFVR!5ZC'*DGCTH [FBBB@ HHHH **** "BBB@
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MZ)DK2K-O?^/[2_\ KZ;_ -$R5I4 %%%% !1110 4444 %%%% !1110 4444
M%%<QX[\,W_BO0%T_3M7ETN<3K)Y\18$@ C;\I![_ *5KZ%I\VE:#8V%Q<M=3
M6\*QO.Y),A QN.>>: -"BBB@ HHK \9^)X_!WA6[UR2U>Y2WV Q(P4G<P4<_
M4T ;]%9OA[5'UOPWINJO"(6O+:.<Q@YV[E!QG\:\S^"VH7M]J_C!;N\N+A8K
M\K&)I6<(-S<#)XH ]>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"LV;_D8;;_KTF_\ 0XZTJS9O^1AMO^O2;_T..@!+'_D-ZG](?_036G698_\
M(;U/Z0_^@FM.@ HHHH **** "BBB@ HHHH **** "BO(M(U"]?\ :4UNQ:\N
M&LTT\,MN96,:G;%R%S@=3^=>NT %%%% !1110 4444 %%%% !1110 4444 %
M%17)(M9B#@A#R/I7E?[/]_>ZCX+O9;Z\N+J07K //*SD#:O )/2@#UFBBB@
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M10 5FV7_ "&]4_[9?^@UI5FV7_(;U3_ME_Z#0!I4444 %%%% !1110 4444
M%%%% '#?%/QM?^!/#4&IZ?;6T\LEP(BMP&*@$$YX(YXKLK&=KJPMKAP TL2N
M0.@) ->4?M$@GP#:D X%\F3_ ,!:O4M)_P"0-8_]>\?_ *"* .'\'_$#4O$7
MQ%\0^'+FUM8[73-_E21!M[8<*-V21T/85G^)/BQ=>&_B5)X=ETY+FT^SJT*P
M(S7$TK ;4'..2?3I6#\+B&^.7C@@@C][T_Z["I+N*WE_:F@\_;E+-6BW'^/R
MCC],T ;&K>./B/H=JVLW_@RR&D1C?-%%=;YXD]6(...^ <5W>@>)K+Q1X8CU
MO27#1RQL0K]4<=58#H0:TM0\O^S;KSMOE^2^_=TQ@YS7C_[/1G/@'5@^?(%T
MWE^F=@W?TH 9HWQF\2:[I\MKI?AJ+4=>$K@QV^Y888Q@!G)/4G/&1TKN[KQM
M)X:\ 0:_XMM19WY&U[.$Y+2DG"+R>H&>IXS7&?L\QH-!U^4(/,.ILI;') 48
M'ZG\ZA_:"^TNGA:&$(4>^;B7_5E_EV[O;D_K0!KIXO\ B?=V']L6O@S3UT\K
MYBVLEP3<NG7(Y SCMC/M76^!_&MCXYT'^T;2)[>6-S%<6TGWH7'.,]QSP?Y5
MSV?C . /"G_?$W_Q59'@7PCKOAK3_&D]W<V$D]_"TD46GR;A'+MDSP>1R1CZ
M4 7'^)6O^)=<O-.\!:';7\%B^R?4+V7;"6YX4 @D<'!R<]<5E>(?B[XI\.3V
M6E:EX:M[/6)IU7>[F2WEC/&Y&4@@Y['-7?V>&MS\.YUBQYPOY/.&><[4Q^&/
MZU4^/<EOGPG&V/M!U'*\\A?ES^N* .P^)GC&^\$^#EUBQM[>><SQQ%)PQ7#
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M^&=&C9G%J]^//QT("G&?UH N0>._B-J6G?V[IW@NT_L@KYB0S7!^TRQ_WEY
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MK.K>)+"%BZ79,JJAC(PSXXP'Z9ZFJ?@Z1=*_:(\4VEZQ2:]B+6^[C>/E;C\
M?RH ?XPT3QIX/\'ZK<CQ)-XATR:U>"\M[U/WD8=2OF(V2>"0<>F?PZ7X'?\
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MK>V_V>2(.Q+@>6<<AO0@\5Y/X+URU\0_M#:W?6,BRVOV1HXI5Z.%VC</;.:
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M?VE_]?3?^B9*TJSK[_C^TK_KZ;_T3)6C0 4444 %%%% !1110 4444 %%%%
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MSM;NQNO"_BJ"!YK?2;T/.%ZJ-RLI^AVD9^E &G#\&X[>U%S#XIUM-=QN-_\
M:#@O[I_=SVZX[UA?!235)O&GC ZS.\M_&ZQRG.%W!FR0O09QFN_'Q.\&MHPU
M0:]:>24W"/?^]SC.W9UW>U>??!#4)-6\9>,M0EC>)KB59-CC#*"S8!'KC% %
MK1O^3HM=_P"P:/\ T"&K7Q%\2Z[J?CC3/ /AN\:QEN5$MY>)]Y$Y. >V "3C
MD\>]5=&_Y.BUW_L&C_T"&JWBZY3P?\?](\1:F"FEWEMY'VC'RHVTJ<_3*GZ&
M@#5O?@U)8:=)=>'O$^M0ZW&I=)I;G*S-UPP[9Z?XUM?"7QQ<^-?"\K:B%_M.
MQE\BX91@/QE7QVSR/J#75ZGXBTG2-'EU6[OH%LXXS)Y@D!W#T7U)[ 5YA^S_
M *;<_P!F:]X@GC:./5;L>4#P&5-QW#VRY&?]F@#E_ .BZYXM\3>+=.&O7MAH
MZ7SM<FV?][(=[A4#'[JXR3]!3_&NCZQ\'=4TO5?#.MWUQ;7DC126MY)YBLPZ
M CC((/U!'6ND^!__ "'?'7_83_\ 9I*3]H/_ )!GAO\ ["']!0!=G^#UWK%E
M]OU;Q;J\FO.OF>;'+B*)^NU5_N@\=?RJU\%O$^KZYHNIZ=K<YN;S2;K[.9V.
M6<<]3WP0>:],3[B_05X]\"_^0CXU_P"PG_5Z (_/U3XJ^/\ 6M)_M>ZT[PUH
M[")X[-]C7+Y(Y;T.T_08]<U4\7Z1>_"%M/\ $/AS5[Z73FN5AO;"[E,L; @_
M-[="/J16%X9\%^&+[XE^*-"\71NMX+@RV6^4Q"1"S$D<\Y!4BMKQEX,^%G@R
M.T6YTN\O+J[E$45K:W9:0^^"PXS@?4B@#?\ CI>^;\*X;VUE=!)=02(Z,02K
M*Q[>QJOX=^'^M>)?[)\4>(_$5['.K17-OI]N<10HN"J'/7( S]3UZT_XYP):
M_"*WMXHVCCBN+=%1CDJ I !/M7H_AO\ Y%C2O^O2+_T$4 >36]Q-_P -230^
M=)Y7V8GR]YV_Z@=NE=O\79'B^%>O/&[(XB3#*<$?O$[UP=W)#I'[4,5Q?3)!
M#=6G[MY#M4DQE0,_48KI_C5K^EVOPVU*Q>\B-U>A(X(D8,S$.K$X'0 #K]/6
M@#0^%<CR_"+27D=G<V\F68Y)^=N]<S^SI_R(M]_U_-_Z"M=)\*/^2/Z1_P!>
M\G_H;5S7[.S;? 5^P!.+UC@=_D6@#8U+P#KWBKQ=?7/B76Y(_#ZG%E8Z?<NF
MX9ZR<#GOP3S]*YJX@O\ X9?%'PWIFDZM>7.BZU)Y4EG=RF01DL%)!/\ O C\
M1TK/\(V]O\5]8UNZ\7:[<@6USY<.D17'DQI'SR5[^GKQR:R=8T7PGX?^,_A'
M3O"^"8[R)KLK,9 &+C:N3W Y_$4 =M^T#<RV7AW1;J!I!)%J (".5W?*3@X^
ME:/AWX=ZO<ZQIWBKQ'XEO9]21A/]CC.((P1_JP/09[8K,_:&_P"16T?_ +""
M_P#H)KUNT_X\H/\ KFO\J )J*** "BBB@ HHHH **** ,[6?^/:W_P"ON#_T
M8M,U7[^G_P#7XG\FI^L_\>UO_P!?<'_HQ:9JOW]/_P"OQ/Y-0(U****!A111
M0 4444 %<?\ %3_DEWB'_KU/\Q785Q_Q4_Y)=XA_Z]3_ #% 'E^D>.;VV^&_
MAWPCX3'VGQ)?0%28SG[(A8Y9CV..>>@Y]*]0\!^"(O!7A]H)+F2\U&<;[JY=
MB=S8^ZN>BCG'XFO%X/#5_H'@/PW\1O"X\N^LX?\ B81)TFCW$;B.XQPWMSU&
M:]Y\*^*K#QCX8AUC3V^212)(B?FB<#YE/T_48/>@#SWX#3S3P^*?-EDDVZCA
M=[$X'/K5$3:K\7?'^KZ8FK76G^&-(;RW2T?:UPV2.3[E6//0?7-6_@#_ *GQ
M7_V$O\:H?!Z6+PMX\\6>&-3D6"\><20>8=OF@%NF?9E(]0: *GQ0\&7_ (+\
M$7;Z/J]Y<Z)<,L=W8WLGF>62P*O&>WS  _6NUM69/V?%9&*L-%)!4X(^0U2^
M//B"PL_ $VEFXC:^OI$$4(.6VJP9FQV  Z^]7+?_ )-Y'_8$/_H!H XSX:>#
M]4\<^ [1M9U_4+;2(7DCMK:SEV&4[V+/(QSGDD =@M7?#TFL?#OXNVG@]M6N
MM2T74(=\*W+;FC.&Q]""O.."#76_ [_DDFC_ ._/_P"CGKF_%W_)QOA7_KV'
M_L] &I\1_$6LWGC#1? N@7K6$VH#S;N\C^_'&,G ].%)]^!5+Q!\*_[ \/W6
ML>'?$6LQ:S9Q-.)9+DOY^T9*D>^#6)\4M$TMOC)H5UXD5_["OX/)>7)15<;@
M 6'N5/T-;>O?#+X7>'M!N-8O+=S;0QEP$O6)D/95^;DGH* (M3N;KXH? H:J
MC%-7LPTK& [<R1Y##KQE><5V/PK\3?\ "4^ -/NY)-]U OV>XR1G>G&3]1@_
MC3OAE!HH\#V\NAZ;=6.FW3O*D-VP9VR<%NIX.*\E&OR?!WQ1XRT<AQ;7D!NM
M+XR/-;A/RW'/^Y0!TVFR3>/?CS>7B32_V-X<41*JN0KS D#(SUW[C[A!7LU<
M'\(?"[>&? 5I]I4B_OS]LN=W4%A\JGZ+C/OFN\H \<^*\\T7Q/\ AZD<TB*]
M_&&56(##SH^H[UH_'V:6#X<[X97C;[7&-R,0>_I65\6_^2I?#K_L(1_^CHZT
MOV@O^2;?]OD7]: *VF_#.]\8>';'4O$OB34X[J:VC:"WLY=D-NFT;< YR< $
MGU)I?A)K>MV_B?Q#X+UF^>_&E-F"XD.6VAMI&<YP<J0.W->E^'?^19TK_KSA
M_P#0!7E?P_\ ^2]^./\ </\ Z&M #UGF_P"&GA#YTGE?8"?+W';GRSVJ/Q[/
M,GQ[\&Q)-(L;1+N0.0#\[]10O_)T@_[!Y_\ 19J#XGS1:9\:_!>IWC>39!0C
M3,/E!WMU/_ A^= 'KGB$E?#>ID$@BUEP0>GRFO/?V?YI9_AS(\TKR-]NE&YV
M)/W4]:ZOQMXETG2?!NI7-Q>PD26SI$B."TK,I"JH[DDBN0_9Z_Y)M)_U_P O
M_H*4 <;HFG>(?$'Q-\::#I6KS:=8O=E[NY5BSHBNP$:<\;MQ_!?PK4\??#B;
MPI\.EO-(U2_NKG3+TWC2S2?/Y;!%8<8X!16_.M+X7_\ )7OB%_U\?^U'KUR^
MLX=1L+BRN4#P3QM'(I&05(P: ,SPKX@A\1^$M/UI74+/ 'D[!6'##VP0:\U^
M&AN/&GQ)\0^-9GE^P6\AM+&,L0O3&<9QD)C\7-<+;^)KSP-X9\6?#YO-;4&N
MO(L-JY++(<-^:X_[ZKWWP+X:C\)>#=.TA0/,BCW3,/XI&Y8_F: .BKQ?P7+/
MX5^.7B#PW/-(UKJ"&YM1)(6 _B &?8L/PKVBO'?C# V@^*O"GC6+Y5M+H6]R
MV. A.?Y%Q0!3^,7]I>*?&6F>$=(N)8I+:RGOYS&2!G:=@./]W'_ Q76?"7Q*
MFI_"NSO+J9F?3T>"X=NO[OD'_ODK6)\*=OBCQIXO\;.-\-Q.+&S8]?*7!/\
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MA.R\:>&[C1[UFC5\/'*O6-QT;_ZU;]% 'D5KH'Q>TO3DT.TU?1Y;.-/*COI
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MCDCVKTFB@#CO!7P\L/!%_JMS8W4LB:@X;R6156( G 7';G'X5V-%% '(^/?
M5KX]LK*UNKZ>T6UF,RM"H)8XQSFK'C36+;PMX(N[Z[TYM2M((TCFMQCYT)"D
MG/&.:Z:HYX(KJ"2">))89%*NCC*L#U!'>@#R'PUX!^&7B328/$-K 8;>91)-
M9F^/EQ,.J.,]C6?\.%M-3^-WB/4-&CB72+2W%O$85Q'CY5 7''\)/OUKMY_@
MWX$N)VE.B"/<<E(KB6-#_P !5@*ZO1M"TOP_8BRTFQAL[<'.R)<9/J?4^YH
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M<:0QK'&BI&@"JJC 4#H *\2\>6-KXW^..@>'U@21-.A$U_)CDH#OV'V^Z/\
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MUK"^"^E:=<_"C1IKC3[661C/EY(58G]])W(KC/C9IVCVOB+PX/#\-O%XB:Y
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MC.T]>?3.* .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH S=%_P"/ _\
M7Q/_ .CGHT#_ ) EO_P+_P!"-&B_\@\_]?$__HYZ- _Y EO_ ,"_]"- &E11
M10 4444 %%%% !1110!Q'Q#\>3>!_P"Q_*T^.[_M"X,!WRE-G3GH<]:[>O%O
MV@Y4@A\*S2MMCCOV9CZ ;2:U-0^(?CB>T;5]"\$&310ID26ZEVS2QC^,(#D
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M0>^1SF@#T2BBB@ HHHH **** "BBB@ HHHH **** "LW4?\ D):5_P!=W_\
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M'/\ $.,\'K[<<US?B#Q9X_\ AR;74?$4FFZSH\TJQ2M;1>5)$3D\>O ./Z4
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MH;92CQ#/)!P,@>O/TKT;PUXBL?%7AZUUG3V)@N%SM;[R,."I]P>* ->BO!_
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MZURR\+7MQX;M8[K5DV>1#(N5;+J&XR/X2QZ]J/!]UKE[X8M+CQ';1VVJMO\
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M>)/%OA+4=.CA:WTRX:2Y,DFT@%HSP._"FO0KA&DM98U^\R$#ZD4 >2_L[_\
M(FZN.PU60 >G[N.J/P@@MV^*7CZ=MOVE;R5%YYV&9R>/J!75_"'PAJW@WP[J
M%EK"1)-/?-.@BDWC:40=?J#7FO@K1M<O/B-XWU/PWJ,5KJ=GJ$RB*X3=#<(T
MKY5L<CD @CN* /4OC&$/PHUW>%XCCVY]?,7I7+PM.W[+[&?.[^S& S_=#';^
MF*DU?PA\0/B!+!8>*+C3]*T2.19)8;%R[S$>_P#CZ]Z[;Q9X;>]^'5_X=T:&
M-&:T^SVT9;:H P ,_04 <+HTL\/[+YDMBPE&G3X*]?\ 6/G],UF?#5OB1;^
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MD7RY"VSS$SW/J#R,]LBNAO= G\9^ SI'BBV2VN[B("80.'"2*>'4_4 X]\4
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MQR1\F$J-HX[\9!KF+'X=^.)(%TK5_';RZ*!L>."+;-)'TV%R,C(XSDF@#/\
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MB/\ T&&O9:X72? EWIWQ8UCQ@]Y ]M?6XA6!5.]3B,9)Z?P'\Z .1\=J&_:
M\%AAD;0?U:O5/$O_ "*NL?\ 7E-_Z :YCQ#X$N]9^)6@^*(KR".WTU</"RG>
M_7H>G>NOU:S;4-'OK)'"/<6\D2LW0%E(R?SH \Y_9_\ ^29)_P!?DO\ [+6=
M\/O^2Z^//H/_ $(5VGPV\(7/@CPF-'NKJ*YD$[R^9$"!AL<<_2JOAKP-=Z'\
M0_$7B26\@E@U7_5PHI#)R#R>G:@#D?BS_P E5^'7_7_'_P"CHZZWXC^.[CPE
M'IUAI5I'=ZUJDOE6D<I(1>0"S>O)'&1UI/&?@.\\3^,?#&M07L$,6CW"S21R
M*2T@$BM@8]EJQ\0?A[:^.K.U/VJ2RU&R<O:W48SM)QD$>F0/IB@#FM9T;XGK
MX>U"^U'QGIUM$EK))-:V^GHZA0I)4,RYZ59^ W/PL@_Z^9O_ $*H1\./&.LV
MCZ?XI\;/=:<4(,%K$$,I[;VP#C...^*Z?X<^$;KP5X171;NYAN'6:1Q)$"!A
MCGOWH X;X"?\??C+_L(C^;T?'D ZEX)!&0=0;^<==9\.? EWX*FUU[J\@N1J
M-R)T$2D;!\W!S_O4?$7P'>>-+O0)K6]@MQIER9W$JD[P2AP,?[I_.@#N&_U)
M_P!VO'?@%T\6_P#82_\ BJ]C*Y0K[8KA_AOX$N_!(UK[5>07/]H77GIY2D;1
MSP<_6@#DO!*@_M#^,&P,B @'_@25M_'K_DEEW_U\0_\ H5:.@> [S1_B;KGB
MF6]@DM]1C*I"JD.G*GD].U7_ (C>$[CQKX/FT6UN8K>626-Q)*"5 4Y[4 :O
MA08\'Z+C_GP@_P#0!7F'@/\ Y+_XV_ZYG_T-:]9T:R?3-#L+"1U=[:VCA9E&
M Q50"1^5<CX<\"7FB_$G7_$\M[!);ZFI5(54AT^8'D].U &9KWC;Q)JWCNX\
M&^#(K**XLXA)>7U[DK'P.%4?[R]CR>V,UPOQ@TCQII_@R.3Q%XMM]3M7NT"V
ML=C'$=^&YW  X'/YUWOBGX7WUYXK;Q3X5UUM'U:50L^Y=R2<8S^0'&".*QO$
M/P>\1>*](SKGBS[;JJ2 P9CV6\*<[@%'4GCGVH ['QM_R1_5_P#L$M_Z!5?X
M-?\ ))]#_P!R3_T8]='J6A+J_A&?0KJ4HMQ:&V>2/ME<9&:XWP#X$\6>#;V&
MTG\30W>@0[]EH(<-SG')'')SUH POAW_ ,ET\=_[Q_\ 0ZC\+-';?M,>)X[P
MA)IK4_9P_5N(F&/^ @_E78>&/ =YH/Q"\0^))KV"6#5"3'"BD,GS9Y)XI_C?
MX;6GBR_M-7M;Z?2];M,"&\@YR!R P[X/\SUH Z7Q))!%X8U5[H@0"SE\S)[;
M#FO-OV>H[A/A[=/+GR'OI# #V7:H/_CP-2WOPY\;>)+=--\2^-4DTL8\R.SM
MMCS8/\1X_P /:O2='T>QT'2+?2]-@6&TMTV1H/U)]23R30!Y)^S?$B^$]6E"
M@.UZ%8^H"#'\S4WQT_Y"7@G_ +"?]4KJ/A;X$N_ .AWEA>7D%T\]QYRM"I
MV@8.?I3OB'X&N_&5UH$UK>06XTR[^T.)5)WC*G Q_NT =S1110 4444 %%%%
M &=K/_'M;_\ 7W!_Z,6F:K]_3_\ K\3^34_6?^/:W_Z^X/\ T8M-U;[^G_\
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M<NM.T+1(YC#%--%YT\A'?!!'IV&,]ZZSX=^"IO!W@U]"O[B&[+S2.S1 A2K
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MB?R-:59NK_>T_P#Z_$_D: -*BBB@ K-LO^0WJG_;+_T&M*LVR_Y#>J?]LO\
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MA=0NX9I]\R010P %Y'8X &2!^M;2,616*E21DJ>H]J '4444 %%%% !1110
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MTEXALWO+AK6.VRD#2L8U.R+HN<=S7L8=2<!@3]:\4\.?\G/>)/\ KU_]IQ4
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MD8  GU Y/X5Q_AOX77'B[0[;7O%WB'5KC4+^(3QI#<;$@5N5P,=<$'T'3'%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VH?\A+2O^N[_P#H
MIZT:SM0_Y"6E?]=W_P#13T -'_(S?]N?_L]:=9@_Y&;_ +<__9ZTZ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "LW5O];IO_ %^+_P"@M6E6;JW^MTW_ *_%_P#06H =?_\
M'[I7_7TW_HF6M"L^_P#^/S2S_P!/1_\ 1,E:% !1110 4444 %%%% !1110
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MM6F1NADC\O?D[AM./K7F_P"T,GE>&O#L>YGVWVW<W4X0\FNG^-__ "2K4_\
M?B_]#% '3Z9J6CV/@B+5=/@:#1X;,W,<:1X*Q!2W"^N,\5S[?&+P<FAV^JO>
MS*ER6$-OY),S[3@G:.V>Y]_2FV7_ "00_P#8OR?^B37-_L_>';"+P4^LR6\<
ME[=7#IYKKDI&N %&>@SD_C0!W/A3XB^&O&;M#I-]FY0%FMYD*2 #O@]1]*W-
M7UG3M!TZ2_U6\BM+5.#)(<#/H.Y/L*\@\9:=:Z3\?O!]U80K;RWO_'P8AM#\
ME>0/;@U6^,NIPO\ $OPOIFIVMS>:1!']JEM+6/S'F8LPQMR ?N ?0F@#LH?C
M9X,DG1'N;R""1MJ74UJRQ,?9J]!AFBN($F@D22*10R.AR&!Z$&O(]<^(WA[6
M_#UWI$W@OQ,89H6C53I:@*<<$8?C!P>*U?@8VI)\/$M-2AN(I+:X=(UG4J0G
M!  (Z9)H ]*HHHH **** "BBB@ K-U?[VG_]?B?R-:59NK_>T_\ Z_$_D: -
M*BBB@ K.M\1Z[>J>LD<;CZ#(K1K-U _9K^SO>B F&4^BMT)]LX_.@#2HHHH
M**** "BBB@ HHHH *YWQUX;_ .$L\&:EHP($L\>82W02*<KG\0*Z*B@#QOX1
M>.[+3-('@[Q',NFZMILC0HES\@=<Y !/&1D_48KU&ZUW2(;:1Y-5LD4*>3<+
MZ?6J'B+P+X:\5.)-8TJ&>8# F&5<#_>'-<Q!\"O D$PD_L^XDQ_#)<L10!S/
M[."A_"^MIGK<J/\ QRE^"MY#X?\ $7BCPOJ3K;:A]K\V-)& \P#(X]>,'Z&O
M6]$\.Z1X;M&M='T^&SA=MS+$/O'U)[UE^)OA_P"&_%LR7&J6&;M  MS"YCD
M'0;A0!Q'Q_\ $-A;^!3HXGC>]O9XRL2L"512&+'T&0!^-=%!X.TGQI\-?#=C
MK"2M#%9V\J^4^T[O* Z_C4@^$?@X:/<Z;_9[E;K;YT[3,TS;2"!O/(&1T%=?
MI]C!I>FVMA;!A!;1+#&&.2%48&3WX% ''>'/A'X6\+:W#J^F172W4(8(9)MP
MY&#QCT-<;X<_Y.>\2?\ 7K_[3BKVRN=M/!6C67C&[\50QS#5+I-DKF4E2,*/
MN].BB@#R[7;U/ 'Q^77=5#II.K6_E_:-N50X .?H5&?8UUGCWXD>';?P7J<6
MGZI!?7UW:21V\-JPD;YD.7('15&6)/I53XD^,H=#\3:7H_B#1+.Z\-7P'FW<
M\;.8SDAL#ID<'UP365XJU?X:^&O!&KKX=&E'4-1LY+:%+/#R,9%V=>2H ;/.
M.E &M\';^#2O@Q#?W3A(+;[1*[$] &)K@O!7@;6/B/=ZKXU/B&\T2:ZNG2)[
M53N=.,C(8$ <#'M7H?@'P4+OX,V.@:['<PK=!I9H4<QN%9RRJ<<\C&1[XKN]
M#T6R\/:-;:3IT9CM+9=L:L<G&<\GN>: /+KCX*:U=VTEO<_$G7)H)%*O'+O9
M6!Z@@RX(JK\"M2N-(OM=\#:DV+FPG:6$'/(SM?&>WW2/J37M=<V? NA_\)H/
M%B131ZMMVLZ2D*PV[>5Z'C^5 '25X?\ LX_\>'B3_KZC_DU>X5SGA/P1HO@J
M*[CT:.9%NG5Y?-E+Y(SC&?J: .CK@_C/_P DDU[_ '(?_1R5WE<'\9_^22:]
M_N0_^CDH B^#WB'3]3^'&E6\=Q&MS91>1/"SC<A4\''H1@_C7'>,)X/&?QS\
M-:=I,@N1I0\R[EB.Y8\-N//M@#ZFMKPK\./#/BGX?^';[4+)TO/L$:M<6TIB
M=QCHQ7K^-=UX9\&Z#X0MFAT73TM]X DDR6=\>K'F@#S;XN?\E0^'7_80C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTSW7OUZD\4NOZCKWB3XJ^"=9N]"N].TS[6BVJ3*3)M#J6=P/NYR,>PKZ"HH
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M "<?@"/?->RT4 >/^+?'][XM\':II_A?0-3)DM9#=75U;F..&(*2X']YR 5
M'K5GX6Z$=6^![:+>QR0?:Q<0L'4J5W,<'!_.O5Z* /%?"/B_4_AMI0\+^*]!
MU$I9LRVM[9PF2.5,Y[>Y/]<8K>\,ZWXQ\7^.1J@MKO1_"4$.%MKJ)%>Z?!P>
M1N')SP<?*!WKTRB@#QOQ9H^M>"OBD/'>DZ9/J>FW<?EW\%OS(GR@$X], $>X
MYQFEU/XA^)_&K6FE^!=)U/3IC,IN=0N[=0D28Y'S9'OZ\#'6O8Z* /&?C]9W
M<OAKP]'&DUU)'>C>R1DDX3DD <5TOQJAEG^%^I1PQ/*Y>+"HI8GYQV%>@T4
M<%9Q2#X$F(Q.)?[ D7R]IW9\D\8ZY]JJ? N":W^&%I'/%)%(+B;*NI4_>]#7
MI%% 'D/Q MIY/C;X%FC@E>*,_.ZH2J_,>I[5>^)_AK61K^B>-O#MI]MO]).R
M:T!^:6(D_=_[Z8'OSGM7J%% 'E-[\8)K[39;70_"^N/K<B,L<,EK@1/TRQZ$
M"NT\$6WB&V\+VP\47GVK5G)>4[5'E@]$^4 ' KHJ* "BBB@ HHHH **** "L
MZ_\ WNI:? .<2-,?8*/\36C6;8'[7J%Q?_\ +,#R(3Z@'YC^)_E0!I4444 %
M1SP1W,$D,J[D=2K#VJ2B@#/T^XD1VL+H_P"D1#Y7_P">J=F'OZCL?PK0JM>6
M4=XB[B4D0[HY4^\A]1_AWJJFHRV6(M339V%R@_=M]?[I^O'O0!IT4U'61 Z,
M&4]"IR#3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""\LK74+=K>\M
MH;B%NL<J!E/X&LNQ\'>&=-N!<6/A_3+:8=)(K5%8?B!6W10 4444 %%%% !1
M110 56O]/L]4LI++4+6&ZM9<;X9D#HV"",@\'D _A5FB@"&TM+:PM(K2S@CM
M[>)=L<42A50>@ Z5-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4455NM0MK/ EDS(?NQH
M-SM] .: ++NL:%W8*JC)). !6=9AK^[_ +0D4K$JE+96ZX/5SZ9XQ[?6FBVN
M-4</?)Y5H,%;4G)<^KG_ -E_.M2@ JM>V@O+?R]Q212'C<#[C#H?\]JLT4 4
M["\-RK13*([J+B6,'IZ$>JGL:N54O+!;HI*CM#<Q_P"KF3J/8^H]JKKJ<EJ0
MFI0^3V$Z9:-OQZK^- &G13(IHITWPR)(OJC BGT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO-M_G3O[2L/^?VV_[^K_ (T 6J*J_P!I6'_/[;?]_5_QH_M*P_Y_;;_OZO\
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MF=;25O\ 0W.+>0_P'_GF3_(_A]=6F2Q1SQ-%*BO&XPRL,@B@!]%98BO=-&(
M;NU'2-F_>(/0$_>'UY^M31:O92ML:7R9.\<PV,/SH O44BLK#*D$>H-+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 44$@#).!5.?5+*W.'N$+]D3YF_(4 7*SKRYDGF^P63
MXF.#+*!D0K_\4>P_&FF6_P!0XA0V5N>LD@_>,/9>WU/Y5<M;2&R@$,";5SDD
MG)8]R3W/O0 ^"".VMXX(EVQQJ%4>U2444 9][!+#.+^T4M(HVS1#_EJ@]/\
M:'./Q%6[>XBNX%F@</&W0C^OH?:I:SY]/D2X:ZL)%AG;_6(PS'+]1V/N/UH
MT**S5U=83LOX9+5^FXC<A^C#^M7HKB&<9BFCD![JP- $E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%(2 ,D@#WH 6BJ<^JV-N=K
M7"L_9$^9OR%0%[_41A%:RMCU=_\ 6L/8?P_4\^U "WD[W<YT^T?#?\O$J_\
M+)?0'^\?TZ^F;\,,<$*0Q*%C10JJ.P%,MK6&S@6&! B#MZGU)[GWJ:@ HHHH
M **** "D(#*58 @\$'O2T4 9[:-:;R\ DMG/5H'*9_#I2&PO1PFK3@>\49_F
M*T:* ,W[!J'_ $&)O^_$?_Q-'V#4/^@Q-_WXC_\ B:TJ* ,W[!J'_08F_P"_
M$?\ \31]@U#_ *#$W_?B/_XFM*B@#-^P:A_T&)O^_$?_ ,31]@U#_H,3?]^(
M_P#XFM*B@#-^P:A_T&)O^_$?_P 31]@U#_H,3?\ ?B/_ .)K2HH S?L&H?\
M08F_[\1__$T?8-0_Z#$W_?B/_P")K2HH S?L&H?]!B;_ +\1_P#Q-'V#4/\
MH,3?]^(__B:TJ* ,W[!J'_08F_[\1_\ Q-'V#4/^@Q-_WXC_ /B:TJ* ,W[!
MJ'_08F_[\1__ !-'V#4/^@Q-_P!^(_\ XFM*B@#-^P:A_P!!B;_OQ'_\31]@
MU#_H,3?]^(__ (FM*B@#-^P:A_T&)O\ OQ'_ /$T?8-0_P"@Q-_WXC_^)K2H
MH S?L&H?]!B;_OQ'_P#$T?8-0_Z#$W_?B/\ ^)K2HH S?L&H?]!B;_OQ'_\
M$T?8-0_Z#$W_ 'XC_P#B:TJ* ,W[!J'_ $&)O^_$?_Q-'V#4/^@Q-_WXC_\
MB:TJ* ,W[!J'_08F_P"_$?\ \31]@U#_ *#$W_?B/_XFM*B@#-^P:A_T&)O^
M_$?_ ,31]@U#_H,3?]^(_P#XFM*B@#-^P:A_T&)O^_$?_P 31]@U#_H,3?\
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M0?\ ?L?X4?8+/_GT@_[]C_"K%% %?[!9_P#/I!_W['^%'V"S_P"?2#_OV/\
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>-% $4-M!;#$,,<8[[5 S4M%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img76291469_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 6^!=P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]K[_ /@!_J[A/^@A_P#@'_VQYCD>M&1ZUZ=_PKC3?^?V]_[Z7_"C_A7&F_\
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M@_[^"C^T;+_G\@_[^#_&D=?/'N6:*K?VC9?\_D'_ '\%']HV7_/Y!_W\'^-
M<\>Y9HJM_:-E_P _D'_?P?XT?VC9?\_D'_?P?XT!SQ[EFBJW]HV7_/Y!_P!_
M!_C1_:-E_P _D'_?P?XT!SQ[EFBJW]HV7_/W!_W\'^-']HV7_/Y!_P!_!_C0
M'/'N6:*K?VC9?\_D'_?P5/'+',@>-U=3T*G(H&I1>S'4444%!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-&&)@YT91CNTSQ&G"5U&%<@>QKO/^%:-_P!!(?\ ?G_Z]'_"M&_Z"0_[\_\
MUZNZ/EO[+Q?\OXK_ #.$\Z7_ )Z-^='G2_\ /1OSKN_^%:-_T$A_WY_^O1_P
MK1O^@D/^_/\ ]>BZ#^S,9_+^*_S.$\Z7_GHWYT>=+_ST;\Z[O_A6C?\ 02'_
M 'Y_^O1_PK1O^@D/^_/_ ->BZ#^S,9_+^*_S.$\Z7_GHWYT>=+_ST;\Z[O\
MX5HW_02'_?G_ .O1_P *T;_H)#_OS_\ 7HN@_LS%_P OXK_,X3SI?^>C?G1Y
MTO\ ST;\Z[O_ (5HW_02'_?G_P"O1_PK1O\ H)#_ +\__7HN@_LS&?R_BO\
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M7;1_AH\;&?QY^H4445H<P4444 %%%% !1110 5S/B'_C]3_<KIJYKQ ";U<
M_<KP.)/]Q?JCKP7\4RX)/)G23&=ISBMO_A)/^G7_ ,?_ /K5@[3Z4;3Z5\5A
M<QQ.$3C0E9/R7ZH]2I1IU'>2-[_A)/\ IU_\?_\ K4?\))_TZ_\ C_\ ]:L'
M:?2C:?2NO^WLQ_Y^?@O\C/ZI1[?F;W_"2?\ 3K_X_P#_ %JX_6M*_MC59KWS
MO*\S'R;<XP,=:TMI]*-I]*RJYQCJL>6<[KT7^1K1IPHRYJ>C.=_X1<?\_?\
MY#_^O1_PBX_Y^_\ R'_]>NBVGTHVGTKG^O8C^;\$=/MY]SG?^$6'_/W_ .0_
M_KTH\+@$'[7T_P!C_P"O70'Y>O%)N'K1]>Q'\WX(/;U.YN0>(/)@CB^SYV*%
MSO\ 3\*D_P"$D_Z=?_'_ /ZU8.T^E&T^E=BS[,%_R\_!?Y'"\)1?3\S>_P"$
MD_Z=?_'_ /ZU'_"2?].O_C__ -:L':?2C:?2G_;V8_\ /S\%_D'U2CV_,WO^
M$D_Z=?\ Q_\ ^M1_PDG_ $Z_^/\ _P!:L':?2C:?2C^WLQ_Y^?@O\@^J4>WY
MF]_PDG_3K_X__P#6H_X23_IU_P#'_P#ZU8.T^E&T^E']O9C_ ,_/P7^0?5*/
M;\S>_P"$D_Z=?_'_ /ZU'_"2?].O_C__ -:L':?2C:?2C^WLQ_Y^?@O\@^J4
M>WYF]_PDG_3K_P"/_P#UJ/\ A)/^G7_Q_P#^M6#M/I1M/I1_;V8_\_/P7^0?
M5*/;\S>_X23_ *=?_'__ *U'_"2?].O_ (__ /6K!VD=J2C^WLQ_Y^?@O\@^
MJ4>WYG:V5S]KM$GV[=V>,Y[U8JAHO_()A_'^9J_7W^"J2J8:G.;U<4W\T>/5
M2C-I=PHHHKJ("BBB@ HHHH **** .#^)7_'M8_[[?R%>> X(->B?$E&:WL=J
MD_,W0>PKSWRI/[A_*KCL?(9K_O4OE^1W$7Q(>*%(_P"S =JA<^=C./PI_P#P
MLM_^@6/^_P#_ /8UPGE2?W#^5'E2?W&_*G9$K,\6OM?@O\CN_P#A9;_] L?]
M_P#_ .QH_P"%EO\ ] L?]_\ _P"QKA/*D_N-^5-967J"/K1RH/[3Q?\ /^"_
MR/0(?B0\LR1_V8!N8+GSLXS^%=\#D UX-:?\?D'_ %T7^=>\I]P?2IDK'LY3
MBJM=3]H[VL+1114GL!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5@>*_^/"'_KK_ $-;]8/BO_CPA_ZZ_P!#36XI;&W%_J4_W13Z
M9%_J4_W13Z0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6^(W_
M "3_ %C_ *X?^S"OF+O7T[\1O^1 UC_KA_[,*^8C7G8SXT?19/\ PI>OZ(^A
MOA#/$G@.%6D0$7$G!/O7=_:8?^>J?]]"OD%9I$&%=@/0&E^T3?\ /5_SHAB^
M6*C85;*O:5'/GW\CZ]^TP_\ /5/^^A1]IA_YZI_WT*^0OM$W_/5_SH^T3?\
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M0>>&!Z48'I110 8'I1@>E%% '"?$GBTLL<?.W3Z5YVK$,#D\>]>B?$K)M+$
M?QM_(5YUM;T-?-9BO]HE\OR/JLL_W:/S_,]#M_B)9Q6\4;6$I9$"DAAV%2_\
M+)L_^?";_OH5YOAO2C#>E"S#$)6O^ /+,,];?BSTC_A9%G_SX3?]]"C_ (61
M9_\ /A-_WT*\WPWI1AO2C^T<1W_ 7]F8;M^+/2/^%DV?_/A-_P!]"C_A9%G_
M ,^$W_?0KS?#>E&&]*/[1Q'?\ _LS#=OQ9Z1_P +(L_^?";_ +Z%'_"R;/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %8/BO\ X\(?^NO]#6]6!XK_ ./"'_KK
M_0TUN*6QN1?ZE/\ =%/ID7^I3_=%/I#"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH RO$FC_ -O^'[S2_.\G[3'L\S&=O(/3\*\Q_P"%%C_H.?\
MDO\ _95['16<Z4)N\D=%'%UJ*Y:;LCQS_A18_P"@X?\ P'_^RH_X46/^@Y_Y
M+_\ V5>QT5'U:EV-O[2Q/\WX(\<_X46/^@Y_Y+__ &5'_"BQ_P!!P_\ @/\
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M#W/H\N_W6'H%%%%([0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW=6\C-^''_)0-(_ZZM_Z":^GJ^3?#>L#0?$%GJAB\W[.Y8IG&<@CK^->I_\
M"\X?^@))_P!_Q_\ $T8:K"$6I,>986M6J*5-7T/7Z*\@_P"%YPX_Y DG_?\
M'_Q-'_"\X?\ H"2?]_Q_\371]9I=SSO[.Q/\OXH]?HKR#_A></\ T!)/^_X_
M^)H_X7G#_P! 23_O^/\ XFCZS2[A_9V)_E_%'K]%>0?\+SAS_P @23_O^/\
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MQ^/IOEG4DGYMC5*D]HK[C:\,:M=ZG/J"74@80.JIA0.H/I71UQ_@G_C[U?\
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M_P W^->I>")I9_#,$DTCR.7?+.<D\T-6.O!YE'$U.11MI<Z*BBBI/3"BBB@
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M*D_N-^5'E2?W&_*OK[[';?\ /O#_ -\"C[';?\^\/_? H^I>8?VROY/Q_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q7_ ,>$/_77
M^AK>K \5_P#'A#_UU_H::W%+8W(O]2G^Z*?3(O\ 4I_NBGTAA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%_'#_D/
MZ;_U[M_Z%7NE>%_'#_D/Z;_U[M_Z%7/BOX;/1RO_ 'A?,\[T3_D.V'_7Q'_Z
M$*^N*^/()GMYTFC;:Z,&4^A%=?\ \+3\7?\ 03_\A)_A7)AZT::=SU,?@YXA
MQ<&M#Z4HKYK_ .%I^+O^@G_Y!3_"C_A:?B[_ *"?_D%/\*Z/KD.S//\ [(K]
MU_7R/I2BOFO_ (6GXN_Z"?\ Y!3_  H_X6GXN_Z"?_D%/\*/KD.S#^R*W=?U
M\CZ4HKYK_P"%I^+O^@G_ .04_P */^%I^+O^@G_Y!3_"CZY#LP_LBOW7]?(^
ME**^:_\ A:?B[_H)_P#D%/\ "C_A:?B[_H)_^04_PH^N0[,/[(K]U_7R/HN^
MMEN[5XR,G&5YQSVKA#X=\5$G$ML!GCI_A7E__"T_%W_03_\ (*?X4?\ "T_%
MW_03_P#(*?X5PXJC@\3+GJ1U^1U4,%BJ*:BXOUN>G_\ ".^*_P#GK:_I_A1_
MPCOBO_GK:_I_A7F'_"T_%W_03'_?E/\ "C_A:?B[_H)_^0D_PKF_L[+_ .3\
MC?V6,_N_<>G_ /".^*_^>MK^G^%'_".^*_\ GK:_I_A7F'_"T_%W_03_ /(*
M?X4?\+3\7?\ 03_\@I_A1_9V7_R?D'LL9_=^X]/_ .$<\5_\];7]/\*/^$<\
M5_\ /6U_3_"O,/\ A:?B[_H)_P#D%/\ "C_A:?B[_H)_^04_PH_L[+_Y/R#V
M6,_N_<>G_P#".^*_^>MK^G^%'_".>*_^>MK^G^%>8?\ "T_%W_03_P#(*?X4
M?\+3\7?]!/\ \@I_A1_9V7_R?D'LL9_=^X]/_P"$<\5_\];7]/\ "E&A>)8"
M);B2W,*?,^W&=O>O+_\ A:?B[_H)_P#D)/\ "O5O .N:AX@\"WM[J5P9IQ)(
M@;:!@!!QQ]34SRW RA+ECJD^QC6>)HQ4I\MKVT0M=)X=_P"/.3_KI_05S=:^
MDZI!8P/'*KDEL_*!7S61UZ=#&*=5V5F98N$ITK11TU%9/_"0VG]R;_OD?XT?
M\)#:?W)O^^1_C7V_]L8'_GZCR_JU7^4UJ*R?^$AM/[DW_?(_QH_X2&T_N3?]
M\C_&C^V,#_S]0?5JO\IK45D_\)#:?W)O^^1_C1_PD-I_<F_[Y'^-']L8'_GZ
M@^K5?Y36HK)_X2&T_N3?]\C_ !H_X2&T_N3?]\C_ !H_MC _\_4'U:K_ "FM
M163_ ,)#:?W)O^^1_C1_PD-I_<F_[Y'^-']L8'_GZ@^K5?Y36HK)_P"$AM/[
MDW_?(_QH_P"$AM/[DW_?(_QH_MC _P#/U!]6J_RFM163_P )#:?W)O\ OD?X
MT?\ "0VG]R;_ +Y'^-']L8'_ )^H/JU7^4UJ*R?^$AM/[DW_ 'R/\:/^$AM/
M[DW_ 'R/\:/[8P/_ #]0?5JO\IK45D_\)#:?W)O^^1_C1_PD-I_<F_[Y'^-'
M]L8'_GZ@^K5?Y36HK)_X2&T_N3?]\C_&C_A(;3^Y-_WR/\:/[8P/_/U!]6J_
MRFM163_PD-I_<F_[Y'^-'_"0VG]R;_OD?XT?VQ@?^?J#ZM5_E-:BLG_A(;3^
MY-_WR/\ &C_A(;3^Y-_WR/\ &C^V,#_S]0?5JO\ *:U%9/\ PD-I_<F_[Y'^
M-'_"0VG]R;_OD?XT?VQ@?^?J#ZM5_E-:L3Q=_P BM??[@_\ 0A4O_"0VG]R;
M_OD?XUD>)M:MKGP[>0HD@9E &0,?>'O54\VP4Y*,:BNSGQ6'JJA-N/1_D>65
MZUX#_P"15@_WW_\ 0C7DM:=GX@U73[86]K>R11 DA1C S7J-7/C<!BHX:KSR
M5]+'MM%>-?\ "6Z[_P!!&7]/\*/^$NUW_H(R_I_A4\I[/]MT?Y7^![+17C7_
M  EVN_\ 02E_3_"C_A+M=_Z",OZ?X4<H?VW1_E?X'LM%>-?\)=KO_01E_3_"
MC_A+M=_Z",OZ?X4<K#^VZ/\ *_P/9:*\:_X2[7?^@C+^G^%'_"7:[_T$I?T_
MPHY0_MNC_*_P/9:*\:_X2[7?^@C+^G^%'_"6Z[_T$9?T_P *.4/[;H_RO\#V
M6BO&O^$NUW_H)2_I_A1_PENN_P#02E_3_"CE#^VZ/\K_  /9:*\:_P"$MUW_
M *",OZ?X4?\ "7:[_P!!*7]/\*.4/[;H_P K_ ]EHKQK_A+M=_Z",OZ?X4?\
M);KO_01E_3_"CE#^VZ/\K_ ]EHKQK_A+M=_Z"4OZ?X4?\)=KO_01E_3_  HY
M6']MT?Y7^![+17C7_"6Z[_T$9?T_PKUS3Y'ETVUDD;<[Q(S'U) I-6.S"8^&
M*;44U8LT444CN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q7_Q
MX0_]=?Z&MZL'Q7_QX0_]=?Z&FMQ2V-N+_4I_NBGTR+_4I_NBGTAA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>3_%3
MPCK?B/6;*72[,S1Q0%6;<%P=Q/<UZQ145(*<>5FU"O*A/GCN?-/_  JWQ=_T
M"_\ R*G^-'_"K?%W_0+_ /(J?XU]+45S_4X=V=_]KU^R_KYGS3_PJWQ=_P!
MO_R*G^-'_"K?%W_0+_\ (J?XU]+44?4X=V']KU^R_KYGS3_PJWQ=_P! O_R*
MG^-'_"K?%W_0+_\ (J?XU]+44?4X=V']KU^R_KYGS3_PJWQ=_P! O_R*G^-'
M_"K?%W_0+_\ (J?XU]+44?4X=V']KU^R_KYGS3_PJWQ=_P! O_R*G^-'_"KO
M%W_0+_\ (J?XU]+44?4X=V']KU^R_KYGS3_PJWQ=_P! O_R*G^-'_"K?%W_0
M+_\ (J?XU]+44?4X=V']KU^R_KYGS3_PJ[Q=_P! O_R*G^-'_"K?%W_0+_\
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M #]S_P#?PT?VC>_\_<__ '\-']ES_F0?5GW.ZHKA?[1O?^?N?_OX:/[1O?\
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M8+3_ )]H?^^!1]AM/^?:'_O@4?ZJU_\ GXOQ#^T(]CBL48KM?L-I_P ^T/\
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M%%%0?1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H:4Z,Y^T2;)Q=&DL/*48K;L>_4445ZA\N%%%% !1110 4444 >#7W_']/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L'Q7_QX0_\ 77^AK>K \5_\>$/_ %U_H::W%+8W(O\
M4I_NBGTR+_4I_NBGTAA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:SXML-#NQ;7,5PTA4-^[4$8/U(I5\7:4=+74))'BC=BJ(Z_.Q'7 %<5\1/\
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MBO>/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJ_\
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MVHZC&/W*17$Q;M\[@#_T+]* /INBB@]* /&?C1X%T>]*^)3K-OI&I1J 6F;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_NBGTR+_4I_NBGTAA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC1S(/[$Q'\R_'_(\<_"CGTKV/_A#/#__ $#(_P#OIO\ &C_A#/#_ /T#(_\
MOIO\:.9!_8F(_F7X_P"1XY^%'X5['_PAGA__ *!D?_?3?XT?\(9X?_Z!D?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5X-\;O^1KL_\ KR7_ -#>O>:\&^-W
M_(UV?_7DO_H;USXK^&>CE?\ O"]&</X8_P"1KT?_ *_H?_0Q7U@",5\=H[1N
M'1BK*000<$&M'_A(M:_Z"MY_W_;_ !KCH5U3331ZV-P+Q+33M8^M,BBODO\
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M5<*?Q:GHA9A\,2:BBBOMCRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *YCQWX*M?'>A1Z7=W4ULB3K.'B )R 1CG_>-=/10!XE_PS?HO_0;O_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO"O\6IZ([,P^&)-1117VQY84444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3T1V9A\,2:BBBOMCRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/]T4^D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M56);D3/(1$^\8.,<^M>>^)?@KXHUCQ1JFIVVOP1P75R\L:,\F54G(!P,<=*
M/=O-C_O"CS4_O"OG7_A0GB_G_BH[;_ON7_"C_A0GB['_ ",=M_WW+_A0!]&*
MRMT(/TI:\\^%G@35?!%MJ::IJ*7C73QM'L9B%"@YZ_7]*]#H **** "BBB@
MHHHH **** "BBB@ HHHH **** "L#Q7_ ,>$/_77^AK?K!\5_P#'A#_UU_H:
M:W%+8VXO]2G^Z*?3(O\ 4I_NBGTAA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"_
M%S_D0+K_ *ZQ_P#H0KNJX7XN?\B!=?\ 76/_ -"%9U?X;.C"?QX>J/G*OIWX
M;_\ )/='_P"N3?\ H;5\Q5]._#?_ ))[H_\ UR;_ -#:N+!_&_0]K./X,?7]
M&=51117HGSH4444 %%%% !1110 4444 %%%% !535?\ D$WG_7%_Y&K=5-5_
MY!-Y_P!<7_D:F?PLNG\:/"CU->E?#;_D%7?_ %V'\A7FK=37I7PV_P"05=_]
M=A_Z"*^=RW_>%\SZ7-/]V?R.VHHHKZ0^7"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *X7XN?\ (@77_76/_P!"%=U7"_%S_D0+K_KK'_Z$*SJ_PV=&$_CP]4?.
M5?3OPW_Y)[H__7)O_0VKYBKTSPY\79/#^@6FE?V,LXMU*B3[25W9)/3:?6O/
MPU2,)-R/H,RH5*U-1IJ[N>]T5XQ_PO63_H7U_P# P_\ Q%'_  O:3_H7U_\
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M>Q_;/]S\?^ ?'GER?W6_(T>6^/NM^1K[#VCT%,F53"^5!^4]O:CZE_>_ ?\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %,F_U+_P"Z?Y4^F3?ZE_\
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MIZ([,P^&)-1117VQY84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0.#D?3*Y_$U[17 _"3P5/X*\(""_55U&[D,]P%.=O "KGO@#\R:[Z@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *P?%?_'A#_UU_H:WJP/%?_'A#_UU
M_H::W%+8W(O]2G^Z*?3(O]2G^Z*?2&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4R;_4O_ +I_E3Z9-_J7_P!T_P J!H^/#T%>Q? C_F/_ %@_]GKQ
MT]!7L7P(_P"8_P#6#_V>O*PW\5'U.8_[K+Y?FCV2BBBO5/E0HHHH **** "B
MBB@ JIJO_()O/^N+_P C5NJFJ_\ ()O/^N+_ ,C4S^%ET_C1X4W4UZ5\-O\
MD%7?_78?^@BO-3U->E?#;_D%7?\ UV'\A7SN6_[POF?2YI_NS^1VU%%%?2'R
MX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>(_\ CTA_
MZZ?T-;-8WB/_ (](?^NG]#7EYU_N%3T_5'1A?XT3FSWKM[3_ (\X/^N:_P J
MX@]Z[>T_X\X/^N:_RKYWA7^+4]$=F8?#$FHHHK[8\L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBLKQ)KEOX;\.WVL7(+16D1D*CJQZ #ZD@?C
M0!JYII12<D#-?,_A+6/B!\1O'EEJJSW?]F6M[').L<ICMXD# E ,X8X[<D]Z
M^DKZ\@T[3[B\N7V06\;2R-Z*HR3^0H +B:UM(_,N)8X4_O2.%'YFBUNK2[3?
M:SQ3+ZQN&'Z5\G./%7QI\9SB!\QQY9%D8K#:Q9X_'Z<DU9U7P=XV^$D\.NVE
MV# &"O/:NQ3/]V12!P?<8H ^L**Y[P1XI@\8^%;/6(5V-*NV:/\ N2#AE_/I
M[$5T- !1110 44A.!DUX3XM^-&LWWB-M \"68N75C']I6+S7D8=2B] H]2#Z
M]* /=Z*^=;GQ_P#%GP2Z77B2Q6ZLF(R984VCVWQ8VGZ_E7M7@[Q=I_C3P_%J
MVGDJK'9+$_WHG'53^?7N* .@HHHH **PO%WBO3_!V@S:MJ+-L3Y8XT^]*YZ*
M/\\5XU:^./BSX[,EWX8L(K'3U8A'"1@,/3?+]X_[N* /H*BOGRP^,OBWPEKZ
MZ3XZTT.H($DBQA) ">&&WY6'7H.?6O?;2ZAO;2&ZMW$D,R+)&XZ,I&0?R- $
MU%%% !6#XK_X\(?^NO\ 0UO5@^*_^/"'_KK_ $--;BEL;<7^I3_=%/ID7^I3
M_=%/I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M )!-Y_UQ?^1J9_"RZ?QH\*/4UZ5\-O\ D%7?_78?^@BO-6ZFO2OAM_R"KO\
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M:W59,_W\9;_QXFO/?BK\5=!M_"E_I.D:C#>ZA>1M;D0'<L2GAR6''3(&.YH
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M)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWB/_ (](?^NG]#7EYU_N%3T_4Z,+_&B<V>]=O:?\><'_ %S7^5<0>]=O:?\
M'G!_US7^5?.\*?Q:GHCLS#X8DU%%%?;'EA1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !3)O]2_^Z?Y4^F3?ZE_]T_RH&CX\/05[%\"/^8_]8/\
MV>O'3T%>Q? C_F/_ %@_]GKRL-_%1]3F/^ZR^7YH]DHHHKU3Y4**** "BBB@
M HHHH *ANX#<V<\ 8*9$9,GMD8J:BDU=6&G9W1YN?AI>$DC48/\ OV?\:/\
MA6EY_P!!*W_[]'_&O2**X?[-P_;\6=_]J8G^;\$>;_\ "M+S_H)6_P#WZ/\
MC1_PK2\_Z"5O_P!^C_C7I%%']FX?M^+#^U,3_-^"/-_^%:7G_02M_P#OT?\
M&C_A6EY_T$K?_OT?\:](HH_LW#]OQ8?VIB?YOP1R7A?PA/H&I2W4MW','B,8
M54([@_TKK:**ZJ5&%*/+#8Y*U:=:7//<****U,@HHHH **** "BBB@ HHHH
M**** "BBB@ K&\1_\>D/_73^AK9K&\1_\>D/_73^AKR\Z_W"IZ?JCHPO\:)S
M9[UV]I_QYP?]<U_E7$'O7;VG_'G!_P!<U_E7SO"G\6IZ([,P^&)-1117VQY8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117C7Q3^).MV.
MOQ>$/"<3MJDJKYLL:;G!;E50= <8))Z9_&@#V3(I:^1/$,7Q%\,:CILOB+5-
M2A>]DS'G4#)NVE<_=8XQN'YUZO\ %ZY\<Z%K=IXA\.2W(TNWM0MRL;!D#!R2
M7C/;!'../6@#V2BN8\ ^+XO&WA2VU=(Q%*28YXAT21<9 ]N01[&NGH ****
M"BBB@ HHHH 3'-+110 48HHH **** "BBB@ K!\5_P#'A#_UU_H:WJP?%?\
MQX0_]=?Z&FMQ2V-N+_4I_NBGTR+_ %*?[HI](84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !3)O]2_^Z?Y4^F3?ZE_]T_RH&CX\/05[%\"/^8_]8/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR O$3[C[R_3GZT >ST54T[5+#5[1;K3KR"Z@;I)#(''Z=ZMT %%%% !1110
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M3_CS@_ZYK_*N(/>NWM/^/.#_ *YK_*OG>%/XM3T1V9A\,2:BBBOMCRPHHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F3?ZE_]T_RI],F_U+_[I_E0-'QX>@KV+X$?\Q_ZP?\ L]>.GH*]B^!'_,?^
ML'_L]>5AOXJ/J<Q_W67R_-'LE%%%>J?*A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!YYXA\&:MJ>MW-W;_9_*D(*[I"#T^E=7X9T
MVXTG0X;.YV>:A;.PY')S6Q17-3PM.G4=2.[.JKC*E6DJ4MD%%%%=)RA1110
M4444 %%%% !6-XC_ ./2'_KI_0ULUC>(_P#CTA_ZZ?T->7G7^X5/3]4=&%_C
M1.;/>NWM/^/.#_KFO\JX@]Z[>T_X\X/^N:_RKYWA7^+4]$=F8?#$FHHHK[8\
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;,JR[HV3!8''7Z&NBKG/"G@G0_!D=U'HMNT*W+*TNZ0OG ..OU-='0 4444
M%%%% !1110 4444 %%%% !1110 4444 %8'BO_CPA_ZZ_P!#6_6#XK_X\(?^
MNO\ 0TUN*6QMQ?ZE/]T4^F1?ZE/]T4^D,**** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)O\
M4O\ [I_E3Z9-_J7_ -T_RH&CX\/05[%\"/\ F/\ U@_]GKQT]!7L7P(_YC_U
M@_\ 9Z\K#?Q4?4YC_NLOE^:/9****]4^5"BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?O$-SJOA2]TRY=Y/[-G58W9L_NV!POX%3^=>O4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6#XK_X\(?\ KK_0UO5@>*_^/"'_ *Z_T--;BEL;D7^I
M3_=%/ID7^I3_ '13Z0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3
M?ZE_]T_RI],F_P!2_P#NG^5 T?'AZ"O8O@1_S'_K!_[/7CIZ"O8O@1_S'_K!
M_P"SUY6&_BH^IS'_ '67R_-'LE%%%>J?*A1110 4444 %%%% !1110 4444
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MEMIQG&TXZ5[I6-<>$O#EW<27%SH&ES3R-N>22SC9F/J21DF@#Q'_ (:4NO\
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M)!.,'=CVZ5Z5110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'BO\
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M!#9?M&>((H MWI&GS./XT#IGZC)JS_PTAJW_ $ ;3_OMZ]Z7P_HZ($32K%5
MP += !^E._L'2/\ H&6?_?A/\* .,^%GQ$N_B!;ZG)=6$5J;-XU7RR2&# ^O
MTKT.J]K8VEDK"UMH8 W+"*,+GZXJQ0 4444 %%%)D"@!:*3</6EH **** "B
MBB@ HHS10 4444 %8/BO_CPA_P"NO]#6]6!XK_X\(?\ KK_0TUN*6QN1?ZE/
M]T4^F1?ZE/\ =%/I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4H$PV, YJ&]UF"U8HH,D@Z@=!^-;RS##QH+$2E:+V_X;<E49N7(EJ:5%<_\
M\)(^?^/88_W_ /ZU:-EJT%Z0@RDG]T]_I6&'SC!8B?)">K[W7YE3PU6"NT7Z
M*BN)?(MY)<9VJ3BL:'Q \LZ1_9U&Y@,[JUQ68X?"SC3JRLWMHR:=&=1-Q6QO
M445@/XA=92OV=>#C[U/&9A0P=G6=K[:/] IT9U+\J-^BHVEVVYEQT7=BL1/$
M3-(JM H4G!.[I2Q698?"N,:LK<VVC"G0G4NXK8WZ*Q)_$*(Y6&'>!W)Q3K77
MXI9 DT?E9Z'.16"SO NI[-5-?G;[]BWA:J7-8V:*.HS17JG.0W5PEK;O,_11
MT]:YB;5;VZEPCLN>BQ\5TE]9B]@\HR%!G.0,U4LM%CL[@3"5G(' (Q7SV:X;
M'XJO&G2?+3TNT_OZWT.S#SHTX-RUD8LDNIVN&DDG4'IN8XK7TG5FNV\B?'F8
MR&'>I=<=%TUU;&YB OUS6'HZ,^IQ;>W)^E>4W6RW,84*=1R4K73\W;_@G1[M
M>BYR5FCKJ***^V/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2OF;Q
MQXXT_0/B^^OZ"+G^T+:1K74+>= L4VT;#M8'/('<=0#7TS7!:E\&_!6K:G=:
MC=Z;*]Q=2M+*PN74%B<DX!XYH YN#]HSPJT2F;3]720CYE6*-@#]=XS^52?\
M-%>$/^?+6/\ OQ'_ /'*UO\ A1?@+_H%3?\ @7)_C1_PHOP%_P! J7_P+D_Q
MH V_!'Q!TGQ[%>2:5%=QBT95D%P@4_-G&,$^AKK*Y[PKX)T+P9%<QZ):M MR
MRM+ND9\E<XZGW/YUT- !1110!'<3Q6T$D\SJD4:EW=C@* ,DG\*^<-1\6^,O
MBWXLGT?PO/)8Z5'GI(8P$SC?*PY)/]T?EU->J_&;4_[,^&.JD,0]R%MEP?[[
M#/\ XZ&KGOV>-*2U\#W6HE1YM[=M\V.=J  #\RWYT <5K'@CXB_#FR?7--U]
M[F"$!IQ#(QVCN61AAEKUWX8>/4\>>&S<RHL6H6S"*ZB7IG'##V//X@UV-W;1
M7EI+;3H'AF0QR*>ZD8(_(U\V_ RY?2OBCJ>CJ[&*2&:,C/5HWX/Y _G0!],4
M444 %><?%WQ^O@_P_P#9+)S_ &Q?J8[<+UC7H9/PZ#W^E=MKNM6?A[1;K5;^
M39;6R%WQU/H!ZDG  ]Z\,^'>E7GQ-\?W?CC7(V-A:2?Z+"W*;Q]U!ZJHY/J2
M/4T <S\'[G5%^+EE9W]Q=;U\X2Q2R-]X1MU!/K7U57S3X+S_ ,-*7F3G_3+O
M_P!!>OI:@ HHHH *P?%?_'A#_P!=?Z&MZL'Q7_QX0_\ 77^AIK<4MC;B_P!2
MG^Z*?3(O]2G^Z*?2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX$$'X6V0'::;/_?9K:^*6BOKOPYUBTAB,DZ1>?$HZED(;CWP"/QKSW]G;Q'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4R;_ %+_ .Z?Y4^F3?ZE_P#=/\J!H^/#T%>Q? C_ )C_
M -8/_9Z\=/05[%\"/^8_]8/_ &>O*PW\5'U.8_[K+Y?FCV2BBBO5/E0HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(S&Y0,6 (P<9-<[X+AEE\9Z3LC9MMTC':,X (YKZ'C\#>%8FW+X?TX'_ *X
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M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %96O^(]*\+Z>+_6+M;:V:01ARI.6.<#CZ&M6L#Q=X0TSQKI":9JHE\A)
MEF4Q/M8, 1UP>Q- &)_PN'P+C/\ ;T7_ 'ZD_P#B:/\ A</@7/\ R'HO^_4G
M_P 36'_PS]X-_P"HA_X$#_XFC_AG[P9G_F(?^! _^)H W/\ A</@7_H/0_\
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MU&<&(,.J("-WXEF_*O8JC@AAMH(X((TCBC4(B(,*H'  '85)0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %8/BO_CPA_P"NO]#6]6!XK_X\(?\ KK_0
MTUN*6QN1?ZE/]T4^F1?ZE/\ =%/I#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]B"#^-=97AW[-HG_ +'U\MN^S&YC\O/3=M.['X;:]QH **** "BBB@ HHHH
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M $VB:'<:GH^J27S6Z&22WEB",4')*D'D@<XKB/AOXZOO!7B2"19F.FSR*EW
M22K(3]X#^\.H/X5]<3:OH\B/#-J%D58%75ITY!X(/-<BG@/X8M* FF:,7)X
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M^O$_^C&KLOV<O^1)U#_K_;_T!* /9*\6_:'\2_8?#MGH,+D2W\GFR@?\\DZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1/I.D7TES<R3Q,/W#H %;).6 H XKX$<_%*QSSB&;'_?!KTS]H[_ )$_3/\
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M'H_.M6(/0SID?\"%?3^M_&OP--HM[!;ZK)-++;R(BK:RC)*D <J.]?,.C_\
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M.3P=X'M-.N0!>2$SW(!R!(W;\ %'X&@"U\1?$8\+>!M3U)9-DXB,5N>_FO\
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M0!Z?17'>$_B9X>\9ZC+8Z1+.T\4?FL)(MHVY _J*[&@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK7U':W$=Y:0W,+;HID$B-ZJ1D'\C0!+1110 5@^*_P#CPA_ZZ_T-;U8'BO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;4]3T:&YO&VYE9F!..G0X[5TW"C Z"EKR#XM?%A/#L<F@:%()=8E&V65.1;
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MT_G7MU5(\K(_X<_4****D]P**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I"<"EHH ^;?%WQM\37VN7&BZ&MMID:7+6ZSD@R
M-AMN2S?*H_#CUK6T+X%7>NR+JGBWQ&]TTOS%+67S2V>>9&S^@/UKO_%'P?\
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M/J<#]: /IP=!2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"+I/\ AFR'_H:I_P#P#'_Q=>\44 >(Z;^SO!I^IVMY_P )-</]GE67;]E
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M=*^H:Y>7<"_\L8XUBS]3DUZSH/A[2_#.EIIVD6D=M;)SM7JQ]6)Y)]S6G10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*/\ @2J1^M ';45GZ5KNE:Y;F?2]0MKN,8R89 VW/KCI^-:% !169J_B+1]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% 'SI\>_&%]<Z[#X2L9GCMXU1[E$./-D;E5/L
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M':0B_4AB?RH ]?\  NOR>*/!>EZQ,JK-<0YE"]-X)5L?4C/XUT5<G\--&N=
M^'NCZ?>(4N4AW2(>JEB6Q^&:ZR@!&Z5\I_"GPAI7C+QYJMOK$1FM8(I91&&*
M[F\P '(YXR:^JI6"QLQZ#DU\I?"_QOI7@?5-?U+4$EFEE01P0Q#YI#O)(R>
M.!0![7_PH_P)C_D$O_X$2?\ Q5;/AKX<>&O"6HO?Z/8M!</&8F8RLWRD@XY/
ML*\JN/CUXFMY!=R^$UBTUF&TR"0,5_WSQG\*]/\  7Q(T?Q[:R&SWV]Y",S6
MDI&]1_>!'WE]_P \4 =E1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5@>*_\ CPA_ZZ_T-;]8/BO_ (\(?^NO
M]#36XI;&W%_J4_W13Z9%_J4_W13Z0PHHHH **** "BBB@ HHHH **** $)"@
MDD #J37.:KK!G)@MSB/H6_O?_6I==OI3.;53MC&,X[U0L1:"3?=.=HZ*!G-?
M'9OFTZU5X.@^5;-O3U^7Y_GZ6&PZC'VL]>R+.E:4UVXEE!$(_P#'JZA5"J%
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M\ 30!]-4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8/BO_CPA_ZZ_P!#6]6!XK_X\(?^NO\ 0TUN*6QN1?ZE
M/]T4^F1?ZE/]T4^D,**** "BBB@ HHHH **** "BBB@#,N]&BO+AIFED4GL,
M5!_PCD'_ #WE_2MJBO-J91@JDW.=--O7J;K$54K)F+_PCD'_ #WE_2KEAI<=
M@[LDCL6&/FQ5ZBJHY5@Z,U4IP2:]12Q%22LWH%%%%>@8A1110 4444 %%%%
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M3GD9SS7H5% 'BG_#-^A8_P"0YJG_ 'S'_A2_\,X:'_T'-4_*/_"O:J* .?\
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MZ/J$HBMKZ-I&Z*P*D_3(%:U.,XS5XNXIPE!VDK!1115$A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%5KZ_L],M)+N^NH;:WC&7EF<*J_4FN,N
M/C+X"M[@POKZ%AU*6\K+^87!_"@#O**R-$\4:'XCB:32-4MKP+]Y8G^9?JIY
M'XBM>@ HH) ZUQ=_\5_!>FZLVF3ZW&;I7\MECB=U#9QC<!C/XT =I10.110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2<C[1,V]P.B^@KFP4?\ :6Z7P'5CY?[+%5OC_K]#H****]L\$**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#YL^*I\2^-?B-%X=M;>]73(9D@AS
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M[P0/TKKOAY\9-/\ &E^-*O+7^S]3()C3?N2; R0IXP?8_G0!Z?1110 4444
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MT&KZ3=Z=<AC!=0O#)M.#M8$''OS7SCH!\0? _P 5WAU/39KK1+G$<ES"N58
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\5_P#'A#_UU_H:WJP?%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\5_P#'A#_UU_H:WJP?%?\
MQX0_]=?Z&FMQ2V-N+_4I_NBGTR+_ %*?[HI](84444 %%%% !1110 4444 %
M%%% !115>^OK?3;&:\NI!'!"A=W/8"@:3;LBQ17D4GQUM5=MNAS,@/!^T $C
MZ;:]6L[@7=E!<A2HEC60*>V1G%1"I&?PLVK8:K12=16N3T4459@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;#;)&?\ :4\C^1H WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \5_P#'A#_U
MU_H:WZP?%?\ QX0_]=?Z&FMQ2V-N+_4I_NBGTR+_ %*?[HI](84444 %%%%
M!1110 4444 %%%% !7AWQ<\9'4+W_A'-/?=!"_\ I++SOD'1?H/Y_2N]^(_C
M!?"^A-';R :E= K .Z#N_P"';WKSWX4^#6U:_/B#4XF>V@;, ?\ Y:RC^+W
M_G]*Y:\G)^RC\SU,#2C2B\35V6WFSS2^M)["ZN+2YC,<\+%)$/\ "PZBOK31
MO^0)8?\ 7M'_ .@BOE[QB<^+M;)ZF\F_]"-?4.C?\@2P_P"O:/\ ]!%9X16E
M)'1FTN:E3;_K8NT445W'AA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %'2B@C(H CBGBG3?%*DBY(RK C([5)7S_K7PU^(/
MA;6[W6O".K-<1W$[2F")]CX)SAD;Y6Q_D5+I'Q[U/2+O[!XST"6&5.&D@0QN
M/K&W!_ CZ4 >]T5SWA[QQX<\4Q;])U2"=^\1.V1?JIP:Z'- $5Q/%:V\D\\B
MQQ1J7=W. J@9))]*^<+TW7QG\=WMT?.C\-Z/"Y4CT )'_ G(S[ >U=#\:_&=
MQ?W4'@/0@9;NZD1;KRSR23\L7\B?P]Z[SPYX.MO!/PZFTR$*UP;:22ZE'_+2
M4H<GZ#H/84 >2?LW?\C1K7_7FO\ Z&*]Q\<>(!X7\&ZGJX_UD$)\KC/[QCM3
M_P >(KP_]F[_ )&?6_\ KS7_ -#%>@_'R9HOAG*J]);J)&^G+?S44 <)\#_!
M=GXHNM1\4Z]$M\8YS'"DXW*TA&YG8'@]1C/J?:O4_'?PZT7Q-X;NH8].MH;]
M(RUM/%&$97 R 2.H/3!]:SO@5$D?PML61<&265V]SO(_D!7I)Z4 >"_LZ^)I
MI4U'PS<2EEA7[3;*>JC.''TR5./K7M-WH&CW\[3WFDV-Q,V,R36Z.Q_$BOG3
MX/*+?XU7T40V1^7<KM'INX'Z"OIR@#(_X13P[_T -+_\ X_\*\ ^.L^EKKFG
M>&M%TNT@G0"6<V\"(S._")D#/3G'^T*^B]4U"WTG2[K4+M]EO;1-+(WHH&37
MS3\,-/G^(/Q=N?$&H1AHK:1KV48^4.3^[7\#@CV6@#Z!\$>'4\*^#=,TA1AX
M(09><YD/S/\ ^/$UT%%% &;XAOI-,\.ZE?Q#,EM:RRH,9^94)'ZBOG;X(>&+
M'QCXFU76=>"WSVFV013?,'D<L=[#OC:>#QS7TO<0175O)!.@>*5"CJ>C*1@C
M\J^:=7T;5?@EXI;5M&U.RN+"<E/L<LO[QHR<[73KQV8?_6H ^B+[P_I&H6+6
M=YIMI-;%=OEO$N /;T_"OF[P_"W@;]H%=)TN9S:->&V9-V=T3C(5O7&1^*UL
MWG[2.HRV9CM/#MO;W##"S2W1D4'UVA1_.MGX2^ I;O7#XXUO5+6_O)"TD202
M"3:[=6<CH<$X% 'N(Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#XK_X\(?\
MKK_0UO5@>*_^/"'_ *Z_T--;BEL;D7^I3_=%/ID7^I3_ '13Z0PHHHH ****
M "BBB@ HHHH **** /F[XK322?$"^61RZQB-44GA5V X'XD_G5S3OB]K6EZ?
M#8V>FZ5';PKL1!')P/\ ONO<+SPUH>H7+7-YH]A<3O\ >DEMU9C]215=O!OA
MC!_XI[2_PM$_PKC=":DY1E:YZZQ]!TXTZD+V/E[4;V35-2NKV=5$ES(TKA.
M"QR<>W->O_#GXA:QK>O6NBW<=J+9+<@,B$-\B\=3[5Y/K\4<&NZC%!&J1I<2
M*B*.%&XX KZ8\.>']&L=/L+NTTJS@N3;)F:.%5<Y49YQGFLL/&3F[,[,QJ4X
MT4I1O?;R-^BBBO1/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\5_P#'A#_UU_H:
MWJP?%?\ QX0_]=?Z&FMQ2V-N+_4I_NBGTR+_ %*?[HI](84444 %%%% !111
M0 4444 %%%% !1110!S4_P /O"EU/)//HEL\LC%G8[N2?QKHHHDAB2*-0J(H
M55'8#H*?1244MD7*I.>DFV%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH IV.E:?I@D%C9P6_FN7D,2!2[$Y))
M[FKE%% !1110 4R:))X7BE4/&ZE64]"#P13Z* ,'0?!GAWPQ<33Z-I4-G+,N
MR1HRV6&<XY)K>HHH SM7T'2=>M_L^JZ=;7D7831AL?0]1^%9VC> _"WA^X^T
M:7H=G;S]I0FYA]"V2/PKHJ* "HKFWBN[:6WG0/#*I1T/1E/!%2T4 <_H?@?P
MSX;O'O-(T>VM+AUV&1 2<=QR3CI70444 %<SJ?P^\*:SJKZIJ.B6UQ>N06E;
M=DX&!G!QT KIJ* $ "@ # ' JEJ>BZ9K5N;?4["VNXC_  SQAL?3/2KU% '(
MVWPN\$6EP)XO#=CYBG(WJ7 _!B1^E=7##%;Q+%#&D<:C"HB@ #V I]% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#S#X]V<EU\,Y9(QD6]U%*_TR5_FPIOP"N8YOAG#$ART%S+&
MX]"2&_DPKN_$^B1^(_#.HZ/*VQ;N!HP_]UOX3^! /X5\Z_#;QG+\+/$>H^'_
M !+!-!:R2CS"%+&&0<;L=U(]/8T ?3[' S[U\Q_!Q3=_&R_N(AF,+=2$^Q?
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M8<J.>_X1N;_H)2?]\G_&C_A&IO\ H)2?]\G_ !KH:*+L.5'/?\(U-_T$I/\
MOD_XT?\ "-3?]!*3_OD_XUT-%%V'*CGO^$:F_P"@E)_WR?\ &C_A&IO^@E)_
MWR?\:Z&BB[#E1SW_  C4W_02D_[Y/^-'_"-3?]!*3_OD_P"-=#11=ARHY[_A
M&IO^@E)_WR?\:/\ A&IO^@E)_P!\G_&NAHHNPY4<]_PC4W_02D_[Y/\ C6?J
MVFS:9#')]MDDWMMZD8X^M=C6!XK_ ./&#_KK_0TTW<3BK#%\.3L@/]HR#(ST
M/^-+_P (U-_T$I/^^3_C6_'_ *I/H*=2NQ\J.>_X1J;_ *"4G_?)_P :/^$;
MF_Z"4G_?)_QKH:*+L.5'/?\ "-3?]!*3_OD_XT?\(U-_T$I/^^3_ (UT-%%V
M'*CGO^$:F_Z"4G_?)_QH_P"$:F_Z"4G_ 'R?\:Z&BB[#E1SW_"-3?]!*3_OD
M_P"-'_"-3?\ 02D_[Y/^-=#11=ARHY[_ (1J;_H)2?\ ?)_QH_X1J;_H)2?]
M\G_&NAHHNPY4<]_PC4W_ $$I/^^3_C1_PC4W_02D_P"^3_C70T478<J.>_X1
MJ;_H)2?]\G_&C_A&IO\ H)2?]\G_ !KH:*+L.5'/?\(U-_T$I/\ OD_XT?\
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M^3_C70T478<J.>_X1J;_ *"4G_?)_P :/^$:F_Z"4G_?)_QKH:*+L.5'/?\
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MQ:B_U*?[HI](J[4"^@Q2TAA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -?_ %;?0U@^%/\ CSN/^NG]!6^1D$>M4M,TU-,B>-'+AVW9-/H+J7J*
M**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .>O_\ D;;+_<'_
M +-70U0GTQ)M4AOBY#1# 7L>O^-7Z;$@HHHI#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K \5_\>4'_77^AK?JCJ>FIJ4*1NY0(V[(IK<3V+D?^J3Z
M"G4BC:H'H,4M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% #9/]
M4_\ NFL+PI_QXS_]=/Z"MYAN4CU&*I:9IJ:9"\:.7#-NR:?074O4444AA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <]>_\C=9_[@_]FKH:H3:8
MDVJ17Q<AHQC;V/7_ !J_38D%%%%(84444 %%%% !1110 4444 %%%% !1110
M 4444 %<_P"*_P#CTM_^NG]*Z"J.IZ:FI11H[E-C;@136XGJBXGW%^@IU(!A
M0/04M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)O]3)_NFL3
MPI_R#YO^NO\ 05NLNY"OJ,53TS3DTR!HD<N&;=DT^@NI=HHHI#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH YV[_P"1PM?]P?R:NBJA+IB2ZK%?
MF0AD&-O8]?\ &K]-B04444AA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7/:CXZ\+:3=M:WVO6$,ZG#1F8%E^H'3\:X'XZ>/;GP[I4&B:7.8KZ_4M+(AP
MT<73CT+'(S[&L?PC\ +"YT*"\\27=V;ZXC#F&%PJP@\@$D$EO7M0![7INJV&
MKVHNM.O(+J ])(9 Z_F*N5\NZ_I6K_ _QO97^EWDMQIEUR _ E0$;XW X)&0
M0?<&OIC3;^#5-,M;^V8M!<Q++&3U*L,C^= %JBBB@ HHHH **** "BBB@ HH
MHH **** "BBD8X!-  S!5))  &237/V7CGPQJ.KII5GK=E/>NQ588Y-Q) R0
M.QX!_*O#?$/BKQU\4-<NO#V@6TEOI:2F*3RLJI4'&99/3V'Y&L#X;:5+H?QW
ML-*FD262TNKB%G3[K%8W&1F@#ZRHHKR3XZ>.+SPUH=OI6F3^3>:ANWR*<.D0
MQG![$DXSZ T =WJ?CCPQHUTUKJ&N6,%POWHFF!9?J!G'XU?TG7M*UR%IM+U"
MVO(UZF"4/CZXZ?C7A?P^^!UAKOAJUUKQ!>71DO$\R*"%@H5#T+$@Y)ZU@>/?
M ]_\)-6T_7?#NIW/V=W*I(^-T;CG:V.&!&>W8T ?4E%8WA/7!XE\*:;K 0(;
MJ .ZCHK=& _$&MF@ HHHH **** "BBB@ HHHH **** "HYYXK:%YIY4BB099
MW8*JCU)/2GG@&OF+XDZ_J_C_ .)B>$K"XV645T+6%%;Y6<?>D;UQSCV''6@#
MW4?$CP:9_)'B332^<?Z\8S]>GZUTL$\5S"LT$B21N,JZ,&!'L17CZ?LZ^'!I
MHB?4M1:\QDW&5QG_ '<=/;.?>N*\!ZKK'PT^*G_"(7UR9;"XN%MW0GY<OCRY
M5],Y&?8\\B@#Z9HH%4-:UBST'1[K4[^416UM&7=C^@'J2< #U- %36O%N@^'
M9(H]7U6VLWE!:-96P6 X) J_INIV6L:?%?Z?<QW-K*"8Y8SE6 ../Q!KY \9
M7FL^,8[OQO?+LL7O%L;=#_ -K,%7U  Y/J:^D/@Y_P DHT+_ *YR?^C7H [J
MBBB@ HHHH **** "BBB@ HHHH ****  G%<YJ'CWPKI=RUM>:_I\4Z\-'YP8
MK]0,XKR[X_>,]2TXVGAO3IG@2ZB\VY>/(9U)("9]."3Z\4GA']G_ $V;1K>\
M\1W5V]Y/&'-O$P18LC.#P22/P% 'L>D^(-)UR,R:7J-K>*.I@E5L?4#D5I5\
MQ?$/X=77POFL_$?AS5+E;<2B/<S 20N<D<C 93@]NW->[?#[Q,_B[P3IVL2J
MJSR*4F5>@=25/YXS^- '3]*YN^\?^%--NFMKO7]/CF4X9/.!*GWQG%>7?&KQ
MOJ,^KVW@?09'6>Y*+=/&V&9G^[%GMP03]1[UJZ-^S[X;M]*$>K3W=[?.HWS)
M+L5&_P!@8Z?7- 'JFG:K8:M;"YT^\@NH3TDAD#C\P:N5\H:S9:I\&/B/ VFW
MDTEHVV50>!/"3@HX'!Z$?D1BOJJVG2ZMHIXSF.5 ZGU!&10!+1110 4444 %
M%%% !1110 4444 %%%% !6+K7BS0?#CQ)J^J6UFTH)C65L%@.I JWK.KV>A:
M1=:G?RB*VMHR[L?Y#U)/ 'J:^1/&5[K/C-+SQO>KLL6O%L;=#_ -K,%7UP!R
M?4T ?7^F:G9:QI\5_IUS'<VLH)26,Y5L'!Q^(-6ZX+X,?\DHT/\ W)/_ $:]
M<G\>?'=[H=K;>'M,F:">]C,EQ,APPBSM"@]LD'/L/>@#TC4O'7A?2+DVU]KM
MA#..L9F!8?4#.*N:1XET77E8Z5J=I>;?O"&4,1]1U%>2^#?@'I)T>"\\3/<7
M-[.@=H$D*)%D9QQR2._.*YWXD?"K_A [./Q-X7O[N)+>4>8A?YX<GAE88XS@
M<^M 'TC17%_"WQ;-XQ\#VM_=D&]B8P7) P&=?XL>X(/US7:4 %%%% !1110
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MH+VW2XMIHYH7&5>-PRL/8CBIJ^7?#E[JWPE^+ \/S7CSZ;-<)%,G(21' VR
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M<7%R9'/ 5057ZG[N*^HSR*^,?"7AD^(_B3;Z%>;XXY+IQ< '!VIN9A]3M(H
M]>O_ -HF$7$O]E>&KB[M(SCSI)]F1ZX"G'YUT_@KXO\ A_QK?)ITULUAJ+?Z
MN&<AUD]E;')]B![9KO+'1].TRQCLK*SA@MHU"K'&H Q_7ZFOG'XZ^'K7POXM
MTW5]'C%F]VIE98?E"2HP^9<=,Y'XB@#UGXV7@M/A;J2C.;AHX1CMEP?Y*:R_
MV?+*.W^'37"@;[F\D=C] % _0_G4?Q7N)]7^"$.H,HWNMM<2X[;@,_JPJW\
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M"K_7Z T >(?#'QO)\,IK[PWXML[FRMFF,J3&(MY;X 8''WE(48(S^M>@ZO\
M';P9::?+)IMW+J-WC]U;QV\B;F[99E  ]>IK@O"GAC7OC2\FM^*M5FBTF&0Q
MP16ZA=S=2%SPH'')R373ZS^SWHGV-I= U"^M-0C&Z)II Z,PZ9P 1GU'3TH
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M-OF-DL,3>KH!M_\ 'E%>+_!/QM;>$M0U'PSK\OV%)9MZ//\ *L<P^5E8GID
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M+0>$_%0U^ZUEM1G16\M6M_+P[<%B=QR<$_G0!Z-HNE6^B:)9:9:J%AM85B7
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M=T&U+Q#=75L.D4, B)_X$6;^5>M^'_#FE>%]+33M(M$M[=>2!R7/]YCU)]Z
M-6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***Q;OQAX:L+E[:[\0:5;SH</'+>1JRG
MT()XH VJ*Y[_ (3SPA_T-.B_^!\7_P 53H_''A.618X_$VCN['"JM[&23^=
M&_10"",@Y%% !1110 45'<7$-K!)/<2I%#&I9Y)&"JH'4DGH*K:;K.F:S"TN
MF:A:WD:G#/;RK( ?J#0!=HJIJ&IV&DVIN=1O;>T@!"^;/($7)Z#)J2TO+:_M
MDN;.XBN('&4DB<,K?0B@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **R?$'B32O"^FG4-8NQ;6V\(&*EB6/0 #DUH6MS%
M>VD-U 2T4R!T)4C*D9!P: )J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1ONGZ5\AZUHR>
M(OCC>:/+*84N]4:)I%7)4$]0*^O&^Z?I7RM P7]I)2Q ']LGDGWH [G_ (9M
MTO\ Z&"Z_P# =?\ &I(/V<M,AN8IO[>N6V.&VF!><'IUKVKS8_[Z_P#?0H$L
M;' =2?0$4 .1=B!<YP,4M17-S#9VTEQ<2I%#$I=Y';"JHY))["O&-7^/;W6I
M2:;X/T*;4Y\XCE=6._'4B-?F(^I% 'ME%>"I\:_&6ALLOBKP<T-JQP'2*2W.
M?J^X'Z<5ZYX3\7:3XRTA=1TF?>@.V2-AAXF]&';^1H K?$0X^'?B$_\ 3A-_
MZ":\Y_9N4#P[K+=S<H#^"G_&O1OB+G_A77B'_L'S?^@FO._V;_\ D6M8_P"O
MI?\ T&@#4_:$./ANO_7]#_)ZWO@Z /A5HF/[DG_HQJP?VA/^2;K_ -?\/_H+
MUO?![_DE>B?[DG_HQJ .YHKG_%WC+2/!>DG4-5F(#';%"@R\K>BC^9Z"O)3\
M:_&>NDS>%O!S36B':S-#+<<^F4V@?3F@#WJBO%=%^/)@U./3/&.B2Z3.<!Y5
M5@J$]"R,-P'ODU[+%-'<VZ36\J21R*&1U.Y6!Z$$=10!+17C'AKXMZY=_%!O
M"NN6NGV\/GRVX>%'#;USMY+$<D8Z=Z]F)P,T +17@GCOXYZUH'C&_P!(TBRT
M^2VLW$323H[,S@#=T8  '(_"O7/!7B-?%GA#3M:"JCW$?[Q%Z*X)5@/;(- &
M_17!_%3QY/X#\.0W=E%!->W$XBB2?)4  EFP""<<#KWK7\ ZUJGB+P=8ZQJT
M5O%<7:F18X%955,D+]XDY(&?QH Z6BB@T %%>/>$_BOK6O?$^?PU<V=BEFCS
M*'C5Q(-F<<EB#T]*]AH **\?^(OQ5UKPAXWM-%L;2QEMY$C9FF5RQW$@X(8
M=/0UZ\IR@)[B@!U%>,ZA\9KO1_BC<Z#J4=E#HMO(4>XV.9% 7.>N#S[4S4?C
M#XHU3=)X.\&7EU9AB%NY[>219 .X"XQ^9H ]IHKQ3PW\>3_:RZ5XPTDZ7<%]
MC3*&58R>F]&^91[Y/TKVI65U#*05(R"#G- "T44A.!0!X3\7;IO%'Q*\->#(
M6#PK*DMRJGD%CSGZ(,_\"KW5$"(J* %48 '85\\?#]CXJ_:#U?6F;,=H9Y4]
MUSY2#_ODC\J^B3TH **\5\0_&74?#WQ4E\/W,-@FC03QI+.R.9%0HK,<AL9&
M?2H+_P"-/BC5F>3P?X0GN;)'*_:9H))0X'LF OTR: /<:*\2\*?'U+K58]+\
M4Z8-.F9MAN(\A$;T9&Y7ZY-6M;^-=W=:A<:?X(T"?6)(.&N?*=T_!5Y(]R10
M!['17@FG_'S5]+U-;+QAX=-KDC<T*/&\8/<H^<_F*]SL+ZVU.Q@O;.99K:=!
M)'(O1E/0T 6**Q/%/BO2?!^COJ6K3^7$#M1%&7D;^ZH[G^5>0/\ &[Q;KSL_
MA/P>\]O&<.SQ27!_'9M /YT >]45XEI7QXN+'48]/\9^'YM,E;[TL:,NP=B8
MV^;'N"?I7L]I=07UI%=6LR302J'CD1LJRGH0: )J*\[^+7CW4O >D6%WIL%K
M-)<7!C87"L0 %SQ@CFN;;XYSW>E:?!HNA/JFNW%MYL\-N&:.!L], $GUZCKU
MH ]HHKY_C^._B?1-06+Q7X66")N0L<;P2 >HWD@_I]:]MT#7K#Q-HEMJVF3>
M;:SKE21@@C@@CL0>* *OBWQ58^#M!DU?4$FDA1@@2$ LS'H.2!3?!OBB'QCX
M:@UJWMWMXIV<+'(06&UBO./I7@_Q4\6^.-2T^]TO5O#?V31UN@4N?LLBYP3M
M^<G;S]*K^ ?&WQ"T?PO:V.@>%OM^FH[[)_L<KYRQ+#<K <$GM0!Z]\;?^23:
MS]8/_1R5S_[.?_(AWW_81?\ ]%QUN?&5W?X/:J\B[9"+<LOH?-3(KS#X6?$3
M3_!7@2>V-O+?ZI=:@YM[&#[[C8@R>#@<'ZXH ^E**\ OOC1X\TB<7>J>#EM=
M-+8Q+;S1MCTWDXS_ ,!_"O4? /Q TWQ]I<MS9QO;W$#!;BWD()0G."#W!P>?
M:@#KJ*S=>UVP\-Z-<:KJ4WE6L"Y9@,DG.  .Y)[5XW-\;/%FNNS^$/!TMQ:H
MQ5I)(9)R?KL("G';)H ]VHKPZQ^.^I:5?Q6?C+PS/8,^-TD2,A4>OEOR1]#7
MMEM<Q7EK%<P.'AE021N.C*1D'\J /"M1NF\#?M&QSLY6QUQ5#JO3]Y\N3])%
MS]*]Z%>&?M&V&VQT+5XUVRPSO"9%ZX(#+^15OSKUWPQJO]N>%M+U3C-U:QRM
MCLQ49'YYH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ?+&O:"/$O[0EQI+<Q3WR^;SC]V%#-^@-?4MO;0VEO';V\2111J$1$& JC@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCL,4UE"D9FFGN KO(#EV(/K[5]#J"(P#UQS3J#T- 'R]J6AV?B7]H;4-(O\
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img76291469_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4.!=P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBOGGXH?&Z_CU.YT/PM,((H&,<U\H!=V'!">@'KUXH ]*^*'CJ^\":;IUU9
M6<%RUU<^2PF+ *,9XQ7=1L7B1F&&*@D>E?#6J2^(M3@AU+57U&XAF?;%<7!<
MJ[>BD\'\*T+;Q!XS\%WRJM[JFG3</Y4Q8!QGKM;@CB@#[7HKSGX3?$H^/=+G
M@OHTBU:S"^<(QA95/1P.W(.1_CBNH\8^*K+P9X:N=9OOF6,!8X@<-*YZ*/\
M/ !- &Z[K&I9V"J.I)P!6?'K^C33^1%J]@\V<>6MRA;/TS7QWXE\<^)O'&J
MW=W/()),065OD(I/ 55'4]L\DU6U?P1XI\/6*:AJ>C7=I;$@"9EX!/3.#Q^-
M 'V]17RA\+_BQJGA?5[?3M3N9;O19V$;)*Q8V^3]]">PSR.]?5X((R#D&@ H
MHHH **** "BO*/&?QVT'P^9[/2$.J:C&2AQE8489!RW4X(Z#\Z^>O$OCOQ#X
MKU,WNHZC+D9$<43%(XQZ*!_/J: /MRBOGW]F^YN+C4->\^>67$46-[EL<MZU
M]!4 %5;S4[#3@#>WUM; ]//E5,_F:\T^,GQ-E\&V,6E:2ZC5[M-WF<'R(^F[
M']X]OH37S;:67B#QCJLBVT5[JM\^9'/,C>Y)/3\: /N"UO+6^B\VTN8;B/\
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MM91+;7$:RQ2+T=&&01]017P0_P!]OJ:^X/!'_(@^'/\ L%VW_HI: -VBBB@
MHHHH **** "BFR2+%$\CG"HI8GV%>%>)/VC;:$O!X=TEYF' N+P[5]_D'/ZT
M >[T5D>%-1N-7\(:-J5T5-Q=V4,\I48&YD!.!]36O0 4444 %<YK_CSPOX9D
M\K5M9MH)N?W()=_Q5<D?C7FWQH^*UQH,C>&M F\N_9 ;JZ0_-"#T5?1B.<]A
M^G@_A_PYK7C/6OL6F0275T_S22.W"#NSL>@H ^DG_: \#I*4$FH. <;UMN/U
M.:Z+1/BEX-U^18;/6X$G8<17&8F_\>P,_C7D$/[->KM;*TWB"SCF(!,:PLP!
M]-V1_*O-?&/@37/ U^EOJT"[)1F&XB.Z.3Z'U'H: /MFBOFWX-?%>ZL-1MO#
M.NW#36-PPCM)Y#EH'/ 4G^Z>GL?:OI*@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBFNZQQL[G"J"2?84 .HKPKQ+^T;:P,\'AW27G<<>?>'
M:OO\@Y/YBO7/"6I7&L>#]&U.[*FYN[**:4J,#<R@G [<F@#9HHHH **** "B
MBB@ HHHH **** .=UWQUX8\,WR66LZO#9W+QB58W5B2I) / /<'\J70O'7AG
MQ->O9Z-J\-Y<)&9&C16!"@@9Y [D?G7C_P </ _B;Q+XVM;W1M(GO+9-/2)I
M(RN P>0D<GT(_.G? [P3XE\->,;R[UG2)[.WDLFC620K@MO0XX/H#^5 'O\
M14-Y=16-E/=SDB&"-I'(&< #)KP?Q)^T>N'A\-Z22<8%S>GVZA!_4T >_452
MT:YEO=#T^ZF(,LUM'(Y P"Q4$_SJ[0 4444 %%%% !1110!S.L_$'PIX?U%]
M/U76H+6[0!FB=6) /3H*LZ!XR\/>*99HM$U2*\>!0TBH&&T'H>0*\,^,'@'Q
M5X@^(-S?Z5HMQ=6K0QJ)4*X) YZFNB^!'@_Q!X8U+6'UK2YK))H8Q&TA&&()
MR.#0![=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSZ-I5O8:E:Q-+"UL@C$FT9*L!P<@=>M?,&DZG<Z-JUKJ5G(8[BVE66-AZ@T
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MFE6/=]M!QDXS]RNI^,EK%8_!;4K2 %88%MHT!.<*)8P.?PKY:T#_ )&+3?\
MKZC_ /0A0!]W5Y9X\^-$/@?Q,^BOH;WA6))?-%R$^]VQM->IU\H?'[_DJ$O_
M %Z0_P C0![G\-_B5'\0TOVCTM['[&4!W3B3=NS_ +(QTK0^(/C=/ 6@1ZJ]
M@UZ'G$/EK+Y>,@G.<'TKR_\ 9I_U'B#_ 'H?Y-70?M$?\D^MO^OY/_06H /!
M_P =;/Q5XACTN71CI\;1O(UQ)=AE4*I8\;1V'K6)XF_:,@MKN2W\.:6MTB'
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MX): -#^&UE*RXGU F[D/J&X7_P ="U\L>'M(EU_Q%I^DPAB]W.D7R]0">3^
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M#P\3_P _:C]#7I'QN^)6DZ]I$7AW0;E;U#()KJ>($H O10>_/)[<5YI\,?\
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MOLRR&419^4.0 6^N !^% '>?!CPS_P )'\0[-Y8]UII_^ERY'&5/R#_OK!_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0\8?#7PUXV
M(EU.T:.\  %W;MLDP.Q/((^HKKZ* /E3XA?"6T\&:AH<-OJTUQ'JET8/GA ,
M0RHSP?F^][=*]0T']GSPOIDR3:E<76J.ISLDQ'&?JHY/YUZ+K/AG1O$,MG+J
MUA'=/9OYEN7)'EMQR,'V'Y5K4 1P00VMO';V\210QJ%2.-0JJ!T  Z"H[VRM
M=2LIK*]@2>VF4I)%(,JP/8U8HH \*\0_LXVEQ<2SZ!JYM4;E;>Z3>JGT#CG'
MX'ZFL>P_9KU1IO\ B8Z_9QQ>MO&SM_X]BOHVB@#EO!?P_P!"\#6CQZ7 S7$H
M FNIB#(_MGL/8?K74T44 %%%% !1110 5YC\0/@[!X]\0IJTNM2V;);K!Y2V
MX<<%CG.X?WJ].HH \_\ AS\+H?AY<7\T6JR7WVM$4AH1'MVDGU.>M>@444 9
MFO\ A_3?$VCS:7JMLL]K*.0>"I[,I[$>M>&ZO^S9<_:"VBZ["8220EY&0RCL
M,KG/Y"OH6B@#PGPY^SC:V]S'/XAU;[4BG)MK52JM]7/./H!]17N%I:6]A9PV
MEI"D%O"H2.-!A54= !4U% '(_$+P+'X_T2#39=0>R6*<3;UB#YX(QC(]:\U_
MX9HM/^AHG_\  ,?_ !=>\44 >#_\,T6G_0T3_P#@&/\ XNM#3_V</#\)!O\
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MPQG'>O%O^&:+3_H:)_\ P#'_ ,77O%% $=O%Y%M%#G=Y:!<^N!BDN8?M-I-
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M(VIW!#"%B"/,;D<5]"_ :":W^&J1SQ21.+N7Y9%*GMZT >>Q_LV:P;L"77K
M6V?OK&Y?'^[C'ZUZ]X#^&NB^ K9_L8:YOI1B6\E W,/11_"/;]:[*B@"AK?_
M " -1_Z]9?\ T$U\'U]XZT"=!U$ $DVLF !DGY37PU_9.I?] ^[_ ._+?X4
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M_K+^()H&NY3(8A:A@OMG<,UV?P\\"1_#_0[C3(K][T37)N/,:()C*JN,9/\
M=_6NNHH \\^(WPKA^(5]8W,NK261M8VC"K )-V2#G[PQTJ+X=_"2#X?ZU<ZE
M%K$EZ9[<P&-H @&65LYW'^[^M>D44 %>5^*O@/X<\1:A-J%I<7&F7,[%Y!$H
M>,L>I"G&,GWKU2B@#Q;3/V<M%M+E)KS6[VYV,&"QQK%T_.O:%4*H4= ,4M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >"_%GXI^*?"/C=]+TFYMX[46\<@5X%<Y.<\GZ
M5K_!?XB>(?&NJZK!K5Q#)';0(\8CA"8)8@]*\U_: _Y*?)_UYP_UK?\ V:O^
M0[KW_7M'_P"A&@#Z.HHHH ^7O$/QM\;:;XDU.RM[RU$-O=21Q@VJDA0Q _2O
M;OA9XBU'Q5X"L]6U61)+N62569$"C"N0.!["OD[QC_R.FM_]?TW_ *&:^G/@
M5_R2C3O^NL__ *,:@#N=:UFP\/Z1<:IJ=PL%I NYW/Z #N2> *^=_%'[0VMW
MMR\7AVVBL+4$A995$DKCU.>!_GFM3]I+69O/T;1$<B#:]U*H_B;.U?R^;\Z\
M]^$GA.R\7^.H++4?FLX8VGEC!P9 O1?IDC/MF@"K+\5/',LID/B6^4GLCA1^
M0%=%H/QZ\7Z5,@U"6'4[8?>29 KGZ,O?ZYKZ<M] T>TM5M;?2K*.!5VK&L"A
M0/3&*^>?C1\,QIFMVFH^&=)N'@O5;S[>UA9UC<8Y 4?*"#T]10![OX.\8Z7X
MVT)-4TQR!G9-"_WX7[J?Z'O705\W_ 2UU_1/&ES:WFDZA;65Y;-O>>W=$#*<
MJ<D8SU'XU](4 %%%% !1110!\Y_$3XO^+_#GCW5M)TZZMDM+:15C5K=6(!13
MU/N37,?\+Z\>?\_MI_X")67\8?\ DJ^O_P#75/\ T6E=U\"O!?A[Q1HFK3:S
MID5W)#<(L;.3\H*DXX- ',_\+Z\>?\_MI_X")2K\>?'A8#[;:<G_ )]$KWS_
M (5'X$_Z%VV_-O\ &C_A4?@3_H7;;\V_QH ZRVGDDTJ&=B/,: .3CN5S7RW<
M_';QU%=31K>VF$=E'^BKV-?5#1I%9M&@VHD>U1Z "O@V^_X_[G_KJW\S0!]H
M_#W6KWQ#X%TO5=1='N[B,M(R(%!.XCH*Z>N(^$/_ "2S0O\ KB?_ $(UV] '
M*?$G7;_PU\/]5U?3'1+RV$9C9T# 9D13P?8FOG^P^.GCFXU&U@>]M-DDJHW^
MBKT) KV_XS_\DDU[_=A_]')7R1I'_(9L?^OB/_T(4 ?>=%%% !1110 4444
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M7DO_  OKQY_S^VG_ (")7TGXF\$Z!XP^S_VW9?:?L^[ROWC+MSC/0^PKG_\
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M N?LU_\ (?US_KVC_P#0C7T?7SA^S7_R']<_Z]H__0C7T?0 4444 %9GB/\
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MU.!PJK^0K>U;X+^-]%TUM1>PCG2-2[K:S!W0#J<=_P ,UV_[-6G027FO:DR
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MQ)).FK:!<S.[+B[AWMGCA7'_ *#^M=#\?_#7]K^"$U6&/=<:7)O) Y\IN&_
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M+4T^_!!:1!8SZ.^.#[ $^N*Y.7]HO5X(XX-*\/:9:V\:A4CD+N%4#  VE0*
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MR3R.OV67AG)'05]5GH:^3_@%_P E/A_Z]9?Y"OK ]#0!\,^(;RZ7Q+JH%S,
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M\/K,CW^H.F8E.2D:L&+'TY  ]>?2O!/A[HTVO>/=&L84W@W*22\<"-#N8G\
M:K:5X=\1^,-3*V-E>7]S(V9)FR1]6<\#ZDU].?"SX70> K.2[NY$N=8N5"R2
M*/EB7KL7\>I[X'I0!Z-65JGB;0M$G2'5=9L+&5UW*ES<)&6'J 3TK5KX\^,6
MN_V[\2]3='#PVA%I&1Z)][_QXM0!]8:7XCT37'D32=7L;YHP"XMIUD*@],X/
M%:=>=?!?PC_PB_@6&:=,7VI8N9O4*1\B_@#G_@1KT6@ KY]_:1URZ6XTC0D=
MEM6C-U( ?OMDJN1[8/YU]!5XW\>? E]XAT^TUS2H'N+FQ4QS0IRS1$YRH[X.
M<^Q]J /-_@;X-TGQ9XCOI=8B%Q!8Q*ZV[?==F)&3Z@8Z>]>S_%'3M#T7X6:S
MY.G65JODB.(10HGS%@ !@?YQ7S!X;\3ZSX,U@:AI4YM[@#:Z.N5=?[K*>HKO
M!=>._C1)Y=Z?*TFR5I9&AA*1!@I(XSEG/0#/&?K0!YYX;<Q^*=(=>JWL)'_?
M8K[COO\ D'7/_7%OY&OAK2TFL=9LKJ2VFV07"2-^[/16!/;VK[DO#NTR<CO"
MV/\ OF@#X)K[A\$?\B'H'_8.@_\ 18KXD^R7/_/O+_WP:^W/!((\"Z """-/
M@R",8^04 >3?M*_\@K0?^N\G_H(K@/@/_P E5L?^N$__ * :]"_:2BDETO0A
M'&[D329VJ3_"*X'X%6\T?Q3L6>&15\B;EE('W#0!Z+^TE:2R^&=&ND4F*&Z=
M7/IN7C_T&O+/@MJD6E_%#3&F(5+@/;[CT!9>/U 'XU]1^,/#-KXO\,7FC77R
MB9<QR8YC<<JWY_IFOCGQ%X5UWP=JQM=3M)K>6-MT4RYV. >&1N_]* /N*OF#
M]HC5X+WQO:6$+JS6-J%EQ_"[$MC\MOYUG67QO\?R6,>F6\T%Q.5\I)OLV^8D
M\ ^A/X5S_C/P;KF@-IUUK'GRZAJ<+7,ZMEF1BY&&/KC!/N<=J /0?V:_^0_K
MG_7M'_Z$:^CZ^</V<%D@\2ZS')%(A>T4@LI X;_Z]?1] !7SU\?=8\0Z%XIT
MZ73=:U&RM;FTQY=O=/&I96.3@$#.&%?0M<'\5O 1\=^&1#:E$U.T8RVS,<!N
M,%">P/\ ,"@#S/X"^,=5U'Q;?:=K.MWEYYUKN@2ZN&D^=6!.W<3SMS^5>T^-
M]0BTOP/K=W,P5$LY!SW)4@#\S7QE/::SX5UD":*ZT[4+5\J2"CHP[@UH:WXW
M\4^*;=+35M7NKR!3N$6 %)]2% S^- '.JK.X1069C@ =S7W5X:L?[,\+Z59%
M=I@M(T(]"%&:^>/A%\)=0U36+;7M=M)+;3+=A+#%*-K7#CE>#SM[Y[U]-T ?
M#?B_6[KQ%XLU+4[QV:26=L G.Q0<*H]@.*^DOA/\//#EGX+TO5IM.MKS4+R!
M;AY[B,.4W<A5!R!CIQ7AGQ.\ ZCX/\3W;"VE?2KB5I+6X ++M)SM)[,.F/QI
MWA;XM>+O"VE#2=.GAGM@3Y27$1D,>>R\CCVYH Z7]H?[##XOTVTLXH8WBLLR
MK$H7!+G&<=\#]16M^S2Y&I>((_X3#"3^!;_&N \6>$_%"Z/!XL\1"X:]U2Y8
M>7(GS[0H(9@/NYZ 8Z"NY_9P=K?Q'K-K+$Z-+:+(I92/NN ?_0A0!J?M+?\
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M < #N2:^7?!7PN\2ZUXZM)/$.C7MM8^<;B[FN8B@?!W%?JQX_&OJZB@!
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M** "BBB@"O>6%GJ$/DWMI!<Q?W)HPZ_D:BL='TS2]W]GZ=:6F[[WV>!8\_7
M%7:* "BBB@#Y0^/O_)3Y_P#KUA_E76_LS?ZSQ/\ 2U_]JUV/CGX,6OC?Q*^L
MS:U/:N\:1^4D 8#:,9SD5J_#GX9V_P .VU(P:G+>_;A&#OB";-F[T)SG=^E
M'53^'=$NKK[5<:/I\UQG/FR6J,^?J1FM%$6- B*%4#  & *6B@ HHHH H7NA
MZ3J3A[_2[*Z8=#/;HY_45)9:7I^FJ5L+"UM5/400J@/Y"K=% !1110!5O=,L
M-3C$=_8VUV@Z+/$L@'X$4MGI]EIT/DV-I;VL7]R",(/R JS10 4444 %%%%
M!1110 4444 1SV\%U$8KB&.:,]4D4,#^!JC:^'=#L9A-9Z-I]O*.CPVJ(WY@
M5I44 %%%% %*]T?2]3(-_IMG=XZ>? LG\Q19:1IFFC%AIUI:_P#7"!4_D*NT
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%9^M:U8^'](N-4U*4Q6L R[!2Q]. .M>$>+OCIJ6I+):>
M'(&T^W/!NI,&9A_LCHOZGZ5O1P\ZOPK0F4U'<]?\1_$+PSX5NDM=5U$)<.,^
M5$C2,H]6"@X_&L[3_B]X-U/4;>PM;^=KBXD6*-3:2 %B<#DKQ7RO++)/,\TT
MCR2N=SN[%F8^I)ZUN>"?^1ZT+_K^B_\ 0A7H/+Z<87;=S#VS;/L6JFIZE;:/
MIESJ-XY2VMHS)(RJ6(4=>!R:MUROQ)8I\.==*G!-JP_.O*@N:23.ANRN8_\
MPNSP-_T$;C_P#E_^)H_X79X&_P"@C<?^ <O_ ,37R]706_@7Q9=6\5Q;^'=0
MEAE4/&ZQ<,I&01[8KUG@:$=V_O.=5I/9'T#_ ,+L\#?]!&X_\ Y?_B:5?C5X
M'=U4:C<98@#_ $.7J?\ @-> _P#"O?&7_0LZE_WZ_P#KT^'X?>,1<1,?#.I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .&^,'_ "3#5_\ =3_T(5\_^$OAYX@\83*;*U,%EGY[R<%8P/;N
MQ^E?6-]86FI6QMKVWCN("03'(N5)!R,BID1(T5(U544855& !771Q3I4W&*U
M,Y4U)W9\G_$CPG9^#-<L]*LY9)O]$62663J[DG)QV'M69X)_Y'K0O^OZ+_T(
M5V?QZ_Y'RW_Z\E_]"-<9X)_Y'K0O^OZ+_P!"%>I3DY4+O>QSR5IGV+7&?%=U
MC^&6M%F"@QH,GU+J *[.N"^,L@3X7ZFI!.]X5'M^]4_TKQ:&M6/JCJG\+/EA
MONGZ5]E^$H_*\&Z(F",6$&0>N=@KXU'45VNN_%+Q)JT,-K:WDFFV$$2Q)%;M
MAF  &6;J3Q7L8NA*M91.:G-1O<^KJ*^+8?$.MV\XGAUG4$E!R&%RYY_$UZEX
M ^--];WT.F>*9A<6DI")?$8>(D\;\=5]^HKAJ8"<5>+N;1K)NQ] 44BL&4,I
M!!&01WI:X#4*AN[J&QLY[NX<)!!&TDC'LH&2?RJ:O*_CGXE_LOPK%HT#XN-2
M?#X/(B7D_F<#\ZTI4W4FHKJ3)\JN>"^)=<F\2>([_5YR=US*652<[4Z*OX#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGXE>/8_!&B
M(T"I+J=T2MM&W1<=7/L,CCN37S5J7BOQ!J]X;J^UB]DE)R-LS(%^@& !7?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MR+XL?$7Q!X.\0V5EI+6@AFM/-;SH=YW;V'7([ 5Z[7SM^T%_R..E_P#8/_\
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M (JC_A>7C7_GIIW_ ("G_P"*KS>BCZM1_E0>TEW/2/\ A>7C7_GIIW_@*?\
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M****Y2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB8T5;4^'X)Y;:>.XMY7AFC8-')&VUE/J#7U/\+/&DGC+POOO"/[1LV\FY(&
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M],G;*G=6'<8K[#TS4(=6TJTU"WSY-S$LJ9Z@$9P?>O*O^&>]#_Z#>I_E'_\
M$UZ9X<T2/PWX>L]'AN);B.U0HLDN-Q&2><<=\5EC*U*K9PW*IQE'1GS)\6O^
M2GZS_O1_^@"F?"K_ )*=HG_71_\ T T_XM?\E/UG_>C_ /0!3/A5_P E.T3_
M *Z/_P"@&O1_YAO^W?T,/^7GS/K(G R:^:OB]\0?^$FU0Z-ILI_LFS?YV4\7
M$H[_ .Z.WYUVOQE^(?\ 9=J_AG29R+Z=/]+E0_ZF,_PY_O-^@^M?/T<;R2)%
M$C.[D*B*,EB> !7+@<-;][+Y?YFE6?V46](TB]UW5K?3-.A,MU<-M1>P]23V
M ZDU]9^"_"%CX,T"+3K4!YF^>YGQS-)W/T[ =A6!\+/AZG@_2?ME\B-K-VH,
MK=?)7M&#_,]S]*]"K#&8GVCY([(NE3Y5=[A1117":A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5\[?M!?\ (XZ7_P!@_P#]J-7T37SM^T%_R..E_P#8
M/_\ :C5V8'^,C.K\)Y+1117N'&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7M?[._\ Q_>(?^N5O_.2O%*]
MK_9W_P"/[Q#_ -<K?^<E<V,_@2_KJ:4OC/>****\ [ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHK,\0:Y:>&]"N]6OFQ!;INP.KGH%
M'N3@4TFW9 :=%?(GBKQ]KWBR^DEN[R6&U)/EVD3E8T7TXZGW-9NF>*->T=E;
M3]8O;<+T5)CM_$=#7H++IVNWJ8>W5]C[-HKYMT?X[>)K':FHPVNHQCJ67RW_
M #7C]*ZB?]H2S.G.8-#G6]*D(KS Q@^I.,D>V*QE@JR=K7+56+/:J*^2O!\^
ML>(O'VEV[W]VYGO!-+B5L!0=[=^G%?6M1B*'L6DW<<)\VI7L[&TTZW%O96T5
MO".0D2!1^0KS7X^?\B!;_P#81B_] DKU*O+?CY_R(%O_ -A&+_T"2EAM:T?4
M)_"SYN/2OL'P%_R(&@_]>47_ *"*^/CTK[!\!?\ (@:#_P!>47_H(KT,Q^"/
MJ8T-V=%1117D'2>>>/OBG'X&U:#3VTA[QIH/-#B<(!SC&,&O*_%'QLU[7K&:
MPLK>+3+>8%7>-BTI4]1N[?@,UVWQ8^'GB#Q=XCL[S28H'ABMO+8R2A3NW9KR
M/7OA_P"*/#<#7&I:3*ELO6>,B1![DJ3@?7%>MA:>'<8MVYCGJ2G?R*6@>$]<
M\37*0:3ITTP)P92I6)/<N>/ZU]0^ ?!D'@GPXE@KB:ZD;S;F8#&]SZ>P' KY
MC\-^,]>\*7"R:5?R)$&W-;.=T3^N5_KUKZ?\#>,K3QMX?74($\JXC/EW,&<^
M6_\ @>HI8_VMO[O];A1Y?F><?M#W#"TT&W!^5I)78>N H'\S7A->U_M#?\?F
MA?[DO\Q7BE=."7[A&=7XV=UXJ^*OB'Q#*8;2YDTW35&V.WMVVDK_ +3#D_3I
M7(V^KZG:S^?;ZC=Q3?WUF8'^=?0GP]^$VBV.@VU[KEA%?:A<QB1DN%W)$",A
M0IXSZFLOXL?#+2(/#DVNZ'9164]F TT,"A4DCSR<= 1UX]ZRAB:"G[**T*<)
MM<S9E?#OXRWD=[!I/B>;S[>4A([UOOQD]-Y[CWZU[Y7PX1D8KZS^%VL2ZW\/
M=+N)VW31H8';U*' _3%88[#QA:<2Z,V]&> ?%K_DI^L_[T?_ * *P/#FMS>'
M-=@U:VB66>W#&-6Z E2,GZ9S6_\ %K_DI^L_[T?_ * *@^&,$5U\1=)MYXUD
MAE,B.C#(8%#D&NZ+2H)OM^AB_C.7NKJ>]NYKNZF::XF<O)(YR68]37KOP'\.
MZ1J&H7FL74L<VH63!8+9A_JP1_K??N!Z8-</\0/!L_@KQ+)989K*;,EI*?XD
M_NGW'2LWPOXCO?"GB"VU:Q/SQ'$D9/$J'[RG_/7%%1>UH_NWN.+Y9^\?9=%9
MVA:U9>(M%MM4L)!);W";AZJ>ZGW!XK1KP&FG9G8%%%%( HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBN3\8?$+0_!MN?M<XGO2,QV<1!=OK_='N?UKR)_V@?$9=BFE:4$R=H99"0/<
M[JZ*>%JU%>*T(E4C'1GT317#_#'QI?\ C;0[J^U"WMH)(;CRE6W# $8!YR3Z
MUW%8S@X2<7NBD[JZ"BL[7-=T[PYI4NI:I<K!;1]SU8]E4=R?2O$-=^/VISSN
MFA:=#;6X)"RW/SR-[X!P/IS6E+#U*OPH4IJ.Y] 45\M_\+H\<^;O_M.';G.S
M[+'CZ=,UTV@?'[4(KA(]?TZ&>W) ::URKJ/7:3@_3BMY8"LE?<A5HL]^HJAH
MVLZ?K^F1:CIEREQ;2CY67L>X([$>E7ZXVFG9FH45C>)_%&F>$M(?4=3FVH/E
MCC7EY6_NJ.]>%:U\>/$=Y.XTF"VT^#D)N3S9/J2>/TK:CAJE76*T(E.,=SZ.
MHKYCL?CAXRM90UQ/:7B9Y26W5?U3%>Q> _B?I?C7_1"ALM45=S6SMD.!U*'O
M].HJJN$JTU=["C4C+0[JBBO'/CIKVKZ*=%_LO4[NR\TR>9]GE*;L 8SCK65*
MFZDU!%2ERJY['17QT_COQ<(V(\3:MT/_ "]O_C7U]9,SV%NS$LS1*23U)P*U
MQ&&=&UWN*$U(GHJO?W]MIEA/?7DRPVT"%Y';H *^6_%WQ,USQ!X@GO+'4+RP
MLA\D$$,I3"#H6QU)ZTJ&'E6;ML$YJ)]645\L>"SXR\9Z_'I]MK^JI N&N9_M
M#XB3UZ]3V%?4%E:I8V4-JCR.L2!0\KEF;'<D]317H>Q=F[L(3YM;$]%%%<Y8
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7SM^T%_R..E_]@_\ ]J-7T37SM^T%_P CCI?_ &#_
M /VHU=F!_C(SJ_">2T445[AQA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5[7^SO_P ?WB'_ *Y6_P#.2O%*
M]K_9W_X_O$/_ %RM_P"<E<V,_@2_KJ:4OC/>****\ [ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KS#XUZ=K>L:#I^GZ/87-VK7!DG$*
M;L!1QG\3^E>GT5=*?LYJ2Z"DKJQX%\.O@XNHP7-[XLM+JW"OY<-J28R>,ECW
MQSQ^-;^K_ '1;@,VE:E=6;]EE E3^A_4UZ]16\L95<N9.Q"I1M:Q\Q:O\$_%
MVFLS6L,&HQ \-;R -CW5L?IFN>C^'WB^6Y^SKX<U$/G&6@*K_P!]'C]:^OJ*
MUCF%1+5(ET(GF7PL^&3>$%?5-5*/JTR; B'*P)W /=CW->FT45QU*DJDN:1K
M&*BK(*\M^/G_ "(%O_V$8O\ T"2O4J\M^/G_ "(%O_V$8O\ T"2M,-_&CZDU
M/A9\W'I7V#X"_P"1 T'_ *\HO_017Q\>E?8/@+_D0-!_Z\HO_017H9C\$?4Q
MH;LU]3U*TT?3+C4;^7RK6W0O*^TMM4=\#)-<A_PN+P)_T&S_ . LW_Q%=1XA
MTM=;\.:CI;=+JW>+/H2,"OC.ZM9[&[FM+J-HKB!S'(C=58'!%<V$P].LGS/5
M&E2;CL?96@>(M+\3Z;_:&D7/VBU\PQ[]C)\PZC# 'O6A/!%<P203(LD4BE'1
MAD,#P0:^7_AQ\39_ _G6=Q:F[TV=_,*(V'C;N5SP<^A_.NT\0_'V"?2Y8- T
MVZBNY%*B>ZV@1Y[@*3D_E2G@JBG:"T!58M79XQJUM%9ZU?VL)S%#<R1I_NAB
M!7JG[/MS*GB/5[8,?)DM4=E[;@V ?UKR!F+,SNQ+,2S,>Y/4U]%? [PC<:-H
MMSK5]$T5QJ.T1(PP1".02.V22?IBO0QDE&BTS&DKSNC,_:&M&:PT.\5?E262
M-C]0"/Y&O!STKZV^)/AI_%7@F]L8%W7<>)[<>KKV_$9'XU\E,K(S(ZE64X93
MU!]*G 34J7+V'65I7/MRTDCFLX)(F#1O&K*1T((XK!^(,J0_#SQ SL #82J,
M^I4@?J17CW@7XU?V!HT6E:W93W<-NNR"> C>%'12&(!QZYZ5F?$7XLR^,+(:
M7IUK)9Z:6#2^:09)2#D XX !YQDUQ0P=554FM.YHZL>4\TKZ=^"$#P_#:W9B
MV);B61=Q[9 X]N*^<=&T>]U_5K?3-.A:6YG;:H ^Z.['T ZYK[!\/:-#X>\/
MV.DV_,=K$$S_ 'CU)_$Y-=.8S2@H=2*"UN?,?Q:_Y*?K/^]'_P"@"F?"K_DI
MVB?]='_] -/^+7_)3]9_WH__ $ 4SX5?\E.T3_KH_P#Z :Z/^8;_ +=_0C_E
MY\SZ)\?>#K?QGX:EL7"K=QYDM)B/N2?X'H:^2[NTN+"\GL[J)HKB!S')&PY5
MAU%?;M>*_&[P)]I@/BO3HOWT2A;V-1]Y.TGU'0^U<&!Q'*_9RV9M5A=71QWP
MD\>GPMK/]FW\I&DWK@$GI#(> WT/ /YU]-@@@$'(/>OASK7T1\&/'O\ :^GC
MPYJ4V;ZU3-N[GF6(=O<K_+\:UQV'O^]C\R:,_LL];HHHKRCH"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP
M_P"+GQ(U_1M?E\/Z5*EG"L2,\\8_>MN&< _P_AS[U[A7B/CSX:Z]XR^)-Q<6
ML:6^G^5$K7<QPO"C(4=2?TKJPGL_:7J;6,ZE[:'ATDDUU.TDCO--(2S,Q+,Q
M[DU'7TW;?#;0_!O@W5Y8(_M6HFPE#W<P^;[A^Z/X1].?>OF3M7KT:\:M^79'
M-.#CN?1'[/\ _P BCJ/_ %^'_P!!%>MUY)^S_P#\BCJ/_7X?_017K=>-BOXT
MCJI_"CYG^-GB2;5O&CZ4LA^QZ8 @0'@RD98G\"!7$^&] N_$^OVND66T33MR
M[=$4<LQ^@KZ@U#X8^#M5U&XO[W15ENKAS)+(9Y1N;UP&Q5C1/A]X6\.:DNHZ
M3I2VUVJ%!()I&P#U&&8BNN&-IPI<D4[V,W2;E=G'K\ _#(L1$U[J)N-O,P=0
M-WKMV]/;]:\.\7>&+KPAXCN-(NG$FS#1RJ,"1#T/^-?8Q(4$D@ =2:^6?B_K
M]IX@\>2O8R++!:1+;B5>CL"2V#W&3C-/!5JLYM2=T*K"*6AI?!'Q)/I?C%=(
M:0_8]2!4H3P)5!(8>G (_*OI7I7RM\(-,GU'XD:=)$I\NTW3RMCA5"D#\R17
MT7XUU%M)\$ZS>HVV2.U?8<]&(P#^9%98Z*=9);LJD_<U/FSXF>+)?%?B^YD6
M0FQM6,%JN>-H/+?\"(S],4WX?> KKQUJLL*S?9K*V :XGVY(ST4#U.#^5<?7
MTM\"]/6T\ &ZQ\]W<NY..PPH'Z'\Z[J\_84?<]#&"YY:GGWQ ^#Q\+:*VL:5
M>RW=K#C[1'*H#HO]X$=1ZUYC97EQIU]!>VDK17,#B2-U/(85]FZY8QZGH-_8
MRKN2>W>,CZJ17Q7M9,HXPR_*P]QUJ,%6E5BU/6Q56*B[H^QO!WB*/Q5X4L-7
M0!7FCQ*@_A<<,/SKRG]H?KH/UE_D*T/V?-0>70=6TYC\MO<K(@_WUY_45G_M
M#]=!^LO\A7+2A[/%\J_K0TD[T[GALG^J?_=-?;MA_P @VU_ZXI_(5\12?ZI_
M]TU]!_%/XA_V)H,'AW2YL:E<6Z?:)%/,$94<>S']!^%=.-IRJ2A&/G^A%*2B
MFV<G\8?B%_;VH-H.ESYTRV?]\ZGB>0?S4?J>?2O-](TF]US5;?3=/A,MS.X5
M%';W/H!U)JI'&\TJ11(SR.P5549+$] /4U]/?"SX>IX1TG[;?1@ZQ=*/,)Y\
ME?[@_K_]:KJ3AA:5EN2DZDKLW_!/@^S\%Z!'I]M^\G;#W$Y',C^OT'85TE%%
M>+*3D^9[G4E9604445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OG;]H+_D<=+_[!_\ [4:O
MHFOG;]H+_D<=+_[!_P#[4:NS _QD9U?A/):***]PXPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]K_9W_X_
MO$/_ %RM_P"<E>*5[7^SO_Q_>(?^N5O_ #DKFQG\"7]=32E\9[Q1117@'8%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7'?$OPA>^-?#,6F6-Q;P2I=).6GSMP%88X!Y^85V-%5";A)26Z$U
M=6/G;_AGWQ'_ -!;2O\ R)_\37NGAK3)=%\,Z;ID[I)+:VZ1.\>=I(&,C/:M
M6BM:N(J55:1,8*.P5P/CGX5:1XRE-\DAL-3Q@SQKE9/3>O?Z]?K7?45G"I*#
MYHNS*:3T9\SW_P "_%]JS"V^Q7B@\&.;9G_OK%16GP/\9W#[9X+.U&?O27 8
M?^.YKZ=HKJ_M"M;H9^QB>5>$/@CI.B7$5]K,_P#:=W&0RQ;=L*'Z=6_'\J]5
M  &!P***YJE6=1WD[FBBH[!7FOCGX/Z9XJN9-2L)AI^I/RY"YCE/JP['W'Y5
MZ512IU)4WS18.*DK,^8KOX(>,[>3;!!9W2_WH[@*/_'L5<TOX#^)[N1/[0N+
M.QBS\_S^8P'L!P3^-?2-%=3Q]:UM#/V,3EO!G@+1_!-HR6"-+=2@":ZE^^_M
M[#V'ZUU-%%<DI.3O)ZFB26B/%?&WP;UOQ-XOO]8M=1T^*"X*E4EW[AA0.<#'
M:D\&?!G7/#?B_3]8NM2T^6"V9F9(M^XY4CC(QWKVNBM_K=7DY+Z;$^SC>X4R
M6*.:)XI45XW4JRL,A@>"#3Z*YBSP36?@#J,NL74FD:E8Q6#N6ACGW[T!_A.
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MOI7)CZ#DO:+H:49V]UGL=%%%>2=(4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "BBB@ HHHH *]K_9W_ ./[Q#_URM_YR5XI7M?[._\
MQ_>(?^N5O_.2N;&?P)?UU-*7QGO%%%%> =@4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVSF6:VG021R*>&4UYV+P_LIZ;,VISYD6****Y30**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *.LO+'H6H/#GS5MI"F.N[:<?
MK7G?P(MK./P1/<Q*ANI;MQ.P^]P!A3[8Y_$UZBP#*58 @C!![UX+J.A>,OA5
MK]Y?^%X'OM#N7WF%8S(%&>%91R",X##M7312G"5.]F[&<M&I'1?#G_DJOCG_
M *[?^SFJOQ'BAM/C#X*NK0!+V:4+,4ZLH=0N?S85P&A>._$^B>(M8U6UT RW
MFJONDC:WE(0Y)^4#GOWKO/ 7@_Q+KOC!?&OC$-%)$O\ HMO( &)QP=O\*C)P
M.N:ZIP]G-U)/2UO72Q$7=61[-1117F&X4444 %?.W[07_(XZ7_V#_P#VHU?1
M-?.W[07_ "..E_\ 8/\ _:C5V8'^,C.K\)Y+1117N'&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7M?[.__
M !_>(?\ KE;_ ,Y*\4KVO]G?_C^\0_\ 7*W_ )R5S8S^!+^NII2^,]XHHHKP
M#L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN#^+7B?5
M?"?A2VO]'FCBN'O4A9I(PXVE')&#[J*\8_X75XY_Z"%K_P" B5U4L)4JQYHV
M,Y5(Q=F?4=%?+G_"ZO'/_00M?_ 1*/\ A=7CG_H(6O\ X")6G]GU?(7MHGU'
M17RY_P +J\<_]!"U_P# 1*/^%U>.?^@A:_\ @(E']GU?(/;1/J.BOES_ (75
MXY_Z"%K_ . B4?\ "ZO'/_00M?\ P$2C^SZOD'MHGU'17RY_PNKQS_T$+7_P
M$2C_ (75XY_Z"%K_ . B4?V?5\@]M$^HZ*^7/^%U>.?^@A:_^ B4?\+J\<_]
M!"U_\!$H_L^KY![:)]1T5\N?\+J\<_\ 00M?_ 1*/^%U>.?^@A:_^ B4?V?5
M\@]M$^HZ*^7/^%U>.?\ H(6O_@(E'_"ZO'/_ $$+7_P$2C^SZOD'MHGU'17R
MY_PNKQS_ -!"U_\  1*/^%U>.?\ H(6O_@(E']GU?(/;1/J.BOES_A=7CG_H
M(6O_ (")1_PNKQS_ -!"U_\  1*/[/J^0>VB?4=%?+G_  NKQS_T$+7_ ,!$
MH_X75XY_Z"%K_P" B4?V?5\@]M$^HZ*^7/\ A=7CG_H(6O\ X")1_P +J\<_
M]!"U_P# 1*/[/J^0>VB?4=%?+G_"ZO'/_00M?_ 1*/\ A=7CG_H(6O\ X")1
M_9]7R#VT3ZCHKY<_X75XY_Z"%K_X")1_PNKQS_T$+7_P$2C^SZOD'MHGU'17
MRY_PNKQS_P!!"U_\!$H_X75XY_Z"%K_X")1_9]7R#VT3ZCHKYQ\,?%WQEJ?B
MO1["ZOK9K>YO8895%JH)5G (SVX-?1U<]:A*BTI%QFI;!1116)04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM#=::[G)6W<%!]%8'%>FT5<*LZ?PNPG%/<\GL?@#X;MY=UY?ZA>+_<++&/\
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MBBBO<.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX>_["5O_ .C%K[&KR,Q^.)TT-F%%%%><;A1110 4444 %%%% !1110 4444
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MKFQG\"7]=32E\9[Q1117@'8%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >5_'[_D0[/_L)1_\ HN2OG"OH_P"/W_(AV?\ V$H__1<E?.%>
MW@/X)R5OB"BBBNTR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#=\$_\ (^>'O^PE;_\ HQ:^QJ^.?!/_ "/G
MA[_L)6__ *,6OL:O(S'XXG30V84445YQN%%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *VHW7V'3+N["[C!"\N
MWUVJ3C]*^?\ X<_#Z/XA/J/B+Q%=7#QO<%0J-AI7ZL2<=!D 8]_2OH*^-N+"
MY-V0+81-YI/0)@Y_3->$> /'^B>!=0U'0;F^%WHTMP9[2^A4MMSQAUZC@#\<
M^M=F'<_9S]GOH93MS*^QVW_"CO!G_/*]_P# C_ZU6=/^#GA/3-2MK^VCO!/;
M2K+&6GR-P.1D8JW_ ,+9\$?]!Z#_ +Y;_"IK3XG>#[^]@L[;6H9)YW$<:!6R
MS$X Z5+EB;:W':!UU%%%<IH%%%% !7SM^T%_R..E_P#8/_\ :C5]$U\[?M!?
M\CCI?_8/_P#:C5V8'^,C.K\)Y+1117N'&%%%% !1110 4444 %%%% !1110
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MMWIW@:!XK"W?;]HC4;F_VF=N%!P< 5TX=57?D=EU(GR]3I/^%">$?^>^I_\
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MQ#_URM_YR5XI7M?[._\ Q_>(?^N5O_.2N;&?P)?UU-*7QGO%%%%> =@4444
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M:BN?^/2;_<;^5" ^'T_U:_04ZFI_JU^@IU?4'GL**** "BBB@ HHHH ****
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M5\X5]'_'[_D0[/\ ["4?_HN2OG"O;P'\$Y*WQ!1117:9!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!N^"?\
MD?/#W_82M_\ T8M?8U?'/@G_ )'SP]_V$K?_ -&+7V-7D9C\<3IH;,****\X
MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN?^/2;_<;^52U%
M<_\ 'I-_N-_*A ?#Z?ZM?H*=34_U:_04ZOJ#SV%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2/\ <;Z4M(_W
M&^E 'V=X7_Y%'1?^O"#_ -%K6M63X7_Y%'1?^O"#_P!%K6M7S,_B9WK8****
MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO'OQ%\0^*K;36*>7#<)]MC^SQHZ1Y^;(/(_"NC\ S"T^,'C73Y6 EF?SE7U
M;/\ )Q53QU,FD?&[PK>6+!+FZ"Q7(7C>A;;S]03^5=3<')P4%M=?<9I.U[GL
ME%%%>8= 4444 %?.W[07_(XZ7_V#_P#VHU?1-?.W[07_ "..E_\ 8/\ _:C5
MV8'^,C.K\)Y+1117N'&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7M?[.__ !_>(?\ KE;_ ,Y*\4KVO]G?
M_C^\0_\ 7*W_ )R5S8S^!+^NII2^,]XHHHKP#L"BBB@ HHHH **** "BBB@
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MP]_V$K?_ -&+7V-7D9C\<3IH;,****\XW"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *BN?^/2;_<;^52U%<_\ 'I-_N-_*A ?#Z?ZM?H*=34_U
M:_04ZOJ#SV%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !2/\ <;Z4M(_W&^E 'V=X7_Y%'1?^O"#_ -%K6M63
MX7_Y%'1?^O"#_P!%K6M7S,_B9WK8****D84444 %%%% !1110 4444 %%%%
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M!_C(SJ_">2T445[AQA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\C,?CB=-#9A1117G&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!45S_P >DW^XW\JEJ*Y_X])O]QOY4(#X?3_5K]!3J:G^K7Z"G5]0>>PHHHH
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M !_>(?\ KE;_ ,Y*YL9_ E_74TI?&>\4445X!V!1110 4444 %%%% !1110
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M?3_5K]!3J:G^K7Z"G5]0>>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]XA_ZY6_\Y*YL9_ E_74TI?&>\4445X!V!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'E?Q^_Y$.S_ .PE'_Z+DKYPKZ/^/W_(AV?_ &$H
M_P#T7)7SA7MX#^"<E;X@HHHKM,@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH W?!/_(^>'O\ L)6__HQ:^QJ^
M.?!/_(^>'O\ L)6__HQ:^QJ\C,?CB=-#9A1117G&X4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !45S_ ,>DW^XW\JEJ*Y_X])O]QOY4(#X?3_5K
M]!3J:G^K7Z"G5]0>>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5_'[_ )$.S_["4?\
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M+7V-7D9C\<3IH;,****\XW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *BN?^/2;_<;^52U%<_\>DW^XW\J$!\/I_JU^@IU-3_5K]!3J^H//844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(_W&^E+2/]QOI0!]G>%_^11T7_KP@_\ 1:UK5D^%_P#D4=%_Z\(/
M_1:UK5\S/XF=ZV"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7SQ^T!'(_C#2RD;L/L'55)_P"6
MC5]#UXY\7B1XCL>?^73_ -G:O3RFC[;%*%[:,Y,;6]E1<[7/ O(F_P">$O\
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M ,>DW^XW\JEJ*Y_X])O]QOY4(#X?3_5K]!3J:G^K7Z"G5]0>>PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M1_N-]*6D?[C?2@#[.\+_ /(HZ+_UX0?^BUK6K)\+_P#(HZ+_ ->$'_HM:UJ^
M9G\3.];!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KQSXO?\C'8_\ 7I_[.U>QUXY\7O\ D8['
M_KT_]G:O9R'_ 'U>C_(\[-/]V?R//:***^Z/EPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *].^#G_'UK'^Y
M#_-Z\QKT[X.?\?6L?[D/\WKR\Y_W&I\OS1W9;_O,?G^1ZO1117P!]6%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5_'[_ )$.S_["4?\
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M,:].^#G_ !]:Q_N0_P WKR\Y_P!QJ?+\T=V6_P"\Q^?Y'J]%%%? 'U84444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\/?]A*W_ /1BU]C5Y&8_'$Z:&S"BBBO.-PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HY_^/>3_</\JDJ.?_CWD_W#_*FMQ/8^75^Z/I2TB_='
MTI:_4CX<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "D/W3]*6D/W3]* /I;0O^1>TS_KTB_] %:%9^A?\B]I
MG_7I%_Z *T*_,*O\27JS[:G\"] HHHK,L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O'/B]_P C'8_]
M>G_L[5['7CGQ>_Y&.Q_Z]/\ V=J]G(?]]7H_R/.S3_=G\CSVBBBONCY<****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O3O@Y_Q]:Q_N0_S>O,:].^#G_'UK'^Y#_-Z\O.?]QJ?+\T=V6_[S'Y
M_D>KT445\ ?5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'E?Q^_Y$.S_["4?_ *+DKYPKZ/\ C]_R(=G_ -A*/_T7)7SA7MX#^"<E;X@H
MHHKM,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH W?!/_ "/GA[_L)6__ *,6OL:OCGP3_P CYX>_["5O_P"C
M%K[&KR,Q^.)TT-F%%%%><;A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %1S_P#'O)_N'^525'/_ ,>\G^X?Y4UN)['RZOW1]*6D7[H^E+7ZD?#A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4A^Z?I2TA^Z?I0!]+:%_P B]IG_ %Z1?^@"M"L_0O\ D7M,_P"O
M2+_T 5H5^85?XDO5GVU/X%Z!1116984444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>.?%[_D8['_KT_\
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MHU(R>CM;NKGI=%%%?,GM!1110 5XY\7O^1CL?^O3_P!G:O8Z\<^+W_(QV/\
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MO7EYS_N-3Y?FCNRW_>8_/\CU>BBBO@#ZL**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \K^/W_(AV?_ &$H_P#T7)7SA7U'\7XHYO"-LLL:
MNOVU#AAG^!Z\2^PVG_/K#_W[%?493@I5L-SI]6>1C<9&E5Y6CB:*[;[#:?\
M/K#_ -^Q1]AM/^?6'_OV*]/^S)_S')_:4?Y3B:*[;[#:?\^L/_?L4?8;3_GU
MA_[]BC^S)_S!_:4?Y3B:*[;[#:?\^L/_ '[%'V&T_P"?6'_OV*/[,G_,']I1
M_E.)HKMOL-I_SZP_]^Q1]AM/^?6'_OV*/[,G_,']I1_E.)HKMOL-I_SZP_\
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MYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]'^1YV:?[L_D>>T445]T?+A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Z=\'/\ CZUC_<A_F]>8UZ=\'/\
MCZUC_<A_F]>7G/\ N-3Y?FCNRW_>8_/\CU>BBBO@#ZL**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH X+XM_\BG;_P#7ZG_H#UXO7M'Q;_Y%
M.W_Z_4_] >O%Z^YR#_<UZL^8S7_>/D@HHHKVCS0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH UO"__(V:/_U^
MP_\ H8KZ/KYP\+_\C9H__7[#_P"ABOH^OD.)/XL/3]3Z#)OX<O4****^;/9"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG_X]Y/\ </\ *I*C
MG_X]Y/\ </\ *FMQ/8^75^Z/I2TB_='TI:_4CX<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D/W3]*6D/W3
M]* /I;0O^1>TS_KTB_\ 0!6A6?H7_(O:9_UZ1?\ H K0K\PJ_P 27JS[:G\"
M] HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M +C4^7YH[LM_WF/S_(]7HHHKX ^K"BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %%%% '!?%O_D4[?\ Z_4_] >O%Z]H^+?_ "*=O_U^I_Z
M]>+U]SD'^YKU9\QFO^\?)!1117M'FA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!K>%_^1LT?_K]A_P#0Q7T?
M7SAX7_Y&S1_^OV'_ -#%?1]?(<2?Q8>GZGT&3?PY>H4445\V>R%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5'/_P >\G^X?Y5)4<__ ![R?[A_
ME36XGL?+J_='TI:1?NCZ4M?J1\.%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2'[I^E+2'[I^E 'TMH7_(O:
M9_UZ1?\ H K0K/T+_D7M,_Z](O\ T 5H5^85?XDO5GVU/X%Z!1116984444
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M9==OX_W$9_T9&'WV'\7T';W^E>N,RHI9B%4#))Z 4V&&.WA2&% D<:A451P
M.@KSKXI^(;VQ@BTBVC>**Z0M+/\ WQ_<!_G6TIU<UQB6U]O)&<8PP.'O_39R
MWC_QB?$%]]BLI&_LV!N,<"9O[WT]/SKBZ**^WP^'AAZ:I4UHCYFM6E6FYSW8
M4445N9!7IWP<_P"/K6/]R'^;UYC7IWP<_P"/K6/]R'^;UY><_P"XU/E^:.[+
M?]YC\_R/5Z***^ /JPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH UO"__ "-FC_\ 7[#_ .ABOH^OG#PO_P C9H__ %^P_P#H8KZ/
MKY#B3^+#T_4^@R;^'+U"BBBOFSV0HHHH **** "BBB@ HHHH **** "BBB@
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MJ?P+T"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA3\P&?;I7T';2>;:PR#^- WYBO0X@FJD*-6.S3_0Y,IBX2J0>Z_X)YI\8_\
M5:/_ +TO\EKRJO6/C%$[6FDS!3L6216/H2%Q_(UY/7L9(_\ 88?/\V>=F?\
MO,OE^1[Q\-?^1'L_]^3_ -#-7_&O_(EZO_U[-5+X;H4\#6!((W&1N?\ ?-/^
M(5S]E\$:@>?WBK%Q_M,!7RTUS9FTOY_U/=@[8--_R_H>7_#3_D>K/_KG+_Z
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M_BP]/U/H,F_AR]0HHHKYL]D**** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ?P+T"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=O\ ]?J?^@/7B]?<Y!_N:]6?,9K_ +Q\D%%%%>T>:%%:WAWP_=^)-56RM<*
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MQ)(4>PS^=;_:N>\*^)(]?M[F)RJWEI,\4J#N Q"L/J!^=?'T_:^QGR?#I?\
M&W]>A]%/D]I'FWUL7/$>N0^'=$GU"92VSY40?Q.>@KYZU/4KK5]1FOKV0R3R
MG)/8#L!Z 5](ZA86^J6$UE=IO@F4JP_J/>OGCQ%H-SX=UB6PN 2H^:*3M(G8
M_P"-?0\.2H^]'[?Z>7ZGD9Q&I[K^S^IE4445]4>$%%%% &MX7_Y&S1_^OV'_
M -#%?1]?.'A?_D;-'_Z_8?\ T,5]'U\AQ)_%AZ?J?09-_#EZA1117S9[(444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<__ ![R?[A_E4E1S_\
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M%15DK(R;;=V36EY<V%PMQ:7$D$R@@21,589Z\BM'_A*O$/\ T&]0_P# AO\
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MN'^525'/_P >\G^X?Y4UN)['RZOW1]*6D7[H^E+7ZD?#A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A^Z?I
M2TA^Z?I0!]+:%_R+VF?]>D7_ * *T*S]"_Y%[3/^O2+_ - %:%?F%7^)+U9]
MM3^!>@4445F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY_Q]:Q_N0_S>O+SG_<:GR_-'=EO^\Q^?Y'J]%%%? 'U84444 %%%% !1110
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M]?(<2?Q8>GZGT&3?PY>H4445\V>R%%%% !1110 4444 %%%% !1110 4444
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MG(?]]7H_R/.S3_=G\CSVBBBONCY<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O3O@Y_Q]:Q_N0_S>O,:].^
M#G_'UK'^Y#_-Z\O.?]QJ?+\T=V6_[S'Y_D>KT445\ ?5A1110 4444 %%%%
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M4<__ ![R?[A_E36XGL?+J_='TI:1?NCZ4M?J1\.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'[I^E+2'[I
M^E 'TMH7_(O:9_UZ1?\ H K0K/T+_D7M,_Z](O\ T 5H5^85?XDO5GVU/X%Z
M!1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Z=\'/^/K6/]R'^;UYC7IWP<_X^M8_W(?YO7EYS_N-3Y?FCNRW_>8_
M/\CU>BBBO@#ZL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M X+XM_\ (IV__7ZG_H#UXO7M'Q;_ .13M_\ K]3_ - >O%Z^YR#_ '->K/F,
MU_WCY(****]H\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** -;PO_ ,C9H_\ U^P_^ABOH^OG#PO_ ,C9H_\
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M,:].^#G_ !]:Q_N0_P WKR\Y_P!QJ?+\T=V6_P"\Q^?Y'J]%%%? 'U84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P7Q;_ .13M_\ K]3_
M - >O%Z]H^+?_(IV_P#U^I_Z ]>+U]SD'^YKU9\QFO\ O'R04445[1YH4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 :WA?_D;-'_Z_8?_ $,5]'U\X>%_^1LT?_K]A_\ 0Q7T?7R'$G\6'I^I
M]!DW\.7J%%%%?-GLA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M1S_\>\G^X?Y5)4<__'O)_N'^5-;B>Q\NK]T?2EI%^Z/I2U^I'PX4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(?NGZ4M(?NGZ4 ?2VA?\B]IG_7I%_Z *T*S]"_Y%[3/^O2+_P! %:%?F%7^
M)+U9]M3^!>@4445F6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% &5J_AO2-<0B_LHY'Q@2 8<?\"'-<2WPN?3M:M+_2KW=#%.
MKM%-PP4'G##K^E>ET5V4,?B*"Y82T[;HYZN%HU7>2U[A1117&= 4444 %>.?
M%[_D8['_ *]/_9VKV.O'/B]_R,=C_P!>G_L[5[.0_P"^KT?Y'G9I_NS^1Y[1
M117W1\N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS3_=G\CSVBBBONCY<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'+U"BBBOFSV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY_\
MCWD_W#_*I*CG_P"/>3_</\J:W$]CY=7[H^E+2+]T?2EK]2/APHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0
M_=/TI:0_=/TH ^EM"_Y%[3/^O2+_ - %:%9^A?\ (O:9_P!>D7_H K0K\PJ_
MQ)>K/MJ?P+T"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_UDI?R/\ _L:I_,CYPHKZ/_ .$7\/\ _0$T[_P&3_"C_A%_#_\ T!-._P#
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M_P# 9/\ "C_A%_#_ /T!-._\!D_PH_UDI?R/\ _L:I_,CYPHKZ/_ .$7\/\
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MB_A__H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?\ \(OX?_Z FG?^ R?X4?\
M"+^'_P#H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?_P (OX?_ .@)IW_@,G^%
M'_"+^'_^@)IW_@,G^%'^LE+^1_@']C5/YD?.%%?1_P#PB_A__H":=_X#)_A1
M_P (OX?_ .@)IW_@,G^%'^LE+^1_@']C5/YD?.%%?1__  B_A_\ Z FG?^ R
M?X4?\(OX?_Z FG?^ R?X4?ZR4OY'^ ?V-4_F1\X45]'_ /"+^'_^@)IW_@,G
M^%'_  B_A_\ Z FG?^ R?X4?ZR4OY'^ ?V-4_F1\X45]'_\ "+^'_P#H":=_
MX#)_A1_PB_A__H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?\ \(OX?_Z FG?^
M R?X4?\ "+^'_P#H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?_P (OX?_ .@)
MIW_@,G^%'_"+^'_^@)IW_@,G^%'^LE+^1_@']C5/YD>#>%_^1LT?_K]A_P#0
MQ7T?69%X<T2"9)H='L(Y48,CK;H"I'0@XX-:=>)FF81QLXRBK61Z6!PDL-%I
MN]PHHHKRSN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG_P"/
M>3_</\JDH(!!!&0>U-;@SY97[H^E+7T?_P (OX?_ .@)IW_@,G^%'_"+^'_^
M@)IW_@,G^%?7?ZR4OY'^!\__ &-4_F1\X45]'_\ "+^'_P#H":=_X#)_A1_P
MB_A__H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?\ \(OX?_Z FG?^ R?X4?\
M"+^'_P#H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?_P (OX?_ .@)IW_@,G^%
M'_"+^'_^@)IW_@,G^%'^LE+^1_@']C5/YD?.%%?1_P#PB_A__H":=_X#)_A1
M_P (OX?_ .@)IW_@,G^%'^LE+^1_@']C5/YD?.%%?1__  B_A_\ Z FG?^ R
M?X4?\(OX?_Z FG?^ R?X4?ZR4OY'^ ?V-4_F1\X45]'_ /"+^'_^@)IW_@,G
M^%'_  B_A_\ Z FG?^ R?X4?ZR4OY'^ ?V-4_F1\X45]'_\ "+^'_P#H":=_
MX#)_A1_PB_A__H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?\ \(OX?_Z FG?^
M R?X4?\ "+^'_P#H":=_X#)_A1_K)2_D?X!_8U3^9'SA17T?_P (OX?_ .@)
MIW_@,G^%'_"+^'_^@)IW_@,G^%'^LE+^1_@']C5/YD?.%%?1_P#PB_A__H":
M=_X#)_A1_P (OX?_ .@)IW_@,G^%'^LE+^1_@']C5/YD?.%%?1__  B_A_\
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MOB"6*1XY$L)BKHQ!4[3R".E?&O\ PD.M?]!C4/\ P)?_ !K['^(G_)./$?\
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M;O\ D;-7_P"O(?\ H8KZ5H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFWT'3H)?$5HDL=M&CJ0V00H!'2KW_"U_ O\ T,EI^3?X5\Y?\*2^(7_0 _\
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M *]&_F*^,H96@FCE3[Z,&7Z@YK[-^*7_ "2_Q#_UZ-_,5\8QJ&E13G!8 XH
M^X_"GB"S\3^&K'5;.59$EB7> >4?'S*?0@UY-^T7XFM4T>Q\-Q2*]W),+F95
M/,:*"%S]23^5<=K7PN\=>#YVN/"UQJ%UITR!P]C*5EZ9PZ*02?ID?RKF]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <A\4O
M^27^(?\ KT;^8KXRA_U\?^\/YU]XZGIEGK&FW&G:A")[2X39+&21N'ID<UR
M^#G@ $$>'8LC_IO+_P#%T =G9?\ 'A;_ /7)?Y"IZ:B+'&J(,*H  ]!3J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img76291469_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +.".@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK&FZQ!YVFW]O=QXSF&0-CZCJ/QIN+2N27:***0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!:HHHKE-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"U1117*;!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB6*,26VH6YQ<V-P-DT)]QW'N.*VJ;33LR HHHH **** "BBB@ HHHH ****
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M_J4N@^$77S(SMOM6(W16GJJ=GD]NU=)X<\+Z=X9M'BLU>2>9M]Q=3-NEG?\
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MYW--)'SIX9\/ZSXDU-[/0UW7:1&0@3B([<@'DD>HKK?^%3_$<C!B?_P8K_\
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M-Q,L3R26S,<+]HC* _CTK54*LH\RB[&3KTHRY')7]3=HHHK(U"BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "N*UN\N_%VKR^%-$G:&TBQ_;&H1GF-3_RQ0_WV[^@JWXKUJ]-U!X9T$_\
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MZ)-<>$];7PEJ<CR6LN6T>\D.?,0=86/]]>WJ*["NAJQB%%%%( HHHH ****
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MO?5I$N$6K-'GUO<"<,"K1RQG;)$W#(?0U4GMY+*5KNS7*GF6 =&]Q[UV&NZ
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M=K(T%Z@S)9S_ "R+]!_$/<5T->+*+B[-'IIIJZ"BBBD,**** "BBB@ HHHH
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MHHHIE!1110 4444 %%%% !1110 4444 %%%-9T4@,Z@GL3B@!U%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3X:V.IRR7^CRC3-1;E@BYAE/^TG;ZBO-K^"_T2\%GK5HUG,W"29S%+_NMT_
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MDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%1W%Q#:6\EQ<2K%#$I=Y'. H'4F@ GGBMH'GGE2*&,;GDD8*JCU)/2O.-<
M^-_AG3'>+3TN-4E7C=$-D>?]YN3^ KR?XC?$.Z\8ZH\%M))%HT+8AASCS<?Q
MMZD]AVKAJVC2ZR*43TW6?CCXHU#*:>EMID9XS$N]_P#OIO\ "N U+6M4UF4R
M:EJ%S=MG/[Z4L ?8=!^%4:*U44MBK!1115 %%%% &CH,=Q)K5J;>,NZ.&(]%
M[_I7MD<5W=Q(LS>1"  57[S?X5Q?PSL(F@FNV +ER/RZ?SKT6OB\ZQ*J8CD2
M^'0][ 4N2E=]2.&&.!-D2!5]N]244C,%4LQ  ZDUXQW"U%/<16Z[I7 ]!W/T
MJNUW+<,4LTR.AF;[H^GK4D%DD3>9(QEF/5W[?3TIVMN*_8B"37TJ/,ACMT.Y
M8SU8^IJ]4<LZ0X#$EF.%11EF/H!WHNM+UHHKS:?=16S#.(E#.?J!R/RKJPN#
MK8N:A27^1SXG%4L+!SJ/]7]Q3NG%U<1VT9RJ-OD8=!CH*MU7$MO;+Y>#%C^%
MD*G]14L3M<$"W@GG)Z"*)F_I7Z!EF5O T>5ZMZMGYKF^85,QKJ2BTEHEU'UL
M^#X6FU^>=<^7!!L8]MS$''Y#-1V7A;5;Y@;C%A!W)(>0_0#@5V>FZ;:Z39K:
MVD>V,<DDY+'N2>YKHKUH1@XIW;*R[ 55456HK)%NBBBO,/H0HHHH **** "B
MBB@ HHHH **** "BBB@#YF^+O@S_ (1GQ)]OLXMNF:@2\>T<1R?Q)_4?7VKS
MROL+Q9X<MO%?AN[TBYPIE7,4F.8Y!]UO\]B:^1M1T^YTK4;BPO(S'<V\ACD4
M]B*Z:<KJQ:96I\,LEO-'-"[1RQL'1U."I'((IE%:#/K/P!XNC\8^%X+TE1>Q
M8BNXQ_#(!U^AZC_ZU=37RI\-O&+^#O%$<TK'^SKK$-VOHN>'^JGGZ9KZJ5UD
M171@R, 58="#T-<LX\K(:L+6%XB\(:1XGB'VZ I<H/W5W#\LL?T/<>QXK=HJ
M4W%W1+2>C/#M>\+:WX6WRW*'4--7D7L"?,@_Z:)V^HXK,1UD171@RL,@CN*^
M@V575D=0R,"&4]P>HKP+4-*?P]K]_HK@^7"_F6S'^*%N5_+I^%?0Y9CYU9>R
MJ;]#Q\=A(PC[2!'1117MGE'4?#/5AIOB&[T25L6^H#[1; ]!*H^=1]1S^!KU
MJOG>>2XMFAOK,XN[.19X3[J<X_$9%>]Z1J<&M:/::G;?ZFZB$BCTSU'X'(KY
M7-</[*MS+:1]!@*WM*5GNB[1117F'<%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %JBBBN4V"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q5:/>>
M&+^*,9<1^8HSUV\_R!K8HP",$ @]0>] I+F31YM!(LT$<J'*NH(JGJ!>>>"Q
M1BHDRTA'7:.WXU;2W-A>WNG'/^C3$)D\E&^93^1JI='R=5M)C]QPT1]B>17-
M:S/(:MHR[%%'!&(XD"*.@%5K^S%S$7C^2X3YHY!UR.WTJY12 KV5S]KLXYL8
M8CYAZ$=:VO"=S]FUN\L2<)<H+B,?[0X;\2,'\*YVR_T>_NK7^$GSD^AZ_K5I
M[@Z?>V>HKG_1I@7QW0\,/R-5%V9=*7+),]+HH!# %2"I&01W%%=!ZH4444 %
M>;^*O^1UN/\ KUB_K7I%>>^-+=K7Q-!>,/W-U (PW8.O;\J\_,TWAW8[< TJ
MVISNH?=MO^NZU<JGJ'W;?_KNM7*^:>R/<"J=O_R$[OZ+_*KE4[?_ )"=W]%_
ME0MF#+2_\A/2_P#K]B_]"%>M'K7E6G0-?^)--M8ADQRB>0C^%5YY_&O5:]_*
M4U2;\SQ\R:YT@HHHKUCS@HHHH **** "BBB@ HHHH **** ,WQ#_ ,BWJ?\
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M2])NKE?[ZIA/^^C@?K7TWHOPX\)Z#M:TT>&24?\ +:Y_>O\ ^/<#\!74 !0
M  !T K)UNR)YCY^T;X"ZU=%7U?4+:QC/)2+,K_T _6O0M&^#7A'2MCSVTVHS
M+U:Z?Y2?]T8%>@4V66.&)Y975(T!9G8X"@=236;G)BNSB?%&@Q:9]GU'3+.*
M*UB0QSPV\84*O4. /3O6-'+'*FZ-U9?4&LKQ?XPF\5SM8:>[Q:'&V'D'#7;#
M^2?SK#7Y0 . .*YZ_"M?&?OZ<E%OH[_>:4L_I8;]U--VZHZJ:^CC?RXP9ICT
M1/Z^E,6TDN&#WC[AU$2_='U]:YR*:2&421L58=ZU%UZ0+AH4+>N<5X^-X:Q^
M%DE"'.GUCK_P4>EA<\P>(BW*7*^ST-KY(D_A1%'T J?3].U#6F'V&,1V^?FN
MI1\O_ 1_%_*K7@K3+/Q#I::S>AYLRND=NW$:[3C)'?\ &N^ "@!0 !P .U1A
M<FE>^(T\O\RJ^9JUJ.OF96D>';'1_P!Y&IFNB/FN)>6/T]!]*UJ**]Z%.-./
M+!61Y$YRF^:3NPHHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O&?CAX+\^V3Q58Q9EB CO54=4Z*_X=#[8]*]FJ.X@ANK:6WN(UDAE0I(C
M=&4C!%.,N5W&G8^)Z*Z3QUX4F\'^)[C3FW-;-^]M9#_'&3Q^(Z'Z>]<W76G=
M7+"OH3X*>,_[5T@^';V7-Y8KFV+'F2'T^J_RQZ5\]UH:'K-WX?UJTU6Q?;<6
MT@=>>&'=3[$<4IQYE8&KGV916'X:\7:-XKL([C3;R)Y2@:6VW?O(CW!7KP>,
M]*W*Y+6,PKSOXJZ1FPM/$,*?O;!O+N,#EH&/_LIY_$UZ)4-W:PWUG-:7*!X)
MT,<BD=5(P:TI5'2FIKH1."G%Q?4\#!! (.0>0:*8;*?2+^[T:Z_UUC(8PW]]
M.J-^(I]?;4JBJ04X[,^7J0=.;B^@5V?PKU<6US?>')G.T$W=F#_=/WU'T//X
M^U<935OIM'U"SUFW&9;&7S"O]^,\.OXJ37)F&']M0:6ZU1T8*M[*JK[,^A**
MBMKF*\M(;JW</#,BR1L.ZD9%2U\@?1A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!:HHHKE-@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOQ
M;;_9=;LKX<)=(;=_]X?,OZ9_*L/4X#/82!/]8GSI]1S7;^*K%K_P[=+&/WT(
M$\?./F3G^6:X^"9;BWCF7E74-^=8S5G<\[$QM/U$MIA<VT<PZ.H-2UGZ;^YD
MN;,_\LGW)_NMR*T*S9@C/O\ _1[NUO.RMY;_ .ZW_P!?^=79HEGADA<95U*F
MH[V#[59RP]V7CV/:FZ?<&YL8I#][&UAZ$<&F!V?A.^:^\/6_FMF>WS!+D\Y7
MC)^HP:VZXWP?*T>M:G:@DQND<V.P;H?SX_*NRKHB[H].C+F@F%%%%,U"JFI:
M9::O9/:7D>^)N>#@J>Q![&K=%)I-68TVG='E_B/PM<Z);177V\7-FMP@VNF'
M7.>2>F*KUZ=J6GP:IIT]E< ^5,NTD=1Z$>X->:7NEZKHLAAN[26XA7A+FW0N
M&';('(->!F&"<&I4EH>S@\5SKEJ/493M%T&\US4+]K6[CMXHF59'9"Q)QVIE
MK;ZCJCB+3["<EO\ EK,A1$]R3U_"O1= T6+0M+6U1O,D)WS2G^-SU/TJ,!@G
M4E>HO=*Q>*5.-H/4;H?AZST&%Q!NDGD_UL\GWG_P'M6M117T,(1@N6*LCQ92
M<G>6X44451(4444 %%%% !1110 4444 %%%% !7*:OX2E>\DOM'FCAEE.98)
M1^[<^HQT-=712:3W)G",U:1Y98PSVU]J,%TBI<),-ZJ<@' Z&KU:OBC1;F._
M_MBPA:;>H2Y@3[Q Z,OJ:YT:O8X.Z?8PZJZD,/PK"46F>94@X2LQ=6.-+G_W
M0/U%:MCX2U2_2)=2FBM;3:-T<#;G<8Z9[5!I6E7'B&\B=X9(M+B8.[R#!F(Z
M #T]Z]#JX1TU-Z%!2]Z1';V\5K;QV\"!(HU"HHZ 5)116IW!1110 4444 0W
M5U%96DUU.VV*%"[GV%>5+/+>33WT_P#KKIS(P_NCL/P&*ZKQW?[H[;1XVYG/
MFSX/2->@_$_R-<I-*L$#RMPJC->!FM?FFJ2Z'LY?2Y8NH^I6E_TK44B_Y9P?
M._NW85=JK81,EOOD_P!9*=[?C5JO)?8]!!5*$^?J,LP^Y$OEJ?4]ZEO)S;VS
M,OWS\J#U)IUK +>W2/J0,L?4]Z%HK@+.)9 EO;C-Q.XBB'^T:]3TVPBTS3;>
MRA^Y"@7/J>Y_$UQ?@VQ^VZS-J#C,5F/*C]Y".3^ _G7?5]!E=#DI^T>[_(\;
M,*O-/D70****]4\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JVH7UOI>G7%_=N$M[>-I9&] !FK-<9XH!\
M3>)M.\(1'-JN+[52/^>2GY(S_O-^@JX1YGKL#+OP_P!.N&LKKQ)J4974M:?S
MV4]8H?\ EE'^"\_4UV5( %    '  [4M3.7-*XTK(****D84444 %%%% !11
M10 4444 %%%% '#?$O1VNM(BU6 ?O[%LMCO&>OY'!^F:XNWF6X@25?XAS[&O
M:IHHYX7AE4/&ZE64]"#7BFHZ;)X8\03:;+G[+*=]NY[J>G^'X5[N7U?:T71>
M\=5Z=?NW/G,ZPKNJT?F2T445T'SP4444 %%%% %.?3+:<[BFQO5.*;%:ZA:
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MS_H'6G_?A?\ "C^R-,_Z!UI_WX7_  H_=^8?[1Y?B+_:NG?\_P#:_P#?Y?\
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MJ#)<ZS*N&D'W8%_N)_4]Z[&BBOE9SE.3E)W9[\8J*LM@HHHJ2@HHHH ****
M"BD)"@DD #J2:$=9%#(RLI[J<B@!:*** "BBB@ HHHH **** "BBB@ HHHH
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ME'8=^OUZ,;B:=*D[O5G+A*$ZE1-+1'JY^\?K2445\>?1A1110 4444 %%%%
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M<ENF=N%P]*6#C!K1K7YF)X>T*ZT>XE:6XBDCD &U,]0>O/XUQ:?\AK_MY/\
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MH.FOBE^2_P SS<#@.3$.I]E;%JBBBO"/="BBB@ HHHH **** "BBB@ HHHH
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MR[J@_P!H@5Z';_"73!@WVK:G='N%=8E/X 9_6MBT^'/A*S(*Z-#,WK<%I?\
MT(FN2>=4U\,6SHCE<W\4CQHZK8[]BW"R/_<C!8_D*NVUIJ]__P >.@ZG/[F
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MFN^KC_#$ FUN68@$6T.!D=&<_P""G\Z["MH;'H896A<****LZ HHHH ****
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M02L<SP#R9?J.A_$8KH*\*K?G=S[3#N/L8\KTL@HHHJ#8**** "BBB@ HHHH
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MBNC!D8 J1T(IU>(>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=-M;HYLNQCI5U%OW7H>HT445XQ]:%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT25Y?"\)8G(A9?P (HJ1IQC&JHZ/H%"I7G.IA9SU6SL<)I=W-87T5Q;1B65
M0JD$YR,=J[[1-1N-0LI)[N%8&1R, %1C&<\UQWA+_D8+7_=?_P! -=AXEE>+
MP_=,I() 7/L2 ?YUIC+2J*G;5VU^9CE/-3P\J_-HKZ?)&3?>,@DYBL+<2@'&
M]\X;Z 5 GC*\BE N[% O<+N4_K5?P9"DFJ2R,H+1QY7/8D]:V_&$22:-YK*"
MZ2+M;N,]:4HT85%2Y?F5"IBZN'EBO:6M?2VFAKV-[!J-JEQ;MNC;CG@@^AKF
M3XMN8M5:WFB@$"2E&<!L[0>O7K2>!I&WWL>?D&QL>_(_I7.WB>9K5PA. UPP
M_P#'J*6'@JLX2U2#$X^L\/2JP=FV[_(Z>S\637NKPVT=O&D,C[<L26Q_*NJJ
MG;:58V:H(;6-2G1MOS9]<U<KBJRA)^XK(]?"TZT(OVTN9LXOXA0L\.ERL,VZ
MS.C^S,N!_(BN"L=(-G>F;S=R@$* .?QKV/6-.35M(N;%\#S4(5O[K=5/X'%>
M60LY0K*NV:-C'(OHP."*]' S3AR]CP<ZHRA551;2_0HW$+2W7V.5S]F=7DB3
MLLAQN/UX%1:5IL]I+*9MNQEVX!SNJ]?1L]OOC_UL1\Q/PZC\14T4JS0I*ARK
M#(KM22/'<FUJ5K',+2V;?\LCE,]T/3\NE69HEGA>)_NN,&JU[^XDBO!TC.V3
M_</^%7*8GW/0O"FJMJN@Q23'-S"3!/\ [R]_Q&#^-;=>;^%-0_LWQ&L+G%OJ
M $9]!(OW3^(R*](KPL32]G4:Z'V>7XCV]!2>ZT84445@=H4444 %%%% !111
M0 4444 %%%% !1110 4444 <EXK1EU:SEP-CP.F?<,#_ "KG8?EU&Z3^\J./
MU%=9XOBS;V%QNP([@H1Z[E/^%<FWR:K&?^>D+#\B#6$]SS<0K5&6JI62;]-\
MD]0'B/YD5=JK9_++=1_W9BWY@'_&H,3T+2)VN=&LIW^_) C-]<#-7:Q?"K[M
M B3=N,4DB'VPYP/R(K:KI6QZT'>*84444R@HHHH **** "BBB@ KE?B1<M;^
M =45,[[E%M5 ZDR,$_D3755R'C8?;-2\*Z2.?M6K)*Z_WDA4NP_E6E+XU_6P
MI;'9V%JMCIUK9IC;!$D0QZ* /Z58HHK(L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *ANKNVL;9[F[GC@@09:21@J@>Y-<]XX\;Z=X'T1
MKZ\(DN'^6VM0V&F;^@'<U\K>+?&VM^,]0:YU2Z/E _N[6,D11CT [GW/-;4J
M+GKT$W8^B-2^-OA*VF-MI\T^I7.2JBWB(3/J6; Q[C->.:C?SZIJ-Q?73[II
MW+L?KV^@KEO#<2EIY2/F&%'M705WTJ4:>QC.5W8****V(-/P]HL_B#7+;38
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MX5U#_GAK$4;'T6164_TK:A\?W_D1/X3H:***U,@HHHH **** "BBB@ HHHH
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M1 %4#L!3J\B<G*3DS[2C25*FH+H%%%%2:A1110 4444 %%%% !1110 4444
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M*** "BBB@!K1QNX=HT9QT8J"1^-.ZT44 %%%% !1110 4444 %%%% !1110
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M -B_%RV0Y$5XS0$#OO&5_7%>1G%+GHW_ *[GIY74Y:G*?3%%%%?''T84444
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M0/X6[J?I5RO!-(UW4M#F,EA<&,-]Y",HWU%>M>#M=N?$&D275VD:R)*4_=C
M(Q7E8_*YX:]1.\?Q/0PF/C7M!KWCH:***\H[PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** #KUKRG4=/.CZS=:?C$0/FV_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M('E;H@S7*L[2.TCG+,<FNK"4^>I=[(TI1N[B49QTHHKV3I+>FZ=<:KJ$5E;
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MZSVTK12KT937H7AWQ?%J6VUOBL5WT#=%D_P-<\Z36J-(SON=31116184444
M%%%% !1110 4444 %%%% !1110!:HHHKE-@HHHH **** "BBB@ HHHH ****
M (KFXAM+:2XN'"0Q*6=CV KP_P 2:_-XAU5[I\K"ORP1_P!U?\3U-=5\1_$/
MF3#1;9_D3#7!'=NR_AUKSZOJ\FP/LX>WFM7MY+_@G@9EBN>7LH[+?U_X 444
M5[AY04444 %%%% !1110 4444 %%%% !1110 4444 :MCJT<-NL,ZL-@PK*,
MY%6()QJ5Z'5"((.1N_B8]*PJWM%*?82!]X.=W]/TKR,5AXTK./4PJ14=4:-4
MK;_2+R6Y_@3]U'^'4_G3]0N?LMF[@_.WRH/<U'I,J/81HI&Y!AAWSZUR6>YE
M;2Y=)"@DG ')-<K<3FZN9)CT8_+[#M6SK%T([<P*W[R3@@=E[UA5WX&E=N;Z
M&M*/4****],W"BBB@#NOA]XG-E<C1[M_]&F;]PQ/^K<_P_0_SKU*OG,$@Y!P
M1WKVCP7XA_MW1@LS9O;;"3>K#LWX_P Z^9SK \K^L06CW_S/<RS%77L9?+_(
MZ2BBBOGCV HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N4\5^+$TI&L[)@]ZP^9NHB'^-3>+O$JZ-:?9K9@;Z8?+_TS7^\?
M?TKRMW>1V=V+.QR6)Y)KJH4>;WI;&52I;1"7#O=-(\SL[R<LS'))]:U+"X-Q
M:*6/[Q?E?ZBLJI;.<6UW\QQ'*,$GH&[&O2I.SL>'F=#GI^T6Z_(T;V$SVS!/
M]8OSH?\ :%/MYA<6Z2C^(9(]#W%2,ZHI=F"J.23VK+TNY!FEB(VK(QDC!],]
M*WOJ>"HMQ;70LZ@'CC2ZB&9(#G'JIZBHSJ\7E@I#*7(X7;Q^=7G*B-B^-F#N
MSZ5S\'$*_3CZ5,Y..QUX+#1Q$G&70>NXEG<Y=R6;'J:6BBN9NY])""A%1CL@
MHHHH*"BBB@ HHHH 9+,D*[G; _G50ZG%GA'(]:H7$S3S,Q/'0#T%15HH]R;F
M[#<13CY&Y'4'K4M<_'(T3AU."*WHW$D:N.C#-3)6&G<=1114C"BBB@ HHHH
M*O:5JUWH]XMS:2%3_$A^ZX]"*HT4FDU9@G8]HT36[;7+(3P';(.)(R>4/^%:
M=>(Z7JESI%\EU:OAE/S+V<>AKV#2=4M]8T^.[MVX8?,IZHW<&O/K4>1W6QU4
MY\WJ7J***P- HHHH **** &2C,$@]4;^5<[\+#_Q;G2E_N"1?R=JZ7;N!7U&
M*Y7X5_+X*$/>"]NHCSZ2M6B_AOU7ZAU.VHHHK(H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "L+QGJXT'P9J^IY :"U<IDXRQ&%'YD5NUY)^T%J_V/P3
M:Z:K8>_NAN'JB#<?_'ME73CS22!GS1DGEB23R2>YHHHKU3,**** "BBB@ JY
MI.GRZMK%EIT(S)=3I"OU9@/ZU3KT;X(Z/_:GQ)M9V3=%81/<MGINQM7]6S^%
M3.7+%L9]3VUO':6L5M"NV*)!&B^@ P!4M%%>26%%%% 'SG\7[/\ LKXH07Z+
MA+R&.1CZL/D/Z!:IUVWQ_P!+\W1=+U9%^:WG,+MZ*XR/U45P5G-]HLH9O[Z
MGZ]Z^NR6KS4N4^>S6G::D3T445[1Y04444 %%%% &0MV=%\>:1J@SM2>-VQZ
M!L']*^K@00"#D'H:^2_%$.^RBE'5'QGT!'^(%?2_@K5/[9\%Z1?G[\MLF_\
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MI_"?Z?A76U\#B*,J%65.70^NHU55@IKJ%%%%8F@4444 %%%% !1110 4444
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MY+,3W)KVLGP_--UI=-O4\O,JW+%4UU&T445]&>*%%%% !1110 4444 %%%%
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MJ\U14UT_4****]T\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGT'(_0UR8J&BD;49:V.CHHHKB.@**** "N3TK_1?B[K4707NF6\X]RC,A_\
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MHXCD?F2*PI[J>YNFN9Y6EF9MS.YR2:SA1DI\ST]"Y5$XV6I[7XG_ .17U/\
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MXMZU+>^)5TM7/V>R0?*.A=ADG\L#\ZZ+X7^#],G\/KJ^HV<-U/<.WE"9-P1
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M/&7_ $*=I_X-%_\ B*ZNBCG7\J_'_,+>9RG]L>,O^A3M/_!HO_Q%']L>,O\
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M:YO3;HTLC8^2)0"3[+WXK*C1]IJWH.4K'M=G\3?#%_?6]G;W4YFN)%BC!MG
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MQM2.(P7M$[=?GV.C"PE1Q7(U?^MST6BBBOF3W0HHHH **** ,#QG:_:?#<[
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MX^M5JZSP'8>?JLMXPRMNF%/^T?\ ZV:F3LKC2NST7   '0<"BBBN,W"BBB@
MHHHH **** "BBB@"U1117*;!1110 4444 %! (((!!X(/>BB@"II^EV6E121
M6-ND*2.9&"]R:M[0WRGHW!HHIRDY.\G=B2459;'SS>1&"^N(F&"DK+C\34-;
MGC"V^R>+=2CQ@-+Y@'LPS_6L.OT*C/GIQGW29\?4CR3<>S"BBBM" HHHH **
M** "BBB@!"H/4 _A2;%_NC\J=10 @4#H /PI:** "BBB@!-B_P!T?E2T44 !
M (P:3:O]T?E2T4 %)M7^Z/RI:* $(!Z@'ZT  = !2T4 %%%% !1110 4444
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M;62/=+3_ )%B#_KS7_T"N%^%W_(0O_\ KBG\S7G9\5>(40P_VQ>K&HV;!(0
M.F*N:-J5_86^^UNIK=W&&,;8+ =,U/U:48R5]Q^U3:?8[;XG?\AFQ_Z]S_Z%
M7F]_!-+*K(I9<8P.U;-YJ%YJ$BR7MS+<.HVJTC9('I5:MJ2<(I$3?,[E:SM1
M;IEN9#U/I[59HHJF[DE#4+EH_P!RG!(R3[57L;4S.)''[M?U-:4MO%.09%R1
MT.<5(JA5"J, = *J]E9"MJ+1114C"BBB@ HHI55G=412S,< #J30!O\ @_2/
M[5UR,R+FWM_WDGH?0?G7K=8OAC1!HFDK$P'VB7YYC[^GX5M5YM:ISRTV.NG'
ME04445B6%%%% !1110 $!@0PR#P1[5R?PZ8Z;_;/A>0_-I-XWD#_ *=Y/G3'
ML,D?A765Q^J'^P_B5HNK#Y;;5HFTRY/;S!\T1/OU4?6M*>J<?ZT$]-3O****
MR+"BBB@ HHHH **** "BBB@ HHHH *Y+XF>'O^$E\ ZG9(@:X2/SX,]G3D?G
M@C\:ZV@C(P::=G<#X-HKJOB/X?\ ^$:\>ZI8*I6!I?.@S_<?YA^62/PKE:]:
M+NKD!1113$%%%% !0"5(93AAR#Z&BB@#[/\  GB >)_!6EZH6W2R0A9LGGS%
MX;\R,_C71UX+^SOXAYU/PY*_3%W "?\ @+C_ -!/XU[U7EU8\LVBT%%%%9C"
MBBB@ K%\6ZZGAOPMJ&JN1N@B/E@]W/"C\R*VJ\1^/.O-(^F^&[=LLY^TS*#_
M ,!0'\<G\!6U"G[2HHD5)<L6SSCPY"\@N+^8EI9F(W'J><D_G6[4-K;K:VL4
M"]$7%35][1I^SIJ)\A6J>TFY!1116IF%%%% !115>]N1:64LY_@7CZ]J3:2N
MQI-NR*^BZ6_BWXB:?I:9,$<@,I'0(OS,?TQ^5?5   P!@"O&/@+H#+:ZAXCG
M7YYV^SPDC^$'+G\3@?\  :]GKX;,*[JUFSZS"4E3II!1117"=(4444 %<OX\
M\4'POX?:>'!O)V\J 'H#CEOP']*ZBO(/C4[_ &K2(^=@21A]<BM:,5*:3)D[
M(XSP_H.I>.?$$J-<DR8,L]S-EMHS_,]A6[XK^%MSX?TIM1M;T7L,6#,IBV,H
M_O#DY%;OP41?*UA\?/OC7/M@UZ+XC2-_#.JK+]PVDN[_ +X-=-2O*-3E6Q"B
MG&YY;\+O&=U'J4>@7\[2V\P(MF<Y,;CG;GT/\ZI?$7P9J%IJ6I^(W:W^R2SK
MM 8[^0!TQ[5R'AMF3Q3I#(2#]MA''^^!7M?Q6_Y$2X_Z[1_SJI^Y67+U$M8Z
MGBWA[P[=^)]2.GV;0B41F3]Z<# _#WKWOP-H-UX;\,QZ==F(RK([$Q'*X)KR
MSX1?\CHW_7J_\Q7N]9XJ;OR="J:TN%><?&7_ )%>S_Z^Q_Z"U>CUYQ\9?^17
ML_\ K['_ *"U84/XB*EL<A\(?^1R?_KU?^8KK_BOXIGTFQ@TFQE:*XNU+2R*
M<%8^F!]3G\C7(?"'_D<G_P"O5_YBF_%S?_PFWS_=^S1[/IS_ %S77**E7U[&
M:=H%#P7X$N?%S3S&X%K:1-M:4IN+-UP!D=NI]Z?XO\,ZEX,@.G&Z^TZ7?$,#
MMP-Z'/(YP?YBO2OA)L_X0=-OWOM,F_Z\?TQ5/XR^7_PBUGNQYGVP;/7[C9I>
MVDZW+T'RKEN<U\%XT'B+4&"*&%IC(';>M5/B[<M-XR6$D[8+9% ^N3_6KOP8
M_P"1@U'_ *]1_P"ABJGQ?M'A\7QW!4[)[92#[@D'^E4O]X^0OL'2?!:V5=(U
M2[P-[W"Q9[X50?\ V:O1-5U2TT739M0OG9+:$ NRJ6(R<=!SWKS;X+7T9L]4
MTXL!()5G"^H(VD_^.C\Z] \2:-_PD&@76E^?Y'G@#S-F[;@@],C/3UKEK6]L
M^8N/PZ&!_P +5\)?\_TW_@+)_A6AHWCSP_K^HK8:?=2R7#*6"M ZC Z\D8KR
MWQ;\-?\ A%]#;4O[6^TXD5/+^S[.O?.XU7^%'_(]P?\ 7"3^5:NC2<'*+)YI
M7LSW74-/M=5L9;*]B$MO+@.A)&[!![?2LG7K"TT[P/K%O96T5O"MA-A(U"C[
MAK?K(\5_\B?K7_7C-_Z :Y8MW2-&?/'A;_D;M&_Z_H/_ $,5]/5\P^%O^1NT
M;_K^@_\ 0Q7T]75C/B1%/8****XS0**** "BBB@ HHHH **** "BBB@ KE/B
M+J<NG>#;J*U)%[?LMC; ==\AVY'T&3^%=77!:Y)_;?Q-TO3A\UMHL#7TX[><
M_P L8/N!EA]:UHQO.[Z:DS=D;FEZ?%I.DV>G0 "*UA6)<>PQ5NBBMC$****
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M,CD9A@CC(QFC4/#6@Z%H37%\\\LR1X#&Y=3*_8 !L=:\_MO$FK+ JV^K70B
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MX@T]M0TF18AFXA(FA_WAV_$9'XUJ44,4DI*S/+;F02VT=[!\QB.['?'1@?\
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MN[+"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117+>/\
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MYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M M),P^4=3S@#\365:I[.FY&E&G[2:B>B_ ;0FFN=3\27"Y.?L\)([GYG(_\
M'1^)KW"L+P;H*^&O"6G:4 -\40,IQUD/+'\R:W:^"KU/:5'(^OIPY(I!1116
M)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKL*AM;6"QM(;2UC6*WA01QHHX50, 5-73)WVV, HHHI %%%% !1110 4444
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M.<D^^T<5TW@K6KW7=(FNKYHVD68H-B;1C%>;>'_".H^(098=L%J#@SR#@GT
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-=TC7<[*JCNQP*
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MA_LCH!712A;WW\C.<NB-2PL;;3+""QLXA%;0((XT'8"K%%%69A1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@HHHIE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7"^(/#U]#J4]Y96[7-M<-YCI'C?&_?CN#UKNJ*PQ&'A7ARS-J
M-:5&7-$\XT_PY?ZM,D<]M+:V6<RO+\K,O]U1UR?6NMLO"NDV-RMQ'"\DB'*&
M:0N$^@/%;5%9T,%2HK17?=EU<74J/>R"BBBNLY@HHHH **** "BBB@ HHHH
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M+=\@'*MJ;@_F(@?SK2G3YWY$RE80O/\ $C4%NIU>'PE;2;H(6&&U%P?OL/\
MGF#T'>NV      '  IJ1I%&L<:*B* JJHP !V%.KH;Z+8QW"BBBD 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 5-1U*TTJT:YO9A%$.!GJQ] .YKS?Q+XW&M6<EA;V?E
MV[,#YDC?,<'/3M7=>(_#T'B"Q$3GR[B/)AE_NGT/L:\]T[P)K%[<RQS(MK'$
MVUI).=Q_V0.H]Z]C+HX2,?:U'[R[_IW/,QKQ#?LX+1_U\CG+>9K:YBG0 M&X
M< ],@YKTS1OB%9WTJP:A%]CD;@2!LQD^YZBLV?X92"(FWU-6DQTDCP#^(K.T
M;P+?W.K/#J,306T!'F.#GS/93WSZ]J[L15P.*@Y2EM]__!.6C#%8>245O]QZ
MJ"" 000>A%%,AACMX(X8E"QQJ%51V I]?,OR/="BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** +5%%%<IL%%%% !1110 4444 %%
M%% !1110 4444 -DD2&-Y9&"H@+,3V KSM[AKRXGOY>&N&W\_P *?PC\!73>
M++S991V"'Y[H_/[1C[WY\#\37'W7[^XCM?X"-\O^[V'XG^595'T.'%3N^4AO
M-0MOLSM',?,0AT90>&!R,&M]_$NLW+":)K:VC/*Q&/><>YR/TJ@%4+M"C;C&
M,<55LAY<MS O^KC<;!Z C.*A-K8YXSE'9G;:#KC:H9;>YB6*\A )"G*R*?XE
M].>W:MJN0\+6[2ZQ<78R(X(?)SZLQR1^  _.NOK:+NM3T:,G*"<@HHHJC4**
M** "BBB@ HHHH **** "BBB@ HHHH *9++'!&9)I$CC7J[L% _$T^O._%%S)
M?>()X)<^1:X2.,]"2,EB._6N;%8A8>GSM7-\/0=:?+<[4ZUIQLKFZANX9TMX
MVD<1."0![5P-SK6JZA)YTM[/ "<K#;OL"#L,CDGZUD7D:R8BC7$S@X8'&%[Y
M]NV*>1=Q+NWI+@<IMVD_0UX>)S"I6BDO=/6H8.%)MO4[/PKKMS-=MIU_-YQ9
M2\$K<,<=5/J<<@_7TKKJ\E@N6C:"]MC^\B82I]1V/U&0?K7JEI=17MI#=0G,
M4R!U^AKT\MQ+JTW&;U1P8Z@J<U*.S)J***](X0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#F_%&CM-')JMM(J3PPGS%?[LB#G\"/6N8LX
M_*LX4]$!/U/->DR1I+$\<BAD<%6![@UQ,_AW5+!C%;PB\MUXC=7 <#L&![CU
M%93CU1QXBD[\T48^H$&*.$D 2R!3GT')_E6EHT(U+6K=(QYD-N_G3./N@C[H
MSZYP<>U:ND>&6:4W6L0PN=I6.V.'5<]6)Z$_RKI88(;:(101)%&.BHH 'X"B
M,.K%2P[NI2)****U.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ&
MMWSZ;HUU=Q@&1$^3/3<3@?J:!-V5V6Y)X82HEFCC+?=#N%S],UC>(=;ET]H;
M2S"&ZF4N6<96-.F<=R>U<BUK'(S/<_Z1,W+RR_,6/X_RJE +F2=I;5Q]G"B.
M/SR3@ G[O?&:R=3L<4\4VK)6-R/6M:MG\T7OVH#EH98U ;Z%0"*[:TNHKVSA
MNH3F.50R^WL?<=*\XAN'\[R+A DN,J5.5<>W^%=-X3O-CW&FNW _?PCV/WA^
M!Y_&B$G>S'AZKYN63.GHHHK4[0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(U'2[_P;J,WB#PU;M<6
M$K;]2TA/XO66$=G'<=Z[31M9L-?TN'4M-N%GMIAE6'4'N".Q'<4^N.U/0-1T
M'4)M?\(JOG2-OO=*8XBO!W9?[DGOWK6ZJ*TM^_\ G_F+;8[VBL?PYXET_P 3
MZ=]JL7970[)[>4;98'[JZ]C6Q633B[,M.X4444@"BBB@ HHHH ^7/CKX>_LC
MQW_:$2$0:G$)<]O,'RL/Y'\:\PKZH^.'A[^VOA_+>1H#<:8XN5..=G1Q^1#?
M\!KY7KTJ$N:'H0QT:[Y%7U-=UX8M@EM+<D<NVQ?H*XJU'[[Z"O1M(0)I%L!_
M<S^9KVLL@G/F['D9I-J"B7:***]P\,**** "BBB@ JEX;TD^+OB196&-UK ^
M^7TV)R?S/%2:A="SL)I^ZC"_4]*]!^ _AXV^CWOB"=?WMX_DPD_W%/S'\6_]
M!KQ\XQ'LZ7*MV>GEE'FGS,]@    & ****^//HPHHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% %JBBBN4V"BBB@ HHHH **** "BBB@ HHHH ***CG1I;>6-#AG0J#Z$B@#A
M-0O1J&J7-X3^Z4^5%GLB]_Q.36=8@R*]TP^:8Y'LHZ5 Q;[+%IQ!2<'RID[I
MM^]_GWK2    & . *YF>1)N3NQDLJPQ/*_W5&35>W!MK-II1^\?,CCW/0?R%
M%U^_N(;7JO\ K)/]T=!^)_E6OH]I]OUJ%",Q6^)Y/<@_(/SY_P" T)7T",7*
M5D=3HE@=-TF&!_\ 7',DI_VVY/Y=/PK0HHKI/6225D%%%% PHHHH **** "B
MBB@ HHHH **** "BBB@ KB_&=AY-[!J*+\LP$,I_VARI_$9'X"NTJGJE@FJ:
M9/9OQYB_*?[K#E3^!Q7/BJ/MJ3@;8>K[*HI'E;?)?HQZ2)M!]P<U8J">.26!
ME9=MQ&W3^ZZGD5)%*)HED7HPSCTKY)KN?1ID,/[BZDA_@?\ >)_4?Y]:[3P5
M?_)<:7(W,9\Z'/\ =)^8?@?YUQEVI\L2H,O$=P]QW'Y5<LK[[#>VE_&20CC.
M/XD;AA^1_,"NK!UO95E+H]&88FE[2FXGJE%!X.**^K/G0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *@O+6.^LIK67[DR%#^(J>B@-SS5DE\F:WD
M^6>,M$_^\.,_CU_&F6+J]C"5&,*%(]"."*WO$UG]FU2.\08CNAL?VD4<?FO_
M *":YZ/_ $>_>+^"8>8GLW\0_D:YY*SL>54CR2:'7R,8!+&,R0G>OOZC\15B
MWO/LLUMJ,1)$1#G'\2'[P_+GZ@4M5+3]S+-:-T0[X_\ =/;\#FDF0G9W1Z>C
MK(BNC!D8!E8="#T-+6#X3NS-IDEHQ):SD\L$_P!TC*_D./P%;U="=U<]:$N:
M*D%%%%,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#E]?\ "\\VH+KWAZX2PUZ(8+,/W5VO]R4#K[-U
M%7O#7C"'6KB73+ZV?3=<MQ^_L9CSC^\A_C7W%;58OB+PQ8^(X(_/+V][ =UK
M>P';- WJI]/;H:T4E)<L_O%ML=-17"Z;XNOM!OH]&\9[(G=@EIJR+BWNO0-_
MSS?V/!KN000"#D'H142@X[E)W%HHHJ1A1110!#=6T5[:36LZ!X9D:-U/0J1@
MBOB7Q#H\OA_Q%J&DS [K2=HP3U*Y^4_B,'\:^X*^>?V@O"C6VIVGB>VC8Q7(
M%O=$#A7 ^4GZCC\*Z<-.TK=Q,\9M3B;ZC%>BZ)*)=(MR#DJ"I^H->:JVUPP[
M&NQ\,7ZK(UJQ^67YD/OW%?0Y;44:EGU/(S.DY0YET.HHHHKWCP0HHHH ***9
M+*D,3RR-M1!DFANP;F)KGG:AJ%EI-J-TTTB@+ZLQPM?4NA:3#H6@V.EP?ZNU
MA6,'U(')_$Y/XUX3\'="D\0>-)_$%PG^C6'*9Z&1AA1^ R?RKZ'KXO-<1[6M
M9;'U.!H^SI(****\L[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_$OBK3O#%HCW1>
M:ZF.VVLX1NEG;T5?Z]!65X@\;&*_;0O#<"ZGKG1P#^YM ?XI6'3_ '>IJ'0O
M"R:;=RZKJ-RVI:Y./WM[*/NC^Y&/X%'H*WA2^U,B4[:(J6.@ZCKNJ1Z]XL"&
M:,[K+2U;=#:#^\W]^3W[5UE%%:MW,@HHHI %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %JBBBN4V"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** %W'&,FDHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %JBBBN4V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]=\(Z-XA=
M9KRV*7D?^KO+=C',A]G'/YUN44U)Q=T!QRKXU\,?ZB:/Q-IZ_P#+.<B*\0>S
M?=?\>36MHOCW0]8N/L;3/I^HC[UC?IY,H/L#PWX$UMUG:QH.DZ_;^1JNGP7:
M#[ID7YE^C=15\\9?$ON%JMC=HK@5\*Z[H)W>%_$,HA'33]4S/#]%?[Z_K4R^
M/[K2"(_%F@7FG=OMELIN;9O?<O*_0BCV5_@=_P Q\W<[BBL[2M>TG7(!-I>H
MVUVGK#(&(^HZBM&LVFM&4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJK?ZG8Z7;M<7]Y!:PJ,EYI @'YUR
M4WQ)M;V1H/#.EWNN3 X\R%/*MU]S*W&/IFKC3E+9"<DMSMZP==\9:%X=PE_?
M)]I;A+6$>9,Y] B\US<FE>+O$/.MZXNF6K=;+2.&(]&E;GZXK4T7PMHOA_+:
M=81QS-]^X?+RM]7;)-:JC%?$[^G^9#J=C.DU?QEXE&W3[-/#E@W_ "\7BB2Z
M8?[,8X3\34^D^"]*TR[^WS^=J6IGK>W[^;)_P'/"_@*Z*BM.:RM'0S;;W G)
MR:***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6J***Y38**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img76291469_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Z".@# 2(  A$! Q$!_\0
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MHH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=%
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MHH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=%
M7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJG10%RYY\?K^E'GQ^OZ53HH"Y<
M\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=% 7+GGQ
M^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJG10%RYY\?K^E'GQ^OZ53HH"Y<\^/U_
M2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=% 7+GGQ^OZ4>
M?'Z_I5.B@+EY)%<G:<XI&F16P3S]*AM?O-]!3)_]<U("QY\?K^E'GQ^OZ53H
MIA<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+
MESSX_7]*//C]?TJG10%RYY\?K^E'GQ^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>
M?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_
M7]*//C]?TJG10%RYY\?K^E'GQ^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I
M1Y\?K^E4Z* N7//C]?TH\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//
MC]?TJG10%RYY\?K^E'GQ^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K
M^E4Z* N7//C]?TH\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJ
MG10%RYY\?K^E'GQ^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z*
M N7//C]?TH\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJG10%R
MYY\?K^E'GQ^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//
MC]?TH\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJG10%RYY\?K
M^E'GQ^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH
M\^/U_2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJG10%RYY\?K^E'GQ
M^OZ53HH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_
M2J=% 7+GGQ^OZ4>?'Z_I5.B@+ESSX_7]*//C]?TJG10%RYY\?K^E'GQ^OZ53
MHH"Y<\^/U_2CSX_7]*IT4!<N>?'Z_I1Y\?K^E4Z* N7//C]?TH\^/U_2J=%
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MYJ?;=6_"F3_ZYJ!]".BBB@04444 %%%% !1110 4444 %%%% !1110 4444
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M4/'4FMC5[*)7N(Y?(<G?\H48^IQ0!Z517*>/?%TGA?2DN+*.WGN)9O+VR/\
M<XSD@<_RJ?P/KDVM^%;.]O[B%KR9I-RJ0IXD8 !?H!0!TF?I17FNL?#V6_\
M'4FMC5[*)7N(YO(<G?\ *%&/J<5Z6QY9CP.ISVH 2BF)/#(VU)HG;^ZK@FGT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)Q@ H2?K74_&*!;7P[X?MU!"Q2M& 6R0!&!U[T"Z%@?\D%_[=A_Z,%'P6_Y
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M4TWQ9JVI(22LT<# LVS&![+QVJI\;?\ C^TC_KB__H5>F>&/^16TG_KTB_\
M011T'U//O'VA:QJGB19=1U:SLM!#*L8>[VMLP-S;,<MG/Z5QOB :/X9U.TNO
M!FN22@ LX5C\C ]^ "#Z5/K%Q!??%&=?%$DHL8[IHV&3\D8^[TY (P>/6H_'
M\OAIKRVA\,V\*PQH?.FA4A78]!D]<"F)G?>._#EKXA\,IXDN99([JUT_>D:
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M6VP[V91@8[$' YK@OAQ.]U\2X[EQAY?.<CTSSB@#WRBBBD42V_\ K?PHN?\
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M7YL-0\XR?8 Z>3NS@/\ Q;?PKC;+4(/#_P 6);R_+)#;WDPD(4DC*LN<=>]
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MVLQ3:'&J6R6^QML7E@MD]OIBO2O%O_)&HO\ KWM_Z4!<I?".YCLO!6KW4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJW10!SLG@3PM+=FZ?1;?S2<\%@N?]T';^E2OX-\//JZZJ=+C%ZK*ZR*[K@J
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MX)_:FGQ7)3A6;*L!Z;@0<53'@CPR--?3QI$(MG=790S@L1TRV=QQD\9KH**
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:,;=V" 01V/-8O\ 8_Q;V_\ (6DSC_GX3_XFNN\$^ X/"9ENIKC[5J$R[6D
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M *W\*6X_U@^E);_ZW\*6X_U@^E R&BBB@04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?A1<?ZP?2@9%1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **,44 %)2U5N&/F #L*3945=V+5%(OW1GKBEIB"BBB@04444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 36W5J9-_K6I]MU:F3?ZTT#Z$4G^J?_ '3_ "KA=-_Y!T'^[_6NZ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBAZBB[,?1113("BBB@ HJ*:4Q*,#)-.C?S$#?G059VN/HHHH)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&.!FDW88M%
M-5\]:=0FGL 4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!-;=6IDW^M:GV_5J;-_K30,AD_U3_[I_E7"Z;_R#H/]W^M=T_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M],AJP44A('4XI: (YDWQ$ <CD5!:OARA[]*MU +=<E@2&#<4GN7%KE:9/12
MY^M+3("BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110! ]P%EV;>.YJ?%4;H8G)]1FKJG<H/J,TD:2BDDT,9.X%"M@X-24FT'M4N
M&MT3?N+13/+]&-* P!^:G=]A6'44S+CMFG DCD8H4KA86BBBJ$%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!-;=6IDW^M-/M^K4V;_6F@9"_P#J
MW_W3_*N%TW_D'0?[O]:[J3_5/_NG^5<+IO\ R#H/]W^M<>+V1Z.7_$_Z[%O!
MQG!QZU8L'VW&.S#%:2%7C4J!M(XJO>B&*V>5P%(^Z1US6:H.'O)G2Z_/[C6Y
M-//';1&25MJC]:Y;5M660F1SLC'"J.IJOJ>ID#S)6+'HBDU@*ESJ5P<?,?4]
M%%5.;EH=%##J'O,6YOIKH[%RJ'HJ]ZN6FB,P#7+;1_<7K^-5I+2;39XII KH
M&SE3Q]*UGU>T6+>KEB?X0.:E)=3>4G;W"S#:P6Z@11JOOCG\Z6XGB@B8RN ,
M=">3^%8-QK%Q-D1GRE_V>OYU09BQRQ)/J:;DNA*I-ZR+VFWZV<LF]28W].HK
M2.MVO82'_@-<]14J31I*G%N[.B76K0]?,'_ :BO]4MI+1XXF+LXQTZ5A44<S
M$J44[G0:3;0&R60HKNQ.XD9Q[4ZXT>WFR8\Q-_L]/RK#M[J:V;,4A7/4=C6O
M:ZTCX6X78W]X=/\ ZU--;,B49IW1FS6UUIT@?D#LZ]#6GIVL'> 6\N7ID'AJ
MTR$ECYVNC#Z@US.I6Z6UXR1_=(# >GM0U8<9*>C/0=*O8YH_*/RRYR0?XJT7
M8(C,>@&:\VT[4VB=8Y7(P?D?N*[*UU![Y5MW*JQX8CN*TC4M&QQU\,U+F6Q&
M3DDGO25JK8P+U4GZFJU]#'$$*#:2>E<\J$HKF9<,1&4N5%.BBBL#<* "3@ G
MZ5/:P>?)@_=')K45%0850![5O3H.:N85:Z@[;LQ"".H(^M%;A4,,$ CW%59K
M&-QF/Y#Z=JJ6&DMM2(8J+^)6,VBG21O$VUQ@TVN=JVC.I-/5!1112 **** "
MBBB@ HHHH **** "BBB@"[H/_(:N/^O5?_0ZZ6N:T#_D-7'_ %ZK_P"AUTM>
MK0_AH\#%?QI!1116QSA44]O%=0-#,@>-NH/\QZ&I:* *$,\EI,MI>.75N(+@
M_P ?^RW^U_.K],FACN(6BF0/&PP5-4H99;&5;6Z<O$QVP3MU/^RW^UZ'O]:!
MFA1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)OV&;#V:CYP.H-/HJN1= N,W,.JT\<BBBA)KJ(****H HHHH **** "BBB@
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MY^B#J?\  5AV.IA/]&O,Q31G:2PQT['T-:J3*3N5T8^N0:YK..C,I1+1$EP
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M<YJ35]7TV'/$1R.:5).S?G4M1M%DY'%1*#3YHD)WT8_M448._ITIZ$ [.XI
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M39Z>'E>F@HHHK$V"BBB@ HHHH **** +V@?\ANX_Z]5_]#KI:YK0/^0W<?\
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M179^.E7.3BKI"2N#RYX7\Z6-21EOPS3DC"\GDT^HC"3?-(;:V1'(-Q"YJ0#
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M@ HHHH KW-TENO)RYZ+5&VDGFN_, W=CGH!3C8327+&1AM)SNSUK1BB2% B
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M4^V*&$5=I%73[F::=E=MRXS]*TJRM)7YY6] !6K2CL:5TE.R"BBBJ,@HHHH
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MO+5;ZW^9E7)Q_$O_ -:KB[>A<969QNDKMTN#W&:-6;;IDY]1C\S5Q555"J
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MTC]N*YG0_P#1_'#1#O)(GZ$_TK6+]Y'GM>Y5CY'H=%%%=AXI:C_U:_2BB/\
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M%$N6/Z>] !;VTMU,(HERQ_(>]=KH6A%CY, ]Y92/\_E2Z%H1<B&$<=992/\
M/Y5W5M;16D"PPKA1^9/J:F4K&,Y]$-M;2*S@$4*X ZGN3ZFIZ**R,!KNL:,[
MD!5&23V%8UC&VJWS:A,/W,9Q"A]N]/UF5YY(--A.'F.7([+6K#$D$*11C"(,
M 56R'LC+U_5_[,M L9_TB7(3_9'<UPX9G8N[%F8Y)/4U<\0W1N==GY^6+$:_
MAU_7--TJR.H7T=N#@'ECZ*.M:Q5D:)606UK/<28MXFD;N%%:J:+?[ P@R/\
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M:)QE6&#7.W%C<6CGY2\?9E&:RFM;GH86HN7D>Y'13 97.%C8GV!JPFG7TO\
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M_G7I)ZFO-M/_ .0A;?\ 70?SKTD]37!E/P2.S,/BB)1117K'G!1110 4444
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MY'8TUT<-NC;\* :3?8FHJ))LG:XP:E!STIDM-!1110 M%%% @HHHH&%+24M
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M5FZ$358B:.)DT://S6CK]%(J$Z/;@\QR#\37>48'I4?5UW+^M/L<(NE6P/\
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M;(?1ABF5@>D/BB>>58HUW.QP!7;:%H9+""'KUEE(Z?Y]*S/#^FMM1PN9YCA
M>PKTNQLH[&V6)!SU9O[QI2=C*I.V@^VMHK2!885PH_,GU-3445B<X4$@ D]!
MR:*I:O/]GTJ=P<$KM'U--:C*>D#[7?7>HL.&;9']*V:J:7!]FTR"/&#MR?J:
MMT-Z@]SS76(VBUN\5NOFD_GS_6KOARZCM-6C:4X1U,>3V)Z5J>*]):3&HPJ2
M5&V4#T[&N83I6Z]Z)I>Z/4**X_3?$%Q:HL4P\Z(<#)^8#Z]ZWX-;L9P/WOEG
MT<8_^M63@T9M%\@@[EZ]QZU2U:(7&F2D=4&\>V.OZ9JTMU;L,K/&1[,*H:K?
M01V<JQR*TKJ5VJ<]?6E%.XCES6II6L"S7R)P3#G((ZK_ /6K*SFFFMVKFB5S
MNX9HKB,/#(KKZ@U)7!13RV[AX9&1O53BM6#Q'<Q@":-)1ZCY36+@^@G!]"MK
M-L+74I HPC_.OX]:KV$_V:^AF[*PS].AJWJVHPZB(62-TD3(.<8Q696BVU+6
MVIZ#165!KEBMK$))B) @##83SCZ4U_$=DOW5E?Z+C^=9<K,N5FO7+>(;L37:
MVZ'*Q=?]XT^Z\1RR*4MX_*S_ !$Y-8A))))R3U)JXQMJRXQMJQ\4;33)&OWG
M8**R_$=FR0.&'SP/@_3H?Z5MVT<L"QW^,11RJ,^OK3_%%L'N;A0.)HMP_+_$
M55];%IZGG-%%%!L%%%% &IH%V]IJ:&-L,2&4^C#D5]'P-#JNE0RLN8YXU<8/
M()&<@]B*^8()/)GCD_NL#7T)X$O1=^&HXR<M [1_AU'Z']*[</*\+=CY[-:?
M+64UU7Y&W;S21R"UN6S+C*2=/-'_ ,5ZC\:MU%<6Z7,6Q\C!RK#JI[$>]1VT
M[[S;7&!<*,@CI(O]X?U':MSS"S1110 4444 %%%(2%!). .I- "UGW6HX;RK
M8;W/&0,_E4<US+>R^1; [>Y]?_K5HV=A':+D?-(>K?X5%V]CH4(TUS3U?;_,
MI6VDM(WG7C%F/.W/\ZUE144*BA5'0"EHII)&<ZDIO4****9F%%%% &(YQK#?
M]=#5^;_5_C6:#OUEB/\ GH:T9S^[_&LCMZQ(,T9IM%!H.S1FFT4 .S1FFUG3
MZO#$Q6-3(1W!P*3:6Y<*<INT4:0P.@Q]*7-9":VA_P!9"R_[IS5J/4K23'[T
M*?\ :&*2DF5*A4CNCDK@_:_%MPTO/EL0H/\ L\#_ !K7C!/\,A_W:H^(;-[>
M]75[/#H<>;M.<'IGZ$5+8W<=Y&'CR3W7/(-<=5-2N=\7>"L7<Q+R;>0GU9C3
MA=(GW;:,?6E1VZ)<LC?W9*D:2]C&64,/4 '^52OZT,GY_FR/^T)?X51?H*:;
M^X/\8_*G?;/[\$9/TH^U0'K:I^'_ .JCF_O#Y5_(,^VW'_/0TAN[@_\ +5OS
MIYGMO^?;_P >IIG@[6P_[Z-*[_F&DOY?R&&XE/5\_45!-\\3Y &5-3M*A^[
M@_$FJMW)Y=I,YP,(34OU+BO*PG@PYL;H>DB_RJIJ/_(\6W_7:#_V6K_@^,KI
MDS_WI?Y"J&H?-XYM_P#KM#_2NM=#'_E[/T/1:***[CP"U'_JU^E%$?\ JU^E
M%(82?ZMOI56K4G^K;Z55IB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ>W81A:HNZ23Y3C^$&G%(]-LG,:EL<\]2:AZF\%RJ_5[#KBY3S1:@YDDXZ<
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MW5 IU<DM7J>U3O"*2,F;2"RX#)(/[KBLBY\/P#+26I0=V0X%=;5'5'Q;*O\
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M:* $HI:* $HI:* $HI:* $HI:* $HI:* 'P_ZS\*6?[X^E)#_K/PI9OOCZ4
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M*R6H!14?GJ0=OS$=A3,SR=!M%9NK'IKZ%*+ZB7$A!V X]:6"''SMU["I%B
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MO[\R%K>W;"]'D'\A18:4F]-SGAHEN&=&9BR,5)4Y!^E']B0#I-*/H16D %
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MJU^E%"?ZM?I12&#_ '&^E5JLO]QOI5:@04444P"BBB@ HHHH **** "BBB@
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M-)R2W&E<D%+24M,04444 %%%% Q:***!!1110 4444#%HHHH$%%%% PHHHH
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M23T^E9DL L]56-22H<$9]#6_8C%C!_N"L74>=9&/[RU;6AA"3<F=CH2AFER
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MEN0#%#+DL0>F<=*7/&U[ARO8Q[#4+K3+I;FTE,<B^G0^Q'<5ZOX;\10:]:9
M"748'FQ_U'M7EFK:3<Z+J#V=T%WJ,JRGAE/0BH].U"XTN_BO+9RLB'IV8=P:
MBI352-UN5";@[,]RHJIIMTFJZ=!>P3'RY5SC:,@]P:M^2_\ SV/_ 'R*\UJV
MC.L**3R'_P">Y_[X%'V>3_GX/_? H 6T^[+_ -=#3)8F@8RQ*2AY>,?S'^%3
MPQ>2A&XL222<8J2D!#;LKD,I!4C((ITWWQ]*B>-K64SPJ6C/,D8_]"'^%/=U
MDVNC!E89!%,!M%%% !1110!6%T0Y#+Q^M658.,J<BHY(%DYZ-ZU6(D@?KC^1
MKD<ZE)^_JC6T9;;EZBF1R!T#$@'ZT_K73&2DKHS:L%%%%4(*BN?]6/K4M,G4
MM'@=:SJJ\&D5'<;;?ZL_6IJBMU*Q\]^:))@G Y:IA)0IIR!J\M![NJ#)I58.
MN1TJJJO,V2?J:M(@1=HI4ZDIN]M!RBDO,6EIK'"D]<57^T/[54ZL8;B46]BU
M15<7![J*>)U*Y/'M0JT'U#D9+02 ,GBH?,D?[BX'K3C$&.68FCVCE\*"UMQ1
M*K-@ FI*BWQQ\#]*D4Y&<$4X2OHWJ#0,P52338ON9P!FFN#(X4?='6B5L (O
M4U+EJY=$-+H)(S,<#I[4J1=V_*I%7:H&:6FJ=WS2%S=$+THHHK0D**3<O]X5
M$[DMM'3V[U,IJ*&E<>T@' Y-+&Q8<TQ(N[?E4W2ICS-W8W;9!111D>M:$A44
MBX;/K4M(R[EQ4SC=#3LP0[ES3JC0;203S4E$7=:@]PHHHJA!1110,6BBB@04
M444 %%%% Q:***!!1110,*6DI: "BBB@ HHI&940LQ 4#))[4 ,FF2"(R.>!
M^9/H*J1H[R&>;_6,,!>R#T_QI%+74@G<$(/]4A[?[1]ZFIB"BBB@ HJ.XSY+
M8.*BM&)#*3G%9.K:HH=RE'W;E+5[RZM9(_)^6,CEL9R?2IK#58[K$<F$F].S
M?2KTD:2H4=0RGJ#6!J&D/;YEM\M&.2O=:<N9.Z.FE[*I'DEH^YT-8.M6\TER
MTJ1EHT0!B.U:EKYJ6D3&3S@4!.1S^=2Q%6\P=03GZ@TVN96,Z<G2GS+46W_X
M]X_]T5)4</\ J]O]TE?R.*DJD8RW"BBBF(JZA]H^QM]F!\SCIUQ[5A?:=2BZ
MM./]X&NGHSCO42C?6YO2K*"LXIF!8ZE<R72QW$Q5#WV@<_E6T\3$??+>S?T(
MZ5!<3*^5 !'<D9IUO$^W)=U7L :RA53ER+4JHU+WDK#;B*>YM2L4H5@>ZX((
M]Q_A445^]K&B:@"DA/RL!D$>^*9]DN[2[>XBF,L1RSHQY/\ ]>GQW=EJJ>3(
MN&[(_!_ UI?7S'96[Q\MT:"LKJ&0AE/0@]:6LF&PN["Y!MY/,MR?F0G!_P#U
MU?BO+>60Q+(/,'5#P15)]S&=.VL7=?UN3T4451F%%%% !1110 5'//';0M+(
M<**DK+UYL6*+_><4I.RN:4H<\U%EZVNHKN+S(CD X((Y!J:LO05Q8NW]YS6I
M2B[JX58J$W%= J#:PN\@<$5/12G#FMY$)V(6C/VA7'3O4U%%.,5&]NH-W"BB
MBJ$%%%% !1110!+#U:F1_P#'W<?\!_E3X.K56F64W,JCY8VQEAU/'04 %Q,T
MRR)$2$4'<X[\=!7(:)&TMC!-(2?EZGN<UV.U5C*@ *%(P*YC1^-'M?\ <_J:
M:.K"NS9=JNRL"20<=<U8H(!!!Z&L*^'C623>QV1E8Y6YU:ZFE)25HT!PJJ<5
MIZ->-=;XYOF=!D-ZBJ-UHERDS>0HDC)R.>1]:T])TYK)'>4CS7[#L*B--RDN
M=7L>E7E0]C[EKD#_ .E:\J]5B_I6NR*QR1S61I7SZC<N>HS_ #K9K6,8SB^9
M7N<-5V:2Z !@8%%(QVJ2:B-PJ*S/\JJ,DTY5J<)*#=FS-1;V)J*P7\1-YOR6
MX,?NW)K8M;F.[@6:/H>QZ@U49QEHC2I0J4U>2'/'N.0:<JA5Q3J*F-&$9N:6
MK,[NUAHC4'.*S)]"MY92Z.T8)R5'(_"M6BFJ4$K)%0JS@[Q9#:VL5I"(HA@=
M23U)J:BLW6;R2TMU6(X>0XW>@JFU%7",959VZLO2L5 QWJEJ)+Z=)G^$@_K7
M/1WEQ%('$SD@Y(9B0:Z:7%QI3,HQOCW8_6N-1G.JY)Z6V.FI0=#EOJ>?ZLN+
MP'^\HI]HNHW,!6&1A$.,DX_ 5+K$>4BD Z$@U<T60-8;>Z,0:S2U.B4K1N8,
MT,D$ICE4JP[5'6SKL/,4P''W3_,5C5+5F7"7,KBBEI!2T#8ZE%-!I:9+'"EI
MN:7-!-A:0T9I,T!8#244AH*0AI*6DI%(2E R0!U-)2C.1C.>V*0SL(TV1H@_
MA %<](?.UPXZ>9_*K UQUAVO#^^ Z]!]<57TM#)>M*W. 23[FK;OL8PBXW;.
MUT%/EE?W K3FMHYQR,-V8=:SM-,UO:;A"61N<T^2^F?@$(/:J]I!1M)'#.G.
M55RBRQH2&/7[I#R5M0/_ !^NDKF?#_.N7)/_ #ZK_P"AUTU=-'^&CS,3_&E<
M****U, HHHH **** /FWXDZ9]@UR0!<!)60?0_,OZ&N)KW#XO:(9D%W&N?-C
M_P#'TY_4?RKP_K7)75I7[GNY;4YJ/+V"BBBL3T HHHH 4$J002".A%=5HGB<
MAD@O7*N#A)^GY_XURE% SW;2M=64+#=L Y^[)V;ZUNUX-H_B"6PQ#<;I;;MZ
MI]/;VKTK1?$86%/WGGVK=&!R5_SZ5E*'8AQ['7U4U&P2_M]A.V1>4?T-6(9H
M[B(2PN'0]"*?6>Q&QEZ;J+M(;*\^2Z3C)_C'^-:+O@[5&7/;T^M4=3L([Y0J
M?+=+RD@_A^OM5>QU)[:7['J2F.;M,>CT[7U0;[&NJ;><Y8]33J**D04444 9
M>HZ,EXQEA(CF/7/1JYZYTZ[MB?,@?']X#(_.NUHZ5:FT4G8\_((Z@BDR/6N_
M:*-_O1HWU4&H_LEM_P ^T/\ W[%5[0KG.$'/3FIX;*YN#^Z@D;WQQ7;+!"GW
M88U^B 5)2]H'.<[9^'&)#7;@#^XAY_.M^.*.WB"1JJ1J.@Z"B66.",R2N$0=
M2:Q7FN-<?R;<-#9 _/(>KU.LMR;M[BSS2:U<FUMV*VB'][(/XO84NL7J6-HM
MC;?*S+@X_A7_ !-6KJ>WT6P"Q* W1$[L?4UY[KNK."Z;RUS+RS?W1515_0J,
M;LR]9OA<SB&,YCCX^IKH+,YLH#ZQK_*N,KLK+BQ@_P"N:_RK0VDK(HZ^,V"G
MT<5S==+KW_(/'^^*YJ@<=@HHHI%$]G%YUY%'V+#/TZU]%>#K/['X8M01AI09
M3_P+I^F*\,\*::^I:M'$@.781J?3/4_@.:^CHHE@A2)!A$4*!["NZA&T+]SY
MS-*G/7Y5]E?B_P"D/HHHK8\X*J:@<0J/4U;JG?\ /ECWJ9;&E+XT7(%VP1CT
M6I*1?N+]*6F0]6%9W_'QJ!/\*?TJ_(VR-F]!5*Q7Y7<]2:3WL:0TBY%O\*A'
M^CG'_+$]/]C_ .M4U! (((R#U%49!7GGB>_DUC7$T^W.Z.)O+4#N_<_T_"NM
MUJ_.CZ3/-G^'9">X8]!_7\*Y+PE9>9--?2#.WY$)]3U/Y?SK"M+[)Z6!@HJ5
M9]-$=':V\6F6"0K]R->3ZGN:S)96FD+MU/Z5<U&;D0@].6JA6#/0H0LN=[L*
M***#H ]*MZ:.)#]!50]*MZ<?DD'N*<=R*OP,OYK#'WV^M;6:QW79/(OO3D94
M.H4445)T!6?K,/FV!8=8SN_#O6A37021LC#(88-(!FE2?:K&(YP^-H/N*T0I
MN 67Y;A.HZ;O?ZU@^'6(EN;!CAP=Z?45OMF6,7,?$J?? _G6-K,PJ:2!9([G
MY)_DEZ!QW^M120S6K@\CT85,42]4LF%G'5>S5'%=/#F*5=Z="IZBD[=?O)5^
MGW#UNDE4)<IG_;'44R6T(7S(6\Q/;J*>UK',I>V;/JAZBJZ/)!)\I*L.HI/^
M\$;?8^XDCNOE\N<>9'^HIKH8&62-MR'[K#^1IY:*Y'($4OK_  M_A466B+(X
MX/5?ZTF4EV^XKW@5[6< 8!0\?A6?H1S8L/1S5S4'$=C.W^R0*JZ*FW3P3_$Q
M-:4C:.QKVL?FW"+VSDT_Q)=?9M'D .&F/EC\>OZ58TV+"M*>_ KG/%-PUUJ<
M-E%R8P!@?WF_^MC\ZVZ',_?K)=$;W@6R\G3)KMA\T[[5_P!T?_7KJJKV%HMC
MI]O:J.(D"GZ]_P!<U8KL@N6*1XM>I[2HYA1115&)93[B_2BA/N+]**0P?[C?
M2JU67^XWTJM0 4444Q!1110 4444 %>?:J2WBO5"W)7RD7V&W./S->@UY]J?
M_(TZO_O1?^@"HJ;'+B_@7J5+FY2V1259W8X1%ZL:H/:WTUY'>&.W5T&!&2>>
MO4^O-6  ^MMNY\J$%?;)YJ[6)YY7MKH3ED9#',GWT/\ ,>HI9V*3V,BG#K>1
M8/IEL']*AN0$U.S<<,VY#[C%27C!/LKL<*MU$2?;<*%N-;GJ!ZFDJ@=;T[)_
MTE?R-)_;>G?\_*_D:Z+H];VD.YH5E^('"Z4X)Y9E _/-/?7=.1<B?=[*I)KG
M-3U-]1F!P4B7[J_U-3*2L95JL5%I,9IH+:E; =?,%=O7,>';-I+HW3#Y(^![
MM73T06@8:+4;A1115G097BC_ )%'6_\ L'W'_HMJOV?_ !XVW_7)/_015#Q1
M_P BCK?_ &#[C_T6U7[/_CQMO^N2?^@BJ^P+J34445(PILB"2-D;HPP:=12
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MB%:%%8O"1W@VBU5?4CB8O$K,,$T^EHKIBK*S,V)12U!/<"/Y5Y;^5*<XP5Y
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M<UV^(U^7NQZ"NAM+"&TCVA0S'[S$=:I1N1.HHE+0Y8A#(A95DW9.3U%)J^H
M(;:)@2?OL#T'I5/5XXH[XB( ?*"P'8TNG67FL)I%_=CH#W-.[V)44WSLNZ59
M,BAMI,LG 'H*[:P$5O:)%N"L/O \'-5='L?*3[3(/G8?(/0>M6;^'=&)0.5Z
M_2K2<(\R.*M4C5G[,L2M$T;!W7;CGFL:BBN:K4]IT-:5+V::N7_#W_(;N/\
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M:C1<WS/8O'DGBBBBMCT@HHHH **** "BBB@#)\4?\BCK?_8/N/\ T6U7[/\
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M,5<U'25,SJP\N8?Q#H:PY[::V;$B$#LPZ5RNZT.U*,GS(U5T)#"-TK"7'/'
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M:;]V+-JBN=USQC9:#?BSN+:YD<H'W1A<8/U(JUJ_B*VT;2[>_GAFDCG*A5C
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M%.&/]\^GTH ;N-W()#_J5.44_P 1_O'^E3444Q!1110 4444 %%%% !1110
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M5?8%U)J***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?-.D@9I,!E '7CI^E)MDCV2L?F<;\^YK"UEO-UN1?1E7^7^-=<T2O$(V'
M'TKFJP=5-)[;'14C&E"#_F6HD,HF3(X/<5(> 3Z5G)OM[@#'.<8]:ORJ6B<
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MM53J5INVI(96](E+?KTI4TVSC;=Y"L_]Y_F)_$U:4!1A0%'H!B@"I]IN9/\
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M/:CXLN-9ACU6TFCLR&WLUOM .#CGZUVM%%A0H.-K2844451T!1110!E>*/\
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M* "BBB@ HHHH **** "HA\TWTJ4G ID0ZF@I;$N::5!()[4M%!)',<@"G@8
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MK1O'K0!+FC-1;QZT;QZT 2YHS46\>M&\>M $N:,U%O'K1O\ >@"7-&:CW^]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5-/DU!AV85<J-HE:99.XK&K!RY6NC+BTKW*[?)J"GLP
MJY32BLRL>J]#3J=.FX.7F[BD[V"BBBM20HHHH **** "BBB@ HHHH DAZFFR
M?ZPTZ'J:;)_K#2 K7O\ R#[K_KB__H)KPQ/]6OTKW.]_Y!]S_P!<7_\ 037A
MB?ZM?I7/B-CULK^)_P!=AU.%-I17,>PQXIPI@-+3(:'YHS3<T9H)L!III<TT
MF@I(0UU\2[(D7T4"N0!P0?0YK?&MVWD!L-YF/N8[_6G%HBK%NUB@#YNNEO\
MIH?T%=]IB;-/B]QN_.N TM3+>O*1T!)^IKT.SQ]BAQTV"M\/NV8XK2*1/4-U
M<+:P-*W;H/4U*[K&A=B H&237.7ET]_<@(#M!PB_UK>I/E1S4J?._(9"KW4[
M2R9/.2?4UTEHZM;J%ZJ,$4VRM%M+<)@;CRQJI<*UK<[HSM!Y&*XWS4WSLJ<H
MUGR+IL:E5);!'8LC;,]L9%+;7BRX1_E?]#5JM?<JKN<UYTI=C/\ [.?_ )Z+
M^5.73A_%*?P%7J*2H4^Q3Q%3N5TLH$_AW'_:-6.@P**:SJO4\UI&*CLC*4I2
MW8ZBHC/Z+3DD#G'0TR1]%%,DECB&78"AM+5C2;T0^D9E498@#U-4I-0 XC7/
MN:IR2O*<NQ-83Q$5MJ=$,-*7Q:%FYO2X*1<+W/<U3HHKCG-S=V=T(1@K(***
M*@H**** "BBB@ HHHH **** +_A[_D-W'_7JO_H9KJ*Y?P]_R&[C_KU7_P!#
M-=17JT/X:/!Q7\:04445L<X445%<7$5K TTS[47\R?0>IH 6::.WA::9@D:C
M))JG##+?2+<W2%(E.8;<]O\ :;W]NU$%M-=3+=WR[=IS#;]H_=O5OY5H4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1DXQVHHH 88XVZQH?JHI/(A_
MYX1?]\"I** &"&(=(HQ_P$4X#;]T8^E+10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 UONTJ#"TC=J<.E(?06DI:0]#0(8HY)I]-7I3J
M!L****8@HHHH *0@$$$9!X(-+10!Q>O^#0Y>ZTM0&/+6_8_[OI]*PM/UZ]TE
MS;7"-)&AP8Y.&7Z'M7J-9^IZ+8ZM'BZB&\#"RKPZ_C6$Z5]8GH4<=9<E977X
MF18ZO8ZDN(I1O/6)^&_+O^%22Z?$_*Y0^W2N>U'P3?VK&2R<7*#D ?*X_#O^
M%9\.MZMIC^5,6..-DZG/Y]:Q=U\2.V$5+WJ$CIWT^9?N[7'L<5 UO,O6)_RJ
MK;^,82 +FU=3ZQD$?KBM"/Q+I4G_ "\%#_MH12T+YZT=XE5H\C#)D>A%5FTN
MUD.?LPR?08K:&M:81_Q_P#ZO0VMZ6O\ R_0'Z-F@?MY_RF3'HD7\-F#_ +P_
MQK0ATME 'R1KZ**9+XGTN/[LKR'T5#6;<^,>"+6UP?[TI_H/\:- YZ\ME8Z*
M*RABYV[F]6JCJ'B&QL 5#^=*/X(ST^I[5S!N]:UQS%$)I ?X(EPN/\^M;>F>
M!97(DU*81K_SRB.6/U/0?K32<MD934(:UI?(Q)[O4_$5T(8XV<9^6*,?*ON?
M\378:!X3@TPK<W>V>['(_NQ_3U/O6Y96%KI\ AM(5B3VZGZGO5FMX4DM7N<-
M?&N:Y*:M$****V.$**** "BBB@ HHHH **** "BBB@"=/N#Z44)]P?2BD,'^
MX?I4%3O]P_2H*!!1113 **** $--)I33&- "%JB:0*I8D!0,DDX ILLJQHSN
MP55!))Z 5\R^.O'^H>*M3ECAN)(=*1BL,"$KO /WF]2?TK?#X>59V6Q$YJ*/
MHUM<TE20VK:>".QNX_\ &F?V]I'_ $&-._\  N/_ !KY!*@]0#1M7^Z/RKN_
MLY?S&7M_(^OO[>TC_H+Z=_X%Q_XT?V]I'_07T[_P+C_QKY!VK_='Y4;5_NC\
MJ/[.7\P>W\CZ^_M[2/\ H+Z=_P"!<?\ C1_;VD?]!?3O_ N/_&OD':O]T?E1
MM7^Z/RH_LY?S![?R/K[^WM(_Z"^G?^!<?^-']O:1_P!!?3O_  +C_P :^0=J
M_P!T?E1M7^Z/RH_LY?S![?R/K[^WM(_Z"^G?^!<?^-']O:1_T%]._P# N/\
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M.U2P1&*+:3D]2:5(41R^,N>I-25G3IRYG.?R\D4Y*UD%%%%;D!1110 4444
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MUI*\ZI4<W=GITZ:IJR"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH O\
MA[_D.7'_ %ZK_P"AFNHKE_#W_(;N/^O5?_0S745ZM#^&CP<5_&D%%%07=W%9
M0^;+GD[551EG;L .YK8YQ;FYBM(#+*V%'  &2Q[ #N356VM99YUO;X8D'^I@
MSD0CU]V]^W:EM;266<7M\ 9Q_JH@<K"/;U;U-7Z "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH :W44ZD-+2&%(>E+2'I0(!TI:0=*6F 444
M4 %%%% !1110 4444 %17%K!=ILN(8Y5]'7-2T4AIM:HY^Z\&Z/<9*0O W_3
M)N/R-9DOP_B))AU!P/1T']*[.BH=.+Z'1'%UX[2.#/P_N<_+J,./>,TJ_#^?
M/SZC%C_9C-=W12]C T^OU^_X(X^'P!:J<S7TS^RJ!6M:^%-&M""+7S6'>5BU
M;5%4J<5T,IXJM/>3&QQI$@2-%1!T51@4ZBBJ.<****8!1110 4444 %%%% !
M1110 4444 %%%% $Z?<'THH3[@^E%(8/]P_2H*G?[A^E04""BBBF 4444 --
M1.:E-0O2 PO%LC1^#];=3AEL)R#[^6U?)5?6/C$_\49KO_8/N/\ T6U?)U>O
MEWPR.>ON@HHHKT3 **V/"NB2>(O%&G:5&"1<3*'(&=J#EC]  :^G/^%6^"/^
MA<L__'O\:YJ^*A1:3-(4W+4^2Z*V_%^AMX;\6ZEI)!"03'RLGDQGE3^1%5]
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M_0A7V*?]:_\ O&O*S+>/S.FALR934@J-:D%>8;#J***8!1110 4444 %%%%
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M)J]PHHHK W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"_P"'O^0W<?\
M7JO_ *&:ZBN7\/?\ANX_Z]5_]#-;U[?1V2)D&2:0[8H4^](WM[>I[5ZM#^&C
MP<5_&D+>WL5C$&?<[N=L<2<M(WH!4-I8R>?]MOB'NR,*H.5A7^ZOOZGO2V=B
MZ3&\NV62\<8R/NQ+_=7^I[U>K4YPHHHI@%%%% !1110 4444 %%%% !1110
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M*Z/)H$FI>%&E2>./S4A\TRI.N,_*22<XZ8.#^->;_%:XFN/B9K7G.S>5(D:
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M>_\ @)+_ /$UW%%'U2'=A_:%7LOQ_P SA\R_\^E[_P" DO\ \31F7_GTO?\
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MX0]JVFF?1_P]^).B:_X9BT37;J*UOHH?L[BX?:LZ!<;@QXSCJ#W^M:/AZU\
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MFTBMW#B,8QO8CCCKZDUXE\2KJUU#XBZU=6D\-S;R2J4EB<.C#RU'!'!Y%<L
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M5_\ 8T?6:/\ ,@]G+L>>T5Z%_P *7\8?W=._\"O_ +&C_A2_C#^[IW_@5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ?%U-))]\TL74TDGWS2 ;1113 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"=/N#Z44)]P?2BD,&^Z?I4%3M]T_2H* "B
MBB@04444 )2$4ZDH C*TPK4V*3% $!2DV5/MHVT 5]E&RK&VC;0!7V4;*L;:
M-M %?91LJQMHVT 5]E&RK&VC;0!7V4;*L;:-M %?91LJQMHVT 5]E&RK&VC;
M0!7V4;*L;:-M %?91LJQMHVT 5]E&RK&VC;0!7V4;*L;:-M $&RE"5-MHVT
M,"T\"EQ2XH !2_C1BEH **** "BBB@ HHHH **** "BBB@ HHHH =']_\*67
M[P^E)']_\*67[P^E #**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ?%U-))]\TL
M74TDGWS0 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )T^X/I10GW!]**!
M@WW3]*@J=ONGZ5!0 4444""BBB@ HHHH 2BEHH 2BEHH 3%&*6B@!,48I:*
M$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6D
M) !)( '))H ,48KC=:^*?A+0YF@FU+[1.IPT=JADQ]3]W]:RK;XX>$+B4)(=
M0M@3C?+;@@>_RL3^E;+#U6KJ+)YX]ST>BJ.E:UIFN6@NM+OH+N$_Q1-G'U'4
M?C5^LFFG9E"44M%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH =']_\
M"EE^\/I1']_\*)?O#Z4 ,HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJA
MJ^MZ;H%D;S5;V*U@!P&D/WCZ =2?85YMJ/QZT.WE9+#3+R[4?QNRQ _3J?S
MK6G1J5/A5R7)+<]8HKR;3_CUH=Q*J7^F7EHI_C1EE ^O0_D#7I.CZWIFOV0O
M-*O8KJ#."T9^Z?0CJ#[&BI1J4_B5@4D]C0HHHK(H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.!N'_H-?2E>5C*:IU6EU-Z<KQU"BBBN4T"BBB@ HHHH **** "BBB@ HHHH
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M_@7=O<> I878D6U[)&N>P(5OYL:,PIIP4^J%1EK8],HHHKR#H"BBB@ HHHH
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MCN]0 $:-P4B'(R/4GG\!58NHH4GYBIQO([;['XI_Z"NC?^"R7_Y(H^Q^*?\
MH*Z-_P""R7_Y(K?HKP^=_P!)'78P/L?BG_H*Z-_X+)?_ )(H^Q^*?^@KHW_@
MLE_^2*WZ*.=_TD%C ^Q^*?\ H*Z-_P""R7_Y(H^Q^*?^@KHW_@LE_P#DBM^B
MCG?])!8P/L?BG_H*Z-_X+)?_ )(H^Q^*?^@KHW_@LE_^2*WZ*.=_TD%C ^Q^
M*?\ H*Z-_P""R7_Y(H^Q^*?^@KHW_@LE_P#DBM^BCG?])!8P/L?BG_H*Z-_X
M+)?_ )(H^Q^*?^@KHW_@LE_^2*WZ*.=_TD%C ^Q^*?\ H*Z-_P""R7_Y(H^Q
M^*?^@KHW_@LE_P#DBM^BCG?])!8P/L?BG_H*Z-_X+)?_ )(H^Q^*?^@KHW_@
MLE_^2*WZ*.=_TD%C!%IXI!R-5T;_ ,%DO_R10;3Q23SJNC?^"R7_ .2*WJ*.
M=_TD%C ^Q^*?^@KHW_@LE_\ DBC['XI_Z"NC?^"R7_Y(K?HHYW_206,#['XI
M_P"@KHW_ (+)?_DBC['XI_Z"NC?^"R7_ .2*WZ*.=_TD%C ^Q^*?^@KHW_@L
ME_\ DBC['XI_Z"NC?^"R7_Y(K?HHYW_206,#['XI_P"@KHW_ (+)?_DB@VGB
MD D:EHKGT_LZ5?U\\UOT4<[_ *06.?-SXAM.;G2K:]C[M8S[7_[XDP/_ !^I
M[#6[+4)VME9X;M!EK6X0QR@>NT]1[C(]ZV:I:EI-CJ\ BO;=9-IRC@E7C/JK
M#E3[@T7B]T%F345@0WEYH5Y%8:O*;BTF;9:Z@1@Y[1R]@W8-T/L:WZ3C8 HH
MJ"\O+?3[.6[NY1%!$NYW/8?U/8#O26H$DDB11M)(ZHBC+,QP /<UC+KL^H$C
M0].:^CZ?:Y9/)MR?9L%G^JJ1[TVVTJ?7I([_ %R(QVP.ZWTQN57T>7^\_?;T
M7W/(Z4    8 JM(^;%JS &F^(+CYKC6H+7/\%G: [?\ @4A;/UP/I2_V#J?_
M $->I_A;VO\ \9K>HHYW_20[&#_8.I_]#7JG_@/:?_&:/[!U/_H:]4_\![3_
M .,UO44<[_I(+&#_ &#J?_0UZI_X#VG_ ,9H_L'4_P#H:]4_\![3_P",UO44
M<[_I(+&#_8.I_P#0UZI_X#VG_P 9H_L'4_\ H:]4_P# >T_^,UO44<[_ *2"
MQ@_V#J?_ $->J?\ @/:?_&:/[!U/_H:]4_\  >T_^,UO44<[_I(+&#_8.I_]
M#7JG_@/:?_&:/[!U/_H:]4_\![3_ .,UO44<[_I(+&#_ &#J?_0UZI_X#VG_
M ,9H_L'4_P#H:]4_\![3_P",UO44<[_I(+&#_8.I_P#0UZI_X#VG_P 9H_L'
M4_\ H:]4_P# >T_^,UO44<[_ *2"Q@_V#J?_ $->J?\ @/:?_&:/[!U/_H:]
M4_\  >T_^,UO44<[_I(+&#_8.I_]#7JG_@/:?_&:\G^.6@7UMI6E:C/JEUJ$
M<4SQ$SQQ+Y>X \>6B]=O?->[5D^)M MO$_AZ[TB[X2=,*V,E&'*L/H<5I1K<
ME12?Y$RA=6/C(G R:]I^'?PJ@M;5?$_B\)!;1+YT-K,0 %'.^7^B_GZ5Y5XD
M\.:AX9U:?2]2B:.5"0KX^61>S*>XKT^+X_W4=K% WAFVD6-0OS79YP,9^Y7K
MXCVDX+V74YX**?O&1\3OB7+XLD.E:2LL6BQ-R=I4W!'0D=E'8?B?0>9U[#/\
M?+B:UF@7PQ:QB5"A*W1XR,9^Y7F/AWP]J'B75H-+TV%I)7(#/CY8U[LQ["G0
M7LX6E'E2\[BGJ]'<]9^!N@7USI>JZC!JEUI\<LR1 P1Q-YFT$\^8C=-W;%>L
M_P!@ZG_T->J?^ ]I_P#&:G\+^'[;POX=L](M>4@3#/C!=CRS'ZFM>O(K5N>H
MY+\CIC&RL8/]@ZG_ -#7JG_@/:?_ !FC^P=3_P"AKU3_ ,![3_XS6]167._Z
M2*L8/]@ZG_T->J?^ ]I_\9H_L'4_^AKU3_P'M/\ XS6]11SO^D@L8/\ 8.I_
M]#7JG_@/:?\ QFC^P=3_ .AKU3_P'M/_ (S6]11SO^D@L8/]@ZG_ -#7JG_@
M/:?_ !FC^P=3_P"AKU3_ ,![3_XS6]11SO\ I(+&#_8.I_\ 0UZI_P" ]I_\
M9H_L'4_^AKU3_P ![3_XS6]11SO^D@L8/]@ZG_T->J?^ ]I_\9H_L'4_^AKU
M3_P'M/\ XS6]11SO^D@L8/\ 8.I_]#7JG_@/:?\ QFC^P=3_ .AKU3_P'M/_
M (S6]11SO^D@L8/]@ZG_ -#7JG_@/:?_ !FC^Q-73F/Q/=N?2>UMR/\ QU%/
MZUO44<[_ *2"QS[2^([ $S6=IJ<0_BM'\B7_ +X<E2?^!CZ5:T[5[+4]ZV\I
M$\?^MMY5*2QG_:0\CZ]#VS6M69J^B6VK(CL6@O(N8+N'B6(^Q[CU4\'O1=/<
M+,N45CZ9J=S]L?2=55(]1C7>CIPEU'_?4=CZKV^E;%2U9@%%%8^I:E<M?+I&
MDA'OW4/+*_*6L9Z.P[D]E[_2A*X%C4=8LM,*1SR,]Q)_JK>)2\LG^ZHY_'H.
MY%5ED\1WX!BM+/2XC_%=.9Y?^^$(4'_@;5>TG1+72(V,9::ZEYGNYN99CZL?
M3T X'85I55TM@LS!_L35WYD\3W:'TAM;<#_QY&/ZT?V#J?\ T->J?^ ]I_\
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M  ;W/_Q=;U%'/+N%D8/_  B5E_S_ .M_^#>Y_P#BZ/\ A$K+_G_UO_P;W/\
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M@GPC;>#/#L6FP,))B?,N)L8\QSU/T'05T=>7B*[J5&XO0WA"T;,P?^$2LO\
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M ,(E9?\ /_K?_@WN?_BZ/^$2LO\ G_UO_P &]S_\76]11[27<+(P?^$2LO\
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MY_\ BZ/^$2LO^?\ UO\ \&]S_P#%UO44>TEW"R,'_A$K+_G_ -;_ /!O<_\
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M!_X1*R_Y_P#6_P#P;W/_ ,71_P (E9?\_P#K?_@WN?\ XNMZBCVDNX61@_\
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MLFL?#UI'*<S2+YTK=V=_F)/XFB.B;%U-:BBBH*"BBB@ HHHH **** "BBB@
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MO8_L\XE!U'Q!NC[BW@VD_BQ->Y45T_7*UK<QG[*/8Y[PQX)T+PC 4TJS5)6
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M%N6C!CC"#: .P^M><>$=7UBR^*OC?3O#]C%<ZI?7C;'N&Q# B2/N=\<G[R@
M=2: /H>L7Q9=:S9>&+VX\/VR7.JHJF")UW!CN&>,CMGO7G6O^*OB'\/?)U37
MUTW6-&>14F:UC,3PD^G\@3FNO\7^*I+/X8WOB;0YD+?9DGMY'4,,,R]1]":
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M  A/BGPMXTTZ(I!:,MG<*HZH!@ ^N4W#\!7M=O/'=6T5Q"X>*5 Z,.A!&0:
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M[PDGS& 4#KTXS^=9NA?#;4_$^B0:SXH\4:S_ &E>1"58[:?RDMPW(  [X(H
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M+F5[<W#W+. H&TD #OT]J\]^#UFFHZO\2+*1Y(TGNEC9XFVLH+3C(/8U@2>
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M&B?"_P 6>$_$-S+X>\3V\6D75R)IH)H<N5W9QT(S@D9R* *WB_\ Y.-\(?\
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MZR^'FHZ'XK\+V_\ 9LBW'EW$=NQ5'  (&WIR P/K7J'Q%D$OPNU^13D/I\C
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M/_(3\-?]A,_^DT]7#?[_ ,A/8;+_ ,C]I_\ V"[G_P!&P5T%<_+_ ,C]I_\
MV"[G_P!&P5T%$MD""BBBH&%%%% &1>>*-$T_6[?1KO4H(=1N0IAMV;#ON) P
M/<@U=U+4K/1]/EO]0N$M[6$ R2N<*HSCG\37/ZO\/M&UKQEI_BFZ>[&H6(01
M!) (SL8L,C&3RQ[UK^(="M/$V@W6CWYE%K=*%D,3;6P"#P<'N* +&F:I8ZSI
M\5_IUS'<VLN=DL9RK8.#^HJG;^*-#NM=ET2#4X)-3BSOM@WSKCD\4[PWX?LO
M"V@VVCZ>93:VX(0S,&;DD\D >M9-A\/=%T[QO=>+87NSJ5SNWJT@,?S  X&,
M]O6@#D?B_P"*M3T_5=!\-V.HMI,.J2?Z3J"G!1-P& >W7.?I6;XP^&G@WP_X
M/U'5[[4]0N;Q+9S%-<7Q+3R[3L&!P<G';I7J/B;PGHWB_3A8ZS9K<1*=T;9*
MO&WJI'2N6TKX*^#M+D9S!=7C>6T<9NYMXB!!!*C  //<'% %3X+_ /)';?ZW
M'_H1K,_9X_Y%;5_^P@W_ *"*]%\->%-/\*^'AHFGR7#V@+D><X9ANZ\@"H?"
M'@O2_!-C<6>E-<M%/-YS^>X8[L8XP!Q0!YS\<_\ D9/ /_7^_P#Z'#1^T'93
M"Q\/ZP$9K:RO,3%1G:&P03_WSC\:]$\4>"-*\77NE76I/<K)I<IE@\F0*"Q*
MGYL@Y^X/UK;O["TU2QFLKZWCN+69=LD4BY#"@!EEJMCJ&EPZE;744EG+&)5E
M##;MQG.:\4^'6L6VO?M#>)M0LW#VTEE*L;KT=5DA4,/8XS791?!/PC%,VW^T
MOL;-N:Q^VL(#]0.?UK;T;X>Z%H'BJY\0Z='+#<SV_P!F,*L!"B?+PJ@<?<'?
MUH ZJO'/CI_R$O!/_83_ *I7L=<YXH\%:7XNFTR74FN5;3IO/A\EPN6R#SD'
M(^44 =$1E2*^;OAYX$\/:QXF\2:'XC>YBU6TNV\J-9VB\R/)RP Z]C]"*^DJ
MY/Q3\./#?BZY2\U&UDCOD "W=M(8Y0!TY'!_$4 >;>+_  /\-/"D^GVFH0:Q
M=W-_+Y<%O;76]\Y R0S# R<9JQ\;86TK6_!.OM$YT^PN@LQ'.S#(P!]R%;\J
M[KP[\+O#'AS4AJ<%O/=ZB#E;J]F,KKVX[9]\9KI]4TJPUO39M/U*UCNK28;9
M(I!D'_ ^XY% #TU&RDT\7Z74)LS'YHG#C84QG=GIC%>+?"'5(-;^+'C74K;F
M"X&^,^J^9P?QKKK?X*>$;>4@C49;/=N%C)>,8 <Y^Z,$\^IK>T'P)HOAOQ!J
M6LZ:LT<^H +)'N'EH <@*H Q0!YIX5>+2_VF/$L5W,D375JXA#G&\L8G 'J=
MH)_"MGX_:S86_P /GTQ[F/[9=S1F*$'+$*P)..PXZ^]=;XM^'/ASQI)'/JMJ
MXNXQM2YMWV2 =<9Z'\160GP8\(IH=WI@BNS]K*&:Z:;=.0IR &(P!D=A0!B:
MQI]QJ7[-<,-JADE33HI=JC)*J06_( G\*Z3X2ZW8ZI\-='%O<1E[2!;:=-PR
MCH,8([<8/T-=7H^E6^B:-::7:ES;VL0BC\PY8J/4]ZXG5?@GX-U2^DNUM[JQ
M,I)ECLY_+1\]<J0<?08% &A:>-=,\977B+P[I$5U)+9V\D3W11?(9B"H"L&R
M3G/4#H:\E^$_@+PKXFT>\M=7DNDUJRN&2>!+HQE5Z [1[@C->[^'?#&C^%=.
M^PZ-91VL).YL9+.?5B>36%XB^%OACQ)J9U.>">TU$G+75E,8G;MSU&??&: .
M$U'PA\./#7C;0M(^S:O>:O<S(\"07'F"$AAAI,L,#@GH>%-)\1L:!\<O"OB*
M].S3I$2!ICPJ$,V<GZ.#^%>B>&/AQX;\)737FGVCR7[ AKNYD,DISUY/ S[
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MIBI8PL%;@Y')!H O:;J5GJ]A%?:?<)<6LHS'*AR&'M7D?P[_ .2Z^._^!?\
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M6*[N9I(6A2:ZFWM"K#!V<8!QWQQ72^%/"VG^#M#32-,:=K9':0&=PS98Y/(
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M1O[-^U?VS-Y7F^?L\GYD7.-IW??]1TH [.BBB@ HHHH **** "BBB@ HHHH
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M3GC%>B#POIGA#X>ZQIFD)*EK]EN)=LDA<AC&<\GZ5S7[/_\ R3-/^ON7^8H
MWX_%FC2?%&7PP-'(U5(?.-]Y:8(V ]?O=#BM?Q3XPT7P=IPO=8NO*5SMCC4;
MGD/HH'6O-;7_ ).CN_\ KP'_ **%1:]:IXA_:3T[3]1(EL[&S$T4+\KN"ENG
MUP?PH W!\;=,A5+C4/#NNV.GR'Y;R6V^0^AX.>:]&T[4;/5M/AO]/N([BUG7
M='+&<AA3KZQM=2L)[&]@2:UG0QR1.,AE/:O'_P!GZ>>WC\3Z$TIEM=/O1Y)/
M8DNK?GL!_.@#H5^,_A]+S5K6YMKR&;3Y_LZQA0[W+Y(Q&JG)Z9Y]:9I7QIT.
M[UF'2]4T[4M%FG(6)K^(*K$],G/';GIS7*?"73+:Y^+/C+4)HD>:VG=82RY*
M%I&R1Z' Q6I^T9;PMX#L+AHU,R:BB*^.0ICD)&?0X'Y4 >PU4U2YBLM(O;N>
M+S88('E>/ .]54DCGCG%&ELSZ39,Q)8P(23W.T55\4?\BEK/_7C/_P"BVH R
MO 'B/2O%/AS^U-(TS^S[=YF0Q%$4EA@9^7C_ /56&/C-X?CO]:L[FWNX9M,N
M3:A H=[F0,RXC53D_=)Y[53_ &?_ /DF<?\ U]R_S%<Y\*-*MKGXP^.=1FC1
MYK6]G2'<,["TSY(]#A<?C0!U6F?&O0[K6(M,U33M2T66<A8FOH@JL3TR0>/K
MTKTOK7D?[0]K!)\/X+IXE,\-ZBQR8Y4$-D ^^!7I^D$MHM@S$DFWC))[_**
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MS\/0ZQIX=(W)5XY!\T;#J#6EJBJ^D7J.H96@<$'N-IKRK]GLE/ VI[1]V^?
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M+5]"OM*+K9HOV7[/(7ENG8+A0N..I[]JP?V;O^05XB_Z^H__ $%J?I-M#/\
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MBON-O/3*<U[/10!XIXH^)0\9^#-3TWPKX?U.0R6S?:;B>$1QV\>,MR"<MC@
M?K6QX'36I/@-:IX=F2'6%@?[.753\X<DKA@1DC(Y]:]3HH \7TSXQP6VCQZ7
MXUT#56UN-=DT?V)2+@\@$*<8)],8]*E^#'A;4+34/$.N7FF2:5IVI.5M;"1=
MN$+$YV]0 " /J<<5['10!X;X>O[OX-ZOJVEZWI5W/H-W<&XM=0M8=ZIGC##M
MQCCK[<UL?\)OXB\<>*-,M?!=I>6.BQ2;M0U&ZM%"R)D<)O![9QW)/8#->M44
M >9_$#Q#XR\)^*-.U6QMYK_POLVWMK;VZNZ$9RV[&X<$8YQQ[UQ/CWQ;IOQ/
MT6+1_#/A?4;S5&E5EN)+4)Y [_,#QGH<\>]?05% &5X9TR;1?"VE:9<2^;-:
M6D<+O_>95 /\JT9X([FWD@F0/%*I1U/0@C!%244 >%V6G^*?@SK=Z-.TB?7/
M"MY)YNV#F2 ^IP#@@<<C!P.0:V?^%_Z&SF&/P]X@:YZ>5]G3J.H^_G]*];HH
M \7^"^EZNGBOQ3K5_I%YI]MJ$IEA%U$4)W2,V!GK@'K3-;L]4^&WQ5N_%\&F
MW5_H&J1G[9]E7>\+'!)(^HR.W)YKVNB@#QKQK\13XM\$:K8^%-*U"X62VD-W
M>3P&**"$ E^3]YB 0 /7\*Z/X*(1\*],5T(^:7(8?[9KT*B@!OE1@Y"+^5>)
M^/$<_M&^#V",5%M#D@<#][+7MU% 'F?Q5\%ZQK4^D^(_#>UM9TF3<D3$#S%R
M#QGN".F>034=OX]\<ZO;?8+/P!>6.IN-C75ZY2VB/0ODKE@.NT?K6G\4?#OB
M37-)LY_"^H36]]9S>884N&B$Z^A((!QCO[UEOXX^($VF&TA\ 74>K,NS[0\J
M^0K8QO\ IGG% '.? BY31](\97-],"EI<!YI3WVJ^3^E.^%7AFV\;:EK_C/Q
M+IL%V+VY,=M#=1!P@')X([#:H/L:[;X4>!KGP1X:FAU&5)-1O9OM%QLY"< !
M<]\<G/J37>4 <Y_PK_P;_P!"KHW_ (!1_P"%>4O9+\,?CU;26EL(="UQ/+V1
M)A(]Q ('8!7"GV#8KWFB@ KQ#P%&Z_M">,&*,%(EP2.#\ZU[?10 4444 %8/
MC?\ Y$;7/^O*7_T$UO5@^-_^1&US_KRE_P#035T_C0GL1>-O^12OOK%_Z-2N
MCKG/&_\ R*5]]8O_ $:M='0_@7J_T#J%%%%0,**** "BBB@ HHHH **** "O
M)8M%U0?M'W&KG3KH::UD$%WY3>46\M1C=C&<BO6J* *6KZ9!K.CWFF7(/D7<
M+0OCT88KR;PU?^-/AE9-X>O_  M>Z[IL$C&RO--^<["<X*C..?7&.>O%>S44
M >9>'(?''B7QU'XAUB.ZT'0[>(K#I7VDDSM@C,BCCOGD#H!SBJ?C7PGK^C_$
M*V\?>%;)=0E\OR[^QW[6D 7;E?7*X'J"H.#7K-% 'E.M>)?&7C'P[>Z9I/@_
M4-(,T#K/=:C\NU=IRL:?>=F^Z.._Y7?@CI.H:1\/A::I8W%G/]ID8Q7$11L'
M'.#VKTFB@#PGPS;^+_A#J&J:9'X6N]>T>ZG\RWGLCN8<8!( )'& 0<<CC/>C
MX\T[QSXLUCP[J]YX?N+:VCN@(K"!6G>% RDR2LHP"?3' %?0E% ' _%?P+<>
M-?#\!TV18]6T^0S6I9MH;/5<]B< @^H'UK ?Q]\0YM,;2E^'U\FM-'Y1O-^+
M</C&\'&/?&[\:]=HH XOPUX:URQ^'5SI6M:I+J&KW<$H>6>9I C.I 0,>P_Q
MKA_A-=^*?"/E^$-4\'Z@(FNF/]HJ#Y2 C)).""..H/>O;** /)[?1=47]HVY
MU8Z==#3FL@@NS$WE%O+ QNQC.:L_$;P1K=SXCT[QEX2,1UFQ 62WD8*)T'0<
M\="002./>O3Z* /*+SXA>.;_ $]K#3/A[J=MJ\BE#/<'$$1Z;E8@!O;)'XUO
M_"[P(W@7PT\%U*LVI7<GG74B\@'& H/<#GGU)KN** /)?A9HNJ:;X[\9W-]I
MUU;07-SN@EFB9%E&]CE21SU[5;^.^D:EK7@2UMM+L+F]G748W,5O$9&"A) 3
M@=LD?G7I]% %73$:/2K-'4JZP(&4C!!VCBJWB**2X\,:M##&TDLEG,J(HR6)
M0@ #UK3HH \X^".E:AH_P]2UU.QN+.X%S(WE7$91L$\'!K.^%VBZIIOQ \=7
M5]IUU;6]U?.]O+-$RK*IED.5)'(P0>/6O6** /-?CEI.HZS\/UM=,L;F]N/M
MD;>5;Q%VP V3@=J[[2D>+1[&.12KK;QJRL,$$*.#5RB@ HHHH **** "BBB@
M HHHH **** "L&]_Y'C2/^P?>_\ HRVK>K"O?^1XTC_L'WO_ *,MJJ&_W_D)
MC=._Y'C7/^O*S_G/6_6!I_\ R/&N?]>5G_Z%/6_3GO\ =^0(****@84444 %
M%%% ',?$6TN;_P"'FNVEG!+<7$MHRQQ1*69SZ #K6;\-=.O=/^$>FV-[:3V]
MVEO,K02QE74F1R 0>>A'YUW-% 'EGP+T?4]&\+ZE#JFGW5E*]\SJEQ$8RR[1
MR >U1?%71=4U/QSX%N;'3KJY@M;W?<20Q,ZQ+YD1RQ X& >OI7K%% $%ZK/8
MW"J"6,3  =2<5YG\"]'U/1O"VHPZII]U92O?,ZI<1&,LNT<@'M7J=% 'DOPX
MT75-/^*GCF]O-.NK>UNKAFMYI8F5)1YK'*DC!X(/%7_CCI.HZSX!%KIEC<WM
MQ]JC;RK>(NV!G)P*]+HH HZ+&\.@Z=%*C)(EM&K*PP5(49!KS/X;Z+JFG_%/
MQU>WFG75O:W5RS6\TL3*DH\UCE21@\$'BO6J* /(/&OA[Q)H/Q-M?'GA_2O[
M7B$/E7-I&<2#@J<=SD'@@'&.E4O&FK>./'?@G4K2T\(WFDVB(K2K< O/=$.N
M(TC"@C^\3Z+7ME% '%?#&PO-.^%VE65[:S6UU'#('AF0JZDLW4'FN?\ @-HV
MIZ)X/O;?5=/NK*9KPLL=S$T;$;5Y (Z5ZK10!Y3\8=&U35=9\&R:=I]U=I;:
MAOG:")G$:[H^6P.!P>OI6Q\4O!5_XJTRPO=%D2/6])G^T6F\@!^A*Y/ .54@
MGCCWS7?44 >6CXB^-6LOL?\ PKG4QK&W9Y@.+;=C[V\C&,\XS^/>NB^'6B>(
M=&T"1O%&ISWNIW4IE=))S*L [(I/].*["B@ HHHH **** "BBB@ KGO%G^KT
M;_L+6W_H1KH:Y[Q9_J]&_P"PM;?^A&KI_$A2V#Q%_P A#PY_V%1_Z(FKH:Y[
MQ%_R$/#G_85'_HB:NAHEL@04445 SS;XR^%-:\6Z#I=KHEH+F:"^$TBF5$PF
MUAG+$=R*Z?QEX3MO&?A6?1;MS%O :.5>3'(.AQW^E=%10!Y1ITWQ=\/Z?'HX
MT32=7$*".#4#=A!M' WJ2"W'H!6S\// NH>'IM5UCQ!?)>:UJSEI_*)\N)<D
M[5SZD^PX '3)[ZB@#QC3_"OQ"^'>L:C_ ,(M;V6MZ1>R^8L%S/L>+KC[S#GG
M'!.<=!6AH?@GQ5KWQ M/&7C/[%:/91[+6PM&W;3@_>.2,?,3U.3Z"O5Z* /)
M-9\'>,O#?CZ^\6>##:W\5^N+C3[J3;R<9P20.HR#D8SCD57N_!_CGXAZYI5Q
MXOM]/T?2].E\T6MM)YDDC9'<%ASC&<C [&O8Z*  # P.E<I\1-&T'7?",]EX
MAOH+"U9E,=W,ZH(I/X2"2!GJ,=P375UB>+?#%GXP\-W6BWS.D4X!$B?>1@<A
MA^- 'G^B>%_B=::5;Z=8^--(ET?RU%O>^299A%CY2N5P>.F6/'0UA?"W2TTG
MXV^)[*"XGNDMK=DDN)CN9WW+DL?4G-=)IW@GXD:%IHTC2_&-@=/C&R&2XM2T
ML2^@ZCCWS71> OA]:^"8[RX:\EO]4OFWW5W*,%N2< =ADGZT 8VJ>$]:N?CQ
MI'B:*S#:1;V1BEG\U!M;;(,;<[C]Y>W>M+XD?#[_ (3:RM)[*[%EK-@_F6ER
M1QGKM..0,@'(Z8Z&NYHH \K_ +1^,BV7]F_V#HYN<;/[5^TKLZ?>\O=G/X8]
MJW?AMX '@C3;J2[NOMFL:@_FWMQS@GDA5SSC))R>23]!7;T4 >:^$O"FM:7\
M7?%6NWEH(]-OTQ;3>:AWG*_P@Y'0]15_XN^'-5\4^!9--T>V%Q=FXC<1F14X
M&<G+$"N[HH S]!M9K+P[IEI<)LG@M(HY%R#A@@!&1[BN%\)>%-:TOXN>*M=O
M+01Z;?IBVF\U#OY4_=!R.AZBO2J* /-?%W@?78_&,7C3P;<6Z:L(_*NK6Z)$
M=PF,=?H!QQT!SFLO6],^)WC^Q71=2T[3O#NFNZFZE2Y$TD@!SA=I/'L<?6O7
MJ* ..\5^%YI/A7>^&M%A,THLUM[=&<*7((ZDX&3@FK/P[TB^T'P'I.F:E#Y-
MY;Q;9(]X;:<GN"0:ZBB@#SGXF^!-5\1WFD:]X>NHH=9TF3?$DW"2#(8<^H([
M\<FLZZA^*GBS2;O2]4T_3M#MI(7$LMM,'FF.TX1/G(4,< D]C7J]% 'G7P9\
M+:QX2\(7%AK=H+:Y>[:14$J/E2JC.5)'8U7^'?A+6]!\>>,]3U*S$-IJ5X\M
MK)YJ-YBF5V!P"2.&'7%>FT4 >/:EX.\;>%/'^I>)_!T5EJ<&I_Z^SN7",O<\
MDCOR"#WZ5D>/O!OQ,\=Z+;7.H6UC'-#,!#I-I,H"J0=TCNS8+<*  3U/O7O%
M% '(?$K1=1\1?#W4=+TRW\Z]G5-D1=5SA@3R2!T'K6AX(TV[T?P3H^G7T7E7
M5O;+'*FX-M8=LC(-;]% !1110 5A>(?^0IX:_P"PF?\ TFGK=K"\0?\ (4\-
M?]A,_P#I+/5PW^_\A/89-_R/^G_]@NY_]&P5T%8$W_(_Z?\ ]@NZ_P#1L%;]
M$MD""BBBH&%%%% !1110 5B>+M/T?5/"U_9Z]-%!ITD>)9I7""/GALG@$'%;
M=4-;T>UU_1+S2;T,;:ZB,;[3@@'N/>@#ROPSX4^(.DZ7%:>%_&FBWOA]L_9K
MB6,R,BD\[,*0<'/&[%87AW19-%_:.AM)=0GU*[6S:6\NI1RTC19)P/NCD #L
M,5U&D?#_ ,>^$[1M,\/>+;)],R3&E[;$M%GKC&?\*W?!/PX'AG5[W7]4U.35
M=>O05EN77:JJ<$A1[D#\   * *'CSPGK6M_$;P=JVGV8ELM.FWW4GFHOEC>I
MZ$@G@'H#6]\0? UKX\\.G3Y9OL]U$_FVUQMW>6_N/0C@_P#UJZRB@#RFTN_C
M#I%@FE'1-(U22-1''J1N@HQTRZE@6/X#\:U?AW\/KOPW>ZAX@U^]6^\0ZD3Y
MTB9V1J3G:O3/0=N, #W]!HH \V7PIK0^/+^)C:#^R#8^2)_-3[^P#&W.[K[5
MT7Q$TB^U[P!K&EZ;#YUY<1!8H]X7<=P/4D <"NGHH YKX?Z5>Z'X#T?3-1A\
MF\MX-DL>X-M.XGJ"0>M<TGA36A\>9/$QM!_9!L?)$_FI]_8!C;G=U]J]*HH
M\]\?^!-2UC6M-\4^&;N*U\0::-J";_5S1\_*?0_,P]P<<5CZLOQ8\5Z5+H<V
MC:5HL5POEW%\+H/N7OL522N1Z_F*]:HH Y6U\)C0_AM<>&]/9KB46,T*NY"F
M61E;DYX&2?PK-^$7AS5?"W@6+3=8MA;W:SR.8Q(K\$\<J2*[RB@#A/BCX$N?
M&^B6JZ?<I;ZE8S>?;M)]QCW!X./K[5DVDOQ;U>)=*U&PTO287 CGU2*4/)MZ
M%HU#'#D>HQSVKU&B@#RGX*^"]=\'0ZXFMVGV?[3-&T),R2%P-V3\I..HZU:T
M3PEK5G\<=>\23V872;NW5(9_-0[B$C&-H.X<J>H[5Z910!Y/XM\%>++#X@CQ
MOX.-I=7,D(BGLKE@NX8 ."2!@X!Z@@BLGQEX<^*'CWPO-%J-GI]@(71X=,M9
ME+W#[@"7<MM  +$#/7MTKVZB@#D)]$U&3X1KH:V__$R&CI:^3O7_ %@B"D;L
MXZCKG%1_"S0=2\-> ;+2]6MQ;WD3R%XPZOC+$CE2179T4 %%%% !1110 444
M4 %%%% !7-^$O^2?:/\ ]@Z/_P! KI*YOPC_ ,D^T?\ [!T?_H%6OA?JOU$]
MRUX0_P"1*T'_ +!UO_Z+6MJL7PA_R)6@_P#8.M__ $6M;5*?Q,%L%%%%2,**
M** "BBB@ HHHH *\T^(OA/6M?\<>#-2TVS$UIIMUYET_FHOEKOC.<$@GA3TS
MTKTNB@""]C>:PN(D&7>)E4>I(-<!\&_"VL>$_#%[9ZU:"VGEO&E11*CY4@#.
M5)':O1J* /)1X.\8> _$NHZCX)BL]1TG49/-ETNYD\MHWSGY"< =3@YZ<$'
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M8&Y<[CCCH!_6O5** /&O"G@#Q7I/QAD\0:NRWMO-;L9KU70*964954SN"@Y
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M/_7-:WVFB5MK2(&]"PS0 ^BBB@ HHHH **** "BBB@ HHHH **** "L'QO\
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M=V  'N3639>,/#6HW0MK+7],N)STCBND9OR!H VJ*** "BBB@ HHHH ****
M"L*]_P"1XTC_ +!][_Z,MJW:PKW_ )'C2/\ L'7O_HRVJH;_ '_D)C=/_P"1
MXUS_ *\K/_T*>M^L#3_^1XUS_KRL_P#T*>M^G/?[OR!!1114#"BBB@ HJM?:
MA9:9:M<W]W!:P+]Z2:0(H_$U7TO7]'UM6;2M4L[T(<,;>=9,?7!H T:*:[I$
MC/(RHBC)9C@ 5C0>,?#-U>?8[?Q!IDMSG'E)=(6S],T ;=%'6LR+Q'HD\EY'
M%J]B[V1Q=*LZDP')&'Y^7D'KZ4 :=%96F>)]!UF9H=,UK3[R51DI;W".1^ -
M-U'Q3X?TBY%MJ.MZ?:3MTCGN41C^!- &O13(IHKB)989$DC895T.01[&J9US
M2AJW]DG4K0:CMW_9?.7S=N,YVYSC'- %^D9@JEF("@9))X%8Z^+?#CZA_9ZZ
M]IIO,[?(%TF_/IC.:T-1_P"09=_]<7_D: $L=2L=4@,^GWMM=PAMIDMY5D4'
MTR">>:M5Y'^SM_R3NY_["$G_ * E>GZEK.F:- )M3U"ULHB<![B54'YDT 7:
M*H:9K>E:U$TNEZE:7L:G!:WF60#\C4=QXCT2SU6/2[G5K*'4)<;+:2=5D;/3
M"DY.: -.BD9@JEF("@9)/:J&E:[I&N)*^DZG:7RQ$"0VTRR!2>@.#Q0!H45E
MZGXDT/175-4UBQLF;[JW%PJ$_F:MV6H6>I6RW-C=0W,#?=DAD#J?Q% %FBJF
MH:I8:3;&YU&]M[2 =9)Y B_F:KZ9XCT36BPTO5[&]*_>%O.KD?D: -.BBB@
MHHHH *Y[Q9_J]&_["UM_Z$:Z&N>\6?ZO1O\ L+6W_H1JZ?Q(4M@\1?\ (0\.
M?]A4?^B)JZ&N?\1?\A#PY_V%1_Z(FKH*);($%%%%0,**** "BBJFIZI8:-8R
M7VI7<-K:Q_>EF<*H_/O0!;K)T+Q/HWB6.Y?1[Y;I;:3RIBJLNUO3D"L32?BG
MX,US45T^QUN)KF0[8UDC>(.?12P )^AKC?V?_P#D'^)_^PF?Y4 >QT5S_B'Q
MOX;\*LJ:SJL-M*PRL/+R$>NQ03C\*;X=\=^&?%<CQ:-JL5Q,@R865HY,>NU@
M#CWQ0!T5%8NN^+-%\-W>GVVJW9@FU"7RK91$[[VR!C*@XY8=<5CZI\5O!.CW
M[65WKL/GHVQQ%&\H1LX(9D! .?4T =E1573=3LM7L(K[3KJ*ZM91E)8F#*:S
M_$'BW0?"L"S:UJ<%H&!**QR[X]%&2?P% &U17*:%\2O"'B.\6TTW6H7N6.$A
ME5HF<XS\H<#/X5U$LL<$3RRNL<: LSL<!0.I)H ?2,P52S'  R37#S?&+P'#
M=FW;7XV8':72&1X\_P"^%V_K776.HV&L:<EY8W4-U:2J=LL3AE8=^10!GZ!X
MOT'Q2UR-%U%+LVQ EVHR[2<X^\!Z&MNN \(ZA\/M*T_7=2\-@06]HW_$Q=(I
ML@C/9AD]_NUQ$/QEL6^+,\T^NS_\(JEKB!!;.!YA"YRH7<>=W)% 'KWB'Q3H
MOA6UBNM;OELX97\M'9&;+8SCY0>P-:=K<PWEI#=6[B2"9%DC<#&Y2,@_D:XK
MQGJ7@34O"NEZGXH(FTBZD5K-VBEY=D)'RJ-P^7/45V=G%;V]A;PVJA+:.)5B
M7T0# '/M0!/17&:I\5_!.CWK6=WKL)G0D.L$;S!2.H)0$"NAT7Q!I'B.S^UZ
M/J$%Y #M9HFSM/7!'4'V- &E16)JWB[1-$UG3])U"\,-[J!Q;1^4[;^<=0"!
M^)%8MU\6_ MGJ7V"7Q!!YP.TLB.\8/NX!7]: .UHJ&UNK>^M(KJTGCGMYE#Q
MRQL&5U/0@CJ*FH **** "BBB@ HHHH **** "L+Q!_R%/#7_ &$S_P"DL];M
M87B#_D*>&O\ L)G_ -)9ZN&_W_D)[#9O^1_T_P#[!=U_Z-@K?K F_P"1_P!/
M_P"P7=?^C8*WZ);($%%%%0,**** "L/5/&.@:-K-KI&H:BD%_=X\B$HQ+Y.!
MR!CKZUN5Q/B2/P/)XYT:'7(5?Q!+@V&4D/1B1RORCD'K0!VU%8GB;Q=HGA"S
MANM<NS;0S2>6C")Y,MC.,*#V%9>L_%'P9H&HM8:AKD27*-M=(XWDV'T8J" ?
MK0!U]96N^)=%\,VJW.LZC!9Q,2$\QN6QUPHY/X"I+;7M+O-$?6;2]BN-/2-I
M6GA.\;5&6Z<Y&#QUKY]\9^,_"/B?XN>'[ZZNC=^';6WVW"RVTFT-ES]PKD\[
M,\'- 'MH^(7A0^'CKXUB(Z6)O(-P(WP)/[N-N>X[5T5O<17=M%<P.'AE02(P
M_B4C(/Y5XA\49_#EW\%A=>%K>W@TR:_1@(+8P*S@[2=I .> ,X[5Z_X<('A7
M222 !90Y)_W!0!J45Q%Y\7? MC=-;RZ]$[J<,8(I)5'U95(_6NHTC6M-UZP6
M]TJ]AO+9CCS(6W 'T/H?:@"_17.W'COPU9Z]=:+=:FD%]:PF>994941, Y+D
M;>X[UF67Q;\#7^HK8P:_#YS-M4R1O&A/L[*%_6@#M:*Y;Q!\1O"7A>Z^RZMK
M,45QU,4:-*R_4("1^-:NA>)-'\367VS1M0AO(0<,8SRI]&!Y!^M &I16'JOC
M#0M$UNQT?4;WR+Z^_P"/>,QN0W..6 P/Q(K#E^,'@.*^^QMXA@,F<;TC=H_^
M^PNW]: .XHKG=;\=^&/#MI!<ZGK-M%'<()(0A,C2*>C*JY)'N*?X;\;>'/%J
MR?V)JD5T\8R\>"CJ/4JP!Q[XH WZ*K7^H6>EV4M[?W,5M;1#+RRL%51[DUQ\
M?QB\!RW0MQKR*2VT.\$BQY_WRNW]: .YHK&UKQ5HOA_18]8U&]"6$C*J31(T
MH8L,C&P'@XZUY)X"^,-F^O\ B ^)-<G>&:Z5--7[,Y41[GQ@(OR\%>N#0!ZQ
MJ_C'0-"U:TTO4]12WO;S;Y$11B7RVT<@$#GCFMRN(\4KX&E\9Z+!X@B5]<DV
MG3\I*>CY'*_*/F'>NRN+B"TMY+BYF2&&-2SR2,%51ZDGI0!+17#-\8O 2WGV
M8^((BV[;O$,ACS_O[=OZUV5E?6NI6<5W97$5Q;2C<DL3AE8>Q% $]%<]-XY\
M.6WB&[T*XU)(;^SA\^=)$94CCVAMQ<C;T8=ZR[3XM^!;W4180^((/.)V@R(Z
M(3[.P"G\Z .UHH!R,CI10 4444 %%%% !7-^$?\ DGVC_P#8.C_] KI*YOPC
M_P D^T?_ +!T?_H%6OA?JOU$]RUX0_Y$G0?^P=;_ /HM:VJQ?"'_ ").@_\
M8.M__1:UM4I_$P6P4445(PHK/UO6]/\ #ND3ZKJDY@LX #)($9\9( X4$]2*
MPK_XF^#M,L+2\N]:B2.[B6:% CM(R-T;8!N ^HH ZVBL7P[XMT+Q7;//HFI0
MW:IC>JY5DSTRIP1^(I-7\6Z+H6K:?I>HW;0W>H-MMD\IV#G..H! Y/<B@#;H
MKFM/^('A?5O$7]@Z?JT5UJ.&;9"K,N%&3\X&WCZU8\1>,O#WA1%;6]4@M&<9
M2,Y9V'J%&2?RH W:*Y;0?B-X2\2W0M=+UF&2Y/"PR*T3M]%< G\*I_$;QWI_
MA#0[N%[YK;5[BSE>PQ T@,@&%.=I4?-C[W% ':T5Y5\)_B58:WHUAI6IZM-<
M^(9FD9U>%^>21\VW:./>NZ\0^+] \*Q*^M:G!:%P2B,2SOCT49)_ 4 ;=9/B
M#Q-HWA:SCN]:OEM()'\M79&;+8SCY0?2L[P_\0_"OBB[-II.KQ37/40NC1.W
MT5P"?PJ'XA'PA'H,4OC-%;3EF&S*2-AR#CA.>F: .GM+J&^M(;JVD$D$R!XW
M QN4C(/-35DRZEI/A_PNNH._D:3:VZL&",VV/ QP 3T(]ZQ;OXI>#+'2[34;
MC6XD@NTWPKY;F1ER1G8!N R#R1VH ["BL7P[XMT+Q7;//HFI0W:IC>JY#IGI
MN4X(_$5'JOC+0M$UZQT34+TQ:A?8^SQ"%VWY;:/F ('([F@#>HIDTJ00R32'
M"1J68XS@#DUD^&_%6C>+K"2^T2[-S;QR&-G,3IAL XPP![T ;-5-3U.ST;39
M]1U"<06D"[Y9""0H]<#FL)?B)X5,FJH^K1Q'2G"7AF1XQ&Q)  + !B2IZ9J!
MO%/A#Q=X)U347N?M>@P[HKQC#(N-H5B,8#'AE/% &]HFNZ9XCTU=1TB[6ZM&
M8JLBJ5!(Z\$ UHUS_@I/#P\+6LGA:,)I$I9X<*ZYY()P_/4'K5+6OB;X/T"]
M>RU#6HA<H=KQ0H\S(?1@@./QH ZVBL;P_P"*]"\4V[S:+J4%VJ8WJAPZ9Z;E
M."/Q%;- !16+XE\6:-X0L8[W6[LVUO))Y2N(GDRV"<84'L#5*Y^(?A6T\10:
M!)J\3:G/*L*01HSX<G 5BH(4Y/<B@#IZ*R-?\4:)X7MEN-:U*"S1L[ Y^9\?
MW5')_ 5E:%\2_"'B.^6RTW68GNF.$AEC>)G_ -T.!G\* .LHIKND4;22,J(H
MRS,< #U-<5+\7O D5_\ 8V\00F3=M+K&[1@_]= NW]: .@C\3Z-+XEE\.I?*
M=6BC\U[;8V0N <YQCH1W[UKUXQI,T5Q^TYJ,T,B212:6K(Z'(8%(\$&O23XR
MT(>+E\+&\/\ ;++O%OY+XQMW_>QMZ#/6@#>HJEJ^K66A:5<:GJ,IAL[9=\L@
M4MM'3H 2:CT/7-.\1Z3#JFE3F>SFSLD*,F<'!X8 ]10!HT5RNO\ Q(\)>&;P
MV>J:S%'<C[T,:-*Z?[P0''XU9@\<^&KKP]<Z[;:K#/I]JNZ>2(%VC^J ;@>>
MF* .AK&\0^*]#\*P0S:W?I9QSL4C9D9MQ SCY0:\AT_XR63?%>_GO==G_P"$
M76T*6J"V?'F$IR5"[B>&Y(_G7>>-+_P'?Z!H^H^*0)M.NV5[%FBE.XNNX'"C
M(ROK0!W$,J3P1S1-NCD4,K>H(R#3ZCACC@MXXXP%BC0*H] !Q7':C\6O ^EW
MC6EQKT+2J<-Y$;RJI]V12!^= ':T5GZ/KNE^(+(7FDW\%Y;YP7A?.#Z'T/L:
MJ:EXMT32-=L-%OKPQ7]^,V\?E.0XZ?> P.G<B@#;HKB9OB[X$@U'["_B&#S=
MVW<J.T>?]\#;^M=E;W$-W;QW%O*DL,JATDC8,K ]"".HH DHHHH **** ,#P
ME_QXZC_V%;S_ -'-11X2_P"/'4?^PK>?^CFHJZGQ,4=A/''_ ")&L?\ 7LU=
M!7/^./\ D2-8_P"O9JZ"A_ O5_H'4****@84444 %%%% !3)?]2_^Z:?3)?]
M2_\ NF@#YR^$WA:X\5S>(+.ZU"ZMM#BO2\L-H_EO/*<@!F'.T#/'<FMCQ]X+
M7X6VEMXN\&75S9F"Y1;JT>4M%(IX&0>HSP0<_>R,8J/X&>)M,TW4O$.D7]S'
M;37%X98&F8*LA!(*@GC=TXK9^.?B2QO?#MOX5TR:.]U;4+J,""!@Y0 YYQT)
M.T 'WH N_%_4(=:^!QU2)"([I;6X0-U7<RG'UP<5G^$_A<?$^DZ/XA\4:K>R
MW(CBDM+6!PL5O&H&Q<$'/ !.,5:^*6F/HWP!CTR1@TEI%9PNPZ%E9 2/Q%=]
MX)_Y$;0_^O&+_P!!% 'F_CC5-7\9?%"V^'VF7TUAI\,0FU&:$[7<;0Q&?3!4
M?5N:NZQ\$M(LM(EN?#-YJ&G:Q!&7BN!<L3(PYP^/7VK(\07H\!?M 1^(=5!3
M2-7MA!]I R(SM53GZ,BD^S5Z9XA\;:!H?AV?5)M5M'C\IFA6.97,QQP% /.3
M0!SGPQ^($OB'P#=ZAK&3>Z3O6[8+@N%7=NQZD _B*X_P3X:?XO27_BGQ==74
MME]I:*RT^.4K$BCOQV&<>IP<U?\ A!X9OY_AIXAFN$\F77O-,"L,<%"H;Z$D
M_A3_ ($:]96'A^]\,:C-'9ZI8W<F8)FV,RGJ0#UP001]/6@#DOBWX/F\'66D
M6NG7]S+H$UZK):W#[S;S $#8?[I4GCVKM?CY_P DLM?^OR'_ - :L'X^>)]-
MOCHVAV5S'<7$-X)YS$=RQ\%54D<9.2<>U=+\=;2:Y^%"O%&SB"XAEDP/NK@C
M)_$B@#T+PWQX8TK_ *](O_017D_@(#_AH;QEQ_RQ;_T*.N\\,>,_#;^"M.O#
MK=C'%':H)!+.JLA"@$$$Y!SVKS;X5:I#K?QO\5:E;JZP7%N[Q;Q@LF]-K8/J
M,'\: -#6IKWXE?%BZ\)&^N;3P_I,9-TEN^QIWX!!/IDX_"K6L_"R_P##%[I^
MJ_#>6:VN8YA]JM)KHB&9,=2#UZ8/UR,8K-TN^C\$_M ZXNM2I:VFM1F2"XE.
MU#D@@9/'7(^M=OXQ^*.D^&%L8;(1ZS?WDXBCM+2X4O@]SC/?  [Y]J /.OCM
MX/T73[>QUJWM#'J&HZBJW,GF$[@4)(QT'05Z;IO@S0_"7A;5O[&M# +JT9I<
MN6W$(<=?J:XW]H5]OA;09)!LQJ2LPSG;\C9KT:74[#4_"5Y)87MO=(+%R3#(
M'QE#UQTH X+]G]UA^&]U(W"K?2L?H%6L#PMIEU\:M9U36_$%[=IX?MY_*L]/
MADV*>_S8]!C/<EJWO@%%YWPTO(LXWWLRY],JM9/P9UVV\(76K^!]>FCLK^&[
M,D33-M67( (!/L%(]0: &^-O"D_PG@M_%7@V]NH;6*=4N]/ED+Q.K=\>G&#W
MY&#78?$34X=;^!^HZI "(;NRBG0'L&9#6+\;_%-A-X7'AC3IX[W5M0GCC%O
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M* =!J0'Z"N@^-_\ R2K4_P#>B_\ 0Q0!4N]7U+0OV=[+4=)#?;8M'MMC*,E
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M:XTYI;7S7.2ZA RDGV#8_"KGBOXN^%;'PO<RZ=JL-]>W$++:P099BY& 6&.
M">_-5_A-X7N_#7PQN3J"-'=Z@9+MXF&#&"@"@CL<+G\: *'[/<BP_#6\E;[J
M7TK''H$2N0\(:MX0\3>(=8\2>/M4M9+HW!CLK2Z<[(HAT(7ICM^!-==^SY$L
MWPTO(FSM>^E4X]"B5S?@1O#?@G6M9\+^-K&TM[G[49;2ZNX0R2QG@88CIQG/
M3KWH I>+]8\(>&?%^@^)? NHVR.)_+U"ULW.R2+(ZKTP1N!_X">HS7J?Q1\
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MYL?#ND*/LIN5V-,X)8$#W8@G'&% ZT 5OC9IQU?XC>#=.$C1BYW1,RMM(4N
M<'Z9KTZ_\!^%Y?#4VD_V)9):B$HI2%0Z<<,&QG=[UP'Q1/\ Q>'P%_UT/_H8
MKV*Y_P"/2;_<;^5 'E'[.]Q-+\/[N&21GC@U"18@3]T%$) ]LDG\37KE>/?L
MYD'P-J6#_P Q)_\ T6E=+>_$8VGQ5MO!?]GAA.BM]I\S&,J6^[CVH [RBN:\
M>>*SX+\*7&MBU%UY3HOE%]N=S8Z_C5_PQK1\1>&-.U@P^3]L@67R]V=N>V:
M-:BO/_"?Q*/B?QSJ_APZ<(!IY?\ ?"7=OVOMZ8XKT"@ HHHH **** "L+Q!_
MR%/#7_83/_I+/6[6%X@_Y"GAK_L)G_TEGJX;_?\ D)[#9O\ D?\ 3_\ L%W7
M_HV"M^L";_D?]/\ ^P7=?^C8*WZ);($%%%%0,**** "O'/'W_)>O O\ N'_T
M)J]CKQOQ^?\ B_7@7_<_]F:@"/\ :/Y\(Z3_ -?W_LAKT+2_ ?AS3]"CTQ](
MM+A3&!/)/$KO,V/F9F/)).3G\J\]_:/('A+2,G_E^_\ 9#7M% 'BGP0C^P>(
M_&>BQ,386]U^[B;D#YF7^0 _"E\4VT"_M(^$XE@B$9LSE @P>)NU.^#I!^(7
MCO!'_'U_[.].\5G_ (R6\)?]>1_E-0!?^/L<<7PR*1HJ+]KBX48'>NTMK&UU
M+X=VME>SO!:SZ9&DTJ2;"J&,9^;MQ7'?M _\DU/_ %]Q?UJ;QWI>L:Q\$+>U
MT57DG-I;/)%']Z6(*"RCU[''?% %#2?&/PN\(Z7_ &%IC-?6ZY$KQ6AN#)D\
M[V"X;_ZU9WP-FLW\5^-!I8=-->X62WB92FU2SX&WM@'%+X1^*OA/1_#=GI$'
MA^_CU>"(1/806>YY) .3GJ<GN>:/@I+=OXY\;-J4 M;^6=99;;<"8RSL2OT&
M<4 4;SP_I_B/]I:YM-3A$UM%;+.8C]URJK@-ZC)SCVKI?C9X7T1?AE?W\.F6
ML%S9-"T,D,*H1F14(X'3#'BL[33_ ,90ZC_V#C_Z"E=1\;/^20Z[](/_ $?'
M0!%\+_".BP^ =,O)["WN[R^@$]S<7,0D>0MS@EL\ 8&/:N4\'V4/AO\ :'UO
M2-,406%Q9F5H%&%4_*P 'H"3^=>C_#<Y^&_A['_/C'_*N TP_P#&4&I?]@X_
M^@I0!1^,&E0ZY\6/!NEW)86]T%CEVG!*&3YA^(R*]%\3>"/#<_@K4+!='LX8
MHK5S$T4*JT95200V,YXZ]^]<3\1R/^%Y> _]Y?\ T8:]6U__ )%S4_\ KTE_
M] - 'DGP%\+Z3>>$7UN^M(KR]>=H$>Y42>5&N,*@/3J>E0^*=,M/#/Q_\)W.
MD01V?V]0EQ'"NQ&R60G XY!'XC-;W[/W_),E_P"OV;_V6LSXC$?\+S\!_P"\
MO_HPT =S\0]&\-ZQX?1?%.H26>FV\PE)6?RP[ $ '@[NO05POB/X@?#K4?!U
M_HUK:/-"+:1+;R]/;RT<*=I#8XP<<U)\;[&_.H^'-7?3I=2T*PF+WMK'D@\C
MD@=L C/^-,U?XJ:-K_A34-,\(:)>75W+:2*R_91'';H4.YF(.!@9P.YQ0!N?
M \"Z^$^G+< 3*LLP42#< !(<#FL#X*VT$GB;QX'@B8+J7R[D!V_/+T]*W_@.
M0?A58@$$B>8'GI\YKA/ _C"P^'_CKQ98>(;>\MY=0U M 1#D$;WQ^!W#!H W
MOB1_R7#P+]/_ &<TOQQGNM3UCPGX12=H;35;P"X*_P 7SJJ_@-Q./7'I3?B0
M?^+X>!?I_P"SFMCXQ>$]6U:#2/$6@1&;5-%G\Y85&3(N5;('<@J#CN": .T@
M\'>'+?1QI*:+8_8@FPQM"IW<8R3C)/OUKRWX72/X6^*OB3P3%)(VFC=<6R,V
M=F"/YAA^5;D'QU\.KIX^WV>I6VK !7T[[.=Y?T7VSZX/M5;X5>'=7N_$^M>.
M]=LVLIM3)6VMI 0Z(3R2#R. H'TH YK4O#UKXE_:=O;&_4R62P1S3PYP)0L,
M9"GU&[:<>U=K\6O".@R?#?5+E-*M()[*(2P200JC(01QD#I[5A:<?^,J-6_Z
M\%_]$Q5W'Q5_Y)=XA_Z]3_,4 .^%UQ-=?#+0)IY&DD-J 68Y) ) _0"NNKC/
MA-_R2SP__P!>Y_\ 0FKLZ "BBB@ HHHH *YSPC_R3[1_^P='_P"@"NCKG/"/
M_)/M'_[!T?\ Z *M?"_5?J)[EGPA_P B3H/_ &#K?_T6M;58OA#_ )$G0?\
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M.^&XHVTK1[2WDA0A9EC!DQCG+GDY^M>4_";2K?QMXJ\1^+M?@2]N$N?)MDG
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M7/@SXS:;XYFTZXN=':#RIY+==QC;8R$GTP"",XSC% '??%;_ ));XA_Z]?\
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M_P"I?_=-/HZC!H \'^#?AW1_$VB^*+/6+"&\@&I[E$@Y4X/*D<@^XKU'P_\
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M2/PKJ:* ,[6]!TOQ'IKZ?J]E%=VK')20=#Z@CD'W%9V@>!?#GABRO+31]/\
ML\%X,3KYTC[Q@CJS$C@GI7144 9'AWPSI'A33FT_1;4VUJTAE*&1W^8XR<L2
M>PJ#Q#X+\.^*@O\ ;6DP73J,+(<K(H] ZD,/SK>HH YC0/AYX4\,7/VG2=&@
MAN!G$SLTKK]&<DC\*V=8T>QU_2;C2]2A\^SN%"RQ[V7<,@]5((Y [U>HH IZ
M3I5EHFE6^F:?#Y-I;KLBCW%MH^I))_&J)\):(WBH>)C9G^UQ'Y0N/-?[N,8V
MYV]/:MJB@ K(\0>&-(\4VD-KK-J;F&&43(HE=,..ARI![UKT4 <CK'PO\&:[
M>F\U#0X7N#RSQR/$7/JVPC<?KFN@TG1].T*P2QTNRAM+5.1'$NT9]?<^]7J*
M /.OC9K4.E?#B]MF59)]1*VL,9ZDDY)'T _E6Y\.O#B^%? VF:;M F\L2SG'
M61N3_A^%;]YIEAJ/E_;K&VNO*;='Y\2OL/J,C@U:H *@O+2"_LI[.Y3?!.AC
MD7)&5(P1D<U/10!Y]_PI#X>_] $_^!L__P 76KH7PS\'>'+Q;S3-#@CN4.4E
MD=Y60^JER<?A7644 %%%% '(ZU\,/!GB&]:\U'0H7N7.7DB=XBY]6V$9/UK>
MT?0]+\/V(LM)L8+.W!SLA3&3ZGU/N:T** ,#Q%X)\-^*RK:UI,%U(@PLO*2
M>F]2&Q[9J/P_X"\+^%IC-H^CP6\Y!'G$M))@]1O8DX_&NCHH QO$'A31?%*V
MBZS9FY%I+YT/[UTVOZ_*1G\:L:YH6F^)-)ETO5K?[19RD%X][)G!R.5(/7WK
M1HH J6>F6=AI,&EV\"K900K!'$Q+ 1@8"G.2>/6N1G^#W@*XO#=/X>A5R<[8
MY9$3_O@,%_2NYHH J:=IECI%DEEIUI#:6R?=BA0*H_ 5E?\ "%>'_P#A+_\
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M%+110 4444 %%%% !7.>$?\ DGVC_P#8.C_] %='7.>$?^2?:/\ ]@Z/_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\)ZB^O7MEX@TJXMGAGD@@$,UL6& V  &7)&>_/:NA^!?_))M+_ZZ3_\ HUJ
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M **** "L+Q!_R%?#7_83/_I+/6[6%X@_Y"OAK_L)M_Z2SU<-_O\ R$]AL_\
MR/\ I_\ V"[K_P!&P5OU@3_\C_I__8+NO_1L%;]$MD""BBBH&%%%% !1110!
MQ7Q7\1MX9^'FI7,+E+JX46EN0<'>_&1[A=Q_"MWPKI;Z)X4TO39'9Y8+9%E9
MF)+/C+')_P!HFO./C&[W_BWP'H>-T%QJ2R3)C((#H,_@"_YUZMJ+M'IEVZ,5
M987((."#M- %FBOGOX87'CKQYH-Q9+XGN["QMYCY^H,YFN968#"(6/R@#G(/
M>M0ZCXN^&'C_ $32M3U^?7M$UB40J]US(C%@I.2205+*>N"#TST /<**\_\
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M5N9-&U+P]?R2/>Z)>/;$RMEFC))4GU[UZ-7D.BO_ &1^T?K=C",1:E8K._\
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M .H:5#@@$\USOA?XZ>']&\+:7IL^D:U)+:VR1.\4,95B!C()<<4 $?BGQO\
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MZ4 >K5RWB+QU8>'?$NBZ#-;3RW>K2K'$4P$0%@I)/X],5Q_@?7O$>D_$W4O
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M#W B8-CZ[Z ,CX*6D%A\0_'%I:Q"*"&58XXP3A5$C@#GFG^!"UO^T5XPBNW
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MINO_ (W1_P )AI/]S5/_  4W7_QNMZBB\.WX_P# #4P?^$PTG^YJG_@INO\
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MS5/_  4W7_QNMZBB\.WX_P# #4P?^$PTG^YJG_@INO\ XW1_PF&D_P!S5/\
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MQ?\ \_VA_P#@%+_\=K?HHYWV"Q@>3XO_ .?[0_\ P"E_^.T>3XO_ .?[0_\
MP"E_^.UOT4<[[!8P/)\7_P#/]H?_ (!2_P#QVCR?%_\ S_:'_P" 4O\ \=K?
MHHYWV"Q@>3XO_P"?[0__  "E_P#CM'D^+_\ G^T/_P  I?\ X[6_11SOL%C
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M_P _VA_^ 4O_ ,=K?HHYWV"Q@>3XO_Y_M#_\ I?_ ([1Y/B__G^T/_P"E_\
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M:-_\9H^W^*/^A?T__P &C?\ QFM^BCF7;\_\PMYF!]O\4?\ 0OZ?_P"#1O\
MXS1]O\4?]"_I_P#X-&_^,UOT4<R[?G_F%O,P/M_BC_H7]/\ _!HW_P 9H^W^
M*/\ H7]/_P#!HW_QFM^BCF7;\_\ ,+>9@?;_ !1_T+^G_P#@T;_XS1]O\4?]
M"_I__@T;_P",UOT4<R[?G_F%O,P/M_BC_H7]/_\ !HW_ ,9H^W^*/^A?T_\
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M_I__ (-&_P#C-;]%',NWY_YA;S,#[?XH_P"A?T__ ,&C?_&:/M_BC_H7]/\
M_!HW_P 9K?HHYEV_/_,+>9@?;_%'_0OZ?_X-&_\ C-'V_P 4?]"_I_\ X-&_
M^,UOT4<R[?G_ )A;S,#[?XH_Z%_3_P#P:-_\9H^W^*/^A?T__P &C?\ QFM^
MBCF7;\_\PMYF!]O\4?\ 0OZ?_P"#1O\ XS1]O\4?]"_I_P#X-&_^,UOT4<R[
M?G_F%O,P/M_BC_H7]/\ _!HW_P 9H^W^*/\ H7]/_P#!HW_QFM^BCF7;\_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img76291469_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *("#0# 2(  A$! Q$!_\0
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MRP@N;M+B-O+EME!\L%20YST K(\":Q<W&EV]I<6M]*2'=KZ3YHV.>FXG.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ><^%]"TO6=6U\ZC917)BNR$+Y^7);/\
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M8T:RURQ-I>QEDSN5E.&0^H/K0F#B]2'Q0(#X7U+[1CR_(;KZXX_7%5? ^?\
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MXA!H-M';H$VVRA HZ';7-?#01_V%='C[5]J;SO[W;&?U_6NP@B%O;Q0@DB-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $*VMNER]RL$
M2SN,-*$ 9AZ$]:FHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH KWEC:ZA 8+RWBGB/.R10PJG8^'-&TV;SK+3+6
M"4='2,9'XUJ44"L@HHHH&%%%% !1110 4444 13VMO=!1<013!&W*)$#8/J,
M]ZEHHH **** "BBB@ HHHH CGMX;F%HKB*.6)NJ2*&!_ T]55$"(H55&  ,
M"EHH **** "BBB@ HHHH BGMX+J(Q7$,<T9Y*2*&!_ U(JJBA5 50,  8 %+
M10 4444 %%%% !1110 4444 %%%% !1110!4O]+L-4C$=_9PW"CH)$!Q]*BT
M_0]*TIBUAI]O;L1@M&@!_.M"B@5D%%%% PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B>UMY)XYY((GFCX2
M1D!9?H>HJ6B@ HHHH **** "JE_I=CJD0COK2&X0=!(@./I5NB@#/T_0M*TI
MBUAI]O;L>"T: '\ZT*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **1F5%+,P4#J2<5!]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?;[/_
M )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\ ?P4?
M;[/_ )^X/^_@H L457^WV?\ S]P?]_!1]OL_^?N#_OX* +%%5_M]G_S]P?\
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M8G5;F[L+F",@S6R1%=H)QPW4]:5A\QV]%8FK^(HM+\-#5Q$7\Q$,,1.-S,.
M:RI!XTBTYM1:^L-ZIYILO(XQC.W=G.<46&Y'845RUUXDFNO $NN66(+CRP0"
M-P1MP!'/7O5.RF\8ZQI$-_;7=E:AHP4C>+<TW^T3T7/8"BPN8[6JEEJ=EJ1G
M%G<)-Y#^7(4Z*WIFL+1-7U+Q+X:E>"2.RU&.7R7D,>]001D[3ZBL+P);:H\]
MY);W\4=M'>D7,1A!,I[D'^&BP<VUCT6BBH7O+6-RCW,*L.JLX!%(HFHJO]OL
M_P#G[@_[^"C[?9_\_<'_ '\% %BBJ_V^S_Y^X/\ OX*/M]G_ ,_<'_?P4 6*
M*K_;[/\ Y^X/^_@H^WV?_/W!_P!_!0!8HJO]OL_^?N#_ +^"C[?9_P#/W!_W
M\% %BBJ_V^S_ .?N#_OX/\:ECECE&8Y$<>JL#0 ^BBF2310C,LJ(/]I@* 'T
M57^WV?\ S]P?]_!_C1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W\%'V^S_Y^X/^
M_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W\%'V^S_Y
M^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W\%'V
M^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W
M\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/
MW!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9
M_P#/W!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15
M?[?9_P#/W!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@
M"Q15?[?9_P#/W!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_
M[^"@"Q13(Y8YDWQ2*Z],J<BL_P 17#VOAO4IXCATMW*GT.* ,:Z\8SW&H2V/
MA_2WU*2$[99M^V)3Z9[U&OC*]TVZCA\1:.]A%*VU;B-_,C!]S5KP#:QVWA"S
M=!\TVZ1SW)R1_("K7C&VCN?">HK( =D1D4GLPY!JM+V(UM>YM@AE#*001D$=
MZ6N)M]6O;3X617\$H6ZBA"J[+NQA]O0^U36<GBW6=,@OK>\LK)7C!CC>'>TG
M'WF/\.>N .!2L/F.PHKG?#7B.34[&\&HQK!>6#E+D+]WC/S#\C^59VG7_B7Q
M-"^H:?=6NG6)<K LD/F/( >I]*+!S([.BN=\,ZY=ZA-?:=J<<:7]BX5VB^[(
MIZ,!VZ5A:#J_BKQ MW%;W5K$L,Q!NI(<D#L@4=?4DT6#F1W]%<KX?UK5?[?N
MM!UD0R7,4?FI/",!UXZC\?YUU5#5AIW,/6M<FTO5M'LXX$D6^F,;LS$%!QR/
M7K6Y7'^+O^1F\+?]?9_]EK6\0WFL6\5M#HUF)IYY-C3/RD"_WB,\T6%?<VJP
MO$.O3:-<Z7%% DHO+D0L68C:..1Z]:R-1U+Q#X9GLIK^\MM0L[B989 L'ELA
M/I@\]Z9\0I6@ET*9(S(Z7>Y4!^\1C _$TTM1.6AV]%<CJ)\86%C)J8O;&7R@
M9)+)8#@*.2 V<G ^E6Y?%MNG@Y=?$1.Y,+#G_EIG&W/U[^E*P^9'1UGZYJ#Z
M3HEW?QQK(\$9<(QP#^-<_CQHVG?VC]NL4?9YOV+[/D8QG;NSG-&H:RFO?#6\
MOU3RV>!@Z9SM8'!%%@YCH]'OGU+1[.]D18WGB60JIR 2.E-UN_?2]%N[Z.-9
M'@C+A&. :K^%O^15TO\ Z]D_E3/%W_(I:G_UP-'4+^[<QK/Q%XLU"SBN[7P_
M:/!*-R-]K R/H:W=$N]9NA/_ &OIL5EM(\KRYA)OZYSZ=JY?P]XJEL/#]E:K
MH.J7 CCP)8HLH_/4'/2NITC5I-:MIV-A>:>R'8/M* $Y'4#O38HN_4U:*X_3
M/$=YIFKW>D^)9HPZJ9;>Z"!%D0?3O_\ 7%2:+?Z[XA6]U"*=+.QD4I8(\(8D
M_P#/1O4>U*P^9'0V^IV5W>7%I;W"23VQ F1?X">Q]ZMUYMX;M-9?Q/K2V^IP
MQS1SK]J<VX(FY.<#^'O70:EK.J7OB)M"T,P1/#&)+FZF7<$ST 7N:&@4M-3J
M:*Y&/5M:T37[+3M9FM[RVOB4BN(H_+97'8CIW'YU%K>NZW;>,X-*TWR9%F@R
ML<B\!CGYBW7 QG%%@YD=G17$7VJ>)/#5W9S:I<VM]8W$HB?RHO+9"?3_ #VK
M2\5:_=:7/I]A8^3'<WSE1//]R(#')]3S18.9'2UBW^I:K;^(+.SMM+,]C* 9
MKK=_JN3V_ ?G6:LOBS3-0M//:'5K.=]LI@A$;0C^]UY%3ZKJ]]:^-='TZ&55
MM;E',J% 22 <<]J+ V=+17,^(=?O8-5M=$T>*-]0N%WF27[D2>I'?H:HZAJ'
MB?PQ$E_J$]KJ5B&"S+'%Y;Q@]QZT6!R1VE%<WXKUNXL?"?\ :>F3JC.8RDC(
M&&UCZ'VJ@TOC*YTL:I#<V5NOE"1;1HMS,N,\MV)ZX%%@<CLZ*R/#.M'7M"@O
MFC$<C$K(HZ!@<''M6N2 ,G@4BD[A15?[?9_\_<'_ '\'^-'V^S_Y^X/^_@H
ML457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W\%'V^S_Y^X/^
M_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W\%'V^S_Y
M^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W\%'V
M^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/W!_W
M\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9_P#/
MW!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15?[?9
M_P#/W!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@"Q15
M?[?9_P#/W!_W\%'V^S_Y^X/^_@H L457^WV?_/W!_P!_!1]OL_\ G[@_[^"@
M"Q15?[?9_P#/W!_W\%'V^S_Y^X/^_@H L45''<0S'$4T;_[K U)0 44UY$C7
M<[JJ^K'%0_;[/_G[@_[^"@"Q15?[?9_\_<'_ '\%'V^S_P"?N#_OX* +%%5_
MM]G_ ,_<'_?P4?;[/_G[@_[^"@"Q15?[?9_\_<'_ '\%.CN[:5PD=Q$['^%7
M!- $U<SJWBQ[;5#I.E:?)J-^HS(JMM2,>Y_&NFKA+JRUKPWXIO=7T_3_ .T;
M2]YD1#\Z=SQ]?K31,FRQ)XQU32)H_P#A(-#-K:R,%\^&42*I]Z[)6#J&4@J1
MD$=Q7&KXVT/46%CK5A+:EB,QWD(9,^O_ -<BM_6KN\T_1FDTBQ^UW'RI%$F,
M 'OU' %#0)^9J54U34(M*TNYOY@3' A<A>I]JY75+GQ9H.E?VK<7]G=)'@S6
MWV?: "<<,#GO3_&7V^]\+27T%TD5@UJ'FMFC#,^2",-VZT6!RT-+P[J^L:OB
MXO-*BM;*2/?#(LVYFYX!';BN@KD= FO](\-KJ6HW\<VGQV:O% D(5DXX&[OZ
M4RQE\7ZU8KJ4-[96,<PWPVS0;\KVW-[T-"3T.P9@JEF(  R2>U5K#4;/5+<W
M%C.L\(8IO7ID=:YJSU?4O$?ANX\B:*PU"VE:*YS'O4@ Y !Z9_3%9W@"VU63
M1UEM]0CBL=\J^0806#XX;=]<'%%A\VNAZ!17,^#M;O-3M[RTU1E.H6<QCDPH
M7([''X$4EKJ]_J7CBYLK655TRQCQ/\@)>0]L]O\ ZU%@YD=/7'3^*=;E\17V
ME:9I-O<FUY)>?82O'//'4UV->;0ZJ^D?$'6YDL+J]+J$V6R;F7[IR?:A!)VL
M=+8:EXJEOX8[W0K:"V9L22K=!BHQUQWKI*Y_2_$\NI:A':MH>IVH<$^=/%A!
M@9Y-9[ZWK.O:W=V&@O!:VUDVR6ZF3>6?T _ _E18$TCL*P=4UZ:P\2Z5I:6\
M;QWN[?(6(*8]!WK.M]<U?1]?MM*UXP7$5YQ;W<*;/F]&'^>M1^(_^2@>&O\
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M3NKCZ*YWP5JMYK/AY;N_D62<RNNY4"C /' J/2M8OKKQMJ^FS2JUI;1JT2!
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MBO8?[?TJU!X>M -]YNNYV^\\I)&?85%'$G_"82MCD6P;\<X_E6Y0Q)7W,_\
ML+2_^?&'\J/["TO_ )\8?RK0HHN.R,_^PM+_ .?&'\J/["TO_GQA_*M"BBX6
M1G_V%I?_ #XP_E1_86E_\^,/Y5H447"R,_\ L+2_^?&'\J/["TO_ )\8?RK0
MHHN%D9_]A:7_ ,^,/Y4?V%I?_/C#^5:%%%PLC/\ ["TO_GQA_*C^PM+_ .?&
M'\JT**+A9&?_ &%I?_/C#^5']A:7_P ^,/Y5H447"R,_^PM+_P"?&'\J/["T
MO_GQA_*M"BBX61G_ -A:7_SXP_E1_86E_P#/C#^5:%%%PLC/_L+2_P#GQA_*
MC^PM+_Y\8?RK0HHN%D9_]A:7_P ^,/Y4?V%I?_/C#^5:%%%PLC/_ +"TO_GQ
MA_*C^PM+_P"?&'\JT**+A9&?_86E_P#/C#^5']A:7_SXP_E6A11<+(S_ .PM
M+_Y\8?RH_L+2_P#GQA_*M"BBX61G_P!A:7_SXP_E1_86E_\ /C#^5:%%%PLC
M/_L+2_\ GQA_*C^PM+_Y\8?RK0HHN%D9_P#86E_\^,/Y4?V%I?\ SXP_E6A1
M1<+(AMK6"SB\JWB6./).U>F33-1LUU#3;FS<X6>)HR?3(QFK-%(9Y]X8\11>
M&8'T+Q!NM)+=SY4K*2C*3GJ/T/O4GB7Q3;Z[9'1- W7UQ=X1VC4[47//)_GT
MQ7;SVMO=*%N((IE'02(&'ZT6]I;6H(M[>*$'J(T"Y_*JNMR.5VL<KXBTY=*^
M&DU@&SY,**6]3N&3^>:ET;Q?HT.@6JWE[';3P0JDD,APX( ' [YZC'K5_P 8
M6=SJ'A6^M;2%IIY% 1%(!/S#UJQ8Z7;-IE@+RQ@>XBMXT/F1JS*0HR,T=-0L
M[Z',>%;"?4[?Q#J;1M"FJLZP!QC*D-S^OZ&L70+3PU]@-MK=S-8ZE;LR31/<
MO$#@]0,X_*O50   !@"JT^GV5TX>XM+>9AT:2,,?U%','(<MX)CTZ2ZU&[TR
MQGBMPPB2ZFG9_M !)R 1Q_\ 7J+X;$&RU7!!_P!-:NV1%C0(BA5 P !@"HH+
M6WM0PMX(H0QW,(T"Y/J<4KC4=CDK<C_A;-V,C/V <?\ ?-7;KP+I5W<SW$D^
MH!YG9V"73  DY.!VKH1:VXN3<B"(3E=IEV#<1Z9ZXJ6BX<JZG&^+ L?B3PHF
M>ET0,G_=J/QKJ$L.K:98W-Y-8Z1.&-Q<0DJ6/]W=V'3\Z[&6V@GDCDE@CD>(
MYC9T!*'U![4LT$-Q&8YXDE0]5=0P_(T7!QW/*/$"^'H6L$T6ZEN9/M*&:4SO
M(BC(P"2<9/Y\&ND^(<QMYM"F5#(T=YO"+U;&#@>]=:--L! (!96WE!MXC\I=
MN[UQCK4LMM!.T;30QR-&VY"Z E3ZC/0T[BY=SF=9\::)_8-PUO>QSSS1,D<"
MGYRQ&,$=1C-8USH%]'\+(;7R6-U$PN6AQ\V-Q)&/7!KNQI]D+C[0+.W$^<^:
M(EW9]<XS5FE>VP^6^YYFJ^"#I/VPW]QY@3)MS>.'W8^[C/KQ6F\,<'PMO6CL
M'L$EB:0022EV&3U)('7KBNO.FV!G\\V5MYN<^9Y2[L_7%3RQ1SQ-%-&DD;##
M(XR"/<&G<2B9?A4Y\*:61_S[)_*H_%YQX1U,G_G@:V8XXX8UCB14C4855& !
M["DEBCGB:*6-9(V&&5QD$>XI7U*MI8XOPUXNT"P\-V-K=:E%'/%'M="&.#D^
M@KI=-U_2M8$QL+V.80 &0@$!0<]<CV-2?V-I7_0-L_\ OPO^%2Q:=90QR1Q6
M=O&D@Q(J1* X]#@<T.PDFC@[^WF^(=]=-:NL>FV*LEO-M_UTI]_[O_UJWO!V
MO_VC:-IMV@@U.Q'ERP],@<!@/T__ %UT<%O#;1"*WACBC'1(U"@?@*8+*U6Z
M-T+:$7!X,HC&\_CUHN"C9W.'T'5+'2_&WB**^N8[=Y[A1$)#C?SV_,54U2PT
MVU\=7AUUYH;.\17M[A9&C4-P"I(_K_6O0I;"SGF$TUI!)*,8=XP6&.G)%236
M\-S'Y<\,<J?W9%##\C3N+ET//K>V\./XFT^TTF&XU*17\UYQ>,R6^.<G.0?I
M5^Z(_P"%MV(R,_8VX_!J["WM+:T4K;6\4*GJ(T"@_E2FUMVN1<F"(SJ-HE*#
M<!Z9ZT7#E.2^(Q TG3LD#_3X_P"1JSXPOM)@:RM-;TYYK.=C_I/\,+>Y'(X]
M*Z2>VM[I56X@CF53N D0, ?7GO3I8HYXS'+&DB'JKC(/X4KC:W/+Y39:5J^F
MIX1U:>YEFF"RVJRF1-G<GT_R:Z#72!\2/#PR,^7)_(UU=O86=H2;:T@A)ZF.
M,+G\J>]K;R3I.\$331\)(R LOT/44[BY3C-><Z#X[LM=N48Z?+!]GDE49$1Y
MY/YC]:7Q;XETW4-"DTS2[A+Z\O-J1Q0?,>H.3Z=*[5T61"CJ&4C!5AD&H8-/
MLK5R]O:6\+'JT<84_H*5Q\K.-\96K:=\,H[25AOA2%&.>XQFNJ3_ )%U?^O3
M_P!DJW/;0741BN(8YHSR4D4,#^!I^Q=FS:-F,;<<8]*+@EJ<G\-R#X0C(((\
MZ3^==:0&!!&0>"*C@MH+6+RK>&.&,'.R-0H_(5+0W=C2LK&<-!TH# L8?RI?
M["TO_GQA_*M"BB["R,_^PM+_ .?&'\J/["TO_GQA_*M"BBX61G_V%I?_ #XP
M_E1_86E_\^,/Y5H447"R,_\ L+2_^?&'\J/["TO_ )\8?RK0HHN%D9_]A:7_
M ,^,/Y4?V%I?_/C#^5:%%%PLC/\ ["TO_GQA_*C^PM+_ .?&'\JT**+A9&?_
M &%I?_/C#^5']A:7_P ^,/Y5H447"R,_^PM+_P"?&'\J/["TO_GQA_*M"BBX
M61G_ -A:7_SXP_E1_86E_P#/C#^5:%%%PLC/_L+2_P#GQA_*C^PM+_Y\8?RK
M0HHN%D9_]A:7_P ^,/Y4?V%I?_/C#^5:%%%PLC/_ +"TO_GQA_*C^PM+_P"?
M&'\JT**+A9&?_86E_P#/C#^5']A:7_SXP_E6A11<+(S_ .PM+_Y\8?RH_L+2
M_P#GQA_*M"BBX61G_P!A:7_SXP_E1_86E_\ /C#^5:%%%PLC/_L+2_\ GQA_
M*C^PM+_Y\8?RK0HHN%D9_P#86E_\^,/Y4?V%I?\ SXP_E6A11<+(RIO#NGNN
M88C;R#E9(B00:IC6;C38Y[2]'FW<6/)8?\M@>!70UB:K$C:]I3$<EFS^'(H0
MFK;"V^ABYQ<:J[7$[<["<(GL!5G^PM+_ .?&'\JT:*+CLC/_ +"TO_GQA_*C
M^PM+_P"?&'\JT**+A9&?_86E_P#/C#^5']A:7_SXP_E6A11<+(S_ .PM+_Y\
M8?RJ2WTJPM9A-!:QQR $!E'/-7**5PL@KBE\57.B>*+ZR\0RE+)SNLYA%A0O
MN0.>./8BNUJ.>W@N4V3PQRK_ '9%##]::!I]#@O%_B'2->TH:9I>-1OIG7RA
M"A.SGKG'X?C5OQ1<ZCH?A72K6.:2!/W<%W<Q#+1J%YP>V?7V]ZZ^WLK2T)-M
M:PPD]?+C"Y_*I7C25"DB*Z,,%6&0:=Q<K/*?$2>%HM"F_LR_GO;U@"&-R\FU
M<\LPZ ?7OBNM\0$?\*RF.1C[#'S^"UT*Z9IZ121)8VRQR##H(E ;ZC'-2O;P
M26_V=X8V@V[?+905QZ8Z8HN+E.9:REU+X9QVEN-TLEBFP#N0 <?I7-:3%X/F
MTB.2_OI[6[C3;/"]TZ,K#KA<_P J].CC2*-8XT5$4855& !Z 57ETVQGF\V:
MRMY)/[[Q*3^9%"8.)S?A"&W;0+ZXLM-GM(KAFV"68R-* ,!N1QFJ?PYU2Q71
METQKJ,7OG2,("?F(Z]*[H    8 [572PLX[C[0EI LYS^\6,!N>O.,TKCY;6
M.)\13OX3\6C6XD)M[Z!HY5'3S%'!_0?K6YX+TM].T!);@'[9>,;B<GKEN@_*
MJ_BC3;W6]9TFQ6V8Z;')Y]S-D8XZ+USZ_G75=*;>@DM0KA_#Y!^)FOC(SY0X
M_%:[BH4M+:.X>XCMXDFDX>14 9OJ>II)E-7)JX#0K^#PIX@U?3M7<6R7,YGM
MYWX1P2>,_C_.N_J*>VM[I-EQ!',G]V1 P_6A,&KZG#ZQ?0>*?%.C6>DN+F.S
MF\^XGCY5 ".,_A^M6?$9 ^('AH9&3YE=?!;6]JFRW@BA3^[&@4?I1):V\L\<
MTD$3RQ_<=D!9?H>U.XN4X_Q40/&WA<$C)E;^E-\4[]'\7Z5X@EC=[%$,$S*,
M^7G/)_[Z_2NRDM;>:6.66")Y(SE'9 2GT/:I&574JRAE(P01D&E<.4XWQ1XJ
MTF[\/SV>GW4=[=W:^5%#!\S$D]2.U7E\/N_@!=&G ,_V7&.N)/O ?G6Y!IUE
M;2>9!9V\3_WHXE4_F!5FB_8+=SS3PK<R>(M<TD3 E-'LR'SWD)V@_D!^55=:
M:;3=8USP_;+SK$L30X[;C\W]1^%>G06=K:L[6]M#"SG+F- N[ZXZTKV=M+<)
M<26\+SI]R1D!9?H>HI\VHN30S;SPW97VD6NF2M,D%OMV>3(8SP,<D4S2_#-G
MHHN6LY+IWFCV$3S%QWQC/3K6W12N59'GW@G7],T;1)M.U2[CL[J"=]\<QVG'
MM4GA.]34/'NMW4:LJ2PJR!QABN1@X[9Z_C7:2Z?97$PFFL[>24='>)2?S(J1
M+6WCN'N$@B69QAY @#,/<]33N2HO0X6/5K72/B5J\MZ_EP2Q1QF8CY4.U2-Q
M[ ],T>*M3M?$]QIVBZ1*MW(;A997BY6-1W)_$_E6K8:5<CQSK-W<VF;&X@1$
M=\%7("Y&/P[BNCM[.UM 1;6T,(/7RT"Y_*BZ!)M6)ZJW6G6=ZZO<VZ2LHP"P
MZ"K5%269_P#86E_\^,/Y4?V%I?\ SXP_E6A13N*R,_\ L+2_^?&'\J/["TO_
M )\8?RK0HHN%D9_]A:7_ ,^,/Y4?V%I?_/C#^5:%%%PLC,D\/:7(A M5C/9H
MR014%I/<Z9J":?=RF:&7_CWF;KG^Z:VJQO$?RVEM*/OI<IM/I0A-6U-FBBBD
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5%-;PW&SSHU?8P9=PS@^M2UG:UK,
M&AV/VNXCD=-P7$8!/ZD4 :-%<;_PLG2O^?2]_P"^5_\ BJ/^%DZ5_P ^E[_W
MRO\ \50!V5%<;_PLG2O^?2]_[Y7_ .*H_P"%DZ5_SZ7O_?*__%4 =E17&_\
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M_P ^E[_WRO\ \50!V5%<;_PLG2O^?2]_[Y7_ .*H_P"%DZ5_SZ7O_?*__%4
M=E17&_\ "R=*_P"?2]_[Y7_XJC_A9.E?\^E[_P!\K_\ %4 =E17&_P#"R=*_
MY]+W_OE?_BJ/^%DZ5_SZ7O\ WRO_ ,50!V5%<;_PLG2O^?2]_P"^5_\ BJ/^
M%DZ5_P ^E[_WRO\ \50!V5%<;_PLG2O^?2]_[Y7_ .*H_P"%DZ5_SZ7O_?*_
M_%4 =E17&_\ "R=*_P"?2]_[Y7_XJC_A9.E?\^E[_P!\K_\ %4 =E17&_P#"
MR=*_Y]+W_OE?_BJ/^%DZ5_SZ7O\ WRO_ ,50!V5%<;_PLG2O^?2]_P"^5_\
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MDZ5_SZ7O_?*__%4 =E17&_\ "R=*_P"?2]_[Y7_XJC_A9.E?\^E[_P!\K_\
M%4 =E17&_P#"R=*_Y]+W_OE?_BJ/^%DZ5_SZ7O\ WRO_ ,50!V5%<;_PLG2O
M^?2]_P"^5_\ BJ/^%DZ5_P ^E[_WRO\ \50!V5%<;_PLG2O^?2]_[Y7_ .*H
M_P"%DZ5_SZ7O_?*__%4 =E17&_\ "R=*_P"?2]_[Y7_XJC_A9&E?\^E[_P!\
MK_\ %4 =E17'#XC:6?\ ETO?^^5_^*H_X6-I?_/I>_\ ?*__ !5 '8T5QO\
MPLC2O^?2]_[Y7_XJC_A9.E?\^E[_ -\K_P#%4 =:+>$7)N!&OG%=I?'./2I:
MY[0_%]CKU^]I;07".L9D)D4 8R!V)]:Z&BXW%K<****!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %126\,LL<LD:M)'DHQ'*Y]*EJK<7T=O=V
MULRL7N"0I'08&>: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5%/;PW*!)XUD4,& 89P1T-2U5O[Z/3X%EE5V5G"
M+UR: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<G\0O^1<'_75?ZUUE
M<G\0O^1<'_75?ZTT)GE=%%%,04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M0>E%!Z4 2PL'X_B%3&/BL\L58,IP1T-:=K,MS'QPZ_>6@"LZ8J,BKTD=573%
M '4?#G_D99_^O5O_ $):]3KRWX<_\C-/_P!>I_\ 0EKU*LX]3IK_ &?1!111
M5& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/J?\ R'-)_P!Y
M_P"5;%8^I_\ (<TG_>?^5-"9L4444AA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5C>)?^0=#_U\Q_SK9K&\2_\ (.A_Z^8_
MYTUN)[&S1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R?Q"_Y%P?\ 75?Z
MUUE<G\0O^1<'_75?ZTT)GE=%%%,0445W/ACP?I>LZ%'?7;7 E9F!V2;1@''3
M% '#45Z);^#_  G?.8;34Y))L'"I<JQ^N,5SNH^%GTGQ'8V$\C2VEW*JI*OR
MDC(!!]",TAG.T5UOC'PS8:!:VLEF9RTLA5O,?=P!FN2IB"BBB@ HHHH ***G
ML85N=0M8'SLEF2-L'!P6 /\ .@""BNN\8^&-/T"TM9;,SEI92C>9)N&,$UR-
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ H/2B@]* (6J!ZG:H'H A:GV=\]C/O7YHVX=/4?XTQJ;#;R7<ZPQ#+'OV
M]30!Z-X$GAD\4RS)(OEM9$@DX_B%>E?:(?\ GM'_ -]"O+? NEVO_"12VCIY
MD:VA;D]6W#)KT3^P-+/6T7_OH_XU$>IT5[^[Z(T$ECD)"2*Q'H<T^L+3+6&T
M\17L,$82,1)@"MVFS!!1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "L?4_\ D.:3_O/_ "K8K'U/_D.:3_O/_*FA,V****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO$O\ R#H?^OF/^=;-
M8WB7_D'0_P#7S'_.FMQ/8V:***0PHHHH **** "BBB@ HHHH **** "BBB@
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M<?$?4)('2WL+>"1O^6F\OCWQ@<US-AJU[INH_;[><_:"279^?,SU#>N:I44
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M1-16]MXXWD52NV3.,'Z50HH DNY3>74UQ*J[I9&D( X!)R<5#Y<?]Q?RIU%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %8^I_\ (<TG_>?^5;%8
M^I_\AS2?]Y_Y4T)FQ1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6-XE_P"0=#_U\Q_SK9K&\2_\@Z'_ *^8_P"=-;B>
MQLT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<G\0O^1<'_75?ZUUE<G\0
MO^1<'_75?ZTT)GE=%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E%
M!Z4 0M6C96PMQYCC,I'_ 'R*@@0*V]NO;VJR9.* )))*J.^:5WS4)- '6_#K
MGQ-/_P!>I_\ 0EKU*O+/AS_R,L__ %ZM_P"A+7J=9QZG37^SZ(Q[7_D:+_\
MZXI6Q6/:_P#(T7__ %Q2MBK9SH****0PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Q]3_Y#FD_[S_RK8K'U/_D.:3_O/_*FA,V****0PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO$O_ "#H?^OF
M/^=;-8WB7_D'0_\ 7S'_ #IK<3V-FBBBD,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KF_&=FVH:7!:(ZHTMPJAF&0.M=)6/K_ /S#_P#K[2FA/8XS_A6FH?\
M02M?^_3?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#
M_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN
M%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?
M^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6
MO_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3
M_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?
MXT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?M
MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6F
MH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\
M*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]
M+HHN%CS3_A6FH?\ 02M?^_;?XT?\*TU#_H)6O_?MO\:]+HHN%CS3_A6FH?\
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M*U_[]M_C2?\ "M-0_P"@E:_]^V_QKTNBBX6//?">D2Z'XXN+&:9)7%COWHI
MP6''/TKT*N4@_P"2HW7_ &#%_P#0ZZNHCU.BO]GT1CVO_(T7_P#UQ2MBL>U_
MY&B__P"N*5L5;.=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5C>)?^0=#_ -?,?\ZV:QO$
MO_(.A_Z^8_YTUN)[&S1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/
MJ?\ R'-)_P!Y_P"5;%8^I_\ (<TG_>?^5-"9L4444AA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>)?^0=#_U\Q_SK9K&\
M2_\ (.A_Z^8_YTUN)[&S1112&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?C
M3_D$Q?\ 74?R-=)7-^-/^03%_P!=1_(UCB/X,_1_D:T/XL?5?F<+1117R9]*
M%!.!FBK6F69U#4[>U'1W^;_=')_2JC%R:BMV*344VRW%X:U>:%)4M5V.H9<R
M '!]JRB""01@@X(KU!M1BBUB'3 !N>$R ^F#P/Y_E7">);/[#K<X"XCE_>K^
M/7]<UW8O"0I0YJ;O9V9Q8;$SJ2Y9JVET91('4XH((.""#Z$8KMO#.@O:EKN[
M2"02(K1'[Q7OW'':LOQ)HMU!<W>INT7D/(, $[N<#TK.6"J1I*J_N[+N:1Q<
M)5?9HYVBMNP\+WM]:"Z:6*WB8;E,F22/7V%,U+PW>Z;;?:=\<\ Y9X_X1ZX]
M*R^K5N7GY=#3ZQ2YN7FU,>BKFG:9=:K<&*V0';R[L<*H]ZUI_!E_%"SQ3PS,
MO\ !4GZ9I0P]6<>:,;H<Z].$N64K,R+#3+S4VD6TC5S& 6RP7&>G7Z5#<VTM
MI<R6\ZA98SA@#G'&>OXUK^'(]4,]TNFO#%(%42"8>YP/KUJCJ,5Y)K4T,X66
M\9PI$0X8X&,?A52IKV,9I.[?R^1*J/VKBVK)?,HT5TD?@J_:,,]S;QN1]S!.
M/QK#OK&XTVZ:WN4VN!D8Y##U%34P]6FN:<;(J%>G-VB[LKT5T%IX0U"Y@662
M2*WW<A'!+8]\=*H:KHEWI#*9PKQ.<+*G3/H?0TY8:K&//*+L*->E*7*I:F=1
M6Q#X:U"XTY+V+RG1TWJ@8[C[=,9JX/!=^8MWVFW\S&?+P>#Z9_\ K4XX2M+:
M+$\326\CFZ!R,CITS6KINA7=[?2P%41K9U\Y)"1QGH,=>!76:]H<E_8V]M8K
M!$L<FXJ?E&,$=A[UI2P=2I!S2V_$BIBH0FHOK^!Y]3D1Y9%CC1G=CA549)-.
MGB:WN)87QOC8HV.F0<5I^'M2L]*O);BZ21F*;8]B@X]?Z5STX*4U&3LC><FH
M.45<%\+ZRR!OL@&1G!D7/\ZS)K>:WG,$T3QS @;&&#STKHU\0WU_XE@%E(XM
MF=5$)4<K_$3^M7O%Z1>=I;''G&X"CU*Y&?UQ79+#494Y3I-^Z[:]?0Y8UZL:
MD85$M5TZ'-_V#J__ $#IO_'?\:CFT?4K>%YIK*5(T&68XP!^==QK]WJEN;5-
M+B\QY"V\;-V  /<8KF=5U77EM6MM1@6**8;2?+Z_0@D9IU\+1I77O:>6A-'$
M5:EG[NOWF!115[3-*N-6FDBMVC5HU#'>2.,X["N",7-\L5J=LI**O+8HT5T,
M'@[49FD$DD,(1MH)RV_W'M43>%-26_6U C967=YXSL ]^^?:MOJE>U^5F7UF
MC>W,C#HK=O\ PG?V-JUPLD<ZH,LJ @@>O/6LBTM9KZY2WMDWR/T&>,>I/I43
MHU(249+5EPJPG'FB]"&BNCF\&7\<#.EQ!(X&?+ ()]@35#4= O-+M%N;AH2C
M,%PC$G)_"KGA:T%>428XBE)VC(RZ***YS8**** "BBB@ HK5@\.W]U8P7</E
M-',< ;CE1SR>.!Q5D^%+EX'DM;VUNF3JD9Y^F:W6&K-743%XBDG9R,&BD)V_
M>X/3!XHWK_>'YU@;"T %F"J"68X  R2:0,IZ,/SK9TK5K32+&:86HFU$L1&S
M#A%QZ_7/2KIQC*5I.R(FY17NJ[,^ZL+NQ"&ZMWAWYV[L<TVUL[F]D:.U@:9U
M&XJN.!^-=)XP=I;72I&QN968X]2%J#P8VS4KM_[MOG]:Z7AHK$^QOI_P+F"K
MR]A[6VO_  ;&;_8.K_\ 0.F_\=_QJG<6L]G-Y-S$T4F =K8SBM%+SQ%-#Y\<
MFH-$>0P4D8_*LV>XFNI3+<2O+)C&YSS@=JRJ*DE[J=_.QI!U&_>M\B.BBBL#
M8**** "BBB@ HHHH **** &FH7J8U"] $]I>")O*E/[L]#_=_P#K5?=*PI*M
MZ??A2+:=N#PC'M[&MH2Z,SG'JC=\'C'C6X'_ $Y?^S"O1:\\\*#'CBX'_3C_
M .S"O0A7T>$THQ/&Q_\ %^2,BU_Y&B__ .N*5L5CVO\ R-%__P!<4K8KJ9PH
M****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q]3_ .0YI/\ O/\
MRK8K'U/_ )#FD_[S_P J:$S8HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K&\2_\@Z'_KYC_G6S6-XE_P"0=#_U\Q_S
MIK<3V-FBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ!X2N6O-6U*Y9%1I0K,J] <FGZ;$LGCO4789,:97V)"BJ>A:Y;1ZMJ-Y?2K
M+C:5!!/0GCCVQ51M9CM?%<VHP'S;=VP=O\2D#./Q%*-:G&E3;=[2;_/6P2I3
ME4G96O'_ "TN3>([^>U\5K,C9-LJ%%).#D9.?KFBVU.3Q!X@TU;J")!$Y/R
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M^ _^AAA_[\R__$T?\+=\!_\ 0PP_]^9?_B:/8U?Y7]P<R[G;45Q/_"W? ?\
MT,,/_?F7_P")H_X6[X#_ .AAA_[\R_\ Q-'L:O\ *_N#F7<[:BN)_P"%N^ _
M^AAA_P"_,O\ \31_PMWP'_T,,/\ WYE_^)H]C5_E?W!S+N=M17$_\+=\!_\
M0PP_]^9?_B:/^%N^ _\ H88?^_,O_P 31[&K_*_N#F7<[:BN)_X6[X#_ .AA
MA_[\R_\ Q-'_  MWP'_T,,/_ 'YE_P#B:/8U?Y7]P<R[G;45Q/\ PMWP'_T,
M,/\ WYE_^)H_X6[X#_Z&&'_OS+_\31[&K_*_N#F7<[:BN)_X6[X#_P"AAA_[
M\R__ !-'_"W? ?\ T,,/_?F7_P")H]C5_E?W!S+N=M17$_\ "W? ?_0PP_\
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M? ?_ $,,/_?F7_XFCV-7^5_<',NYVU%<3_PMWP'_ -###_WYE_\ B:/^%N^
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MR_\ Q-'L:O\ *_N#F7<[:BN)_P"%N^ _^AAA_P"_,O\ \31_PMWP'_T,,/\
MWYE_^)H]C5_E?W!S+N=M17$_\+=\!_\ 0PP_]^9?_B:/^%N^ _\ H88?^_,O
M_P 31[&K_*_N#F7<[:BN)_X6[X#_ .AAA_[\R_\ Q-'_  MWP'_T,,/_ 'YE
M_P#B:/8U?Y7]P<R[G;45Q/\ PMWP'_T,,/\ WYE_^)H_X6[X#_Z&&'_OS+_\
M31[&K_*_N#F7<[:BN)_X6[X#_P"AAA_[\R__ !-'_"W? ?\ T,,/_?F7_P")
MH]C5_E?W!S+N=M17$_\ "W? ?_0PP_\ ?F7_ .)H_P"%N^ _^AAA_P"_,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O7/@1_R%K[_ *ZQ?^@O7D=>N? C_D+7W_76
M+_T%ZY<9_ E_74NG\1]#T445X)VA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5C>)?\ D'0_]?,?\ZV:QO$O_(.A_P"OF/\
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M5+_SQE_[]G_"CRI?^>,O_?L_X46870RBG^5+_P \9?\ OV?\*/*E_P">,O\
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M]@Q?_0ZZNICU-\1O'T1B6?\ R-=__P!<E_I6W7+3:=_:/B2]B\]XMJJV5[\
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M33;5TCGO+>YB1V) 4L[C)QS7,?M$?\?GA[_<G_FE8VBV_P 4H?A^EQHUW$-
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MS[VW-G//ITKK/@;X?U:'QK<:A<6%S:VUO:/%(TT3)EV*X49')X)]L5D?&_\
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M _\ /O\ %_YA_:.)_F_(]+_X7%=_] 6#_P "#_\ $T?\+BN_^@+!_P"!!_\
MB:\THH_L? _\^_Q?^8?VCB?YOR/2_P#A<5W_ - 6#_P(/_Q-'_"XKO\ Z L'
M_@0?_B:\THH_L? _\^_Q?^8?VCB?YOR/2_\ A<5W_P! 6#_P(/\ \31_PN*[
M_P"@+!_X$'_XFO-**/['P/\ S[_%_P"8?VCB?YOR/2_^%Q7?_0%@_P# @_\
MQ-'_  N*[_Z L'_@0?\ XFO-**/['P/_ #[_ !?^8?VCB?YOR/2_^%Q7?_0%
M@_\  @__ !-'_"XKO_H"P?\ @0?_ (FO-**/['P/_/O\7_F']HXG^;\CTO\
MX7%=_P#0%@_\"#_\31_PN*[_ .@+!_X$'_XFO-**/['P/_/O\7_F']HXG^;\
MCTO_ (7%=_\ 0%@_\"#_ /$T?\+BN_\ H"P?^!!_^)KS2BC^Q\#_ ,^_Q?\
MF']HXG^;\CTO_A<5W_T!8/\ P(/_ ,31_P +BN_^@+!_X$'_ .)KS2BC^Q\#
M_P ^_P 7_F']HXG^;\CN-'^)%QI#WS)ID4IN[EK@YF(VD]NG-:?_  N*[_Z
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M_P#T.2O+Z^@PW\&/H<=3XF%%%%;D!1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO$O_(.A_P"OF/\
MG6S6-XE_Y!T/_7S'_.FMQ/8V:***0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N*^*7_(G/\ ]=DKM:XKXI?\B<__ %V2NK _[U3_ ,2_,PQ7\"?H_P CP^BB
MBOTD^-"BBB@ HI,CU%+0 4444 %%%% !1110 44$@=31UH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBCI0 44 @]#10 44F1G&1FEH **** "BBB@ HHHH ****
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MM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M&\2_\@Z'_KYC_G6S6-XE_P"0=#_U\Q_SIK<3V-FBBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KBOBE_P B<_\ UV2NUKBOBE_R)S_]=DKJP/\ O5/_ !+\
MS#%?P)^C_(\/HHHK])/C0J6UMI;V[AM8 3+/(L: >I.!45=Q\+=(^W^*#>NN
M8K&/?R.-[<+^FX_A7/BJZP]&55]%_P ,;8>DZM6,%U/4;7PYX?M(;?3VTZPD
MF6'C? A=PN 6/&>I'/O7A'B'2VT7Q!?:>0=L,IV9[H>5_0BN^U+Q6(OB];GS
M/]%M\6#^GS?>/X,1_P!\U#\7M(\N\LM6C7"S*;>4C^\.5/Y9_*O RQU<-B(1
MJN_M8W^>_P"7YGK8U4ZU&3@O@=OD<YX*\)+XLO;F.2\-O%;*K/L3<S9)X&>!
MT]ZR_$=A!I/B._T^V+F&WEV)O.6Q@=3^->L_#OQ0VN02V364< L8(D#HV3)U
M'/''3]:Y7XA>+GNY=1\/_P!GQ((IUQ<!_F.,'IC^M=5#&8J>82I2CHDM+K3;
M7S]#"IAZ$<(IIZ][;^7D<!'%),Q6*)Y".H12Q'Y4CQO$VV1'1NNUU(/Y&O6-
M%\0^5X46R\'Z#>RW2*%,\MNHB9^-S,V[YCUX^E;.IZ?<>(OA_,^O:?'!JD4$
MC@#&4=<D$'G .!QGO53S>5.I:I"RO;=<WK;L3'+U.%XRN[7VT]+GAE2203PJ
M&E@EC4\ NA4?K7J/PK\/6C:=)KUU$LDQD*0;USY:KU8>Y.>?:K&D?$?3-:;4
M;3Q#':VUF3B .I82(200W7GH>W6M*N9S52<*--R4+7UUU[+J33P,7",JD^5R
MV_X)QO@?6-!TBXO6UVV2=)$01!K<2X()SUZ=161XCN[&^\0WEUIL8CLI'!B4
M)L &T _+VY!KT'X;6]A'XF\016,B7%BH3R'QG*98CKZ=/PJDF@0:_P#%[4[>
MY0-:0'SI4' ;"J /H2>:R6+I4\95FTU:*;U].EM'\S1X><L/"":U=OSZGG:6
M\\B>9'!*Z?WEC)'YU'UKVK6_'4?A[Q=::(MO;QZ<B+]HD((,>[IM XP!CMWK
ME/$=EH'B7QEI<>@W49^W.4NQ"A 7'._!'4C/Y5MA\QJ3:=6FXQ:NGNK>>FFA
ME5P4(IJ$[M.UMON.#CAEFSY44DF.NQ"V/RIK*58JRE6'!!&"*]QUV_U#PG;6
M>G>%_#K7*;2SE(F9% XP2O5CUR?UJCXXT>+7O!BZZUBUIJ4$*S,KIM<+QN1O
MIR1GT]ZQI9SS2@Y0M&3LG=-_-=#2>7<L9<LKRCJ]-/DSQK(]:E\B;RO-\F7R
ML9W[#M_/I7N.ABPC^&%K-?P));)8;I5(^\H&2/QK*\&>/[CQ!K9TF[L+:&"2
M)C (L_*%_A(/!X],=*;S:K*-25.E=0;OKV^0?V?!.,93UEMH>101^?<10A@I
ME=4!/09.*[+QCX(MO">B6<XNY;BZFG\MV("H!M)X7ZCKFMR]N8O 'C>>&ST^
M*6VU41.BLVT0G<00O'3)SCZ5UOC;Q,WA?3[6Y6RCNO-F\O:[;=ORDYZ'TK&O
MF->5>C[&/NRU2NO>T_"WXFE+!THTJGM'JO+;_.YX#73>#KOPU:S7A\26ZS(R
MKY.8B^#SGIT[5@W]U]NU&YNS&(S/*TFQ>BY.<57KVZM+VU/DDVK]GK]YYE.?
MLY\RUMW/6K&Y^&^I7\%E:Z4CSSN$1?LS#)JK\0?#^AZ4-&BL;""WEN;P*XC&
M"Z< _AR*A^$NA^=>W.MRI\D \F G^^1\Q_ 8'XFLCQ9K7]M_$2#8X-M:W,=O
M&<\?*XW'\\_@!7@4Z3CCW3I3DXP5W=WU[?UYGKRJ)X52J12<GI9'<Z]I?@3P
MVD#ZEI$""<E4V0LV2.O3ZURNN:E\/Y=#O(]*L4COVC(@;[.RX;ZGI7:>+KWP
MGY-I=ZXT=XD3,L,,9\S+,!DE0>>!WXK$UOP=H&N^%#K/AV!8)%B,L?E@J) .
MJLO8\'\:Y,%5BHTYUW45WO?W;WV_S-\1"3<HTE';:VIY)1G'6@'(S7H?PA57
MUS4E90P^S*<$9_BKZ?%XCZO1E5M>QX6'H^VJ*G>USS^.*28D1122$<D(I;'Y
M4TJROL*L'!QM(YSZ8KUS5?'">&_&4FE6>E0"W>=&NI<D/([XRP[< CKZ=JV/
M&UW8^&XX_$2Z=!<:ID6T+R=!G)R<>@!]^:\W^U:JG"+I?&O=U6OKV.[ZA3Y9
M-5/AWT/#9(98<>;%)'GIO0KG\Z9TKWC2KR#Q]X)D?4+2-"^^-E'(5UZ,I/([
M&N ^&'A^WU?6Y[J\C66&Q52J,,JTA)P2.^,$_E6E/-5[.K*K'E=/=7OZ$3P'
MOPC3E=2V.*:"9(Q(\,JQG^-D(7\ZCR#WKUG7_B*(/$T^BR:=;SZ4D@M[@ODL
MW9L#IQGI[5;^*\<<'A&V2*-%7[6B\#L%;%*&9U?:4X5:5N?;7I]PYX&GRSE"
M=^7?0\;HHHKV#S0HHHH **** $R/6I7@FB0/)!*BGHSH0#^)KU.*^MM)^$>E
MZA)9PW$\; VZR+E1+O8!CZX&34?@KQAJ'B?59M%UR.WN[:XA9N8@N,8X(Z$8
M_&O)EF-7DG4C3]V#:>O;MH>@L'#FC"4]9)-:=^YY91716>AZ5/XAU.POM773
M;>UE=8I)%W;\.1CJ.U:O_"(^%?\ H=H/^_(_^*KKGC:4'9W_ / 6_P D81PM
M22NK?>CB*]'T^T\/^$O!]MK.H6<.IZG=@;(7(8)N&0,'(  ZG&<UB:GX:\.V
M>FW%Q:>+(;NXC7*0"( R'TZUS>G6L%WJ=M;SSK:PRR!9)V Q&#W-95>3%T[J
M344]=&F_+H_N+I\V'G9I-O;5.QZ1I']@?$*&[L#HL.EZA#'YD4UL!C&<9X S
MSC(/K7+^"_"Z:]XAEMKTXM+,%[C:<;L' 7/;)!_ &NXT?2K/POX?O]2\,.-=
MOV38TB2+B,#G[H]^<<DUC_#MBOA?Q7>;OWYB)W^_ELV?S)KRUB'"E6=!M1O%
M*^Z;T>^J\KG>Z2E.FJJ][5NVS2V\F$'BSPG=ZLNE/X8LTTR1_)6YVJ&ZX#'
MR!GWS7*^,/#W_"->(9;)&9K=U$L#-UV'L?4@@BL!6**&4X*X(^M>C_%I0UUH
MTY_UCV[!C^(/]37=&DL+BJ<*;?+-.]VWJM;Z]3DE/V]"<II7BU;3OT/.:***
M]8\\**** "BBB@ HHHH *4TE*:0#33#TIYIAZ5,BD-CE>"598VPZ]#706US'
M?0;TX8<.GH?\*YQJ(+F2TG$L1Y'4'HP]#7+474W@^AZO\,EV^(9Q_P!.S?\
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M_P"!D?\ C1_PICQW_P! JW_\#(_\:^IJ*/[0J]D'L8GRS_PICQW_ - JW_\
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M9'_C7U-11_:%7L@]C$^6?^%,>._^@5;_ /@9'_C1_P *8\=_] JW_P# R/\
MQKZFHH_M"KV0>QB?+/\ PICQW_T"K?\ \#(_\:/^%,>._P#H%6__ (&1_P"-
M?4U%']H5>R#V,3Y9_P"%,>._^@5;_P#@9'_C1_PICQW_ - JW_\  R/_ !KZ
MFHH_M"KV0>QB?+/_  ICQW_T"K?_ ,#(_P#&C_A3'CO_ *!5O_X&1_XU]344
M?VA5[(/8Q/EG_A3'CO\ Z!5O_P"!D?\ C1_PICQW_P! JW_\#(_\:^IJ*/[0
MJ]D'L8GRS_PICQW_ - JW_\  R/_ !H_X4QX[_Z!5O\ ^!D?^-?4U%']H5>R
M#V,3Y9_X4QX[_P"@5;_^!D?^-'_"F/'?_0*M_P#P,C_QKZFHH_M"KV0>QB?+
M/_"F/'?_ $"K?_P,C_QH_P"%,>._^@5;_P#@9'_C7U-11_:%7L@]C$^6?^%,
M>._^@5;_ /@9'_C1_P *8\=_] JW_P# R/\ QKZFHH_M"KV0>QB?+/\ PICQ
MW_T"K?\ \#(_\:/^%,>._P#H%6__ (&1_P"-?4U%']H5>R#V,3Y9_P"%,>._
M^@5;_P#@9'_C1_PICQW_ - JW_\  R/_ !KZFHH_M"KV0>QB?+/_  ICQW_T
M"K?_ ,#(_P#&C_A3'CO_ *!5O_X&1_XU]344?VA5[(/8Q/EG_A3'CO\ Z!5O
M_P"!D?\ C1_PICQW_P! JW_\#(_\:^IJ*/[0J]D'L8GRS_PICQW_ - JW_\
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M@P&"EAX3YY7E)W;1V8O%*M*/*K1CLCTG7?A28;."?P[*]XS'YUFD094C@J0
M/_UUU%G$/ OPW=-0E3STCD.T'(,KY(0>O7]#7D^F^*]>TBW%O8ZG-% /NQG#
MA?H&!Q^%5=4UK4]:E634KV6Y9?NAS\J_0#@5R3R_%U^6E7J)P3O_ 'G^AT1Q
MF'IWG2BU)JWD9XX KT7X/_\ (>U+_KU7_P!"KSNK5CJ=]IDCR6%Y-:NXVLT3
M;21Z5Z6-H/$8>5*+LV<6&JJE551]#H_&_P#R4JY_Z[P?R6NW^+W_ "+5G_U]
MK_Z"U>17%[=7=V;NYN))KDD$RNV6)'3GVP*L7VMZKJ<*PW^HW-S&K;@DLA8
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MTEU,(HQR>I[ >M;\<45G (HAP.I[L?4URU'K9&\%U.O^&MM FNRPK&IC6U;
M89_B7GZUZG]DMC_R[P_]\"O+OABV[Q#.?^G9O_0EKU>O@<9IB:G^)GU\-:-+
M_#'\C'LD2/Q-?*BJJB%,!1@5LUCVO_(T7_\ UQ2MBL&""BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L?4_^0YI/^\_\JV*Q]3_ .0YI/\ O/\
MRIH3-BBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "L;Q+_R#H?\ KYC_ )ULUC>)?^0=#_U\Q_SIK<3V-FBBBD,****
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M_F?W,/[*Q/9?>>045Z/H/PXT_5Y-266^NH_LEVUNNP+\P'<Y'6MC_A3^E_\
M04OOR3_"DL^P35^9_<RIY1BH/E:7WGD%%>O_ /"G]+_Z"E]^2?X4?\*?TO\
MZ"E]^2?X4_[=P7\S^YD_V5B>R^\\@HKU_P#X4_I?_04OOR3_  H_X4_I?_04
MOOR3_"C^W<%_,_N8?V5B>R^\\@HKU_\ X4_I?_04OOR3_"C_ (4_I?\ T%+[
M\D_PH_MW!?S/[F']E8GLOO/(**]?_P"%/Z7_ -!2^_)/\*/^%/Z7_P!!2^_)
M/\*/[=P7\S^YA_96)[+[SR"BO7_^%/Z7_P!!2^_)/\*/^%/Z7_T%+[\D_P *
M/[=P7\S^YA_96)[+[SR"BO7_ /A3^E_]!2^_)/\ "C_A3^E_]!2^_)/\*/[=
MP7\S^YA_96)[+[SR"BO7_P#A3^E_]!2^_)/\*/\ A3^E_P#04OOR3_"C^W<%
M_,_N8?V5B>R^\\@I37KW_"G]+_Z"E]^2?X4O_"H-+_Z"=]^2?X4?V[@OYG]S
M#^RL3V7WGD\ "?-_%5@R\5ZD/A%I@_YBE]^2?_$T?\*CTP_\Q2^_)/\ XFLW
MG6";OS/[F6LMQ*Z?B>2O)FH2<UZ\?A!I9_YBE]^2?X4G_"G]+_Z"E]^2?X52
MSS!+[3^YDO*\2^B^\Q_A-_R&9O\ KW?_ -"6O7J\^\+:%#X;\=7&FV\TDT8L
M?,WR8SDL/0>U>@U\;BJD:N(J5([-MGU"@X4J<);J*_(Q[7_D:+__ *XI6Q6/
M:_\ (T7_ /UQ2MBL62@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K'U/\ Y#FD_P"\_P#*MBL?4_\ D.:3_O/_ "IH3-BBBBD,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q+_R#H?^OF/^
M=;-8WB7_ )!T/_7S'_.FMQ/8V:***0PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "L?7_\ F'_]?:5L5@>*[RUT^TL[N]N([>VBND+RRMM51[FFM6)[&_17-_\
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M_H9M*_\  I/\:/9S[,+HZ2BN;_X6#X._Z&;2O_ I/\:/^%@^#O\ H9M*_P#
MI/\ &CV<^S"Z.DHKF_\ A8/@[_H9M*_\"D_QH_X6#X._Z&;2O_ I/\:/9S[,
M+HZ2BN;_ .%@^#O^AFTK_P "D_QH_P"%@^#_ /H9M*_\"D_QH]G/LPNCI**Y
MO_A8'@__ *&;2O\ P*3_ !I?^%@>$/\ H9=*_P# I/\ &CV<^S"Z.CHKF_\
MA8/@_P#Z&;2O_ I/\:/^%@^#O^AFTK_P*3_&CV<^S"Z((/\ DJ-U_P!@Q?\
MT.NKKB-'U2PUCXBW-YIMY!=VQT\()8'#KN#C(R.XR*[>LHJUTSHK[Q]$8]K_
M ,C1?_\ 7%*V*Q[7_D:+_P#ZXI6Q5LYT%%%%(84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %8^I_\AS2?]Y_Y5L5CZG_ ,AS2?\ >?\ E30F;%%%%(84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8WB
M7_D'0_\ 7S'_ #K9K&\2_P#(.A_Z^8_YTUN)[&S1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5YU\;?^2;77_7:/\ ]"KT6O.OC;_R3:Z_Z[1_^A5K0_BQ
M]43/X6?,-%%%?1G"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4O3!I*4]J
M +<"B1<C\:E:#CI5&*9H) Z\^H]16["([F 21G*G]#Z5G)V&C'DCQVJ C%:\
M]OCM6=)'@U28-'M7P&^_+_N2_P#H25[E7AOP'_UDO^Y+_P"A)7N5?.UOXL_5
MGJ5-H?X48]K_ ,C1?_\ 7%*V*Q[7_D:+_P#ZXI6Q4,Q04444AA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5CZG_ ,AS2?\ >?\ E6Q6/J?_ "'-)_WG
M_E30F;%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %8WB7_D'0_]?,?\ZV:QO$O_ "#H?^OF/^=-;B>QLT444AA1110
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\D=JX*,%"O.,=K&\G>*;/?/B/I?C#5GTFW\)7SV1#2M=3";RU PNT'@D\YZ
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M'YB!UKJ?[<^.'_0,/_@+#_\ %5M*M)/2WS9"@F>-R:=?Q1M))8W<:*,EW@<
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M .0YI/\ O/\ RIH3-BBBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L?4_\ D.:3_O/_ "K8K'U/_D.:3_O/_*FA
M,V****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *QO$O\ R#H?^OF/^=;-8WB7_D'0_P#7S'_.FMQ/8V:***0PKCOB-J'V
M;0$LU;#W<@4C_87D_P!/SKL:YG5?"_\ ;_B!+G4'Q86T86.%3S*3RQ8]AT'O
MBIG=JR-\,X1J*4]EJ>:Z5X>U36HI9;&V+QQ@G>QVAC_=4]S2:+>2:+XDM9YE
M>)H9@DR,,$*>""/QKVV&&*WA2&&-8XD&%11@ >U8OB+PI8^(829!Y-V!A+A!
MR/8^HK)TK:K<[XYBIR<:B]UF]15/2DNHM+MHKW;]IC0)(4.0Q'&1]>M7*W/*
M:L[''ZAX9U2QUJ?5_#EW%')<<SVTX^1SZC^?Y\U!<:/XM\0H+35[BSLK D&5
M;;+-(!V_S^M=O13N1RHHRV"1:')I]F@51;M#$N>/NX'-4/!^EW>C^&K:RO51
M9XRQ8(VX<L2.:W:*+CMK<*Y'4_#6I6NN2:WX=N(HKB88GMYON2>]==10G8&K
MG$7NC^*?$JQVNK26=A8A@TBVK%G?'O\ Y_&K?BSP[=ZC8:5:Z9%&4M)E)#OM
MP@&/QKK**+BY4!&1@]*YGP9H^H:);7UK>I&(FN#) 4?=E3Z^G05TU%*X[:W"
MBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G7QM_Y)M=?]
M=H__ $*O1:\Z^-O_ "3:Z_Z[1_\ H5:T/XL?5$S^%GS#1117T9PA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %*>U)2GM0 TUJ:78*2+F<?*.40]_<U4M8!
M(X9_N#MZUK&?"UG+L4B>XN.O-94\V2:6>?/>J3MFB,0;/;O@0<RS'_IG+_Z$
ME>XUX;\!OOR_[DO_ *$E>Y5\_6_BS]6>G4VA_A04445F9!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %8^I_P#(<TG_ 'G_ )5L5CZG_P AS2?]
MY_Y4T)FQ1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG6;(7=CH=E)"6*[C<[>1UX-%AN2.YHK L=1U_P"S7TVK:7;6HAA+Q>7/OWD
MD@^G05C:9XG\5ZQ8I>66A64D+$@,;G;R.O!HL+F1W%%<MHWBRXN=9.CZOIQL
M;XJ60!]RN.O7Z9KJ:&K#3N%%%%(84444 %%%% !1110 4444 %%%% !1110
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ML8GR/_PK+QM_T+=Y^:?_ !5'_"LO&W_0MWGYI_\ %5]<44?VC4[(/8Q/D?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJI9:C!?RW<<)RUK,89/]X '^M TFU<MT444""BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Q]3_ .0YI/\ O/\ RK8K"U>=(_$6
MAQ,?FE>0+^"YHN%F]$;M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=.-H259N*T9JT52L]8T[4)6BL[V"X=1EEB<-@>^*NUJ<+BT[,****!!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\0*;SQ!<R6[$9MK6W; MSV8GNU9NL/J&GZ;<Z-X@'G03(5MM20<%ARH?T/\
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MD!9?H>U2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8?B63R8+.7&=EPK8]< FMRJ]Y8V]_"(KA-R@Y&#@@TT)ZHP_P#A+D_Y\G_[
M^#_"C_A+D_Y\G_[^#_"KO_"-:9_SR?\ [^-_C1_PC6F?\\G_ ._C?XT]";2*
M7_"7)_SY/_W\'^%'_"7)_P ^3_\ ?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD
M_P#W\;_&C0+2*7_"7)_SY/\ ]_!_A1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&
M_P :/^$:TS_GD_\ W\;_ !HT"TBE_P )<G_/D_\ W\'^%'_"7)_SY/\ ]_!_
MA5W_ (1K3/\ GD__ '\;_&C_ (1K3/\ GD__ '\;_&C0+2*7_"7)_P ^3_\
M?P?X4?\ "7)_SY/_ -_!_A5W_A&M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0+2*
M7_"7)_SY/_W\'^%'_"7)_P ^3_\ ?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD
M_P#W\;_&C0+2*7_"7)_SY/\ ]_!_A1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&
M_P :/^$:TS_GD_\ W\;_ !HT"TBE_P )<G_/D_\ W\'^%'_"7)_SY/\ ]_!_
MA5W_ (1K3/\ GD__ '\;_&C_ (1K3/\ GD__ '\;_&C0+2*7_"7)_P ^3_\
M?P?X4?\ "7)_SY/_ -_!_A5W_A&M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0+2*
M7_"7)_SY/_W\'^%'_"7)_P ^3_\ ?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD
M_P#W\;_&C0+2*7_"7)_SY/\ ]_!_A1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&
M_P :/^$:TS_GD_\ W\;_ !HT"TBE_P )<G_/D_\ W\'^%'_"7)_SY/\ ]_!_
MA5W_ (1K3/\ GD__ '\;_&C_ (1K3/\ GD__ '\;_&C0+2*7_"7)_P ^3_\
M?P?X4?\ "7)_SY/_ -_!_A5W_A&M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0+2*
M7_"7)_SY/_W\'^%'_"7)_P ^3_\ ?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD
M_P#W\;_&C0+2*7_"7)_SY/\ ]_!_A1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&
M_P :/^$:TS_GD_\ W\;_ !HT"TBE_P )<G_/D_\ W\'^%'_"7)_SY/\ ]_!_
MA5W_ (1K3/\ GD__ '\;_&C_ (1K3/\ GD__ '\;_&C0+2*7_"7)_P ^3_\
M?P?X4?\ "7)_SY/_ -_!_A5W_A&M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0+2*
M7_"7)_SY/_W\'^%'_"7)_P ^3_\ ?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD
M_P#W\;_&C0+2*7_"7)_SY/\ ]_!_A1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&
M_P :/^$:TS_GD_\ W\;_ !HT"TBE_P )<G_/D_\ W\'^%'_"7)_SY/\ ]_!_
MA5W_ (1K3/\ GD__ '\;_&C_ (1K3/\ GD__ '\;_&C0+2*7_"7)_P ^3_\
M?P?X4?\ "6I_SY/_ -_!_A5W_A&M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0?O'
MG^OZ99:C*UUIUH;2=CEX]PV/[@=C^E<H\;1.4D0HZ\%2.17M9\-Z8 28W '_
M $U;_&O';^47VKW#VT;LLLI6&,99B.@ ]:YJT8K5'M9;6JSO&;ND5*T--TE[
MUU>4-';9^9A]YA_LY_G2:EHNHZ/Y1O[5H1* 4;.1],CH?:NW\"V=AJVB.EPC
M&>VD*'#D?*>5_K^513BG*TCIQE><*//2?S+NF:Q8:/:+:V.EF*,=3Y@)8^I.
M.35W_A+D_P"?)_\ OX/\*N_\(UIG_/)_^_C?XT?\(UIG_/)_^_C?XUV>ZCYU
MN<G=LI?\)<G_ #Y/_P!_!_A1_P )<G_/D_\ W\'^%7?^$:TS_GD__?QO\:/^
M$:TS_GD__?QO\:-";2*7_"7)_P ^3_\ ?P?X4?\ "7)_SY/_ -_!_A5W_A&M
M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0+2*7_"7)_SY/_W\'^%'_"7)_P ^3_\
M?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD_P#W\;_&C0+2*7_"7)_SY/\ ]_!_
MA1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&_P :/^$:TS_GD_\ W\;_ !HT"TBE
M_P )<G_/D_\ W\'^%'_"7)_SY/\ ]_!_A5W_ (1K3/\ GD__ '\;_&C_ (1K
M3/\ GD__ '\;_&C0+2*7_"7)_P ^3_\ ?P?X4?\ "7)_SY/_ -_!_A5W_A&M
M,_YY/_W\;_&C_A&M,_YY/_W\;_&C0+2*7_"7)_SY/_W\'^%'_"7)_P ^3_\
M?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD_P#W\;_&C0+2*7_"7)_SY/\ ]_!_
MA1_PER?\^3_]_!_A5W_A&M,_YY/_ -_&_P :/^$:TS_GD_\ W\;_ !HT"TCF
MM=N=-\00!+K3W291^[G1QO3].1[&N O+":QDVRJ"I^ZXZ-7LG_"-:9_SR?\
M[^-_C7 ^/X[2RO;6PM5*E4,LN7)Z\#K]#6-:,;7ZGIY=6K*HJ=[Q_(Y"IK:T
MFO)?+A3<>Y/1?K5J+0M4GTMM2BLI6M%_C Y(]0.I'O6GX(-M-KPL[H%HKF,A
M<,1\PY'3VS7/%7:3/6K57&G*5/5HW?#W]G>'U\Q;)KB\(PUP[#CV48X'ZUT'
M_"7)_P ^3_\ ?P?X5=_X1K3/^>3_ /?QO\:/^$:TS_GD_P#W\;_&NU**5D?,
MSG4J2YI.[*7_  ER?\^3_P#?P?X4?\)<G_/D_P#W\'^%7?\ A&M,_P">3_\
M?QO\:/\ A&M,_P">3_\ ?QO\:>A%I%+_ (2Y/^?)_P#OX/\ "C_A+D_Y\G_[
M^#_"KO\ PC6F?\\G_P"_C?XT?\(UIG_/)_\ OXW^-&@6D4O^$N3_ )\G_P"_
M@_PH_P"$N3_GR?\ [^#_  J[_P (UIG_ #R?_OXW^-'_  C6F?\ /)_^_C?X
MT:!:12_X2Y/^?)_^_@_PH_X2Y/\ GR?_ +^#_"KO_"-:9_SR?_OXW^-'_"-:
M9_SR?_OXW^-&@6D4O^$N3_GR?_OX/\*/^$N3_GR?_OX/\*N_\(UIG_/)_P#O
MXW^-'_"-:9_SR?\ [^-_C1H%I%+_ (2Y/^?)_P#OX/\ "C_A+D_Y\G_[^#_"
MKO\ PC6F?\\G_P"_C?XT?\(UIG_/)_\ OXW^-&@6D4O^$N3_ )\G_P"_@_PH
M_P"$N3_GR?\ [^#_  J[_P (UIG_ #R?_OXW^-'_  C6F?\ /)_^_C?XT:!:
M12_X2Y/^?)_^_@_PH_X2Y/\ GR?_ +^#_"KO_"-:9_SR?_OXW^-'_"-:9_SR
M?_OXW^-&@6D4O^$N3_GR?_OX/\*/^$N3_GR?_OX/\*N_\(UIG_/)_P#OXW^-
M'_"-:9_SR?\ [^-_C1H%I%+_ (2Y/^?)_P#OX/\ "C_A+D_Y\G_[^#_"KO\
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M_P"_C?XT?\(UIG_/)_\ OXW^-&@6D4O^$N3_ )\G_P"_@_PH_P"$N3_GR?\
M[^#_  J[_P (UIG_ #R?_OXW^-'_  C6F?\ /)_^_C?XT:!:12_X2Y/^?)_^
M_@_PH_X2Y/\ GR?_ +^#_"KO_"-:9_SR?_OXW^-'_"-:9_SR?_OXW^-&@6D4
MO^$N3_GR?_OX/\*/^$N3_GR?_OX/\*N_\(UIG_/)_P#OXW^-'_"-:9_SR?\
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MR*7_  ER?\^3_P#?P?X4?\)<G_/D_P#W\'^%7?\ A&M,_P">3_\ ?QO\:/\
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M_P!?A-P$.8;*-@L4?^]ZG_)J[XE-L\>DZY$RS6T,X61T;AHVZ\]JZL>'-+8
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MC.#VI:175U#(P93T(.12TS,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M '%>.H/$&H/#9:7:S/9[-TK1NJ[VSPIR0<#^M<]K?@==!T)=3CO7-S&5\Q0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7\;#3(+EY;<W"PR)V<-C!V]F&>U:WC_6[N75(="LI&12%\W:<%V8X52?3O\
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M(IE]XTT5[>)=*T"U>[8C>DUNI5?8;>2:].(# @@$'J#44=I;1/OCMX4?^\J
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MJ1I$@2-%11T"C IU#=PC&P4444B@HHHH **** "BBB@ HHHH **** "BBB@
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MTBJJ*%50JCH , 4M5&/*C'$5_;23M9+1!1115& 4444 %%%% !1110 4444
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MO0;R^MPAEA3<H<9&<]ZYZRU#QKJ%C!>00Z1Y4R!TW%P<'U%:_C'_ )%#4_\
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MKM_ ]_IWA[S=.4G#O,%D<#J0M===6L%[:R6US&LL,J[71NC#TK(UC4M/\):
M%BC2,*ICMK=/XF] /3G)J97WOH=%'E^'EYI-DMAXET^^\/MK.\Q6T:DRA^L9
M'4'U_P#KTNF>(;?4KLVAMKJUN/+\U([F/89$SC<O)_QK(\,^&63P=-I^IJRM
M?%I)4!P4W8P/J, UJ:9H$EG?_;KW49;^Y2'R(F=%0(F<G@=2>YI)RT*J1HQ<
MDGZ&U7%#7?$M_K^IV&EQ:<4LI-N9]P.#TZ'D\&NUKSBPU&_T[QCXA:QTF746
M>4!UCD";,$X//7.3^5$WL/#14E)V3:77U.BLG\8F^@%[%I0M=_[TQL^[;[9[
MUTM<YI^O:U=7\,%SX:N+6%R0T[3JP3CT%4/%FIZM9^)=&MM,GVF?<#$WW'.0
M!N[X'7CTHYDE<3I2J34;):=/^!<[*BN$US_A(O#%JFK'7#?1JX$UO+"JJ<_W
M<5M>)?$3:1H,5U;1A[FZ*I C]-S#.3]*?/O<GZO)\O*[W_KJ;TSF."1QC*J2
M,_2L3PAK-SKNA+>W:Q+*973$8(& <#J36=)I/B:TL'O&UTW5P(RTEI)"HB;C
ME01R/8U!X'D:/P#/)$Q5E:=E/<'G%3S/F+]C%4FTTW=?J=M17!>&5\1>(M!A
MGEUR2UB4E5D2)6DE.>2Q/  Z  =JTO#VK:C#K]WX>U>9;B>%!+#<!=ID3CJ!
MWY'ZTU.]B9X9QYDFFX[HZNBN*AO]8\5ZO>Q:=?\ ]G:;9OY7FQQAI)'_ !Z?
M_JJ2#4M6\/\ B.TTK5;L7]G>\07)0*ZMZ-C@\X_,4<Z!X:6UU>U[=?\ (V;Z
M;74UZSCL[6!]+8#[1*Y^=3D].?IVK8KEM7U"\@\=:)9Q7+I;31N98AC#D XS
MQ57Q9J>K6GB/1[;3)]K3[AY38V.<@#=WP.O%'-:XU1<^6*LKJ_Y[G9U4U+4K
M72;"6]O)"D$8^8@$GVX%<?KG_"1^&;1-7.N&^C5U$]O)"JJ03_#BI?'L,]SX
M;.HI>RQVXB3=:8&R0D@@D]>,]J'/1Z!##)RC>5TW;3_ACLK>9+FVBGCSLE0.
MN1@X(R*DK#\,V%U9Z=')<:G/=I-#&8XY%4"(8Z# YZ]_2MRJ3NC"I%1DTG<*
M***9 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'BG7Y] ALG@M
MXYC<7(A8.Q&T$'D8K?KBOB-_QZ:1_P!?Z_R--;DR=D=K17+^.-9OM$TRUGL)
M CO<!&R@;<N"<<_2JFH2^,K73Y-6^U6*K&OFO8B'.U>I&[J2!UZ46!R.PEE2
M&)Y96"1HI9F/0 =345C?6VI6<=W:2B6"3.QP.#@X_I7.W]W?:[X,CU"QN$LU
MDMWDGC:,/O7:05![<@\U6\"0ZC'H=G=2:A'_ &9Y3[;;R0&3YCR7[]_SHMH'
M-K8[.BN,L-2\0^*#/>:9=6^G:<DACA+P^8\N.YSTJ_X<UN^N=1O]'U58OMUE
M@^9$,+*AZ'';M^=%@4CI*QM5U'5;35;"WL=,^U6LS 7$V['E#(&?RR:YG3]8
M\5:Q>:G8V$]LK6]RP^TS1C$:<@* !R3C.36MJ^J:IINI^&K/[1&6NI/+NR(P
M1(0%SCTY)IV#FNCJ:*Y7QCK6I:1<Z2NG;6:XF*/$5!\SIA<]NO6J6KWGB[0;
M,:K<WUC<0(P\ZV2':%!..&ZFE8'*QV]%<=YWB[4=/.JVMS96<3IYL-FT6]BF
M,C<WJ1Z5L>%M;;7]"BO9(Q'+N:.15Z;@>WM18:E<V:R?$FM#0='>[6,2S%EC
MAC)QO<G@?SK6KB]28Z_\0++3E^:UTM?M$W<&0]!_+]:$$GH;/A?7CK^F//+$
ML-S%*T4T0.=I'U]JVZXBW8^'_B1/;L<6FKIYB>@D_P#UY_[Z%:?C?5[W1=#C
MNK&41RFX1"2@;*D'(P?I0UJ)2TU.DHKC;R7QE'ISZLMS8Q*B>:;'RLD*!G!8
M]3CZ5N:7K#ZGX9BU6.V9I7A+B!#RS#(P"?4BBPU(UJKWUPUII]S<JH9HHFD"
MGH2 3BN7C'C.YTU]1DO+6REP76Q:W#8 [%LYS5NPUE]>\"W%_+$L<K6\RNJ]
M,@$<46%S&AX;U:77- MM1FB2*28$E$)(&"1U/TK5KA=%?48?A9#/I<HCNXHV
MD7*!MP#$D8/MFNDT'68]6\/6^I.RKF/,WHK#[W\LT-!%FM17&:/XDU"?1M8\
M079WV,;-]C@"!3M7N3U/8?@:BL[KQ;JFD#5K34[!BRF1;)( ?^ ELYS18.8Z
MC6[N^L=+DGTZR^V7*D;8<XW9//Z5/I\UQ<:=;S7<'D7#QJTD6<[&(Y%8>JZQ
MJ=OX$FU1H/L.HK$&,; -L;< >/\ /6DU3Q'/I/@JVU4HLUU+'$!D87>P')QV
MHL%SIJ*XN23QC!I\>HVU]9:GG#&TBA R#Z-FNP@=I;>.1XS&[(&9&ZJ2.A^E
M#0T[DE%%%(84444 %%%% !1110 4444 %%%% !1110!6U&Y:RTRZND4,T,+R
M!2< D G%<GI_B3Q9JEC%>6F@6<D$@RK&ZQGG'0UTNN_\B_J7_7K)_P"@FN,\
M+^)I].\-V=JF@ZG=*BG$T,8*-R3P?QJEL1)ZG5Z+=Z[<RS#5],@LT4#RVBG$
MFX\YSZ=JV*R=$UF76%G,FEWECY1  N4V[\^GTKF[?6?$FI>)=8TJRFMUC@EP
MLTL61 H[ #[Q/OZ4K#O8[JBN0T_5];T[Q3#HFLR072W,9>&XB381C/4?@?TJ
M?7=<U ZY;Z!HHB%Y(GF2SRC*PK].Y_\ K46#F1=\5:W-X?T4WT$"3.)%38[$
M#GZ5LQL7B1R,%E!Q7F_C5=?M-!\C5+BWO;:65=L\4?EM&PYP1T(/K7HUO_Q[
M1?[@_E0UH"=V245B>*-?_P"$?TU)8XO.NII!%!$>C,?7VK*FC\;6MDU\;^PF
MD1?,:S$&!CJ5#9SFBPW(["N4TOQ-JNM:DQL-)C.E).89+B2;#X'4A>_TJS9Z
MG=^)_#<-WI-RMC<%\2&2,2!2/O+@_AS6!X MM5>U,T&H1QV*7;B:W,()<\9(
M;MVIV);U5CO9VD6WD:% \H4E%)P&;' S7'WGB+Q;IUC)>7F@6<<$2[G87>['
MX"NTK \:_P#(FZG_ -<O_9A20Y;&7:Z_XOO;..ZMO#]F\4J[T8W8&1]#781%
MVA0RJ%D*@LH.0#W%97A7_D5=,_Z]U_E61XFUW5M-\2Z;9:<$E%S$P$#J,,^<
M ENH ZGZ4;L$[*[.OHKF#J&K^'="OM0U^XM[MD(,*6Z;1D\;>GKWJM&OC.XT
MX:B+^RB=D\U;+[/D8QD*6SG-%@YCL**P-)\0RZMX5;58+-GNE5E-LAZR+V!/
M8\?G6:?^$R_LA]3DOK6"94,IL3; @*.=I;.<T6#F.OED2&)Y9&"1HI9F)X '
M4U#8WUMJ5G'=VDHE@DSL< X.#BN8N+[4?$/@A-1M;B.SW02-<QF/>'4 @J">
MG3K3/ -OJ0T6SG>^C;3FB81VOD@,IW==_?O^=%M YM3LJ*X+1=5\4Z])?P6U
MW:PI;W#*;F2$$@=D"C@^I)I;?7/%"ZQ/X=?['+?\.EV5PB)C)8J.O; ]:.4.
M='>45QAU;7]!U[3[35[BWO;2^?RTDCB\MD;Z?B*T?$FN7EE=V6E:7'&^HWI.
MUI,[8U'5CZ__ %C18.9'145Q>I:AXD\,1Q:A?WMMJ%D9%2=$@\MD![@CK^-6
M/&6O7^DII4FFN"+B;#(4!\P8& ,],T6#F.LJ*XN(;2WDN+B18X8UW.[' 45Q
M^K7/C#2+!]7EN["6*/YY;18<!%] W4XJ?Q+-=ZKX.&H6=RMO:O;&2>%XPQD!
M ^4'MCGFBP<QU%I=P7UI%=6T@D@E4,C@$9![\U-7+>"+?4DT:SFGOHY;%[9?
M)MQ"%:/ZMWXKJ:&-.Z"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSP
M\1_PL+Q(/:/^0KLZ0*H8L% )ZG'6DU>QI"IR1DNZM^(M%%%,S,/QEQX0U/\
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MA9#GL<=*?<W8\7^*]+_LV.1]/T]_.EN60JI;@X&>O0?K7=%0PPP!'H:  HP
M /04^3I?0AXE7Y^7WK=].U[?\$X[7"/^%C^'A_TSD_D:C\3D?\)YX:_WF_G7
M:E5+!BH)'0XZ4%5)!*@D="1TH<11Q%G%VV37WW_S.6^(IQX-N<_WX_\ T(4W
MQ9#)-\/9%B0N1#$Q"C)P,9-=6RJPPP!'H12XXQVIN-[DPK\JBK;._P"7^1A^
M%];L-5TR&*TE+R6T,:RJ5(V'&,<_0]*W*:J*F=J@9]!3J:V,YM.3<5H%%%%,
M@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img76291469_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +U".@# 2(  A$! Q$!_\0
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <CE
M#[>E3@@C(JM4D38.#T-3)%)DU%%%04%0/)NX'3^=.E?^$?C457%=26PHHHJB
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )(Y,<-T]:
MFJK4T3;A@]14R74I,DHHH)P,FH*&LP49-0,Q8Y-#,6;-)6B5B&PHHHIB"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H!(.1UHHH G1]X]Z?5
M8$J<BK .0"*B2L6F+1137;:N>_:I&)))MX'6H.IR:**T2L0W<****8@HHHH
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MEQ;+;S>2ZSE22<9R,'WK1TIJ/,UH%U>QTU%%%9@%%%% !1110 4444 %%%%
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M>NWGC+PSI]Y)9WFOZ=;W,3;9(I)PK*?0BO(OV??^0QKW_7M%_P"A&N*^)?\
MR4_7/^OM?Y+53HJKB))O^M!*7+!'U6[I'&TCL%15W%CT ZYK&L?&/AK4[R*S
ML->T^YNI<B.&*<,S8&3@?0&M#4/^0)=_]>C_ /H!KYA^$?\ R4S0/]Y__135
MS4J*G"4F]BI2LTCZH9@JLS$*J@DL3@ >IKE9_B9X*MKHVTGB2S\P'!*;G4'_
M '@"/UKS_P"/'B>Z@>R\-6LS1P31?:;O:<&09(1#[<$D=^*J>&/A'INL_#$:
MK(UPVLW<#SVNQ\*F,[$V]#G')/K50H04%.H[7!R=[(]J75]-;23JJW]LVG!#
M(;I9 8PHZG=7AWQ4^(]_+K,=CX:\0J=*:V5I'L7&3(2P(+CGIC@'O4GPV\)>
M*+:XU+0=<TK4+/0=5M'2X8D 1OV9>N">1TYX]*X_XE^%-/\ !OBB+3--DN)(
M&M$F)N'#-N)8=0!QP*VH4J:JVO?L3.3Y;GN?@#Q7H=QX6T#3/[;LY-4-I&C6
MYF!E+A<D$=<]:P_%_A/X:WWB:]NO$&O&TU.;:TT)OECV_* /E(XXP:;\.OAG
MH=O8^'_%:3WYU VZ7.PRKY6YEYXVYQSZUYG\9_\ DI^J_P#7&#_T4M33IQE6
M:A)K?\QMVC=H^F+&""UTZUM[9BUO%"D<3$YR@4!3GOQBLS6O&/ASP]+Y.K:S
M:6LV,^4S;G _W5R:QO&GB6;PI\,QJ-KQ>/!#;V[$9VNZ@;OP&3^%>._"_P "
M0>.]4U&]UFXN'M+8J92LF))Y7R>6//09/U%94Z*E%U)O1#<K.R/=]'\;^&-?
MN!;Z7KEI<3M]V+<4=OHK $_A6_@YQWKYS^*OPYL?!L=AJFC2W M9I3$\<K[F
MBD W*RMUYP?IBO5?A-XIN?%/@Z*2^D,E]93&VFD/60  JQ]R",^XI5:,5!5(
M.Z!2ULS=M/&'AK4+Y+&SU[3Y[N1BJ0QS@LQ'8#\#5*_^(O@[3+UK.[\0V:3J
M=K*A9PI]"5! KYET:UO;[QC;V6GW#6UU=7K0).IP8][%6/\ WR37IGCKX/:/
MX;\%W&K:5>79N+%5:43L"LRD@'  &T\YK:6&I0DHRD]1*;:T1[=97MIJ-G'>
M6-S%<VTHRDL+AE8>Q%3UX7^S]J%Q]OUO2S(QMO)2Y5">%?=M)'ID$?E7NE<U
M:G[.;B5%W5S&\5V&DZGX8OK37;DVVF.JF>82!-H# CYCTYQ7+^ ?#G@72=7N
MKKPIK!OKLV_ERI]K$H5"P.< <<@<UI_%'_DF.O\ _7L/_0UKS']G_P#Y&/6O
M^O)/_0ZTA!NC*5_D)OWDCV/4/%WAS2;Q[/4=<L+2Y0 M%-,%8 C(R/I3-9\9
M^&_#Y1=5UFUMGD4.L98LY4]#M4$XKY]^,Y ^)VHD]!!!_P"BQ7>:7\%K/7/#
MD>I:OJM\^NW\*SF<."D99054J1\P P#S],5;H4XPC.<MPYFVTD>GZ+XBT;Q%
M;O/H^I6][&AP_E-\R?53R/Q%:=?*_P ,;VYTGXFZ2D<A4S7#6DZJ>'4Y!!]1
MD _A7U166(H^RE9,(RYD%%%%8%!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 2P]#23=12P]#23?>'TJ?M%=".BBBJ)"BBB@ HHHH *QO%__ ")6
MO?\ 8/G_ /0#6S6-XO\ ^1*U[_L'S_\ H!JH_$@>Q\V_"[0=.\2>,[?3=5@,
MUHUO(Y0.5Y5<CD<U[/J'P4\'W-A-%9VL]G<E#Y<ZW#-L;'!(8D$>HKP'PIXB
MO_"VLPZKID,4MTD31A)4+J0PYX!!KK=8^,GC'4=,FLWCM;%)E*--!;,CX/!
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MH.*A;P?+I7P]N/#'AJ^DMY75UAN;ELLF]LORHZX) P.*\QT7X<>%/"NHS_\
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M)(W5P!E6/J<'!/M7A_PS_P"2J:+_ -?<G_H#UE3I22FKVM^)3DM#O/VA/O\
MAWZ3_P#LE==\(XHY_A-9PRDB.0W*.0<84NP/Z5R/[0GW_#OTG_\ 9*Z[X1?\
MDFM/K<_^AM3G_NL?7_,2^-F3X5\)?#*R\2V%QH7B#[5J<+EK>$7RON(4Y^4#
MGC-=_J7BOP]H]W]DU+6K&TN-H;RIY@K8/0X-?.'PD_Y*CHG_ %TE_P#1;U[;
MXK^%>B^,-<.JWUY?Q3F)8MD#*%PO3J#SS2KTXQJ)5).U@C*ZND:__"?^#_\
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MC/"WBK0-0TW2M.M-:LKB_P#LD8,"3!I,J@W<=<C!S7&>(O!_PPNO$E_/K'B
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M@NSO#:3>([,3*=IVEG4'W8 C]:^:?!VF76M>*+'2;.[>T>^+023)U6(@[_\
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M_@;X;:5X(#W$<C7NIRKL>[D7;M7NJ+_"/U-*$Z=!2<97;&TY-7./_:%.=/T
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M%MY;6/Q'T6XNYXX(0[J9)&VJ"48#)[<\5]'^)[JWN_ VO26UQ#.@L)U+1.'
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M(_.D"!B'!(!/?%>K^-O$OA&PTF"U\3#[5I^I!O+$<1F1]N.0R]",C!%<%/\
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M10 4Y/\ 6+]:;3D_UB_6AC)I/]6:KU8D_P!6:KU,=AR"BBBJ)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***4 GH,T )131)&7V"6,O\ W0XS3B".HQ0,** ,]*7:W]T_E0 E%+M;
M^Z?RHP<XP<T )12[6_NG\J-K?W3^5 "4444""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?\
MBE\5;G1;Z7P_X>D5+N,8N[S ;RB1]Q,\;L=3VZ=>GK5W<BSLKBZ89$$3RG_@
M()_I7R3X7M/^$H\=Z9!>DR#4+X/<$\[@27;\^:Z\+3C)N<]D1-M:(ZG1OA?X
MR\:V@U:^O1!%.-\<FHS.[R@]&"\X!]\50U_PKXM^&%S;W::@\<,C;8KNQF8)
MNZ[64]#[$8/-?3\LL5O!)+(RQ01(69CPJ*!R?8 5QFM^)/AUXDTXZ?J^NZ5<
MVI<2>6;K;\PZ'((/>KABZCEJKQ[6!P1'\+O'4OC30YQ?JBZG8LJ3E!A95(^5
MP.Q.""/4>]=U7(>"M-\#6DM[-X.>T=RJ+<FWN&EP,DKG)..]<5\4OBK?:-JD
MF@>'I4AF@ ^UWFT,RL1G8@/ P#R??':L?9^TJN--6]>A5[+4]E3[XKY6\!7U
MY)\3=&C>]N70ZA@JTS$$9/;-=EIT_P 7] L%\17+37UBJB::SNI%=S'U)*?>
M7CGCD>E<)\/7$GQ-T*11@/?;@,YQG)KIH4N2,]4]/\R)/5'UC1117G&A\R?&
M"]O(/B5JZ0WES&@2(A4F90/W8[ U]%>'B6\,:06))-E"22<D_(*^;OC+_P E
M-UC_ *YQ?^BQ7T!#K%IX?^'=GJUZQ%O:Z;"[ =6.Q0%'N20/QKNQ"_=4[&<?
MB9T5%?.,'C3XC?$'7WMM#NI;7 ,@@M6$<<*9ZNYY/U/4]!5KQ!X^^(GA6UBT
M/5Y3;ZFL@FCOE6-_.AP1MZ$'G'/![&H^J3ORW5^Q7.K7/H2J6KZG#HNC7NJ7
M! BM(6F;/? X'XG KE_A5KFI^(O!":CJ]V;JZ:YE3S"BKA5( &  *Y[X[:]]
MA\+VFB1/B749MT@!_P"64?/ZMM_(UE&DW5]F^XV[*YX9/JNL7\MS?R7EZ2\F
M^9EF<*K.20.#@=\?2OH_X1:^VO> +59I3)=6#&UE+'+$#E"?JI'Y5P_@SP*=
M1^">MR-'_IFJ9N+?UQ#_ *O\R&_[ZK*^!.O?8O%EQI$C[8=3@RBG_GJG(_-=
MWY5W5^6K3DH_99G&Z:OU/H<#)Q7CWC+XX06$EQIWART,MU&S1/>72XC1@2#M
M3JQSZX'UKV('!!]*X"U^%WAS1%U/57A:_P!0D6>82W6"L98,?E3H.O4Y-<-%
MTT[S5S1WZ'G'PX\=>*M8^(.E6&HZY<W-K,[^9$X7:V$8]AZ@5]"U\K_"/_DI
MNA?[TG_HIJ^J*VQL5&HDE;0FFVUJ%%%%<984444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% $L/0TDWWA]*6'H:2;[P^E3]HKH1
MT4451(4444 %%%% !1110 4444 %%%% !1110 445X7\4?&7C3PGXSFM+#67
MBL+B%9[5#!&=H/#+DKDX8'\ZUI4G5ERH3=E<]THK(T?78+[P?9Z]*P$+V0NI
M3TQA<M^H-?.<OQ@\</*\T>LLL9<NL?V>/ &<A?N^G%52P\ZC:704I);GU'16
M;;ZW;3>&(]>X^RM9"\.#T79N(_I7C?PU\;^,_%_CB"UNM7=M/C5[FYC$$8&P
M=%R%SR2HJ8492C*78;:0GC[P#XZUCQKJM_I$$[6,S*82M\$! 0 _*6&.0:]G
ML2VF>&[4WNY6M+)#/SN(*(-WU/!^M>+?$[XA^*_#_CK4-.TK5FM[2*.(I&(8
MVP2@)Y*D]:ZCXA2_$"6WLY/#A=M,?3-U\0(L%B"6^]S]WTK><)SC!2:2Z?\
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M35^P<Z/H6BFQR)+$DL;;D=0RGU!&13JY2@HHHH **** "BBB@ HHHH ****
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M1(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI(.\-DY(XXJ\+S*C)Q5W?_(4[<RN;G_"G_B!_P!!"#_P8R?X5T7B_3-5\,_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:UHKS?9=WE%$AC(W8ST//052TR7Q=\(?$5P\VE-+#*GERY1F@G4'*LKKT/\
M+)!%6=5\8>./B/JMI!HUE>V:1@JD5B\B+D]6DDX';OP*Z)<SGSQ2MW)6UF=W
MHVDZKH?P#UK3M8M7MKF*"Z*Q.02$/(Z$]R:X;X$JK?$%R1DKI\I'M\R"O6]3
MT:[TKX/7^DS7$VH7T>F2+)*2TCRR$$G&<D\G ]@*\P^".F:A9^.Y9;K3[NWC
M_L^1=\T#H,[DXR17/":=*H^Y37O(ZKX_#_BD]*X_Y?\ _P!IM2_ %%'A'5)
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MTEV1D8V4.Y&4J5.P9!!Y%:5>0]S8****0!1110 4444 %%%% !1110 4444
M%%%% %A/N+]*@/4_6IT^XOTJ ]3]:F.Y3$HHHJB0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#RKX^?\B7IW_807_T!JA^ $42^&-7F4#S
MGO0KGN0$&!^IJ;X^?\B7IW_807_T!J\W^'WB/Q)X1LK[5],TLZEI+R+#=Q#/
MR2 95OE!*\'&<$?I7H0@YX6R[_J9MVF=Q^T&D?\ 9WA^0@>;Y\R@]]NT$_AG
M%7?A.7/P;U8/]T/=A/IY?/ZYKS?6]3\4?%KQ);BVTIP(AY4$,:MY4 )^9G<C
M'ID\=!@5[SIOAR/PO\.9-$MR9FAL9@[JO,LC*Q8@>Y/ ^E*I^[HQIO>XUK)L
M\!^$.G6VI_$73(KN))HHHY)Q&XR"RI\N1['G\*^D_$LLT?A36)(2?-2QF9,=
MCL-> _!K2M2M/B)9RW6G7D$0MI@7EMW10=OJ1BOH]T21&CD4.C@JRGH0>"*G
M&2_>I^007NGS'\%8XI/B5IYDP2EO,\>?[VS_  )KWWQTD4G@#Q L^/+^P2DY
M]0N1^N*\*\0>"_$GPW\4IK&C0S3V4,QDM+J*,R!%.?W<BCD<$@]B*F\0?$[Q
M3XXTEM!M=$$2W!"SBSCDD>3G.T9^Z">O\ZUJTW6J1J0>@HOE5F)\"Y)E^(;*
MF=CV$HE^@*D?K6Q^T#_R&="_Z]I?_0A77_"7X?7/A*SN-3U9535+U GD@Y\B
M('.TD?Q$\GTP*S/C=X3U;6X],U32K26\%HLD4\,*[G4$@A@.I'!!Q2]K&6*4
MD] Y7R6.F^$7_)+=&^DO_HQJ\3^+\DD_Q0U5),X00QH#_=V#'ZDUT/PX\0>.
M]/O-*\/PZ9<_V.+H"4S6#YBC9LO\YQ@<D^U;?QE^'NH:KJ \1Z-;/='RA%=V
M\0S)\OW74?Q<<$#G@44[4L0W)[W_ #!^]'0IQZA\;HX4A335$:J$5?LT'3&,
M=?2LCP'X"\8Z+X\T?4;K1)[>VAG)FD+IA4*D'H>G-2V_QI\4VFC+I3Z/&VHI
M%Y*W3I('X& QCQRWZ9[5O?"/0/%LVK?V]K]YJB6$<;+!!>3OF=VXW%&/W0,G
M)'7&*<N>G"5TE?\ $-&T<G\=?^2A_P#</B_FU>JZQ_R0:3_L!)_Z *\U^-FE
MZC>>/A+:Z?>7$?V&)=\,#NN<MQD"O3M6MYW^!SVRP2FX.BHGE!#OW;!QMZY]
MJB;7LZ0U\3/+O@,BMX\NF*@E=.<J?3YT%=;^T !_PCNBG'/VU_\ T6:YWX&Z
M;J%GXVNY+NPN[>,Z>ZAYH&0$[TXR1UKJ?CO97=[X?T=;2UGN&6\8LL,3.0-A
MY.!53:^MIB2]PG^ ?_(CW7_81?\ ] 2O'_#O_)6=/_[#7_M4U[+\#;6YLO!5
MW'=6T]O)_:#L$FC9"1L7G!'2O+/'?A'7/!_C&XU2VMIFLVNS>6EW%&75#NW@
M-CH0>QZXJJ<E[:I&^XFGRH]T^)K!/AOXA+' ^RD?FPKQ[X#?\CW=_P#8.?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% 'EOQXBDE\&Z>L44DC#4 <(A8_<;TJM\ 8IH/#^LB2*2,F\0@.A7(V>]>N
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MZU,=RF)1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !3D_UB_6FTY/]8OUH8R:3_5FJ]6)/]6:KU,=AR"BBBJ)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %A/N+]*@/4_6IT^XOTJ
M]3]:F.Y3$HHHJB0HHHH **** "BBB@ HK-UO7M-\.V*WFJ7/DQ/((HPJ%WD<
M]%15!+$^@I-#\0Z7XCM)+C3+@RK%(8IHWC:.2)Q_"Z, 5/UHN,TZ**J7^IV&
MEQ+)?W<5NC'"^8W)^@ZT";25V6Z*@M+RUO[<7%G<1SPGH\;9'_UJGH!-/5!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !3D_UB_6FTY/\ 6+]:&,FD_P!6:KU8D_U9JO4Q
MV'(****HD**** "BBB@ HHZUQ]W\2M"M+RZC\G4Y[.SE\F[U*WLV>UMW[AG'
MIQG .,T-V&=A16'KGBO3]"%FCQW5]=7N3:VEA%YTLR@9+ 9 V@$<DBK.@Z_8
M>)-.-[I[R;4D:&6*:,QR0R+]Y'4\JP]*+@:=%%% @HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBO RK+XC\=/<*K7#:QY<FX
M<F$1*$!]L$XKM:Y?6O >E:WJ<VH&ZU.QGN8UBO/[/NC"MV@X"RC'/'&1@XXS
M2:&BE\)"Y^&6EY),8><0D_\ /,3/M_#%=LO+ 'UJO96=MIUC!96<*06MO&(X
MHDZ*H& *GIK8#PS7+FXO==O9KS)F\YDPW\ !P%'H,5U'@;4]9@L[JVL--_M"
MWC=2%:Y$(B)SP"0<YQT[?C6G\0=$L_[-?6(X=EX)$61U. ZGCD>O3FMGP7'
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MK1_^#6/_ .)K6HHY N9/]L^(_P#H5H__  :Q_P#Q-']L^(_^A6C_ /!K'_\
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M/_OHT^BBX6&9F_NQ_P#?1ICRRIC*(<^C&IJAG_AIK5@-^T2?\\U_,T?:)/\
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MMSJT\D@U+3K>T0*"C17/FECZ$8&*T:.P^@HJT>G%65KW"BBB@84444 %%%%
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M$^XOTJ ]3]:G3[B_2H#U/UJ8[E,2BBBJ)"BBB@ HHHH **** "BBB@ HHHH
M\Y\<Q2:+XHT_7H%/SD%L=W3J/Q7^5>AQ2QW$,<\1W1R*'0CN",BL3QCIAU3P
MQ=(B[IH!Y\?U7J/Q&:I?#[4_MWAL6S-F2S?R_P#@!Y4_S'X5*T9R0_=XB4>D
MM?GU.KHHHJCK"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ"BHK:ZM[RW2>UGCFA8</&V0:EJD>BG?5!1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %:3_6-]:;3I/]8WUIM:K804444P"C)( )X'2BB@!P=@,!CCTS2*Q4Y4
MD?2DHI !))R3D^]&3@C/!ZBBBF 9) &>!T%4-;TBWU_2I=/NY)TC<JRRP2%)
M(V4Y5E/8@U?HH6@&#9>&/*UFWU?4M8O]6O;6-HK9KD1HL(;AB%10"Q'&36]1
M10VV(=YC@8WMCZT@)4Y!(/J*2BE88XN[#!9B/0FCS9/[[?G3:*+( /)R>M%%
M%, HHHH ?%_K!5BJ\7^L%6*SEN-!1114@%%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH ?%_K!5BJ\7^L%6*SEN4@HHHJ0"BBB@ HHHH **** "BBB@
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MM% "44M% "44M% "44M% "44M% "5+#]X_2HZDA^\?I2EL-$U%%%9#"BBB@
MHHHH **** "BBB@ HHHH EAZ&DF^\/I2P]#23?>'TJ?M%=".BBBJ)"BBB@ H
MHHH ***S=;U[3?#M@+S4YS%&\@BC5$+O+(>B(HY9CZ"@9I45AZ'XLTO7[N:R
MMQ=6U_"@DDL[ZV:WF"$X#[6'*Y[BJ5O\1/#=SJD5E'<W&R:<VT%XULXM9ILX
MV)+C:3D$>A[4706.IHHHH$%87C,%O!^I*.I10/\ OM:W:PO&9QX0U$_[*?\
MH:T/8SK?PI>C_(YOX9SF&^U33WX8%9,>ZDJ?Z5T7@O\ Y%>'_KO/_P"C&KF=
M,QI/Q9G@^ZEPS #V=0P_45TW@O\ Y%>'_KO/_P"C&J5N<F$T:@^G,OQ1OT44
M51WA5/4-'T[6!$FHVD=RL;90/GY2>M7*5?OCZT,&E)69QGA3P]I$MO/=R:?"
MT\&H3K$YSE C_*!SVKLNM8'A#_D&7O\ V$KG_P!#K?I(QP\4J:L@HHHIFP44
M44 %%%% !1110 4444 %%%% !44_\-2U%-_#51W!D-%+16A(E%+10 E%+10
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M** "BBB@ HHHH **** *TG^L;ZTVGO\ ZQOK3:U6Q(E%+13 2BEHH 2BEHH
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MPS=+_P \U_[[_P#K4;I?^>:_]]__ %J?11<+#-TO_/-?^^__ *U&Z7_GFO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,J[MQCP"2<=.<5#*1[3#YWV>+[24-QL'FF/.W?CG&><9S3ZBM8X8K."*W;=
MD:K$V[=E0.#GOQCFI:L0H4GH#7GWQ!U3Q9ICP76G7-O8:3%=VL;.JAYKHR2!
M67GA%&?J:Z34_"MEJVII?SWNJQ2H% 2VOY(HS@YY13@^_K6=\1[&[U'PO%#9
M6TMQ*-1M9"D2%B%64%C@=@*3!&;\0]<GTWQ'X>T\:]<Z-8W4=T]Q+:QJ\KE
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M6T44$ @@]#5$A@^E&#Z5'Y$7]P4>1%_<%/0-23!]*,'TJ/R(O[@H\B+^X*-
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M110 4444 %%%% "K]\?6K%5U^^/K5BHD-!1114@%%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH ?%][\*EJ*+[WX5+4/<84444@"BBB@ HHHH
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M_1113- I5^^/K24J_?'UH&<_X0_Y!E[_ -A*Y_\ 0ZWZP/"'_(,O?^PE<_\
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MI4ER6M()<Y#*F,\$D@$D#)XI68[G8'/\77'/UHHHJB1K,X/RIN'KNQ2;Y/\
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M5HDTNYM)+6<0R3SPA!=8'#(W\2CIFG:P&K1113$%%%% !1110 4444 %%%%
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MF\\QL-!'+R)4[$@C!'<8KKZX'QM%INH^+=(TCQ+J*VV@3VDT@@^U&!;BY#*
MLA!!V["Q R 3GZ4I;#1+X5L?$DWB@:IK.DQZ7';Z6NGR;+A9?MLH8$2#;T4
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MZ\,>([C[-I6LP3W!&1"V8W;Z*P!/X5T-#BXNS0!1112 **** "BBB@ HHHH
M**** "N;\;Z;<ZEH$0MK3[;]EO;>[ELN/])CC<,T8SP3CD \$@"NDKF/'MU?
MVWAZ"+2M0DL+^[O[>TAN5"D(9'"Y8,#QC/N3@4GL-'$:3)=Z_)IVFVGAC5;)
M[;Q ^IM>7UI]G2V@\UGVJ<\LRX7:..>>E>O'K7FFKZ/XLTC5-&@;X@ZBT.HW
M!M,FSAWI)L9U8#'S+\I!';(KJ_!VI7VHZ+.FISQ7-[97D]E+<PKM6<QM@.%'
M0D8R/4&DALZ"BBBJ)"BBB@ HHHH ****  $CH:P_&.G'5/#%W&HW2PCSX_JO
M)'XC-;E''0C(/!'K0T3.*G%Q?4Y3X>ZD+WPT+9FS)9N8_P#@!Y7^H_"NKKS?
MPWGPY\0;O27.(;@M&F>_\49_+(KTBDC#"2;IV>ZT^X****9TA1110 4444 %
M%%% !1110 4444 %%%% !1110 A^Z?I4-3'[I^E0U2 ****8!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3X^IIE/CZFD]@)****D HHH
MH **** "BBB@ HHHH **** )8>AI)OO#Z4L/0TDWWA]*G[170CHHHJB2&[F>
MWLYYXH'N)(HV=88\;I" 2%&>YZ?C7$^(IX]0BTVZO_AK<:S-+;;V61(G:U)/
M,9W=^]=Y7$^*M5CTWQQH!UG4Y--T(0RRI*)#'%-=AEVI*W]W86(!P"<^E*0T
M4= T30M8OGM[WX5PZ3$L9<3W5M"58Y V_+SDYS^%>A1QI#$D42*D:*%1%& H
M'  ]JXK0M:MM4^(^H_V'JSZEI4E@);S9+YD$%P&"QB,] 60,2!Z UV]$0844
M44Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[ZR@U*PGLKE=
MT,R%&]O<>XZU8HH!I-69YOX1O9O#7B2Y\/:@V(Y9,(QZ"3'RL/9AC\<5U7C7
M_D4;[ZQ_^C%K*^(.A&\T]=6ME/VFT'[S;U://7ZJ>?IFJ]SKHU[X;W4LC#[7
M"8H[@#^]O7#?0CG\ZG;0\]-THSH/LVO0[L]:*#UHJCT0HHHH$%%%% !4<G:I
M ,]*;(C'&%/Y4T!%101@X-%4 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 /C^]^%25''][\*DJ6 4444@"BBB@ HHHH **** "BB
MB@"PGW%^E0'J?K4Z?<7Z5 >I^M3'<IB44451)POC>\\8:-<W^IZ)9B_TTZ4Z
MF,7"1FTG4LWG;6!\S@CY1UVXJ.Q\2^.)=-M9#\.HIF>%&,IU6!-Y*CYMN.,]
M<=J[\9R,=:QX/%?AZY^T>3K=C(+>5()F68;4D8D*I/3)(('TJ;#-2%G>WB>6
M+RI&0%X\YV''*Y'7'3-/HHJA!6%K'C3PUX?O4LM5UFUM;E@#Y3$EE!Z%L [1
M[G%&J>*8-*U2.P?2=;N6<*?.M-/>6(;CCEQP,=_2J6M:7?:7!J=[X1T;3+O4
M]19C?&[G.9"%PHQR#_NY4?G2;&;&I>(-(TC2EU2_U*V@L7QY<Y?*R9&1MQG=
MD<\9J72M7T[7=/2_TJ\AN[5R0)(FR 1U![@^QYKROP3%I\NM> [6VDGN+"TT
MF]GMS=)M87'F[9,KR 5^8#K@5U?AQ5M_BIXUM[?Y8'BLKB1%^ZLS(P)QV+
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M<?W;?F*3<W_/-OS%785QU%-W-_SS;\Q1N;_GFWYBBP7'44W<W_/-OS%&YO\
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M#?9I>V=P'W+<1X4."/X65F QSD$&KFMZWI_AW29=4U2<P6<157D"%\%F"C@
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M&^EVV'OIY;M^ZC]VGZ<G\ZU_[=U/_H4]6_[^V_\ \<H_MW4O^A3U;_O[;_\
MQRBR*CA*:=Y>\_,U+*PL].B\NRM8;=/2-0,_CU-3LH=64]&!!_&L3^W=2_Z%
M/5O^_MO_ /'*/[=U+_H4]6_[^V__ ,<IW1TI)*R(_P#A"="R"8;HD=";R0D?
M0YXK6L-/M],M!:VHD$0)8"20N<GKR>:S?[=U+_H4]6_[^V__ ,<H_MW4O^A3
MU;_O[;__ !RC0B-*$7>*2-RF30PW*;+B&.9?210P_6L;^W=2_P"A3U;_ +^V
M_P#\<H_MW4O^A3U;_O[;_P#QRBY=B.\\$>'[S)^P_9W/\5NY3].E<_<_#+8W
MF:;JK1MV$R8/_?2UTG]NZE_T*>K?]_;?_P".4?V[J7_0IZM_W]M__CE+0PGA
M:,]X_H<I]B\?:+_J)WNXE[*ZS#\FYK,UGQCKUW;'3KJ-;)L$3!(RC2 CH0>@
M^G6N^_MW4_\ H4]6_P"_MO\ _'*Y7Q?97>L+_:(\/:G:3P1GS))'@*,@YRV'
MSQST%(YJ^&G&#]G)^ES,\.^./[#S'K5VW]E*F!(REC!V&,<E>V.U>@6GB+1;
MX(;;5K1]_P!T-($+?0-@UYS8>$EOM.;^U_#>J7\-PJM&()HHUQU#9W@D_6JO
MB+X;KKL,:0Z3XAM3%DH&-M(O/K^\![5M3Y=%)V*PJKQ@E+;\;=#V/!(R.1ZC
MI25XA?\ A?XAVR0)X>MM0L_*/+K=HA<8P.-Y'YUJ:OXD^(_AFSMW&F3ZAC F
M:6U\T8"_WDYY-7&'-:SU9NJSTYHM7/6Z*\NG^,::3:6TNLZ.=\N RVLN&4XR
M?E?M^-:<OQ;T6"V@N)M.U".*;&UG:,8R,C/S<4N65D[;CC7IR2:>YW4]Q#:P
M-/<3)#"GWI)&PJ_4U2/B#1 ,G6+''KYZUB+XUM+[3WN$T6>YL]F]F^TVS*5'
M?!?G\JP(?%&C#7KB]_L1G@N((H8[?RX@4<$Y)R=HSD<UFVTR:M;D:2:U/24=
M)(UDC8.C ,K*<@@]Q3JQ5UG4%4*OA+50H& %DM\ >WSTO]M:E_T*>K?]_8/_
M (NG<Z#9HK&_MK4O^A3U;_O[!_\ %T?VUJ7_ $*>K?\ ?V#_ .+HN!LT5C?V
MWJ7_ $*>K?\ ?V#_ .+H_MO4O^A3U;_O[!_\71<"T^N:1%*\4FJ6:2(2&1I@
M"I'4$5/:7]E?AS9W<%R$(#&%PVW/KBN"\3>(+%R+.70);2\2XBGE+B%B5#!B
MI*D\D>OXUT.G:^;BV^TZ9X2OO(E.=T#6Z@X]</U'O4\VIA"HY5'"ZT.DHK&_
MMK4@,GPIJH'J9K<?^U*J3^,!;'%QHMS$<XQ)>VJG\C)5)WV-CI**X>[^*>C6
M#JES:7"2-]U/M$!9N<< /ZU4O?C'H6G21I=Z7JL;2?=&(SGG']ZJ49-I);D\
M\>YZ'5.^T?3=5,1U&SAN%BSM,G\ /6N(U;XQ:)HZQ_:-,U$M)G:%,>./4[O>
MLKQ'XPD\0PQ6]O&]M:@;GC\P,9">F<=O:IDFHJ3V9SUL32C"[UO^)UG@W0])
MDTZ*_-C UU'=3;)NZ[7(7OV&*[.O&O".H7-AXELEMW;9<2B*6//#J?;U'7->
MRGK4(,%4C.GHK6*]_>PZ9IMU?W!Q!;0M-)]%&3_*OE[1+*_^*?Q#Q?W3(]V6
MFGE SY,*\[5!Z8X4?G7OWQ-D:+X9^(&0D'[+M_ L ?YUY+\ XU/C347(^9-/
M.T^F76N_#>Y2G46YT3U:1D?$OP&G@'5-.GTR\N7M;G+0R2,!)#*F"?F&/4$'
MZU[I\//$DGBOP58ZE<$&[&8+D@8S(G!/XC!_&N,^/Z ^%]'?'S"_('T,;?X"
MI_@&['P5J"D_*NHM@>F46BHW4PZG+=,2TG9'JE%%%<)H%%%% !1110 4444
M%%%% !6'XPET.+PM>_\ "1IOTM@JR( 2SL6&T(%YW;L8QR#S6Y7-^.=-U/4_
M#\::-;0SZE;WD%U;":78BO&^X,?4<8QQG/44/8:.%\.S>&HO$%LW]A>/+B\<
MFVM[G5H9'2U63Y25);Y!@\MC(%>HZ1H]AH&EPZ9IENMO9P A(U)/4Y))/)))
MSDU@6>K^/I;V".]\*Z;#;,ZB:5-4W%$S\S!=O.!DXKK/I4Q&PHHHJB0HHHH
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M+]+U&FBBS@[3MR<#/&?:N\[\41!A1113$%%5;C4["TO+6SN;V"&ZNR1;PO(
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M/"8]0NK-3;VMV_V>.X$T8(&"ZGY7QV/M7JGA#Q*?$%@ZW/EK?0MM=5X\P=F
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MT-18IJPAN_\ V)/^^:-_^Q)_WS3\48IZ ,W_ .Q)_P!\T;_]B3_OFGXHQ1H
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MYJ*>P/##\"/UI;,Y/X>)\I+\4=W1113.L**** "BBB@ HHHH **** "BBB@
MHHHH #T-19J4]*CIH&)FC-+13$)FC-+10 F:,TM% "9HS2T4 )FC-+10 F:,
MTM% "9HS2T4 )FC-+10 F:,TM% "9HS2T4 )FG)U-)3DZF@!U%%%2,**** "
MBBB@ HHHH **** "BBB@"6'H:2;[P^E+#T-)-]X?2I^T5T(Z***HD9,TB02/
M%%YLJH2D>[;O;' R>F3QFN4O_%DU[H&IP:/#-;>)H+<NNF748%PA[LBGB4 9
M(*DJ3@=ZZXYP2%W$#A<XR?2O'[759?%&H:)#JFK6>JW5Y<%9]'AM?(N-'.UB
MTB2J1(AC*A26^]GCM4ME(Z/P7J,USX@F@L-5UO5=(%H7N)M6MS&T-SN 54)1
M2<KO)7! P.>:[VL/3+?7]-OEL[J[35=+*GR[N;$=S"1T5P!MD!_O *?4'K6Y
M30F%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@^
M-/\ D4;[ZQ_^C%K>K!\:?\BC??6/_P!&+0S.O_"EZ/\ (WCUHH/6B@U"BBB@
M1'<6\-W;26]Q$LL,B[71QD,*\UU'2]2\!ZI_:>F.TNG.0K!N1C^Y)_1J].IL
MD:31/%*BO&X*LC#(8>AI-7,:U!5%?9K9F?HFN6>OV(N;1B&7B6%OO1-Z'V]#
MWJE%_P C_??]@R'_ -&-7)ZUH-_X.U$:UHCL;,'#J>?+!/W6'=#V/:H(_';+
MXCDU5].'ERVZ6[Q+)\P"DG(/KD]*5^YRO$\MHUM&G_GJ>FYHS45I=0WUG#=V
M[[X9E#HWJ#4U:'>G?5"9HS2T4 )FC-+10 "L'P9_R*5C_P!M/_0VK>K!\&?\
MBE8_]M/_ $-J74S?\1>C_0W<T9I:*9H)FC-+10 F:,TM% &%XA_Y"'AS_L)C
M_P! :MS-8GB'_D(>'/\ L)C_ - :MRDMV9P^.7R_)"9HS2T4S03-&:6B@!,T
M9I: ">@S0 J]:?2*C _=/Y4M)C"BBBD 4444 %%%% !1110 4444 6$^XOTJ
M ]3]:G3[B_2H#U/UJ8[E,2BBBJ).2\6P:M->VUO:^+-/TJUOE^RK975@DYN7
M.=P&6!(((!&/YUBQZ%XN\-Z?86,GQ(L(("ZVEK]ITI,LV#MC#%^3@<#KQ5K6
M;G3])^+5AJ.NM%#9RZ5Y&G75QQ%%<"0EUR>%<J5P3C(!%.^)&M>&[GP-J5E/
M>V5Y=7,3)86\,BRRM<D8C**N3D,1R*@H[B%9$@C2:022J@$CA=H9L<G';)[4
M^JVG+<II=FEXVZZ6",3'.<OM&[]<U9JT(****!!1110 4444 %%%% !1110
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MRB5XXB^]GD8<;B<<#H!78TT#..U/P;K-QXGO-;TCQ?/I#74<<;P16,<BD(,
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M=,3(F8*DF'E;DKAL$ #/->B'DT(&%%%%,04444 %%%% !1110 4444 %%%%
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M2R2>8S@\YW=ZLUY9H\OC:RTB Z9!*]BP+1*8U?@GL#R!5[_A+O%]G_Q]Z,&
MZ[K9U_44TSJCC(J*YHM?(]%HKSM/B;<1'%WHRKZ[967_ -"%78?B=IC_ .NL
M;I/=65OZBGS(M8V@_M?F=O17+P_$'P]+]Z:XB_WX#_3-7XO%OAZ8@)JUL">S
MDJ?U%%T:*O2>TE]YI27EK$Y22Z@1QU5Y5!'X$TD5S;SL5AN(96 R1'(&(_(U
MP?C?5/#\D<T%O96MYJ-S'S>H%/E=@=W=O:M'P7JFC7SR1VNE6^GZ@L?S^4H_
M>IZ@_7J#0GJ9+$IU?9W1V%%%%4=04444 %%%% !1110 4444 %%%% !1110
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MC5!X&L;VUAE'VP0Q*'A@P=TH!^]MXR/3Z5!1WMO'##:PQ6RHL"(JQ*GW0@&
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ME&\_\\G_ $I]%%P,#Q"Y.H>'?D88U(=>_P C5N;S_P \G_2L;Q$"-0\.<?\
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MC8O>2EU!5@>PR. :ZK4&E:]SMU/./!FB7OQ4\>W7B/7$SIMO(&EC)^5B/]7
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M@XI1&PHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX=_Y"OB7_L(_^TUK?J49T?@^_P#-GEOQ[_Y$:Q_["*?^@-5']G[_ ) >N?\
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MA!1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !2BDI10 M%%%( J"2RLYIO.EM+=Y?[[1*6_/%3T4 %+DTE% "Y-&3244
M%'6BB@!=Q]32444 2P]#23?>'TI8>AI)OO#Z5/VBNA'1115$A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4AI:0TP$HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,+P[_P A7Q+_ -A'_P!IK6_6!X=_Y"OB7_L(_P#M
M-:WZE&='X/O_ #84444S0**** "BBB@ HHHH **** +"?<7Z5 >I^M3I]Q?I
M4!ZGZU,=RF)1115$E>>PLKIP]S9VTS@8#2Q*Q ],D46]A96DGF6UE;0OC&Z*
M%5./J!5BBBPPHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 T]:*4]:2F 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 56O[^WTVT:ZNBXB4@$I&7.3TX'-6:4
M9!R.* =[:'%6'B;3+?Q#K-Y*;L07(@\IA:2'=M4@\8XYKM58.BNN<, 1D8X-
M+N;^\?SHI(SIPE%6;O\ +_@A1110:!1110 4444 %%%% !1110 4Y/\ 6+]:
M;3D_UB_6AC)I/]6:KU8D_P!6:KU,=AR"BBBJ)"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!IZT4IZTE, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 4=:6D'6EH ****0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4E+24 %%%% !1110 4 D=#BBB@!=[?WC^=)110 44
M44 %%%% !1110 4444 %%%% !1110 4"B@4 +1110 4444 %%%% !1110 44
M44 %%%% $L/0TDWWA]*6'H:2;[P^E3]HKH1T4451(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %!HH- "4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5-1O);&W66'3[F^8MM,5OMW >O)'%6Z*!--K0Y'2+[4[/4-2DE\.:
MGMO[P3*1L_=C:J_-\WL3Q77]Z04M)*Q-.#@K7N%%%%,L**** "BBB@ HHHH
M**** +"?<7Z5 >I^M3I]Q?I4!ZGZU,=RF)1115$A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4M)2T %%%% !1110 4444 %%%% !1110 4Y/]8OUIM.3_6+]:&,FD_U9
MJO5B3_5FJ]3'8<@HHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBFRRQPQ-++(D<:C+.[!
M0H]23TH =15%-;TF1PB:K8,S' 5;E"2?SI9]7TNUF,-QJ=E#*O5)+A%8?4$T
M7&7:*;'(DT:R1.KQN RNAR&'J".M.H$%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4E+10 E%+10 E%+10 E%+10 E%+10
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M: ,\W_IG)_WS1YO_ $SD_P"^:?11H SS?^F<G_?-'F_],Y/^^:?11H SS?\
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MKFYOGU'5=1E66]O70)YA4;555'"JHZ#GK0EJ%S=HHHJB2/S?^F<O_?-+YO\
MTSD_[YI]%/0!GF_],Y/^^:/-_P"F<G_?-/HHT 9YO_3.3_OFCS?^F<G_ 'S3
MZ*- &>;_ -,Y/^^:/-_Z9R?]\T^BC0!GF_\ 3.3_ +YH\W_IG)_WS3Z*- &>
M;_TSD_[YH\W_ *9R?]\T^BC0!GF_],Y/^^:/-_Z9R?\ ?-/HHT 9YO\ TSD_
M[YH\W_IG)_WS3Z*- &>;_P!,Y/\ OFCS?^F<G_?-/HHT 9YO_3.3_OFCS?\
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MWR:DS13T#4C\Y/\ :_[Y-'G)_M?]\FI**- U(_.3_:_[Y-'G)_M?]\FI**-
MU(_.3_:_[Y-'G)_M?]\FI**- U(_.3_:_P"^31YR?[7_ 'R:DHHT#4C\Y/\
M:_[Y-'G)_M?]\FI**- U(_.3_:_[Y-'G)_M?]\FI**- U(_.3_:_[Y-'G)_M
M?]\FI**- U(_.3_:_P"^31YR?[7_ 'R:DHHT#4C\Y/\ :_[Y-'G)_M?]\FI*
M*- U(_.3_:_[Y-'G)_M?]\FI**- U(_.3_:_[Y-'G)_M?]\FI**- U(_.3_:
M_P"^31YR?[7_ 'R:DHHT#4C\Y/\ :_[Y-'G)_M?]\FI**- U(_.3_:_[Y-'G
M)_M?]\FI**- U(_.3_:_[Y-'G)_M?]\FI**- U(_.3_:_P"^31YR?[7_ 'R:
MDHHT#4C\Y/\ :_[Y-'G)_M?]\FI**- U(_.3_:_[Y-'G)_M?]\FI**- U(_.
M3_:_[Y-'G)_M?]\FI**- U(_.3_:_P"^31YR?[7_ 'R:DHHT#4C\Y/\ :_[Y
M-'G)_M?]\FI**- U&+*K' SGW4BGT44 %%%%( HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***4#) ]: $Q17F4$&M>,+3Q#KT7B
M#4].ELKNXM]*M[24+"HAX#2)C]X68'(/;I7:^%-8?Q!X2TG5Y45);NU2215&
M 'QAL>V0:28[&Q1113$%%%% !139/,$3^4%,NT[ YP"V.,^V:X#PJ=?M?B3J
MMAKFMOJ$ATN&Y:-%V00NTA&V-/0  9/)ZFAL9Z#@T5POB71=0/\ ;6NZOXMO
MM-L+2/?81Z=.8D@55ZR@C]XQ;''/7 ZBN@\(WVHZGX/TB^U>+RM0GMD>==NW
M)/?'8D8..V:286-JBBBF(**** #!-%<7K^@W]W?ZGJNK>++W2M&M80UG'ITY
MA\G R\DQQ\YST'3'&*BT;QA?V?PJTO7M=MVEU>YC6.&V4;7NYF8B( =BXVL<
M= 2<4KCL=S17!_#R76UUKQ78Z[J;7]U;7-N2<GRXF>+>R1@]%!.!]*[RFG<
MHHHH$%%%87BFPU/4;"&"PU@Z5;"3??7$0_?>0 25C.#M)]:&,W<8HQQFO,O"
M&O>7K.N2Z1K-_KGA.QT_SWGO93(\=T,L8T=@&92G)SD UB:1KT>K6VG:C<>/
M=2LM?O94<$1NVFQ%CD6Q7 CR%(!RV[/?M4\P['M%%*>O3'M251(4444 %% &
M3@5Y5XC\2:KJGB'1K_2KZ:V\/P:[;Z8#$2!J$C,?-8GO&NW:.Q);TH;L.QZK
M@GI17FOC#5(;;QK+:^)_$&I:'H7V9'TY[&9H5N),GS=[H"VY<KA>F*W_ (>7
MNJW_ (7:XU.>6YC-U(-/NIP!+<6F?W;R ?Q$9_#%),+'5T444Q!1110 =:*\
MX\9>(XF\9Q>'KO5K_3=.ALA=3#3=WVJ[E=B$C78"^T!2QV_C5>37KNQ\!9T3
MQ/)JKZAJL6G6-W<Q?O[(2,%*R9Y9U&>6 /(I<P['I^,45P4$=[X.\=Z'I(UC
M4]3T[6X[B-QJ,WG-#/$H<.K8! 89!7I7>T)W ****8@HQFBL[6M(36]/^QO?
M7]D-X?SK"X,,G';<.WM0,TL'T-)@UYGI&D36OQ8BT[3_ !!K]W9:59FXU%;W
M4&F1I)!B*+!Z'&7_ "]*/%FFZUH^BZUXGU'Q??P:A#(S:9;V4NVV4=(HC$1^
M\9CP2<_I2N%CTRBJVG2W,^EV<U["(+N2"-YXAT20J"R_@<BK-, HHHH$%%%%
M !1110 4444 %%%% $L/0TDWWA]*6'H:2;[P^E3]HKH1T4451(4444 %%%%
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M44TK!<****!!1]?THHH \ZU#3OB#?:!?>%[N+2M0BNU>$ZW+/L(B8]6@"_?
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M]7T"S*O969U%($>7&?-E!!WD'("]!7<Z7<W]WI\<^IV"V%VQ.^W2<3!.>/G
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M/0![>=R-09+I8)C%Q\D;D$+NYRV,C'O5OPD-2M;(:;<>%K;0K&UC"VR07RW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEM?"^B:3=ZS?6=G&9(HYDC6&(#:I>20@;FP<#DG!-*OCS2CX;?5VANE=+O\
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M#23=14_:*Z$=%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S_CC29-;\#ZQ80,ZW#6S20&-BK>
M8GSK@CW4#\:Z"E!P0:&,\PUS4I/'/A#P?H]K>26\_B+;)<2Q'YDCAC+R\_[X
M456N-;NM=^$'A_35EE35-6NH-(F93B1&1\2L?^ QDGZUI>!?!VJZ%XLU&:_C
M1-*L%EM]% *G,4TQE<X'((^5><=Z;HG@W5;+XHWM[<1!?#]O/<7^GL&!W7%P
MB*XQG( P_4=_>HU&=#?>*'MM5GT;0M"N]8GL$3[4(9HXDMPPRJ[I"-SD#.!^
M)II\>:7+X=T_5[.&ZNGU&;[/:6*(!/),"0R$$X7;M.23@ =>E<UJ_@SR?&.L
M:I<>#H/$UKJ;)+"PEC26VD"!61@Y *G .1T]#3]5\"W=UX7\/YT'1Y;G3+I[
MB?1K8^7;S(X(9%9C]\ J<G@D&G=AH;\'BDZA_:FC:AIEQI.L0V#W0MI94D#P
MD%=Z.A(.&X/0@UC^!_%"KX=\*Z';6T^HZA+81S73(X"VD1Z/(Q[GLO4XJ;P_
MX<:"XU2YMO!NGZ!!)9/! N5:[E=NNYD8JJ<#CDYYR.E9W@_PKK?@E-%N+'3R
M\-[;1P:Y8+(NZ&51A;A"3@^C 'GMGLM0/3J***LD**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% $T0^3/J:)A\H/I3U&U0*&&Y2*SOK<NVA6HHZ'%%:$!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113D&YP*!D
MZC"@5!(,.:L5'*N0#Z5$7J4]B&BBBK("BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "GQC+BF5+".":3V&MR0C((JM5JH)%P^>Q
MJ8L<AE%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5)$N3N/04U$+?2K &!@5,GT*2"BBBH*(I4_B'XU%5JH7CQ
MRO3TJXOH2T1T4451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !4\:;1D]338X_XF_ 5+42?0I(*.M%%245W7:V.W:FU990PP:@92IY
M_.M$[DM#:***9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+94\S>S,/E9E.WISQSQ6+J'B37=-\%>.K!]4EFO] E1+;4=BK(T;A64-@8+
M$@G S0!ZW17F6OWOB/PEX7@N6UN[U/5=:O;:T5EMXL6Q?);R(^ 3@8 <X) R
M>N9O"UQXH@\31V_V?Q'-H\T$AFDUX6^Z&8<H4:(Y*GD$$<<$4 >CT5XYINN>
M(++5M/\ ^$@UO6-*U>6]6*Y@O[)6TRX4L?W<$B+A3C&&+=0<]:L7^O:]KOB3
M7([?_A*(K33;LV=L-$AMRF]5!9I3*<N26'RC  QW- 'K=%>8:KK'C!_#O@I+
MB<Z-K=_J2VM[B-7&-LF3MY!R%#8Z9-6K,:K8>/KKP?-X@U&\L;W2&O8KF4QB
MYMI!)L.UPH&,'(R#C _$ ]!AGAN%+0RI(JL5)1@P!'!''<5)7G'P>TQ[7P[=
MW+:G?W(>]N8Q#/(IC7;,PW !0=S=3SU["KOC*YUB3QOX4T?3-7FTZ&_2\-R\
M2*Q941",!@1NY.#VSG!Z4 =U17FMCJ>L:3?>-= FU>XODTW3EN[*[N OGQEX
MW)#,  V" 0<4:MKVK0_!+2-8BOI4U&:&P:2X&-S&1XPQZ8Y#'\Z /2J*\]UI
MM9U7XK+H%IKUWING?V(+J9;94+LWG%?E+ [3TR>>!COFLS0K;Q+KLWB'3[CQ
MCJ$,>AW;VUM-!#$LLIVA@TQ*D. "!@!<\Y[8 /0M7UZRT273H[SS-VH7:V<&
MQ=W[Q@2,^@^4\UIUXSJ&MZGXK\"_#K5'FBM]2N]:B4S>6"JN!*A?;T)XSCIF
MNG6;5/"GQ T327UJ]U73M;BN=R7VQI()(D#[E957Y2#C:>E '?T5X?8^)/&7
MB'1!XATZ+Q,=2G9I+2""*U.FA Y 1@S!V&!@MP<].E=3K=QXBU7XAZ5HMGK,
M^C07.C-<W21HCLK"0 A<@@-R!NYXSCUH ]'HJC+(=(T)Y9));MK.V+,[XWRE
M%Y)P,9./3O7FT<GBF;X>OX\_X2B==0^QMJ"V BC-D(@"_E;-NXG:,;MV<T =
MWXC\5:?X96T6[CN[BYO',=M:V<!FEE(&6VJ/0<FMF&3SH(Y0CIO4-M=<,,CH
M1V->1^(K5_$OC'X>ZHFK:M8C5X9I5C@F0?9?]&#?N\J<$YPV<Y'I7I7B&:6R
M\)ZK/!,Z306,SI*,;@RH2&],Y&: -6BO(I;GQ-I7PPL?'+^*+NYOHK*"YDLY
M4C%M-&VW*%0N[=AOO;LY_34\5:Q>7OB2*PL]1USRH[-)I;#0;9#<([DE7EED
M^15QT3.2>>E 'I-1S3PVZJTTJ1JS!078 %CP!SW->2S>+/$=U\&H-56^>#6!
MJ*VGVAHE4L!<>7EU'&2.H''6E\?^&+^VT[07O/%6L7<\NO6JE@8XU0NX&Y%"
M<%2,KR<9[T >F/K,*>((]&-O=&>2W-P)A"3" #C!?H&XZ5HUPHOK_3OBAIVB
M'4;JXL$T%YG68AFED60+O8@#+8^@K,\,KXI\6>'+7Q=:^)9+:]NY&DBT]T1K
M)(1(5\M@%WD[0?FW YH [RTUF&\UJ_TM+>[26R"%Y9(2L3[AD;&Z-COCI6C7
M 6^M:DWC/X@6;7LIM["RMI+2/C$+-"S,5X[D \U@Q3>*+?X5VOC9_%5U+J,%
MBEU]F>.,6TL?!V.NW<6(XW;@<GC% 'KM%>;>)M=N]1U>PM+._P!:2)[!+J33
M]#MU-TK.?E:263Y$3' 7@D^HK*N/%OB&7X+ZAJ?VN:#5K74!9QW$D:I(0MRJ
M NHRN[!PV..M 'KU1I/#++)%'*CR1$"158$H2,C([<5Y_<-K?A?QOX<MI?$-
MWJ=MK3S0W45S'&%1UCW!XMH&P9_AR>*R_".C:C9>)/'4VGZOJ%Y?6LWEV\5Y
M,ICN)3 I0RX49(.!D$<4 >L45Y+X9UO58?$.D6^K:YK=IJ5RQCO=/UJR58+A
M]O/V61%VC#=!N.1CO78_$.?5+'P9=ZGH]Q)%=Z>5O-J8Q+&ARZ-QT*[OR% '
M4U1UC5(M%TF?49X;F:.$ F.VB,DC9('"CD]:\T\1>--1?Q/#JVE:@8_#ND?8
M?[0CV\3BZ;DY_P!E&C;_ (%3O$'B/6I- \?Z[9:E-!:V$B6.G! !L>,J)G&1
MSEF*Y_V30!Z@EY WV<&18WN%W1QR':[<9/!YX'7TJGI^O66I:QJNEV_F?:=,
M>-+C<N%RZ[EP>_%>>>)='FU#XH^#)#K6J0-=6MT^(94 A*11YV94XW?Q9SGM
MBI-.T>_UGXC>.XK?6[O2X%GM"39*@D=_(&,LP.%'H!SGK0!ZE68FO63^)I?#
MX\S[=':+=M\OR>66*CGUR.E8OPTUR_\ $/@:SOM4E6:\$DL,DJJ%\S9(RAL#
M@$@"L#4=.O-4^-=W:VVISZ=$= B,TUL%\XCSGPJLP(7GDG!/&.] 'IE%>3)X
MSUW1/ GBQY;G^T=0T;5#IUI<RQ@,ZLT:JS@8!8;SZ9P*LZ%<^++;Q+IHCA\4
MW-C.[+J7]M1VH1 1P\7EME<-_#R,'VH ]0HKRG3X_$7B#_A,;H^+-1LX=+U6
MZALXK=(_E**&&\E263D +QWY/;/N=;\36?PRM/B)+XBN)+S$,C:<L,:VCQM(
MJ%-N-V[!)W;NO3 Q@ ]FJ.:>&VA::>5(HE^\[L%4?4FN \9:I>2^)XM*M-2U
MDQ1VHEELM!MT-R'+$!Y)9/D5,#A<@D\\BN/\27>I>)_@9>7VJ7U]'<6-\;=E
MVI']H"W*(/.4 C<.ORD#<.] 'N=%<--+?Z-XZ\):&FJWMU:RVMZ]PURRL\Y4
M*5+D*.FXXP!4MGJM_)\0/%M@]W(;6TL;62"+C$;,K[B/K@4 =7J%XFG:=<WL
MD<LB6\;2,D*%W8 9PJCJ?:C3[U-2TZVO8XYHTGC614F0HZ@C.&4]#[5YCX<F
M\22_"JZ\6:AXEN[B[?1;AX8%1%CB(5BK],LXVYR>.2,5:O/$%_+X'\'I_;%[
M'?:G9Q2SI86XEO;H")6;RL_*G)R7; % 'IM%<!\.=;U2^U3Q%I.H/J#1:;)!
M]G_M-(Q=*LB%BLAC^4],@]<'FKOC[59[2/3;"UU.ZM9KR5LP:?;^=>7"*N66
M+/RIU!+MP!0!V)(4$D@ <DFFPS17$*S0R))$XRKHP(8>H(KRC1[[5M=TSQKH
M-]?ZU;1:9'$]O)=>4EZJO&SE)"@*D';]<&NF^%5@]G\.]'D:_O+K[1:Q2A;A
MPPA&T?(F ,+['/UH [2BO+O$>O:OJ/CK4M$MAXA2PTR"!F&@I!YCR2 MEWE/
M"@# 51R<DG@"IVU_Q'9_#TMK5W-I6J/??9+:>2T66YN(R<H5AC)7SF7(QT!!
M/3F@#TJBO+/#'B35=/\ %FHZ9=_V[)I\6CMJ*QZVL7VD.K[3M:/@H1V;D$5=
M\-6GBG7M%TKQ4GB>1+N\*W$M@\2&S$#'/EJH&X,%Q\^XG(H [/3M=L]4U+5+
M"V\SS]-E6*XW+@;F4,,'OP:TZ\MTC1M0UGQOXYCM]=N]+@2]A(-DJ"1I/)7!
M9F!^4?W1C.3S72_#37[[Q-X TW5-297O)/,25U4*'*2,F[ Z$A0: .MK.UG6
M8=$M8KB>WNIEEF6$+;0F1@6Z$@=%]37+_P#"07'ASQ]K%EK5Z[:3<V!U.Q>0
M#$(B&)XP>^!A\=A7/W.L>)+7X=:9K=SJ-Q%?:MK,$WE\8@MY9/EA''39CKSD
MF@#UFLZ_UF'3]2T^QDM[J22^=DC>&$ND>T Y=APHYXS7!>,K_7[;Q-="\NM?
MT_0TA1K"[T6U6=%DP=[7(VLV <8  !'?-3OXBU*6^^'ACUB*ZBU)YENIK5-L
M5T%B)!VD9'(SCC!S0!Z&D\,DTD*2HTL6/,16!*9Z9';-25YAX'T22V^*'C*1
MM9U2X^RS6RE9I4(GW09'F849VYPN,8 '6NA\=:QJ5BNC:7I-PEI=:O?K:?:V
M0-Y";2S,H/!;"X&>.: .NHKS])]5\(>.-"T>;6KS5]-UI9T O@AF@EC0/N#*
MJY4C@@CBC0-:U*Z^'OB:_GO9'NK:XU%8)CC,8C+!,<8XP* .\EGAA*"65(S(
MVQ [ ;F]!ZGVJ2O&=<M+O7M*^&6H7.MZG%<7KVJ2F"15 <P,QE&5.)#DC/3'
M:O6YY?[,TB69C)/]E@+$L?FDVKGD^IQ0!;K$\1^*M/\ #*6@NX[JXN+R0QVU
MK9P&664@9.U1Z#DUPD+^*;KX?MX['BF>/4/LC:@M@(XS9"( OY13;NSM&-V[
M.:K>(;23Q)XO^'VJIJ^K6(U>.658X)47[+_HV[]WE#@G.#G.1Z4 >N12B2!)
MBK(&4-AQM*Y&>1V-9FK>(].T?3K>_GE,EM<3QV\;P#>&9VVKT[9[TSQ+8->^
M%KZU6_N[5A 3Y]NX63Y1GJ01SC!X[FO)3I]S:? [PW)!J-Q-/<WFGR0B[(>.
M!MX 50 /D![$GZT >YT5Y\)M8\-_$G0M*DUV\U.SUJ&Y:>.[2/\ =21*&#1[
M5&T'.-O-5]&C\0^.+;4=:C\37FDF.[GM]/M;5(S%&(V*@S!E)D)(R1D>U 'I
M-%>4R^*?$WB+P+X;UBUM[]+6X:5=8;1HU>Z782BF%6S\I=23C) Z4S_A-+_3
M/ >LW&GZS+J]U!>16EK]LM#'=VQD95"S(0H9ADD' #=Z /6:*\R\/7/BJW\4
MZ?&EOXGGTN?>NH-KB6P$9VY1XC$V1\W!7!&#[5T/Q&NM4TSPC+J^DSRI/IDT
M=W)'&1B>%6_>(V>VTD_A0!UE9^MZO#H6DS:C/!=3QQ;<QVL1ED.2!PHY/7\J
M\ZU[Q=JH\;1:CI]\R>'=+GLK6]CP-DQN027S_L!X3^-5_$OB/7?^$1\>^(;/
M4I[>"UO([+30H&$$4B)*Z\<[F+C/M0!ZN+J'?#&TJI),I:.-B S <G Z\9YJ
MEINNV>JZCJ=C;>9YVFRK#<;EP-S*&&#WX-<%XBT:6]^,'AR3^VM4@^T6=Q(%
M@E0+%L$>53*G ;^+.<]L4S1]&U'6?&OCF.WUV[TN!+Z(@V2H)&D\E<%F8'Y1
MQ\HQG)YH ]3K,AUVSG\1W.A)YGVVVMTN),K\NQB0,'UX-8WPTU^^\3?#_2]5
MU)E>\E$B2NJ[0Y21DW8'0D*#6!<Z=>:I\9-7MK?5;C3H#H]N9I+4*)F_>/M"
MLP.T=<\>@H ]+HKS"V\4ZII>E>,=+OM;C^TZ)/%%:ZI=6^\LLR@H&1!\[C..
M!R<9'6HO#>MZU9^.])TJ63Q')9:C;W#R_P!NPPJ2\84AXO+Y4<X*MC&1WZ '
MJE%>-W6O>(M-U&6XU[6-7T34%O-L9GLUDT=X2^%7>BD@E<?,S @GM6AKNO:S
MJOC?6-)@7Q(EAI0A11H*0;WD=-Y:1I3TP0 H&#C)H ] USQ!8^'HK.2^\W;>
M7<=G%Y:;OWCDA<^@XZTZ'6H)]?N='6WNUFMXEE:9H"(6!QPK]">>E>9:_=:[
M=>"/"K>([>2'44\2VB,9$5&D02-M<JI(!*XR <9S77Z?JE]+\6-9TQ[IVL8=
M-@EC@.-JNS,"1^5 '845XG9WOBH_"0>-G\6WS7UJLDL5NT49A=%E*[91MRY(
M!YR,<8'&3N^*/$^K7WBFPT*RCUF.U;2UU"X.BK$;AB[;57,I 5!@Y(Y)(% '
MI]9D^NV=OXBM-#?S/MEU \\>%^7:A .3Z\BL7P%<^(9K*_AUVWOE2&XQ937Z
MQK/+"1QY@C)7<#D9XSQ6-XJM+R^^+/AZVL[][$OIET)9XT5I FY,A-P(#'CG
M!QS0!Z-17F%IXGU;PU#X]L[F]EU8>'HHI[.:Z"^8PDB+A7*@9 (Z\'&:I:5J
M'C-+S2+R"#Q1=RSS1?VBFH0VJV9A;[[1!&W(1G*]<XYH ]<HKS:W@UWQ+X\\
M7:=_PD^H:?IVGRVP@BM%C#AFA#'YF4X7/..Y/45@V6H^*M1^&5WXQF\5W4=]
MIR3>5!!!&L$HA8J?-4J2Q;:>00!G@4 >STV21(8VDE=4C099F. !ZDUYWXE\
M0W=]%X>@MM0U&WDOK3[9/8:-;B2\E4JN"KO\D:!CR6QGH*YV>^U7Q#\*O&<&
MHW^JPMI$T\<33"..>6-80PBGV@JWWL';C/% 'LR.LB*Z,&1@"K*<@CU%.KS2
M![_0;7P!96^K7T\5]<@3FX=6+(;<MLX4?*"!C^=;IU*]_P"%OC2_M3_8/[!-
MQ]GXV^;]H"[_ %SCB@#JY9!#"\C!B$4L0HR3CT%4]&U6+6])@U&""Y@CFSB.
MZB,4BX8CE3R.GY8KA/ ?_"0:MI\^NZCXCNI8+>XO(H+)8T"LJNZ@R-C+$'IR
M ,#WJEIOB?59O@_X>O)M;FBU/49O*::.V\^YG&]\I"H&-^% #$8 &3ZT >KT
M5YSX$UG5F\7ZEH5XVLM9QV4=W"-:2(7*,SLI&Z,X9#CC/(P17HU ')ZU\0-.
MT779-&.FZQ?7L<2S.MA9-.%5LX)QTZ5?\.^+](\3FYCL)94NK4@7%I<PM%-"
M3TW(P!_'I6!IG_);]=_[ ]M_Z&U0ZOY<'QQ\/R6Q59I-*N1?$'!\D$%"WMOS
MU]* /0JC,\(N%MS+&)F4N(]PW%1P3CKCFO%+_P 6:];6/_"16>I:[?'[7&HF
M2SCCTEXFE";%5L2'@X#C.3WQS6]=Z'))\>K=QK6JQ[M(:ZVI*@  G4>3]W_5
MGJ1USWH ]1HKQSQ-XDUC?X@U33M5UZY_LUY?LYTRTC%A!Y8Y68R<RG(.XKD#
MMZ5ZMI5U)?Z+97<RA);BWCD<+T5F4$XS]: ,X>+M/?Q6_AV"&]N+N(#[1+#;
MLT-N2NY1(_121T^M;U>3^%-%N+'QOXWF&O:O.UBT0Q-,A$Y:VX,F$&2O&,8Z
M#K3-%UCQ#I?PL;QUJ6N7&I7(TTF*R:-5A5BP"LV!N9AW.1P2* /6Z*\OUQO$
M7@CPY!XKF\37>IR)) =0LIXX_(E21E4B$*H*$%@0<GIS5V[76]<^)NK:+#XA
MO=.TN#3[>9DM53S-[,P^5F4[1QSQS@"@#T.BO(M*;Q1K7A_Q'=S^,+V*70+N
MZM+5H((E\XPC(>8%3OSD# P..Y->A^$-6GUWP=H^JW047%W:1RRA!@;BHS@=
MAF@#:HKSBRAUSQ+XS\76#^);^QTZPN(4@CLQ&L@9H@Q^9E.%]NY/6J<'C#5)
M? EU'=:O]GU2UUF31_MD5GYLMV4;K#$./,9>/[H()X[ 'J=%>:^"-:U8>.;O
M0+IM;-C_ &:M[&NN+%]H5_,V'#1\%"/7D$&JO@FR\0>)_")U;4O%^J*CFYBA
MBM1'&RJLK*&9BI);Y?8 8&* ._U7Q!9Z5H_]J;)[RW+*H^PQF=FR<9 7J >M
M:M>'Z1+J'ASX 66IZ?J]\MQ</;[0[J5@!G"LL8V\ @G.<UVNH7&I^)O'U_X=
MM]7N])L-,LXII'L@@FGED)Q\S!L(H'0#DGK0!U.IZS!I=U86\MO=RM>S"%&@
MA+JA]7(^ZON:TJ\\U>[\2:(_@RQOM76XN;C5_L]S/!&(Q<1;6(W+T!P!G'&:
MC@BUKQ'\0O%VE_\ "2:A8:98&T\N*T$8<,\6XX=E.%R,D8Y)ZCN >CT5Y;#X
MOU0>"=8@N]:2WU/3]9?1XM06T\Z2Y(8;=D2C!E(.,=,C)J3P;K>KQ_$!]!N'
MUUK"33&O%374B\]7$BKE6C_@(/0\@B@#TZHWGABDCCDE1'E)$:LP!<@9( [\
M5X_97'BB\^'>K>*7\6WT=SILEY):P)%'Y;+$[?+*"N7SMP.1@8J77[2;Q'XL
M^'6IG5M3LGU6"639:RJHMS]FWGR\J<$YP<YR/2@#U^BO)O%>I^(+#7M4DU+4
MM?TJPA4'3+S3[19[-5"C+7.%9R=V<@X& <5Z7HUR][H=A=27-O<O-;QNT]N"
M(Y"5!+)GG:>HH O45YKHR>(?'%GJ&NQ>)KS2F2ZG@T^TMDC,,8C8J#,&4F0D
MC)&1[50NO%^O:_X,\#ZAIUX-,O\ 5=36UN'6,.G D5R%/493<!GTYH ](O=9
MAL=5T[3I+>[DDOBX22*$M''M&3O8<+G/&>M:->?7\NJ^'_%_@71O[;O;R&[E
MO1=O/MW3XBW+NP!]T],5%H[:WXTO-=U)/$=WI2Z=J4UC9VMJL9B7RL#=,&4E
MRQ.<9&!TH [35]:AT869FM[N;[5<I;+]FA,FQFSAFQT7CDUI5X_9>)]<E^&O
M@+47U.<WE_KD$%W,=N9HVED!4\=, =/05O7:ZUK?Q,U;18?$-YIVEPZ?;S,E
MJJ>9O9F'RLRG:..>.>!0!Z%17F.G^*]67X?:^UWK4,6H:9JDNEP:C+:^8TNU
MU56\I/O2$,0 !UQG/-,\+:UK%MX\LM(FD\1/8WMG-,PUZ*$/O0K\T9CY ^;!
M5NG% '42^/\ 1(O#6JZ^QN?L6F736EQB+YMZNJ' SR,L.:ZA6#*&'0C(KP>^
M_P"2'^/_ /L.W'_I1'7HDVIW^B_$C3K>YNG?1M:LVC@1@-L%S$-Q /8,F>O4
MB@#M:*Y'P%?:AKMKJ/B&[N)39ZC=,=.MV&%BMD^5&QC(+X+'ZBL_Q;/KES\0
M="T32]:ETRVO+*Y>X:.-7)"[<%0PP&YQGM0!WU%>:>)+N_AUJST*#6]?NEM;
M%&F@T:",WCR$D"6:5P(U4@?=&"3D]*S9_%GB*?X,3:H+R2#5X=1%HMQ)$JN0
M+D1Y=1E<XX(''6@#UVD)P"3T%>>RR:UX6\>>'+.;Q!=ZI:ZV9X[F*ZCC C=(
M]X:+:HV#/&W)XJ+1WU[QH^LZO%XBNM,%E?SV=C:01QF$"/C=,&4E]QZC(QVH
M [3P[KUEXGT&UUG3O,^R7(8Q^:FUN&*G(^H-:E>*^$M6U.'X;> =!TFZ^PSZ
MS-<1R7FP.88XVD=MH/&X] 3G%=;9W.J>%O'VE^'KC5[K5].U:WG>)KT(9[>2
M(!CEU"Y0@]",@]Z .]HKQNSG\3WOP_UKQ0_BV_BGTV2\DM((XXO+98G;Y9<J
M2^=N.HP,5=N=0\1Z1I/A?Q5+XBN+J75KNTCN[!HD%L(YQ]V-0-RE<C#%B3CF
M@#T:WUF&XUR[TE;>Z6:UC21I7A(B8-T"OT8^M:-</;7=_J7Q%\5:))J5U#9Q
MZ?;&'R64- SAMS(2#@\9YS6%X8EU.;7M2UJR\0ZS?^&-*BE0&^E1QJ$RJV[9
MA!B-?[W=AQQF@#U6BO$[+7O'&HZ/:Z_86WB6YU6XV3I;&*V33'C9@=@&[S -
MG1L[B>>]=;<7&J^*O'^JZ%#K%YI&GZ/;0._V(()9Y906!+,K850,;0.2: .L
MTK7K+6;K4K>U\SS-.N3:S[UP-X /'J,$5?>>&.6.)Y4627/EHS %\#)P.^*X
M+X8QW4.H>,HKVY6YN$UIE>94";\1ISM' .,9QWS5#QIH;WOQ;\(%=9U2V^TI
M>;1!*@$&R),^7E3C=_%G.>V* /4**\]MCK/C3Q%KZKK][I%AI-W]BMX; 1AW
MD"AFDD+*VX$L,*,# K8\ Z[?ZWHMXFJ-'+?Z;?SZ?//&FQ9VB;&\#MD$<#OF
M@#JJ*\[\8ZG>3>*4TNTU+6C%#:B66QT"W0W =F.'DED^14P.%R"3STK&F\6>
M(KCX,MJ@O)(-7CU%;1;EXE5B!<B/+J,KG'! XZT >NT5YY))K7A?Q]X<L9M?
MN]4M=;^T1W,5TD8$<B1[PT6U1M&>-O/%4H/%VJ>'O#7BK3+Z>:^US2+D063N
MH+W(N#_HQ/ !.6P<?W: /4**S]#L[O3]#LK6_O'O+R.)1/<.>9'_ (C],YQ[
M8KRWQ/XCU?SO$&I:=JVO7/\ 9AE^S_V7:1BQMS&N2L[2<RG(^8KG Z>E 'KT
MD\,4D<<DJ(\IVQJS %SC.!Z\5)7D7B.QN=>\3_#S4)-8U*SFU*-V9;2156!O
MLVXF/*G!.<'.>/2M'Q+J>H77BB[T^RU3Q!,EC%&!;Z!;1EH9"N=T\DN%8GC"
M*>G44 >F52U?4XM&TJXU":&XFC@4,T=M$9)&Y X4<GK7F]KXQUS7?#'@:T6[
M%EJ'B)I%N;V&-=R1Q*2Q0'@.P YP0,G Z5I>(8?$?A/P1XGG'B&:\ABMA)I\
M\RK]I@;^(,P ##/0XR.E '?6TZW5K#<(KJLJ*X5UVL 1G!'8^U2UYY>:GJFN
M>*=%\*P:K<Z=$^C#4[RZM@OG3?,$"*S A><L3C/;BH/$NI^*?"7AZST]]0DU
M*\O]5%I;7<%NAN5MRI;[K81I<*1G@'.>M 'I5%>>>#[CQ+#XF-K-;^(9-"DM
MBS2ZXL'FQ3@\;6B;E2,\$<$5@^'_ /A*-4^%W_"5R^,+]+ZWAN9[>/9%Y++&
M[_+,-N7SMQG(P"...0#UUYX8YHXGE199<^6C, 7P,G [X%25XW?P3>*?&OP\
MU=M4U.R?5;&XN/*MY5 MB($8B/*G ;.#G.1CI7IWBC5I-!\*ZKJT40EDL[62
M9$;HS*I(S[9ZT :U%>1^(4\2:/X#MO$D7C&_EN[IK5KB(K%Y)$CH"(0%!3&[
MKDY&<]>-;77UW5?BROA_3_$%SI=@=#%W,(41F+>>5RNX':W3GG@?C0!Z-17G
MD(UCQ5XLUK2AX@OM,L-#\FW7['Y8FN96C#&21F4\<X"@8-8][XMUY/ >MQ2W
MY.J:/K46G&^A0(9T\V,;BO0,5;! XH ];HKD?$^IWMGXT\'6EO<O';WES<)<
M1KC$@6$L ?H1FL73+?7?$WB3Q9:R>)[^QL;&_6*VCLQ&KJ?+4\LRGY>?N_7)
MH ](K.AUF&;7KC2%M[L301+*TK0D0L#V5^A/M6-\/M;O]<\-,^IR)->V=W/9
M2SHFQ9C&Y7>!VR,?CFJ]CJE])\6-:TQ[J1K&'3()HX#C:KLQ!(_*@#LJ*\0T
MZ_\ %;_!Z/QPWBV^:_MT>:.W:*,PNBRE2L@VY8D _-D8X],U[+$YU#2T<,\)
MN(0=R'YDW+U!]1F@".]U:SL-,O\ 4))1)#81O)<"(AV4(NYA@=\=JDTV_AU7
M2[34;;=Y%W"D\>\8.UE##(['!KR#PWH[67A3XF3MJNHW"QW.IV[132*4D(B4
M^:P"@F0]">GM4\;:_P"&O WA+Q#'XAN93)]A@DT]HT%L8) JA ,;@P!'S;CD
MB@#V*BO+O$6OZOJ7CG5-%MAXB2PTN*#(T%(/,>212VZ1Y3PH' 51SR2> *ZW
MP/=:]=>'1_PD5O-%>QS/&K3(B/+$#\CLJ$JK$'D ]0: .DK,TO7;/6+K4K>U
M\SS-.N3;3[UP-^T-QZC!%<I=3ZIXH^(.K:%!K-WI.GZ/;P._V(()9Y906!+,
MK84 8P!R:Y:QUS5O"GAWQ[>B>"[U1-;6W2X9 B%G6)!(RC@8!!(Z9H ]GHKS
MC5AKG@6;1]1;Q)>ZQ!=W\-E?6UZD>&\TXWQ;5!0@\[<D$?2MCPOJ=]>>-O&5
MI<W+RVUG<VZ6T;8Q&&A#,!]2: -S7-=L_#UC'>7WF>5)/';KY:[CN=@J_ADU
MIUXIJ.IZGK'P8M+NXO/.OSKB(DTX! *W95,@8R!@5U.I2:QX/\3>'I#KU[JE
MIJ][]BN[:[5"%=E)62+:HV $'*\C!]LT ==HWB"QUV74H[/S=VG7CV<^]-O[
MQ0"<>HY'-:E>.VGB"Y\+^&/B1JUDBO=1>(94A##(#N8D!([XW9Q[5HZ'<^++
M;Q)IGEP^*;FSFD*:E_;,5JL:@CB2+RVRF&_AY&#[4 >F7-PEI:37,N?+A1I&
MP,G &35;1]5MM<T:TU2SW_9KN(2Q[UPVT],BL"7Q/)JEMJMBWA[7+)4M)C]I
MN[=$B;"D8!#D\]N*X;2K;7])^#>G^)[3Q)<I<V&G)/%9B-/LK1+SL=<;BQ7(
M+;@<GMB@#U$^(+%?%2^'#YOV]K,WH^3Y/+#[.OKGM3]$UJ#7K!KNWM[N!!(T
M>RZ@,3Y7O@]O>N+L[O\ M#XTZ9>["GVCPGYNP]5W3J<?K6++XFUT?!;5M634
MYAJ<6I-#%<G&57[4J =,8P<?2@#V"BO.[A]<\+>-O#<$WB&[U2WUF66"[AN8
MT"*ZQ[@T04 H,C[N3Q3-&?7/&U]KFI0^(;S2X].U*:PLK6W2,Q?NL O*&4E]
MQ/3(P.E '9^'/$%CXHT*WUC3O-^R7&_9YJ;6^5BIR/JIK4K@O@N<_"?13@#F
MXSCIGSY*A==:UWXE>(-'3Q#>V&E6MI:R>7:A!)O<-]UV4[1P<\9/% 'H=%>2
MW'C77])\,:W8"<WVJV.L1Z5;7HA4NZR;2K%.%:0 D8X!.,]ZT/#5SXIM_%=E
M"MMXEGT>X207TFNBW!A<+E&C,1S@D$%3P,B@#THG )K.T/68=>TN/4+>WN[>
M-V91'=PF*08..5-<3X$&O:[J.IZE?^([HV=AK-W;PV*1H%=%; #MC) SP!C&
M.^:R-*\7:_+\+_#K)J!.KZSJS:<+^=%<P@RR#?MZ$A4P : /7J;(XCC:1L[5
M!)Q[5P+2:MX-\6Z#8R:Y>:OIVL226\B7X1I89%3<'1E5?E.,%3T[54TI]>\9
M66KZ]'XAN=.\BZN+>QLHHXS JQDKF8,I+EL9/(QVH [K0=;M/$>AVNKV'F?9
M;I2\?F+M;&2.1^%)9ZU#>ZSJ&F);W:2V.S?+)"5B?<,C8W1L=_2N=^$O_)*_
M#_\ U[G_ -#:H-/UC49?&WCZSDO)6MK"WM7M8SC$):%F8KQW(!YH [NBO&#J
M7BC3/A;IOCJ;Q1=W%ZB0.]FT48MY8WD5-K#;NW8;)?/7TKV&[MS=V<UN)YH#
M*A02PD!TR,94D$ CMQ0!3U/7;#2M%O=6FF\RULE9IC#ARNWJ,#N/2KMM.EU:
MQ7$>?+E0.N1@X(R*\2TS2WM/A!XWN6U34+D&2_A\J>12@*R'Y\!0=Q[G./85
MO7DVO>%H_!NIG7[F[.IWUKI]U9/&@M@DBGF,!=RE<=<G/>@#U2BO*=7U_6]8
M\8:U80+XECL=+DC@A_L)+?+2% S-*TIR?O !0,8'-=OX,NM<N_"UI)XCMC;Z
MJ-R3 JJEL,0K84D E<$@'KF@!;CQ;80:AJ]@L%[/=:7!'//%! 79E?.T(!]X
M\=*Y_P#X6QI?VW[%_P (_P")_M?E^;]G_LI_,V9QOV]=N>,^M.T+_DLOBW_K
MQLOY-4O_ #73_N6O_;F@!=0^)NGZ9!Y]UH/B1(!")GE.F/LC4C/S'H"._I6C
MX>\:6WB2[\BWTC6[5?*\U9KVP:&)AQT8\$G.1[9J/XD_\DU\1_\ 7A+_ .@U
MLZ%_R+VF?]>D7_H H T**XOQ[JES;2:7I]IJ5Y;R73N9+?3+<2WDZ*!Q&6^5
M ">6;'L:Y_1O$FM?\(SX\MKB;4DDT:V9K.74$C6[CW6YD&\IE20<$'T(SZ4
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MDTRN1M4J@0!<#I@=\TSPKX;M/"7AZWT6REFEMX&=E><@N=SECG  ZL>U;-%
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MV:1/[F< !?8 =O05TE% ' O\)]-?34TPZWKG]FP2+):VANE,=N58,,?+EAV
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M#C! QG/XT[3/ MOI_B&VUZ;6-5U#488'M_,NYE8,C8.-H4 8QVQG)SFNKHH
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ME8EG<_4D]S@8':KPTFP&M-K ME_M!K<6QGR<^4&W;?3&>: /(6U#4/#GP_\
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M.HI ;99\G(C+;MOIC/-8]Q\/O"=U>75U/H=J\MT&\X<[7+#!;;G;N_V@,^]
M%_POQX2T;C'^@P<>G[M:\@CTK5/%4'B/6+N+1WN+:]NH1?WVJ3PRZ:(R0NU4
M0K&% #=>>IZU[A;6T-G:0VMO&(X(46.-!T50, ?D*PM1\">%]7U0ZE?:+;37
M38,CG($N.F]0</\ \"!H XN[N9=/\3_#G6]:O(+JU-E+:OJ2-^Y^T21+MDW$
M#AP" <"M?QWJWB;P]/:ZI8:M9#3)KRWMOL;VFYSO8*Q\S=^/2NVO-.LM0L7L
M;RT@N+1UVM!+&&0CTP>*YVS^&?@RPO$N[?P_:B:-@T9?<X0@Y!56) Y]!0!R
M^M:;J6I_'*2'3-;FTB9?#J,TT4"2EU^T$;<."!R0<^U.^(6G:KIWP^@@O=>F
MO[PZO:M'>O;QHT>9%QA5&TX///7->AC1]/&N'6A;)_:)M_LIN,G=Y6[=M],9
MYI=4TBPUJU6VU&V6XA61951B<!U.5/'H: /-M;TG5=$\5^$[CQ!KLWB#3IM2
M6"*">!(!!<LI,<H\L ,1AAANF>*]0%U;F[-H+B(W(3S##O&\+G&[;UQGO5?4
M]'T_68H(M0MEG2"=+B(,2-DB_=88[BJ&E^'$L/$^M:]-/Y]UJ)B1/DQY$,:@
M!!R>K;F)XSD<<4 8WQ(N(Y++2M&\NZGN-2O52*UAN1;I<!5+,DLA!(CQU"_,
M> *P? D%WI7C7Q)HQALK*U@L8)6L;"ZDFABE8MR-X!5BH&0 !T->AZUH.E^(
MK#[%J]C%=V^X.%D'W6'0@CD'W%5])\)Z#H4KRZ7ID-K))"(9&CSET!)&[GDY
M)Y//O0!XS!H%I:? 2V\61S7?]O6L GMK[[2^^']]@(HS@)@D;<8.2>M=KJ5O
M#XK^*%OH>NAI=*BT5;V&S+E8YIFDVLS $;]HZ ].M=F?"^B'PU_PCO\ 9\?]
MD;=GV7)VXW;L9SGKSUI-9\+:)X@@@BU33X[@6_\ J6R5>/M\KJ0P]\'F@#C/
MAU9VNG_$#Q]9V4SS6T,UFB,\ID*XB;*;B23M.5&>F,=JO^-&8?$'P" S &[N
M<@'@_N:Z?2/#6C:#-=3:5IT%F]T$$QB& ^P$+D=. 3]<Y-6+O2+"_O[&^NK9
M9;FQ9GMI"3F,L,$CZB@#SK3?"NE^*/'GCA-96>ZMXKJW6.W,[K&C&!<N I'S
M>_;M6[\)KZ[U#X<:=+>W$EQ,CS0^;*VYF5)75<GO@ #\*ZFTTJQL;V]O+:W6
M.XOG5[F0$YD91M!/T'%)I.D6&A:<EAIELEM:HS,L2$D L2QZ^Y- 'EWB?5KC
MP5XC\5V=LSF37[*.XTQ,_P#+VS"!E7U.61\>@K*:"71;74_A9:W5PTUYJ5LE
MM,6_>"TE0/,P]E\N0'_>KV+4=!TK5KZPO;^QBN+G3Y#):R..8F..1^0_(42:
M#I<NOQ:Z]E$VJ10F!+DYW*ASQZ=S^= 'EU[I-_XF\?\ B#3FTW2]0M=)6VBM
M+34+Z:!;>,Q [T2-6!+$GYSR, "H+^;6E\%>%='.KV.I17NJO:RW$=_((9HQ
MO*0-.%WD9&TX&3MQW->FZWX/\/\ B.XCN-5TR*XGC7:LN61]O]TLI!*^QXJU
M<>'M'N]$&BSZ;:OIBJ$6U,8V*!TP.V/44 >?>']%O?#_ (BU2T,FBZ?:RZ0\
MCZ-87TLQWAL"<*Z#8,$J<=>.M8/PU"ZE?>&K'Q&Q1+;3$N="M48^1.1GS)&/
M\4R_W3PHY'K7K&C^$]"T&WN(-,TZ*!;D8F;+,\@QC#,Q+$<\#/%(WA+06L--
ML3IL7V?3)%ELU#,# PZ%6!S^O- %G7-8TS0=)EU'6)U@L8BHDD9"P&Y@HR "
M>I%<%KT,VF_$7PSJ-YJAUNUOKQXK.P<*ILRRDB:/9@.%'!+ D ]<UZ3<VT%Y
M;26US#'-!*I22.10RL#U!!ZBL/1/ WACPY>O>Z3HMM:W+@CS5!+ 'J%))VCV
M&* /._#6CWMW:>,)V\57FCR6.M7LOEVQ1 C$[A)-N!+J1C .!@?EZ-X(UB\U
M_P $Z1JNH1B.[NK99) !@$_W@.P(Y_&DU;P-X8US4EU#4]%M;FZ& 9'4C?CH
M' X?&/XLUOJJH@1%"JHP !@ 4 >2Z#H_B#4_%_C1M(\4OI$*ZKMDB6QCG+GR
MU^8,_0XXIOCCPM#X;\)^&M+TN[F2YG\3VTKW\P$DC7#ELS,#@,<XXZ< 5ZA8
MZ18:;<7MQ9VRQ2WLOG7#*3^\?&,G\*34M'T_6%M1J%LDXM+A+J#<3\DJ9VL,
M=QDT <UI_@>];7;+6/$?B2YUJ>P+-9QFVCMXHF88+%4^\V.A)XJS\1-0BL/!
MURLDM]&]W)':Q?895BE9W8 *'880'H6/09[XKJJJZEIMEK%A+8:C:Q75K,,/
M%*NY6H \M\,Z?>>'_BGI^FI8:?I,5SITTUQ9V%]).' 90CR!U #9R PR3SSQ
M5/2_"VFZSX9\:ZIJ!NIKNUU746M'^T.OV5D)(:, X4YY)[].E>DZ3X)\-Z%=
M076F:3!;W$*NB3*6+X;&06));H.N<=L5>M]!TNULKZS@LT2WOI)9;F,$XD:3
M[Y//>@#S2[OY/$?A7P-IEU'<:EJ>I6@N6MGN_L]O<;(QN:X8 LP!(.U1R>O
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M]<\,Z-XCCB35M/BN?*.8W.5>,]]KJ0P_ TMOX:T6TT&70[?3H(M,F1DDMT&
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MA022>ON35R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img76291469_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /'".@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$=_ID'AY;J&UG:'S_MFS=M."=NPXYSWH ]OHJM87D6H:;;7T1_=7$*S+_NL
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M08 +*"<>W- %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M);3W4^\PD!N-Q&"0?2O3_$G[/NA6?A^]O-)U&_CO+:%ID\]U96VC.. ,=.M
M$_[.FC:E8:#JNH7<<D5I>2H+='!&[:#N<>QR!G_9KS+3?^3AA_V,#_\ HTUZ
M5\"?B%JFOW%UX=UB<W,EO!YUM,P^;8"%*D]\97'XUYKIO_)PP_[&!_\ T::
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ3F8%8@^_IQU&.E '71?ZE/]T4^D5=J*OH,4M !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;?\ ?G_Z]'_"?Z__ ,];;_OS_P#7IV%<]9HKR;_A/]?_ .>MM_WY_P#KT?\
M"?Z__P ];;_OS_\ 7HL%SUFBO)O^$_U__GK;?]^?_KT?\)_K_P#SUMO^_/\
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M_KT?\)_K_P#SUMO^_/\ ]>BP7/6:*\F_X3_7_P#GK;?]^?\ Z]'_  G^O_\
M/6V_[\__ %Z+!<]9HKR;_A/]?_YZVW_?G_Z]'_"?Z_\ \];;_OS_ /7HL%SU
MFBO*8O'NO/,BF2VP6 /[G_Z]:G_"7:O_ ,](?^_7_P!>N7$8NG0:4^ITT,-.
MLFX]#T*BO/?^$NU?_GI#_P!^O_KT?\)=J_\ STA_[]?_ %ZY_P"U*'F;_P!G
M5O(]"HKSW_A+M7_YZ0_]^O\ Z]'_  EVK_\ /2'_ +]?_7H_M2AYA_9U;R/0
MJ*\]_P"$NU?_ )Z0_P#?K_Z]'_"7:O\ \](?^_7_ ->C^U*'F']G5O(]"HKS
MW_A+M7_YZ0_]^O\ Z]'_  EVK_\ /2'_ +]?_7H_M2AYA_9U;R/0J*\]_P"$
MNU?_ )Z0_P#?K_Z]'_"7:O\ \](?^_7_ ->C^U*'F']G5O(]"HKSW_A+M7_Y
MZ0_]^O\ Z]'_  EVK_\ /2'_ +]?_7H_M2AYA_9U;R/0J*\]_P"$NU?_ )Z0
M_P#?K_Z]'_"7:O\ \](?^_7_ ->C^U*'F']G5O(]"HKSW_A+M7_YZ0_]^O\
MZ]'_  EVK_\ /2'_ +]?_7H_M2AYA_9U;R/0J*\]_P"$NU?_ )Z0_P#?K_Z]
M'_"7:O\ \](?^_7_ ->C^U*'F']G5O(]"HKSW_A+M7_YZ0_]^O\ Z]'_  EV
MK_\ /2'_ +]?_7H_M2AYA_9U;R/0J*\]_P"$NU?_ )Z0_P#?K_Z]'_"7:O\
M\](?^_7_ ->C^U*'F']G5O(]"HKSW_A+M7_YZ0_]^O\ Z]'_  EVK_\ /2'_
M +]?_7H_M2AYA_9U;R/0J*\]_P"$NU?_ )Z0_P#?K_Z]'_"7:O\ \](?^_7_
M ->C^U*'F']G5O(]"HKSW_A+M7_YZ0_]^O\ Z]'_  EVK_\ /2'_ +]?_7H_
MM2AYA_9U;R/0J*\]_P"$NU?_ )Z0_P#?K_Z]'_"7:O\ \](?^_7_ ->C^U*'
MF']G5O(]"HKSW_A+M7_YZ0_]^O\ Z]'_  EVK_\ /2'_ +]?_7H_M2AYA_9U
M;R/0J*\]_P"$NU?_ )Z0_P#?K_Z]'_"7:O\ \](?^_7_ ->C^U*'F']G5O(]
M"HKQW6?B-XBL=0,,,ML$V \PYZ_C6?\ \+1\3_\ /6U_[\?_ %Z^FPN3XC%4
M(UZ=K25U=_\  /"Q&84:%65*=[Q=CW*BO#?^%H^)_P#GK:_]^/\ Z]'_  M'
MQ/\ \];7_OQ_]>NC_5[%]U]__ ,O[6P_G]Q[E17AO_"T?$__ #UM?^_'_P!>
MC_A:/B?_ )ZVO_?C_P"O1_J]B^Z^_P#X ?VMA_/[CW*BO#?^%H^)_P#GK:_]
M^/\ Z]'_  M'Q/\ \];7_OQ_]>C_ %>Q?=??_P  /[6P_G]Q[E17AO\ PM'Q
M/_SUM?\ OQ_]>C_A:/B?_GK:_P#?C_Z]'^KV+[K[_P#@!_:V'\_N/<J*\-_X
M6CXG_P">MK_WX_\ KT?\+1\3_P#/6U_[\?\ UZ/]7L7W7W_\ /[6P_G]Q[E1
M7AO_  M'Q/\ \];7_OQ_]>C_ (6CXG_YZVO_ 'X_^O1_J]B^Z^__ ( ?VMA_
M/[CW*BO#?^%H^)_^>MK_ -^/_KT?\+1\3_\ /6U_[\?_ %Z/]7L7W7W_ / #
M^UL/Y_<>Y45X;_PM'Q/_ ,];7_OQ_P#7H_X6CXG_ .>MK_WX_P#KT?ZO8ONO
MO_X ?VMA_/[CW*BO#?\ A:/B?_GK:_\ ?C_Z]'_"T?$__/6U_P"_'_UZ/]7L
M7W7W_P# #^UL/Y_<>Y45X;_PM'Q/_P ];7_OQ_\ 7H_X6CXG_P">MK_WX_\
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M?,/_  O#QM_S\6'_ ("__7H_X7AXV_Y^+#_P%_\ KT?V?5\@]M$^GJ*^8?\
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M ->C_A-];_YZ6_\ WZ_^O1]6F'LV>FT5YE_PF^M_\]+?_OU_]>C_ (3?6_\
MGI;_ /?K_P"O1]6F'LV>FT5YE_PF^M_\]+?_ +]?_7H_X3?6_P#GI;_]^O\
MZ]'U:8>S9Z;17F7_  F^M_\ /2W_ ._7_P!>C_A-];_YZ6__ 'Z_^O1]6F'L
MV>FT5YE_PF^M_P#/2W_[]?\ UZ/^$WUO_GI;_P#?K_Z]'U:8>S9Z;17F7_";
MZW_STM_^_7_UZ/\ A-];_P">EO\ ]^O_ *]'U:8>S9Z;17F7_";ZW_STM_\
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MKZF-[+FW/"=KZ!1115""BBB@ JAK/_((N/HO_H0J_5#6?^01<?1?_0A6-?\
MA2]&:T/XL?5?F<A1117S1](%%%% !1110 4JJSLJ(I9V(55'<GH*2NS^%F@?
M\)!X^L(I(]]M:G[3-E<C"] ?J<5,YJ$7)]!Q5W8]TMKBU^&'PRTX7"#='Y4;
M@C;NED8;B?ID\^U<[\>-#&H>&++7+=0[6<F'91G,3]\^@./SJ;XT:#XF\31Z
M;IVBZ5+=6D>Z69TE106Z!2&89P.?QKJ--TC4-<^%Z:-KUH8+Z2R-O+'(5.'
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M>(M:UDF'4]5O+R*.1BB3REPIZ<9J,+[3VT[OKK^.PZG+RHR:***](YPHHHH
M**** ._^"_\ R4_3_P#KC-_Z :]T^(/_ "#K/_KL?_037A?P7_Y*?I__ %QF
M_P#0#7NGQ!_Y!UG_ -=C_P"@FO*Q7^\Q]/\ ,[<-L<!1116AV!1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7FWQ+_Y"6G_ /7%_P"8KTFO-OB7_P A+3_^N+_S%- SB****HD**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK]G[_D2]2_["3?\ HJ.N/'_P6:T?B/6:***\,ZPHHHH **** "BBB@ HHHH
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MF:6*=1U ))(;TY]L5X*002&!!'!!Z@U=*M&JKQ%*#CN%%%%:DA1110 4444
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M$ BA@&72$;1)Z# ]_3%)IB^'O$-G*(-/B39\KJ8E1UST.1]/6I?%O_(J7'_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ'T]JYRB@1VMS\2;Z6%DM[&&!ST<R%\?A@5QLLTEQ,\TTC22N=S.QR2:910
M4444P"BBB@ HHHH **** )(/^/B+_?'\ZWJP8/\ CXB_WQ_.MZO!S?XX^A[.
M6?!(****\@],**** "BBB@ HHHH *=$_E31R8SL8-CUP<TVBGL!U?_"<2_\
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MY?F#T8Y)Q^-<92PU"5-RE+KV"I-2LD%%%%=9D%%%% !1110 4444 =_\%_\
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M7N_Q99Y_A/X>N-;79KA>(D%0'W&,^8".PZ9]\5X154*KJ0YF*<>5V"BBBMB
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M $?_  D/A3_H65_[[7_&N>U&YM+F^DFL[<6UNQ^2+/W:Z7_A/9/^@)I_Y?\
MUJ?X>\367]N74FI6L$,-WMQA 5C8<?D: *OA_P 7KHEM%;/IL4JH6)F4XD.3
MGT]ZT?%^E+?KI^L6MU(\=ZZ1!9CD+OY7'H/:B;P3IDMZ9(==@2T8[MI92P]@
M<XJ'Q5KMF+.RT?2'W16;*PF!SAE&% /?'K0!KZ]IM]I^@0:%HEC-+&ZYN)D
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M+;/8+SM#J'([@G./RJ\57P\[T,7!JVV[OZ6Z^I%"E5C:I0DG??;0SOB3H/\
M9FJ0:@EW+<17RE@9FW,I&,\^F",5SOA[7!H.HM>"RM[S=&8_+FY49(.?KQ^M
M=-XU\86FI:[IHL(UFL],D#JS#B4Y4D<_P_*!^=;NL:5X;\<6UOJ&G:K;:?<H
MFQHWVJ.N<,O'(R>12I5Y4L-3IXN#M)--]NU[:[#G24ZTYT)*Z>B[][7\RW:Z
MA!\2O#]W8Q-<:=<VZC,:/^[;/3/J,@C%>/2(T4C1NI5U)5@>Q%>KV$FA_#C2
M+J6/4H]0U.Y482-@02.@P.@R223S7E$DC2RO(YW.Y+,?4FM,JCRRJ>R35*ZY
M;_COK8C'.\8<[]_K^@VBBBO8/."BBB@ HHHH **** "BBB@ JAK/_((N/HO_
M *$*OU0UG_D$7'T7_P!"%8U_X4O1FM#^+'U7YG(4445\T?2!1110 4444 %%
M%% !1110 4444 >N_L_?\C3JG_7HO_H5<!XUU*YU7QKJMW<S22.+IUCWMGRU
M#$*H] !BNX^ ]Y:V7B74WN[F&W0VJ@-+($!.[MFO.O$#*_B/4V1@RFZD(93D
M$;CT-<L%_M$GY(T;]Q'KGQ"GENO@-X5GGD:29I;?<[')/[F3J:Y73/&?P^M-
M*M+>^\#+<W<4*)-/YJCS'  9NO<Y-;WC:^LYO@1X6M8KN![B.2W+Q)("R_N9
M,Y .1UK%TOXNRZ7I-G8#PMH\PMH4A$LBG<^T ;CQU.,UC3@W3LE?5];%MI2)
MO^$Z^&G_ $3U?^_R_P"-<WXN\0^%M9@ME\/^'%TAXF)F?S WF C@<5U/_"ZY
MO^A0T/\ [Y/^%9M]\4#JFM:->S^'M.MXM/N?-D2W0$S*>&4Y&.F<5I"$HROR
MO_P(4I)JUS \'>*QX3U*:]&EVFI"6+RO+N?NKR#D<'GBO8;R[MOC+X%OGLI;
MO3KS3AEK3S,Q.V,KN Z@X('I5/Q1X4\)?$3[/KFA^([#3IC$L;PR[47 YY7(
M(89(I#J/AKX2>$;^QTW5$U?6M0'(1P5!P0"<<!1D^YK&I.-2TH)\Y44XZ/8\
M(W*R@;@"PXYYKV?P?\9;2T>UTN]T"&TA=8[<W5D0'Z!=S#'/K5/X7ZSX5NO"
MU]X0\0"&VDN2_E7<B@;@P P'(^4C&15S3_A-X<TW51?:EXSLIM.MW$JI'(BN
MX4YPQW'T[5K6G3E>%5/38F*:UBSG/B[X2D\.>)UNQ>7%Y!J*F59;AMSJPZJ6
M[^U>>UW_ ,5_&]MXPUZ!-.).G62E(W/'FL>K >G85P%;X?F]FN?<B=N;0***
M*V("BBB@ HHHH **** "BBB@#O\ X+_\E/T__KC-_P"@&O=/B#_R#K/_ *['
M_P!!->%_!?\ Y*?I_P#UQF_] ->Z?$'_ )!UG_UV/_H)KRL5_O,?3_,[<-L<
M!1116AV!1110 4444 %%%% !1110 4444 %%%% ';>"I&AT75I$.&0[@?<)7
M'0S2F]BN#(QF,BL7SSG/K75^$IX8M"U99)8T9L[0S $_)7(P<219_O+_ #K&
M"]^1*W9V?CK8)]-E= W'S>XR"16?_;OAK_H7A_WV*N^-;F)I-->*2.7R^2%8
M$<8X.*J_\)K)_P! BQ_+_P"M40BW!:?C826B&?V[X:_Z%X?]]BLC5+NQO+E9
M+"S%I$%P4!SD^M;7_":R?] BQ_+_ .M6-JVJ'5KI)S;16Y5-NV+H><Y_6M(1
M:>WXC1I>"O\ D9(O^N;_ ,JK^*_^1FO?]Y?_ $$5-X.DCB\11O(ZHHC;EC@=
M*@\4.DGB.\='5U)7#*<@_**2_B_(/M&/7:S?\DOB_P!X?^C:XJNQEGA/PUCA
M$L?F@CY-PW?ZWTIU?L^H2Z''5O>#?^1GMO\ =?\ ]!-8-;GA"1(O$EN\CJBA
M7RS' ^Z:JI\#&]B'Q1_R,^H?]=!_Z"*R:U?$KK)XDOG1E92XPRG(/RBLJG#X
M4"V"BBBJ&%%%% !1110 4444 %%%% !1110 5W/P]_U=_P#[R?R-<-7<_#W_
M %=__O)_(UCB/X;)G\)X[\=?^2BC_KRB_FU>:5Z7\=?^2BC_ *\HOYM7FE>A
MAOX,?0\NI\3"BBBMR HHHH **** "BBB@ HHHH [/X4?\E+T?_?;_P!!-:GQ
MOU&XO?'\MG+*[6UK"@CB)^521DD#U/'Y5C_"Z>*W^(NDRSRQQ1J[%GD8*H^4
M]S5GXNW$-U\1[^6WFCFB:./#QN&4_+ZBN5K_ &E/R_4U3_=G:>%YYI_V<O$"
MS2-((A.B;CG:HVD >U</X8\3^#=(T<6NN^$UU2]\QF-P9 ORGH.3VKK?"M[:
M1?L_^(K62[@2X<S[86E4.W"]%SFN5\*_$B3PMHHTU?#^F7P$C2>=<CY^>W3I
M6<8M\Z2OKWL4W:QK?\)U\-/^B>K_ -_E_P :RO$7BOP1J>BS6FC>#ETZ^<C9
M<^8#LYYX!K:_X77-_P!"AH?_ 'R?\*R?$OQ.E\2:%<:6WAW2K,38_?P*=ZX.
M>.*<*<E)/E?_ ($#DK;G)Z#JXT37;34Q;07GV9RWD3<H^01@_GG\*]U\)^.K
M+XCVEQX6EM9]$N7@9U?3Y JLHX('''4<=ZH2+X-^*/A&RA%_:Z)J]F,LK!$^
M;&#G. RG /'-+X8T+PM\+?.\0:GXEMM0OO*:***V8$<\X"@DDG Y/ K.M.%1
M:IJ:V_K8<4X]=#QCQ!I$OAW7KW2;E@7M9FCW]-X!X8?48-=IX(^*2>$=/MK%
M_#]I=)$SL;E2%F.XD]<>^*M^"_B#IJ?$#5M2\16L/V35FR9)(P_V8@DKVZ8.
M#]!6SJ?PF\.ZCK+WMAXQL(-.G<R-$70L@/.%.[&![UK4J1?N5E_7R)C%[Q&_
M%G1(M=\.6'CO3KV[GMIE0/!<-D1(_3:/X?FX(]3[5XS7KWQ+\7Z);>%+/P1X
M;F%Q;6^P3S@[EPG1<]R6P21Z>]>0U>%4E3U^7H34MS:!111729A1110 4444
M %%%% !1110 5]%?L_?\B7J7_82;_P!%1U\ZU]%?L_?\B7J7_82;_P!%1UQX
M_P#@LUH_$>LT445X9UA1110 4444 %%%% !1110 4444 %%%% !1110 5S_C
MJPNM3\":Y8V4+375Q9R1Q1KC+,1P.:Z"B@#C/A3I-_H?PXTO3M3M7M;R'S=\
M3D$KF1B.A/8@UV=%% !1110 4444 %%%% !1110 5R/Q!\&S>.-*LM+%\+:S
M2\2>Z&TDRHN?D!!XZ_F!7744 ,AACMX(X84"11J$15& H P *?110 4444 %
M%%% '.>.?"J^,?"\^E"<6\Y=98)RN?+D4Y!Q^=;EE'/#86\5S*)9TC59)%&
M[ <G'N:GHH C\B'S_/\ *3SL;?,VC=CTSZ5)110 5#>)/)93I:R+'<-&PB=Q
ME5?'!([C.*FHH YOP+X33P9X6@TD3">8.TL\X7;YCL<DX_(?A72444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7FWQ+_Y"6G_
M /7%_P"8KTFO-OB7_P A+3_^N+_S%- SB****HD**** "BBB@ HHHH ****
M"BBB@!,#.<#-+110   =!1110 4444 )M7T'Y4M%% !28!.<#-+10 4444 %
M%%% !1110 4444 %%%% !1110!)!_P ?$7^^/YUO5@P?\?$7^^/YUO5X.;_'
M'T/9RSX)!1117D'IA1110 4444 %%%% !1110 48S110 48&<XYHHH ****
M"BBB@   Z"BBB@!,#T%+110 4444 %%%% !1110 4444 %%%% !1110!Q_B7
M_D+G_KFM9%:_B7_D+G_KFM9%?M^0_P#(LH?X5^1^6YM_OU7_ !,****]8\X*
M*** "BBB@ HHHH **** "C STHHH .M%%% !1110 4F!Z"EHH *, ]1110 8
M Z4444 %%%% !1110 4444 %%%% !1110 50UG_D$7'T7_T(5?JAK/\ R"+C
MZ+_Z$*QK_P *7HS6A_%CZK\SD****^:/I HHHH **** "BBB@ HHHH ****
M$(!Z@'ZTM%% "8 .<#-+110 4444 (54]0#^%  '0 4M% !UI-B_W1^5+10
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M+A8XO_A7T/\ S^'_ +Y_^O1_PKZ'_G\/_?/_ ->NTHHN%CB_^%?0_P#/X?\
MOG_Z]'_"OH?^?P_]\_\ UZ[2BBX6.+_X5]#_ ,_A_P"^?_KT?\*^A_Y_#_WS
M_P#7KM**+A8XO_A7T/\ S^'_ +Y_^O1_PKZ'_G\/_?/_ ->NTHHN%CB_^%?0
M_P#/X?\ OG_Z]'_"OH?^?P_]\_\ UZ[2BBX6.+_X5]#_ ,_A_P"^?_KT?\*^
MA_Y_#_WS_P#7KM**+A8XO_A7T/\ S^'_ +Y_^O1_PKZ'_G\/_?/_ ->NTHHN
M%CB_^%?0_P#/X?\ OG_Z]'_"OH?^?P_]\_\ UZ[2BBX6.+_X5]#_ ,_A_P"^
M?_KT?\*^A_Y_#_WS_P#7KM**+A8XO_A7T/\ S^'_ +Y_^O1_PKZ'_G\/_?/_
M ->NTHHN%CB_^%?0_P#/X?\ OG_Z]'_"OH?^?P_]\_\ UZ[2BBX6.+_X5]#_
M ,_A_P"^?_KT?\*^A_Y_#_WS_P#7KM**+A8XO_A7T/\ S^'_ +Y_^O1_PKZ'
M_G\/_?/_ ->NTHHN%CC$^'\*.K"\.001\O\ ]>K?_"'?]/8_[X/^-=1WIU<]
M:E"HTYJYM2J3@O==CE?^$._Z>Q_WP?\ &C_A#O\ I['_ 'P?\:ZJBL?JU'^5
M&OUBK_,SE?\ A#O^GL?]\'_&C_A#O^GL?]\'_&NJHH^K4?Y4'UBK_,SE?^$.
M_P"GL?\ ?!_QH_X0[_I['_?!_P :ZJBCZM1_E0?6*O\ ,SE?^$._Z>Q_WP?\
M:/\ A#O^GL?]\'_&NJHH^K4?Y4'UBK_,SE?^$._Z>Q_WP?\ &C_A#O\ I['_
M 'P?\:ZJBCZM1_E0?6*O\S.5_P"$._Z>Q_WP?\:/^$._Z>Q_WP?\:ZJBCZM1
M_E0?6*O\S.5_X0[_ *>Q_P!\'_&C_A#O^GL?]\'_ !KJJ*/JU'^5!]8J_P S
M.5_X0[_I['_?!_QH_P"$._Z>Q_WP?\:ZJBCZM1_E0?6*O\S.5_X0[_I['_?!
M_P :/^$._P"GL?\ ?!_QKJJ*/JU'^5!]8J_S,Y7_ (0[_I['_?!_QH_X0[_I
M['_?!_QKJJ*/JU'^5!]8J_S,Y7_A#O\ I['_ 'P?\:/^$._Z>Q_WP?\ &NJH
MH^K4?Y4'UBK_ #,Y7_A#O^GL?]\'_&C_ (0[_I['_?!_QKJJ*/JU'^5!]8J_
MS,Y7_A#O^GL?]\'_ !H_X0[_ *>Q_P!\'_&NJHH^K4?Y4'UBK_,SE?\ A#O^
MGL?]\'_&C_A#O^GL?]\'_&NJHH^K4?Y4'UBK_,SE?^$._P"GL?\ ?!_QH_X0
M[_I['_?!_P :ZJBCZM1_E0?6*O\ ,SE?^$._Z>Q_WP?\:/\ A#O^GL?]\'_&
MNJHH^K4?Y4'UBK_,SE?^$._Z>Q_WP?\ &C_A#O\ I['_ 'P?\:ZJBCZM1_E0
M?6*O\S."O_AS:WESYTUVV_:!\HP/YU6_X5?8_P#/W)^5>@2??_"F5[N'QF(I
M4HPA-I):(\JMAZ4ZCG.-VS@O^%7V/_/W)^5'_"K['_G[D_*N]HK;^T,5_P _
M']YE]4H?RHX+_A5]C_S]R?E1_P *OL?^?N3\J[VBC^T,5_S\?WA]4H?RHX+_
M (5?8_\ /W)^5'_"K['_ )^Y/RKO:*/[0Q7_ #\?WA]4H?RHX+_A5]C_ ,_<
MGY4?\*OL?^?N3\J[VBC^T,5_S\?WA]4H?RHX+_A5]C_S]R?E1_PJ^Q_Y^Y/R
MKO:*/[0Q7_/Q_>'U2A_*C@O^%7V/_/W)^5'_  J^Q_Y^Y/RKO:*/[0Q7_/Q_
M>'U2A_*C@O\ A5]C_P _<GY4?\*OL?\ G[D_*N]HH_M#%?\ /Q_>'U2A_*C@
MO^%7V/\ S]R?E1_PJ^Q_Y^Y/RKO:*/[0Q7_/Q_>'U2A_*C@O^%7V/_/W)^5'
M_"K['_G[D_*N]HH_M#%?\_']X?5*'\J."_X5?8_\_<GY4?\ "K['_G[D_*N]
MHH_M#%?\_']X?5*'\J."_P"%7V/_ #]R?E1_PJ^Q_P"?N3\J[VBC^T,5_P _
M']X?5*'\J."_X5?8_P#/W)^5'_"K['_G[D_*N]HH_M#%?\_']X?5*'\J."_X
M5?8_\_<GY4?\*OL?^?N3\J[VBC^T,5_S\?WA]4H?RHX+_A5]C_S]R?E1_P *
MOL?^?N3\J[VBC^T,5_S\?WA]4H?RHX+_ (5?8_\ /W)^5'_"K['_ )^Y/RKO
M:*/[0Q7_ #\?WA]4H?RHX+_A5]C_ ,_<GY4?\*OL?^?N3\J[VBC^T,5_S\?W
MA]4H?RHX+_A5]C_S]R?E4-W\*-.N+5XI+N78V,XX/6O0Z;)_JS2>/Q,M'48U
MA:*=U%'E/_"D]$_Y^[G_ +ZH_P"%)Z)_S]W/_?5>G45'M9]V='*CS'_A2>B?
M\_=S_P!]4?\ "D]$_P"?NY_[ZKTZBCVL^[#E1YC_ ,*3T3_G[N?^^J/^%)Z)
M_P _=S_WU7IU%'M9]V'*CS'_ (4GHG_/W<_]]4?\*3T3_G[N?^^J].HH]K/N
MPY4>8_\ "D]$_P"?NY_[ZH_X4GHG_/W<_P#?5>G44>UGW8<J/,?^%)Z)_P _
M=S_WU1_PI/1/^?NY_P"^J].HH]K/NPY4>8_\*3T3_G[N?^^J/^%)Z)_S]W/_
M 'U7IU%'M9]V'*CS'_A2>B?\_=S_ -]4?\*3T3_G[N?^^J].HH]K/NPY4>8_
M\*3T3_G[N?\ OJC_ (4GHG_/W<_]]5Z=11[6?=ARH\Q_X4GHG_/W<_\ ?5'_
M  I/1/\ G[N?^^J].HH]K/NPY4>8_P#"D]$_Y^[G_OJC_A2>B?\ /W<_]]5Z
M=11[6?=ARH\Q_P"%)Z)_S]W/_?5'_"D]$_Y^[G_OJO3J*/:S[L.5'F/_  I/
M1/\ G[N?^^J/^%)Z)_S]W/\ WU7IU%'M9]V'*CS'_A2>B?\ /W<_]]4?\*3T
M3_G[N?\ OJO3J*/:S[L.5'F/_"D]$_Y^[G_OJC_A2>B?\_=S_P!]5Z=11[6?
M=ARH\Q_X4GHG_/W<_P#?5'_"D]$_Y^[G_OJO3J*/:S[L.5'F/_"D]$_Y^[G_
M +ZH_P"%)Z)_S]W/_?5>G44>UGW8<J.+\*?#"Q\.>(8-3T^[D^TQJZKYOS+@
MC!XKKM<T:YU2WBCNKJ/:C[ALC(YQ]:O6/_'VOT-7;W[B_6N6K.3FFV:P5MCB
M?^$,C_Y^C_WS_P#7H_X0R/\ Y^C_ -\__7KJ:*/:3[FEWW.6_P"$,C_Y^C_W
MS_\ 7H_X0R/_ )^C_P!\_P#UZZFBCVD^X7?<Y;_A#(_^?H_]\_\ UZ/^$,C_
M .?H_P#?/_UZZFBCVD^X7?<Y;_A#(_\ GZ/_ 'S_ /7H_P"$,C_Y^C_WS_\
M7KJ:*/:3[A=]SEO^$,C_ .?H_P#?/_UZ/^$,C_Y^C_WS_P#7KJ:*/:3[A=]S
MEO\ A#(_^?H_]\__ %Z/^$,C_P"?H_\ ?/\ ]>NIHH]I/N%WW.6_X0R/_GZ/
M_?/_ ->C_A#(_P#GZ/\ WS_]>NIHH]I/N%WW.6_X0R/_ )^C_P!\_P#UZ/\
MA#(_^?H_]\__ %ZZFBCVD^X7?<Y;_A#(_P#GZ/\ WS_]>C_A#(_^?H_]\_\
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M^$,C_P"?H_\ ?/\ ]>NIHH]I/N%WW.6_X0R/_GZ/_?/_ ->C_A#(_P#GZ/\
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M'*CS'_A2>B?\_=S_ -]4?\*3T3_G[N?^^J].HH]K/NPY4>8_\*3T3_G[N?\
MOJC_ (4GHG_/W<_]]5Z=11[6?=ARH\Q_X4GHG_/W<_\ ?5'_  I/1/\ G[N?
M^^J].HH]K/NPY4>8_P#"D]$_Y^[G_OJC_A2>B?\ /W<_]]5Z=11[6?=ARH\Q
M_P"%)Z)_S]W/_?5'_"D]$_Y^[G_OJO3J*/:S[L.5'F/_  I/1/\ G[N?^^J/
M^%)Z)_S]W/\ WU7IU%'M9]V'*CS'_A2>B?\ /W<_]]4?\*3T3_G[N?\ OJO3
MJ*/:S[L.5'F/_"D]$_Y^[G_OJC_A2>B?\_=S_P!]5Z=11[6?=ARH\Q_X4GHG
M_/W<_P#?5'_"D]$_Y^[G_OJO3J*/:S[L.5'F/_"D]$_Y^[G_ +ZH_P"%)Z)_
MS]W/_?5>G44>UGW8<J/,?^%)Z)_S]W/_ 'U1_P *3T3_ )^[G_OJO3J*/:S[
ML.5'F/\ PI/1/^?NY_[ZKT'P#X4M?".CW-E:2R21S7)F)D['8JX'_?-7:TM.
M_P!0W^]_05C6G)PLV5"*3T+E%%%<9J%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !4%Q]Y?I4]07'WE^E $-%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 =Z=3>].J)EQ"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,GW_ ,*93Y/O
M_A3*[8?"CFG\3"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR?ZLTZFR?ZLT+<"O111
M6A04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 6+'_ (^U^AJ[>_<7ZU2L?^/M?H:NWOW%
M^M<]7XRX%*BBBI- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *MV
M71ZJ5;LNCTGL)E;4/^/G_@(JK5K4/^/G_@(JK73#X48O<****H HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K2T[_ %#?[W]!6;6EIW^H;_>_H*SJ_"..Y<HHHKE- HHHH \I
MUKX8>+]2UN]O;7XD:I96\\S21VT;R[8E)X48D P/I7G,>D>,Y/BHW@C_ (6#
MK08(7^U_:9L<1[_N>9^'6OIRO"K?_DZU_P#K@W_I/0!T.A?#+Q=I>O6-_>?$
M;5+ZVMYEDDM9'EVRJ.JG,A&#]#7&:C'XH\5_&W7/#UAXPU72K>(F1!%<2E%
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M((Q]!7IE>->!;>Z^('Q$D\?W?V:WM+5/)M;2.<22# P"X!^7J2<XZ].]>RT
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M%>&IM5GC\Z7(CMX-V#+(>@^G<^PKAO@GNO[_ ,8ZW(2S7>H[5+#H 7.,_P#
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M>ZUP\?PYC3XIGQO_ &FY<H4^R>2,<Q[/O9_'I0!W%>%^%S_QDYXA_P"N;_\
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MVO>WC[F Z';Z9&!DDG Q0!V]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5!<?>7Z5/4%Q]Y?I0!#1110 4444 %%%%
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M7>S;Y"2<G"@@C/L<>U-T7X-Z7::K#J>NZM?Z_=PD&,WA^08.1D$L3CTSCVH
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MJK!\'H9YXCKWB?5M9M82"EM,Q5?Q.YL_A@UZ/!!%;6\=O!&L<,2A$11@*HZ
M4TFW=AT) <$&O*_ *-IOQ9\::=+D&5A-&#_$-Q.?R(KU2O-O%$(\/?%KP]XB
MX6VU)#I]RY/1L?+^?R_E1/HP1Z2.3BO%-W_"P_CB,9DTG0AP>JL4/7TY?GW
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M:=_J&_WOZ"LVM+3O]0W^]_05G5^$<=RY1117*:!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5!<?>7Z5/4%Q]Y?I0!#1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %0V]G:VGF?9;:"#S7,DGE1A-[?WC@<GW-34
M4 %%%% !1110 5##:6UO)-)!;0Q23-NE>.,*9#ZL0.3]:FHH **** "BBB@
MHHHH **** "BBB@ [TZF]Z=43+B%%%%0,**** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@"&6TMIYHIIK:&26$DQ2/&&:,GKM)&1GVJ:BB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M"X^\OTJ>HIF4$97- %>BI-Z?\\Q1O3_GF* (Z*DWI_SS%&]/^>8H CHJ3>G_
M #S%&]/^>8H CHJ3>G_/,4;T_P">8H CHJ3>G_/,4;T_YYB@".BI-Z?\\Q1O
M3_GF* (Z*DWI_P \Q1O3_GF* (Z*DWI_SS%&]/\ GF* (Z*DWI_SS%&]/^>8
MH CHJ3>G_/,4;T_YYB@".BI-Z?\ /,4;T_YYB@".BI-Z?\\Q1O3_ )YB@".B
MI-Z?\\Q1O3_GF* (Z*DWI_SS%&]/^>8H CHJ3>G_ #S%&]/^>8H CHJ3>G_/
M,4;T_P">8H CHJ3>G_/,4;T_YYB@"/O3J=O3_GF*7<O]P5$BHC**?N7^X*-R
M_P!P5-BAE%/W+_<%&Y?[@HL RBG[E_N"C<O]P46 913]R_W!1N7^X*+ ,HI^
MY?[@HW+_ '!18!E%/W+_ '!1N7^X*+ ,HI^Y?[@HW+_<%%@&44_<O]P4;E_N
M"BP#**?N7^X*-R_W!18!E%/W+_<%&Y?[@HL RBG[E_N"C<O]P46 913]R_W!
M1N7^X*+ ,HI^Y?[@HW+_ '!18!E%/W+_ '!1N7^X*+ ,HI^Y?[@HW+_<%%@&
M44_<O]P4;E_N"BP#**?N7^X*-R_W!18"M)]_\*95AY(PW,0/XTWS8O\ GB/S
MKK@_=1S26K(:*F\V+_GB/SH\V+_GB/SJ[OL*Q#14WFQ?\\1^='FQ?\\1^=%W
MV"Q#14WFQ?\ /$?G1YL7_/$?G1=]@L0T5-YL7_/$?G1YL7_/$?G1=]@L0T5-
MYL7_ #Q'YT>;%_SQ'YT7?8+$-%3>;%_SQ'YT>;%_SQ'YT7?8+$-%3>;%_P \
M1^='FQ?\\1^=%WV"Q#14WFQ?\\1^='FQ?\\1^=%WV"Q#14WFQ?\ /$?G1YL7
M_/$?G1=]@L0T5-YL7_/$?G1YL7_/$?G1=]@L0T5-YL7_ #Q'YT>;%_SQ'YT7
M?8+$-%3>;%_SQ'YT>;%_SQ'YT7?8+$-%3>;%_P \1^='FQ?\\1^=%WV"Q#14
MWFQ?\\1^='FQ?\\1^=%WV"Q#14WFQ?\ /$?G1YL7_/$?G1=]@L0T5-YL7_/$
M?G1YL7_/$?G1=]@L0TV3_5FK'FQ?\\1^=->6((<P _C0F^P6*-%6//@_Y]E_
M.CSX/^?9?SJ[OL.Q7HJQY\'_ #[+^='GP?\ /LOYT7?8+%>BK'GP?\^R_G1Y
M\'_/LOYT7?8+%>BK'GP?\^R_G1Y\'_/LOYT7?8+%>BK'GP?\^R_G1Y\'_/LO
MYT7?8+%>BK'GP?\ /LOYT>?!_P ^R_G1=]@L5Z*L>?!_S[+^='GP?\^R_G1=
M]@L5Z*L>?!_S[+^='GP?\^R_G1=]@L5Z*L>?!_S[+^='GP?\^R_G1=]@L5Z*
ML>?!_P ^R_G1Y\'_ #[+^=%WV"Q7HJQY\'_/LOYT>?!_S[+^=%WV"Q7HJQY\
M'_/LOYT>?!_S[+^=%WV"Q7HJQY\'_/LOYT>?!_S[+^=%WV"Q7HJQY\'_ #[+
M^='GP?\ /LOYT7?8+%>BK'GP?\^R_G1Y\'_/LOYT7?8+%>BK'GP?\^R_G1Y\
M'_/LOYT7?8+%>BK'GP?\^R_G1Y\'_/LOYT7?8+!8_P#'VOT-7;W[B_6H+66)
MKA0L 4X/.:LW+*JKN3=S6%1^\:1*%%3>;%_SP'YT>;%_SP'YTBR&BIO-B_YX
M#\Z/-B_YX#\Z (:*F\V+_G@/SH\V+_G@/SH AHJ;S8O^> _.CS8O^> _.@"&
MBIO-B_YX#\Z/-B_YX#\Z (:*F\V+_G@/SH\V+_G@/SH AHJ;S8O^> _.CS8O
M^> _.@"&BIO-B_YX#\Z/-B_YX#\Z (:*F\V+_G@/SH\V+_G@/SH AHJ;S8O^
M> _.CS8O^> _.@"&BIO-B_YX#\Z/-B_YX#\Z (:*F\V+_G@/SH\V+_G@/SH
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MGR??_"F5VP^%'-/XF%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-D_U9IU-D_U9H6X%
M>BBBM"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH L6/_ !]K]#5V]^XOUJE8_P#'VOT-
M7;W[B_6N>K\9<"E1114F@4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %6[+H]5*MV71Z3V$RMJ'_'S_P$55JUJ'_'S_P$55KIA\*,7N%%%%4 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M50W>[;+,Q.  WIQT7IW- 'T+16%X*NKB^\#Z)=7<SSW$MHCR2R'+.?4FMV@
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MHH **** "BBB@ HHHH AD^_^%,I\GW_PIE=L/A1S3^)A1115DA1110 4444
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M:R^3<*@PK'&0P';//'J#0I=&#1V%O=6]Y")K6XAN(B2!)#('7(ZC(XJ6O,O
M$QT+X@>+/"3Y$)F_M&T7& %?&X#_ +Z7_ODUZ;33N#04444Q!1110 4444 %
M%%% !39/]6:=39/]6:%N!7HHHK0H**** "BBB@ HHHH **** "BLSQ#KEMX;
MT&[U>\21X+90S+&!N;)  &?<BO#?$'CSQQ?:GI&I,;G1-)O+GR[6WB<H9%#+
MDMW;.>IX].*F4U$:5SZ%HI$Y5<GJ!R:\:M_$?B_XF>(M0MO#>JC1M%LF"_:$
M!WOR<'(Y).,XR !1*5A)'LU%>,ZKK'C7X77MA<:QK']OZ+<R>7(TBGS$/4X)
M.0<9(YP<'->R1R++$DB'*. RD=P:(RN#0ZHC=6XNA:FXA%R5WB$R#>5]=N<X
M]ZEKS;P--_PD7Q%\5>(W!:*V*Z;:D] H)+8_%<_\"IMVL@/2:*\R\?\ C/78
MO%-AX/\ "OEIJ5VH:2X< [ <X STP 23C.,8JAJ?A_XD>&=-GUFW\9R:FUNA
MEEM9D)4J.3@,2#^0J7/71#L>N45Q_A_Q]:ZM\/)/%5S#Y0MD?[3$AZ.N.%]C
MD8^M<?H2>/?B+:RZV/$LF@Z>[LMK!;*?F ]<$$@>ISGFAS[!8]@J)[JWCN([
M=[B%)Y 3'$T@#N!U(7J?PKS7PWXI\0Z#XW3P=XMN([PW"[K*_5<%_0'US@]>
M0:M_%I9--L=&\46P(GTB^4L5&28WX(^G'ZT<^EPL>B45';SQW5M%<Q',<J"1
M3[$9J2K$%%%% !1110 4444 %%%% %BQ_P"/M?H:NWOW%^M4K'_C[7Z&KM[]
MQ?K7/5^,N!2HHHJ30**** "BBB@ HHHH **** "BBB@ HHKDOB-XR/@GPLVH
M11I)>3.(;9'^[NZDGUP.<4 =;17D.F^%OB;KFFPZO=>.)=/N+A!+':(#L (R
MN=I &?3!K7^&_C76-5UG4_"WB5(_[8TXG]]& /- .""!QD<'-*XCT>BO'M2\
M4^*_&_CJ^\->$[^/3-/L"5GO5&7.#@G/7KP ,>]0:[-\0/AC!;ZQ<^(O^$@T
MLRB.XBN%.1GIC))'0\@]:+@>T454TS4(=6TJTU&V)\BZB65,^A&:MTQD4EU;
M0SQ02W$,<TV?*C>0!I,==H)R<>U2UYEI<X\3?''5+KA[7P_:"UA[[96/S'ZY
M\P?@*F^)_CO4_#USIF@>'TC;6=38!'< ^6I;:N >,LV1D],&BXCT>BO)9O"'
MQ/L+)]2A\<R75\B>8;)@QC8CDJ,G!]N!73?#7QNWC;PPU[=1I%>VTGE7 3A6
MXR' [9';U!HN,[2BO'(-;\8_$W7M2B\.:Q_8F@V,GEK<Q@[Y6YP<CDYP3U
MQ5K2?$GBCP5XWLO#/BV^&J6&HX6SU C#ALXY/7J0"#G&0:5Q'JDMS;P/%'-<
M0Q/*VV)9) ID;T4'J?85+7!_%VQEE\%-J5MQ=Z3<)>1,#@KM/S?I77:+JD>M
MZ'8:K$1LNX%EXZ D<C\#D?A3&7J*** "BBB@ HHHH **** "BBB@ HHHH *M
MV71ZJ5;LNCTGL)E;4/\ CY_X"*JU:U#_ (^?^ BJM=,/A1B]PHHHJ@"BBB@
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MX+V":;XC7LT4<BL\163#J#DK]_OTK>^)6D_VQX U6%%)FAB^T18ZAH_FX]R
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M6[\8/&^H>%]+L-,T3C6-5E,4+@ E%& 2,\9)90/J?2N?\1?\G0^&_P#KQ_\
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MSKG.=@"XXXP<CO7I]?/L$&J_##XK:)X=TK7[O4=,OROF64S!C&I)'(Z \9R
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M%O<R;U?()!/3(XP0<]:V/@Q_R/\ \0/^OI/_ $9+6Q^T!_R3)_\ K\B_]FH
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M>-8-A!_PDGQUO]1(+6GAZS6W0Y^7SY 3Q^#-^*BO3** "BBB@ HHHH ****
M"BBB@ HHHH .].IO>G5$RXA1114#"BBB@ HHHH **** "BBB@ KB/%'PI\,^
M*M0;49XKBSU!B"UU92;&8CN0003[XS7;T4 <;X4^&/AOPC=&]LX);F_YQ=W;
M^9(,]<< #Z@9KLJ** $90RE6&01@BO,OA7"?#FN>*O!K_*MG=B[M 2?FAD&.
M,^@"#ZDUZ=11<#E/%GPY\.>,I$GU2T9;M%VK<P/LDQZ$]#^(-8&C_ WPAI5Z
MEU,+W461@R)>2AD!'LJJ#]#D5Z513NPL0W-I;7EG):7,$<MM*FQXG4%67T(]
M*\TO_@)X0N[DS02ZE8J>3%;SC9_X^K']:]1HI)V"QS?A3P+H'@R*1=(L]DTH
MQ+<2,7D<>A)Z#V&!7+_$.#_A)/'?A/PLN6B65M0NP#TC7@9_+]:],HIW"P?0
M8'I1112 **** "BBB@ HHHH **** "BBB@"&3[_X4RGR??\ PIE=L/A1S3^)
MA1115DA1110 4444 %%%% !1110!S'A;P-IOA+4-4O;&XNY9-1D\R43LI"G)
M/RX4>O?-='/!#=6\EO<1)+#(I5XW&58'J"*DHI6L!YI=? [PI/=/+;S:E9Q/
M]^WM[@>6W.<'<"<?C7;>'_#>D^%].%CI%FEM#G+$<LY]68\D_6M6BA)(=V%<
MG\2O#Y\2> M2LXUW7$2?:8/]].?U&X5UE%#5U81@>"=9&O\ @O2M1W O) JR
M8/1U^5A^8K?HHH0'+Z;X$TW2_&VH>*H;B[:^OE=)(W9?+4,5)P N?X1U)J_X
MC\*Z-XLL5M-8LEN$0YC;)5T/^RPY'3\:V:*+(+GET/P%\)QW(DDN=5FCSGR'
MG4)].%!_6O1M,TRQT;3XK#3K:.VM81A(XQ@#U_'WJW10DEL-ML\U\!P?VW\0
M?%GBQP3"LW]FVC$\83&\CV^53_P(UZ5110E8384444P"BBB@ HHHH **** "
MFR?ZLTZFR?ZLT+<"O1116A04444 %%%% !1110 4444 %<UXJ\$Z=XOGTZ6_
MN+J)K"0R1"!E 8D@_-E3_='3%=+10U?<  P /08KB/$?PI\,>);Z2^FAGM+N
M4YDFM)-A<^I!!&??%=O12:3W XGPU\*O#/AF]2^@BGN[R,YCFNW#E/<  #/O
MC-=M110DEL 5YMX8@_X1GXM^(-'(VVVKPC4+;D\N"=P'ORY^@%>DT4-7 P/$
M_@S0_%T$<>K6GF/%GRYD8JZ9]".WL>*Y2S^!WA.VNA--)J-X@.1#/.-G_CJ@
M_K7I5%#BGJT%V116\$%JEM%#&ENB>6L2J H7&,8],5Y[J7P2\)W]VUQ";ZPW
M'+1VLH"9^C*<?05Z/10XI[A<P/"_@S1/"%O)'I-KLDEQYLTC;I'QZD]O88%<
MY\5S)J.GZ-X9MR3/J]\JD*<'RTY;\.?TKT*BAQTL@N1V\$=K;16\0Q'$@11[
M 8%2444P"BBB@ HHHH **** "BBB@"Q8_P#'VOT-7;W[B_6J5C_Q]K]#5V]^
MXOUKGJ_&7 I4445)H%%%% !1110 4444 %%%% !1110 54U+3++6-/FL-0MT
MN+68;7C<9!_P/O5NB@#R^;X#>$Y+GS([C5(8\Y\A)U*?3E2?UKNO#WAK2?"V
MG?8=(LUMX2=S$$EG/JS'DUK446 X_P 5?#/PWXNNC>7UO+#>E=IN;9]CL/?J
M"?<BL[0?@UX4T*^CO2EU?SQ,&C-Y(&"$=#M4 '\0:]!HHL 4444 >:F$^&?C
MDLN2MGXCLR!Z>?'@G]!G_@==EXC\+Z/XKT\66L6BSQ*VY&R59#ZJPY']:V**
M+ >7P_ ;PG'<B62XU2>('_423J$/_?*AOUKT?3]/M-*L(;&PMX[>UA7;'%&,
M!15FBBP'$^*OA7X:\67IOKJ.>UO6QON+1PC/C^\""#]<9J]X2^'^@># [Z9
M[W4B[7NIVWR,/3/  ^@%=1118#A?BW>RQ>"'TVVYN]5GCLXD R6W'YL#Z5UF
MC:7%HFAV.EP@!+2!8N.A(')_$Y/XU>HH **** "BBB@ HHHH **** "BBB@
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MKJJ*.72R"YA>#-#_ .$<\'Z9I97;+#"#,,Y_>-\S_J2/PK=HHII65@"BBB@
MHHHH **** "BBB@ K2T[_4-_O?T%9M:6G?ZAO][^@K.K\(X[ERBBBN4T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"X^\OTJ>H+C[R_2@"
M&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH .].IO>G5$RXA1114#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"&3[_X4RGR??_"F5VP^%'-/XF%%%%62%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %-D_U9IU-D_U9H6X%>BBBM"@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L6/_'VO
MT-7;W[B_6J5C_P ?:_0U<O?N+]:YZOQEP*=%%%2:!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5;LNCU4JW9='I/83*VH?\ 'S_P$55JUJ'_ !\_
M\!%5:Z8?"C%[A1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %:6G?ZAO\ >_H*S:TM._U#
M?[W]!6=7X1QW+E%%%<IH%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[)O/_P"F2?E1Y_\ TR3\JAHHY4%V3>?_ -,D_*CS_P#IDGY5#11RH+LF\_\
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M !1110 4444 %%%* 2< $GVH 2BG>6_]QORI"K+]Y2/J* $HHI2K 9(('N*
M$HHHH **IW&JZ?::A:Z?<7D4=Y=[C;P,?FDVC)P/:KE !12A2QP 3]*0@@X(
MP: "BE ). "3[4%67J"/J* $HJI>:I8:=-:Q7MW%;R7<@BMUD./,?^Z/>K=
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MKU621(HVDD8*B LS$\ #J: /(_C5J$NJW&A>!;%R+C5KE7GV]5C!X_7)_P"
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M59LX\LS*&_+-.U"VDO=,NK6&Y>VDFA:-)T +1D@@,,]QUKQ?PSX(^%WB/PW
M(=16;4YHE:2>6[*3K,5&?E)['M7;^%M+UCX>>!+]-7OWULV8>>!858OL"Y\L
M9R3R#CZT <]XR\,^&/!GPFET9[2&[OIT-O9R-$IN+BY8Y5@1SD$Y^@Q7I'AR
M"\M?#&E6^HL6O8K2))R6R3($ ;GOSGFO&?#GBRQN/$#^*_%^GZW<:P,K9VL>
MFR-#81YZ)ZL>[5[?IM_%JFFV]]"DJ13H)%69"C@'U4\@T 6J*** "H+C[R_2
MIZ@N/O+]* (:*** "BBB@ HHHH **** "BBB@#A/B!XNUW1KFRT7PSI+7NJZ
M@C&.7&5A P,D?CWXKA/A8VO6WQ=U?3M=U.:\NH;9S-F8LF\[2<#IQG'2O=@!
MNW8&[&,XYQZ5XQX._P"3BO%/_7%_Y)0![/7GWQ+\57=FEMX5T#+^(-7_ ':;
M#S;QG@N?0]<?B:Z;Q9XGLO"'AVYU>]8$1C$46<&60]%'^>E<C\+O#M[(;OQM
MX@!;6=7!:)6_Y80GH .V1C\,>M &1\!9KU[3Q%#>WDUT\%TD8:21GZ @XS7L
M%>/_  (Z^+/^P@/_ &:O8* .:^(&NGPWX$U;4D;;,L)BAYP=[_*,>XR3^%1?
M#?2?[&^'NCVS+ME>'SY0>N]_F/\ .N3^/3O)X5TG3Q]V[U%5;GT''_H5>GPB
M.TL(@S+'%#"N68X"@+R2?3B@#-\5>);'PCX=NM8OSF.$8CC!YE<_=0?7]!DU
MX;X4O/$[_&G0I]>O)UDU1)+PVOF,$1&BDVKMZ#  XKJ+$O\ %WX@_;Y%;_A$
M]"DQ;HWW;J;U(_7Z8'<T:]_R<UX=_P"O,_\ HJ6@#TKQ9KX\+^&+W6?LCW9M
MPFV",X+EG5 /S85\]^,M5\=3ZIH.K>()IM.AU"=A:V,,C1^7&K)DL >^\=>>
M*^G"JL,,H89S@C->)?'[G6/!G_7>?_T*&@#VX]:\OCF/AGX^20<K9^([('T7
MST!Q^.%Q_P #KU ]:\C^,F;+Q!X*U>/_ %UMJ&T>^2K?^R_K0!ZY12L,,1Z&
MDH **** "BBB@ HHHH **** #O3J;WIU1,N(4445 PHHHH **** "BBB@ HH
MHH *\9@N];^+OB;5(;+6;G2O"VG2>4CVO#W#>N??&?8$5ZGXCGDM?"VL7$1V
MR16,[H?0B-B*\$^%"^+M9\.76D^&;J+2;=9VEO-2D7<SR,  B#V4 _C5+:XF
M=5+X;\;?#_Q)ILOAZ^U/Q!H\[D7=M-\YC (SG)[@\$=P<U[)VKQ:X\2>-/AA
MX@TV#Q5JD>M:%?N4-T5PT1R,G/48R#CN,U[2.1FDP1%=7,=G:374S!8H4:1V
M/8 9)KSCX,K+J.DZUXHNE(N=:U!Y,DY_=IPH^@+,/PK>^*%T]I\,]?D3JUJ8
M_P &(4_H:;\++1;+X8Z#$H^];F4\]W9F_K1T'U.-\47OBWQI\1Y/"6D75SI&
MC6RYN+M(V7S, %B&[\D*!GMFJ/B3P9XD^'&C2>)-!\7W]V;5E:>WN^5=,^F2
M"/4>E>U7LT\-C/);Q>=,D;-'%G[[ <#\:\ \;>*/%VMPVVD^,--?PSH5Q*OV
MB>*!I=V#D G--"9Z/??$4P?"%/&<=L!<2PJ$A/*K,6V?]\[@3]*Y?P_\.M<\
M8:-!KWB/Q?JL5U>IYL4-J^U8E/(SSC\!7:ZCX<\,W?PM_L?[6D.@+:*T5WNR
M$4?,),]SGG\:\R\)>-O&VF:2VF^'M'_X272;-C%;7S0/'\H[=>0*%Y"]3>\+
M:[XA\)?$X>!M=U-M5L[F/?:7,GWUR,K_ "((K0^)\K^'?%?A/Q;$&"0W!L[H
M@X!C?U_,_E6)\,OLWB?QY>^(]?U/=XFA0HFF-"8OLZCC@'[V >WJ374_&RT6
MZ^%^H%L9@ECE7Z@X_K1U'T/0@0P#*<J1D$=Q16+X0NWOO!NBW4GWY+.,G_OG
M']*VJD84444 %%%% !1110 4444 %%%% $,GW_PIE/D^_P#A3*[8?"CFG\3"
MBBBK)"BBB@ HHHH **** "O./''BCQ3)KO\ PBGA'3F^V20K)+J#?=A5B1QV
M'3J?PKT>D  +$  GJ0.M)JX(\:^!T^H-J_B>VU"^GNY+>18RTDK,,AF!(STS
MBN[\9^"#XP:S;^W+_3/LP88M#_K,XZ\CIBN%^"O_ "-/C3_KZ_\ :CU[+4Q5
MXE2T9Y/+\&5@ADFE\<ZXL<:EW8GH ,D_>K-^!D-]=:KKNHF_N[K3(\6T#7,C
M,6.[.<$XZ#]:Z/XT>(VT;P6=.MV_TS57^SHH/.S^(_R'XUT?@+PZOA;P7IVF
M%0)Q'YLY]9&Y/Y<#\*5O>T"^ATE<'\7]8ETOP'-:VQ/VO4Y5LX@#@X;EL?@,
M?C7>5Y-\5PU[XX\#Z8?]6UUYQY[[A_\ $U4MA1W/1M'L(]$\,6=C&N$M+15P
M/9>:\.^'O@:[\<:1>ZE=>*=7L_+NVA1(I2P( !R<M[U[WJ;,FEWSQCYUMY2H
M SSM.*\*^&VF>.M2\-W&GZ1=QZ!91W#-+=20MYTSG!P >@ QTJ9;H:.[T#X5
M'0M=M=3_ .$KU>\^SL6\B8_(^01@_-[U%\5_$?B'3H],T7PU',MYJ,A5[F.,
MGRER% SC"Y)Z]@*Q[+Q/XM\!^,[#0O%]ZNJZ;J1"6]\!\RL3CKUX) (/8@U[
M"&(& 2 ?0TUJK('OJ>.7WPN\1:-I$^KZ=XUU*75[>%I2C$[)"!DJ,D]<<9%=
MC\,_%\OC/P?'?W2JMY#(UO<;1@,P .X#W##\<UF?%7QLFA:0VA:?NGUW4T\F
M&&/[T:O\N\^YZ >O/:M3X9^$I/!O@V"PN2#>S.;BYQT5V &W\  /J#0M'H#V
MU,'P5,= ^*?BOPPV5M[MAJ5J#TRV-^/^^O\ QRO3J\G\6 V'Q[\(WL?WKF$V
M[CV^9?Y/^E>L4X]4)A1115""BBB@ HHHH **** "FR?ZLTZFR?ZLT+<"O111
M6A04444 %%%% !1110 4444 9/B;6_\ A'/#MYJWV9[HVZC;"AP7)8 #]:\'
M\5:EXWN-4T/5]=FET^"^N=MM8Q.4V(&7D@>N>_-?1I4,,, 1UP1FO(?C?_R$
MO"/_ %]O_P"A1UG46EQQ/7E(V*2<# R:\7TJ77?BYKNI3G6+K2?#UG)Y<45J
M=KN>V??')^HQ7LZ@&, ]"H!_*O$/"NL2_"/6]4T/Q':W']FW$WG6][#'N4]@
M?Q ''4$&B?2^P(M:LVN_"+5=.N_[9N=6\.W4OE3Q7/+QGKQ[XR1CT(KV9&5T
M5U(*L,@CN*\!^*_C!/&.@0_V/9W)TBSG#S7L\>P/(0554'?C<3^%>V^'6+>&
M=*9B239PDD]_D%$'JTM@9I=.3TKS7X=S'Q!XU\6>)W^:/S5L+5LY'EKR<?7:
MI_&NZUVY:S\/ZC<I]^&VD<?4*37$_!&U6W^'$4@ZW%U+*3^2_P#LM4_B2#H9
M'Q/@NM7^(?A?0[?4+JRCN@5ED@D*X!8<X!Y( -7/^%,'_H==<_/_ .RK-^(K
M:TGQ8T"71K 75S' !!YB'RUD8L,L>G'!_"K>L:/\4-$LIM:A\5Q7[P*99+)8
ML)M'7 /!Q6;W=T,[9%3P+X$F:2YGOTTVW>0RS'YY.21G\3BO//#/AG7OB/IY
M\1:]XEOK2"=V^S6MDVT*HX]>!Z?2NW\.:[8?$/P!)<7D2Q13QO;WL>[ 0@?,
M0?3!!%>:>%O$?B'PW)>:)X0M_P#A*=(MY"4E,#((V/8,#S3DUIV$C8CO]>^&
MWCO2M%OM8EU70]3PL9N.9(^=O7U!Q[$5O_%Z&:TT+3O$%J&^TZ/?)+E>NP\-
M^' _.N4\-W!\9?$J&[\877V+5+#BST=H2@XY&&/7U]37I?CVU6]\ Z[ ^,&T
M9LGU7#?TH6L6'4V[*[CO[&WO(2#'/&LBD>A&:GKC?A5=/=_#71V?K&C1#Z*Q
M KLJT3NKB"BBBF 4444 %%%% !1110!8L?\ C[7Z&KM[]Q?K5*Q_X^U^AJ[>
M_<7ZUSU?C+@4J***DT"BBB@ HHHH **** "BBB@ HHHH *X/XQWDMC\-+Z:"
M66*0S1(KQ.589;U%=Y7G?QLBGG^'$T-O%)*SW465C4L< GTH>P&'I'P@DU#1
MK&]F\9ZW')<0)*R*V0I8 X!W>]=IX-\$?\(?)=O_ &[J&I_:55<79XCP<Y')
MZYKD=/T+XF:YH-E=Q^(X- 1;=%M[".,@A H"[SZG&>?6M/X<^-M7U+6-1\+>
M)XT76M/R1(H \U0<'..XX.>X-)")_'7BKQ+;ZQ!X8\)Z8TVI7,(D:\896!2<
M9] 1ZFN4^#,FJIXS\2V.J7\UW-;J%8O*SKNWG)&:]L0 2 @ $D9..37C/PK_
M .2H^-?^NA_]&-1U ]EHHH+; 7QG:,X]:8SS'P]/_P )+\;-?U+.^VT6V6P@
M&.C$G<1^*O\ @:].KR;X#A[C0]<U&4[I[C4F#OW)"J?YL:UOB=XNNM/AM_"^
M@DR>(-6/E1A.L,9X+>Q/.#VP3VI+81P_Q3\6:GXA;4H= N)(M'T'8;NZA<KY
MTS.(PH(Z@;C^1/I7K'@*5Y? &A2RR,[M9H6=V))..I)KB/&?A:U\'_ 74-)M
ML,Z^0\\N.993-'N;^@]@*ZGPG*T'PCTV5#ATTO<I]PIH6X'(+=:U\5O%6J65
MEJ\^E>&=,;RFDM>'G?/'/OM)]A]:+GPSXV\!Z[87'AJ^U+7]+E?_ $JUG.XJ
M,C@Y/<9P1T(KEOA1_P )7JWAV[T?PW<Q:7$EP9KO4I%W,2R@(BCU^5B?K72W
M?B'QK\--=T]/$FIKKFAWLGEFXV_.A[X[@@<XZ'FD!U?Q<TY[WP#=74'%QITB
M7D3=UVGG\<5TWAW5TU_PWIVK(0?M4"R-C^_T;_QX&I=9MX[S0=0@;#1RVL@]
MB-IKA?@9=2W/PVC20Y$%W+&GLORG'YDU74#TBBBB@84444 %%%% !1110 44
M44 %%%% !5NRZ/52K=ET>D]A,K:A_P ?/_ 156K6H?\ 'S_P$55KIA\*,7N%
M%%%4 4444 %%%% !1110!C^*M8ET#PQ?ZG;V[7$\,?[J)5+;G)PO YQDC->7
M^'O WB/QOI"Z]KWBK4[*XN68PP1 KL4,1R,C'(.!Z5[2"0<@D'VK+\0>(+#P
MUH\^JZG-L@C' ZM(W91ZDU,HWU>PTS@/ /B'6]/\:ZAX'\07GVZ2!#):W+?>
M8  X]QMY]L&F>.-1\3Z_XYM?"&ASW&GV14&YO$1@#P2?F] .P/)J+X7Z3J&N
M^*-2^(&J0^2MYN2RC/4J?E+?0*-OOS7K>YB-N3CTJ8IN(/1GBWB+PIXA^'.E
MGQ%HGBF^O5MW7[1;W7(92?3)!'K7JOAW6(_$'AS3]7C38+N$2%/[IZ$?F#7F
MWQ0\0R^([V+P!X>7[1?3R@W;J?EB YVD^W4UZ7H&D1:!X?L-)A;<EI"(]W]X
M]2?S)HC\3ML#V-&O-M3G.O\ QOTS3.3;:):M<N/X3*P_^N!^%>E 9(%>4_#G
M=>?%#QQ?R<L)0BY/3YSQ^0%.>Z0(Z_Q]XK'@[PG<:FJJ]TQ$5LC#(,AZ$^P
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M_P#$^GQ>#ET.&XCFO;J='>-&W&.->=QQTYV@?6N\\2?#OPQXKN5NM4TU6N@
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M\:R/B#XPM?"7A9=3N=+;5;*>589$1AM"L"0QR",< ?B*Q/\ A0_@+_H'7/\
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MDHHH **** "BBB@ HHHH **** #O3J;WIU1,N(4445 PHHHH **** "BBB@
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M_?.<8KL-/TZRTFRCLM/M8K:VC'RQQ+@"E9B+:_?'UKQGX5_\E1\:_P#70_\
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M+3O]0W^]_05FUI:=_J&_WOZ"LZOPCCN7****Y30**** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #)]:*** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "H+C[R_2IZ@N/O+]* (:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M[TZF]Z=43+B%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9/O\ X4RGR??_  IE
M=L/A1S3^)A1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !39/]6:=39/\ 5FA;@5Z***T*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"Q8_P#'VOT-7;W[B_6J5C_Q]K]#5V]^XOUK
MGJ_&7 I4445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5NRZ/
M52K=ET>D]A,K:A_Q\_\  156K6H?\?/_  $55KIA\*,7N%%%%4 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAJ-EJMFEYI]W#=6SYV30N'5L'!P1QUJS6)X2TW2-)\,6=IH,PFTQ5+02"3S
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M&5UPNT''RD=S0![5_P +"\&_]#3H_P#X&Q_XUT:LKHKHP96&01T(K@A\%_
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M*U:>2QLL0VZ+DR,J<* /4UY/X=^&>J>.4N-8\?WFK13/*1#99\HH!WPP( ]
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MIX@L@C_W?-08'X_*/^^Z.;1,=CTVBBBJ$%%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** "FR?ZLTZFR?ZLT+<"O1116A04444 %%%% !1110
M4444 %%%% !3E/S+]:;2K]\?6@#Q?]G[_CSU_P#Z[Q?R:O9Z\8_9^_X\]?\
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MT:STNUSY%K$(E)[XZG\3DUPG@R^^'O@K1Q9V?B33)+B0 W-R9/FE;^BCL*]
MLKZUU*SCO+&XCN+:4926,Y5ATX-3#75[C99'+"O*/AKFY^)?CF\D(+F<+[CY
MS_A7JU>6>%HAH?QP\3Z<_ U&$74/'&,[L?\ CWZ42W0(H?'FY:W_ .$8?9YJ
MQW,DGE9^^1LX_I6B/A_XKUZT34M4\:7ECJ$JAUM;52(8<\A>&&<<=C^-2_&K
M1;J^\-V.KV49DFTFX\UD S\AQDX]BH_.MC2_BEX2O="BOY]7@M7$8,MO*<2*
MV.0%[]#C'6I:7,[AT,GX9^*M8N]4U;PKXCD$VIZ8QVS<9=0=ISCK@XP>X-5/
MC I@UKP5?QG$L.HX'O\ -&?Z?K5?X76T^N^-_$7C9K:2"SNV:*UWC!8,P)_(
M*O/O5CXF1G6/B'X(T2,Y99VN9%_V-RDG\HVHU<!]3U6BBBM20HHHH **** "
MBBB@ HHHH **** "M+3O]0W^]_05FUI:=_J&_P![^@K.K\(X[ERBBBN4T"BB
MB@"&[L[:_MGM[NWBN('^]'*@93^!KES\+O!!N?M!\-V7F9ST.,_3.*ZZB@""
MTLK73[9;>SMHK>!>D<2!5'X"EN[2VOK9[:[MXIX'&&CE0,I^H-344 <K:_#7
MP99WGVN#PY8K-G.2FX _0Y'Z5U(4*H50 H& !T I:* ,K1/#6C^'%N%TBPCM
M!<OYDP0GYV]3DU9U32K'6]-FT[4K9+BTF $D3YPV"".GN!5RB@"MI^GVFDZ?
M!86,"P6L"[(HUZ*/3FJ&M^%=!\1J%UC2K6\(& TB?,!Z;ASC\:V** ,71/"'
MA[PV2VCZ1:VCGJZ)EO\ OH\UM444 <O=_#GP=?:A]NN/#UB]QG);9@$^X'!_
M*KS^$= ?6K76#I< O[2,16\R@CRU (  '  R>W>MJB@"M?:?9ZI:/:W]K#<V
M[_>CE0,I_ USUC\-?!FG70N;7P[8I*.A9"X'X,2*ZJB@  P,"BBB@!LB++&T
M;C*,"K#U!K+T+PQHOAF&:+1=/BLXYV#R+&3\Q'&>36M10!%<VT-Y:S6UQ&)(
M9D,<B'HRD8(_*N0_X5)X#_Z%JU_[Z?\ ^*KM** .+_X5)X#_ .A:M?\ OI__
M (JMK4?".@ZMJ-EJ%_IL5Q=6.W[-(Y;]WM.1@9QUK:HH **** ,72_"6@Z+>
M7MWINF0VT][G[0T9/[S))Y&<=2:Q?^%2> _^A:M?^^G_ /BJ[2B@#B_^%2>
M_P#H6K7_ +Z?_P"*KK(+&UM]/CL(H$%I'$(4A(RH0# 7![8XJQ10!R;_  Q\
M%27ANV\-V/G%MV=I S_NYQ^E=/;VT%I;I!;0QPPH,)'&H55'L!TJ6B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[)_M<_\ ST-'VN?_ )Z&H**.5=@NR?[7/_ST-'VN?_GH:@HHY5V"[)_M<_\
MST-'VN?_ )Z&H**.5=@NR?[7/_ST-'VN?_GH:@HHY5V"[)_M<_\ ST-'VN?_
M )Z&H**.5=@NR?[7/_ST-'VN?_GH:@HHY5V"[)_M<_\ ST-7;&1Y(F9SD[OZ
M"LNM+3O]0W^]_05G524="H[ERBBBN8L**** /*=9\6_%6UUJ]@TSP99W%C',
MRP3,3ET!X)_>#J/:N87XO?$A_$A\.KX5TPZN 6-K\^[ 7=U\S'3GK7OM>%6_
M_)UK_P#7!O\ TGH Z'0O%GQ3N]>L;?5O!UG:Z?),JW$Z$YC0GDC]X?Y5EZW\
M4_&:?$+4_"_AW0;"_:T;Y P8.5"@DD[P.]>T5X#HVI6.E_M*>(;C4;VVLX-C
M+YEQ*L:YV)QEB!F@#:_X37XQ_P#0B6/YG_X[7I'A&_UO4O#T-SXATZ/3]29F
M$EO'T4 \'J>H]Z3_ (37PI_T,^B_^!\7_P 56O:W=M?6T=S:7$5Q;R#*2PN'
M5AZ@C@T )?7D.GV%Q>W+[(+>-I9&]% R:\C^'WQFOO%7B]=(U33[6TMKI':R
MEC#@N5/ .20> >G<5>^.>O2V_ANT\-6)S?ZU.L(4'GRP1GWY) S]:YSXG^%&
M\'>&/">NZ4I%QH#1PR,,Y89W9/MNW9_WJ />*\=\4_$_Q?8_$:\\*^'=#L=0
M>%$= X;>P**QS\X'&:]4T75(-;T2RU2V8-#=0K*I^HS7BIU"RTS]I_4+F_O+
M>T@%J 9;B58U!\I.,L0* -3_ (37XQ_]")8_F?\ X[7HO@[4=>U/P^ESXDTV
M/3M1,C!H(^@4'@]3U'O3O^$U\*?]#/HO_@?%_P#%5J6NH65]8B]M+N"XM""1
M/#('0@$@X8<<$'\J +-%>36WQ*\6>,+NZ;P)X=M)],MI3$;[4)2HD8#. H((
MZCUXQG&:TO!_Q*O=4\63^$?$NCKI>N1)O41R;XY<#<0.N/EY')XSTQ0!Z/7&
M_$WQ?>^"/"1U>PM[>>83)'LG!*X/T(-=E7EG[0'_ "31O^ON+^9H ]$T2^DU
M/0=.OY559+JUBF=4Z LH) ]N:OUA^&[B*T\":/<3R+'#%IL#N['A0(U)-<):
M_$?Q=XPGN)/ _ANUDTR!S']NU*0JLI']U001^OOCI0!ZO17GOA'XCW.I>))O
M"WB;2?[)UZ-=Z(K;HIQC)*GMZCDY]<\5;\??$%?!\EAI]EI[ZEK.HMMMK56V
MCKC)/UXQ]>E ';T5Y-JOCKXB>$[-=6\1>&-+FTL$>=]@G;S(<G^+)(_(8]Z]
M(TG6K+6=!MM9MI,65Q")E>3Y=JXR<^F* -&N!^*/CO4/ UII4VGVMK.UY<F%
MQ<!B%&!R,$<\UAQ_$_Q/XLU2Z@\!>';>ZL;5]DE_?N51SCL 1_,\8)QFN%^*
M_BS4-8M]'TC7M'?2M:M+P2/$&WQ2QL!AT8=L@C'./7T /<?&>L:SHWA274-"
MTX:AJ"E-EN49@02,G"D'@59\):EJ>K^%[*^UFR%EJ$JDS6X4KL.X@<$D] #6
M?X]\27?A'P%>:W910RW%NL6U)P2AW.JG."#T/K6CX3U>?7O"6E:M<I''/>6J
M3.L8(4%AD@9).* -FBO$?"GQI\1>);2:TL_#D.H:Z93Y<-L6BBBB '[R1F)_
MB. ,C^6;T/Q8\1^&_$%IIGC_ ,.P:?#>-MBO+5R44=,G+-D D9Y! .<>H![!
M15/5M4L]$TJZU._E$5K;1F21\9P!Z#N?:O,M-\?^/_%L3:GX8\*6*:/N(BDU
M"<AY\'!VX( Z>A&>YQ0!ZS17C]K\7M:O/'FC>&7T&/3KB:3RM0BN\LT9]8V4
M@$$<C(_.O8* &NZQHSNP5%&69C@ >IJEI>M:;K<4LNF7L-W%$YC:2%MR[AV!
MZ'\*P/']QXI@T=AX<L]/N(VAE%V;QF!5-O\ #@CGK7E?P-NO&,>B1Q:58:9+
MHAO3]IFF=A,.!NV@''3VH ^@J*XGQY\1[7P;):6$%E+J6LWIQ;V41P3SC+'!
MQSV[^U<W=>./B=HEDVK:QX+L7TU 7ECM9SYT2^K?,W;T'UQ0!ZU16)X4\5:;
MXQT&'5M,=C$_RO&XP\;CJK#UK;H **X+QI\1)]"UVT\-Z%I1U77[M-Z0F0(D
M:\G+'Z G'''>N=U/XE>-O!?V:[\9>&+ :9/*L7GZ?.=R,03C#,<G )QP#CK0
M!ZU<W,%G;27-U-'!!&NYY)&"JH]23P*ATS5+'6M/CO\ 3KE+FTD+!)4^ZVUB
MIQ^((KS?XLZCXGG\)WSZ-::;/X<N--\RXN)683#<3G8 <8V[2..YK-^"=SXQ
M_P"$9T* V.E_\(QB?_2-[?:/OR'IG'^LXZ=* /9:*\[TCQ_J6H?&#5?"$MM:
M+8V<1=)55O-)VH>3NQ_$>U=+XVUVX\->#M2UBTCBDGM8MZ)*"5)SWP0?UH W
MZ*YKP#XBNO%?@G3M;O8H8KBY5RZ0@A!AV7C))Z#UKD;_ .)^N:SXDN]"\!Z#
M%J+V3;;F]NW*PJ0<$#!'?WR><#B@#HOB9XNO/!/@]]8L(()YUG2/9."5PV<]
M"#72:/>/J.B6%[*JK)<6\<K*O0%E!('MS7@OQ6\7ZU<^"9M \5Z'_9FJ-/'+
M!+ V^"X52=VTY.TCC@FNY\4^+=;\%?#/0-7TFSM+J%8($N5N%8E5,8P1M([\
M<^M 'IU%4-%U6#6]$LM4MF!BNH5E7!SC(Y'X'BN*U#Q]J;_%FT\':-;6DL"Q
M"2^FE5BT8ZG;A@.A4<CJ: /1**** "BBB@ HHHH **** "BBB@ J"X^\OTJ>
MH+C[R_2@"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .].IO>G5$RXA1114#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"&3[_X4RGR??\ PIE=L/A1S3^)A1115DA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !39/\ 5FG4V3_5FA;@5Z***T*"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"Q8_\?:_0U=O?N+]:I6/_'VOT-7;W[B_6N>K\9<"E1114F@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %6[+H]5*MV71Z3V$RMJ'_'S_ ,!%
M5:M:A_Q\_P# 156NF'PHQ>X44450!1110 4444 %%%% !1110 4444 %%%%
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MZ4N@:5ILLJF.34A=J5P>,JH8E3^!_"@#'^ 3/%K'BZS@8MI\=PIB/;=N8?R
MKW&N2^'O@:V\">'OL"3&XNYG\VZN#_&^,<>@':NMH \P\>?#K7-1\66OB_PG
MJD5GK-O&(S'./D< $9!P>QQ@C!]JPKKXF^//!9A;QQX4@DT]I!']KM&')]>"
MRYQD@';GFM?QMX#\21^.H?''@V:W?45C"7%I<L0LN%V\<@$%<#!(Y&<UEZ]H
MGQ1^(UC'HVLZ;I>@Z9YJR3R+,)7?'H%9L^N..1UH [3Q]?6^I_!_6+^T??;7
M.FF:)L8RK $'\C57X*?\DBT+Z3_^CY*V=9\*"X^'%SX5TUUC']G_ &2W:0G
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M C'&:B\%:?\ "\^(5F\+[!JL"L4#37 ;!&"560X88/4 T7$>ET444#"BBB@
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M\.10W5M?V)8-]H"J)-IP=N&)/Y4 >7>+?B;'\2+2/PGH=K]@2]D7SKG5)DA
M4," !N.3G'<GC@5[7X<T>/P]X=T_28I/,6T@6/S,8WD#D_B:XKXWVFDR_#J]
MN;](/ML;1_8Y'P)-Y89"GJ?EW<>WM6[\,Y[VY^'.ARZ@7:<VX^9^K*#A2?7*
MXH Y#X;LVE_%;QUH@)\EY_M4:]ERQ_HZ_E6G'XS\)^(O[0L/&=EI>GWNFW#Q
M?9=29')7L\9=1U_V>>GJ*ROA\3J/QG\=:BG^JA?[-P."=Y .?^V9_.O3KW1=
M)U*5);_2[&[E3[CW%LDC+]"P.* .-^$37+^'-0;=.=(_M&8:3Y^[=]ES\N-W
M.WTS[UZ!2 !5"@  #  ["EH **** "BBB@ HHHH **** "BBB@ [TZF]Z=43
M+B%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH *\:^/K-/#X9TXMB&XO26
MQZ@ #]&->RUY!\?[.<:%HVLP*Q%A>?.0,A0PX)_%0/QIQW!['KZHL0"(H5$^
M50.P'05XU\/T^P_'7QG8PG; \;2E!P-Q9&S_ ./'\Z]9L=6L]2TB#5H)T-G-
M$)A)NX"D9Y^E>2_"<MK_ ,2?%_BJ/)LW8V\3=GRPP0?]U/U%"ZB/9J***0PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH AD^_^%,I\GW_ ,*97;#X4<T_
MB844459(4444 %%%% !1110 4444 %%%% !1110!#=RM!8W,R??CA=U^H4D5
MY7\ XE;PYK-X0#-/?G<<=@N<?F37J\\/VBWE@)P)8VCSZ9!']:\A^!MVNGOX
M@\,W1,=];W9E$3\$K]T_7D?K4/XD-;,M?'Z%?^$,T^\'$]O? 1N.J[E.<'_@
M(KT[3Y&FTRTE;[SPHQ^NT5Y5\<[Q;^#0_"UJP>]O;L2% <E1]U21[DG\C7K-
MK"+:T@@'_+*-4_(8H6[![$M%%%6(**** "BBB@ HHHH **** "BBB@ HHHH
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MF7DVH6YV!WVK"6(!!W9)QSZ59^$OAJ32-&O-7NKNVN;O5I?-?[-()$0 DX#
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MO'NWM79ZE\)/"-SI/V:QTM+"ZA7-M=VS,LL3CD-NSD\@=: .2^!?_(:\<?\
M81'_ *%)7JW]OZ0-8.D'4[3^T0N\VOFCS N,YV]<8YKR']GM+B.X\7)=OON5
MNXQ*W]Y\R;C^>:S?&&B2^(?VATTF*[>TBNK%4N7B.&:+8=Z@^I'% 'MEGXFT
M+4)[J&SU>RN);52\ZQ3JQB4=2V#P*ETG7-*UV!Y])U&VOHHVV.]O*'"GK@D=
MZYNT\!>'/!^AZM+HMAY$TMC)')(9&8N I/.3CKZ5QW[./_(F:E_U^_\ LHH
M]4U37M)T0P#5-2M;+SV*Q>?*$WD8X&>O4?G6B"" 0<@UXI^T%_K/"/\ U_-_
M[)74_%[Q)>>&?AO-<6#M'<W+):I*IP8PP)+#WP"/QH Z>]\8^&M-O/L=[KVG
M6]S_ ,\I;E5;\B:L/XAT:/4K;3GU2S%[=('@@,R[Y5.>5&>1P?RKB?!7PJ\,
MV?A*S_M/2H+Z_NH%DNI[@%RS,,G&>@&>W-<)'X5@\)?M&Z!86;R'3Y(WFMH9
M'+^2ICER@SVW!B/K0!]"445S/Q"\12^%? FJZQ!C[1#$%ASSAW8(I_ MG\*
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MSKTRH8[2VAN);B*VACGFQYLJ1@/)C@;B!DX]Z )J*** "BBB@ HHHH ****
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M:+H^IWFI:?I\5O>7I)N)5)S(<YYR?6M:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *@N/O+]*GJ"X^\OTH AHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M#O3J;WIU1,N(4445 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AD^_^%,I\GW_PIE=L
M/A1S3^)A1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !39/]6:=39/]6:%N!7HHHK0H***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** +%C_Q]K]#5V]^XOUJE8_\ 'VOT-7;W[B_6N>K\
M9<"E1114F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6[+H]5*M
MV71Z3V$RMJ'_ !\_\!%5:M:A_P ?/_ 156NF'PHQ>X44450!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !6EIW^H;_ 'OZ"LVM+3O]0W^]_05G5^$<=RY1117*:!1110 4444
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M AHJ;[./^>R4?9Q_SV2BX$-%3?9Q_P ]DH^SC_GLE%P(:*F^SC_GLE'V<?\
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M*]%6/LJ_\_$='V5?^?B.CG0697HJQ]E7_GXCH^RK_P _$='.@LRO15C[*O\
MS\1T?95_Y^(Z.=!9E>BK'V5?^?B.C[*O_/Q'1SH+,KT58^RK_P _$='V5?\
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M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!#+]_\*93Y/O\ X4RNV'PHYI_$PHHHJR0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ ILG^K-.ILG^K-"W KT445H4%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %BQ_X^U^AJY>_<7ZU3L?^/M?H:NWOW%^M<]7XRX%*BBBI- HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *MV71ZJ5;LNCTGL)E;4/^/G_@
M(JK5K4/^/G_@(JK73#X48O<****H HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K2T[_4-_O?T
M%9M:6G?ZAO\ >_H*SJ_"..Y<HHHKE- HHHH **\R^)_Q$USP=K.BZ;HNGV=Y
M+J(8!;C=G<&4 ## <Y[UF-XR^,4&))O EBT8.6$<F6(]L2G^5 'L%%>:^"OB
M]9^)-9;0=7TZ71=9!VK!.3B1L<@9 (;T!Z^M>E4 %%%% !1110 45%<W,%G;
M27-U/'!!&-SR2L%51ZDG@5#INIV6L6*7VGW*7%K(2$E3[K8.#C\10!;HKSZW
M\>ZC+\9KOP6;6U%C#;B59@&\TDQHW/..K'M7H- !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Q]Y?I4]07'
MWE^E $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45Q_C/XC:1X
M,EALYHI[W4[@9BLK898@],GMGMU/M61H7Q?L+_6(-)UO1;_0+RX.(!> ['SP
M.2JD9/'3% 'H]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z=3>
M].J)EQ"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%5=2U*ST?3;C4;
M^=8+2W0O)(W8#^?TH M45Y*WQTMY"]U9^$M8N='C)WWX&%4#J<;2/S:O1?#O
MB+3/%6C1:KI4_FVTG!!&&1AU5AV(IM-!<U:***0!1110 4444 %%%% !1110
M 4444 %%%% !1110!#)]_P#"F4^3[_X4RNV'PHYI_$PHHHJR0HHHH **** "
MBBB@ HHHH **** "BBB@ HHKAO%GQ0TSPUJHT>VL;O5]7QDVEH/N]\$X/..P
M!I-I E<[FBN%\+?%'3O$.K_V->Z?>:-JQ&5M;P??[X!P#G'."!7=4)W!JP44
M44P"BBB@ HHHH **** "BBB@ HHHH **** "FR?ZLTZFR?ZLT+<"O1116A04
M444 %%%% !1110 4444 %%%% !1110 4444 %%9FO:_IWAK2)=3U2;RK:/ X
M&68GHJCN37GZ_&NW4"[N/"NKPZ2Q^6_QE2#T.-H'_CU2Y);A8]3HJKINHVFK
MZ=!J%A.L]K.N^.1>A']#VQ5JJ **** "BBB@ HHHH **** "BBB@ HHHH **
M** +%C_Q]K]#5V]^XOUJE8_\?:_0U=O?N+]:YZOQEP*5%%%2:!1110 4444
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M "M+3O\ 4-_O?T%9M:6G?ZAO][^@K.K\(X[ERBBBN4T"BBB@#Q#XR_\ )2O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRI KRKX!3*/#FLV;8$T-^2RY[%>OY@U#^)#6S&_':T6SL=#\2VZA;VQO @D
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ML[N(SK&HP%Z,H ]/F->O5Y'HS?VA^T7K,\'S16UJ8I&'0, JX_,'\J]<HI[
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M-+GS4Y;RD7&W=NZ@]J['QSIMWK/@;6=.L(O.N[FU>.*/<%W,>@R2 /QKH**
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M!X'JA-=S\._ T?@?0I())_M6HW;^;>7'.';L!GG R>3R<D^U=?13N%@HHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% $,GW_PIE/D^_P#A3*[8?"CF
MG\3"BBBK)"BBB@ HHHH **** "BBB@ HHHH ****  '!R.M>3:KX(\5>%?%M
MYXB\!FUGBON;C3K@A1G.3C) (SDCD$9[UZS12:N-.QY/I7@KQ7XJ\5V?B#QX
MUM!%8X:VTZW8%0P.<G!( SSU)/L!7K%%%"5@;N%%%%,04444 %%%% !1110
M4444 %%%% !1110 4V3_ %9IU-D_U9H6X%>BBBM"@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH Y'X@^"4\:Z)'!%,MO?VS^;:SL. >ZG'.#[=P#VQ7'7
M%K\8-4T\Z#<Q:=;P.GE2:D)%WNO0]&)Y'<(#7K]%2XINX7,+PAX7M?"'AR#2
M;5C)M)>64C!DD/5L=N@ 'H*W:**I*V@!1110 4444 %%%% !1110 4444 %%
M%% !1110!8L?^/M?H:NWOW%^M4K'_C[7Z&KM[]Q?K7/5^,N!2HHHJ30****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO&WA.V\:>&IM)N'\I]PD
M@F SY<@S@X[CD@CWKH:* /'(;7XRV6F+X?BBTZ2%4\E=4,JEU7IG);/3OL)_
M&NX\ >"H?!'A_P"Q>:)[R9_-NIP" [^@SV X_,]ZZNBBP!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5NRZ/52K=ET>D]A,K:A_Q\_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %07'WE^E3U!<?>7Z4 0T444 %%%% !1110 4444 %%%%
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M/M6H?] [_P C+5^B@+%#[5J'_0._\C+1]JU#_H'?^1EJ_10%BA]JU#_H'?\
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MT?:M0_Z!W_D9:OT4!8H?:M0_Z!W_ )&6C[5J'_0._P#(RU?HH"Q0^U:A_P!
M[_R,M'VK4/\ H'?^1EJ_10%BA]JU#_H'?^1EH^U:A_T#O_(RU?HH"Q0^U:A_
MT#O_ ",M'VK4/^@=_P"1EJ_10%BA]JU#_H'?^1EH^U:A_P! [_R,M7Z* L4/
MM6H?] [_ ,C+4<DVH.0?[/QC_ILM:=%(+&3NU#_GP_\ (JT;M0_Y\/\ R*M:
MU%,+&3NU#_GP_P#(JT;M0_Y\/_(JUK44!8R=VH?\^'_D5:-VH?\ /A_Y%6M:
MB@+&3NU#_GP_\BK1NU#_ )\/_(JUK44!8R=VH?\ /A_Y%6C=J'_/A_Y%6M:B
M@+&3NU#_ )\/_(JT;M0_Y\/_ "*M:U% 6,G=J'_/A_Y%6C=J'_/A_P"15K6H
MH"QD[M0_Y\/_ "*M&[4/^?#_ ,BK6M10%C)W:A_SX?\ D5:-VH?\^'_D5:UJ
M* L9.[4/^?#_ ,BK1NU#_GP_\BK6M10%C)W:A_SX?^15HW:A_P ^'_D5:UJ*
M L9.[4/^?#_R*M&[4/\ GP_\BK6M10%C)W:A_P ^'_D5:-VH?\^'_D5:UJ*
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M[60<J,#R-1_Y\A_W]6CR-1_Y\A_W]6M^BCVL@Y48'D:C_P ^0_[^K1Y&H_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/SHTS6=.UD7)TZ[CN1:SM;S;/X)%ZJ?<9K@_@T"FE^*HWX=/$=T&4]1\L?\
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MZTWPHF=_#_A_2=&*1-:0K*SSIN92I4@!=W/\ZZGXBAETKP2';<PU>T!/J<4
M:VLZM?P?%KP[ID5W(EC<65Q)- /NNRD8)^E=O7GFO?\ );O"W_8/N?YBO0Z
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M=Z?X:\/Z7X8FM'FB2:1FF8'HWRC ;.,9SSBKWCB!W^!6B6]Q(SLYL4=\\G)
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M@K@O@I%&OPGT2144.RS;F Y/[Z3J:B^-4TT?@18PQ2TGO8(KQP<8B+<_K@4
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MI_B&WAO;:TD>6:%MS6HQCS/3Y20:F\)2JOA"RFDUS^UTV.YU&3"^:NYCD^@
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MD\,F!NCW$8.!P >* .P\;_$/2_"'AG^U%F@NIYTW64"OQ<?,H)##(P V:W=
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M<^']/N_$-GKDL;F_LXGBA<.0 K=<CH:U**ADO+6*YBMI+F%+B;)BB9P&?'7
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MN,\"N;T70K'4?B'H%YX<TC4H[#2S-+>:EJ*2*\S,FU4!D^8X_+K7LM% '/\
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M!R.AX]:X/QW;6<GC2WDU[P]>-IOV8"#6-*\WSXWR<QOY?.WKV]*]2HH \K\
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MIZXK>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **XS7O'=S9^(F\/>'M FUW58HA/<1)<I;I"AZ9=N,GCBM
M#PEXNA\4Q7L;64^GZC82^3>64Y!:)L9&".&4]C[4 ='117/^-/$Q\(>&+C65
MLC>M$R*(!+Y>XLP7[V#Z^E &_@ DX&3WH*AAA@"/<5S7@;Q@GC306U#[&;&>
M*=X)[5I-YC93ZX'\JQ/&OQ/'A+Q!:Z5!I!U N(S<RBY\O[/YC[4R-ISGD]J
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M# 'Y5R>B>(O&5]J\%MJO@0Z99/N\R\_M>&;R\*2/D49.2 ./7-=A0 @55S@
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MFB:4^LRN$:*VCD\HNK=\D'''/2@#:HJ*UEDFM(998C#(Z!GB)R4)'(SWQ4M
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MG/\ %0!N4444 %%%% !1163XGUO_ (1SPSJ.L_9_M'V.%I?)W[-^.V<''Y4
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MJ-U$N8[1) AE.1QN(./7IVI^E75S>Z5:W5Y9M97,L2O+;,^XQ,1RI.!G'3-
M%RBBB@ HKG?$WBK_ (1R_P!!M?L?VC^UK]++=YNSRMW\6,'=]./K714 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:_X-\?\ BCPA<Z#J.KZ'$FU!&UM%(#.588\PG.P8&<*#DXY H O>+];U,?\
M")>'--O9+.YUQ]LUZN"\<2(&?;G^(YX/:N;^(/AJY\/KX5,6NZI?V4GB"T$D
M.I3^>RR?-M97(R!C=D=.G3'/<^)?!T^M6.C3V5ZEIK.C,)+2=EWQEMH#*PX)
M5L 'O6'X@\'^,_%4NBS:GJ&CP+IVHPW1M;7S"D@4DLQ=AG=T 7 ')R3Q0!:U
M2_O?#?Q<TN2:\N7T77X#:B&24F*"Z3!4J"<+N&!@=234EC>WWB'XLWWD7=Q'
MHV@6X@>*.1ECGNI!D[@#A@J^O0T[XO6UO)\.KV]EG%O<:<\=W:3=TG5AMQ[G
M.W_@5:/P]T*70O"-NMYSJ5Z[7U\V,%IY3N;/TX7\* -[5+]-+TF\OY 2EM"\
MK =PH)_I7F_A/1=:\5^%X/%-[XKUB#4[T//##;S!;:!<D*GE8*L, 9SS^/->
MG7-O'=VTMO,NZ*5"CCU!&#7 Z/X3\9>'-*/AW2]7TMM'3<MM=W$3FY@1B3MV
M#Y7(SP<CZ=J ,#P3<75K\"]>N!*T-Y&]\QD@8J5<$Y*D<CGI6SX%T36)O#VF
M^)=6\3ZK=73V!*V@FQ;A2GREAU9QUW$YS5G0/ >H:/\ ##4_"TEU;R75R+@1
MS;F*_O,[2QQG/KQ75>'-*DTCPKIVDW31R26UJD$A3)5B%P<9'2@#E/A%J-[J
M7PVCNKZ\N+JX,TX\V>5G? 8XY)SQ6)X2\6ZCIGP9UGQ!<W$U_=VEQ<^6US*S
MGA@%&3DX&>E:NC>#O&'AN&YT72-6TA-#EFDDCFFMW:Y@5SDJ%!"''8D_AVI^
MB^"(_#WPMU;0/$5TDMM(;B66: ,Q$;<AL8!+#&< 4 5)O#.LP^!I]>_X2_6A
MK;6+73N;C-ODIN*"'&U1CH1@@\YK2\,^+K/1_AGX<U'7[VZ=[FV0&8Q2W#NV
M,DL5#'\37,E_$TGPPN"?$VC2>'%L'$.H1P2+=2QA2%4JV%4G[I//TS7=?#6)
MX?AMX>CD0HXLH\JPP1Q0!S_Q"\5+?_"F]UGP[?741$T:1S(LEN^?, (Y"L!V
MJVUOJ'@?PIJ_B:^U[4-8OA9"1HKEP+=) .-D8QM&2,\]*V/'WAR[\5^$;C2+
M*6&*>62-@TQ(4!7#'H">WI6MJ6D6^L:#<:1>@M!<P&"3;UP1C(]^XH \9_M5
MI/"PU6/Q9XME\4&#ST6.SN?LK2XSY8C\KR]G;/XYK>\>:A<:KX*\!ZA=P&"Y
MN-;T^2:(J1L<JQ88//!S6FGAGX@1:,OAV/Q#I::>L8@74DBE6]6,<< ':&QQ
MNS^O-:GBWP==ZUHWA[3[*[4_V7J5M=/+>2,SR)$&!^;!)<Y'7KSS0!%X^N[*
MVETW^T_%MQHMD2YDM;,$7%X<# 5ERX [[1SGJ.*Y_P $ZU)<^/\ 5O#EGJNK
MWNB-IHNHGU%95GMY-X0JK2*'((.03GIQT-;WB3PGKDOC.T\5^'+S3Q?Q69LI
M+?448Q&,MNRI7E6Y/^<T>'?"OB*R\>7GB/6M1L;H7>GK;LENC)Y3J^0J Y^3
M&3DG))/% '+_  ^\-Q6WQ/\ &)&JZO)_9T]MM\R]9O/W1M_KO^>F.V>E4;/Q
M+;^*+[5KW7/$/B6Q2.\EM[*UT>"X6.*-#@,SQH0[$\X)./3FNWTWPMKVC?$3
M6-9M+G3I=(UAHGN8Y0XGC,:%1LQ\IZGK_P#KK0>%?%GAF\U!/"NH:2^F7URU
MT+?4HY-UL[_>V%/O*3S@X_Q ,G3?'6L:;\*=;U;4A-->Z=-)!:3W-LT37"9
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MOH?SH Q/'.@:VOPCU5?$.L37%S8"1H9;2=D%Q$2 HG7: Q ZCI1XBM;GPO\
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M%FI^(M(T&-(O[-N-)WQPMD?.9'0$EL]CP.?:NZ\#2>;X<5U\2KXAA,K>3>;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\<$,32%5'\3;0=H]SCH: -FBBN/F^)_A6$W*?;II)K:YDMI((K:1Y Z$!OE
MR5&?O=* .PHK+T/Q'I/B/2_[1TJ\2XM@2&8<%".2&!Y4CT-81^*/A,2?\?\
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M4SK>ZCN^S((V(;;UR0,#\:@\0>,-$\,/!'J=V5GG_P!5;Q1M+*X[D(H)Q[T
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MF22,_P"RZD,/P-.T/PQHOAN.5-)T^*V,IW2N,L\A_P!IV)8_B:UJ* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/TG1-.T*":'3
M;86\<TS3R*&9MSL<L>2>M:%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!PUWK/A?QEK&K^$->LPK:<\<ABNY
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MQ:<J-&+<<KM8DD<^N3^= '#^"+N'Q;XSUSQI$=]C'!%I]BW^R%$DO'8[F _
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5Y:0W,+;HID#H?4$9% $M%<1XQ\;ZAX;\2Z+I%AH_P#:4FIK+M19-K[UQCV
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M<.L^(_#MI;Z*SHLQM[DO/:AB &<$8(!(SB@#T2J*ZSISZT^C+>1'4DA^T-;
M_.(\@;OIDC\ZN@AE!'0C(KR+4+S4[/\ :!O?[(TY;Z\ET%8T1Y/+C3]ZI+N?
M08[<DD"@#UZBN-\+>,=1U#Q+?^&=?TR*QUBT@6Y'V>7S(IHB0-RDC/!('/\
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M#8W>F6DKQ;;B[*7$Q0\[4 PN>P:N[TN\FO\ 2[:ZN+*6RFE0,]M*06C/<'%
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M%>2^,M5\:0?$_0+6PM[ PN9S:1-=.JS@)R90!P1VQFO5XC(84,H59"HWA3D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% 'G7Q)2VDU#35UKPS)J>A[7\R]M$=KBTD[;0IS@\<BL_P"'L&H)K>KG3CK
M\)_90MJFJ[MYF_BV!OFV_6O5:* /+_AMI]XOPDU.S>UFCN99+T)%(A1F+9QP
M?7-9NAVL_B?X(77A""TO+;5K2S$3I=6[1J7#[@%)X.=N/QKV*B@#P@VWAR;2
M$T^#P1K<_B$HL36%UYXA#\ EI-VW9U.17MFEV@L=*M+18DA$,*IY<9)5,#&
M3R0*MT4 <#XDMIY/B[X.G2"5X8X+L/(L9*H2HQD]!4'Q3\.2:I-X?U@6%QJ-
MMI=Q(;NTMF*R/%(H!9<$$E2H.!UKT6B@#Q[2-.\.ZMXHTG_A'O"=_(EM.)[B
M]U/SXEM=O*[ Y^9R1Z8IWBN61OB!?1>+;;7IM"$<7]EQ:8LAA<XR_F>7SNW<
M#/:O7Z* /(OAYH@GE\>V2Z5>Z5'>F)(4NMV_RFB8*=QSD\DD9.,XI?#'BW4/
M"/@RW\,7/AS5)?$5BC00P1VS-#.<G8PD' 7!&37KE% 'F?Q$.J?V1X/U:]TZ
M626QU2"ZOXK%#+Y0"G=M'4@$XJ/QG*^M^(OA[J-C:W3VQU$2L6@8&->.7&/E
M_&O4** /-=4%WX-^)MYXFFTZ[O='U.S2"66TB,KV\B'C*CDJ?:F6)N?&GQ/T
MWQ%:Z=>6FD:5:R1B>[B,37$C]E4\X'J:]-HH X#PS;W$?Q<\8SO!*D,D-J$D
M9"%?"G.#T/X5#X9M;B/XS>,+A[>9()+:W"2M&0KD#G!Z&O1:* ,WQ"^I1^'-
M1?1D5]2%NYME;H7QQ7@FKV]EJ7@:]C&B^*K_ ,4FWS<R7BS;8G!&]NNTCK@
M'-?1M% 'F/C^TFG\%^$([6UF?R]6L69$B8E%"MDD8R />K'QCM;B[T#04MK>
M:=EURV=A%&7*J ^2<=![UZ-10!YQXG@NO#OQ,T_QDUE<W>EMIS:?=?98S))
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M\$+B,\,.>M=!:>$+C5/A9X@L;/0(]$GU)G>VMC*S/(!]QI=Q.&;'(^E>JT4
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M5U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0_[B_P J\A\&F+^S?B>]B2+$W5P8"O SY;;L?C0!ZCH,VJW&C6\NMVT%MJ+
M^=% Q9%.>Q/M6E7D=A#XAO?@'HB^'S-)>-'&9TBEV2RP[CO57/1B._UJ+PH?
M"EKXMT^*S3Q'X9U)BRFQO=XBOCCE26W!L<\@C^5 'L-%>6:9IL/Q&\5^)VU^
M2YELM*O?L5I91SO'&FT<R$*1ECZGI3_$S:Y\/?AE?00ZU)>3R78M[&ZF!WVT
M4C  ,Q)W%1G#<=O2@#U"BO+-?^'UGX=\(WNNZ3J.HPZ]8VQNOM[73NTS(-S!
MU)VD-@C&,<U7\>:K=Z_\)?#6I)*;2[O[RQ<O'_RS=^X]0"<XH ];K,U'7K'2
M]2TW3[EW%SJ4C1VZJN=Q49.3VP*\P\=>';;P':Z7XCT2\U%=4_M&"&XFFNWD
M^U(Q.X2!C@YQ4GQ#\(:)??$OPK+<6KL^J7,JW9$SC>$B 7&#QT'3% 'H=_=>
M((_$FGP6-C:2Z.ZG[9/(Y$D9[;1T/:MNO,M<@33_ (N^ +"V+I;0VEU&B;B1
MM6/ SZ\#O5;6-&7Q!\<IM/N;R[BL?["1YH8)FC\X>:1M)!SC.#QUQB@#U:BO
M+O"]M_PBOQ<OO"^FSW/]C2Z8MXMM-,T@BD+X)4GD9 _6IOA-([ZAXTWNS8UJ
M0#<Q.![4 >ET5YK\-)6_X23QX993L35!RS<*-I]>E<IJ2^&;S3=6O;&+Q5KE
M^GF31Z[&&VPNN<;'+*-BD?P@C% 'LNN:U9^'M%NM6U!F6UMDWR%%W'&<<#ZD
M51\0W^NIH,5WX8L;:\O)&1A%=L47RR"2>#UZ5YKXOM$\2? "UU_6%>;5(+".
M5)MY7YF9020#@Y'K4WQ T:R\._!:*#2TDMXWN+:5L2L3N8C/).: /7XC(84,
MJA9"HW = >]/KSCQS?7MUJWA'PK;WD]G;ZN[F[G@8I(8T3=L##IGG-9?BG1;
M?X92:)K7AJ6ZMTFU&*SN[1YWECN$?/)#$X88X(]: /6Z*\M\8:<^M?&#P]IY
MOKJUMI=,F:<6TIC:1 WW=PY&>,D<XR*98:=%X*^,.EZ)HTUS'I6IV$LLUI+.
MTB"122&7<3@\8H ]5HH)P":\C\%:!:_$?3KKQ7X@FOIKFXNY5LXTN7B%G$IP
MJH%(PW?- ':^$O$USXAO?$$%Q!#$NF:B]I$8\Y=0 <G/?GM73UY%X!AFM-!^
M(,$]T]S-%J%RC3L?F?"8W$^OK[UL?#1W?X'Z>[.S.;2X^8G)^_)WH ]%HKQ*
MP\0ZAH'[-VG7UC+(MY*?(64?,Z;YF!(SWQG'OBH;[3)=.M(;OPGX;\7P>(H9
M$8W=SAA<#<-XE_>$,",]J /<ZRY_$%C;^)+307:3[==0O/&H7Y=B\$DUHPNT
MD$;NA1F4$J>JDCI7C^M^"M"N/CAI<$EHYCO+&:[F'G.-TH;@]>/H.* /8Z*\
MOO+7_A-_B=J?A[4[BX71=(M(G%G#,T8GD?\ B<J02!VI^EQOX+^*EIX9T^XN
M9-%U*Q:X6UGD:06\BDCY"Q) ..E 'IM%%>*_#'P99>*?!;SZ]<WEY#]LG6WM
MQ<NB0@.<G"D98G)R?:@#VJBO+/!NHWA\+^-M$N;N>Z31;BZM+:>=BSF((=H+
M=R/\*QO#O@:RU/X26VN7]_J4VIQV#SVTZW;K]FVJ2H10<8&!GCDT >V45XYJ
M'C/6!\$?#EZMQ<_VEJUQ#8/<VX#3 $L&9<_QD(0.G+=JI75C)I+V5_X.\+>+
M+7589T,S7&&2ZBS\ZR9D.21T..M 'N%%>;:G(X_:"T.,.VPZ1*2N>.K=J37Y
M''QZ\)('8(;&Z)4'@_(W:@#TJBO(9M&B\1_&_7=+OKF[&G_V9%++;PSM&LI#
M  ,0<XYSCO4&E^$;?_A9.K>#FU#4CX<ALTOET_[4X7>QV[2V=Q7J<9Y.,]*
M/9:*\S\&PMX:^(VO^%[.XN)-'ALHKR"":0R&%F."%)YP:H>$/#UK\2+.^\1>
M)IKNZE:]EAMH$N7CCM40X 4*1@]\T >MT5YUX U*_$GBGP[>W<UXFC7)AM[B
M8YD,94D!CW(]:YCP%X&T_P 2_#S[?J]YJ,\WF3_9MMVZ"UPQP4 .,Y&23G-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUYK>HH \ZO\ P!XEUL6#ZUXQ%U)87<=S"D>GI%&2IY+ -DDC(ZX&>E>BT44
M<Q%X3>/XC3^*_MJE9;%;3[-Y7(P<[MV?TQ3T\+.GQ"E\4_;%*/8"S^S>7R"&
MW;MV?TQ7244 </)X(UC3-2OKGPMXC&EV]_*9Y[6>S6XC60]63D%<]2.15B'X
M>V"^"M1\.7%Y=7!U$M)=WCL/,DD8@[O08(''3BNPHH \SU/X;^)M:\.-HFI>
M-C+:H$$ CT]$^Z1M\S!RX '08YY.:[C6-#@UOPS=:+>$-%<6YA9MO0XX8#U!
MP1]*U** .5\!^#3X-TF>">_;4;ZYF,MQ=NA4OP%48). % '6N6^-&G?VC%X<
M@L)V@UNXOC:6KI][RI$*S$_[(7&?_KUZG56?3;&ZO;:]N+."6ZM=WV>9XP7B
MW##;2>1D=<4 )I6FV^CZ3::;:)LM[6)8HU] HP*I^)O#UKXI\/7>C7CRQPW"
MC]Y$V&1@0P8'V(%:]% 'GK_#W6M7?3X/$WBG^T]-L)TGCMX[)86E9/N^8X)R
M,=<8S6VWA-V^)*>+?MJ[%T[[%]F\KG.\MNW9]^F*Z>B@#G'\+NWQ"C\4?;%"
M)8&S^S>7R26W;MV?TQ^-!\+N?B$/%/VQ=@L/L?V;R^<[MV[=G],?C71T4 <1
M<^!M2L=<OM4\*Z__ &2VH,'N[::U%Q"[_P!]02"I_&M+PIX0C\.27][/>RZA
MJVHR"2[O)5"ER!@*JCA5'I72T4 >=)\*8&\%2:%/J&Z[2]DOK2_CBVM;2,VX
M$#=V[\\UKZOX.NM:T[2);C5S#K^EG?!J5O" "Q&&S&Q(*D=1FNNHH XW3?!N
MJ2>(;36O$GB ZI/8JPM(8;86\,988+E026;'J:O:?X6:Q\=ZQXE-X'748(81
M;^7@Q^6,9W9YS]!7244 <;JJ:UJ/Q,TFVMY;VVT>PM'NKIXRR1W$C':L9/1L
M8W8[?C79444 <[X;\,-H&K:_?-=B<:M>?:@@CV^5QC;G)S]>*HZOX-OG\23>
M(/#NM'2=0NHDANU>W6>&X"_=9E)!W < @]!]<]A10!RN@^#/[/\ [5N=6U&7
M5-2U90EW<,HC78%VA$0<*,'ZGUKGA\--=70F\-+XQD/AU@8S UDC7'E$Y*>:
M3[]=OM7I=% '*:WX$LM2TW28;&XETZ\T8*-/NXL,T0 "X(/WE( R#UJC#X&U
M34=:T_4?%7B'^U%TZ3SK6V@M1;Q"3L[@$EB.W.*[FB@#G+[PLUYX]TGQ*+P(
MMA;2P&W\O)??WW9XQ]*S?'_@ >-5L7AU%M.NK8LC3(FXR1.,/'P1@&NUHH I
M#2;+^Q?[(\D&Q\C[/Y7;9MVX_*N(3X?>(;?23H%KXSFBT'88EB^QH;A(C_ )
M<^G&<9Q7HE% '+:QX$TW5/#%CHL4DUI_9S1R6-S&<R0NG1N>ON#UK"USX>^(
M?%%E:P:UXM64VL\<T:P6 BC9E/+.NXDMC@8( R>*]&HH P-9T/4]1UC1;NRU
MN:QMK&1FN;9 =MV"!@-AATP>H/6M^BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img76291469_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *!".@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;2/^@#J'_?R/_&OG^BCZC1[![:1] ?\ #0VD?] '4/\ OY'_ (T?\-#:1_T
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MI_C7F5%>4>=]?K]_P1Z;_P +3LO^@7=_]]I_C1_PM.R_Z!=W_P!]I_C7F5%
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MH_X6%:?] ^Y_[Z7_ !K@:*/J]/L'(COO^%A6G_0/N?\ OI?\:/\ A85I_P!
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M7Z"FA,=1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-_'AZK\S5HHHKTSZ\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?M$XU5(_)8;HRI7@YZ<=L4SP['L\+1M:!?/=&;/K)SU_2H/#4&LBYN)]5DF
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M;^8KBQ_\!_+\SKP/\=?/\C#HHHKP3W@K=\&:$?$OC'2])VDQ33!IO:)?F?\
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M^UC0_P#A'KHG5)[E;29S;O'F-R I)(&=I_G7J/B6/5_!G@ZSTSP'H@GF#B,
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MW<6.N,9(_P"^2:#;EA4P\H1ES-:[6_KJ-^&W_(IC_KXD_G7-_#;_ )&S4_\
MKB__ *-%=)\-3GPD"/\ GXD_G7-_#;_D;-3_ .N+_P#HT4%+_EP4_B-_R-S?
M]>\?_LU<G76?$;_D;F_Z]X__ &:N3H//Q/\ &EZA11108!1110 4444 %%%%
M !4]G_Q]I^/\J@J>S_X^T_'^573^->IMAOX\/5?F:M%%%>F?7A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4MM_Q^
M6_\ UV3_ -"%15+;?\?EO_UV3_T(4,#VJBBBO(.8**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD#VKGJ*3A%JUM!\SO<T[?Q'K-KKQUR'4KA=4)W-<[LLWJ&[$<#CI6WJ_Q/\
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MI?ZS?R7VIW<MW=28#2RMDX'0#T'L*V] ^(/BKPS:?9-*U9X[4?=AE1943O\
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M)%%SJ6[1[$C*O-'F63TPF1@>YQ]*R?B)X&3P'JEE9)J+WHN86E+M$(]N&QC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ KB_$'_(:G^B_P#H(KM*XOQ!_P AJ?Z+_P"@BOL>"/\ D8R_P/\
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M[GO7)0IU,1C85U3<(Q5M5:^_^9T59PI8:5)S4G)]-3#KW3X<_P#)/[;ZS?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3:6K(*T]&UN?1I7*()8I,;XR<<CN#ZU0F@FMI/+GADB?KM=2#3 "S!5!9B<
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M=S)::_I\J6L?FSLLZXC3.-Q/89(JCIGQ/\%ZOJ:Z=9:_;273-M16#('/HK,
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M** "BBB@ KB_$'_(:G^B_P#H(KM*XOQ!_P AJ?Z+_P"@BOL>"/\ D8R_P/\
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M]04FXMR/*Z***[S **** "BBB@ KI_!/_'[>_P#7%?\ T*N8KI_!/_'[>_\
M7%?_ $*N;%_P)?UU,<1_"9V-%%%>">2%%%% !1110!9CTV_FLFO8K.=[53M,
MRKE0<XQ^=:?_  AOB+[/Y_\ 94NW&[;N7=_WSG.?:NK\,7\FF?#"]O855I89
M)63<,@-D8/X=:YOP[XBUA/$MD9-1N)EGG6.5)7+*P)QT[8[8H.OV-*/)S-^\
MON.=(*L592K*<%2,$'T-)78>-[>QA\=H;A62UE2-[GR^I'()&.^ *3R_A_\
M\]-4_-J#-X>TG'F6CZZ'(5<TJU@O=6M;:ZF\FWDDQ))D#:O4G)X%='Y?P_\
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M]Z+?19[.WM%7?/),&!8]%  '. 3_ /KJ[\3M'UOQ!X'NM(T%(FN;MT20R2!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ]TC/;+"3,B]63S!N ]\9KQD<$$<8Z>U6[_5-0U21)-1O[J\=!M1KB5I"H]
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M>#?"^I6.M+JFIP&RMK5&;,K %B1CUX !)S7+^(M0CU7Q#?7L/^IDD^0^J@
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M$^ /^>8IH3.'HKN?^$!MO^@C-_W[6C_A ;;_ *",W_?M:=P.&HKN?^$!MO\
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MO=?C_D']H4NS_KYG+T5U'_"$C_H*S?\ ?E:/^$)'_05F_P"_*T?V;5[K\?\
M(/[0I=G_ %\SEZ*ZC_A"1_T%9O\ ORM'_"$C_H*S?]^5H_LVKW7X_P"0?VA2
M[/\ KYG+UQ?B#_D-3_1?_017KG_"$C_H*S?]^5K-N_AI8W-R\TVH7#2-C)"
M=J^AX:_X3\7*M5U3BUIZKO;L>/G<EC,.J=/1W3U]'ZGD5%>K?\*MTW_G^N/^
M^11_PJW3?^?ZX_[Y%?<_V]ANTON7^9\I_95;NOQ_R/*:*]6_X5;IO_/]<?\
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M=-_Y_KC_ +Y%']O8;M+[E_F']E5NZ_'_ "/*:*]6_P"%6Z;_ ,_UQ_WR*/\
MA5NF_P#/]<?]\BC^WL-VE]R_S#^RJW=?C_D>4T5ZM_PJW3?^?ZX_[Y%'_"K=
M-_Y_KC_OD4?V]ANTON7^8?V56[K\?\CRFBO5O^%6Z;_S_7'_ 'R*/^%6Z;_S
M_7'_ 'R*/[>PW:7W+_,/[*K=U^/^1Y317JW_  JW3?\ G^N/^^11_P *MTW_
M )_KC_OD4?V]ANTON7^8?V56[K\?\CRFBO5O^%6Z;_S_ %Q_WR*/^%6Z;_S_
M %Q_WR*/[>PW:7W+_,/[*K=U^/\ D>4T5ZM_PJW3?^?ZX_[Y%'_"K=-_Y_KC
M_OD4?V]ANTON7^8?V56[K\?\CRFN=\3?\?%K_N-_,5[Q_P *MTW_ )_KC_OD
M52OO@_HEV\;3W=TQ4$#&!7/B<YH5J;A%._R_S.C#9?5I5%.35OZ\CYXHKWS_
M (4KX=_Y^+O_ +ZH_P"%*^'?^?B[_P"^J\WZW#L_Z^9Z?LV>!T5[Y_PI7P[_
M ,_%W_WU1_PI7P[_ ,_%W_WU1];AV?\ 7S#V;/ Z*]\_X4KX=_Y^+O\ [ZH_
MX4KX=_Y^+O\ [ZH^MP[/^OF'LV>!T5[Y_P *5\._\_%W_P!]4?\ "E?#O_/Q
M=_\ ?5'UN'9_U\P]FSP.BO?/^%*^'?\ GXN_^^J/^%*^'?\ GXN_^^J/K<.S
M_KYA[-G@=%>^?\*5\._\_%W_ -]4?\*5\._\_%W_ -]4?6X=G_7S#V;/ Z*]
M\_X4KX=_Y^+O_OJC_A2OAW_GXN_^^J/K<.S_ *^8>S9X'17OG_"E?#O_ #\7
M?_?5'_"E?#O_ #\7?_?5'UN'9_U\P]FSP.BO?/\ A2OAW_GXN_\ OJC_ (4K
MX=_Y^+O_ +ZH^MP[/^OF'LV>!T5[Y_PI7P[_ ,_%W_WU1_PI7P[_ ,_%W_WU
M1];AV?\ 7S#V;/ Z*]\_X4KX=_Y^+O\ [ZH_X4KX=_Y^+O\ [ZH^MP[/^OF'
MLV>!T5[Y_P *5\._\_%W_P!]4?\ "E?#O_/Q=_\ ?5'UN'9_U\P]FSP.BO?/
M^%*^'?\ GXN_^^J/^%*^'?\ GXN_^^J/K<.S_KYA[-G@==/X)_X_;W_KBO\
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M*^M/^?\ G_[X%'_"OK3_ )_Y_P#O@4!]0J]U_7R. HKO_P#A7UI_S_S_ /?
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M_2T?68![1'%45VO_  @,7_04F_[]+1_P@,7_ $%)O^_2T?68![1'%45VO_"
MQ?\ 04F_[]+1_P (#%_T%)O^_2T?68![1'%45VO_  @,7_04F_[]+1_P@,7_
M $%)O^_2T?68![1'%45VO_" Q?\ 04F_[]+1_P (#%_T%)O^_2T?68![1'%4
M5VO_  @,7_04F_[]+1_P@,7_ $%)O^_2T?68![1'%5+;?\?EO_UV3_T(5V'_
M  @,7_04F_[]+3H? D,<\4AU.9MCJV/*49P<T?68![1'<4445P&(4444 %%%
M% !1145Q<06L+37$T<,2]7D8*H_$T 2T5#;7=M>PB:UN(IXB<;XG#+GZBIJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***JOJ=A'=BTDOK9+END+2J'/_ <YH M4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG?L;ES*Q#9&3@'@<^E 'T*KI,A"R*QQSM(-<1\.OAW!X$?4VAUF34?MI3.]
MOE[=WH3UW?I6IX2\ ^'_  4]U)HEM+"UTJB7?,SY"YQUZ=37G?[//^J\5?\
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MK[4YOLZ2H<,B 98KZ'H,]L^M,T;X&^$8= AM]5LGO-2>/-Q=F=U;S".2H!P
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MW[1?_).K3_L)Q_\ HN2K>A?";0]<\/VFH^*UFU35[RUC:2=IV40C;\J1A2
MH('?)&>] 'I\<L<T:R1.LD;#*LIR"/8TVXN8+2%IKF>.&)?O/(X51]2:\5^$
M8N_#/Q,\3>"4O))]+M4::%9#G80RX(]"5?G'4@5G>-[[3=4^.2Z1XXN9+?PY
M:P*UK$SLD4C% =S$= 6+#/\ L@9H ]TL=5T[4PQL-0M;L+][R)EDQ]<&KE>+
M:Q\+;&>YTO6_A;?6-E=VTF962]=XY$ZCD;NXP1T(->T+G:-V-V.<4 +1110
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M4_BK1$T^WUBYTIUG6;[1;9W$ $;>".#G/X"M^B@#R8?!;4R<?\+$UO\ -_\
MXNN=^&%OJ;?%_4;6WU_4-4TC2$D62:XF8K(Q&P?+N(^]NQ[+FO4?B-XG'A'P
M-J&I(X6Z=?L]KZ^:_ (^@RWX5A_!3PT= \ PW<Z$7FJM]JD)Z[.D8_+YO^!4
M :/Q#\9:GX7BTZQT/2'U+5]4:1+90"5CV[<L5')^\/0<')KS[X>7'BB#XVWN
MF^)M5FN;M;-Y9XA.6B5F5& "_=X#8X&!VKW7 W;L#<!@''.*\<T?_DZ37?\
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M=\/Z5XETUM.UBRCN[5F#;'R,,.A!'(/)Y% $NG:MIVJPB33[^VNEV*V890^
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M#GA#0M2BU!;:XOKJ(AHGOIO,V$="!@#([9%=_0 4444 %%%% !1110 4444
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M2D^ /^NX_P#1RUZ\_P!]OK6+J_A71M>U/3]1U*U>6[TYMUJZRLH0[@W('!Y
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M^A]NN:FO+.VU"SFL[VWCN+69=DD4BY5A[UP1^"?@K[49?L]^(B=WV879\O\
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M\;,LUG),N^( \'MP1SG%=77G>J_!+P3JE^]V+2ZLF<[GCM)]D9/^Z0<?08H
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M0HYX]PLR"BI_L<_]P?\ ?0H^QS_W!_WT*.>/<+,@HJ?['/\ W!_WT*/L<_\
M<'_?0HYX]PLR"BI_L<_]P?\ ?0H^QS_W!_WT*.>/<+,@HJ?['/\ W!_WT*/L
M<_\ <'_?0HYX]PLR"BI_L<_]P?\ ?0H^QS_W!_WT*.>/<+,@I1UJ;['/_<'_
M 'T*46<_]P?]]"HJ23B]0:9#14_V2?\ NC_OH4?9)_[H_P"^A7,39D%%3_9)
M_P"Z/^^A1]DG_NC_ +Z% 69!14_V2?\ NC_OH4?9)_[H_P"^A0%F045/]DG_
M +H_[Z%'V2?^Z/\ OH4!9D%%3_9)_P"Z/^^A1]DG_NC_ +Z% 69!14_V2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TK''2M
MAONGZ5CCI0 4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "KD?^K7Z53JY'_JU^E1/8N ZBBBLBPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&3[YJ
M:H9/OFMZ'Q&=7X1E%%%=9SA1110 4444 %%%% !1110 4444 %%%% !1110
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M[28?-#,J2[ESW'((/O7IGQ'^(Q\ W.BJUE'/;W\K+-(\A7R54KE@ #GAC^5
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MS:-<^%/%<.1+IVH>6Q ZH<-@_P#?+#\:]2+*WS)]QAN7Z'D4 %%%% !5R/\
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M'LG_  COQD\&>(%RL=Z#87! X(SMY_"0?]\BBRO8-3UFBE(P2/2DJ"@HHHH
M*AD^^:FJ&3[YK>A\1G5^$911176<X5!>WMIIMG+>7US%;6L0R\LKA54?4_RJ
M>N5\9>!;+QO/I:ZE=3I963N[V\/!G+8QD]@,'G&>>U)WMH",[PQ\5=&\7>*Y
M="TNTNBJ1O(MW)A5<+CD+U&<]Z[NO&?#UA9Z7^T?J%C86T=M:P:>4CBC&%4>
M4G^<U[, 20!U-3%M[CD9^N:S9>'M$N]6U"39;6L9=O5CV4>Y. *Y'X<?$E_B
M!/J4;:2E@+)$8%9S)OW$CN!CI6+?RGXJ?$>+1(&+^%=!E$MZXY2ZGS@+[CJH
M]@Q[BJWP?Q_PGOCX !0+K  & !YLG I<S;';0ZWQK\1K7P5J5A83:3>7\U[&
M7C%LPSP<8QC)-8/_  N@?]"1X@_[X_\ L:J^-[J&'X\>#WN9D@@MK4S22R.%
M15!D)))Z?=KIXOC'X'FO_LBZ^58G:)7AD6(G_>(X'N:5]=QVTV.DT'5?[=T*
MTU3[)/9_:%+?9YQ\Z8)'/Y9_&M&D#B10ZL'5@&# Y# ]"#W%+6B(./\ ''B;
M4-&O?#^D:-Y/]IZO>B(&5-X2$8WMC/N/R-=#KNMZ=X<TFYU74I_)LX!RV,LQ
M/ 4#N3Z5YRDW]N?M(NC'=#H6GD(". Y49/US+^E=GXR\&V/C?2H-.U&ZNX((
M9O.'V9E!9L$#.0>.34IMW:*LCBH?C%JVHQ-?:1X U*\TE"<W.]LD#K@*I'ZF
MNT\%^-M(\<Z>]QIC/'-$P6XMIL;XB>A..H/."*TUN=)\-Z5#;27UK8VEG"J*
M)9E3:BC .,^WXUY/\*$.K?%#Q9XDTV-H]"E,D:'9M61F<,N!ZX!;';(I7:>X
M:6-2;XW6\4\D7_"(ZTVQBN1CG!QZ5!-\>;&VC\R?PKK$29QN=E49^I%>N^8_
M]]OSKQCXHW,WC3XB:#X!M96,$<BSWQ4_=)&3G_=CR?JU#NNHU9GK6EWZ:KH]
MCJ,<;1I=P).J,02H8 X.._-6P"3@=:;'%'!$D,*!(HU"(@Z*H& /R%0:C;RW
M>E7MK!)Y<T]O)%&Y_A9E(!_,U?0@\_OOBW]HUFXTKPCX=N_$4UL<330L5B'T
M(!R/<XSVJUH'Q3MK_7X_#^O:/=Z!J\N!%%<G*2,>@#$ C/;C!]:Y;X/^(=(\
M):7J/AKQ#)'HNKQ7;22"\/EB5< #YCQQ@\9Y!R,\U#\1=2LO'_C'PUH_A9EU
M&]M)C)/>V_*0H2I^_P!"!M+9Z=AR:SYGO<NRV/0/B)XCU+PEHEIK-DL3VT-[
M&E_&\>XF%C@[3V.>/QKK$DCFC26%@\4BAT8=U(R#^58WC;3!K?@O7-/ZF:TD
M*9_OJ-RG\U%8?PBU9M7^&>E/(<RVNZT;Z(?E_P#'2OY55_>)Z';T4458@J*;
MJOTJ6HINJ_2G'<"*BBBM!A6'XK\6:7X.T?\ M'5'?:S;(88QEY6ZX']2>!6Y
M7+^*_ >F>,;W3KG4KF[3[ 28XH2NQ\D$[@0>N /I2E>V@(Y(_&'4K>W74K[P
M+J4&C/C;=ASG!Z'E0/UYKT?1]7L=?TFWU339Q-:7"Y1L8(/0@CL0>"*K^+M1
ML]/\(ZQ=ZEL^R"TD1HVZ.64JJ#ZD@"N ^#+W6C_"O4=1N<B%9I[FV#?W4C&3
M]-R_I6:;4K,?0U_$7Q/BTWQ _A_0=&N=>U6+_71P,0D9'49 ))'?L#Q5CPE\
M2;3Q'JTFB7^FW&C:VBD_9+@\28&2%) .<<X(Y'(K"^!-ECPOJ6LRX:[U"]8/
M*?O%5 .,_P"\S'\JJ_&8?V3K_A/Q/ 1'<P7/E/(.K*I5ES^;#Z&ES2MS#LMC
MUTD*I9B%5022QP /4FO/[KXO^'8_%-KH-C'-J+SS) ;J!E$2NS!>"?O 9ZCC
MTS73^+O#R>+/#\^CM=O:0W$D;/)&,ML#;B!]>G->2^-?#.D>%?&W@&PTBU$,
M7VE6=R<O*WG)\S-W/Z#M3G*2V$DCW0C!(]*2G/\ ?;ZTVM1',?$#Q/+X3\)3
M:A:JC7\DJ6]HCC(:1CZ=\ $UN"X.GZ.MSJUS$C6]N)+N?&U 0N7..PSGBO.?
M'\G]K_%3P5X=8DP1R?;95[$[B1^D9_.N^\2:'!XGT*[TB[GGA@NMOF/ 0'P&
M#8&01U K--MNPS@1\8+O5;F8>%_!VH:O:PG#W!8K^BJ<?0G-='X.^(>F>,)[
MBR6WGT_5;<$RV5S][ X)4]\'J" 16MH>EZ7X.\/VVDV]U'!:VX8A[B5$9R3D
MLQX!//Z"O+[&XA\5?M#KJOA\B6QLH<W=W&/DD(C*$Y[Y) 'KC-3>2:NQZ,[3
MQA\2+3P?K5II4NCWM_<74(FC^S,/[S+C&"2?EK&_X7*G_0E:_P#]\_\ V-5/
M%-S;VWQ_\.W%W/';V]IIYFDFD<*J@"4Y)-=-;_%WP5=7PM$UTHY;:))872,G
M_>(X^IQ1=MO4+'2:+J7]LZ+9ZD+6:U%S'O\ (F^_'R1@^_&?QJ]1G=ALA@1D
M$'.1ZYHK5;$F;KOB#2O#6FM?ZO>1VT X7/+R'T1>K&L7P/X^L?':7[V5C<VJ
MV90-Y[JV_=G&,=/N_K2:I\.M)\1>-8M?UEY+J.*..*&Q/$8*]6;UR>W ]<UR
M'P255U'QBJJ%47B@!1@ ;I.E9\TN9)CLK'H'C*_U/2O"&I:EHYB%[:1><HEC
MWJ54_,,?3/Y5<T'5H=>\/Z?JT'^KNX%DV_W6_B7\""*O2VZ7<,EK* 8YT:)P
M>X88/\Z\S^"EV\>AZSX?F?=)I-^R+_NMD?\ H2M^=4W:0=#TZBBBK$%*.M)2
MCK45/A8F+1117(2%9VNZ[IWAK1Y]5U2?RK6+ .!EG8]%4=R:T:YSQCX+L/&^
MGVUEJ-U=P0V\IF7[,5!9B,<[@>@S^= UYG'0_%_5KV!M0T[P#J5SI"GFY#L2
M0.I&%(_6NT\(^,M)\::6U[I;NK1$+/;RX$D)/3/J#S@CT-:;W^E>'K"-)[ZT
ML+2TB50LDJIL11@?+G/;TYKROX/1M?>.O%7B*R@>+0[B1DA!7:'8R!@ /903
M[;J!V31U/BCXEVFAZXN@:7IESK>MG[UM;'"QG&<,0"<XY( X[FLZ+XLOIVH6
M]IXO\+WV@"X.([AB7C_'(!QZXSCTKGO"M[;^ OBMXDA\4O\ 97U-F>TU&4'R
MW4N6^]V# CGL5P:O_%KQ5H>O>%D\.Z/<Q:QJMW<QM!'9_O?+P>3D<9(XQUYI
M#LMCT[5M7L-$TB?5=0N4BLH4#M*/FR#T"XZDY&/7->?6_P 5M;U6)KW0_ &I
M7NEJ2/M!D(9@.N %(/X$U!\0_"^M2?!C2=,A#SW>EI"]W%'\Q=50J<>NTG\A
M70>&?B'X0E\+V##6;+3_ +/;I&]I/)Y;PLJ@$!3R>1P1G-,$E8O^#O'6D^-;
M><V2RV]Y;'%Q9W Q)'SC/N,\>W<5TU>/^ E/B+XQ:_XNTNWDBT-HWB69D*"9
MR%' ]RI8^G?DU[!03)69GZ[JL.A>']0U:?'EVD#2X_O,!\H_$X'XU3\%WVJ:
MMX/TS4=7,1O;R+SB(H]BJK$[1CZ8/XUQWQPO)!X3T_1X6Q)JE^D9_P!U>?\
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MA+6_%_AS3K30[,74T-WYCJ953"[&&<L1W- 'HFFVL-EI=I:VT:QP0PI'&BC
M50  *\I\4^ ?%^D^/;KQGX'NK=Y[M,7-G<$#=P,@9X(.T'J"#7KL*E((U88(
M4 _E7D6M:9X^\'_$&\\0Z%#/K^BWH)>P>Y.82Q!(52>,$<%0>#C% &;)\3KR
MSU6PT_XG>"+>!2_[J\,(=$;C+*&W CIG:V1[U[B"& (((/((KP[Q!I'C;XN7
M^F6>I^'?^$>T2UF\V:2>8/(W8X& <XS@8QSR:]PC18HUC0850% ]A0!F^(];
ML_#GAV^U?4 3:VL1=U R7[!1GN20/QKS/0=2^)_C33EU727T;P[I,Q+6T;P^
M9(Z^O((QGO@9]*[[QSX9_P"$O\&ZCH@E$4EP@,3MT#JP9<X[9 S7FWA?6_B=
MX7TBV\,2>!Q?26J^3;WGV@)'L'3<>00/J.!ZT 4O <6JP?M"ZS#KE]!>ZDFG
MXFG@CV*W$6.,#H,#\*F^*\4<WQH\"1RH'1I(@RGH?WU:7@KP-XIT3XMWVOZR
M$NH;RS;SKR-U"><VQBJIG=M!!49'0"KOC[P?KNM_%#PEK.GV0FL-/>,W,OFH
MNP"7<>"<GCT% 'J$P!@D!&05/\J\:_9R 'AC6P!@#4/_ &05[-("T3@=2"!7
MFGP6\)ZWX2T/5+;6[,6TL]YYL:B57RNT#.5)[B@#F_@+B[\1^--1N3_ITERH
M<'JH9Y&/ZC]*[?XQV]O<?"K7/M"J1'&DB$]G#KC'\OQKE+WPMXH^'OCW4/$W
MA335U?2=3):[T]9-LB,3N./^!$D$9P&(QWIWBZU\>?$KPQ=68\/G0[&-1*MO
M-<*T]Y(#\J=@B _,<\DJ,4 =?\)/^25^'_\ KW/_ *&U=I7,?#O2;[0O &CZ
M9J4/DWEO"4ECW!MIW$]02#P173T >27GCCQ)XG\::CH/@&QT^,6!V7NJWBY
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M,5I?%KP5X@\0WV@ZWX;$$E_I,K.(97"[OF5E(SP<%>02.M 'HFK_ /(%O_\
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M:!;:YIUI$$66 [GV+P.5.> .ZUZ'\1_#>J^)_"DEKHFHRV.I0R":%XYFB$A
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M1@<_D!^%<?\ M'Q1QZ#H5\N%NXKUEC<?>"E<G]56G:!9>/OA2UQI-KH9\2Z
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M,@@Y'3'K'K1^)OQ)M!H<OA^/P[I4KJ;J:9CE@"#CGDC/. .<<FJ2ML)L]/\
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M#P[!XR\*7>D^<(UN LMO-C(5A\R'W!Z'V-9*ZND/L5_%'@G0?'$=I)J?FRK
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M'(]QSFI=!T[XA_#'[5IEAH<7B#2))3+&T+'(8C&0 =RY &001QUJTOA;Q?\
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ML)/L2O*C*#Y@V8"G(^3/6@3U=SGM4NKWXC_$^^\'->RVGAW3%9KJ*$@-<LA
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M0254C(.5R0",@@]/235=+^(?Q5EMM.U?24\.:!'*)9MQS(Y&>Q.6/7 P!W-
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M0!F?\(_IX\4?\)&J2+J1MOLK,KX1X_\ :7N??V%:=%% !1110 4444 %%%%
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M'FP_\^X_[ZJ&B@";S8?^?<?]]4>;#_S[C_OJH:* )O-A_P"?<?\ ?5'FP_\
M/N/^^JAHH F\V'_GW'_?5'FP_P#/N/\ OJH:* )O-A_Y]Q_WU1YL/_/N/^^J
MAHH F\V'_GW'_?5'FP_\^X_[ZJ&B@";S8?\ GW'_ 'U1YL/_ #[C_OJH:* )
MO-A_Y]Q_WU1YL/\ S[C_ +ZJ&B@";S8?^?<?]]591T*+B, 8Z9JA5R/_ %:_
M2HF]"X$NY?[GZT;E_N?K3**SN78?N7^Y^M&Y?[GZTRBBX6'[E_N?K1N7^Y^M
M,HHN%A^Y?[GZT;E_N?K3**+A8?N7^Y^M&Y?[GZTRBBX6'[E_N?K1N7^Y^M,H
MHN%A^Y?[GZT;E_N?K3**+A8?N7^Y^M&Y?[GZTRBBX6'[E_N?K1N7^Y^M,HHN
M%A^Y?[GZT;E_N?K3**+A8?N7^Y^M&Y?[GZTRBBX6'[E_N?K1N7^Y^M,HHN%A
M^Y?[GZT;E_N?K3**+A8?N7^Y^M1.\8<YA!_&G5#)]\UM0UD9U=$.\R/_ )XC
M_OJCS(_^>(_[ZJ*BNJR,+DOF1_\ /$?]]4>9'_SQ'_?5144607)?,C_YXC_O
MJCS(_P#GB/\ OJHJ*+(+DOF1_P#/$?\ ?5'F1_\ /$?]]5%119!<E\R/_GB/
M^^J/,C_YXC_OJHJ*+(+DOF1_\\1_WU1YD?\ SQ'_ 'U45%%D%R7S(_\ GB/^
M^J/,C_YXC_OJHJ*+(+DOF1_\\1_WU1YD?_/$?]]5%119!<E\R/\ YXC_ +ZH
M\R/_ )XC_OJHJ*+(+DOF1_\ /$?]]4>9'_SQ'_?5144607)?,C_YXC_OJCS(
M_P#GB/\ OJHJ*+(+DOF1_P#/$?\ ?5'F1_\ /$?]]5%119!<E\R/_GB/^^J/
M,C_YXC_OJHJ*+(+DOF1_\\1_WU4<LL((S;@_\"-)44W5?I3C%7"X[SH/^?8?
M]]&CSH/^?8?]]&H**OE07)_.@_Y]A_WT:/.@_P"?8?\ ?1J"BCE07)_.@_Y]
MA_WT:/.@_P"?8?\ ?1J"BCE07)_.@_Y]A_WT:/.@_P"?8?\ ?1J"BCE07)_.
M@_Y]A_WT:/.@_P"?8?\ ?1J"BCE07)_.@_Y]A_WT:/.@_P"?8?\ ?1J"BCE0
M7)_.@_Y]A_WT:/.@_P"?8?\ ?1J"BCE07)_.@_Y]A_WT:/.@_P"?8?\ ?1J"
MBCE07)_.@_Y]A_WT:/.@_P"?8?\ ?1J"BCE07)_.@_Y]A_WT:/.@_P"?8?\
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M0 ]RHHJM)J-E%<"WDO+=)CTC:50WY9S0!9HHJ.>X@M8C+<31PQCC?(P4?F:
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M'(-+0 444=* "BJ\%[:73.MO=0S,GWA'(&*_7'2O(_V>YYI]'\0&::64K?@
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M<CJ,%Q\0O ^FW6BZS/HAN]ESYT18LHP0T9VD'AL]^U<N/A/XK) 'Q,U,D_\
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M/B"-=XE>4B.5QSMZY /0$D^XIN>NB"QZI17%?##QE<>,/#4CZ@ -3L9?(N2
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M.KNVN;1K>YO=/\S[/(/FBF"API![AABJ?PPU]O$7P_TZXE;=<6P-I,2<DLF
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MMH23DF-22>_ J2@ ZTNUO[I_*O*/BEXHUM_$FC^!?#5R;2^U,!KBZ4X9$8D
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MW,$C!SP.&)^G>OHZQO;2]MXWM;F&="BL&B<,"".#Q7C_ ,!_^0WXZ_Z_D_\
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M&6*.9L^6=F\'TSP5..O!^G<?$WPQJWBBRLK6#7(-*T6.0OJ3/(4:1,C !QC
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MP+$8ST^\:Z&B@!" P((!!X(/>O.-1^"?ABZOI;S3I]2T:24YD73KCRT/X$'
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M4NJ.5/RL&'(]P*L:3I=MHFD6FF62LMM:Q"*(,VXA1P,GO5RB@#E_%_P_\/\
MC>*$:O;.9X,B*XA?9(@/;/<=\'-<W8? WPO;W<4^H7.J:MY1RD5]<[D'M@ 9
M'M7IE% "*JHH55"J!@ #  I:** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z
M?I6..E;#?=/TK''2@ HHHH$%%%% '+>+/A[X>\9ND^IV\L=Y&NQ+NW?9)M[
M]0P';(K-T+X1>%M#U&/4'%WJ=W$0T;W\@=4(Z':  2.V<UW=% "[CNW=3G/-
M<[I'@G0]$\07FO6<5PVI78<2S3SF3[Q!; /3)'Y<5T-% !1110!6U'3X-6TN
M[TVY&8+N%H)/8,,9_#K^%<I\+8M3L/!O]CZK;30W.EW4MLK2H5$L><JRYZKR
M1D>E=I1DGJ: //G^"G@:21G:ROLL23_IA_PIO_"D? O_ #Y7W_@8?\*]#HH
MBDM8)K)K*:%)K9HO)>*0;E=,8P?7BO.I?@7X.DOO/5]2BMRVXVB3C9^9&[]:
M]*HH K:=IUGI&G0:?I]M';6D"[8XHQPH_J3U)/6LBW\%:':^+IO%,,,XU:;<
M7D,Q*'<NT_+]*Z"B@ K$G\):/<^+;?Q1+%,=5MXQ'&XE(0+M*\KWX8UMT4 *
MN"PR<#N:X#X=Z9>RZQXG\5:I9S6MUJMX8X(IT*.L"=#@\C/RC_@-=]023U-
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MV16Y=V%IXP\*1VVK6TZ07T,4D\!)BD1N&VGN"&'2MBBIY5>X7//O^%)^!O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#6:+67'1?^^A6
MDWW3]*QATH G^RR^B_\ ?0H^RR^B_P#?0J&B@1-]EE]%_P"^A1]EE]%_[Z%0
MT4 3?99?1?\ OH4?99?1?^^A4-% $WV67T7_ +Z%'V67T7_OH5#10!-]EE]%
M_P"^A1]EE]%_[Z%0T4 3?99?1?\ OH4?99?1?^^A4-% $WV67T7_ +Z%'V67
MT7_OH5#10!-]EE]%_P"^A1]EE]%_[Z%0T4 3?99?1?\ OH4?99?1?^^A4-%
M$WV67T7_ +Z%'V67T7_OH5#10!-]EE]%_P"^A1]EE]%_[Z%0T4 3?99?1?\
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M HHILDB0QM)*ZHBC+,QP /4F@!U%0VMU;WMLEQ:3QSP/G;)$X96YQP1P:FH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 (WW3]*QQTK8;[I^E8XZ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ/X-A8MI^FGS+S!XS@-)GZ*%4>Y-.*NQ,[+X.>&?^$<^']K),F+S4C]LFSU
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M]XT%/9'G.J_#32Y]6\0>*=7E?4+F2*:2UMW_ -5;@1G;D'[Q';H!Z5!\"O\
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MB<3VLC_=$@!&#[$$CVSGG%<GIGCOQYHVEQ:5JOP_U*^U*!!$MU;OF*;' 9F
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MC4@B%"=Q&1QDG' X 45Z910!Y!X_\-^)M(^)&G^/?#6G_P!J>7%Y-S9J<.0
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MS75Q:/'%&" 68C@<\5D?"31-1\/?#NQTW5;5K6\CDE+Q,P) +DCH2.AKN**
M"O(_&_A'Q#H_Q MO'WA&T6^GV!+ZQW;6E&-N1ZY7'N"H.#7KE% 'EM]K_C+Q
MQH]SH]AX3OM!2YB9+F^OV *)CE8TP"S-]T'H,YJS\$O#NK^&/!=S8ZU8O9W+
M7SRJCLIRI1 #\I/<'\J])HH \M^'GAC6M'^)?C/4]0L'@LK^=FMI692)!YC'
M( )(X(/-5?$47C_PG\1)O$&E07WB#0+E,-IRW#'R20,A4YP<C((!X)%>N44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M13]R_P!P?G1N7^X/SHL RBG[E_N#\Z-R_P!P?G18!E%/W+_<'YT;E_N#\Z+
M,HI^Y?[@_.C<O]P?G18!E%/W+_<'YT;E_N#\Z+ ,HI^Y?[@_.C<O]P?G18!E
M%/W+_<'YT;E_N#\Z+ ,HI^Y?[@_.C<O]P?G18!E0R??-6=R_W!^=0NZ!SF$'
M\:VH:2,ZNQ#14GF1_P#/%?SH\R/_ )XK^==5WV,+$=%2>9'_ ,\5_.CS(_\
MGBOYT7?8+$=%2>9'_P \5_.CS(_^>*_G1=]@L1T5)YD?_/%?SH\R/_GBOYT7
M?8+$=%2>9'_SQ7\Z/,C_ .>*_G1=]@L1T5)YD?\ SQ7\Z/,C_P">*_G1=]@L
M1T5)YD?_ #Q7\Z/,C_YXK^=%WV"Q'14GF1_\\5_.CS(_^>*_G1=]@L1T5)YD
M?_/%?SH\R/\ YXK^=%WV"Q'14GF1_P#/%?SH\R/_ )XK^=%WV"Q'14GF1_\
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M/YT/_/LG_?1H\Z'_ )]D_P"^C1=]@(**G\Z'_GV3_OHT>=#_ ,^R?]]&B[[
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M%%% !12!@PR"#]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'4\@CV-%P)**4*6.%!)]!0002",$=C0 E%* 2< 9- &[.TAL=<'.* $HHHH
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MBB@ HH(P 20,],G&:4@@X(Q0 E%* 2< 4@YS@@XZX.<4 %%%!X )( /3)Q0
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MNC)_4D5]!M+&C*KR(K-T!;!->)^ _P#DXKQE_P!<I/\ T..CXO 'XL^ >/\
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ME"M;3QWKE@PYPZDDC(SVSWKLIK'5]-^#>H66NW4=UJ4&E7$<LT;%@^$;:<D
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MS=,4W11/(JNVW<5!.*Y+X8^-[GQKX9DU345M;><W;Q)#"2 % 7'4DD\FK?Q
M\'Z+XJT.275[9YFL(9I;<K*R;6*^QY^Z.M>7_!#X?^'=;\-P>(;ZTDDU*UU
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M>IQR0PSSP1T.*^A: "J%SKFD65TMK=:K8P7#?=BEN$5S] 3FN5^+7BNY\(>
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MX#MKG/CY=/!\/K:%?NW.H(K_ $5&8?J*]+LH5M].M($&$CMXT4#T" 4 >?\
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M5D&SS,>F-VW/^UFO7@2.A(KRCXA>//&^A2:E;Z5X7=+&([4U@JTH52HR^T#
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MM3M@F9M-O2.,H3QGZ!B?^ BH/A#X:U(W&H^.-=!74-9R88R,%8V;<6([ D
M>@]ZN_'2W6?X932G[UO=PR*?J2O_ +-4_9']H])8;6(]*2L_0;E[WPWI-W(<
MR3V4,C'U)09K0K1$!1113 *BFZK]*EJ*;JOTIQW BHHHK085S_C/Q+)X4\.M
MJ,%@]_</,EO#;J2-SMG'3DCCH.3704=P>X.0?2DTVM / XKGQHGQ8\*R>*+R
M2&74)HY18Q2%4BCWD!"@.!T/')]>:]\RH!9VVHH)9CV ZFO)O'/_ "77P/\
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M@@4'MDY)(YX]Z1O@=HZVI%MK6KIK&,"^,PP9/4J!G&??/O4_QAL= ET*SO\
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M'^N6@<=R[1112.@*R/%.IW>C>%M2U&PM7N[R&$F"!$+EY#PORCD@$Y/L*UZ
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M><%6!QS@C%>N5Y)\%X=%N9]6U<ZG/?>*IV(U 747E/""<D!>XW#D^P&!7K=
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MA)R2>?F)/=LU>\3>$M%\864-GKEH;F"&3S442LF&P1G*D=B: -'3/^059_\
M7!/_ $$5Y%\._P#DN_CO_@7_ *,6O9(HDAA2*,81%"J/0#I6/IOA'1=(U^_U
MRRM#'J-_G[3+YK-OYST)P.1V% 'DOFQ^$/VF+BXU)Q!9ZQ!B&>3A265<<]OG
M0K^(KU?QEKMGX=\)ZC?W<J+B!UB0GF60@A44=R3BG>)_"&A^,+!;/6[);A$.
MZ-P2KQGU5AR/Y&L+0OA+X5T&\2\C@N;RXB!6%[V<R>4#Q\HX /OC(H YC]G+
MCP%?_P#81?\ ]%QU[!6+X:\*:-X0T^2QT2U-M;R2F5D,K/EB ,Y8D] *VJ /
M"HIX_!_[2]Y+J4BV]GK$&(9I.%)95QS_ +Z%?RKTCQ]X]L/ >AI?W$:W4\LB
MI#:K*$>3/4C@\ #KCT'>M#Q/X/T/QA8I::W8K<+&<QN"5>,]]K#D?3H:YW0_
M@UX.T+4H[]+2>\N(B&B-[+Y@C(Z$+@#CWS0!R'QQM]0U7P-X<\2?8'A-I(LU
MS;$[C")%4X8X[$!2?4UZSH'B+3?$FAP:MIUS');2H&)W#,9QRK>A'>M&>"&Z
MMY(+B))89%*O'(H96!Z@@]17G5W\"_!5Q<O+%!>VB2'+P6]T5C;VP<\>P- '
M)6DT?C7]I-=0TMA-I^C0;9;A.48JK+P>GWWP/4*34OQH_P"2F> O^OE?_1T=
M>M>'?"^C>%-/^PZ+81VL).7VY+.?5F/)/UJ#6_!NA>(M4T_4M4LS-=Z>P>V<
M2NNPA@W0$ \@=: -ZO%/V=_^//Q/_P!?R_R:O:ZP_#?A#1/"272:+9FV6Z<2
M3 RN^YAW^8G'7M0!Y7H'_)TFN_\ 7J?_ $7%7>_%K_DE?B#_ *]Q_P"AK6K;
M^#="M?%=QXGALRNKW";))_-<AA@#[N=O11VK0UC2++7M)N-+U&$S6=PNV6,,
M5W#.>H((Z4 ><>$],GUG]G&/3K89N+C3;A(E]6W/@?B>*P?@UH'@GQ-X.6WO
M]&L)]9LY'2Z$R?O""Q*L1UQ@X_X#7LFC:-8^'](M]*TR$PV=N"L498MM!))Y
M))/)-<KX@^$?A/Q#J;ZG+:SV=[(=TDUE,8BY]2.1GWQDT <S>GP+HGQ,T?PU
MI7@ZRN]1D=)'N+=@#9D-G)&#RH7=C([5E>/I!X5^/OASQ)>-Y>FW,0B>=A\J
M'#(V3[!E/XUZ;X4^'WAOP:9)-(L=MS(,27,SF25AZ;CT'L,5J:]X=TGQ/I;Z
M=K%E'=6S'.UL@J?52.0?<4 4O%OB[3_"7A>?6[AXYD1088EE ,['&%4\YZ]L
M\<USVMZW-XH^!^JZP^GO9-=Z9-*MN[[R$P<'.!U #?0U#I_P.\$V-\ERUI<W
M8C.4@NIR\:_\!XR/8YKT-X(9+=K=XD:!DV&,J"I7&,8Z8QVH \R^!VLZ6?AM
MI>GC4+7[:DLR-;F4"0$R,P&WKT(-8MQ_R=7:_P#7B?\ T0U=UIOPL\&Z/KD6
ML6&C+!>PL7C99I-J'&,A2V._I6JWA#1'\6IXH:S)UA(_+6?S7P%VE<;<[>A/
M:@"MX^\,KXM\%:EI&T&:2/?;D]I5Y7]1CZ$U\_VGB.^\=>$O"_PWC\U+T7IB
MO'*GY8(_NY^BELC_ *9CUKZEKG-,\">&]'\1W6OV&FK#J=UO,DV]B/F.6PI.
M!D^@H U&TN&+0&TFT410+:FVB7LJ[=HKPOX+^'_"FIVNJ:#XBT:SEUZQNVW)
M<K\[)@# SUVLK9],CUKZ#KC?$_PO\+>++[[??6<D-_WNK20Q.WUQP3[D9H X
M_P 80> /">OZ/HUKX*L-2U/4)0H@A(5HAD!2>#U)..G0U[%7(>%_AGX8\)7C
M7VGV;RWY!'VNZD,L@SUP3P/J #77T 4-=!;P_J2@9)M90!_P UY3^S]K6EP^
M!9-/EU"VCO!?O^XDE"N=RKMP"<G.#T]*]E(!!!&0>H-<9%\*/!,&MPZO!H<<
M5W#*LT9CE=45P<@A VWK[4 <5X^_Y."\$?\ 7)?_ $.2NO\ B%XQ\.^'VT_2
M?$NER7=CJC%-[1HT*8(!+;CQC<#QS6]J'A'1-4\16.OWEH9-2L0%MYO-8;!D
MG[H.#R3U%2^(?#6C^*M,.GZU9)=6^[<H;(9&]58<@\]J /)_B!\)_ ^G^$[_
M ,0:;.VES00M-;O%<%HI'Q\J@$G[QP!M/>MCP+XUO--^",7B/Q!'>7XM69"R
M -+)%YFP,=Q&<9P2>RU:MO@/X(@N%DD@OKB-3D0371*#\!@_K7H2Z=9+IG]F
MK:0"Q\KR?LX0>7LQC;MZ8QQB@#S&T\!_#;XCZ$FO66GBR^T!FD-M*(GB;/(9
M 2@/'I6)\#KF[L_%WB;P[:ZE)J&@V)/V>4G<H(?:I4]!N4$\<';FNGN?@/X(
MGNFFC@OK9'.6A@NB$/MSDX_&NU\.^&-&\*:;]@T6Q2U@)W-C)9V]68\D_6@#
MR7P5<P:3^T1XNM;V58);M7\@2';O)9' &>^TY_"MOX]ZW86WP_N-):=6O[N2
M,QP*<L%5@Q8CLO&,^I%=3XM^&WAKQI-'<:K9N+N-=JW,#^7)CT)Z'\0<54T_
MX1^#M/T:\TP:<\\=Z%%Q+-,QE<*P8#<""!D X&,XYH S=)TN;6OV>H-.M@3/
M/HNV-1_$VW('XD8KE_@WH'@CQ/X-2"^T:PGUFSD=+H3+F0@L2K$=<8('_ 37
MLVEZ9::+I=MIMA$8K2V01Q(6+;5'09/)KD=?^$?A/Q#JCZG+;3V=[(=TDUE,
M8BY[DCD9/<XR: .;O#X%T7XFZ/X9TCP=8W>I/(LCW$#!?L9!SDC!Y4#=C([>
MM>O5S'A3X?\ ASP9YCZ18[;F48DN97,DK#TW'H/88%=/0!Y;\?M*N-2^&YGM
MXV?[#=)<2!1G"892?PW _3-=?X%URR\0>"M*O;.9'7[-&DJ@C,<BJ RD=B"/
MZUT,D<<T3Q2HKQNI5D89# ]01W%>>3_!+P9+?27,5O>VL<IS);6]TR1/[8Z@
M>P(H X35-;L]<_:<T1[&59H;51:F5#E795D+8/?!;'U!K9_:"_X]?"W_ &$#
M_(5Z!!\//"UKJ^FZI;:4D%UIL0AM3%(RK&OS'[H."<NV202<U<\1>$M%\5I:
M+K-H;@6DGFPXE9-K>ORD9Z=Z *7CWQ=IW@[P^+[5=/N+ZRGE%O)'"BN/F!/S
M!B!@XQ^-<;?_  J^&_B70/[<L@NFV\T/G"ZMKC$<8QGYE)*C'<<=,<5Z?J>F
M6.LZ=-I^HVL=S:3+MDBD&0PZ_P ^<UYX?@)X(\\N(M0$).?LXNSL_EG]: ,+
MX&W6IZ_X'\0:3>7<L]G$YMK2:3)VAT.X GL,J<=MU-^ NKPZ/%J_@S5"MKJU
MM>M(L,AP9. K!?4@KGZ$&O7](T?3M!TV+3M*M([6TB^['&./<GN3[GFL#Q5\
M-O#'C&X6ZU2Q(O%  NK=S')@=,D<''N#0!ROQZU^SM/ KZ&)5?4=1EC6.W4Y
M?:K!BV/3@#W)K:ATB;0?@9+IERNVX@T242K_ '7,;%A^!)%2^'?A-X2\-ZBN
MHV]G+=7R'*3WLIE9#Z@=,^^,UV%]90:C87%C=)OM[B-HI4R1N5A@C(Y'!H \
M[^ O_)++3_KXF_\ 0JP?V@K*>&#PWXBBC9X]-NR)<#(&XJRD_BF/Q%>K>'_#
MNE^%])32](MS;V:,SK&79\$G)Y8DU<OK&UU*RFLKVWCN+:92DD4B[E8>A% $
M6GZM8:GI,.J6EU%)92QB59@PV[<9Y/;'?TKQ#P3K5OX@_:0UG4K1M]K):R+#
M(!PZH(T##V.W(KMHO@?X+BNFD$%\;9FW&S-V_DD^XZG\37367@GP_IWB-M?L
M]/6#43"(-\;L$$84*%"9V@84=!VH \C\7:=H]A^T-!/XHM(9M(U>V54>X'[M
M'"! 2>G!0?3>#7:^*?"_PY\*>&[K6KSPWI;1PQEHX]H4S-_"BGU)_P :[#Q%
MX7T;Q7IWV#6K&.ZA!W)G(9&]58<@_2N/LO@?X+M+J.:6"\O4B.8X+JY+QK_P
M$8R/8YH U/ US97WPY2]T[0UT6TN8Y9([16W<<C=T'7&?I7'_LX_\B+J/_81
M;_T6E>O^1%]G^SA%6'9L"*, +C&!CIQ63X:\)Z-X0L);+1+0VUO+(974R,^6
MP!G+$GH!0!D?$7QEH_A#1X#KNF3W]C?.8&1(T=,XSA@Q YP?RKD/$WPE^'EY
MX<N=<L)AID0A,\=W;W&8N!D'#$C!]!@UZCK.B:;XATN73=6M([JTE^]&_KV(
M(Y!]QS7 )\!/!"S[S%J#PYS]G:[.S]!G]: (_@)J^K:MX!D_M266=+>Z:&VE
ME)+&,*IQD]0"2/T[5ZE573M.L])T^&PT^VCMK6!=L<4:X515J@ HHHH ****
M "BBB@ HHHH 1ONGZ5CCI6PWW3]*QQTH ****!!2KC<,],\TE% 'B7A?4+?P
M_P#'SQ*GB"9(+F]\Q+6XF^53N=64 GH"@P#^%=Q\4M<TBP^'NKV]Y=6[RWD'
MDV\ D#-(Y(P0!V7KGVK7\2^#/#_BZ-%UK3UFDC&(YT8I*@]-PZCV.16#I?P<
M\%:7=I<BPN+QT.56\GWH/^ @ '\<T <YI7AS4-0_9K?39(I#=/&]Y;Q$'<46
M3>H ]P&('N*Z+X0^(-.U3X?:=907$2W=@AAG@9P&7YB0V/0@]?K7?9(((X(Z
M8[5P^M?"3P=K>H/?2V,]K/(2TALIO+5R>I*X(&?;% ')ZQ=0>+?C_H$6CNMS
M%H\:M=W$9W(NQF=N>^,A?J:]C/)K'\.^%=$\*636NBV*6R2$&1R2TDF.FYCR
M?ITK8H \^^-6EMJ7PUNI8TW26,\=S]%SM8_DU=AX?OUU7PSI6H(05N+.)^N>
M=HR/S!%6KZQ@U/3[K3[H V]U$T,@/]UA@_XURGPQLM6TCPB=%UBUFAFTZZEA
MADD7 FB)W*R^HY/Z4 =HGWOP->1? ;_D%^)/^P@O_H+5ZV#CI61H'A?1_"\5
MS%HUHUNES()9@96?<PSS\Q..IH V%&Y@/7UKQ'1''Q&^.ESJY_>:3H0_<=U;
M82(_^^GR_P"%>U3PI<6\L$F[RY4:-]K%3M(P<$<C@]:R?#OA31/"=M/;Z)9?
M9HYW#RYD9RQ P.6)./:@#9ZG)ZU@6_C30KKQ;-X7AN)3JT.[?$82%&T;C\W3
MI6_6'!X/T*U\43>)8;)EU>;=YD_G,0=PP?ESCI[4 >8>(;V'0/VC+'4]>;9I
M\D""UGD^Y%F,H#^#YSZ9S7J>OZ_HNE>';V]U&^M3:&W<;1*K>=N4@*H!^;.:
M?KWAO1_%%B+/6;".ZB4Y0G*O&?56'(KDK7X)^"+:Z6=K2]N IR(I[HE/R !(
M_&@#,^ -I=6_@>^GF1E@N+XM!NZ,%4!B/;/'X4747]L_M)VFTDQZ-IX>3T#;
M"1^LBUZG;P06T,5O#%'#;Q*$2.-0JHH[ "N'^'NC:C'J?B7Q+K-E+:7^KWA$
M<,RX=(%^[D=LY'_?- '=4444 %%%% !5R/\ U:_2J=7(_P#5K]*B>Q<!U%%%
M9%A1110!YO\ %+XE'PC%'HVD@2:_>*/++8V6ZL<!SG@DG.!TXR?0T_AQH/AG
MPE%)JNJ^)-)O/$EYEKBY>]1O*W<E5)/)]6[_ $KJ_$7PZ\+>*]2&HZUIK7-T
M(Q$'%Q(GRC) PI [FLG_ (4I\/\ _H"2?^!DW_Q57=6L39W.XM+ZSU"$S6-W
M!=0AMID@D#KGTR.]8_CK_DGOB3_L&7'_ * :L^'?#6D^%--;3M%M3;6K2&4H
M9&?+$ $Y8D] *O7]C;ZGIUSI]Y'YEK=1-#,FXC<C#!&1R.*GJ4<#\#?^256/
M_7Q/_P"AUZ-6;H6@Z;X9TF/2](MS;V<;,RQEV?!8Y/+$FM*AN[!;'.^/=*?6
M_ .N:?$-TLEHS1KZLOS ?FM9/P@U!=1^%NBL#EH$>W?V*N0/TQ7<#@^M<!\.
M]!O_  IKGBC1'M)ETAKL7>GW!'[ME<?,@/J/E'X&FMA=3OZ\;^'?_)=O'?\
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M/'7U[7O#>D^)M+33-7M3<6:.LBQB1DPR@@'*D'H37,?\*9\ ?] 23_P,E_\
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M +Z%'V2;T3_OH4<T>X69!14_V2;T3_OH4?9)O1/^^A1S1[A9D%%3_9)O1/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ4X[@18'I1@>E%%:## ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]* !GI12CK45/A8F+@>E&!Z445R$A@>E&
M!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !
M@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E
M%% !@>E26X_?+4=20?ZY:!QW+M%%%(Z HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ H'4?6B@=1]: +=%%% !7C^I_
M&+78O&&J^']'\&R:I)I\K(S03L6*@XW%0AQU%>P5X)X0UO2]#^/'C2?5=1M;
M&%_,17N)1&&;S%. 3WX- &K<?&;Q1I,?VK6?ASJ%K9+]^;>X"_B8\?F17I7A
M+Q9I?C/0H]6TJ1C$6*21R##Q..JL/7D?G6-KOQ*\$6VB7CS:[IUZAA=3;03+
M*TN01MVKGKT].:Y?]G[0-0TGPG?7M] ]NE_<!X(I 0VQ5QNP>QSQ],^E 'KM
M%><^)OB/J$?BO_A$_"&D)JVLHN^X>5]L-N,9^8]^HSR.H')XK*N_B-XR\%7=
MFWCK0;$:7=2^7]NTUV(B/NI)SW..,@'&<4 >MT5S/C7QKI_@OPNVMW"FX5BJ
M6\4; &9V&0 >PP"<^@KB)_&'Q8M]+?79/">DC34A\]K?SCYXCQG/WNN.<8S[
M4 >NT5S?@;QE9^.?#4>L6D30'>T4T#MDQR#&1GN,$$'T-<'X=^,>K^)A>6&F
M>&TN=:CFV10).1$L8^]+(Y "@'  ZDF@#V"L7Q;K<_ASPM?ZO;637LUL@9;=
M207RP'8$]\].U>=7?Q+\9^#=0M6\=>';.+2KJ3RQ=Z>Y;RC[C+9('..,C.,X
MKT+Q1XB&A>#+[Q!:1QW:V]OY\:[\+(#C'([8- $7@CQ'<^*_"UOJ]WIS:?-*
M[J;=B25VL0#R ><9Z5T5<_X'\1R^+?!VGZY-;);27:N3$C%@N'9>I_W<UY[#
M\<9!?:QI\F@/<ZE;7AM;*SLW9WN"&8,Q^7Y0 HZ ]: /8J*Y'PUXNU"\\(7^
MN^)M&ET,V;2,\$@;=Y2(&W88 \\C\*Y'2/'/Q%\:VCZKX7T#2+;2A(R1-J,K
M%YL''&TC'\LYYXH ]<JE>ZOIVG3VT%[?6\$UU((X(Y) &E8G "CJ>?2N.\!_
M$2?Q-K&I>']9TO\ LS7=.&9H5?>CKG!*GM@E?7J"#7E'CO6/%MS\3?"ESJ/A
MF&TU&"9?L5LMTKBYQ(,9;^'GU]: /I6BN;\/:YK,FA7FH>+-*AT1K9F8J+@2
MKY2J"7)'3O\ E7"6GQ+\:>-+BZ?P+X:M6TRWD*?;-1<@2'T #+@X(..<=Z /
M7Z*\S\._%"^'BQ/"?C/1ET?5I<?9Y8Y-T,Y/0 \XS@X.2,\<&N@^(OBZX\$>
M%&UJWLH[MDF2-HY)"@ ;(SD ]\4 =917DB?&'5=5GMH_#?A"\U2$>4MU>1AS
M"CL 752%.0I)&3CITK9LOB-=#XKW'@G5--AM@59[2Y24GSAC>N01W7=^(Q0!
MZ%1574;^WTK3+K4+M]EO:Q--(WHJC)_E7*?#3QGJ7CK1+C5[S2XK"V\[RK<)
M(7,F/O'D#C) ^H- ':T444 4]2U?3M&MOM.IWUO:0D[0\\@0$^@SU/M5SJ*^
M=_CGJ?B2XN+&WO\ 0(K;3[?46^Q72W 8W/'&5_AR.>:]@\(ZMXJU-KL>)/#L
M6D+&$\@I<K+YF<[NG3''YT 4/AUX^E\=1:L\FG)9_8+@0@+*7W]>>@QTKMZ^
M;_A/XEU33!K^E^'M&;5-7N;WS KMY<,,8R"[O]3@#O77#XI>+/"WB:PTKQWH
M-G;6U^X6*[LG)5<D#/WF!P2,C@@'/ID ]BHJCK.L66@:/=:KJ,PBM+9"\C=?
MH .Y)P /4UY=IWC_ .(OC"%M1\*^%;"+2=Y6*74)CNF X.,,O\B.V3B@#U^B
MO._!?Q-?6_$$_A?Q#I9T?Q#""1 7W)+@9.T^N.>^1R#5SXE^.[CP%ING7<%C
M#="ZN?(;S92@3@G/ /H: .XHKS'3_BGJFO>);2UT+PE?7&A2W(A?5G5PFW."
MXPN,#D\G\JN^./B)=Z#XBT[POH&EKJ>O7R[UCD?9'&O."3W^ZQZC &: /0:*
M\CU;Q]X_\#Q0ZAXMT#2KG2I) CRZ9*P:(GL0Q.3^GO7IDNN:?!X?.NRW"IIP
MMA=><>GEE=P/Y=J -"BO([+Q]\0O%T+ZGX1\+V"Z.)"L4FH38>< X)&&4#T[
MC/&3@UTOP^^(2>,Q?6-Y8MIVM:<^R[M&.0.2,@_4$$=J (?"_P 0-1U_QYJW
MAZXT"2SMK'SMEXS,1+LD"#@J!R#GK^==[7#>&O'MQKOQ#\0>&9+"*&+2P2LZ
MR$M)A@.1CCK1X\^(B^%+NRT?3+!M4\07Y'V>S1L *3C<Q],@_D>0!0!W-%>0
MW_Q$\>>##;WOC/PU8_V1-*(VFT^4EH<],@L<_IG'6O6+6Z@O;2&[MI%E@GC6
M2-UZ,I&01^!H FHILDB11M)(P5$!9F/0 =Z\ETWXB>-/',][-X(T334TNVE,
M0N]3D;,I S@*I&#@@XYQD9- 'KE%><^$?B-J-_XOG\'^*-(CT[6XXS(C02;H
MI@!GCTXY')Z'H14WQ*^(\GP_N=%7[#'<07TCK,[R%3$JE,D  YX8_E0!Z!17
ME6H^,OB5<P-J^@>$+4Z.,O$ETY-S-%V;8&&W(YVX)^M=+\.O'UKX_P!!>]CM
MS:W=N_E7-N6W;6QD$'N#S^1]* .PK+\2:LV@^&=3U=81,UE;23B(MM#[5)QG
MMTKCO&7Q*NM+\26_A3PQI8U;Q!*-SQLVV. $9&X^N.>H '>N9\7>+O&FE^#M
M5L_&OA^UAM;^TFMXK[3I-ZQRLA"*ZY) )XSF@#T7P#XK?QIX1MM<DM%M&F>1
M?*63>!M8KUP/2NFKS?X%?\DHTW_KK/\ ^C&KTB@ HKR_Q#\6Y?#_ ,1)_##:
M.;I5A4P&!B99Y60%$"XP,L<9[#GVK-UKQ]\3/"]O_;.M>$M.&C@KYJ03EI(@
M2!\S!B!Z9VXR: /8J*\O;XC^(/%:C_A7NA17L*1J;B]U!O+BCD(!\H#(W, 1
MG!_Q+O!OQ-U.^\7OX0\6Z.FF:T%+1-$Q,<N!NP,D]0"002#@]* /3J*YOQOX
MST_P-H#:G?*TKLPC@MT.&F<]AZ#C)/;\A7&CQ-\7);$:LGA/25M-GF?86E;[
M25QG^]UQVQGVH ]6HKEO 7C>R\>>'_[1MH6MYXG\JYMG.3$X&>O<$'@_X5S.
MN_$S5[OQ;/X5\#:/#J>H6H/VJYN'VPPD<$<$9P>"<CG@9H ZSQWXH?P=X0O-
M<CM%NFMR@\EI-@;<X7K@^OI26?B>:\^':>*$L<S/IQO5M%<G+;"P0'&?;I7D
MOQ+\6^)D\#7V@^,]#BLKF\6-K.\LGWP2LLBLR'D[3@$]:])\'7K:;\&]+OTC
M$C6VCB8(3@,5CSC/X4 6/A[XOO/&FA3ZA?:0^ER1W!A$+LQW *IW<J/[Q'X5
MUM<A\-_&4WCKPL=8GLX[1_M#P^7&Y884#G) ]:P-9^(VNW_C6[\)^"M(MKN\
MLE)NKN]D*Q1GC(P,'@G'7KVXS0!Z=17E4?Q'\3>&?$VFZ-XZT:RABU%_+M[_
M $^1C'NR!RK$G )&>A&0<5U7C_QS:> ] %_- ]S<SR>3:VR'!D?&>3V [GZ>
MM '5T5Y%?^,?BMHVFS:YJ/A32?[,AC\V6".8^=&G<D[CT'7CC\*Z./QSJFO^
M"-/\0>#]#&I37$OES6DUPL1AQD-R>#@@?4'- '6V.KZ=J<US%87UO=/;,$F$
M,@?RV/8XZ'VKD/'GC[4/"&KZ596>@R:DE[G?*K,/*^8#LI]:\F^#FL>+=.MM
M730/#,.I127:FX=[I8O*;!XYZ\5ZSX]^(%QX.UWP[IT.GQ7*ZM.8F=Y"ICPR
M+D8'/W_TH [RBN>\<>(Y?"7@[4-<AMDN9+4(1$[%0V75>H^N:XBP^(WC'QAH
MUO=>#O#5LY$?^E7%[*5B67O'&,J6P,9/3G':@#UBBO-/ GQ-OM:\2W/A7Q/I
M TO78%+!4/R28 ) !S@X.X<D$=_78^(OC^+P)IEJ\=FU]J-]+Y5K;!MH8C&2
M3Z#(X'4D4 =G17D^I>*_BIX>TR76]5\.Z'-IT*^9-;VTSB:).Y)R0<>P-=_X
M5\26?BWPW9ZW8JZPW*D['^\C D,I^A!H P?A_P"/9?&T^MQR:<EI_9MP( 5E
M+^9DMST&/N_K7;UXQ\!?^/[QI_V$%_G)7L] !17,>._&^G^ ] .I7JM-+(WE
MV]LAPTK]<9[ =2?ZD"N/MO%GQ6-L-7G\&Z>^G%/-^QQS%;G9^+'YL=MN?;M0
M!O>&?B!+X@\?Z_X9;3D@32MV+@3%C)APOW<#'7/6H]1\?ZA8_$VU\*)H$DMI
M,4W7X=L+N4GIMQQC'6N$^$&J6VM_&#Q?JEF7-O=1-+'O7:P!D4X(]:[W4_']
MQ8?%C2_!JV$3PWL'FFY,A#+PYQMQC^#]: .[HKB_B#X_3P7#86UK8MJ.KZE)
MY5G:*V-QR!DGTR0,=\URFJ^.OB;X3LFUCQ#X7TJ32D=1*+2<^9$"<#)W-W(&
M<=: /7Z*Q]-\3:9J7A2'Q(LXBTZ2W^T-)+QY:@?-N]Q@@_2O.+/XD^-O&DUS
M-X'\-6ATN"0H+O4I"/,(] &&#SG SCO0!Z_17FGAOXH7C>+%\)^,='&CZQ)C
M[.Z/NAG)Z 'G&<'!R03QP>*W?B/XPN/ _A7^V;:RCO&$Z1-')(4 #9YR >X'
MYT ==17DJ?&#5=6O+:+PWX0O-4MMT:7-]&',*.0-P4A>0I)Y..G2NE^(7Q#M
M_ ]M:0Q6CW^KWS;+2S0X+'(&3UXR0 .I/XD ':UQ'P]\>R^.)-9633DL_P"S
MK@0#;*7\S.[GH,?=K"'C'XDZ)#_:OB3PI8MHZX>X%C-F>WC[L1N.[:.OT[=:
MR?V?)H[C_A+9X6W127R.C$8R#O(.* /:J*\X\1_$?4O^$L?PGX.T=-5U>)=U
MS+,^V&WXZ$\9ZC/(ZXY/ R[GXC^+_!=_9#QYH5BFF7<GEB_TUV*Q'_:4DY]<
M<< XSB@#UNBN=\;>))?"_@N^UZTMX[MK94<1L^U65G49R/8YKSX?&O4]3L;8
M^&_"%WK%UY*/>- ',4#L,E 0I)(X]/QH ]CHK@_&_P 0YO#,VE:3INEMJ/B#
M5 #!:;]JH.F6/UR.W0Y(Q7-:K\0?B)X,@CU+Q7X9TR32FE$;O8S'?'GIG+-_
M+'N,T >PT55TW4+?5M+M-1M'WVUU"LT3$8)5AD?SJU0 4444 %%%% !1110
M4444 %%%% "-]T_2L<=*V&^Z?I6..E !1110(**** .#\5_$^W\+>)AH0T&_
MU&Y,*S VSCD,,_=P3QBLO_A<LG_0BZ_^7_V%4[K5++3/VB;N_P!1NX[2UM-)
MR\LKX ^0=/4_-T'-=5IWQ>\&ZIJ"V4&MO'*[;4:XB:-&/LQX'XXH ZFRO!>:
M7;7[QM;+- L[),<&(%<D-]._TKSF7XO76H7MU'X3\(WNN6EJ2);H%E!_W0%/
MX9Y]JV_BYJ,NF?#+6'C)62?9;9]G8;O_ !T$?C5SX;:=%I/PYT."%0ADMEN9
M"O\ $[_,2?P('X4 +X,\<Z9XVLYY+2.6UO+5MMS9S_?C[ Y[C.1['K73UY#-
MMT#]I>$6P"1ZS:9F4=&9T.3_ -](#]:]>H BN;F&RM)[RY;;;V\;2RMZ*HR?
MY5S?P]UO5?$OA1=:U7RU:[N)#;1QQA-D(.%!]3D'GZ5E_&756TOX:7RQMMDO
M9([4?[I.YOT7'XUU/AG3QI/A31]/4 ?9[.)3CUV@G]2: (_$?BC1_">F&^UB
M[6%"#Y<0YDE/HJ]3]>@K-\"^.K3QW8WEW:6,]HMK*L9$L@8L2"<C XZ5'=_#
MG1=7\;R^)M7W7LFQ%@M''[J/:N,L/XN><<#ZUR7P%_Y!?B3_ +""]/\ =:@#
MU#5-3LM%TNYU+49Q!:6R;Y)",X'H!W). !W)KS0?&/4[BUDU6Q\":A/H4;$-
M>&0AL#J>%*\?B!ZTWX\7<CZ)H>BQN4&H7Q+X[A0 ,_B^?PKU2TM(=-L[>PMX
MU6WMHEA2,#C:HQC% &;X:\2:;XLT.+5M+D9H')5T<8>)QU1AZ\_B#FM:O(?A
M6HT7XD>-?#<1Q:QRF6&//"[9"!C_ ("WZ"O7J "O//B%\5[;P-J,&FP:>FHW
MK)YDZ-*4$*G[H) /)ZX[#'K72^,O%5KX-\,W&KW.UY%_=VT)/^NE(^5?H.I]
MA7C'BWPQ=:3\(Y==UEFDU_6M2AN+IW^\B%9"J>WJ1[@=J /?M/G-_IUG=$"(
MW,"2X'.PNH/XXS^E<M\/O$]]X@L]4L]8\O\ M?2KU[:X\M-@9<G:P7MT8?A7
M1:'_ ,BYI/\ UXP?^BUKSNVE_L']HN[M%;;!KUBLA7UD"Y!_.-O^^J /4J**
M* "BBB@ JY'_ *M?I5.KD?\ JU^E1/8N ZBBBLBPHHHH **** ,SQ#J_]@>'
M[W5OLDUW]F0/Y$/WWY P/SS7FW_"\_\ J2M;_P _\!KUP'!XIV\]W('<D]*I
M-"=SR?3?C?:W_B#3M'E\,ZE:37TZ0HTS@8W-MW8(&17JQX->)>#'/Q$^-.J>
M*Y<R:9HX\JR#<C/*IC_Q]_J17MM$K A0,D"N*\#>*;[Q9JOB2ZWQ_P!C6EX+
M2P"Q@,Q4?,Q;OG@CZUK>-M6?0O VMZE&<2PVC^6?1V&U3^9%87P;T\:?\+-(
MX^>Y\RX?CJ6<X_0"A;7#J5O%7Q8A\,^*I/#Z>']0U&Y2)9<VS Y!&>%P3Q69
M_P +JG_Z$/7_ /O@_P#Q-9W]J6&D_M&:_JFJ7D5I9VFFKNEE? R4B  '4DYZ
M#FNRTGXO^"M8U%;&WUDQ3.VV,W$31*Y[ ,>!^.*JWD*YV%G<&[L;>Y,3Q&:)
M9/+?[R;@#@^XSBIJ#G//6BLRADLL5O!)/-(L<,2%Y'8X"J!DDGT KS+PC\88
M_&'CIM!M-)$=DPE:*[:8[W5 2"4QQG'3/%1?$;5;OQ7XBM/AOH4Q5[@B75[E
M#_J(1SL/X8)'?*CN:RM,TZUT?]I"#3;&(16EKI0BB0=E$/ZGN35I::DMZG>?
M$C7M6\+^%1K>E>6PM+F(W4;QAO,A)VD#T.2.:ZBTNH+ZR@O+9]]O<1K+$WJK
M#(/Y&J/B72TUKPMJVF.,BYM)(Q[-M.#^>*X_X(ZNVJ?#2UAD),NGS26ASUP,
M,OZ-C\*70?4]$HHHJ1A1110 4444 %0R??-35#)]\UO0^(SJ_",HHHKK.<**
M** "N/\ B%X_M? 6E03O;B[OKE]L%KOV[E'WG)P< <#W)^M=-J6HVFCZ9<ZE
M?S"&TMHS)*Y[ =AZD] /4UXM'8WGBSPSXN^(VM1;#-I\T&D6[#(AA *EA^HS
MW)8]Q42=M$5%'J?@GQ*WB_PE::X]HMHUPTB^2KEPNUBO4@=<5R>J?&*'3_$6
MI:+!X8U2_FL)FBD>V8,#@XW8"G /O6A\%!GX5:0/^FL__HUJY'P=XCTCPYX_
M^(6K:Q?I9P&\\I-QRSMYCG"J.6/':DV[(=M6;</QCEEFCC_X0;7EWL%W%>!D
M_P"[7J##:Q&<X.,URGA_XG^%?$]\MCINKM]K?A(;A&B:3V7/!/MG-=53CZDL
M*X^T\37^I_%6^T"T>(:5I=D'NSY>7:=NBANP&1_WR:Z]Y$AC>:3[D:EV^@&3
M_*O+?@COU'3_ !'XCG!\_4]3)+'J0!NQ^;FB6Z0+8]/N+B"TMI+FYFC@@B7=
M)+*P54'J2>E<%I/Q>T/7?&\'AO2[:YN%G=D2^)"QDA2Q(4C..,=JW?&?@VU\
M;6%E87UW-!:07(GE6'[TH"D;<GIUZX->:S:/IV@_M&>&=.TNTCM;2*S&R-!Z
MQRY)/4D^IYI2;3&DCVZN7\9>/]#\$6F_4)O-O'&8K*$@RO[G^Z/<_AFNH'!!
MKR_7OAMHVE:1XO\ $ESNO]5N;>ZN(Y)A\MON!("+ZC.-Q_#%5*_02MU.T\(>
M)H?&'AN#6K>VDMHIG=!%(P8C:<9R*W*\^^"7_)*]/_Z^)_\ T.O0:(NZ![G-
M>,_& \'6-K='2;O4OM$ICV6W5,#.3P:XW_A>"_\ 0EZW^?\ ]C7K 8KT)'T-
M4->UV/P[H%_K%T[&*SA,FW=]YNBK^)('XTFGO<::./\ !GQ2M/&7B&;18]&O
M+&XB@:9C/(#C:0,$8!!YJ]?>)[[2OBGIV@W;1'2=5LR;0^7ADN%/(+=P<?\
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M:D[9EFM4$A_VU^5OU&?QK<K1.ZN(****8!2CK24HZU%3X6)BT445R$A2@$G
MZTE4-<TPZUH-_I8G-O\ ;(&A\X#)0'J<=Z .,\3_ !B\.>'-273X$DU:X!VR
M_9)%"1'TW'AC].GK7H78'U ->#?%'P7HO@WP?H=OI5N?,DO_ -]<R\RRD)W/
M8>PXKWD?=3_=7^5!32LK&=K>O:7X<TUM0U>]CM;=<X+'+.?[JKU8_2N?\#?$
M2Q\>3:C'96%Q:BR5&+3.K;PQ(' Z=/>I=:^'>D>)_&%MK>LM)<Q6\"0QV/2,
MD,3N8]\YZ<=.:XWX.JJ>-?'B(JHBW "JHP !+)@ =A0%E8]1U?5['0=)N-4U
M*<06ENNYWQDGL !W)/ %>>VWQ3\0:M"U]H?P^O[S2P2!<-*0S@=< +@_AGGB
MKWQFT34=;\ E=-1Y7M+E;B6&,9:2,*0<#OC.?SJWX:^(WA"7PQ8$ZQ9Z<UO;
MI%):3OL>%E4 J%[CC@CK]: 2TN7_  ;X[TKQK!/]C2:UO;8_Z19S_?CYQD'N
M,\>H[BNGKR#P$C>(_C!KWC#3;:2'0WC>))G0H)W8*.![[2Q].,\FO7Z!25F9
M^O:M#H7A_4-6GQLM(&EQ_>8#Y1^)P*I>#+[5-4\':9J.L/&U[=Q>>WEQA%"L
M?E&![8_.N/\ CA>2#PIIVC0L!)JE^D;?[J\_^A%?RKTJ"V2SMH;2, 1P1K$H
M'8* !_*@.AA>+/&FB^#+#[1JEP#.RYAM(R#++]!V'N>*/!GBRW\::"=6MK26
MUC$S0^7*X8Y !SD?6L/4/ASHJZEXA\47P:_OYXII84E'[NW_ '9Q@?Q$8ZG@
M=A5'X%?\DX/_ %_2_P EH'96.W\0:_I_AC19]6U24QVT6!A1EI&/15'<G_Z]
M>>?\+BU2.T75I_ FH)H+GY;P2$G;V;E=N/QQ[U!\7LZOXR\&>&7/^C7%P)95
M[-N<)_(-^=>N2VT%U#)8R1J;65# T6/EV$;<8],4!HEJ4]'U>QU[2+;5--G\
MZTN%W(^,$=B".Q!X(J[7DGP+G>"V\2Z&SDI8WH9 3G&=RG_T 5ZW0)JS.0\9
M_$/3_"%Q;V M9]2U>Y ,-C;_ 'L'@%C@XR>@ )-8@^*]WI-Y;Q>,/"5[H=O<
M-MCN@QD0?4$#].?:L;1O+'[36K_VA@3&%_L6_P!?+3;M]]F[]:[+XL"V/POU
MK[9LVA4,._\ YZ[QMQ[]?PS059:(ZJX\Z?3YCI\T?GR0EK:7 =-Q7*-Z$9Q7
M._#WQ1+XL\)Q7UX%74897M[Q%7:!(IZX[9!'ZU2^#]_+>_#'27D8E[=I( 3_
M '5<[?R! _"L3P4XT/XR>,/#J\6]V!?0KG@-PW\I#^5 K;H]1HHHH)"I(/\
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MX "@]\ <GU)KR+X32>*],E\0:OX;M(=4A2Y$5WIDDGELX^8JZ,>,CD8]#W[
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MW7A4>(+2V!2TN[6Y"G9V4\$X';(! ]: *7Q7 LOC+X&O;0!;R66.-RO!91,
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M(Q)=W-J\<2%@NYB.!D\"@#F_@>BI\)=(*J 6:=F/J?-<?T%<EXQ_Y.6\*_\
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M"\ADE+()%?AG+#E21T- '&? 7_C^\:?]A!?YR5[/7F?PE\(ZWX6NO$SZQ:+
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M,2Z?J2YLY%2=XR<"95A5@OT)'/T->J>,?"&A:MX-U"RDTVSA6&UD>WDCA5#
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MH2I]B <]QP<]:]M(P2/2O(O#W@KQ3XE\>6_C/QPD-I]C -EIT3 E2,E<X)P
M3GKDGT%>N4 >:_'>)Y/A=<,HR(KN%V]ADC^9%=SX?F2Y\,Z3/&<I)90LI]B@
MJ#Q9H@\2>$=5T?C==6[+'GH)!RA_[Z KG?@]JIU/X:Z=')D7%@SV4JGJI0\
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MRB@"CH^D66@Z/:Z5I\7E6EK&(XTSGCU)[DGDGWJ]110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (WW3]*QQTK8;[I^E8XZ4 %%%% @
MHHHH **** "BBB@ HHHH 4$JP8=0<BLK1/#VG>'8KN+3(Y(HKNX:YDC:3<HD
M;KM'\(]O:M2B@ HHHH **** "BBB@ HHHH 4$@Y!P1WK*T#P[IOAFPDLM+BD
M2*29IY&ED+N[MC)+'KT%:E% !1110 4444 %7(_]6OTJG5R/_5K]*B>Q<!U%
M%%9%A1110 4444 %%%% !1110 5E6/AS3=.U_4M;M8Y([S4@@NOWAV.5& =O
M0'W]SZUJT47 **** "BBB@ HHHH R?$7AO3O%.GQV&JI+):I,LQCCD*!V7.
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MBB@!&571D90RL"K*1P0>"*SM!T'3_#6DII>EI*EG&[.B22%RI8Y(!/;-:5%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 C?=/TK''2MAONGZ5CCI0 4444""BBB@!RQNPRJ,1Z@4ODR_P#/
M-_\ ODUXIXLT!/%_QV&BW%Y>6UM_9JR,UL^#E4SWX[UK_P#"B]$_Z#^N?]_4
M_P * /42,'!ZTJJS'"J2?855L;5--TNWLT=Y([2!8U=SEF"KC)/KQ7@7C?5?
M''BWPK=>(;V)M%\.VSI]GM 65YV9@H8]VQDG)P/04 ?0Q!!P1@BBL'P.S/\
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M/-7J1SVJ')WLAV5KGJQ4KU!'U%)7.>#O!MIX+LKJUL[Z\NUN)!(S73 E2!C
MQVKG/&>K^--5\3-X1\)6GV9/*1[K5VSB)7&< ]%X],L>V*;E9:A:YZ.59?O
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MMGXE\2.VFVD]SY-GID99"BE2V\KU[8RW/L!0!]045';_ /'K!_US7^0J2@
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M>^*XK]HC_CQ\,_\ 7\W\EKJOC1H=WKOPUOH[*-I)[9TNA&HR653\V/P)/X4
M8_P[^%'AX^$K/4M=L(]4U/48ENII;DE]N\;@!^!&3U)SS7.W=L?A%\7]*ATB
M25/#VO,J2V;.65&+;3C/]TE2#UP2*] ^%_C'2?$'@?3(XKN%+NSMDM[BW9P&
M0HH7.#V(&0??V-<#XXN[?Q_\:/#.BZ+(EU'I;^;=SQ?,B8<,XSTX"@?5L=:
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MT#P/K6BWG@>\EM]:EN.+2WN#)@<;2.21D\8)YS[&OI2(N84,H D*C<!T![T
M/KS/X\_\DKO/^OB'_P!#%>F5YG\>?^25WG_7Q#_Z&* .H^'O_).O#G_8.@_]
M %<#^T=_R(FG?]A%?_1<E=]\/?\ DG7AS_L'0?\ H K@?VCO^1$T[_L(K_Z+
MDH AT^]^-HTVU%MI>B&#R4\LLRY*X&,_/Z5UW@FX^(LVJW"^,;+3H+$0YB:U
M(+&3<.#ACQC-,TKXI>!X-(LH9/$EFLD<"*P^;@A0#VK9TCQ_X5U[44T_2];M
MKJ[D!*Q)G) &3U'H* *7Q/\ %(\(^ ]0OXWVW<J_9K7!Y\QP0"/H,M_P&LWX
M1^&[?P]\.+2WNO*-QJ"FZNE8CG>!A3]$VC'KFN,^(8;XC?%[2?!,,CC3M.!E
MOFC/0D!F_$+M4'L6-;__  SUX*)_UFJ_^!*__$T 8/PJN#X*^*'B#P+/)_HM
MPYGLB3D$@;EQ[F,C/NE=-\??^273_P#7U#_,UY[\1?A]!\+9]#\5>&9+IDMK
ML"83N'PW5>@'! 8'\/6NV^-&I6^L?!B/4K1]UO=2V\T9]FY_.@#(\.7GQE7P
MSI2Z9IFC-8"TB%LTC*&,>P;2?GZXQ78^#[GXG2ZZ%\66.F0Z9Y3$O;,I??QM
M'#'CKVJKX2^)G@NP\':)9W7B&TCN(+&&.1#NRK! "#QV-=)IGQ$\(ZSJ,.GZ
M=KMK<7<Q(CB3=EB 3QD>@- '3T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 C?=/TK''2MAONGZ5CCI0 4444""BBB@#Q/68_$[_'O4&\.6B)<R
MVBVZWES&QAA4QH6DST)'( YY[&KGB&W^)7@2R/B%?%2Z[9P,#=VTT1 "DXR%
M/\.3U!!'%=)J'Q/BT7XB'PMK5E'86+*&AU%YCM8,N5)&, $Y7.>"*K_%/QEH
MEEX$U&PBU&VNKW4(O(A@MY5D.&(RQP3@ #\3B@#LO#^M6_B3P]8:S:J4ANXM
M^QCDHV2&4_0@BN4^-!)^%FIDG)\V#_T8*T_AMHUSH'P\TC3[U&2Y"--)&W5"
M[%@I]P"*S/C/_P DLU/_ *ZP?^C!0!O>!?\ DGOAO_L'0_\ H-;]8'@7_DGO
MAO\ [!T/_H-;] 'EOQ]N9(? %I"A^6XU!%?Z!&(_6O3+2)8+"UA085((U ]@
MHKAOC/I3:G\-+QXTW26,L=T/90=K?HV?PKK/#>H+JWA;2-04@BXLXG./7: 1
M^8- &JI.<=N>*\B^ W_(+\2?]A!?_06KUU/O?@:\B^ W_(+\2?\ 807_ -!:
M@#I?BI!X9G\%O_PE$\L$"R@VTEN TPFP>$!X.1G(/&.XXKAM+U+XS?\ "*J;
M"R$MJ(O]&GN8H_M;1X^5@I.2<8QD$_6KOQX@N(CX9U9HFFTVTN&6= ,C<2K#
M/U"D?A7I5OXP\-WVFC5H=<L%LV7?O>=5*#T92<@CIB@#B?@TGAXZ=J4^GW%W
M/KLD@.J&^7;,IR> ,GY=V><YSU[5Z=7C/PQE_M_XN^*O$VG1.FCR+(@8J5#L
M[+MX]3M+8[9KT*U\<:-=^-)_"<7VG^U(-^_,6(_E7<<-GT]J .+^(FC:SH?C
MK3/B!HED]^ELJQWMM&"6  *DX'."IQGL13]2^)A\7Z)=Z-X5T+4WU"\@>&66
MZC"16J%2'9F!/1<XZ?TK<\2?$E?"?CK3]#U&P2'3KQ%?^TVE(" Y!^7&, C!
MYZ'-7?&GCG1M \)W]RNJ6DUS- Z6L,,RNTKL, X4]!G)/M0!R/[/A/\ PAFJ
MC/ U#C_OVM2:^6LOVCO#4\1P+RR$4@]1B1?Y8_*MGX.Z#/H/P\MOM4317%]*
MUVR-P0I "9^JC/XUD31?VS^TE"RY,>BZ>K.>P;8<#\Y1^5 'JE%%% !1110
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M+:0^^YN\8$I/!(]SC:H],GVJ+QUX[/CGQ(_@[3]6M]&T*%RM_?W4@C\[:<,
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M4GFD:5D/JNXD ^X&:[&BB@ K/UK0],\1::VGZM:)=6C,&,3D@$@Y!X(-:%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 1ONGZ5CCI6PWW3]*QQTH ****!!1110!D:_X6T/Q3;)!K6G1W2QY\MR2K
MQYZ[6'(^G2LK1/AGX/\ #UXEY8:.K7*'<DMS(TI0^H!X!]\5UE%  22<GDU3
MU72=/US3I-/U2U2ZM)""\3D@$@Y'0@]:N44 0V=I;Z?9065I$(;:W01Q1J20
MBCH!GFIJ** (;NT@U"RN+*Z4-;W,30R@]U88/\ZY7X:Z7J^@^%&T75[=XVL;
MJ6.VD8@B:$G*L,'IDGCZ5V%%  #CI69HWA[1_#T<\>CZ?%9I<.))1&6.]AT/
M)/J:TZ* (KJUM[ZTEM+NWBN+:9=LD4JAE<>A!KBG^#G@.2Z\_P#L:1><^6MU
M($_+.<?C7=44 5=.TVQTBPCL=-M(;2TC^Y%"N%![GW/N>:IP^%]#M_$$FO1:
M;$FK2[B]T&;<VX8/&<<CCI6M10!F:YX>TCQ+9"SUFPBO(5.Y-^0R'U5AR*Y_
M2_A1X)TB]2[M]&\V9#N3[3,TJJ>QVG@_CFNSHH 4$%\L>,\UQ'P_T'4K*]\1
M:_K=HUKJ6L7I80N06C@7[H.#CG/_ (Z*[:B@ HHHH **** "KD?^K7Z53JY'
M_JU^E1/8N ZBBBLBPHHHH *RI_#6C7/B&#7YM/C?58%V17)9MRC!&,9QT8]N
M]:M% !7'Z_\ "[P=XDOWOK_2 +MSF26WD:(R'U8 X)]\9KL**:=@L8OA[PEH
M/A2W>'1--BM!( )'&6=\>K')/TZ5M444@%!P0:X/P#X<U#PGK_BC36M771)[
MI;S3Y]PVG</F3'48^4?\!KNZ*:86,'Q'X,\.^+$0:WI<5R\8VI,"4D4>@92#
MCVZ5EZ'\*_!GAZ^2]LM'5[F-MT<EQ(TNP^H!. ??%=E11=A9!DYSWKBM7^$W
M@K6]1:_NM&"3NVZ0V\K1*Y[DJ#C\L5VM%";06*>E:3I^AZ='I^EV<5I:1_=B
MB&!D]2>Y/N>:I7GA/0=0UZWUR[TV*74[?;Y5RS-N3:<KP#C@GTK9HHN%ADT4
M=Q#)#/&DL4BE7C=0RL#U!!ZBN''P;\!C4/MG]A\YW>29W\K/^[GI[=*[NBA-
MH+#8XXX8DBBC2.)%"HB* J@=  .@KAM'\/ZC=?%G7/%&IV;P6T$"6.F;V!\Q
M?XW !X'!Z_WZ[NBA,+!1112 **** "H9/OFIJAD^^:WH?$9U?A&4445UG.%%
M%% $-W:6U_9RVEY;Q7%M,NV2*50RN/<5Q2_!OP&MW]H_L5SSGRC<R&/\L_UK
MNZ*32>X[M$5M;6]E:Q6MI!'!;Q+MCBB4*J#T %3 D'(ZBDHIB,O1O#>C>'C<
MG2-/BL_M3AY]A8[R,X)R3ZGIZUJ444DK %</:^']0TCXOW>LV=HSZ1K%EB[D
M4C$,Z]"1G/.T=!U8UW%%#5P3,#6O!'AGQ%?"^U?1X+NZ""/S'=P=HZ#A@.]9
MW_"J_ O_ $+5K_W\E_\ BJ["BERH=V9^BZ%I?ARQ-EH]DEG;&0RF.,L07( )
MY)/0#\JY_6/A9X+UR[>[N]&6.X=MSO;2M%N)ZD@''Z5V%%/E079B>'?"&@>%
M(I$T338K5I!B27)>1QZ%CDX]NE2:[X6T+Q,+<:UIL5[]GW>5YC,-F[&<;2.N
M!^5:]%%E:PKD<L$,]L]M-$DL#IY;Q.NY67&,$'J,5Q$OP;\!S7?V@Z,Z$G)C
M2YD"?EGI^-=W10TF--HK:?IUEI-C%8Z?:Q6MK$,)%$N%'_U_>N1U[P_J&O\
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M_A)+#_GG??\ @%-_\31_PDEA_P \[[_P"F_^)K7HH R/^$DL/^>=]_X!3?\
MQ-'_  DEA_SSOO\ P"F_^)K7HH R/^$DL/\ GG??^ 4W_P 31_PDEA_SSOO_
M  "F_P#B:UZ* ,C_ (22P_YYWW_@%-_\31_PDEA_SSOO_ *;_P")K7HH R/^
M$DL/^>=]_P" 4W_Q-'_"26'_ #SOO_ *;_XFM>B@#(_X22P_YYWW_@%-_P#$
MT?\ "26'_/.^_P# *;_XFM>B@#(_X22P_P">=]_X!3?_ !-'_"26'_/.^_\
M *;_ .)K7HH R/\ A)+#_GG??^ 4W_Q-'_"26'_/.^_\ IO_ (FM>B@#(_X2
M2P_YYWW_ (!3?_$T?\))8?\ /.^_\ IO_B:UZ* ,C_A)+#_GG??^ 4W_ ,31
M_P ))8?\\[[_ , IO_B:UZ* ,C_A)+#_ )YWW_@%-_\ $T?\))8?\\[[_P
MIO\ XFM>B@#(_P"$DL/^>=]_X!3?_$T?\))8?\\[[_P"F_\ B:UZ* ,C_A)+
M#_GG??\ @%-_\31_PDEA_P \[[_P"F_^)K7HH R/^$DL/^>=]_X!3?\ Q-'_
M  DEA_SSOO\ P"F_^)K7HH R/^$DL/\ GG??^ 4W_P 31_PDEA_SSOO_  "F
M_P#B:UZ* ,C_ (22P_YYWW_@%-_\31_PDEA_SSOO_ *;_P")K7HH R/^$DL/
M^>=]_P" 4W_Q-'_"26'_ #SOO_ *;_XFM>B@#(_X22P_YYWW_@%-_P#$T?\
M"26'_/.^_P# *;_XFM>B@#(_X22P_P">=]_X!3?_ !-'_"26'_/.^_\  *;_
M .)K7HH R/\ A)+#_GG??^ 4W_Q-'_"26'_/.^_\ IO_ (FM>B@#(_X22P_Y
MYWW_ (!3?_$T?\))8?\ /.^_\ IO_B:UZ* ,C_A)+#_GG??^ 4W_ ,31_P )
M)8?\\[[_ , IO_B:UZ* ,C_A)+#_ )YWW_@%-_\ $T?\))8?\\[[_P  IO\
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MB@#(_P"$DL/^>=]_X!3?_$T?\))8?\\[[_P"F_\ B:UZ* ,C_A)+#_GG??\
M@%-_\31_PDEA_P \[[_P"F_^)K7HH R/^$DL/^>=]_X!3?\ Q-'_  DEA_SS
MOO\ P"F_^)K7HH R/^$DL/\ GG??^ 4W_P 31_PDEA_SSOO_  "F_P#B:UZ*
M ,C_ (22P_YYWW_@%-_\31_PDEA_SSOO_ *;_P")K7HH R/^$DL/^>=]_P"
M4W_Q-'_"26'_ #SOO_ *;_XFM>B@#(_X22P_YYWW_@%-_P#$T?\ "26'_/.^
M_P# *;_XFM>B@#(_X22P_P">=]_X!3?_ !-'_"26'_/.^_\  *;_ .)K7HH
MR/\ A)+#_GG??^ 4W_Q-'_"26'_/.^_\ IO_ (FM>B@#(_X22P_YYWW_ (!3
M?_$T?\))8?\ /.^_\ IO_B:UZ* ,C_A)+#_GG??^ 4W_ ,31_P ))8?\\[[_
M , IO_B:UZ* ,C_A)+#_ )YWW_@%-_\ $T?\))8?\\[[_P  IO\ XFM>B@#(
M_P"$DL/^>=]_X!3?_$T?\))8?\\[[_P"F_\ B:UZ* ,C_A)+#_GG??\ @%-_
M\31_PDEA_P \[[_P"F_^)K7HH R/^$DL/^>=]_X!3?\ Q-'_  DEA_SSOO\
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M)H_M^R_YYWW_ ( R_P#Q-;U%'(@YF8/]OV7_ #SOO_ &7_XFC^W[+_GG??\
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M)H_M^R_YYWW_ ( R_P#Q-;U%'(@YF8/]OV7_ #SOO_ &7_XFC^W[+_GG??\
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M0^1')_VO;_\ /&^_\ I?_B:/[7M_^>-]_P" 4O\ \37644>VD'(CD_[7M_\
MGC??^ 4O_P 31_:]O_SQOO\ P"E_^)KK**/;2#D1R?\ :]O_ ,\;[_P"E_\
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M[-'*?VQ;?\\;[_P"E_\ B:/[8MO^>-]_X!2__$UU=% >S1RG]L6W_/&^_P#
M*7_XFC^V+;_GC??^ 4O_ ,375T4![-'*?VQ;?\\;[_P"E_\ B:/[8MO^>-]_
MX!2__$UU=% >S1RG]L6W_/&^_P# *7_XFGQ:S:+*&,5]@?\ 3E+_ /$UU%%(
M%!(P?[?L?^>=_P#^ ,O_ ,31_;]C_P \[_\ \ 9?_B:WJ*"S!_M^Q_YYW_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img76291469_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &#",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0)LVFN[9#AKB('T+BD^W6G_/S#_WV*IIX?TM%Q]D1O=B2:=_8.E?\^47Y4]
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M6X#3%#U4$C&:FUK39]0^'NDRVT1F:V6.5HEZNF.0/PIZ"N_P+%Q;^)K73WU
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MQ)K%[!8:E'IFGV;^5Y@4-)*_?&>@J;1M7U&R\3G0=3NX[Y)8O-M[E0 W'56
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M_,/_ 'V*/MUI_P _,/\ WV*J_P!@Z5_SY1?E1_8.E?\ /E%^5&@:EK[=:?\
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MW\.B#X+LR#D9;^=;;:'ICNSM9Q%F.2?4TGN4F[(L_;K3_GYA_P"^Q1]NM/\
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MZ,]@?:M^D"84444#"DI:2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/UR0Q:+=LIP=F,U/IT2P:=
M;QH,*(Q_*G7=K'>VLEO+NV.,':<&I8T$<:QKG"@ 9H%U'4444#"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:\:2H4
MD174]0PR*=10!!]AM <_98?^_8J95"@!0 !V%+10 UT212KJK*>S#(I(X8H1
MB*-$'HJ@4^B@!&174JZAE/4$9%1?9;<1&,01>63DKL&/RJ:B@!CPQ2*%>-&5
M>0",@4TV\#2^:88S)_>*C/YU+10 UT61"CJ&4]01D&E5510JJ HX  X%+10!
M$+:!9/,$$8?^\$&?SJ6BB@!&574JZAE/4$9!J#[#:?\ /K#_ -^Q5BB@!J(L
M:A44*H[ 8%(D4:,S)&JLW+$#!/UI]% #$ACB+&.-%W'+;1C)HCACA!$<:H"<
MG:,9-/HH 9Y48E,OEKYA&-^.<?6B2&*88EC1QZ,H-/HH C^SPY0^4GR?<^4?
M+]/2I***  @$8(R#3(XHX4V1(J+Z*,"GT4 ,>*.1E9XU9E.5)&2/I3Z** (O
MLUN9/,,$>_\ O;!G\ZE(!&",BBB@");6W0,%@C4,,, @&?K3UC18Q&J*$ QM
M XQ3J* (EM;=$9%@C"M]X!1@_6I%140(BA5'  & *6B@!D<,<((CC5 3D[1C
M)H$48E,HC7S",%L<D?6GT4 ,DABF7;+&CCT90:5$2-0J(JJ.RC IU% #$ACC
M9F2-59N6(&"?K08HVE$AC4R*,!B.1^-/HH CE@BF $L22 =-R@T\ *    .@
M%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5@>)8$D>P+*"3.$/T-;]5KRQAO3#YI;]TXD7:<<BFA-718
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M]Q_M[2?^@C;?]_!1_;VD_P#01MO^_@KP[RT_N+^5'EI_<7\J+!<]Q_M[2?\
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M /7-OY4 /CE2:,21N'0]&!R#3ZR_#H T&UQ_=_K6I0)!1110,**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P _,/\ WV*^(M\G_/67_OL_XT;Y/^>LO_?9_P :/[._O?@'MUV/MW[9:_\
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MV?\ &C^SO[WX![==C[=^V6O_ #\P_P#?8H^V6O\ S\P_]]BOB+?)_P ]9?\
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M:[_T";G\A_C1_P (UKO_ $";G\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\
M0)N?R'^- &716I_PC6N_] FY_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T
M";G\A_C1_P (UKO_ $";G\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\ 0)N?
MR'^- &716I_PC6N_] FY_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T";G\
MA_C1_P (UKO_ $";G\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\ 0)N?R'^-
M &716I_PC6N_] FY_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T";G\A_C1
M_P (UKO_ $";G\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\ 0)N?R'^- &71
M6I_PC6N_] FY_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T";G\A_C1_P (
MUKO_ $";G\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\ 0)N?R'^- &716I_P
MC6N_] FY_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T";G\A_C1_P (UKO_
M $";G\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\ 0)N?R'^- &716I_PC6N_
M] FY_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T";G\A_C1_P (UKO_ $";
MG\A_C0!ET5J?\(UKO_0)N?R'^-'_  C6N_\ 0)N?R'^- &716I_PC6N_] FY
M_(?XT?\ "-:[_P! FY_(?XT 9=%:G_"-:[_T";G\A_C1_P (UKO_ $";G\A_
MC0!ET5J?\(UKO_0)N?R'^-02:/J<-W%:R6,R7$P)CB.,N!UQ2&DWL4J*U/\
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M^0_QH_X1K7?^@3<_D/\ &@#+HK4_X1K7?^@3<_D/\:/^$:UW_H$W/Y#_ !H
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M$W/Y#_&C_A&M=_Z!-S^0_P : ,NBM3_A&M=_Z!-S^0_QH_X1K7?^@3<_D/\
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M% !1110 4444 %%%% !1110 4444 %%%226\\2[I;>:-?5XRH_,B@".BBB@
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MC_KY?_T&NLKD_$__ "-7AC_KY?\ ]!J9['1AOXGR?Y,ZM_N-]*R/#7_()/\
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MD%%%%;$!1110 4444 %%%% !5K3/^0O8_P#7S'_Z$*JU:TS_ )"]C_U\Q_\
MH0I2V8X[GV5HO_()A^A_G6A6?HO_ ""8?H?YUH5\R=RV"BBB@84444 %%%%
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MM$^O:*^0O^%B^,O^ACO?S'^%'_"Q?&7_ $,=[^8_PH_LZ?=![:)]>T5\A?\
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MR%['_KYC_P#0A2ELQQW/LK1?^03#]#_.M"L_1?\ D$P_0_SK0KYD[EL%%%%
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH K:C_R#;G_KFW\J@T+_ ) =G_US%3ZC_P @
MVY_ZYM_*H-"_Y =G_P!<Q3Z"ZFA1112&%)2TE "T444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBCH,F@ HI 0>A!^E!90<%@#]: %HIN]?[R_G3NM
M!132Z@X+*#]:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(6"]2
M!]30 M% ((R#D44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M S_X4?V+J_\ T"=0_P# 9_\ "CF7<+,HT5>_L75_^@3J'_@,_P#A1_8NK_\
M0)U#_P !G_PHYEW"S*-(%5>B@?05?_L75_\ H$ZA_P" S_X4?V+J_P#T"=0_
M\!G_ ,*.9=PLRC15[^Q=7_Z!.H?^ S_X4?V+J_\ T"=0_P# 9_\ "CF7<+,H
MT5>_L75_^@3J'_@,_P#A1_8NK_\ 0)U#_P !G_PHYEW"S*-%7O[%U?\ Z!.H
M?^ S_P"%']BZO_T"=0_\!G_PHYEW"S*-%7O[%U?_ *!.H?\ @,_^%']BZO\
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M=% ^@I:O?V+J_P#T"=0_\!G_ ,*/[%U?_H$ZA_X#/_A1S+N%F4:*O?V+J_\
MT"=0_P# 9_\ "C^Q=7_Z!.H?^ S_ .%',NX691HJ]_8NK_\ 0)U#_P !G_PH
M_L75_P#H$ZA_X#/_ (4<R[A9E&BKW]BZO_T"=0_\!G_PH_L75_\ H$ZA_P"
MS_X4<R[A9E&BKW]BZO\ ] G4/_ 9_P#"C^Q=7_Z!.H?^ S_X4<R[A9E&BKW]
MBZO_ - G4/\ P&?_  H_L75_^@3J'_@,_P#A1S+N%F4:*O?V+J__ $"=0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4-W_QYS_]<V_E4U0W?_'G/_US;^5 %'P[
M_P @*U_W?ZUJ5E^'?^0%:_[O]:U*;W$M@HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"MJ/_ "#;G_KFW\J@T+_D!V?_ %S%3ZC_ ,@VY_ZYM_*H-"_Y =G_ -<Q
M3Z"ZFA1112&%)2TE "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &;KY(T.Z(.#M_K5"'P?X;E@CEDT2
MQ9W4,S&$9)(Y-7_$'_("N_\ <_K5RT_X\X/^N:_RJDVEH+J9'_"%^&?^@%8?
M]^%H_P"$+\,_] *P_P"_"UNT4<\NX61A?\(7X9_Z 5A_WX6C_A"_#/\ T K#
M_OPM;M%'/+N%D87_  A?AG_H!6'_ 'X6C_A"_#/_ $ K#_OPM;M%'/+N%D87
M_"%^&?\ H!6'_?A:/^$+\,_] *P_[\+6[11SR[A9&%_PA?AG_H!6'_?A:/\
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M_?A:/^$+\,_] *P_[\+6[11SR[A9&%_PA?AG_H!6'_?A:/\ A"_#/_0"L/\
MOPM;M%'/+N%D87_"%^&?^@%8?]^%H_X0OPS_ - *P_[\+6[11SR[A9&%_P (
M7X9_Z 5A_P!^%H_X0OPS_P! *P_[\+6[11SR[A9&%_PA?AG_ * 5A_WX6C_A
M"_#/_0"L/^_"UNT4<\NX61A?\(7X9_Z 5A_WX6C_ (0OPS_T K#_ +\+6[11
MSR[A9&%_PA?AG_H!6'_?A:/^$+\,_P#0"L/^_"UNT4<\NX61A?\ "%^&?^@%
M8?\ ?A:/^$+\,_\ 0"L/^_"UNT4<\NX61A?\(7X9_P"@%8?]^%H_X0OPS_T
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M_?A:/^$+\,_] *P_[\+6[11SR[A9&%_PA?AG_H!6'_?A:/\ A"_#/_0"L/\
MOPM;M%'/+N%D87_"%^&?^@%8?]^%H_X0OPS_ - *P_[\+6[11SR[A9&%_P (
M7X9_Z 5A_P!^%I?^$,\,_P#0"L/^_"UN44<\NX61A_\ "&>&?^@%8?\ ?A:3
M_A"_#/\ T K#_OPM;M%'/+N%D87_  A?AG_H!6'_ 'X6L'5]&TO1O%/APZ?8
MVUIYERPD,2!=V%X!KNZ\^^)<S03:1+'S)%(T@ Z\ 5%2<N75G5@X\U9+O?\
M)GH-%5["Z2^L+>ZC(*S1AQCW%6*9SM6=F%%%% @HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 5M1_Y!MS_ -<V_E4&A?\ (#L_^N8J?4?^0;<_]<V_E4&A?\@.
MS_ZYBGT%U-"BBBD,*2EI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%_WP*+H.5]SDO^$HU#^]#_WQ1_PE&H?WH?\ OBNM^Q6O_/O%_P!\"C[%:_\
M/O%_WP*+H.5]SDO^$HU#^]#_ -\4?\)1J']Z'_OBNM^Q6O\ S[Q?]\"C[%:_
M\^\7_? HN@Y7W.2_X2C4/[T/_?%'_"4:A_>A_P"^*ZW[%:_\^\7_ 'P*/L5K
M_P ^\7_? HN@Y7W.2_X2C4/[T/\ WQ1_PE&H?WH?^^*ZW[%:_P#/O%_WP*/L
M5K_S[Q?]\"BZ#E?<Y+_A*-0_O0_]\4?\)1J']Z'_ +XKK?L5K_S[Q?\ ? H^
MQ6O_ #[Q?]\"BZ#E?<Y+_A*-0_O0_P#?%'_"4:A_>A_[XKK?L5K_ ,^\7_?
MH^Q6O_/O%_WP*+H.5]SDO^$HU#^]#_WQ1_PE&H?WH?\ OBNM^Q6O_/O%_P!\
M"C[%:_\ /O%_WP*+H.5]SDO^$HU#^]#_ -\4?\)1J']Z'_OBNM^Q6O\ S[Q?
M]\"C[%:_\^\7_? HN@Y7W.2_X2C4/[T/_?%'_"4:A_>A_P"^*ZW[%:_\^\7_
M 'P*/L5K_P ^\7_? HN@Y7W.2_X2C4/[T/\ WQ1_PE&H?WH?^^*ZW[%:_P#/
MO%_WP*/L5K_S[Q?]\"BZ#E?<Y+_A*-0_O0_]\4?\)1J']Z'_ +XKK?L5K_S[
MQ?\ ? H^Q6O_ #[Q?]\"BZ#E?<Y+_A*-0_O0_P#?%'_"4:A_>A_[XKK?L5K_
M ,^\7_? H^Q6O_/O%_WP*+H.5]SDO^$HU#^]#_WQ1_PE&H?WH?\ OBNM^Q6O
M_/O%_P!\"C[%:_\ /O%_WP*+H.5]SDO^$HU#^]#_ -\4?\)1J']Z'_OBNM^Q
M6O\ S[Q?]\"C[%:_\^\7_? HN@Y7W.2_X2C4/[T/_?%'_"4:A_>A_P"^*ZW[
M%:_\^\7_ 'P*/L5K_P ^\7_? HN@Y7W.2_X2C4/[T/\ WQ1_PE&H?WH?^^*Z
MW[%:_P#/O%_WP*/L5K_S[Q?]\"BZ#E?<Y+_A*-0_O0_]\4?\)1J']Z'_ +XK
MK?L5K_S[Q?\ ? H^Q6O_ #[Q?]\"BZ#E?<Y+_A*-0_O0_P#?%'_"4:A_>A_[
MXKK?L5K_ ,^\7_? H^Q6O_/O%_WP*+H.5]SDO^$HU#^]#_WQ1_PE&H?WH?\
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M_"4:A_>A_P"^*ZW[%:_\^\7_ 'P*/L5K_P ^\7_? HN@Y7W.2_X2C4/[T/\
MWQ1_PE&H?WH?^^*ZW[%:_P#/O%_WP*/L5K_S[Q?]\"BZ#E?<Y+_A*-0_O0_]
M\4?\)1?_ -Z'_OBNM^Q6O_/O%_WP*/L5K_S[Q?\ ? HN@L^YY;?32VVK0:AI
MI6WO+B41M'$,)+GN5KO]ISCN.N/6N7UV^L(?&D37#1PVFEP&5L+RTC= !W-2
M1:?K'C >?-)+I6F#YH(U_P!;(>S-[5A=7=CU.23IQ=1]-W^"\]"WXINKRRT"
M6>R?RW#!9' Y5#P2/>LG1;E=$M\62Q,\OS23R#<\A/J:GGOKJRCET+Q,H N$
M,<%^H_=R>F[T/2M?P.\-]X;BCGAB:>U8P2$J#G:>#^5.+7-J17A-4-'I?IU7
M3[BM_P )1J']Z'_OBC_A*-0_O0_]\5UOV*U_Y]XO^^!1]BM?^?>+_O@5M='G
M<K[G)?\ "4:A_>A_[XH_X2C4/[T/_?%=;]BM?^?>+_O@4?8K7_GWB_[X%%T'
M*^YR7_"4:A_>A_[XH_X2C4/[T/\ WQ76_8K7_GWB_P"^!1]BM?\ GWB_[X%%
MT'*^YR7_  E&H?WH?^^*/^$HU#^]#_WQ76_8K7_GWB_[X%'V*U_Y]XO^^!1=
M!RON<E_PE&H?WH?^^*/^$HU#^]#_ -\5UOV*U_Y]XO\ O@4?8K7_ )]XO^^!
M1=!RON<E_P )1J']Z'_OBC_A*-0_O0_]\5UOV*U_Y]XO^^!1]BM?^?>+_O@4
M70<K[G)?\)1J']Z'_OBC_A*-0_O0_P#?%=;]BM?^?>+_ +X%'V*U_P"?>+_O
M@470<K[G)?\ "4:A_>A_[XH_X2C4/[T/_?%=;]BM?^?>+_O@4?8K7_GWB_[X
M%%T'*^YR7_"4:A_>A_[XH_X2C4/[T/\ WQ76_8K7_GWB_P"^!1]BM?\ GWB_
M[X%%T'*^YR7_  E&H?WH?^^*/^$HU#^]#_WQ76_8K7_GWB_[X%'V*U_Y]XO^
M^!1=!RON<E_PE&H?WH?^^*/^$HU#^]#_ -\5UOV*U_Y]XO\ O@4?8K7_ )]X
MO^^!1=!RON<E_P )1J']Z'_OBC_A*-0_O0_]\5UOV*U_Y]XO^^!1]BM?^?>+
M_O@470<K[G)?\)1J']Z'_OBC_A*-0_O0_P#?%=;]BM?^?>+_ +X%'V*U_P"?
M>+_O@470<K[G)?\ "4:A_>A_[XH_X2C4/[T/_?%=;]BM?^?>+_O@4?8K7_GW
MB_[X%%T'*^YR7_"4:A_>A_[XH_X2C4/[T/\ WQ76_8K7_GWB_P"^!1]BM?\
MGWB_[X%%T'*^YR7_  E&H?WH?^^*/^$HU#^]#_WQ76_8K7_GWB_[X%'V*U_Y
M]XO^^!1=!RON<E_PE&H?WH?^^*/^$HU#^]#_ -\5UOV*U_Y]XO\ O@4?8K7_
M )]XO^^!1=!RON<E_P )1J']Z'_OBC_A*-0_O0_]\5UOV*U_Y]XO^^!1]BM?
M^?>+_O@470<K[G)?\)1J']Z'_OBC_A*-0_O0_P#?%=;]BM?^?>+_ +X%'V*U
M_P"?>+_O@470<K[G)?\ "4:A_>A_[XH_X2C4/[T/_?%=;]BM?^?>+_O@4?8K
M7_GWB_[X%%T'*^YR7_"4:A_>A_[XH_X2C4/[T/\ WQ76_8K7_GWB_P"^!1]B
MM?\ GWB_[X%%T'*^YR7_  E&H?WH?^^*/^$HU#^]#_WQ76_8K7_GWB_[X%'V
M*U_Y]XO^^!1=!RON<E_PE&H?WH?^^*/^$HU#^]#_ -\5UOV*U_Y]XO\ O@4?
M8K7_ )]XO^^!1=!RON<E_P )1J']Z'_OBC_A*-0_O0_]\5UOV*U_Y]XO^^!1
M]BM?^?>+_O@470<K[G)?\)1J']Z'_OBC_A*-0_O0_P#?%=;]BM?^?>+_ +X%
M'V*U_P"?>+_O@470<K[G)?\ "4:A_>A_[XH_X2C4/[T/_?%=;]BM?^?>+_O@
M4?8K7_GWB_[X%%T'*^YR7_"4:A_>A_[XH_X2C4/[T/\ WQ76_8K7_GWB_P"^
M!1]BM?\ GWB_[X%%T'*^YR7_  E&H?WH?^^*/^$HU#^]#_WQ76_8K7_GWB_[
MX%'V*U_Y]XO^^!1=!RON<E_PE&H?WH?^^*/^$HU#^]#_ -\5UOV*U_Y]XO\
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MQ1_PE&H?WH?^^*ZW[%:_\^\7_? H^Q6O_/O%_P!\"BZ#E?<Y+_A*-0_O0_\
M?%'_  E&H?WH?^^*ZW[%:_\ /O%_WP*/L5K_ ,^\7_? HN@Y7W.2_P"$HU#^
M]#_WQ1_PE&H?WH?^^*ZW[%:_\^\7_? H^Q6O_/O%_P!\"BZ#E?<Y+_A*-0_O
M0_\ ?%'_  E&H?WH?^^*ZW[%:_\ /O%_WP*/L5K_ ,^\7_? HN@Y7W.2_P"$
MHU#^]#_WQ1_PE&H?WH?^^*ZW[%:_\^\7_? H^Q6O_/O%_P!\"BZ#E?<Y+_A*
M-0_O0_\ ?%'_  E&H?WH?^^*ZW[%:_\ /O%_WP*/L5K_ ,^\7_? HN@Y7W.2
M_P"$HU#^]#_WQ1_PE&H?WH?^^*ZW[%:_\^\7_? H^Q6O_/O%_P!\"BZ#E?<Y
M+_A*-0_O0_\ ?%'_  E&H?WH?^^*ZW[%:_\ /O%_WP*/L5K_ ,^\7_? HN@Y
M7W.2_P"$HU#^]#_WQ1_PE&H?WH?^^*ZW[%:_\^\7_? H^Q6O_/O%_P!\"BZ#
ME?<Y+_A*-0_O0_\ ?%'_  E&H?WH?^^*ZW[%:_\ /O%_WP*/L5K_ ,^\7_?
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M&U-QR0.PJ>B@+NUN@4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;<=N*Q4FGN>E.C"=-/EM=JUM=/,LOXZUK49)Y=$TE9;2#[SODG'K_P#6K?\
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MEQD%"M*,59!1115G,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(CT)QQ^5:$WB37-)UBWA\36-I+%)C!6,$J">JGV]*+"YG<],!! (Y!I*%(9
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M/<X"1L,'&<Y([5W!52<D GZ4M"A9ZO8*N+YXR48V<MPHHHK0XPHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BN/^/67_ '#_ "J6
MB@#S'X9HZZS?[HY%'E#ED(_B-:FO:YXCT#Q#YK0_:=(8Y58XLG&.03V(KN0J
MCH /H*4@$8(S57UN0HV5KGEDWV_QWXFM)DL9;:R@P&>08PH.3^)]*M^+]-OM
M*\56_B"TMFGA&TL%&=K#C!]B.]>C@ #  'TI2,]:.8.0\IU6ZU#Q[J5G!:Z;
M-;PQ??>0'"YZDGZ5ZE!$(((X@<A%"@_08IX '0 ?2EI-W&HVU"BBBD4%%%%
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M:(-3OAJ:IO\ M#3$AFQR"O3%-RULB(T5RJ4W:^Q:\#:A=ZEH<LU[<-/(+F1
MS8Z \"NFKB/ Q;_A"[TGA_-FSCUQS6?X.T$Z[H(EU"^NVMED=8H8YBHSGEB>
MI-3&3LD;5J,7.<F[)/L>CT5Q.BO<^'_&3^'VN9;BQGA\Z#SFW-&>XSZ=:@MX
MY_&GB+45N;N>'3+%_*2"%RF]O4D4^?[S/ZM9MM^[:]_7R.]K&U:PU>ZU2QFL
M-1%M:Q-FXB*Y\T9Z5S5[%/X)UK3Y+2[GFTV\E$,L$[E]I[$$U<\6.X\5^&0L
MCJK3G(5L \=Z3EIJ5"BU).+NFGT[+L=E17#_ ! -Q]KT-+:=H97N2JL#P"<<
MGUJ#Q'X9_L?19]8M-4O_ +?;CS&E>8D2'//':FY-7TV)AAXR46Y6YMM#M-4U
M!-*TNYOI$9T@0N57J:32K\:II5M?",QB>,.$)R1FN7\06\>L^!X]6NMXN8K3
MS5V.0NX@9R.]6_!6C6MII%IJ,1E\^XMU\S=(2OKP.@HYGS6!TH*BY-^]>QU-
M%%%6<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %(S!5+,< #)-+1U&#0!PMIJ_B/Q1<W4NCS6UE8P2&-&E3<TA%:GAO
MQ#<WCW]CJL:1WU@?WK1_==?45H:WK-CX<TQ[F4*I_P"6<2#!D;T K)\&Z3=Q
MB\UG4UVWFHG<8O[B=A6>JE:YW2<)4I2<4ET[W_4?9>*[FXGL9IM/$>G7\IBM
MY1)E\\X++V!Q74UBVGA72K*_6[BBDW(Q:*-I"8XF/4JO05M54;]3GK.FW^[1
MQ&O7.JW'C>VTFRU26SBEMRY*J",C/8U;/AOQ%_T-EQ_WX6LKQ#]O_P"%C6?]
ME^3]L^RG9Y_W,<YS6F!X[W+DZ3MW#=][IGFHZNYV.ZA#E<5IUM_D=9&K+&JL
MVY@ "WJ?6G5QWQ&>2/PPC*[*_GIRK8J&Z\'^=HS7TVJWS:D(O-\X2D*"!G 7
MIBJ<G>R1S1H1<%.4K7=MCMZ*Y'2/$5P/A[_;%T?,N(HFY/\ $1P,_I5/0_"_
M]MZ5%JNJZA>O>W0\Q6CF*"('H !1S7V#ZORW<W9)V[ZFCHNHWEQXTUNTFN'>
MW@V^5&<83('2NIKA/!\=S#XPUR*[F\Z= JM*1RX[$^^,55TO3I]9\5^(+:2^
MN(K)9P94CD(+GL,]A]*2D[&M6A%R>MDDOT/1:*X"^MG\%Z]ILME=W#V-Y+Y,
MUO-(7 /J,_6K6O7%YK7BV#PY!=26EJL7G7#Q'#./[H-/G,_JUVFG[K5[^FYV
MM96OV>IWVG"+2;X65QO!\TC/'<5RVOZ%)X5L/[9T6]NE>W(,L,LI=9%SSG-6
M?&M\;SP'%>1,\?G-$_RM@C)I.6C3*IT??A*#NF[;=?0[&W22.VB29]\JH [_
M -XXY-25R'C-V3X?NX=U(CCY5L'MWJO#X0_M#1([R]U2]:^:$,LB2D+'QP M
M/F=[)$1HQ<>>4K:VV.V)PI/H*R?#^O)X@M9[B.!X4BF:(!SDG'>L+PUN\4>"
MS!JLLLACE9#(CE6;:>,D50\ :+:744FHR&;S[>[=4VR$+@<#(Z&ES-M6+]A"
M,)\[U3M_7J>AT445H<84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M2EI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#(\3Z,==T&>Q1@LIPT;'H&'(KG;'Q7JFDVB66K:%>-/"H020+N5P.E=S14N
M.MT;PK)1Y)JZ.)T^UU/Q)XFM]:U"S:RLK,'[/#)]]F/<U)XW@FFU/P^8H9)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img76291469_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ')!P@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MJ&:YB@8*Y()&>!FA*X$U%5?M]O\ WF_[Y-'V^W_O-_WR:?*^PKHM455^WV_]
MYO\ ODT?;[?^\W_?)HY7V"Z+5%5?M]O_ 'F_[Y-'V^W_ +S?]\FCE?8+HM45
M5^WV_P#>;_ODT?;[?^\W_?)HY7V"Z+5%5?M]O_>;_ODT?;[?^\W_ 'R:.5]@
MNBU157[?;_WF_P"^31]OM_[S?]\FCE?8+HM455^WV_\ >;_ODT?;[?\ O-_W
MR:.5]@NBU157[?;_ -YO^^31]OM_[S?]\FCE?8+HM455^WV_]YO^^31]OM_[
MS?\ ?)HY7V"Z+5%5?M]O_>;_ +Y-'V^W_O-_WR:.5]@NBU157[?;_P!YO^^3
M1]OM_P"\W_?)HY7V"Z+5%5?M]O\ WF_[Y-'V^W_O-_WR:.5]@NBU157[?;_W
MF_[Y-'V^W_O-_P!\FCE?8+HM455^WV_]YO\ ODT?;[?^\W_?)HY7V"Z+5%5?
MM]O_ 'F_[Y-'V^W_ +S?]\FCE?8+HM455^WV_P#>;_ODT?;[?^\W_?)HY7V"
MZ+5%5?M]O_>;_ODT?;[?^\W_ 'R:.5]@NBU157[?;_WF_P"^31]OM_[S?]\F
MCE?8+HM455^WV_\ >;_ODT?;[?\ O-_WR:.5]@NBU157[?;_ -YO^^31]OM_
M[S?]\FCE?8+HM455^WV_]YO^^31]OM_[S?\ ?)HY7V"Z+5%5?M]O_>;_ +Y-
M'V^W_O-_WR:.5]@NBU157[?;_P!YO^^31]OM_P"\W_?)HY7V"Z+5%5?M]O\
MWF_[Y-'V^W_O-_WR:.5]@NBU157[?;_WF_[Y-'V^W_O-_P!\FCE?8+HM455^
MWV_]YO\ ODT?;[?^\W_?)HY7V"Z+5%5?M]O_ 'F_[Y-'V^W_ +S?]\FCE?8+
MHM44U'$B!UZ$9%.I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^W_O-_WR:.5]@NBU157[?;_WF_[Y-'V^W_O-_P!\FCE?8+HM455^WV_]YO\
MODT?;[?^\W_?)HY7V"Z+5%5?M]O_ 'F_[Y-'V^W_ +S?]\FCE?8+HM455^WV
M_P#>;_ODTY+R&1PBDY/3BCE8718HHHI#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BF2RI"F]R0,XX%0?;[?^\W_
M 'R::38KHM455^WV_P#>;_ODT?;[?^\W_?)HY7V"Z+5%5?M]O_>;_ODT?;[?
M^\W_ 'R:.5]@NBU157[?;_WF_P"^31]OM_[S?]\FCE?8+HM455^WV_\ >;_O
MDT?;[?\ O-_WR:.5]@NBU157[?;_ -YO^^31]OM_[S?]\FCE?8+HM455^WV_
M]YO^^31]OM_[S?\ ?)HY7V"Z+5%5?M]O_>;_ +Y-'V^W_O-_WR:.5]@NBU15
M7[?;_P!YO^^31]OM_P"\W_?)HY7V"Z+5%5?M]O\ WF_[Y-'V^W_O-_WR:.5]
M@NBU157[?;_WF_[Y-'V^W_O-_P!\FCE?8+HM455^WV_]YO\ ODT?;[?^\W_?
M)HY7V"Z+5%5?M]O_ 'F_[Y-'V^W_ +S?]\FCE?8+HM455^WV_P#>;_ODT?;[
M?^\W_?)HY7V"Z+5%5?M]O_>;_ODT?;[?^\W_ 'R:.5]@NBU157[?;_WF_P"^
M31]OM_[S?]\FCE?8+HM455^WV_\ >;_ODT?;[?\ O-_WR:.5]@NBU157[?;_
M -YO^^31]OM_[S?]\FCE?8+HM455^WV_]YO^^31]OM_[S?\ ?)HY7V"Z+5%5
M?M]O_>;_ +Y-'V^W_O-_WR:.5]@NBU157[?;_P!YO^^31]OM_P"\W_?)HY7V
M"Z+5%5?M]O\ WF_[Y-'V^W_O-_WR:.5]@NBU157[?;_WF_[Y-'V^W_O-_P!\
MFCE?8+HM455^WV_]YO\ ODT?;[?^\W_?)HY7V"Z+5%5?M]O_ 'F_[Y-'V^W_
M +S?]\FCE?8+HM455^WV_P#>;_ODT?;[?^\W_?)HY7V"Z+5%5?M]O_>;_ODT
M?;[?^\W_ 'R:.5]@NBU157[?;_WF_P"^34L-Q'/G82<=<C%%F@NB6BBBD,**
M** "BBB@ K,U+_7I_N_UK3K,U+_7I_N_UJX;DRV*=%%%;&04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M7],ZR_A_6J%7],ZR_A_6IG\)4=S0HHHK U"BBB@ HHHH *S-2_UZ?[O]:TZS
M-2_UZ?[O]:N&Y,MBG1116QD%%%% !1110 445B^)_%6E^$M,%[J4C9<E88(Q
MF29AV ]!W)X%-)MV0&U17AU[\<]8EF*Z?I%C A/RB4M*Y'O@@?E4NE?'2^69
M5U?2+::'.&>T8HZ_0$D'Z5O]4JVO8GF1[915/2M4LM;TN#4M.G$]I.N4<#!]
MP1V(/!%>=^+OBS>^&?%%YH\6C6EPEOMQ+),ZLV5!Y X[UE"G*;Y4M1MV/4**
MSM U-M:\.:;JKQ+"]Y;K,8U)(0GL":T:AJSL,**XSX@^.;CP3%ISP:?!>?:V
MD4B61EV[0IXQ]?TKAC\>-0'7P]8#_MYDK:%"I-<T4)M(]LHKQ/\ X7S?_P#0
MOV'_ ($O7HO@/Q9+XRT"74YK.*U9+EH/+B<L" %.<G_>I3H5(*\D":9T]%%<
M[XV\2R^$O#;:M#:1W3K,D7ER.5'S9YR*SC%R=D,Z*BO$S\>-0'7P]8#_ +>9
M*GMOCQ(7'VOP[%LSR;>Z.?\ QX5O]5J]B>9'LM%<[X7\<:'XN1ETZ=DND7=)
M:3C;(H]1V8>XK4UO4&TC0-1U-(EE>TMGG6-C@,5&<$BL7&2?*UJ47J*\J\+_
M !>O?$7B;3](ET2T@2[DV&5)G++P3D \=J]5ISIRINTA)W"BBBH&%%%% !11
M10 4444 %%%% !1110 4444 %%%% !17GOCWXE77@S6X-/@TJVNUEMA.7EE9
M2"688P/I70^"O$LOBWPTFK36L=J[3/'Y4;%A\IZY-:.E)1YVM!71T-%%%9C"
MBBB@ HHHH **** "BBB@#:MO^/6+_=%2U%;?\>L7^Z*EKG>YLM@HHHI#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P6^\
MWU-;U8+?>;ZFM*?4B8E%%%:F84444 %%%% !1110 45Q/Q"\>7'@AM.%OIT%
MY]L60MYLC+LVD=,?6K?@'Q?/XTT>ZOI[*&T:"X\D)$Y8$;0<\_6M/92Y.>V@
MKJ]CJZ**QO%FN2>&O"][K$5NEP]L%(BD8JK98#DCGO4)-NR&;-%>*?\ "]]1
M_P"A=L?_  (DKU?PYKD'B3P]9:O;C:MPF7CSGRW'#+^!_I6DZ,Z:O)"33V-2
MBN9\=^*YO!V@1ZG!9Q7;/<+!Y<KE0 0QSD?3]:H_#[QU<>-DU%KC3X+/[(8P
M/*D9MV[/7/TJ?9RY.?H%^AVE%%5-5O&T[1[Z^2-9&MK>28(QP&*J3@G\*A*^
M@RW17B8^/&H;0?\ A';#&/\ GXDI\7QYNB_[WP[:E?\ IE=,#^HKH^JU>Q/,
MCVFBN)\,?%'P_P");B.S8R:=?2'"0W)&V0^BN."?8XKN%7+A3QDXK&4)0=I(
MI.XVBO&[[XWW]IJ%S:KH%DXAF:(,;AP3AB,U[&#E5/JH/YBJG2E"W,MQ)IBT
M445F,**** "BBB@ HHHH **** "BBB@ HHHH **** "BN4\?>,)_!>D6M]!8
MPW;3S^24E<J%&TG/%4OA]X^N?&\^HQW&FP6?V-(W!BD9MVXD<Y^E:>RER<]M
M!7UL=Q11168PHHHH **** "BBB@ HHHH *FM/^/N+Z_TJ&IK3_C[B^O]*3V&
MMS9HHHKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"KJ'_'K_P "%95:NH?\>O\ P(5E5M#8RGN%%%%62%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45@^,O$,OA7PQ<:Q#;1W+Q.B
MB*1BJG<V.HYKS$_'C4!U\/6 _P"WB2M849S5XH3:1[917B?_  OF_P#^A?L/
M_ EZ[#X??$2X\;7]];3Z;;V@M85E#0RLY;+8P<TY8>I%<S071WE%<]XM\9Z5
MX.LDEOR\MQ-GR+6+&^3'4\\*ON:\LNOCEKDLI%EI6GP+V5]\K8]^113H3FKI
M: Y)'NE%>,:-\<YS.B:WI,+0$X::R8AE]]IR#],U[#8WEMJ5G;WEG.LUK<*'
MBE3HRG_/2IJ4IT_B0)IDU%>/ZK\:[_3=8OK!=!LI%MIWA#M.X+!21DU2_P"%
M]7W_ $+^G_\ @2]:+"U7K8.9'MM%>0Z;\=89+A5U70S#"3S+:3;ROOM8<_G7
MK-C=6VI6MO=V<ZS6UPH>.5.C*>]9SI3I_$@33V):*\9NOCEJ%O=SP#P_8L(I
M&3<;A^<$C/Z5$GQYO2PW>'K(K_L7+Y_45I]5J]A<R/:Z*\ZT#XR:!JLZ6^I0
MRZ5*YPKRL'B)]V'*_B*]%[ @@@C((.0164Z<H.TD-.X4445 PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "K^F=9?P_K5"K^F=9?P_K4S^$J.YH
M4445@:A1110 4444 %9FI?Z]/]W^M:=9FI?Z]/\ =_K5PW)EL4Z***V,@HHH
MH **** "OGSXS74TWC\V\C-Y5O:1"('H-PW,1^)_2OH.N&^(/P\C\8I%>6DZ
M6VJP)L5I!\DR=0K8Y!'.#[UOAIQA4O(F2NB+X0Z?I">"8+NRB@DOY&?[9)@-
M(K \*>X &,?7-0_$CX=2>*/LEYHEO9PZBC%;AG81++'CC.!RP/Z&O([WPQXO
M\(W)G:RU"S9>ES:,64X[[D_K6II7Q<\6Z<ZB:]CU")3AH[N,$_3<,$5TNC/G
M]I3E<FZM9GJOPS\+:UX2TJ_L=7:W*2SK+ ()O, XPV>!CHM>1_%7_DI6K?\
M;+_T6M>X^#O&%CXRTEKNU1H+B%@ES;,<F-CT(/=3V->'?%7_ )*5JW_;+_T6
MM+#.3K/FW"?PZ'NG@7_DGWAW_KPC_K6_6!X%_P"2?>'?^O"/^M;]<4_B?J:'
MD/QW_P"/70/^NL__ *"E1_!G1=*U71-6DU'3;2[>.Z14:>(.5&S.!FI/CO\
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M /!G;_XT?\)%XK_Z$6?_ ,&=O_C1[*7E]Z_S#F1UE%<G_P )%XK_ .A%G_\
M!G;_ .-'_"1>*_\ H19__!G;_P"-'LI>7WK_ ##F1UE%<G_PD7BO_H19_P#P
M9V_^-'_"1>*_^A%G_P#!G;_XT>REY?>O\PYD=917)_\ "1>*_P#H19__  9V
M_P#C1_PD7BO_ *$6?_P9V_\ C1[*7E]Z_P PYD=917)_\)%XK_Z$6?\ \&=O
M_C1_PD7BO_H19_\ P9V_^-'LI>7WK_,.9'645R?_  D7BO\ Z$6?_P &=O\
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M_P"O[_V05W2_W5?UU,_MGIU<C\4?^2:ZQ_NQ_P#H:UUU<C\4?^2:ZQ_NQ_\
MH:URTOXD?5%O8\)\+>'6\21:W#"I:[M; W5N!_$RNN5_%2:[;X)>)/L^I7/A
MV=\178,]MD])5'S*/JO/U6JWP-./&&H$=K _^C%K&\=Z1/X(^(/VG3_W432+
M?V+#@+\V2OX-D?0UZ,VIRE2?R,UHKGI7QL_Y$6#_ *_XO_07K%^ _P#JM?\
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M@U"S@NX18R.(YD#*&#+S@]^37I_Q<_Y)O?\ _7:'_P!#%>#^'?\ A(/[2?\
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M$?K7N'A3Q/8>+=(CU*QW)A_+FA?[T3]=I]?4'O65:-6$.66Q46F[H^:/$O\
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M@&< ]U(SC/3!KM?@OXBFU+0KK1;J0O)IQ5H&8Y/DMGY<_P"R1Q[&KWQDV?\
M"O7W?>^V0[/KD_TS7#? \O\ \)?J 7[GV [O^^UQ1=U,.W+=!M(]XHHHK@-
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M[,O) )'45S49Q=-TY:+N4T[W1TWQIUJSA\*1:.)XWO+JX23RE8$JB9))],G
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M%/W!ZFK_ ,4/!6L>,'THZ2+8BU602>?-Y?WB,8XYZ&O/C\%?%YZKIG_@8/\
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MU+_7I_N_UK3K,U+_ %Z?[O\ 6KAN3+8IT445L9!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $V_\=HYXARLM6W_ !ZQ?[HJ6F1)Y<2IG.T8S3ZQ>YH@HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKR)&,NZK]30 ZL
M%OO-]36E)J4"_=RY]NE998$D^IS6L$T9S:8M%)N%&X5H0+12;A1N% "T4FX4
M;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0
MM%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N
M%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "T4FX4;A0 M%)N%&X4
M +12;A1N% "T4FX4;A0 M%)N%&X4 +12;A1N% "U-:?\?<7U_I4&X58L5+W2
MXZ+R:3V&MS8HHHKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6
ML^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE
M5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^B
MP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/
M,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]26\;W5S' GWI&V_
M3WHL,Z?P_;8@>Z8<R?*OT'_UZVJ9%$L,*1(,*BA13ZXY.[N;I604445(PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JW]]%86YD
MD.6/"KW8TZ]O8;"V::8\#@ =6/H*XF\OY;ZX,TIYZ*HZ*/05I3I\VO0B4K$T
M]W)<S-+*V6/Y >@J/S*K;Z-]=5C*Y9\RCS*K;Z-]%A%GS*/,JMOHWT6 L^91
MYE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&
M^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS
M*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMO
MHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L
M^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*/,JMOHWT6 L^91YE5
MM]&^BP%GS*/,JMOHWT6 L^91YE5M]&^BP%GS*W?#;;FN?^ _UKF=]=#X5;<U
MW_P'^M147NLN&YTE%%%<AL%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 44C,%4LQ  ZDFLN[\1Z7:9#72R,/X8OF/Z4TF]A-I;FK17(
M77C8G(M+3'^U*?Z#_&L6Z\0:E=Y$ETRJ?X8_E'Z5JJ$GN2ZB/0;F_M+09N+B
M./V+<_E6/<^+;./(MXY)CZ_='ZUPWF9))Y)[FCS*U5"*W(=1]#HKGQ1?SY$9
M2!?]@9/YFLJ:ZEN&W32O(?5V)JEYE'F5JH);(AMO<M;Z/,JKYE'F4[ 6O,H\
MRJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJ
MOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF
M4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>
M918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>91
M8"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"
MUYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UY
ME'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'
MF55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,KIO"=GO:6^<<#]W'_4
M_P!*Y*/?-*D48+.[!5'J37IUC:)8V,-LG2-<$^I[G\ZQK2M&W<NFKNY8HHHK
MD-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN[
MJ&RMGGG?:B_K["EN+B*U@>>9PD:#+,:\]UC6Y-5NMW*0(?W<?]3[UI3IN;\B
M92L2:EJDNI71ED^5!PB9X4?XU3\RJOF4>97:HV5D87N6O,H\RJOF4>918"UY
ME'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'
MF55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F5
M5\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\
MRCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RC
MS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*
M+ 6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,H\RJOF4>918"UYE'F55\RCS*+
M6O,H\RJOF4>918"UYE'F55\RCS*+ 6O,KIO![;FO/^ ?UKC_ #*ZOP4VYK[_
M (!_6LZJ]QE0^(ZZBBBN(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<EN,CDUC&<I3:2T1;BDKLS?,J6&"XN03!;S2A3@F-"V/RJAOKN_A^VZSOO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHK-O_$&DZ9D7=_#&P_@#;F_(<TTF]@O8TJ*X:^^)5E'
ME;&SFG;L\AV+_4US=]XZUN]R%G2U0]H%P?S.36T</-^1#J11ZQ/=6]K'ON)X
MXD_O2,%'ZUSU[XZT6URL4CW3CM"O'YG KRF:YEN9/,GEDE<_Q2,6/ZTSS*WC
MA4MV9NJ^AV][\0KZ;*V=M%;KV9_G;_"N>O-:U'4,_:KV:0'^'=A?R'%9/F4>
M96T:<8[(AR;W+(<#IQ2^957S*/,J["+7F4>957S*/,HL!:\RCS*J^91YE%@+
M7F4>957S*/,HL!:\RCS*J^91YE%@+7F4>957S*/,HL!:\RCS*J^91YE%@+7F
M5V'P[;=JU[_UP7_T*N%\RNT^&K;M8OO^O=?_ $*LJR_=LJ'Q(Z;Q)X7EUV\A
MGCNTA$<93#(6SSGUJ[H.BP^'=.D0S[V9O,EE;Y1T_0 5S'Q U;4-.U&R2SO9
MK=7A8L(VP"<BN*NM9U&]C\N[O[F:/^Z[G'Y5A"E.<$KZ&CDE+;4Z_3]3CU;X
MCK<1@-"P>./(ZJ$(S^/)KK=5@TBTFBU34O*18%*)O7(!8CD#N>*\W\$OGQ?9
M#V?_ -!-=)\37*VNF#)P97R/^ TYP_>1BNPHOW6RCJ?V7Q3XNM8-.E!@>(!W
M5=NT DMP>^"/SKJ-5U&P\':7"EO: EVV1QH<%L#EB?\ /6N'\!S*OBR$,P&Z
M&15SW/!_H:VOB8CK_9LV#Y>70MZ$X('Z'\J)1_>1IO8$_=<C<T76['Q=:W%M
M<V:J\8&^)_F!!Z$'\*XC5-,_L7Q1%9ABT1FB>(MU*EAP?IR*T_AHKOJ6H2@'
MRUB5">V2<X_(4GCBX1_&.F1+]Z/RM_XR9'^?>G%<M5P6P/6-V=MK0TZWTN6X
MOH4:WAQ(5VCYB#P/?G%8WA_QG'K&I?8);,6Y<$Q$/N!P/NGCKBK/CI'?PG=%
M 3L*.V/[H89KS[P>CW'BRP$8SL9I&]E"G_$5G3IJ5-MCE)J22-OQUI$.FW4-
M];1A(K@E711P''.1]1_*NC\/Z-::#HW]H7:*;GRO-ED89*#&=H],?J:S?B9.
MD>E649/SM.6 ]@IS_,5O:\K7G@^]^SCS#):EDQW&,T.3<(I]1I)2;,?3?'T&
MH:E%:36+0Q3ML1RX;!/3(QWJCXXT&"RC75+1%B5G"31J,#)Z,!V]#7%Z1NN=
M9L(XLEGG3;CZYS^5>G>/9TA\)W"L 6E=$7Z[@?Y UI**IU(J/4E/FB[CO!:)
M+X6MR44G<XR5!_B-5KO4/#NA:?<:5%+$+A8BI 0LS/C^(XZG]*L> SGPG;G_
M &Y/_0C7ENH2EM4O2Q))N),D]_F-3"'/4DFQN5HH];\-^((->2Y:"T:W\DJ&
M#$'.1[5E^(_%=K8W=WICV+R2^5CS05Q\R\?EFJ7PR;=#JG_72/\ D:Y_QTQC
M\7W(;(W)&5SW^7M1&G'VKB#D^2YV/P_C1_#9W*K$3N,D?2N1GL7U3QK=6$1V
M^9=N"0/NJ#DG\JZWX='=X98_]/+_ -*Y_1I53XIW(9@-T\ZC/<^GZ4XMJ<VA
M/9'6:E?:?X-TF(6]H"7;8D:D N>I+&H]$UZR\60W%I<V:JZ#+1/A@RGC(-9'
MQ,1Q;Z;,%/EK(ZEO0D#'\C6?\-E>36;V4 ^6D 4GMDMD#]#4J"=+GZCYGS<O
M0SM?TK^Q->%JI)A=EDB)Z[2W0_0Y%>F:O%IZ:5/)?0JUM&OF.H7KM.<?F*X7
MXAW"'Q#I\*XWQQ@MCW?@?I^M=9XU./!^HG_87_T(43O)0OU!:<Q#X>\6VVM7
MC6*6;VS*A:,$@@J/IT/(KF?'EA!8ZK!/ @C%RC%U48&X$<_CG]*I_#]\^*@/
M^G>3^:UI_$QMMUIO^Y)_-:M14*R2$W>%V<=YE;OA/1UUO52LX)M8%WR <;CV
M7_/I7,>97>?#.9#/J418;RL; >PW#^HK:JW&#:(@KR-S7?$]KX9DAL;:S61R
MF[8A"*B]!4]L^F^--#,DEOM.2ASC?$X]#^1KB/B CQ>*2[+A98$*'UQD&NE^
M&Z.-"N)2#LDN#M]\  D?C_*N:4%&FIK<T4FY6,WPOJ,6AZM/HMU"TES)=B-9
M% P.,9YY]_QKL->UBWT2Q2YN8'F1I @5 ,Y(///TKS^XN$G^*49CQM%ZB<=R
M%P?UKI/B.=OAZ _]/*_R:B<$YQOU!.T6<#>W2W5_<W"*5265G53U )SBH/,Z
M?6JOF4>9R/K7:D8GM>N''AJ^/_3LW\J\=$G KV'7L_\ "+W^ 2?LS=/]VO%@
M9-H_=R=/[AKEPOPLTJ[FKI#YUO3_ /KX3^=>B^.7:/PV[HQ5UFC96'8AN#7F
M6CLPU[3@RLN;F/J"/XA7I/C\X\*R'_IK'_.G57[R(0^%DQ\KQ?X0RN!+(F1_
ML2K_ /7_ $-97PZW"#4U=2KK*H93V(!R*ROAYK/D:E+IDK?N[D;XL]G Y'XC
M^5=UI^E+8:IJ5S'@1WC))M'9@"&_/@_G653W%*'W%Q]ZTCSCQB^/%=Z/]S_T
M$5A^96KXU?'BZ^'^Y_Z *P/,KKIKW$8RW9ZC\/#NT2X_Z^#_ "%<GXP?'BN]
M'^Y_Z"*ZCX;G=H5S_P!?)_\ 017(>,V(\77P"L?N=%/]T5A37[Z1I+X$7?!$
M[KXI@13@21NK#U&,_P Q71?$,;+&PN%8K+'.=C#MD9_H*S_ &A727;ZM=0M%
M&$*0!QAF)ZMCTQQ^-1?$C4TDO;33HVRT(,LN#T)X4?ED_C0_>KJP+2&ITWA_
M4;3Q+HKI/%'YP7RKB,*!U'4>QJAX9\*/INIW=S> .(F,=MG^)?[_ .7'YUF_
M#K2IC+-J[LZ0E3#&H.!)SR3[#H/?-=A<M%KNC7<-A>;=X>$31G[K X(_.LIO
MDDXQ>A4=4FSSSQ9KJ:IJ)@M=HL[<D*5'WV[M].PKG_,J&>*6SN)+:=#'-$Q1
MU]"*C\RNV,4E9&+=V=5X4NM%M;N:ZU>9%:, 0*Z%AD]3P#ST_.NEN/&LG]JQ
M16&G2W.GDJ&G6-\G/4CCM69\/]$MKN&75;J-9660QPJPR%P!EL>O-3ZCX\NX
MO$!TRPL8F5)Q;YE)W,V<' '2N::4IM)7L:+2)8\?:9;+IR:E'&J7"R*C%1C>
M#Z_2M7PWXAM]<\](;1H# %W$D?-G/I]*K^/UW>%)FSC9+&WU^:L3X9MNEU+Z
M1_\ LU0ES4;OH5>T[&OXA\66NEW\VGR6+RR>4#Y@*X^8'UKS17PH&>@K<\?L
M8_%C[@5#P1[2?XNO2N:\RNFC!*":ZF4VVRUYE'F55\RCS*UL26O,H\RJOF4>
M918"UYE'F55\RCS*+ 6O,KHO!>F_VEKBRN,P6H\QO0M_"/Z_A7)F3 S7K_@[
M23I7A^+S%Q<7'[Z7U&>@_ 8_6L:\N6'J7!79T%%%%><= 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4$X&3THKSOQIXO\QI-)TV3Y!\MQ
M,IZ^J+_4_A5TZ;F[(F4E%7(_%WBO[?(^G6+_ .BJ<2R#_EJ?0?[/\ZY+?57?
MBCS*]*$%%61SMMN[+7F4>957S*/,JK"+7F4>957S*/,HL!:\RCS*J^91YE%@
M+7F4>957S*/,HL!:\RCS*J^91YE%@+)DKVFZM3>Z-):JX0S0; Q&<9%>&F2O
M;=3ED@\-74L3LDB6K,K+U!"]:Y<2M8V-:?4Y_2? AL=1@NKF^$JPL'5$3;EA
MTR<]*=X]U6&#3%TY74W$[!F7^Z@.<GZG%<"/$NME1G5[SI_?J@\[2.SN[.['
M)9CDGZDU:HR<E*;V)<U:R/8?#\$=WX3LE90/,M]A; STQFL;6M5\/66B7FDV
M4D*S+&8U2-"?F]VQU_&MOPH<^$M./_3#_&O&I'),GJ2W\ZRI0YIN_1ERE9(]
M0\&Z!;V^FQZI=QJ]Q,N]-XXC3M@>IZYJ%/B):MJ B-DXM2^P3;QG&<;MN.E;
MNGL+[P?!]G;)DL@BD>NS'\Z\70.^V !O-8B, #G=G&/KFG3@JDI.8I-Q2L>F
M>-M @%@^JVL:QRQ8,P48#J>,X]14_@!$D\/2%D5C]I?DCV%:7B21;/P?>^:V
M=MOY>?4D8'ZFLSX<'/AJ3_KZ?^2UG=NCKW*LN<@U/Q39>'=4FM+'3UED+^9<
MONVY8\X''7I["MB_LK/Q5H"3QJ-\D?F02$?,C>G]"*\Q\3!X/$^IK("I\\N,
M_P!T\@_E7IWA%&M_"&G^<-A$1<Y[ DD?H:JI!0C&2W%%W;3.(\(:(FM:C(UT
MI-M; &1/[S'HOTX.:ZO7?%EOX=NH["WLA*X0,RJP14!Z#IUXK,^&L\<B:J@8
M%C,) /53G!_2N?\ '2O#XMN2^<2(CI[C&/Y@U;7/5<9;(5^6%T=XL>G>,]"6
M=H=C-E0Q WQ...O?^M<=X2B>W\9+:SJ"\8EC<=L@?_6KI/AW$Z^&FE;.V6=V
M3/H,#(_$&L+1[A+CXIW#QG*&28 COA<?S%3'3GBMD-ZV9V>J1Z/92QZGJ7E(
M(EV1[UR 3Z#N>*Q#XSTM-6$5M;FY2=D42*H4*2<=#S5;XF-MM--_ZZO_ .@U
MPFG/G5+,?]-T_P#0A3I4E*',Q2DT[(]FUK4H](TJ6]EA,R(0"@QSDX[UPMMJ
MT.M>.M/N8K<PQX"%&P>0&.>/K73^.L_\(C>$ G!0G'8;A7GGA&0-XJT[!R#(
M?_032HP7LW+KJ.;?,D=I\0E2/2+4JJKFX'0?[)H\%Z! FGQZK=1J\\N6B#CB
M->QQZGKFF?$HXT6T_P"OC_V4UMZ&PO/!]GY# E[0(#[[<?SJ+M45;JQV]\Q#
M\1+8:@8OL3FU#[/.WC.,XW;?2G^,]!MY-.DU6UC6.:$;I-@P)$[_ (CKFO,<
M/CR"#YN?+V]]V<8^N:]FUAQ8>#[KSVSY=H4)]3MV_P ZTJ05.47$F+YD[F+\
M/%233+PLJMB<=1G^$4_4_$NF>&=6GMX;!I9G82W,BD C(Z#/7C''2H?AF<Z3
M>^TX_P#017(^-'QXJU$>Z_\ H(H4%*M),+V@FCTO7+.UUKP[+*8]Q\@S0/CY
ME.W(Q7D8DRH/J*]BMS_Q2D1_Z<1_Z!7B:R?(/I58;9H53H6]Y)P!DG@#U->I
M:;IEEX5T-[RX0-.D?F3RXRV?[J^@[5Y1;3K'>6\CG"I*C,?0!@37K?C)'G\(
MWQB^;"*_'=0P)_045]XQZ,*>S9GZ1XW@U?4DL)[$PB?*HQ<."<9P1BL_Q/I5
MMH.K6&L6\.+4S@RPH. PYX[<X/%<GX:5[GQ-IL<9.?/5^/1>2?R%=[\19TC\
M.1Q$_/)<)M'TR34N*A42CU&GS1;9OZ/J4.K:9%>01-%&Y.$;&1@D=OI7GOBO
MQ#:ZOY4%O;20O;S/O+ ?-VXP:Z[P*<^$K0^[_P#H9KRF[D_TZZ_Z[R?^A&BC
M!>TEY!.3Y42>97H'PY;=9:A_UV7_ -!KS7S*]%^&;;K'4?\ KLO_ *#6N(7[
MMDT_B,;QP^/%4P_Z91_R-<[YE;GCS?\ \);/A'(\F/D*3V-<WE_^><G_ 'P:
MNFO<1,MV>I_#\Y\..?\ IY?^0JKX>U;R?%^L:7(WR37+R1?[PZC\1S^%3?#D
M[O#+G_IY?^0KA-8O);/Q=?W,#8EAO&=#[@USJ'/.<31NT4SH?$6F?V;XQLYD
M7%O=SHZXZ!]PW#^OXUT'CXX\,D_]-X_YU;N88/$^AV5Y!C<'CN8B>Q!Y'\Q5
M'XAG;X6)_P"GB/\ G41ES2BGNBFK)GFOF4>957S*/,KNL8%KS*/,JKYE'F46
M M>91YE5?,H\RBP%KS*/,JKYE'F46 M>97<_#AMSZE](_P#V:O//,KOOAFVY
M]3^D7_LU8UU^[9=/XCT&BBBO..@**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BJ%_K6F:6I-[?008_A=QN_+K7*ZA\3]*@RM
MC;SW;?WB/+7\SS^E7&G.6R$Y);G<TR6:*",R2R)&@ZL[  ?C7D&H?$;7+S*P
M-#9H?^>2[F_,_P"%<S=7UU?R>9>7,UP_K*Y:NB.$D_B9FZJZ'L=_X\T"QRHN
MS<R#^&W7=^O3]:Y>_P#B?=296PL(X1V>9MQ_(<5Y]OHWUO'#07F0ZDF;=_XE
MUC4LBZU&8H>J(=B_D*R]P!SW-0;Z-];J*6Q%[D^^C?4&^C?3L(GWT;Z@WT;Z
M+ 3[Z-]0;Z-]%@)]]&^H-]&^BP$^^C?4&^C?18"??1OJ#?1OHL!/OHWU!OHW
MT6 GWT;Z@WT;Z+ 3[Z-]0;Z-]%@)]]&^H-]&^BP$^^NB\'^(;3P_J%S<7:3.
MDL011$H)SG/.2*Y;?1OJ904E9C3L[G5>,?$5IXAO;6:S29%BC9&$J@')(/&"
M:YS?4&^C?1&"BK(&[NYN>'-5@T?7[:_N%=HH@VX1@%N5(K7\9>*K'Q%#9)9Q
MSH8'9F\U0,@C'&":XS?1OI.FG)2ZCYG:Q;@NI;6YBN('*31,'1AV(KT:U^(&
MC:EI_P!GURT*L0-Z^5YL;GU'<5Y=OHWTITHSW",FMCU&7Q[H.E6)AT2R+L<E
M46+RD!]3GDUP:7T]_KT%W<R;YYKJ-G;_ ($.![5E;ZEMIUAO+>9@2L<J.0.I
M 8'^E*-*,+V!R;W/=?$.J)HVCRWLD'GQ*RJ\?JK$ _SKF;/Q?X.TM));"V>&
M5Q\RQVQ#'VST_7%9'B;Q[I^N:#/806MU')(5(:0+M&&![$^E<%OK"EA[Q]_0
MTE4UT-SQ!X@G\0:D;J5?+C4;(8@<[%]SW)[UO^%O'@TFU33]2C>6V3B*6/ED
M']TCN*X3?1OKHE2BX\K6AFI-.YZK%XO\&V4[W=K;;;D@Y:.T*L<]>2!7&^)?
M%%QXCND9D\FUBSY4.<G)ZLQ[G^5<YOHWTH48Q=^HW-M6/0O"_C?3-%T**QN8
M;II49B3&@(Y)/J*XFZG6:\N)ER%DE=U!ZX+$C^=4]]&^JC346VNHG)M6.G\*
M>*#X<O)FDA::VG $BJ<,I'0CUZFNFU3X@Z+>6$\26-R\SQ,B-)&HVDC'7)Q7
MF6^C?4RHQE+F8*;2L=YX0\9:=X?T3[%=QW+R^:SYB0$8./4CTKF+_4C-KUSJ
M5HSQ%[EIXF/#+SD5E;Z-]4J<5)R[@Y-JQZA9_$'2=0T_[-KMH58C#@1>9&_O
MCJ*<_CSP]I-DT6BV3,Q.0BQ>4F?4DUY;OHWUG]6@/VC-"[U&?4-2:^NWWS22
M!W(] 1P/8 8%=MXC\=Z7J^@7=A;PW:RS* ID0!1A@>>?:O.=]&^KE2C)IOH)
M2:.B\*ZU;:'K8O;I96B\IDQ& 3DX]2/2KGC+Q+9^(9[-[..=!"KAO-4#.2,8
MP3Z5R.^C?3]FN;GZAS.UB??5W2=7N=&U*.^M2-Z<,K='4]5-9>^C?5.*:LQ'
MJC>-_"^KVJ#5;1@Z\^7+!Y@4^Q _PJMJOQ#LK>P^R:!;E6V[4D:/8D0]E[G\
MJ\TWT;ZQ6&@BO:,U-)OTL=;L[Z?>Z0S"23'+-Z_4UT_B_P 8Z?K^DQVMI%<I
M(LRR$RH , 'T)]:X3?1OK1TTY*3Z"4FE8GWT;^GUJ#?1OJ[$GK*_$S1511]G
MON!C_5K_ /%4O_"S=%_Y][[_ +]K_P#%5Y+OHWUS_5:9I[21V_B'Q;8:MK&D
M7=O'<+'9R[Y Z@$C(/'/M5GQ3XVTW7-#>RM8KI96=6!D0 8!]B:\_P!]&^K5
M"*MY"YWJ6X+F6VN(KB!MLL3AT;T(.17IL?Q-T<QKYEM>A\#<%C4@'OCYJ\GW
MT;Z<Z49_$*,G'8V_$>JP:OK]S?VZNL4NW:)  W"@?TK+WU!OHWU:C960F[G=
M>$/&&G^'],FMKN*Y=WF,@,2 C& .Y'I70?\ "R]#SG[->Y_ZY+_\57DN^C?6
M,L/"3NRE-I6/2=3^)P:%H]+LG60CB:XQA?\ @(Z_G7!&?[3>>;>32MYC[II1
M\SD'J1ZFJ>^C?5PI1@O=$Y-[GH][X_TV'0&L-%M[F&41B*(N@41CIG@GG'ZU
MB^#_ !6GAV6>*Z662SE&[;&,E7'?D]QU^@KDM]&^DJ,%%Q[ASN]SJ_%VM:1K
MEU%>V$5Q%=8V3>8@ =>QX)Y'3Z?2N;WU!OHWU<8**LA-W=SL_!OB^+0!+:7J
M.UI*V]609,;8P>.X.!6UJ'C+PQ#*^I6%B+C52,([0%,'&,DG^G->9;Z-]9RH
M1<N8I3:5CT+Q%XWTS6O#LUC'%=+<.%(+( N003W^M8'A?Q(?#NHR3-$9H)E"
M2(IP1@\$?K7.;Z-]4J,5%QZ"<FW<]1OOB)HES:R*+&ZDE*,$WQKP2/7)Q7FB
MMA0,]!4.^C?1"E&&P2DY;D^^C?4&^C?6EB2??1OJ#?1OHL!/OHWU!OHWT6 Z
M/PEI7]M>(K>!ES!%^^F]-H/ _$X%>UUQWPZT?[!H/VV5<3WIW\]0@^Z/YG\:
M[&O,Q$^:=NQTTU9!1116!84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !117$^-_&8TE&TS3I ;]Q^\D'_+!3_[,>WIUJX0<W9";25V5_&_C'[-Y
MFD:;)^_(Q<3*?]6/[H_VOY?6O-MV*@W\DDDDG))ZFC?7ITZ:@K(YI2<G<GWT
M;Z@WT;ZTL23[Z-]0;Z-]%@)]]&^H-]&^BP$^^C?4&^C?18"??1OJ#?1OHL!/
MOHWU!OHWT6 G+5Z-?_$'2;K1+BRC@O!+) T2EHUQDKCUZ5YEOHWUG.E&=K]"
ME)K8G#8 HWU!OHWUI8D])T/Q[I6F:#:6,\-VTL,>QBB @GVYKSXOEF/J2:K[
MZ-]1&FHMM=2G)L['PIXU?04-G=QM/8EBR[/OQ$]<>H]JZ7_A+O!BWAOUM_\
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M#UM=QWD=P[32!U\I0< #'.2*XK?1OIS@IJS$G9W1ZU_PLW1?^?>^_P"_:_\
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M^)'I-%%%>8=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"ZN>,+*C?=8'Z&EW5[-I5WX1\:V\UO#8PL\8!>&6 1R*#T8$?S!KS'QGX?\
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M*%10%4#H *=117D'4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^SUAB5^Z9=/XD>H4445Y1U!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14%W?6EA$9;NYAMXQ
M_%*X4?K7(:G\5/#5AE8)I;^0=!;)E<_[QP*N-.4_A0G)+<[:@D $DX [UXOJ
M?Q@U:X++IME;VB=GE/F/_0?SKCM2\2:SJY/V_4[F93_!OVI_WR,"NF&#F_BT
M,W570][U3QIX>TC*W6J0&0?\LXCYC?DN:X[4OC# N5TO3))#VDN6V#_OD9/\
MJ\C! &  *-]=$<'36^IFZLF=;J7Q!\2:EE6U VT9_@MEV?KU_6N;DE:60R2N
MTDAZL[%B?Q-5M]&^NB,(QV1#;>Y8WT;ZK[Z-]5818WT;ZK[Z-]%@+&^C?5??
M1OHL!8WT;ZK[Z-]%@+&^C?5??1OHL!8WT;ZK[Z-]%@+&^C?5??1OHL!8WT;Z
MK[Z-]%@+&^C?5??1OHL!8WT;ZK[Z-]%@+&^C?5??1OHL!8WT;ZK[Z-]%@+&^
MC?5??1OHL!8WT;ZK[Z-]%@+&^C?5??1OHL!8WT;ZK[Z-]%@+&^C?5??1OHL!
MU'@9L^.-)'_34_\ H)KU[QQX=N_$VAQV-G-#%(MPLI:;., $=@>>:\;\!MGQ
MUI'_ %U/_H)KUCXDZUJ&@^&X;O3;CR)VNDC+;0WRD-D8/T%<.(4O;1Y=S:%N
M1W.,_P"%2:]_S_Z=^;__ !-<CJVCW6D:Z^C2O%+=*R(#&3M)?&.OU%7_ /A8
M_BS_ *"W_D!/\*R'N-1\3:]'YL@GU"]D2(.0%!/0=.@ _E71!54[S:L0^7H>
ML'P3X4\+: U]KL9NVC4>;*^X@L3C"*/<XIEMX1\'>+]$:[T*-K-@60.FY2CC
MLR$\]OSZTV;PCX1\':*MWX@>2]<D*6G9FWN>R1@X[?\ UZZ'P1?:!?Z5/)X=
MLC:6JSE9$,6S+X'.,GMBN*4Y*/,FWY]#5)7LTCQ*UT>^N]?71(T'VPSM 1V4
MJ3N)]@ 37J$_A+P5X1TJ.;7L7#.P3SI]Q+MC/RHO05D>%UC/QJUKS#AU,YC'
MKDKG]#2_&9V%QHRY.S;*<9XS\M;SE*=2,+V35R$DHMEWQ)\/=)N]#;5?#@$3
MK%YR1HQ:.9,9XST..E'P<8/IFK$=#<)_Z *X"TUCQ>EA%#93ZO\ 8@FV-8H&
M9-OH#MZ?C7>?!?']F:N , 7*#'I\@I58RC1DI.XXM.2LB[K&G^!]/\1W<_B.
M[BEO;QA((I2VV)< #A>G3J:J^,OA]I<6ASZIHD?V>2WC\UHD;,<J#D]3P<<Y
M%<+\1F_XKG5\_P"Q_P"@"O9X?F^'Z9YSI8SGO^ZJ)<U-0DF]1JTFU8^>M^1U
MI=]58W_=K]!3M]>A8P/5_A/XB^:;P_</ZS6N?_'U_K^=;[>"E;XDC7-H^Q^7
MYY7_ *>!\H_3YOK7A]IJ,^EWD.H6S;9[9Q*A]QV^A&1^-?26J:G)9>&+O5(T
M!DBM&G5">,A<@5Y^(BX3O'[6AO3::L^AYA\5/$8O=4CT6WDS!:'?/C^*4C@?
M@#^9]JP/!WA>;Q7JCP^88;2 !KB51DC/11[G!^F*YB2XDGE>::0R2R,7=VZL
MQ.2:]E^#\<8\+W<J_P"L>\8/^"KBMZG[BC:)$??EJ%SI7PWT6\CTN^6U%WP#
MYSNS<]-S=!^.*PO'?@*#1K$ZOI&_[(A'GP,Q;8">&4GG'3(K2UAOAE-K-\=3
ME8WQF87&3/\ ?'!''';M5W5_'W@R\\.7NF0ZJDADM7ACC\N3).T@#)'TK"+J
M)IQYGWN6U%IWL<M\/_!=OXD6>_U%G^QPOY21(=OF-@$Y/H,CI72"T^'+^(SX
M?&G1_;=QBR%?;OQG;NSUKF_A[X$3Q!9?VIJDTZ6>\I%!%(4\TCJQ([9XXZXK
MHK#4/A[:^*K73=.TU9-06<1QW$<)95D&?XR>>_/-55DW.5FW;MT%%:(Y7Q[X
M/C\+W%O<64CM8W)*A9#EHW SC/<$9Q]#71^$O ^A:WX1M-0N+:5KN17W%;AU
M!8,0. <#H*L?&,XT#3CV^V?^R-6U\,SGP#IQ]Y/_ $-JF56?L%*^MQJ*YVCG
M[KX;Z3I/A.[N;N26XU&&U>4R"4HH<*3PH[9]<YKR@/P.:L:SJ-UJ.MWUS=W$
MDLK3N,EC@ ,0 !V  Z50WUV4H22]YW,I-/9%C?[U[=\.-.31_!8OK@!'NMUU
M(Q[)CY?_ !T9_&O%M(T]]9UFSTV/.;F54)'9?XC^ S7T3K6COJ/AR?2+.X%F
M)8A") F[8G0@#([<5SXN2LH=RZ2W9ROPU\3/KDVM13'YS<FZB![1OQC\,#\Z
MX'Q_IG]D>,;Q%&(;G%S'Q@?-]X#_ ($#^=>@>%/AW/X7UQ=136/.3RVCDA\C
M;O!Z<[CT(!JK\7]*\_1;35HTR]I+LD('_+-^/T;'YU%.<%7]S9E23<-31^'%
MIH<&D)-ILR/?S6\37JB8N5?'=<_+SGBH_&&G>#Y]0:XUB[CCU (@*&Z*'9GK
MM!],]JY[X,'-UK/^[%_[-6-\5VQXW/\ UZQ_S-)4V\0U=AS>Y>QZIX1MO#]M
MILR>'9Q-:F8EV$K/A\#/)]L5QGCFR\'A-8N5NE_MX L(_/;/F8&!MZ=.U7_@
MZ<^&+S_K\;_T%:\X\=-CQQK'_7?_ -E%.E3?MI*[T"4O<6AT?@3P(GB&W.IZ
MD\B6(8K%$AVF8CJ2>RYXXZ\UT]MIGPVU/47TFTBM'O/F4+&S@DCKM;."1[&M
M_P ,+;6_P_T[S!LMA8*TFW/ *Y8\<^O2N,L;KX5:==6][:W!CEMV$D;DW!VD
M=#S_ %J7.4Y2WTVL%DDMCF/&_A-_"E_&8I&DL+G/D.WWE(ZHWKZ@]_PKM+#X
M>Z+JGA*VO+>WD2_N+171VN'VK(5ZD9Z9YQ65\1?&7A[Q%X;CM=+U!+FY2Y23
M:(V!"@$$Y('K7>>&Y6A^'^G3)C>FGJRY]0F:JI4J*G%O1W",8\S.,\3^ M&\
M/^#;N\C:>:_@1")GE(R2P!^4<=S7F&^HI+VXO)&N;F>2::4[W=W)+$TS?773
MA**M)W,9--Z([GX9ZQ:Z9XJ*7;K&EW"84D;@!\@@9[9P1]<5Z+XV\%?\)4MM
M-!="WN[<,JEUW(ZG'!].1UKQWP_X4U3Q2ER=-6W9;<JLGG2%>H)&.#GI6S+X
MA\8> [Y=,NKV.7$:NL4I\Y IR!ACAAT-85:;=3FIR]XTC*T;26A/_P (AXU\
M,7#W>GQL7VE#+9.')7@GY6&<<#MVKF-6UK5-6<?VI=RSRP!E42J%*9ZC  ]!
M7K'@GXC-XFU(Z9>6*P71C:1'B;<C 8R,'D'GWK ^,FFVMO+IVI11A+BX+PRE
M1C> ,@GW'(HIU)>TY*BU[A**Y;Q9WVF_\B!:G_J&+_Z+KYXA?]S'_NC^5?0V
MF'_BWUH?^H6O_HJOG&%_W$?^Z/Y4L)O+U"KT+>_E?]X?SKZ1U>QEU/PY=V,+
M(DMQ;-&K/G )7'.*^9M_*_[P_G7TIX@NY[#PE?W=L_ESPVC/&^ <,%X.#2Q=
M[QM_6PZ6S/,O^%1Z]_S_ .G?F_\ \37.^)O"][X5FMH[V>WE-PK,IA+<8QG.
M0/6G#XC^+,?\A;_R G^%96L>(M4U]X7U2Z\]H01&=@7 /7I]!6T(UN;WVK$-
MPMH5=]=_\(FSXGO_ /KS_P#9Q7G&^O0O@ZV?%-__ ->7_LZT\0OW4A0^)%WX
MP-C5=+_ZXO\ ^A"N,\-:M)HWB2PO8G90)ECD"_QHQP0?7K^==?\ &5L:MI7_
M %PD_P#0A7%^%].DUGQ1IUE&A<&99),?PHIR2?3ICZD5-&WL%?:Q4_CT/:/B
M39)=^![YR/GM]LR'T((S^A-<IX)\.>$_%.DEI;65+^WPEQ&+EQD]G ST/Z'(
MKJ/B;?I9>!;U&;#W)6",>I+ G] :\J^'SZG_ ,)I9C2L;SG[1N^[Y/\ %N_3
M'OBN>C&3H-IVL7-KG1I'P+=_\)Z=!&_[)GS_ #\?\N^?7^]GY?KS6CX]T+PO
MX8LH[>SMI3J=QS'NN'81H.KD$\^@'^%>OE%W[PJ[\8W8YQZ9KYL\476HW'B?
M4'U9=EZ)2KQ@\(H^Z%_V<8QZYS54*DJTM79+\13BHHH[Z-]5]]&^NZQB6-]&
M^J^^C?18#2TRQFU?5+73K?\ UMQ($!]!W/X#)KZ2LK.'3[&"SMUVPPH(T'L!
MBO+/A!H?F376O3+\J9M[?/KU=OY#\Z]:KS,74O+E70Z*4;*X4445R&H4444
M%%%% !1110 4444 %%%% !1110 4444 %%%8OB;Q+9>%]):]NVW.?EAA!^:5
M_0?U/:G&+D[(&[$/BWQ7:>%M-\Z3$MW+D6\&>7/J?11W->"7^I76J7\U[>S&
M6XF.78_H!Z >E-U?6;S7=3EU"_DWS2= /NHO95]A5'?7K4*"IKS.6<^9EC?1
MOJOOHWUO8@L;Z-]5]]&^BP%C?1OJOOHWT6 L;Z-]5]]&^BP%C?1OJOOHWT6
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MC?NU^@IV^H-]&^NBQ!)*Q,+@<G::^@]>UW2)? =_!'JMB\S:>ZK&MPA8MLZ
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MJ>/TKR_?1OKKA@Z4>E_4S=63-;4]?U;6GWZGJ=U=G^[+*2H_X#T_2L\$ 8
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MY*1_VXP_S>OIFOF;XZ?\E(_[<8?YO7)@/XWR-*WP'FM%%%>V<@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '
M:OL'P#_R3WP]_P!@^'_T 5\?=J^P? /_ "3WP]_V#X?_ $ 5YV8_!'U-Z&[.
MBKY5^,7_ "5/5_\ =@_]%+7U57RK\8O^2IZO_NP?^BEKGR[^*_3_ "+K?"<-
M1117LG*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML?LV?)M5/:)> ?QY;\:YNMZ;DXIRW,Y6OH%%%%6(**** "BBB@ [5]@^ ?\
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M"7]=32E\:/=:***\$[ HHHH **** "OG?]H/_D;])_Z\#_Z,-?1%?._[0?\
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M_H KX^[5]@^ ?^2>^'O^P?#_ .@"O.S'X(^IO0W9T5?*OQB_Y*GJ_P#NP?\
MHI:^JJ^5?C%_R5/5_P#=@_\ 12USY=_%?I_D76^$X:BBBO9.4**** "BBB@
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M%%%>"=@4444 %%%% !7SO^T'_P C?I/_ %X'_P!&&OHBOG?]H/\ Y&_2?^O
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M\^9AAC@=.%X'US7964W!J&[,H6O=D/Q&\4'Q;XQOM11R;./]Q:#MY2D\_P#
MCEOQKVWXN6LVM?"B"?3HFN$22WN<1*6)CQU '7[P/TKYK  &!TKT#PC\7M?\
M)Z6NF"&WO[.(8A6<E6B'H&'4>QZ5C6H2M!T_LEPFKN_4];\ 0R^'O@JLNIQ-
M;[+:XN&2088(2S#(]Q@_C7S$G$:CV%=YXQ^*^O\ C"P.G2I!8V#$&6&WR3+C
MD!F/;V'I7"T\-2E#FE/=LFI).R04445U&84444 %?5_PD_Y)9H/_ %Q?_P!&
M-7RA7U?\)/\ DEF@_P#7%_\ T8U>?F/\->IO0W9VE?,WQT_Y*1_VXP_S>OIF
MOF;XZ?\ )2/^W&'^;UR8#^-\C2M\!YK1117MG(%%%% !1110!I>'];G\.:]:
MZO:PP33VQ+1I."4R01DX(/&:O^)?&NM^*=;75;NY:WF1%2..UD=$C _NC.<D
M\FN>HJ7"+ES-:CYFE8[K1OB_XST<*AU%=0B7^"]3>?\ OH8;]:K^+?B?XB\9
M62V-\]O;660SP6JE1(1TW$DD@>G2N-HJ%0IJ7,HJX^>5K7/H+X:>!_!7B?P)
M8:A=Z+;7%\-T5T^]P?,4GK\W7&T_C7%^)/@MXE3Q/<P:+8PRZ7/*S6\OGJJP
MH>=K G/RYQWSBN/\+>,=;\'7KW&CW019<>=!(NZ.7'3(]?<8->A#]H36]O.A
M:>6]1,^/RKEE3Q%.HY0=T^YJI0DM3VNW-MX2\(0"^N5%OIEFBRS-P"$4#/XX
MX'OBOCFYG%S>7%P%*B:5Y I[;F)Q^M='XL^('B'QGMCU.Y1+1&W):6Z[(P>Q
M/)+'ZFN7K3"X=TDW+=DU)J6B.I^&O_)2O#__ %]?^RFO?/C/_P DNU/_ 'X?
M_1JU\TZ+JUSH.M6FJV8C:XM7\R,2@E2<$<@$>M=7XD^+/B+Q3H<^D:A#IZVT
MY4N8865OE8,,$L>XI5Z$YUHS6R_S"$THM,X6D) !)Z"EJQ87,=GJ-M=2VR74
M<,JR- [$+)@YVDCG%=C,D>P2Y^&GP3$7^KUSQ">>S1JR\_\ ?*<>S-53]GN:
M*/Q1JUN6 DDLD**>I"OS_,5PWC7QI?\ CC5X;^]ACMU@B\J*")B549R3D]S_
M $%9.CZO?Z#JUOJ>F7!@NX#E' R.>"".X(X(KD]A*5*2E\4C;G2DK;(]8F\/
M:J?VCUF%E,8#=+>><$.SRA&.=W3J,?6I/VA[N)M0T&S!_?1QS2L/16*@?JI_
M*J7_  T%K_V?;_8VG>=MQYF]\9]=O],UYEK>MZCXBU:;4]4N#/=2XRV,!0.B
MJ.P'I44J-1U(RFK<JL.4X\K2ZF?1117<8!1110 4444 ':OL'P#_ ,D]\/?]
M@^'_ - %?'W:OL'P#_R3WP]_V#X?_0!7G9C\$?4WH;LZ*OE7XQ?\E3U?_=@_
M]%+7U57RK\8O^2IZO_NP?^BEKGR[^*_3_(NM\)PU%%%>R<H4444 %%%% &SX
M7\2W?A+78]7L8+>:YCC9$%PI*C<,$\$'./YU)KGC#6M>\0RZW/>RV]T^W8+:
M5D6(   +SP.,_4UA45')'FYK:CYG:QW^C_&7QGI*B.2]AU&,# 6]BW-_WTN"
M?QK*\8_$/7_&\26^I20PV<9W+;6RE4+8QN.223Z9/%<K14JA34N915RN>6US
MU^Q^/M]8Z?;6B^'K9Q!$L08W;#.T 9^[[5UG@3XP7?C#Q7#HTVC0VJ2122>:
MEP7(VC/0J*^=*U_#/B.^\*:W'J^G+ US&C(!.I9<,,'@$?SK"I@Z3B^5:E1J
MN^I].?$;QI-X&T*WU&"QCO&EN1 4>0H "K'.0#Z5Y/\ "GQHC_%+5)+M5MT\
M0,S*F_*I-N+*N>^06'UQ7*^+?B7KOC/2XM/U2*Q2&.83*;>)E;< 1U+'CDUQ
MP)!!4D$'((."#ZU-'")4G&6['*K[UT?27Q@^'VI>+TT^_P!%2.2]M=T3PR2!
M-\;8.03QD$?K70?#GPL_@CP5'97\L8N6=[FZ8-\B,>HSZ  #/L:\=T;XZ^)M
M-L4MKRVM-29  L\I9)"/]HC@GWQ63XN^+'B+Q;9-I\GDV%@XQ+#;9S+[,QYQ
M[#'OFL/JV(E%4G;E1?M()\W4P_&NNKXE\9ZKJT9)@FFVPD_\\U 53^(&?QK!
MY/"@LQX '4GTHK0T/4UT77+/4VLX[S[+()5@E8JK,/NDD>AP?PKTTN6-H]#G
MO=ZGJ_BLCX<_"&Q\+1,JZMK&9+TCJ%.#)_[*GTS5G]G:XB5O$-L6 F8P2!>Y
M4!P3^9'YUY9XO\57OC+7WU:^1(F,:Q1PQDE8U'8$^I)/XU6\/^(=3\+ZQ'JF
ME3^5<("I##<KJ>JL.XXKE>'E*BXOXGK\S7VB4[]#U/PKX?U2W_:&U":6RG6"
M*XN;AIC&=FR0'8=W0YW#]?2L_P"/]U%-XSTZW1LR06/[P>FYR0/R%2S?M!:^
M]NR1:/IT4Q7 D+NP!]=O_P!>O+=3U.]UG4KC4=1N&N+NX;=)(W<]A[ #@#L*
M5*E4=15*BM96"4HJ-D5:***[3$**** "BBB@!LG^J?\ W37VMH?_ "+^F_\
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MD_6ODCPSXDOO">MQZMIRP-<HC1@3J67#=> 1_.NX_P"%]>+_ /GWTG_OP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>"O^A:T[_OU1_P *T\%?]"UIW_?JC^T8=F'L'W/D:BOKG_A6G@K_ *%K3O\
MOU1_PK3P5_T+6G?]^J/[1AV8>P?<^1J*^N?^%:>"O^A:T[_OU1_PK3P5_P!"
MUIW_ 'ZH_M&'9A[!]SY&HKZY_P"%:>"O^A:T[_OU1_PK3P5_T+6G?]^J/[1A
MV8>P?<^1NU?8/@'_ ))[X>_[!\/_ * *K_\ "M/!7_0M:=_WZKI+2TM["SAM
M+2%8;>%!''&@P%4#  KEQ6*C6BDD:4Z?(R:OE7XQ?\E3U?\ W8/_ $4M?55<
M_J7@?POK%_)?ZCH=E<W<N-\LD>6;  &?P %9X6LJ,^9KH54CS*Q\>45]<_\
M"M/!7_0M:=_WZH_X5IX*_P"A:T[_ +]5W?VC#LS'V#[GR-17US_PK3P5_P!"
MUIW_ 'ZH_P"%:>"O^A:T[_OU1_:,.S#V#[GR-17US_PK3P5_T+6G?]^J/^%:
M>"O^A:T[_OU1_:,.S#V#[GR-17US_P *T\%?]"UIW_?JC_A6G@K_ *%K3O\
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M7US_ ,*T\%?]"UIW_?JC_A6G@K_H6M._[]4?VC#LP]@^Y\C45]<_\*T\%?\
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M"UIW_?JC_A6G@K_H6M._[]4?VC#LP]@^Y\C45]<_\*T\%?\ 0M:=_P!^J/\
MA6G@K_H6M._[]4?VC#LP]@^Y\C45]<_\*T\%?]"UIW_?JC_A6G@K_H6M._[]
M4?VC#LP]@^Y\C45]<_\ "M/!7_0M:=_WZH_X5IX*_P"A:T[_ +]4?VC#LP]@
M^Y\C45]<_P#"M/!7_0M:=_WZH_X5IX*_Z%K3O^_5']HP[,/8/N?(U%?7/_"M
M/!7_ $+6G?\ ?JC_ (5IX*_Z%K3O^_5']HP[,/8/N?(U%?7/_"M/!7_0M:=_
MWZH_X5IX*_Z%K3O^_5']HP[,/8/N?(U%?7/_  K3P5_T+6G?]^J/^%:>"O\
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M5OQ]17T<B+&BHBA44 *JC  ]!6%:DJ346]>OD5&7-J.HHHK$H**** "BBB@
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M ^,G_)69O]RU_D*]U^)7F?\ "N->$2LSM:LH55+$Y('0?6N_$6E[)I6O_P
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M5VQQ1*%51[ 5QM[\(?!FHW]S?7.FS-<7$K2R,+J499CDG ;BG#%Q=24IK1Z
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M&DSZ9J"R-:3@"1(Y&0L <XRI!Q5'PSX-T+PA%<)HMGY'VA@TK-(SLV.@RQ/
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M;Q#9V+Q:B6=]ZS/MRX(/R9VXP>F*BUKX;>%_$&MMJ^I6,DMZVS+BX=1\N-O
M..U7];A[;VEG:UB?9OEL=;1117G&P4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '(_$3Q=>^"O#\>K6FFI?)YZQ3!Y"@C!!PV0#WP/QK(\-?&'P[
MJOAU[_5[NVTR\A+"6T:0LV!T*< MD8Z#KQ7?W5K;WUI+:W<,<UO*I22.1<JP
M/4$5YU<_ KP9<7)F2._MUSGRHKD[/IR"?UKHINBXVJ)W[HA\U]#S#X6VLWB+
MXO'58(G2VAFGO921]P/N"J3ZDM^AKZ:K)\/>&=(\+:?]AT>S2VA)W.026=O5
MF/)-:U&)K*K.ZV00CRHY_P <>'E\4>#=2TK \V6(M"?21?F7]0!^-?*T?B"^
M'@V3PJL;&.74%NL9YW!=NS'NV#]17V0[JB,[L%51DDG  KYC\"V5OXO^-+7L
M-NJ6*7<VH; . H;Y/S8J:Z<%.T)<VRU(J+56/>/#7AD:%X MM!3:LPM"DK>L
MK@EC_P!]$U\X>!-$\-W?BBYT;QF[V@56CC9I?*"3*V"K'MD9QGT]Z^M*X[Q/
M\,/"_BR[-Y?V<D5XPP]Q;2>6S^F[L?J1FL:&(Y>92Z]45*%[6Z'DWB'2OA#X
M=U$:?LU?4)2N6.GW(D523@*3N'S>PS6E\;[NYTGP_P"'/#UD9X=-: [HW8[G
M\L*%1SWQG)'K]*[[P]\(O"/AR^BO;>TFN;F([HGNY=^P^H7 &??%=#XE\+:1
MXMTS[!K%MYT2MO1E8J\;>JD=*T^LP52+U:7<7(VF>)SZ/\.M*^$7]HQ-:WFL
MW-J%1WES,+AAR F?EVG/;H.]:O[.W^I\1>N^#^3UV6A_!SPAH5V]U';7%U,R
M,BM=2[]@88.  !G!//45N>&/ ^@^#WN7T6UD@-R%$NZ9WSMSC[Q..IHJ8B#I
MR@FW?N"@[IG@7PX_Y+A!_P!?5Y_Z#)7T)XLUZR\->'+K4]1M)KJRCPDT<48<
ME6.WD$@8YYK-TOX:^%]&\0+KEE8R1Z@KNXD-Q(PRX(;Y2<?Q&NHN;:"\MI;:
MYB2:"52DD;KE64]0166(K0J34ELBH1<4T>%6OA7X7^.=-NM0TN[FT"6-R'BE
MF10G&=WEL2-I]B*R_@9=7]OX]N=-L[AYM+,$K3A<^6=I 20 ]"3^AKT.Z^!/
M@NYNO.6*^@7.?*BN?D'L-P)'YUV/AOPIHOA.Q:TT:R6!'.Z1R2SR'U9CR:VG
MB8>S<4V[]^A*@[W-JBBBO/-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^8/C)_R5F;_ '+7^0KZ(\4:K=Z'X9U#5+*S%Y<6L1E$!8KO /S<@'H,G\*R
M=<^&WA?Q'K+:MJ=C)+>,$!=;AU'R]. <5UM=56M&<8)+8B,6F_,\M\%_&G2M
M?^U)KAM-&ECPT6^<E)5[_,0!D<<>]>7:_<Q^/_C,C:*K2PSW,,<<@'WDC W2
M>PP"?IBO8=7^"W@W5[Q[K[+<V3R-N=;.;8A/^Z00/PQ6]X6\">'_  <LATBS
M*S2C;)<2N7D8>F3T'L,"M8UJ-.\Z:=VMB7&3T9TE0WEK#?64]I<)O@GC:*1?
M56&"/R-345P&I\A_;=0\"7_BCP^-Q-S$]A(V<84-E7'KE,_]]5[M\%?#O]B>
M XKR6/;<ZFWVEO4)TC'_ 'SS_P "KRKXA1P^+OC6VEV2 >9-#8R.O\3+]]C]
M!D?\!KZ7@ACMH(X(4"11J$11T  P!7I8NI^[BNLM68TU[S/EK7=+TVS^,]_9
M>)_,CTN>_>25U8IB.3+(V1V!(S]#75>)/#GPA\,0P.\U]?//]V.PO!*P7^\>
M0 /QKUWQ3X'T#QC'&-7L_,EB!$<\;%)$![!AV]CD5S6G? [P7I]TL[V]W>;3
MN$=S/N3/N !G\:2Q4)).3:MT74?(UL<WXENX/#_P'MI/"J7]G9:C.H'VAOWR
M1R%B3D$XW8'?HU87PVT;X=_\(;=:SXD>UFO89'\V&XEP8U'W0J C<2.<\Y)Q
MVKWO4=(T_5M)ETN^M(YK&5-C0D87:.F,=,8&,=,5PUA\$?!ECJ<=[Y%W<>6P
M9(;B?=&".G& 2/8DU$,1#D<6VFW?0;B[W/*_@<P;XF!E&U6M)RJ^@RN!^50_
M$+_DN4__ %^VG_H,=>\:7\/?#>B^(I-=L+)XK^0R%G\YROS_ 'L*3@#VQQ46
MI?#7POJ_B!M<O+&1]0:1)#(+B11N0 +\H./X15_6X>U<];6L3[-\MCIKZZ6Q
ML+B[:.218(FD*1C+,%&< =SQ7B-M#\+?B9J5VT4%SHM^5\TR-(D F)ZD+N*D
MCOP#S7NM>>ZU\%_!VM7LEVUK<6DDC;G6TEV(3W.T@@?ABN:A4C"]VT^Z-))L
M\:\-P3>&/C'::9X=U,WT0O4@::'A9XC@N& X.T;N>F5R*^IZY?PM\/?#?@]V
MFTJR/VIEVFYF<O)M] 3T'TQ744\36562:Z?B*$>5!1117,6%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S9\5KZ?QC\5+?0
M+ AQ;,EC%Z>:Q!<GZ< _[M?2=<GIGPW\,:3XA&NVME)_:.]Y/.DN'?YGSN."
M<9Y-=&&JQI2<GO;0B<7)6/+U^!GBN-0B>*X511A55Y@ /89KB;W3]1^%OQ%L
M'O)EGEM7CN3+'D"6-B0_7GIN!KZRKFO$W@+P[XON8+C6;)IYH$,:.LSH=I.<
M':1GFMZ>-E>U35,F5/L8WQ==;GX3ZI- ?,C989%9>A4R(<_3%<!\%?&>@>'M
M*OM-U6_%K<W%XK0JT;$/N4*,$ ]QWKVZ#1K"#0X]&\@2V"0BW$4Q,@,8&-IS
MG/''-<O;_"+P1;7RW<6C8D1PZ*;B0JI!R,#=BLZ=:FJ3I2ON-Q?,I([>BBBN
M0T/$?VB?^/;PY_UUG_\ 04KO?A7G_A5^@8Z_9C_Z$U:7B?P9H?C!+5=:M7G%
MJ6,6V9DP6QG[I&>@K1T?2;/0M)MM+T^,QVENNR-"Q8@9SU/)ZUTRK1="-/JF
M0HOF;/+M%^-WF^*FT?Q%ID&DQ([PR3F=F$<BG # J, D=?I7(_&[Q9I/B/4=
M)LM&N$O?L@D:26$[E+/M 13W/';U%>O>*/AGX8\6W1O-0LWCO",-<6TGENP[
M;NQ_$57\-_"?PIX8OX[^UM9KB[B.8Y;N3S#&?4#  /OC-:PJT(-5$G==.A+C
M)JS-CP/I4^A^"-&TVY&)X+5!(I_A8C)'X$XK?HHKBD^9MLU6A\V^/H)?A_\
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M:YSQ5\-?#/B^Y^UZE:.EWMVFXMY-CL!T!['\17-3J051RE=7[%M.UCY]\?\
MAS3/ ^O6;>'=>:ZD93*"D@,MLP(V_.G7/.._%?4.B2W<^@Z=+?KMO'MHVG7&
M,2%1NX^N:Y+P_P#!_P (>';V.\@LYKJXB;=&UW+O"-V(4 #/OBN\J\37511B
MM;=0A&P4445R%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 8</@[PW;:M_:L.BV2:AYC2_:
M1$-^\YRV?4Y-;E%%-R;W ****0!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!'<0175O+;SQK)#*A1T;HRD8(
M/X5F:1X5T'0)I)M)TFTLI9%V.\$04LN<XK7HIIM*P!1112 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH P[3P=X<L=5&J6NBV45^&9Q<+$-^YLY.?4Y/YUN444VV]P"BBBD 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8
MFI>#O#FLWQOM2T6RN[H@ RS1!FP.@YK;Z444W)O1@%%%%( HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img76291469_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /2"#0# 2(  A$! Q$!_\0
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M\ABCR+K_ )_/_(8H LT56\BZ_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\
M(8H\BZ_Y_/\ R&* +-%5O(NO^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABC
MR+K_ )_/_(8H LT56\BZ_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\
MBZ_Y_/\ R&* +-%5O(NO^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_
M )_/_(8H LT56\BZ_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y
M_/\ R&* +-%5O(NO^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/
M_(8H LT56\BZ_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\
MR&* +-%5O(NO^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H
M LT56\BZ_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\ R&*
M+-%5O(NO^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H LT5
M6\BZ_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\ R&* +-%5
MO(NO^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H LT56\BZ
M_P"?S_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\ R&* +-%5O(NO
M^?S_ ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H LT56\BZ_P"?
MS_R&*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\ R&* +-%5O(NO^?S_
M ,ABCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H LT56\BZ_P"?S_R&
M*/(NO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\ R&* +-%5O(NO^?S_ ,AB
MCR+K_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H LT56\BZ_P"?S_R&*/(N
MO^?S_P AB@"S15;R+K_G\_\ (8H\BZ_Y_/\ R&* +-%5O(NO^?S_ ,ABCR+K
M_G\_\AB@"S15;R+K_G\_\ABCR+K_ )_/_(8H LT51A%U,9!]JQL<I_JQSBI?
M(NO^?S_R&* N6:*K>1=?\_G_ )#%'D77_/Y_Y#% %FBJWD77_/Y_Y#%'D77_
M #^?^0Q0!9HJMY%U_P _G_D,4>1=?\_G_D,4 6:*K>1=?\_G_D,4>1=?\_G_
M )#% %FBJWD77_/Y_P"0Q1Y%U_S^?^0Q0!9HJMY%U_S^?^0Q1Y%U_P _G_D,
M4 6:*K>1=?\ /Y_Y#%'D77_/Y_Y#% %FBJWD77_/Y_Y#%'D77_/Y_P"0Q0!9
MHJMY%U_S^?\ D,4>1=?\_G_D,4 6:*K>1=?\_G_D,4>1=?\ /Y_Y#% %FBJW
MD77_ #^?^0Q1Y%U_S^?^0Q0!9HJMY%U_S^?^0Q1Y%U_S^?\ D,4 6:*K>1=?
M\_G_ )#%'D77_/Y_Y#% %FBJWD77_/Y_Y#%'D77_ #^?^0Q0!9HJMY%U_P _
MG_D,4>1=?\_G_D,4 6:*K>1=?\_G_D,4>1=?\_G_ )#% %FBJWD77_/Y_P"0
MQ1Y%U_S^?^0Q0!9HJMY%U_S^?^0Q1Y%U_P _G_D,4 6:*K>1=?\ /Y_Y#%'D
M77_/Y_Y#% %FBJWD77_/Y_Y#%'D77_/Y_P"0Q0!9HJMY%U_S^?\ D,4>1=?\
M_G_D,4 6:*K>1=?\_G_D,4>1=?\ /Y_Y#% %FBJWD77_ #^?^0Q1Y%U_S^?^
M0Q0!9HJMY%U_S^?^0Q1Y%U_S^?\ D,4 6:*K>1=?\_G_ )#%'D77_/Y_Y#%
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M0Q0!9HJMY%U_S^?^0Q1Y%U_S^?\ D,4 6:*K>1=?\_G_ )#%'D77_/Y_Y#%
M%FBJWD77_/Y_Y#%'D77_ #^?^0Q0!9HJMY%U_P _G_D,4>1=?\_G_D,4 6:*
MK>1=?\_G_D,4>1=?\_G_ )#% %FBJWD77_/Y_P"0Q1Y%U_S^?^0Q0!9HJMY%
MU_S^?^0Q1Y%U_P _G_D,4 6:*K>1=?\ /Y_Y#%'D77_/Y_Y#% %FBJWD77_/
MY_Y#%'D77_/Y_P"0Q0!9HJMY%U_S^?\ D,4>1=?\_G_D,4 6:*K>1=?\_G_D
M,4>1=?\ /Y_Y#% %FBJWD77_ #^?^0Q1Y%U_S^?^0Q0!9HJMY%U_S^?^0Q1Y
M%U_S^?\ D,4 6:*K>1=?\_G_ )#%'D77_/Y_Y#% %FBJWD77_/Y_Y#%'D77_
M #^?^0Q0!9HJMY%U_P _G_D,4>1=?\_G_D,4 6:*K>1=?\_G_D,4>1=?\_G_
M )#% %FBJWD77_/Y_P"0Q1Y%U_S^?^0Q0!9HJMY%U_S^?^0Q1Y%U_P _G_D,
M4 6:*K>1=?\ /Y_Y#%'D77_/Y_Y#% %FBJWD77_/Y_Y#%'D77_/Y_P"0Q0!9
MHJMY%U_S^?\ D,5&QN(;B!6N-ZR,01L [4 7:***!D-W_P ><W^X?Y4Z#_CW
MB_W!_*FW?_'G-_N'^5.@_P"/>+_<'\J!=22BBB@84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6S^]<_P#7
M9OZ5:JK9_>N?^NS?TJU0""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M72?_  +3_&K-AXK\/:I>+::?K>GW5RX)6*&X5V(')P :\=_X9VNO^ADA_P#
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M_P"AETG_ ,"T_P :^2='TTZQKUCIBR")KRZ6 2%<[-S8SCOUKUW_ (9VNO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9LUMX+F./R\3*^YE+?W2>QKURO/G.-*I)0LTS5)RBKA1117(:!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %6S^]<_]=F_I5JJMG]ZY_Z[
M-_2K5 (**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:L%>2 (4)(!P,L#QFN&G"<W:&YK)I;D?QL@BMOA<\$$210QW$"I&BA54!N
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M*266Y3['!KQ[X!?\CY=_]@]__0TKU;QG_P D5OO^P6G_ *"M>4_ +_D?+O\
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MKNF0ZCIERES:3#*2)^H(Z@CT->5_%[P9X4TKP--J%GIUI87T4L:V[0+L,A+
M%2!UXR?;%0_L\-='1]<1MWV,7,9B]/,*G?C\-E%2E2E1]K3TL"E)2Y6>T5Y/
M?_'O0;+4;JT32]0G$$K1"6,Q[7VG&1ELXXKL/B'X@_X1KP-J>H*X6<Q>3!_U
MT?Y5_+.?PKYGTGPE-J/@37/$:[\:;)$B #AP3^\)^@*G\Z,+0A.+E4VV%.;3
MM$^L=$U>VU_0[+5K/=]GNXEE0-U&>Q]P>#]*A\2:[#X:\.WNLW$,DT-HF]HX
M\;B,@<9X[UYM\ M>^U^&[W0Y7S)83>9$"?\ EF_/'T8-^==9\5O^27Z__P!>
MX_\ 0UK*5+EK>S>URU*\;G(_\-"Z%_T!-4_./_XJD/[0VA $_P!BZG^<?_Q5
M<7\$M!TK7]>U6'5M/@O(HK5&19EW!26ZBO;/^%;^##_S+>G_ /?JNBM'#4I\
MKBR(N<E<I^)/B3I_AKPUI&MW%A=S0ZFJF..,KN3<F_G)QT]*Y3_AH70O^@)J
M?YQ__%57^/MM#9^$]!MK>-8H(;K9&BCA5$9  _"H_@SX1\/Z]X(EN]5TBTN[
M@7TD8DE3)V@+@?3DTH4Z*H^TDNH.4N;E1J:?\>M$U#4K2Q31]21[F9(59C'@
M%F"@G#>]>L5S4'P]\(6UQ%/#X>L$EB<.CK%RK Y!'XUTM<M5TVU[-6+C?J%1
M7-Q%:6LUS.P2*%#(['LH&2?RJ6O./C9K_P#8_@*6SC?%QJ<@MEQUV=7/Y#'_
M  *IIP<YJ*ZC;LKF,/VA= )&=&U,(3][]WP/7[U>NPS1W$$<T3!XY%#HPZ$$
M9!KY"G\)30?#FT\5-NV7%\UOMQP(P,*WXL&'Y5] _!S7O[;^'MI%(^ZYT\FT
MDR<G"_</_?)'Y5V8K#TX0YJ?>S,X3;=F;GC7QC:>"-%CU.\M9[B-YU@"0;=P
M)!.>2./EK@O^&A="_P"@)J?YQ_\ Q57/C]_R(%K_ -A&+_T!ZY_X)^%=!U_P
MOJ%QJVDVMY-'>E%>9-Q"[%./IDFE2I4E0]I-7"4I<W*CKM!^-?A/6KV*SE>Y
MTZ:4[4-V@"$]AO!('XXKI?&?BZU\%Z$-5N[:>XB,RP[(<;LMGGDCTKY^^,7A
M?1_#'BJW@T>(00W-MYLEN&)6-MQ'&>@/I[5U'BV]N=0_9RT"YNV9IC+"I9NI
M"EU!/X 53PU-N$H[-B4WJGT-K_AH70O^@+J?YQ__ !536O[0/AJ:8)<Z=J=O
M&?\ EIL1P/J V:P/@=X;T37=%U>35=*M+UXKE51IX@Q4;,X&:D^-?@WPWH?A
M^SU/2[*"PO&NA#Y</RB5"I)^7IQ@'(]:IT\/[7V5G<.:?+S'M&GZK8ZMI46I
MZ?<)<VDJ%XY(SPP_QXQBN!\-?&C2?$WB*ST:WTJ_AFNF95DE*;1A2W.&)[5B
M? %[H^%-<60O]D6Y_<Y^Z&V?/C_QVO,OA/\ \E0T+_KK)_Z*>ICAH?O$]>78
M;F_=\SW[QS\2=/\  ES907MA=W+72,ZF#;\NT@<Y(]:WO"_B"#Q3X=M-9MH)
M88;D,5CEQN&&*\X..U>,_M#_ /(7T'_KA-_Z$M>C?"'_ ));HO\ N2?^C&K*
M=&*P\:BW?_!&I-S:.WHHHKD- HKA?&WQ+M? VMZ?9WVGS3VMW$TC30,-\9!
M^Z>HY]:V/#WCGPWXH5?[*U6"28];=SLE'_ #@_E6CI34>>V@N97L=%117 ^,
M/BC9>"?%%MI6HV$\MM/;"?[1 P+(2S+@H<9'R]0?PI0A*;M% VEN=]16%H'C
M+P]XGC#:3JMO.Y&3#NVR+]4.#^E;M3*+B[-#O<*AO+E;.QN+IU++#&TA5>I
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ME/C)I]GI7PH%C86\=O:Q740CBC&%4;B>/Q)J4J$YQC!-:A[R3;*?_#0NA?\
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M$5A=I<I%B'A95;.05Z9&,Y]C79.CAXU%2:=V9J4VN8]?76[&?0'UJSF2[LA
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MGX_T/QI-=1:0UPS6RJTGG0E.&SC&?H:I:Q\5/#6A^(GT*]DNQ>HZ1L$@)7+
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M4YQ44FSV:H+V!;JPN+=Y7B66)D,B'#(",9![$4EC=+?:?;7BJ46>)90IZ@,
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M+XC\90Z%!<&V6\G>.1U&=L8)8\=^%Z>N*^A]-\&:/\,-#UO6-*>[EF%DS/\
M:) P8H"PX &.:\4^%G_)7M-_Z[W'_H#U].ZSIR:OHE]IKG"W5N\)/IN4C/ZU
M6-J-34+Z=14EHV?,_P *-$@\8_$%I-;'VQ(XGO9UF.?.DW #=ZC+9Q[5Z)\:
MO!NC0>#SK5AIUM9W=I*@+6\8C#QL=I! X/4$?2O-O NM2?#/XA2IKMO+$J(U
MI=JJY9 2"' [C(!XZ@\5V'Q;^)VA:_X971=#N6NC-*DD\WELB(J\X^8#))Q^
M5:U(U'B(N/P_@)6Y&GN;'P-U!M<\%ZMX?OR9K:V?RE#'.(I5.5^@(;\Z\V\(
MW,OP_P#BW#;73[4@NFL9R>AC<[0WT^ZU>N? _P ,W6A^$I[Z]B:&?4Y1*L;C
M!$2C"$CMG)/T(KAOCYX?^Q>)++7(EVQ7\7E2D?\ /5.A_%2/^^:SISBZ\Z?2
M0VFHI]A?CWKCW_BBPT&W)<646]T'>63H/^^0/^^J[OQ%'+\//@<UG9,8[J.V
M2W,B]1)(0';ZY9L'Z5Y9\.;2[\<_%:+4M2/G- ?MURV."4 5!C_>V_D:]P^)
M^AW'B'X?:I96:&2Z55FB0=7*,&P/<@$5-7EING1>RW''5.1\_?#S7_!WAN:Z
MNO$NES:A<':ML@A22.->=Q(9A\Q..<=JS/%VMZ'<^*_[6\)0RZ;  DJQLJQF
M.8$DE0I( Z?K76?"?Q/X4T=;_3_%-K:A99!)!<W%J)0I PR'@E>@([=:U=9^
M)&F3^)DTOPEX/T/48)66&&2>QPTLA/.T #Y?KZ&NIMJJVHO[]"$O=6I/\:O$
MT]_X5\+VR,5BU& 7TX' ;Y5VCZ98G\!73_"+P3HJ^!+74K[3;:[O-1#22/<1
M+)M3<0JC.<# S[YK%^/7A^8Z-HNK00*(+(&VG6)<)$K ;2!V7(Q^(J;X8?%'
MP[I?@BWTK6[X6=S8;D7>C,)4R2"N >><8]JY6I/"KV7?6Q?V_>/+OB;H%IX9
M\=ZCIU@NRT(2:*,=(PXR5'L#G'M7UI;?\>D/^XO\J^0_'WB ^*?%][K ADA@
MG"BV61<,8E&%8_7!/XU]>6O_ !Z0_P#7-?Y4L;S>SI\V_P#PP4[<SL2U\>KI
M<VL?$2XT>UE\AKW4I;??V56D.>.XQGCO7V%7REX9_P"2W6O_ &&I/_0VI8%V
M4VNPZO0]R\-_#W1/AXEYJ]A+>3W"V;+*9Y 0P'S'  &.5KYYT#7=(D\9'7?&
M$,]_;RL\\D2*&\R0_=# D J/3V':OKJ]MEO;"XM6.%FB:,GT!!']:^5_!ES9
M>!OB!+:>*[!'MX@]K<++ )?+.05D"D'(XZCLU5A)N:FY:O\ $516M;8?\1/$
MW@OQ(+.?PYI4FGW2$K<9ACB21,<<*Q!(/MT->C:+K$^L?LW:DUS(9)+6UFM=
MY.2RI]W/_ 2!^%9_C+XF>#M,^SQ^%]"T34W.6GDFL0L:#L!P"3^E=9J3SS?
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M9+P C: .XVXXJY14L2W%[+H).T-31\=>/-#\5>'+>QTWPN^G_9Y5,%T54!4
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MD<3;T64'"G&,T_1M"TOP]9&STFRBM+9G,ACCZ%C@$_H*T:*.9VM?0+!1112
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MS(X^C,21^%=+16CJU&K.3L+E78;)&DL3QR*&1P58'N#UKD_^%7>"/^A;LO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *MG]ZY_Z[-_2
MK55;/[US_P!=F_I5J@$%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU/4Z*S=6\0Z-H2JVJZI9V6_[HGF5"WT!.34VFZMIVL6WVG3;ZWO(,X\R"0.
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M/A6_AO2VDO[Q%A027,P#R[6!9F9CU.">M7/%6@:CJGPJN-#M(5?4'LHH1&7
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MM&%F:_DE1A(&\Q"% ;CIG!XKO*QQ#3JMHJ.QYQ\<O^277W_7>'_T,5VWA_\
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MUR/16U_1[!6\_35.3O.?GV?Q<8['[O/6LNPU+P'XA\;:).+._P##&O6LH\J
MVRVXN#GA&(!![CMG)%=CXPTOQD-<L=:\*Z@DB0+LN-*N9"L4PY^8'UY]N@K
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M#LS?.5/!( P,],FMSX9Z1XS\*00^'=4TNQ.DPM(POHKD%CDD@;>O)/H.*T?
M_AK5=%\7^,=0O[=8[;4KT2VK"16+KE^2!TZCK5SG:51I[[?>)+8Y?4-+LO#G
M[07A\:/;QV4=_9R&XBA7:C\./NC@?='XC->QUP&O^&-6OOB]X<U^WMT;3;*V
M>.>4R*"K'?CY>I^\.E=_6-:7,HZ]"HJUPHHHK H**** "JEU_P ?5I_UT/\
M(U;JI=?\?5I_UT/\C0#+=%%% $-W_P ><W^X?Y4Z#_CWB_W!_*FW?_'G-_N'
M^5.@_P"/>+_<'\J!=22BBB@84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$D; XR5!-6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1SQZ\X-,\?6/A'7?$VEZ1JVH76FZ]L,EC=V^8R 2>-^-O53QG.>G7GG[Z_\
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MZ]H;:PVE1G7DLDU'+>8MD6,6,G;C=STQGWKSSXF2QP?$?X>R2NL<:WDF68X
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M^2<^(/\ KQD_E0!KZ#_R+VF?]>D7_H K0K/T'_D7M,_Z](O_ $ 5H4 %%%%
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MQMAIZV!A5[41"'RG&X%,8P<]>/6K%%3S.UAG%1_"3P/%?"[70HBP;<(FE<Q
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MY.E2_P#@9+_\57H%%5&K.*M%M TGN8_AOPOI/A+3Y+'1K=H+>24RLK2,^6(
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M/^O2+_T 5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6S^]<_]=F_I5JJ
MMG]ZY_Z[-_2K5 (**** "BBB@ HHHH **** "BBB@ KC/'OA[6/$%J88=<ET
M[1H[>1[N*V&)KA@,A=_\*^OKTQ79U3U?_D"WW_7O)_Z": .%^"#K'\(M+=CA
M5:X)/H/->L'P?X3T[XGZ;>^+/$SW-U/>74JV*I<.BV42G:OE@'&<C.3GITZY
MW/@G&)O@]IL1. YN%)^LKU0^$VO:9X>\%WFA:S?P65[H=S/'<QW#A&";RP8
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M@"+[7;_\]X_^^A1]KM_^>\?_ 'T*EP/048'H* (OM=O_ ,]X_P#OH4?:[?\
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M_H K0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** *MG]ZY_Z[-_2K55;/[US
M_P!=F_I5J@$%%%% !1110 4444 %%%% !1110 4V2-)HGBD4,CJ593W!ZTZB
M@"EI.D:?H6FQ:=I=JEK:19*1)G R23U]R:S]6\%^&M=ODOM5T2RN[I, 2RQ
ML0.@/]X>QS6[10 V.-(8DBB14C0!551@*!T '84ZBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8!7BGD.9"I)!5CWP<8/7FO9* /GKP\GQ1^)=SJ%^?$-QH,%NV(H0C1*6/(4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5L_O7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BL'Q5XPT?P=8Q7.K3.IG?RX(8D+R2MZ*H
MZ_RY'J*Y<_&?P^/^85X@_P#!<W^- 'HU%-C<2Q)( 0& 89'/-.H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#YO^'6WQ/^T)K&IWB"4V[W$\>X9"[6$:?D",?04>.%7PW^T?I-
MY8H(FN9K:60)QN+MY;_F,Y^M0Z9>6_PP^/VIMK.Z#3[LR[9MI($<IWHW'4 C
M:<=,'TI\UW#\3/VA+"ZT@//IMBT3-/M(!CB.XMST!8X&?44 ?2=?,GB+7VT/
M]I"]U.'3IM0N(6$4%I ?FED:W"*.A[MV!KWFY\<:#:>+X/"TUTZZM. 4B\IB
M#D$CYL8Z UPVK_$K0/#OQ0.E:UX6M[*59!C66"LVUEX?A,X/W3SQSZ8H JZ)
M\;+^+Q9%H'C'PZ=(EG=4CD!8;"QPNY6ZJ?[P/X>GLM?,WQ4U6Q^(WQ(T+2_#
M$OVR5%$#7,(^4EFR<'N%&23TZU[KXY\2)X0\%:AJY8&:&+9 #_%*W"_J<GV!
MH \1\=SO\3?C=8^&K9RVGV,GV=RIX 7YIF^O&W_@(KZ/BB2&)(HE"1HH55'0
M =!7A?[.WAQVBU3Q9=@M+<.;:!VZD9#2-^)VC\#7N] !1110 4444 %%%% !
M1110 54NO^/JT_ZZ'^1JW52Z_P"/JT_ZZ'^1H!ENBBB@"&[_ ./.;_</\J=!
M_P >\7^X/Y4V[_X\YO\ </\ *G0?\>\7^X/Y4"ZDE%%% PKD_B-'=2>$F6#[
M6;?[1";X6>?.-MO'F;,<YQUQSC-=910!Y)X9_P"$7'C?2Q\/Q<B#;+_:NP3"
MW\K:=N[S./,W[<8YQG-=E?>#$AO)-3\-W;:+J+G=((DW6UP?^FL70G_:&&]Z
MZ@*JYV@#// I: $3=L7?C?CYL=,TM%% !13)98X8FEE=8XU&69C@ >I-5-/U
MK2]6W_V;J5I>;/O_ &>=9-OUP>* +U%4]0U?3=)17U'4+6S5SA3<3+&&/MDU
M9BFBN(EEAD22-QE71@0P]010 ^N8^(O_ "3GQ!_UXR?RKIZYCXB_\DY\0?\
M7C)_*@#7T'_D7M,_Z](O_0!6A6?H/_(O:9_UZ1?^@"M"@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3_A;/A[_ )X:C_WX'_Q5'_"V?#W_ #PU'_OP/_BJ .[HKA/^%L^'O^>&H_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8VO^%-!\4PI%K>EV]XL>=C.,,F>N&&"/P-/T'PQHGABV>WT73+>RC<@OY:_,
M^.FYCR?Q-:U% &'/X.T"Y\3Q>))M.5]7A "7/F/D8! ^7.WH3VJ37O"NA>)X
MDCUK2[:]"9V-(OS)GKAAR/P-;%% &#H'@OPWX79WT72+:TD<;6D4%G(]-S$G
M'MFI_$/A?1O%5I%::W9"[MXI/,2,R.H#8(S\I&>">M:]% %+2-(L-!TN#3-,
MMEMK. %8XE)(4$Y/)R3R3UJ[110 4444 %%%% !1110 4444 %5+K_CZM/\
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MPCJW^D]CG^%J:$SS:BBBJ$%%%% !1110 4444 %%%% !1110!-:?\?\ :_\
M7>/_ -"%>]5X):?\?UK_ -=X_P#T(5[OY\(/^M3_ +Z%2QHDHJ/[1#_SVC_[
MZ%'VB'_GM'_WT*0R2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H DHJ/[1#_ ,]H
M_P#OH4?:(?\ GM'_ -]"@"2BH_M$/_/:/_OH4?:(?^>T?_?0H DHJ/[1#_SV
MC_[Z%'VB'_GM'_WT* )**C^T0_\ /:/_ +Z%'VB'_GM'_P!]"@"2BH_M$/\
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M_P#5)_NBN[!X>%9-RZ&52;CL?2O_  OKP?\ \\M5_P# 4?\ Q5'_  OKP?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTV^BMM?UN[LI+"/6M2DO+:TE7:Z1GH6'8G/Z>]>AT44 %(R*XPRAA[C-+10
MSR8O^>2?]\BCR8O^>2?]\BGT4 ,\F+_GDG_?(KC/B0B)HMGM51_I/8?[+5VU
M<7\2O^0+9_\ 7R/_ $%J:$SS.BBBJ$%%%% !1110 4444 %%%% !1110!+:?
M\?UK_P!=X_\ T(5[QY,1/^K3_OD5X1:?\?\ :_\ 7>/_ -"%>]5+&AGDQ?\
M/)/^^11Y,7_/)/\ OD4^BD,9Y,7_ #R3_OD4>3%_SR3_ +Y%/HH 9Y,7_/)/
M^^11Y,7_ #R3_OD4^B@!GDQ?\\D_[Y%'DQ?\\D_[Y%/HH 9Y,7_/)/\ OD4>
M3%_SR3_OD4^B@!GDQ?\ /)/^^11Y,7_/)/\ OD4^B@!GDQ?\\D_[Y%'DQ?\
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M1110!PWB;X=VOB3Q"NKW'B'5;2:- L,=M.$$/')7C(SW]:CT[X=BQU.TO/\
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M5((]15>RU"SU&.22SN8YTCE:%S&V=KJ<,I]"#VH X_\ X5/X=_YZ7_\ W_\
M_K4?\*G\._\ /2__ .__ /\ 6KL+34+._:X6TN8IFMI3!,$;)CD&"5/H>1^=
M6: .&_X5/X=_YZ7_ /W_ /\ ZU'_  J?P[_STO\ _O\ _P#UJ[FB@#AO^%3^
M'?\ GI?_ /?_ /\ K4?\*G\._P#/2_\ ^_\ _P#6KN:* .&_X5/X=_YZ7_\
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M@ HHHH *XOXE?\@6S_Z^1_Z"U=I7%_$K_D"V?_7R/_06IH&>9T4451(4444
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MJ*^N_L+!?RO[V?/_ -J8GO\ @CTG_A<%_P#] JW_ ._C4?\ "X+_ /Z!5O\
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M110 5S'Q%_Y)SX@_Z\9/Y5T]<Q\1?^2<^(/^O&3^5 &OH/\ R+VF?]>D7_H
MK0K/T'_D7M,_Z](O_0!6A0 4444 %%%% !1110 4444 %%%% !1110 4444
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M>BV?S) OSR8P9'/+,?J?Z5S_ ,5O&E]X*\*-=:=8S37,Y,27(4&.V/\ >?\
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M&/B-[JUA:8I<7QV2A1DKQ@KD @'G'O0!ZMIMA;Z5IEIIUHI6WM84AB4G)"J
M!^@JU7DGA;[?X?UKPI<VWB'5-3T7Q+"P-KJDOFR6[^5YJLK?@5(_GQCUN@#A
M?%&C^)=/\4Q^*O"D-M>S/:BTO=.N'\L2HK%E9&[,"2.>U8YM/'GCK4=+BU[1
MK70-%L[N.[G07 FEN&C.548Z#.,]/Z5?\47_ (IUKQPGA7PWJD6CQ06(O;N]
M: 2NVYRJHJGCMG^O8I9^#_B!!?6\MS\13/ DJM)#_9D:^8H.2N<\9'&: -3P
MGH.MVWB+7=?\036S75^R0V\-MG;%;QEMN<_Q'<2>OZX'8444 %%%% !1110
M4444 %%%% !1110 5Q?Q*_Y MG_U\C_T%J[2N+^)7_(%L_\ KY'_ *"U- SS
M.BBBJ)"BBB@ HHHH **** "BBB@ HHHH FM/^/\ M?\ KO'_ .A"O>J\%M/^
M/^U_Z[Q_^A"O>JEC04444AA1110 4444 %%%% !1110 4444 %%%% !1110
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MT''3'/I6?X8USX0W7B6QA\/VMDFK.Y%LT=C(C!L'HQ4 <9H ]7HHHH ****
M"BBB@ HHHH **** "BBB@#Q/Q)_R-.J?]?#?R%9=:GB3_D:=4_Z^&_D*RZHD
M****8!1110 4444 %%%% !1110 5WWPR_P!9J?TB_P#9JX&N^^&7^LU/Z1?^
MS4F,]"HHHJ1A7G7Q@_Y 6G?]??\ [(U>BUYU\8/^0%IW_7W_ .R-7HY1_OM/
MU_0Y,?\ [M/T/'Z***_0CY$**** "BBB@ HHHH **** "BBB@"WI7_(9L/\
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MN[' 4 9)- '#:UH=UX@^*NBS3Z<RZ5HT#W'VIU&)9V(VH#U(& WU%=Y7*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX)!!KL-+UGX?W.IP0Z5>>'WOV;]RML8O,)P?NXYZ9H ZVBBB@ HHHH ****
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MW52Z_P"/JT_ZZ'^1H!ENBBB@"&[_ ./.;_</\J=!_P >\7^X/Y4V[_X\YO\
M</\ *G0?\>\7^X/Y4"ZDE%%% PHHJ.=VB@DD2-I&52P1>K$#H/K0!YMXMGNO
M"_B76M4ETR[O-,UK35MC/:QF1K:9 X 91SM8,.?6LCP]J%QXKT_P7H6GZ7>I
M%HTEO<W]]<0&.-#"F-B$_>+'CCM5JQ^)^L'Q/JHD\*^()H!# 8[!;8>9;'#9
M9AU ;C'^[6@WC/Q+K^L:-9:9X7UO2X_MR/>W%Y %C\@9W+D^OY\4 >E4444
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M9 P.01/'D'_OJ@#["HKGO!%QKD_A.S'B.S>VU6)?*F#,K>9MX#\<<C]<UT-
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ML_\ KY'_ *"U- SS.BBBJ)"BBB@ HHHH **** "BBB@ HHHH FM/^/\ M?\
MKO'_ .A"O>J\%M/^/^U_Z[Q_^A"O>JEC04444AA1110 4444 %%%% !1110
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M>0"JD*>3SD&@#TVBBB@ HHHH **** "BBB@ HHHH **** /$_$G_ "-.J?\
M7PW\A676IXD_Y&G5/^OAOY"LNJ)"BBBF 4444 %%%% !1110 4444 %=]\,O
M]9J?TB_]FK@:[[X9?ZS4_I%_[-28ST*BBBI&%>=?&#_D!:=_U]_^R-7HM>=?
M&#_D!:=_U]_^R-7HY1_OM/U_0Y,?_NT_0\?HHHK]"/D0HHHH **** "BBB@
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M3^5=/7,?$7_DG/B#_KQD_E0!KZ#_ ,B]IG_7I%_Z *T*S]!_Y%[3/^O2+_T
M5H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YO\ &F^\3V/@F1_#R,(F.+V>$GSHH_50.@]3V'YUZ12$!E*L 01@@]Z
M/@$DDY/)HKT#XMZ7X8T[QI/#X9G+DL?M5M&G[N"3N$;OWR.WZ#S^@ KU?P_X
MG^+'AKPM_:<$-W-HBIO66]C\Q53U!8[@OZ5@_"S3O"]_XR@A\5SF*'@V\3@K
M'-)G@.W8=/8]/K])_%50GPKU]5 51:X '  W"@#Q>YU_XQ>.=#26TM;E=.G!
MQ)8HL(E'(/S9R1UJ#PAHOQ1\$BX.D>$T\^<C?//"CR #^$'=P.^*]G^#?_)*
M-#_W)/\ T8U=W0!X-_PD_P <_P#H78?_  '7_P"+H_X2?XY_]"[#_P" Z_\
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M_JW2_P"?C^XX/[9J?RH]]_X6'X8_Z"0_[]/_ (4?\+#\,?\ 02'_ 'Z?_"O
MJ*/]6Z7_ #\?W!_;-3^5'OO_  L/PQ_T$A_WZ?\ PH_X6'X8_P"@D/\ OT_^
M%>!44?ZMTO\ GX_N#^V:G\J/??\ A8?AC_H)#_OT_P#A1_PL/PQ_T$A_WZ?_
M  KP*BC_ %;I?\_']P?VS4_E1[[_ ,+#\,?]!(?]^G_PH_X6'X8_Z"0_[]/_
M (5X%11_JW2_Y^/[@_MFI_*CWW_A8?AC_H)#_OT_^%'_  L/PQ_T$A_WZ?\
MPKP*BC_5NE_S\?W!_;-3^5'T3;^+-*NX1-;&[GB8D"2*SE93CKR%J7_A)+'_
M )XW_P#X S?_ !-9'PS_ .1%L_\ ?E_]#:NNKYC$TE1K3IK6S:^X]NC-U*<9
M]T9'_"26/_/&_P#_  !F_P#B:/\ A)+'_GC?_P#@#-_\36O16)IJ<O=_$/PQ
M87+6UYJ0MIU +131.C@'D9!&:A_X6=X._P"@W!^1_P *\&^,X!^*>IY'_+&#
M_P!%BN"VCT%>G3P$9P4K[F$JK3L?6W_"SO!W_0;@_(_X4?\ "SO!W_0;@_(_
MX5\D[1Z"C:/05?\ 9T/YB?;L^MO^%G>#O^@W!^1_PH_X6=X._P"@W!^1_P *
M^2=H]!1M'H*/[.A_,'MV?6W_  L[P=_T&X/R/^%'_"SO!W_0;@_(_P"%?).T
M>@HVCT%']G0_F#V[/K;_ (6=X._Z#<'Y'_"C_A9W@[_H-P?D?\*^2=H]!1M'
MH*/[.A_,'MV?6W_"SO!W_0;@_(_X4?\ "SO!W_0;@_(_X5\D[1Z"C:/04?V=
M#^8/;L^MO^%G>#O^@W!^1_PJ>T^(/AG4+@6]CJ/VJ<@L(H(G=B!U. ,X%?(6
MT>@KT3X(@#XFVV!_RZS?R%9U<!&$'*^Q4:K;L?1/_"26/_/&_P#_  !F_P#B
M:/\ A)+'_GC?_P#@#-_\36O17FF^ID?\))8_\\;_ /\  &;_ .)J:TUJUO;@
M011W:N03F6UD1>/=E K1HI!J%%%% PHHHH **** "BBB@ HHHH **** "BBB
M@#GO$OA2T\13Z;>R7=S97NF3>=;W-L^U@#C<A]58  BN3UKX8'5-3O8[?Q1-
M:>'M2NA=ZAI2(I$LF06*OG*AB 2/7\,3?$72%\1>*_"VBZI<3PZ!<M/YPB<H
M)IU4&.-F[9&[ ZG!QS2_\*-\"'_F'7/_ (&2_P#Q5 'HJ*J(JJ % P /2N<\
M6WGBVTCM#X4TRPOG9F^T"[EV;!@;<<C/>NBC18HUC4850%'T%.H \S_MGXO_
M /0K:!_X%G_XNJB:;\0O$'C7PUJ/B#1=,L[/2IY)&>UN=Q(=,<@L?0=*T=6U
MSQIKOC#4]$\(OIEE;:2L:W-U?*S&21UW!5 !X ]OQJWHNG_$R+6;636=:T.?
M358^?';P,LC+@]"5]<4 =W1110 4444 %%%% !1110 4444 %%%% 'B?B3_D
M:=4_Z^&_D*RZU/$G_(TZI_U\-_(5EU1(4444P"BBB@ HHHH **** "BBB@ K
MOOAE_K-3^D7_ +-7 UWWPR_UFI_2+_V:DQGH5%%%2,*\Z^,'_("T[_K[_P#9
M&KT6O.OC!_R M._Z^_\ V1J]'*/]]I^OZ')C_P#=I^AX_1117Z$?(A1110 4
M444 %%%% !1110 4444 6]*_Y#-A_P!?47_H8KZ:KYETK_D,V'_7U%_Z&*^F
MJ^3XE^.G\_T/?R;X)_(****^8/:"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JI=?\?5I_UT/\C5NJEU_P ?5I_UT/\ (T RW111
M0!#=_P#'G-_N'^5.@_X]XO\ <'\J;=_\><W^X?Y4Z#_CWB_W!_*@74DHHHH&
M%%%<]XR\4IX3T5+L6DEY=3S+;6MK&<&65N@SV'6@#DM;\>V?A'XHSP:KJLSZ
M;/91@VZ(S"TESD,0!R&7N,X/6MJQ^*_@[4M1MK"UU4R7-S*L42>1(-S$X R1
M6;I'C#5?^$FM-(\9>%H-,FU$'['<QNLJ2,HSL8\X./?\*] 6SM58,MM"&!R"
M$&10!-1110!YUX\U/^W-<MO \-VEI;3(+C5[EY FVVSQ&I/\3GCCH*J:/<Z9
M:_&V^2WN+6.T70X((-LB[.' "+SZ=J[+5O!7AK7;XWNJZ+:7=R5"&65,G Z"
MN5L/A5IMK\0+G4SI>G#1!;1_9+90<Q7"L"7VXP.AYS0!)\+OFU#QH\G_ !\'
M791)D<X &/ZT>%L+\9/&JQ?ZHPVI?TW[/_UU/?>%/$>C>*-0UOPA=Z<$U3:U
MY9:@'V>:!CS%*\Y]1_D:O@OPI+X;M[ZYU"]%]J^I3_:+VY5=JEN@51V4#I0!
MU%>=?$^+Q6?#NNO9W.DKHOV)M\<T;F?I\V"#CZ5Z+7,?$7_DG/B#_KQD_E0!
MKZ%_R+VF?]>D7_H K0K/T'_D7M,_Z](O_0!6A0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444V26.&)Y976.- 69V. H'4D]A0 ZBO&
M/^&@M(_X3G[!Y)_L#'E?;L'=YF?OX_N=O7O[5[)%+'/"DT,BR1.H9'4Y# ]"
M#0 ^O-OC7XNG\+^"O)L)FBU#49/(B=#AD7J[#T..,^]>DUX1^T&&AUGPI=S\
MV23,'';(92?TH ZWX5_#6P\,>'H;Z_M4GUF]B#SR3*&,88?<&>G!Y]:\SN?!
M>A0_M&P:$EFHTMF%P;4\IGRR^W']W/;TXKZ3B=)84DC(,;*&4CH0>E>%WO\
MR=9;?]<5_P#1!H [;XE_#73/%OA^1[6WAM=5M$+VT\40!;:/]6V.HXP/2O/=
M%\7WGB7X >)[+4I&DO=,B$)D=B7="1M+9YR,$?A7T$[*B,S'"@9)]J^2/#/A
MGQ/XQOO%$?A6ZCATZ:8K<)))L652Y*CH?3- 'OOP;_Y)1H?^Y)_Z,:N[KGO
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MX"UE/#-Z-6,Y OYB=AAC ZA,9Z9_4]JR? 5HD=Y?:_/&SP:5 710N=\K A0
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M<VMZPBPR +D$\$'&>M+X_P#B-X;?PM?Z/I5_!J^J:E ]I;6MDPF+-(-N3MR
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MC6;6+6/#&F6NG,Q$\\5X'9!@\@;N><4 =W1110 4444 %%%% !1110 4444
M%%%% 'B?B3_D:=4_Z^&_D*RZU/$G_(TZI_U\-_(5EU1(4444P"BBB@ HHHH
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MHH **** "BBB@ HHHH *J77_ !]6G_70_P C5NJEU_Q]6G_70_R- ,MT444
M0W?_ !YS?[A_E3H/^/>+_<'\J;=_\><W^X?Y4Z#_ (]XO]P?RH%U)****!A7
MG?Q4OH]*D\*ZE-%/)!::NLT@AC+MM"-T KT2B@#Q#Q7\2]%UO4O#=S:V.KA=
M,U-;J;S+)@?+"L#M]3DCBNPTWXO>']4U2TT^"RUA9KF584:2R*J"QP,G/ KO
MZ* "BBB@ HHHH **** "N8^(O_).?$'_ %XR?RKIZYCXB_\ ).?$'_7C)_*@
M#7T'_D7M,_Z](O\ T 5H5GZ#_P B]IG_ %Z1?^@"M"@ HHHH **** "BBB@
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MR0*XK3_C#<W#QZE?>$[^R\+32;(]7=]P4$[5=TQPI/?)Q[U*?BMJVIAG\->
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M9_[\O_H;5UU?G&8?[W5_Q/\ ,^QPO\"'HOR"BBBN,Z#Y9^,__)4]3_ZXP?\
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MC!Y'U /I.BN,^%OBVX\9^!K74KP+]MC=K>X91@.ZX^;';((/U)KLZ "BBB@
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M_P E3U/_ *XP?^BQ7!5]%A_X4?1'%4^)A1116Q 4444 %%%% !1110 4444
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M\):'\7?%!\2W>GFXNHK=[::X(<1($PT1S]QL@-CN"*Z[2O$W@*]U.WMM*O\
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M@NX][R*AR%W,3C/<C/:NOH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK^=<?\^I_P"^Q1YUQ_SZG_OL5\Z=I8HJOYUQ_P ^I_[[%/CDE9\/ 47UW T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 54NO^/JT_ZZ'^1JW52Z_X^K3_ *Z'^1H!
MENBBB@"&[_X\YO\ </\ *G0?\>\7^X/Y4V[_ ./.;_</\J=!_P >\7^X/Y4"
MZDE%%% PHHHH XSQ#X#G\4:U)-J'B/4XM)**JZ;:2>4I(')9AR<FM/0O!'AO
MPT =*TBVAE'_ "V*[Y"?7>V353Q3X\L?#%TEB+*^U+47B,_V6RBWLD8ZNYZ*
MO!Z^E&G>/M,OM4TO3Y8+JUEU2SCN[229/W4NY=QC#C@N!U% '5T444 %%%%
M!1110 5S'Q%_Y)SX@_Z\9/Y5T]<Q\1?^2<^(/^O&3^5 &OH/_(O:9_UZ1?\
MH K0K/T'_D7M,_Z](O\ T 5H4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445X%\8?C"%$_AGPS<@L08[R^C;IV,:']"?P% %[]H$FXO?"5C(
M/]&ENVWD]#DH/Y$_G7ML<:0Q)%&H5$4*JCH .@KX_O/&ESXP\&VVC:M<#^U-
M)<2:=<=#,F,-&Y_O  $'OC!YY/T+\,/B)9>-=!ABFGC36K=-MU;YPS8XWJ#U
M!_0T <*__)U(_P"N(_\ 1->ZNBR1LCJ&1@0P/0BO"G_Y.I'_ %Q'_HFN^^)G
MQ#L? ^@3;9XWUB="MK;9RV3QO8=E'7GKTH ^=EN]2TY_&GA?1M+EO;.\N/+;
MRD9O("2G:0 ._2OI7X9:3>Z)\.]'T_483#=1Q$O&3DKEB0#[X(KE_@9X2N-$
M\,3ZUJ 87VL,)L-U$?5<^Y))_$5ZK0 4444 %%%% $5U<Q6=I-=3-MBAC:1V
M]% R?T%?$WC?Q5<^,O%=YK$Y8)(VV",_\LXA]U?ZGW)K[(\2:!;^)]#GTB[G
MN8;:? E-NX5F7/W<D'@]Z\^_X9Z\%?\ /35?_ E?_B: /E>N@\$^)9/"/B[3
M]93>8X9 )D0X+QGAE_*N[C^'&@O\<6\'EKS^S!$6SYH\S/E[OO8]?:O3?^&>
MO!7_ #TU7_P(7_XF@#U"SNX+^R@O+:0203H)(W'0J1D&IZY&>73OA;\/RRB\
MN[#3EPB,ZM)AFZ9X& 37*:E\<K(B%/#NAWNM2F%9K@0@[8,C.TD Y([]O>@#
MUFBN'\ ?$_2/'JRP012V>I0+NEM9>>,XRK=QGZ'VK+\5_&.PT+79-#TC2KO6
M]2BXFCMP0L9[C."2?H,#UH ],HKS3PC\8]/\0:ZFA:II=WHVJ2'$<5QRKGJ!
MG ()'J/QKTN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@"K9_>N?^NS?TJU56S^]<_P#79OZ5:H!!115;4;62]TVZM8;F2UEFB:-)
MXOO1$C 8>XZT 6:X_P"*<5C)\,M?_M!8S&MHS1EQTE_Y9X]]V*Q!\,?$0'_)
M2_$'Y_\ V5$?PA%[>V\OB7Q5K.NVMNXD2SN9,1,P_O#)S^E '8>#GNI/!.A/
M>[OM36$!EW==VP9S[UMT@    P!T I: /,/%NDVOC#XB2Z%K<TQTVRT<7EO9
M),8Q/(SLI=L'+;=JCVS[G/.V%NFE^$/AYXIM+J6'5BUKIOE"0[+J!W8-&5[D
M!BP/M],=SX[TSPGK6I:1INM7DUIK-P[)I\MG(R7 R/FP0" O^]Q7'^#;+X<Z
M3XZATB'7=0U36+%F@LQ?R%H87&=R18 7<.?QZ<T >T4444 %%%%  1D8->9V
MGA_XD^')+S3]&U;2]2TV>5GM[C5GE:>V![<9W =OZ=*],HH YKP1X23P?H36
M;737=Y<3-=7ETPQYLS?>..PX KI:** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH JZG_R"KS_K@_\ Z":^8D^XOT%?3NI_
M\@J\_P"N#_\ H)KYB3[B_05]9PU\%3U7ZG@YSO#YCJ***^G/$"BBB@ HHHH
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MAA@;EOX<D'H/3ZURRZ;I_AOXTZ/IWA6!;5)[.5]5M(&(B" ?([+T#9Z?_7H
M]2N;RVLT#W5Q# I. TKA03^-2JRNH92&4C((.0:\LT'1-/\ '_C'Q1JGB"W7
M4+>PO#I]C;S$F*)4'S,%Z;B3UJ_\/-^B>*?$_A!99'L-/DCN+%)&+&*.1<E
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MWA#4KS64U_PWK)TK5Q"()2\0DAN(P<@.I[@DX/O5#2_!7B*]UZRU7QAX@BU
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M^GW_ +\?_7H_LS&?\^W]P?7*'\Z.XHKA_P#A:WAO_I]_[\?_ %Z/^%K>&_\
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M\?\ UZ/[,QG_ #[?W!]<H?SH[BBN'_X6MX;_ .GW_OQ_]>C_ (6MX;_Z??\
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M.J?]?#?R%9=:GB3_ )&G5/\ KX;^0K+JB0HHHI@%%%% !1110 4444 %%%%
M!7??#+_6:G](O_9JX&N^^&7^LU/Z1?\ LU)C/0J***D84444 %%%% !1110
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M ]&HHHH **** "BBB@ KF/B+_P DY\0?]>,G\JZ>N8^(O_).?$'_ %XR?RH
MU]!_Y%[3/^O2+_T 5H5GZ#_R+VF?]>D7_H K0H **** "BBB@ HHHH ****
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MZ%N57ZORBMV:8;#JK?F=NB]7L>1Q1232I%$C/([!411DL3T K6_X1/Q%_P!
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MOE?+C[NXY_,4 >?>)_%_B#XQ:VWA?PA#+%HBL/M%PP*B09^_(?X4XX7J?3/
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MHJ#[0W_/M-^0_P :/M#?\^TWY#_&@">BH/M#?\^TWY#_ !H^T-_S[3?D/\:
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M_B:[^BC^U<9_S\8?4</_ "(X#_A4>A?\_>H?]_$_^)H_X5'H7_/WJ'_?Q/\
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M+^UG6ZLKR,;C#*N<''<8)!'?-<%!\.O'MQ)J]K?^*=.AL-7E$E]+9VQ\Z4;
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M-MU_?A_[X/\ C1MNO[\/_?!_QJ>B@"#;=?WX?^^#_C1MNO[\/_?!_P :GHH
M@VW7]^'_ +X/^-&VZ_OP_P#?!_QJ>B@"#;=?WX?^^#_C1MNO[\/_ 'P?\:GH
MH @VW7]^'_O@_P"-&VZ_OP_]\'_&IZ* (-MU_?A_[X/^-&VZ_OP_]\'_ !J>
MB@"#;=?WX?\ O@_XT;;K^_#_ -\'_&IZ* (-MU_?A_[X/^-&VZ_OP_\ ?!_Q
MJ>B@"#;=?WX?^^#_ (T;;K^_#_WP?\:GHH @VW7]^'_O@_XT;;K^_#_WP?\
M&IZ* (-MU_?A_P"^#_C1MNO[\/\ WP?\:GHH @VW7]^'_O@_XT;;K^_#_P!\
M'_&IZ* (-MU_?A_[X/\ C1MNO[\/_?!_QJ>B@"#;=?WX?^^#_C1MNO[\/_?!
M_P :GHH @VW7]^'_ +X/^-&VZ_OP_P#?!_QJ>B@"#;=?WX?^^#_C1MNO[\/_
M 'P?\:GHH @VW7]^'_O@_P"-&VZ_OP_]\'_&IZ* /E?XR;O^%HZEO(+>3!G
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M^2<^(/\ KQD_E0!KZ#_R+VF?]>D7_H K0K/T'_D7M,_Z](O_ $ 5H4 %%%%
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MNV[&VVF2<Q[9.RGUW=![X]:]X_X4%X%_Y][[_P "C0!TO_"RO!7_ $,VF_\
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M)?ORD#!8^YZU<JKIEK-8Z7:VMQ=R7DT,2H]Q(,-*0,%C[FK5 !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\L_&?_DJ>I_\ 7&#_ -%BN"KO?C/_ ,E3U/\ ZXP?^BQ7!5]%A_X4?1'%
M4^)A1116Q 4444 %%%% !1110 4444 %>B?!'_DIMM_UZS?R%>=UZ)\$?^2F
MVW_7K-_(5CB?X4O0NG\2/I^BBBOG3M"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K)\3>(;/PKX>N]:OTE>VM5!=85!<Y8*  2!U([UK51UC1[#7]+FT
MS5+<7%G. )(BQ ;!!'((/4"@#R__ (3_ ,:^* IT.PTCP_8R#*7FK7:M(1ZB
M,'@_4$>].B^'VB:M+%=>-O&[^()D.X0->+#;H3UPBGC\"/I71_\ "G/ '_0N
M0_\ ?^7_ .*H_P"%.> /^A<A_P"_\O\ \50!V\:HL:K'C8  N.F*=3418XU1
M!A5  'H*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12,ZHN
MYV"CU)Q3/M$!!/G1X49)W#@>M &-XP\56/@SPW<ZS?Y98QMCB4X:60_=4?7]
M ">U<]\,OB2WQ$@U*1M*%A]B:-<"?S=^X-_LC&-M<#>2/\8_'EU/AF\(^'XW
M*X)"W,F#@_B0#[*.Q:G_ +-'-EXC/_36#^3T >\UY?XO^--AX?\ $#Z!I.DW
M.M:I&VR2.%MJA_[H(!+$=\#C\\>H5Y]XFA\(_#2*;QE_8.Z]DF*/+ <R%I,E
MC\QQSS0!6\%_&+3O$^N?V%J.FW&C:N<A()SE78#)7) (;'8BL[Q?\:+GPUXU
MNO#=IX9?4I80FUHKDAGW('/RA#TS^E<7X5D?XJ_&:/Q.'M-.M[!XY!:F8&>1
M8Q\N%ZMSC)Z <<U2UW6[[2?VCM0OM+TPZCJ"OY-M;*V SM $R?89)/3IU% '
M?Z%\8M<U?7]/TZ?P)?6D5U<)"]P\CXB#'&XYC'3ZBO7:\2TGXP^)='\90>'_
M !YHD%C]I9526 $>7N.%;[S!ESP2#QSUQBO;: "BBB@ HHHH **** "BBB@
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MHH **** "BBB@ HHHH **** "BBB@#Y9^,__ "5/4_\ KC!_Z+%<%7>_&?\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J77_'U:?]=#_(U;JI=?\
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M^E?.K'<Q. ,G.!T%>@?%#Q+XNU^;34\4Z2=-,2.8(_*9!)DC+8).<8 KSZ@
MKI_ C>''\206GBFU,NFW)\LRH[*T+'[K9!Z9Z_GVKF** /9OC)\/O#G@ZRT:
M31;62)KJ=DD+S,X90!CK]:^B]&LK;3]%LK2S@2"WBA54CC& HQ7S'XEN/B+X
MWT;1X+OPK<F"S59()8;9\R J "22<Y !KKT^(?Q<CC1%\%X55"C_ $.3L/K0
M![W7@OP _P"1H\7?]=!_Z&]*/B-\7<_\B7G_ +<Y/\:Y+PA+\2?!E]J5WI_A
M&XDDU!@TGG6CD*<D\8(]30!]345X-_PL;XO?]"9_Y)R?XT?\+&^+W_0F?^2<
MG^- 'JOCGQ?:>"?"]QJUSAI!\EO%_P ])#T'T[GV%?'?B/Q-JWBO5I-2U>Z:
M>=N .BH/[JCL*[/XG^*/&FO6.G0^*=$.FPQR.\)\EH_,; !ZGG _G7FM !7I
MWPH^*5YX1U2#3-1N&ET&9]KHW)MR?XE]!GJ/ZUYC10!]_(RNBNC!E89!'0BE
MKYUT#X@_%.#P[IL-AX6-W:1VZ)#<&UD8RH!@-D'GBM#_ (6-\7O^A,_\DY/\
M: />J*\&_P"%C?%[_H3/_).3_&D_X6-\7O\ H3/_ "3D_P : />J*\&_X6-\
M7O\ H3/_ "3D_P :/^%C?%[_ *$S_P DY/\ &@#T/XG^/%\!^&/M<2+)J%RQ
MBM$897=C)9O8?KQ7R)JVL:CKNH27^J7DMU=2'+22MD_0>@]A76_$[Q)XK\0:
MC8CQ3IATZ6"(^3#Y31[@3RV">>GZ5PE !7LOP:^*=]I>L6GAK5[AI],N7$4$
MDK9:W<_= )/W">,=LUXU3HW:*19$8JZD,I'8B@#[]HKP*#XC_%QK>)D\'EU*
M*0_V.3YACKU[]:D_X6-\7O\ H3/_ "3D_P : />:*\%_X6-\7O\ H3/_ "3D
M_P :7_A8WQ>_Z$S_ ,DY/\: />:*\&_X6-\7O^A,_P#).3_&C_A8WQ>_Z$S_
M ,DY/\: /5_''BJ'P9X3O-9E3S'C 2&,]'D;A0?;N?85\8ZSK-_K^JSZEJ=P
M\]U.VYG8]/8>@'85Z/\ $CQ9X_USPW%;>)/#[:=IZW"OYHMW0,^#@$DX]:\I
MH *W/"OBO5?!VM1ZGI4Y1QQ)&3\DJ=U8=Q_*L.B@#[I\,^(;/Q3X>L]9L2?)
MN4W;3U1NC*?<'(K6KRO]GUF/PR 8G"WTH7Z87^N:]4H **\]^)]WJL%YX4M]
M(U&6RN+O5!#O4G:<K_$O1@.N#Q6+XPT[7? YTG4M'\5:K<SWEZEE-%J4HFB9
MI 0'"X 7!&<#VH ]<KE/$%[XX@U39X?TG2;FQV*?,N[ED?=SD8';I7)^+M/U
M?P'867B*R\4ZO?3K=PQ7<%],'AG5VVG"  )[8Z5ZO0!Y5HGC7XA^(/MWV#0=
M";[%<M:S;[IUPZ]<>H]Z](TV:].D03:M'!;WGE[KA(GS&C=\$]JX7X3??\6_
M]AR;^E6_BWXA&B>"Y+6*Y2WNM4<6<4CM@1JWWW)] N?S% %;P=\2KCQ)XJFT
MVZL([:RN8Y)M*G!.;F-'*DG/';/'H:[C5M5L]#TFZU._E$5K;1F21^N /3U)
MZ"O&O%VN>%-*T;PQ>^&M<TZXOO#DT:I!#,"TT)&V0 #KGK^==%\9KQ+WX:6=
MQ;2;K2[O;8LPZ-&V3S[=* +EKXK\>ZU9+JND>%+&/3I%WP1WUX4N)4[' &%S
MVS5BW^)$>I?#[6/$-E9^5?Z6LB7%E<-_JY5ZJ2.H]Z[F)42%$B $:J H'3':
MN6^(L,47PX\1F.-$+V;EBJ@9..IH VO#^HR:OX=TW4IHTCENK:.9T0G:I902
M!GMS5+QMK\_A?P=J.M6T,<TUJ@98Y20IRP'..>]9&E>*M'\+^ ?#4FKW+0)<
M6<21E87DR1&"?N@X_&L[Q_KVF>(_@YKM_ID[36NT1EC&R'(=<C# &@!UKKGQ
M/O;*"Z@\/^'S%/&LB9O'!PPR.WO7?637+V%NU['''=&-3,D9RJOCY@#W&<UY
M]H\/Q,.@Z>;2\\+B#[+'Y0EAGW!=HQNP<9QC.*EUZ_U;6_'6G>#H-2ETZ%;$
MWNHW%D=LDG.T(C')49YSUYH ]#HKD= T3Q!H'B6X@.IS:CX<E@#1&]G\RX@F
M!Y4'&64CU/'\^NH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *MG]ZY_Z[-_2K55;/[US_UV;^E6J 04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 <+XD^$WAOQ3KLVKZBU\+J955A#/M7"C XQZ"LK_A0W@[^_JG_@5_
M]C7I]%;+$54K*1/*CS#_ (4-X._OZI_X%?\ V-'_  H;P=_?U3_P*_\ L:]/
MJO>WUKIMG+>7MQ%;VT2[I)96"JH]R:?UFM_,PY(]CSC_ (4-X._OZI_X%?\
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M">MIJVFM?&Y2-HP)IPRX;KQBNWHI/$59*SD'*D%%%%8E!1110 4444 %%%%
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHK(\4/K4?AJ^?P]'')JP0?9DDQM+
M9'7) Z9ZF@#7KPOXI>!_$OB"_P#$.M:EJSP>'M-MC-8VH?=YC+&"<*#A?FSE
MCS[8KI_!UW\5Y?$UNGBFPLHM(*OYKQ&+<#M.W[K$]<=JZ?XB_P#)-_$?_8/F
M_P#030!YM^S7_P BYK?_ %]I_P"@5;N_@YJ7B+XG7'B#Q1>VEYH[R.4M8Y9
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M_P"^S_A6W_PC6A?] 73O_ 5/\*/^$:T+_H"Z=_X"I_A0!B?\+2\#?]#-8?\
M?9_PH_X6EX&_Z&:P_P"^S_A6W_PC6A?] 73O_ 5/\*/^$:T+_H"Z=_X"I_A0
M!B?\+2\#?]#-8?\ ?9_PH_X6EX&_Z&:P_P"^S_A6/_8ND_\ "Z/LO]EV/D?V
M#O\ *^SIMW>=C.,=<=Z[/_A&M"_Z NG?^ J?X4 8G_"TO W_ $,UA_WV?\*/
M^%I>!O\ H9K#_OL_X5M_\(UH7_0%T[_P%3_"C_A&M"_Z NG?^ J?X4 8G_"T
MO W_ $,UA_WV?\*/^%I>!O\ H9K#_OL_X5M_\(UH7_0%T[_P%3_"C_A&M"_Z
M NG?^ J?X4 8G_"TO W_ $,UA_WV?\*/^%I>!O\ H9K#_OL_X5M_\(UH7_0%
MT[_P%3_"C_A&M"_Z NG?^ J?X4 8G_"TO W_ $,UA_WV?\*/^%I>!O\ H9K#
M_OL_X5M_\(UH7_0%T[_P%3_"C_A&M"_Z NG?^ J?X4 8G_"TO W_ $,UA_WV
M?\*/^%I>!O\ H9K#_OL_X5M_\(UH7_0%T[_P%3_"C_A&M"_Z NG?^ J?X4 8
MG_"T_ W_ $,UA_WV?\*/^%I^!O\ H9K#_OL_X5-XH\/Z+#X2UF2/2+!'6QG*
ML+9 0=AYZ55\#Z!HUQX#T"672;"21K"$L[6Z$D[!R3B@"3_A:7@;_H9K#_OL
M_P"%'_"TO W_ $,UA_WV?\*V_P#A&M"_Z NG?^ J?X4?\(UH7_0%T[_P%3_"
M@#$_X6EX&_Z&:P_[[/\ A1_PM+P-_P!#-8?]]G_"MO\ X1K0O^@+IW_@*G^%
M'_"-:%_T!=._\!4_PH Q/^%I>!O^AFL/^^S_ (4?\+2\#?\ 0S6'_?9_PK;_
M .$:T+_H"Z=_X"I_A1_PC6A?] 73O_ 5/\* ,3_A:7@;_H9K#_OL_P"%'_"T
MO W_ $,UA_WV?\*V_P#A&M"_Z NG?^ J?X4?\(UH7_0%T[_P%3_"@#$_X6EX
M&_Z&:P_[[/\ A1_PM+P-_P!#-8?]]G_"MO\ X1K0O^@+IW_@*G^%'_"-:%_T
M!=._\!4_PH Q/^%I>!O^AFL/^^S_ (4?\+3\#?\ 0S6'_?9_PK;_ .$:T+_H
M"Z=_X"I_A7$WFB:2OQITRV&EV0@;1)F,7D+M)\U><8QF@#;_ .%I>!O^AFL/
M^^S_ (4?\+2\#?\ 0S6'_?9_PK;_ .$:T+_H"Z=_X"I_A1_PC6A?] 73O_ 5
M/\* ,3_A:7@;_H9K#_OL_P"%'_"TO W_ $,UA_WV?\*V_P#A&M"_Z NG?^ J
M?X4?\(UH7_0%T[_P%3_"@#$_X6EX&_Z&:P_[[/\ A1_PM+P-_P!#-8?]]G_"
MMO\ X1K0O^@+IW_@*G^%'_"-:%_T!=._\!4_PH Q/^%I^!L?\C-8?]]G_"NL
MBECGA2:)P\<BAD8="#R#6<?#6@D8.BZ=_P" J?X5IJJHH55"JHP !@ 4 +11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% %6S^]<_]=F_I5JJMG]ZY_Z[-_2K
M5 (**** "BBB@ HHHH **** "BBB@ KA?B#;>+KZWG@T;48=+TB.RDFNKM 3
M<NZACY:<_*, 9;@\\'M5K4(/B&VLRMIUYX<73/-'EK/%,90G&<D'&>M;OB/_
M )%?5_\ KRF_] - &#\*KFXO/ACH=Q=3RSSO"Q>25RS-\[=2>37G^AZ;8:[=
M^)M3\1^,M6TJ-->N;2V5=7^SQ[5((4;N/XNU=W\(O^24Z!_UP;_T8U8W@WP=
M\/\ 5)]>NK=(M;G>^E%U]O@R;9R<E%5E&T9S\P&3CKQ0!VWAC1+;0=)^SVFI
M7VHPR.9EGO;GSV.0. W]WBMFO,/@\1 WBK3["5Y=!L]5>/3F)W* <EE5NX'R
M_GGO7I] !113)(S(  [ISU4T /HJ#[,?^?B;\Q_A1]F/_/Q-^8_PH GHJ#[,
M?^?B;\Q_A1]F/_/Q-^8_PH GHJ#[,?\ GXF_,?X4?9C_ ,_$WYC_  H GHJ#
M[,?^?B;\Q_A1]F/_ #\3?F/\* )Z*@^S'_GXF_,?X4?9C_S\3?F/\* )Z*@^
MS'_GXF_,?X4?9C_S\3?F/\* )Z*@^S'_ )^)OS'^%'V8_P#/Q-^8_P * )Z*
M@^S'_GXF_,?X4?9C_P _$WYC_"@">BH/LQ_Y^)OS'^%'V8_\_$WYC_"@">BH
M/LQ_Y^)OS'^%'V8_\_$WYC_"@">BH/LQ_P"?B;\Q_A1]F/\ S\3?F/\ "@">
MBH/LQ_Y^)OS'^%'V8_\ /Q-^8_PH GHJ#[,?^?B;\Q_A1]F/_/Q-^8_PH GH
MJ#[,?^?B;\Q_A1]F/_/Q-^8_PH GHJ#[,?\ GXF_,?X4?9C_ ,_$WYC_  H
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M \Q\>?!G_A-O%1UP:^UBWE)&(UM=Y!7/.[>/Y5ER? S6Y3F3XC:HY]6C<_\
MM6O8OLQ_Y^)OS'^%'V8_\_$WYC_"@"KH&F2:+H%AIDMV]W):PK$UPXPTA QN
M/)Z_4UHU!]F/_/Q-^8_PH^S'_GXF_,?X4 3T5!]F/_/Q-^8_PH^S'_GXF_,?
MX4 3T5!]F/\ S\3?F/\ "G)"4?<9I6]F(Q_*@"6BBB@ HHHH **** "BBB@
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M4&I7=8T+NP50,EF. *;#<0W*;X)HY4Z;D8,/TH 6&*."&.&)0D<:A54=  ,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !116!J?C;PQHU_)8ZEKEE:W48!>*63#+D9'Z&FHN6B0&_17*_\+*\%?\
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M ,><W^X?Y4Z#_CWB_P!P?RIMW_QYS?[A_E3H/^/>+_<'\J!=22BBB@84444
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M^IF'[1%#.Z2+-&#@E70D$@D9'44 =-15'6-6L]"TBZU2_D\NUMHS)(P&3CT
M[DG  ]37/Z9XX>XU:RL-6T&^T=M14M8R7+(RS8&XJ=I.Q\<[30!UU%<AJ?CI
M[?5+ZRTK0;_5UTT W\ULR*L)(SM7<07?'.T5HR^,=$A\*P>(VNF.G7"J866,
ML\C-PJ!1R6)XQZT ;U%8/A+Q,OBO2)+];&>R,=Q);M#.1O!0X.<=#[5O4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5;/[US_P!=F_I5
MJJMG]ZY_Z[-_2K5 (**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNHR:<=<M_!6JR^' AD-]YT2R&,?QB$G<5QSG/3FJ.L:K!X]\,>-K?PWI6_9
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M$U.,2E]N#"(RF>OR],8[XYK0\:Q0:!\,/ H:RNX;>UU6TE:UN"))E7#L5;:
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M4A=&6X:ZD_X_!R1(K'USD*/[W'4T =/X(F\*76AFZ\(16D=A+(2ZVT7EXDP
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M^)5AX1F7S-)TNV:^U%0<!I'4K$A]QNW?0UZ'J>HVVD:5=:C>.$M[6)I9&/8
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M:3W$ES("Y;,CG+'GISVJ_0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!5L_O7/_79OZ5:JK9_>N?^NS?TJU0""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ,,C@^]6:* "J5[H^F:F\;W^G6=V\?W&G@60K],CBKM% "*JHH55"JHP !@
M5%=VEM?VLEK>6\5Q;R##Q3('1AZ$'@U-10!#-9VUQ9M9S6\,EJZ>6T+H"A7I
MM*GC'M2BUMUM!:""(6P3R_)"#9LQC;MZ8QQBI:* ,37=,U$>%+BP\*S6VEWJ
M1@69$*^5'@@[=NT@ C(Z<9KSV_T/Q=K>@W6A1>"M&T2YOT$5]JT=S$5D7(W$
M(B[B3CH>E>NT4 5=-L4TS2K.PC8M':P)"I/4A5 !_2K5%% !7)ZU\-?"GB'5
MI=4U33#/>2A0\GGR+D*,#@,!T%=9151G*+O%V$TGN<)_PIOP)_T!3_X%2_\
MQ5:.A_#CPKX;U5-3TK33!=HK(K^?(V W7@L175453K5&K.3^\7*ET(;JTMKZ
MUDM;RWBN+>08>*9 Z,/0@\&GQ11P1)%$BQQHH5$08"@<  =A3Z*S**U[IUEJ
M,:)?6=O=)&XD19XE<*PZ,,C@CUJ.]TC3-3>)[_3K2[>(YC:>!9"A]LCBKM%
M%._TG3=4"#4-/M+P(<H+B%9-I]L@XJ2*PLX+EKF&T@CN'18VE2,!F1>BD@9P
M.P[58HH HW.BZ5>W<=W=:99SW,?W)I8%9U^C$9%37EA9ZA$D=[:07,:.)%6:
M,.%8=& /0CL:L44 17-M!>0/!=01SPN,-'*@96^H/!J.QTZRTRW%O86=O:0@
MY\N")8US] ,59HH H7FB:3J,\<]]I=E=31_<DGMT=E^A(R*R?'^D7FM^ =8T
MO381+=W%OLABW!03D<9. .E=+10!@:)X;L8-*TA[_2[-M4M+.&%IVA1Y$94
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5+K_CZM/\ KH?Y&K=5+K_C
MZM/^NA_D: 9;HHHH AN_^/.;_</\J=!_Q[Q?[@_E3;O_ (\YO]P_RIT'_'O%
M_N#^5 NI)1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@"K9_>N?^NS?TJU56S^]<_P#79OZ5:H!!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %5+K_CZM/^NA_D:MU4NO\ CZM/^NA_D: 9;HHHH AN_P#CSF_W#_*G0?\
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M$2R6D<XD:')Z'O\ F!7!Z39V_B']GB"[UJ"/4+BVTRZDAEN%WM&RB0*03SD
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M3@ C;U&6'7/&>G?U:O)=!M;[XG>-+3QA?026OAO2V/\ 9%O+PUQ)G_7$=AD
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M%93DQQA 0OX9- '1?"'4+W5/ACI-WJ%W/=W+^;OFGD+NV)& R3R> *[BO/\
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MM;I[3_A(;R."YGC;:1&=NY0??</KC'>@#TB'5=.N;IK6"_M9;A?O1),K./J
M<U)<7UI:/"ES=00O,VR)99 ID;T7/4^PKSOQ/\*?"UMX,NSI.G)I]_8V[3VM
M]"Q6970;@2V<G..<^O':N:UR:^\;_ #3?$KY.L:6PNQ+C#,8G*.W'J!N^HH
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M17-O)//=O>/-%*7!&P9+$@<Y!-6/A;JNO>(= N==UJZ:2&^N7:P@,2)Y4 )
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M(553/ ''*^M;/A]/BB-=M3K\OA]M+RWGBU#^9C:<;<C'WL?A7?44 %>;^(?
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M%M0\'^$!I6IM UQ]IDES Y9<,>.2!3?"'A34-#\8^+M6NV@-MJUQ'+;B-R6
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M "=YV;O,'.WIGWH ]*HKQJZL]6\0?'?7=&AUV^T_3AI\,EP+:4J[*!'\J'^
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M<T@LK2PNV@CM45BH( ZMD'GVYS3_ (=6NH6/Q>\86FIWAO;B&VMT%RRA6E0
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MM>-BK#YUZ$5R.G> KW6OA_::SJ'BS7!JSZ>D\#P792*#Y 4 0=>,9.<DY.:
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M;(.UHL@%K&C1_=">H&.<\GFO/-)\7>&_%PNM7\9^--0L9I9V%KIMI-+%';1
M_*?D!W,?4T ?0U5[^]ATW3[F^N6*P6T332$#.%4$G]!7FWP@\4S:O<>(-%;5
MI=8M-,G4V6H39\R6%\X#$\DC;U/J?:O2KVS@U&PN+*Y3?!<1-%(N<95A@C\C
M0!Y=I&N?$CQ[8_VSH<FDZ%I$C,+5;F,RS2J"1EN",9!]/QZUM>#?$_BB3Q+?
M>&/%FFQ+=V\0FAU"S1O(G7CC)Z'GVZ'@8YP+#P9\1O =N;/PIK&G:KI".SQ6
M>HH4= 3G (_^* SS@9K<\)?$6]U/Q-)X5\3:(^CZXD?FQJ'\R.=1U*GMT)ZD
M<'G(Q0!)IWB?5;CXTZQX;DF0Z7;:>D\48C 8.=F3NZG[QKO:\JT?_DY+Q#_V
M"(__ &E7JM 'CFF:U\1/%?BOQ19:-KNFV=KI-^UNB7%H&)7<P7D#T7O77^'=
M,^(-MK4<OB#7],O-.",'AM[;8Y;'RG.WUKS?PG<^-+?QUX]_X12QTJY0ZL_V
M@WSLI4[Y-NW!'O7IGA>[\?SZJZ>)]-T6WL/*)5[*1V?S,C Y8\8S0!V%%%%
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M/G_KRC_PKD?#'AK4?!OQ8U:*PTZ0>&-7A$RO$ ([>8<[<=A]X<#^)?2O3Z*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N%^+>@:IXB\$&UT>W%S=PW45P(2P4N%)R 3@9YKNJ*
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MI#),@,#D?*CJ0RYQVR,'V)KI** /+H]=\=Q:(-+_ .$"SK:1>2MZ)X?LVX#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 5;/[US_ -=F_I5JJMG]ZY_Z[-_2K5 (**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI=?\?5I_
MUT/\C5NJEU_Q]6G_ %T/\C0#+=%%% $-W_QYS?[A_E3H/^/>+_<'\J;=_P#'
MG-_N'^5.@_X]XO\ <'\J!=22BBB@84444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %6S^]<_\ 79OZ5:JK9_>N
M?^NS?TJU0""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML[-YD88*Q,V[(8G) "X'&<UN^(?$6OOXO\.Z1H,UK!'JME/-(]U$7$>T*0V
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MP92._7/Z\G=?%#4+^74+RQURTTY;6>6*TTZ32)[DW(0D R2KPI8@\+G QG-
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %5+K_CZM/^NA_D:MU4NO\
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MM:5]CT6\MIX(K6T=//6(C!D)8X..@48R:Z6U\-SV_P 0]0\2-/&8+JPBM5B
M.X,K$DGMBNDHH RO#UMK-KI0BUZ_AO;[S')FAC\M=I/RC&!T%<_XG\+^(+SQ
MCI_B+0+[3H)K6TDMBE[$[J=QSGY2/YUVM% '-Z+:^+LW2>(;W2)H7B*Q"R@D
M1@Q[MN)XQ3?"'A>3P]X"M/#EW.D[Q0R1/+&" 0S,>,^S5TU% 'G=E\/=1_X1
M[PIH6HWUK-8:/<F>Z1$;_2=A)A7GL,_,#UQ72^(/".E:]X?U#2VL[:(W4+1B
M585RC$<,..QP?PK?HH S= M+^P\/V%GJ=Q'<7L$*QRS1YQ(0,;N>YQS[UR=Y
MX5\66GC;6-?\/ZEI$4>IQP(\=[!(Y7RUVC&TCU-=]10!QE]X?\3Z]X)UK1M<
MO]+:[O(S'!+:1.B(I ^\"2>OI6<?#7Q!N])71[CQ'H]G9>2('FLK-S/L VD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !52Z
M_P"/JT_ZZ'^1JW52Z_X^K3_KH?Y&@&6Z*** (;O_ (\YO]P_RIT'_'O%_N#^
M5$Z&6"2,8RRD#-0(M\B*@^SX48[T"+=%5?\ 3O2W_P#'J/\ 3O2W_P#'J N6
MJ*J_Z=Z6_P#X]1_IWI;_ /CU 7+5%5?].]+?_P >H_T[TM__ !Z@+EJBJO\
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M /'J/].]+?\ \>H"Y:HJK_IWI;_^/4?Z=Z6__CU 7+5%5?\ 3O2W_P#'J/\
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M%RU157_3O2W_ /'J/].]+?\ \>H"Y:HJK_IWI;_^/4?Z=Z6__CU 7+5%5?\
M3O2W_P#'J/\ 3O2W_P#'J N6J*J_Z=Z6_P#X]1_IWI;_ /CU 7+5%5?].]+?
M_P >H_T[TM__ !Z@+EJBJO\ IWI;_P#CU'^G>EO_ ./4!<M455_T[TM__'J/
M].]+?_QZ@+EJBJO^G>EO_P"/4?Z=Z6__ (]0%RU157_3O2W_ /'J/].]+?\
M\>H"Y:HJK_IWI;_^/4?Z=Z6__CU 7+5%5?\ 3O2W_P#'J/\ 3O2W_P#'J N6
MJ*J_Z=Z6_P#X]1_IWI;_ /CU 7+5%5?].]+?_P >H_T[TM__ !Z@+EJBJO\
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MZ6__ (]0%RU157_3O2W_ /'J/].]+?\ \>H"Y:HJK_IWI;_^/4?Z=Z6__CU
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MZ6__ (]0%RU157_3O2W_ /'J/].]+?\ \>H"Y:HJK_IWI;_^/4?Z=Z6__CU
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MF6<Y)_>/WKF?''Q*UK1/B'H^C66E:E]B\T^>D=JK/?# .(23R!GGH<U:\)>
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MI^AG6-5N+N6!_*FE:YD^5Q]T 9Z9)J#QIH6KW=M\,5M],NYC93P&Z$<+-Y
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MYMF$SN( YKH;^UU_P3\3_$6NV_AR\UNQUFV"P-:()-DH PL@ZA<@Y/H1UYH
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M"4="5;'<9R*RO^%EK-+JT>G^&M8O_P"R;J6"\>!8]J!#R5+,-Q/7:,G'7'%
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M,1QACDX]2?4GFK]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<]E:I%.RX1V4'(![D4_XH:=>:IX*DM;&UENIC=VS>5$NXE1,I)QZ  FNRHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img76291469_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0 ".@# 2(  A$! Q$!_\0
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M A53U /U% 51T 'T%+10 A (P0#2;%_NC\J=10 4444 !&1@TW8G]U?RIU%
M"!5!R% /TI:** "BBB@!"H/4 _6DV)_=7\J=10 W8G]U?RHV)_=7\J=10 @5
M1T 'T%+110 A /4 _6DV)_=7\J=10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI+Y@TOS02 YA3VV[0/Q->J^/O#VI>*M&M]&LIH8;.>ZC.H.[$,8%.2J8'))
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M&U?:L^U^'_V/X::AX62_,EW?QRM/>2)]^:3DMM'09QQZ"M7P;:^(;#1(['Q
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MW\*ZSK.FG0(MB2W-NCBZN84(PA!^5>@R1G\>_IL4200I#$H2.-0JJ.@ X H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !55-
M,L8]3DU-+2%;Z2,1/<!!O9 <A2?3-6J* "BBB@ HHHH **** "BBB@ I" P(
M(!!X(-+10!@Q>"?"T%^+Z+P[I:70;<)5M4!!]1QP?>MZBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!'19$9&&588(]15+2-'L-!TN'
M3-+MA;V<.1'$K$A<DD\DD]2:O44 %%%% !1110 4444 %%%% !1110 5S>J>
M /"VLZA)?WVD1/=RC$DL;O$T@_VMA&[\<UTE% %33=,L='L(['3;2&UM8AA(
MHE"J*MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 17+%;6
M9E)!",01VXKQ#X&^)M>USQ)J<&K:Q>7T4=DKHD\FX*Q<#(KVZZ_X\Y_^N;?R
MKY[_ &>B%\5:N3P!IZD_]]T ?1#ND8R[*HZ9)Q3J^;M!LKCXS_$+4I-9O[F/
M3+56D2")\;$W[410>!TR6QDFJ_B73=1\+_%#1-!.LWUUI\,UL;3S9B&6)I/N
M-C&[!#?AB@#V'XF^/E\#:)&UO''-JEV2EM')]U0/O.WL,CCN2*\\T;P7\1/'
M6FQZWJGBZZT^.Y_>00[G!*GHVQ&4*#V'/%97Q]=Y?'MA#*?W*V* #MAI&W?R
M_2O=/$6KCPMX/N=3M;(W8LH5,=NAV[QD* " <<'TH \6TOQGXJ^&_CV+PYXF
MU-M2L9)(U8ROO(1SA9$8_-QW4YZ'ZU]"UX:GQOAOM6M;>\\%HDTTL<6^>8;E
M#, #@QY[YKW*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6D7WCGP:^A2P3:K%8,-6EMB&Q ( %64CC._;@'D8H ]9HHHH **** "BBB@
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MW6C>*M9\,7\;QM+EU!0@":([7 /N,'_@->^T44 %%%% !1110 4444 %%%%
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MY.&D7#%$SSSZL7->MT4 ?._P$1U\=:N6CD4?8WY9"/\ EJ/6OHBBB@ HHHH
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRV;=#*H930!8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BF2RQP1/+*ZI&@+,S'  '>N=A\>:#->"W%Q(H)P)GC(C/
MX_XT =+11UHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\
MOXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_
MV_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1
M]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^
M-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\
M;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_9
M8O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344
M 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^
M-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\
MOXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_
MV_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1
M]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^
M-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\
M;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_9
M8O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344
M 0_98O\ ;_[^-_C0+6($'Y^/^FC?XU-10 4444 %%%% !1110 5D^*-(.O\
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MS?\ Q59GVWQHO_,)TQOI<$4G]I>,EZZ!9-_NW8HNQV1J?\(WIW_3W_X&S?\
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MZSX:<D6MOK=T?^F3SG/YM4<TL\\$HLO#.M*Q0[)9KV50IQUQNY^E>A !1@
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M )B\'_?R;_XJN]HHNPY4<%_PA_B+_H,Q#_MI-_\ %4?\(;XA_P"@X@^CS?\
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MCFJ:Y)-?.=.DN;>U1L1C[3*S./5LMW]*Z'2==\.3:>K:M/<6MV#@HMW.0_\
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MHRH%#^JD@=#_ #Q1<+'"V'B0+>K_ &A!(]JS8;RKJ96C'J/GYQ[UZ -.\/L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QSQU9:5J?B7Q>-?$<
MES9Z&)-&AG?"@%',CH,X+!PH]>!5ZP33[7QYX.GTF5?[5O\ 3RNK1Q29#P)
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MT%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA?$/@
M&74-2EO=.N8HS,VZ2*4'&[N01Z^E=U10!S_A;PPGAVWE9Y1-=38\QP,  =%'
MM70444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCMY- 'KU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9FOZ):^(=&N--NAA)1\K@9,;CHP]P?\ "M.BJC)Q:E%V:$TFK,X'
MP!KMU;SS^$M9.W4;#Y82?^6D8Z8]<#!'L?8UWU<+\0_#MQ<0P^(](#+JVF_/
M\@^:6,')'N1R0.^2.];_ (4\1V_BC0X;^$J),;9HP?N/C^1ZCV-=N)BJT/K,
M.OQ+L^_H_P [HYZ+=.7L9?+T_P" ;=%%%<!TA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %V1G'KM_P#KUV<$\5U;QSP.'BD4,C#H0: L96WQ+_SUTG_OW)_\51M\2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"@"0YP<=:@W7/_/*+_OL_P"%3T4 0[KG_GE'_P!]G_"C=<_\\H_^^S_A4U%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN5\:Z
M9XBUI-.T[1;TV-E+/_Q,KF*39,L0QQ&<=3SS["N9@AN/!?Q/T+0]-U;4;ZPU
M6"9KFSO;@SF'8,K*K'E02,8]C^ !ZA17EVGV%S\2-?\ $%Y>ZSJ=KI6G7C6%
MC;V%P8!N0#?*Q'WCD\9Z5M_#C6-1N[76-&U:Y:[O=%OWLS<M]Z:/JC-[X_E0
M!VU%%)N7^\/SH 6BDWK_ 'A^=&]?[P_.@!:*3>O]X?G1O7^\/SH 6BDWK_>'
MYT;U_O#\Z %KQWQWI5SX'\60>,=(7997,P^UI_#',W&X_P"S)T/HV#WKV'>O
M]X?G574;&SU;3;G3[Z-)K6YC,<J,>JD?YYKHPN(="ISK5=5W75&=6FJD>5D>
MBZO;:[I,&H6C9CE7E3U1NZGW!J_7A>D:KJ_POUK4M&GC^W6HP8&=\"53]R3O
MAL?*P[XKT+PAX_MO$T[64UO]DO54NJ[]RR =<'CD>E=F)RVI&+KTE>GNGY>:
MWT.>EC(.7LINT]CLJ*3>O]X?G1O7^\/SKRSL%HI-Z_WA^=&]?[P_.@!:*3>O
M]X?G1O7^\/SH 6BDWK_>'YT;U_O#\Z %HI-Z_P!X?G1O7^\/SH 6BDWK_>'Y
MT;U_O#\Z %HI-Z_WA^=&]?[P_.@!:*3>O]X?G1O7^\/SH 6BDWK_ 'A^=&]?
M[P_.@!:*3>O]X?G1O7^\/SH 6BDWK_>'YT;U_O#\Z %HI-Z_WA^=&]?[P_.@
M!:*3>O\ >'YT;U_O#\Z %HI-Z_WA^=&]?[P_.@!:*3>O]X?G1O7^\/SH 6BD
MWK_>'YT;U_O#\Z %HI-Z_P!X?G1O7^\/SH 6BDWK_>'YT;U_O#\Z %HI-Z_W
MA^=&]?[P_.@!:*3>O]X?G1O7^\/SH 6BDWK_ 'A^=&]?[P_.@!:*3>O]X?G1
MO7^\/SH 6BDWK_>'YT;U_O#\Z %HI-Z_WA^=&]?[P_.@!:*3>O\ >'YT;U_O
M#\Z %HI-Z_WA^=&]?[P_.@!:*3>O]X?G1O7^\/SH 6BDWK_>'YT;U_O#\Z %
MHI-Z_P!X?G0"#T(- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4C+N0KDC(QD4M% 'R7K4>M>$=4FTG5K%Y)(W(AG(($RYX8''S9_.NJ
M^'UUK%EJES"+]]+U^<I);Z9?Q&.&[AV\ $_Q9)QW_7'T255L9 ..1D=*PO%?
M@_2?&&F_9-2A_>)\T%S'\LL#>JM_3H:]AYO5G%0J:K[_ ,/Z\CB6!I1DY15F
MRKH7C2UU*Z.FZC ^F:NG#6L_&\^J'N/\\UU%>,7\\^@20Z!\1XFO=,+;-/\
M$D2D.A[+(>H/O[=^HZ>'5==\'QQM?LVN>'RH,=_!\TL2'H6_O#W_ %[5E/"T
MZVM#1OIT?^%_H]?4M59T]*FJ[_YK]3T"BJFFZI9:O9)=V%S'/ _1D/3V(['V
M-6Z\V47%\LE9G2FFKH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO^_ 4=%8\L<=A43R^5N:#NNZU7X;?-(J.)BW9Z/ST/;6NK=)U@>>)9F^[&7
M8_05+7Q\]EJE_</J%[+OO)&WF5Y29">N=W;\^*^D/AAJVHZSX%LY]4+M=1N\
M!DD^]($; 8^I]^^*C$X&KAXJ4UN.EB*=5M0=['8T445Q&X4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
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M"?H?4=-&LTUK9K9]O^ 1."DK-71$NIZ[X'98=:$FJZ)G:E_&N981Z2#N/?\
M7M7:6-_::G9I=V5Q'/ XRKH<C_ZQ]JY[P9XRM?&%A/#/;FTU:U/E7^G3#YHF
MZ'@]5/K^%4[[PA>Z->/JG@^=;:5CNFT^0_N)OH/X3_GBNB7LJ[Y:GN3[_9?K
MV]5IZ;F"4Z7P^]'MU7^9VU%<WX?\8VFL3G3[N)]/U>/B2SGX)/JI_B%=)7'5
MHSHRY:BLS>%2,U>+"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445RR^$+Q==&I'Q;KS1_:/.^Q&6/R<9SY>-F=O;KTH H^,]1N=7U.W\$:1.T
M5U?1F74+F/K:6G1CGL[_ '5^I-<EX2U>3PO^S_J6HV7RRVKW0@+<[6,I53[X
M)!_"M/2_#_Q"T#4]9OK.+PW<S:C=-/+<W<LWFL@X1.!@*J\ ?6N5\(:7XA\3
M?!?6=.ABL'T^XCG>S$;-Y[SB7<5;^':<$#OTS0!LZQX!L]!^'3>);&>[3Q19
M6RWSZF9W,DL@ 9PP)P5/(QC^M>J:+?\ ]JZ%I^H$ &ZMHYB!T!90<?K7EFM_
M$32]>^&9T737EG\1:C;"P&F!&\Z.4@*^X8X ^8Y->I:)8'2M!T[3R03:VT<)
M(Z$JH!_E0!>) !)Z"H/MMO\ \]/T-6** (/MMO\ \]/T-'VVW_YZ?H:GHH @
M^VV__/3]#1]MM_\ GI^AJ>B@"#[;;_\ /3]#1]MM_P#GI^AJ>B@"#[;;_P#/
M3]#1]MM_^>GZ&IZ* (/MMO\ \]/T-'VVW_YZ?H:GHH @^VV__/3]#1]MM_\
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M0!!]MM_^>GZ&I(Y4E7<AR,XZ4^B@ HHHH **** "BBB@ HHHH **** /G?\
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M>F>/PH ^A/'/B >&/!>J:J&Q+%"5A&>LC?*GZD5XSX&\#RZM\&O$MXT9>[U
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MD9OBT?[NV4,I)W#@Y( 'U_"@#=T+6M2U_P" 6NWVK7DEW=&*Z0R. #@# '
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M)YJ[;7,%Y;QW%K-'/!(-R21,&5AZ@C@T 2T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5G:YH6F^)-)FTS5;9+BUE'
M*MU4]F4]B/45HT4TVG= >"ZKXU\1?"6YF\+"XMM:B$:RV,]RQ\RWC)("2 ?>
MZ<<_IP.B^&WQ>E\5ZN-%UFT@M[V1&:WF@R$EP,E2"20<9/7G!K*^,?PXUC6-
M:3Q#HELUYNA6*YMT(\P%?NLH[C!P1UXKD/"?@[Q?X6O[;Q?-X:FFM]/<L]HS
M[)V4J5+*G7@'/OZ5Z:A1J4>9VYG^9A>:E;H?3E%8OAGQ7H_B[3!?:1="50<2
M1-\LD3>CKV/Z'M6U7F-.+LS<HZKHVGZW:&UU&TCN(CT##E?<'J#]*Y(Z-XE\
M(Y?0;DZKIB\G3[IOWB#_ &&_I^AKNZ*Z*.*G27)O'L]5_P #U5F95*,9OFV?
M='/:#XRTO79#;!GM-07A[.Y&R0'VSU_"NAK&UWPMI/B*,?;K?$Z_ZNXB.V5#
M[-_C7.^=XK\'_P"O5M?TA?\ EH@Q<Q#W'\7^>E;>PHU]:#M+^5_H_P!'9^IG
M[2I3_B*Z[K]5_D=W165H?B32O$-OYNG72R$??B;Y9$^J]16H2 0"1D]*XYTY
MTY.,U9HWC*,E>+NA:***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \_\:^"[U]23Q;X2=;7Q';#YX^D=Z@ZHXZ9P.#]/8C9\%>-++QCICR1HUKJ
M-L?+O;&3B2!^A!'7&0<'^N:Z>O/_ !KX+O3J:>+O"+K;>(K8?O(^D=]'W1QZ
MX'!^GL1O&2FN2?R?Z/R_(EJVJ/0**\WM?C7X6&E0S:H]Q9:AN,=Q8F!VDA<=
M<X'3T-=QHNN:;XATV/4-)O([JU?@.AZ'N".H/L:B=*<-9(::>Q+J.F6.K6C6
MM_:QW$+=5D&?R]#[BN0;PYK_ (58S>&+PWEB.6TR\;./]QNWT_G7=45K1Q52
MDN5:Q?1ZK^O-:F=2C&;OL^ZW.9T3QMIVJW'V&Z633=34X:TNAM;/^R>A_G[5
MTU96M^'-*\0V_E:C:K(0/DE'#I]&ZBN:\CQ7X/YMG;7](7_EDYQ<Q+['^+_/
M K;V-"O_  7RR_E>WR?Z/[V9\]2G_$5UW7ZK_([JBL30?%>D^(D(L[C;<+_K
M+:4;94/NI_I6W7'4ISI2Y)JS-XSC-7B[H****@H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J."WAM8A%;PQQ1@DA(
MU"C\A4E% $*VELERUPMO$L[##2A &/U/6IJ** "BBB@ HHHH **** "BBB@
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M6KA6AM9?]9%!&NU-P[$]<4 =W114<D$4Q!D0,1TS0!)14'V*W_YY+1]BM_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP0FUF*Y[9QCZ9KTZN7\<?\(G=Z/_ &5XKOK2VM[G+1>=.(F#+_$A/<9_7WH
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M&H6%@L.VP@SNE##>X7'<\ GT% 'L>A?$CPEXCOA8Z9K,,MTQ(2)U:-GQ_=W
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M\MBL\][<X\^]NI/,FD'H3V'L* .FHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH CG@ANH'@N(DEAD&UXY%#*P]"#UKS*\\(Z[X O)=6\"EKO378O=:
M#,Y*GU,)['V_GTKU&BKA4</3L)JYSGA+QMI'C&S:2PE,=W%Q<V4PVS0-T(9?
M3/?I71UQ7BWX>VVN7BZUI%T^C^(H>8KZ#CS/]F0?Q#WZ_4<51\/_ !"N;35$
M\.>.+5=*UGI#<_\ +M>#U1N@)]/7T/%6Z:DN:G]W7_@BO;<]#HHHK$H****
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MNCDC<,K#V(J7[7;_ //9/SK"Q1-5/5K-M0T>]LT*AYX'C4L,@$@@&IOM=O\
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M .>R?G0!-14/VNW_ .>R?G3HYXI21'(K$=<&@"2BBB@ HHHH **** "BBB@
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M2DKQ=T%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7^!/$FJ_&/3M?LK!9-,ADM3),9T4@(Q+?*3GCZ5Z7XLT/_A)?"FIZ,)1"UW
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MU*\UNW6'4KR4*%$BR%8E&1\P)'+$G\!5'XD^ M>F\767C/PHJ3:A;[/-MF8
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M1110 4444 %%%% !1110 4444 %%%% !65X@\.:5XHTM]/U>T2X@;IGAD/\
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MM9OFL8M#N[=AD/+=QF*-/JQ'/X9KW7P_\2+>PFM_#WBVPD\/ZG&@CC,YS;S
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MU*VG)_A#X;_OD\UG4P=>FN:4=.^Z^]:%0KTYNR>OXFI1117,;!1110 4444
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M\*/TUNV'UW#^8K=:RM'^_:PM]8P:@?1=*D^_IEDWU@4_THYL&_LR_P# E_\
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M 'RO^%'DS?\ /R__ 'RO^% $]%0>3-_S\O\ ]\K_ (4>3-_S\O\ ]\K_ (4
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MY^6_[Y7_  H GHJ#R9O^?EO^^5_PH\F;_GY;_OE?\* )Z*@\F;_GY;_OE?\
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M3XQZ/:N(M>TC6=%ES@_:K0E!^(_PK1OOBMX/M=#N-3M]7@O/* VV\#?O78]
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MSMBA0*HSU/N?>KE% '-6GP^\)6.M?VQ;:#9QWP;>) IPK>JKG:I]P*Z6BB@
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M^U=34RBXOEEN"=]4%%%%2,**** "BBB@"*>VANH7AGC5XW4JP8=0>#7D-_\
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M08+.2#2+O4C<720,ML,F(-GYV_V1_6@#SKQ=I6G:QXW\2:?JUG]IU6YT<?V
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M:GMY6H'_  KT6BJ]O5_F%RH\X'POU. 8L_B#XDB'8//O_P *\1^)6A:MX?\
M&,\>KWMQ?F9%>&_G&#.@ &/0%>F/H>]?6M5K[3K'4X/(O[.WNX<Y\N>,.N?7
M!%:T<7*$KRU)E335CY\^ >GW\WC"[U*%773X;5H9I/X7=B"J^Y&"?;\:^C*A
MM;2VL;=+>TMXK>!.%CB0*H^@'%35EB*WM9\UK%0CRJP4445B4%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#;FK^5Y$#W-\DK11@<K&BGY1@=O2@#T"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *@O+*UU&TDM;VVBN+>08>*5
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MVG=M&<#C/;I0!Z=1110 445B^(?%6E^&%MVU-KD"X+"/R+:2;IC.=@..HZT
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M )XI_P!_/_K4;[G_ )XI_P!_/_K4 345#ON?^>*?]_/_ *U&^Y_YXI_W\_\
MK4 345#ON?\ GBG_ '\_^M1ON?\ GBG_ '\_^M0!-14.^Y_YXI_W\_\ K4;[
MG_GBG_?S_P"M0!-14.^Y_P">*?\ ?S_ZU&^Y_P">*?\ ?S_ZU $U%0[[G_GB
MG_?S_P"M1ON?^>*?]_/_ *U $U%0[[G_ )XI_P!_/_K4;[G_ )XI_P!_/_K4
M 345#ON?^>*?]_/_ *U&^Y_YXI_W\_\ K4 345#ON?\ GBG_ '\_^M1ON?\
MGBG_ '\_^M0!-14.^Y_YXI_W\_\ K4;[G_GBG_?S_P"M0!-14.^Y_P">*?\
M?S_ZU&^Y_P">*?\ ?S_ZU $U%0[[G_GBG_?S_P"M1ON?^>*?]_/_ *U $U%0
M[[G_ )XI_P!_/_K4;[G_ )XI_P!_/_K4 345#ON?^>*?]_/_ *U&^Y_YXI_W
M\_\ K4 345#ON?\ GBG_ '\_^M1ON?\ GBG_ '\_^M0!-14.^Y_YXI_W\_\
MK4;[G_GBG_?S_P"M0!-14.^Y_P">*?\ ?S_ZU&^Y_P">*?\ ?S_ZU $U%0[[
MG_GBG_?S_P"M1ON?^>*?]_/_ *U $U%0[[G_ )XI_P!_/_K4;[G_ )XI_P!_
M/_K4 345#ON?^>*?]_/_ *U&^Y_YXI_W\_\ K4 345#ON?\ GBG_ '\_^M1O
MN?\ GBG_ '\_^M0!-14.^Y_YXI_W\_\ K4![C(S"F/\ KI_]:@":BBB@ HHH
MH ***P?$'C'2/#$T$.I-=!YE+)Y-I),,#@Y**<4 3>)?$MCX6TK[=>B60O(L
M,%O NZ6>5ONH@[DU@Z?\09/[?LM&\0>'KW0[C4-WV)YY$DCF(ZKN0_*W(X/K
M7,^.=9N=7\5_#^;0X%G^T23S6HNU:- ^T ,ZD!OE!+8ZG'O6G+J'B?PQXJT*
MV\27FGZW8:I<FWBG2S$$MK,1E<#)!4]/7^H!K:MX^DM]<NM'T/P_?:Y=605K
MTVS(B09&0NYCRV/X16WX9\26'BO18]3L/,5"S1R13+MDAD4X9&'8BN5^%'[R
M#Q3<2G-U)K]T)L]1@@ ?E1\.0L?BCQ[%%_J!K&X = Y7YOUH ]"HHJ%GG#';
M$A&>"7_^M0!-14.^Y_YXI_W\_P#K4;[G_GBG_?S_ .M0!-14.^Y_YXI_W\_^
MM1ON?^>*?]_/_K4 345#ON?^>*?]_/\ ZU&^Y_YXI_W\_P#K4 345#ON?^>*
M?]_/_K4;[G_GBG_?S_ZU $U%0[[G_GBG_?S_ .M1ON?^>*?]_/\ ZU $U%0[
M[G_GBG_?S_ZU&^Y_YXI_W\_^M0!-14.^Y_YXI_W\_P#K4;[G_GBG_?S_ .M0
M!-14.^Y_YXI_W\_^M1ON?^>*?]_/_K4 345#ON?^>*?]_/\ ZU&^Y_YXI_W\
M_P#K4 345#ON?^>*?]_/_K4;[G_GBG_?S_ZU $U%0[[G_GBG_?S_ .M1ON?^
M>*?]_/\ ZU $U%0[[G_GBG_?S_ZU&^Y_YXI_W\_^M0!-14.^Y_YXI_W\_P#K
M4;[G_GBG_?S_ .M0!-14.^Y_YXI_W\_^M1ON?^>*?]_/_K4 345#ON?^>*?]
M_/\ ZU&^Y_YXI_W\_P#K4 345#ON?^>*?]_/_K4;[G_GBG_?S_ZU $U%0[[G
M_GBG_?S_ .M1ON?^>*?]_/\ ZU $U%0[[G_GBG_?S_ZU&^Y_YXI_W\_^M0!-
M14.^Y_YXI_W\_P#K4;[G_GBG_?S_ .M0!-14.^Y_YXI_W\_^M1ON?^>*?]_/
M_K4 345#ON?^>*?]_/\ ZU&^Y_YXI_W\_P#K4 345#ON?^>*?]_/_K4;[G_G
MBG_?S_ZU $U%0[[G_GBG_?S_ .M1ON?^>*?]_/\ ZU $U%0[[G_GBG_?S_ZU
M&^Y_YXI_W\_^M0!-14.^Y_YXI_W\_P#K4;[G_GBG_?S_ .M0!-14.^Y_YXI_
MW\_^M1ON?^>*?]_/_K4 345#ON?^>*?]_/\ ZU&^Y_YXI_W\_P#K4 345#ON
M?^>*?]_/_K4;[G_GBG_?S_ZU $U%0[[G_GBG_?S_ .M1ON?^>*?]_/\ ZU $
MU%0[[G_GBG_?S_ZU&^Y_YXI_W\_^M0!-14.^Y_YXI_W\_P#K4;[G_GBG_?S_
M .M0!-14.^Y_YXI_W\_^M1ON?^>*?]_/_K4 345#ON?^>*?]_/\ ZU&^Y_YX
MI_W\_P#K4 345#ON?^>*?]_/_K4Z-I23YD:J.Q#9_I0!)1110 4444 %%%5O
M[0LC-Y/VRW\W=MV>:-V?3&>M &/KOCGPSX:NDM=6U:&WN67<(0K2.!ZE5!('
MN:U-*UC3M<T]+_2[V&[M'SMEB;(R.H]C[&O+H=;M_ ?Q'\2B^L)]5FU21;N.
M;38_M$\,>,>7*G5 .W8UCPW4D'PT^('BFP>&TBU:7,-G;R M:YQ&V\#[DC;B
M2.U 'IUM\1?"%YK(TFWUZTDO"_EJH)VLW]T/C:3[ UU%><^+/#>G6WP1NK&&
MVB1++31/"R@ I(BAMX/]XD=>^:['PS>2:AX5TB\F):6>SBD<GJ6* D_G0!JT
M4AS@XZ]LU#_I?_3#]: )Z*@_TO\ Z8?K1_I?_3#]: )Z*@_TO_IA^M'^E_\
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M@ HHHH **** "BBJL^IV%M>P64][;Q75QGR8'E4/)CKM4G)_"@"U14<\\-M
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MT>4-_F9W;L^N>:Z"B@#RS3O[>\ ^)?$32>&K[6K+5KTWD-[I^UY!D?ZMU)!
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MH9-B7)P,>81R0,'CWKI*CG_U$G^Z?Y4 <!\$P!\,;(  #SY^!_UT:O0Z\_\
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MNKV]A&\*?NHN2<8Z#&.2/:N0,FL1?!+PUHMX]Q%)K.HQ62[B1(MH[DA2?]P
M?0TR?QII/C#Q(+WQ2NHV^AV$N;'2!83/Y[#I+,0N#[)_]?/8>,&/CGP-:ZQX
M:@FN+C3+^.\@ADB:)Y3$WS*%8 ]"<>N* */Q"\/:3X/TG1_$.@:=!I]WIE]
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MESXG^(.H^,WLKFTTU;)=/T\7,9C>8;MSR;3R!G@>M 'HM%%% !1110 4444
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M#T<4<,RPC$)O ?FV <<#(./\*A^)GC.>/5X_"<$MYIEK+&'O]4AMGE98R/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&7\Q  "O?..:3P/H>N^$[R]T&8"Z\.QL9-,NFF!DA4G/DLO4@9.#[>_';44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX^M 'H5%5K&Z6[M(I0\;.T:LP1L@$C-.O;R'3[&XO;E]D%O&TLC>BJ,D_D*
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MH$F ';< <4 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYAKC]+UOPUXI\3ZAK?Q%OKHQRC-K;Q*[  D\?+G:JC''<DDYKN_@-HM];?\
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MR?2@#Z$TE[&71[)],*?8&@0V^S[OE[1MQ^&*X;XWSO#\,;P)G$D\*-]-X/\
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M6C:@/#@FE1'*2*FT1Y7]YC^][\U]'6-G#IVGVUC;*5@MXEBC!.2%48'/?@4
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M]IX]^"FE7FN37<MQI=O</#(LN"Q3<%W$@YX5?RK>^,UE=WWPW$%G:3W,WVF
M^7#$SM@'DX S4GPUTN[/P>BTVX@EMKF6*YC\N="C*69P,@C(ZTP/*O@_X%T?
MQLM_=:L;D26,D#0^1($&3ECG@YY45I>+5'_#2^FG S]JL_\ T$57^&]UXO\
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MLK8!Q_"&!!(]17(:!=^&UU[55^)=CJ-SJ,S8\TEBT+Y.[*@@^F,9  Z5Z_\
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MM^I- &[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0UU?:Q<O.YZMAL 'V [>])\)_P#1XO%6F1X^RV6NW$<"CHJG!P/;.:@M=/\
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M% $'VD_\^\WY#_&C[2?^?>;\A_C4]% $'VD_\^\WY#_&C[2?^?>;\A_C4]%
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MZ* (/M)_Y]YOR'^-'VD_\^\WY#_&IZ* (/M)_P"?>;\A_C1]I/\ S[S?D/\
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M^\WY#_&IZ* (/M)_Y]YOR'^-'VD_\^\WY#_&IZ* (/M)_P"?>;\A_C1]I/\
MS[S?D/\ &IZ* (/M)_Y]YOR'^-'VD_\ /O-^0_QJ>B@"#[2?^?>;\A_C1]I/
M_/O-^0_QJ>B@"#[2?^?>;\A_C1]I/_/O-^0_QJ>B@"#[2?\ GWF_(?XT?:3_
M ,^\WY#_ !J>B@"#[2?^?>;\A_C4D;F1<E&3GHW6GT4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YGXU\7>*([CQ!
M'X;-A;6GA^U6:\N;E#(\LC)O$:+T'RXR3W-;EEXAUBW\96NF:I#;/INK6YFT
MV>'(='1%9XY!T[D@CZ?3)\;>"M;O[C59O#FHV<(UNU%O?V=XIVR;5VB2-AR&
M"G'3' J?PKH&M7>O6^L^)-4TZ>?2X&M;2RTXDQP%@ [.3R7(&,=J ._HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 445POCCXI:-X)N4L989KW4&4.;>$@;%/0LQX&>
MPZU4(2F^6*NQ-I:L[JBN2\$?$+2/'-O-]B$MO=P &:UFQN4'HP(X8>_YUUM$
MH2@^62U!-/5!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HJ&ZO+:RA,UU/'#&.K2, *YN3QF+V
M0P:!IUQJ4@X\T+LB7ZL: .JK&U3Q5H^DMY<]T'G[00C>Y_ ?UK,&@Z_K/S:W
MJWV:!NMI8?+QZ%^IK9TOP]I6C+_H5G&C]Y"-SG_@1YH \Q\6S7M_J"ZI<Z?<
MV=M*@CA$X[#^6<]*C\*:3<ZQK"K;S3V\4:DRW$)P4&.@/J?Y5[%+%'-&8Y8U
MD1NJN,@_A20P0VT?EP1)$@YVHH4?D*!6.:'@+3&.;FZU&Y/?S;IL'\JLQ>"?
M#D6"-+B=AWD9F/ZFN@HH&48=%TNW&(=.M4^D*_X5<1$C&$55'H!BG44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_"-?$[_ *'RR_\ !8G^%'_"-?$[_H?++_P6)_A1[)?S+\?\@OY'HU%><_\
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M5$48"@<  >E/I5)\[OT!*P4445 PHHHH **** "BBB@ HHHH **** "BBB@
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M%MZ6MO%M!['![G!KC+'1-1U2\%G!:S!R=KLZ%1&.Y)->Y44"L16\"6UM' @
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MO&?AK2-0%AJ.N6%M=G_EE), P^OI^->'?&GP;H?A!-&O-"L_L1E:1'1')!*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]@FF .$DA0LKCUSV_&O::*!6.7\(^&%TO2]]_;0M>ROO.Y0QC'9<_K^-=0
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MWXM^!;GQKX>@.G;#J-B[/%&[;1*K##)GL> 1[BN'_P"$P^(;>$3X4_X0J_\
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M/ ._)([TXWVCZQ\8=)D\/O#<7%G9W']J7-K@IY; "-&8<$[^0.V* /1Z***
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MX@@XFT^\NV^?U,9XW#]?J.:[N+X;^%(_^84K_P"_*Y_K42HX6F[2G+_P%?\
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M72=.B\JTM4V1J3D^I)/<DY)^M %^H6A8L2)Y!D]!CC]*FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
M"CR'_P"?B7]/\*FHH A\A_\ GXE_3_"CR'_Y^)?T_P *FHH A\A_^?B7]/\
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M[I CE%<^I Q7445A#$5:<G.$FF^MS25*G)<LDFB*VMH+.VCM[:)(H8UVHB#
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M;_P->MBBBX61C_\ "/1_]!/5O_ UZ/\ A'H_^@GJW_@:];%%%PLC'_X1Z/\
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M5<&]B::]U$@J+FXQE >NQ1P,]SR?>G>.?ACI7C:>"]>XGL-2A 5;NWQEE!R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBBO-.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.=U?P;IFJ2?:(E:RO0<K<6_RG/J1W_G67_:7B;PP=NJ6_P#:NGK_ ,O, _>*
M/]H?X_G7;44[@9FD>(-,UR+=8W*NP&6C/#K]16G7.ZMX,TS4I?M,(>QO0<BX
MMOE.?<=#^A]ZRQJGB7PP-NK6W]J6"_\ +U /G4?[0_Q_.@1V%Q:V]VFRYMXI
MD_NR(&'ZURVN?#S0;^PN39Z;#;WQC;R9(B4 ?'&0.,9]JW=)U[3=;AWV-RKG
M'S1GAU^HK2K:CB:M%WIR:^9%2E"HK25SY>N+>>SN7MKF%X;A#AHW7# _2O=/
MAK;-;^"+,M*L@E9Y5VMD*"Q^7Z^OO74M!"[AWB1G P&*@G%<(=WP]\0YY_X1
MG4I.?2SF/\E/^>G/MXG,7F5'V,8\LEKWO;=+SZKOL>;0P:P=3VC=T]/0[^BD
M!# $$$'D$4M?.GK!1110 4444 %%%% !1110 45BZOXHTS1V\F24S79X6V@&
M^0GZ#I^-9?D>)O$?_'Q)_8M@W_+*,[IW'N?X: -35_%.F:0_D/*9[L\+;0#?
M(3]!T_&LO[-XE\1\W4G]BV#?\L8CF=Q[G^&MK2/#VF:(F+.V D/WIG^:1OJQ
MK4H S-)\/Z9HD>+*V59#]Z5OF=OJQK3HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBL7Q?J%UI7@_5]0LI!'=6]I))$Y4,%8#(.#UH
MVJ*\Q^#7C#7/%VG:M+K=VEP]O-&D92%8\ KD_='->G4 %%%% !1110 4444
M%%>/_&/QUXC\):QI=OHE[';Q7$#O('@63)# #J..M>NQ,6B1CU*@F@!]%%%
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MRRYEV>C7K_FC.>+5%?OE;\4_Z\SU6BN)\#^.SXFEEL;V&.&^C3>ICSMD7H<
M]"../>NVKDQ&'J8>HZ=16:-Z5:%6'/!Z!1116!H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !17#>-/BIH?@N\6PFCGO+\J&:"W _=J>A9B<#/IUKF)_&VH_%-X_#_A!
M;C3K5XP^JW\X >!#QL0 \DX/(_3DUM&A-KF:LNY/,MC2\1>)M3\::S-X0\&3
MF.*,[=4UA>4MUZ%(R.KGD<?AW([?PUX9TSPGHT6EZ7 (X4Y=SR\K=V8]R?\
MZW2G>'?#FF>%M&ATO2H!%;QCDGEI&[LQ[D_YXK5I3FFN6.WYC2ZL****R&%%
M%% !1110 4444 %<OXD\5G3[E=(TB#[=KDP^2!>5B']YSV'?%5-:\3WFHZB_
MA_PL%EOQQ<7A_P!5:COSW;_/)K7\-^%[/PY;OY9:>]F^:XNY>7E;OSV'M7?"
MC"A%5*ZNWM']7V7EN_34YI5)5'R4]NK_ ,O/\BIX:\*?V9.^JZI/]NUN<?O;
MEN1'_LH.P[?X=*Z>BBN6M6G6GSS>O]:+R-J=.-./+$****R+"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G-6\&:;J,OVFWW
M6%Z#E;BV^4Y]2!U_0UFG5_$?A<8UFV&I6"_\OEO]]1_M#_'\Z[6JFJV/]I:3
M=V6\IY\31[O3(IW$>?S?$J_-T6@L+<6^>$D9MY'N1P#^%=A#<Z7XN\.$3(IM
MKE"DD3D;D/<?4'H?H:\OF\-:Y;W#0OI=R[*?O1)N5O<$5O\ @32/#'BKPXM[
MA[BY21H[A&9HVA<'[I4'CC'/>JCS+WX]!.ST9J>%]3GT'5&\)ZO.'" MIUVQ
MXFB_ND]F'],>F>U\Z+_GHG_?0KD]2^'NE3Z;-'IZM;717,4AD9@&[9!)XK%\
M):+H.LP366HZ<UOK-DWEW</G.,GLXYZ'V_PKIK)XB+Q$4E;XK?G;HG^?JC&#
M]DU2;]/\CT;SHO\ GHG_ 'T*/.B_YZ)_WT*YW_A ?#O_ #Y/_P!_G_QH_P"$
M!\._\^3_ /?Y_P#&N,Z#HO.B_P">B?\ ?0H\Z+_GHG_?0KG?^$!\._\ /D__
M '^?_&C_ (0'P[_SY/\ ]_G_ ,: .B\Z+_GHG_?0K&\1^);?0+%9=HGGD;;%
M$&QD]R3V JM_P@/AW_GR?_O\_P#C6/XB\!0)8K+H=N1.AR\1D)\Q?;)ZC]:!
M$.G_ !)E\XKJ-BIC(^4VV=V>PP>M:OD^)O$?^N?^Q-/;_EFAW3N/<_PUQ^B>
M$=5OM3A%Q9S6MO&X:225=O .< =S7KU &5I'AW3-$4_8[<"4_>F?YI&^K&M6
MBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5SGQ _Y)[X@_Z\9?_0371US?Q ('P\\0$G %A+R?]TT ><_LZ_\ ()U[_KXB
M_P#0#7LMS<1VEK-<S';%$AD<^@ R:^9_A7\2]&\"V&I0ZC%<S-=RHZ?9PI
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M,55=6IN50H1H0Y(A1117,;!1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#&V Q]\8S0!V=%%1FXA4D&:,$<$%A0!)147VF#_GO'_WT*/M,'_/>/\ [Z%
M$M%1?:8/^>\?_?0H^TP?\]X_^^A0!+147VF#_GO'_P!]"C[3!_SWC_[Z% $M
M%1?:8/\ GO'_ -]"C[3!_P ]X_\ OH4 2T5%]I@_Y[Q_]]"C[3!_SWC_ .^A
M0!+147VF#_GO'_WT*/M,'_/>/_OH4 2T5%]I@_Y[Q_\ ?0H^TP?\]X_^^A0!
M+147VF#_ )[Q_P#?0H^TP?\ />/_ +Z% $M%1?:8/^>\?_?0H^TP?\]X_P#O
MH4 2T5%]I@_Y[Q_]]"C[3!_SWC_[Z% $M>=?%&_N-2_LSP/IDA6^UR7$[+UB
MM5.78_7!'N 17>S7]I;P23S7,211(7=BPPJ@9)KSGX<#_A(=;U?Q]J!"-?N;
M;38Y" 8[9#C/_ B/T/K6U)6O4?3\^A+['HNGV%OI>G6UA:1B.WMHEBC0=E48
M%6:B^TP?\]X_^^A1]I@_Y[Q_]]"L7J42T5%]I@_Y[Q_]]"C[3!_SWC_[Z% $
MM%1?:8/^>\?_ 'T*CGU"SM;>2XGNHDAB7<[EQA132;=D)M(?=W4%C:2W5U*L
M4$2EG=S@**X:VM[GXAWZ7UZDD'AJW?-M;-PUVP_C;_9]O_KU%$9/B%J"W-XQ
MMO#-N^8;=FVM>,/XF_V?\^N.]2:UCC5$DA5% "JK   =A7H.V"5E_$?_ )+_
M /;?EZ[<R_?N[^#\_P#@?F3(BHBHBA548"@8 %+47VF#_GO'_P!]"C[3!_SW
MC_[Z%><=1+147VF#_GO'_P!]"C[3!_SWC_[Z% $M%1?:8/\ GO'_ -]"C[3!
M_P ]X_\ OH4 2T5%]I@_Y[Q_]]"C[3!_SWC_ .^A0!+147VF#_GO'_WT*/M,
M'_/>/_OH4 2T5%]I@_Y[Q_\ ?0H^TP?\]X_^^A0!+147VF#_ )[Q_P#?0H^T
MP?\ />/_ +Z% $M%1?:8/^>\?_?0H^TP?\]X_P#OH4 2T5%]I@_Y[Q_]]"C[
M3!_SWC_[Z% $M%1?:8/^>\?_ 'T*/M,'_/>/_OH4 2T5%]I@_P">\?\ WT*/
MM,'_ #WC_P"^A0!+147VF#_GO'_WT*/M,'_/>/\ [Z% $M%1?:8/^>\?_?0H
M^TP?\]X_^^A0!+147VF#_GO'_P!]"C[3!_SWC_[Z% $M%1?:8/\ GO'_ -]"
MC[3!_P ]X_\ OH4 2T5%]I@_Y[Q_]]"C[3!_SWC_ .^A0!+147VF#_GO'_WT
M*/M,'_/>/_OH4 2T5%]I@_Y[Q_\ ?0H^TP?\]X_^^A0!+147VF#_ )[Q_P#?
M0IR312-A)$8^@8&@!]%%% !1110 4444 %%<%>V_C7Q'XJU&V@U&;P[HED%6
MWFC@CDDO'.<MELX4>GT_"GHGCV_LO"OBJ;7C%=WOAN>2!YX%V+=8'R''123P
M<=* /2:*\GO9O'NB>$D\:7'B".ZE2-+JZT<VJ+ (3@E$8?,& /7/8UZA8W<>
MH:?;7L.?*N(EE3/7# $?SH L44$@#)Z4WS$_OK^= #J*;YB?WU_.CS$_OK^=
M #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^=
M #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^= #J*;YB?WU_.CS$_OK^=
M 'EWB*QN?AKXED\7Z- \F@WK@:U8Q_\ +,D_Z]!^//U/8\>E6=Y::KI\5W:R
MQW-I<1AD=>5=2*DF6WN(9(9A')%(I5T?!# \$$=Q7E=C._PF\3+IES*7\':K
M,?L<Q;/V"8\E&/\ </K^/9JZ%^]7]Y?C_P $G;T-J!F^'WB$6LA/_"-ZE)^Y
M8]+28_PD]E/^>AKOZHZKI]CK.F3V%Z%>"9<$9Y'H1[CJ*YCPGJUSI6H/X2UF
M7?<P+FQN3TN(>P_WAC]/;GHJ?[53=5?''?S7\WJNOW]SGC^YER?9>WD^W^7W
M':T4A91U8#ZFD\Q/[Z_G7GG4.HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^OYT .HIOF)_?7\Z/,3^^
MOYT .HIOF)_?7\Z4$,,@@CVH 6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KRCQU\93X2\43:+::3'?&"-#+(]R8\.PSMP%/;!_&
MO3[Z\AT[3[F]N&VP6\32R-Z*HR?Y5\Z>!/#DWQ$E\:ZW>(&EN8)$@+#[L\AW
MC'^Z%0?C0![WX6U^+Q1X8T_6H4\M;J(.T>[.QNC+GV((K8KQ7]GO7C-I>I^'
MYCB2VD%S$IZA7X<?@P_\>K5^)_Q+U;P1XDTRSLK>TEM)X/.F\V-F? ?!"X8#
M..GO0!ZK2,P52S$  9)/:O#?%?CSXG^'S;ZW<Z;8V.D7$@$5LZ"1ESRJRD'*
ML1Z=ZZ'Q-XG\2^(?AI9:QX;TRU>SO[&<ZD+AQN@39AMGS#)^_P!CT'% 'H6G
M:YI>KS7,6G7]O=O:L%F\EPX0GH"1QGBN&N_B??6WQ-7PD-!+V[74<'VWS&Z,
MH;=C;CC..M>9?!ZZ\86JW<?A;3K*ZL7N8?MKW#A6C&/X1N&?ER>]>@:C\2=;
MM/C)!X2C@LCITEQ%$7:-O-PT>X\[L=?:@#U:BBN5^('C2'P/X;;4#$)[J5Q#
M:P$X#N1G)_V0 2?_ *] '0ZC=&QTN[O @<P0O*%)QNVJ3C/X5Q?PS^(LWQ A
MU&273$L?LAB "S&3?O!/]T8QBN*MO$WQ1O/"=UXAO;"PN]"N+:0M;QKY<RQ%
M2/,0<\#KR22!T[U!^S_<Q:=H_BFZF8^3;+#([ ?PJCD_H* />:K:A=&RTVZN
MP@<P0O(%)QG:"<9_"O&=)\=?$7Q__:%]X672K&SLS\L$PWROD9 R<\D=^!GB
MNL\+^*-=\2>"-;'B'1+C3+^VMY%)D@>))E*-AE#=",$$<]O6@#CK3X^:O?*3
M:>#6N" "P@G>3;GUVQG%;6A?'C2;S4%L=<TRYT>0L$,LC;T5C_>X#*/<C%<Y
M^SF?]-UT=O(@_FU;WQ^T.QE\+VNM^2JWL%RD!D Y>-\@JWJ 0"/3GUH [_QG
MXD;PKX1O-<BMENS;A"(C)M#;F"]<'USTKA?!?QJ'B;Q1;Z-?:3'8"Y5A#,MR
M7S(!D*05'4 X]ZQY=3FU3]F%WN'9Y8%6V+,<DA)PJ_H!7%S:%/\ \*CT+Q;I
MW[N\TN]E621!R%,N4<_[K@?@QH ][^(7C"3P/X;35HK);QFN4@\MI-@^;/.<
M'TK1\(Z\WB?PIIVM/;BW:[B\PQ!]P7DC&<#/2O+?B=XAA\5?!+2]8AP//O(/
M,0?P2#<'7\"#7=?"HA?A9H!)  MLDG_>- &1\1?BL/ ^KVNFV^FQWTTD)FEW
M3^7Y8)PHX4Y)P?RKI/ GBZ/QKX7BU98!;R^8\4T ?=Y;J>F<#.1@].]>.>%K
M./XF_&#7-5NE\S3HHI0FX9&TCRHOQQN;ZU<^!>HS:)XKUKPG>G;(VYU4_P#/
M6(['_-<'_@- 'OE%%% !1165KM[JUA;Q7.EZ:FHJC_Z1;B41RE,=8\_*6![$
MC/K0!JTR*:*=2T4B2 '!*,#S7!>)=;MO%OA"ZM](%W<2PS1'4M*CS#>^0''F
M1[#A@2N1[\@'FLGPG::2_C>PN?!V@ZCI-A%!*-4:>WD@BE! \M-K_><-SD#@
M9YYH ]6HHHH **** "O.?@[_ ,@7Q!_V'KO^:UZ-6+X;\,6/A:VO(+%YW2[N
MY+N3SF#$.^,@8 XXH Y;X/L(O#NK6+D"ZM=8NDG0_>!+9&1[BD^$_P"_3Q7J
M,0'V6\UZX> CHRC R/;-:FM?#;1=9U:?4A<ZEI\]TH6[_L^Z,*W('_/0 <\=
MQ@UT>DZ38Z'I=OINFVZ6]I;KMCC7L/ZGN3WH NU')"DA!;=QZ,1_*I** (?L
ML?K)_P!_&_QH^RQ^LG_?QO\ &IJ* (?LL?K)_P!_&_QH^RQ^LG_?QO\ &IJ*
M (?LL?K)_P!_&_QH^RQ^LG_?QO\ &IJ* (?LL?K)_P!_&_QH^RQ^LG_?QO\
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M:/LL?K)_W\;_ !J:B@"'[+'ZR?\ ?QO\:/LL?K)_W\;_ !J:B@"'[+'ZR?\
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MC>3ZC_9G@?2VVWVN28G=1S%:KR['ZX_0BN\L-.M=,TZVL+2)8[>VC6*-<=%
MP*\_^&T$OB36M7\?WL9!OW-MIJ..8[5#C/\ P(C]#ZUZ56U7W4J:Z;^I*UU$
MV+_='Y4;%_NC\J6BL2A-B_W1^5&Q?[H_*EJ.>>*U@DGGD6.*-2SNQP% [FFD
MWH@V&W,UM9VTEQ</'%#&I9W?@*!WK@HH;GXC7XGF22V\+V\F8XR-K7K#N?\
M9_SUZ*JW/Q'U 2.)(/"UO)\J\JUZP/4^B_YZ]._BBC@A2&%%CC10JHHP% Z
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M\BC[-!_SQC_[Y%2T4 1?9H/^>,?_ 'R*/LT'_/&/_OD5+10!%]F@_P">,?\
MWR*/LT'_ #QC_P"^14M% $7V:#_GC'_WR*/LT'_/&/\ [Y%2T4 1?9H/^>,?
M_?(H^S0?\\8_^^14M% $7V:#_GC'_P!\BC[-!_SQC_[Y%2T4 1?9H/\ GC'_
M -\BC[-!_P \8_\ OD5+10!%]F@_YXQ_]\BJ6L:!IFO:/<Z7?VJ26MPNUP
M1Z$'L1U!K2HIIM.Z \P\&ZE<>%=>'@/Q,5D(!.CZA(HQ=1=HR?[XZ8_#TROQ
M<EBMK72HHK=$F,KR).HPR!0. 1ZY'Y5U?C3PC:>,=":RF;R;N(^;9W2_?@E'
M1@1SCU']0*Y'1KI?'6GW'A'Q8IM?$^DM\[I@&0=!,G8@@C(]P>,C'I8*M3AB
M(UY;+?\ *_\ F<N*IRJ494X[O8X3P]XAO-#U:&X69G@9P)XI#N5U)YR#W[YK
MW^TFTR_B\VSDM;A/[T15A^E<7H?PJL-.OUNM0NS?A#E(3$%0GU89.?ITK4O/
MASH,\IGLTGTVX[264I3GZ=*[<SQ&!Q51.+:?=+1^NST.3!4<30@U)7\KG4?9
MH/\ GC'_ -\BC[-!_P \8_\ OD5Q_P#8WC72.=.UZ#4X1_RRU"/#'_@0Y_6C
M_A-=5TSCQ!X8O(%'6>T(FC_3I^=>9]1E+^#)2]'9_<[/[CM^L)?&FOR^]'8?
M9H/^>,?_ 'R*/LT'_/&/_OD5C:9XT\.ZL0MKJD D/_+.4^6WTPV*W000"#D'
MH17-4I5*3Y:D6GYFL)QFKQ=R/[-!_P \8_\ OD4?9H/^>,?_ 'R*EHK,LB^S
M0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/&/\ [Y%'V:#_ )XQ_P#?(J6B
M@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (O
MLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\ WR*E
MHH B^S0?\\8_^^11]F@_YXQ_]\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"
M+[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0?\\8_P#OD4?9H/\ GC'_ -\B
MI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH
M B^S0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/&/\ [Y%'V:#_ )XQ_P#?
M(J6B@"+[-!_SQC_[Y%'V:#_GC'_WR*EHH B^S0?\\8_^^11]F@_YXQ_]\BI:
M* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\
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M'<2W5O8R30-/(,%F=<J3^3"OH&J&LZ+I_B#2I],U2V2XM)AAT;]"".01V(H
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M5;OJSW HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQPK:\DU:7Y^AN4445R&X4444 %%%% !1110 4444 %%%(S*BEF(50,DDX %
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M<<F)P6.3QG?]T#&1@J<Y!KMOC7H-]:>*=*\6PZ>;^PA6-+J+;O4%'+ ./[K
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MD41#$9B^0J/0$=J!'"_#F6X77YXHL_9W@+3#L""-I^O6O4:HZ7H]AHUN8+&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3'N_N*Q'7)[>QKZ0T/P;X<\.*!I.CVMLX_Y:A-TA_P"!G)_6G7HTJ,^5MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6UO,:7X?MDUJ^N$^X!F%%/>0GC'M_*N?B^#P:R:X75/[-UAY?/#V$"+#&W7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;TW0M,TA,6-E%$>[@98_4GFM&B@ HHHH **** "BBB@ HHHH **** "BBB@
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MDB5C^9KU\JS-8+F4HW3_ $.#'8)XFS3LT<E\)[&>V\,SW$T01;FX+Q$KAF0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)JS;;"UN=K=K.S+'_OIJ[*TE\*V 'V33!"1T*:9(#^>S-:'_  DFF@8!NO\
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M6HK)_P"$DTWUN_\ P"F_^)H_X233?6[_ / *;_XFBP71K45D_P#"2:;ZW?\
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MU%9/_"2:;ZW?_@%-_P#$T?\ "2:;ZW?_ (!3?_$T6"Z-:BLG_A)--];O_P
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M?_$T6"Z-:BLG_A)--];O_P  IO\ XFC_ (233?6[_P# *;_XFBP71K45D_\
M"2:;ZW?_ (!3?_$T?\))IOK=_P#@%-_\318+HUJ*R?\ A)--];O_ , IO_B:
M/^$DTWUN_P#P"F_^)HL%T:U%9/\ PDFF^MW_ . 4W_Q-'_"2:;ZW?_@%-_\
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M45#]KB_V_P#OVW^%'VN+_;_[]M_A0!-14/VN+_;_ ._;?X4?:XO]O_OVW^%
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M8;#++QT^;/--'P\\47*_\3'XCZNV>HM8EA'Z&O0/M<7^W_W[;_"C[7%_M_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !61XJTAM>\*:KI*,%DN[62)">@8J<?KBM>B@#QR
M'XAVT7PW7PRUI=GQ:MG_ &9_97D/YGF[?+#9QC;WSFO2?"&C/X>\(:3I,I!E
MM;9(Y".F['S?KFMG8N_?M&[&,XYQ2T <[XI\*Q>(8XY$E\B\A!"2$9# _P +
M#TK)T#P =/U*.]U"Z2?R6W11Q*0-W8DGT]*[BBG<5@HHHI#"BBB@ HHHH *X
M#5OART]_)/IMY'#%(Q8Q2H3L)]".U=_10!C>&_#T'AVQ:%)#+-*VZ64C&X]@
M!V K9HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** $90RE6 ((P0>]>?WOPU9[T
MM8WZ16S-G9(A+(/0$=?QKT&B@"AHVD6^B:9'96VXJO+.W5V/4FK]%% !1110
M 5RR^"(UUX:K_P )%XC+"X^T?93J!\CKG9LQ]SMCTKJ:* /,M-\)^/=!O-6N
M=/U3P\[:A=O<RS75O*\K _=4D$<*. .W-<KX-T3Q!XF^#6KV$<MBUC=)/]DA
M5&$WGB7<=S$[=I(('U%>[TBHJ+M50H] ,4 >/:QX_M?$/P\/AK3[>ZD\47UL
MMC)IQ@=7A<@*[.2,!0,G/_U\>J:-8?V5H=AIVX-]EMXX<COM4#/Z5<"*'+A1
MN/!..33J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY!].* /:*ADN[:*989+B))6^ZC. 3^%<%XAN]0^&WPEF5=4EU*_@46]K=3H
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M80*@D;6'L2?LHBQ\H/\ #N)SP/:M2RU6W^'OQ.\00ZZXM=+UYTN[.^D&(_,
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M[U*\\#12ZC)=2I]HE%G)=?ZU[8']V6)Y/&>3VQ7<4  # X%% !1110 4444
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M!JUY%!);Z7?:K/<:;"ZE2L!(P0#T!(.!7H=     P!T%% !1110 4A(4$DX
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ML*]0(!!!&0>H-16EG:V%NMO9VT-O N=L<*!%&>3@#B@":BBB@ HHHH ****
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M!U;OR#Q0!Q?Q"TBYUOX27UI9H\ER+6.:-$ZL4*M@>O /%<IX@\2>"=1^#O\
M8^ER6D]S/:I!9Z;"H,ZSX 'R=0P;DGO@\G->R*H50J@!0, #M52/2=-AOFOH
MM/M$NV^].L*B0_5L9H 9H<%S;:!IUO>$FZBM8DF).?G"@'GZYJ_110 4444
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M+E)KR01P6D9R/-=CP>AP.<D?@>^JA>:)I.HS":^TNRNI0NW?/;H[8],D=.:
M.,\&KX>TW1KW3?#GB*QU3Q%=1R7$]T;A9))Y\??8 GY02..P^ISR<^E^-O"W
MPUUBPN='T4VTEM/+?WGVUVFE9P=\A&W!;T&>P%>O6>@Z/IUQ]HLM)L;:;!7S
M(;=$;!ZC(&:N3P0W,#P7$22PR*5>.10RL#V(/44 <E\,IM6E\$Z:-2MK2&!;
M6$6;6\I<R1;!AGST;V%=C3(88K>%(88TCB10J(BA54#H !T%/H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSWQ0 M%%% !17.>)O%#^']4\/V:6BSC5KX6C,9-OE#&=P&#GZ<5T= !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%-D+B)S& 9-IVAC@$]LT .HKFO WBMO&'ATZC+:"SN8[B2WGMP^_8Z'&,
MX';!Z=ZQ]"^)"ZU\0;[PV=/\JVB,RVMYYF1</$0' &.V3W/2@#O:*YO6_$\F
MF^*]!T"UM%N)]3:1I&,FWR(D );&#GT XKI* "BBB@ HKG)?$[Q?$2W\+?9%
M*2Z<U[]H\SD$/MV[<?CG-='0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !117,?\)7)%\1O^$5N;-8XYK'[7:W
M(DSYA!PRE<<8Y/7M0!T]%<+\0?B(?!$^GPQ::;]YP\LX$A7R(5*@OT/=OTKH
MO$/B"#0?"E]KQ4316UL9U4-CS./E&>V20/QH V**H:)>7.HZ'8WMY;K;7%Q
MDKPJVX1EAG;G SC-7Z "BBN=\;^)G\(^%I]8CM5NFBDC3RFDV [G"]<'IF@#
MHJ*13N4'U&:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNX;O18G+:9(78SQ1D_ZMP1@@=B#_ $P ==1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img76291469_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )Z"#0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHJO+?V<$HBFNX(Y#T5Y #^1H L44 @@$'(-%
M!1110 45Y^_QC\+I<3P"/5)&@D:)S'8NP#*<'D?2M[PSXWT'Q:9X]*NV:X@Y
MEMYHS'(@]2I[4 =%161H_B33]=OM4M+(RF73+C[-<;TV@/[>HK7H **** "B
MBB@ HK'U'Q+I^EZ[I>C7)E^UZF7%N%C)7Y1DY/;K6Q0 4444 %%%% !1110
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M"#T(/:JFK:K9:)I=QJ6HSB"TMUW2R%2=HSCH,GO0!<HKAO\ A<7@+_H8(_\
MOQ+_ /$UMVWC/0+SPW<>(8-0#Z7;EA+/Y;C:5QG@C/<=J -ZBN%/QC\!#.=?
MCX_Z82__ !-=G97D&H6,%[:R>9;W$:RQ. 1N5AD'GV- $]%%% !1110 4444
M %%%% !1110 4452U;5K+0]+N-3U&<06=NNZ60J6VC..@!/4B@"[17"GXQ^
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ME:C%=W%GCSQ$"57)(X;&#R#T)H VJ*P/$7C;P]X4F@BUO45M'G5GC!C=MP!
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M=S*L)N;2\$QMV;@>8NT<>XKGOB!=-K&C>"_$]Q!?Z/IT=V6N63 FM$D "R<
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MEOLFV;F8 DR$C"(!WY/08YJQH?CC4W\6KX8\2Z&-,U">)IK66&?SHIE7J <
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MBEX*TM/#OB?Q3<>==:D]L! 9GRELORKB->V>>?>O0O#7_(JZ/_UY0_\ H K
M^+/_ "2SQ!_U[#_T):W_  U_R*NC_P#7E#_Z * -2BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKFZLX)I[5B\$DD89HB>I4GH>.U%_IMCJEN(-0M(+J$.'$<T8=0PZ'![BK5%
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M>P&< 5T=% ',:+X4TU]!T;^V=%LIM1M;.*)GG@21T95 (W8/3ZUTP 50J@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445P_BOQ)K#^*+'PCX9:WBU*XA-S<WDZ;UM80<9V]V)Z9_KP
M=Q17!Z;)X[T3Q;::?J<J:]HMVC;KZ.V6%[5ATW '!!_STJK=ZYXG\6>,=3T3
MPQ?V^E6&D;8[J^DMQ,\DQYV*IX '>@#T:BN(\%^)M7N-=U;PMXD\A]7TT+*M
MS NU+F%NC[>Q'&?K7;T %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Y1\4O&
M&JI%J&F>&;MK=]*MQ=ZG>1GF($XCA!_O,3D^P^M 'J]%<7KOBR;PU\,+?6R/
MM-^]I L(?_EI,Z@#/XDD_2N;U:Q\?>%O#A\4R>*7U"[ME6>]TR6W00,G\2IC
MD$#O[4 >L454TK48=7TFSU&W_P!3=0I,GL&&<?K5N@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>*?]_/\ ZU&^X_YXI_W\_P#K5-10!#ON/^>*?]_/_K4;[C_GBG_?S_ZU344
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ"]C_P"!"?XT?\)#HO\ T%['_P "$_QH TJ*S?\ A(=%_P"@O8_^!"?XT?\
M"0Z+_P!!>Q_\"$_QH TJ*S?^$AT7_H+V/_@0G^-'_"0Z+_T%['_P(3_&@#2H
MK-_X2'1?^@O8_P#@0G^-'_"0Z+_T%['_ ,"$_P : -*BLW_A(=%_Z"]C_P"!
M"?XT?\)#HO\ T%['_P "$_QH TJ*JVFI6-^S"SO+>X*C+"*0-CZXJU0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%4-4US2M$A
M$NJ:C:V2-]TSRA-WTSUI=+UG3-:MS/I>H6UY$#@M!*' /OCI3Y7:]M +U%%%
M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%I_WW6S%$D,"0QJ!&BA57T & *3R(O\ GDG_ 'R*^=.TR/\ A,/#O_08M/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(2%4DD
M #DD]J6O$?C/\1C")?">C2GS7&W4)HSRH/\ RR7'<]_;CN<:T:4JLN5$RDHJ
M[.=^)GC>Z\?>(8/#/AT//8+,(T6,_P#'Y-G[W^XO;MP6],>Q_#_P/:>!]!%L
MA66_GP]Y< ???'0?[(Z#\^]<[\(_AS_PB^GC6-5A UFZ3"QL/^/6,_P_[Q[_
M )>N?3ZVQ%6*7LJ?PK\281?Q/<****Y#0**** "BBB@ HHHH **** "BBB@
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MQYUO*NV2//3(]/<9%<!?^._&7BCQSJ7A[P6MA;PZ;N\RXN5W>85.T\G(&6X
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M&*S^./C?;>$+R\N(=(MXP6BB?;O/E^8Q^IX7)Z 5<:#<W"3M;<'+2Z/=%8,
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M'_/N/^_@H GHJ#S;C_GW'_?P4>;<?\^X_P"_@H GHJ#S;C_GW'_?P4>;<?\
M/N/^_@H GHJ#S;C_ )]Q_P!_!1YMQ_S[C_OX* )Z*@\VX_Y]Q_W\%'FW'_/N
M/^_@H GHJ#S;C_GW'_?P4>;<?\^X_P"_@H GHJ#S;C_GW'_?P4>;<?\ /N/^
M_@H GHJ#S;C_ )]Q_P!_!1YMQ_S[C_OX* )Z*@\VX_Y]Q_W\%'FW'_/N/^_@
MH GHJ#S;C_GW'_?P4>;<?\^X_P"_@H GHJ#S;C_GW'_?P4>;<?\ /N/^_@H
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M/=2*% 1>B(HZ**ZJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "JNHZE9:38RWNH745M;1#+RRMM _SZ5QGCCXJZ+X/#VD9&H:MCBU
MB;B,_P#31OX?IU]J\;@LO&WQEUG[1,Y%C&_^M8%;6W]D'\3?F?4BNJEAG)<\
MW:)$IVT6YT/C3XV7^K2G2O"$4T$4AV"[V$SRGTC7^'Z]?I4G@GX(7-^ZZGXP
M>2-';?\ 85?,DA/.97[?0<^I%>F>"_AOH?@J(26T9NM188DO9@-Y]0HZ*/8?
MB3785<\3&"Y*"LN_42@WK(KV-A::9916=C;16]M$NU(HE"JH^@JQ117%N:!1
M110 4444 %%%% !1110 4444 %%%% !1110 445ROBWQS8^%BEOY375\Z[A
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M,IWRN-W=CT^@P*]BL;ZUU.QAO;*=)[:9=T<J'(8>HKS_ ..7_)-+C_KZA_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2+)&PRKH<@CV-/KS'P9"/"OQ1UWPC9LXTB6U34+2!F+"!B<,JYZ _P!!7IU
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+378+'G-I\$/!=K>BY:VN[A0<B">X+1_B!@D?4FO0'M87LVM/+"P-&8MB_*
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M]M_C1]EB]'_[[;_&IJ* L0_98O1_^^V_QH^RQ>C_ /?;?XU-10%B'[+%Z/\
M]]M_C1]EB]'_ .^V_P :FHH"Q#]EB]'_ .^V_P :/LL7H_\ WVW^-344!8A^
MRQ>C_P#?;?XT?98O1_\ OMO\:FHH"Q#]EB]'_P"^V_QH^RQ>C_\ ?;?XU-10
M%B'[+%Z/_P!]M_C1]EB]'_[[;_&IJ* L0_98O1_^^V_QH^RQ>C_]]M_C4U%
M6(XX4C)*[N?5B?YU)110!RDOQ(\+0>)&\/RZ@R:BLWDM&T+A0V,\MC;CWSBL
M6;XW^"8=1:T%[<R*K;6N([=FB'OGJ1[@5X[XETM=<^.5YI4C%([O5$BD93R%
M(7=C\,UZS\3_  1H$?PVO9++3+6TFTV(2V\D,85AM(R"1R01GKWYKO="C!P4
MK^\9*4G>QZ';ZG8W6FQZE!>0O92('2<.-A4]\TS^VM*_Z"=G_P!_U_QKPSX6
MV<OBSX9>*/"TMXMM )HS%-(NX1;_ )CQD<93/7J:/^&?X?\ H;+/_P !1_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT0_@AC"#\A5BBBN?<L**** "BBB@ HHHH **** "BL#5_&N@:+E;J_C>8?\
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M<JQ=5-M/<OV<3Y^_X9WU3_H8++_P'?\ ^*KJ/'?PWO;WX8:1IUD1=ZGH<:[
M@QYZ[=KA0>YP"![8[UZS10\75;3;V#V<;6/EZQ^*NJZ9X!E\'#3R+L(UK'<,
M2'CC;(*F/&2P!(!^GI7I7P1\%7GA[2+O5M3MVM[J_"K%"XP\<2Y(W#L23G'H
M!7J1MH#,)C#&91T<J-WYU+55<2I1<81M?<%"SNV>7>$?B+KVN_$B^\/7EA;1
M6,#7 25(G#'8V%R2<<BN7^-O@[48-<B\7Z7%(\95!<F)=S0R(?DD('\.,#/;
M'O7O-%3'$<E13@K>0.-U9GS#XJ^(NL_$RQT[P_9:.1,)%DECMR9#-*!@8X^1
M1DGG\^*]@TWX=K!\(W\(3R(+F>!FEE'*B=CN!^@; ^@KN8K:"!F:*&.,MU**
M!FI:=3$72C!62U!0ZL^7_"GC36?A+>ZII.IZ.SF8AC#*_E[9 ,!E;!#*1CIZ
M#%;WPD\,:MXA\;R^--6@=+=)))TD=2HGF?/W0?X5!//T'K7OTMO#/CSH8Y-O
M(WJ#C\ZD  &!P*N>+NG:-F]V)4[=3PCQUX@\>>!_'+7[7=U=: \XFACVCRBA
MZQ,0N5(Y S['FN>\:_$'4?BE]AT31=$G5$E\TQ*WF/))@@9(&%4 GD_TKZ79
M0RE6 (/4$=:9#;P6X(AACC!Z[% S^5*&)A&SY-5U!P;ZZ'/^ _#3>$O!MAI,
MC*]Q&I>=EZ&1B6;'L,X_"NDHHKEE)R;D^IHE;0****D HHHH *Y?Q/X7L?&"
M6TUMJ<MEJ=@Y:VOK)P7A)ZJ?4''(/I67\6[R\@\(065C<-;R:G?P6+RH<%4<
MG=@_ACZ$UR/BOP5;_#/1(=>\(W=W;:AYJ6DOF2ETG63Y<LO3()##TQ0!J6WP
MHEMXWC\1>,;FZT=K@W5Q9[%@CGD)W%I&SR">2/Y5ZG"T;0HT)0Q%04*?=*]L
M8[5YK;?!'P])&K:S?:KJER>97GNV"NW<X'^->D6UO%9VL-K NR&%%CC7.<*!
M@#\A0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$,9=1U5 >23TST'Z5]4HBQHJ(,*HP .PI:*Y:^(E6=V7""BM HHHK L****
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M(Y/Z5S1N?'/C8XC^TFU;^X/(AQ]>-WZUZ9H_@+P]HVUXK);B<?\ +:Y_>-^
M/ _ 5TH  P!@"C^T,)AM,+2N^\O\O^&#ZI7K?QYZ=D>6Z/\ "!%VOK%^3W,-
MJ,#\6/\ A7>:3X:T;0U T_3X8GQS)C<Y_P"!'FM:BN#$YCB<3_$GIVV1U4<)
M1I?!$****XCH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2P)W./\ GA:(>%]F;/YL3VKZ<@@BMK>.""-8X8E"(BC 50, #\*X?X4>#/\
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M'X"I***^4;;=V>ZE8****0!1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !163?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME<K=H]EHCHH8*E1U2N^["BBBO..L**** "BBB@ HHHH **** "BBB@ HHHH
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M,@Y% !1110 5S_@[_D"2_P#7[<_^C6KH*Y_P=_R!)?\ K]N?_1K4 =!1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW76T4 4=*T?3M$TY=/TRSBM;122(8QA02<FJ%GX+\,Z?JAU.ST*P@O2<B9(
M"#ZCT_"MVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYN;YI;FB5M$%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)
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M,K)&P96'L1UJ2O-/!=I:>'OB;XA\.:+*?['6TBNS;!]RVT[,05'ID8.*]+H
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MFLWPQNPQ,&HV[_\ 72(J?T)JJ?!'B>S;-M,IQT,-TR?H<4 >J45Y68O'=B<
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M &@A\RXQS/+\S_AZ?A6U0!D:-X:TS0US:P;IL8:>3YG/X]OPK7HHI#"BBB@
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M_ISA_P#0!0!I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD#I_L)Z*/U/)[ =\(1PT>>?Q/9=C)MS=EL/^'OP^LO VEGE;C5;A1]JNL?\
MCB>BC]>I[ =G117%.<IRYI;FB22L@HHHJ1F/KOB?2?#D2-J-SL=_N1(-SM]
M.WN>*S='^(?A_6;Q;2*>6"=SA%N4V;SZ Y(S[5XSXFU";5/$VHW4[%F,[(HS
MD*BD@ ?@*RJ^OH\/4717/)\S7R1X%3-JBJ/E2Y4?4M%>4Z9\6UM=+MK>\TZX
MN+F*,)),)%&\COS5K_A<=I_T!KC_ +_+_A7B2R7&IM*%_FO\STEF.&:OS'IE
M%>9?\+CM?^@+/_W_ %_PI/\ A<=O_P! 6;_P(7_"C^QL=_S[_%?YA_:&&_G_
M #/3J*\P_P"%R0?] 27_ ,"!_P#$TA^,D/;1'_\  D?_ !-']BX[_GW^*_S#
M^T<-_-^#_P CU"BO+3\9$[:(W_@2/_B::?C(.VB?^3/_ -C3_L3'?R?BO\Q?
MVCAOYOP?^1ZI17E1^,A[:(O_ (%?_8TT_&5^VBI_X%?_ &-/^Q,=_)^*_P P
M_M+#?S?@_P#(]7KCM>^)&BZ)=O9J)KRXC.)%@ VH?0L3C/L,UR5W\7[JXLYX
M8=+C@ED0JDHN,E"1C.-O:O./J23ZGO7HX#()-N6+5ET5]_N./%YJDDJ&I[[X
M<\>:/XCG^RPM);W9&1#. "W^Z1P?YUIZMXDT?0T)U"_AA;M'G<Y^BCFOG!)'
MA<2QNR.ARK*<$'U!KT71OA1>WH2ZU>_6%9 '*0_/(<^K'@?K3QF48/#RYZE1
MQB^F[^7_  PL/F&(K1Y80O+OT+NL?%]5W1Z/IY/8371P/P4?U-8 M?''C<[I
M/M)M6[R'R(<?3^+\C7J.C^"M T3:UM8(\P_Y;3_O'_,]/PQ705Q_VEAL-IA*
M6O>6K_KYG3]3K5OX\].R/--(^$5I#M?5[YYV'_+&W&Q/SZG]*[S3-$TS1HO+
MTZQAMQW*+\Q^IZG\:OT5YV(Q^(Q/\6;:[=/N.NEAJ5'X(A1117(;A1110 44
M44 %%%% !1110 5@Z-_R,GB'_KM#_P"BA6]6#HW_ ",GB'_KM#_Z*% &Z6"]
M2!]34<UU;VT8DGGBB0\!G<*/S-><?&+_ (\-)_Z[2?\ H(JAX5\!IXG\-V][
MJ]]<^7M:.SBC8;8D!/)!!R2<UZU/+Z7U:.)JU+)NUK7[^?D<,\7/VSHPC=I=
MSUB*6.>,212)(AZ,AR#^-/KQ+P;?7GA;QZ=%>8O;R7#6LJ#[I;^%P.QSC\#6
MMK*?$7^W+_[ U[]C\]_(VF/&S/&,]L5=3*.6MR>TBDU=-Z71,,?S4^;D=[V:
M6IZO17C>SXH?WK_\XJZ/PNOBL6>M?\)&;@Q_9?W/FE.N&SC;^%9ULK]G!S]K
M%^2>I=/&\\N7D:]4=^'4]&!Q[U%#?6EQ(8X+J"5QU5) Q'X"O!/!&DW6O:I+
MI<-[):6\T&ZZ:/[S(I&%'U)%/\6: W@CQ! -/O)"3&)X9?NNA!(P<=>GZUV?
MV)259X?VOOVNM/SU.?\ M*?LU5Y/=O;<]_JL=1L1+Y1O;<29QL,JYS],UPGQ
M&UF_C\&:;+:R/$E\4\^1/E."F[;GMD_RKC=-T'PKJWAY$CU=;77R,D7;[(]V
M>1TZ8[@YKGPV5*='VU632;MHKV\WV1K5QKC4]G!7=KZNWW'NU%<[X,TW5=(T
M,6>J7D-WL;,$D3EOW9 P"2!G!SCVKHJ\JM!4YN,7=+J=M.3E%2:L%%%%9EA1
M110!S]I_R/FI_P#7C!_Z%)705S]I_P CYJ?_ %XP?^A25T% !1110 4444 %
M%%% !1110!SGBCP/H?B[R7U*"1+J#B&[MY#'-&/0,.WL:X'5OACHVBWMK>7_
M (RUZ&6\G2RBE#YDD9ONH6 SCCOP*]AKF_&'ARY\1IHRVT\4/V'4X;V3S 3N
M5,Y48[\T 3>%O!^C^$+.6WTJ%PTS;YYYG+RS-ZLQZUO444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\]_&OQ9+KNOV_A+2MTT=M*HF2
M/K-<GA4]]N?S/M7K/Q$\7Q^#/"=Q?*5-[+^YLXS_ !2$=<>BC)/TQWKROX'>
M$'U/59_%VI!I$@=DM6DY,LQ^_)SUQDC/J3Z5VX:*A%UY=-O4SF[OE1ZSX"\)
MP^#?"EMIJA6N6'FW<@_CE(^;\!P![ 5TU%-=TCC9W8*B@EF8X  [FN24G.5W
MNRUHA6940N[!549))P *\=\;>.)_$%S_ &'H7F/:NWELT8^:Y;^ZO^S_ #^E
M)XS\:W/B6[&AZ&)'M'?83&/FNF]!_L_S[\5V7@CP-#X;A%Y=A9=4D7!8<K"#
M_"O]3W^E>[0P]/+Z:Q.)5YOX8_J_ZT]=O,JU9XN3HT7:/5_HAG@;P+%X>A6^
MOE635'7ZK #_  K[^I_ <=>UHHKQ\1B*F(J.I4=VST*5*%*"A!:!1116!H%%
M%% !1139)$BC:21U1%&2S' 'XT .IDLT<$32S2+'&HRS.< ?C7'ZU\0K*SW1
M::@O)1_RT)Q$OX]3^'YUR\=GXD\:3"65F-OGAY/DA7_=7O\ K]:=A7.DUKXB
M6EL&BTJ,7,@_Y;/E8Q].[?R]ZYR'2_$GC&=9[AG\C.1+-\L:_P"ZO?\ SS79
M:-X%TS3"LUP/MMR.=TH^53[+T_/-=1T&!0!S>C>"=+TG;+(GVNZ'/FS#@'_9
M7H/YUTE%%(84444 %%%% !1110 4444 5YK"SN/]=:02?[\8/\ZSIO">@3DE
M]*MP3W1=O\JV:* .6F^'V@RG*1W$7^Y,?ZYK.F^&=HW^HU*X3V=%;_"NZHH
M\;\1>%YO#;P%I5GAFR!(J;<$=CR>U8=>[:AI]KJEF]I>0B6%^H/8]B#V-<F/
MAIIWG[C?79AS_J\KG_OK%,5C-^&^GK-=WE]+"KI$%CC=ESA^IQ^&*](JO8V-
MMIMI':VD2Q0H,*H_SR:L4AA1110 4444 %%%% !1110 4444 %%%% !1110
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M]VR,-ZCT8'O[BO<:*[,'F>(PLFXNZ?1G/B,%2KJTE;T/&_"OPTU*YU"*YUN
M6UG&P8PLP+RX[8'0>M>R=***SQN/JXR:E4Z;);%X;"T\/'E@%%%%<1T!1110
M 4444 %%%% !1110 4444 %%%% !6#HW_(R>(?\ KM#_ .BA6]6#HW_(R>(?
M^NT/_HH4 <C\8O\ CPTG_KM)_P"@BK7@/QAHMMX1M[2^OX;:>S#(R2M@L,D@
MCUX/;GBJGQC8"PTG) _?2=?]T5+X5\':%XC\%Z5<WUKF<(Z^;$Y1F =NI'6O
MI$J']E4_;WMS/;?KW/'?M/KT_9VO;K\CE= $GB;XI"_MT80_:FNV)'W8U^[G
MZ_*/QK;UFY^(JZY?BPCO?L8G?R-L<9&S/&,^U>B:+X?TSP_;-!IMJL(<Y=LD
MLY]R>36G7/7S:#K<T*:<4DDI*_S-J>!DJ=I3:;=W8\;^U?$__GG?_P#?J.NC
M\+2^*Y+/6O\ A(UN!&+7]SYR*.<-G&W\*]!ILL:31/%(NY'4JP]0>M85<S52
M')[**\TM36&#<)<W.WZL\8^$7_(TW'_7D?\ T):D^,'_ ",-E_UY_P#L[5Z9
MI/A30]"NFN=-L%MYF3RRP=C\N0<<D^@I=7\*Z)KUPD^IV"W$J)Y:L7887.<<
M$>M=?]K4?[0^M6?+:W2_YG.L#4^J^QNKW,+6=>TS1O!^D1:OITM[:7=NB%51
M64$(",Y(Y]/I7&:QHW@FZ\-R:MI6H&TN-FY+-Y0Q+?W"AR1Z9!Q7K=QI&GW>
MF#3;BUCELP@01.,@ # ]^/7K7-K\,/"RS>9]CF(S]PSOM_G66#Q]"BKMRB[W
MTU37FFR\1A:M32R:M;7=?,R/A!+>OI.H)*SM9QRJ(-QR%;!W >WW?SKTBH+2
MSMK"UCMK2"."",86.-< 5/7G8W$+$5Y54K)G9AZ3I4E!N]@HHHKE-@HHHH Y
M^T_Y'S4_^O&#_P!"DKH*Y^T_Y'S4_P#KQ@_]"DKH* "BBB@ HHHH **** "B
MBB@#SG6OA;:ZAJ]WJ,WBS7;4W4QD$4=YL1"?X5'I5;_A3$'_ $-_B7_P--9T
M'A.V^)'CKQ1<^(+FZ>UTNZ%C:6T4I14 7);]<_C]*IZ/X2U'Q-K^J>%]0\1Z
MD-$\.2"& 0RE99O,RZB1N^U>.E '<>$?!-IX4UFXEC\1:EJ$\L&PV]Y=>9M&
MX'<%Z]L9]Z[2N4\*_#S0?!][/>Z8MTUU/'Y4DUQ.9&*YSCTZ@5U= !1110 5
MROBKQW8>&+VTTT6EYJ6K78+06-E'ND*C^(]@.OY&NJK'_P"$:TA/$S^)3;_\
M30P>09VD; C] N<#ZXH R_#/CRS\0ZG/I%Q87NDZO"GFM97T>UF3^\IZ,.E,
M\0_$"VT?6QHEAI=_K.K",2R6UB@/E(>A=B<#/I7-Z/<_\)O\8/\ A(=,&=&T
M.V>R%WCBYE;.0I[@;NOM[U8^%H%UXA\=:C* ;B36&A+=PB#Y1].: .K\*>,-
M/\6VMP]I'/;W5I)Y5U9W*;)8']&'Y\^U=!7FE@?L?[0NJQ1#"7FCQRR@#@LK
M8!/O@5Z70 45"UU K%6D (."*3[9;_\ /5: )Z*@^V6__/5:/MEO_P ]5H"Y
M/14'VRW_ .>JT?;+?_GJM 7)Z*@^V6__ #U6C[9;_P#/5: N3T5!]LM_^>JT
M?;+?_GJM 7)Z*@^V6_\ SU6C[9;_ //5: N3T5!]LM_^>JT?;+?_ )ZK0%R>
MBH/MEO\ \]5H^V6__/5: N3T5!]LM_\ GJM'VRW_ .>JT!<GHJ#[9;_\]5H^
MV6__ #U6@+D]%0?;+?\ YZK1]LM_^>JT!<GHJ#[9;_\ /5:/MEO_ ,]5H"Y/
M14'VRW_YZK1]LM_^>JT!<GHJ#[9;_P#/5:/MEO\ \]5H"Y/14'VRW_YZK1]L
MM_\ GJM 7)Z0D $D@ =2:A^V6_\ SU6O,OC1XX31O#8T6PGQ?ZFI5F4\Q0=&
M;V+?='X^E:4Z;J344)R25SS?Q?JMW\5OB9;Z7I3DV2.;:T;JJH.9)C]<9^@4
M5]':/I-IH6CVFEV,>RVM8Q&@[X'<^Y/)]S7E_P $O"L.B:&VOWP5+[45 @5A
MS'!V_P"^B,_0+7JLFH6D,3RR7$:1HI9W8X"@=R:WQ4TVJ4-E^9$%9<S)Y)8X
M8GEE=4C0%F9C@*!U)->,^,/&=WXKO5T31$D:S=]@"##73?T3V_$TSQ?XPO/%
M]^NC:,DALF?:J*,-<MZGT4=<?B?;N/!GA;3_  Q:^=/+%-J<BXEE'(0?W5]O
M?O7JT:%/+::KXA7J/X8]O-_U^.WG5*L\7+V5)V@MW^B)?!7@F#PS;?:;G9-J
M<B_/(.1&/[J_U/>NNJ#[9;_\]5H^V6__ #U6O%KUZE>HZE1W;/1I4X4HJ$-$
M3T5!]LM_^>JT?;+?_GJM8FER>BH/MEO_ ,]5H^V6^"3*H Y)/04!<GI&944L
M[!5 R23@ 5R>L^/M-L T5E_IMP/[AQ&I]V[_ (5QSS^(?&4V&<_9L].8X$^O
M][]:=A7.NUGX@Z?8[HM/7[;,.-P.(U/^]W_"N46+Q)XVFW,6:VSP6^2!/H/X
MOUKI=%\&:/8;9=0F6]G'.UAB-3[+W_&NN6ZM44*LB*H&  , 4 <YHO@+3=.V
MS7G^FW Y_>#$:GV7_'-=4 %    '  J'[9;_ //5:/MEO_SU6D!/14'VRW_Y
MZK1]LM_^>JT#N3T5!]LM_P#GJM'VRW_YZK0%R>BH/MEO_P ]5H^V6_\ SU6@
M+D]%0?;+?_GJM'VRW_YZK0%R>BH/MEO_ ,]5H^V6_P#SU6@+D]%0?;+?_GJM
M'VRW_P">JT!<GHJ#[9;_ //5:/MEO_SU6@+D]%0?;+?_ )ZK1]LM_P#GJM 7
M)Z*@^V6__/5:/MEO_P ]5H"Y/14'VRW_ .>JT?;+?_GJM 7)Z*@^V6__ #U6
MC[9;_P#/5: N3T5!]LM_^>JT?;+?_GJM 7)Z*@^V6_\ SU6C[9;_ //5: N3
MT5!]LM_^>JT?;+?_ )ZK0%R>BH/MEO\ \]5H^V6__/5: N3T5!]LM_\ GJM'
MVRW_ .>JT!<GHJ#[9;_\]5H^V6__ #U6@+D]%0?;+?\ YZK1]LM_^>JT!<GH
MJ#[9;_\ /5:/MEO_ ,]5H"Y/14'VRW_YZK1]LM_^>JT!<GHJ#[9;_P#/5:/M
MEO\ \]5H"Y/14'VRW_YZK1]LM_\ GJM 7)Z*CCGBE)$;AB.N*DH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"\5^&5\5:
M2E@^HWM@%F67S;.38YP",9].?TKC?^%,0?\ 0W^)?_ TUV/B[Q;I_@S11J>H
MK,\;2B&-(5RS.02!SP.AYKC6OOB9XR4'3K6T\+Z9(,K/.PFN&4]P!P/T^M &
M?K'PUT/0;-KG5?'^NV<(!.Z6_P $_0=2?85ZII/D_P!C6/V>9YX/L\?ERR?>
M==HPQ]R.:\B\#> ]+U;Q7XE_X2-IM<N=+NU@CFO')#Y7<6*YQU[=*]GCC2*-
M8XT5$0!551@ #H * '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ HK%UCQ9HFA@B^OXEE'_ "Q0[W/_  $<_G7 ZO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7FD^H:CJD[WNJF WLIRXMP0BCH ,\\# S79:/\.KF>-)=3G^S(>?(BP7_$]
M?IFNF?P-H+6!M5M2C'D3AB9 ?7)_ETKC;5K)'3J>1UN:#XKNO#D,D45O#+%,
M^\^9E3G&.#^%=;;_  UL8YPUQ?7$\0.?+"A,^Q(_IBNO%C:"V2V^S1&!%VK&
M4! 'IBI"QQMK\3+-\"ZT^>/U:)@X_I6S:^-_#]UC_3A"Q[3(4_GQ4MUX0T&[
M)+Z;$C'^*+*']*QKGX;:=)_QZWES ?1L./UY_6@-3KK>]M;L9M[F&8?],W#?
MRJ>O,+CX;ZI 2]G>6TI'3[T;?F,U#]B\;Z1@1F^*#M'()E_+F@#U6BO+8_'G
MB&P?9>P1/CJ)H6C/Z?X5JVOQ,@; N]-D3U:&0,/R.*+!<[VBN;MO'7A^X^]>
M- ?2:,K^O2MJVU*QO #;7D$V?[D@-(9:HHHH **J7^IV6EP":^N8X(R< N>I
M]AWJMI_B31]4F\FSOXI)<9"'*L?H#C- &I1110 45!<7EK:+NN+B*$>LCA?Y
MUBW7CCP_:@XO?.8?PP(7_7I0!T-%<'=_$RW7(M-.E?T:9P@_(9K(?QSXCU%]
MEC B9X @@,A_,Y_E3L*YZG52ZU33[$$W5[;PX[/( ?RKS3^R?&NL ^>;P(>T
MTPB'Y#_"KEK\-+V1@UY?P19Z^6A=OS.* .CNO'V@VY(2>6X/_3&,D?F<"L2[
M^)V 1::;CT:>7'Z#_&M.U^'6CPX-Q)<W+#KN?:#^ K<M/#NC6/-OIMLI_O%
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MXE\ZZ(PUQ(/F_#^Z/I6Y0(AM+2WL;9+>UA2&%!A408 J:BBD,**** "BBB@
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M !H^RQ?[?_?QO\:FHH A^RQ?[?\ W\;_ !H^RQ?[?_?QO\:FHH A^RQ?[?\
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M-344 0_98O\ ;_[^-_C1]EB_V_\ OXW^-344 0_98O\ ;_[^-_C1]FC'3?\
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M7^W_ -_&_P :/LL7^W_W\;_&IJ* (?LL7^W_ -_&_P :/LL7^W_W\;_&IJ*
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MFNCHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTGQ#\(M;UA-+M]+L%FE;RXFGL B2GL 2._;.*]7BBC@A2&)%2.-0J*HP% X
M% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\L 2 6)X!(]LUZK9V%II\(AL[:*",?PQJ!7GSJ2J2<YN[9U0BHKEBK(\VLO
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MFM&BBN-MMW9H%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \\^,GS^#[.WD8K9SZI:Q79!Q^Z+\Y]L@5
M7^+1ATKX>0^']*BBMCJ=U#8PPQ*%PK-EL ?3]:[O7-%L?$6BW6DZC%YEK<IM
M< X([@@]B#@CZ5Q6@_":'3-=L=3U/Q#J6L#3O^/&"Z/RPGL>O./PYQZ4 ,^)
M7A_2--^$-Y MO#%_9MNC6LBJ%9)%("D'U)Z^N:[O2)I;C1;">?/G26\;OG^\
M5!/ZURGB7X>-XL\30WFJ:U=-HT.QAI*#$;NN>6.>A^F?>NW "@   #@ 4 +1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15'4=8T_2
M8]]]=Q0^BD_,?H.IKC=3^) ^:/2K,M_TVN.!^"CG\R* .OUG7-/T&R-UJ$XC
M3HBCEI#Z*.YKQWQ+XFU?Q9(8F7['IH.5@SR_H7]3[=!^M7[72]<\8WC7W^NY
MV_:93MC7V7_ZU=?IGPYL8,2:E.]V_>-?D3_$_G7;0Q*PWO0C[_=]/1?J[_(Y
MJM%UM)/W>RZ^K/.=#MKJVN"-*ADEO6&!+''N=!_LG^'Z]?>NNT[X>ZE?2?:-
M4N1;[N6&?,E/U)X'ZUZ/:V=M90B&U@CAC'18U %35A6KU*T^>H[LUITH4X\L
M%9'.1>#_  [IUA,)K9&C*'S9[A\D+W.X_=_#%>:S:E\-DU/R!XLG$>[!VQ,R
M#_MIMQ^-'[0.OW4$&F:!"[);W(:XN,''F!2 JGVSDX]A7A-=>&P2J0YYO<BI
M5Y79'U\NK^%O"7A>._6_M8=+8;XYEDWF<_[..78^U>,^*_B_KWBR[_L;PK;7
M-I;S'8OE+NNIQ^'W!].?>N*\$^%9O&WB.#15O?LT:1O,7<%]B C=L7IDY'I7
MT[X3\#Z'X-L_)TNU_?,,2W4OS2R_5O3V&!1*%+#/7WI#3E-::(\P\$_ L?N]
M0\7/N)^<:?$_?_IHXZ_0?F:]LM;2WL;6.UM((X+>)=L<42A54>@ Z5-17'5K
M3JN\F:1BH[!1116104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M11534M3LM(LGO+^X2"!.K,>I] .Y]A3C%R?+%78FTE=ENO/?%WQ+M].,ECHA
M2YO!E7GZQQ'V_O']/Y5Q_C+XD7.KQS06KFQTH<,Q.'E'^T>P]A7/Z#X-U;Q3
M!]LN)?[$\/ 9:]G&V28>D:GH#ZG]>E?04,NHX2*K8UZ](_Y_Y?\ #'EU,74Q
M$O9X;;K+_(Q[G4M2UW63::?%/JVLSG)"_-CW8] !^ %>D>%_A)INAJNN^-[R
M"[NQAA [?N(CZ'/WS[=/8]:LV>LZ#X-T]M.\(:<BY_UE[.,M(?4]V_' ]!2V
MGA[Q#XKN%N[Z21(CR)KGC _V$_\ U5R8W-*N(]V/NQ['3AL'"CKN^YK:O\1$
MC3[/HL "@;1/*N /]U/\?RK+L?"VO^)IQ>:A+)%&W/G7/+$?[*=OTKN-&\(:
M5HVV1(O/N1_RWFY(^@Z#\*WJ\HZSDF^'FC'3Q;J9UG!S]IWY8GZ=,>V*KV/P
MWL(+@27=W-=(#GRBH13]<<D5VM%(8BJJ($10JJ,  8 %+110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%9>O'6TL5ET%;.6ZCD#-!
M=DJLR8.5##[K=,'!''(K$B\5V^OVE[H;>=HGB&2WD1+2]^1PQ4@/&PXD4'G*
MD].U &@OC?PNVK?V4NOZ>;[?L\GSUSN_N^F?;K6_7B<C6;^"#X/'P[OUUO[-
M]F %FOE";&/.\_TW?-NZU['IT$UMIEI!<R^;/%"B22?WV"@$_B: +-%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4456U"_M]+L)KRZ?;#$N3CDGT ]S0!9HKRZ[
M^(NK2SEK2&WMX<\*ZEV(]SD?I6]HGQ M+J&1=6V6DT8R&7)20>PZY]J N=G2
M,RHI9V"J.22< 5Y_JOQ) RFEVF>PFN.!^"CG\S6.NG^*O%C!YS,;=N0TY\N(
M?1>_Y4["N=GJGCK1M/+)%*;R8<;8.0#[MT_G7(7?C+7]<E:#3D-N@Y*VXW,!
MZLYZ?7BM)_"6@^&[#[?XAOC*J](Q\BL?[H Y8UQNHZYJ?B^Z71=!L/LM@3\M
MI  N\?WI2.,?I]:[\%EU3%>]\,%NWL<N(Q<:.F\GLC)N]3 N& )N9B<&3<6W
M'Z]37<>%OA]=ZALOO$6Z*#JEB/E+?[_H/;KZ^E=!X0^']EX>"7EYLNM3QG?C
MY(O9!_4\_2NSK;$8C#4/W>$6O\SW^7;U(HT:U3WZ[_[=6WS[C(HHX(DBAC6.
M-!A408"CT I]%9NMZ_I7AS3VOM7O8K6 ="YY8^BCJQ]A7E).3\SMV-*N0\8?
M$CP_X-1H[RX^T7^,I90$-(?3=V4>Y_#->4>+/C1K7B&Y_LKPE;SVD4IV)*J[
MKJ;_ '0,[/U/N*M>#O@;=W[C4?%T\D*.=YLXY,RR$\YD?M]!D^XKLCAHTUS5
MW;RZD.;>D3D=:U;Q3\7=>5K321+]E1A%#;K\L*GD[Y#C).!UQ["N5DT/5X;T
MV<FDWZW0.WR3;/NS],5]D:7I.GZ)81V.F6<-I;)]V.)<#ZGU/N:N5HL?R>[&
M.A+HWU;/)?@U\/+[PV+C7-9A\B^N8Q%#;M]Z*/.26]&) X[ >]>M445Q5:DJ
MDG*1K&*BK(****S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M4UW2*-I)'5$499F. !ZDUYAXL^)VXO8>'#N8_*UYMS_W['?ZG\/6NK"X.KBI
M<M->KZ+U,:^(A1C>;.J\5>-M.\,1&)C]HOV&4MD/(]V/\(_6O%=7US6/%>K
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M3#L1CC;[GBO(-S>IJ30O#DNHZN\&F0Q(TJ;Y2?E5,$#=^O05I#V5[R3^_?\
M#3\29<UM"?7_ !%K'BER+R3['IX.5M(SU_WC_$?KQ[5-H7A*_P!4P;&U\N ]
M;F7A?P/4_A7H>C> M-TXK->?Z;<#G]X/W:GV7_'-=4 %    '  K6KC*E2/L
MUI'LMO\ @_,SAAX1ESO67=_UI\CF-&\"Z9IFV6X'VVY'.^4?*I]EZ?GFNH
M&!P***Y#<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M JC\!5FBN6K7G5=Y,N,5'8****R*"BBB@ HHHH **** "BBB@ HHHH ****
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MGF_W_,.?_1=7O.UT?\N6G_\ @4__ ,;I/E6PU?J:M%9?G:]_SY:?_P"!3_\
MQNCSM>_Y\M/_ / I_P#XW4V*N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__
M  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI
M167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\
M^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_
M )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\
MC=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW
M_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\
M;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__
M  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI
M167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\
M^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_
M )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\
MC=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW
M_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\
M;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__
M  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI
M167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\
M^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_
M )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\
MC=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW
M_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\
M;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__
M  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI
M167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\ C=%@N:E%9?G:]_SY:?\
M^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW_/EI_P#X%/\ _&Z/.U[_
M )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\;H\[7O\ GRT__P "G_\
MC=%@N:E%9?G:]_SY:?\ ^!3_ /QNCSM>_P"?+3__  *?_P"-T6"YJ45E^=KW
M_/EI_P#X%/\ _&Z/.U[_ )\M/_\  I__ (W18+FI167YVO?\^6G_ /@4_P#\
M;H\[7O\ GRT__P "G_\ C=%@N:E%98FUS<-UE8!<C)%T_3O_  5J4AA1110
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MC-\K#X3U4+T'R!<_KFNC#X=5GK)12[F=2HX+1-^ATFL>,=3OPRW=_P"3$?\
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M 4444 %%%% !1110 4444 %>=W_A7Q1X?\5ZAKO@V33YH=4(>\L+\LJB4?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BLS7/$&D^&M/-]K%]%:6X.T,YY8^@ Y)]A7+6OQA\&W%U'!)?7%J)#M26ZM
M7BC8_P"\1C\Z .\HI%8,H92"",@CO2T %%%% !1110 4444 %%%8.K>+])T7
M7]+T2\DE6]U-MMLJQDJ3G')[=: -ZBBB@ HHHH **** "BBB@ HHK,USQ#I'
MANQ^V:Q?PV=N6VAI#]X^@ Y)^E &G16/H'BO0O%$,DNBZG!>",XD"$AD^JG!
M'Y5L4 %%%% !1110 4444 %%%% !1110 457OKZVTVQGO;V=(+:!#)+*YP%4
M=35;0]>TSQ)IBZCI-T+FT9F02!&7D'!&& - &C1110 4444 %%%% !1110 4
M444 %%%<G>_$WP7I]])97/B"U6>-ML@4,ZH?0LH('YT =914-I=V]_:175I/
M'/;RKNCEC8,K#U!%34 %%%% !1110 4444 %%%% !116*WBW04\21^'O[2A;
M5I 2+9,L1@$G) P#@$X)!H VJ*AN[NWL+26[NYXX+>)2\DLC!54#N2:YW2?B
M-X0US45T_3M>M9KICA(^5+GT7<!G\* .HHHHH **** "BBB@ HHHH ***.E
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MAJ"0BXPOD7:F"13GC!(P#]#5[Q?XXN_!_B[1TOX(D\,WB,D]YY;%HI>< D'
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MK:V4;A,@=79C]U1ZUS>N_$;Q'X8BMH]9\*Q0W%U<)%!+#>>9 ^3@@MM!5AU
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MTYX]"?\ ZY(!ZE$'$*"0@R!1N([GO3Z165T#HP96&00<@BEH **** "BBB@
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M K.O="TO4=4L=2N[..6\L2QMIFSF(MUQ^5:-% !1110 4444 %%%% !1110
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MC =U'0%NI J6XMH+N!X+F&.:%QAHY%#*WU!X-2T4 9^FZ'I.C!QIFF6EGO\
MO?9X53=]<"M"BB@ HHHH **** "BBB@ HHHH R=0\+Z!JUT;K4=&L+NX*A3+
M/;J[$#H,D=.345KX.\,V-W%=6F@:;!<1-NCECM45D/J"!Q6W10!3U'2M.U>
M0:E8VUY$#D)/$' /XU+:65KI]LMM9VT-O GW8X4"*/P%3T4 %%%% !1110 4
M444 %%%% !6'<>#/#%W<27%QX?TR6:5B[R/:H69CU))')K<HH RM-\-:%HUR
MUQIFCV-G.Z;&DMX%1BN<X) Z9 K3=%D1D=0R,"&4C((IU% %73]-LM)LTL].
MM(;2V3)6&! BC/)P!5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVMG#P6=]?-+ A'3Y>^/?-;NL>&+'6]6T?4;IYUFTF9IK<1N I8@ [ACD<>U
M'&?!ZXL(++4](GMFMO$]M<,=5\]MTMPQ/$FX\E3GZ#\<GTVN=U#P7IE_XKL_
M$RR7-KJEJNSS+9PHF3^[("#N';_]0QT5 !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img76291469_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 69"#0# 2(  A$! Q$!_\0
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MHH **** $V*23M&3[4FQ?[H_*G44 %%%% !3=B_W1^5.HH ;L7^Z/RI0JCH
M/H*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:3Z'  ]L^M/^-/CK[- WA;3IL32J&OI%_@0](_JW?V^M '!?$CQG+XU\0O\
M9-YTJP#"W4 _,!PTI^O;T&/6M;X&?\C]-_V#Y/\ T..M6W\"GPQ\&?$&J7\6
MW5KZS^93U@BW*0GU/4_@.U97P,_Y'Z;_ +!\G_H<= 'T71110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "FE%8Y*@GW%.HH **** $*AA
M@@$>] 4*,  #VI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 (S!5+,0 .I)Z5']JM_\
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MP+K-A;>.[+39=,OI/+74-/+ 1'C.X'L,YZ#C.,XQ6M\5?&NK^#_[ _LDV_\
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M$.Z\86^JZ5=62:;XGTY662W?)C+<@-ZX#8!'TY.: .GN?%FC6OBBT\-27?\
MQ-KI2\=NJ$X4*S9)Q@<*>];=?-5_%X[_ .%[:8DUQHQ\2?9#Y,BJWV<)Y<GW
MAC.<;OTKZ!\/+K2:) OB&2TDU,;O-:T!$9^8XQGGIC\: $\2W6KV?AZ[N-!L
MH[W5$4&"WE.%<[AG)R.V3U'2O-/^$K^-'_0C:9_W]'_QZO8*@O;R#3[&XO;E
MQ'!;QM+(Y_A51DG\A0!X]H_Q0\=-\0],\*Z]X?TVTENF!E6(LSI'@G=D2,!P
M">:Z/XG^/-:\'W>A66A6%K>W>J2O$([@-RP*!0,,.I;O7+?!FUG\4^+O$/Q
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M?9\?+Y>-NW\J\UL_ACXL\(S31^"O%R0:;*Y?['J$'F",GT.#S[X'OF@#(^.
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MX/T(KUCP/X%TWP-H;Z=:.]Q).WF7-Q*!NF;&.G8>@_GDFN23X7:_X7U2ZNO
M?B5-.L[I]\FGWD/F1*?]D\_AQG'<T 86M^$M?N/&GAJ?Q7XZT9KVVNDDM(!
M(I)1YBDJNT#.2 !FK'[01B'_  B1GV^3]N??NZ;?DSGVQ72>'OAI>)XKC\5>
M+=<;6=7A7;;HD?EPP=>@[XR<<#KGD\US?[0<$=S_ ,(E!,"8I;YT< XR#L!Y
MH ]I4@J"I!&.,5XAX:/VG]I_Q%+9$&".V99BO3(2)2/KO'Z5T4W@CX@6$!TO
M0O'$::2/EA-W;!KB!.RAP/FP._'X5O> ?A]8>!+&X$4\E[J%VP>ZO)A\TA]
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M'4\UC?L[QQK8^)GMUQ:F^58CG/ #8'Y$4 >U4444 <5\7/\ DEFN_P#7)/\
MT8E?*-?9/BWP^/%7A:^T0W)MA=JJ^<$W[<,&Z9&>GK7E/_#.T?\ T-$G_@"/
M_BZ]+!8BG3@U-]3"K"4GH>&5]8?"?_DEV@_]<&_]#:N"_P"&=H_^AHD_\ 1_
M\77J_A30!X7\+V&BBY-R+1"GG%-F[+$],G'7UHQN(IU8)0?4*4'%ZE3Q]XE7
MPEX*U+5]P$T<6RW![RMPOY$Y^@->)_#JQ^*GA_0GN] \/:?<0:HPNC<7DJ^9
M("/E_P"6BG'4C(_B/K7I_P 2_ >J>/9-)LXK^WMM)MIO.NHVW>9(>G&!CA=V
M/=J[Z&&.V@C@A0)%&H1%'10!@"O--SYL^)=E\3];T2/4O$GA_3[:WTIC,+BS
MD4R(#@'_ ):,<9P>!VS7N7@+Q(OBSP5IFK[@9I(@DX':5?E?]1GZ$5NWMG!J
M%A<65T@DM[B-HI$/\2L,$?D:X7X7>!-7\ V^I:?=ZC;7>GSRB:W6,,&1NASD
M8Y 7IW% '+_!3_D=O'__ %__ /M26NJ^(/CZ^\/:II?AW0+&.\U_5#^Y$QQ'
M$N<!FZ9Y![CH?QY^3X6>*M$\6ZIK'@_Q/;V,.I2-)+#<0EL%B3CH0<$G!X-=
M!X\^&Q\7OINIVFJR:=KVG*!#>(N0V#GD @CYN01TR>#0!S_B32OB;%X4U:\U
M7Q;I$=LME*T]M#9 @KL.Y Q7//3/O63X5$A_9<U/RL[O(NLX]-YS^F:W;CX<
M^-O$6G36'BKQFMQ:>40EM:0B-97Q\ID8 $@-@D8YQ74_#_P?-X4\#1^'M2EM
M[O#2[S&#L=7).#GZXH R_@A) _PHTD0E=R-,LN.S^8QY]\$5U!U'PT/%8L?.
MT_\ X2 I]S"_:-NW/7KC;^E<!;_"WQ/X3N[G_A!O%:6>GW+EVL[V'S!&?8X.
M?3. <8SFM_P1\.!X;U:[\0:OJ<FK^(+Q=LMTZ[51>,A1^ Y]   * .2TK_DZ
M35_^P?\ ^TXZBO'2/]JBS-T0%:SQ!O\ 4PMC'X[JZ^R\!WUM\8+[QDUY;M9W
M%MY*P -Y@.U!D]NJFI_'OPYMO&4MGJ%O?2Z9K5B<VU[$,D '(!&1T/(.>,F@
M#J-9N=+M-)GGUI[9-.4#SFNL>6.0!G/'7'XUXU\=IK2]\$>&[C2)(/[*:]^2
M2%1Y(^4@' XQPWZULW?PT\:>*4AL/%_C*.XTB)E9X+* (TV.FXX _G]*[O6_
M!FC:YX0_X1F>W,>GK$D<(B.&AV#Y2I/<8_'G/6@#DD\/_%9HU,?CG2BA *E=
M.3!';'RU3^&GAV32O'WB*]O/%&FZMJ<Z%;R"T7:\<F\9++T'((^M/M/ OQ'T
M>Q&D:7XYMCIB+LBDN+3,T2=  >>@Z<_E74> _ -CX&L+A8KB6]U"\?S+N\E&
M&E;GMV')/4G)/- 'G^A&$?M1Z[YFW>;0^7G^]Y<73\,UZUXEFMX/"VK2W97[
M,MG*9=W0KL.17A\WA[_A(_VBO$%M'?W&GW<%N+BUN[<_-%*J1 $C^(8)!'<&
MNLU+X=^._%$0TWQ)XUA;2,CS([*U"/, <_-P!V]Q[4 ,_9WBG3X=7#RY$4FH
M2-%GN-J D>V0?R-4OV=_^01XB_Z_Q_Z#7K.BZ/8^']'M=*TV$0VELFR-.OU)
M/<DY)/J:\LTOX5>+O">N7LOA7Q5;6VF7DP=X9X=S 9SC&""0"1GC- 'L5%%%
M 'C'QY_Y"'@O_L(-_..O9ZX+XC^!+[QI=:!+9W=O;C3;DS2"8,=X)7@8_P!T
MUWM 'GWA#_A [CQWKUSH+/)X@W/]O\Q9 5._#;=PQ][^[[5C_M"QV;?#N-YQ
M']I6\C%N3][)!W ?@.?I5CQ7\);F\\4OXI\)ZX^BZO)S,-I,<A[GCIGN,$'K
M4.F_"/4M3UFUU3QYXCDUQK0YAM%7;"#[],CU  S@9)'% &!\8+.^NO@KX9O)
MU)FMC;-<^VZ(C)S_ +1 _&O:-&U"'5M$L=0MW#PW,"2JP]" :-8TBRUW2+K2
MM0A$MI<QF.1,XX]CV(."#ZBO)8OA%XRTF"72-"\=R6^A2EOW3H?,16Z@8_H5
MS0!'\/BFN?'OQCK5OB2U@0P"0="V508^HC:O;*YKP1X)TWP+H0TW3RTC.WF3
MW$@^:5\8R?0>@[?F:Z6@#Q?X_ &;P>",@Z@V1_WQ7M%<%\2O =]XVDT-K*\M
M[<:=<F:3S@QW [>!C_=-=[0!XI^SZ!O\7''/VY.?^^ZD_:#_ ./+PQ_V$3_(
M5U'PR\!7_@<ZV;V\MKC^T+A94\D,-H&[KG_>%.^)O@2^\<V^D1V5W;VYL;DS
M.9@QW# X&/I0!S7[1HF/@C32@;R!J*^;CI]Q\9KU;2'@DT6Q>VV_9VMXS%MZ
M;=HQC\*Q/B#%X>N/!E]!XGN/LVF2[4:<*28W)^5A@'D'':N"\,>#?'%MHEM!
MX;^(%M)X>F3=;326>Z18S_=##CZ9X]J (K22&3]J:[\DJ2MAM<J?XA$N?QZ5
M[37@/@_1;;0_VB[C3K2YFN_(L6:XN)GW/)*R*79CZEFZ5[]0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17,^,?'F
MA>!K..?5[AO,FSY-O"NZ23'4@=A[G KA8/V@M&6YC74]!U:PMI#\D[H&!'KC
MCCZ9H ]@HJKIVHV>K:?!?V%PEQ:3KOBEC.0PKC/&WQ:\/^"KP:?,)[[4R 3:
MVP!*9Z;B>!G/3D^U '>T5YGX7^-WA[Q!JR:5=V]UI-](VR-;H#8S'HNX="?<
M"O3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **PM4\:>
M&=$OFLM3URQM+I0&,4TP5@#T.*I_\+*\%?\ 0T:7_P"!"T =3163HWB?0_$+
MS+H^JVE\T(!D$$@;8#G&<?0UK4 %%9&L>*M \/S11:OJ]G922J61)Y0I8=,X
M]*N:9JEAK-BE]IMW#=VLA(6:%MRG!P>?J* +=%%(2%!)( '))H 6BN*U'XM^
M!=+NC;7'B&W:0,5/D(\H!'J4!%=#HGB/1O$ELUQHVI6][$IPYB?)4^A'4?C0
M!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%]V3QUR>:[7PEX3TSP9H,>DZ6C")27DD<Y>5SU9CZ\#\JW:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y&P\ VEA\1;_
M ,8I>SM<WD7E-;E5V*,*.#U_@'YUUU%% !1110 4444 %%%% !1110 4444
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MN$E8]2Z$HQ_$J36;\8_^23Z]_P!<X_\ T:E4?@6''PHTW?G'FS;?IYC?_7H
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MVIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_P"?6?\ (?XT 6**K_:F_P"?6?\
M(?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_GUG_(?XT 6**K_ &IO^?6?
M\A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO\ GUG_ "'^- %BBJ_VIO\
MGUG_ "'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_Y]9_R'^- %BBJ_P!J
M;_GUG_(?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_ )]9_P A_C0!8HJO
M]J;_ )]9_P A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO^?6?\A_C0!8H
MJO\ :F_Y]9_R'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_P"?6?\ (?XT
M 6**K_:F_P"?6?\ (?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_GUG_(?
MXT 6**K_ &IO^?6?\A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO\ GUG_
M "'^- %BBJ_VIO\ GUG_ "'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_Y
M]9_R'^- %BBJ_P!J;_GUG_(?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_
M )]9_P A_C0!8HJO]J;_ )]9_P A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-
M'VIO^?6?\A_C0!8HJO\ :F_Y]9_R'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?X
MT?:F_P"?6?\ (?XT 6**K_:F_P"?6?\ (?XT?:F_Y]9_R'^- %BBJ_VIO^?6
M?\A_C1]J;_GUG_(?XT 6**K_ &IO^?6?\A_C1]J;_GUG_(?XT 6**K_:F_Y]
M9_R'^-'VIO\ GUG_ "'^- %BBJ_VIO\ GUG_ "'^-'VIO^?6?\A_C0!8HJO]
MJ;_GUG_(?XT?:F_Y]9_R'^- %BBJ_P!J;_GUG_(?XT?:F_Y]9_R'^- %BBJ_
MVIO^?6?\A_C1]J;_ )]9_P A_C0!8HJO]J;_ )]9_P A_C1]J;_GUG_(?XT
M6**K_:F_Y]9_R'^-'VIO^?6?\A_C0!8HJO\ :F_Y]9_R'^-'VIO^?6?\A_C0
M!8HJO]J;_GUG_(?XT?:F_P"?6?\ (?XT 6**K_:F_P"?6?\ (?XT?:F_Y]9_
MR'^- %BBJ_VIO^?6?\A_C1]J;_GUG_(?XT 6**K_ &IO^?6?\A_C1]J;_GUG
M_(?XT 6**K_:F_Y]9_R'^-'VIO\ GUG_ "'^- %BBJ_VIO\ GUG_ "'^-'VI
MO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_Y]9_R'^- %BBJ_P!J;_GUG_(?XT?:
MF_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_ )]9_P A_C0!8HJO]J;_ )]9_P A
M_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO^?6?\A_C0!8HJO\ :F_Y]9_R
M'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_P"?6?\ (?XT 6**K_:F_P"?
M6?\ (?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_GUG_(?XT 6**K_ &IO
M^?6?\A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO\ GUG_ "'^- %BBJ_V
MIO\ GUG_ "'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_Y]9_R'^- %BBJ
M_P!J;_GUG_(?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_ )]9_P A_C0!
M8HJO]J;_ )]9_P A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO^?6?\A_C
M0!8HJO\ :F_Y]9_R'^-'VIO^?6?\A_C0!8HJO]J;_GUG_(?XT?:F_P"?6?\
M(?XT 6**K_:F_P"?6?\ (?XT?:F_Y]9_R'^- %BBJ_VIO^?6?\A_C1]J;_GU
MG_(?XT 6**K_ &IO^?6?\A_C1]J;_GUG_(?XT 6**K_:F_Y]9_R'^-'VIO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX:#\/_\ 0'U7\HO_ (NOGFBO9^HT>QR^VD?0W_#0?A__ * ^J_E%_P#%T?\
M#0?A_P#Z ^J_E%_\77SS11]1H]@]M(^AO^&@_#__ $!]5_*+_P"+H_X:#\/_
M /0'U7\HO_BZ^>:*/J-'L'MI'T-_PT'X?_Z ^J_E%_\ %T?\-!^'_P#H#ZK^
M47_Q=?/-%'U&CV#VTCZ&_P"&@_#_ /T!]5_*+_XNC_AH/P__ - ?5?RB_P#B
MZ^>:*/J-'L'MI'UGX'^(>G^.VOEL;*[MOL83?]HV_-NW8QM)_NFNPKPO]G?_
M %OB+Z6__M2O=*\K$TXTZKC'8Z(2<HW84445@6%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7(?%+_DF/B#_ *]3_,5U
M]<A\4O\ DF/B#_KU/\Q6E+^)'U0GL?)=%%%?2' %%%% !1110 4444 %%%%
M'M_[._\ K?$7TM__ &I7NE>%_L[_ .M\1?2W_P#:E>Z5X.-_CR^7Y'92^!!1
M117*:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F?QJ\
M=3>$/"R6E@634=3W112@?ZI!C>W^]@@#ZY[5R_P:TWPOX4T"35]3U[1TUF_B
M^X][%N@BZA,9X8\$_@.QKN?B-\-(/B'_ &=YVJ2V7V+S,!(@^_=M]2,8V_K7
MG]U^S?8VUI//_P ))<-Y<;/C[*O.!G^]0!YY\(=1LM,^*ME>7]W!;6RB?=--
M($09C8#D\5];65]::E:1W=C<Q7-M)DI+$X96YQP1UYKXN\ ^%H_&?C"TT.6Z
M:U2=9&,JIN(VH6Z9'I7LGC^Z\3_"/P?X;L/#FIDV,7G0SSO;1L6<MO7(8''!
M;\J $^+WASXBZIXDN)="_M&71&@1?(M[O"D@?-^[W#/Y<UQ?P:UOPSH?BR&V
MUW27357F\JWOI')6!SQM,9^Z<\;NV>W)KTGX??&S1[WPQCQ9JT=OJUNS>8SQ
M;1,N25*A1C..,=>/>O$]0D;QW\6)I=$MWQJ.H;H5Q@A<_?/IP"Q].: /LVL_
M7I&B\.ZG(@RR6DK >I"&LSQIXPL_ _A\:M?6\]Q#YJP[(<;LMGGDCTIGA/Q3
M8_$#PM+J%I;SP6\K26Y2;&[@8)X)'>@#Y"\(:-J/B'Q/9Z/I<[07-X6B,H8C
M;&5.\G'4;<Y'?I7?_$CX+_\ "$^'(]:L-3DO8HW6.Y62,*5W<!EQVSQ@^HKF
M_"M^WPU^*T,FK1/MT^XD@N %Y"L"A8#OPVX>HKU'XQ_%'P[JW@E]%T._2^GO
MG0R&-2!%&I#<DCJ2 ,?6@#=^ GBZ]\1>%[O3M1G:>XTQT2.5SEC$P.T$]\%2
M,^F*]:KQ;]G3P_<Z?X<U+6;F%HUU"5%@+#!=$S\P]LL1^%>TT %<A\4O^28^
M(/\ KU/\Q77UR'Q2_P"28^(/^O4_S%:4OXD?5">Q\ET445](< 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC\+>';71XKNXNTMUP)9VRWT'H/0=JV:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%O:W_P ^&G_D_P#\51_8.-[+[P_M3#=_P/9:*\:_X6]K?_/AI_Y/_P#%4?\
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M%_RKU6X^#_@6ZN9;B;0E:65S([>?(,L3DG[U '._\-$^#/\ GUUC_P !T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M****Y30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<MKWBJ'3O%>C>&YM.%RNK!P9&8;4"^JD<UH^*=+O=9\-WMCI
MU\]C?2)F"X1RNQP<C)'..,'V->":WX3\86'C'0M,O_$:SZK>;_L5S]ID/DXZ
M\D9&?84 ?1%CI>GZ8K+86-K:*YRP@A6,,?? KFO'&I:5X/LF\5RZ+!>7R.D
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M_P#ZYQ_^C4JC\"R__"J--WYQYLVWZ>8W_P!>LCX_>)[6R\&_\(_%,KZAJ,J
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M@ HHHH **** -#03M\1:8<$XNXC@?[XKZ--V ?\ 4S_]^S7SGH'_ ",FE_\
M7Y#_ .ABOI2OD>)/XE/T9[^3?!+U*_VM?^>,_P#W[-<E\3K@2?#/Q OERK_H
MIY9"!]X5VM<A\4O^28^(/^O4_P Q7SU+^)'U1[+V/DNBBBOI#@"BBB@ HHHH
M **** "BBB@#VO\ 9[E$4OB+*.V1;_=7/_/2O</M:_\ /&?_ +]FO$_V=_\
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M,_\ W[-'VM?^>,__ '[-6** *_VM?^>,_P#W[-'VM?\ GC/_ -^S5BB@"O\
M:U_YXS_]^S1]K7_GC/\ ]^S5BB@"O]K7_GC/_P!^S1]K7_GC/_W[-6** *_V
MM?\ GC/_ -^S1]K7_GC/_P!^S5BB@"O]K7_GC/\ ]^S1]K7_ )XS_P#?LU8H
MH K_ &M?^>,__?LT?:U_YXS_ /?LU8HH K_:U_YXS_\ ?LT?:U_YXS_]^S5B
MB@"O]K7_ )XS_P#?LT?:U_YXS_\ ?LU8HH K_:U_YXS_ /?LT?:U_P">,_\
MW[-6** *_P!K7_GC/_W[-'VM?^>,_P#W[-6** *_VM?^>,__ '[-'VM?^>,_
M_?LU8HH K_:U_P">,_\ W[-'VM?^>,__ '[-6** *_VM?^>,_P#W[-'VM?\
MGC/_ -^S5BB@"O\ :U_YXS_]^S1]K7_GC/\ ]^S5BB@"O]K7_GC/_P!^S1]K
M7_GC/_W[-6** *_VM?\ GC/_ -^S1]K7_GC/_P!^S5BB@"O]K7_GC/\ ]^S1
M]K7_ )XS_P#?LU8HH K_ &M?^>,__?LT?:U_YXS_ /?LU8HH K_:U_YXS_\
M?LT?:U_YXS_]^S5BB@!D4@E7<%=><888-/HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQCXE\/^$[>WU/68
MDDN02MJJQ!YB>^S/0>IR!735X_XXTJ+6_C9X;T_5N=-DM2R(WW9&4LQ7\2%S
M[8H C/[0FF9/_%/WO_?^/_&D/[0NF!2?^$?O>/\ IXC_ ,:]932=-C1433[1
M548"K"H 'Y4O]EZ?_P ^-M_WY7_"@!]C="^T^VNU4HL\2RA2<D;@#C]:L4BJ
M%4*H  & !VI: "BBB@ HHHH **** "N1\:_#K1_'DVGR:K/>Q-8[_*^S2*N=
MVW.<J?[HKKJ* $50JA1T Q7G_C?X0:!XTO?[29YM/U,@;KFWQ^\QT+*>I'J,
M&O0:* /,?"7P1T#PWJR:K>7-QJU]$V^)KD (C#HVWG)'J2:].HHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /GCQM_R.VL?]?'_LHK!K>\;?\ ([:Q_P!?'_LHK!K]+PO^[T_\*_(^,Q'\
M:7JPHHHKH,0HHHH **** "BBB@#1T#_D9-+_ .OR'_T,5]*5\UZ!_P C)I?_
M %^0_P#H8KZ4KY'B3^)3]&?09-\$O4*Y#XI?\DQ\0?\ 7J?YBNOKD/BE_P D
MQ\0?]>I_F*^>I?Q(^J/8>Q\ET445](< 4444 %%%% !1110 4444 >W_ +._
M^M\1?2W_ /:E>Z5X7^SO_K?$7TM__:E>Z5X.-_CR^7Y'92^!!1117*:!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445RGQ%\4W?@[PE)J]E!!/,
MLT<82;.W#'!Z$&JC%RDHKJ)NQU=%?.O_  T%XD_Z!&D_^1/_ (JC_AH+Q)_T
M"-)_\B?_ !5=7U&MV(]K$^BJ*^=?^&@O$G_0(TG_ ,B?_%4?\-!>)/\ H$:3
M_P"1/_BJ/J-;L'M8GT517SK_ ,-!>)/^@1I/_D3_ .*H_P"&@O$G_0(TG_R)
M_P#%4?4:W8/:Q/HJBOG7_AH+Q)_T"-)_\B?_ !5'_#07B3_H$:3_ .1/_BJ/
MJ-;L'M8GT517SK_PT%XD_P"@1I/_ )$_^*H_X:"\2?\ 0(TG_P B?_%4?4:W
M8/:Q/HJBN'^&'C2^\<:%>7]_;6UO)!=&%5M]V"-BMDY)Y^:NXKEG!PDXO<M.
MZN@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7E7QBA\07DFE6VBZ*]V(RTXNX(6::VD!&W8X(VY_'.*
M]5K+U_Q%I?AG36O]6NE@@!VKQEG;LJ@<DT >.P>,OB]#"D;:!),5&/,ET]MS
M?7# ?I3V\;_%X*<>&AG'_0.?_P"+KJ=(^-&B:WXAL])L]/O]UU,(DED"J 3W
M(SFMQOB/H$'C&;PQ=RRVU[&ZHKRKB*1F ( ;/!Y[XH Z73Y)YM-M9;I-EP\*
M-*N,88@9&.W-6:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXUN56T^RATW3K:QMQB&WB6) ?11@?RJS0 4444 %%%% !1110 4444 %%%%
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MZERI7)],'@^E>Q_'#QEX=G^'\VDVNI6E[>WDD9B2WE638%<,6)&<<#'OGZT
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MU4W2JH_U<0<N<^GRU]AT %%%% 'SQXV_Y';6/^OC_P!E%8-;WC;_ )';6/\
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M_P"1/U3_ +"!_P#1:5ZY7S^*_C2.VG\*"BBBN<L**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5\]2_B1]4>P]CY+HHHKZ0X HHHH **** "BBB@ HHHH ]O\ V=_];XB^EO\
M^U*]TKPO]G?_ %OB+Z6__M2O=*\'&_QY?+\CLI? @HHHKE- HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\W^.7_ "32?_KZ@_\ 0J](KS?XY?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH *\W^.7_)-)_P#KZ@_]"KTBO-_CE_R32?\
MZ^H/_0JVP_\ %CZDRV9\R4445]$<(4444 %%%% !1110 4444 ?0_P"S[_R)
M^J?]A _^BTKURO(_V??^1/U3_L('_P!%I7KE?/XK^-([:?PH****YRPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E_X@>#?'7C#XC7UR^C
M7ILS<_9[:4KF-(0VU6'/0CYC]377^/?@UX2T/X=WU_81307]C")!<O,S>:00
M"&4G;S[ <X^E>W3316\+S32)'%&I9W=@%4#DDD]!7S#\7?B@_C.\7PYH D?2
MDE +H"6O),X&!UV@]!W//I0!J_LW:O>C6]6T<R,UBUM]I$9/"2!E7(],AN?7
M ]*JW?PA\<^*O';ZCXAMQ%9W=UNGF2ZC9HXL]%&3T7 '%>F?!WX>OX*\//=:
M@@&L7X5IEZ^2@^[']><GWX[5UGC2]U33O!NJ7FBHSZE%#N@5(O,);(Z+WXS0
M!XS\7OA5X8\,>"QK&C126EQ!+'&RM,SB8,<?Q$X/?CT/%;W[.FKWM]X4U+3[
MF1Y(+&X46Y8YVJX)*CV!&?\ @5>+^*/%?B?Q%J%K;^,[J_BM4<,81;"/8.A9
M8_E!./7\Z^F?A;9>&+/P3;CPK.;BSD8M+-)_K6EP,[QV(XX],?4@':U\^?M+
MR#S_  Y%@YVSMG\4KZ#KY^_:,T^_OM5T,VEG<W$<5O*7,43.%RR]2!QTH =X
M.^!7A[Q!X.TK5[V_U&.XNX!*ZQN@49],J>V*[;PI\%]!\(>([;6[&^U"6XMP
MX5)G0J=RE3G"CL:\FT?X6^//&OA:VO[C4UM[:&+R[&RNI'7Y$R!A0,+TZGD]
M:9\+/B#K?A?QE!X>UBYGDT^>X^R2P7#EC;R9V@J3TPW!'3% 'U+1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH **** .'^)G_(,L/\ KX/_ * :\WKTCXF?\@RP_P"O@_\
MH!KS>J0F%%%%,04444 %%%% !1110 5ZWX"_Y%*V_P"NDG_H9KR2O6_ 7_(I
M6W_723_T,TF-'2T445(SYX\;?\CMK'_7Q_[**P:WO&W_ ".VL?\ 7Q_[**P:
M_2\+_N]/_"OR/C,1_&EZL****Z#$**** "BBB@ HHHH T= _Y&32_P#K\A_]
M#%?2E?->@?\ (R:7_P!?D/\ Z&*^E*^1XD_B4_1GT&3?!+U"N0^*7_),?$'_
M %ZG^8KKZY#XI?\ ),?$'_7J?YBOGJ7\2/JCV'L?)=%%%?2' %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/+Y?D=E+X$%%%%<IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGX%VZW7Q6L9)<,889I1N&<ML(S_X]FO5_P!HNUCE\ 6=RP_>0WZ!3Z!D?/\
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M^)G_ "#+#_KX/_H!KS>O2/B9_P @RP_Z^#_Z :\WJD)A1113$%%%% !1110
M4444 %>M^ O^12MO^NDG_H9KR2O6_ 7_ "*5M_UTD_\ 0S28T=+1114C/GCQ
MM_R.VL?]?'_LHK!K>\;?\CMK'_7Q_P"RBL&OTO"_[O3_ ,*_(^,Q'\:7JPHH
MHKH,0HHHH **** "BBB@#1T#_D9-+_Z_(?\ T,5]*5\UZ!_R,FE_]?D/_H8K
MZ4KY'B3^)3]&?09-\$O4*Y#XI?\ ),?$'_7J?YBNOKD/BE_R3'Q!_P!>I_F*
M^>I?Q(^J/8>Q\ET445](< 4444 %%%% !1110 4444 >W_L[_P"M\1?2W_\
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M7I%>;_'+_DFD_P#U]0?^A5MA_P"+'U)ELSYDHHHKZ(X0HHHH **** "BBB@
MHHHH ^A_V??^1/U3_L('_P!%I7KE>1_L^_\ (GZI_P!A _\ HM*]<KY_%?QI
M';3^%!1117.6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTMXS'!;(2T%L\P2&V3N[L<9/J>O8#M7OGP^\,^%?A_HYBAU;3Y[^8 W5XTZ
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M!XE\):7K& K7=NKNJ] _1A_WT#6!\8P#\)M>R/\ EG&?_(J52^!<C/\ "C3
MW1))U'T\QC_6@#T:BBB@ HHHH **CEGBAQYDBIGID]:9]MM?^>\?YT 3T5!]
MMM?^>\?YT?;;7_GO'^= 7)Z*@^VVO_/>/\Z/MMK_ ,]X_P Z N3T5!]MM?\
MGO'^='VVU_Y[Q_G0%SCOB9_R#+#_ *^#_P"@&O-Z]$^)$\4VF6'ER*V+@]#_
M +)KSNJ0@HHHIB"BBB@ HHHH **** "O6_ 7_(I6W_723_T,UY)7JW@:Y@B\
M*6ZR2JK;Y."?]LTF-'545!]MM?\ GO'^='VVU_Y[Q_G4CN?/_C;_ )';6/\
MKX_]E%8-;OC1@WC75RIR#/U_ 5A5^EX3_=Z?^%?D?&8C^-+U84445T&(4444
M %%%% !1110!HZ!_R,FE_P#7Y#_Z&*^E*^:M!(7Q%I9)P!=Q$G_@8KZ.^VVP
M.//3\Z^1XD_B4_1GOY-\$O4GKD/BE_R3'Q!_UZG^8KJ/MMK_ ,]X_P ZY+XG
MW4$GPSU]4E1C]E/ /^T*^>I?Q(^J/9>Q\H4445](< 4444 %%%% !1110 44
M44 >W_L[_P"M\1?2W_\ :E>Z5X/^SW-'#+XB\QU7(M\9/_72O<?MMK_SWC_.
MO!QO\>7R_([*7P(GHJ#[;:_\]X_SH^VVO_/>/\ZY32Y/14'VVU_Y[Q_G1]MM
M?^>\?YT!<GHJ#[;:_P#/>/\ .C[;:_\ />/\Z N3T5!]MM?^>\?YT?;;7_GO
M'^= 7)Z*@^VVO_/>/\Z/MMK_ ,]X_P Z N3T5!]MM?\ GO'^='VVU_Y[Q_G0
M%R>BH/MMK_SWC_.C[;:_\]X_SH"Y/14*74$CA$E1F/0 UR_C'XD^'/!,3+J-
MWYE[MW)90?-*V>F1T4>YQ^- '745\W6?[07B;4O$MK;0Z?ID%E<721!&C=W5
M&8#[VX G!ZX_"OH^21(HVDD8(B LS,<  =2: '45\Z>)/CUK^JZX=-\&62+$
MTAC@D:'S9ISV*KT'L,$_RJJGQD^(GA'5(H?%>FB6-_F,5Q;>0[+ZHR@#]#0!
M]*T5E^'=?L?$^@VFL:<Y:VN4W -]Y3T*GW!!%:E !17B?Q6^+GB#P5XP72=+
MM]/>W^RI*3<1,S;B6SR&'' KDQ\=?B&1D:+88/\ TXS?_%T ?3%%>3_"?XA^
M)_&6L7]KKMA;VT,%N)(VBMWC);<!@EF/:O43>VP)!G0$<'F@">BH/MMK_P ]
MX_SH^VVO_/>/\Z N3T51?6M+C<H^I6:.IP5:=01]1FD_MS2/^@I9?^!"?XU7
M)+L3SQ[E^BJ']N:1_P!!2R_\"$_QH_MS2/\ H*67_@0G^-/V<^P<\>Y?HJA_
M;FD?]!2R_P# A/\ &C^W-(_Z"EE_X$)_C1[.?8.>/<OT50_MS2/^@I9?^!"?
MXT?VYI'_ $%++_P(3_&CV<^P<\>Y?HJA_;FD?]!2R_\  A/\:/[<TC_H*67_
M ($)_C1[.?8.>/<OT5176]*=@JZG9LQ. !.I)/YU/]MM?^>Z?G4N+6Z&I)[,
MGKS?XY?\DTG_ .OJ#_T*O0?MMK_SWC_.O.OC=<0R_#6X$<BL?M4'0_[5:X?^
M+'U%+9GS11117T1PA1110 4444 %%%% !1110!]#_L^_\B?JG_80/_HM*]<K
MQ_X SQ0^$-3$DBJ?[0/4_P#3-*]9^VVO_/>/\Z^?Q7\:1VT_A1/14'VVU_Y[
MQ_G1]MM?^>\?YUSEW)Z*@^VVO_/>/\Z/MMK_ ,]X_P Z N3T5!]MM?\ GO'^
M='VVU_Y[Q_G0%R>BH/MMK_SWC_.C[;:_\]X_SH"Y/14'VVU_Y[Q_G1]MM?\
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MBBB@ HHHH **** "BBB@ HHHH **** .*\3Z-XLM]:.O^%M321O+5)])N_\
M4S!<\J?X6YZ\?6E\.?$?3=7O3I.J0RZ-KB8#V5Y\NX_[#=&'ZUOZ]XDT?PQ9
M"[UB^CM8F.U-W+.?10.37!W_ (O^&7Q"V:7J%RAE8[899XFA=&/39(1P?QH
M/%XUCP;X];QGI^ER:II]U9K:WL46=\6TY##&>.G./7I6-J_Q0U'QGI-QX?\
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M7\2/JCV'L?)=%%%?2' %%%% !1110 4444 %%%% 'MW[.XS+XB^EO_[4KW3
M]!7AG[._^M\1?2W_ /:E>Z5X.-_CR^7Y'92^!"8'H*,#T%+17*:"8'H*,#T%
M+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/
M04M% "8'H*\G\1_!F/Q?\1KO7]6O1'ICK$%MX/\ 62E4 .YNBCCMD_2O6:*
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M  MW1/\ GQU#_OA/_BJ/^%NZ)_SXZA_WPG_Q5']E8W_GVP^O8;^='H%%>?\
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M!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M%
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MI/\ ]?4'_H5>D5YO\<O^2:3_ /7U!_Z%7@X?^+'U/7ELSYDHHHKZ(X0HHHH
M**** "BBB@ HHHH ^A_V??\ D3]4_P"P@?\ T6E>N5Y'^S[_ ,B?JG_80/\
MZ+2O7*^?Q7\:1VT_A04445SEA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!\QZC_R%;W_ *^)/_0C5:K.H_\
M(5O?^OB3_P!"-5J_4(?"CXB?Q,****LD**** "BBB@ HHHH Z;X??\CWI?\
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MR.VL?]?'_LHK!K]+PO\ N]/_  K\CXS$?QI>K"BBBN@Q"BBB@ HHHH ****
M-'0/^1DTO_K\A_\ 0Q7TI7S7H'_(R:7_ -?D/_H8KZ4KY'B3^)3]&?09-\$O
M4*Y#XI?\DQ\0?]>I_F*Z^N0^*7_),?$'_7J?YBOGJ7\2/JCV'L?)=%%%?2'
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M?XT<K[!<OT5#;W5O>1F2VN(IT!VEHG##/ID5-2&%%%% !1110 4444 %%%%
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M *]3_,5U]<A\4O\ DF/B#_KU/\Q7SU+^)'U1[#V/DNBBBOI#@"BBB@ HHHH
M**** "BBB@#V_P#9W_UOB+Z6_P#[4KW2O"_V=_\ 6^(OI;_^U*]TKP<;_'E\
MOR.RE\""BBBN4T"BBB@ HHHH **** "BBB@ HHHH **** .+^(E[=6=E8-:W
M,T!:9@QB<KD;>^*X+^W-7_Z"E[_W_;_&NW^)O_'CIW_7=O\ T$UYS5(3+_\
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M_H8KZ1KY#B3^+3]'^9]!DWP2]0KS?XY?\DTG_P"OJ#_T*O2*\W^.7_)-)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)IP^=X)#+P0.!M/XUKZ)\8?"M]X2AU?4=5M;2[6'-Q9[OWBR <JJGE@3T^M
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M[%?QI>IW0^%!1116!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5\]2_B1]4>P]CY+HHHKZ0X HHHH **** "BBB@ HHHH ]O\ V=_];XB^EO\
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M*** "BBB@ HHHH ^C/V?_P#D1[__ +"+_P#HN.O5Z\H_9_\ ^1'O_P#L(O\
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M;?\ "S+[_H&6_P#W];_"C_A9E]_T#+?_ +^M_A185STFBO-O^%F7W_0,M_\
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MXL?4]2?PL^:****^B.$**** "BBB@ HHHH **** /HS]G_\ Y$>__P"PB_\
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M$'_7J?YBNOKD/BE_R3'Q!_UZG^8KYZE_$CZH]A['R71117TAP!1110 4444
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MS->+A_XL?4]2?PL^:****^B.$**** "BBB@ HHHH **** /HS]G_ /Y$>_\
M^PB__HN.O5Z\H_9__P"1'O\ _L(O_P"BXZ]7KY_%?QI';3^%!1117.6%%%%
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M]%M7OE>!_#G_ )'S3O\ MI_Z+:O?*^+XC_WJ/^%?FSZ3)_X#]?T05YA\>O\
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M.2.< CH0?S]D\(Z\OB?PEIFLJ INH [JO17'##\&!H VJ*** "BBB@ HHHH
M**** "BBB@ HHHH X?XF?\@RP_Z^#_Z :\WKTCXF?\@RP_Z^#_Z :\WJD)A1
M113$%%%% !1110 4444 %>M^ O\ D4K;_KI)_P"AFO)*];\!?\BE;?\ 723_
M -#-)C1TM%%%2,^>/&W_ ".VL?\ 7Q_[**P:WO&W_([:Q_U\?^RBL&OTO"_[
MO3_PK\CXS$?QI>K"BBBN@Q"BBB@ HHHH **** -'0/\ D9-+_P"OR'_T,5]*
M5\UZ!_R,FE_]?D/_ *&*^E*^1XD_B4_1GT&3?!+U"N0^*7_),?$'_7J?YBNO
MKD/BE_R3'Q!_UZG^8KYZE_$CZH]A['R71117TAP!1110 4444 %%%% !1110
M![?^SO\ ZWQ%]+?_ -J5[I7A?[._^M\1?2W_ /:E>Z5X.-_CR^7Y'92^!!11
M17*:!1110 4444 %%%% !1110 4444 %%%% '"_$W_CQT[_KNW_H)KSFO1OB
M;_QXZ=_UW;_T$UYS5(3"BBBF(**** "BBB@ HHHH *]>\"_\BC9_[TG_ *&U
M>0UZ]X%_Y%&S_P!Z3_T-J3&CHJ***D9\Z^,?^1SUC_KY;^E8E;?C'_D<]8_Z
M^6_I6)7Z9A?X$/1?D?&5_P"++U84445N8A1110 4444 %%%% &IX:_Y&G2/^
MOR+_ -#%?2-?-WAK_D:=(_Z_(O\ T,5](U\AQ)_%I^C_ #/H,F^"7J%>;_'+
M_DFD_P#U]0?^A5Z17F_QR_Y)I/\ ]?4'_H5>#A_XL?4]>6S/F2BBBOHCA"BB
MB@ HHHH **** "BBB@#Z'_9]_P"1/U3_ +"!_P#1:5ZY7D?[/O\ R)^J?]A
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M']OZ-_T%[#_P)3_&IO[*T[_GPM?^_*_X4?V5IW_/A:_]^5_PHT#4A_M_1O\
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M+FW/F7:WH?RHVMZ'\J^FO[,L/^?*V_[]+_A1_9EA_P ^5M_WZ7_"K_UDJ?\
M/M?>3_8T?Y_P/F7:WH?RHVMZ'\J^FO[,L/\ GRMO^_2_X4?V98?\^5M_WZ7_
M  H_UDJ?\^U]X?V-'^?\#YEVMZ'\J-K>A_*OIK^S+#_GRMO^_2_X4?V98?\
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MJ:;5CXN^PWG_ #Z3_P#?LT?8;S_GTG_[]FOM/^S;'_GRM_\ OTO^%']FV/\
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MO^%&@:D/]OZ-_P!!>P_\"4_QH_M_1O\ H+V'_@2G^-3?V5IW_/A:_P#?E?\
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MI?\ "BZ"S/!O.C_YZ)_WT*/.C_YZ)_WT*]Y_LS3_ /GQMO\ OTO^%']F:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'F]U\;O"UG=SVL]OJJRP2-%(/LPX93@_P 7M7HT<BRQK(AR
MC@,I]0:^6_BKI7]F?$354 Q'=%;E?^!CG_QX&OH+X?ZD=6\ Z)=D_,;54;/7
M*_*?Y4 0^+OB!HO@N:TAU07+R72LR+;QAR N,D\C'6HO"?Q(T+QEJ,]CIBW:
M30Q>:1<1! 5SCCDYZBO&/BW?R:W\2Y;.WS)]F6.SB0=W/) _X$P'X53^&%^V
MB_$S3HY?E\V1[.0>A8$8_P"^@* /J%V5$9V.%49)]!7GFG_&?PQJFJ6VG6D&
MIO/<S"&+_1Q@DG .=W3O]*Z+QYJ?]C^!=9O0VUUM61#_ +3?*/U(KPGX,Z0-
M0^(-M,R Q:? \YR.C8VK^K4 ?3%%%9=SXDT*RG\FZUG3X9<XV27**V?H30!J
M45'#/#<Q++!*DL;='1@P/XBI* "BJE]JFGZ8@>_OK:U4]#/*J9_,TEAJVFZH
MI;3[^UNP.I@F5\?D: +A.!FO.K3XU>%KW4H+&*'4Q--,(%+6X W%MO)W=,UZ
M(WW3]*^/_#__ "..F_\ 82C_ /1M 'V#12.ZHI9V"J.I)P!42W=L[!5N(F8\
M !P2: )J*** "L?5/%?A_1+I;75-9LK.X9=XCFF"MM]<'M2>*?$EGX4\/W.K
M7IRL8Q'&#S+(?NJ/J?ZFOD_5M4O=<U2YU74',EQ<R%G;'RCT4>P&!B@#Z]TW
M5;#6;,7FFWD-W;%BHEA<,I(ZC(JQ<7$-K \]Q*D,,8R\DC!54>I)Z5P'P5_Y
M)S!_U\S?^A5YO\:?$]WJ7BJ70A*5TZP"$Q \22D9+-ZX! 'XT >LS?%;P3!+
MY;:]"YZ9CC=U_,*170:/XATCQ! TVDZC;WB+PWE/DK]1U'XUXYX8^"4.K^&[
M74=2U6X@N+J(2I' BE8U897.>2<8Z8KSRX&J_#[QG,EO<;+[3IL>8A(69>H!
M'=6!Y!H ^N**KV%T+[3K6\5=HGB24#TW '^M6* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH \/^/VF%;G1=64<,KVLA _X$N?_ !ZMKX(ZO&O@2_@F;"Z=
M<.['/1&7?_/=6U\8=,_M'X<WT@4%[-DNE^BG#?\ CI->%^&?$C:)X>\460DV
MMJ-HD<0'=]V#_P".,U &C\/XI?%/Q9M+V7+;KJ34)21TP2RY_$K53QU;2>&_
MB=J4D0V&*\6]AV\<,1)_/-=S\ M*W76L:NR\(J6L9QW/S-_[+53X]Z9Y.OZ7
MJ:IA;JW:!SZLAR/T;]* .D^->M))X TV*!CMU.>.0$'J@7?_ /$U6^ >E^7I
M&K:LRC,\ZP(?]E!D_JWZ5Y=XE\2'6/#OAFS:3<VG6;QR^S;L#_QU5KZ)^'.E
M?V-X T>U9=LC0":3_>?YC_/'X4 >??&CQU>6=XOAK2[E[<",27LL;8<AONH#
MV&.3]16-X=^"%YK/AZ'4KO5$LI[F,2PP>3OP#R"YR.3UX]:Y?XGL_P#PLG7#
M+GB1<9_N[%Q746WPT^(\MI#)!K@$+HK1@:K, %(XX ]* .>\+>(]5^&_C&6S
MG=A:Q7'D7]J&RC#."ZCL1U![]*]X^('BX>$_"$NI6^Q[J8B*T!Y!=NC'U &3
M^%>.W/P4\;7+222SZ=+-)DM))=NS,?4DIDUO_&N"XL_"?A.UN&S)$3'*5.5+
MK$!U_.@#D/"'@K5OB9J=[?WVINL<3 37<P\QV<\[5&<#CGT'%1>+_"&I_#37
M;*>TU%R)<O:WD2^6P9<95AGW'L0:=X-\'^+/$.F3W7A[4UM;=)C'*@OI(27
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /./B1IO@[0]-O/$NJ>'X-0U&8K'&)%9O-DQA0>< 8'Z>M<.GA/
M3/"&H>'Y/$^CP7MCK<8CN08B397).0$"\A<$ C_9)KWR6*.>,QRQK(AZJXR#
M^%#Q1RLC21HY1MR%E!VGID>AY- &;H'AO2?#%E)9Z/:BVMY)3,R!V8;B ">2
M>P%:M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M DG!4@_G0!V5%%9>D>(M(U][I=*OXKO[(_ES&+)"MZ9Z'\* -2BBB@ HHHH
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M4[2WNOAY+;V\LR)+,7;]VA(!;IV'->K4 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?)/QVOY+WXIWT3-E+2&*",>@VAC^K&N[N
MOV@-(T.WMM(T/0VOK*UA2#S9)?)5E50/E7:3CZXKS3XQ0O!\5M=#]6D1Q]#&
MI%?2FG?#KPQ'X)BT$Z7;/!);A9)3&/,=R.7W==V><]J ,WX;^)/!/BX/=Z)H
MMCINJ6P_>0BVC25 >-RLHY4],CUY'-> ?$*9];^,NI17#$JVH+:_1%(3'Y"I
M?A'//I?Q?TR"!RX>:6VDV]'3:V?PX!_"J_C-39?&G4FG^4+JXE)/'REPP/Y&
M@#Z?\>:9%>_#C7; 1KL&GR&->P*+N7\BHKP/]G>_DM_B#<6@?$=U8N&7U964
M@_EN_.OH;QK<QVG@77KB0_(FGSGKU^0@5\Z_L\VC3_$>6<*2MO8R,3V!)51_
M,T ?4]>8?'#P=JGBSPI;-I$1N+FQG,IMU^](A7!V^I'!QWY[UZ?7DGQX\;:A
MX8T&RTW2IGM[G4F??.APR1KC(4]B2PY] : .(^%GQ6TSP)H5UX>\0V-Y#+#<
M/(K1Q9;)P"KJ2"""/_U8KG+^RU7XT?$FYU#1]-F@LI7CC>>0?+!&J@;G;INP
M"<#Z"NL^%7PCT;Q;X6/B#Q#-<W$EW(ZQ)'*5VA25+,>I8D'VX%<=KZ:E\'?B
M7)!HFH3-#%LF17;B6-AG9(!P>XS[ C% 'UK;0+;6L5NA)6) @SUP!BI:@LKI
M;ZPM[M 0D\2RJ#U 8 _UJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \C\=LP\7W.&8?NH^A/I7,RW A0N\C #_:-;OQ%NXK3Q
M7=,Y&?*CP/\ @->2:UX@>X<QQM_]:NFA0E5>FQG.:B=AX=U]KCXA:!;)(Q5K
MQ01N/3!KZ0KY#^'C%OB3X>+')-ZO/X&OKRKQE)4Y1BNPJ4KJYX)XGUO3O#O[
M2EMJ>K7(MK.*R >4JS8S$P'"@GJ17::E\<O ME8R3VVJ/?3*IV00V\@9SV&6
M4 ?6N1US3K'5?VG+2SU&T@N[9[(;H9T#H<1,1D'WKU>U\$^%;*836OAS289!
MT=+.,$?I7&:GG/[/^A:C9Z7K&N7UN;>/59D:",KM)5=Q+ ?W27P/H:C_ &?^
MOB[_ +""_P#L]>T  # &!7B_[/\ U\7?]A!?_9Z .E\6_$6]T[Q;;>$?#6DI
MJ>N3()'\Z79%"I!/S=^@R>G!'7-9&I?$KQ=X*O+(^-O#]@NFW4GEB\TV9B(S
M[JQ.3CG''0XJQJ_CK6-3\;WOA[P-HMC<W]DN+W4;T[4C/ QQ@G!XZ]NG&:X3
MXQ1^/(/"5H/%-[HDUI)>*(TLHW$@<*V.6'3&?TH ]XU_Q#IWAO0+C6M1FVV<
M*!LKR7)^Z%'<DD 5YW9^.?B5KFG?VWHW@ZP72F!>&*YG/GS)ZKR!R.G'/;-9
M_P"T \R_#;1E0L(6O(Q)CH?W38S7K>C>3_8>G_9MOD?9H_+V]-NT8Q^% &#X
M!\>67CK0GOHH6M+FW?R[NVD.3$V,]>,@^O'0^E<NOQ*\1^*M7O+3P%H%M=V5
MF^R34;^0I$[>B@$'Z<YQR0*W]5CT"V\*>+3X672QJ)LYS<BQ\O?YFQ\>8%YS
MG=U]Z\Q^$]K\0F\#1/X8O= BT]IY"4ND<RA\X.[ ^F/;% '=:%\1]5A\80^%
M/&>C1:9J-RN;2XMY-\,YYX&<XSC Y//'%<]^T3(D6F^&Y'.$2^9F.,X  J#7
M?"OC35?%OAJ\\3:_X7MY[*Z5[9(Y6BEE&]"P4,/F/ P/4^]3_M$A#IOAL28V
M?;FW9Z8P,T =!+XJ^(NK6IU3P[X6T]=,8%[=-0G(N+B/LP4$!<CH#ZUI?#WX
MC0>-TO+2XL9-.UBP;;<VDASCG&02 >HP01D&NV0*$4( $ ^4+TQ[5XCX:$9_
M:>\0&R'[H6S^=LZ;ML>[/_ OUH ZSQG\3VT7Q##X8\/:4VL^()<$P*VU(LC(
MW'UQSC@ <DBLC4?B%X^\(1)J'BOPG9/I1<++-ILY+0Y]06/]![UE?#09^._C
M@WO_ !^!I?*W]?+\T=/^ [/PKU?Q<EM)X-UM+S'V<V,WF9&>-AH MZ-K%EK^
MCVNJZ=,)K2Y0/&_3\".Q!R"/45>KQWX&-K)^$MV+$6QN5O)19?:BWE=$SNV\
MXW;NE=5N^*G_ #S\&_\ ?RZ_PH [BF2R"*%Y"K,$4L0HR3CT'<UQ6[XJ?\\_
M!O\ W\NO\*-WQ4_YY^#?^_EU_A0!U6CZQ8:_I4&IZ9<I<6DZY21?U!'4$'@@
M\BI[R[@L+&>\N7$<$$;2R.?X549)_(5X-X/_ .$X/Q-U<^'AI*Z?]H U00&0
MV'G<;]FX;O,_W>,^V*ZGX\>(9;'PI;>'K'<U_K4PA")]XQ@C('U)5?Q- &7\
M*=)_X36Y\6^,-7B)363)8PJW\,)'S#\MB_\  33_ (&ZC/I%_K_@34&Q<Z=<
M/+"#W7.U\>V=K#_>JEX;UGXG^%_#UEHUC\/H?L]K'M#-)RQZEC\_4DD_C7)Z
MIK7B?PY\4]+\:^(?#W]CK<2+%.(SE)5 VN>IYVD?]\B@#U3XRS>)U\)ZC%IM
MII\FBM9DWLLSL)D.[^  XZ8ZUG?!RY\:?\(YH4,EAI0\->5)BX$C?:,9;'&<
M?>XZ=*ZWXH.LGPLU]T8,C69*L#D$9'-0_"#_ ))1H'_7%_\ T8U %'Q1\1M1
MMO&2>#_"NDQ:EK/EB29YY=D4 (S\V.3Q@GD=1U)K,O/B7XJ\':K86_CC0+*.
MQO9/+2]TZ8E4/?*L23C.>W'3-/O_ !UK>M>--2T+P'HNGS7-A\E[J=Z<(K9Q
M@8P3R".^<'C S7#?%V/QQ!HVDKXJO-%GMWO@8EL8W#JX4\DL!Q@G]* />?$7
MB'3_  OH-SK.I2E+6!<G;RSD\!5'<DUYY:>./B7K>G?VWI'@ZP72F&^&&XN#
M]HF3U7D#D=..>V:H_M%-./ FE*F[R&OE\S'3_5MC/ZUZUI/E?V-8^1CR?L\?
MEXZ;=HQ^E '/^ O'=EX[T)[ZWA>VNK=_*NK5SDQ/C/7N#V/'0^E9OPK\=:CX
MZTK4KK4;:U@>UNO(06X8 C:#D[B>>:Z/1(O#4,VH#0%TM9F?-X+$Q[M_/^LV
M]\[NOO7FG[.O_(N:[_V$3_Z * .A\3_$B]@\4_\ ")^$M(75];5=\YDDVPVX
MQGYCWQD9Y'4#D\51C^)7B+PYXBL-*\>:%;64-^^RWO[&0M%NR!@@DGJ1GGC.
M<8K#^#3,_P 3?'K77_'X;@YW?>QYK[O_ &7]*]5\10^&I8K8^)%TLQK)F Z@
M4 #_ .SO[_2@#(\>^/[;P3;6D26<FH:K?OY=G91'#.>!D]<#) Z$DGZXYJ^\
M8?%#1-.?6=4\(Z6^G1+YDT%M<GSXDZDDY(.!UP#7-_$-=:N/V@- 32);.*\%
MD#9O>*3%G]Z3G&??'OBNHN[#XNRV4\=SJ?A06[QLLN^.0#:1SG*],4 =QX<\
M367BGPS;ZYIQ;R9D)V/]Y&'!5O<$5YAX3^,/B7Q5;W%EI_ARWO=;68X6)FBM
MX8<#YY'8GDMD #&<5T7PA\/S>&_ MY92ZKI^I*UU))'+83^;&H**-N<=<@G'
MO7/?LYK$/#NNN OG&_ 8]]H08_#);]: +L_Q/\4>$=8M+;QYX>M;:PNWV1W]
MA(61#[@DYQU/0XZ U=^,=SXF_P"$2U!-+M=-FT)[(F[GE<^:OS?P '!XQZTS
MX_F ?#"43;?,-W#Y.>N[)SC_ (#NJ77A,/V=G%QGS?[$BW9Z_<7K0!F?!FY\
M9?\ "-:'#)8Z5_PC7ER[;@.WVC[SXXSC[W'3I7K]<-\'/^23:!_USD_]&O7<
MT 87B;PCI'B^&S@UF!I[>UG\]8@Y56;!'S8Y(Y/%>83V\%G^TYI%M;0I#!%I
MNR..-0JHHCDP !T%>V5XOJ'_ "=+IO\ V#S_ .BY* /5?$DAA\+ZO*IP4LIF
M!],(:\.^&'Q(TKPE\/K;3ELK[4]3>>65[6QB+M&N0 6/;(';->Z:\;$>']1_
MM.8PV!MI%N) <%(RI#'\LUSWPVTGPGI?AM_^$1G%U92S,7N6.YW<8&"< \<8
M&/YT 1^"_B?H7C6XELK43V>I1 L]G=*%? ZE><''?N/2N)\7(->_:-\,Z3<J
M'M;*W\\1D<%@'DS_ ..)^50?$B)-/^.O@R[TR-5U"X>,7 3@NGF;<G_@)<?0
M5/XD?^R?VF?#M[<?+!=VHBC<]"S+)'C\R/SH ]4\5:=#JWA/5K"X0/%/:2*0
M>QVG!^H.#^%<%^S]?R7?PU$$CEA:7DL2 G[JG#X_-C7?^)KZ'3/"VJWL[A8H
M+25R3[*:\]_9[L7M?ANUP\>W[7>R2*<?>4!5S^:L/PH ]7KR'5_BYK&D_$K4
M_"\6B1ZB(T"V45LK":65E5@&8G 49;)QP!7KU>)Z"BM^U%KQ902MEE2>QV1#
M^1- %G6OB3\0?!X@U#Q+X2L1I,CJK-:3EGCSV)W$9_  ^M:0^(7BWQ2)+GP)
MX9AN=+CX6^U*3RQ,PZA$R#P>,Y['I5_XW?\ ))]7_P!Z'_T:M:?PL4+\+_#P
M4 #[(IX^IH RO 'Q+F\3ZS?>'M;THZ5KMD"SP[LJX& <9Y!&0<<Y!R#6CX_^
M(-MX)M[6&.TDU#5KYMEI91'!<],GK@9('3)/XXXJU _X:GO>!_R#Q_Z*2H?$
MC*W[3OAY;P_N5M5\@/TW;9,8]]WZT ;TGC'XC:):?VMK_A*Q?2E >=+"<F>W
M3J6()(; ZX_2K_PI\>ZAX]T[4[N^MK6%;:Y$4/D*PW#&><D\]*[^39Y3^;M\
MO:=V[ICOFO&OV==G]@:_Y>-G]H?+CTVC% 'L]%%% !7!_%HD>$[<@D'[8G0X
M_A>N\K@OBW_R*=O_ -?J?^@O7?E?^^4_4Y<;_N\_0\9\Q_\ GH__ 'T:/,?_
M )Z/_P!]&FT5^AV/D;L^B?!A)\&:.223]E3K]*W*PO!G_(EZ/_UZI_*LWXF^
M*/\ A$O >HZA&^VZD7[/:^OF/P"/H,M^%?FF*_CS]7^9]I1_AQ]$<+X>?_A/
M_CQJ.M_ZS2_#T?V>V/56DY4$?4^8V?9:K>$7_P"$!^.VL>&I#LT[6AY]J">
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M;LWRF4G[V-IQG\=WZT 2^*?BOXP\%Z:T6O>&;2#492IM+F)VDM9N?G!PP96
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M"2_EVRW*?WE3<N,]LYJC^T?_ ,B'IO\ V$T_]%25ZEH**GAW3$10JK:1  =
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;&3PG_PDEE:QV^HV$R%YH5",T9.WG'4@E2#VYKO_  #KK^)/ FCZK*X>>:W
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M30!Q>C^-Y_&WP-UV^G"C4;>RN+>YV# 9A'G<!VR#^>:B_9S'_%O+S_L)R?\
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M/\Q6E+^)'U0GL?)WG3?\]YO^_C?XT>=-_P ]YO\ OXW^-,HKZ2QPW8_SIO\
MGO-_W\;_ !H\Z;_GO-_W\;_&F446"['^=-_SWF_[^-_C1YTW_/>;_OXW^-,H
MHL%V/\Z;_GO-_P!_&_QH\Z;_ )[S?]_&_P :9118+L?YTW_/>;_OXW^-'G3?
M\]YO^_C?XTRBBP79[;^S[<.LOB'>9I>+?'5L?ZRO;OM8_P">$_\ W[->)_L[
M_P"M\1?2W_\ :E>Z5X.-_CR^7Y'72^!%?[6/^>$__?LT?:Q_SPG_ ._9JQ17
M*:%?[6/^>$__ '[-'VL?\\)_^_9JQ10!7^UC_GA/_P!^S1]K'_/"?_OV:L44
M 5_M8_YX3_\ ?LT?:Q_SPG_[]FK%% %?[6/^>$__ '[-'VL?\\)_^_9JQ10!
M7^UC_GA/_P!^S1]K'_/"?_OV:L44 5_M8_YX3_\ ?LT?:Q_SPG_[]FK%% %?
M[6/^>$__ '[-'VL?\\)_^_9JQ10!7^UC_GA/_P!^S1]K'_/"?_OV:L44 5_M
M8_YX3_\ ?LT?:Q_SPG_[]FK%% %?[6/^>$__ '[-'VL?\\)_^_9JQ10!7^UC
M_GA/_P!^S1]K'_/"?_OV:L44 5_M8_YX3_\ ?LT?:Q_SPG_[]FK%% %?[6/^
M>$__ '[-'VL?\\)_^_9JQ10!7^UC_GA/_P!^S1]K'_/"?_OV:L44 5_M8_YX
M3_\ ?LT?:Q_SPG_[]FK%% %?[6/^>$__ '[-'VL?\\)_^_9JQ10!7^UC_GA/
M_P!^S1]K'_/"?_OV:L44 5_M8_YX3_\ ?LT?:Q_SPG_[]FK%% %?[6/^>$__
M '[-'VL?\\)_^_9JQ10!7^UC_GA/_P!^S1]K'_/"?_OV:L44 5_M8_YX3_\
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M '[-'VL?\\)_^_9JQ10!7^UC_GA/_P!^S1]K'_/"?_OV:L44 5_M8_YX3_\
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MC-*'NKID*($&,1QYZG  'IU/O]076@Z1?+"MYI=E<B%-D?GP+)L7T&0<"M
M 8 P!10!Q_BSPIH*>#=<:V\/Z<+@:?.8C%9)OW>6V-N%SG/3%>%_ _PU+)X]
MD76=$=[7[%)@7EH2F[<F/O#&>M?4E% 'G_Q4O]7\-> XW\*(]O<)<QQHEK;A
MML>&R N" .!VIGPTNM8\6_#>ZC\4M.]S<R3VTGG1>4WEE0.F!ZGFO0Z* /D3
M^SO%GP:\;"_%DTD<)9%G*$P7,1Z\CIV..H(%3^*/&'BOXPWMEIUEI#""%\I;
MVJLPWGC<[G@8'K@#FOK-E5U*L 0>H(I(XHXAB-%0>BC% '*_#GP</ _@^WTI
MI%ENF8S7,B]#(V,@>P  ]\9[UUE%% !7(?%+_DF/B#_KU/\ ,5U]<A\4O^28
M^(/^O4_S%:4OXD?5">Q\ET445](< 4444 %%%% !1110 4444 >W_L[_ .M\
M1?2W_P#:E>Z5X7^SO_K?$7TM_P#VI7NE>#C?X\OE^1V4O@04445RF@4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<A\4
MO^28^(/^O4_S%=?7(?%+_DF/B#_KU/\ ,5I2_B1]4)['R71117TAP!1110 4
M444 %%%% !1110![?^SO_K?$7TM__:E>Z5X7^SO_ *WQ%]+?_P!J5[I7@XW^
M/+Y?D=E+X$%%%%<IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%%%<IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 C,%4LQ 4#))/ %?,_C#5[[XS?$BV\.:)(?['M'(649*$#[\Y_DOX?WJ^B
MM<MY;S0-2MH%W336LL<:YQEBI &?J:^9=&^&?Q9\/-,^CV\UBTP D,%]$I8#
MIGYO<T 6/CSH]GX?OO#>DZ?%Y=I:Z>4C7O\ ?.2?4D\D^IKZ \"?\D_\/?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$$+$%Y\L \@\Y.0">.*\*U!;_P"&GQ8:XGMR\EC>F>,-P)HF)P0?=2>>Q^E
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M3]0:.\?[EO<H8V?_ '>Q/L#FNUH **** "BBB@ HHHH **** "BBB@ HHHH
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M!1110 4444 %%%% !1110![?^SO_ *WQ%]+?_P!J5[I7A?[._P#K?$7TM_\
MVI7NE>#C?X\OE^1V4O@04445RF@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'C]W\>]/LO%4NA7FA3P^5>&TEG>X7:H#[2Y&.G>MKXO:'X=
MG^'6JWUY:VD<\,6^VN%15?S,_* PY.3QCWK$^)/P13Q7JTNMZ+>16=_-S/#,
M#Y<K ?>!'*GIG@@]>.<\1#\!_'>H"&SU+6+5+*'_ %8>ZDE5/]U,8'Z4 /\
MV;KF[7Q7JUJCO]D>R\R1?X=X=0I^N"U>B:WXR^%GB[4X]#UEXKJ[6<VR>=:R
MH4<MMP),#:,]\XKIO ?@'2_ .D/:6):>YF(:YNI!AI2.@QV4<X'N:\Y^(/P'
MFUW7+K6?#U[!#)=.99K6XR%WGJ58 ]3DX(ZT 7/B#X2\%_#_ .'6KSZ=I=O;
MWUY']E@>1VDD8L1D*7)(P,GCTK _9JTR0W.NZJR8B"1VR-ZG)9A^B_G6;:_
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M]=Y?_9* /:KB[CL-*EO)CB*" RN?157)_E7@_P (/#\'C_Q)KGC3Q) MZXN
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MV_PH^VP_]-/^_;?X4!<L457^VP_]-/\ OVW^%'VV'_II_P!^V_PH"Y8HJO\
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M2O!QO\>7R_([*7P(****Y30**** "BBB@ HHHH **** "BBB@ HHHH ****
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MXU\T44?V?2\P]M(^Q/"?C#2_&>GS7ND^?Y,,ODMYT>P[L ]/H16_7D?[/O\
MR)^J?]A _P#HM*]<KRJ\%"HXKH=$7=)A1116104444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_KU/\Q77UR'Q2_Y)CX@_Z]3_ #%?/4OXD?5'L/8^2Z***^D. **** "BBB@
MHHHH **** /;_P!G?_6^(OI;_P#M2O=*\+_9W_UOB+Z6_P#[4KW2O!QO\>7R
M_([*7P(****Y30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-_C
ME_R32?\ Z^H/_0J](KS?XY?\DTG_ .OJ#_T*ML/_ !8^I,MF?,E%%%?1'"%%
M%% !1110 4444 %%%% 'T/\ L^_\B?JG_80/_HM*]<KR/]GW_D3]4_["!_\
M1:5ZY7S^*_C2.VG\*"BBBN<L**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 1F5$+NP55&22< "LRR\1Z/J6D3:M9:A#/80;_,N$.579
M][\JS_%OBQ?"T=F7TB_U%;IVC*V<>\I@9R1Z5XKJ&IPVM[J'AK2K+5K'2/$,
ML<\EM):,MQ!@_O5B3^(.  ,=.: /H/3-4L=:T^*_TVZBNK64926,Y!_^O[5/
M<7$-I;R7%Q*D4,2EWD=L*H'4D]JX7P;XQTF?4+7PMI>@:KI\$-NQC:ZMO*4!
M<<'G))SFM+Q=XPA\/75M87&A:CJ<-Y$Y<VD(E"@<$,/?- &NOB71F\.GQ M_
M$=*"&0W0SMV@X)Z9ZU>L[RVU"SBN[.>.>VF4/'+&V58'N#7SJU[ LTG@E+76
M4\/RW@U VWV1OM:Q8W& )G[NX [O2O7_  =XTT_7+Z71;#1-1TZ*RMU9/M4'
ME+MSM"J,T =E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6/XD\3Z3X4TS[?JUSY49;:B*-SR-Z*.YK8KR;Q?I]MXD^-F@
MZ-J@WZ?#8O.L).!*V6./QVC/LM %G1?C7IVN^(K+2K72+M1=S"))I)% &>Y
MS_.MR7XG:%:>-9_#%]YMK<QNB).^#$[, 0"?X>N.>*P/&]G:V7Q(\ Q6MM#!
M&+J3Y8HPH_A["M#XN^'-*OO VJ:I+:Q)?VD7FQ7*J ^00-I/<'I@T >AT5A>
M"KR;4/!.BW5P29I+2,N3U)QC-;M !1110 4444 %%%% !1110 4444 %%%%
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MKP<;_'E\OR.RE\""BBBN4T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KS?XY?\ )-)_^OJ#_P!"KTBO-_CE_P DTG_Z^H/_ $*ML/\ Q8^I,MF?
M,E%%%?1'"%%%% !1110 4444 %%%% 'T/^S[_P B?JG_ &$#_P"BTKURO(_V
M??\ D3]4_P"P@?\ T6E>N5\_BOXTCMI_"@HHHKG+"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (YVE6WD:!%>4*2BLV S8X!/;FO*(
M/ 6O:MX4\0:CK9\OQ7>S^?;-&X/V<PG,2QL.@)SWZ$9KUNB@#*\-R:Q+X=LG
MUZ"*#5/+'VA(GW+N]<^IZD"K6IO>QZ9<OIL,4UZ(R8(Y7VHSXX!/85;HH \@
M'@'7AX ;4LN?&QOAJGF;EW^8#M\K=G&W9VZ5ZKIKWLNF6KZE#%#>M&IGCB?<
MJOCD ]QFK5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@#A_B9_R#+#_KX/_H!KS>O2/B9_R#+#_KX/_H!KS>J0F%%%%,04444
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M?$7TM_\ VI7NE>%_L[_ZWQ%]+?\ ]J5[I7@XW^/+Y?D=E+X$%%%%<IH%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<A\4O^28^(/^O4_S%=?7(?%+_DF/B#_KU/\ ,5\]2_B1]4>P]CY+HHHKZ0X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\(@C-JJJ9-HP3EOF<\=%X[8KI/A5\9M6OO$-OX>\3R+<"Z;RH+HH$=).RMC
M(/3.,Y_3VKPQ?:1J7ANQO-"CCBTR6/,"1QB-5&3D;1TYSQZU\G7*QZG\;'_L
MK;)'-KN8#'P"/.SD>W>@#[(HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.VG\*"BBBN<L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ****  D 9)P!7SY\7?C(LZ7'AOPO<9C.8[N_C/##ND9]
M.Q;\!ZUI?M!^+]6TF"QT&PF^SVU]$TEQ(A(=U!QLSV4]_7ITZ^5_#W6?!7AR
M\35?$-GJ&HWT3Y@MXXD,,1'1CEAN;TXP/<] #U#X*?"F73I(?%>OP[+@KNL;
M5QS&#_RT8=CCH.V<]<8]UKQF3]I#PT /+TC56]<B,?\ LU>Q6\PN;:*=00LB
M!P#U&1F@#R7]HO\ Y)_9_P#803_T!ZI_LV_\BEK'_7\/_1:U<_:+_P"2?V?_
M &$$_P#0'JG^S;_R*6L?]?P_]%K0![5574M0MM)TNZU&\?9;6L332MZ*HR:Y
M+XE?$'_A7NFV-Y_9WVW[5,8MOF^7MP,YZ&@W$WQ*^$4\L$ M)]5LI!'$7W!6
MR0 3QP2H_.@#Y]O&U#XT>/S%I&DV&GEMTC2*FTB,$?/,P^\W0=.IQ3?%7P\U
MKX6WMCJMU'IVJ6;2;49XC)%OQG:Z-CJ 2/I3?ACXK3X;^.;A];M)XXWB:TN5
MV?O(3N!SM[X*\CT-=-\9OBGHWB_1[31=#\R>%)Q<S7,B%!D!@% //\1)/TH
M]M^'GC"U\:^$;?4[>!;:2,^1/;J>(G4#@>V""/8UU5>7_ GPW?>'_ ;2W\3P
MRZA<&Y2)QAE3:%7(]\9^A%>H4 %%%97B'Q'IGA;2SJ6K3-#:AUCW+&SG<>G
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M+D@R9+;MV<8W9QSCM7444 5-+TVWT?2[;3K3?]GMHQ''YCEVP.F2>35NBB@
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MY0,8VGTKK&_:#4*3_P (M+P/^?O_ .PH ]KHJO877V[3K:[V;//B27;G.W<
M<?K5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#A_B9_R#+#_KX/_H!KS>O2/B9_R#+#_KX/_H!KS>J0F%%(3BHW
M>FD(5GJN\E->2J[R5I&)+8KR57>2FO)5=Y*WC$EL<\E5GDIKR57>2MHQ(;'2
M25[_ /"4Y^'MF?\ IK-_Z,:OG9Y*^AOA"<_#FR/_ $VG_P#1C5GBE:G\RJ?Q
M'=4445YYN?/'C;_D=M8_Z^/_ &45@UO>-O\ D=M8_P"OC_V45@U^EX7_ '>G
M_A7Y'QF(_C2]6%%%%=!B%%%% !1110 4444 :.@?\C)I?_7Y#_Z&*^E*^:]
M_P"1DTO_ *_(?_0Q7TI7R/$G\2GZ,^@R;X)>H5R'Q2_Y)CX@_P"O4_S%=?7(
M?%+_ ))CX@_Z]3_,5\]2_B1]4>P]CY+HHHKZ0X HHHH **** "BBB@ HHHH
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MD@CM[0,5&#G:F1T 4 G'4F@#W71O%&A>(=W]D:M9WK)]Y8906'N1UK6KY_\
MBE\/K3P#;VGC'P>9=.FM+A5EB1V91G@,,Y.,\$=#NKVKPQK:>(_"^FZPBA!=
MVZRE1_"Q'S#\#D4 :U%%% !1110 4444 %%%% !1110 4444 </\3/\ D&6'
M_7P?_0#7FQ.*](^)QQI=A_U\'_T UY@\E7%7)8KR57>2FO)59Y*VC$EL<\E5
MWDIKR57>2MHQ(;'/)59Y*:\E5WDK:,26Q7DJN\E->2J[R5O&)+8YY*^C?@X<
M_#:Q/_3:?_T:U?,[R5]+?!<Y^&5@?^FT_P#Z-:L,:K4OF72^([^BBBO*.@^>
M/&W_ ".VL?\ 7Q_[**P:WO&W_([:Q_U\?^RBL&OTO"_[O3_PK\CXS$?QI>K"
MBBBN@Q"BBB@ HHHH **** -'0/\ D9-+_P"OR'_T,5]*5\UZ!_R,FE_]?D/_
M *&*^E*^1XD_B4_1GT&3?!+U"N0^*7_),?$'_7J?YBNOKD/BE_R3'Q!_UZG^
M8KYZE_$CZH]A['R71117TAP!1110 4444 %%%% !1110![?^SO\ ZWQ%]+?_
M -J5[I7A?[._^M\1?2W_ /:E>Z5X.-_CR^7Y'92^!!1117*:!1110 4444 %
M%%% !1110 4444 %%%% !1110!X#JGP3\37OQ'N/$,5UI@LY-3^UA6F??L\S
M=C&S&<>]>]3P17-O+;S('BE0HZGHRD8(J2B@#YIUOX"^*=&UEKOPK>1W$"OO
MMV$_DSQ^V3@<>H//H*73_@=XU\2:LEUXLU(0QY DDEN/M$Q4'HO4#OU/'H:^
ME:* *>E:7::+I5KIEA$(K6UC$4:>@'KZGWKR+X:?"77_  ?XZEUK4;C3WM6A
ME0+!([/EB"."H';UKVFB@#Y\\;_ _P 4>(_&FJZQ976EI;7<WF1K+,X8# '(
M"$=O6L[_ (4?\1^/^*AL^  /]/GZ#_@%?2E% '@_@OX1>-="\::9J^J:O9SV
MMM(6E1;N5V8;2. 5 /7UKWBBB@ HHHH **\<\1_$#Q'IWB74;*VNH5@@G*1@
MP*2!]:S/^%F^*O\ G\@_\!UKVX9!BIQ4TU9Z[O\ R/-GFE",G%WT/=J*\)_X
M6;XJ_P"?R#_P'6C_ (6;XJ_Y_(/_  '6K_U=Q?>/WO\ R)_M?#^?]?,]VHKP
MG_A9OBK_ )_(/_ =:/\ A9OBK_G\@_\  =:/]7<7WC][_P @_M?#^?\ 7S/=
MJ*\)_P"%F^*O^?R#_P !UH_X6;XJ_P"?R#_P'6C_ %=Q?>/WO_(/[7P_G_7S
M/=J*\)_X6;XJ_P"?R#_P'6C_ (6;XJ_Y_(/_  '6C_5W%]X_>_\ (/[7P_G_
M %\SW:BO%]%^(GB6]U[3[6>[A,,US'&X$"@E2P!YKVBO.QN JX.2C4:U['7A
ML5#$)N'0*\W^.7_)-)_^OJ#_ -"KTBO-_CE_R32?_KZ@_P#0JPP_\6/J;RV9
M\R4445]$<(4444 %%%% !1110 4444 ?0_[/O_(GZI_V$#_Z+2O7*\C_ &??
M^1/U3_L('_T6E>N5\_BOXTCMI_"@HHHKG+"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKP^\^)/B>&_N8DN
MX D<SHH^SKT#$"H?^%F^*O\ G\@_\!UKW5P]BFKWC][_ ,CS'FU!.VI[M17A
M/_"S?%7_ #^0?^ ZT?\ "S?%7_/Y!_X#K3_U=Q?>/WO_ "%_:^'\_P"OF>[4
M5X3_ ,+-\5?\_D'_ (#K1_PLWQ5_S^0?^ ZT?ZNXOO'[W_D']KX?S_KYGNU%
M>$_\+-\5?\_D'_@.M'_"S?%7_/Y!_P" ZT?ZNXOO'[W_ )!_:^'\_P"OF>[4
M5X3_ ,+-\5?\_D'_ (#K1_PLWQ5_S^0?^ ZT?ZNXOO'[W_D']KX?S_KYGNU%
M>2>$/'?B#5_%5C87ES"]O,S!U6%5)PC'K]0*];KS,;@JF#FH5+7:OH=F'Q,,
M1'FAL%>9_';_ ))PW_7[#_,UZ97F?QV_Y)PW_7[#_,UEA_XL?4VG\+/FBBBB
MOHCA"BBB@ HHHH **** "BBB@#Z,_9__ .1'O_\ L(O_ .BXZ]7KRC]G_P#Y
M$>__ .PB_P#Z+CKU>OG\5_&D=M/X4%%%%<Y84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7R%\;_P#DK>L_[L'_ *)2OKVOD+XW_P#)6]9^
MD'_HE* /K'2?^0-8_P#7O'_Z"*FO+N"PLI[RYD$<$$;2R.>BJHR3^0J'2?\
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M\M4FTVZYM[@+G'^ZW.,_J*CT#XE6=W?#1_$-I)H.MC@V]T<1RGUC?H0?\YH
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M#Q'I9)P!=PY)_P!\5](?:8/^>\?_ 'V*^;] &?$>E@\C[9#_ .ABOI+R8O\
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M/^^11Y,7_/-/^^10 W[3!_SWC_[[% N8"<"://\ O"G>3%_SS3_OD4>3$/\
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M?#R\_8IF_P!*@7_8;^(>WZ5UGA?QMHGBV G3KG;<Q\36<PV31'N"I_F.*;X
M:[?P!H37V[[0;--V[KC''Z8JMXH^'NC^))EOE\S3M7C.Z+4;,[)5/;./O?C0
M!UM%97ARUU:RT."VUN]CO;Z,LK7*+M$BY.TD>N,9]ZU: "BBB@ HHHH *:X+
M1LJG!((!]*=10!\^Z5\"O&6B7SWVF>*[2UNW4JTT8?>0>3SCO6U_PKGXJ?\
M11#_ -]R?X5[110!S_@S2=:T7P\EGK^J_P!J7PD9C<9)RIZ#GGBO/_%GPDU>
M+Q3+XI\":LFF:A,6::!R55F/WBI (P>I4C&>:]@HH \3TWX1>)O$FOVVJ_$7
M6H[Z&V^Y9Q-D-SG!P %4]\#)KVM5"J%4 *!@ #@"EHH **** "BBB@ HHHH
M**** "BBB@ HHHH \Y^+[;=&TS_KZ/\ Z U>//)7KGQE;;HNE_\ 7V?_ $!J
M\9>2NVA&\3&;U'/)59Y*1Y*K/)77&)FV.>2J[R4UY*K/)6T8DMCGDJL\E(\E
M0,V:VC$AL5FS3:**T$%?4/P4_P"27V'_ %VG_P#1K5\O5]0_!3_DE]A_UVG_
M /1K5PYA_"7J;4/B/0J***\4ZCYX\;?\CMK'_7Q_[**P:WO&W_([:Q_U\?\
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MY;^E8E;?C'_D<]8_Z^6_I6)7Z9A?X$/1?D?&5_XLO5A1116YB%%%% !1110
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M1^S_ /\ (CW_ /V$7_\ 1<=>KU\_BOXTCMI_"@HHHKG+"BBB@ HHHH ****
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M?21"0HJX4*A PH [FO0*XZD'"3B^AJG=7"BBBH&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8
MWB3PKH_BRP%GJ]H)D0[HW!VO&?56'(KD]/\ @GX.L+Q+AX;N\V'(BN9@R9]P
M ,_0\5Z+10 BJ%4*H  & !VI:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#XUMMT/2O^OL_^BVKQ-Y*
M]G^.+;="TC_K\/\ Z+:O#GDKT\+&]-'/4?O#GDJL\E(\E5GDKLC$R;'/)59Y
M*1WJ(G-;*)+8I.:2BBK$%%%% !7U#\%/^27V'_7:?_T:U?+U?4/P4_Y)?8?]
M=I__ $:U<.8?PEZFU#XCT*BBBO%.H^>/&W_([:Q_U\?^RBL&M[QM_P CMK'_
M %\?^RBL&OTO"_[O3_PK\CXS$?QI>K"BBBN@Q"BBB@ HHHH **** -'0/^1D
MTO\ Z_(?_0Q7TI7S7H'_ ",FE_\ 7Y#_ .ABOI2OD>)/XE/T9]!DWP2]0KD/
MBE_R3'Q!_P!>I_F*Z^N0^*7_ "3'Q!_UZG^8KYZE_$CZH]A['R71117TAP!1
M110 4444 %%%% !1110![?\ L[_ZWQ%]+?\ ]J5[I7A?[._^M\1?2W_]J5[I
M7@XW^/+Y?D=E+X$%%%%<IH%%%% !1110 4444 %%%% !1110 4444 <+\3?^
M/'3O^N[?^@FO.:]&^)O_ !XZ=_UW;_T$UYS5(3"BBBF(**** "BBB@ HHZ5!
M+, .*$K@.DE"CBO7_ #;O!MF?]J3_P!#:O$)I^O->U?#=MW@:Q/^U+_Z,:JG
M&T;BB]3JZ***R+/G7QC_ ,CGK'_7RW]*Q*V_&/\ R.>L?]?+?TK$K],PO\"'
MHOR/C*_\67JPHHHK<Q"BBB@ HHHH **** -3PU_R-.D?]?D7_H8KZ1KYN\-?
M\C3I'_7Y%_Z&*^D:^0XD_BT_1_F?09-\$O4*\W^.7_)-)_\ KZ@_]"KTBO-_
MCE_R32?_ *^H/_0J\'#_ ,6/J>O+9GS)1117T1PA1110 4444 %%%% !1110
M!]#_ +/O_(GZI_V$#_Z+2O7*\C_9]_Y$_5/^P@?_ $6E>N5\_BOXTCMI_"@H
MHHKG+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RKXR?$ZY\%6UOI>D;
M!JUVAD,S ,((\XR >"Q(.,\#!]J\KT[PM\6/$^C_ /"2P:EJ#HZ^9"'OV224
M#NBYQCTSC/:IOVB+.>'X@V]TZGR;BQ3RV[':S C]1^=>R>#?B!X7?X>:=>2Z
MO:6RV=G'%/%+*%>-D4 C;U.<<8'/:@#@O@U\5M6U'7E\,>([AKEY@WV6XE_U
MBNO)1CWR <$\Y&._'OE?%F@ZJ)_BS8:K;JR+/K*S(O0A6FSC\CBOM.@!KND4
M;22,%1069F.  .YKYE\1_$KQ?\1/%W]A>$)KBVLW=HX([=_+>51UD=^H&.<9
M  ]37N7Q*O9+#X;>(+B)MKBS= ?3=\O]:^8OAEXUL_ FJZCJLUD]Y=/:>1:Q
M*=H+%E));L,#L#0!J:T_Q)^%6J6LEYK%R!<?/&PN3/#+MQE2&],C.1WXKZ0\
M">*%\9>#K#6O+$4LRE9HUZ+(I(;'MD9'L:\8L?VBK\:HL>O>';4VF[YA!N$L
M8/?#D@_I7ONDZA8ZMI-MJ&FR))9W""2)T& 0?;L?:@"[1110 4444 ?,>H_\
MA6]_Z^)/_0C5:K.H_P#(5O?^OB3_ -"-5J_4(?"CXB?Q,****LD**** "BBB
M@ HHHH Z;X??\CWI?^\__HMJ]_KP#X??\CWI?^\__HMJ]_KXSB/_ 'F/^']6
M?1Y/_ ?K^B"O,_CM_P DX;_K]A_F:],KS/X[?\DX;_K]A_F:\7#_ ,6/J>I/
MX6?-%%%%?1'"%%%% !1110 4444 %%%% 'T9^S__ ,B/?_\ 81?_ -%QUZO7
ME'[/_P#R(]__ -A%_P#T7'7J]?/XK^-([:?PH****YRPHHHH **** "BBB@
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M#_Z+2O7*\C_9]_Y$_5/^P@?_ $6E>N5\_BOXTCMI_"@HHHKG+"BBB@ HHHH
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M_KU/\Q77UR'Q2_Y)CX@_Z]3_ #%?/4OXD?5'L/8^2Z***^D. **** "BBB@
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MJ=T/A04445@4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >._M"_\
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MM_\ OZ/\:/[0LO\ G\M_^_H_QKP;RX_[B_E1Y<?]Q?RHL%SWG^T++_G\M_\
MOZ/\:/[0LO\ G\M_^_H_QKP;RX_[B_E1Y<?]Q?RHL%SWG^T++_G\M_\ OZ/\
M:#J-B.M[;_\ ?U?\:\!E,2#[BY^E9=S-'S\J_E5QIN0G*Q]('5-/'6_M?^_R
M_P"-6(IHYXQ)#(DD9Z,C @_B*^4+F6/GY$_*OH'X6$-\.-)(  Q+T_ZZM5U*
M/)'F%&=W8[&BBBL"SYCU'_D*WO\ U\2?^A&JU6=1_P"0K>_]?$G_ *$:K5^H
M0^%'Q$_B844459(4444 %%%% !1110!TWP^_Y'O2_P#>?_T6U>_UX!\/O^1[
MTO\ WG_]%M7O]?&<1_[S'_#^K/H\G_@/U_1!7F?QV_Y)PW_7[#_,UZ97F?QV
M_P"2<-_U^P_S->+A_P"+'U/4G\+/FBBBBOHCA"BBB@ HHHH **** "BBB@#Z
M,_9__P"1'O\ _L(O_P"BXZ]7KRC]G_\ Y$>__P"PB_\ Z+CKU>OG\5_&D=M/
MX4%%%%<Y84444 %%%% !1110 4444 %%%% !1110 4444 %%,EEC@B:6:1(X
MT&6=S@ >I)KR/Q;^T!H6AWHM-&M?[:=21+*DWEQ+[*VT[OP&/<T >OT5S'@'
MQ<?&_A6'6S9?8_,D=/)\WS,;3C.<#^5=/0 45%<W,-G:RW-S*L4$*%Y)'. J
M@9))KPGQ#^T:4OWMO#6CI<Q*<+<798>9[A%P0/J<^U 'O=%>'>$OVAH+_4XK
M#Q)IL=@)6""[@<F-#_MJ>0/?)Q7N(((R.10 4444 %%%% 'S!>?\?]S_ -=G
M_P#0C4-37G_'_<_]=G_]"-0U^HQ^%'Q$OB844451(4444 %%%% !1110!U/P
MY_Y'S3O^VG_HMJ]\KP/X<_\ (^:=_P!M/_1;5[Y7Q?$?^]1_PK\V?29/_ ?K
M^B"O,/CU_P D[3_K_A_DU>GUYA\>O^2=I_U_P_R:O'PW\:/J>G/X6?-=%%%?
M0G"%%%% !1110 4444 %%%% 'TA\ O\ DG]S_P!A*7_T".O4Z\L^ 7_)/[G_
M +"4O_H$=>IU\]BOXTO4[H?"@HHHK H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \=_:%_P"1<T;_ *_6_P#1;5\_5] _M"_\BYHW_7ZW_HMJ^?J]
MS _P4<E;X@HHHKL,@HHHH **** "BBB@ KZA^"G_ "2^P_Z[3_\ HUJ^7J^H
M?@I_R2^P_P"NT_\ Z-:N',/X2]3:A\1Z%1117BG4?/'C;_D=M8_Z^/\ V45@
MUO>-O^1VUC_KX_\ 916#7Z7A?]WI_P"%?D?&8C^-+U84445T&(4444 %%%%
M!1110!HZ!_R,FE_]?D/_ *&*^E*^:] _Y&32_P#K\A_]#%?2E?(\2?Q*?HSZ
M#)O@EZA7(?%+_DF/B#_KU/\ ,5U]<A\4O^28^(/^O4_S%?/4OXD?5'L/8^2Z
M***^D. **** "BBB@ HHHH **** /;_V=_\ 6^(OI;_^U*]TKPO]G?\ UOB+
MZ6__ +4KW2O!QO\ 'E\OR.RE\""BBBN4T"BBB@ HHHH **** "BBB@ HHHH
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MD7_H8KZ1KYN\-?\ (TZ1_P!?D7_H8KZ1KY#B3^+3]'^9]!DWP2]0KS?XY?\
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M&B\RXDO8V?=($54 ;)8^@...?I7@WQ)^&D/P]T31#)>M=ZA>/-Y[J-L:A0F
MHZ_Q'D]?05]<5X+^TQ_QY^&_^NEQ_*.@#KO@+_R2NS_Z^)O_ $.O3*\S^ O_
M "2NS_Z^)O\ T.O3* /-OCM<S6WPLOA"[*)IHHWQW4MDC]!7#_LVZ9ITRZWJ
M,D,<E_"\4<;,,M&A#$X],D?^.U[3XI\.VOBOPU?:+>$K%=1[0X&2C Y5A]"
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MC?\ 7ZW_ *+:OGZOH']H7_D7-&_Z_6_]%M7S]7N8'^"CDK?$%%%%=AD%%%%
M!1110 4444 %?4/P4_Y)?8?]=I__ $:U?+U?4/P4_P"27V'_ %VG_P#1K5PY
MA_"7J;4/B/0J***\4ZCYX\;?\CMK'_7Q_P"RBL&M[QM_R.VL?]?'_LHK!K]+
MPO\ N]/_  K\CXS$?QI>K"BBBN@Q"BBB@ HHHH **** -'0/^1DTO_K\A_\
M0Q7TI7S7H'_(R:7_ -?D/_H8KZ4KY'B3^)3]&?09-\$O4*Y#XI?\DQ\0?]>I
M_F*Z^N0^*7_),?$'_7J?YBOGJ7\2/JCV'L?)=%%%?2' %%%% !1110 4444
M%%%% 'M_[._^M\1?2W_]J5[I7A?[._\ K?$7TM__ &I7NE>#C?X\OE^1V4O@
M04445RF@4444 %%%% !1110 4444 %%%% !1110!YI\8WV:7I/O</_Z :\:F
MG]Z]<^-S[-)T?WN7_P#0#7B,T_O7H8:%X)F%1ZCYI^O-9\T_O3)I^M4I)"QK
MT(4S%L=),2>*AHHK=*Q 4444P"BBB@ KZF^#/_)+=+_WY_\ T:]?+-?4WP9_
MY);I?^_/_P"C7K@S#^$O7_,VH?$=[1117C'4?.OC'_D<]8_Z^6_I6)6WXQ_Y
M'/6/^OEOZ5B5^F87^!#T7Y'QE?\ BR]6%%%%;F(4444 %%%% !1110!J>&O^
M1ITC_K\B_P#0Q7TC7S=X:_Y&G2/^OR+_ -#%?2-?(<2?Q:?H_P SZ#)O@EZA
M7F_QR_Y)I/\ ]?4'_H5>D5YO\<O^2:3_ /7U!_Z%7@X?^+'U/7ELSYDHHHKZ
M(X0HHHH **** "BBB@ HHHH ^A_V??\ D3]4_P"P@?\ T6E>N5Y'^S[_ ,B?
MJG_80/\ Z+2O7*^?Q7\:1VT_A04445SEA1110 4444 %%%% !1110 4444 %
M%%% 'F_Q,_Y".G?]<9/YK7#UW'Q,_P"0CIW_ %QD_FM</5(0444UW"#FF(5F
M"C)JC<76,\U'<W77FLBYN^O-;TZ39$I$MS==>:Q[F[Z\U'<W77FLFXN220#7
MH4J)C*0^XNLY&:HLQ8Y-!))R:2NR,4C-NX5]5?![_DEFB_27_P!&O7RK7U5\
M'O\ DEFB_27_ -&O7%F/\)>O^9K0^([FBBBO&.H^8]1_Y"M[_P!?$G_H1JM5
MG4?^0K>_]?$G_H1JM7ZA#X4?$3^)A1115DA1110 4444 %%%% '3?#[_ )'O
M2_\ >?\ ]%M7O]> ?#[_ )'O2_\ >?\ ]%M7O]?&<1_[S'_#^K/H\G_@/U_1
M!7F?QV_Y)PW_ %^P_P S7IE>9_';_DG#?]?L/\S7BX?^+'U/4G\+/FBBBBOH
MCA"BBB@ HHHH **** "BBB@#Z,_9_P#^1'O_ /L(O_Z+CKU>O*/V?_\ D1[_
M /["+_\ HN.O5Z^?Q7\:1VT_A04445SEA1110 4444 %%%% !1110 4444 %
M%%% !1110 5X+^TQ_P >?AO_ *Z7'\HZ]ZK,UCPYHOB 0C6-+M;X0Y\K[1$'
MV9QG&>F<#\J .&^ O_)*[/\ Z^)O_0ZE^*7Q-N/AY+IB0:9%>B]60DO*4V[=
MOH#G[WZ5W>F:3I^BV2V>F6<-I;*2PBA0*H)ZG JMK'AK1/$#0MK&E6E\801&
M;B(/LSC.,^N!^5 '/:YXCUR?X3CQ)H4$::F]G%>"$KY@"G#. .^%S^5>5^#?
MVA;N*]G3Q?'YULZCRI+. !HV&<Y&1D'],5]"6MK;V-I#:6L*0V\*!(XXQA44
M#  '85RNJ_"SP3K-RUS>>'[;SG;<SPLT6X^IV$9H ^<_'WBJZ^*_CBRBTBPF
M"!1;6<+<NV3DLV.!U_ "OJGPYH\?A_PWIVD1MN6SMTAW?WB!R?Q.35;0/!OA
MWPN"=&TBVM'8;6D5<N1Z%CD_K6Y0 4444 %%%% 'S!>?\?\ <_\ 79__ $(U
M#4UY_P ?]S_UV?\ ]"-0U^HQ^%'Q$OB844451(4444 %%%% !1110!U/PY_Y
M'S3O^VG_ *+:O?*\#^'/_(^:=_VT_P#1;5[Y7Q?$?^]1_P *_-GTF3_P'Z_H
M@KS#X]?\D[3_ *_X?Y-7I]>8?'K_ ))VG_7_  _R:O'PW\:/J>G/X6?-=%%%
M?0G"%%%% !1110 4444 %%%% 'TA\ O^2?W/_82E_P#0(Z]3KRSX!?\ )/[G
M_L)2_P#H$=>IU\]BOXTO4[H?"@HHHK H**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBJ]Y?6FGVYN+VZ@MH5ZR32!%'XF@"
MQ15+3M9TO5T9]-U*TO57[QMIUD ^NTFKM !1110 4444 %%%% !1110 4444
M %%%% 'CO[0O_(N:-_U^M_Z+:OGZOH']H7_D7-&_Z_6_]%M7S]7N8'^"CDK?
M$%%%%=AD%%%% !1110 4444 %?4/P4_Y)?8?]=I__1K5\O5]0_!3_DE]A_UV
MG_\ 1K5PYA_"7J;4/B/0J***\4ZCYX\;?\CMK'_7Q_[**P:WO&W_ ".VL?\
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M2_\ ?G_]&O7!F'\)>O\ F;4/B.]HHHKQCJ/G7QC_ ,CGK'_7RW]*Q*V_&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 1F5$9V("J,DGL*^==$TR;XY>/M4U'5KNX3P]IS;8+>)L9!)" 9Z$A2S
M'&>WICW+Q=,]OX,UR:,D/'I\[*1V(C;%>9_LX1HO@G4Y /G;4""?4"-,?S-
M&!\1/ATGPU@M?&/@RZNK1K694GB:0N &X!R>2"< @Y!S7MOA?7(_$OA?3=9B
M4*+N!9"@.=K=&7\""/PK"^+<2R_"OQ K]!;AOQ#J1^HK(^ \[3?"NR1ND4\R
M#Z;R?ZT >ET444 %%%% !14<L\,./-E2//3>P&:C^W6?_/U!_P!_!0!8HJO]
MNL_^?J#_ +^"C[=9_P#/U!_W\% %BBJ_VZS_ .?J#_OX*/MUG_S]0?\ ?P4
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M]_!1]NL_^?J#_OX* +%%5_MUG_S]0?\ ?P4?;K/_ )^H/^_@H L457^W6?\
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M^"N<LL457^W6?_/U!_W\%'VZS_Y^H/\ OX* +%%5_MUG_P _4'_?P4?;K/\
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MXX\0:IH^HV<5A<B))(F9@8U;)! [BN7_ .$W\1?\_P"/^_*?X5I?$>:*;5;
MQ2HX$#@E6!Q\PKC,CU%4A7.A_P"$W\1?\_X_[\I_A1_PF_B+_G_'_?E/\*Y[
M(]106 &21185SH?^$W\1?\_Z_P#?E/\ "JES\1/$$(.W4%S_ -<4_P *YF\O
M=JD*&_ 5S=]>R'.(Y#]$-=%*CS/4B4['6W?Q6\4Q9V:H@_[=X_\ "L6X^,?C
M4,1'K"#_ +=8O_B:XNYDN)6.(9L?]<S_ (56\B;_ )X2_P#?L_X5Z=/#4TM4
MC!SET.U_X7%X[_Z#:_\ @)%_\31_PN+QW_T&U_\  2+_ .)KB?(F_P">$O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,_7;$ZGX>U*P7[UU:RPCZLA']:\@
M_9POU&BZWH\GR7-O="8H>&PR[3Q[%/UKV^O&O%/PN\1:7XOF\6?#Z_CMKJX)
M:XM'8*&)Y;&1M()YVMT/(]@#H_C9J<6G?"W5$=]LEV8[>(?WB6!(_P"^5:I?
M@UILFF?"S1TE7:\ZO<8]G<E?_'<5Q$?PU\=^/-;M+KXA:A%%IUJV1:0,I+>H
M 3Y1GNQ).*]QAACMX(X845(HU"(BC 4 8 % #Z*** "BBB@"K>:98:CL^VV=
MO<[,[/.C#[<]<9^E5?\ A&M"_P"@-8?^ Z?X5J447%9&7_PC6A?] :P_\!T_
MPH_X1K0O^@-8?^ Z?X5J44[A9&7_ ,(UH7_0&L/_  '3_"C_ (1K0O\ H#6'
M_@.G^%:E%%PLC+_X1K0O^@-8?^ Z?X4?\(UH7_0&L/\ P'3_  K4HHN%D9B^
M'=$0Y32;%2?2!1_2G_V#I'_0,L_^_*_X5H44@LC/_L'2/^@99_\ ?E?\*/[!
MTC_H&6?_ 'Y7_"M"B@+(S_[!TC_H&6?_ 'Y7_"C^P=(_Z!EG_P!^5_PK0HH"
MR,_^P=(_Z!EG_P!^5_PH_L'2/^@99_\ ?E?\*T** LC/_L'2/^@99_\ ?E?\
M*/[!TC_H&6?_ 'Y7_"M"B@+(S_[!TC_H&6?_ 'Y7_"F-X<T1SEM(L6/J;=3_
M $K3HH"R,O\ X1K0O^@-8?\ @.G^%'_"-:%_T!K#_P !T_PK4HIW"R,T>'M%
M P-)L@/00+_A2_\ "/Z-_P! JR_[\+_A6C12&9W_  C^C?\ 0*LO^_"_X4?\
M(_HW_0*LO^_"_P"%:-% &=_PC^C?] JR_P"_"_X4?\(_HW_0*LO^_"_X5HT4
M 9W_  C^C?\ 0*LO^_"_X4?\(_HW_0*LO^_"_P"%:-% &=_PC^C?] JR_P"_
M"_X4?\(_HW_0*LO^_"_X5HT4 9I\/Z,1@Z598_ZX+_A3?^$:T+_H#6'_ (#I
M_A6I10*R,O\ X1K0O^@-8?\ @.G^% \-Z&I!71[ $=Q;K_A6I11<+(S_ .P=
M(_Z!EG_WY7_"C^P=(_Z!EG_WY7_"M"B@+(S_ .P=(_Z!EG_WY7_"C^P=(_Z!
MEG_WY7_"M"B@+(S_ .P=(_Z!EG_WY7_"C^P=(_Z!EG_WY7_"M"B@+(S_ .P=
M(_Z!EG_WY7_"C^P=(_Z!EG_WY7_"M"B@+(S_ .P=(_Z!EG_WY7_"C^P=(_Z!
MEG_WY7_"M"B@+(S6\.Z*^-^DV38Z9@4_TIO_  C6A?\ 0&L/_ =/\*U**+A9
M&7_PC6A?] :P_P# =/\ "C_A&M"_Z UA_P" Z?X5J44[A9&7_P (UH7_ $!K
M#_P'3_"C_A&M"_Z UA_X#I_A6I11<+(R_P#A&M"_Z UA_P" Z?X4?\(UH7_0
M&L/_  '3_"M2BBX61E_\(UH7_0&L/_ =/\*/^$:T+_H#6'_@.G^%:E%%PLC+
M_P"$:T+_ * UA_X#I_A1_P (UH7_ $!K#_P'3_"M2BBX61E_\(UH7_0&L/\
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M_P"P=(_Z!EG_ -^5_P *8WAS0W.6TBQ)]3;K_A6G10%D9?\ PC6A?] :P_\
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M_"C_ (1K0O\ H#6'_@.G^%:E%%PLC+_X1K0O^@-8?^ Z?X4?\(UH7_0&L/\
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M_H&6?_?E?\*T** LC/\ [!TC_H&6?_?E?\*/[!TC_H&6?_?E?\*T** LC/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0?RR >LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?./QB:X\-_&/1O$MW:-<:>H@D0=F\MOF0>_0_B*^CJS-5M
M-%UN!])U1+.[1^MM,58YQU Z@^XYH QM"^)?A#Q#&C66N6JR,,^3</Y4@]L-
MC/X9JQXF\"^'/&CVLVM61NFM@PA9)G3 ;&?ND9Z"N*UG]GSPCJ!=]/EO=-D)
M) CD\Q!_P%LG'XBO.M:TWQI\#M2LKRSUDWND32%50D^4Y')1XR2%)'<>_- '
MOOC1!'\/]=1<X739@,G)_P!6:\R_9\U?3=/\#ZA'>ZC9VTC:D[!)IU1B/+CY
MP3TKT/Q#J,6L?"K4M2A!$5WI$DR@G. T1./UKQ#X1_"O0/'/AB[U'59;U)X;
MQH%$$BJNT(C=U/.6- 'M_B;QQX6TOP]?3W>KV$R&%U$$<ZNTI*GY0H))STKS
MO]G+0;ZRT;5=8N8WBMKYXTMPPQO";LL/;+8S[&L[QM\#+#P[X?NM>\.W]U]I
MT]?M!@N@DBLJ\MCY1R!D\Y!QBO1?A)XON?&7@>.\O5C%Y;2M;2F- JMM ((4
M<#AATXR#0!YW^T+_ ,C/X3_[:?\ H:5[_7@'[0O_ ",_A/\ [:?^AI7J_CGQ
M+JOA?2;>[TGP_/K4TDXB:" L"B[2=WRJW&0!T[T =17B?[1FJRIH>C:'"Y!O
MKEI'4?Q!   ?Q<'\*O6GQ8\8W%[!#+\--2BCDD5&D+280$X)_P!5VKF/VDO,
M&L>&6B)#^7-L(XYW)B@#T=O'/@GX?:;8^'[S5H89;*!(6@A1I60A1G=M!P3U
MY]:DL-)\!>.=>A\7:>\-_J-JT9$\4[J8V7E=R9'ZCFH_"_PI\-:5H<<>I:7;
M:EJ,Z;KRZNT$K22'EL;LX&?2O,]4TQ?A9\<]'.AF2'2]5,:O;AB5VN^QDYZ@
M'##/3CTH ^BJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \W^.O_)*-1_ZZP?\ HQ:T/@__ ,DHT#_KD_\ Z,>L_P".O_)*-1_ZZP?^
MC%K0^#__ "2C0/\ KD__ *,>@#N*\<_:._Y$;3O^P@O_ *+>O8Z\<_:._P"1
M&T[_ +""_P#HMZ /1O!/_(A>'?\ L&6W_HI:NZWHUEX@T:ZTK4(5EMKF,HP(
MSCT(]"#R#ZBJ7@G_ )$+P[_V#+;_ -%+6[0!\\_ /4+G1?&FO^$;B0M&-[@=
MA+$^QB/3(/\ XZ*^A))$BC:21@J("S,>@ ZFOG7X6/\ VQ\?=>U.V7_1A]JD
MW)]W#2 +^><UZ#\</%)\/> )K2"3;=ZH?LJ8/(3'[P_]\\?\"% '(_#=7^(/
MQ>UOQI<KNL;',5FK#(&053\D#$^[54\!RGX=?'#5?"LIV:?J3;8,],GYX3^1
M*?4TOPT^*7@GP3X+MM+F-^UZ[--=.EL"#(W8'=T  'X5S'Q8\=>'O%6KZ1KG
MAV2[CU.S.UVEAV956W(0<GD-G\Z /JJBL?PKKT/B?PMIVLP8"W4(=E'\+]&7
M\&!'X5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S_\ M"_\
MC3X3_P"!_P#H:5] 5\__ +0O_(T^$_\ @?\ Z&E 'T!1110!\_?%3_DO?A+_
M +=?_1[5] U\_?%3_DO?A+_MU_\ 1[5] T %?/UQ_P G9K]5_P#245] U\_7
M'_)V:_5?_244 ?0->1?'_P +V^I^"_[=2)1>Z:ZYD P6B8[2I]<$@CTY]:]=
MK@?C/>0VGPJUD2L 9A'%&/5BZ_T!/X4 3?"+7IO$/PUTNYN7+W$"M;2,3DL4
M. 3[E=M.^*_BG_A%/ %_<Q/MO+D?9;;!Y#N#EA]%W'\!6)\ +1[;X812OG%S
M=S2KGTX3C\4->=_&?Q38:O\ $O3M%OII!HVDNOVOREW%G;#/@=SMPOL<T ;V
ME_#0S?L]3P-#G5;I?[50$?,& RB_C'D?5S73? CQ1_;O@-=/F?-UI3^0<]3$
M>4/Y97_@-1)\?_ T<:QH-15%& HM1@#T^]7F'PY\6:9H7QFG_LN60:%J\S0*
M)5V%-YRF1GLWRY]": /<_BKI=YK'PSUNSL(VDN#$KK&HR7".K$ =SA3Q7F/P
M4^)?AO0_#/\ PC^L7 T^X2=Y$FD!\N4-SRPZ$=.?:O?)IX;>/S)Y4B3.-SL%
M'YFN*UWX5^"?%DC7LVG1I-*23<V4GEESZG'RD^^* .HBN])\1:=/%;W=M?6L
M\9CD\B8."K#!&5/'!JAX7\%:#X-BN8]"M'MDN2K2JTSR9*YP?F)QU/2O(=9_
M9^OM)5[_ ,(>(+D7,8+)#*?+=L=ED3'/U ^M=!\$/B#JGBB"_P!&UR0S7U@J
MND[##NA."&]2#CGOGVH ]>HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P/'/_ "(7B#_L
M'S_^@&O,/V?-7TS3_ U_'>ZC9VTC:B[!)IU1B/+CYP3TKT_QS_R(7B#_ +!\
M_P#Z :\$^$?PKT#QSX7N]1U6:]2>*\:!1!(JKM"(W=3SEC0![=XG\<>%M+\.
MWTUWJ]A,AA=1!'.KM*2I^4*"2<]*\]_9RT&^L=%U75[F-XK>^>-+<,,;PF[+
M#VRV,^QK-\;? RP\.>'[K7_#NH77VC3U^T&"Z"2*RKRV/E'(&3SD'&*]&^$G
MB^Y\9>!XKR]6,7EM*UM*8U"JVT @A1P.&'3C(- #?B#\2[?P9+;:996;ZGKM
MYCR+*,G@$X!;&3R> !R?:N:N_%GQ@TFR?5[[PKI4EC&IDDMX7)E1?4X<GCV!
MKB;W6]5MOVA]7U&QT-]<O+0O'#:JVTHH14W X/0'T[UWQ^)/CX@@_"V](/4&
MY/\ \10!V?@7QMI_COP^-3LD:&1'\N>W<Y:)^N,]P1R#_P#7KE_&GQ:'@WQY
M9Z'=64)T^2%)IKLNVY%);.% Y/R\?6L/X&:#K^AZOXA.J:/<Z9:77ER112IA
M<[FX!]@<5B?$R"*Z_:&\,03QK)%(;171AD,/.;@T ='>>-_BK?6QU71?!4$.
MEXWI'<G=/(G8[ ZG)'8#\Z=H_P =[74O#CM_9,K^)/.%O#I4!+&=SG# XR%&
M#GC(]\U[!7S_ /#.QMS^T#XKD\I0;<W1B '"DR@$CTX)'XF@#3U?XA?%7PU
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MV2?R'Y5Y]^TC&GG>%I-HWEYU+8YQ^[X_4T >]T4U/]6OT%.H **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!A0?=FQ^=>8? KPJFKV^K^+M<MHKN:_G9(C/&'!YW2/@^K''_ 37M]U:6U]
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MD1>:1=^W<<&0COC.?3UJAICZU>P6=_X4^)4.MZ@75KBQOVC6.5<98! -T9H
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M!D_A7CFO^)+CPQHC:K8_%*/5-=MRAN-/9HI()R2 RHBC*XR3G.<#M0![O17
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M[]K6,QL3O +#)SWXKKYY#%;RR  E$+ 'O@5Y7\&/^0KXZ_[#4G_H35ZC>?\
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MMHBLL<A(5LNJ\X^M.\'Z7K.C^'H[/7M5_M._5V9KGGD$\#GTK%^,'_)*-?\
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MJVI:S\:&TNSO9HM(T6Q$EY%&PVRSR9VJWT4@_530!Z!139)%AB>5SA$4LQ]
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M_AC1OL?GB]1 &N9,_=$C#" <_E[BMOPWI_B27^U;*7Q7%JNASP;;'4X9$-U
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MV]\E[])E:.3F(G@;V'?:"6Q[59U[4]9^&/P^OKZ^UQ]<U.>X5+::ZB$:1,X
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M-<P*9(R 6!!R#]:SO%.F^.]"\-7/BL^,W:_M8Q<36"VRBUV]T4=>,]3R<=J
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M;F/S=\,Z%'7,C$9!Y'%7/B1X7G\8>![[2;1U2Z;;+!N. 74Y )[9Z?C75T4
M><6WC;Q%<Z(-*7P5K4?B 0>2S2Q*MHLFW&_SB<%<\X&3VK*\&:1JEK^S_JFE
MW.G7<6H&VO46VDA99'9@VW"D9.<C%>N44 >;V5KXKL/@II,.@VZQZW;VL>ZU
MNXN7 ^\F&Q@X]?3'>N*\3:2/&5M;V^@?#G4M$\1>>COJ#VXM8H"#\QW@C?\
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M%/X'%6:* /$/!9O_  QH_P#84_PWOKGQ$6DWW[PHT%PQ8D.\YZ#GGK[=:O\
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MPQ'97 EO[NY@%J)(^"8Q'GYL\C('?TJYJVI:EI/[05U=Z=IDFI*NC)]IMH6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img76291469_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1""T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA<I/%G!*]CZ$=1534_%&C:1<?9[V^1)\9\M068#W !Q18+HUZ:'1F*AE+#J
M>E4],UC3]8A:73[J.=5.&VGE3[@\BLG1K#1;?Q/JL]C>M+J#G_2H2P(CR<],
M<4[!<Z2BL[5-=TS155M0O(X"_P!U3DLWT YJ+2_$NCZQ*8;&^CDF SY9!5L?
M0XI6"ZV-:BJFH:I8Z5$DM]<QP1NX16<]6/:LVZ\9>'[*\:UGU*,2H=KA59@I
M]"0,46"Z1NT4R&:.XA2:&19(W&Y74Y!'J#3Z!A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 (S*B%F8*H&22> *R!JUW?,?[,M!)$#CS
MYCM4_0=32ZP#=W=GIFXB.8EYL=T7M^)K51%C1410JJ, #H!3%N9?_$__ .G#
M_P >H_XG_P#TX?\ CU:U%%PL9/\ Q/\ _IP_\>H_XG__ $X?^/5K447"QD_\
M3_\ Z</_ !ZC_B?_ /3A_P"/5K447"QD_P#$_P#^G#_QZC_B?_\ 3A_X]6M1
M1<+&3_Q/_P#IP_\ 'J/^)_\ ].'_ (]6M11<+&3_ ,3_ /Z</_'J/^)__P!.
M'_CU:U%%PL9/_$__ .G#_P >H_XG_P#TX?\ CU:U%%PL9/\ Q/\ _IP_\>H_
MXG__ $X?^/5K447"QD_\3_\ Z</_ !ZC_B?_ /3A_P"/5K447"QD_P#$_P#^
MG#_QZC_B?_\ 3A_X]6M11<+&3_Q/_P#IP_\ 'J/^)_\ ].'_ (]6M11<+&3_
M ,3_ /Z</_'J/^)__P!.'_CU:U%%PL9/_$__ .G#_P >H_XG_P#TX?\ CU:U
M%%PL9/\ Q/\ _IP_\>H_XG__ $X?^/5K447"QD_\3_\ Z</_ !ZC_B?_ /3A
M_P"/5K447"QD_P#$_P#^G#_QZC_B?_\ 3A_X]6M11<+&3_Q/_P#IP_\ 'J/^
M)_\ ].'_ (]6M11<+&3_ ,3_ /Z</_'J/^)__P!.'_CU:U%%PL9/_$__ .G#
M_P >H_XG_P#TX?\ CU:U%%PL9/\ Q/\ _IP_\>H_XG__ $X?^/5K447"QD_\
M3_\ Z</_ !ZC_B?_ /3A_P"/5K447"QD_P#$_P#^G#_QZC_B?_\ 3A_X]6M1
M1<+&3_Q/_P#IP_\ 'J/^)]D?\>'_ (]6M11<+!7"_$G[FB_]??\ A7=5R7CK
M1]1U:'3O[.MQ.\$YD8%PN!CCJ:([BGL=;7 ^)B)OB1X?BBYD3:S =AN)_D#5
MZ34_'#J5BT&RC8]&:X#8_#-2>&O#%Y:ZG-K>MSK/J<HPH7E8P>OXXXXX IK0
M3=]$4#;IK?Q0GCO0)8-/MPT43#*Y^7G'U;/X"K_C[2[:?PU->"-8[FTVR12H
M,,.0,9_&F:[H^IV?B*+Q%HD:SR[/+N;9FV^8OJ#],?D*JZL_B+Q7;+I<>CR:
M9;.P-Q/<2*3@'. !U_STH["Z-%?Q7>2:A\+K2[F_UDHB9CZGN:[C3_\ D%VO
M_7%/_016/K_AP7_A$Z/9D*8D00[C@$KT!^O]:S['5?%#V<.FC0&@N501&\EE
M'E* ,;L#DGVHW0]GJ0?#3_D':E_U]G^0J'P/803>(=>O9$5Y8;IHXRPSMRS$
MD>_3FM/P+H]_HUC>Q7\/EO)<;D^8-N& ,\&LS2;#Q%X?U'5+]--^T6]Q<,6M
MEE4.RY)5U/3O@@^M/N);(=XYA33];T/5K91'=&Y$;LHQO''7\,C\:F\5?\CU
MX8_ZZ-_,4TV&L>*O$%E=ZE8'3],LFWI#*P9Y&X/./H/P^M7_ !!I%]>^+-!O
M;>#?;VKDS/O VC(['D_A0%MS*\;3/-XJT:R>SEO8(U,YM(\9E;GUXXQ^6:9X
MBNKO7=%DL1X1U&*3@PR,J8C(/L?3BMKQ5HM_<WEAK.DA&O[%C^Z<X$J'J,_G
M^=4;_4/%&N6HT^ST:XTJ20CS;N68 (,\[<<T+H#6K-!M;O\ 2-$TKSM'OKVY
ME@ F$*@F-@!G=[G/Z5;TG6YM8AN_-TF\L/*48^TJ!OR#T^F*U;6$VUI# TKR
MF- ID<Y9B!U/N:?("T3@=2I J2[,\P\&Z%J&J:1+-::]=:?&MPRF*%<@G ^;
MKUY_2I[JRG\&Z_::IJ,@U:&=_*^T39\V$^H&2.F?UZ5/X?M_%WAZP>T@T."9
M7E,I9[E0<D 8X/M4]SHOB3Q3J-K_ &U!;V.GV[[S''(&9C^'<]/;FJOJ9):>
M9+\13F+12/\ G^7^E3?$S_D55_Z^H_ZU/XTTB^U5-+%C )?(NEDD^<+M4=^:
ME\<Z5>ZQX?6VL(?.F$Z/MW!>!G/)I+H4T]2#QP<>!93[1?S%7?#>D6$?A>TB
M^RQ.L\"O*74$R,PR2?7K3/%>F7FI>$I+*TA\RY(CPFX#H1GD\5JZ/!+:Z+96
M\R[98X$1USG!  -+H5;WCD/A])]DL==C!)AMKIRB>@ /^ J3X=VL=W8WFLW"
MB6\N;E@TC#) X.!Z=3^E7?!NC7VEG5Q?VXC%Q=-)'\X;<ISSP>*H:;;ZUX.N
MKJT@TN74],FD,D+0.H=">Q!]L?E5/J2M+7(-;TZVL?B/HDUM&L?VEMTBJ, L
M.,X]P?TKT&N$FTOQ!J?BW2M8NK)(8(V_U(E4F!!G[Q[DYSQTKNZEE1ZA7#Z!
M_P E,\0_]<U_]DKN*Y71]'O[7QUK.HS0;;2X0"*3>#N/R]NHZ&A!+=&[J_\
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M_P#'J/\ B?\ _3A_X]6M11<+&3_Q/_\ IP_\>H_XG_\ TX?^/5K447"QD_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &9-;S-XBM;@1DPK ZL_8$D8%:=%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69KEO-<V420Q
MEV$\;$#T!Y-:=% /4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% $4=Q#+-+$DBM)%@.HZKGI4M9.G?\AO5O\ >C_]!K6H$@HH
MHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!P7Q'_U4/T'_H5>>5Z'\1_]5#]!_P"A5YY5$A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X+XC_P"JA^@_
M]"KSRO0_B/\ ZJ'Z#_T*O/*HD*.E%7-) .M6 (!!N8\@_P"\* */F)_?7\Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%  *:U.%-:@"-JB:I6J)J $BGDMI1+$V&'Y$>AK>M
M;J*_B)4;9!]Y/3Z>U<ZU-61X9%DC8JZG((H Z&6'VJNB[;NV_P"N\?\ Z$*G
ML=0COTV-A+@#E>S>X_PITD>VXMC_ -/$?_H0J)_"S?#?QH^I[A1113,@HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R=.
M_P"0WJW^]'_Z#6M63IW_ "&]6_WH_P#T&M:FQ(****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ."^(_^JA^@_P#0
MJ\\KT/XC_P"JA^@_]"KSRJ)"KFD?\AO3_P#KYC_]"%4ZN:1_R&]/_P"OF/\
M]"% 'K'BW2KK6=":TM AE,B-\[8& >:Q?"/@Z[T?4FO[^2+>(RD<<9)ZXR2?
MPK9\7ZC=Z5X>ENK*01SJZ ,5#<$X/!KSF7QGXAFC,;:B5![QQ*I_,"D,V_'^
MH1W&OZ;8QL&-LZM)C^%F9<#\AG\170?$'_D4Y?\ KM'_ .A"O+(&9[Z!F8LS
M3H2S'))W#DFO4_B#_P BG+_UVC_]"% '*>#[3P^(I+W6;JU\X/MB@G< *!_$
M0>N:WM.\0^'M;UQ]'32H"K;Q'+Y:%9-O7@<@8SBJG@SPM8RZ6NKZE$LYDRT:
M.,HB@XSCN3@U>T/Q=8:IKT5C8Z2(HV#%)_E!V@=< <9^O>@#E/&FA0:%J4;6
M@*VUPA=8\YV,#R![<BNIT;PUIGA_1#JNK1)-.L7FR%UW",8^ZH/?MGUJA\2R
M%N])8] 7)^F5KI?&/[SP?J)3Y@8@W'ID'^5 %&PBT#QII$C+IPMV1RAPBI)&
MV,@@K[$5Q>D>%Y;[Q1/I,\A$=HQ,\B<$J#QCT)R/IS5+2='U?5(Y7TM)&2-@
MLA2?R^<9]1GBNP^'L$EIJ>LVMV"+V/RPX9MQQSW[]: +6HZKX6\*SIIITU7<
M*&<1PJY4'N2>2:K>*_#%A=:.=:TB-$94$S+$,++'C)..QQS5G7?$6@6.LSVU
M_HQGN4"[I3"C;@1QR3G_ /51-XMMGT:2.+0M22T: JK" ",*5QG(. * )?AS
M_P BR_\ U\O_ "%5;O7/"VB:Q=6\EBT\[RE[F?R@^&/)Y//&>@Z59^&XQX78
M>ER_\A7G>NQR0:[J23G+BXD+$\9!.0?R(H [OQ=X6L;C2I-6TR)(Y8T\UA$,
M+*F,DXZ9QSFN>\&^&8]>N)+F[S]B@(!0''FMUQGT Z_6N]T_,7@B'[1P%L,M
MD=!L_P *ROAJZ'PNR+C>L[;_ ,0,?IB@!FH>(?"^AWK:=_9BOY.!(8K=2$[X
MYY)J'Q/X3T^[TEM7TB-8Y%C\[9&,)*F,GCL<<\5Q/B!6C\1:H) 01<N3GT)R
M#^5>HZ(IM? UK]I&W99;G#'MM)_E0!X\#D9%6+&SDU'4+>RA($D\@0$]!ZG\
M!DU5C_U:\8XZ>E;W@YUC\7:>7( +,HSZE3BF([NZM?#_ (.T<22V:2DD(-R!
MY)7^I_\ U"JV@VWAGQ'<37\&G(DRJ$FMI4&T$\A@.GJ,BJOQ-20VFFR#/EK*
MZM]2O'\C5#X:(YU:_< [! JD]LECC^M(9+JEKI>G_$*PM6L+;[%-"$>+8-NY
MB0&QZY I?'^B6=A96=U8VD5NOFF.3RU"YR,C/Y'\ZH?$0LOBB-D.&6W0J?0A
MCBNKU=3XG\ F6W7?-+"LL8 _C!&1^8(H H>"_#VGS>'4N[^S@GDGD9E:5 <+
MG '/TS^-<_X\TJ#2=7ADM85AMYX<A47"AE/./P(KH_&-S_8'A;3[&V;;()(P
MN.XCPQ_4#\ZN>)],'B32M*FMUW9N(GR.T;_>_0C\J *L&CZ5I'@I+Z]TZVFN
M([;S6:2,$LYY /XD"D^&N?[#N\]?M)SC_=6H?B1?B*QM-,C(!E?S' _NKT_7
M^53?#7_D"7?_ %\G_P!!6@"AI?AH:QXQU:]NTS8P7;@*1Q*_I]!W]_QK.\9W
M6DPW)TO2["UC>,_OYXXP"#_<!_G^7K7?:9J4&IG4K1!Y,UK</#($.#ST<?7/
MY@UY%J^ESZ-JDUC<99D.Y9#_ ,M%/1O\??- %*BG+'*XRD4KCU5"1^E-(()!
M!!'4'M3$-D)$;$=<&O2=5T[P_IFA:?J=W81L452(8E"_:'*\!CZ#DUYM)_JG
M_P!TUWOCK_D6]!_#_P!%TADVC:]I'B*\&E7FA6T/G*?+9 ",@9QP 0<=Q7*Z
MOH;V'B9](MCYA>11!N/4-T!/Z9]JF\&_\C=I_P!7_P#035WQA%//X],-L=MQ
M((5B.[;AB..>U $'_"!^(O\ GU@_[_BC_A _$7_/K!_W_%7_ /A&?&O_ #^O
M_P"!S4?\(SXU_P"?U_\ P-:@#G-5T:^T6:.&_C1'E4LH5PV0.#41N[F[N+);
MB>2587C2)6/"*"  !5O7M/U;3KF"/5YC+*Z$QDS&3"@\\GIS6;!_Q]0?]=4_
M]"%,1V?Q,_Y"FG?]<'_]"%8/AC6DT'6ENYE+0,ACEVC)"DCD?0@5O?$S_D*:
M=_UP?_T(54^'^GP7NO2RW"!_LL0=%89&XG&?PY_.D,TM6\$RZS?/JFE7D1M[
ML^:5F5E*D]2..G?! IUV]MX(\-S:8LC7&HWH8EO+(09&,YZ8 [=37.^(M=U.
M[UR[5KN>*.&9DCBC<J$"G';J>^:ZGPS/+XE\)ZA9ZJWGB%BB32<M]W(.?4'O
M0!7\%K]E\%ZQ=)@/^\P>_P L?%>?H/W:CVKT#P*3>^%-7T]6!D.[ Q_?3 /Y
M@UY^#MC^88*CD'L10!WVL/\ :?A7ITSCYE,6/P.W^5<'7>^(HQIWPWTRQDR)
M7,7RGKG[Q_*N"H0!1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  *:U.%
M-:@"-JB:I6J)J (FJ)JE:HFH CW,C!E8JRG((/(-;=IJPO#;Q3+_ *0D\;9
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M#& /7VKCJ*8CH;+Q(-/\87.K0AS:7,K>8A'S&,^WJ.O_ .NK_BWQ%H>OV2-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444  IK4X4UJ (VJ)JE:HFH B:EM[66[F$<
M0Y[L>BCU-3VMG)>2;4^5!]YST'_UZW8XXK2$11#"CJ>['U- #+:VAL(2D0RQ
M^^YZM_\ 6ICR;[BV'_3Q'_Z$*;++SUJ&-LWEM_UWC_\ 0A43^%F^&_C1]3WF
MLG0?]1=_]?4E:U9.@?ZB[_Z^I*HQZFM1112&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9.G?\AO5O]Z/_P!!K6K)T[_D-ZM_
MO1_^@UK4V)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!P7Q'_ -5#]!_Z%7GE>A_$?_50_0?^A5YY5$A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>"HTYT[R5]3"K-Q>AZO_ ,- ^*/^@5H__?,O_P 71_PT#XH_Z!6C_P#?,O\
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M /%UY111]5H_RA[27<]7_P"&@?%'_0*T?_OF7_XNC_AH'Q1_T"M'_P"^9?\
MXNO***/JM'^4/:2[GJ__  T#XH_Z!6C_ /?,O_Q='_#0/BC_ *!6C_\ ?,O_
M ,77E%%'U6C_ "A[27<]7_X:!\4?] K1_P#OF7_XNC_AH'Q1_P! K1_^^9?_
M (NO***/JM'^4/:2[GJ__#0/BC_H%:/_ -\R_P#Q='_#0/BC_H%:/_WS+_\
M%UY111]5H_RA[27<]7_X:!\4?] K1_\ OF7_ .+H_P"&@?%'_0*T?_OF7_XN
MO***/JM'^4/:2[GJ_P#PT#XH_P"@5H__ 'S+_P#%T?\ #0/BC_H%:/\ ]\R_
M_%UY111]5H_RA[27<]7_ .&@?%'_ $"M'_[YE_\ BZ/^&@?%'_0*T?\ [YE_
M^+KRBBCZK1_E#VDNYZO_ ,- ^*/^@5H__?,O_P 71_PT#XH_Z!6C_P#?,O\
M\77E%%'U6C_*'M)=SU?_ (:!\4?] K1_^^9?_BZ/^&@?%'_0*T?_ +YE_P#B
MZ\HHH^JT?Y0]I+N>K_\ #0/BC_H%:/\ ]\R__%T?\- ^*/\ H%:/_P!\R_\
MQ=>444?5:/\ *'M)=SU?_AH'Q1_T"M'_ .^9?_BZ/^&@?%'_ $"M'_[YE_\
MBZ\HHH^JT?Y0]I+N>K_\- ^*/^@5H_\ WS+_ /%T?\- ^*/^@5H__?,O_P 7
M7E%%'U6C_*'M)=SU?_AH'Q1_T"M'_P"^9?\ XNC_ (:!\4?] K1_^^9?_BZ\
MHHH^JT?Y0]I+N>K_ /#0/BC_ *!6C_\ ?,O_ ,71_P - ^*/^@5H_P#WS+_\
M77E%%'U6C_*'M)=SU?\ X:!\4?\ 0*T?_OF7_P"+H_X:!\4?] K1_P#OF7_X
MNO***/JM'^4/:2[GJ_\ PT#XH_Z!6C_]\R__ !='_#0/BC_H%:/_ -\R_P#Q
M=>444?5:/\H>TEW/5_\ AH'Q1_T"M'_[YE_^+H_X:!\4?] K1_\ OF7_ .+K
MRBBCZK1_E#VDNYZO_P - ^*/^@5H_P#WS+_\71_PT#XH_P"@5H__ 'S+_P#%
MUY111]5H_P H>TEW/5_^&@?%'_0*T?\ [YE_^+H_X:!\4?\ 0*T?_OF7_P"+
MKRBBCZK1_E#VDNYZO_PT#XH_Z!6C_P#?,O\ \71_PT#XH_Z!6C_]\R__ !=>
M444?5:/\H>TEW/5_^&@?%'_0*T?_ +YE_P#BZ/\ AH'Q1_T"M'_[YE_^+KRB
MBCZK1_E#VDNYZO\ \- ^*/\ H%:/_P!\R_\ Q='_  T#XH_Z!6C_ /?,O_Q=
M>444?5:/\H>TEW/J_P"'&N7/B;1FUJ[BBBN+M59TA!V#!9>,DGH!7:UYO\%O
M^1&M/^N8_P#0WKTBO#JI*I)+N=4-@HHHK,H**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)UKQ)IF@1J
MU]/AW^[$@W.1ZX';WK1MKA+JUAN(L^7*@=<C!P1D5P/BOPO::;H.KZJ[O<WT
M\@82R?\ +,%Q\JCZ<9KM=%_Y .G_ /7M'_Z"*;2L2F[V9>JIJ.I6>E6C75[.
ML,2]V/)/H!W/M67IFMZA>^)=0TZ?3C#:VX/E7!#?O.0.XQW[4FJ^%K/4]8_M
M2^9YUAAVQVS?<!&3N/KU_2BW<=]-#0T;6;37;$WEEYGE!RG[Q-IR.O'XUH5Q
MWPT.?"K$_P#/R_\ 2NQH>C"+NKA1112&%%%% !1110 4444 %%%% !1110!P
M7Q'($,.?1?\ T*O.]R^HKVFY56\4V88 C[,_!&>XK4\B+_GDG_?(IDV/ MR^
MHHW+ZBO??(B_YY)_WR*/(B_YY)_WR*+CL>!;E]11N7U%>^^1%_SR3_OD4>1%
M_P \D_[Y%%PL>!;E]11N7U%>^^1%_P \D_[Y%'D1?\\D_P"^11<+'@6Y?44;
ME]17OOD1?\\D_P"^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\
M\D_[Y%%PL>!;E]11N7U%>^^1%_SR3_OD4>1%_P \D_[Y%%PL>!;E]11N7U%>
M^^1%_P \D_[Y%'D1?\\D_P"^11<+'@6Y?44;E]17OOD1?\\D_P"^11Y$7_/)
M/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\\D_[Y%%PL>!;E]11N7U%>^^1
M%_SR3_OD4>1%_P \D_[Y%%PL>!;E]11N7U%>^^1%_P \D_[Y%'D1?\\D_P"^
M11<+'@6Y?44;E]17OOD1?\\D_P"^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?
M\\D_[Y%'D1?\\D_[Y%%PL>!;E]11N7U%>^^1%_SR3_OD4>1%_P \D_[Y%%PL
M>!;E]11N7U%>^^1%_P \D_[Y%'D1?\\D_P"^11<+'@6Y?44;E]17OOD1?\\D
M_P"^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\\D_[Y%%PL>!;
ME]11N7U%>^^1%_SR3_OD4>1%_P \D_[Y%%PL>!;E]11N7U%>^^1%_P \D_[Y
M%'D1?\\D_P"^11<+'@6Y?44;E]17OOD1?\\D_P"^11Y$7_/)/^^11<+'@6Y?
M44;E]17OOD1?\\D_[Y%'D1?\\D_[Y%%PL>!;E]11N7U%>^^1%_SR3_OD4>1%
M_P \D_[Y%%PL>!;E]11N7U%>^^1%_P \D_[Y%'D1?\\D_P"^11<+'@6Y?44;
ME]17OOD1?\\D_P"^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\
M\D_[Y%%PL>!;E]11N7U%>^^1%_SR3_OD4>1%_P \D_[Y%%PL>!;E]11N7U%>
M^^1%_P \D_[Y%'D1?\\D_P"^11<+'@6Y?44;E]17OOD1?\\D_P"^11Y$7_/)
M/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\\D_[Y%%PL>!;E]11N7U%>^^1
M%_SR3_OD4>1%_P \D_[Y%%PL>!;E]11N7U%>^^1%_P \D_[Y%'D1?\\D_P"^
M11<+'@6Y?44;E]17OOD1?\\D_P"^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?
M\\D_[Y%'D1?\\D_[Y%%PL>!;E]11N7U%>^^1%_SR3_OD4>1%_P \D_[Y%%PL
M>!;E]106 ZD5[[Y$7_/)/^^17+^ HXW\/S%D4G[;/U'^V:7-K8M4[P<K[6_$
M\JW+ZBC<OJ*]]\B+_GDG_?(H\B+_ )Y)_P!\BG<BQX%N7U%&Y?45[[Y$7_/)
M/^^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\ /)/^^11<+'@6
MY?44;E]17OOD1?\ /)/^^11Y$7_/)/\ OD47"QX%N7U%&Y?45[[Y$7_/)/\
MOD4>1%_SR3_OD47"QX%N7U%&Y?45[[Y$7_/)/^^11Y$7_/)/^^11<+'@6Y?4
M4;E]17OOD1?\\D_[Y%'D1?\ /)/^^11<+'@6Y?44;E]17OOD1?\ /)/^^11Y
M$7_/)/\ OD47"QX%N7U%&Y?45[[Y$7_/)/\ OD4>1%_SR3_OD47"QX%N7U%&
MY?45[[Y$7_/)/^^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\
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MY?44;E]17OOD1?\ /)/^^11Y$7_/)/\ OD47"QX%N7U%&Y?45[[Y$7_/)/\
MOD4>1%_SR3_OD47"QX%N7U%&Y?45[[Y$7_/)/^^11Y$7_/)/^^11<+'@6Y?4
M4;E]17OOD1?\\D_[Y%'D1?\ /)/^^11<+'@6Y?44;E]17OOD1?\ /)/^^11Y
M$7_/)/\ OD47"QX%N7U%&Y?45[[Y$7_/)/\ OD4>1%_SR3_OD47"QX%N7U%&
MY?45[[Y$7_/)/^^11Y$7_/)/^^11<+'@6Y?44;E]17OOD1?\\D_[Y%'D1?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6O61/_R-5G_U[/\ S%:]#&@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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MNH6W1RQG#*?\]N]5Z*F,(Q7*EH-R;=V>G6WQY\7P0+'+#I=PXZRR0LK'ZA6
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M;J5&,T^B@"M+IUC/-YTME;R2_P!]XE+?GBIQ&@D,@10YX+8Y-.HH :(HQ(9
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M^$M\2_\ 0Q:O_P"!LG^-8]%')'L%V;'_  EOB7_H8M7_ / V3_&C_A+?$O\
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M^$M\2_\ 0Q:O_P"!LG^-8]%')'L%V;'_  EOB7_H8M7_ / V3_&C_A+?$O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#$5]&T4?7JW</91/G+_AG[Q1_T%='_ .^I?_B*/^&?O%'_ $%='_[ZE_\
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M?_OJ7_XBC_AG[Q1_T%='_P"^I?\ XBOHVBCZ]6[A[*)\Y?\ #/WBC_H*Z/\
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M!^H[UC7L'C/7K(:3=V=K9PN0+BZ60'>H] #W_P XKO**+@XW*]C9Q:?806<
MQ%"@1?H*L444B@HHHH **** "BBB@ HHHH \D^/'_(JC_KI%_P"AFOG:OHGX
M\?\ (JC_ *Z1?^AFOG:O:P'\+YG)6^(****[3(W_  3X</BOQAI^CMO$$KE[
MAD."L2C+8/8]A[D5[9?_  $\-?V=<_8)]2%YY3>09+@%=^/ER-O3.*R?V?=
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M)->\=,IQ3L^AZ_\ '[0/M?AVQUV)?WEA-Y4I'_/.3 Y^C!?SKAO@.JCXC2$
M9^P2\X_VDKUW3-2L/'OPKCBOKN!9K^Q,,WF2 %9@-I;';YAG\J\1^$^M6GA?
MXAHVKRI;Q/%+:22NWRQOD8R?3*XSTYJJ+DZ$Z;W0I?&I'3?M#JK>(M$RH/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX')P!^%<?14.G%R4WNBN9VL%!&1@]***LD0 *,  #VH*ANH!^HI:* "BBB@
MHHHH 0@$8(R/>@  8 P*6B@ (!&",BGB:8)L$\P3&-HD;&/IFF44!<0  8
M'M2D C!&:** '/))( ))9' Y =RP'YTVBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!1UI*4=:2@!#2&E-2V]M+=S"*%=S'J>P'J:EC(HHI)Y5B
MB0N[< "NDL;"+3$WL0]R1R_9?8?XU);6T.FPE4^:5A\\AZGV'H*J7-UG/-9V
MNRMA]S==>:O^"Y3)XMM?\_Q+7-2RECUK>\!G/BVV_#_T):SQ2MAY^AT8+_>(
M>I]>T445X1J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &3IW_(;U;_>C_P#0:UJR=._Y#>K?[T?_ *#6M38D%%%%(844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'DGQX_Y%4?\ 72+_ -#-?.U?1/QX_P"15'_72+_T,U\[5[6 _A?,Y*WQ!111
M7:9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 *.M)2CK3HT
MWMC.!W- #[:UDNY=B<#^)CT6NAB6&Q@\J$=?O,>K'WJA!*D,01!@"HYKDGO6
M;NRMB6YNLD\UG22EC39)"341.:M*PK@3FNE\!?\ (VVWX?\ H2US-=-X"_Y&
MVV_#_P!"6N?&?P)^ATX+_>(>I]?4445X)L%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &3IW_ "&]6_WH_P#T&M:LG3O^
M0WJW^]'_ .@UK4V)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!RWB;0=.\3:I;:7JT!GLWB,AC#LGS*>#E2#W
MK*_X4QX$_P"@._\ X%R__%5T]Q_R-5G_ ->S_P Q6O6BJSBK1;1/*GNC@?\
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M  +E_P#BJ/\ A3'@3_H#O_X%R_\ Q5=]11[>K_,_O#DCV.!_X4QX$_Z [_\
M@7+_ /%4?\*8\"?] =__  +E_P#BJ[ZBCV]7^9_>')'L<#_PICP)_P! =_\
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M !5=]11[>K_,_O#DCV.!_P"%,>!/^@.__@7+_P#%4?\ "F/ G_0'?_P+E_\
MBJ[ZBCV]7^9_>')'L<#_ ,*8\"?] =__  +E_P#BJ/\ A3'@3_H#O_X%R_\
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M_F?WAR1[' _\*8\"?] =_P#P+E_^*H_X4QX$_P"@._\ X%R__%5WU%'MZO\
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M_A3'@3_H#O\ ^!<O_P 51_PICP)_T!W_ / N7_XJN^HH]O5_F?WAR1[' _\
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M!<O_ ,51_P *8\"?] =__ N7_P"*KOJ*/;U?YG]X<D>QP/\ PICP)_T!W_\
M N7_ .*H_P"%,>!/^@.__@7+_P#%5WU%'MZO\S^\.2/8X'_A3'@3_H#O_P"!
M<O\ \51_PICP)_T!W_\  N7_ .*KOJ*/;U?YG]X<D>QP/_"F/ G_ $!W_P#
MN7_XJC_A3'@3_H#O_P"!<O\ \57?44>WJ_S/[PY(]C@?^%,>!/\ H#O_ .!<
MO_Q5'_"F/ G_ $!W_P# N7_XJN^HH]O5_F?WAR1[' _\*8\"?] =_P#P+E_^
M*IP^#7@4=-'?_P "I?\ XJN\HH]O5_F?WAR1['"_\*>\#_\ 0(?_ ,"I?_BJ
M:?@WX&/72'_\"I?_ (JN\HH]O5_F?WAR1['!?\*9\"?] =__  +E_P#BJ3_A
M3'@3_H#O_P"!<O\ \57?44>WJ_S/[PY(]C@?^%,>!/\ H#O_ .!<O_Q59FN?
M#SPQX5MK74M'T]K>Z^UPQ;S/(_RLXR,,2*]1KA?B+?2*EC8P)O9&-[(H_N1X
MQ^I_2HJUZC@TY/[SIPE-.O&R.ZHJ*VN$N[6&XB.8Y4#J?8C-2U)@U;0****
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M57_M"R_Y^[?_ +^#_&@7]F2 +N DG 'F#D_G5W,.5]BQ1110(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#)T[_ )#>K?[T?_H-:U9.
MG?\ (;U;_>C_ /0:UJ;$@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH R+C_D:K/_KV?^8K7K UFZ.G:S:WK1,\
M8B:/@XY)J/\ X2V/_GRD_P"^Q3L3=(Z.BN<_X2V/_GRD_P"^Q1_PEL?_ #Y2
M?]]BBS#F1T=%<Y_PEL?_ #Y2?]]BC_A+8_\ GRD_[[%%F',CHZ*YS_A+8_\
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M/^^Q19AS(Z.BN<_X2V/_ )\I/^^Q1_PEL?\ SY2?]]BBS#F1T=%<Y_PEL?\
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MT5SG_"6Q_P#/E)_WV*/^$MC_ .?*3_OL468<R.CHKG/^$MC_ .?*3_OL4?\
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M7MX  +VZ '  G;C]:='=ZA-*D45U>R2.=JHDSDL?0#-,MK66\G$,(&X\Y)P
M/6N^\/OIGA^/='8R37;##W#L,_1?05I"G*9QXG%4J"L]7V+7AGP?=0F.]UF\
MN9)1\R6OVABJ_P"]SR?;I]:[:N<_X2V/_GRD_P"^Q1_PEL?_ #Y2?]]BNJ,.
M561X-6NZLN:3.CHKG/\ A+8_^?*3_OL4?\);'_SY2?\ ?8IV9ES(Z.BN<_X2
MV/\ Y\I/^^Q1_P );'_SY2?]]BBS#F1T=%<Y_P );'_SY2?]]BC_ (2V/_GR
MD_[[%%F',CHZ*YS_ (2V/_GRD_[[%'_"6Q_\^4G_ 'V*+,.9'1T5SG_"6Q_\
M^4G_ 'V*/^$MC_Y\I/\ OL468<R.CHKG/^$MC_Y\I/\ OL4?\);'_P ^4G_?
M8HLPYD='17.?\);'_P ^4G_?8H_X2V/_ )\I/^^Q19AS(Z.BN<_X2V/_ )\I
M/^^Q1_PEL?\ SY2?]]BBS#F1T=%<Y_PEL?\ SY2?]]BC_A+8_P#GRD_[[%%F
M',CHZ*YS_A+8_P#GRD_[[%'_  EL?_/E)_WV*+,.9'1T5SG_  EL?_/E)_WV
M*/\ A+8_^?*3_OL468<R.CHKG/\ A+8_^?*3_OL4?\);'_SY2?\ ?8HLPYD=
M'17.?\);'_SY2?\ ?8H_X2V/_GRD_P"^Q19AS(Z.BN<_X2V/_GRD_P"^Q1_P
MEL?_ #Y2?]]BBS#F1T=%<Y_PEL?_ #Y2?]]BC_A+8_\ GRD_[[%%F',CHZ*Y
MS_A+8_\ GRD_[[%'_"6Q_P#/E)_WV*+,.9'1T5SG_"6Q_P#/E)_WV*/^$MC_
M .?*3_OL468<R.CHKG/^$MC_ .?*3_OL4?\ "6Q_\^4G_?8HLPYD='17.?\
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M3,9/(A1!DL%XX'UR:RJR?+8[\NI*57F?0Q"<#)Z4I!4[64J<9PPP<5Z5X9\
MQVA2\U@)-<#E+?JB?7^\?TKH->\,V&OVX6=/+N%&(YT'S+[>X]JR5)M7/0GF
M-*,^5:KN>0Z/<16NLV<TZAH!*%D!_NG@_P \_A7LO_"/Z7_SZ+_WTW^->/ZW
MH%]H4_DWL?[M\B.=/N/]#V/M7K7A?4?[4\-V5R3F3R]DG^\O!_EFKHMJ\3FS
M*$9QC5CKT)O^$?TO_GT7_OIO\:/^$?TO_GT7_OIO\:TJ*WNSR;(S?^$?TO\
MY]%_[Z;_ !H_X1_2_P#GT7_OIO\ &M*BB["R,W_A']+_ .?1?^^F_P :/^$?
MTO\ Y]%_[Z;_ !K2HHNPLC-_X1_2_P#GT7_OIO\ &C_A']+_ .?1?^^F_P :
MTJ*+L+(S?^$?TO\ Y]%_[Z;_ !H_X1_2_P#GT7_OIO\ &M*BB["R,W_A']+_
M .?1?^^F_P :/^$?TO\ Y]%_[Z;_ !K2HHNPLC-_X1_2_P#GT7_OIO\ &C_A
M']+_ .?1?^^F_P :TJ*+L+(S?^$?TO\ Y]%_[Z;_ !H_X1_2_P#GT7_OIO\
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M']+_ .?1?^^F_P :/^$?TO\ Y]%_[Z;_ !K2HHNPLC-_X1_2_P#GT7_OIO\
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M[Z;_ !H_X1_2_P#GT7_OIO\ &M*BB["R,W_A']+_ .?1?^^F_P :/^$?TO\
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MHHNPLC-_X1_2_P#GT7_OIO\ &C_A']+_ .?1?^^F_P :TJ*+L+(S?^$?TO\
MY]%_[Z;_ !H_X1_2_P#GT7_OIO\ &M*BB["R,W_A']+_ .?1?^^F_P :/^$?
MTO\ Y]%_[Z;_ !K2HHNPLC-_X1_2_P#GT7_OIO\ &C_A']+_ .?1?^^F_P :
MTJ*+L+(S?^$?TO\ Y]%_[Z;_ !H_X1_2_P#GT7_OIO\ &M*BB["R,W_A']+_
M .?1?^^F_P :/^$?TO\ Y]%_[Z;_ !K2HHNPLC-_X1_2_P#GT7_OIO\ &C_A
M']+_ .?1?^^F_P :TJ*+L+(S?^$?TO\ Y]%_[Z;_ !H_X1_2_P#GT7_OIO\
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M']+_ .?1?^^F_P :/^$?TO\ Y]%_[Z;_ !K2HHNPLC-_X1_2_P#GT7_OIO\
M&C_A']+_ .?1?^^F_P :TJ*+L+(S?^$?TO\ Y]%_[Z;_ !H_X1_2_P#GT7_O
MIO\ &M*BB["R,W_A']+_ .?1?^^F_P :/^$?TO\ Y]%_[Z;_ !K2HHNPLB"U
MM(+*+RK>,1IG=@$GG\:GHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"&Z69K29;9E6=D(C9N@;'!-97A[
MPO8^'X/W0\ZZ8?O+EQ\S?3T'M6W12LKW+522BXIZ,****9!!=V=O?VSVUU"D
MT+C#(XR#69X?T(^'S=6T,QDL9'\V%7^]&2,,,]QP.?K6U12LKW+522BXWT84
M444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?6=.U3Q#
MXO LI&M;2QC\IKO'1FY8)ZMC SVKN*.E3*-]#6E5=)N26IGZ1HMCH=I]GLH=
MH/+NW+R'U8]S6A115)6,Y2<G>3U"N.\1>"A=1W5QHS"VGN$*SV^<13CW'9O>
MNQHI.*>Y=*K*E+FB8_A>YGN/#]LMW&\=U ODS(XP0R\?J,'\:V***$K(F<N:
M3:5@HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:7H$HMX$+#S!P6"G!<M@X&>@'M2:N]!QE9:GI%%>8-KWB+PAK$=OK-S]LMG
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MHHHK4\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;.XY;'0 =A[55T9J+=D^AM4445!J%%%% !1110 4444 %%%% !1110 4444
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MAE+I8[IY_M#*QW(%Q@$=OK3@FM+&6*G3J^]SW?16L;]%%%:G %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEBBBJJ:E8R3^0E[;--G'EK*I;\LT DWL60ZDX# GTS2UY%X/'_%?I_UTN/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBBMCR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img76291469_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_16.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *Y!+ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%%% !1110 4444 %%%% !1110 4444 >,?M(_\B7I7_80'_HMZ]4\.?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M..I/N3DGW- &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,SR)I\J-!N.=B.&^4>V5)Q[U[30 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM].WG7<B]"Y&-H]@!C\SWH [*BBB@ HHHH :Z>8A7<RY[J<&H?L@_P">T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7.>*/OVOT;^E='7.>*/OVOT;^E=.$_C+^NACB
M/X;,"BBBO8/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .TT;_D#VO^Y5ZJ.C?\@>U_W*O5X57^)+U9ZE/X$%%%%9
MEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<YXH^_:_1OZ5T=<YXH^_:_1OZ5TX3^,OZZ&.(_ALP**
M**]@\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH [31O\ D#VO^Y5ZJ.C?\@>U_P!RKU>%5_B2]6>I3^!!11169844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7.>*/OVOT;^E='7.>*/OVOT;^E=.$_C+^NACB/X;,"BBBO8
M/."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .TT;_D#VO^Y5ZJ.C?\@>U_W*O5X57^)+U9ZE/X$%%%%9EA1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<YXH^_:_1OZ5T=<YXH^_:_1OZ5TX3^,OZZ&.(_ALP****]@\X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M[31O^0/:_P"Y5ZJ.C?\ ('M?]RKU>%5_B2]6>I3^!!1116984444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117/W_CKPII=X
M;2^\0Z=!< X:-KA<J??T_&@#H**AM+RUO[9;FSN(KB!_NR0N'4_0CBGS316\
M+S32)'$@W,[L JCU)/2@!]%<[;>//"5Y??8K?Q%ILEP3M""X7D^@YP?PKHJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_?0H FHJ'[7;?\]X_P#OH4?:[;_GO'_WT* )J*A^UVW_ #WC_P"^A1]KMO\
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MUVW_ #WC_P"^A1]KMO\ GO'_ -]"@":BH?M=M_SWC_[Z%'VNV_Y[Q_\ ?0H
MFHJ'[7;?\]X_^^A1]KMO^>\?_?0H FHJ'[7;?\]X_P#OH4?:[;_GO'_WT* )
MJ*A^UVW_ #WC_P"^A1]KMO\ GO'_ -]"@":BH?M=M_SWC_[Z%'VNV_Y[Q_\
M?0H FHJ'[7;?\]X_^^A1]KMO^>\?_?0H FHJ'[7;?\]X_P#OH4?:[;_GO'_W
MT* )J*A^UVW_ #WC_P"^A1]KMO\ GO'_ -]"@":BH?M=M_SWC_[Z%'VNV_Y[
MQ_\ ?0H FHJ'[7;?\]X_^^A1]KMO^>\?_?0H FHJ'[7;?\]X_P#OH4?:[;_G
MO'_WT* )JYSQ1]^U^C?TK=^UVW_/>/\ [Z%8'B26.5[;RW5\!L[3G'2NG"?Q
ME_70QQ'\-F%1117L'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% '::-_R![7_ '*O5F:1<0)I-LKS(K!.06%7?M=M
M_P ]X_\ OH5X57^)+U9ZD/A1-14/VNV_Y[Q_]]"C[7;?\]X_^^A699-14/VN
MV_Y[Q_\ ?0H^UVW_ #WC_P"^A0!-14/VNV_Y[Q_]]"C[7;?\]X_^^A0!-14/
MVNV_Y[Q_]]"C[7;?\]X_^^A0!-14/VNV_P">\?\ WT*/M=M_SWC_ .^A0!-1
M4/VNV_Y[Q_\ ?0H^UVW_ #WC_P"^A0!-14/VNV_Y[Q_]]"C[7;?\]X_^^A0!
M-14/VNV_Y[Q_]]"C[7;?\]X_^^A0!-14/VNV_P">\?\ WT*/M=M_SWC_ .^A
M0!-12*ZNH9&#*>A!S2T %%%% !1110!\^?&ZSBL?BCX5UJ\'^@2>4DK,/E C
MEW-^CU]!*RN@=&#*PR"#D$5SOC;P7IOCG06TS4=R%6\R"=!\T3XQD>H]1W_(
MUYM:_#CXIZ5:+HVF^.+==) V*[;A)&OHORDK] U &<GEZG^U7YFFD%+53]I9
M.F5@VMG'N0/K27[+X5_:@AN[L[+75%78[<#]Y'Y?7_?7%>C_  \^&NG^ K>>
M59WO=4N@/M%W(,$CKM4<X&>>I)[]J?\ $3X=6'Q TN**64VM_;$FVNE7=MSU
M5AW4X'T_F =;>WD&G6%Q>W4@CM[>-I9'/15 R37B'[/UM-J&K^*?$KJ5CN9A
M&F>[,Q=AGVROYTLGPE^(NL0KI&M^-DDT92 56221G4=,J0,_BQKU_P ->'-/
M\*:#;:/ID92W@'5OO.QZLQ[DF@#6HHHH **** $(!&",BD\M/[B_E3J* &^6
MG]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6
MG]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6
MG]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6
MG]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3J* &^6
MG]Q?RH\M/[B_E3J* &^6G]Q?RH\M/[B_E3JSM=URP\-Z)=:MJ4WE6ELFYSW/
M8*!W). !ZF@"_P"6G]Q?RH\M/[B_E7FF@_'/PQXAUVSTBTL]52XNY!%&TL2!
M03ZD.3^E=EXL\46/@[P_-K.HQSR6T3*K+ H9\L0!P2!W]: -GRT_N+^5'EI_
M<7\J\C_X:,\'_P#/AK/_ 'XC_P#CE'_#1G@__GPUG_OQ'_\ '* /7/+3^XOY
M4>6G]Q?RKC_ _P 2]&\?3WD6E6][$UHJM)]IC500Q(&,,?2O,O'/Q&\5Z]\0
MV\&>#I_L@CF^S&5,!Y) /G)8CY57!Z<\$\\"@#WWRT_N+^5'EI_<7\J^;O\
MA.?'OPO\:VVE^*]1&I64@220,WF!HF)!='(# C!X/IT[U](&:)8#.TBB(+O+
MD\!<9S]* %\M/[B_E1Y:?W%_*O)_ASKNM>.O'FN>(3?W4?ANU<V]E:!L1R-C
M&2.YV_,?=QZ5ZU0 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_
MN+^5<[XF4*]K@ <-T'TKI*YSQ1]^U^C?TKIPG\9?UT,<1_#9@4445[!YP444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!V6CHITBV)4$[/2KWEI_<7\JIZ-_R![7_<J]7A5?XDO5GJ4_A0WRT_N+^5'E
MI_<7\J=1698WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'
MEI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'
MEI_<7\J=10 WRT_N+^5'EI_<7\J=10 WRT_N+^5'EI_<7\J=10 @  P!@4M%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S%\6
M?&-Y\0?%UOX4\.A[BSMYO+18CQ<S]V_W5Y /U/>O0?C?\1/^$;T8Z!IDV-5O
MXR)'4\P0G@GV9N@]LGTJG\$OAU_8>BOXFU2$C4KR$_9HW',,)'7V9OT&/4T
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M>*/OVOT;^E=.$_C+^NACB/X;,"BBBO8/."BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .TT;_D#VO\ N5>JCHW_ "![
M7_<J]7A5?XDO5GJ4_@04445F6%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC/? POX4 ==1110!YM\:?%,NA^#QI5@2=4UE_LD")][8>'(_ A?JU-G\.?\
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M*V7_ '_7_&O#<#THP/2CVS[!_9</YF>Y?\)#HW_05LO^_P"O^-'_  D.C?\
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MU?3H-0T^X2XM)T#Q2H<AA_GMVH M4444 %%%% !1110 4444 %%%% !1110
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MH<DC'WA[UX_7-6^(]S+/X3]?T04445D>B%%%% !1110 4444 %%%% !1110
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M_:9/^?27\U_QH^TR?\^DOYK_ (T 6**K_:9/^?27\U_QH^TR?\^DOYK_ (T
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M *Y#_P!"%>,US5OB/<RS^$_7]$%%%%9'HA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>@_"_[VJ?\ ;+_V:O/J]!^%_P![
M5/\ ME_[-5TOB1R8[_=Y?+\ST.BBBNL^="BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N<\4??M?HW]*Z.N<\4??M?HW]*Z<)_&7]=#'$?PV8%%%%>P><%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 =IHW_ "![7_<J]5'1O^0/:_[E7J\*K_$EZL]2G\""BBBLRPHHHH ****
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M?F>AT445UGSH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SGBC[]K]&_I
M71USGBC[]K]&_I73A/XR_KH8XC^&S HHHKV#S@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#M-&_Y ]K_N5>JCHW_(
M'M?]RKU>%5_B2]6>I3^!!1116984444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#XU_Y$[4_^N0_]
M"%>,U[-XU_Y$[4_^N0_]"%>,US5OB/<RS^$_7]$%%%%9'HA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>@_"_[VJ?]LO\
MV:O/J]!^%_WM4_[9?^S5=+XD<F._W>7R_,]#HHHKK/G0HHHH **** "BBB@
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M_:_1OZ5T=<YXH^_:_1OZ5TX3^,OZZ&.(_ALP****]@\X**** "BBB@ HHHH
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M^?N3_OE?\*/(F_Y^Y/\ OE?\* +%%5_(F_Y^Y/\ OE?\*/(F_P"?N3_OE?\
M"@"Q15?R)O\ G[D_[Y7_  H\B;_G[D_[Y7_"@#)\:_\ (G:G_P!<A_Z$*\9K
MV#QC%(GA'4BUP[CRAP0/[P]J\?KFK?$>YEG\)^OZ(****R/1"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]!^%_P![5/\
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MF_Y^Y/\ OE?\* +%%5_(F_Y^Y/\ OE?\*/(F_P"?N3_OE?\ "@"Q15?R)O\
MG[D_[Y7_  H\B;_G[D_[Y7_"@"Q15?R)O^?N3_OE?\*/(F_Y^Y/^^5_PH L4
M57\B;_G[D_[Y7_"CR)O^?N3_ +Y7_"@"Q15?R)O^?N3_ +Y7_"CR)O\ G[D_
M[Y7_  H L457\B;_ )^Y/^^5_P */(F_Y^Y/^^5_PH L5SGBC[]K]&_I6WY$
MW_/W)_WRO^%8/B-'1[;?*TF0W4 8Z>E=.$_C+^NACB/X;,.BBBO8/."BBB@
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M7.>*/OVOT;^E='7.>*/OVOT;^E=.$_C+^NACB/X;,"BBBO8/."BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .TT;_D#
MVO\ N5>JCHW_ "![7_<J]7A5?XDO5GJ4_@04445F6%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M@^-?^1.U/_KD/_0A7C->S>-?^1.U/_KD/_0A7C-<U;XCW,L_A/U_1!11161Z
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7H/PO^]JG_;+_P!FKSZO0?A?][5/^V7_ +-5TOB1R8[_ '>7R_,]#HHHKK/G
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/%'W[7Z-_2NCKG/%'W[7Z
M-_2NG"?QE_70QQ'\-F!1117L'G!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '::-_R![7_ '*O51T;_D#VO^Y5ZO"J
M_P 27JSU*?P(****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH P?&O_(G:G_UR'_H0KQFO9O&
MO_(G:G_UR'_H0KQFN:M\1[F6?PGZ_H@HHHK(]$**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT'X7_>U3_ME_[-7GU>@_"_
M[VJ?]LO_ &:KI?$CDQW^[R^7YGH=%%%=9\Z%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<YXH^_:_1OZ5T=<YXH^_:_1OZ5TX3^,OZZ&.(_ALP****]@\
MX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH [31O^0/:_[E7JHZ-_R![7_<J]7A5?XDO5GJ4_@04445F6%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!@^-?^1.U/\ ZY#_ -"%>,U[-XU_Y$[4_P#KD/\ T(5XS7-6^(]S
M+/X3]?T04445D>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5Z#\+_ +VJ?]LO_9J\^KT'X7_>U3_ME_[-5TOB1R8[_=Y?
M+\ST.BBBNL^="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<\4??M?HW]
M*Z.N<\4??M?HW]*Z<)_&7]=#'$?PV8%%%%>P><%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 =IHW_('M?]RKU4=&_Y
M ]K_ +E7J\*K_$EZL]2G\""BBBLRPHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'QK_ ,B=J?\
MUR'_ *$*\9KV;QK_ ,B=J?\ UR'_ *$*\9KFK?$>YEG\)^OZ(****R/1"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]!^%
M_P![5/\ ME_[-7GU>@_"_P"]JG_;+_V:KI?$CDQW^[R^7YGH=%%%=9\Z%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !1110!VFC?\@>U_P!RKU4=&_Y
M]K_N5>KPJO\ $EZL]2G\""BBBLRPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KP+1I#=?M5:B\N6,2R*F><8A"\?K
M7OM>!?+X?_:G+W/RQ:BO[IO4R18'_CZD4 >^UX'\$F\GXH^,[5.(]TA [?+,
M0/YU[Q/-';023S.$BC4N[,>%4#))KPKX!1/J7BCQ9XA"D03R;4)'4N[.1^ Q
M^= 'O-%%% !1110 C,JC+$ #N33//A_YZQ_]]"FW5I;WUL]M=P1S0/C='(N5
M.#GI6;_PBGA__H"V/_?A?\*!:FIY\/\ SUC_ .^A1Y\/_/6/_OH5E_\ "*>'
M_P#H"V/_ 'X7_"C_ (13P_\ ] 6Q_P"_"_X4] U-3SX?^>L?_?0H\^'_ )ZQ
M_P#?0K+_ .$4\/\ _0%L?^_"_P"%'_"*>'_^@+8_]^%_PHT#4U//A_YZQ_\
M?0H\^'_GK'_WT*R_^$4\/_\ 0%L?^_"_X4?\(IX?_P"@+8_]^%_PHT#4U//A
M_P">L?\ WT*//A_YZQ_]]"LO_A%/#_\ T!;'_OPO^%'_  BGA_\ Z MC_P!^
M%_PHT#4U//A_YZQ_]]"CSX?^>L?_ 'T*R_\ A%/#_P#T!;'_ +\+_A1_PBGA
M_P#Z MC_ -^%_P *- U-3SX?^>L?_?0H\^'_ )ZQ_P#?0K+_ .$4\/\ _0%L
M?^_"_P"%'_"*>'_^@+8_]^%_PHT#4U//A_YZQ_\ ?0H\^'_GK'_WT*R_^$4\
M/_\ 0%L?^_"_X4?\(IX?_P"@+8_]^%_PHT#4U//A_P">L?\ WT*//A_YZQ_]
M]"LO_A%/#_\ T!;'_OPO^%'_  BGA_\ Z MC_P!^%_PHT#4U//A_YZQ_]]"C
MSX?^>L?_ 'T*R_\ A%/#_P#T!;'_ +\+_A1_PBGA_P#Z MC_ -^%_P *- U*
MWC.:)O!^I!9$),8X##^\*\<KVP>%/#X.1HUC_P!^5IW_  B^@_\ 0(LO^_(K
M*=-2=[G;AL:Z$''EO\_^ >(T5[=_PB^@_P#0(LO^_(H_X1?0?^@19?\ ?D5/
ML%W.G^U9?R?C_P  \1HKV[_A%]!_Z!%E_P!^11_PB^@_] BR_P"_(H]@NX?V
MK+^3\?\ @'B-%>W?\(OH/_0(LO\ OR*/^$7T'_H$67_?D4>P7</[5E_)^/\
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MOY/Q_P" >(T5[=_PB^@_] BR_P"_(H_X1?0?^@19?]^11[!=P_M67\GX_P#
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M_P#?A?\ "C0-34\^'_GK'_WT*//A_P">L?\ WT*R_P#A%/#_ /T!;'_OPO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 45B-XQ\+HQ5O$FCJP."#?1 @_\ ?5/A\6^&[B410>(-*ED/14O8V)_
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MTNT$^W-:/P3\3W>B:Q??#S73Y=S;2N;3<>C DO&/4'[X_'VJ/XR?\E;\#_\
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MMNM0_P!+ER.<-]P?]\@'\37@?B/PY>^(/B+XW;3CFXTZ:XO?+4?,ZK* VWW
M;/X5]>QQI%&L<:A40!54= !T%>#_  X&?VA_&0/3_2O_ $<M '>_"7QR/&OA
M&-KB0'5++$-V.[''RR?\" _,&JOQT_Y)/J?_ %U@_P#1JUYSK4$WP6^+<.L6
MJ-_PCNJEM\:#A4)&],>J$AE]L#UKT+XVSQ77P?O[B"19(96MW1U.0RF12"/P
MH UOA%_R2KP__P!<&_\ 0VKM:XKX1_\ )*O#_P#UP;_T-J[6@ HHHH ****
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MAX^T2QL=/NK:W>WN?.9K@M@C:1@8!]:[;3K9K/3+2UD96>&%(V*]"0H''Y4
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M'^Y=?^CHZ]A\42^'UT.:W\33V<6F77[E_M<@1')Y R2.>,C'/&:\V\0?"+Q
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MOK%$BUVU3]R_03J.?+8_R/8^QK!^$/Q0EOY!X1\3NT6L6Y,5O+-PTVW@QO\
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MVMP;N2-T-N6XV@@YW >M 'HU%%% !1110 4444 %%%% !1110 4444 %%%%
M!7@/[0''B[PA]6_]&)7OU>9_$WX;ZGXWUO1+ZPO+2!-/SYBSELMEE/& ?2@#
MTRBBB@#Q_P"-GBO5[&XT;PKHMRUG/J[XEN5;:P4L$"@CD DG)'.![FK^G? 3
MP;;VJ+J$=WJ-UC]Y/+<,NYNY 4C _/ZUH?%'X:CQ[96LUI=+::M9$^1*V=K
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MEI<+J#1F,6Y;*[2Y.<@?WA73^.O#]SXI\%ZEHMI+%%/=(JH\N=HPZMSC)[4
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MQ( R3@"O+_B5\,+[Q+K5GXE\.:@ECKEH  7)"R;3E2" <,,XZ8(^E5K3P_\
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M?Q-9UW\&_&_B:6*/Q5XV6>SC8'RXM[_DI"J#[\UZ[X;\.Z?X4T*VT?3(REM
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MZYRN"H/0EOSKL_ WAA/!W@^PT4.DDD*$S2)T>1CEB,]LG ]@* .BKP7X;_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img76291469_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" E^"_H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVKEJ49TW[QM"I&>Q8HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45%<W,%G;O<7,R0PH,L[M@ ?6O*O
M%?Q3>7?9^'\QIT:[8?,?]P'I]3S["M*=*51VB1.:@M3T;4/$FBZ5/Y%]J5O!
M-C/EL_S >X'2KUK=V][;K<6L\<\+_=DC8,I_$5\O22/-(TDKL\C'+,QR2?4F
MO1_@_?7(UB^L-[&U:W,Q4] X91D>F0Q_(>E=-7"*$.9/8RA7YI6L>P4445Q'
M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5C:_X7TKQ);^7?VX,BC"3IQ(GT/I['BMFBFI.+NA-)JS/ _$_@#5?#I>=%-Y
M8#GSXUY0?[:]OKTKDJ^J2,C!Z5YSXX^'EE<6-SJFD0^1>1J9'@C'R2@=<#L<
M<\=?3G->A1Q=_=F<M2A;6)XZK,C!E8JP[@XJ9+VZC;<ES,I]1(14%20027-Q
M'!$H:21@B D#))P.37<[=3G+":OJ4;;DU&[4^JS,/ZU,GB'6XSE-8U!3TRMR
MX_K5YO WB=6(.C7.1Z '^M1'P?XC!(.B7W'I"36?-3?5%6F1IXK\0QDD:YJ)
MS_>N7/\ ,U,GC/Q)'G&M7AS_ 'I,_P ZKGPOX@!Q_8>I?^ DG^%1?V#K'_0)
MOO\ P'?_  HM3?8+S-)/'GBB/.W6)SG^\%;^8JY9?$KQ/:7"O+>K<Q@_-%+$
MN&_$ $?G7-_V9?\ _/C<_P#?IO\ "GV>D:CJ%RMO:64\LK' 54/Z^@]S2=.E
M;5(%*?<^C=%U6'6]'M=2MP1'.F[:3DJ>A'X$$?A5^L?PMI#Z%X9L=-E8-)"A
M+D=-S,6('XDUL5X\K<SML>A&]M0HHHJ1A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <+X]\"2^))(]0T^2-+V-/+9)#A9%SD<]B,GZ_A7#6_P *
MO$LQQ(EI /62;/\ Z"#7N=%=$,34A'E1E*C&3NSR6U^#EPW-WK$2>T4);]21
M6U:_"/0XL&XNKV<^F]57]!G]:] HI/$U7U&J,%T.9M?A_P"%[3!328Y&]9G9
M\_@3BMNUTK3K''V2PM8,?\\H57^0JW2,P52S$  9)/:LG.4MV6HI;(\O^+^L
M[(;+1HVY<_:)@/09"C\]Q_ 5Y/6QXHU<Z[XDO;_),;R;8L]D'"_H,_C6?8V<
MVHW]O90#,L\BQH/<G%>Q1A[.FDS@J2YI7/7_ (3:-]DT*?5)%Q)>/M0_],UX
M_5L_D*]"JO8646G:?;V4 Q%!&L:_0#%6*\BK/GFY'="/+%(****@H**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKN>74[:-F7MWV/N.H+R]M=/MGN;VYAMH$^]+,X11]2>*\ \$?&RZT?2Y['Q
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MHHKR3N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=:BHJR"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
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MARQOW"BBBN4V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M36_7SLHN+:?0[4[JX4444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8+6-(3;.,20 # ##Z#J.#72U\W5O[23:MJ=T=D%%%%9E!1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1KZ*HP!^0J>BBO$.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[8Q",AOL;*?-\KNY';''!YQD\8YXBON3K7D7C/X'V6KW$E_X>GCT^X<EGMI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS8-?TBYUF;2(=1MY-1@7=);*X+J..WXBM*FTUN 4444@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:SS-TB+%)#]%;!/Y5OU\.*Q5@RDA@<@CM7:?\+5\6?\ "+_V'_:+;<X^U_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!\^^-@W@'XUV7B",,MG>.MP^/0_),/<]6_X$*^@5974,I#*1D$
M'((KS7XW^'_[6\$'4(TS<:9)YP]?+;"N/_06_P" UI?"7Q!_;_@"R\Q]US9?
MZ)+D\_+]T_\ ?)7GUS795_>48U.JT?Z&4?=DT=S1117&:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<_XXUI_#W@K5M4B;;-# 1$WH[$*I_-A705Q'Q=3S?A=K*!E!*Q,-QQG;*C$?
M7 -:4DG4BGW1,M$SY39BS%F)+$Y)/>DHHKZ0X0HHHH **** "BBB@ HHHH *
M*** "BBB@!58JP920P.01VK[$\$:T_B'P5I.J2MNFF@ E;U=258_]]*:^.J^
MK_A+!);?"_1$E7:Q21P/9I78?H17GYBE[-/S-Z&[.UHHHKQSI"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)<6*![=V.2T.<;3_ +I('T(':O7:\&K3=.;BSLC+F5T%%%%9E!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'C#Q98^#=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&G5T['71^$****X34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KY8^,T$D7Q1U1W7"S)"Z'U'E*O\ -37U/7D7QP\&3:OI
ML/B&PB,EQ8H4N$49+0YSN'^Z23]"3VKKP510JZ]=#*JKQ/GBBBBO=.0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBE52S!5!+$X '>@#ZN^$D\EQ\+
MM$>1LL$E0'V65U'Z 5VM8'@C17\/>"M)TN5=LT, ,J^CL2S#_OIC6_7S=5IU
M)-=V=\=$@HHHK,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_93+-;7"!XW7N#5JN)JVC-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<80@UNRHR;;"BBBL"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,(MX(L+&1-MU(OVBY]?,?D@_087_@-=7117ESDY2<GU.A*RL%%%%2,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HJK?ZE8Z5;FXU"\M[2$?\ +2>0(/S->?ZU\;_">F;DLVN=3E'_
M #PCVIGW9L?H#6D*4Y_"KB<DMSTJBOG36/CYX@N\KI=C::>AZ,V9G'XG"_\
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MSQ5J<7LPLS)HJ26"6!]LT3QMZ.I!_6HZH04444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ-54B^IZ)152PU33]5A\[3[ZVNXO[\$JN/S!JW7,U;<L**** "BBB@ HHHH
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M)MZFQ96<&GV%O96R;(+>-8HU]%48 _(5/117B'6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4=O<07=NEQ;31S0R#<DD;!E8>H(X-25S&@4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5=]_\B.5RUD</X<^$_A3P\%?["+^Z'/GWN).?9?NC\L^]=NJJBA5 50,  8
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O)/CGXK;3M$@\.VDA%SJ'SS[3R(0>G_ F&/HI'>O6Z^>_#R_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH YOQ_JYT/P'K-\K;9%MS'&?1W^13^!8&N)^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#DI/\ _$5!_P *6\#_ /0-F_\  J3_ !H_X4MX'_Z!LW_@5)_C1_LO][\
M_>>1/_PN'P'_ -!W_P E)_\ XBC_ (7#X#_Z#O\ Y*3_ /Q%0?\ "EO _P#T
M#9O_  *D_P :/^%+>!_^@;-_X%2?XT?[+_>_ /WGD3_\+A\!_P#0=_\ )2?_
M .(H_P"%P^ _^@[_ .2D_P#\14'_  I;P/\ ] V;_P "I/\ &C_A2W@?_H&S
M?^!4G^-'^R_WOP#]YY$__"X? ?\ T'?_ "4G_P#B*/\ A</@/_H._P#DI/\
M_$5!_P *6\#_ /0-F_\  J3_ !H_X4MX'_Z!LW_@5)_C1_LO][\ _>>1/_PN
M'P'_ -!W_P E)_\ XBC_ (7#X#_Z#O\ Y*3_ /Q%0?\ "EO _P#T#9O_  *D
M_P :/^%+>!_^@;-_X%2?XT?[+_>_ /WGD3_\+A\!_P#0=_\ )2?_ .(H_P"%
MP^ _^@[_ .2D_P#\14'_  I;P/\ ] V;_P "I/\ &C_A2W@?_H&S?^!4G^-'
M^R_WOP#]YY$__"X? ?\ T'?_ "4G_P#B*/\ A</@/_H._P#DI/\ _$5!_P *
M6\#_ /0-F_\  J3_ !H_X4MX'_Z!LW_@5)_C1_LO][\ _>>1/_PN'P'_ -!W
M_P E)_\ XBC_ (7#X#_Z#O\ Y*3_ /Q%0?\ "EO _P#T#9O_  *D_P :/^%+
M>!_^@;-_X%2?XT?[+_>_ /WGD3_\+A\!_P#0=_\ )2?_ .(H_P"%P^ _^@[_
M .2D_P#\14'_  I;P/\ ] V;_P "I/\ &C_A2W@?_H&S?^!4G^-'^R_WOP#]
MYY$__"X? ?\ T'?_ "4G_P#B*/\ A</@/_H._P#DI/\ _$5!_P *6\#_ /0-
MF_\  J3_ !H_X4MX'_Z!LW_@5)_C1_LO][\ _>>1/_PN'P'_ -!W_P E)_\
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M_P#$4?\ "X? ?_0=_P#)2?\ ^(J#_A2W@?\ Z!LW_@5)_C1_PI;P/_T#9O\
MP*D_QH_V7^]^ ?O/(G_X7#X#_P"@[_Y*3_\ Q%'_  N'P'_T'?\ R4G_ /B*
M@_X4MX'_ .@;-_X%2?XT?\*6\#_] V;_ ,"I/\:/]E_O?@'[SR)_^%P^ _\
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M_P#$4?\ "X? ?_0=_P#)2?\ ^(J#_A2W@?\ Z!LW_@5)_C1_PI;P/_T#9O\
MP*D_QH_V7^]^ ?O/(G_X7#X#_P"@[_Y*3_\ Q%'_  N'P'_T'?\ R4G_ /B*
M@_X4MX'_ .@;-_X%2?XT?\*6\#_] V;_ ,"I/\:/]E_O?@'[SR)_^%P^ _\
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M^\\B?_A</@/_ *#O_DI/_P#$5R_C;Q1\,/&VE_9[O7/*NX@?LUTME/NB/O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU,1/S#_@+'_QX>E>PU\[6ING-Q9VQES*X4445D4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ1,VFGXFD)Z%_P" ?F,_\!-1%7=CIJU%3@YOH>[:+IXTK0[#3QS]F@2(GU(
M!/YU>HHKN/EFVW=A7,_$.^&G?#S7;C=M)M'B!]"_R#]6KIJ\H^/6KBT\'VFF
M*V)+ZY!(]4C&3_X\4K:A'GJQ7F1-VBV.^ =D8/!%W=,,&XO6VGU554?SW5ZK
M7+_#K23HOP_T:S==LGV<2R ]0SDN0?INQ^%=117ES59/S""M%(****Q*"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!?) YZ?N4X_/-=V7J]5^AC6^$X:BBBO:.4*]'^"=F+CQR\Y'%M:2.#[DJO\
M)C7G%>O? :-3JFLR_P 2PQJ/H6/^ K'$.U*14=SW"BBBO%-PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP:[_ .3H
ME_ZZQ_\ I(*]YKP:[_Y.B7_KK'_Z2"NO";S_ ,+,ZG3U/>:***Y#0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \]U
M[X3:7XA\<1Z_>W4[VY4&>S8DB1EP% ;.57'4?EC/'?PPQ6\$<$$:1Q1J%1$&
M%4#@ #L*?15RJ2DDI/82BEL%%%%0,**** "HKFVAO+6:UN8UE@F0QR(W1E(P
M0?PJ6B@#YSMI;SX,?$IX)C)+HEWU/7S(2>&_WT/Y\_WJ^A[:Y@O+6*YMI4E@
ME0/'(AR&4\@BN?\ &_@ZS\:Z ]A<$1W"9>VN,9,3_P"!Z$?X"O)? 'C6_P#A
M]K<GA'Q6KPV8?$;OR+=CW![QMUR.G7UKNDOK,.9?$M_/S,E[CL]CW^BFHZ2Q
MK)&RNC ,K*<@@]"#3JX34*K7VGV>IVK6U];17$#=4E4,/K]?>K-% TVM4>8:
MU\&=.N6>71[V2S8\B&4>8GT!ZC]:XR\^$GBNV8B&WMKL>L,ZC_T/;7T%16;I
M19V0Q]:&E[^I\X_\*Q\8?] 8_P#@1%_\55RS^$GBNY8":WMK0>LTZG_T#=7T
M%12]C$MYG6?1?U\SR_1?@QI]LRRZQ?27C#DPPCRT^A/4_ABO1['3[/3+5;:Q
MMHK>!>B1*%'U^OO5FBKC%1V.2K7J5?C=PHHHJC(*CN+B&UMI;BXE2*&)"\DC
MG"JH&22?3%.=UC1G=@J*,LS'  ]37@?C_P ;7WQ UF+PAX35YK1I-LDB<"X8
M<YSVC7&<]^O85M1HNK*W3JR92Y44;V>\^,_Q)CMK8RQZ)9YPV,>7"#\S_P"^
MYQC\/0U]#6MK!96D-K;1+%!"@CC1>BJ!@"N?\#>#;/P5H"6,&V2YDP]U<8P9
M7_\ B1T _J37356(JJ;48?"MA0C;5[A1117.6%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5YA\9/ [>(=%76;"/=J6GH=RJ.98>I'U7DC\
M?45Z?15TZCIR4D*45)69YQ\)/'J^*=$&FW\V=7LD ;<>9XQP']SV/X'O7H]>
M"_$;P7J'@K7T\9^%@T5NLGF3)$.+=SU..\;9Y'09QT(KT_P)XZT_QMI"S0LL
M5_$H%U:D\H?4>JGL?PZUO7I)KVM/X7^!$)/X9;G5T445RF@5R_B'P!H'B-FE
MN+8P73<FXM\(Y/OV;\1FNHHI-)[E0G*#O%V/$M3^"VJPL6TS4+:YC[+,#&_]
M0?S%8#_"_P 8(V!I.X>JW$6/_0J^C**S=&)VQS&LEK9GSFGPO\8.V#I.T>K7
M$6/_ $*M_3/@MJLS!M3U"VMH^ZP@R/\ T _,U[;10J,0EF-9K2R.7\/> - \
M.,LMO;&>Z7D7%QAW!]NR_@,UU%%%:));'%.<IN\G<****9(5YU\6?'J^%-#.
MGV4V-8OD(CVGF&/H9/8]0/?GM6WXZ\=:?X(TDSSD37TH(MK4-\TA]3Z*.Y_K
M7EWPZ\&:AXWU]_&?BD&6V:3S(DD7BX<=./\ GFN.G0XQTS750I)+VM3X5^)G
M.3^&.YU7P:\#MX?T9M;U"(KJ.H(-BL.8H>H'U;@G\/>O4:**QJU'4DY,N,5%
M604445F,**** "OGG]H&R\KQ3I=Z!@3V?E_4HY/\G%?0U>1_M :8;CPMIVHJ
MN3:711CZ+(O/ZJM=6#ERUD9U5>+/G>BBBO>.,*[#X7:B--^(6ELQPD[-;M[[
MU(7_ ,>VUQ]2VMS)9W<-U"<2PR+(A]&!R/Y5,X\T7'N-:,^R:*JZ9?Q:II5I
MJ$!S%<PK*OT89Q5JO!:L= 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%G>6X4445S&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8ZQ9SW<, \R%7VOO8EGPIP3\Q/.*X,P5Z:MW-J'Q'=T445XQU!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@UW_R
M=$O_ %UC_P#205[S7@UW_P G1+_UUC_])!77A-Y_X69U.GJ>\T445R&@4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPDJ6JU1U0J*6G4ZFBBBN0T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCYN:FMSHI5-+2/7:***\PZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O!KO\ Y.B7_KK'_P"D@KWFO!KO_DZ)?^NL?_I(
M*Z\)O/\ PLSJ=/4]YHHHKD- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJMB<!_EEB)RT4@ZJ?\>X(->+B\-[)\T=F==.IS*SW-NBBBN(U"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XSXF>#5\8^%9
M(84!U&US-:-ZMW3/HP&/K@]J^4'1HW9'4JZG#*PP0?0U]Q5\Z?&[P5_9.LCQ
M%918LK]\3A1Q'/U)^C=?J#ZUZ6 KV?LW\C"M#[2/)J***]8Y@KJ/ /BM_"7B
M:&[9C]BF_=72#G*$]<>H//YCO7+T5,HJ2LP3L?9D<B31)+&ZO&X#*RG((/0B
MG5Y5\&?%W]H:6_AZ[DS<V:[K<L>7B_N_\!/Z$>E>JUXE2FZ<G%G0G=7"BBBH
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT445R&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5X-=_P#)T2_]=8__ $D%>\UX5=V\W_#4$;>3)M9DD!VG!46P!;Z9!&?:NK";
MS_PLSJ=/4]UHHHKE- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQU#P]<Z#<2$S:>V^')ZQ,>GX-G_OH5YV84KQ51=#>C*SL>N4445Y!TA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -DC2:)X
MI$5XW!5E89!!Z@U\D_$3PB_@[Q7/9(K?8I?WUHYYS&>V?53Q^&>]?7%<1\4?
M!P\7>$Y5MX]VI6>9K4@<L<?,G_ @/S KKPE?V5379F=6',CY2HH(()!&"**]
MTXPI\,TEO/'/"[1RQL'1U."K Y!%,HH ^K?!7B:/Q7X8MM1!47 'EW*#^&0=
M?P/!'L170U\X?"?Q7_PC_B=;.YDVV&H8B?)X23^!OSX/U]J^CZ\;$4O9SMT-
MXNZ"BBBL"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!1110 4444 %%%% !1110 4444 %%%% !112JI9@J@EB< #O0 *I9@J@EB<
M#O7T-I?P2TU](LFO7V79@0SKLSM?:-P_/-8_PI^%%PEY!XA\16[0K$0]I9R#
M#,W9W'8#L#SGD\=?=:\K%XM\W+3>QT4J>EY!1117F'0%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%8WB;Q3I7A+2FO]5N/+3D1QKR\K?W5'
M<_H.^*:BY.R!NQI7M[;:=9RWEY/'!;1+NDED;"J/<U\]?$3XPW.NF72O#[R6
MNF\K)<?=DN![?W5]NI[XZ5RWCGXAZMXWO/W[&WTZ-LPV:-\H_P!IC_$WOV[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "BF2RQP1F261(T7JSG 'XUDR^+_  S
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M$MPGR6X-O;9_OD?.WX*0/^!&O>Z\;'U>:?(NAU48V5PHHHK@-@HHHH ****
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M$\1:=_9'B34M/QA;>Y>-?]T,<?IBOKNOG/XS:=]B\>O<*N%O;>.;CID?(?\
MT$'\:[<%*TW'N9U%H>>T445Z9D%>Y?L]:G_R&M)9O^>=S&OYJQ_] KPVN_\
M@SJ?]G?$FR0MM2\CDMF/U&X?^/*M<^*AS49(NF[21]2T445\^=H4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\\?'
MCPN+#7K;Q!;QX@OQY<^!P)E'!_X$N/\ ODFOH>N=\<^&U\5>$+_2\#SV3S+<
MGM*O*_3/0^Q-;X:K[*HI="*D>:-CX]HI65D=D=2K*<$$8(-)7T)Q!3XI7@F2
M6)RDB,&5AU!'(-,HH ^M?"FN)XC\,6&J+C=-&/,4?PN.&'Y@ULUXI\#-?VS7
M^@2OPX^U0 ^HP''Y;3^!KVNO$K4^2;B;Q=T%%%%9%!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH[SX+6TD_P 3;"1,[8(II),?W?+*\_BPKZCKS?X2_#^7PCIDU_J2@:K>J R
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M(J5)5'>1LDD%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC.7-*X45]'?!7PG;6W@LZE?6D4L^HRF1?-C#;8U^5>H[G<?H17I']C:7_P!
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M]&=GQQ/B.M?PQKT_ACQ)8ZQ;C<UM)EDSC>AX9?Q!(JWXU\(WG@WQ!-I]RK-
M26MIR.)8^Q^HZ$=C7.U[R<:D>Z9QZIGV;X=\2Z7XHTN._P!+N5EC8#>F1OB/
M]UAV/^16M7Q%;7=S93":UN)8)1T>)RK#\15Z[\3:]?P^3>:WJ5S%C&R:[D=?
MR)KSI9=K[LM#=5]-4>R_&;XAV+Z5)X9TFY2XFF8?;)8FRL:@YV9'\1(&?0#'
M>O!J**[Z-&-*/*C&<G)W9T'@?27UOQOH]@J[E>Y1Y!_L*=S?^.@U]AUY'\%?
M DNC6+^(=2A*7EY'MMHV',<1YW'T+<?@/>O7*\G'55.I9;(Z:4;1U/"_VAX'
M\S0+CK'B=#['Y#_GZ5XA7U=\4?"DGBSP;-!:IOOK5OM%LHZLP!!7\03^.*^4
MF4JQ5@0P."#U%=V!FI4N7L8UE:5SV']G[5K>UUS5M+E=5EO(HY(LG[QC+9 ]
M\/G\#7T#7Q#;7,]G<QW-M*\,\3!TD1L,I'0@UZ-9?'3Q?:6HAD&GW; 8\V>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]+D?K6"T4B2>6R,'Z;2,'\J^X**[HYE+K$R=!=&?&VF>$/$6L.JV&BWTP/\
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MN6.Y<8W#0=!T_P .:3%IVG0B.&/DD\L[=V8]R:TJ**\IMMW9L%%%%( HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %8GBKQ3IWA'1)=3U"3@?+%$#\TS]E7_'M
MUJSKNNV'AS1Y]4U*816\(_%SV51W)KY1\:^,M0\:ZX]]=DQP)E;:V#96%/ZD
M]2>_T  ZL+AG6E=[&=2IRKS*GBCQ/J/BW6Y=4U%\NWRQQK]V)!T51Z?S/-8U
M%%>[%**LCC;N%%%%, KH?!WA"^\8:P+.U_=P)AKBX(RL2_U)[#^F34?A3PK?
M^+=92PLU*H/FGG(RL2>I]_0=Z^G/#WA[3_#&D1Z=IT6R->7<_>D;NS'N:Y<1
MB%35EN7&-Q^@Z#I_AS28M.TZ$1PQ\DGEG;NS'N36E117E-MN[-@HHHI %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC'YFH=.^.VH+*HU/2+66//S&V9D(]P&+9_.JWPP^&]CXDT^36-9\Q[7S#'#
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MD^M:%>=/EYGR[&B\PHHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]_?VNEV$]]>SI!;0
M(7DD<X"@5-)(D,3RRNJ1H"S.QP% ZDGL*^9?BI\1W\6Z@=-TV1ET6V?@CC[0
MX_C/MZ#\?IOAZ#K2LMB)S4497Q$\?77C?6-R[X=+MR1:VY/_ (^P_O']!QZD
M\9117OP@H148['&VV[L****H05K^&_#E_P"*-9BTVP3+MR\C#Y8E[LQ]/YGB
MH-%T6^\0:K#IVG0F6>4_@H[LQ[ 5].^#_"-CX/T=;.U_>3OAKBX(PTK?T [#
MM]<USXBNJ2LMRHQN3^%_#-AX4T:/3K%<X^:68CYI7[L?Z#L*VJ**\AMMW9N%
M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /GGXT:'_9OB]-1C7$.HQ;R?\ IHN%;]-I_$UYO7TI\6=!_MKP1<31
MINN+ _:4P.=HX<?]\DG_ ("*^:Z]?"SYJ:\C":LPHHHKI)-/P]K$OA_Q#8:M
M!G?:S+(0/XE_B7\1D?C7V9:W,5[:0W5NX>&:-9(V'\2D9!_(U\05]+? _P 2
M?VOX-;2YGS<Z8_EC/4Q-RA_#YA] *\[,*5XJ:Z&]"6MCTZBBBO(.D**** ,'
MQAXJL?!_A^;5+WY\?)#"#@S.>BC]23V -?(>I7O]HZE<WOV>&W\^1I/)@7:B
M9/11V%>D_'?6Y+[QG%I(<^1I\"_)G_EHX#$_]\[*\LKV\%14*?-U9R597=@H
MHHKM,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^I_A!_87_  @5M_8N
M[=N/VSS,>9Y_&[=CMC&/;'?-=[7S=\"-;DL?&<NDESY&H0-\F?\ EH@+ _\
M?.^OI&O Q=-PJOSU.RG*\0HHHKF-#S'X\?\ )/8_^OZ+_P!!>OFFOI#X^R[/
M =H@(_>:C&"#UP(Y#_05\WU[> _@_,Y*WQ!1117:9&GX;_Y&G2/^OV'_ -#%
M?7=?(WAE6?Q7HZ*,LU]  /?>*^N:\[';HUIA1117 :!1110 5\__ !R_Y':S
M_P"P<G_HR2OH"O'_ (K>"/$7B7Q1;7FD:?\ :;=+)(F?SHTPP=R1AF!Z,*Z<
M+)1J7;(GL4?@]XFT70M(U*+5-1@M9))U9%D.-PV]:])_X6%X1_Z#]G_WT?\
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MXRT"+5++*$G9-"QRT3CJI]?4'N"/I6_7BRBXNS.I.^J"BBBD,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU&)QU7>;"BBBNDS.A\!P?:/'FAIC.+R-_P#OD[OZ5]6U\U?"*T-S\1;!\$K
MDLI_[X*C]6%?2M>9C7[Z7D:T]@HHHKB- HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,3Q?JTVA^$M2U*W*B>"'=&6&1N) '
M'U-?.WB;X@:]XKM([34)HEMD;?Y4$>T,PZ$]2>I]J^FM2TVSU?3Y;"_@6>UE
M #QMG!P01T]P#7.6_P ,O!MM/YT>APELYQ)))(O_ 'RS$?I750JTZ:]Y79$D
MWL><?!CPE+<:HWB.[A*VUN"EJ6'WY#P6'L!D?4^U>Z4V.-(HUCC1411A548
M'H!3JRJU74ES,J*L@HHHK(84444 %%%% !1110 4444 %%%% !1110 4444
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MQ_\ H+5Y7\)_^2F:1_VV_P#1+UZI\:_^1$3_ *_8_P#T%J\K^$__ "4S2/\
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MYP>G'YUY'\&M;_LWQE]AD;$.HQ&+VWK\RG_T(?\  JE^->L?;O%\.G(V8["
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M5TSC/WHV7^M?65>-F*_>KT.JA\(4445P&P4444 %%%% !1110 4444 %%%%
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M_P!D0IKVKP_\3"1<V\+CF!3W(/1S^@]SQZG117C5*CJ2YF;I6"BBBH&%%%%
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M*XKXMP27'PNUM(URP2)R/9948_H#6^&J2A45GNR*B3B[GRA1117T)Q!1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5O3G2492[=3'5.]CV[_A9O@W_H.0_P#?M_\ XFMFYBL/%'AR6)7$UC?VY"N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $%[>VVG6,][=S+#;P(9))&/"J.IKY0^(
M/C>Y\;:^UP=\>GP92T@)^ZO]X_[1ZG\!VKJ_C'\0_P"W+Y_#NES9TVV?_2)$
M/$\@/3W53^9Y["O)J]C!8;D7M);LY:M2^B"BBBO0,0HHKH_!?A*Z\8:ZEE#N
M2V3#W,X'$:?XGH!_@:4I**NPW-OX9^ 7\5:C]NOD*Z1;-\^<CSV_N ^GJ?\
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MN>?^ U$Y*$7)C2N['T%HFFIHVAV.FQX*VL"19'\1 P3^)R?QJ_117AMW=V=
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M?:+E]JEXHPHXR2<.>  3^%<]XO\ C'=Z1XBN--TFQMI8K20Q327&XEV!PP4
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MG3UCJCIA53T9ZM10"" 0<@]Z*XC4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRGXQ
M?$'^P=..@:9-C4[M/WSJ>8(C_)F[>@Y]*[#QUXPM?!?AV74)=KW+YCM8"?\
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M$]NY^>%L=#ZCT/0_G705XTHN+L]SI3OJ@HHHI#"BBB@ HHHH **** "BBB@
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MH%%%%, HHHH **** "BBB@ HHHH **** .]^#,$DOQ1TMT7*PI,[GT'E,O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/@SXZEE"/I$<*G^.2[B('_?+$_I7I/@WX&V6DW$5]XBN(]0N$.Y;6,'R0?\
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MO=9] T445XYU!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBO-G.4W>1JE8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/7/Z^7DEB2223R2:"2Q))))Y)-)7L4Z:@K(S;N%%%%6(**** "BBB@ HHHH
M**** "M30_$.H^'KU;FPG*\_/$>4D'HP_P FLNBDTFK,#Z2\-^(+7Q+H\=_;
M_*WW98B>8W'4?U!]*UZ\4^$^J/:^)I-/+?NKR(_+_MJ-P/Y;J]KKRJU/V<[(
MT3N@HHHK$84444 %%%% "@E2"#@CH16U978N$VMQ(O7W]ZQ*?%(T4BNAP10U
M<:=CHJ*CAE6:)9%Z']*DK,L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"I=Z7I]_P#\?EC;7&?^>T*O_,5D3> _"DYR_A_3
MQ_N0A/\ T'%=%15*4ELQ6.2_X5CX-_Z 4/\ W\D_^*IT?PU\'1ME="MR<8^9
MG;^9KJZ*?M9_S,+(PK?P7X8M<>5X?TT$="ULK$?B0:V+>UM[1-EM!%"G]V-
MH_2I:*ER;W8[!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9^+GP_P F7Q-I,//WKZ%!
M_P"10/\ T+\_4UXO7V:0&!! (/!!KY\^*'P[;P]<OK&E0DZ3*W[R-1_Q[,3T
M_P!TGIZ=/2O1PN(O[DOD93CU1YK1117>9A3HY'AE26)V21"&5E."I'0@]C3:
M* /H[X7_ !5B\011:+KDRQZNN%BF;A;H?T?V[]O2O5J^'%9D=71BK*<@@X(-
M>_?#'XO+J'DZ'XEG"WG"6]ZYP)O17]&]^_?GKY.+P=O?I[=CIIU;Z2/9:***
M\TW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHJEJVKV&AZ;-J&I7*6]K",L[G]!ZD]
M@.332;=D!/=W=O8VDMU=S)#;Q*7DDD;"J!W)KYL^)GQ2G\5RR:5I;-#HJ-R>
M0UR1W;T7T7\3V H?$3XEWWC2[-M!OM='C;]W;YP9?1I,=3Z#H/UK@Z]?"X/D
M]^>_Y'+4JWT04445Z!B%%%% !7N'PQ^&/V/R=>UZ#_2>'M;5Q_J_1W'][T';
MZ]#X8_#'['Y.O:]!_I/#VMJX_P!7Z.X_O>@[?7IZ]7G8G$W]R!K"'5A1117
M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM5N=.O$V7%O(8W';CN/8]1[&OL*O(OC5X2^T6D?B6TC_ 'L $5V /O)GY6_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445S7COQ5%X/\*76IDJ;@CRK5#_'*>GU Y)]@:J,7)J*$W97/
M'OCGXP_M'5X_#=I)FVL3ON2#P\Q' _X"#^;'TKR&I)YI;F>2>9VDED8N[L<E
MF)R2:CKZ*E35."BCBE+F=PHHHK0D*]^^#GA'^RM';7KN/%Y?+B$,.4AZ@_\
M NOT KROX?>%&\6>*(;:13]A@_?73?[ /W<^K'CZ9/:OJ-$6-%1%"JHP% P
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?,7QC\7?\ "1>+&L+:0FPTPM"N#P\N
M?G;\Q@?3WKVGXG^+1X2\'SS0OMO[O-O:X/(8CE_^ CGZX]:^3^M>GE]'7VC^
M1SUI?9"BBBO5.<* "3@#)-%>B_"+PI_;GB3^T[F,FRTXA^1P\O\ "/P^\?H/
M6HJ34(N3&E=V/6OAQX3'A3PO%',F+^ZQ-=$]0<<)_P !''USZUU]%%>)*3E)
MR9NE8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5K\XLI/P_G6'6YJ'_'C)^'\Q6'5QV)D%%%%,D**** "BBB@ J*ZMHKRT
MFM9UW13(T;KZJ1@U+13 ^:_$6A7/AW6)K"Y4X4YBDQQ(G9A_GKFLJO1?BAXI
MM=2NAH]K#%)]D<^9<D9(?NJGT]?4CVKSJO7I2E*"<C-A1116@@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH [[X3Z6]UXFDU K^ZLXC\W^VPV@?ENKVNN
M2^'/]E?\(E!_9><Y/VG?C?YO?/Z8]L5UM>5B)\U1FB6@4445@,**** "BBB@
M JUIYQ>I[Y_E56K.G_\ ']'^/\C0]AHW****S+"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BEN(
MH?\ 6. ?3O0!+16;+JO:*/\ %O\ "J4MU--]^0X]!P*?*Q7-B6\@B^]("?1>
M:IR:J>D4>/=JS:*KE1-R:2[GE^](<>@X%0T44Q!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%<-\5_%G_"+>#9_(DVW]]FWM\'E<CYG_ =_4BKA!SDHKJ)NRNSP[XK^+#XI
M\93""3=I]CFWML'@X/S/^)'Y 5PM%%?10@H145T.%N[NPHHHJQ$EO!+=7,5O
M!&TDTKA$1>K,3@ 5]6^#_#D7A;PU:Z9'M,BC?.X_CD/WC_0>P%>1_!7PM]OU
M:7Q!<IF"R/EP CAI2.3_ ,!!_-AZ5[S7FXRK=\BZ&L%U"BBBN$T"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O%W6<H_V<
MU@UTCJ'1E/0C%<X058@]0<5429"44451(4444 %%%% !61XIU-M'\,:A?QG$
MD41$9]';Y5/YD5KUS'Q#B>;P'JBH,D*C?@)%)_0&KII.:3!GS\26))))/))I
M***]DR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [[X3ZH]KXFD
MT\M^ZO(C\O\ MJ-P/Y;J]KKP/X:1/)X\L&49$:RLWL/+8?S(KWRO-Q:2J%QV
M"BBBN4H**** "BBB@ JYIJYO ?12:IUI:2G,DGT H>PUN:=%%%9EA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !13)
M)HX5S(X7ZUGS:IVA3_@3?X4TKBN:3,%&6( ]35.;4H8^$S(?;@5E2323',CE
MOK3*I1%<M37\\O&[8OHO%5:**8@HHHH$%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %6H;^>+C=O7T;FJM% S8AU*&3A\QGWY%7%8,,J01ZBN;I\<T
MD)S&Y7Z4G$=SHJ*S(=4[3)_P)?\ "M".:.9<QN&^E2U8=Q]%%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% "$A022 !R2:\K\7?&:STR>2RT"".^G0[6N7)\E3[ <M]<@?6CXS>+I
M=,T^'0+*4I/>H7N&4\K%G 7_ ($0?P!'>O!J[\-AE)<\S.<[:([>;XN>-)92
MZ:HD*G^!+6(@?]]*3^M<SK>NZCXBU W^J7'GW)0(7V!>!TX  K.HKNC3A'6*
M,[MA1115B"BBB@ HHHH **** .KT_P")/BS2]/M["RU7RK:!-D:?9XFP/JRD
MUT&C?&OQ#9RJ-4BM]0A_B^012?@5X_2O-**RE1IRW0^9GUEX8\6:5XMT_P"U
M:;-\R\2P/Q)$?0C^HX-;E?)7A?Q'=^%M>M]3M&/R';+'GB6,]5/^>#@U]7V=
MW#?V4%Y;OO@GC66-O56&0?R->9B*'LGILS:,KDU%%%<Y04444 %%%% !1110
M 4444 %%%% $=Q;PW5O)!<1)-#(-KQR*&5AZ$'K7D'C'X,)*9+[PPP1S\S6,
MC?*?]QCT^AX]QTKV.BM*=65-WBQ-)[GQQ>V5UIUW):WMO);W$9PT<BE6'X&H
M*^M/$7A/1O%-IY&J6BR,!A)E^62/_=;^G3VKP[Q9\(]9T'?<Z;NU*Q&3F-?W
MJ#_:7O\ 4?D*]*EBH3T>C,G!H\\HH((.",$45U$!1110 4444 =9H'Q*\5^'
M D=GJDDMNO M[G]ZF/09Y4?0BO4-$_:!LY0L>N:1+ W0S6C;U^NUL$#\37@=
M%85,-2J;HN-24=F?8&C^/_"NN[18:W:M(W2*5O*?_OEL$_A72=:^&ZU]+\4Z
M_HF!INL7ML@_Y9QS'9_WST_2N.>7+[$OO-57[H^S:*^8M/\ CAXRL@HGFL[X
M#_GXMP#^:%:Z:S_:'N% %]X=B<]V@N2OZ%3_ #KFE@:RV5RU6B>[T5Y';_M!
M>'V'^DZ3J<9_Z9B-_P";"M&+XZ^#I,[O[0C_ -^W']&-9/"UE]DKVD>YZ717
MG'_"\/!G_/>]_P# 8U!+\=_"$>[9'J<N.FRW49_-A1]6K?RL/:1[GIU%>/W/
M[0>BIG[+HNH2^GFLD?\ (M6#>_M"ZFX/V#0;2#T,\S2_R"U<<'6?03JP[GOU
M17%S!:0M-<SQPQ+]YY'"J/J37RWJ7QA\:ZB"HU-;1#U6UA5/_'CEOUKCK_4[
M_5)O.U"^N;N7^_/*TA_,FMX9=-_$[$.NNB/IW7/C#X/T8,L=\VHS#_EG9+O'
M_?9POY$UYCX@^/.NWX:+1K2#38CQYC?O9?PR-H_(_6O)J*[*>"I0W5_4RE5D
MRWJ.JZAJ]T;G4;V>[G/\<TA8_09Z#VJI1176E;1&84444 %%%% !5W2M(U#6
M[]++3;62YN'Z(@Z#U)Z >YXKL_!_PIU?Q'Y=W?AM.TT\AW7]Y(/]E3T^IX^M
M>\:!X;TKPS8"TTNU6%.-[GEY#ZLW4_R';%<M;%1AI'5EQ@V<7X(^$UCH)CO]
M9\N^U$894QF*$^P/WC[G\!WKTJBBO,G4E-WDS5)+8****@84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\_P#QE\*_V5KJ:W;1XM=0)\W'19NI_P"^AS]0
MU>8U];>*= A\3>'+S2IB%,R?NW(^XXY5OS_3-?)]W:S6-Y/:7,9CG@=HY$/5
M6!P17K82KSPY7NC&:LR&BBBNH@*^K/A5XM/BOP="UQ)NU"RQ;W.3RV!\K_B/
MU!KY3KN?A1XK_P"$6\9P>?)ML+[%O<9/"Y/RO^!_0FN7%T?:4]-T:4I<LCZK
MHHHKP3L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KY4^*WBO_A*/&<_D2;K&QS;V^#PV#\S?B?T
M KW3XJ^*?^$7\%7+0R;+Z]_T:VP>02/F;\%SSZXKY2KU,OH[U'\CGK2^R%%%
M%>H<X5/96<^H7T%E;(7GGD6.-1W8G J"O7/@GX6%S?3^([F/,=L3#:Y[N1\S
M?@#C_@1]*SJU%3@Y,:5W8]=\.:';^'- L]*MP-L" ,P&-[]6;\3FM6BBO$;;
M=V= 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *Q+^+R[MO1OF%;=4M2A\R 2 <I_*FMQ,QZ***L@**** "BBB@ J*
MZMHKRTFM9UW13(T;KZJ1@U+13 ^:_$.A7/AW6)K"Y4X4YBDQQ(G9A_G@YK*K
MZ3\0>'-.\26/V:_B)*Y,<J</&?4'^G2O!/$^ACP[KT^F"Y%QY04[PNWJ,@$>
MN"*].A7516>Y#5C'HHHKH)"BBB@ HHHH **** "BBB@ HHHH **** "BKVCZ
M3=:YJ<6GV80SRYVAVVC@$GGZ UZMX9^%=KITR7>L3)>3(05@0'R@??/+?H/K
M652M&GN-*X?"OPS+I]E+K-W&4FNE"0JPP1'G.?Q('X >M>BT45Y=2;G+F9HE
M8****@ HHHH **** "MRPB\JT7/5OF-9-M#Y]PJ=NI^E;_2IDRHA1114E!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45%-<Q0#+
MMSZ#K69/J4LF1'\B^O>FE<5S3FN8H!\[ 'T'6LZ?4Y'R(AL'J>M4"23DG)HJ
ME$EL5F9V+,22>YI***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR067VVY7GSKO#\^R_='Y9]Z[*BN2>)J3W9:BD   P!@"BBBL"@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_C;X8^
MRZE!XBMDQ%=8AN<#I(!\I_%1C_@/O7DM?7/B31(?$7AZ]TJ; %Q&0C$?<<<J
MWX$ U\F7=K-8WD]I<QF.>!VCD0]58'!%>KA*G-#E>Z,9JSN0T445UD!7UG\,
M?%'_  E7@JTN99 U[;_Z/<\\EU'#'ZC!^I/I7R97I/P6\3_V'XR&GSOMM-4
MA.>@E'^K/YDK_P "KDQE+VE.ZW1I2E:1]-T445X1V!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$6- JC"CH*=4-W*2L%%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%1S3QP+ND;'H.YH DJG<ZA'#E4^=_;H*HW-_)/E5^1/0=352J4>Y+9)-/)
M.VZ1L^@["HZ**HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDD,4N/,C1\=-R@XI]%
M$/V.U_Y]H?\ O@5(D:1KMC157T48%.HH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLQ[FFT5:5B6PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!\X_%[PY_8OC!KV%-MKJ0,ZX' D_C'YD-_P*O/Z^F_
MBAX=_P"$@\%W/E)NNK+_ $F''4[1\P_%<_B!7S)7KX6IST_-&$U9A1117227
M-)U*XT;5[34K5ML]K*LJ>A(.<'V/2OLS2=2M]9TBSU*U;,%U"LJ>P(S@^XZ5
M\3U]"_ 3Q)]LT*[T">3,MB_FP GK$YY ^C9_[[%>?F%+F@IKH;496=CU^BBB
MO'.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\V^-GB,Z+X(:PA?;<ZH_D#!Y$8Y<_EA?^!5Z37RY\8_$7]N^/+B")]UMIR_
M94QT+#ES_P!]9'_ 175@Z7/55]EJ9U96B>?4445[QQA116KX:T63Q#XDL-*C
MS_I$H#D?PH.6/X*":3:2NP/=O@]X>_LCP@+^5-MSJ3>:<CD1CA!_-O\ @5>A
MU'!#';6\<$*!(HU"(HZ*H& *DKPZDW.3DSH2LK!1114#"BBB@ HHHH ****
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M<?*:'S"/<$#^M=_7G7@+_D.S_P#7LW_H2UZ+65?XRX;!1116)04444 %%%%
M!1110 4444 %%%% !1110 4444 %5-4FDM])O)HCB2.!V4^A"GFK=4=9_P"0
M%J'_ %[2?^@FJCN#/("2Q))))Y)-==X N)!J5S;;CY30^81[@@?UKD*ZGP%_
MR'9_^O9O_0EKMJ_ S".YZ+1117 ;A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %/BE>%]Z,0?YTRB@#
M:M;Y+C"MA9/3U^E6ZYKI6C::B1A)SD=G_P :EQ*3-2B@$$ @Y![T5)04444
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M  B_C;3]0=]MLS^3<<\>6_!)^G#?\!KEZ*F45*+B^HT[.Y]R=:*XSX6^(O\
MA(_ 5A-(^ZZM1]EG)Z[DQ@GZJ5/U)KLZ^;G%PDXOH=R=U<****D84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &-XKUQ/#?A;4=7<C-O
M"3&#T:0\(/Q8BOC:61YI7EE<O([%F9CDDGJ37N_[0'B#R[33?#T3_-*3=3@'
M^$95!]"=Q_X"*\&KVL!3Y:?,^IRUI7E8****[C$*]D^!F@;I+_Q!,G"_Z- 2
M._!<_P#H(_$UXXJL[A54LS'  &237UEX1T-?#GA73],  DBB!E([R'EC^9/X
M8KDQE3EAR]RX*[-NBBBO*-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*AL%%%%8EA1110 4444 %%%% !1110 4444 %%%% !1110 51UG_ ) 6H?\
M7M)_Z":O55U/_D$WG_7!_P#T$U2W!GC==/X$;;K\@_O6[#]5/]*YBNF\"_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOIZ'X6^"X)1(FAH6'9YY7'Y,Q%>4_&3P['H_B.UN[.VC@LKJ *JQ(%573@@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]NKB3Q_HJO/*RFX&07)!X-?0_BYBO@O764D$:=<$$=OW;5\Y?#K_ )*#HO\
MU\?T-?1GC @>"=>R<?\ $NN/_1;5GB_XL1PV9\P:/=W+:W8 W$I!N8P07/\
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MW"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*"BBB@ HHHH **SM4URPTA,W4WSD96).7/X?XUR-[X^NG)6RM8XE_O2'<W]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$'Q @NM3^'&J):Q2I.\"R>41\X 9692!GG (XS7SWX/UJT\/>*;+5+VT-S!
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MD^Z?X1Z5XQ6M.IS]"91L%%;?A)5?Q+:HZ*ZL'!##(^X3_2O3/L5K_P ^T/\
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M-_"Q[^U95%#5QIG2T50L;WS (I3\_8GO5^LVK%A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9_\  _\ T!J]&?PLPCN>IT445YQN%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110  D'(X-;-C>>>OEN?W@_\ 'JQJ56*,&4X(Y!%#5QIV.DHJ
MM9W0N8^<"0=1_6K-9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@OQRTC[-XBL=51
M<)=P&-R.[H>I_P" LOY5[U7G_P 8M*_M'P'+<*N9+&9)Q@<[?NM^C9_"M\-/
MEJHF:NCYQHHHKV3 *W/!NK_V#XRTG4RVU(;E?,/^P?E?_P =)K#HI22DFF"=
MM3[DHKG? FK_ -N>!M'ORVZ1[94D/JZ_*WZJ:Z*OF91<6T^AWIW5PHHHI#"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KXW\9ZM_;GC/5]1#;DFNG\L_[ .U?_'0
M*^J_&>K?V'X,U?40VUX;5_+/^V1M7_QXBOCBO4RZ'Q3^1SUWL@HHHKU#G"O6
MO@5I7G:SJ6JNORV\*PH3_><Y/Y!?_'J\EKZ/^#NE_P!G^ H9V7#WLSSG/7&=
MH_1<_C7-BY<M)^94%J=_1117D&X4444 %%%% !1110 4444 %%%% !1110 5
MYE\<O^1)L_\ L(I_Z+DKTVN%^*WA[5/$OA>VL](M?M-PEZDK)YBIA0C@G+$#
MJPK6@TJB;)EL>/\ PG_Y*9I'_;;_ -$O7TU7AGP]^'OBG0_'.G:CJ.E^1:0^
M;YDGVB)L9B=1PK$]2.U>YUMC)*4TXN^@H*R/#?CO_P AG2/^O=__ $(5<^ ?
M_,P_]NW_ +5K0^+7@[7O$VIZ=-H]A]ICAA99#YT:8).1]YA5GX1>$];\+_VQ
M_;-E]F^T>1Y7[U'W;?,S]TG'WAU]:T<X_5N6^O\ P16?.>@ZM?#2]&OM0*[A
M:V\DY7UVJ6Q^E?+#7&I^-/%,"W=UYEY?3K$'D/RIN.  .RC/05]77-O%>6DU
MM,NZ*9&C=?52,']#7SAXB^%_B30M1<V-G/?V@;,,]LNY\=LJ.01],5.#E%73
MT833.[/P4\.Z?ITMSJ>KZ@1#&7DDC,<:@ 9)P5;^=>)67_'];_\ 75?YUW^G
M>%OB%XM:*QU.;58=.W#S&U"1U4 =]C'+'TX_$51MOA5XTCNX7;1<*KJ2?M4/
M3/\ OUTTYJ-U.:;):OLCU;XR?\D^G_Z^(OYUY)\)_P#DIFD?]MO_ $2]>U_$
MO1-1\0>#I;#2[?[1<M-&P3>J< \\L0*\[^'OP]\4Z'XYT[4=1TOR+2'S?,D^
MT1-C,3J.%8GJ1VK"C.*H23>NI4D^8].^(7_)/];_ .O8_P Q7SCX0_Y';0?^
MPC;_ /HQ:^E_&6GW6J^#]4L+*+S;F> I&FX+N/U) %>*>&_AEXOL/%&D7ESI
M'EV]O>PRRO\ :8CM57!)P'R>!VHPLXQIR3833N>Y^(CHXT&[.O>3_9FS]]YW
M3&>/?.<8QSG&*\RO_@KI6I6PO?#NLLL4HWQ++B6-A[,,$#\ZWOBAX-UWQ5:V
MYTJ]5HH.6L7.P.W]X-T)[8/'O7C_ /PC7CK2-]M#INMPJQ^9;59&4_\ ?&0:
M6'C[MXSL^P2>NJ,))+S0M8+03F*\LYB!)$W1E..#W'\Z^C?%-Z^I?".[OI$V
M/<Z:DS+C&"RJ<?K7D_A?X2:]JU]$^J6S:=8*P,C2G$C#T5>N?<X_'I7L7CR&
M.W^'&KPQ*%CCM-B*.P& !5XB<93BEJ[BBFDSYKT'4AHWB#3]2*%UM;A)64=2
M 02/RKZMT_7-,U32UU*SO89+0KN,F\ +_O?W3[&OD_1K :KKFGZ<9/+%W<QP
M;\9V[F"YQWZUOZQ\-O%6D7+Q'29[N,'Y9K-#*K#UP.1^(%:XBE"HTF[,46T6
M/BCXAM?$?C.2>QD$MM;0K;)*O1\$DD>V6//M7H7PNT.6Y^%6K0D$-JAG2,GC
M*F,1@_F&KB/#7PE\0:Q>(=1MGTVR!'F23##D>BKUS]<#^5?0UA8V^F6$%C:1
MB.W@01QH.P%88BI&,%3@]BHIMW9\AVL\NF:I!<&,B:UF5]C#&&5LX/XBOJW2
M/$^CZWID=_:7\!B90SJT@#1G&2&&>"*\^^(/PGDUF^EUC0#&EU+\T]JYVB1O
M[RGH">X/!ZY]?*KCP-XJMIC%)X>U$L#C,=NTB_\ ?2@C]:TG[/$13O9B5XG1
M_%[Q/9>(/$=O!I\RSVUE$4,R'*N[')P>X& ,_6NQ^!.G2PZ-JNH.I"7,R1IG
MOL!)(_%\?A7'>&_A!X@U:Y1]3B.F6606:3!D8>BKV/UQ^->_:7IEIHVF6^G6
M,0BMH$V(O]3ZD]2:SKU(1I^R@[CBFW=GS+\1?^2@ZU_U\?T%>Y_"?_DF>D?]
MMO\ T<]>;>-/AQXLU;QCJE_8Z5YMM/-NC?[1$NX8'8L#7JWP]TF^T/P-IVG:
MC!Y%W#YOF1[U;&978<J2.A'>C$3BZ,4GV_((I\Q2^*__ "3/5_\ MC_Z.2O#
M_AM+'#\0]&>1PB^<5R3W*D ?F0*^D]=TF+7="O=+G.U+F(Q[L9VGL?P.#^%?
M-NK?#CQ7I%T\1TBYND4_+-:(958>HV\C\0*,+*+IR@W:X33O<^HJ*\O^#VDZ
M]IRZQ+K=M=P^<(!#]JSN(7S,X!Y&,BO4*XZD%"3BG<M.Z"BBBH&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+?7?GR;$/[M>GN
M?6K.HW>T&!#R?O'^E9=5%=26PHHHJB0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***PO&6I2Z3X1U*\@)658MB,.JEB%!'TW9JH
MJ[20'*^+OB<NF74FGZ-''/<1DK)/)RBGN% ZGWZ?6N)_X65XK\S=_::XSG;]
MGCQ]/NYKDZ*]2%"$5:QG=GL7A'XG+J=U'I^LQQP7$A"QSQ\(Q[!@>A]^GTKT
M>OE:OHSP;J4NK>$=-O)R6E:+8['JQ4E23]=N:Y,314/>B5%W-VBBBN0H****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF_$WB==)4VMKA[QAR3
MR(QZGW]O\FHQ<G9 W8U]0U:RTN/?=SJA(RJ=6;Z"N5N_B!\Q6RLLCL\S?T'^
M-<9/<374S33R-)(QR68Y)J.NJ-"*WU,G-]#ICXZU8G(2U'L(S_C1_P )UJ_]
MVV_[]G_&N9HK3V<.Q/,SIO\ A.M7_NVW_?L_XUD:MJUQK-TEQ<I&KK&(_P!V
M" 0"3W)YYJA134(IW2!ML*Z>V\<:A;6T<'V:V98U"*<,#@#'/-<Q11**EN)-
MK8ZW_A/]0_Y]+;_Q[_&@>/[[/-I;$>VX?UKDJ*GV4.P^9G6R>/K]EQ':6Z'U
M;<?ZBL'4=9U#5#_I=PSJ#D(.%'X"J%20P37$@C@B>1ST5%)--0C'5(&VR.MO
MPYH$FLW@9P5M(S^\?U_V1[_RK3T?P1<3LLNI-Y,77RE.7/U]/YUW=O;PVD"0
M01K'$@PJKVK.I62TB5&'<>B+'&J(H5% "@= !3J**Y#4****0!1110 52U#5
MK+2X]]W.L>?NKU9OH*R/$WB==)4VMKA[QAR3R(QZGW]O\GSF>XFNIFFGD:21
MCDLQR36].BY:O8B4[;':7GC\!B+*RR/[TS8_0?XUG'QWJQ.0EJ/8(?\ &N8H
MKH5*"Z&?,SIO^$ZU?^[;?]^S_C1_PG6K_P!VV_[]G_&N9HI^SAV#F9?U;5I]
M9NEN+A(E=4"?NP0" 2<\D\\U0HHJDDE9".GMO'&H6UM'!]FMF6-0BG# X QS
MS4W_  G^H?\ /I;?^/?XUR5%3[*'8?,SK1X_OL\VEL1[;A_6B3Q]?LN([2W0
M^K9;^HKDJ*7LH=@YF7]1UG4-4/\ I=PSJ#D(.%'X"J%206\US((X(GE<_P *
M*2?TKJ]'\#W$S++J3>3%U\I3EV^IZ"FY1@@2;,OPYH$FLW@9P5M(S^\?U_V1
M[_RKU%$6.-410J* % Z "F6]O#:0)!!&L<2#"JHX%2UQU*CFS6,;!1116904
M444 %%%% !1110 4444 %%%% !1110 4444 %17-U;V<#3W4\<$2_>>1PJC\
M36=XCU^U\-Z/)?W/S8.V.,'!D<] /Y_05X#KOB'4O$5Z;F_G+#)V1#A(QZ ?
MUZUT4:#J:]!-V/;9?B'X4AD*-JZ$C^Y#(P_,*16AIGBG0]8<1V&IP2R'I&3M
M<_16P:^;:4$J002".0172\'&VC)YCZHK(U/Q3H>CN8[_ %."*0=8P=SCZJN3
M7BO_  G_ (@_L'^ROMC8SC[1_P M=G]W=_7K[US!)8DDDD\DFHA@W]IC<CZ!
MB^(?A2:0(NKH"?[\,BC\RH%=%;75O>0+/:SQSQ-]UXW#*?Q%?+=:FA>(=1\.
MWJW-A.5Y^>(G*2#T8?UZTYX-6]UB4CZ5HK)\.>(+7Q)I$=_;?*2=LL1.3&XZ
M@_S^AK6KA::=F6%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"W8W?D2;'/[MNOL?6MJN:K4TZ[W 0.>1]T_TJ9+J4F:-%%%24%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M28)K<****YBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWO<U0HHK1*Q 4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"3NVSI04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@KS3Q>\<GB2X>-E92J<J<@_**WP_Q$5-C#KVQ&WQJV,;@#BO$Z]GAFB\B/\
M>I]T?Q#TJL1T%3ZD]%%%<IH%,EE2")Y96"1H"S,>@ JI>ZSIVGH6N;N)2/X
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MJDC]<5Q]>K? JQ\WQ'J5\02(+41_0NP/\D-95Y<M.3''<]XHHHKQ#H"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>400M(W;H/4U)61J5Q
MYDOE*?E3K]::5Q-E-W+N78Y).33:**L@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHKSCXG>+I],2/1M/E:*XF3?/*AP50\!0>Q.#^'UJZ<'.
M7*@;L=5J7C+P]I,Y@O-4A253AD0-(5/H0H./QHTWQEX>U:<06>J0O*QPJ.&C
M+'T 8#/X5\YT5W?4XVW(YCZIHKSCX8^+I]3231M0E:6XA3?!*YR60<%2>Y&1
M^'TKT>N&I!PERLM.X4445 &?K<C1:-<LIP=H7\"0#_.N%KT.\MEO+.6W8X#K
MC/H>U<#<6\MK.T,RE77J*X<6GS)]#W\HG'DE#K>Y%6KX=D9-9B5>CAE;Z8S_
M $K*KH_#6G/YIOI%*J 1'GOGJ:QHIN:L=N-G&-"7-U1T]%%%>H?)A6+K.C->
MN+BW($N,,IXW?_7K:HH:35F-.QR$'AZ_DD"RHL2=V+ _H*ZNW@2VMTAC'RH,
M"I**48I#<FPHHHIDA1110 4444 %%%% &7XCO);#0+NX@)60*%5AVR0,_K7D
MQ)8DDDD\DFO9[JVBO;66VG7='(I5A7#7'@"]$Q^S7=NT6>#)E3^@-=-&<8JS
M,YIO8Y"BNI_X0+5?^?BS_P"^V_\ B::W@35E/$EJWT=O\*W]K#N1RLYBBNF_
MX075_P"];?\ ?P_X4C>!M7 R#;GV$A_PH]I#N'*SFJ*Z+_A"=9_N0_\ ?RC_
M (0G6?[D/_?RCVD.X<K.=HJU?Z?<:9=&VND"R@ X# \'Z55JT[B"BMM?"6MN
MBNEF&5@&!$J=#]31_P (AKO_ #X_^1D_^*J>>/<?*S$HK;_X1#7?^?'_ ,C)
M_P#%5/!X)UF4@21Q0CU>0'_T'-+VD>X<K.=K;T#PY<:S,'8&*T4_/*1U]E]3
M_*NITWP-96S"2]E:Z<<[,;4_+J:ZA$6- B*%51@*HP *QG76T2XP[C+>WBM+
M>."! D48PJCM4M%%<QH%%%%( K+\1WDMAH%W<0$K(%"JP[9(&?UK4J&ZMHKV
MUEMIUW1R*585479Z@]CQ@DL2222>2325U]QX O1,?LUW;M%G@R94_H#4/_"!
M:K_S\6?_ 'VW_P 37;[6'<PY6<M173MX$U93Q):M]';_  I/^$%U?^];?]_#
M_A3]I#N'*SF:*Z5O VK@9!MS["0_X4S_ (0G6?[D/_?RCVD.X<K.=HKHO^$)
MUG^Y#_W\K'O]/N-,NC;72!90 <!@>#]*:G%[,3315HHK;7PEK;HKI9AE8!@1
M*G0_4TW)+<$FS$HK;_X1#7?^?'_R,G_Q5'_"(:[_ ,^/_D9/_BJ7/'N/E9B4
M5T4'@G692!)'%"/5Y ?_ $'-=%IO@:RMF$E[*UTXYV8VI^74U,JL%U!0;.6T
M#PY<:S,'8&*T4_/*1U]E]3_*O3K>WBM+>."! D48VJH["GHB1HJ(JJBC 51@
M 4ZN2I4<V:QC8****S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH YCXAQ/-X#U14&2%1OP$BD_H#7S[7U)=6T5Y:36LZ[HID:-U]5(P:^;_$.A
M77AW6)K"Y4_*<QR8XD3LP_SUS7?@YJSB1(RZ***[20HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *ZWX:1/)X\L&49$:RLWL/+8?S(KDJ]D^%GAF33K&7
M6;N,I-=J%A4CD1]<_B<?@!ZUC7FHTWYC2U/1:***\DT"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "G(Y1PZG!!R*;10!T,$HGA61>_4>A
MJ2LC3;CRY?*8_*_3ZUKU#5BTPHHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH/\ -S7@]?37PHL_LGPZTTD8:8R3-^+G'Z 5R8QVIV[EPW.THHHKRC8****
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MK0 P,"BBDHJ.R'.I.?QMOU"BBBF0%%%% !1110!1U/4XM-@#,-TC?<0'K_\
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MDG2K,DY)@3_T$5>(V0J9:HHHKE- HHHH **** "BBB@ HHHH **** "BBB@
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M?E?C\>U)H:9LT445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM:CK/*D8_$@?UK[% "J%4  #  [5P8YZ11I3%HHHKSC4**** "BBB@ HHHH
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M;]&L6QC-O&?_ !T5<K@>YN@HHHI %%%% !1110 4444 %%%% !1110 4444
M%%%% !7F_CK_ )&!?^N"_P S7I%>;^.O^1@7_K@O\S6]#XR)[',U[)IG_()L
M_P#K@G_H(KQNO8M(;?HMBWK;QG_QT5IB-D33+E%%%<AJ%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>*=,;6/#&H6$8S)+
M$3&/5U^91^8%?-Q!4D$$$<$&OJBO*?B!\/YWN9=9T:$RB0E[BV0?,&[LH[Y[
MCKG].S"U5%\K)DCRRBE(*D@@@C@@TE>@0%%%% !1110 4444 %%%% !1110
M4444 %%%% !76_#2)Y/'E@RC(C65F]AY;#^9%<E7LGPK\,RZ?92ZS=QE)KI0
MD*L,$1YSG\2!^ 'K6->:C38TM3T6BBBO)- HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *.E%% &]:3>?;J_\71OK4]8^FS>7/Y9/
MRO\ SK8J&K%H****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \'^.U
MIY?B/3+S&!-:&//J4<G_ -G%>4U[G\>+7?H^CWF/]5</%G_?4'_V2O#*]C"N
M])&$]PHHHKH).X^$-Y]C^)VDY.$F,D3>^Z-L?KBOJROC7PA=_8?&>B7.<".^
MA9OIO&?TS7V57CYBO?3\CIH/1H****\\W"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ***Y#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH/5F[1117E'2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDZ]_V#KC_P!%M7RUHW_(=T__ *^8_P#T(5GAJ,*D6Y#E)IGU_1117&6%%%%
M!1137D2)&>1U1%&2S'  H =168GB/0WF\E-:TYI?[@ND)_+-:8((!!R#3::W
M ^?;CXT>*8KF6-4T_:CE1F!NQ_WJ]QT"]EU/PYI=_/M\ZYM(II-HP-S("<>V
M37R5>_\ ']<?]=6_G7U9X0_Y$G0?^P=;_P#HM:[<73C&*<49P;;-JBCI65+X
MFT"";R9=<TV.7IL>[C#?EFN))O8T-6BF0S17$2RPR))&W*NC @_0BGT@"BHY
MIX;:(RSRI%&.KNP4#\36?'XET&:;R8M;TUY1QL6Z0G\LTTF]@-2BCK3))8X@
M#)(B ]-S 4@'T5''/#*2(Y8W(Y(5@:K0ZSI=Q?&Q@U*SENP"3 DZM( .OR@Y
MIV8%VJNI7T6EZ7=ZA.KM%:PO.X0 L552QQG'.!5JL7Q?_P B3KW_ &#KC_T6
MU$5=I SC/^%Y>&?^?'5_^_,?_P <KTVOC*OLQF5%+,P51U). *ZL51C3MR]2
M(2;W%HJ%;NV=@JW$18\ !QDU7OM9TO3&"ZAJ5G:%N@N)UCS^9%<MFRR]145O
M<P7<(FMIXYHCT>-PP/XBJU]K6E:8P74-3L[1CR!<3K&3^9%%GL!>HJ*WN8+N
M$36T\<T1Z/&X8'\14C,J*69@JCJ2< 4@%HJ);JW=@JSQ,QZ ."35>^UC3-,(
M&H:E9VA/(^T3K'G\R*=F!=HJ"TO;2_A\ZSNH;F(_QPR!U_,5/2 ***S)_$6A
MVLPAN-9TZ&4G 22Z16SZ8)II-[ :=%1P7$-U$);>:.6,]'C8,#^(J2D 45$U
MU;HQ5IXE8=07 (ILU[:6UL;F>YAB@'6620*OYGBBP$]%86MZM#/X*UG4-*OX
MI1'93M'<6TH8*ZHQR&!Z@U\_Z%XU\3S^(=,AEUV_>.2[B5U:<D,"X!!K>EAY
M5$VNA+E8^G:***P*"N=\4^-M%\(PH=1F8SR#,=M"-TCCUQT ]R1715\K?$"]
MN+[QYK4EP6+1W3PH">B(=JX_ 9_&NC#T55E9[$RE9'H[_'J 38C\/2-%_>:[
M ;\MA_G7:>$_B-H?BV7[-;-);7H&?L\X +#N5(.#_/VKD?#7PF\.ZEX+L[RZ
MFG:[N[99S<))@1%AG 7IQT.?0]*\;TZZN-,UJVNK-R9[>=6C*'[Q!X_ _P!:
MZ51HU$U#1HCFDMS[ HHHKSC4**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^9?BQ%Y7Q)U7 P'\IA^,29_7-?35?./QFB\OX@RMMQY
MEM$V?7@C^E=F"?[SY$5-CS^BBBO4,0KV;]GJ;;K6M0Y7Y[>-\=^&(_\ 9OY5
MXS7K/[/\A'C74(L<-IS-GZ21_P"-<^+5Z,BZ?QH^BZ***^?.T**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N:^(,@B^'FOL6VYL95S]5QC]:Z6N1^*$@B^&NNL03FW"\>[ ?UK2EK4CZ
MH4MF?)-%%%?2' %%%% 'UCX+C\OP/H2YSFPA;\T!_K6[67X94+X4T=5 "BQA
M  [?(*U*\&?Q,Z%L%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8A5+'H!
MDTM5K^3R[-_5OEH Q7<R2,YZL<TVBBM#,**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGV%P\6D1.8U6)L?:,'[S$=0>PZ8QWHT_X.>*K_3ENR+.V+KN6"XE82$=N I
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M/$K1Y)@^T-"?]KR0<?GC\ZSQ$54IJIU''1V.7^(?Q'OO$&HW&GZ=<O!I$3%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7SY\<(PGCBV8$_/81L?\ ON0?TKZ#KP3XZ@?\)5IS8&39 $_\
M#:NK!_Q2)['EE%%%>L8A7IOP)D"?$-E+8+V4J@>O*G^E>95Z)\$I GQ+M5(S
MO@F4>WRY_I6.)_A2]"X?$CZ@HHHKYT[0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXM2"/X7ZVS9P
M4C7CU,J#^M=I7#?&'_DE>M?]L/\ T?'6M#^+'U1,_A9\J4445]&<(4444 ?8
M.C\:)8?]>T?_ *"*NU7L55-/MD4858E 'M@58KP'N=(4444@"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K,U9_]7']6/^?SK3K$U!]]X_HORTX[B>Q5HHHJR HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV<HQ '&[KD^_%>X:KHVG:Y9FTU.SBNH#SMD7H?4'J#[BN&N/@GX5FF+QRZC
MN?\ 5QSJ5_\ 'E)_6M%B:=2*55"Y6GH>(:]KNI>+-<:_O3YES+B...)3A1V5
M1R>_YFOH/X9^%9?"WA58[M=M]=/Y\Z_W.,*OX#]2:O>'O /AWPS*)["Q!N0,
M?:)F+N/IG@?@!72UG7Q"G'D@K(<8VU9\L_$7_DH.M?\ 7Q_05[G\)_\ DF>D
M?]MO_1SU:U'X<>$]6U">_OM*\VYG;=(_VB5=Q^@8"MS2=)L=#TR'3M.@\BTA
MW>7'O9L98L>6)/4GO16KQG34%T",6G<CU^SDU'PYJEC%_K+FTEA3ZLA _G7R
M7:7$NG:C!<JN)K>59 K#^)3G!_$5]BUQNO\ PO\ #/B&\>\GMYK:YD.9)+5]
MF\^I!!&??%+#5XT[J6S"4;[%;P5\2X/&>K/IT6F26LD=L9W=I0PR&5<#C_:Z
M^U=W7*>%?A[HGA"\DO-.-T]Q)$8FDGD#?*2"1@ #JH[5U=8U7#F]S8I7MJ<S
MX_T&7Q'X,O["V&;G:)85_O,ISC\0"/QKYHTK4[WP[KD%_;?NKNTD)VR+T/(*
ML/ID&OKVN9\0> /#GB64SW]@%NCUN(&*.?KC@_B#6V'Q"IIQDM&3*-]4>:ZC
M\<Y[K2GM[;0XH[F1"C/--YB#(P?EVC/T)_.O*(K2YN(9YXH))(H &E=$)6,$
MX!)[<U[_  _!+PM%-O>;4IE_N23*!_XZH/ZUVVF^'](TC36T^QT^WAM'&'B"
M9$@Q@[L\MQZYK98BE37[M"Y6]SP/X;_$-_"=S_9]_E](G?<V!EH6/&X>HZ9'
MXCW^BK>XANK>.XMY4EAD4,CH<A@>A!KD6^%/@IW9CH@R3DXN9@/R#\5T.BZ'
MI_AZQ^Q:9"\-L&+"-IGD"D]<;B<?05SUZE.H^:*LRHIK<T:***YR@HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_CQ_R&](_Z]G_]"KW2
MO$/CTJC4-$?'S&*4$^P*_P")KIPG\5$3V/(****]<Q"N^^#,@3XH:8ISETF4
M?7RF/]*X&NY^#W_)5-%_[;_^B)*RK_PI>C*A\2/JNBBBOG#N"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KAOC#_ ,DKUK_MA_Z/CKN:X;XP_P#)*]:_[8?^CXZUH?Q8^J)G\+/E2BBB
MOHSA"BBB@#[(L_\ CRM_^N:_RJ:H;/\ X\K?_KFO\JFKY]G2%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 $X&3TKG';?(SG^(DUNW;[+25O]G'Y\5@5429!
M1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7AOB_PSKEYXMU*XMM*NY89)LHZ1$AA@=*]RHK6E5=-
MW0FKG.> [.YL/!>GVUW \$Z>9NCD&",R,1Q]"*Z.BBHD^9MC"BBBI **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "JVH.T>FW4B'#+"Y!'8@&
MK-5[X!M/N01D&)@?R--;@>,UZQX8=I/#=BSDD[,9/H"0/T%>3UZMX5_Y%FR_
MW3_Z$:Z\1\*,J>YL4445QFH4444 %%%% !1110 Y&V2*X_A(-=&#D9'2N:K?
MM'WVD3?[./RXJ9%1)J***DH**** "BBO /BC>^(_#WC*=;;7-4BLKM1/ B7D
M@5<\,H .!A@>/0BM:-+VDN6XI.Q[_17D7P8\5WNIS:EI6IWUQ=S +<0O<2M(
MVW[K#+'./N\>YKUVE4ING+E8)W5PHKQ#XP>+]1M?$MOI>EZE=V@M8=TWV:9H
M]SOS@[2,X4*>?4U/\')M>UO6;S4-0UC4KFSM(]@CFNG=&D;IP3@X /YBM/J[
M5/VC8N;6QZW/K&EVMXEG<:E9PW3_ '8))U5V^BDY-7:^2/$%EJT/B2\M]4CF
M;47F._*DF0D\%?4'M7TYX0AU"W\(:5#JN[[:ENHE#_>'H#[@8S[TZU!4XIIW
MN*,KFW1117,61SSPVT+S7$J11(,L\C!54>Y/2HK'4;'4X3-87MO=Q X+P2K(
MN?J#7FWQOM=3G\/6,EJ)&L8I6:[5 3@X&QC[#YOQ(KDO@G;:F?%<US;K(-/6
M!DN7Q\C'^$?[V>?IGUKIC03I.I<ARUL>_P!%%%<Q84444 %%%% !1110 444
M4 %%%>2?&7Q?=Z6UAH^EWL]K<-FXGDMY2C!>0JY'//S$CV%:4Z;J2Y4)NRN>
MMT5\MZ'X]U_3=<L[RZUG4KJWBE!E@ENG=73HPP3CIG\:^H8I4GA26)@\;J&5
MAT(/(-76H.E:XHRN/HHHK H**** "BBB@ HHHH *Y_QQ:W%]X)U>UM87FGEM
MRJ1H,LQR. *Z"BG%V:8'S1X7\&>);7Q;HUQ/H=_'#%?0/([0D!5$BDDGT KZ
M7HHK6M6=5IM$QC8****Q*"BBB@ KE9?B1X0@F>*36XED1BK*8WX(X(^[755\
M@:S_ ,AW4/\ KYD_]"-=.&HQJMW(E*Q]<VMU#>V<%W;2"2">-9(W ^\K#(/Y
M&IJQ?"'_ ").@_\ 8.M__1:UM5SR5FT6%9%_XJT'2[MK2_U>SMKA0"T<LH5A
MD9'%:]?-GQ?_ .2C7W_7*+_T 5MAZ2JRY63)V1]#Z;JVGZQ;M<:;>0W<*N49
MX7# -@'&1WP1^=7*\R^!O_(DWG_81?\ ]%QUZ;6=6')-Q0T[JX4445 PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJ;;;4+_>85CUI:LW
M,2?4UFU<=B'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-;B0AW'4* 68CWP#4X>C3E2<I(<I-.R/0;_XZZJUV3I^E6<=L#P+@L[D?4$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@#&U-LW>/[J@53J>];=>2GWQ4%:+8AA1110(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKB?$7C&2*=[/3& V
M':\^,\^B_P"-7"#D[(3:1VU>-ZE(TVJ7<CG+-,Y/YFB74KZ9]TMY<.WJ9#54
MDDDDY)KKI4N0RE*YVW@73+6>*>]FB625'V)N&0O&<CWYKJ]0>UL]/GGF6-41
M#DD#\J\DAN[FW4K!<2Q*3DA'*@G\*)KNYN%"SW$LH'(#N6Q^=3*BY2O<:G96
M(:].\*6D#^&;-I+>-F.\DL@)/SM7GNF:;<:K>I:VZY9C\S=E'<FO7+6VCL[2
M*VB&(XD"K^%+$2T2"FNHQM.L7.6L[<GU,2_X5-%#% FR*-(U_NHH I]%<MV:
MA1112 **** "BBB@ JYIC8N\?WE(JG4]DVV\B/OBA[#1O4445F6%%%% !111
M0!X)\;=!^Q>(K;68DQ%?1[)"/^>B #]5V_D:\ZDU6[DT:'26DS:0SO.J?[3!
M0?\ T']37TM\0_#4GBCPA<65M&'O(V6:V!(&7';)X&02/QKP_P#X5/XV_P"@
M+_Y-0_\ Q=>IAZT'32D]48RB[Z'>_ W0O)L+_795^:=OL\)/]Q>6/T)P/^ U
MZ[6;X>TB/0?#]CI<6,6T*H2/XFZL?Q))_&M*O/K3YYN1K%61\@:S_P AW4/^
MOF3_ -"-?4OA#_D2=!_[!UO_ .BUKPK4_A;XRN-6O)XM&W1R3NZG[5",@L2/
MXZ]\\-VD]AX7TBSN4\NXM[*&*5,@[65 ",C@\CM77BYQE"-F1!-,^4]9_P"0
M[J'_ %\R?^A&OJ7PA_R).@_]@ZW_ /1:UX5J?PM\97&K7D\6C;HY)W=3]JA&
M06)'\=>^>&[2>P\+Z19W*>7<6]E#%*F0=K*@!&1P>1VHQ<XRA&S"":9YS\=_
M^0%I/_7RW_H-<Q\#?^1VO/\ L'/_ .C(Z[WXL^&=7\3:3I\&CVGVF2&=G<>8
MB8&W'\1%87PI\$>(O#7BBYO-7T_[-;O9/$K^=&^6+H0,*Q/131"<?JSC?4&G
MS&9\=M.E36M+U/:3%+;FWW=@RL6Q_P"/_I2_!?Q58:8U]HVH7$=O]H=9H))&
M"JS8P5R>AZ8_&O7/$GAVQ\4:+-IE^I\M_F1U^]&XZ,/?_P"O7@&N_"GQ1H\[
MB"S.HVX/RS6OS$CW3[P/X$>].E.%2E[*3L$DT[H]M\9>+],\/>'KN5[N%KIX
MF6W@5P6=B,#CT!ZFOF?1].EU;6;+3X5+/<S+&,>YP3^ YK6LO /BN_F$46@7
MZ$]YXC$/S? KV7X>?#)/"LG]IZE)'<:HR[4"<I #UP>['IG\![TG3P\'9W;%
MK)DWQD_Y)]/_ -?$7\Z\D^$__)3-(_[;?^B7KVOXEZ)J/B#P=+8:7;_:+EIH
MV";U3@'GEB!7G?P]^'OBG0_'.G:CJ.E^1:0^;YDGVB)L9B=1PK$]2.U11G%4
M))O74<D^8].^(7_)/];_ .O8_P Q7SCX0_Y';0?^PC;_ /HQ:^E_&6GW6J^#
M]4L+*+S;F> I&FX+N/U) %>*>&_AEXOL/%&D7ESI'EV]O>PRRO\ :8CM57!)
MP'R>!VHPLXQIR3833N?0]%%4-;DU"+1+U]*M_/O_ "B+>/<JY<\ Y8@8'7KV
MKA2N[&A\\?%7Q#_;OC6XCB?=:V(^S1X/!(/SG_OK(^@%<W:>'-<U"V6YLM&U
M&Y@?.V6&U=U.#@X(&.M=$?A3XW=RSZ.2S')9KN$_B?GKZ(T/2HM#T.RTR'E+
M:)8\_P!X]S^)R?QKTYUXT8*,-3%1<GJ?+G_"(>)O^A=U?_P"D_\ B:R&66VG
M9'5XIHVP0059&!_0@U]E5X?\0OACKFH>+KC4-"L!<6UV!+)B:--DG1AAF'7&
M[\32HXM3=I:#E"VQZEX-UX>)/"EAJ61YKQ[)@.TB\-^HS]"*Y+6/ ?@WQIJ]
M^=/OA;:I!(1="U8$;^Y9#[GDC'.<\YK.\ ^%/&.DZ-K.BW2/I27<8DMKM98Y
M/*DX!&%8GYACGMM]<5P.H?#OQIH-X98K"YF922MQ8,7)]QM^8?B!64*<5.7+
M.W8;;MJBKXW\$W'@K4(+>6\BNH[A"\4B*5. <'*\X_,UZC\$-:N[_0[_ $ZY
M=Y([%T\EFYVJX;Y0?0%?UKS&'P5XUU^\4SZ7J3R'Y?-O@R8'U?M7M'ASP%<>
M'?!%WI5IJ7V?5;P;I;R-<A&QC"@]@,C/!Y)XK3$3C[/ED[L44[W,W6/ ?@WQ
MIJ]^=/OA;:I!(1="U8$;^Y9#[GDC'.<\YKR;QOX)N/!6H06\MY%=1W"%XI$4
MJ< X.5YQ^9JUJ'P[\::#>&6*PN9F4DK<6#%R?<;?F'X@5!#X*\:Z_>*9]+U)
MY#\OFWP9,#ZOVK2E[FO/>(GKT/3O@AK5W?Z'?Z=<N\D=BZ>2S<[5<-\H/H"O
MZUXCJMA)I>KWEA*I5[>9XB#['%?2_@'P<G@W03:O*LUY.WF7$BYV[L8"K[#]
M>?I6#\1/A@OBB<ZKI4D<&I[0)$DX2<#ISV;'&>_'3K6%.O"-:79E.+<3G_#W
MPH\+>(]&M]0LM:O7$B R(K1DQMCE2-O!!IMQ\,O!%KK<6C3^)KJ._E7<L3,@
M^@)VX!/8=37"2>#/&>D3,J:/JB.?E+6J,X/XIFM'0_A3XHUFZ7[5:-I]N3\\
M]UP??"_>)_(>]:M6NW4T)^1[KX0\)VG@[29=/L[B:>.2<SEIL9!*JN. ./E%
M?+^L_P#(=U#_ *^9/_0C7UGI.GC2M)M;!9YK@01A/-F<L[X[DG_(KY\U/X6^
M,KC5KR>+1MT<D[NI^U0C(+$C^.LL+42E)R94UHK'NOA#_D2=!_[!UO\ ^BUK
MYF\7_P#([:]_V$;C_P!&-7U!X;M)[#POI%G<IY=Q;V4,4J9!VLJ $9'!Y':O
M"_$GPR\7W_BC5[RVTCS+>XO9I8G^TQ#<K.2#@OD<'O2PLXQG)MA-.R/8OA[_
M ,D_T3_KV'\S7S]\1?\ DH.M?]?']!7T5X-T^ZTKP?I=A>Q>5<P0!)$W!MI^
MH)!KQ_QI\./%FK>,=4O['2O-MIYMT;_:(EW# [%@:,/.*JR;?]7"2=D>D_"?
M_DF>D?\ ;;_T<]?.>L_\AW4/^OF3_P!"-?3/P]TF^T/P-IVG:C!Y%W#YOF1[
MU;&978<J2.A'>O%M3^%OC*XU:\GBT;=').[J?M4(R"Q(_CJ\/.*J3;8I)V1Z
MW\/O&&EZUX7L8/M4,5[;0K#- [A6RHQN /4'&?QQ7#_&CQ7IVH6UGH=A<QW+
MQ3?:)WB8,J$*55<CO\S9].*YOQ'\)_$.CW!>PM9-1M&&5:'#2+_LLHYS[C(/
MMTK-TKX;^*]6N4B71[BU0GYI;M#$JCU.>?R!IPI4E+VBEH#<K6L=/\#;%YO%
M-]?8/E6]IL)_VG88_16K'^+_ /R4:^_ZY1?^@"O<O!OA.U\'Z$EA WFS,?,N
M)\8,C_T Z 5YE\1_ 'B?7O&EUJ&F:9Y]K(D863SXER0H!X9@>M33K1E7<F[*
MP.+4;'0_ W_D2;S_ +"+_P#HN.MCXI^'O[>\%7+1)NNK+_28L=2 /F'XKG\0
M*B^%/A[5/#7A>YL]7M?LUP]Z\JIYBOE2B '*DCJIKNB 001D&N:I.U9RCW+2
M]VQ\D:#K]UX?GNY;4\W5I):MSC <=?J" ?PK9^&>@_V]XWLHW7-O:G[5-QQA
M2,#\6VC\ZQ_%5C:Z9XKU2RLI ]M!<ND9'8 ]/PZ?A7M'P4T'[!X9GU:5,37\
MF$)'/EID#\VW?I7H5YJ--R6[,HJ[L>G4445Y!N%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7A'QWDSXATN/'W;0MGZN?\*]
MWKP'XZ2$^,+"/ PM@K9^LDG^%=6$_BHB>QY?1117K&(5Z!\%O^2G6'_7*;_T
M6U>?UZ3\#59OB/&0,A;64GV' _K6.(_A2]"H?$CZ;HHHKYT[@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *Y_P =1^;X \0KG&-.G;IZ(3_2N@K+\2Q>?X5UB' ;S+*9<'H<H150=I)B
M>Q\7T445],< 4444 ?5O@202^ ]#8,6Q9QKD^PQC]*Z&N3^&<OG?#G1FR#B)
MEX]G8?TKK*\*HK3?J="V"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(3A2?04
M <],VZ:1O5B?UIE%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 445Q_BGQ3<:?>&PL2J2* 9)" 2">0 #QTQ^=5&+D[(3=CL**\\TG
MQM>Q72KJ3B>W8X9@@#)[C&,UZ!%+'/$DL3J\;C*LIR"*<X.&X*28^BBBH&%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%,EEC@B>65U2-!EF8X %,!]%>>:MXVO9;IETUQ!;J<*Q0%G]SG.*T_"W
MBFXU"[%C?%7E8$QR!0"<#)! XZ9K1T9)7)YU>QV%%%%9%!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Q_
MBGQ3<:?>&PL2J2* 9)" 2">0 #QTQ^=5&+D[(3=CL**\\TGQM>Q72KJ3B>W8
MX9@@#)[C&,UZ!%+'/$DL3J\;C*LIR"*<X.&X*28^BBBH&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,EEC@B>6
M5U2-!EF8X %,!]%>>:MXVO9;IETUQ!;J<*Q0%G]SG.*T_"WBFXU"[%C?%7E8
M$QR!0"<#)! XZ9K1T9)7)YU>QV%%%%9%!1110 4444 %%%% !1110 4444 %
M%%% !5>]O[33;8W%[<Q6\(XWRN%&?3GO1?WL.FZ?<7MP<0P1M(^.N ,\>]?.
MGB'Q#>^(]3>[NY#MR?*BS\L2^@_J>];T:+J/R$W8]K_X6+X4\S9_:RYSC_42
M8_/;BN@LK^TU*V%Q97,5Q">-\3AAGTX[U\O5K>'O$-[X<U-+NTD.W(\V+/RR
MKZ'^A[5T3P:M[KU)YCZ3HJO87L.I:?;WMN<PSQK(F>N",\^]6*X=BPHHHI %
M%5GU"RC<I)=VZL.JM( 1^M.%]:$9%U 0>XD%.S I^(;M['0+RXC)#A-JD=BQ
M"Y_6O)*]-\675O)X9O$2>)F.S 5P3]]:\RKKPZ]UF53<[;3/ L<]C'->W,B2
MR -LC ^4'L<]ZX^[A%O>SP*25CD9 3U(!Q7K;ZC9V=BLT]Q&B*@/+#GCL.]>
M27<PN+V>=00))&< ]LG-%&4I-MA-);&[X;\-PZY;3223R1-&X7Y0#GBMZ/P!
M8JX,EW<.OH,#^E'@"-ETNZD(^5IL#\ /\:ZVLJE22DTF5&*L5+#3+/3(/*M(
M5C4]3U+?4]ZMT45BW?<L****0!1110 4444 %%%% !3X6VS1MZ,#^M,HH Z6
MBD!RH/J*6LS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O"_&7Q4\1:;XDU;2M/FMX[>&4Q1R&'+I@8
M.">.N>HKW2N6OOAQX2U*^EO;O1T>XE<R2.)9%W,3DD@,!R:VHSA%WFKDR3>Q
M\X^']#OO%&NPZ?:JSRS-F20Y(1<_,['_ #^M?5VGV,&F:=;6-LNV"WC6)![
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?+WQ/F\_XCZR^<XD1.G]V-5_I7U#7R
M?XWF,_CK77.>+Z5/^^6(_I7;@5[[?D9U-C!HHHKTS(*]L_9WAW7OB"? ^2.!
M,]^2Y_\ 9:\3KWS]GF';I6N3_P!^>).G]U6/7_@5<N-=J#_KJ:4OC1[11117
M@G8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\;^-(/LWCG7H>RZA/CGMO)'Z5AUV/Q5M_LWQ-U
MR/UE63_OI%;^M<=7TM)WA%^1P2W844458CW3X#S[M$U:#^Y<H_\ WTN/_9:]
M:KQ+X"S[;W6[?^_'"_\ WR6'_LU>VUX^*5JK-X;!1117.4%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %5[[BSE^G]:L56U#_CQD_#^8IH3,.BBBK("BBB@ HHHH ****
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M.HIHRE&QZ3X;\21ZQ$()RJ7J#D=!(/4?U%=!7BD,TEO,DT+E)$(96'4&O2]
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M&!7Q,RJ!1117H&85]'? &#R_ U[,>LNH/CGL$0?SS7SC7U'\%;?R?AE82?\
M/>6:3_R(5_\ 9:XL>[4?F:T?B/0:***\0ZPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-SY22^6P;8XR#7K.EZI;:M9K<VS9'1E/5#Z&L*\I)61<$FR[1117&:A1110
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M_P"/&/\ '^9JS4/<M!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'XSN/LO@G6YLX(L
M90#[E2!^IKY-KZ;^*UU]F^'&J8.&E\N,>^9%S^F:^9*]/ KW&_,RJ;A1117:
M9A7UU\-;;[)\-]!C];42?]]DM_[-7R+7VEX>M?L/AK2K3&/(LX8L?[J ?TKS
MLQ?N11O06K-*BBBO(.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q;]H:UWZ7H5WC_ %<TL6?]
MY5/_ +)7@E?3'QUM/M/P\\['-M>129^H9/\ V:OF>O<P+O12[')67O!11178
M9&UX/NOL7C/1;@G"I>Q;C_LE@#^A-?6E?&D,KP31RQG#HP93Z$'-?8\$RW%O
M',GW)$#K]",UYV.6L6:TR2BBBN T"BBB@ HHHH **** "BBB@ HHHH ****
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M%%%=)):TVU-]JEI: 9,\R18_WF _K7VUTKY!^'=I]N^(>@PXR!>)(1_N'?\
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M>\,3ZO(L\X:*R!Y;H7]E_P :ZG3/!6GV3+)<DW<H[.,)_P!\]_QKI  H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.U2-R,;LEC^9)K0JZE;FT6Q,86W"BBBL"PHHHH **** "BBB@ HHHH ****
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MHI\*[IHU]6 _6@#H0,*!Z"EHHK,T"BBB@ HHHH **** "BBB@ HHHH ****
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M#QN'4^X.14R7-%H$?95%0VEREY9074?^KFC61?H1D?SJ:O!.D**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,&]7;>2CWS4%7-37%WG^\H-4ZT6Q#"BBB@04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %>]L+34K8V][;17$)YV2H
M&&?7GO7/_P#"NO"GF;_[)7.<_P"ODQ^6[%=115*<H[,+%>RL+33;86]E;16\
M(YV1(%&?7CO5BBBEN 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *GLEW7D0]\U!5S3%S=Y_NJ30]AHV:***S+"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *KW]T+'3[BZ;_ )91L^/4@<"K%8GBYBOA>](.
M.$'_ (^M3)VBV:48J=2,7U:/+9)'ED:1V+.Y+,3W)IM%%>8?7!1110,****
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MRP48R0.I'>FDV[(#0HK@/^%O:!_SYZG_ -^H_P#XNC_A;V@?\^>I_P#?J/\
M^+K7V%3L*Z._HKBM-^)^BZIJ5M806NH++<2"-"\:!03ZX<UVM1*$H_$AW"BB
MBH **** "BBJNIW#VFE7ES'CS(8'D7(XR%)%-:@6J*\0_P"%L>(_[EC_ -^3
M_P#%5[?6E2E*G;F$G<****R&%%%% !112$@ DG '4F@!:*XW6/B9H&E2M#$\
ME],IP1;@%0?]X\?EFL$?&2'S,'1'V>OVD9_+;_6ME0J-72%='J%%<9I'Q-T#
M4Y%AF>6QE8X'V@ *3_O#@?CBNR5@RAE(*D9!'>HE"4=)(=Q:***@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHK/UO5[?0=(GU.Z25X8=NY8@"QRP48
MR0.I'>FDV[(#0HKB+#XI:)J&H6UE%:Z@LEQ*L2%XT !8@#/S].:[>JE"4?B0
M7"BBBH **** "BBB@ HHHH **** "BBB@ HHK-UC7M,T&V\_4;M(0?NKU9_H
MHY--)MV0&E17FUW\8;"-V%II=Q,HZ-)((\_D#1:?&'3Y' N]+N80>K1R"3'Y
MXK7ZO4WL+F1Z3169HWB#2]?@,NG7:38^\G1U^JGD5IUDTT[,84444@"BBB@
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M-7R1X5U/^Q_%>EZ@6VI#<H7/^QG#?^.DU];UY>-C::?<UIO0****XS0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ANTWVDJ_[.?RYK KI2,C!Z5SCKLD9#_"2*J),AM%%
M%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5ROQ(_Y$'4_P#M
ME_Z-2NJKE?B1_P B#J?_ &R_]&I6E+XX^H/8\/T;3'UG6+73HY%C>X?8'89
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MA9:AX=U5K*\M[E4MI0QAE5PIV'@X/%>!VL^JZG90Z'9)--$LC2B"%2=S'')
M],#Z5Z5X-T;4-'\%>($U"UDMY)(Y"JN.H$9YJYT%35V]1)W/(:^I'GBC.))4
M4]<,P%?+=>S?%C1/MFB0ZK$F9;-L28')C;_ X_,UMB8J4HQ;[BB=^DT4I(CD
M1R.NU@:>2 ,G@5X%\.M6.E>,+4,V(;K_ $=_^!?=_P#'@*]6^(.I_P!E^#;U
ME.)+@"W3G'+<'_QW=7+4H.,U#N4GH=#]JM_^?B+_ +[%3 @C(Y%?./A31SKG
MB:RL2,Q,^^7_ '%Y/YXQ^-?1P  P.!16I*FTKW!.X5Y+\3_%TS7;Z!92%(4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_OS2!!^9-5[/7=(U%]ECJMC=-TVP7".?T-?+L8UOQQXFCB:9[O4;MB%,CX
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MTWJ>GT445Y9L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8FH)LO']&^:MNLS5H_]7)_P
M$_Y_.G'<3V,VBBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*Y7XD?\ (@ZG_P!LO_1J5U5<K\2/^1!U/_ME_P"C4K2E\<?4'L>*^'--AUCQ
M#8Z?<-(L4\FQC&0& QVR#7JO_"H= _Y_-3_[^Q__ !%>0:;J$^E:C!?6Q43P
MMN0L,C/TKJ_^%I^)?^>EK_WY_P#KUZ%:-5OW&0K=3T;0OAYI/A[58]1M+B]>
M:,, LKH5Y&#T45L^(-?LO#FEM?7K'&=J1K]Z1O05Y18_$[Q'<:A;0O);;))5
M1L0CH2!70?&&VGDT[3+E Q@BD=9,= 6"[2?R/YUS.E)U$JCW'?30P[KXIZ_?
M7'E:99P0!L[42,RN?Z'\JQ/$NJ>+-1LXCKT-TEJ),QF6S\I=Q!X#;1GC/&:N
M^ /%FG>%Y[PW]K*_GA0LT2@LF,Y&"1P<]O2I?'GCB+Q/%!9V,$L=G#)YA>7
M9VP0. 3@8)_/M70H\L[1CIW%T+WP?<C7=03L;8$_@P_QK.^*?_(Z/_UPC_K6
MA\'_ /D8+_\ Z]?_ &=:S_BG_P CH_\ UPC_ *TE_O#] ^R=;\(+2%="OKT(
M//>Y,1;'.U54@?FQKM]<_P"1?U+_ *]9?_0#7'_"'_D4[K_K^?\ ]%QUV&N?
M\B_J7_7K+_Z :Y*O\5E+8^9J^H;RTBO[*>TG7=#/&T;CV(Q7R]7U171C/LBB
M?,FHV5QHNLW%F[%9K64J&''0\,/T-=A\0O$RZYI^AQQ,,-;_ &F8#H'/RX_
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M_P#HN.O3:\R^!O\ R)-Y_P!A%_\ T7'7IM<>(_BR+CL%%%%8E!1110 4444
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MC\1D5%6//!Q&G9GU[134=9$5T8,K $$=Q3J\(Z HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ JM?Q^99OZK\U6:1@&4J>A&#0!S=%.=#'(R'JIQ3:T,PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "JNI:;::OI\MC?1>;;2XWIN*YP01R"#U
M JU133MJ@.5_X5OX3_Z!/_DQ+_\ %4?\*W\)_P#0)_\ )B7_ .*KJJ*OVL_Y
MF%D<Q%\//"T$R2QZ7M=&#*?M$IP1R/XJZ*ZM8+VVDMKF))89%VNCC((J6BI<
MY/=@<-/\*/#DT_F(U["N<^7'*-O_ (\I/ZUJQ^ O#::8-/.G!X?,$K$R,'9@
M" 2P(/1CQTYZ5TE%4ZLWU"R,;1_"NBZ!<23Z99>1+(FQF\UVR,YQ\Q/I4>J^
M#M!UN]-YJ-AYUP5"E_.D7@=. P%;M%+GE>]]0L9^D:)IV@VCVNF6_D0O(9&7
M>S98@#.6)/0"KD\$=S;RP3+NBE0HZYQD$8(XJ2BI;;=V!RO_  K?PG_T"?\
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MY)]3A']V.92/_'D)KTBBM(U9QTBQ-)G&Z/\ "[PIHTRSIIYNIE.5>[?S,?\
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M%X>TOPU9/9Z1:_9K=Y#*R>8SY8@ G+$GHHK3HHJ&VW=C"BBBD 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[[K=V09JG6OID6RW+GJY_04GL-%ZBBBH+"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\S?''1?[-\>&^1<1:C LN>V]?E8?HI_&O-*^D?CO
MHG]H>"X=31<R:=.&)](WPK?^/;/RKYNKWL'4YZ*\M#CJJT@HHHKJ,SIOA_K'
M]A^.-+NV;;$\HAE]-C_*2?ID'\*^J*^,:^LO!^L#7_".F:B6W22P@2D_\]%^
M5OU!KS\=#:9K3?0W****\\T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &R()(V0]&&*YU
ME*L5/4'!KI*QM1B\NZ+#HXS^-5$EE.BBBJ)"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH X#XO?\BG:_]?R?^BY*X#X;_P#(_:9_VU_]%/7?_%[_
M )%.U_Z_D_\ 1<E<!\-_^1^TS_MK_P"BGKT*7\!_,A[GOU>0_&+_ )"NF?\
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MGVXQ^-52;5"\=P>YZ'?_  M\/3V#16D,MM<[?DG$K-S[@G&/IBO%C]ITK4R
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M'_(IZ-_UXP?^BQ7=B)RC!<I$5J<O\0[&'3?ATME;AA#!)$B;CDX!KS[X;_\
M(_:9_P!M?_13UZ5\4O\ D29?^N\?\Z\U^&__ "/VF?\ ;7_T4]11UH2^8/<[
M7XP_\@C3?^N[?^@UY]X1\./XGUU++S#'"JF29P.0@P./<D@5Z#\8?^01IO\
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MVP2O]GFYXV/QD_0X/X5C7ASTVBHNS/J6BBBO%-PHHHH **** "BBB@ HHHH
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M?VI:?9_/\KR_WB/NV[\_=)QU%=_114SFYRYF-*P4445 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '(?$;1-1U[P];VNF6_GS)=K(R[U7
M"A'&<L0.I%<?X)\$^(=(\7V-]?:?Y5M%YF]_.C;&8V X#$]2*]?HK:-:48<B
MV%;6X5YS\2?"^LZ_J%C+IEGYZ11,KGS47!)_VB*]&HJ*<W"7,AM7. ^&?AO5
MO#W]J?VI:?9_/\KR_P!XC[MN_/W2<=17=W$$=U;2V\J[HY4*./4$8-2443FY
MRYF"5CP;7/A[KNCWS_8[6:]M@V8IK==S8[94<@U;L?#OC;Q*8[34)=1BL<C>
MUZ[  >NUN6/IQ^5>W45O]:E;5:D\IX+;_#KQ6ES$[:5A5<$G[1%TS_O5ZGX^
MTF^UKPO)9Z?!YUP948)O5> >>20*Z>BHG7E*2D^@TCR#P3X)\0Z1XOL;Z^T_
MRK:+S-[^=&V,QL!P&)ZD5Z1XILKC4?#&H6=I'YEQ-"51-P&3]3Q6O14SJRG)
M2?0$K'B.A> /$]GXATRZN-,V0PW<4DC>?$<*'!)P&ST%=O\ $+PMJ_B.W@.G
M78,</)LW.T.W]X'U[8-=O152Q$G)2[!8^>O[!\7Z9N@BL-6B4_>6W5RI_P"^
M.*T_#WPUUG4KN-M1@:QLPV9#)P[#T5>N?<U[E16CQ<K:(7*0M:0-9&S:)6MS
M'Y1C/(*XQC\J\>\1_"[4K*YDFT9?M=H3E8]P$B>W/WOJ.?:O9Z*QIU94W=#:
MN?-Z^$_$3R^6-$U#=TR;=@/S(Q7JWPXT#7M"M9TU-TCM9<-';$[G1NYR.!D=
MN?P[]U16E3$RG'EL"C8\)O\ X>>*9]1NI8]+W(\SLI^T1#())'\5>S:%;36?
MA[3+6X39-#:11R+D'#! ",CCJ*T**BI6E423!*QS'C[2;[6O"\EGI\'G7!E1
M@F]5X!YY) KA_!/@GQ#I'B^QOK[3_*MHO,WOYT;8S&P' 8GJ17K]%$:THP<%
MU"VMSS;XP_\ ((TW_KNW_H->=>&O#D_B:\NK2UE1)XK<S('Z.0RC;GM]ZO1?
MC#_R"--_Z[M_Z#7/_"'_ )&RZ_Z\7_\ 1D==5*3C0NB7N<Y-X-\1P3^2VBWA
M;.,I$77_ +Z&1^M=IX+^&UW'?PZEKD:Q1Q$/';$@LS#H6QT ZX_.O6**QEBI
MR5MBE%#)H4N()()5W1R*48>H(P:\&UOX>Z]I5Y(D%E+>VV3Y<L"[R1[J.0:]
M\HK.E6E3V!JYY7\,M(URRUV:XU*TO(;86C1I]H!4 ET( !]@:S?%7@7Q)J7B
MC4+RTT[S+>:7<C^?&,C [%LU[-15?6)*?.D'+H8'@G3;O2/"%C8WT7E7,7F;
MTW!L9D8CD$CH16+XX\ +XB?^T+!TAU ##A^%F Z9]#[UW-%9JI)3YUN.W0^<
M[KP;XDLY3')HUXQ'>&,R#\UR*TM'^''B#5)E$UJ;&#^*6XX(^B]2?R^M>]45
MN\7.VQ/*C-T'0[3P]I4=A9J=B\L[?>=CU8UYWX_\':]K?B=[S3K#SK<PHH?S
MHUY'7@L#7JU%8PJRA+FZE-'(?#G1-1T'P]<6NIV_D3/=M(J[U;*E$&<J2.H-
M9'Q)\+ZSK^H6,NF6?GI%$RN?-1<$G_:(KT:BA59*?/U%;2QP'PS\-ZMX>_M3
M^U+3[/Y_E>7^\1]VW?G[I..HKOZ**F<W.7,QI6"BBBH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***?#&9IDC'\
M1H UM-B\NVW'JYS^':KE( %4 #  P*6LS0**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYW^+OBU]:\
M1-I%O(?L.GL4(!X>;HQ_#[H_'UKW7Q%J?]B^'-1U+(W6UN\B9[L!\H_/%?(S
MNTCL[L6=B2S$Y)-=V"IW;F^AG4?0;1117I&04444 %%%% $D$\MM/'/!(T<L
M;!T=3@JPY!!KZF\"^)U\6>%K?4&P+E?W5RH[2 #)^A!!_&OE6O5O@9JS0>(+
M_2F;]W=0>:H_VT/^#'\JY<73YJ=^J+@[,]XHHHKR38**** "BBB@ HHHH **
M** "BBB@ KS+XN^$];\4?V/_ &-9?:?L_G^;^]1-N[R\?>(S]T]/2O3:*NG-
MTY*2$U=6/'_A3X(\1>&O%%S>:OI_V:W>R>)7\Z-\L70@85B>BFO8***=2HZD
MN9@E;0*\\^+/AG5_$VDZ?!H]I]IDAG9W'F(F!MQ_$17H=%*$W"2D@:NK'C_P
MI\$>(O#7BBYO-7T_[-;O9/$K^=&^6+H0,*Q/137L%%%.I4=27,P2MH>=?$3X
M9)XJD_M/39(X-45=KA^$G Z9(Z,.F?P/MXU>^ ?%=A,8I= OW([P1&4?FF17
MU516M+%3@K;HEP3/FK0?A1XGUBX07%FVG6Q/S370P0/9/O$_D/>O?_#?AVQ\
M+Z+#IE@I\M/F=V^](YZL??\ ^M6M14U<1.KH]AJ*1YU\5/ EWXJMK6^TL(U_
M:JR&)B%\U#S@$\9!SU]37C</@_QC:W12#1-5BE(VEHX7 (]-PX_6OJFBJIXJ
M4(\MKB<$W<YZRT&+4? -AHFL0,0;"&&>,GYE<(N>?4$=?45XGXB^$7B+2+EV
MT^'^T[/)V/#@2 >C)US],U]&T5-/$3IMM=1N*9\L+X0\9ZBR6[Z/JSA#A1/&
MZJOT+8 KUKX9_#F_\+W+ZIJEV4N)(]@M(9"4 ]7(X8CL.0.M>FT5=3%3G'EM
M9"4$M3SSXL^&=7\3:3I\&CVGVF2&=G<>8B8&W'\1%87PI\$>(O#7BBYO-7T_
M[-;O9/$K^=&^6+H0,*Q/137L%%9JO)4_9]!\JO<\I^+7@[7O$VIZ=-H]A]IC
MAA99#YT:8).1]YA5GX1>$];\+_VQ_;-E]F^T>1Y7[U'W;?,S]TG'WAU]:]-H
MH]O+V?L^@<JO<\\^+/AG5_$VDZ?!H]I]IDAG9W'F(F!MQ_$16%\*?!'B+PUX
MHN;S5]/^S6[V3Q*_G1OEBZ$#"L3T4U[!10J\E3]GT#E5[GBGQ'^'?BG5==FU
M:UF_M2!_]7%N"/ O]T*>"![<GN*X5_#OCF:(:?)IFNO , 1-'*8ACD=?EKZE
MHK6&+E%)66@G!,\;^&WPNU#3M7AUO746 P?-;VH;+;L?>;' QV'KUQCGV2BB
ML*E6527-(I*P4445F,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *BNKF*SM)KJ=ML,*-([>B@9)_(5+7 ?%_6_P"R?!$MM&V)M0<6X]=G
M5S^0Q_P*KIQYY*(F[*Y\^ZOJ,NKZQ>:C-_K+F9I2/3)SC\.E4J**]U*VASA1
M110![1^S]H9EU/4]=D7Y((Q;1$C@LWS-^( '_?5>^5QWPMT+^P?A]IL#IMGN
M$^U3>NY^1GW"[1^%=C7S^*J<]5L[::M%!1117.6%%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\\?&?7/[2\8+I\;9ATZ((?3S&^9OTVC\#7OFJ:C#I.DW>HW!_<VT3
M2M[@#.![GI7R)?7DVHW]Q>W#;IKB5I9#ZLQR?YUVX*%Y.78SJ/2Q7HHHKTS(
M*W/!VAGQ'XOTO2MI*3SCS<=HQ\S_ /CH-8=>U_L_:#YE[J>OR+\L2BTA/^T<
M,Y_ !?\ OHUCB*GLZ;D5"/-)(]X "@   #@ 4M%%?.G<%%%% !1110 4444
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M1117G&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5CZE#Y<_F ?*_\ZV*@NX?/MV3^+JO
MUIIV$S!HHZ459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%17%U;V
MD1EN9XH8QU>1PH_,TP):*Y6_^(OAFPRO]H?:''\-NA?/X_=_6N9O?C%%NV:=
MI$CYZ-/(!_XZN?YUI&C4ELA71ZA17D7_  E'Q$UK/V#3GMT;HT=KM'_?4F12
M_P#"'>/]7YU#5FA4]4ENV(_[Y3(J_86^*207/5+G4+*R&;J[MX!ZRR!?YFL:
MY\<^&+3/F:S;MC_GEF3_ -!!KC;;X.9.Z\UDDD\K%!_4G^E;-M\)_#L.#*][
M<'N'E '_ (Z!1RT5O*X:C[CXJ^&H<^6UW/\ ]<X<?^A$5FS?&+35SY&EW;^F
M]U7^6:Z6W\ >%[;&S2(F([R.S_S)K2A\/:+;X\G2+",CNMN@/YXHYJ*Z-AJ>
M=2_&20G$.AJ/3?<D_P E%,_X6EXAEY@T*(@=?DD;G\*]6B@BA&(HDC'3"*!4
ME'M*?2'XA9]SR7_A/O',HVIX?3<>A6QF)_\ 0J/^$R^(7_0OR_\ @NEKUJBC
MVT?Y$%CR7_A,OB%_T+\O_@NEH_X3+XA?]"_+_P""Z6O6J*/;1_D06/)?^%B>
M-(QNE\/Q!!U/V28?KNI/^%K:W!_Q]:'$,<GATX_'->MT4>UAU@%GW/*HOC+V
MFT/\4N?Z%:T(?C!I#?Z_3KY/]S8W\R*[^:TMKC_76\4F?[Z _P ZSY_"^@7'
M^MT:P)]1;J#^8%'/1?V?Q"S,.W^*/A>;_67,\'_72!C_ .@YK7MO&/AR[P(M
M9L\GH)) A_\ 'L51N/AUX6N,DZ6(V]8Y77],XK(N?A%H4N3!=7L!]-ZL/U&?
MUHM0?=!J=Y#<07*;X)HY4_O1L&'Z5)7E$WP@O('\S3];3>.F^(QD?B":B_L#
MXDZ/S:7\MRJ]DN1(/P63_"CV4'\,PNSURBO(O^$\\;:+_P A;2?,C7[SRVS)
M^3+\OZ5J6'Q@TZ7 O]-N(#W:)A(/UP:3P]3=:AS(])HKGM/\<^&]2P(=5A1S
M_!/F(_3YL _A6^CK(@=&#*>0RG(-9.+CNACJ***D HHHH **** "BBB@ HHH
MH ***.M %W38?,G\PCY4_G6Q4%I#Y%NJ?Q=6^M3U#=RT%%%%(84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #)HHYX9(95#QR*593T((P17R5XFT.;PYXBO=+F#?N)"$8C[Z'E6_$8KZ
MXKSSXI^!6\3Z:NHZ?'NU2T4@(.LT?7;]1U'U([UU86JH3L]F1-71\Z44K*R.
M592K*<$$8(-)7K&(4444 %%%% !7O7P2\/-8Z'=:U.A62^8)#D?\LU[_ (MG
M_OD5Y?X$\%W7C'6EB"O'I\)#74X'W1_=!_O'_P"OVKZ?MK:&SM8K:WC6."%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 8VHP>5/O ^5^?Q[U3
MK?NH/M$#)_%U7ZU@$8.#UJTR&%%%%,04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHQ8V%M;^\404GZD=:NT5E*I*6['8****@ HHHH **** "BBB@ HHHH ****
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MY=]/F/:?[F?9AQ^>*[&*:.>)989$DC895T8$$>Q%92A*/Q(=Q]%%%0 4444
M%7-.@\V?>1\J<_CVJF!DX'6M^U@^SP*G\75OK2;&D34445!84444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >>>.OA99>)WDU#3F2RU0\L2/W<Q_P!H#H?]H?B#7A6N>&=8
M\.7!AU2PF@YPLA&4?_=8<&OKBF2PQ3Q-%-&DD;##(Z@@CW!KJI8J4%9ZHAP3
M/C2BOJ:]^''A#4'+SZ%;*QZ^26B_] (JJOPI\$JP8:(,CUN9B/R+UU?7H=F1
M[-GS*B-(ZHBEG8X"J,DFO1/"7PBUC6I([C5U?3;'.2'&)G'LI^[]3^1KW73/
M#NC:+_R#=+M+5L8WQQ ,?JW4UIUC4QK>D%8I4^Y1TC1[#0=-BT_3;=8+>/HJ
M]2>Y)[D^IJ]117$VV[LT"BBBD 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<YX[
MU\>&_!]_?*^V<IY5OSSYC<#'TY;\*Z.O"/C?X@^UZU:Z%"^8[-?-F /_ "T8
M< _1?_0JVH4^>HD3)V1Y11117M& 4458L+*?4M0MK&V7?/<2K%&OJS' _G1L
M![W\ _#OV30KW7YD_>7K^3 3_P \T/)'U;C_ (!7L-4-$TJ#0M#LM+MO]5:P
MK$#C[V!R3[DY/XU?KYRM4]I4<CNA'E5@HHHK(H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K \:^'U\4>$-1TK:#++$6@)[2+\R\]N
M0!]":WZ*<9.+30FKJQ\.NC1NR.I5E."#U!IM>@_&+PW_ &#XZGN(DVVFI#[3
M'@<!R?G'_?7/T85Y]7TE.:G%274X9*SL%%%%6(]G^!OB+B]\/3O_ -/-N#^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"OB^_P!+P?(5_,MR>\3<K^70^X->KE]6Z=-G-7C]HYVBBBO3, KZ"^"_B/\
MM/PU)I$[YN-.;"9/)B;)'Y'(^F*^?:Z7P'XC/ACQ=9WS-BV<^3<_]<VZG\.&
M_"L<13]I3:ZE1=F?5-%("&4,I!!&01WI:\4W"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MV21(HVDD8*B LS'H .IIU>>?&#Q)_8WA,Z?"^+K4B8A@\B(??/X\+_P(U=.#
MG)10F[*YXCXPU]_$WBF^U,D^5(^V!3_#&.%'MQR?<FL*BBO<BE%61SA1113
MZ_X9^&O^$H\<65K(FZT@/VFY!&044C@_4E1^-?6M>7? [PS_ &3X2?5YTQ<Z
MFP9<CD1+D+^9W'Z$5ZC7AXVKSU;+9'72C:(4445QFH4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** #I7RY\1?$O\ PD_C"ZN8WW6D'[BV
MQT**?O?B<GZ$5[7\5/$P\/>$)HHGQ>7^;>'!Y (^=OP''U(KYIKT,%3WFS*H
M^@4445Z!F%;/A30)O$_B>PTB+(%Q*!(P_@C'+M^"@_C6-7OOP$\+_9].N_$M
MPG[RY)M[;(Z(#\[?BP _X"?6L,15]E3<BX1YI6/8[>WAM+:*VMXUCAA01QHO
M15 P /PJ2BBOGCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /$OCWX5,D%IXGMH^8\6UW@?PD_(Q_$E?Q
M6O"*^UM9TFVUW1KS2[Q=T%U$8V]1GH1[@X(]Q7QOK.DW.A:S>:7>+MGM93&W
MH<="/8C!'L:]G 5>:'(]T<M:-G<HT445WF(5]+_"WQ/_ ,)'X1BCFDW7MCB"
M;)Y8 ?(WXCCZ@U\T5V'PU\3_ /",^+H))I-ME=?N+C)X )X;\#@_3-<^)I>T
MAINBHNS/IZBBBO'-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK$\2>+='\*V?GZG=!7
M89C@3YI)/]U?ZG ]Z\?O?$_C+XGWDFGZ';/::;G:XC8JH'_363_V4?D:VIT9
M3UV7<ER2.^\6_%/P_H"R6D+?VG>\J88&&Q#_ +3]!^&3]*\T8>-OB#SM-GI;
M],YCB(_F_P"HSZ5Z)X4^$6BZ$$N=3"ZG?#G]XO[I#[+W^I_(5W=U:K/ $4!6
M4?)CM[5HJM.GI35WW8FF]SRO0OA?HNF;9;[.H7 Y_>#$8/\ N]_QS7:Q11PQ
M+'%&L<:C"J@P /85(05)!&"."*2HE.4W>3%:P4445 !1110 4444 %%%8^K:
MW]@D$$**\N,DMT6AM+<:5]C8HKC)=>U"7I,$'HB@52EN9Y_];-(_^\Q-9NHB
MU39W$M]:0_ZRYB4^FX9_*J4OB&PCSM9Y#_LK_CBN/HI.HRO9HZ.7Q1U$-K^+
MM_052E\17\F=K)&/]E?\<UDTJJSG"J6/H!FIYVQ\J1/+?W<_^LN96'IN./RJ
MO5R+2;^;[EK(/]X;?YU=B\-7C\R/%&/KDTK-CND8U%=(GA9!]^Z8_P"ZF/ZU
M+_PC%K_SWF_3_"GR2%SHY:BNG;PO ?N7,@^H!JM+X7G7_57$;_[P*_XT<D@Y
MT8T-U/;G,,SI_NMBM2V\27<1 F5)E^FT_I_A5.XTF^MLE[=BH_B3YA^E4J5V
MAV3.RM==LKG ,GE/Z2<?KTK2!! (.0>XKSNK%M?W5H?W$S*/[O4?E5JIW(=/
ML=[17.6OB?HMU#_P./\ P-;5M?VMX/W$RL?[O0_E6BDF0XM%FBBBF2%%%% !
M1110 44C.J*6=@JCJ2< 5E77B"S@R(R9G]$Z?G0VEN-)O8UJAN+NWM5S/,B>
MQ/)_"N5NO$%[<9$;"%/1.OYUELS.Q9F+,>I)R:S=3L6J?<Z2Z\3HN5M82Q_O
M/P/RK(N-8O[C.ZX95]$^7^54:DAMYKAML,3R'_9&:AR;+44AA)8Y)))[FDK6
MA\.WTHRX2(?[39/Z5=3PL/\ EI='Z*G_ ->CDDPYD<Y174CPQ;8YGF_3_"D;
MPO;D?+<2@^X!I\D@YT<O3XY9(CF.1D/JIQ6[+X7D'^JN4;V9<?XU2ET#4(ND
M0D'JC"ERM!S)D<6LZA%TN68>C@-_.KL7B>Y7'FPQN/;*FLF6UN(/];!(GNRD
M5#2YFA\J9U,7B>V;B6&1#[885=BUG3YNERJGT?*_SKB:*I5&3R(]#26.49C=
M7'JIS3J\[5F4Y4D'U!JW%JM]#]RZD^C'=_.J50GV9W-%<I!XENT8><D<B]^,
M&NGMYTN8$FC.4<9%6I)[$N+6Y)1113)"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *K7-A:W@_?PJQ_O=#^=6:*!G.77A@\
MM:S?\ D_Q%8MS8W-H<3PL@_O8R/SKO:0@,"" 0>QJ'33V*4V>=T5V5UH5E<Y
M*IY3^L? _+I6-<^&[N(DPLDR_P#?)_7_ !K-P:-%-,I6^JWUM@1W#[1_"WS#
M]:T(O$]RN!+#&_TRIK)FM+BW/[Z"1/<KQ^=0TN9H=DSIE\4Q'[]JX^C T_\
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MXNS*3N%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBN(^*7B?_ (1SPC+'#)MO;[,$.#RH(^=OP''U(JH1<Y**$W8\8^)7B?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KPWX]>%/\ CU\46L?I;WF!_P!\.?\ T'_OFO<JHZSI-MKNC7FEWB[H
M+J(QMZC/0CW!P1[BMJ%5TJBD3./,K'Q315[6=)N="UF\TN\7;/:RF-O0XZ$>
MQ&"/8U1KZ%--71PA1113 ^E?A7XI/B/PHD-Q)NOK#$,N3RRX^1OQ''U4UW-?
M+7P_\4-X5\5V]V[$6<W[FY'^P3][\#@_@1WKZD5E=0RD%2,@@\$5Y&*I<D]-
MF;0=T+1117,6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M"0!DG %?+_Q'\4'Q1XLGEBDW6-MF"V Z%0>6_P"!')^F/2O8?BUXJ_L#PNUE
M;R 7VH@Q+@\I'_&WY' ^OM7SA7HX*E]MF51] HHHKO,PJ]HVDW.NZS9Z79KN
MGNI1&OH,]2?8#)/L*HU[E\!?"G_'UXHNH_6WL\C_ +[<?^@_]]5C7JJE3<BH
M1YG8]DT;2;;0M&L]+LUVP6L0C7U..I/N3DGW-7J**^>;;=V=P4444@"BBB@
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M1;+\SJHQLKA1117";!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M# %6***^>W.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._C!X._P"$F\*M
M>VL>[4=-#2QX',D?\:>_ R/<8[U\OU]R5\M?%KP;_P (KXI:>UCVZ;J!:6#
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M\P&6(?/W'K5^BA.P'-45JW]EOS-$/F_B4=_>LJM$[D-!1110(**** "BBB@
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M-I^MV9M=1MDGC[9ZJ?4'J#7E&M^"-:\'W?\ :V@7,TMO'SN3_61C_: X9?\
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M_LX;NTE66WF0/'(O1@>AHK4N1W6SV"+N34445B4%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEP3*4FCSV6*2%RDJ,C#LPP:97H,T$5PFR:-77T89K&N_#4+Y:UD,9_NMR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPVBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7E_P 4]!DADM_$UCE)HF59V7J"#\C_ (' _*O4
M*KW]E#J-A/97*[H9T*./8C^=:4Y\DK@U<SO"VNQ^(O#]M?K@2$;)E'\,@ZC^
MH]B*V:\@\"7D_A7QI=^&[YL1SOL4G@>8.58>S#^8KU^G6AR2TV$G<****R&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 52N-*LKK)D@4,?XE^4_I5VBAJX[V,"
M;PO&>8;AE]G7/^%4I/#5ZOW'B<>S$'^5=914N$2N=G&'0=2!XMP?HZ_XTG]A
M:E_S[?\ CZ_XUVE%+V:'[1G'IX>U!NL:+]7']*M1>%YC_K;E%_W 3_A7344>
MS0N=F1!X=LHL&3?*?]HX'Z5IQ010)LBC5%]%&*DHJDDMB6V]PHHHIB"BBB@
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M:7:ZUI5SIM['OM[A"CCN/0CW!Y'N*\4\$ZG=?#GQ[=>&=6<BQN9 @<\*&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ?UO^R?!$MM&V)M0<6X]=G5S^0Q_P*K'PHT/^Q? UK(Z;;B^)NI,]<-]P?\
M?(!_$UPGQ-D?Q1\3M*\-0L3'#LB;!^ZTA#.?P3;^5>X1QI#$D4:A8T4*JCH
M.@KIG[E&,>^I"UE<=1117,6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4-Q;)<IAN".C#J*FHH Y^>W>W?:X^A[&HJZ*2))D*.N
M0:Q[JR>W.X?-'Z^GUJTR6BK1113)"BBB@ HHHH **** "BBB@ HHHH ****
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M%%%>>;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!11168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3%XCV4++=FE.',SHK>WAM;:*WMXUBAB0)&BC 50, "I***\([ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#/C9X P7\5Z7#QQ]O
MC0?@)0/T/X'U->'5]PRQ1SPO%*BO&ZE71AD,#P01Z5\K_$[P))X,U\O;HS:3
M=DO;/UV'O&3ZCMZC\:]? XCF7LY;]#FK0M[R.&HHHKT3 *Z7P1XON?!^O)>1
M[I+27"74(/WT]1_M#J/R[FN:HI2BI*S!.Q]C6%];:G807MG,LUO.@>-UZ$'_
M #TJQ7SU\*_'W_"/7PT?4I?^)7<O\CL>+>0]_93W].OK7T+UKQ:U)TI69O%W
M04445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7->-O%\7@W1!?/:27,DC^7$B\+NZ_,V.!_.NEJIJ>FV
MFL:;/I]]"LUM.NUT/?\ P(Z@U46E)<VPF5?#OB"Q\3Z-#J=@^8Y!AT/WHW[J
M?<?_ %Z\E^)/_$P^,7A^RZJ/LT9 [;IB2?R(K.C;5?@YXS*/YEQHUV>2!Q-&
M#U]!(N?U]#4VI:K8ZO\ ''3[^"ZCDL5,$HESA558PY)/;'.<].:[:=+DFY1U
M5G8ANZLSWB21(HVDD=41 69F.  .I)KG_#OC?1/%%Y>6FFW):6U;E7&WS%Z;
MU]5SQ^7J*\M\7>,M2^(6K)X8\+QR&R=L22?=\[!^\Q_AC'7W_(5Z=X+\%V'@
MW2_(@ EO)0#<7)'+GT'HH["N>5)0A>>[Z%)W>ATU%%%8%!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1S01SKMD7/H>XJ2B@#%N;"2#++\Z>HZBJE=+5.YT^.;+)\C^W0U2EW):,:B
MI)H)(&VR+CT/8U'5$A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!Y!%+7'_  QUS^W/ MB[ONGM1]EE^J?=_-2IKL*QG%QDXL:=PHHHJ1A1110
M4444 %%%% %/4])T_6K-K34K2*Z@;G9(N<'U!Z@^XKR?Q!\&[FRN/[1\(7TD
M4R'<MO)*5=3_ +$G^/YU[)16E.K.G\+$XIGR=XFNM?.MK)KR30:I"BH9'38[
M!?NMD=?3<.N*]L^#GA[^R?"7]HS)BYU)O,YZB(9"#\>6_$5VNKZ%I>O6AM=4
MLH;J+MO'*^ZGJ#[BKD$,=M;QP0H$BC4(BCHJ@8 K:KB>>GRI6)4;.Y)1117*
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5D^)?#MCXIT&YTF_3,4P^5P/FC<='7W'_UN]:U
M%--IW0-7/C#Q'X?OO"^N7&E:@FV:$\,/NR*>C+[&LJOJOXF^ HO&FA[[=535
M[52UM(>-X[QL?0]O0_C7RQ/#+;3R03QM'+&Q1T<8*D<$$>M>]AJZK0OUZG%4
MARLCHHHKI("O<OA'X_\ ML,?AO59O])C7%G*Y_UBC^ ^X'3U'TY\-I\4LD$R
M30NT<L;!D=3@J1R"#V-95:2J1Y6-.S/LNBN'^&_CN/Q=I?V>Z95U:V4><O3S
M5Z>8!_,=C]17<5XTX.$N5FZ=PHHHJ1A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?#ECXIT6;3;Y/E;F.
M0#YHG[,/\\CBOFV;P/KL'BX^&TM6>])^5APC1_\ /3/]W'^'7BOJJF^6GF^;
ML7S,;=V.<>F?2NBCB)4DTB913.;\%^"[#P;I?D0 2WDH!N+DCESZ#T4=A734
M45A*3D[L:5@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&174JR@@]C6=<:9U:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&8UW.F:K8:S9K>:==Q7-NW >-LC/H?0^QJ94YP^) FF7**9--%;PO-/(D<2
ML[N<!1ZDUYOK'QKT"PG:&PM[C42IP9%Q'&?H3R?RHA3E/X4#:6YZ717DMC\=
M]-EE5;[1KFW0G!:*59<?@0M>E:-KFF^(-/6^TRZ2X@;@E>"I]&!Y!]C3G2G#
MXD"DGL:%%%%9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJU#83R\[=B^K<4#*M/CADF.(T+?2M6'388^7S(??@5<50HPH 'H*
M3D.QFPZ7WF?_ ("O^-:$<,<*XC0+]*?14MW'8****0PHHHH **** "BBB@ I
M&570JRAE88((R"*6B@#P.,M\+?BR4)*:1=G'/3R'/!_X P_)?>O? 01D'(->
M>_%[PT-;\)M?PQ[KO3<RK@<M'_&/P&&_X#[U8^%'B3^W_!T4$S[KO3R+>3)Y
M*X^1ORX^JFNJK^\IJIU6C(6CL=U1117*6%%%% !1110 4444 %%%% !1110
M4444 %%%% %35+,:AI-[9, 1<0/$0?\ :4C^M>2? :[(_MNQ8D$&*51_WT&_
M]EKV:O#_ (8XTSXM:]IW1,7$:CW648_0&NFEK2FO0A[H]PHHHKF+"BBB@ HH
MHH **** "F33);P232-M2-2S'T I]8WBIVC\-7A4X)"C\"P!_G0"/.]4U*;5
M=0DNIB?F.$7^ZO852HHK(U"BBB@#OO!6KM=6SZ?.^YX1F,GJ4Z8_#C\ZZRO,
M?"#LGB6V /#AP?IM)_H*].JX[&<MPK@_BYH7]L>"9KF-,W&GM]H4CKLZ./IC
MG_@-=Y3)HHYX9(95#1R*593W!X(K2$G"2DB6KH^2?#>K-H7B33]34D"WG5GQ
MW3HP_%217UPCK(BNC!E89!'0BOD?Q'H[Z!XCO]+DS_HTQ52?XEZJ?Q4@_C7T
M5\,=9.M> ["1VW36P-K(2<\IP/\ QW:?QKNQL4XJ:,X/H<-\==9S)I>B1OT!
MNI5_\=3_ -G_ #KG_@UH7]J>,#J$B9@TZ/S,]O,;A1_Z$?\ @-<YX[UG^WO&
MFIWJONB\TQ1'ML3Y01]<9_&O<OA-H/\ 8O@BWFD3%Q?G[2_'.T\(/^^<'_@1
MJIOV6'4>K!>](\X^.7_([6?_ &#D_P#1DE87@7P%+XW^W^5J"6GV/R\[HB^[
M?N]QC&W]:W?CE_R.UG_V#D_]&252^&7CG3/!?]J?VC!=R_:_*\O[.BMC9OSG
M<P_O"M(N:PZY-Q.W-J1^,/A;J?A/2SJ7VN&\M%8+(R*49,G )!SQGCKW%0_"
MWQ#<:+XTL[99&^R7\@MYH\\$MPI^H)'X$^M;?C[XK6_B?1'T?3+&:&WF93-+
M<;0Q"D,  "<<@'.>U<[\,]%GUCQUIQC0F*TE6ZE?LH0Y'YL *:YG1?M0TYM#
MUKXK:5XGUS2[>PT.U,MGDR702559R/NK@D9 Z_7'I7G7@WX4ZCKE_<+K<=UI
MEK;X!#1;7E)SPN>,<=>>WX?1-<1\0O'LO@C^SO*T]+O[9YN=TI3;LV>QSG=^
ME<5&M4M[."U+E%;L\L^(WPWA\'6MMJ%A=RSV<TODLL^-Z/@D<@ $$ ]AC'O2
M_!G5KBS\<)IZ,QM[Z)UD3ME5+AOKP1_P*LCQG\0=4\9B&&YBAMK2%MZ0Q9.6
MQC))ZG!/IUKT3X0^!GT]O^$CO9H'DDC*6T<,JR!0>K%E)&>V,\9.?;KFW&@U
M5W(6LM#URBBBO*-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBN0\?>.;;P;I7R;9=3G!^S0'
MI[NW^R/U/'J148N3Y4)NQF?$SX@IX8LFTW3Y%;5YTX(.?LZG^(_[7H/Q^OSK
M)(\LC22.SNY+,S'))/4DU+>WMSJ-[->7DSS7$S%I)'.2QJ"O8HT52C9;F,I7
M84445L2%*JL[!5!9B<  9)-)7NGP<^&VWR?%.LP_,?FL+=QT])2/_0?S]*RK
M5HTH\S*C%R=D=)\)_AT/"NG#5=3B']L72?=8?\>R'^'_ 'CW_+USZ9117S]2
MI*I)RD=L8J*L@HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#R?XM_#/^WX)-?T:'_B:1+F>%!S<J.X']\#\QQUQ7SH05)!!!
M'!!K[CKQ'XO?##S1/XFT*#]X,O>VL:_>]9%'KZC\?7/IX/%6_=S^1A5I_:1X
M31117JG,%%%% 'MWPN^)8N%A\/Z[.?/&$M;J0_ZST1CZ^A[].O7V"OC$$@Y!
MP17N_P ,OB:-3$6A:[,!?#"V]RY_U_HK'^_Z'O\ 7KYV)PUO?@:PET9ZO111
M7 :!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8?C&Y:T\(ZE*I
MP3%Y?_?1"_UK<KG/'@+>"]0 &>(S_P"1%IQW1CB&U2DUV?Y'B=%%%=1\F%%%
M% !1110 4444 =7\.KEH/%T,0/$\3QG\!N_]EKV2O%? ()\:6! Z"0G_ +]M
M7M585-SZ#*V_8OU_R"D9E1&=V"JHR23@ 4M?/WQ;\9WFHZ]<:%;3/'I]F=DB
M*<>=)WW>H'0#VS3HTG5ERH]"3LCUF]^(OA'3Y&2?7;8LIP1"&EQ_WP#5O2O&
MGAO6I5BL-8M996^[&6V.?HK8)KYX\-?#WQ!XJM#=V%O&EJ&*B:>38K$=<=2?
MKC%0:MX&\1Z)J-O976G2&6Y<) T1WK(WH"._L<5U_5:5^7FU)YWV/JNBL#P;
MI&IZ)X:MK/5M0>]NUY9F.?+'9 >I ]3_ "Q6_7!)6=D:!1112 **** "BBO%
M=<^,VLZ7X@U+3XM-L'CM;J6!6;?DA7*@GYNO%:4Z4JCM$3:6Y[5169X=U*36
M?#FG:E,B))=0)*RIG )&<#-:=0U9V&%%%%(!DLL<$3RRNL<:*6=W. H'))/8
M5D?\)?X9_P"ABTC_ ,#8_P#XJN5^,?B#^R?"/]GQ/BXU)O*X/(C'+G\>%_X$
M:^=J[*&%]I'F;(E.SL?9@(8 @@@\@BEKB_A;X@_M[P3;"5]UU9?Z-+GJ=OW3
M_P!\X_$&NTKEG%QDXLI.X4445(PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *BDMH9?OQJ3Z]ZEHH SY-*C/
M,;LOL>:JR:=<)T <?[)K:HIW8K(YQXWC.'1E/N,5YE\7]2V:?8:6A^::0S.!
MZ*,#\RQ_*O;R 1@C(KPB]CC\;_'!+5%!L;*38V!QLBR6Z=B^1^(KIPWQ<SV6
MI$D>@>'--_LCPYI]@1AH85#C_;/+?J36G6H^E(?N2,/J,U7?3+A?N[7^AK%R
MN[CL4Z*D>WFC^]&P]\5'0(**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ1+>:
M3[L3'WQ0!'15Q-,N&^]M3ZFK":4@^_(Q^@Q2NAV9ETY(WD.$1F/L,UMI96\?
M2,$^K<U.  , 8%+F'RF-'IUP_4!!_M&K4>E1CF1V;V'%:%%*['9$4=M#%]R-
M0?7O4M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %9GB+2(]>\.W^ER8Q<PLBD_PMU4_@0#^%:=%--IW0'CGP/U>2)M5\.W.5
MDB;[1&C=0>%<?GM_6O8Z\+U0#P7\=8+L?N[2^E61O3;+E7)]@^3^ KW2M\2K
MR4UU)CM8****YR@HHHH **** "BBB@ HHHH **** "BBB@!DL4<\+PS1I)$Z
ME71QD,#U!!ZBO+)O@M8-XQCO(Y0NAG,LEID[@V?N _W#Z]1C'O7JU%7"I*%^
M5B:3W&QQI%&L<:*B( JJHP !T %.HHJ!A1110 4444 %%%% !1110 50O-%T
MV_8M<V<;N>K8VL?Q'-7Z* ,9/"NB1L&%BI(_O.Q'Y$UK0PQ6\0CAC2-!T5!@
M"GT4!<**** "BBB@ KCY_A;X,N+B2>71@9)&+L1<S $DY/ ? _"NPHJHSE'X
M783291TC1[#0=.CT_3+<6]K&250,6Y)R>223^)J]112;;=V,Y_7?!'AWQ+>I
M>:OI_P!IN$C$2OYTB84$D#"L!U8U-H'A/1/"_P!H_L:R^S?:-OF_O7?=MSC[
MQ./O'IZUM44^>5N6^@K(****D8C*KJ58!E(P01D$5Q.J?";PEJ<[3"QDM';D
M_99-@/\ P$Y _ 5V]%5&<H_"[":3//;+X,>$[20/*M[=@'.V>< '_O@+7=65
MC:Z;:1VEE;Q6]O&,+'$H4#\*L44Y5)3^)@DEL%%%%0,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S=>U[3
M_#FDRZCJ,PCACX '+.W95'<FFDV[(!GB'Q#I_AC2)-1U&79&O"(/O2-V51W-
M?,?BOQ5?^+=9>_O6*H,K! #E84]![^I[U+XQ\87_ (QU8W5T?+MX\BWMP<K$
MO]2>Y_I@5SM>KA\.J:N]S&4KA111740%%%;GA/PKJ'B_7(M,T],9^::9AE84
M[L?Z#N:4I**NP2OH7/ O@F^\;:VMI!NBLXL-=7.W(C7T'JQ[#^@KZNT?2+'0
M=*M]-TZ 0VL"[44<_4D]R3R357PQX:T_PIHD.EZ='MC09DD(^:5^[M[G].G0
M5L5X6*Q+K2TV1V4X<J\PHHHKE- HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %-DC2:)XI45XW!5D89#
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MNT@*I_$*#^-?/FL_\AW4/^OF3_T(U]?*JHH50%4#  & !7D%[\"_ME]<7/\
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M^T?)';\SJIT^75[A1117";!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT13_ #/?\*[6BIJXF51<MK(%!+4****YBPHHHH **** "BBB@ HHHH ****
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M****X38**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY<9VT9]/T5GZ+K>G^(-,BU#3;A9H).XZJ>ZL.Q'I6A7F--.S-@HHHI %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)_$SQ?<
M>)-5C\'>'LSJTH2=HS_K9 ?N _W5ZD^H]JV_BA\0CI<;>'M%D+:G,-LTL?)A
M!_A&/XS^GU(Q>^&/P_'ABQ_M+4HP=7N%Y!Y^SH?X1_M'N?P^O53BJ4?:3^2(
M;N[(Z'P7X3MO"&@1V,6U[E\/<S ?ZQ_\!T'_ ->NBHHKFE)R=V7L%%%%( HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH5B>/[-;Y_BY!8CV^4#/UKIJ-_5_WFY"^+0]GHHHKRS8**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6=EL==.FH^H4445R&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN^/;[X<:KH$CZ#);0:K$5,2VUG)")!D;E/R!>F3D^E6Z=)2Y.1^H7=KW/9-
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MINGJZVR,S*';<<DY/-*NJ45R0W'&[U9IT445R%A1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=,\7PK V+35%7+VS-P_NA[CVZC]:\NOAG3UCJC:,[G9T445REA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%<3XE^(-MIC/::8$N;H<-)
MG,<9_P#9C^G\J:3>QE5K0I1YINQV%U=V]E 9KJ>.&(=7D8*/UKD=2^)6DVI*
M6<4MXX[CY$_,\_I7F&HZI?:M<&>^N9)G[;CPOL!T ^E4ZU5-=3QZV:3>E-6.
MVNOB=J\I(M[>U@7M\I=OS)Q^E9S>/O$K-D:@%'H((_ZK7-45?*NQQ2Q=>6\V
M=*OC[Q*K9.H!AZ&"/^BUHVOQ.U>(@7%O:SKW^4HWY@X_2N)HHY5V".+KQVFS
MUO3?B5I-T0EY%+9N>Y^=/S'/Z5UUK=V][ )K6>.:(]'C8,/TKYVJYIVJ7VDW
M GL;F2%^^T\-[$="/K4.FNAVT<TFM*BN?0=%<5X9^(%MJ;)::F$MKH\+(#^[
MD/\ [*?\^U=K6336Y[%*M"K'F@PHHHI&H5PGBGX5Z1XIU:;5)[V^@NY0H.QE
M* *H P",]O7UKNZ*J$Y0=XL35]SQ2?X&:A:R>9I?B&/>.ADB:(C\5)J+_A%?
MBQHG_'EJLMVJ] EZ''X"7'\J]PHK;ZU/[5G\A<B,#P:^NR>&+:3Q&3_:;,_F
M!D52 &(7A1CH ?QK?HHK"3N[E!1112 **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OF7XL?\E,U?_MC_ .B4KZ:KPSXA?#WQ3KGC
MG4=1T[2_/M)O*\N3[1$N<1(IX9@>H/:NO!R49MR=M")JZ.T^#?\ R3Z#_KXE
M_G7"_&3P?_9VICQ#9Q8M;QMMR%'W)?[WT;^8/K7I7PTT34?#_@Z*PU2W^SW*
MS2,4WJ_!/'*DBNBU?2K76])N=-O$W07"%&]1Z$>X."/I2]MR5G);!RWC8^0&
M=F"AF)"C"@GH,YP/Q)_.O<_@1_R M6_Z^5_]!KA+KX1^,8;N:*#3%N(4<JDR
MW$2AUSP<%@1GWKU'X3>&=7\,Z3J$&L6GV:2:=70>8CY&W'\)-=6)J0E2:3(@
MFF<)\<XV'C&QD(^1M/50?4B23/\ ,5K? [6;&VAU33;BXCAN))$EC$CA=XP0
M<9[CC\ZZ[XF>!I/&&EP2V+(NHVA8QAS@2*>JD]CP"#]?7->'-X#\5K=?9SX?
MU#?ZB$E/^^ON_K4TW"K1Y&[#=U*YV'QKU^PU75=-L;*XCN#9)(97C;<H9ROR
MY'<;/UJS\"/^0SJ__7NG_H1K'N?@[XFATBUFBM5N+Z5V\V!)D A0 8R6(!).
M>F<8KM/A+X.U[PSJ>HS:Q8?9HYH56,^=&^2#D_=8T3E3C0<(O^K@K\UV>7_$
M/3I=-\?:Q%(I'FW#7"D]UD._(_/'X5ZW\(_%>FW/A2#1IKF*&^LBR^7(P4R(
M6+!ESUZX/T]ZUOB!\/[?QE:I/#(MOJD"[8I6'RNO7:V.<9Z'MDUX?J/P[\6:
M9,8Y-$NI@#P]LGG ^_RY_6A2A7IJ+=F@LXNY])IX@TB36%TF/4;=[]D,@A5P
M3@=>G?VZX!/:N+^-?_(B)_U^Q_\ H+5Y9X=^'WC.?4K>XL]/N-/DB<.MQ<CR
MO+([X/)^F#7L'Q(\/ZSX@\$V]A9PI=Z@L\;RA&6-3A2&(W-P,GIFL?9PI58V
ME<J[:9X]\)_^2F:1_P!MO_1+UTWQVL)$UW2]1VGRI;8P;NP*L6Q_X_2_#WX>
M^*=#\<Z=J.HZ7Y%I#YOF2?:(FQF)U'"L3U([5ZUXG\-6/BK1)=-O@0K'='*O
MWHW'1A_AW!K2K6C&NI)W5B5%N-CP+X>^%-!\6S7%GJ6ISVE\I!AC1E E7OC(
MY(/;T-=IJ_PC\)Z#I\E]J>O7UO;IU9MA)/H %R3["N+UKX5^*M&N6\BR:_@!
MRD]I\Q/U7[P/X?B:HQ>"_&FL3JKZ/J;O]T-=JR #ZOBMI>\^:-2R%MI8]=\'
M?#7P_I>IV7B+2=7N+U8PQC.Y&1MRE3T'^T?QKB/C+XGOKGQ+)H"3-'8VBH7C
M4X$CLH;+>N 1@?6O1/AOX$N?!UG/)>WK2W-R!N@C<^5'CV[M[X]A[X/Q2^'%
M]KM^-<T9!-<E EQ;9 +8Z,I/4XX(]ABN:G4C[>\G?LRFGRZ'/^!OA):^(M M
M]8U+49HX[@DQPVP4$*&(R6.>>#QBN4^(/A[2_"_B4:9I5S//&D"M,9W5F60D
M\?*!_#M/XU9TK2/B+8;K#3;77K1&)RB"2*//KDX4?7-7-1^$?C!'ADCM!>RS
M1^9.XN(QLD+'*DLP+'&"3TR>^*ZE+EG>4U;L3;31'I'P4_Y$1_\ K]D_]!6O
M'_B+_P E!UK_ *^/Z"O<?A=H.I^'?"36.JVWV>Y-R\FSS%?Y2%P<J2.QKSCQ
MI\./%FK>,=4O['2O-MIYMT;_ &B)=PP.Q8&L*,XJO)MZ#DGRH])^$_\ R3/2
M/^VW_HYZ[.N9^'NDWVA^!M.T[48/(NX?-\R/>K8S*[#E21T([UTU<=5WG)KN
M:+8****S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%17-S!9VTEQ<S1PP1C<\DC!54>Y- $M%>5^(?C;I=B[P:
M+:/?R X\Z0^7%^'=OT^M<)>_&/Q?=.6@N;:S7LL-NI_]#W5TPPE26MK$.:1]
M'T5\S+\6?&RL"=9# =C:PX/Y)70Z3\<]7@=5U73K:[C[M"3$_P!>X/Y"J>#J
M+S#G1[Q17-^&/'6A>+$VZ?=;+D#+6LP"R#Z#N/<9KI*Y91<79E7N%%%%(844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'6-7LM!TJ?4M0E$=O
M"N6/<GL .Y)X%?-/C3QUJ7C&_)E9H+!&_<6JGY5'JWJWO^5;GQ=\6OK7B)M(
MMY#]AT]BA /#S=&/X?='X^M><UZF%H**YY;F,Y7T"BBBNP@**** )()Y;:=)
MX)7BEC8,CHQ#*1T((Z5[W\-/B7_;Y31M9=5U,#]S-T%P!V/HW\Z\ J2">6VG
MCG@D:.6-@Z.IP58<@@UE6HQJ1LQQE8^RJ*YOP+XG7Q9X6M]0; N5_=7*CM(
M,GZ$$'\:Z2O%E%Q=F;K4****0PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDD;;E8>QKRZM&5-VD;*29-11160PHHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
MUHHH \B^(/P9MM7\W5/#:1VM^<M):?=BF/\ L_W6_0^W6OG^]LKK3KR6TO;>
M2WN(FVO%(NUE/TK[=KEO&?@'1O&MGLO8_)O$7$-Y$!YB>Q_O+['\,=:]##XU
MP]VIJC&=)/5'R)172^+_  -K/@R^\G48=]NYQ#=Q@F.3\>Q]CS]1S7-5ZT9*
M2O%Z',TUHPHHHJA!72>%/&^L>$+K?8S;[5CF6UD.8W]_8^X_6N;HI2BI*S"]
MCZG\(^.]'\7V_P#HDGDWBC,EI*1O7W']X>X_'%=/7QK;W$UK<)/;RO#-&=R2
M1L593Z@CI7LO@KXRAO+L/$_!X5+]%X/_ %T4?S'XCO7FUL(XZPU1K&?<]EHJ
M.">&Y@2>"5)89 &1T8,K#U!'6I*XC0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \A^)5R9O$Z
MPY^6"!5Q[G+?U%<=72>/3_Q6NH?]L_\ T6M<W73'9'RN*=Z\_5A1115'.%%%
M% !1110 4444 %%%% !1110 5V/PUN3#XG:'/RSP,N/<8;^AKCJZ3P$?^*UT
M_P#[:?\ HMJF6S.C"NU>'JCVNBBBN8^J"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE^+'_)3-7_[8_P#H
ME*^FJ^9?BQ_R4S5_^V/_ *)2NS!?Q'Z$5-CTWX&_\B3>?]A%_P#T7'7 ?&;_
M )*!)_U[1?R-=_\  W_D2;S_ +"+_P#HN.N ^,W_ "4"3_KVB_D:UI?[S(E_
M =Y\"XD7PA?S!1YCW[(S>H$:$#_QX_G7&_'%%7QO:E5 +:?&6([GS)!_("NU
M^!O_ ")-Y_V$7_\ 1<=<9\<O^1VL_P#L')_Z,DI4_P#>6#^ Z3X#PQC2=8G"
MCS&G1"WL%) _4UC_ !W11KFDN%&\VS GU ;C^9_.MOX$?\@+5O\ KY7_ -!K
M&^.__(9TC_KW?_T(41_WI_UT&_@+GP#_ .9A_P"W;_VK7,_&;_DH$G_7M%_(
MUTWP#_YF'_MV_P#:M<S\9O\ DH$G_7M%_(U<?]ZEZ?Y"?P'>? ZTMD\*7EVB
MJ;F6[*2-WVJJ[1]/F)_&NM\?6UO=> ];2Y"E$M'D7/9U&Y?_ !X"OG[P9XXU
M+P7=226R+/:3\2V\A(5B.X/9N?\ 'M6OXR^*NH^*]-.FPV:6%FY!E59#(\F.
M0"V!QGG&*B>'J.MS+8%)<MCE_"<LL/C#19(<^8+Z$ #OEP,?CTKNOCI+*?%>
MGQ'_ %2V(9?]XN^?Y+6=\(_#,VL^+(=2>,BRTYO-9R.&D_@4>^>?P]Q7H/Q@
M\)7&NZ/!JEA$TMU8;M\:C)>(\G [D$9QZ$UI4J15>-Q)/E,WX$6UL-,U:Z 4
MW1F2-CW";<C\R3^5>F:_:VUYX>U&WO IMWMW$FX< ;3S^'7\*^8_"7C#4O!V
MHO=6&QTE4+-#)G;(!TZ=".<'W-=)XH^+NK>(M)ETV"SAL8)UVS%'+NZ_W<\8
M![\5G5PTY5>9;#4DE8X"VEEANX98?]:CJR?[P/%?1/QD_P"2?3_]?$7\Z\G^
M&?A*X\2>)K>X>)AIUE(LL\A'#$<A!ZDG&?;/M7K'QD_Y)]/_ -?$7\ZNO).M
M!+H$5[K/'/AK8P:C\0](M[E \7F/(5(R"41G&?Q45]15\R_"?_DIFD?]MO\
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MN&G7E3;MU-'&Y\G>,-!C\,^*+O1XYVG6W6/,C#!8M&K'CL,L:]K^"G_(B/\
M]?LG_H*UY7\6/^2F:O\ ]L?_ $2E>J?!3_D1'_Z_9/\ T%:Z\0V\.F_(B/Q'
MHU%%%>::A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2-A_WP!_2N7KT#XI6)2^L;\#B2,Q,?=3D?\ H1_*O/ZZ8.\4?+8R/+7DO/\
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MXP,CG^]7K]3BZJE)*.R'!61YE\<O^1)L_P#L(I_Z+DKS+X3_ /)3-(_[;?\
MHEZ]@^*WA[5/$OA>VL](M?M-PEZDK)YBIA0C@G+$#JPKAOA[\/?%.A^.=.U'
M4=+\BTA\WS)/M$38S$ZCA6)ZD=JUI3BL.TWKJ*2?,>YT445YYH%%%% 'S+\6
M/^2F:O\ ]L?_ $2E>J?!3_D1'_Z_9/\ T%:Y+XA?#WQ3KGCG4=1T[2_/M)O*
M\N3[1$N<1(IX9@>H/:N^^%V@ZGX=\)-8ZK;?9[DW+R;/,5_E(7!RI([&N^M.
M+H12>NAG%/F.UHHHK@- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ J*YN8+.WDN+F:.&&,;GDD8*JCU)-<OXN
M^(>B^$HVBFD^TZACY;2%AN'IN/\ "/KSZ UX%XJ\<:SXNN";Z?9:J<QVL1Q&
MGIQW/N?TKIHX:5379$RFD>A^,_C-@R6/A<>S7TB_^@*?YG\N]>.W-S/>7$EQ
M<S2332'<\DC%F8^I)J*BO3ITHTU:)BVWN%%%%:""BBB@ K:\,^%-8\6ZB+/2
M;4R$8,DK<1Q#U9NWTZGL*[;P'\'-1\1>5J&M>9I^F'E4(Q-,/8'[H]S^ [U]
M"Z/HNG:!IT=AI=I';6R=$0=3ZD]2?<\UPXC&QI^[#5FT*3>K.5\"_#'2/!D2
MW) O-6(^>ZD7[GJ(Q_"/?J?TKN:**\><Y3?-)ZG2DDK(****D84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\'_$_1O%'EVTK"PU(X'V>5N'/^PW?Z<'ZUW%?&->C^$/B[JNA>7::L'U*P'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &2PQ3Q-%-&DD;##(Z@@CW!KFKWX<>$-0<O
M/H5LK'KY):+_ - (KJ**J,I1V8K'&K\*?!*L&&B#(];F8C\B];^F>'=&T7_D
M&Z7:6K8QOCB 8_5NIK3HINI.6["R"BBBH&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !102 ,DX KS;Q?\7]*T3S+31PFI7PX+JW[F,^[#[W
MT'YBKA3E-VBA-I;G>ZGJMAHUD]YJ5W%;6Z=7D..?0=R?8<UXIXQ^,MY?^99>
M'%>SMSPUTW^M?_='\(]^OTKSS7?$6J^)+XW>JW;SOSL4\)&/15Z 5EUZ-'"1
MCK+5F4IM[#G=Y9&DD9G=CEF8Y)/J:;11780%%%% !117I/@;X/ZMXG$=]J1?
M3=+;!#,O[V8?["GH/]H_@#45*D::YI,:BY.R.(T30-4\1ZBEAI-G)<SMU"CA
M1ZL>@'N:^A? GP>TSPV([_5_+U'5!\RY&883_L@_>/\ M'\ *[G0/#FE>&=.
M6QTFT2WB'WB.6D/JS=2:U*\?$8V53W8Z(ZH4E'5A1117$:A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVBBBN8L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=,8J*L@HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZA/5HVY7V(Z@^QKSZE&=/XD:J29>HHHK(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>9>-_A,/$NJ3:M8ZFT-Y+C?'<@NA
MP,#!'*CVP:]-HJX5)0=XB:3W/FVZ^#_C&!R([&"Y /WHKE #_P!]$5>TOX*>
M)+N=1?R6MC#_ !,7\QOP"\'\Q7T)170\94MT)Y$8OACPQIWA325L-/0X)W2R
MOR\K>I/].U;5%%<K;;NRPHHHI %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1TKB/$_Q2\/>'-\,<W]H7J\>
M1;,"%/\ M/T'ZGVKQ?Q3\2-?\4;H99_LEB?^76W)52/]H]6_'CVKHI8:<]=D
M2YI'L?BGXKZ#X>WP6S_VE>CCRK=AL4_[3]!^&37BGB?Q]KWBMF2]NO+M,Y6U
M@^6,?7NWXYKF**]&EAX4]5N9.384445N2%%%% !1177>$?AOX@\8.LEI;_9[
M'/S7EP"J?\![L?I^)%3*<8*\G8:3>B.1 )( &2:]/\&_!?6=>\N[UG?I=@>=
MK+^_D'LI^[]6_(U[!X.^%_A_P@$GCB^VZB.3=W"@E3_L+T3^?N:[6O,KX]O2
MG]YO"CUD8WASPIHWA6R^RZ19)""!OD/,DA]68\GZ=!VQ6S117FN3D[LZ$K!1
M112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:8_\N\AV2#_@)Z_AD5T%<CBXNS- HHHI %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M4-U=VUC T]W<16\*]9)7"*/Q/% $U%<!K7QA\+Z7N2UEEU&8=K=<)GW9L#\L
MUYUK7QJ\0W^Z/38K?38CT*CS)/\ OIN/R KHAAJD^EB7-(]]N[VUL+=I[RYA
MMX5ZR3.$4?B:X+7/C)X:TS?'9&;4YQP!"-L>?=S_ # -> :AJFH:M<>?J-[<
M74O]Z:0L1],]*J5U0P45\3N0ZCZ'H.N?&+Q-JNZ.S>+38#T$ R^/=S_0"N#N
M;JXO9VGNIY9YFY:25RS'ZD\U%177"G&'PHAMO<****L04444 %%%% !16[H'
M@WQ!XGD TG3)YX\X,Q&V)?JYP/PZUZWX<^ $$>R?Q'J1E;J;:SX7Z%SR?P ^
MM85<13I_$RXPE+8\-M;2YOKA+>TMY;B=SA8XD+LWT Y->E^&O@=XAU79-J\D
M>E6QP=K_ #S$?[H.!^)S[5[_ *+X<T;P[;^1I&G6]HA&"8U^9O\ >8\M^)K4
MKSZN82>D%8VC174X[PU\,/"_AC9);V NKM>?M-WB1P?4#HOX#-=C117!*<IN
M\G<V22V"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445B:OXP\/:%N&HZO;0NO6,/O?_OE<G]*:3;L@-NB
MO*-7^.>EV^Y-)TVXNV[23,(D^H')/Z5P.L?%OQ9JNY([Q+"(_P %HFT_]]'+
M?D171#"5);JQ#FD?15_J=AI<!FU"]M[6+^]-($!^F>M<+K'QF\,Z?N2Q^T:C
M*.GE)L3/NS8_0&OGRYNKB]G,]U<2SRMUDE<LQ_$U#75#!17Q.Y+J/H>D:S\:
M?$>H;DT]+?38CWC7S)/^^FX_("N"U#5=0U:?S]1O;BZE_O32%B/IGI52BNJ%
M.$/A1#;>X44458@HHHH **** "BBNM\/_#3Q7XCV/::7)#;M_P O%U^Z3'J,
M\L/H#4RG&*O)V&DWL<E4MM:W%Y<);VL$L\SG"QQ(69OH!R:]\\/? +3;;9+K
M^H27LG4P6_[N/Z%OO$?3;7J.C^'](\/V_D:3IUO:)C!\I,,WU;J?Q-<53,*<
M=(:FL:+>Y\\>'?@CXGU?9+J/E:5;G_GO\TI'L@_J17K/AWX.^%-"V2SVK:G<
MC_EI>89<^R?=_//UKT"BO/J8NK4ZV7D;1I10U$2-%2-51%&%51@ >U.HHKF-
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M?:=9:G;-;7]I!=0-UC
MFC#K^1KSC7_@9X:U/?)ICSZ5.>@C/F19]U8Y_(BO4**TA5G3^%V)<4]SY>U_
MX,>+-&WR6UO'J=NO\5H<OCW0\Y^F:X&XMI[2=H+F"2&9#AHY$*L/J#7V_6=J
MV@Z3KL'DZKIUM>(!@>=&&*_0]1^%=U/,9+2:N92H+H?%E%?16O? 70KT/)HU
MY<:=*>1&_P"^B^G/S#\S7F6N_!_Q?HFYTL5U"!?^6EDV\X_W.&_(&NVGBZ4]
MG;U,94Y(X*BI)H)K:9H9XGBE7ADD4J1]0:CKI("BBB@ HHHH **** +-EJ%[
MITWG6-W/:R_WX9"A_,5VFD_%_P 6:9A9KF&_C'\-U'D_]]+@_GFN"HJ)4XR^
M)#3:/==*^.FF3;4U72[BU;H7@82K]<'!'ZUW&E>.?#&L[19:S:L[<".1O+<G
MV5L$_A7RE17/+!TWMH4IL^SNM%?(^E^)]=T7']G:K=VZC_EFLIV?]\GC]*[7
M2_C;XCM JW\%I?H.K%/*<_BO'_CM<TL%-?"[E*HCZ#HKS#2_CAH%UM74+.[L
M7/5@!*@_$8/_ ([79Z9XQ\.:P!]AUFSD8](S($?_ +Y;!_2N>5&<=T6I)FY1
M1168PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJO=WUI81>;>74%M'_ 'YI @_,T 6**XK5/BOX1TS<HU$WD@_@M(R^
M?^!<+^M<7JGQX8[ETG10/22[ES_XZO\ \56T</4ELB7)(]IJK?:E8Z9#YU_>
M6]K'_?GD"#]37S9JGQ1\7:H6#:J]K&?X+11%C_@0^;]:Y*>XFNI3+<322R-U
M>1BQ/XFNB.!E]IDNIV/HW5OB_P"$]-W+#<S7\@XVVT9QG_>; _+-</JOQUU.
M;<FE:7;VR] \[&5OK@8 _6O)J*Z8X2E'I<ES;.@U;QOXEUO<+[6;IHVZQQMY
M:'_@*X!KGZ**Z%%1T2("BBBF 4444 %%%% !116QHOA37O$+A=)TFZN@>/,5
M,(/JYPH_$TFTE=@E<QZ*]CT'X :G<%9==U*&TCZF&V'F/]"3A1^&ZO3M"^%?
MA#0=KQ:6EW.O_+:]/FM^1^4?@!7)4QU*&VIK&C)GS5H?@WQ%XD9?[*TFYGC)
MQYVW;&/^!MA?UKU#0/V?IY-DOB#55B7O!9#<W_?;# _(U[NJA5"J % P .U+
M7#4Q]27PZ&L:,5N<QH'P]\+^&]KZ?I,)G7_EXF'F29]06Z?ABNGHHKCE*4G>
M3N:I);!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 4444 %%%% $]O>W5H<VUS-"<YS'(5_E6O;>-O%%H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IKHDB%'564]0PR#3J* ,:[
M\(^&[_\ X^M!TR4_WFM4S^>,UA77PD\#W>2VAI&WK%-(F/P#8_2NVHJU5G'9
ML3BGT/+KKX"^$YLF&XU.W/8+,K#_ ,>4G]:Q;K]GBU;)M/$4T?H);4/^H85[
M716JQ=9?:)=./8^>[G]GS6TS]EUG3Y?3S5>/^0:L>Y^!WC.#_5PV5Q_URN0/
M_0@*^G**U6/K(GV,3Y,N/A7XWM<^9X?G./\ GG)')_Z"QK)N/!OB>T_U_A[5
M4']XVDF/SQBOLFBM%F,^J1/L%W/B*>SNK7_CXMIH?^ND97^=05]R52GT?2[K
M/VC3;.;/!\R!6_F*M9EWC^(O8>9\445]BS^!_"EP<R>&]*))R2+1%)_$"LV;
MX5^")_O^'[<<8^21T_\ 06%:+,8=4Q>P?<^3**^I)O@MX'ESLTV>'/\ <NI#
MC_OHFJ$WP&\(RYV3:I%D_P $ZG'YH:I9A2\R?8R/FJBOH>;]GW0&SY.KZDGI
MO\ML?DHJE+^SQ9DMY/B*=..-]J&P?P85:QU'N+V,SP6BO;I/V=YACRO$R-Z[
MK(K_ .SFJLG[/>JC=Y>NV3?W=T3+GZ]<5:Q=%[/\Q>SEV/&Z*]:D_9^\2!?W
M>J:4S9Z,\B_^R&L^]^"/B6Q*"6^TD[\XVRR?_&ZM5J;V8N1GFM%=I>?#'6K%
MU66ZL"6&1MD?_P"(K-O/!FHV,:O+-:D,<#:S?_$U:G%BLSG:*U?^$?N_^>D/
M_?1_PK,D0QR,AQE20<4T[B&T444P"BBB@ HHHH **NV>ESWL)DC:,*&V_,3_
M (>]6H_#EY)(J"2#+$ 98_X4KH+&1175_P#"O]5_Y^++_OMO_B:U$^$6ONBL
M+S3,$9_ULG_Q%2ZD5U'RLX"BO5D^ 'BEBI.HZ.%/4B64D#_OW5F/]GS7"W[S
M6-.5?50Y/\A4/$4UNQ\DCR"BO:(_V>;XK^\\0VRMZ+;,1_Z$*N1_L[1@_O?$
M[,,=%L<<_P#?PU#QE%=?S*]E/L>%T5] 1?L]:4NWSM=O7_O;(E7/YYQ5Z'X
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M8VMOC_GC"J?R'N:MT5DYRENRDDM@HHHJ1A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img76291469_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img76291469_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %]!P$# 2(  A$! Q$!_\0
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MJ*-P]10 M%)N'J*-P]10 M%)N'J*-P]10 M%)N'J*-P]10 M%)N'J*-P]10
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MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
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MN@KB_#R'7?&&IZ^_S6]N?LEH>QQ]YA_G^*NTI,<7?4*XGP?_ ,C=XI_Z^?\
MV9J[:N)\'_\ (W>*?^OG_P!F:A;,'NCI=>U&32="N[^&-))($W!'. >?6L'3
M/%6KZQ-9M9Z(6LV95N;EI,*I_BV \D"M+QG_ ,B?J?\ UQ_J*D\)*%\):6
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M,EN9(9K03L;APS;M[+P0!Q@"MOX!_P#(_P!U_P!@Z3_T9'4O[0'_ "/&F_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDD7_ -H,@>+M))Z?8#_Z,->E_"+P^V@_#RT+H%N[_-Y)N'3=]P'_ ("%_6N
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MU]G?P';M+G>5AW9^E6YM"O\ 4Y(AK&I1S6\;;A#;Q; Q]ZOZSI8U?3&LA*(
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MQ+KR^AMOWN/7 Z_I72UF:1HRZ89II)VN;RX.99F&,^P]JTZ&-!1112&%%%%
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M%I5Y)&Q5T@=E8=00IP:K>';J6]\.Z?<SMNED@4NWJ<=:GU;_ ) U]_U[R?\
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M?04M% 7"D**QR5!^HI:*    8 P*0J"<D#-+10 FQ?04M%%  0",'D4W8O3
MIU% !2$ ]1FEHH 3:N<X&:6BB@!-JDYP,T!0.0 *6B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I3U-)3@I9\"@!]O;O=3"-./5CT45T42PV5OY4(P.I)ZL?4UFVSI!'M7C
MU/K237.1UK-ZLI$ES<YSS7N'PH;=X MS_P!-Y?\ T*OGV20L:]_^$O\ R3VV
M_P"N\O\ Z$:Y,<K4EZETW[QV]%%%>0;A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,FACN()()5W1R*
M59<XR#3;6VALK:.VMTV0QC"KG./SJ6B@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "I]._Y"T/_7-__9:@J?3O^0M#_P!<W_\ 9:!G04445)84444
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MG_GUO?\ P+?_ !KT>BCZQ5_F8<L>QYQ_PH[P3_SZWO\ X%O_ (T?\*.\$_\
M/K>_^!;_ .->CT4?6*O\S#ECV/./^%'>"?\ GUO?_ M_\:/^%'>"?^?6]_\
M M_\:]'HH^L5?YF'+'L><?\ "CO!/_/K>_\ @6_^-'_"CO!/_/K>_P#@6_\
MC7H]%'UBK_,PY8]CSC_A1W@G_GUO?_ M_P#&C_A1W@G_ )];W_P+?_&O1Z*/
MK%7^9ARQ['G'_"CO!/\ SZWO_@6_^-'_  H[P3_SZWO_ (%O_C7H]%'UBK_,
MPY8]CSC_ (4=X)_Y];W_ ,"W_P :/^%'>"?^?6]_\"W_ ,:]'HH^L5?YF'+'
ML><?\*.\$_\ /K>_^!;_ .-'_"CO!/\ SZWO_@6_^->CT4?6*O\ ,PY8]CSC
M_A1W@G_GUO?_  +?_&C_ (4=X)_Y];W_ ,"W_P :]'HH^L5?YF'+'L><?\*.
M\$_\^M[_ .!;_P"-'_"CO!/_ #ZWO_@6_P#C7H]%'UBK_,PY8]CSC_A1W@G_
M )];W_P+?_&C_A1W@G_GUO?_  +?_&O1Z*/K%7^9ARQ['G'_  H[P3_SZWO_
M (%O_C1_PH[P3_SZWO\ X%O_ (UZ/11]8J_S,.6/8\X_X4=X)_Y];W_P+?\
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M_9=K_=;_ +Z-7** LBG_ &7:_P!UO^^C1_9=K_=;_OHU<HH"R*?]EVO]UO\
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M6_[Z-7** LBG_9=K_=;_ +Z-']EVO]UO^^C5RB@+(I_V7:_W6_[Z-']EVO\
M=;_OHU<HH"R*?]EVO]UO^^C4 M8K;5;7RP1N23.3G^[6G5.?_D*V?^Y)_P"R
MTPL7****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (YIXK:%YIY%CB099W. ![FL:#QGX=N;E;>+58#(QP <J"?J1BG>)
M]!D\1:?'9K>&VB$@>3";MX'0=1]:S/&&EZ/9>#;E3:01"- L!50&W]!SW]_;
M--6);9UU%<SIVK2:1\/K74[Z.65X;=691]YAD =?8BM73M1.M:#'?6JM"UQ$
M6C$F,J>0,X]Z+#3)+S5]/L)X8+N\AAEF.(T=P"QSC@5=KRS6?#K:)<Z)<7=Y
M)>:C=7J?:)V/!QC@#TS7J=#0DV]PHHHI%!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !533?\ CU;_ *ZR?^AFK=<>?&^E:5/<6-Q'=F6&
M>16*1@C[Q/!S[T".PHKD/^%CZ+_SRO?^_0_QH_X6/HO_ #RO?^_0_P :+#.O
MHKD/^%CZ+_SRO?\ OT/\:/\ A8^B_P#/*]_[]#_&BP'7T5R'_"Q]%_YY7O\
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M[_WZ'^-%@.OHKD/^%CZ+_P \KW_OT/\ &C_A8^B_\\KW_OT/\:+ =?17(?\
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MC^UK?^[)_P!\TPN7J*H_VM;_ -V3_OFC^UK?^[)_WS2L%T7J*H_VM;_W9/\
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M7J*H_P!K6_\ =D_[YH_M:W_NR?\ ?-%@NB]15'^UK?\ NR?]\T?VM;_W9/\
MOFBP71>HJC_:UO\ W9/^^:/[6M_[LG_?-%@NB]15'^UK?^[)_P!\T?VM;_W9
M/^^:+!=%ZBJ/]K6_]V3_ +YH_M:W_NR?]\T6"Z+U%4?[6M_[LG_?-']K6_\
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MZ+U%4?[6M_[LG_?-']K6_P#=D_[YHL%T7J*H_P!K6_\ =D_[YH_M:W_NR?\
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MZ\=*VJ'L)+5A1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.U=AX4&-%Q_TT-,3-NBBBD(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI5&@# P.E%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC D#.!L(&#FL?PR3=ZWJ^J1@BWE?9&W]XYS_ (?G6G-X<T:>8RR:="7)R<9
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MMT$82")1%Q& @&SZ>E2T4 -DCCE7;(BNOHPR*8;: Q"(PQF,?P%1C\JEHH
M !@<"J;Z1ILDWG/I]HTN<[S"I.?KBKE%    , 8 ID<,46[RXT3<<G:H&33Z
M* &&*,RB4QH9 ,!]O('UI]%% !1110 4444 %%%% !1110 5XCXA_P"1EU3_
M *^7_G7MU>-:YIM_/X@U*6&QNI(VN7VND+$'GL0*:$S$HJY_9&I_] V\_P"_
M#?X4?V1J?_0-O/\ OPW^%4(IT5<_LC4_^@;>?]^&_P */[(U/_H&WG_?AO\
M"@"G15S^R-3_ .@;>?\ ?AO\*/[(U/\ Z!MY_P!^&_PH IT5<_LC4_\ H&WG
M_?AO\*/[(U/_ *!MY_WX;_"@"G15S^R-3_Z!MY_WX;_"C^R-3_Z!MY_WX;_"
M@"G15S^R-3_Z!MY_WX;_  H_LC4_^@;>?]^&_P * *=%7/[(U/\ Z!MY_P!^
M&_PH_LC4_P#H&WG_ 'X;_"@"G15S^R-3_P"@;>?]^&_PH_LC4_\ H&WG_?AO
M\* *=%7/[(U/_H&WG_?AO\*/[(U/_H&WG_?AO\* *=%7/[(U/_H&WG_?AO\
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M_P!\F@".BI/(F_YXR?\ ?)H\B;_GC)_WR: (Z*D\B;_GC)_WR:/(F_YXR?\
M?)H CHJ3R)O^>,G_ 'R:/(F_YXR?]\F@".BI/(F_YXR?]\FCR)O^>,G_ 'R:
M (Z*D\B;_GC)_P!\FCR)O^>,G_?)H CHJ3R)O^>,G_?)H\B;_GC)_P!\F@".
MBI/(F_YXR?\ ?)H\B;_GC)_WR: (Z*D\B;_GC)_WR:/(F_YXR?\ ?)H CHJ3
MR)O^>,G_ 'R:/(F_YXR?]\F@".BI/(F_YXR?]\FCR)O^>,G_ 'R: (Z*D\B;
M_GC)_P!\FCR)O^>,G_?)H CHJ3R)O^>,G_?)H\B;_GC)_P!\F@".BI/(F_YX
MR?\ ?)H\B;_GC)_WR: (Z*D\B;_GC)_WR:/(F_YXR?\ ?)H CHJ3R)O^>,G_
M 'R:/(F_YXR?]\F@".BI/(F_YXR?]\FCR)O^>,G_ 'R: (Z*D\B;_GC)_P!\
MFCR)O^>,G_?)H CHJ3R)O^>,G_?)H\B;_GC)_P!\F@".BI/(F_YXR?\ ?)H\
MB;_GC)_WR: (Z*D\B;_GC)_WR:/(F_YXR?\ ?)H CHJ3R)O^>,G_ 'R:/(F_
MYXR?]\F@".BI/(F_YXR?]\FCR)O^>,G_ 'R: (Z*D\B;_GC)_P!\FCR)O^>,
MG_?)H CHJ3R)O^>,G_?)H\B;_GC)_P!\F@".BI/(F_YXR?\ ?)H\B;_GC)_W
MR: (Z*D\B;_GC)_WR:/(F_YXR?\ ?)H CHJ3R)O^>,G_ 'R:/(F_YXR?]\F@
M".BI/(F_YXR?]\FCR)O^>,G_ 'R: (Z*D\B;_GC)_P!\FCR)O^>,G_?)H CH
MJ3R)O^>,G_?)H\B;_GC)_P!\F@".BI/(F_YXR?\ ?)H\B;_GC)_WR: (Z*D\
MB;_GC)_WR:/(F_YXR?\ ?)H CHJ3R)O^>,G_ 'R:/(F_YXR?]\F@".I]._Y"
MT/\ US?_ -EIGD3?\\9/^^34MA&Z:M#O1ES&^,C']V@#>HHHJ2PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MIIW_ !ZM_P!=9/\ T,U;JIIO_'JW_763_P!#- NI;HHHH&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %4[7_C_O\ _?3_ - %7*IVO_'_ '_^^G_H H$7****!A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 5+W_ %UE_P!=_P#V5JMU4O?]
M;9?]=_\ V5JMT""BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %4Y_P#D*V?^Y)_[+5RJ<_\ R%;/_<D_]EH$
MRY1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/&T>N7KZ==6WV6^52P4-D-CJ.>01Z&NLH:L":>P4444AA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%4]5U.WT?39KZZ)$40R
M0HR6/0 >Y- %RBO.Q\0=8FBEO+;00UC$</(68[?J0,5UOA_Q#:^(=.-U"K1.
MC;98G/*'KU[CWIM-$J29KT5PEWX_N;B_EMM!TEKY8L[I#D[@.X '3W/6M/PK
MXRA\122VLD M[R)=Y0-N5ES@D=^#U%%F"DF['44444B@HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I&574JP#*1@@C((I:* ,,^#O#QF\TZ3;[
MLYZ''Y=*VHXTBC6.-%1%&%51@ >PIU%%Q62,F]\,:)J-P;BZTV"29N6?&"?K
MCK5^TL[:PMUM[2".&%>B1K@5/11<+(****!A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1163XCUR/0=)>Z*^9.Y$
M<$(ZR2'H* ;L:U%>=>$K2[LO'=W#?3M+=M:>;,2>-[%6(_#.*]%IM6%%W"BN
M(\5D_P#"<>&,$@>:> >O(J+Q)G0O'>E:T&86]U^XGYXSTSCZ$'_@-%A.1WE%
M-=UC1G<@*HR2>PKB_!"OJNIZMXCEW8N)3% "> @]O^^1^%%AMZV.VHHK,U/Q
M%I&C2+'J%_% [#(0DEL>N!S2'>QIT5P6LZA:ZGXN\+75C<K/;O(X#QMP2".#
M_P#7KM;V^M=.MFN;R>."%>KN<"G82=RQ16-8^+-!U*Y6VM-3@DF;A4Y4L?;(
M&:UIIHK>%YII%CB099W. ![FD%TQ]%84'C/PY<W"P1:M;F1C@ Y )^I&*VY)
M$BC:21U1%&69C@ >I-%@NF.HK!C\:^&Y)Q"NKV^\G SD#/U(Q6W)-%#"TTLB
MI$HW,['  ]<T6"Z8^BL&'QIX<GN!!'J]N9"<#.0,_4C%;U%@33V"BBB@8451
MU;4!IU@\HP9#\L8]6K*\,ZD75[*9R7&7C)[CN/ZT["OK8Z.BBBD,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BB@G R>E !17'SZ\_]NBZ0DV\?[L*/
MXE[G^OX5UR.LB*Z$,K#(([BFU82=QU%%%(84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%87B74/L]H+2-L23#YB.H7O^?3\Z$)NQNT5EZ#J'V^P <Y
MFB^5_?T/XUJ4#3N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45
M#=7,=G:R7$IPB#/U]JYK0]8D.J2I<M\MTV1Z*W8?EQ^%.PF['5T444AA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %>>V>JV.M^+9=4U2]M[>TT]C%96\T@4EN\A!_ST]*]"K';
MPKH+L6;2;4LQ)),?4FFF3)-G+V>K:<GQ*U"]:^MQ:O:JJ3&0;6;Y> >F:] K
MB+7P=$/&-Y+-I5N=',*B%205#_+G"]1WKMZ&$;]3B/%?_(\>%_\ KJ?YBM;Q
MMI?]J>%[I$4F: >?'CKE>OZ9JOXAT>_OO%6@WMM 'M[60F9]X&T9'8\G\*Z@
M@$$$9!Z@T[["2O<X34O$C7'PU@GB;-W>*+0 'G?]UOT!_,5UFA:8NCZ):6"@
M9BC 8CNQY8_F37%Z5X/U.V\311SQC^QK2YDN8#O4Y)QMXZ^GY5Z)0_((WW8$
MX&:X3P%;1:G+JFMWB+-=S7)0,XSL4#.!Z=<?0"N[KAK*SUGP?J5['::8^I:7
M=2>;'Y+@/$?0@_E^ I(<MTROKNF6UA\0M"FM8EB%S)ND1!@%AQNQZD']*EUF
M)=:^)5CIEY\]G;0><(C]UFY/(_ ?E3I]+\0:KXJTC6+FQ2"WA?\ U(E4M"GJ
MWJ3GH.F*O^)-$U$ZQ::_HH1[VW79) YP)4],^O)_R*HFVX[QKHME<>&+J801
MQS6J>;%(BA2NWMD=L5FZC#J7B?X:V3P RW1V22)G!E"D@_CT/X4_5;CQ)XEL
MCI4.AR:='-@3SW$JD!<\@ <FM35M&U*V\,6UEX>NV@N+3;MY \T <@Y'4]:6
MP/6YS5WKN@ZAIHTC7-'NM*^ZH=81A".X.,C\CQ5SQQ*(M T;3[>22XM;B5$;
M:V6F10,#/<GBEU:Z\1^(-);2CX::"67 >XEE7RUP>J]ZT-7\*37'A6PL;.9?
MMVG['AD;@,RCD>V?\*>@M6F9]_=K>Z)+IB^"]2CB,92/$*?(<<$<]C39=)UK
M4?AC#8-#(E[$0&ADX9T5C@<^V/RJW<:QXJO=/:QA\/2VU](NQKHS*(T]67G/
MTJ]?:3KL7A*"TT_596U2##-,S9,QYRN6SZ\?04AVN<W<Z[HEYI8T?7-%NM+X
M5-ZPCY".X.,C\C7?Z;'#%I=K';3&>!8E$<K-DNN.#GOQ7':I>>)-=T=]*;PT
M\,TH"O<2RKY:^K#O76:+IW]DZ+:6!D\PP1A2WJ>]#''<OT451U87;V#Q64>Z
M63Y2=P&T=SS4EG*ZYJ'V^_.PYABRJ>_J:SX9I+>=)HCB2-MRUH?\(]J@_P"7
M8?\ ?Q?\:/\ A']4_P"?8?\ ?Q?\:TT,M3L;.ZCO;2.XC^ZXSCT/<5/6!H%I
MJ-A+)#<08MW^8'>#M;_Z];]0S1,****0PHHHH **** "BBB@ HHHH **** "
MBBB@ K#\2:C]FM1:QG$LPY(_A7O^?2MLG )QGVKC[S2=7O;N2XDMAESP/,7@
M=AUIHF6VABUU'AC4-T;6$A^9/FBSW'<?A65_PC^J?\^P_P"_B_XT^'1=8MYT
MFBMP)$.Y?WB_XU3LR%=,[6BFQLS1*SIL8C)4G.#Z4ZH-0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH CGF2W@>:1L(@+$UY_>73WMW)<2=7/ ]!V%=5K]
MO?WL<=M:P[HOO2-O SZ#G\ZP?^$?U3_GV'_?Q?\ &JB1*[(-+OSIU^DW_+,_
M+(/5?_K=:[Y6#*&4@@C(([UQ'_"/ZI_S[#_OXO\ C72Z''>V]G]GO(MOEG$;
M;@<KZ<>E$@C<TZ***DL**** "BBB@ HHHH **** "BBB@ HHHH ***ANWF2U
MD:VC\R;'R+D#G\: .8\3:AYUP+*,_NXCE\=V]/PK!R000<$<@CM6F= U9F+-
M;@L3DDR+R?SH_P"$?U3_ )]A_P!_%_QJU8R=V=1H^H#4;!9&(\U/ED'OZ_C6
MA7+Z-I^J:=?AWM_W+_+(!(OX'KVKJ*EFB>@4444AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-K>E6@OK:[0+<VRN%<$=QG_/6@-;&7J+WM_XATG4;'PWJ%E/!,!-(\0 >,D
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M"YS]?J:Z33I;R;3X9+^W6WNF!\R)'W!3GU[\8I/8<=V6JXK6O^2GZ%_U[O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$G@FVN_%;WT\$4>G1(GE6\:@"1QU+ =AQQWKKP     !T H=N@1OU*NIV/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<SRW=Z\1RBW4N]5_#'-=113NQ<J"BBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>33
<FILENAME>vera-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-26T14:42:10.1459+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://veratx.com/20231231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:vera="http://veratx.com/20231231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2" id="DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100040 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfTheBusiness" id="DisclosureOrganizationAndDescriptionOfTheBusiness">
        <link:definition>995455 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" id="DisclosureSummaryOfSignificantAccountingPolicies1">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation" id="Role_DisclosureOtherFinancialStatementInformation">
        <link:definition>995475 - Disclosure - Other Financial Statement Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities" id="DisclosureCashEquivalentsAndMarketableSecurities">
        <link:definition>995485 - Disclosure - Cash Equivalents And Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSale" id="Role_DisclosureNeubaseAssetSale">
        <link:definition>995495 - Disclosure - Neubase Asset Sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>995505 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities" id="Role_DisclosureNonMarketableEquitySecurities">
        <link:definition>995515 - Disclosure - Non-Marketable Equity Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995525 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable" id="DisclosureNotePayable">
        <link:definition>995535 - Disclosure - Note Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>995545 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation" id="Role_DisclosureStockCompensation">
        <link:definition>995555 - Disclosure - Stock Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>995565 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborations" id="DisclosureLicensesAndCollaborations">
        <link:definition>995575 - Disclosure - Licenses and Collaborations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995585 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>995595 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivities" id="Role_DisclosureRestructuringAndRelatedActivities">
        <link:definition>995605 - Disclosure - Restructuring and Related Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1" id="DisclosureNetLossPerShareAttributableToCommonStockholders1">
        <link:definition>995615 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1" id="DisclosureRelatedPartyTransactions1">
        <link:definition>995625 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>995635 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995645 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables" id="Role_DisclosureOtherFinancialStatementInformationTables">
        <link:definition>995655 - Disclosure - Other Financial Statement Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>995665 - Disclosure - Cash Equivalents And Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesTables" id="DisclosureNonmarketableEquitySecuritiesTables">
        <link:definition>995675 - Disclosure - Non-Marketable Equity Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>995685 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable" id="DisclosureNotePayableTable">
        <link:definition>995695 - Disclosure - Note Payable (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable" id="Role_DisclosureStockCompensationTable">
        <link:definition>995705 - Disclosure - Stock Compensation (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995715 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>995725 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>995735 - Disclosure - Organization and Description of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>995755 - Disclosure - Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>995765 - Disclosure - Other Financial Statement Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail" id="Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail">
        <link:definition>995775 - Disclosure - Neubase Asset Sale - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" id="DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>995785 - Disclosure - Cash Equivalents And Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities" id="DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities">
        <link:definition>995795 - Disclosure - Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail" id="DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail">
        <link:definition>995805 - Disclosure - Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail" id="DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail">
        <link:definition>995815 - Disclosure - Non-Marketable Equity Securities - Summary of Non-marketable Equity Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail" id="DisclosureLeasesScheduleOfLeaseCostDetail">
        <link:definition>995825 - Disclosure - Leases - Schedule of Lease Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail" id="DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail">
        <link:definition>995835 - Disclosure - Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails" id="DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails">
        <link:definition>995845 - Disclosure - Leases - Schedule of receivable future annual sublease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="DisclosureLeasesAdditionalInformationDetail">
        <link:definition>995855 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail" id="DisclosureNotePayableScheduleOfNotesPayableDetail">
        <link:definition>995865 - Disclosure - Note Payable - Schedule of Notes Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail" id="DisclosureNotePayableAdditionalInformationDetail">
        <link:definition>995875 - Disclosure - Note Payable - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail" id="DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail">
        <link:definition>995885 - Disclosure - Note Payable - Schedule Principal Installments Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" id="Role_DisclosureCommonStockAdditionalInformationDetail">
        <link:definition>995895 - Disclosure - Common Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails" id="Role_DisclosureStockCompensationAdditionalInformationDetails">
        <link:definition>995905 - Disclosure - Stock Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails" id="Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails">
        <link:definition>995915 - Disclosure - Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails" id="Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails">
        <link:definition>995925 - Disclosure - Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" id="Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">
        <link:definition>995935 - Disclosure - Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails" id="Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails">
        <link:definition>995945 - Disclosure - Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>995955 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail" id="DisclosureLicensesAndCollaborationsAdditionalInformationDetail">
        <link:definition>995965 - Disclosure - Licenses and Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
        <link:definition>995975 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>995985 - Disclosure - Income Taxes - Schedule of Components of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails">
        <link:definition>995995 - Disclosure - Income Taxes - Schedule of Reconciliation of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>996005 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails">
        <link:definition>996015 - Disclosure - Income Taxes - Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996025 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>996035 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail" id="Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail">
        <link:definition>996045 - Disclosure - Restructuring and Related Activities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" id="DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail">
        <link:definition>996055 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>996065 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets" xlink:href="vera-20231231.xsd#StatementBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2" xlink:href="vera-20231231.xsd#DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:href="vera-20231231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" xlink:href="vera-20231231.xsd#StatementStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="vera-20231231.xsd#Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="vera-20231231.xsd#Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail" xlink:href="vera-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail" xlink:href="vera-20231231.xsd#DisclosureLeasesScheduleOfLeaseCostDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail" xlink:href="vera-20231231.xsd#DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails" xlink:href="vera-20231231.xsd#DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail" xlink:href="vera-20231231.xsd#DisclosureNotePayableScheduleOfNotesPayableDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail" xlink:href="vera-20231231.xsd#DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="vera-20231231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:href="vera-20231231.xsd#StatementBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:href="vera-20231231.xsd#StatementStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:href="vera-20231231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="vera-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail" xlink:href="vera-20231231.xsd#Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities" xlink:href="vera-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="vera-20231231.xsd#DisclosureLeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail" xlink:href="vera-20231231.xsd#DisclosureNotePayableAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" xlink:href="vera-20231231.xsd#Role_DisclosureCommonStockAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail" xlink:href="vera-20231231.xsd#DisclosureLicensesAndCollaborationsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vera-20231231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail" xlink:href="vera-20231231.xsd#Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="vera-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="vera-20231231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfTheBusiness" xlink:href="vera-20231231.xsd#DisclosureOrganizationAndDescriptionOfTheBusiness" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" xlink:href="vera-20231231.xsd#DisclosureSummaryOfSignificantAccountingPolicies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation" xlink:href="vera-20231231.xsd#Role_DisclosureOtherFinancialStatementInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities" xlink:href="vera-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSale" xlink:href="vera-20231231.xsd#Role_DisclosureNeubaseAssetSale" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="vera-20231231.xsd#DisclosureMarketableSecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities" xlink:href="vera-20231231.xsd#Role_DisclosureNonMarketableEquitySecurities" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeases" xlink:href="vera-20231231.xsd#DisclosureLeases" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable" xlink:href="vera-20231231.xsd#DisclosureNotePayable" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="vera-20231231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" xlink:href="vera-20231231.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborations" xlink:href="vera-20231231.xsd#DisclosureLicensesAndCollaborations" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="vera-20231231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivities" xlink:href="vera-20231231.xsd#Role_DisclosureRestructuringAndRelatedActivities" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1" xlink:href="vera-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholders1" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:href="vera-20231231.xsd#DisclosureRelatedPartyTransactions1" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:href="vera-20231231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vera-20231231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables" xlink:href="vera-20231231.xsd#Role_DisclosureOtherFinancialStatementInformationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:href="vera-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesTables" xlink:href="vera-20231231.xsd#DisclosureNonmarketableEquitySecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:href="vera-20231231.xsd#DisclosureLeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable" xlink:href="vera-20231231.xsd#DisclosureNotePayableTable" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable" xlink:href="vera-20231231.xsd#Role_DisclosureStockCompensationTable" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="vera-20231231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:href="vera-20231231.xsd#DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail" xlink:href="vera-20231231.xsd#DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="vera-20231231.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails" xlink:href="vera-20231231.xsd#DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AresAgreementMember" xlink:label="vera_AresAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:label="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromBorrowingsNetOfCosts" xlink:label="vera_ProceedsFromBorrowingsNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" xlink:label="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentAndMarketableSecurities" xlink:label="vera_CashEquivalentAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsTextBlock" xlink:label="vera_LicenseAndCollaborationsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LoanFacilityMember" xlink:label="vera_LoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="vera_CashAndCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="vera_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedRestrictedStockAwardsMember" xlink:label="vera_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PnaiMember" xlink:label="vera_PnaiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentAxis" xlink:label="vera_AbandonmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TaxYear2036Member" xlink:label="vera_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NonRevolvingCreditFacilityMember" xlink:label="vera_NonRevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TemporaryEquityIssuePricePerShare" xlink:label="vera_TemporaryEquityIssuePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" xlink:label="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LondonInterbankOfferedRateMember" xlink:label="vera_LondonInterbankOfferedRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidEquityFinancingCosts" xlink:label="vera_PrepaidEquityFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" xlink:label="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_WriteOffOfDeferredCost" xlink:label="vera_WriteOffOfDeferredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" xlink:label="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsTable" xlink:label="vera_LicenseAndCollaborationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedRestrictedStockUnitsMember" xlink:label="vera_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventAxis" xlink:label="vera_EventAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidSoftwareCosts" xlink:label="vera_PrepaidSoftwareCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CowenAndCompanyLlcMember" xlink:label="vera_CowenAndCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseTherapeuticsIncMember" xlink:label="vera_NeubaseTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NonmarketableEquitySecuritiesCarryingValue" xlink:label="vera_NonmarketableEquitySecuritiesCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" xlink:label="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LeasedFacilitiesAbandonedMember" xlink:label="vera_LeasedFacilitiesAbandonedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DiscountedLeaseRelatedRestructuringLiabilityMember" xlink:label="vera_DiscountedLeaseRelatedRestructuringLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" xlink:label="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationAbstract" xlink:label="vera_OtherFinancialStatementInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ContingentMilestoneObligationAccrued" xlink:label="vera_ContingentMilestoneObligationAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementAxis" xlink:label="vera_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccountingPoliciesTable" xlink:label="vera_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TaxYear2032Member" xlink:label="vera_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ResearchContractsCostsAndAccrualsPolicyTextBlock" xlink:label="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MarketableSecuritiesDisclosureTextBlock" xlink:label="vera_MarketableSecuritiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TrdArrExpirationDate" xlink:label="vera_TrdArrExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfSpecifiedCommercialMilestonesMember" xlink:label="vera_AchievementOfSpecifiedCommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedDebtInstrumentMaturityDate" xlink:label="vera_CollateralizedDebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" xlink:label="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmployeeStockPurchasePlanEsppMember" xlink:label="vera_EmployeeStockPurchasePlanEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_RestrictedCashMember" xlink:label="vera_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OperatingLossCarryforwardsExpirationYear" xlink:label="vera_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_FollowOnPublicOfferingMember" xlink:label="vera_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AmplyxAndNovartisMember" xlink:label="vera_AmplyxAndNovartisMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsLineItems" xlink:label="vera_LicenseAndCollaborationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" xlink:label="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedClinicalAndDrugManufacturingExpenses" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseAssetSaleAbstract" xlink:label="vera_NeubaseAssetSaleAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationTextBlock" xlink:label="vera_OtherFinancialStatementInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromSaleOfMarketableSecurities" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="us-gaap_ValuationAllowanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ClassACommonStockIssuedAndOutstandingMember" xlink:label="vera_ClassACommonStockIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_YaleLicenseAgreementMember" xlink:label="vera_YaleLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentDomain" xlink:label="vera_AbandonmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MilestonePaymentsPaid" xlink:label="vera_MilestonePaymentsPaid"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquipmentAbondonedMember" xlink:label="vera_EquipmentAbondonedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidClinicalTrialAndDrugManufacturingCosts" xlink:label="vera_PrepaidClinicalTrialAndDrugManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicensesAndCollaborationsAbstract" xlink:label="vera_LicensesAndCollaborationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AmplyxAgreementMember" xlink:label="vera_AmplyxAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventDomain" xlink:label="vera_EventDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:label="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfIncreaseInRentAnnually" xlink:label="vera_PercentageOfIncreaseInRentAnnually"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CeliaLinMember" xlink:label="vera_CeliaLinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementDomain" xlink:label="vera_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ReductionInContingentFutureDevelopment" xlink:label="vera_ReductionInContingentFutureDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NovartisMember" xlink:label="vera_NovartisMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredTaxAssetsLeaseLiability" xlink:label="vera_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedStockOptionsAndRestrictedStockUnitMember" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AresTradingSAMember" xlink:label="vera_AresTradingSAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandTwentyTwoAtmFacilityMember" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidRecruitingFees" xlink:label="vera_PrepaidRecruitingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnderwritingDiscountsAndCommissions" xlink:label="vera_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredOfferingCostsPolicyTextBlock" xlink:label="vera_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MilestonePaymentsPayable" xlink:label="vera_MilestonePaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" xlink:label="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseAssetSaleTextBlock" xlink:label="vera_NeubaseAssetSaleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_InvestmentInPnaiMember" xlink:label="vera_InvestmentInPnaiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" xlink:label="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccountingPoliciesLineItems" xlink:label="vera_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" xlink:label="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForIssuanceAndSaleUnderSalesAgreement" xlink:label="vera_AvailableForIssuanceAndSaleUnderSalesAgreement"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and other credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of offering costs related to initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost and Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total sublease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain(loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award, Vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of the debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expense and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units R S U [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Series C redeemable convertible preferred stock, net of issuance cost of $389</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares issued during the period value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AresAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ares Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AresAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ares Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AresAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ares Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate offering price of securities under shelf registration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Offering Price of Securities Under Shelf Registration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate offering price of common stock, preferred stock, debt securities and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award minimum employee subscription rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Minimum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchases funded through payroll deductions for employee's eligible minimum annual compensation, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromBorrowingsNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from borrowings, net of costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromBorrowingsNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from borrowings, net of costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock shares issued during the period shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Shares Issued During the Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial fee paid as consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Uncertainties [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment options non vested weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Options Non Vested Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price Opening balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashEquivalentAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashEquivalentAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalent And Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashEquivalentAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalent and marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Non-marketable Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License And Collaborations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaborations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licenses and Collaborations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other DTA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Note Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LoanFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award, Options granted in period, Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash And Cash Equivalents And Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashAndCashEquivalentsAndMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment arrangement options non vested weighted average remaining contractual term.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Arrangement Options Non Vested Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Amortization and Accretion, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Amortization and Accretion, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation, amortization and accretion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses and other assets, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining capacity available</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock capital, Shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Emerging Growth Company Status .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Status [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Conversion Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock conversion basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment options non vested forfeitures in period weighted average exercise price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Options Non Vested Forfeitures In Period Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Cancelled and forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PnaiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pnai Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PnaiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PNAI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PnaiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PNAI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock from underwritten follow-on offering, net of offering costs shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note , Maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AbandonmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Abandonment Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AbandonmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Abandonment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AbandonmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abandonment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note ,Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Secured Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2036 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2036 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2036.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic Value, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NonRevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non revolving credit facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NonRevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NonRevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Issue Price Per Share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issue Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity purchase price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Seventeen And Two Thousand And Twenty One Amended Equity incentive Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Seventeen And Two Thousand And Twenty One Amended Equity incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 and 2021 Amended Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LondonInterbankOfferedRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIBOR [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LondonInterbankOfferedRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">London Interbank Offered Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LondonInterbankOfferedRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">London Interbank Offered Rate Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidEquityFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid equity financing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidEquityFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Equity Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidEquityFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid equity financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock pursuant to employee stock purchase plan, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LEASES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space at woborn massauchets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office and Laboratory Space at Woborn Massauchets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space at Woborn Massauchets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_WriteOffOfDeferredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred costs, written off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_WriteOffOfDeferredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Write-off of Deferred Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_WriteOffOfDeferredCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Write-off of deferred cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject to or Available for Operating Lease [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Subject to or Available for Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space at Brisbane California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office and Laboratory Space at Brisbane California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space at brisbane california.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested as of December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested as of December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax on U.S. statutory rate on income before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaborations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaborations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License And Collaborations [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock pursuant to employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on sale of PNAi technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on sale of PNAi technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis spread on variable rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Event [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross DTL</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross DTL</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, Number of shares available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidSoftwareCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid software costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidSoftwareCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Software Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidSoftwareCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Software Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 44,452,161 and 27,800,861 shares issued and outstanding as ofDecember 31, 2023 and December 31, 2022, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Reserve, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CowenAndCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cowen and Company, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CowenAndCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cowen and Company, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CowenAndCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cowen and Company, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Company shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Shares Licensing Payments In Equity (value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Licensing Payments In Equity (value)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for payment of licensing fees in equity, net of offering cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Neubase therapeutics inc member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Neubase Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neubase Therapeutics Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NonmarketableEquitySecuritiesCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Carrying value of non-marketable equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NonmarketableEquitySecuritiesCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonmarketable Equity Securities Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NonmarketableEquitySecuritiesCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonmarketable equity securities carrying value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decreases based on tax positions related to prior year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of the Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation shares received on disposal.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Shares Received On Disposal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal group including discontinued operations shares received for disposal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of non-marketable equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity securities, FV-NI, unrealized gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends, Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LeasedFacilitiesAbandonedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leased Facilities Abandoned Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LeasedFacilitiesAbandonedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leased Facilities Abandoned [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LeasedFacilitiesAbandonedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased Facilities Abandoned [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DiscountedLeaseRelatedRestructuringLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discounted Lease Related Restructuring Liability Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DiscountedLeaseRelatedRestructuringLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discounted Lease Related Restructuring Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DiscountedLeaseRelatedRestructuringLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounted Lease Related Restructuring Liability [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative net fair value loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative net fair value loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Without Readily Determinable Fair Value Net Cumulative Gain Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities without readily determinable fair value net cumulative gain loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Lease Income, Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Ending</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Beginning</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Severance And Other Employee Termination Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Severance And Other Employee Termination [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Severance And Other Employee Termination [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of Class A common stock pursuant to exercise of options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OtherFinancialStatementInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other financial statement information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OtherFinancialStatementInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Statement Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonClassBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class B [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note , variable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments owned market value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Investment Owned, at Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Investment Owned, at Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving credit facility with borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of lease liabilities based on minimum lease commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ContingentMilestoneObligationAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Milestone Obligation Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ContingentMilestoneObligationAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Milestone Obligation Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ContingentMilestoneObligationAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent milestone obligation accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock Options And Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Stock Options And Restricted Stock Awards [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Stock Options And Restricted Stock Awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock from underwritten follow-on offering net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock net consideration received on the transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note , Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Cancelled and forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonemployees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Underwriting Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total asset acquisition cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Acquisition Related Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2032 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Year 2032 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax year 2032.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research contracts costs and accruals.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Contracts Costs And Accruals [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Contract Costs And Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Liabilities And Other Liabilities Non Current .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state NOL carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain (loss) on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MarketableSecuritiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable Securities Disclosure Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MarketableSecuritiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Disclosure Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MarketableSecuritiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Principal Installments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Restructuring and Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease minimum future commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Sublease Income, Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due within one year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note 2023-12</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateralized Note Two Thousand Twenty Three - Twelve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collateralized note two thousand twenty three - twelve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock in payment of licensing fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TrdArrExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TrdArrExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trd Arr Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TrdArrExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Trading arrangement expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value of Investments in Available-for-sale Marketable Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfSpecifiedCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement Of Specified Commercial Milestones Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfSpecifiedCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement Of Specified Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfSpecifiedCommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement Of Specified Commercial Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedDebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized debt instrument maturity date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedDebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateralized Debt Instrument Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedDebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collateralized debt instrument maturity date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty One Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment owned number of shares placed in escrow account..</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned Number Of Shares Placed In Escrow Account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment owned number of shares placed in escrow account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities gross unrealized loss1.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available for Sale Debt Securities Gross Unrealized Loss1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmployeeStockPurchasePlanEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan Espp Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmployeeStockPurchasePlanEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EmployeeStockPurchasePlanEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock upon vesting of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Gain (Loss), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of non-marketable equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in unrealized loss on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Employee [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive gain (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of company common stock outstanding for increase in shares reserved for issuance under stock plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Of Company Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential increase in shares reserved for future issuance as percentage of outstanding share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, Par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_FollowOnPublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AmplyxAndNovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amplyx and Novartis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AmplyxAndNovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amplyx and Novartis member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AmplyxAndNovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amplyx and Novartis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Temporary Equity , shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Temporary Equity, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Dilutive Shares Excluded From Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaborations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Collaborations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicenseAndCollaborationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License And Collaborations [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Marketable&#160;Equity Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement as Assumed Liabilities upon Acquisition [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement as assumed liabilities upon acquisition member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock follow on offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Follow On Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Class A common stock in follow-on offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Deferred Tax Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment of the loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Percentage Prepayment Of Loan or Maturity Date is Not Extended</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line of credit facility percentage prepayment Of loan or maturity date is not extended.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and drug manufacturing expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical and Drug Manufacturing Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and drug manufacturing expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic Value, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Compensation Arrangements by Share-based Payment Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseAssetSaleAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neubase Asset Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseAssetSaleAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Neubase Asset Sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseAssetSaleAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Neubase Asset Sale [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OtherFinancialStatementInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Financial Statement Information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OtherFinancialStatementInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Financial Statement Information [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_OtherFinancialStatementInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Financial Statement Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sale of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalty accruals associated with uncertain tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options and employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Divestiture of Businesses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of PNAi technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds received from the disposal of business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value licensing payments in equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Licensing Payments in Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for payment of licensing fees in equity, net of offering cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, expenses from transactions with related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ClassACommonStockIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class A common stock issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ClassACommonStockIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class A Common Stock Issued And Outstanding [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ClassACommonStockIssuedAndOutstandingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Common Stock Options Issued and Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_YaleLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Yale License Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_YaleLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Yale License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_YaleLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Yale License Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AbandonmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Abandonment Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AbandonmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Abandonment [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AbandonmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Abandonment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock pursuant to exercise of options, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award, Options exercised in period, Total intrinsic value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for licensing payment, net of costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock for licensing payment, net of costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Class A common stock for licensing payment, net of costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt facility payments description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Accrued And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued And Other Current Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses And Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring and Related Activities Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring and Related Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquipmentAbondonedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment Abondoned Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquipmentAbondonedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Abondoned [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquipmentAbondonedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment Abandoned [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross DTA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross DTA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note 2021-12</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateralized Note Two Thousand Twenty One - Twelve [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collateralized note two thousand twenty one - twelve.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares minimum increase in shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential increase in shares reserved for future issuance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidClinicalTrialAndDrugManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Clinical Trial and Drug Manufacturing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidClinicalTrialAndDrugManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Trial and Drug Manufacturing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidClinicalTrialAndDrugManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical trial and drug manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicensesAndCollaborationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licenses And Collaborations Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LicensesAndCollaborationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licenses And Collaborations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Without Readily Determinable Fair Value Initial Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities without readily determinable fair value initial cost.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average Grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject to or Available for Operating Lease [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Subject to or Available for Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AmplyxAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amplyx Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AmplyxAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amplyx agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AmplyxAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amplyx Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, right-of-use assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Right-of-use Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right of use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Event [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_EventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement of Various Clinical Development and Regulatory Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of various clinical development and regulatory milestones member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PercentageOfIncreaseInRentAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Of Increase In Rent Annually</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PercentageOfIncreaseInRentAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Rent Annually</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PercentageOfIncreaseInRentAnnually_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in rent annually</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CeliaLinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Celia Lin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CeliaLinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Celia Lin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CeliaLinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Celia lin.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, number of shares issued in transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares licensing payments in equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares licensing Payments in Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Company shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for payment of licensing fees, net of offering costs, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ReductionInContingentFutureDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction In Contingent Future Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ReductionInContingentFutureDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Contingent Future Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ReductionInContingentFutureDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in contingent future development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets, lease liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredTaxAssetsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due after one year to two years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt maturities after one through two years fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested stock options and restricted stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Stock Options And Restricted Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock Options And Restricted Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AresTradingSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ares Trading S A Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AresTradingSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ares Trading S A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AresTradingSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ares Trading S A [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued under share based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty two ATM facility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Two ATM facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022 ATM facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidRecruitingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Recruiting Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidRecruitingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Recruiting Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PrepaidRecruitingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid recruiting fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Carrying amount of debt outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net carrying amount of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Temporary Equity Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Temporary Equity Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchases funded through payroll deductions for employee's eligible maximum annual compensation, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based Compensation Arrangement By Share based Payment Award Restricted Shares Of Fully Issued And Outstanding Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Compensation Arrangement By Share based Payment Award Restricted Shares Of Fully Issued And Outstanding Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation arrangement by share based payment award, Restricted shares of fully issued and outstanding common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts and Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Offering Costs .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employer contributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, Shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, Shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Cancelled and Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_MilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of redeemable preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Redeemable Preferred Stock Into Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion Of Redeemable Preferred Stock Into Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Elements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Escrow Deposit Disbursements Related to Property Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares eligible for release from escrow</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit Facility Percentage Prepayment Of Loan or Maturity Date is Extended</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Percentage Prepayment Of Loan or Maturity Date is Extended</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Class B common stock into Class A common stock, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional borrowing capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-marketable equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other DTL</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled and forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled and forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other than Temporary Impairment Losses, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss on available-for-sale marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseAssetSaleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Neubase asset sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseAssetSaleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Neubase Asset Sale [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_NeubaseAssetSaleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Neubase Asset Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income (Loss) Before Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation by share based payment award non vested options outstanding aggregate intrinsic value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation By Share Based Payment Award Non Vested Options Outstanding Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of stock issuance costs on follow on offering.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs on Follow on Offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of costs and underwriting discounts and commissions related to follow-on offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Receivable Future Annual Sublease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SOFR [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_InvestmentInPnaiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investment In PNAI.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_InvestmentInPnaiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment In PNAI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_InvestmentInPnaiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment In PNAI [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of real estate availed on lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Provision for Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction in the carrying amount of operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves and accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Reserve, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restructuring lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock Percent of Fair Market Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and seventeen eip and two thousand and twenty one eip.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Seventeen EIP And Two Thousand And Twenty One EIP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 EIP And 2021 EIP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement Of Specified Bla Filing Or Regulatory Approval Milestones Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collateralized note 2022-11</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateralized Note Two Thousand Twenty Two - Eleven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collateralized note two thousand twenty two - eleven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type of Restructuring [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Restructuring</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock shares issued during the period new issues shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForIssuanceAndSaleUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for issuance and sale under sales agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForIssuanceAndSaleUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available for Issuance and Sale Under Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vera_AvailableForIssuanceAndSaleUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for Issuance and Sale Under Sales Agreement</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AresAgreementMember" xlink:to="vera_AresAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:to="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ProceedsFromBorrowingsNetOfCosts" xlink:to="vera_ProceedsFromBorrowingsNetOfCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" xlink:to="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CashEquivalentAndMarketableSecurities" xlink:to="vera_CashEquivalentAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LicenseAndCollaborationsTextBlock" xlink:to="vera_LicenseAndCollaborationsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LoanFacilityMember" xlink:to="vera_LoanFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CashAndCashEquivalentsAndMarketableSecurities" xlink:to="vera_CashAndCashEquivalentsAndMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAmortizationAndAccretionNet" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="vera_EmergingGrowthCompanyStatusPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_UnvestedRestrictedStockAwardsMember" xlink:to="vera_UnvestedRestrictedStockAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PnaiMember" xlink:to="vera_PnaiMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" xlink:to="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AbandonmentAxis" xlink:to="vera_AbandonmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TaxYear2036Member" xlink:to="vera_TaxYear2036Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_NonRevolvingCreditFacilityMember" xlink:to="vera_NonRevolvingCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TemporaryEquityIssuePricePerShare" xlink:to="vera_TemporaryEquityIssuePricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" xlink:to="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LondonInterbankOfferedRateMember" xlink:to="vera_LondonInterbankOfferedRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PrepaidEquityFinancingCosts" xlink:to="vera_PrepaidEquityFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" xlink:to="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_WriteOffOfDeferredCost" xlink:to="vera_WriteOffOfDeferredCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" xlink:to="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="vera_LicenseAndCollaborationsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_UnvestedRestrictedStockUnitsMember" xlink:to="vera_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EventAxis" xlink:to="vera_EventAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PrepaidSoftwareCosts" xlink:to="vera_PrepaidSoftwareCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CowenAndCompanyLlcMember" xlink:to="vera_CowenAndCompanyLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_NeubaseTherapeuticsIncMember" xlink:to="vera_NeubaseTherapeuticsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_NonmarketableEquitySecuritiesCarryingValue" xlink:to="vera_NonmarketableEquitySecuritiesCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" xlink:to="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCash" xlink:to="us-gaap_DividendsCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LeasedFacilitiesAbandonedMember" xlink:to="vera_LeasedFacilitiesAbandonedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_DiscountedLeaseRelatedRestructuringLiabilityMember" xlink:to="vera_DiscountedLeaseRelatedRestructuringLiabilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" xlink:to="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" xlink:to="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_OtherFinancialStatementInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ContingentMilestoneObligationAccrued" xlink:to="vera_ContingentMilestoneObligationAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" xlink:to="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" xlink:to="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AgreementAxis" xlink:to="vera_AgreementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AccountingPoliciesTable" xlink:to="vera_AccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TaxYear2032Member" xlink:to="vera_TaxYear2032Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="vera_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock" xlink:to="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" xlink:to="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_MarketableSecuritiesDisclosureTextBlock" xlink:to="vera_MarketableSecuritiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" xlink:to="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TrdArrExpirationDate" xlink:to="vera_TrdArrExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AchievementOfSpecifiedCommercialMilestonesMember" xlink:to="vera_AchievementOfSpecifiedCommercialMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CollateralizedDebtInstrumentMaturityDate" xlink:to="vera_CollateralizedDebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" xlink:to="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" xlink:to="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EmployeeStockPurchasePlanEsppMember" xlink:to="vera_EmployeeStockPurchasePlanEsppMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_RestrictedCashMember" xlink:to="vera_RestrictedCashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_OperatingLossCarryforwardsExpirationYear" xlink:to="vera_OperatingLossCarryforwardsExpirationYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_FollowOnPublicOfferingMember" xlink:to="vera_FollowOnPublicOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AmplyxAndNovartisMember" xlink:to="vera_AmplyxAndNovartisMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_LicenseAndCollaborationsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" xlink:to="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" xlink:to="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" xlink:to="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AccruedClinicalAndDrugManufacturingExpenses" xlink:to="vera_AccruedClinicalAndDrugManufacturingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_NeubaseAssetSaleAbstract" xlink:to="vera_NeubaseAssetSaleAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_OtherFinancialStatementInformationTextBlock" xlink:to="vera_OtherFinancialStatementInformationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ProceedsFromSaleOfMarketableSecurities" xlink:to="vera_ProceedsFromSaleOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_ValuationAllowanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" xlink:to="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ClassACommonStockIssuedAndOutstandingMember" xlink:to="vera_ClassACommonStockIssuedAndOutstandingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_YaleLicenseAgreementMember" xlink:to="vera_YaleLicenseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AbandonmentDomain" xlink:to="vera_AbandonmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" xlink:to="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_MilestonePaymentsPaid" xlink:to="vera_MilestonePaymentsPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EquipmentAbondonedMember" xlink:to="vera_EquipmentAbondonedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" xlink:to="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PrepaidClinicalTrialAndDrugManufacturingCosts" xlink:to="vera_PrepaidClinicalTrialAndDrugManufacturingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LicensesAndCollaborationsAbstract" xlink:to="vera_LicensesAndCollaborationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" xlink:to="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AmplyxAgreementMember" xlink:to="vera_AmplyxAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="vera_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_EventDomain" xlink:to="vera_EventDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PercentageOfIncreaseInRentAnnually" xlink:to="vera_PercentageOfIncreaseInRentAnnually_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CeliaLinMember" xlink:to="vera_CeliaLinMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AgreementDomain" xlink:to="vera_AgreementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ReductionInContingentFutureDevelopment" xlink:to="vera_ReductionInContingentFutureDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_NovartisMember" xlink:to="vera_NovartisMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_DeferredTaxAssetsLeaseLiability" xlink:to="vera_DeferredTaxAssetsLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_UnvestedStockOptionsAndRestrictedStockUnitMember" xlink:to="vera_UnvestedStockOptionsAndRestrictedStockUnitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AresTradingSAMember" xlink:to="vera_AresTradingSAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TwoThousandTwentyTwoAtmFacilityMember" xlink:to="vera_TwoThousandTwentyTwoAtmFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PrepaidRecruitingFees" xlink:to="vera_PrepaidRecruitingFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" xlink:to="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_UnderwritingDiscountsAndCommissions" xlink:to="vera_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_DeferredOfferingCostsPolicyTextBlock" xlink:to="vera_DeferredOfferingCostsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_MilestonePaymentsPayable" xlink:to="vera_MilestonePaymentsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" xlink:to="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:to="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" xlink:to="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_NeubaseAssetSaleTextBlock" xlink:to="vera_NeubaseAssetSaleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="vera_CashEquivalentsAndMarketableSecuritiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" xlink:to="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_InvestmentInPnaiMember" xlink:to="vera_InvestmentInPnaiMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" xlink:to="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="vera_AccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" xlink:to="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" xlink:to="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vera_AvailableForIssuanceAndSaleUnderSalesAgreement" xlink:to="vera_AvailableForIssuanceAndSaleUnderSalesAgreement_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_17"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_19"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_20"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromBorrowingsNetOfCosts" xlink:label="vera_ProceedsFromBorrowingsNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_RestrictedCashMember" xlink:label="vera_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromSaleOfMarketableSecurities" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vera_ProceedsFromBorrowingsNetOfCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="vera_RestrictedCashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_StockIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="vera_ProceedsFromSaleOfMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CeliaLinMember" xlink:label="vera_CeliaLinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TrdArrExpirationDate" xlink:label="vera_TrdArrExpirationDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember" xlink:to="vera_CeliaLinMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="vera_TrdArrExpirationDate" order="13.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfTheBusiness" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationAbstract" xlink:label="vera_OtherFinancialStatementInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationTextBlock" xlink:label="vera_OtherFinancialStatementInformationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_OtherFinancialStatementInformationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSale" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseAssetSaleAbstract" xlink:label="vera_NeubaseAssetSaleAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseAssetSaleTextBlock" xlink:label="vera_NeubaseAssetSaleTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_NeubaseAssetSaleAbstract" xlink:to="vera_NeubaseAssetSaleTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MarketableSecuritiesDisclosureTextBlock" xlink:label="vera_MarketableSecuritiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="vera_MarketableSecuritiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicensesAndCollaborationsAbstract" xlink:label="vera_LicensesAndCollaborationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsTextBlock" xlink:label="vera_LicenseAndCollaborationsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicensesAndCollaborationsAbstract" xlink:to="vera_LicenseAndCollaborationsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="vera_EmergingGrowthCompanyStatusPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredOfferingCostsPolicyTextBlock" xlink:label="vera_DeferredOfferingCostsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ResearchContractsCostsAndAccrualsPolicyTextBlock" xlink:label="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vera_EmergingGrowthCompanyStatusPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vera_DeferredOfferingCostsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationAbstract" xlink:label="vera_OtherFinancialStatementInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventAxis" xlink:label="vera_EventAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventDomain" xlink:label="vera_EventDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" xlink:label="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="vera_CashAndCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_FollowOnPublicOfferingMember" xlink:label="vera_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnderwritingDiscountsAndCommissions" xlink:label="vera_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventAxis" xlink:to="vera_EventDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventDomain" xlink:to="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="vera_EventAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_CashAndCashEquivalentsAndMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_FollowOnPublicOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_UnderwritingDiscountsAndCommissions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccountingPoliciesTable" xlink:label="vera_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccountingPoliciesLineItems" xlink:label="vera_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vera_AccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesTable" xlink:to="vera_AccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationAbstract" xlink:label="vera_OtherFinancialStatementInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidClinicalTrialAndDrugManufacturingCosts" xlink:label="vera_PrepaidClinicalTrialAndDrugManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidEquityFinancingCosts" xlink:label="vera_PrepaidEquityFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidSoftwareCosts" xlink:label="vera_PrepaidSoftwareCosts"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidRecruitingFees" xlink:label="vera_PrepaidRecruitingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_PrepaidClinicalTrialAndDrugManufacturingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_PrepaidEquityFinancingCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="us-gaap_PrepaidRent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_PrepaidSoftwareCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="vera_PrepaidRecruitingFees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OtherFinancialStatementInformationAbstract" xlink:label="vera_OtherFinancialStatementInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedClinicalAndDrugManufacturingExpenses" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_OtherFinancialStatementInformationAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_AccruedClinicalAndDrugManufacturingExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_InvestmentInPnaiMember" xlink:label="vera_InvestmentInPnaiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseTherapeuticsIncMember" xlink:label="vera_NeubaseTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseAssetSaleAbstract" xlink:label="vera_NeubaseAssetSaleAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" xlink:label="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" xlink:label="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="vera_InvestmentInPnaiMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="vera_NeubaseTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_NeubaseAssetSaleAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentAndMarketableSecurities" xlink:label="vera_CashEquivalentAndMarketableSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="vera_CashEquivalentAndMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="vera_CashEquivalentsAndMarketableSecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" xlink:label="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NonmarketableEquitySecuritiesCarryingValue" xlink:label="vera_NonmarketableEquitySecuritiesCarryingValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="vera_NonmarketableEquitySecuritiesCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_SubleaseIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" xlink:label="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfIncreaseInRentAnnually" xlink:label="vera_PercentageOfIncreaseInRentAnnually"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="vera_PercentageOfIncreaseInRentAnnually" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LondonInterbankOfferedRateMember" xlink:label="vera_LondonInterbankOfferedRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedDebtInstrumentMaturityDate" xlink:label="vera_CollateralizedDebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="vera_LondonInterbankOfferedRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vera_CollateralizedDebtInstrumentMaturityDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NonRevolvingCreditFacilityMember" xlink:label="vera_NonRevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LoanFacilityMember" xlink:label="vera_LoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="vera_NonRevolvingCreditFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="vera_LoanFacilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_FollowOnPublicOfferingMember" xlink:label="vera_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CowenAndCompanyLlcMember" xlink:label="vera_CowenAndCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandTwentyTwoAtmFacilityMember" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:label="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForIssuanceAndSaleUnderSalesAgreement" xlink:label="vera_AvailableForIssuanceAndSaleUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_FollowOnPublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vera_CowenAndCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_TwoThousandTwentyTwoAtmFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vera_AvailableForIssuanceAndSaleUnderSalesAgreement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmployeeStockPurchasePlanEsppMember" xlink:label="vera_EmployeeStockPurchasePlanEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedStockOptionsAndRestrictedStockUnitMember" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" xlink:label="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_EmployeeStockPurchasePlanEsppMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="vera_UnvestedStockOptionsAndRestrictedStockUnitMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" xlink:label="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_GranteeStatusAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AresTradingSAMember" xlink:label="vera_AresTradingSAMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsTable" xlink:label="vera_LicenseAndCollaborationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventAxis" xlink:label="vera_EventAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventDomain" xlink:label="vera_EventDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementAxis" xlink:label="vera_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementDomain" xlink:label="vera_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsLineItems" xlink:label="vera_LicenseAndCollaborationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" xlink:label="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicensesAndCollaborationsAbstract" xlink:label="vera_LicensesAndCollaborationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" xlink:label="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_YaleLicenseAgreementMember" xlink:label="vera_YaleLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AmplyxAndNovartisMember" xlink:label="vera_AmplyxAndNovartisMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TemporaryEquityIssuePricePerShare" xlink:label="vera_TemporaryEquityIssuePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfSpecifiedCommercialMilestonesMember" xlink:label="vera_AchievementOfSpecifiedCommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AresAgreementMember" xlink:label="vera_AresAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:label="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AmplyxAgreementMember" xlink:label="vera_AmplyxAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" xlink:label="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NovartisMember" xlink:label="vera_NovartisMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MilestonePaymentsPaid" xlink:label="vera_MilestonePaymentsPaid"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MilestonePaymentsPayable" xlink:label="vera_MilestonePaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ReductionInContingentFutureDevelopment" xlink:label="vera_ReductionInContingentFutureDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ContingentMilestoneObligationAccrued" xlink:label="vera_ContingentMilestoneObligationAccrued"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vera_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vera_AresTradingSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventAxis" xlink:to="vera_EventDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AgreementAxis" xlink:to="vera_AgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicensesAndCollaborationsAbstract" xlink:to="vera_LicenseAndCollaborationsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventDomain" xlink:to="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AgreementDomain" xlink:to="vera_YaleLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vera_AmplyxAndNovartisMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="vera_AgreementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_TemporaryEquityIssuePricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventDomain" xlink:to="vera_AchievementOfSpecifiedCommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AgreementDomain" xlink:to="vera_AresAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventDomain" xlink:to="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AgreementDomain" xlink:to="vera_AmplyxAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="vera_EventAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_EventDomain" xlink:to="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AgreementDomain" xlink:to="vera_NovartisMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_MilestonePaymentsPaid" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="vera_LicenseAndCollaborationsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_MilestonePaymentsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_ReductionInContingentFutureDevelopment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_ContingentMilestoneObligationAccrued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="us-gaap_ValuationAllowanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_ValuationAllowanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredTaxAssetsLeaseLiability" xlink:label="vera_DeferredTaxAssetsLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="vera_DeferredTaxAssetsLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="vera_DeferredTaxLiabilitiesRightOfUseAssets" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TaxYear2032Member" xlink:label="vera_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TaxYear2036Member" xlink:label="vera_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OperatingLossCarryforwardsExpirationYear" xlink:label="vera_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="vera_TaxYear2032Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="vera_TaxYear2036Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="vera_OperatingLossCarryforwardsExpirationYear" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PnaiMember" xlink:label="vera_PnaiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" xlink:label="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfIncreaseInRentAnnually" xlink:label="vera_PercentageOfIncreaseInRentAnnually"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vera_PnaiMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="vera_PercentageOfIncreaseInRentAnnually" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentAxis" xlink:label="vera_AbandonmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentDomain" xlink:label="vera_AbandonmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LeasedFacilitiesAbandonedMember" xlink:label="vera_LeasedFacilitiesAbandonedMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DiscountedLeaseRelatedRestructuringLiabilityMember" xlink:label="vera_DiscountedLeaseRelatedRestructuringLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquipmentAbondonedMember" xlink:label="vera_EquipmentAbondonedMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" xlink:label="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AbandonmentAxis" xlink:to="vera_AbandonmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="vera_AbandonmentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AbandonmentDomain" xlink:to="vera_LeasedFacilitiesAbandonedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="vera_DiscountedLeaseRelatedRestructuringLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vera_AbandonmentDomain" xlink:to="vera_EquipmentAbondonedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ClassACommonStockIssuedAndOutstandingMember" xlink:label="vera_ClassACommonStockIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedRestrictedStockAwardsMember" xlink:label="vera_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedRestrictedStockUnitsMember" xlink:label="vera_UnvestedRestrictedStockUnitsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vera_ClassACommonStockIssuedAndOutstandingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vera_UnvestedRestrictedStockAwardsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vera_UnvestedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_WriteOffOfDeferredCost" xlink:label="vera_WriteOffOfDeferredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CowenAndCompanyLlcMember" xlink:label="vera_CowenAndCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandTwentyTwoAtmFacilityMember" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vera_WriteOffOfDeferredCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vera_CowenAndCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_TwoThousandTwentyTwoAtmFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" xlink:label="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromBorrowingsNetOfCosts" xlink:label="vera_ProceedsFromBorrowingsNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_RestrictedCashMember" xlink:label="vera_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromSaleOfMarketableSecurities" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vera_ProceedsFromBorrowingsNetOfCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="vera_RestrictedCashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_StockIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="vera_ProceedsFromSaleOfMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CeliaLinMember" xlink:label="vera_CeliaLinMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ecd_AllIndividualsMember" xlink:to="vera_CeliaLinMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventAxis" xlink:label="vera_EventAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventDomain" xlink:label="vera_EventDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventDomain" xlink:label="vera_EventDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" xlink:label="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashAndCashEquivalentsAndMarketableSecurities" xlink:label="vera_CashAndCashEquivalentsAndMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_FollowOnPublicOfferingMember" xlink:label="vera_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnderwritingDiscountsAndCommissions" xlink:label="vera_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="vera_EventAxis" xlink:to="vera_EventDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="vera_EventAxis" xlink:to="vera_EventDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_EventDomain" xlink:to="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="vera_EventAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_CashAndCashEquivalentsAndMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccountingPoliciesLineItems" xlink:label="vera_AccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccountingPoliciesTable" xlink:label="vera_AccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="us-gaap_ImpairmentOfInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="vera_AccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_AccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AccountingPoliciesLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedClinicalAndDrugManufacturingExpenses" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_AccruedClinicalAndDrugManufacturingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_InvestmentInPnaiMember" xlink:label="vera_InvestmentInPnaiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NeubaseTherapeuticsIncMember" xlink:label="vera_NeubaseTherapeuticsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" xlink:label="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" xlink:label="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" xlink:label="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="vera_InvestmentInPnaiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="vera_NeubaseTherapeuticsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" xlink:label="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CashEquivalentAndMarketableSecurities" xlink:label="vera_CashEquivalentAndMarketableSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="vera_CashEquivalentAndMarketableSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" xlink:label="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfIncreaseInRentAnnually" xlink:label="vera_PercentageOfIncreaseInRentAnnually"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="vera_PercentageOfIncreaseInRentAnnually" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LondonInterbankOfferedRateMember" xlink:label="vera_LondonInterbankOfferedRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedDebtInstrumentMaturityDate" xlink:label="vera_CollateralizedDebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" xlink:label="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="vera_LondonInterbankOfferedRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vera_CollateralizedDebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember" xlink:label="us-gaap_BaseRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NonRevolvingCreditFacilityMember" xlink:label="vera_NonRevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LoanFacilityMember" xlink:label="vera_LoanFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPayments" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPayments"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" xlink:label="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_BaseRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="vera_NonRevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="vera_LoanFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_FollowOnPublicOfferingMember" xlink:label="vera_FollowOnPublicOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CowenAndCompanyLlcMember" xlink:label="vera_CowenAndCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandTwentyTwoAtmFacilityMember" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCash" xlink:label="us-gaap_DividendsCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:label="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForIssuanceAndSaleUnderSalesAgreement" xlink:label="vera_AvailableForIssuanceAndSaleUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_FollowOnPublicOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vera_CowenAndCompanyLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_TwoThousandTwentyTwoAtmFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConversionBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vera_AvailableForIssuanceAndSaleUnderSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmployeeStockPurchasePlanEsppMember" xlink:label="vera_EmployeeStockPurchasePlanEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedStockOptionsAndRestrictedStockUnitMember" xlink:label="vera_UnvestedStockOptionsAndRestrictedStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" xlink:label="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" xlink:label="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_EmployeeStockPurchasePlanEsppMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="vera_UnvestedStockOptionsAndRestrictedStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" xlink:label="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" xlink:label="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_GranteeStatusAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsLineItems" xlink:label="vera_LicenseAndCollaborationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LicenseAndCollaborationsTable" xlink:label="vera_LicenseAndCollaborationsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="vera_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AresTradingSAMember" xlink:label="vera_AresTradingSAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventAxis" xlink:label="vera_EventAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EventDomain" xlink:label="vera_EventDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementAxis" xlink:label="vera_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementDomain" xlink:label="vera_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AgreementDomain" xlink:label="vera_AgreementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" xlink:label="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" xlink:label="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_YaleLicenseAgreementMember" xlink:label="vera_YaleLicenseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AmplyxAndNovartisMember" xlink:label="vera_AmplyxAndNovartisMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TemporaryEquityIssuePricePerShare" xlink:label="vera_TemporaryEquityIssuePricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfSpecifiedCommercialMilestonesMember" xlink:label="vera_AchievementOfSpecifiedCommercialMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AresAgreementMember" xlink:label="vera_AresAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:label="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AmplyxAgreementMember" xlink:label="vera_AmplyxAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" xlink:label="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_NovartisMember" xlink:label="vera_NovartisMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MilestonePaymentsPaid" xlink:label="vera_MilestonePaymentsPaid"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_MilestonePaymentsPayable" xlink:label="vera_MilestonePaymentsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ReductionInContingentFutureDevelopment" xlink:label="vera_ReductionInContingentFutureDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ContingentMilestoneObligationAccrued" xlink:label="vera_ContingentMilestoneObligationAccrued"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" xlink:label="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_LicenseAndCollaborationsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vera_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vera_AresTradingSAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="vera_EventAxis" xlink:to="vera_EventDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="vera_AgreementAxis" xlink:to="vera_AgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="vera_AgreementAxis" xlink:to="vera_AgreementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_EventDomain" xlink:to="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AgreementDomain" xlink:to="vera_YaleLicenseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vera_AmplyxAndNovartisMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="vera_AgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_TemporaryEquityIssuePricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_EventDomain" xlink:to="vera_AchievementOfSpecifiedCommercialMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AgreementDomain" xlink:to="vera_AresAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_EventDomain" xlink:to="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AgreementDomain" xlink:to="vera_AmplyxAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="vera_EventAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_EventDomain" xlink:to="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AgreementDomain" xlink:to="vera_NovartisMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vera_LicenseAndCollaborationsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_MilestonePaymentsPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_MilestonePaymentsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_ReductionInContingentFutureDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_ContingentMilestoneObligationAccrued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_LicenseAndCollaborationsLineItems" xlink:to="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="us-gaap_ValuationAllowanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceTable" xlink:label="us-gaap_ValuationAllowanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_ValuationAllowanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ValuationAllowanceTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowanceLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TaxYear2032Member" xlink:label="vera_TaxYear2032Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TaxYear2036Member" xlink:label="vera_TaxYear2036Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OperatingLossCarryforwardsExpirationYear" xlink:label="vera_OperatingLossCarryforwardsExpirationYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="vera_TaxYear2032Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="vera_TaxYear2036Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="vera_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PnaiMember" xlink:label="vera_PnaiMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" xlink:label="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PercentageOfIncreaseInRentAnnually" xlink:label="vera_PercentageOfIncreaseInRentAnnually"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vera_PnaiMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="vera_PercentageOfIncreaseInRentAnnually" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentAxis" xlink:label="vera_AbandonmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentDomain" xlink:label="vera_AbandonmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AbandonmentDomain" xlink:label="vera_AbandonmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_LeasedFacilitiesAbandonedMember" xlink:label="vera_LeasedFacilitiesAbandonedMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DiscountedLeaseRelatedRestructuringLiabilityMember" xlink:label="vera_DiscountedLeaseRelatedRestructuringLiabilityMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EquipmentAbondonedMember" xlink:label="vera_EquipmentAbondonedMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" xlink:label="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="vera_AbandonmentAxis" xlink:to="vera_AbandonmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="vera_AbandonmentAxis" xlink:to="vera_AbandonmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="vera_AbandonmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AbandonmentDomain" xlink:to="vera_LeasedFacilitiesAbandonedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="vera_DiscountedLeaseRelatedRestructuringLiabilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vera_AbandonmentDomain" xlink:to="vera_EquipmentAbondonedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ClassACommonStockIssuedAndOutstandingMember" xlink:label="vera_ClassACommonStockIssuedAndOutstandingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedRestrictedStockAwardsMember" xlink:label="vera_UnvestedRestrictedStockAwardsMember"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_UnvestedRestrictedStockUnitsMember" xlink:label="vera_UnvestedRestrictedStockUnitsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vera_ClassACommonStockIssuedAndOutstandingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vera_UnvestedRestrictedStockAwardsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vera_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_WriteOffOfDeferredCost" xlink:label="vera_WriteOffOfDeferredCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_CowenAndCompanyLlcMember" xlink:label="vera_CowenAndCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_TwoThousandTwentyTwoAtmFacilityMember" xlink:label="vera_TwoThousandTwentyTwoAtmFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vera_WriteOffOfDeferredCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vera_CowenAndCompanyLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vera_TwoThousandTwentyTwoAtmFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebt" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="5" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" xlink:label="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherIncome" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_EquitySecuritiesFvNiGainLoss" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="us-gaap_GainLossOnSaleOfBusiness"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAmortizationAndAccretionNet" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vera_ProceedsFromBorrowingsNetOfCosts" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="vera_ProceedsFromSaleOfMarketableSecurities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="15" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="16" weight="-1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="17" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="18" weight="1.00" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="19" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="21" weight="1.00" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAmortizationAndAccretionNet" xlink:label="us-gaap_DepreciationAmortizationAndAccretionNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromBorrowingsNetOfCosts" xlink:label="vera_ProceedsFromBorrowingsNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromSaleOfMarketableSecurities" xlink:label="vera_ProceedsFromSaleOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" xlink:label="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" xlink:label="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" xlink:label="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="vera_PrepaidClinicalTrialAndDrugManufacturingCosts" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="vera_PrepaidEquityFinancingCosts" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="vera_PrepaidSoftwareCosts" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="vera_PrepaidRecruitingFees" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="7" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidClinicalTrialAndDrugManufacturingCosts" xlink:label="vera_PrepaidClinicalTrialAndDrugManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidEquityFinancingCosts" xlink:label="vera_PrepaidEquityFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidSoftwareCosts" xlink:label="vera_PrepaidSoftwareCosts"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_PrepaidRecruitingFees" xlink:label="vera_PrepaidRecruitingFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="vera_AccruedClinicalAndDrugManufacturingExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AccruedClinicalAndDrugManufacturingExpenses" xlink:label="vera_AccruedClinicalAndDrugManufacturingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_SecuredDebt" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_NotesPayable" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="vera_DeferredTaxLiabilitiesRightOfUseAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="vera_DeferredTaxAssetsLeaseLiability" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vera_DeferredTaxLiabilitiesRightOfUseAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="vera-20231231.xsd#vera_DeferredTaxAssetsLeaseLiability" xlink:label="vera_DeferredTaxAssetsLeaseLiability"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="vera_ClassACommonStockIssuedAndOutstandingMember" name="ClassACommonStockIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_NeubaseAssetSaleAbstract" name="NeubaseAssetSaleAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_UnvestedStockOptionsAndRestrictedStockAwardsMember" name="UnvestedStockOptionsAndRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AgreementAxis" name="AgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_AvailableForIssuanceAndSaleUnderSalesAgreement" name="AvailableForIssuanceAndSaleUnderSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_TaxYear2036Member" name="TaxYear2036Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_NeubaseAssetSaleTextBlock" name="NeubaseAssetSaleTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_EventDomain" name="EventDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_EmergingGrowthCompanyStatusPolicyTextBlock" name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_EmployeeSeveranceAndOtherEmployeeTerminationMember" name="EmployeeSeveranceAndOtherEmployeeTerminationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AmplyxAgreementMember" name="AmplyxAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_LondonInterbankOfferedRateMember" name="LondonInterbankOfferedRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering" name="PaymentsOfStockIssuanceCostsOnFollowOnOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" name="LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_ReductionInContingentFutureDevelopment" name="ReductionInContingentFutureDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_LoanFacilityMember" name="LoanFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember" name="OfficeAndLaboratorySpaceAtWobornMassauchetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" name="AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TrdArrExpirationDate" name="TrdArrExpirationDate" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_ProceedsFromBorrowingsNetOfCosts" name="ProceedsFromBorrowingsNetOfCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_AbandonmentDomain" name="AbandonmentDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_EmployeeStockPurchasePlanEsppMember" name="EmployeeStockPurchasePlanEsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ResearchContractsCostsAndAccrualsPolicyTextBlock" name="ResearchContractsCostsAndAccrualsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_MilestonePaymentsPayable" name="MilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_TemporaryEquityIssuePricePerShare" name="TemporaryEquityIssuePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_NeubaseTherapeuticsIncMember" name="NeubaseTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares" name="TemporaryEquityStockSharesIssuedDuringThePeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember" name="CollateralizedNoteTwoThousandTwentyTwoElevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" name="StockIssuedDuringPeriodSharesLicensingPaymentsInEquity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_ContingentMilestoneObligationAccrued" name="ContingentMilestoneObligationAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_PercentageOfIncreaseInRentAnnually" name="PercentageOfIncreaseInRentAnnually" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_PnaiMember" name="PnaiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AresTradingSAMember" name="AresTradingSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_UnvestedStockOptionsAndRestrictedStockUnitMember" name="UnvestedStockOptionsAndRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AbandonmentAxis" name="AbandonmentAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" name="InvestmentOwnedNumberOfSharesPlacedInEscrowAccount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" name="ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_LicensesAndCollaborationsAbstract" name="LicensesAndCollaborationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity" name="StockIssuedDuringPeriodValueLicensingPaymentsInEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_LicenseAndCollaborationsLineItems" name="LicenseAndCollaborationsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_LicenseAndCollaborationsTextBlock" name="LicenseAndCollaborationsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" name="IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_MarketableSecuritiesDisclosureTextBlock" name="MarketableSecuritiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" name="AccruedLiabilitiesAndOtherLiabilitiesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_NonmarketableEquitySecuritiesCarryingValue" name="NonmarketableEquitySecuritiesCarryingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_UnvestedRestrictedStockAwardsMember" name="UnvestedRestrictedStockAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_OtherFinancialStatementInformationAbstract" name="OtherFinancialStatementInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering" name="ProceedsFromIssuanceOfCommonStockFollowOnOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_NonRevolvingCreditFacilityMember" name="NonRevolvingCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" name="StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_CollateralizedDebtInstrumentMaturityDate" name="CollateralizedDebtInstrumentMaturityDate" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" name="PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember" name="CollateralizedNoteTwoThousandTwentyOneTwelveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TaxYear2032Member" name="TaxYear2032Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_WriteOffOfDeferredCost" name="WriteOffOfDeferredCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_YaleLicenseAgreementMember" name="YaleLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember" name="CollateralizedNoteTwoThousandTwentyThreeTwelveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" name="TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_LeasedFacilitiesAbandonedMember" name="LeasedFacilitiesAbandonedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_MilestonePaymentsPaid" name="MilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_AgreementDomain" name="AgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_CashAndCashEquivalentsAndMarketableSecurities" name="CashAndCashEquivalentsAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_InvestmentInPnaiMember" name="InvestmentInPnaiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" name="AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" name="IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_CeliaLinMember" name="CeliaLinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AchievementOfSpecifiedCommercialMilestonesMember" name="AchievementOfSpecifiedCommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TwoThousandTwentyTwoAtmFacilityMember" name="TwoThousandTwentyTwoAtmFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" name="EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_ProceedsFromSaleOfMarketableSecurities" name="ProceedsFromSaleOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_NovartisMember" name="NovartisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" name="OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember" name="ConversionOfRedeemablePreferredStockIntoCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember" name="AchievementAsAssumedLiabilitiesUponAcquisitionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_DiscountedLeaseRelatedRestructuringLiabilityMember" name="DiscountedLeaseRelatedRestructuringLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_OtherFinancialStatementInformationTextBlock" name="OtherFinancialStatementInformationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_EquipmentAbondonedMember" name="EquipmentAbondonedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_LicenseAndCollaborationsTable" name="LicenseAndCollaborationsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AresAgreementMember" name="AresAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_EventAxis" name="EventAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AmplyxAndNovartisMember" name="AmplyxAndNovartisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_CowenAndCompanyLlcMember" name="CowenAndCompanyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" name="TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" name="AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vera_PrepaidSoftwareCosts" name="PrepaidSoftwareCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_PrepaidRecruitingFees" name="PrepaidRecruitingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts" name="IssuanceOfCommonStockForLicensingPaymentNetOfCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" name="LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" name="DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vera_PrepaidClinicalTrialAndDrugManufacturingCosts" name="PrepaidClinicalTrialAndDrugManufacturingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_PrepaidEquityFinancingCosts" name="PrepaidEquityFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_AccruedClinicalAndDrugManufacturingExpenses" name="AccruedClinicalAndDrugManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vera_CashEquivalentAndMarketableSecurities" name="CashEquivalentAndMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vera_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056181856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 20, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VERA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vera Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2744449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8000 Marina Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">770-0077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Portions of the Registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant&#8217;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,452,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055876576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 45,681<span></span>
</td>
<td class="nump">$ 43,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">115,035<span></span>
</td>
<td class="nump">71,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets, current</a></td>
<td class="nump">11,307<span></span>
</td>
<td class="nump">11,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">172,023<span></span>
</td>
<td class="nump">125,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">5,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other assets, noncurrent</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Non-marketable equity securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">175,546<span></span>
</td>
<td class="nump">131,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,436<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities, current</a></td>
<td class="nump">8,749<span></span>
</td>
<td class="nump">10,964<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">22,303<span></span>
</td>
<td class="nump">25,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">49,877<span></span>
</td>
<td class="nump">24,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">3,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent', window );">Accrued expenses and other liabilities, noncurrent</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">73,861<span></span>
</td>
<td class="nump">54,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 44,452,161 and 27,800,861 shares issued and outstanding as ofDecember 31, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">410,492<span></span>
</td>
<td class="nump">290,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain (loss)</a></td>
<td class="nump">251<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(309,102)<span></span>
</td>
<td class="num">(213,112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">101,685<span></span>
</td>
<td class="nump">76,908<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 175,546<span></span>
</td>
<td class="nump">$ 131,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities And Other Liabilities Non Current .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613146959744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Shares issued</a></td>
<td class="nump">44,452,161<span></span>
</td>
<td class="nump">27,800,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Shares outstanding</a></td>
<td class="nump">44,452,161<span></span>
</td>
<td class="nump">27,800,861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613139215392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 78,225<span></span>
</td>
<td class="nump">$ 68,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">23,787<span></span>
</td>
<td class="nump">21,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">102,012<span></span>
</td>
<td class="nump">90,903<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(102,012)<span></span>
</td>
<td class="num">(90,903)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7,979<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,786)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">1,877<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Change in fair value of non-marketable equity securities</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(809)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">6,023<span></span>
</td>
<td class="nump">1,848<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(95,989)<span></span>
</td>
<td class="num">(89,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(95,990)<span></span>
</td>
<td class="num">(89,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Change in unrealized gain (loss) on marketable securities</a></td>
<td class="nump">251<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (95,739)<span></span>
</td>
<td class="num">$ (89,280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (3.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.25)<span></span>
</td>
<td class="num">$ (3.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic</a></td>
<td class="nump">42,707,072<span></span>
</td>
<td class="nump">26,570,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted</a></td>
<td class="nump">42,707,072<span></span>
</td>
<td class="nump">26,570,676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055586704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Common Class A [Member]</div></th>
<th class="th">
<div>Common Class A [Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th"><div>Common Class B [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,968,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,238<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value at Dec. 31, 2021</a></td>
<td class="nump">$ 69,592<span></span>
</td>
<td class="nump">$ 193,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (124,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares', window );">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,742,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts', window );">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs, value</a></td>
<td class="nump">80,034<span></span>
</td>
<td class="nump">80,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Class B common stock into Class A common stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(309,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Class A common stock pursuant to exercise of options, value</a></td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">1,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of Class A common stock pursuant to exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of Class A common stock pursuant to employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of Class A common stock pursuant to employee stock purchase plan, value</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of Class A common stock upon vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity', window );">Issuance of common stock for payment of licensing fees, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity', window );">Issuance of common stock for payment of licensing fees in equity, net of offering cost</a></td>
<td class="nump">5,592<span></span>
</td>
<td class="nump">5,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">8,887<span></span>
</td>
<td class="nump">8,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain(loss) on marketable securities</a></td>
<td class="num">(224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(89,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,800,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value at Dec. 31, 2022</a></td>
<td class="nump">$ 76,908<span></span>
</td>
<td class="nump">290,216<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="num">(213,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares', window );">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs</a></td>
<td class="nump">16,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts', window );">Issuance of Class A common stock from underwritten follow-on offering, net of offering costs, value</a></td>
<td class="nump">$ 107,743<span></span>
</td>
<td class="nump">107,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Class A common stock pursuant to exercise of options, value</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issuance of Class A common stock pursuant to exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of Class A common stock pursuant to employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of Class A common stock pursuant to employee stock purchase plan, value</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of Class A common stock upon vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">11,493<span></span>
</td>
<td class="nump">11,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain(loss) on marketable securities</a></td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(95,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,452,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value at Dec. 31, 2023</a></td>
<td class="nump">$ 101,685<span></span>
</td>
<td class="nump">$ 410,492<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="num">$ (309,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from underwritten follow-on offering net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock from underwritten follow-on offering, net of offering costs shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares licensing payments in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value licensing payments in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056538960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (95,990)<span></span>
</td>
<td class="num">$ (89,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAmortizationAndAccretionNet', window );">Depreciation, amortization and accretion</a></td>
<td class="num">(4,086)<span></span>
</td>
<td class="num">(846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Reduction in the carrying amount of operating lease right-of-use assets</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11,493<span></span>
</td>
<td class="nump">8,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts', window );">Issuance of Class A common stock for licensing payment, net of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of non-marketable equity securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expense and other current assets</a></td>
<td class="nump">173<span></span>
</td>
<td class="num">(8,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(309)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(873)<span></span>
</td>
<td class="nump">10,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(2,215)<span></span>
</td>
<td class="nump">7,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2,645)<span></span>
</td>
<td class="num">(2,602)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(92,181)<span></span>
</td>
<td class="num">(67,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(224,930)<span></span>
</td>
<td class="num">(148,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">176,019<span></span>
</td>
<td class="nump">78,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ProceedsFromSaleOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">9,543<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(39,431)<span></span>
</td>
<td class="num">(70,552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">1,056<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ProceedsFromBorrowingsNetOfCosts', window );">Proceeds from borrowings, net of costs</a></td>
<td class="nump">24,741<span></span>
</td>
<td class="nump">19,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering', window );">Proceeds from issuance of Class A common stock in follow-on offering</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">86,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering', window );">Payment of costs and underwriting discounts and commissions related to follow-on offering</a></td>
<td class="num">(7,256)<span></span>
</td>
<td class="num">(6,097)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">133,541<span></span>
</td>
<td class="nump">101,933<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="num">(36,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">43,752<span></span>
</td>
<td class="nump">79,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">45,681<span></span>
</td>
<td class="nump">43,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,352<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of Class A common stock in payment of licensing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">43,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">45,681<span></span>
</td>
<td class="nump">43,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=vera_RestrictedCashMember', window );">Restricted cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAmortizationAndAccretionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAmortizationAndAccretionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for licensing payment, net of costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of stock issuance costs on follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ProceedsFromBorrowingsNetOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from borrowings, net of costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ProceedsFromBorrowingsNetOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=vera_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=vera_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613139289600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (95,990)<span></span>
</td>
<td class="num">$ (89,056)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613147039408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the quarter ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company&#8217;s securities set forth in the table below.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
    <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
     <tr style="visibility:collapse;">
      <td style="width:21.12%;"></td>
      <td style="width:10%;"></td>
      <td style="width:13.84%;"></td>
      <td style="width:9.22%;"></td>
      <td style="width:9.22%;"></td>
      <td style="width:10.74%;"></td>
      <td style="width:25.86%;"></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
      <td colspan="2" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Type of Trading Arrangement</span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name and Position</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Action</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Adoption/ Termination</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rule 10b5-1*</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Rule 10b5-1**</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Shares of Class A Common Stock to be Sold</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Expiration Date</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Celia Lin</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Medical Officer</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">***</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adoption</span></span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 10, 2023</span></span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">X</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Up to </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134,401</span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 19, 2024</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">****</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
      <td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">** &#8220;</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">n-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(c) of Regulation S-K under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
     </tr>
     <tr style="height:11pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">***Dr</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;min-width:fit-content;">. Lin separated from Vera effective January 3, 2024.</span></p></td>
     </tr>
     <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
      <td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">****In connection with her separation from Vera, Dr. Lin terminated this 10b5-1 Plan effective </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 19, 2024</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
     </tr>
    </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=vera_CeliaLinMember', window );">Celia Lin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Celia Lin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Medical Officer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">October 10, 2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">January 19, 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">436 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">134,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 19, 2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading arrangement expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=vera_CeliaLinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=vera_CeliaLinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056446864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of the Business</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware.  The Company&#8217;s headquarters and operations are located in Brisbane, California. The Company operates in one segment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 13, 2021, the Company&#8217;s registration statement on Form S-1 for its initial public offering (the IPO) was declared effective by the Securities and Exchange Commission (the SEC), and the shares of its Class A common stock commenced trading on the Nasdaq Global Select Market on May 14, 2021. The IPO closed on May 18, 2021. Prior to the completion of the IPO, all shares of redeemable convertible preferred stock then outstanding were converted into shares of Class A and Class B common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">S</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ince inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. The Company has incurred recurring net operating losses and has not generated positive cash flow from operations since its inception, and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">309.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as of December 31, 2023. The Company had cash, cash equivalents and marketable securities of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">160.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as of December 31, 2023. The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management believes that the Company&#8217;s cash, cash equivalents and marketable securities as of December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months subsequent to the issuance date of these financial statements. The Company intends to raise additional capital through public or private equity offerings or debt financing or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives. If the Company fails to obtain necessary capital when needed on acceptable terms, or at all, it could force the Company to delay, limit, reduce or terminate its product development programs, commercialization efforts or other operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056212720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the SEC regarding financial reporting. The U.S. dollar is the Company&#8217;s functional and reporting currency.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the research contract costs and accruals, stock-based compensation expense, and the valuation allowance for deferred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s current and potential future product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash represents cash held by a financial institution as collateral for a letter of credit securing its operating lease for office and laboratory space, which is classified as a non-current asset on the balance sheets based on the maturity of the lease.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company holds investments in marketable securities, consisting of U.S. government securities. Marketable debt securities with stated maturities of three months or less from the date of purchase are classified as cash equivalents and those with stated maturities of greater than three months as marketable securities on the balance sheet. The Company determines the appropriate classification of marketable debt securities at the time of purchase. The Company has the ability, if necessary, to liquidate its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying balance sheets. All marketable debt securities are classified as available-for-sale and are reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss within stockholders&#8217; equity. Interest, amortization and accretion of purchase premiums and discounts on marketable debt securities are included in other income (expense), net, in the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of available-for-sale marketable securities sold is based on the specific identification method. Realized gains and losses on the sale of available-for-sale marketable securities are recorded in other income, net in the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company regularly reviews all of the marketable securities for decline in fair value to determine whether unrealized losses have resulted from credit loss or other factors. The review includes considerations for the cause of the impairment but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers. A decline of fair value below cost basis is considered an other-than-temporary impairment if the Company has the intent to sell the security or it is more likely than not that the company will be required to sell the security before recovery of the entire cost basis. Regardless of the Company&#8217;s intent or requirement to sell the security, an impairment is considered other-than-temporary if the Company does not expect to recover the entire cost basis. In those instances, an impairment charge equal to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difference </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">between fair value and the cost basis is recorded in other income (expense), on the statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment loss was recognized for the fiscal years ended December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amortized or accreted cost basis of the marketable securities approximates its fair value.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred offering costs consisting of legal, accounting and filing fees relating to equity offerings. Deferred offering costs are included in other long-term assets on the Company&#8217;s balance sheets. Upon completion of the offering, these amounts are offset against the proceeds of the offering.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space under operating leases and determines if the arrangement is a lease at inception. These leases contain lease and non-lease components. Non-lease components include payments for maintenance, utilities, real estate taxes, and management fees. The lease and non-lease components are combined and accounted as a single lease component. Payments made under operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis over the term of the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is a hypothetical rate based on the Company&#8217;s understanding of what the credit rating would be in a similar economic environment. Operating leases are included in operating lease right-of-use assets and operating lease liabilities, current and non-current, on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases may include one or more options to renew. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured. The lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements are classified and disclosed in one of the following three categories:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; Quoted unadjusted prices for identical instruments in active markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed in the financial statements on a recurring basis.  The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, prepaid expenses and other current assets, non-marketable equity securities, accounts payable and accrued expenses and long-term debt.  Cash, restricted cash, and marketable securities and non-marketable securities are reported at their respective fair values on the Company&#8217;s balance sheets.  The remaining financial instruments are reported on the Company&#8217;s balance sheets at cost, which approximate their fair value due to their short-term nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments that are actively traded. The pricing information for the Company&#8217;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s non-marketable equity securities (see Note 5) are measured at fair value using an option pricing valuation methodology. The option pricing methodology relies on risk-neutral valuation which calculates the value of an asset by discounting the expected value of its future payoffs at the risk-free rate of return. The fair value of the non-marketable equity securities is derived from quoted prices for similar instruments and observable inputs in active markets. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December 31, 2023, and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in money market funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss consists of two components: net loss and other comprehensive loss. Other comprehensive loss refers to unrealized gains and losses that are recorded as an element of stockholders&#8217; equity and are excluded from net loss. For the year ended December 31, 2023, other comprehensive loss consists of unrealized gains and losses on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of employees&#8217; salaries and related benefits, including stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support the Company&#8217;s operations that are directly attributable to the Company&#8217;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred in obtaining technology licenses including upfront and milestone payments incurred under the Company&#8217;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#8217;s research and development activities. Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research Contract Costs and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#8217;s employees, nonemployee directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgments about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#8217;s Class A common stock on the date of the grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all stock options granted, the Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#8220;plain vanilla&#8221; stock option awards, as the Company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. The estimate of expected volatility is based on comparative companies&#8217; volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company determines the fair value of its Class A common stock using the market closing price on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect tax rates expected to be in effect for the years in which the differences are expected to be reversed. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive shares are not assumed to have been issued if their effect is anti-dilutive.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies the guidance in Topic 210, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material impact on its financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company&#8217;s financial statements upon adoption.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053783216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_OtherFinancialStatementInformationAbstract', window );"><strong>Other Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_OtherFinancialStatementInformationTextBlock', window );">Other Financial Statement Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. OTHER FINANCIAL STATEMENT INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid clinical trial and drug manufacturing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,487</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid equity financing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid software costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid recruiting fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical and drug manufacturing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,749</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,964</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related party payable represents amounts due to Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to manufacturing technology and know-how transfer services performed for atacicept pursuant to the license agreement between the Company and Ares (see Note 11).</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_OtherFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other financial statement information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_OtherFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_OtherFinancialStatementInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Financial Statement Information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_OtherFinancialStatementInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056325680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents And Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents And Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. CASH EQUIVALENTS AND MARKETABLE SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash equivalents are classified within Level 1 in the fair value hierarchy because the Company uses quoted market prices to the extent available or alternative pricing sources to determine fair value. Marketable debt securities are classified as Level 2 because they are valued using fair value from an independent pricing service, which may use quoted market prices for identical or comparable instruments or valuations using observable market data. The Company&#8217;s debt securities are accounted for as available-for-sale securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unrealized gains and losses are reported as a component of other comprehensive loss. Fair value of the debt securities were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">115.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and December 31, 2022, respectively.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:33.647%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:12.623%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,665</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,694</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,434</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,685</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable debt securities that had been in unrealized loss positions as of December 31, 2023 and December 31, 2022 were in an unrealized loss position for less than 12 months. Unrealized losses from marketable debt securities are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on evaluation of available evidence.</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:75.975%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.724%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due within one year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due after one year to two years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138877392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Marketable Equity Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Non-Marketable&#160;Equity Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. NON-MARKETABLE EQUITY SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value of non-marketable equity securities is determined using alternative pricing sources and models utilizing market observable inputs. The Company reports the restricted equity securities as non-marketable equity securities on the balance sheet and determines current or non-current classification based on the expected duration of the restriction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying value is measured as the total initial cost, less the cumulative net unrealized loss. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the value of non-marketable equity securities using the measurement alternative </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: </span></span><span style=""></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.48%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Initial cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative net fair value loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrying value of non-marketable equity securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056093472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. LEASES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net lease cost recognized for 2023 is summarized as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.532%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.603%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.143%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of the lease liabilities based on minimum lease commitment amount are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,071</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2020, the Company entered into a non-cancellable sublease agreement for the leased facilities in South San Francisco, California, which ends concurrently with the original lease in September 2025.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, under the terms of the sublease agreement, the Company is entitled to receive future annual sublease payments as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:69.5%;"></td>
        <td style="width:3.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:25.119999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total sublease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The subtenant of the leased facilities in South San Francisco, California, has disclosed in public filings that there is substantial doubt regarding its ability to continue as a going concern. As tenant, the Company remains responsible for minimum lease commitments of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023, on the South San Francisco facilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, the Company entered into a lease agreement that was amended in July 2022 for its headquarters office space in Brisbane, California. The lease term is through November 2024 with renewal options for the Company.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company had not executed any finance leases that were yet to commence. As of December 31, 2023, the weighted-average remaining operating lease term was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years and the weighted-average discount rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% for operating leases recognized in the financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053894432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Note Payable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. NOTE PAYABLE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note payable consists of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">($ in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:26.985%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:12.062%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:14.923%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.062000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:14.923%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.242%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective Interest Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective Interest Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2021-12</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.73</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.57</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2022-11</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.87</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.74</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2023-12</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.37</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total borrowings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The carrying amount of debt approximates fair value due to its variable interest rate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2021, the Company entered into a non-revolving loan and security agreement (the Loan Agreement) with borrowing capacity of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was scheduled to expire in December 2022.  In November 2022, the Company entered into an amendment of the Loan Agreement.  Among other changes, the amendment extended the scheduled expiration of the Loan Agreement to December 2023 and modified the reference rate from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financial Rate (SOFR).  In conjunction with the amendment, the Company borrowed an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Loan Agreement. In December 2023, the Company borrowed the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million from the Loan Agreement. As of December 31, 2023, the Company&#8217;s outstanding borrowing under the Loan Agreement was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In March 2023, upon achievement of a clinical data milestone, the Company elected to exercise a borrower option to extend the maturity of the outstanding loan by 12 months, from December 2026 to December 2027. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The interest-only payment period was also extended by 12 months to December 2026.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The Company is permitted to prepay the loan, subject to certain conditions. Upon the maturity date or prepayment of the loan, the Company is required to make a final payment equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the aggregate principal amount of the loan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The variable interest rate on the drawn amount is adjusted SOFR plus 825 basis points, subject to a per annum floor rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.  The Loan Agreement contains a subjective acceleration clause in the case of an event of default. If such a matter occurs and is continuing, the lender may legally demand the outstanding principal and interest immediately due and payable. There are no financial covenants associated with the Loan Agreement and the loan is secured by the Company&#8217;s assets. The Loan Agreement is available for working capital, capital expenditures, and other general corporate purposes.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principal installments due on the notes are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053916592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. COMMON STOCK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company&#8217;s amended and restated certificate of incorporation authorized the Company to issue </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,600,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock, each with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Each share of Class A common stock entitles the holder to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Class B common stock is non-voting. Class A common stockholders and holders of Class B common stock are entitled to receive dividends, as may be declared by the board of directors. Through </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cash dividends have been declared or paid.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2022, the Company completed a follow-on public offering pursuant to which the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5,742,026</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Class A common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">748,959</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2022, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">210,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">210,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock. In September 2022, the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class B common stock were converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">99,238</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock. The shares of Class B common stock that were converted into shares of Class A common stock have been retired and cancelled, and therefore will not be available for reissuance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-265408) with the Securities and Exchange Commission, which permits the offering, issuance, and sale of up to a maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the Company&#8217;s common stock, preferred stock, debt securities and warrants. Up to a maximum of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of the maximum aggregate offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">400.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million may be issued and sold pursuant to an at-the-market financing facility under a sales agreement dated June 3, 2022, between the Company and Cowen and Company, LLC (Sales Agreement). As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million remains available for issuance and sale under the Sales Agreement.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">283,034</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock to Novartis Pharma AG pursuant to an amendment to a license agreement between the two parties (see Note 11).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2023, the Company completed a follow-on public offering pursuant to which the Company issued and sold  </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,428,572</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Class A common stock at a public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,142,857</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056934272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. STOCK COMPENSATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan (ESPP) and the 2021 Equity Incentive Plan (2021 EIP), each of which became effective in connection with the IPO. The Company has reserved </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">707,942</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,650,796</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock for issuance under the ESPP and 2021 EIP, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may not grant any additional awards under the 2017 Equity Incentive Plan (2017 EIP). The 2017 EIP will continue to govern outstanding equity awards granted thereunder. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">288,775</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares available for issuance under the 2021 EIP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2017 EIP and 2021 EIP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2017 EIP and 2021 EIP was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.638%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.664%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.821%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.743%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.845%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.264%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUMBER OF<br/>OPTIONS</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE PER<br/>SHARE</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>LIFE (YEARS)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE (000s)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,821,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.51</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,291,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111,927</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled and forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,762,236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,611,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,762,236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The aggregate intrinsic value of stock options exercised during the year ended December 31, 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022, was</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.92</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.63</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ESPP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ESPP enables eligible employees to purchase shares of the Company&#8217;s Class A common stock at the end of each offering period at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the fair market value of the shares on the first trading day or the last trading day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of an employee&#8217;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first day of each fiscal year, beginning on January 1, 2022, by a number equal to the lesser of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">440,502</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the total number of shares of the Company&#8217;s capital stock (including all classes of the Company&#8217;s common stock) outstanding on the last day of the calendar month prior to the date of the increase, or such lower number of shares (including no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares) </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">approved by the Company&#8217;s board of directors. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">59,808</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares have been issued pursuant to the ESPP. The ESPP generally provides for six-month consecutive offering periods beginning on September 14, 2021. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. Stock-based compensation expense for the year ended December 31, 2023, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the stock-based compensation expense for stock options, restricted stock awards, and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company&#8217;s statements of operations and comprehensive loss for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years ended December 31, 2023 and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,887</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonemployees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,887</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of unrecognized stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.5 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.049%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:21.676%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:21.676%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company grants restricted stock units (RSU) pursuant to the 2021 EIP and satisfies such grants through the issuance of the Company&#8217;s Class A common stock. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows RSU activity for the period ending </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.19%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.544%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.544999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUMBER OF<br/>SHARES</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>GRANT DATE <br/>FAIR VALUE <br/>PER SHARE</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled and forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the year ended December 31, 2023, the Company recognize</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">d $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">f stock-based compensation for RSUs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.8</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138847248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. EMPLOYEE BENEFIT PLANS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. The Company contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">142,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">95,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to the plan for the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056093472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses and Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicensesAndCollaborationsAbstract', window );"><strong>Licenses And Collaborations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsTextBlock', window );">Licenses and Collaborations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. LICENSES AND COLLABORATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ares Trading S.A.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company entered into a license agreement with Ares (the Ares Agreement), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the Ares Agreement, the Company paid a non-refundable license issue fee to Ares in the form of shares of redeemable convertible preferred stock valued at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">13.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, resulting in Ares becoming a related party to the Company. The redeemable convertible preferred stock subsequently converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,913,501</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock in connection with the IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, the Company paid Ares a milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon delivery and initiation of the transfer of specified information and materials. The Company is obligated to pay Ares aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">176.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified BLA filing or regulatory approval milestones and up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">515.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon the achievement of specified commercial milestones. The non-refundable license issue fee and milestone payment were recorded to research and development expense in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent to the effective date of the Ares Agreement, Ares is performing manufacturing technology and know-how transfer to the Company. The Company recorded related party expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Ares for these services during the years ended December 31, 2023 and 2022, respectively. These amounts are included in research and development expenses on the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered royalties of low double-digit to mid-teen percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed product-by-licensed product and country-by-country basis from the first commercial sale of a product in a country until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii) the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to sublicense its rights under the Ares Agreement, the Company would be obligated to pay Ares a percentage ranging from the mid-single-digit to the low double-digits of specified sublicensing income received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amplyx Pharmaceuticals, Inc.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In December 2021, the Company entered into an asset purchase agreement (the Amplyx Agreement) with Amplyx Pharmaceuticals, Inc. (Amplyx), a wholly owned subsidiary of Pfizer Inc. Pursuant to the terms of the Amplyx Agreement, the Company paid $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Amplyx to purchase assets relating to an anti-BKV monoclonal antibody referred to as MAU868 for the treatment of BKV infection pursuant to a License Agreement between Amplyx and Novartis International Pharmaceutical AG (Novartis). In addition, the Company recognized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million contingent milestone obligation as an assumed liability related to the asset purchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> The acquisition cost of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was recorded as research and development expense in the statement of operations and comprehensive loss on the acquisition date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Amplyx asset purchase, Amplyx assigned the Exclusive License Agreement between Amplyx and Novartis (the Novartis License) and Manufacturing and Supply Agreements to the Company.  Under the Novartis License, the Company has exclusive worldwide rights from Novartis to develop, manufacture and commercialize MAU868. The Company will be solely responsible for all research, development, regulatory, manufacturing and commercialization activities of MAU868.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Amplyx Agreement, the Company is obligated to make future milestone payments to Amplyx and Novartis upon the achievement of specified development, regulatory and commercial milestones. In September 2022, the Company and Novartis entered into an amendment to the Novartis License to modify the terms of future milestone payments. Pursuant to this amendment, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">283,034</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock to Novartis in exchange for a reduction of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contingent future development milestones, including the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million contingent milestone obligation accrued by the Company in December 2021. The value of the shares issued was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on the closing market value of the Company&#8217;s Class A common stock as of the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">effective </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">date of the amendment, and as a result of the amendment the Company recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of research and development expense in the year ended December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company is obligated to make future milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Amplyx and Novartis, respectively, contingent upon the achievement of specified development, regulatory and commercial milestones. In the event that MAU868 is commercialized, the Company will be obligated to pay royalties to Amplyx and Novartis based on net sales by country and by product.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_LicenseAndCollaborationsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Collaborations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_LicenseAndCollaborationsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_LicensesAndCollaborationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licenses And Collaborations Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_LicensesAndCollaborationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138865312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. INCOME TAXES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For financial reporting purposes, income (loss) before provision for income taxes, includes the following components </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provision for Income Taxes</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for income taxes consisted of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.59%;"></td>
        <td style="width:2.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.823999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.823999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes computed using the U.S. statutory federal income tax rate compared to the income tax provision included in the statement of operations and comprehensive loss is as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.98%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.459999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax on U.S. statutory rate on income before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,702</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">489</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,598</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Tax Assets and Liabilities</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred tax assets and liabilities are determined based on the differences between financial reporting and income tax bases of assets and liabilities, as well as net operating loss carryforwards and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. </span><span style="font-size:12pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s net deferred tax assets and liabilities are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.151%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state NOL carryforward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and other credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,731</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other intangibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other DTA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">402</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross DTA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other DTL</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross DTL</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company has federal and state net operating loss carryforwards of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">118.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal net operating loss carryforwards and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of state net operating carryforwards will begin expiring in the year </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2032</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2036</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, if not utilized. The Company also has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">109.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal net operating loss carryforwards as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> that does not expire as a result of recent tax law changes. The Company has $5</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of federal research and development tax credit carryforwards, which begin to expire in the year 2037. The Company has $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of state research and development tax credit carryforwards, which have no expiration date.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Utilization of the federal and state net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Internal Revenue Code of 1986. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed an analysis to determine if such ownership changes have occurred. An analysis will be performed prior to recognizing the benefits of any losses or credits in the financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence including a history of operating losses, management has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">49.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the year ended December 31, 2023 and 2022 has been established to offset the deferred tax assets as realization of such assets is uncertain.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Uncertain Tax Benefits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the following activity relating to the gross amount of unrecognized tax benefits </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.151%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">668</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,513</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. None of these uncertain tax positions will impact the Company&#8217;s effective tax rate if assessed. The Company&#8217;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> interest </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or penalty accruals associated with uncertain tax benefits in its balance sheet and statement of operations for the years ended December 31, 2023 and 2022. The Company files income tax returns in the U.S. and California. The Company is not currently under examination by any major tax jurisdictions nor has it been in the past. Because of net operating losses and research credit carryovers, substantially all of our tax years</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">remain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">open to examination. Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613241084016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that there are no actions pending which would have a material adverse effect on its results of operations, financial condition, or cash flows.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indemnifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the Company did not have any material indemnification claims that were probable or reasonably possible, and consequently no related liabilities have been recorded.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Employee Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including severance and accelerated vesting of equity incentives.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development and Manufacturing Services Agreements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into development and manufacturing contracts with vendors in the conduct of our business. Contracts with these vendors may be terminated at the Company&#8217;s option, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would be obligated to pay for the products or services that had been provided or received at the time the termination became effective,  and potentially additional compensation based upon lead time remaining between the date of notice of cancellation and the scheduled manufacturing run.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053710208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.26%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,762,236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,821,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,893,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,025,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053857808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15. RELATED PARTY TRANSACTIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. Related party transactions and balances in the current periods presented are described in Note 3 and Note 11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613054938112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16. SUBSEQUENT EVENTS</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective January 29, 2024, the Company suspended and terminated the prospectus (the ATM Prospectus) related to the sale of its Class A co</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mmon stock in an &#8220;at-the-market&#8221; offering pursuant to the terms of the Sales Agreement (see Note 8). As a result, the Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. Deferred costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were recognized as general and administrative expense upon termination of the ATM Prospectus.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 1, 2024, the Company completed a follow-on public offering pursuant to which the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,274,194</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its Class A common stock at an offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, including the exercise in full by the underwriters of their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,209,677</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of Class A common stock. The Company received total net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">269.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and offering costs of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056168384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the SEC regarding financial reporting. The U.S. dollar is the Company&#8217;s functional and reporting currency.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">T</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the research contract costs and accruals, stock-based compensation expense, and the valuation allowance for deferred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tax </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s current and potential future product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company&#8217;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted Cash</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash represents cash held by a financial institution as collateral for a letter of credit securing its operating lease for office and laboratory space, which is classified as a non-current asset on the balance sheets based on the maturity of the lease.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Marketable Securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company holds investments in marketable securities, consisting of U.S. government securities. Marketable debt securities with stated maturities of three months or less from the date of purchase are classified as cash equivalents and those with stated maturities of greater than three months as marketable securities on the balance sheet. The Company determines the appropriate classification of marketable debt securities at the time of purchase. The Company has the ability, if necessary, to liquidate its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying balance sheets. All marketable debt securities are classified as available-for-sale and are reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss within stockholders&#8217; equity. Interest, amortization and accretion of purchase premiums and discounts on marketable debt securities are included in other income (expense), net, in the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cost of available-for-sale marketable securities sold is based on the specific identification method. Realized gains and losses on the sale of available-for-sale marketable securities are recorded in other income, net in the statements of operations and comprehensive loss.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Company regularly reviews all of the marketable securities for decline in fair value to determine whether unrealized losses have resulted from credit loss or other factors. The review includes considerations for the cause of the impairment but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers. A decline of fair value below cost basis is considered an other-than-temporary impairment if the Company has the intent to sell the security or it is more likely than not that the company will be required to sell the security before recovery of the entire cost basis. Regardless of the Company&#8217;s intent or requirement to sell the security, an impairment is considered other-than-temporary if the Company does not expect to recover the entire cost basis. In those instances, an impairment charge equal to the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difference </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">between fair value and the cost basis is recorded in other income (expense), on the statements of operations and comprehensive loss. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment loss was recognized for the fiscal years ended December 31, 2023 and 2022.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The amortized or accreted cost basis of the marketable securities approximates its fair value.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred Offering Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred offering costs consisting of legal, accounting and filing fees relating to equity offerings. Deferred offering costs are included in other long-term assets on the Company&#8217;s balance sheets. Upon completion of the offering, these amounts are offset against the proceeds of the offering.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases office space under operating leases and determines if the arrangement is a lease at inception. These leases contain lease and non-lease components. Non-lease components include payments for maintenance, utilities, real estate taxes, and management fees. The lease and non-lease components are combined and accounted as a single lease component. Payments made under operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis over the term of the lease.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is a hypothetical rate based on the Company&#8217;s understanding of what the credit rating would be in a similar economic environment. Operating leases are included in operating lease right-of-use assets and operating lease liabilities, current and non-current, on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leases may include one or more options to renew. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured. The lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Foreign Currency Translations</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value is defined as the exchange price to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements are classified and disclosed in one of the following three categories:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; Quoted unadjusted prices for identical instruments in active markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211; Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed in the financial statements on a recurring basis.  The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, prepaid expenses and other current assets, non-marketable equity securities, accounts payable and accrued expenses and long-term debt.  Cash, restricted cash, and marketable securities and non-marketable securities are reported at their respective fair values on the Company&#8217;s balance sheets.  The remaining financial instruments are reported on the Company&#8217;s balance sheets at cost, which approximate their fair value due to their short-term nature.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Money market funds are highly liquid investments that are actively traded. The pricing information for the Company&#8217;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s non-marketable equity securities (see Note 5) are measured at fair value using an option pricing valuation methodology. The option pricing methodology relies on risk-neutral valuation which calculates the value of an asset by discounting the expected value of its future payoffs at the risk-free rate of return. The fair value of the non-marketable equity securities is derived from quoted prices for similar instruments and observable inputs in active markets. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December 31, 2023, and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">44.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively, in money market funds.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive Loss</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comprehensive loss consists of two components: net loss and other comprehensive loss. Other comprehensive loss refers to unrealized gains and losses that are recorded as an element of stockholders&#8217; equity and are excluded from net loss. For the year ended December 31, 2023, other comprehensive loss consists of unrealized gains and losses on marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and Development Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development costs are expensed as incurred and consist primarily of employees&#8217; salaries and related benefits, including stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support the Company&#8217;s operations that are directly attributable to the Company&#8217;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred in obtaining technology licenses including upfront and milestone payments incurred under the Company&#8217;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#8217;s research and development activities. Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ResearchContractsCostsAndAccrualsPolicyTextBlock', window );">Research Contract Costs And Accruals</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research Contract Costs and Accruals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#8217;s employees, nonemployee directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgments about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#8217;s Class A common stock on the date of the grant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For all stock options granted, the Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#8220;plain vanilla&#8221; stock option awards, as the Company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. The estimate of expected volatility is based on comparative companies&#8217; volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company determines the fair value of its Class A common stock using the market closing price on the date of grant.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect tax rates expected to be in effect for the years in which the differences are expected to be reversed. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive shares are not assumed to have been issued if their effect is anti-dilutive.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies the guidance in Topic 210, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material impact on its financial statements and related disclosures.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company&#8217;s financial statements upon adoption.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Emerging Growth Company Status .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ResearchContractsCostsAndAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research contracts costs and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ResearchContractsCostsAndAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138907424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_OtherFinancialStatementInformationAbstract', window );"><strong>Other Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prepaid expenses and other current assets consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid clinical trial and drug manufacturing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,487</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">597</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid equity financing costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">410</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid rent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">247</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid software costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid recruiting fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">109</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,307</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses And Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued payroll</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,932</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,217</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued clinical and drug manufacturing expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,213</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,334</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Related party payable</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,926</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,780</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued legal fees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">338</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,749</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,964</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_OtherFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other financial statement information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_OtherFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accrued And Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056414304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents And Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table presents the Company&#8217;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:33.647%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:12.623%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.4%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.682%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,650</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,683</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government agency securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,665</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,658</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,500</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,694</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,434</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">271</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,685</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Hierarchy Level</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,495</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. Government bonds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 2</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,418</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,194</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,913</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">225</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">113,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Estimated Fair Value of Investments in Available-for-sale Marketable Debt Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:75.975%;"></td>
        <td style="width:2.3%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.724%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due within one year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">93,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Due after one year to two years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">115,035</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138845760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-Marketable Equity Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock', window );">Summary of Non-marketable Equity Securities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes the value of non-marketable equity securities using the measurement alternative </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: </span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.48%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Initial cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,759</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cumulative net fair value loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,748</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,701</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Carrying value of non-marketable equity securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053923280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net lease cost recognized for 2023 is summarized as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:61.532%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.603%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.143%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31, 2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,577</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,378</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sublease income</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,928</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of lease liabilities based on minimum lease commitment</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, the maturities of the lease liabilities based on minimum lease commitment amount are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,022</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,880</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total minimum lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,071</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Current portion of operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,436</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,395</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Receivable Future Annual Sublease Payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, under the terms of the sublease agreement, the Company is entitled to receive future annual sublease payments as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">: <br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:69.5%;"></td>
        <td style="width:3.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:25.119999999999997%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,954</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,496</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total sublease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,450</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053804848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Notes Payable</a></td>
<td class="text"><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note payable consists of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">($ in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:26.985%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:12.062%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:14.923%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.062000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:14.923%;"></td>
        <td style="width:2.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.242%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Maturity</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective Interest Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Effective Interest Rate</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2021-12</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.73</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.57</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2022-11</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14.87</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13.74</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collateralized note 2023-12</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15.37</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total borrowings</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: Debt issuance costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net carrying amount of debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,877</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,810</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule Principal Installments Due</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Principal installments due on the notes are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:80.236%;"></td>
        <td style="width:1.94%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.823%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total long-term debt</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056520768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Share-based Compensation Arrangements by Share-based Payment Award</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the 2017 EIP and 2021 EIP was as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:44.638%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.664%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.821%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.743%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.845%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.341%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.264%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUMBER OF<br/>OPTIONS</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>EXERCISE<br/>PRICE PER<br/>SHARE</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>REMAINING<br/>CONTRACTUAL<br/>LIFE (YEARS)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">AGGREGATE<br/>INTRINSIC<br/>VALUE (000s)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,821,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.30</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.51</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,872</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,291,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">111,927</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled and forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">238,624</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,762,236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,611,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.10</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,762,236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables summarize the stock-based compensation expense for stock options, restricted stock awards, and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company&#8217;s statements of operations and comprehensive loss for the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years ended December 31, 2023 and 2022 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,845</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,592</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,295</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,887</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,494</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,975</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nonemployees</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">999</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,493</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,887</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of stock options granted during the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:53.049%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:21.676%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:21.676%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">77.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.76</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% &#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table shows RSU activity for the period ending </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.19%;"></td>
        <td style="width:1.72%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.544%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:23.544999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">NUMBER OF<br/>SHARES</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">WEIGHTED-<br/>AVERAGE<br/>GRANT DATE <br/>FAIR VALUE <br/>PER SHARE</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested balance at December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.37</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66,321</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled and forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.60</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested balance at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18.36</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055696336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For financial reporting purposes, income (loss) before provision for income taxes, includes the following components </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.883000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Domestic</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Foreign</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,989</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,055</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The provision for income taxes consisted of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.59%;"></td>
        <td style="width:2.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.823999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.38%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.823999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Provision for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A reconciliation of the provision for income taxes computed using the U.S. statutory federal income tax rate compared to the income tax provision included in the statement of operations and comprehensive loss is as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:54.98%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.459999999999997%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.36%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax on U.S. statutory rate on income before income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,158</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,702</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">489</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">State valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">490</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,582</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,643</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Tax credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,598</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">710</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">506</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant components of the Company&#8217;s net deferred tax assets and liabilities are as follows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.151%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Federal and state NOL carryforward</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,539</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and other credits</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,051</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,762</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitalized R&amp;D</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,264</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,731</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">755</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">519</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,978</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other intangibles</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,313</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,583</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other DTA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">402</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">804</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,360</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross DTA</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">72,091</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,734</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,372</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right of use</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">619</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other DTL</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total gross DTL</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,086</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has the following activity relating to the gross amount of unrecognized tax benefits </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:55.151%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.2%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.224%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Beginning balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">668</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decreases based on tax positions related to prior year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">572</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">265</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ending balance</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,513</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">941</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613053976800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Dilutive Shares Excluded From Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.26%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.26%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A common stock options issued and outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,762,236</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,821,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,679</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">204,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,893,915</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,025,787</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613163888576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of the Business - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 06, 2023</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,102<span></span>
</td>
<td class="nump">$ 213,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashAndCashEquivalentsAndMarketableSecurities', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period new issues shares</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="nump">748,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of redeemable convertible preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,913,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Follow-on Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period new issues shares</a></td>
<td class="nump">16,428,572<span></span>
</td>
<td class="nump">5,742,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CashAndCashEquivalentsAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CashAndCashEquivalentsAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vera_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vera_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055991808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment loss on available-for-sale marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">5,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 44,700<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-8A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613147003440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_OtherFinancialStatementInformationAbstract', window );"><strong>Other Financial Statement Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_PrepaidClinicalTrialAndDrugManufacturingCosts', window );">Prepaid clinical trial and drug manufacturing costs</a></td>
<td class="nump">$ 6,480<span></span>
</td>
<td class="nump">$ 8,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_PrepaidEquityFinancingCosts', window );">Prepaid equity financing costs</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_PrepaidSoftwareCosts', window );">Prepaid software costs</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_PrepaidRecruitingFees', window );">Prepaid recruiting fees</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">3,217<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 11,307<span></span>
</td>
<td class="nump">$ 11,045<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_OtherFinancialStatementInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other financial statement information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_OtherFinancialStatementInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_PrepaidClinicalTrialAndDrugManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Trial and Drug Manufacturing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_PrepaidClinicalTrialAndDrugManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_PrepaidEquityFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid equity financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_PrepaidEquityFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_PrepaidRecruitingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Recruiting Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_PrepaidRecruitingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_PrepaidSoftwareCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Software Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_PrepaidSoftwareCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055325248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 3,932<span></span>
</td>
<td class="nump">$ 3,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AccruedClinicalAndDrugManufacturingExpenses', window );">Accrued clinical and drug manufacturing expenses</a></td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">4,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal fees</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">8,749<span></span>
</td>
<td class="nump">10,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party payable</a></td>
<td class="nump">$ 1,926<span></span>
</td>
<td class="nump">$ 2,780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AccruedClinicalAndDrugManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and drug manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AccruedClinicalAndDrugManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613147246704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents And Marketable Securities - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents And Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value of the debt securities</a></td>
<td class="nump">$ 115.0<span></span>
</td>
<td class="nump">$ 71.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056583328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 159,434<span></span>
</td>
<td class="nump">$ 113,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1', window );">Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentAndMarketableSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">159,685<span></span>
</td>
<td class="nump">113,689<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">44,650<span></span>
</td>
<td class="nump">42,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentAndMarketableSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">44,650<span></span>
</td>
<td class="nump">42,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Government Bonds [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">63,619<span></span>
</td>
<td class="nump">71,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1', window );">Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentAndMarketableSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">63,683<span></span>
</td>
<td class="nump">$ 71,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">19,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1', window );">Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentAndMarketableSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">19,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Unrealized Gains</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentAndMarketableSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 31,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities gross unrealized loss1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CashEquivalentAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalent and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CashEquivalentAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613139401632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash Equivalents And Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">$ 93,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Due after one year to two years</a></td>
<td class="nump">21,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total marketable securities</a></td>
<td class="nump">$ 115,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt maturities after one through two years fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and marketable securities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613163386096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Non-Marketable Equity Securities - Summary of Non-marketable Equity Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost', window );">Initial cost</a></td>
<td class="nump">$ 1,759<span></span>
</td>
<td class="nump">$ 1,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss', window );">Cumulative net fair value loss</a></td>
<td class="num">(1,748)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_NonmarketableEquitySecuritiesCarryingValue', window );">Carrying value of non-marketable equity securities</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity securities without readily determinable fair value initial cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity securities without readily determinable fair value net cumulative gain loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_NonmarketableEquitySecuritiesCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonmarketable equity securities carrying value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_NonmarketableEquitySecuritiesCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613148289168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,577<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(1,928)<span></span>
</td>
<td class="num">(1,928)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease cost</a></td>
<td class="nump">$ 649<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613163864608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 3,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">4,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liabilities</a></td>
<td class="num">(2,436)<span></span>
</td>
<td class="num">$ (2,645)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">$ 1,395<span></span>
</td>
<td class="nump">$ 3,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613149147968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of receivable future annual sublease payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2025</a></td>
<td class="nump">1,496<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total sublease payments</a></td>
<td class="nump">$ 3,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055774768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Operating lease minimum future commitments</a></td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">9.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056710992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable - Schedule of Notes Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total borrowings</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Less: Debt issuance costs</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount of debt</a></td>
<td class="nump">$ 49,877<span></span>
</td>
<td class="nump">$ 24,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=vera_LondonInterbankOfferedRateMember', window );">LIBOR [Member] | Collateralized note 2021-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CollateralizedDebtInstrumentMaturityDate', window );">Collateralized debt instrument maturity date.</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Collateralized note , Effective interest rate</a></td>
<td class="nump">14.73%<span></span>
</td>
<td class="nump">13.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Collateralized note ,Amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR [Member] | Collateralized note 2022-11</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CollateralizedDebtInstrumentMaturityDate', window );">Collateralized debt instrument maturity date.</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Collateralized note , Effective interest rate</a></td>
<td class="nump">14.87%<span></span>
</td>
<td class="nump">13.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Collateralized note ,Amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember', window );">SOFR [Member] | Collateralized note 2023-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CollateralizedDebtInstrumentMaturityDate', window );">Collateralized debt instrument maturity date.</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Collateralized note , Effective interest rate</a></td>
<td class="nump">15.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Collateralized note ,Amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CollateralizedDebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collateralized debt instrument maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CollateralizedDebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=vera_LondonInterbankOfferedRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=vera_LondonInterbankOfferedRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056502144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount of debt outstanding</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=vera_LoanFacilityMember', window );">Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit facility with borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Carrying amount of debt outstanding</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Additional borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining capacity available</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPayments', window );">Debt facility payments description</a></td>
<td class="text">The interest-only payment period was also extended by 12 months to December 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended', window );">Prepayment of the loan</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility percentage prepayment Of loan or maturity date is not extended.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=vera_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=vera_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138874240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note Payable - Schedule Principal Installments Due (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total long-term debt</a></td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613057259696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2023</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, debt securities and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AvailableForIssuanceAndSaleUnderSalesAgreement', window );">Available for Issuance and Sale Under Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vera_CowenAndCompanyLlcMember', window );">Cowen and Company, LLC [Member] | Maximum [Member] | 2022 ATM facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, debt securities and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Cash dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period new issues shares</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="nump">748,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,238<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity', window );">Company shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Follow-on Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period new issues shares</a></td>
<td class="nump">16,428,572<span></span>
</td>
<td class="nump">5,742,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Cash dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,238<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AvailableForIssuanceAndSaleUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for issuance and sale under sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AvailableForIssuanceAndSaleUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price of securities under shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares licensing payments in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vera_CowenAndCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vera_CowenAndCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vera_TwoThousandTwentyTwoAtmFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vera_TwoThousandTwentyTwoAtmFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vera_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vera_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613057221872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share based compensation arrangement by share based payment award, Options exercised in period, Total intrinsic value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued under share based payment arrangement</a></td>
<td class="nump">59,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 11,493<span></span>
</td>
<td class="nump">$ 8,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vera_EmployeeStockPurchasePlanEsppMember', window );">Employee Stock Purchase Plan ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock capital, Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vera_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock capital, Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,650,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, Number of shares available for issuance</a></td>
<td class="nump">288,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember', window );">2017 and 2021 Amended Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share based compensation arrangement by share based payment award, Options granted in period, Weighted average grant date fair value</a></td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="nump">$ 13.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=vera_UnvestedStockOptionsAndRestrictedStockAwardsMember', window );">Unvested Stock Options And Restricted Stock Awards [Member] | 2017 and 2021 Amended Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=vera_UnvestedStockOptionsAndRestrictedStockUnitMember', window );">Unvested Stock Options And Restricted Stock Unit [Member] | 2017 and 2021 Amended Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock Percent of Fair Market Value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate', window );">Share purchases funded through payroll deductions for employee's eligible minimum annual compensation, percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Share purchases funded through payroll deductions for employee's eligible maximum annual compensation, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential increase in shares reserved for future issuance (in shares)</a></td>
<td class="nump">440,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average Grant date fair value</a></td>
<td class="nump">$ 18.36<span></span>
</td>
<td class="nump">$ 18.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Unvested Stock Options And Restricted Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units R S U [Member] | 2017 and 2021 Amended Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares minimum increase in shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company common stock outstanding for increase in shares reserved for issuance under stock plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award minimum employee subscription rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vera_EmployeeStockPurchasePlanEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vera_EmployeeStockPurchasePlanEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vera_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vera_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vera_UnvestedStockOptionsAndRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vera_UnvestedStockOptionsAndRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vera_UnvestedStockOptionsAndRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vera_UnvestedStockOptionsAndRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056386992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details) - 2017 EIP And 2021 EIP [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Beginning</a></td>
<td class="nump">3,821,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted</a></td>
<td class="nump">2,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(111,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of Options, Cancelled and forfeited</a></td>
<td class="num">(238,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options, Ending</a></td>
<td class="nump">5,762,236<span></span>
</td>
<td class="nump">3,821,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable</a></td>
<td class="nump">2,611,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="nump">5,762,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice', window );">Weighted average exercise price Opening balance</a></td>
<td class="nump">$ 10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice', window );">Weighted average exercise price Ending balance</a></td>
<td class="nump">9.42<span></span>
</td>
<td class="nump">$ 10.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable</a></td>
<td class="nump">8.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">$ 9.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual term</a></td>
<td class="text">7 years 7 months 28 days<span></span>
</td>
<td class="text">8 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Options exercisable</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">7 years 7 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue', window );">Intrinsic Value</a></td>
<td class="nump">$ 39,197<span></span>
</td>
<td class="nump">$ 35,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Options exercisable</a></td>
<td class="nump">20,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 39,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment arrangement options non vested weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment award non vested options outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation by share based payment options non vested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613162109824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 11,493<span></span>
</td>
<td class="nump">$ 8,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">10,494<span></span>
</td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Nonemployees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">2,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 6,648<span></span>
</td>
<td class="nump">$ 4,295<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056879360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">79.50%<span></span>
</td>
<td class="nump">75.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">77.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate, Minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate, Maximum</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055443984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2022 | shares</a></td>
<td class="nump">204,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(66,321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled and forfeited | shares</a></td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2023 | shares</a></td>
<td class="nump">131,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 18.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">18.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled and Forfeited | $ / shares</a></td>
<td class="nump">18.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 18.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613138790176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613057274896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licenses and Collaborations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,225<span></span>
</td>
<td class="nump">$ 68,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AgreementAxis=vera_AresAgreementMember', window );">Ares Agreement [Member] | Ares Trading S A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary equity shares issued during the period value</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AgreementAxis=vera_AresAgreementMember', window );">Ares Agreement [Member] | Ares Trading S A [Member] | Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AgreementAxis=vera_AresAgreementMember', window );">Ares Agreement [Member] | Ares Trading S A [Member] | Achievement Of Specified Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AgreementAxis=vera_AmplyxAgreementMember', window );">Amplyx Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ReductionInContingentFutureDevelopment', window );">Reduction in contingent future development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_ContingentMilestoneObligationAccrued', window );">Contingent milestone obligation accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue', window );">Company shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AgreementAxis=vera_AmplyxAgreementMember', window );">Amplyx Agreement [Member] | Amplyx and Novartis [Member] | Achievement of Various Clinical Development and Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_AgreementAxis=vera_NovartisMember', window );">Novartis [Member] | Amplyx and Novartis [Member] | Achievement of Various Clinical Development and Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_MilestonePaymentsPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity', window );">Issuance of common stock for payment of licensing fees, net of offering costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_LicenseAndCollaborationsLineItems', window );"><strong>License And Collaborations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of redeemable convertible preferred stock to common stock</a></td>
<td class="nump">1,913,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ContingentMilestoneObligationAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Obligation Accrued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ContingentMilestoneObligationAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_LicenseAndCollaborationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and collaborations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_LicenseAndCollaborationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_MilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_MilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_ReductionInContingentFutureDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction In Contingent Future Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_ReductionInContingentFutureDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares licensing payments in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Licensing Payments In Equity (value)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AgreementAxis=vera_AresAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AgreementAxis=vera_AresAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AresTradingSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AresTradingSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_EventAxis=vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_EventAxis=vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_EventAxis=vera_AchievementOfSpecifiedCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_EventAxis=vera_AchievementOfSpecifiedCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AgreementAxis=vera_AmplyxAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AgreementAxis=vera_AmplyxAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AmplyxAndNovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=vera_AmplyxAndNovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_EventAxis=vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_EventAxis=vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_AgreementAxis=vera_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_AgreementAxis=vera_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613163391088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (95,989)<span></span>
</td>
<td class="num">$ (89,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (95,989)<span></span>
</td>
<td class="num">$ (89,055)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613058624832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613055532784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax on U.S. statutory rate on income before income taxes</a></td>
<td class="num">$ (20,158)<span></span>
</td>
<td class="num">$ (18,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State Taxes</a></td>
<td class="num">(489)<span></span>
</td>
<td class="nump">3,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(1,598)<span></span>
</td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">506<span></span>
</td>
<td class="num">(231)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">21,250<span></span>
</td>
<td class="nump">19,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="num">$ (3,582)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613056610496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state NOL carryforward</a></td>
<td class="nump">$ 27,539<span></span>
</td>
<td class="nump">$ 21,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and other credits</a></td>
<td class="nump">6,051<span></span>
</td>
<td class="nump">3,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Capitalized R&amp;D</a></td>
<td class="nump">25,264<span></span>
</td>
<td class="nump">12,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">755<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Other intangibles</a></td>
<td class="nump">8,313<span></span>
</td>
<td class="nump">8,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other DTA</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross DTA</a></td>
<td class="nump">72,091<span></span>
</td>
<td class="nump">50,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(71,372)<span></span>
</td>
<td class="num">(49,648)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use</a></td>
<td class="num">(619)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other DTL</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross DTL</a></td>
<td class="num">(719)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets, lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613139410160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income Tax Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases based on tax positions related to prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 1,513<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613049821760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 71,372,000<span></span>
</td>
<td class="nump">$ 49,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">109,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest or penalty accruals associated with uncertain tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 118,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=vera_TaxYear2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=vera_TaxYear2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=vera_TaxYear2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=vera_TaxYear2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613147135536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">5,893,915<span></span>
</td>
<td class="nump">4,025,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vera_ClassACommonStockIssuedAndOutstandingMember', window );">Class A Common Stock Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">5,762,236<span></span>
</td>
<td class="nump">3,821,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vera_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities</a></td>
<td class="nump">131,679<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vera_ClassACommonStockIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vera_ClassACommonStockIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vera_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vera_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140613057152016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Feb. 06, 2023</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period new issues shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,142,857<span></span>
</td>
<td class="nump">748,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock net consideration received on the transaction</a></td>
<td class="nump">$ 269.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discounts and commissions</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering costs</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2022 ATM facility [Member] | Cowen and Company, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vera_WriteOffOfDeferredCost', window );">Deferred costs, written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">9,274,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Class A [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock shares issued during the period new issues shares</a></td>
<td class="nump">1,209,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vera_WriteOffOfDeferredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of deferred cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vera_WriteOffOfDeferredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vera_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vera_TwoThousandTwentyTwoAtmFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vera_TwoThousandTwentyTwoAtmFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vera_CowenAndCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vera_CowenAndCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>99
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@Z;TH;0 2@NAM A%:PNR<:6HVI4:Y.-3B1?DS!Q'[\H.>A\5E.8-'(,/S1I
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M3#[,._J=\KQL6T"[QV [O3%J1UM:[RKV0FGWT^ZU7^PJXMTZ(9?%8?^TH7.
M*X6B%$]$UW(]"G/]T+ 'QI4&%5OQ]OX(N7R.XE7LY*4K!K,43I GLK2/PK0_
M!%Z^M0G4VRE6J2R>JTMLLZ%<6>DURV5[")?]UM79Y<JE"<034RVR0P$*;[KO
MVOWIP?4FI?9-0?FS[FNJ[(I2=(.O_DE;J:PWV<=I1:1J+Y(=:ZR[(9^OD)M[
M'K$DRB8V[LAR/PIS_Z$I*N)_*@N%_.'E^/[BLCO$>.DFH$=.$1:>*!UL!P$<
M'@0T^K+)N9F1WQ6T_?1>IYHQRD1'?]"3C-K&T]>0J08E>9GK2.G?O>>R[A@
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MNC!7H7?TX$L0.[L')$IYS91[09VW6S4W=L)>^>=Z!;F-\8?&[:\[(G:4253
M5E/Z@RL]\<+M!&<H7MFQVG"EA]0><[U&09@ ?;_E7!T,DZ!;S,EO4$L#!!0
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M!5J=3L[G[RZ.>;]L^,W0)NY\*[:D\/XS#VZJT\DA R)+96()&O\>Z)*L94&
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M/7K5&.5[G Z_]&;3-T0_#<.Y[E[>X-?:U\-- +G.(TE+VNJ'Y=U2U:YIM%?
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M4KW.7,B[_PN[!0?1]+6180%TH]K2AM&/PQ]!QH!,^%XW80';<=7'<\1S-8D
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M!GDV-QX)2D_<V7MTNQ'AZC8F CUO'FL'.A%T1/QG.Q[T.&Y>VK^P-(6J"R!
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MO"4P7S9,14T(23@?00(9*:> DEA,1=J9+/!BOFY9LN>A3;B99@1J^>!^91:
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M7WYQQM@R?NC<GEXVNG)=YW;T)]9NC<<'X/>U W\E'W"!]/;9Y_\'4$L#!!0
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MC-AA2J\_E$: OB>";B'5Q&Q0OR>O_@)02P,$%     @ 9J1Z6"-60BQV P
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MX8K>8]3>@/9+I>QVX@,T+_SH.U!+ P04    " !FI'I8\]"Z P %   .#
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M<WJ^HN$#]'NFB0OM@A6L'\2G?P-02P,$%     @ 9J1Z6.M$3H0T"0  ,A@
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULM5EK;]LX%OWN7T%X'F@
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M-&R:IR+=-= #H 955*.ZB Y:_"@2G_5#CT5!U#]@K]^LLF_M]?>M<LFU.+Y
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MQ*I?4MN!\N]W=B"E$D7:%^*S[YY[SKY[Z*VU>;0%HH-G*93M1X5SY44<VZQ
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M&PG>??3UT?4__F*@62I*58Y^I6=S%=-D"B2.UAKV>?;]_/2\YK>.&%<$@$2
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MSY7@B"LMP/.E4K:YH W:3X'G_P-02P,$%     @ 9J1Z6)(9D$6C!   '0H
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ML0%5 A LJW\AM0=(*7.LADIO('F7/%/N+-.>90T=]_B0] %=&$!O=>@&6_3
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M80"?I0Z>NS6VM*ZY(Q"TDCP*,((ENF@+':?%D&=$S?.A3]*CL8=W#2>8[6*
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MH'9>D8:<)+#98 Z_7JE^3H=:6OY#/7JT_!Y;/.M05X6O5LO'X:M%9BZQ+(Y
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MU_]-@9<#>U7K#;QZL?S^\1ECX?"AM0>ZGGYMV];NZ4]L>= .'X#?-Q;\JWS
M">+_8<&+_P-02P,$%     @ 9J1Z6%..D,=] P  S0@  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&ULK59=C],X%'WOK[@*"(%431(G;9JAK=090(NT
M:$<SL#RL]L%-;EJ+Q ZV0V?^_5X[;::(3@5:7NK/>\[].,[M?*?T%[-%M'#?
MU-(L@JVU[648FF*+#3<7JD5))Y72#;>TU)O0M!IYZ8V:.F11- T;+F2PG/N]
M&[V<J\[60N*-!M,U#=</5UBKW2*(@\/&K=ALK=L(E_.6;_ .[:?V1M,J'%!*
MT: T0DG06"V"57QY-7'W_86_!>[,T1Q<)&NEOKC%^W(11,XAK+&P#H'3\ VO
ML:X=$+GQ=8\9#)3.\'A^0'_G8Z=8UMS@M:H_B])N%\$L@!(KWM7V5NW^P'T\
MWL%"U<;_PJZ_.\D#*#IC5;,W)@\:(?N1W^_S<&0PBYXP8'L#YOWNB;R7;[CE
MR[E6.]#N-J&YB0_56Y-S0KJBW%E-IX+L[/(ONT4-[X3DLA"\ACO++5+2+;R7
M?<E=[EY^Y.L:S:MY:(G368;%'O^JQV=/X,<,/BAIMP;>RA++[P%"<G;PF!T\
MOF)G$=]@<0%)/ 86L>0,7C)D(/%XR?_*P#^KM;&:-/3OJ1ST#.EI!O>N+DW+
M"UP$]' ,ZF\8+%\\BZ?1ZS/^IX/_Z3GTY1V]T[*K$50%-QI;+DIX>T^/UJ !
M+DOH [SNM'9!K8Q!:TX%<9;F=! '/CSF4YZOV/-QSP>%HG=LK'.2CJ%2-7T.
MA-S 2R%I1W6&3,TKN!A1?;%9$X*K\?%B=& KR#=14*FL=@5SG*7N-O0L9%=1
MB3KM@ MEB/<Y3,?I+*)Q1F,V8 AI.DT51YCD&>3Y;#C!KYVP#U#U@AB TCB"
M-(^&:SXX-LF I8^H1E5VQS7N;5B201RE1S:%)G '6B%E*XYR>/%LQF+V>M17
M*1FS.(,LSD<?E:78VI].\'.(XW$29?TD2B=P1EN305N3G];6JB#G\4A;JQ^T
M]:?@:U%3@'A28&>Y3@OL0'HF_OJ1]+>H[$#9\@=-]I3/9)PGS(]4G.%\4.$3
M^AM<9F260#I.DG1TBS5]71RX)HT1A?NN0CS.V93N9;-H@*]Q0]A>)I,<DF0V
M.I.+:9P#RR=[T?!?2YI[&EF:.^%$XWR:GA1.>-1B&M0;WTA=PCMI^VXS[ Z]
M>M6WJ,?K?:/_P/6&GA]%6)%I=)&1+G3?//N%5:UO6&MEJ?WYZ9;^;Z!V%^B\
M4LH>%HY@^ >S_ ]02P,$%     @ 9J1Z6*.A%@$_!   RPH  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&ULQ599;]LX$'[WKQBH13<!G%BGC]0VX#CI
M ;1 T"3=A\4^T/+((B*)+DG9=7_]#BE%5AO'&_2E#XG)X1S?G)KQ5L@'E2)J
M^)YGA9HXJ=;KBUY/Q2GF3)V+-1;TD@B9,TU7N>JIM42VM$)YUO-=M]_+&2^<
MZ=C2;N1T+$J=\0)O)*@RSYG<76(FMA/'<QX)7_@JU8;0FX[7;(6WJ._7-Y)N
MO4;+DN=8*"X*D)A,G)EW<1D9?LOPE>-6M<Y@/%D(\6 N'Y<3QS6 ,,-8&PV,
M?C8XQRPSB@C&MUJGTY@T@NWSH_9WUG?R9<$4SD7V-U_J=.(,'5ABPLI,?Q';
M#UC[8P'&(E/V/VQK7M>!N%1:Y+4P(<AY4?VR[W4<7B+@UP*^Q5T9LBBOF&;3
ML11;D(:;M)F#==5*$SA>F*3<:DFOG.3T=,Y4"M??2KYA&19:P:Q8PF<F'U"S
M189PBW$IN>:HX.3.4-3IN*?)L!'OQ;61R\J(_XP1SX?/HM"I@NMBB<N?%?0(
M<0/;?X1]Z1_5>(7Q.01>%WS7#X[H"YHP!%9?\(R^C\4&E<Y-!+IPA0L-C.)@
MXJ)W[1C\,ULH+:F4_CT4A<I&>-B&::\+M68Q3ASJ'X5R@\[TS2NO[[X]XD'8
M>! >TSZ]M5W%?Q!(G2+<%]2B&5V7\)Y:4UE_/@FEZ)T7\(YQ"5]95B*(Q K,
M1;YFQ>XO!:U8&%8;C7T(#OE]%-EAO^_(9"(RF@F\6$%5:_;56&WA>?-JZ'N#
MMPH27K BYBP#1DX04XY,E9+\8QH2X\ZF<H<ZG:8%P95&,W4L5[#8088;-,VE
M4_+)&&C)I!PEDW&Z@Q/[*$I%X5*G<-&A0L-\@;(IMDXK=!\:N4]6^RP74MN8
MSX723W/0(M2IN%::TV@APEYMAWH%=]3DI@DA*0E)K=^#UQ"&W7[DTN&L_JL(
MG?OSVW-X+S8H"Y,Z6(B]G _]H-OW1C!PX03Z<&KOP^")$(WA(MZ!VA?\HP)O
MU.WW(QB0O!>2 G./AIVYD&LAR0&:A%0F!P0I;I'K$G](:.G2'X6=.Z$IC[$9
M/=@:/:9$\_WH:2E[#5XTZH9!2"=_8,)P0LD@&-5#?Q@]293_QQ/E=\-1U$Z4
M)?Q/H@9>-_2&I( <]"/RD C>;X;,"[HC+S"G*F!67T7O#T=P9.A$S=")C@\=
MVA&696:'R*$(&?HOXV2V83PS8,]HHSA3Y$?[<_."87,4T<N'39S1'.$)K^<E
M-NC;LR0AQ#^A9T_1M\+_:P_0V,$D0;MX0$Q?0//E*"F/9,GP[&!))M5+ILX5
MP:F'%Q4=[)!)2N4HZ [#R#ZR1!-_\Z8%Z*VP9P6^J2&WKJ'GRR7JND%TL"QZ
MK04C1[FR:Y0BE\I"5[M&0VTVM5FUH.S9JS6/DKTR+99A0J+N^8#R*:O5J;IH
ML;;KRD)H6G[L,:5M$Z5AH/=$"/UX,0::_77Z'U!+ P04    " !FI'I8]J2@
MC:\"   1!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R-54UOVS ,
MO>=7$-XP+$!7?R1ILRPQT*0=UD.'HNFVP["#8M.Q4%E*)3EI]^M'68F; FFP
MBR6*Y..C*-+CC=(/ID2T\%0):29!:>UJ%(8F*[%BYE2M4)*F4+IBED2]#,U*
M(\L;ITJ$212=A17C,DC'S=FM3L>JMH)+O-5@ZJIB^GF*0FTF01SL#N[XLK3N
M($S'*[;$.=H?JUM-4MBBY+Q":;B2H+&8!!?Q:-IW]HW!3XX;L[<'E\E"J0<G
M7.>3('*$4&!F'0*C98TS%,(!$8W'+6;0AG2.^_L=^M<F=\IEP0S.E/C%<UM.
M@F$ .1:L%O9.;;[A-I^!P\N4,,T7-MYV0!&SVEA5;9U)KKCT*WO:WL.>PS!Z
MPR'9.B0-;Q^H87G)+$O'6FU .VM"<YLFU<:;R''IBC*WFK2<_&SZ7<E/-TP_
MH&4+@7#U6'/[#'/,:LTM1P,?[YW"=,>AI7#.*<RVT%,/G;P!'2=PHZ0M#5S)
M'//7 "'Q;,DF.[+3Y"CB)6:GT(M/((F2WA&\7IM\K\'KO8%W+==H+#TQ:T[@
M$A<6F,P/W,'OBX6QFA[0GT.WX&/T#\=P334R*Y;A)*"N,:C7&*0?WL5GT9<C
M&?3;#/K'T-.Y[R50!;A*5D<J>8CZ4?##U.]+A$():F8NE^!C^8[F?^FJ+*G7
M3-3H*,G7E-!3,B\76YL&A'PJ9*;6Z&H!3%C4DKEVA8]<DE[5ABICNC#JT!O
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M)-@T[4/1!UH:VT0DT4M2]K;HQW=(*=K(5E1[0?3%YF7.X9"',Z0XV7/Q+#<
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M"Y@HG]C*BN);\R2TY$KQS!0W0!,0V@#[5YRKEXI^9:H?.F?_ E!+ P04
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MUB55-)H(OB9"6V,T?5%K4WMC-:S0VSA7 I\R]%/1C5J"(%>LH$7,:$;FBBK
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M)4J]FT9)]#QQ)S:U\Q.LR%N^P26Z^_;64,1&E4HTJ*S0"@RNI]$LN9AG'A\
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M46R$LB!Q3;1X<DY\T_=O'SC=AA98:4<-%88U/7EH/(#6UUJ[Y\!WU?B(%G\
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M:6H@OE\0PI\OT@#E\=OH?U!+ P04    " !FI'I8\@))RG@"  "R!0  &0
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M^M+.X7!F@[@X@@/@$NX+51DF<S,.R8IT5,.L%735"$I>$33#[!@&\0=(HF0
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M^Y[C<V[LFV0CU;TN  QY++G0$Z\PICKW?9T54%)]*BL0N))+55*#H5KYNE)
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M4#3>@/876KO7B>_J_DTN?@-02P,$%     @ 9J1Z6'@PN$PH!   5Q0  !D
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MS5V^UFSN0NL&M=8-W-)P>S:)6&J<.D:S7 JIIG]Q-BL!&D^I>2\*%>Y2MSZ
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M&H:  Z#20.S/">&/$WE ^4[C_0=02P,$%     @ 9J1Z6 ])PA!E P  -0X
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MU;[OELIB%_MEB7,6M O ^Y52=K=Q'^@G=_8;4$L#!!0    ( &:D>EC3TBQ
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M70_U*1)E6RTGBN>V,[UPI?N<':;Z2P2$"=#O$\[586(VJ+]MPK]02P,$%
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M$X0WEZ*F(=FVOE<LF52WE/IQHRZ2P+6!^KYB3)X:^JK27DVG_P)02P,$%
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M88I_&2"- >[/A=";B?E _=\2_0%02P,$%     @ 9J1Z6#D#>8UU!   :!H
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M<VAE970V,RYX;6S-5N]OXC@0_5>LG+2ZD^Z:7Q"@!TB4[FHK[5ZKHMY]-LE
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MW5INW(AIWHCIZ*4*X[IFI]I#D-BY[B\%=;L[A9\^K_N[]H ;Q= >2"BPYW4
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MSEWI"\/KEW<G7][[//H74$L#!!0    ( &:D>EC22;QM$0(  !<F   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNVT 4A>&M"%R 1_<UM@/+
M51JW@3= R*,'+(D$AT'LW4>0"^D0*=(8/!4Q)'CY%\0'8OCTJQS:<=^=ZF[?
MU\7'\7"JJV8WCOV/E.IZ5XYMO>OZ<CI?V73#L1W/RV&;^G;]WFY+TN4RI^%V
M1O/\=#MS\?K9E_^9V&TV^W7YV:U_'\MI_,?@]*<;WNNNE+%9O+;#MHRK)GT<
MKJ=KNASD[CRY6;R\K9KAY4V:-'>00I#.'V009/,'.03Y_$$!03%_4(:@/'_0
M/03=SQ_T $$/\P<]0M#C_$&R1!F7!$D3K FT%N1:"+P6!%L(Q!8D6PC,%D1;
M"-069%L(W!:$6PCD%J1;".P6Q%L(]%;46PGT5M1;"?36R<<V@=Z*>BN!WHIZ
M*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WH9Z&X'>AGH;@=Z&>AN!WC;9
M+"'0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU%O)]#;46\GT-M1
M;R?0VU%O)]#;)YO=!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z!^H=!'H'
MZAT$>@?J'01Z!^H=!'H'ZAT$>L?D9R6!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>
M&?7.!'IGU#L3Z)U1[TR@=T:],X'>&?7.WZEW'3\/I5Y[OM;X_.^D>CS?6ZZ/
MORR_3D[>W@O.Z;:B/O\%4$L#!!0    ( &:D>EC B&UTZ0$  'XE   3
M6T-O;G1E;G1?5'EP97-=+GAM;,W:74_",!0&X+]"=FM8Z=?\B'"CWJH7_H&Z
M'61A6YNV(/Q[NP$F&B4:3'QO6*#M><]ZDN>*ZZ>MHS#:M$T7IMDB1G?%6"@7
MU)J06T==6IE;WYJ8OOH7YDRY-"_$Q&12L-)VD;HXCGV-;'9]2W.S:N+H;I-^
M#K7MIIFG)F2CF]W&/FN:&>>:NC0QK;-U5WU*&>\3\G1RV!,6M0MG:4/&ODSH
M5[X/V)][6)/W=46C1^/CO6G3+K9I6(C;AD)^O,07/=KYO"ZILN6J34?RX#R9
M*BR(8MODNZ)GQY-CNF':??*3\X<RQP+3SD=O74@3\_3[N,-(^M-CEPJ1C_7Q
M5WQ/3*5/?C_JIUU1]</L=+VOUB^'>00V/$Z_XX\S?J__RSX$2!\2I \%TH<&
MZ:, Z>,<I(\+D#XN0?K@$Y1&4$3E**1R%%,Y"JH<156.PBI'<96CP,I19!4H
ML@H4606*K )%5H$BJT"15:#(*E!D%2BR"A19)8JL$D56B2*K1)%5HL@J4625
M*+)*%%DEBJP215:%(JM"D56AR*I09%4HLBH4616*K I%5H4BJT*15:/(JE%D
MU2BR:A19-8JL&D56C2*K1I%5H\BJ460M4&0M4&0M4&0M4&0M_E/69VN7?QP_
M///6U-TAGPU_NYJ] 5!+ 0(4 Q0    ( &:D>E@'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " !FI'I86KK!\0 %  #P$P  &
M    @('$&@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M9J1Z6/QO5<C!"   N5(  !@              ("!^A\  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &:D>EB+0-#@_P<  )PF   8
M          " @?$H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " !FI'I8I3C$-DP"  "D!0  &               @($F,0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ 9J1Z6 N\\)?G!   #P\
M !@              ("!J#,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( &:D>E@C_'%GRP8  (D/   8              " @<4X  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !FI'I8(3M<MQD<
M  ")5@  &0              @('&/P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( &:D>E@=8>IC( 0  '\)   9              "
M@19<  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 9J1Z
M6'14I#O!!0  6PX  !D              ("!;6   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " !FI'I8(U9"+'8#  #M!P  &0
M        @(%E9@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( &:D>ECST+H#  4   X,   9              " @1)J  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ 9J1Z6&%,^H]Q!@  $ \
M !D              ("!26\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " !FI'I8A\^"(*P%   <#P  &0              @('Q=0
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( &:D>ECK1$Z$
M- D  #(8   9              " @=1[  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ 9J1Z6&O#G73@ @  + 8  !D
M ("!/X4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !F
MI'I8RWCZMDT)  !N&@  &0              @(%6B   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &:D>E@ZP:J6H@H  !8<   9
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M970R-"YX;6Q02P$"% ,4    " !FI'I8N'VWMT =  "\8   &0
M    @('DK   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M &:D>EA3CI#'?0,  ,T(   9              " @5O*  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ 9J1Z6*.A%@$_!   RPH  !D
M             ("!#\X  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " !FI'I8]J2@C:\"   1!@  &0              @(&%T@  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &:D>EA0)OT]I ,
M '\)   9              " @6O5  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ 9J1Z6/I+AC-- P  O0<  !D              ("!
M1MD  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !FI'I8
M3XN X+8%  #>#@  &0              @('*W   >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &:D>EB> [.5^ 4  #X0   9
M      " @;?B  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ 9J1Z6/CG<H L P  S08  !D              ("!YN@  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !FI'I8E@=1#AT$  #T%
M&0              @(%)[   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( &:D>E@J*(7D, ,   L*   9              " @9WP  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 9J1Z6)[D;DTQ
M P  ZPD  !D              ("!!/0  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " !FI'I8_M=W?@4#  "C"   &0
M@(%L]P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &:D
M>EBUE3WO00(  % %   9              " @:CZ  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ 9J1Z6$4?:,L?!0  BAL  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( &:D>E@IPF)[-@(  !4%   9
M  " @14. 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M9J1Z6 UZBFQQ @  GP4  !D              ("!@A ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " !FI'I8>#"X3"@$  !7%   &0
M            @($J$P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( &:D>E@+*!V$X@,   H0   9              " @8D7 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ 9J1Z6$48'(LL @
MHP0  !D              ("!HAL! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " !FI'I8[*W7,R<'  "V0@  &0              @($%
M'@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( &:D>EB
M%+H&]P<  (0Z   9              " @6,E 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ 9J1Z6-VFQA>P!   SA0  !D
M     ("!D2T! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &:D>EC3TBQ A @  ,U8   9              "
M@31  0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 9J1Z
M6 L TJRK @  &@<  !D              ("![T@! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " !FI'I8XP2KC<X"  #G"   &0
M        @('12P$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( &:D>EC4O>_,BP,  (X-   9              " @=9. 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ 9J1Z6-:R+Z0=!   I@X
M !D              ("!F%(! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " !FI'I89,3#7@X#  ##"   &0              @('L5@$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( &:D>E@Y WF-
M=00  &@:   9              " @3%: 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ 9J1Z6 [YTH9! P  "0P  !D
M ("!W5X! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !F
MI'I8^1UW[:L%   F+@  &0              @(%58@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( &:D>E@P^JJ<0P,  ,H4   -
M          "  3=H 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 9J1Z6)>*
MNQS     $P(   L              ( !I6L! %]R96QS+RYR96QS4$L! A0#
M%     @ 9J1Z6)9C;S4L!0  >RH   \              ( !CFP! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( &:D>EC22;QM$0(  !<F   :
M      "  >=Q 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( &:D>EC B&UTZ0$  'XE   3              "  3!T 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !( $@ KQ,  $IV 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>146</ContextCount>
  <ElementCount>347</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfTheBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Other Financial Statement Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation</Role>
      <ShortName>Other Financial Statement Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Cash Equivalents And Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash Equivalents And Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Non-Marketable Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities</Role>
      <ShortName>Non-Marketable Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Note Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable</Role>
      <ShortName>Note Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation</Role>
      <ShortName>Stock Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Licenses and Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborations</Role>
      <ShortName>Licenses and Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Other Financial Statement Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables</Role>
      <ShortName>Other Financial Statement Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Cash Equivalents And Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents And Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Non-Marketable Equity Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesTables</Role>
      <ShortName>Non-Marketable Equity Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Note Payable (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable</Role>
      <ShortName>Note Payable (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Stock Compensation (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable</Role>
      <ShortName>Stock Compensation (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Organization and Description of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and Description of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Other Financial Statement Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Statement Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Cash Equivalents And Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents And Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities</Role>
      <ShortName>Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail</Role>
      <ShortName>Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Non-Marketable Equity Securities - Summary of Non-marketable Equity Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail</Role>
      <ShortName>Non-Marketable Equity Securities - Summary of Non-marketable Equity Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Leases - Schedule of Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail</Role>
      <ShortName>Leases - Schedule of Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail</Role>
      <ShortName>Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Leases - Schedule of receivable future annual sublease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails</Role>
      <ShortName>Leases - Schedule of receivable future annual sublease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Note Payable - Schedule of Notes Payable (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail</Role>
      <ShortName>Note Payable - Schedule of Notes Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Note Payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail</Role>
      <ShortName>Note Payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Note Payable - Schedule Principal Installments Due (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail</Role>
      <ShortName>Note Payable - Schedule Principal Installments Due (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Common Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail</Role>
      <ShortName>Common Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Stock Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails</Role>
      <ShortName>Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails</Role>
      <ShortName>Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Licenses and Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail</Role>
      <ShortName>Licenses and Collaborations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995985 - Disclosure - Income Taxes - Schedule of Components of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Income Taxes - Schedule of Reconciliation of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Income Taxes - Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="vera-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Subsequent Event - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration -  vera-20231231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="vera-20231231.htm">vera-20231231.htm</File>
    <File>vera-20231231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img76291469_0.jpg</File>
    <File>img76291469_1.jpg</File>
    <File>img76291469_10.jpg</File>
    <File>img76291469_11.jpg</File>
    <File>img76291469_12.jpg</File>
    <File>img76291469_13.jpg</File>
    <File>img76291469_14.jpg</File>
    <File>img76291469_15.jpg</File>
    <File>img76291469_16.jpg</File>
    <File>img76291469_17.jpg</File>
    <File>img76291469_18.jpg</File>
    <File>img76291469_2.jpg</File>
    <File>img76291469_3.jpg</File>
    <File>img76291469_4.jpg</File>
    <File>img76291469_5.jpg</File>
    <File>img76291469_6.jpg</File>
    <File>img76291469_7.jpg</File>
    <File>img76291469_8.jpg</File>
    <File>img76291469_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="514">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>106
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vera-20231231.htm": {
   "nsprefix": "vera",
   "nsuri": "http://veratx.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "vera-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "vera-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 299,
   "keyCustom": 48,
   "axisStandard": 24,
   "axisCustom": 2,
   "memberStandard": 31,
   "memberCustom": 28,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2023": 3,
    "http://xbrl.sec.gov/ecd/2023": 1
   },
   "contextCount": 146,
   "entityCount": 1,
   "segmentCount": 60,
   "elementCount": 677,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 514,
    "http://xbrl.sec.gov/dei/2023": 41,
    "http://xbrl.sec.gov/ecd/2023": 9
   },
   "report": {
    "R1": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
     "longName": "100010 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100040 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity",
     "longName": "100050 - Statement - Statements of Stockholders' Equity",
     "shortName": "Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_e02b6343-2192-4292-8c98-078fac080977",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e02b6343-2192-4292-8c98-078fac080977",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DepreciationAmortizationAndAccretionNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_5dc0b4e6-1ca3-4772-bc5f-e4b2611208cb",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5dc0b4e6-1ca3-4772-bc5f-e4b2611208cb",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfTheBusiness",
     "longName": "995455 - Disclosure - Organization and Description of the Business",
     "shortName": "Organization and Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation",
     "longName": "995475 - Disclosure - Other Financial Statement Information",
     "shortName": "Other Financial Statement Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "vera:OtherFinancialStatementInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "vera:OtherFinancialStatementInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities",
     "longName": "995485 - Disclosure - Cash Equivalents And Marketable Securities",
     "shortName": "Cash Equivalents And Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities",
     "longName": "995515 - Disclosure - Non-Marketable Equity Securities",
     "shortName": "Non-Marketable Equity Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLeases",
     "longName": "995525 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable",
     "longName": "995535 - Disclosure - Note Payable",
     "shortName": "Note Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStock",
     "longName": "995545 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation",
     "longName": "995555 - Disclosure - Stock Compensation",
     "shortName": "Stock Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans",
     "longName": "995565 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborations",
     "longName": "995575 - Disclosure - Licenses and Collaborations",
     "shortName": "Licenses and Collaborations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "vera:LicenseAndCollaborationsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "vera:LicenseAndCollaborationsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes",
     "longName": "995585 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "longName": "995595 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1",
     "longName": "995615 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1",
     "longName": "995625 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent",
     "longName": "995635 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995645 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables",
     "longName": "995655 - Disclosure - Other Financial Statement Information (Tables)",
     "shortName": "Other Financial Statement Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "vera:OtherFinancialStatementInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "vera:OtherFinancialStatementInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables",
     "longName": "995665 - Disclosure - Cash Equivalents And Marketable Securities (Tables)",
     "shortName": "Cash Equivalents And Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesTables",
     "longName": "995675 - Disclosure - Non-Marketable Equity Securities (Tables)",
     "shortName": "Non-Marketable Equity Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables",
     "longName": "995685 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable",
     "longName": "995695 - Disclosure - Note Payable (Table)",
     "shortName": "Note Payable (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable",
     "longName": "995705 - Disclosure - Stock Compensation (Table)",
     "shortName": "Stock Compensation (Table)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995715 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "longName": "995725 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
     "longName": "995735 - Disclosure - Organization and Description of the Business - Additional Information (Detail)",
     "shortName": "Organization and Description of the Business - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:CashAndCashEquivalentsAndMarketableSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ImpairmentOfInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ImpairmentOfInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:MarketableSecuritiesPolicy",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "995755 - Disclosure - Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Other Financial Statement Information - Schedule Of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:PrepaidClinicalTrialAndDrugManufacturingCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "vera:OtherFinancialStatementInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:PrepaidClinicalTrialAndDrugManufacturingCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "vera:OtherFinancialStatementInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "995765 - Disclosure - Other Financial Statement Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details)",
     "shortName": "Other Financial Statement Information - Schedule Of Accrued Expenses And Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vera:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "vera:OtherFinancialStatementInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vera:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "vera:OtherFinancialStatementInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail",
     "longName": "995785 - Disclosure - Cash Equivalents And Marketable Securities - Additional Information (Detail)",
     "shortName": "Cash Equivalents And Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities",
     "longName": "995795 - Disclosure - Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail)",
     "shortName": "Cash Equivalents And Marketable Securities - Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail",
     "longName": "995805 - Disclosure - Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail)",
     "shortName": "Cash Equivalents And Marketable Securities - Schedule of Estimated Fair Value of Marketable Securities by Stated Contractual Maturities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail",
     "longName": "995815 - Disclosure - Non-Marketable Equity Securities - Summary of Non-marketable Equity Securities (Detail)",
     "shortName": "Non-Marketable Equity Securities - Summary of Non-marketable Equity Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail",
     "longName": "995825 - Disclosure - Leases - Schedule of Lease Cost (Detail)",
     "shortName": "Leases - Schedule of Lease Cost (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail",
     "longName": "995835 - Disclosure - Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail)",
     "shortName": "Leases - Schedule of Lease Liabilities Based on Minimum Lease Commitment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails",
     "longName": "995845 - Disclosure - Leases - Schedule of receivable future annual sublease payments (Details)",
     "shortName": "Leases - Schedule of receivable future annual sublease payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "longName": "995855 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail",
     "longName": "995865 - Disclosure - Note Payable - Schedule of Notes Payable (Detail)",
     "shortName": "Note Payable - Schedule of Notes Payable (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:NotesPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
     "longName": "995875 - Disclosure - Note Payable - Additional Information (Detail)",
     "shortName": "Note Payable - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e95c3e40-5150-4128-b63f-a06464bb547b",
      "name": "us-gaap:DebtInstrumentBasisSpreadOnVariableRate1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail",
     "longName": "995885 - Disclosure - Note Payable - Schedule Principal Installments Due (Detail)",
     "shortName": "Note Payable - Schedule Principal Installments Due (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
     "longName": "995895 - Disclosure - Common Stock - Additional Information (Detail)",
     "shortName": "Common Stock - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
     "longName": "995905 - Disclosure - Stock Compensation - Additional Information (Details)",
     "shortName": "Stock Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails",
     "longName": "995915 - Disclosure - Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details)",
     "shortName": "Stock Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_4135b425-1776-49c1-98fa-141157b08b6f",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails",
     "longName": "995925 - Disclosure - Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details)",
     "shortName": "Stock Compensation - Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_dc44f825-ebce-4f12-ad2f-3c428d8aa752",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
     "longName": "995935 - Disclosure - Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "shortName": "Stock Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails",
     "longName": "995945 - Disclosure - Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)",
     "shortName": "Stock Compensation - Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_8590b670-5825-42b7-a28a-b57150a094ad",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8590b670-5825-42b7-a28a-b57150a094ad",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "995955 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
     "longName": "995965 - Disclosure - Licenses and Collaborations - Additional Information (Detail)",
     "shortName": "Licenses and Collaborations - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f3deb204-a947-4aea-a198-2bd978183c67",
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "vera:LicenseAndCollaborationsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
     "longName": "995975 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails",
     "longName": "995985 - Disclosure - Income Taxes - Schedule of Components of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Components of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails",
     "longName": "995995 - Disclosure - Income Taxes - Schedule of Reconciliation of Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "996005 - Disclosure - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails",
     "longName": "996015 - Disclosure - Income Taxes - Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_2b98fbe6-3c1e-4766-9160-92841f2265a3",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5ed90599-4b8c-4161-b826-92693ffe24bd",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996025 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail",
     "longName": "996055 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_627daa2d-be5a-4f02-9196-f41419329d3c",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "longName": "996065 - Disclosure - Subsequent Event - Additional Information (Details)",
     "shortName": "Subsequent Event - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_c93b8c94-7f03-454e-b44d-c951c33fb0a3",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7e0be373-0021-42a8-b661-4dcf7ed20677",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vera-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "vera_AbandonmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AbandonmentAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abandonment Axis",
        "label": "Abandonment [Axis]",
        "terseLabel": "Abandonment"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AbandonmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AbandonmentDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abandonment Domain",
        "label": "Abandonment [Domain]",
        "terseLabel": "Abandonment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r713"
     ]
    },
    "vera_AccruedClinicalAndDrugManufacturingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AccruedClinicalAndDrugManufacturingExpenses",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and drug manufacturing expenses.",
        "label": "Accrued Clinical and Drug Manufacturing Expenses",
        "terseLabel": "Accrued clinical and drug manufacturing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AccruedLiabilitiesAndOtherLiabilitiesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities, noncurrent",
        "documentation": "Accrued Liabilities And Other Liabilities Non Current .",
        "label": "Accrued Liabilities And Other Liabilities Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities, current",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive gain (loss)",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r79",
      "r146",
      "r534",
      "r552",
      "r553"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r29",
      "r427",
      "r430",
      "r467",
      "r548",
      "r549",
      "r822",
      "r823",
      "r824",
      "r832",
      "r833",
      "r834"
     ]
    },
    "vera_AchievementAsAssumedLiabilitiesUponAcquisitionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AchievementAsAssumedLiabilitiesUponAcquisitionMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Achievement as Assumed Liabilities upon Acquisition [Member]",
        "documentation": "Achievement as assumed liabilities upon acquisition member."
       }
      }
     },
     "auth_ref": []
    },
    "vera_AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of Specified Bla Filing Or Regulatory Approval Milestones Member",
        "label": "Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]",
        "terseLabel": "Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AchievementOfSpecifiedCommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AchievementOfSpecifiedCommercialMilestonesMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement Of Specified Commercial Milestones Member",
        "label": "Achievement Of Specified Commercial Milestones [Member]",
        "terseLabel": "Achievement Of Specified Commercial Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Achievement of Various Clinical Development and Regulatory Milestones [Member]",
        "documentation": "Achievement of various clinical development and regulatory milestones member."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r565",
      "r832",
      "r833",
      "r834",
      "r900",
      "r924"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r747",
      "r757",
      "r783"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r750",
      "r760",
      "r786"
     ]
    },
    "vera_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AgreementAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Axis",
        "label": "Agreement [Axis]",
        "terseLabel": "Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AgreementDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Domain",
        "label": "Agreement [Domain]",
        "terseLabel": "Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r751",
      "r761",
      "r778",
      "r787",
      "r791",
      "r799"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r388"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "vera_AmplyxAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AmplyxAgreementMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amplyx Agreement [Member]",
        "documentation": "Amplyx agreement member.",
        "terseLabel": "Amplyx Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AmplyxAndNovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AmplyxAndNovartisMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amplyx and Novartis [Member]",
        "documentation": "Amplyx and Novartis member.",
        "terseLabel": "Amplyx and Novartis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Line Items",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate availed on lease",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "vera_AresAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AresAgreementMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares Agreement Member",
        "label": "Ares Agreement [Member]",
        "terseLabel": "Ares Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AresTradingSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AresTradingSAMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares Trading S A Member",
        "label": "Ares Trading S A [Member]",
        "terseLabel": "Ares Trading S A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r142",
      "r166",
      "r204",
      "r209",
      "r211",
      "r245",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r421",
      "r424",
      "r440",
      "r530",
      "r608",
      "r713",
      "r724",
      "r863",
      "r864",
      "r908"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r148",
      "r166",
      "r245",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r421",
      "r424",
      "r440",
      "r713",
      "r863",
      "r864",
      "r908"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r743"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r743"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r743"
     ]
    },
    "vera_AvailableForIssuanceAndSaleUnderSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AvailableForIssuanceAndSaleUnderSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for issuance and sale under sales agreement.",
        "label": "Available for Issuance and Sale Under Sales Agreement",
        "terseLabel": "Available for Issuance and Sale Under Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r253",
      "r529"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "terseLabel": "Unrealized Gains",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "vera_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale debt securities gross unrealized loss1.",
        "label": "Available for Sale Debt Securities Gross Unrealized Loss1",
        "terseLabel": "Unrealized Losses",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "auth_ref": []
    },
    "vera_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year to two years",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "documentation": "Available for sale securities debt maturities after one through two years fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total marketable securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r845",
      "r918"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesScheduleOfEstimatedFairValueOfMarketableSecuritiesByStatedContractualMaturitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r527"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair value of the debt securities",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r253",
      "r523",
      "r837"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total asset acquisition cost",
        "terseLabel": "Acquisition cost",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "vera_CashAndCashEquivalentsAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CashAndCashEquivalentsAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Marketable Securities",
        "label": "Cash And Cash Equivalents And Marketable Securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r141",
      "r687"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r107"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents and Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "verboseLabel": "Restricted cash",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r87",
      "r164"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r87"
     ]
    },
    "vera_CashEquivalentAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CashEquivalentAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Cash Equivalent And Marketable Securities",
        "documentation": "Cash equivalent and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "vera_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents And Marketable Securities [Abstract]",
        "documentation": "Cash equivalents and marketable securities abstract."
       }
      }
     },
     "auth_ref": []
    },
    "vera_CeliaLinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CeliaLinMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Celia Lin [Member]",
        "label": "Celia Lin [Member]",
        "documentation": "Celia lin."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ClassACommonStockIssuedAndOutstandingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ClassACommonStockIssuedAndOutstandingMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A common stock issued and outstanding.",
        "label": "Class A Common Stock Issued And Outstanding [Member]",
        "terseLabel": "Class A Common Stock Options Issued and Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r143",
      "r144",
      "r145",
      "r166",
      "r190",
      "r191",
      "r193",
      "r195",
      "r202",
      "r203",
      "r245",
      "r276",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r306",
      "r307",
      "r310",
      "r313",
      "r320",
      "r440",
      "r556",
      "r557",
      "r558",
      "r559",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r596",
      "r617",
      "r641",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r807",
      "r828",
      "r835"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r202",
      "r306",
      "r307",
      "r308",
      "r310",
      "r313",
      "r318",
      "r320",
      "r556",
      "r557",
      "r558",
      "r559",
      "r706",
      "r807",
      "r828"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "vera_CollateralizedDebtInstrumentMaturityDate": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CollateralizedDebtInstrumentMaturityDate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized debt instrument maturity date.",
        "label": "Collateralized Debt Instrument Maturity Date",
        "documentation": "Collateralized debt instrument maturity date."
       }
      }
     },
     "auth_ref": []
    },
    "vera_CollateralizedNoteTwoThousandTwentyOneTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CollateralizedNoteTwoThousandTwentyOneTwelveMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note 2021-12",
        "label": "Collateralized Note Two Thousand Twenty One - Twelve [Member]",
        "documentation": "Collateralized note two thousand twenty one - twelve."
       }
      }
     },
     "auth_ref": []
    },
    "vera_CollateralizedNoteTwoThousandTwentyThreeTwelveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CollateralizedNoteTwoThousandTwentyThreeTwelveMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note 2023-12",
        "label": "Collateralized Note Two Thousand Twenty Three - Twelve [Member]",
        "documentation": "Collateralized note two thousand twenty three - twelve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_CollateralizedNoteTwoThousandTwentyTwoElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CollateralizedNoteTwoThousandTwentyTwoElevenMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note 2022-11",
        "label": "Collateralized Note Two Thousand Twenty Two - Eleven [Member]",
        "documentation": "Collateralized note two thousand twenty two - eleven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r270",
      "r271",
      "r684",
      "r862"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "vera_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital shares minimum increase in shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance",
        "terseLabel": "Potential increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock capital, Shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CommonStockConversionBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConversionBasis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common stock conversion basis",
        "documentation": "Description of basis for conversion of convertible common stock."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r832",
      "r833",
      "r900",
      "r921",
      "r924"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, Par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r596"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, Shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, Shares outstanding",
        "verboseLabel": "Common stock, Shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r73",
      "r596",
      "r614",
      "r924",
      "r925"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 44,452,161 and 27,800,861 shares issued and outstanding as ofDecember 31, 2023 and December 31, 2022, respectively",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r532",
      "r713"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r105",
      "r150",
      "r152",
      "r158",
      "r524",
      "r541"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r128"
     ]
    },
    "vera_ContingentMilestoneObligationAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ContingentMilestoneObligationAccrued",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Milestone Obligation Accrued",
        "label": "Contingent Milestone Obligation Accrued",
        "terseLabel": "Contingent milestone obligation accrued"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ConversionOfRedeemablePreferredStockIntoCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ConversionOfRedeemablePreferredStockIntoCommonStockMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of redeemable preferred stock into common stock",
        "label": "Conversion Of Redeemable Preferred Stock Into Common Stock [Member]",
        "terseLabel": "Conversion Of Redeemable Preferred Stock Into Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r709",
      "r920"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r288",
      "r308",
      "r474",
      "r690",
      "r692"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "vera_CowenAndCompanyLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "CowenAndCompanyLlcMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cowen and Company, LLC.",
        "label": "Cowen and Company, LLC [Member]",
        "terseLabel": "Cowen and Company, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r831",
      "r898"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r410",
      "r416",
      "r831"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r831",
      "r898"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure Abstract",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r67",
      "r68",
      "r110",
      "r112",
      "r173",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r450",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r829"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term debt",
        "verboseLabel": "Carrying amount of debt outstanding",
        "terseLabel": "Net carrying amount of debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r112",
      "r302"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note , Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r58",
      "r304",
      "r450"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateTerms",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note , variable",
        "label": "Debt Instrument, Interest Rate Terms",
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument Line Items",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r450",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r829"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note , Maturity",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r701",
      "r901"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r173",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r450",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r829"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r45",
      "r48",
      "r57",
      "r58",
      "r60",
      "r64",
      "r95",
      "r96",
      "r173",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r450",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r829"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarizes the Unrealized Gains and Losses in Fair Value of the Company's Investments in Debt Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized gain (loss) on marketable securities",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r843"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Fair Value of Investments in Available-for-sale Marketable Debt Securities",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r698",
      "r856"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r897",
      "r898"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r104",
      "r131",
      "r415",
      "r416",
      "r831"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total gross DTL",
        "negatedTotalLabel": "Total gross DTL",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r111",
      "r404"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "terseLabel": "Offering costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "vera_DeferredOfferingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs .",
        "label": "Deferred Offering Costs [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r897",
      "r898"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross DTA",
        "terseLabel": "Total gross DTA",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and other credits",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "vera_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets, lease liability.",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state NOL carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other DTA",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed assets",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Capitalized R&amp;D",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves and accruals",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "verboseLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other DTL",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r896"
     ]
    },
    "vera_DeferredTaxLiabilitiesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities, right-of-use assets.",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "terseLabel": "Right of use",
        "negatedLabel": "Right of use"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contributions",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAmortizationAndAccretionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAmortizationAndAccretionNet",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Amortization and Accretion, Net, Total",
        "label": "Depreciation, Amortization and Accretion, Net",
        "terseLabel": "Depreciation, amortization and accretion",
        "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r345",
      "r376",
      "r377",
      "r379",
      "r711"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Summary of Share-based Compensation Arrangements by Share-based Payment Award",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r49"
     ]
    },
    "vera_DiscountedLeaseRelatedRestructuringLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "DiscountedLeaseRelatedRestructuringLiabilityMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted Lease Related Restructuring Liability Member",
        "label": "Discounted Lease Related Restructuring Liability [Member]",
        "terseLabel": "Discounted Lease Related Restructuring Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationSharesReceivedOnDisposal",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation shares received on disposal.",
        "label": "Disposal Group Including Discontinued Operation Shares Received On Disposal",
        "terseLabel": "Disposal group including discontinued operations shares received for disposal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCash",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Cash, Total",
        "label": "Dividends, Cash",
        "terseLabel": "Cash dividends",
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r97"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r743"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r743",
      "r779"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share Abstract",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r188",
      "r190",
      "r193",
      "r194",
      "r195",
      "r199",
      "r435",
      "r436",
      "r525",
      "r542",
      "r694"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r190",
      "r193",
      "r194",
      "r195",
      "r199",
      "r435",
      "r436",
      "r525",
      "r542",
      "r694"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r196",
      "r197",
      "r198"
     ]
    },
    "vera_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Growth Company Status .",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share based compensation, Nonvested awards, Compensation cost not yet recognized Stock options and equity instruments other than options",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share based compensation, Nonvested awards, Compensation cost not yet recognized period of recognition stock options and equity instruments other than options",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "vera_EmployeeSeveranceAndOtherEmployeeTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EmployeeSeveranceAndOtherEmployeeTerminationMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Other Employee Termination Member",
        "label": "Employee Severance And Other Employee Termination [Member]",
        "terseLabel": "Employee Severance And Other Employee Termination [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "vera_EmployeeStockPurchasePlanEsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EmployeeStockPurchasePlanEsppMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Espp Member",
        "label": "Employee Stock Purchase Plan ESPP [Member]",
        "terseLabel": "Employee Stock Purchase Plan ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "vera_EquipmentAbondonedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EquipmentAbondonedMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Abondoned Member",
        "label": "Equipment Abondoned [Member]",
        "terseLabel": "Equipment Abandoned [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r137",
      "r154",
      "r155",
      "r156",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r186",
      "r201",
      "r246",
      "r247",
      "r321",
      "r380",
      "r381",
      "r382",
      "r411",
      "r412",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r467",
      "r548",
      "r549",
      "r550",
      "r565",
      "r641"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Equity Securities, FV-NI, Gain (Loss), Total",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "Change in fair value of non-marketable equity securities",
        "negatedLabel": "Change in unrealized loss on marketable securities",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r854"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value",
        "negatedLabel": "Change in fair value of non-marketable equity securities",
        "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity securities, FV-NI, unrealized gain (loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r854"
     ]
    },
    "vera_EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Initial Cost",
        "documentation": "Equity securities without readily determinable fair value initial cost."
       }
      }
     },
     "auth_ref": []
    },
    "vera_EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative net fair value loss",
        "negatedLabel": "Cumulative net fair value loss",
        "label": "Equity Securities Without Readily Determinable Fair Value Net Cumulative Gain Loss",
        "documentation": "Equity securities without readily determinable fair value net cumulative gain loss."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r747",
      "r757",
      "r783"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r744",
      "r754",
      "r780"
     ]
    },
    "us-gaap_EscrowDepositDisbursementsRelatedToPropertyAcquisition1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDepositDisbursementsRelatedToPropertyAcquisition1",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow Deposit Disbursements Related to Property Acquisition",
        "terseLabel": "Shares eligible for release from escrow",
        "documentation": "Amount of escrow deposit disbursements related to property acquisition in noncash investing or financing transactions."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "vera_EventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EventAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event",
        "label": "Event [Axis]",
        "terseLabel": "Event"
       }
      }
     },
     "auth_ref": []
    },
    "vera_EventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "EventDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event",
        "label": "Event [Domain]",
        "terseLabel": "Event"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r437",
      "r482",
      "r483",
      "r484",
      "r702",
      "r703",
      "r707",
      "r708",
      "r709"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r325",
      "r330",
      "r437",
      "r482",
      "r707",
      "r708",
      "r709"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r325",
      "r330",
      "r437",
      "r483",
      "r702",
      "r703",
      "r707",
      "r708",
      "r709"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r482",
      "r483",
      "r484",
      "r702",
      "r703",
      "r707",
      "r708",
      "r709"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r256",
      "r301",
      "r318",
      "r432",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r540",
      "r698",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r850",
      "r851",
      "r852",
      "r853"
     ]
    },
    "vera_FollowOnPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "FollowOnPublicOfferingMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-on Public Offering [Member]",
        "documentation": "Follow On Public Offering [Member]",
        "label": "Follow On Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translations",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r787"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain on sale of PNAi technology",
        "negatedLabel": "Gain on sale of PNAi technology",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r826"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r620"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r730",
      "r743"
     ]
    },
    "us-gaap_ImpairmentOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfInvestments",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment Losses, Investments",
        "terseLabel": "Impairment loss on available-for-sale marketable securities",
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r417"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80",
      "r114",
      "r204",
      "r208",
      "r210",
      "r212",
      "r526",
      "r538",
      "r696"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r417"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r262",
      "r625"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r625"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r391",
      "r397",
      "r402",
      "r408",
      "r413",
      "r418",
      "r419",
      "r420",
      "r561"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "totalLabel": "Income Tax Examination, Penalties and Interest Expense, Total",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails",
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax provision",
        "totalLabel": "Provision for income taxes",
        "negatedLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r132",
      "r185",
      "r186",
      "r207",
      "r395",
      "r414",
      "r546"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r393",
      "r394",
      "r402",
      "r403",
      "r407",
      "r409",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax on U.S. statutory rate on income before income taxes",
        "terseLabel": "At statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total",
        "negatedLabel": "Tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "negatedLabel": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r825"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "terseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expense and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r751",
      "r761",
      "r778",
      "r787",
      "r791",
      "r799"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r803"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r803"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r803"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r116",
      "r157",
      "r206",
      "r449",
      "r626",
      "r723",
      "r923"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r162",
      "r163"
     ]
    },
    "vera_InvestmentInPnaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "InvestmentInPnaiMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment In PNAI.",
        "label": "Investment In PNAI [Member]",
        "terseLabel": "Investment In PNAI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r205"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Owned, Fair Value",
        "terseLabel": "Investments owned market value",
        "periodStartLabel": "Investment Owned, at Fair Value, Beginning Balance",
        "periodEndLabel": "Investment Owned, at Fair Value, Ending Balance",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r588",
      "r589",
      "r599",
      "r600",
      "r649",
      "r651",
      "r652",
      "r653",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r666",
      "r671",
      "r672",
      "r673",
      "r717",
      "r724",
      "r922"
     ]
    },
    "vera_InvestmentOwnedNumberOfSharesPlacedInEscrowAccount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "InvestmentOwnedNumberOfSharesPlacedInEscrowAccount",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment owned number of shares placed in escrow account..",
        "label": "Investment Owned Number Of Shares Placed In Escrow Account",
        "terseLabel": "Investment owned number of shares placed in escrow account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r580",
      "r581",
      "r583",
      "r585",
      "r649",
      "r651",
      "r655",
      "r659",
      "r660",
      "r663",
      "r664",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r717"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r580",
      "r581",
      "r583",
      "r585",
      "r649",
      "r651",
      "r655",
      "r659",
      "r660",
      "r663",
      "r664",
      "r672",
      "r674",
      "r675",
      "r676",
      "r677",
      "r717"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNonMarketableEquitySecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Non-Marketable\u00a0Equity Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r117",
      "r118",
      "r136",
      "r213",
      "r214",
      "r438",
      "r439"
     ]
    },
    "vera_IssuanceOfCommonStockForLicensingPaymentNetOfCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "IssuanceOfCommonStockForLicensingPaymentNetOfCosts",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for licensing payment, net of costs.",
        "label": "Issuance of common stock for licensing payment, net of costs",
        "terseLabel": "Issuance of Class A common stock for licensing payment, net of costs"
       }
      }
     },
     "auth_ref": []
    },
    "vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock from underwritten follow-on offering, net of offering costs, value",
        "documentation": "Issuance of common stock from underwritten follow-on offering net of offering costs.",
        "label": "Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "vera_IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock from underwritten follow-on offering, net of offering costs",
        "documentation": "Issuance of common stock from underwritten follow-on offering, net of offering costs shares",
        "label": "Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Net lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r712"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "vera_LeasedFacilitiesAbandonedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LeasedFacilitiesAbandonedMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased Facilities Abandoned Member",
        "label": "Leased Facilities Abandoned [Member]",
        "terseLabel": "Leased Facilities Abandoned [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of lease liabilities based on minimum lease commitment",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payment to be Received",
        "totalLabel": "Total sublease payments",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Receivable Future Annual Sublease Payments",
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfReceivableFutureAnnualSubleasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r166",
      "r245",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r422",
      "r424",
      "r425",
      "r440",
      "r595",
      "r695",
      "r724",
      "r863",
      "r908",
      "r909"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r113",
      "r536",
      "r713",
      "r830",
      "r855",
      "r902"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r140",
      "r166",
      "r245",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r422",
      "r424",
      "r425",
      "r440",
      "r713",
      "r863",
      "r908",
      "r909"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "vera_LicenseAndCollaborationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LicenseAndCollaborationsLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaborations.",
        "label": "License and Collaborations [Line Items]",
        "terseLabel": "License And Collaborations [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_LicenseAndCollaborationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LicenseAndCollaborationsTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaborations.",
        "label": "License and Collaborations [Table]",
        "terseLabel": "License And Collaborations [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_LicenseAndCollaborationsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LicenseAndCollaborationsTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Collaborations.",
        "label": "License And Collaborations [Text Block]",
        "terseLabel": "Licenses and Collaborations"
       }
      }
     },
     "auth_ref": []
    },
    "vera_LicensesAndCollaborationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LicensesAndCollaborationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses And Collaborations Abstract",
        "label": "Licenses And Collaborations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Additional borrowing capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPayments": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFrequencyOfPayments",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt facility payments description",
        "label": "Line of Credit Facility, Frequency of Payments",
        "documentation": "Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving credit facility with borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsExtended",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Percentage Prepayment Of Loan or Maturity Date is Extended",
        "label": "Line Of Credit Facility Percentage Prepayment Of Loan or Maturity Date is Extended",
        "terseLabel": "Extended maturity date"
       }
      }
     },
     "auth_ref": []
    },
    "vera_LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment of the loan",
        "label": "Line Of Credit Facility Percentage Prepayment Of Loan or Maturity Date is Not Extended",
        "documentation": "Line of credit facility percentage prepayment Of loan or maturity date is not extended."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining capacity available",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "vera_LoanFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LoanFacilityMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan facility.",
        "label": "Loan Facility [Member]",
        "terseLabel": "Loan Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "vera_LondonInterbankOfferedRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "LondonInterbankOfferedRateMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIBOR [Member]",
        "label": "London Interbank Offered Rate [Member]",
        "documentation": "London Interbank Offered Rate Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net carrying amount of debt",
        "verboseLabel": "Total",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r112",
      "r292",
      "r303",
      "r702",
      "r703",
      "r919"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableSchedulePrincipalInstallmentsDueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r173",
      "r296"
     ]
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "vera_MarketableSecuritiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "MarketableSecuritiesDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureMarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities Disclosure Text Block",
        "label": "Marketable Securities Disclosure Text Block",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Marketable Securities, Noncurrent, Total",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Non-marketable equity securities",
        "documentation": "Amount of investment in marketable security, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "vera_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price of securities under shelf registration.",
        "label": "Maximum Aggregate Offering Price of Securities Under Shelf Registration",
        "terseLabel": "Maximum aggregate offering price of common stock, preferred stock, debt securities and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r341",
      "r509",
      "r547",
      "r586",
      "r587",
      "r650",
      "r654",
      "r656",
      "r657",
      "r667",
      "r685",
      "r686",
      "r697",
      "r706",
      "r710",
      "r714",
      "r865",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "vera_MilestonePaymentsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "MilestonePaymentsPaid",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments paid.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payments paid"
       }
      }
     },
     "auth_ref": []
    },
    "vera_MilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "MilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments payable.",
        "label": "Milestone Payments Payable",
        "terseLabel": "Milestone payments payable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r341",
      "r509",
      "r547",
      "r586",
      "r587",
      "r650",
      "r654",
      "r656",
      "r657",
      "r667",
      "r685",
      "r686",
      "r697",
      "r706",
      "r710",
      "r714",
      "r865",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureOrganizationAndDescriptionOfTheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of the Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r89",
      "r115",
      "r138",
      "r149",
      "r151",
      "r156",
      "r166",
      "r177",
      "r179",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r192",
      "r204",
      "r208",
      "r210",
      "r212",
      "r245",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r436",
      "r440",
      "r539",
      "r616",
      "r639",
      "r640",
      "r696",
      "r723",
      "r863"
     ]
    },
    "vera_NeubaseAssetSaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "NeubaseAssetSaleAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Neubase Asset Sale [Abstract]",
        "documentation": "Neubase Asset Sale.",
        "label": "Neubase Asset Sale [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_NeubaseAssetSaleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "NeubaseAssetSaleTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neubase asset sale.",
        "label": "Neubase Asset Sale [Text Block]",
        "terseLabel": "Neubase Asset Sale"
       }
      }
     },
     "auth_ref": []
    },
    "vera_NeubaseTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "NeubaseTherapeuticsIncMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neubase therapeutics inc member.",
        "label": "Neubase Therapeutics Inc [Member]",
        "terseLabel": "Neubase Therapeutics Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r751",
      "r761",
      "r778",
      "r787"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "vera_NonRevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "NonRevolvingCreditFacilityMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non revolving credit facility.",
        "label": "Non Revolving Credit Facility [Member]",
        "terseLabel": "Non Revolving Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "vera_NonmarketableEquitySecuritiesCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "NonmarketableEquitySecuritiesCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesSummaryOfNonmarketableEquitySecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Carrying value of non-marketable equity securities",
        "label": "Nonmarketable Equity Securities Carrying Value",
        "documentation": "Nonmarketable equity securities carrying value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "totalLabel": "Total borrowings",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r112",
      "r919"
     ]
    },
    "vera_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "NovartisMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis [Member]",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "OfficeAndLaboratorySpaceAtBrisbaneCaliforniaMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and Laboratory Space at Brisbane California [Member]",
        "label": "Office and Laboratory Space at Brisbane California [Member]",
        "documentation": "Office and laboratory space at brisbane california."
       }
      }
     },
     "auth_ref": []
    },
    "vera_OfficeAndLaboratorySpaceAtWobornMassauchetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "OfficeAndLaboratorySpaceAtWobornMassauchetsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory space at woborn massauchets.",
        "label": "Office and Laboratory Space at Woborn Massauchets [Member]",
        "terseLabel": "Office and Laboratory Space at Woborn Massauchets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, expenses from transactions with related party",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r208",
      "r210",
      "r212",
      "r696"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r712"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base rent",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r466"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "negatedLabel": "Less: Current portion of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseLiabilitiesBasedOnMinimumLeaseCommitmentDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent",
        "verboseLabel": "Non-current operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r461"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in the carrying amount of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r712"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r712"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals",
        "terseLabel": "Operating lease minimum future commitments",
        "totalLabel": "Sublease Income, Total minimum lease payments",
        "documentation": "Contractually required future rental payments receivable on noncancelable subleasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "vera_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "label": "Operating Loss Carryforwards Expiration Year",
        "documentation": "Operating loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r713"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "vera_OtherFinancialStatementInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "OtherFinancialStatementInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other financial statement information.",
        "label": "Other Financial Statement Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_OtherFinancialStatementInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "OtherFinancialStatementInformationTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Statement Information.",
        "label": "Other Financial Statement Information [Text Block]",
        "terseLabel": "Other Financial Statement Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income",
        "terseLabel": "Other income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r618",
      "r668",
      "r669",
      "r670"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party payable",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r713"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r749",
      "r759",
      "r785"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r752",
      "r762",
      "r788"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r752",
      "r762",
      "r788"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForUnderwritingExpense",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts and commissions",
        "label": "Payments for Underwriting Expense",
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net of issuance costs",
        "terseLabel": "Payments of offering costs",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs related to initial public offering",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "vera_PaymentsOfStockIssuanceCostsOnFollowOnOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PaymentsOfStockIssuanceCostsOnFollowOnOffering",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of stock issuance costs on follow on offering.",
        "label": "Payments of Stock Issuance Costs on Follow on Offering",
        "negatedLabel": "Payment of costs and underwriting discounts and commissions related to follow-on offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureEmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r709"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "vera_PercentageOfIncreaseInRentAnnually": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PercentageOfIncreaseInRentAnnually",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Increase In Rent Annually",
        "label": "Percentage Of Increase In Rent Annually",
        "terseLabel": "Percentage of increase in rent annually"
       }
      }
     },
     "auth_ref": []
    },
    "vera_PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of company common stock outstanding for increase in shares reserved for issuance under stock plan",
        "label": "Percentage Of Shares Of Company Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan",
        "terseLabel": "Potential increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "vera_PnaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PnaiMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pnai Member",
        "label": "PNAI [Member]",
        "terseLabel": "PNAI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par or stated value per share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r306"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r596"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r306"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r596",
      "r614",
      "r924",
      "r925"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r531",
      "r713"
     ]
    },
    "vera_PrepaidClinicalTrialAndDrugManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PrepaidClinicalTrialAndDrugManufacturingCosts",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical Trial and Drug Manufacturing Costs",
        "label": "Prepaid Clinical Trial and Drug Manufacturing Costs",
        "terseLabel": "Prepaid clinical trial and drug manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "vera_PrepaidEquityFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PrepaidEquityFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid equity financing costs.",
        "label": "Prepaid Equity Financing Costs",
        "terseLabel": "Prepaid equity financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other assets, current",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other assets, noncurrent",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r818"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r699",
      "r857"
     ]
    },
    "vera_PrepaidRecruitingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PrepaidRecruitingFees",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Recruiting Fees",
        "label": "Prepaid Recruiting Fees",
        "terseLabel": "Prepaid recruiting fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidRent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent",
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r700",
      "r857"
     ]
    },
    "vera_PrepaidSoftwareCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "PrepaidSoftwareCosts",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid software costs",
        "label": "Prepaid Software Costs",
        "documentation": "Prepaid Software Costs"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ProceedsFromBorrowingsNetOfCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ProceedsFromBorrowingsNetOfCosts",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, net of costs",
        "documentation": "Proceeds from borrowings, net of costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from sale of PNAi technology",
        "verboseLabel": "Proceeds received from the disposal of business",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "vera_ProceedsFromIssuanceOfCommonStockFollowOnOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockFollowOnOffering",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock follow on offering.",
        "label": "Proceeds From Issuance Of Common Stock Follow On Offering",
        "terseLabel": "Proceeds from issuance of Class A common stock in follow-on offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised, Total",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "vera_ProceedsFromSaleOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of marketable securities",
        "label": "Proceeds From Sale of Marketable Securities",
        "documentation": "Proceeds from sale of marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r528",
      "r537",
      "r713"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease",
        "documentation": "Information by property that could be leased or is available for lease."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease",
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r323",
      "r341",
      "r371",
      "r372",
      "r373",
      "r485",
      "r509",
      "r547",
      "r586",
      "r587",
      "r650",
      "r654",
      "r656",
      "r657",
      "r667",
      "r685",
      "r686",
      "r697",
      "r706",
      "r710",
      "r714",
      "r717",
      "r859",
      "r865",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r323",
      "r341",
      "r371",
      "r372",
      "r373",
      "r485",
      "r509",
      "r547",
      "r586",
      "r587",
      "r650",
      "r654",
      "r656",
      "r657",
      "r667",
      "r685",
      "r686",
      "r697",
      "r706",
      "r710",
      "r714",
      "r717",
      "r859",
      "r865",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915"
     ]
    },
    "vera_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "documentation": "Recently issued accounting pronouncements not yet adopted."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r744",
      "r754",
      "r780"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "vera_ReductionInContingentFutureDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ReductionInContingentFutureDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction In Contingent Future Development",
        "label": "Reduction In Contingent Future Development",
        "terseLabel": "Reduction in contingent future development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r471",
      "r472",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r613",
      "r615",
      "r648"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r471",
      "r472",
      "r473",
      "r474",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r613",
      "r615",
      "r648"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r471",
      "r472",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r613",
      "r615",
      "r648",
      "r907"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureRelatedPartyTransactions1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r472",
      "r475",
      "r562",
      "r563",
      "r564",
      "r623",
      "r624",
      "r625",
      "r645",
      "r647"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172",
      "r288",
      "r308",
      "r474",
      "r691",
      "r692"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r390",
      "r916"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "vera_ResearchContractsCostsAndAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ResearchContractsCostsAndAccrualsPolicyTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research contracts costs and accruals.",
        "label": "Research Contracts Costs And Accruals [Policy Text Block]",
        "terseLabel": "Research Contract Costs And Accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research [Member]",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r745",
      "r755",
      "r781"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r782"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r753",
      "r763",
      "r789"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "vera_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash [Member]",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r817",
      "r827"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units R S U [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Related Activities",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r261",
      "r264",
      "r269"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r267"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring Reserve, Total",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Restructuring liability",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r265"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Restructuring liability, current",
        "verboseLabel": "Restructuring lease liability",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r860",
      "r861"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r97",
      "r535",
      "r551",
      "r553",
      "r560",
      "r597",
      "r713"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r186",
      "r246",
      "r247",
      "r380",
      "r381",
      "r382",
      "r411",
      "r412",
      "r426",
      "r428",
      "r429",
      "r431",
      "r434",
      "r548",
      "r550",
      "r565",
      "r924"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility [Member]",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock net consideration received on the transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "vera_ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accrued And Other Current Liabilities",
        "label": "Schedule Of Accrued And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses And Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Dilutive Shares Excluded From Computation of Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Notes Payable",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Provision for Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Share-based Payment Arrangement, Expensed and Capitalized, Amount",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income (Loss) Before Provision for Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Principal Installments Due",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r621",
      "r622",
      "r625"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r268"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]",
        "terseLabel": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Table]",
        "terseLabel": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r95",
      "r96",
      "r97",
      "r143",
      "r144",
      "r145",
      "r202",
      "r306",
      "r307",
      "r308",
      "r310",
      "r313",
      "r318",
      "r320",
      "r556",
      "r557",
      "r558",
      "r559",
      "r706",
      "r807",
      "r828"
     ]
    },
    "us-gaap_SecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail": {
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collateralized note ,Amount",
        "label": "Secured Debt",
        "totalLabel": "Secured Debt, Total",
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r112",
      "r919"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "vera_SeriesCRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C [Member]",
        "verboseLabel": "Series C [Member]",
        "documentation": "Series C Redeemable Convertible Preferred Stock",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Share based compensation arrangement by share based payment award, Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Cancelled and forfeited",
        "negatedLabel": "Cancelled and forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Cancelled and Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested as of December 31, 2023",
        "periodStartLabel": "Unvested as of December 31, 2022",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant Date Fair Value, Beginning Balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance",
        "terseLabel": "Weighted average Grant date fair value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Share purchases funded through payroll deductions for employee's eligible maximum annual compensation, percentage",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award minimum employee subscription rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Employee Subscription Rate",
        "terseLabel": "Share purchases funded through payroll deductions for employee's eligible minimum annual compensation, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, Number of shares available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Number of Options, Options exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Options exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Share based compensation arrangement by share based payment award, Options exercised in period, Total intrinsic value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Class A common stock pursuant to exercise of options",
        "terseLabel": "Number of options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share based compensation arrangement by share based payment award, Options granted in period, Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Intrinsic Value, Vested and expected to vest",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Number of Options, Vested and expected to vest",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Vested and expected to vest",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "vera_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedSharesOfFullyIssuedAndOutstandingCommonStock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Restricted Shares Of Fully Issued And Outstanding Common Stock",
        "label": "Share based Compensation Arrangement By Share based Payment Award Restricted Shares Of Fully Issued And Outstanding Common Stock",
        "terseLabel": "Share based compensation arrangement by share based payment award, Restricted shares of fully issued and outstanding common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued under share based payment arrangement",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementRestrictedStockAndRestrictedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "vera_ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment arrangement options non vested weighted average remaining contractual term.",
        "label": "Share Based Compensation By Share Based Payment Arrangement Options Non Vested Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment award non vested options outstanding aggregate intrinsic value.",
        "label": "Share Based Compensation By Share Based Payment Award Non Vested Options Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedPaymentOptionsNonVestedForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment options non vested forfeitures in period weighted average exercise price.",
        "label": "Share Based Compensation By Share Based Payment Options Non Vested Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Cancelled and forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "vera_ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation by share based payment options non vested weighted average exercise price.",
        "label": "Share Based Compensation By Share Based Payment Options Non Vested Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price Ending balance",
        "periodStartLabel": "Weighted average exercise price Opening balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r349",
      "r368",
      "r369",
      "r370",
      "r371",
      "r374",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedPaymentArrangementExpensedAndCapitalizedAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Nonemployees [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r346",
      "r347",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic Value, Options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Options, Ending",
        "periodStartLabel": "Number of Options, Beginning",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Number of Options, Cancelled and forfeited",
        "documentation": "Number of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock Percent of Fair Market Value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r143",
      "r144",
      "r145",
      "r166",
      "r190",
      "r191",
      "r193",
      "r195",
      "r202",
      "r203",
      "r245",
      "r276",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r306",
      "r307",
      "r310",
      "r313",
      "r320",
      "r440",
      "r556",
      "r557",
      "r558",
      "r559",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r596",
      "r617",
      "r641",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r807",
      "r828",
      "r835"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r27",
      "r137",
      "r154",
      "r155",
      "r156",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r186",
      "r201",
      "r246",
      "r247",
      "r321",
      "r380",
      "r381",
      "r382",
      "r411",
      "r412",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r467",
      "r548",
      "r549",
      "r550",
      "r565",
      "r641"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOtherFinancialStatementInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r201",
      "r510",
      "r554",
      "r576",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r619",
      "r620",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r718"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheetsParenthetical",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r201",
      "r510",
      "r554",
      "r576",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r619",
      "r620",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r641",
      "r718"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r748",
      "r758",
      "r784"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock in payment of licensing fees",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Class B common stock into Class A common stock, Shares",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r26",
      "r45",
      "r97",
      "r295"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock pursuant to employee stock purchase plan",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r73",
      "r97"
     ]
    },
    "vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquity": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesLicensingPaymentsInEquity",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares licensing payments in equity.",
        "label": "Stock Issued During Period Shares licensing Payments in Equity",
        "verboseLabel": "Company shares issued",
        "terseLabel": "Issuance of common stock for payment of licensing fees, net of offering costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "vera_StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Company shares issued",
        "documentation": "Stock Issued During Period Shares Licensing Payments In Equity (value)",
        "label": "Stock Issued During Period Shares Licensing Payments In Equity (value)",
        "terseLabel": "Issuance of common stock for payment of licensing fees in equity, net of offering cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock shares issued during the period new issues shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r73",
      "r97",
      "r556",
      "r641",
      "r679"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock upon vesting of restricted stock units, shares",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r73",
      "r97"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r73",
      "r97",
      "r355"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock pursuant to employee stock purchase plan, value",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r72",
      "r73",
      "r97"
     ]
    },
    "vera_StockIssuedDuringPeriodValueLicensingPaymentsInEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "StockIssuedDuringPeriodValueLicensingPaymentsInEquity",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value licensing payments in equity.",
        "label": "Stock Issued During Period Value Licensing Payments in Equity",
        "terseLabel": "Issuance of common stock for payment of licensing fees in equity, net of offering cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A common stock pursuant to exercise of options, value",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r27",
      "r97"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets",
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending Balance, Value",
        "periodStartLabel": "Beginning Balance, Value",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r76",
      "r77",
      "r91",
      "r598",
      "r614",
      "r642",
      "r643",
      "r713",
      "r724",
      "r830",
      "r855",
      "r902",
      "r924"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r165",
      "r305",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r321",
      "r433",
      "r644",
      "r646",
      "r683"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLeasesScheduleOfLeaseCostDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Income",
        "negatedLabel": "Sublease income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r712"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Relating to Gross Amount of Unrecognized Tax Benefits",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r102",
      "r103"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward amount",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "vera_TaxYear2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TaxYear2032Member",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2032 [Member]",
        "label": "Tax Year 2032 [Member]",
        "documentation": "Tax year 2032."
       }
      }
     },
     "auth_ref": []
    },
    "vera_TaxYear2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TaxYear2036Member",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2036 [Member]",
        "label": "Tax Year 2036 [Member]",
        "documentation": "Tax year 2036."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance, Temporary Equity Value",
        "periodStartLabel": "Beginning Balance, Temporary Equity Value",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r387",
      "r533"
     ]
    },
    "vera_TemporaryEquityIssuePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TemporaryEquityIssuePricePerShare",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Temporary equity purchase price per share",
        "documentation": "Temporary Equity Issue Price Per Share.",
        "label": "Temporary Equity Issue Price Per Share",
        "terseLabel": "Temporary equity purchase price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balance, Temporary Equity , shares",
        "periodStartLabel": "Beginning Balance, Temporary Equity, shares",
        "terseLabel": "Temporary equity shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series C redeemable convertible preferred stock, net of issuance cost of $389",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Temporary equity shares issued during the period value",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "vera_TemporaryEquityStockSharesIssuedDuringThePeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TemporaryEquityStockSharesIssuedDuringThePeriodShares",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock shares issued during the period shares.",
        "label": "Temporary Equity Stock Shares Issued During the Period Shares",
        "terseLabel": "Initial fee paid as consideration"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNonmarketableEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Non-marketable Equity Securities",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureNeubaseAssetSaleAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r301",
      "r318",
      "r432",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r540",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r850",
      "r851",
      "r852",
      "r853"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "vera_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trd Arr Expiration Date",
        "documentation": "Trading arrangement expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "vera_TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Seventeen And Two Thousand And Twenty One Amended Equity incentive Plan.",
        "label": "Two Thousand And Seventeen And Two Thousand And Twenty One Amended Equity incentive Plan [Member]",
        "terseLabel": "2017 and 2021 Amended Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationSummaryOfShareBasedCompensationArrangementsByShareBasedPaymentAwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and seventeen eip and two thousand and twenty one eip.",
        "label": "Two Thousand And Seventeen EIP And Two Thousand And Twenty One EIP [Member]",
        "terseLabel": "2017 EIP And 2021 EIP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty One Equity Incentive Plan [Member]",
        "label": "Two Thousand and Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vera_TwoThousandTwentyTwoAtmFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "TwoThousandTwentyTwoAtmFacilityMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two ATM facility.",
        "label": "Two Thousand Twenty Two ATM facility [Member]",
        "terseLabel": "2022 ATM facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureRestructuringAndRelatedActivitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r266",
      "r267"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Agencies Debt Securities [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r693",
      "r707",
      "r917"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureCashEquivalentsAndMarketableSecuritiesSummarizesTheUnrealizedGainsAndLossesInFairValueOfTheCompanysInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Government Bonds [Member]",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Less: Debt issuance costs",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "vera_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions.",
        "label": "Underwriting Discounts and Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain(loss) on marketable securities",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r392",
      "r399"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decreases based on tax positions related to prior year",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest or penalty accruals associated with uncertain tax benefits",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatingToGrossAmountOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to prior year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "vera_UnvestedRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "UnvestedRestrictedStockAwardsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock awards",
        "label": "Unvested Restricted Stock Awards [Member]",
        "terseLabel": "Unvested Restricted Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "vera_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Unvested Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "vera_UnvestedStockOptionsAndRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "UnvestedStockOptionsAndRestrictedStockAwardsMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Stock Options And Restricted Stock Awards [Member]",
        "label": "Unvested Stock Options And Restricted Stock Awards [Member]",
        "documentation": "Unvested Stock Options And Restricted Stock Awards."
       }
      }
     },
     "auth_ref": []
    },
    "vera_UnvestedStockOptionsAndRestrictedStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "UnvestedStockOptionsAndRestrictedStockUnitMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested stock options and restricted stock unit.",
        "label": "Unvested Stock Options And Restricted Stock Unit [Member]",
        "terseLabel": "Unvested Stock Options And Restricted Stock Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r126",
      "r127",
      "r129",
      "r130"
     ]
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceLineItems",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceTable",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfProvisionForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Table]",
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableAdditionalInformationDetail",
      "http://veratx.com/20231231/taxonomy/role/DisclosureNotePayableScheduleOfNotesPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/Role_DisclosureStockCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r195"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r195"
     ]
    },
    "vera_WriteOffOfDeferredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "WriteOffOfDeferredCost",
     "crdr": "debit",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred costs, written off",
        "label": "Write-off of Deferred Cost",
        "documentation": "Write-off of deferred cost."
       }
      }
     },
     "auth_ref": []
    },
    "vera_YaleLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://veratx.com/20231231",
     "localname": "YaleLicenseAgreementMember",
     "presentation": [
      "http://veratx.com/20231231/taxonomy/role/DisclosureLicensesAndCollaborationsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yale License Agreement Member",
        "label": "Yale License Agreement [Member]",
        "terseLabel": "Yale License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-8A"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-4"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>107
<FILENAME>0000950170-24-036729-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-036729-xbrl.zip
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M\D[1A"+<AZ]H=W1I(6<X0')M-?Y)^ZGB>*4/RBH8)I_=*ENLNW1]$":\+>%
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M,N?;SC-S+#XUP<3HCM0$E3N^BGE3H#XZ2!LI_GGQR3T;2H__'W<:MG#V^XD
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M"<%I1(2%0OT>@;A?6GF6^TP80H]>RIDZK1^19%E T:=G.AP4(X2>># -QB,
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M/%^."?XH"7;PPB-QL!G;'[E#67_IW-.8]//WW+R\";JG%:,"IN-. Y?BKF&
M<C0(;-VV:T1AJA?0H*>AR=A4Q$ XBG.#'?M+M<4CL_L0]4SIA ,6.BXL/-'8
MX K:VZ3<WTU#NY[1(.S%QZ[ND!S3QQW]8N.01G%I]WE(F,7=^.>8V9GV^*QR
MVC%1T8>;;:H*/%A<I-_C8@[LH3;1*[+\%5N5;CCKB7^][_/;6VEVO(G"#/AK
MND2J/GW''7R+.T4$D/"Y30^RQ29S*0Z*X6.&F JPL;J4C!22&772XTQ=#$8S
M=\_'% 2*FD:^83#C>LY(2>?0C%-STG:T"[H8-]HU* P ;RB,M>W/6>[0J?*=
M))=!UMKH"\/>-WA\F%ZUC2>KY[Y[X:MJ]+/,>IFP9AEW/[G.D$"OZ7/G W,2
MID,'3W02?L*+TC;B'M[@5@Z>?,F7E\XN/.OOI$\S6V(=G'M<Z9EAY6-[PM-+
M%#%+UZ:O*8=P-QHD.?P5:U#YI?F24VU)E%>)?TX/&Q 03"3U5\CZ$\*T=OCZ
M+G5481@.RY3<]O0SSUKJHV5/4\5J"9-,&5])IT,XJC.)7=2@)RX;GC'YE^ J
M7,>'KKT"392]8OLR-U_:T*=TM*>$BT [)^?T6U47L=?<H*L_,U:6=^2,KNDO
MG4?F)D!78Z6')G 5Q?MN)N2WFHO$<D2C>=VWMPM][R$6%H4,YO4V48D$5R-H
MHALF-9ZM37DP'96Q=U\59G1MK:A\5JD^2"L^>@4@*6O52>3: :Q@?-Z986*:
MS&.2GC+Q+'Y!2*<GQ1"'GJJN%GI8K>K5\W:3N!8VZKK8UR!*RF!AEF<5=4*X
M.IV1.M6]L)H4F_IY<=/I@?,!Y/D9"!OF--%-SR,N-9G @C9TG4C3JA$PW6*R
M^N3WBJ;^1<,G",<9"&=O>HD:%L0]G6<H:I+@L<&HS*'BVJ<+'-UYYRQ8@G%-
MQ@_G\@*Q1]GC\-(JP=.)J].Y]!'0 @2@;HIA6\Z::/\BO3C@>A(!$+NJO+18
M_=Y6&3=@R]WYP2G?.90Y>[M& RJ</#_3B:_Z*O;>].Q7)9(<!C,%7(A5X.[H
M0$AJO/>'[%]G#H1AU*;=]>4420+L0E$VQR%+''6V_#=ON5ED&90)"1JZ.%'Z
MUH_5[T1/I J#:_ 5NG1)]+"5!DE932K0B<3NK$$TUF.PLYYDMU1:IU??,IX+
MC^,F.+TBE)&ZQ^=SD2",TE#T7C&0WGQ@DFJY^=J7R@F<[IQ! L5KY8&6NHND
M5D/UF"7=DD^*V)YXLH!\9N1.U"??P-!>5*EC!;[)Z3^NX<L<KVE%4ML!Z2HD
M@Y]  #M=R/%"&FMGT\(0N'<HE^KSPL^$TOBC:SD&%B(PX71+:S-G.^A4&[*B
M8W2#J],XVH%!JJ;T7I[T-<I_4S"B#*-AFAJ0<OLRE7]?E<\R8<N)1/^'3E48
MWBB&J38D"X0II7^Z(2+@Z&%F,^-H)V-&IS]'64$ V#DQ1K2Y X-]Z#%?X)=\
MF9,S);"NGN\P.=6ZIM2AH^#QSYUY 7R]SOU"&Q27XBE=L=3Y&Z^K]/H8+6FW
M32LSOJF6$^"[KZ_%!M?0:(I 7Y2*G1;4G0EG&O.S5S*%9/88,*M/<:]*4]T?
MG)8:ZWC,!BI1#2^FQJX;W7G]P17537W!NEJOV&[+HX.'9J6-P;8DAPLA2Q)N
MY=O_<8M,17:937E;F#2>56.P#%5/CB*!%Z:Q X3@I2.2&JJ=+%)XM=85_7Y"
M\GD&74#@'8GGCA@=9T&*PE=]&%W!@AZCYWJM\ABF-H<>@_=*:@_,=MV64V:\
MW&7(4+OV/5\2:- <DP&U$%@YN1D5$!^_1 "K;;'@*O(CE6BI=+)UD[B3.KF8
M7U(MG#KKQLSZ.QO^RTV)Z#%SI9Q;]N%@DN27_*S"F^L8<WX'5@/FY\=Z"(#:
MGX+ZB6&@"-IN_ L#G#9HV;(F5->FSJOYU)!&5M*A_H&03(/6!:U)OAF,9$+C
MQ/CEZLQ4N6UUT<PA2?BPWB@;:ZVW3O$L9("G!@%\%X?L9.L3=O!>X^TM7^R"
MX&%*;D]<HV@RP^@%(EQNYUC>=+[(N\N?O-!&"UK4*;N3.<%;HH66U@D7VB[^
M8@QI:U35@ $V0]*\D/Z=S(N]S.FFBLAY_9N4H.#:'8/2K;=S.N6+9*Q03$&4
M#IA[)[5.^+FGD)1S]YBL+Z?(IX3%@DUFV%?'$=8:&Q_V$[(-W<DE^L9Z@84?
M54]5[&8')]%V%%17WQC2!K4_W(F\.9AYO4><N,61W!73X\"'?!'XQN.\=R^N
M=.TB7#_45E;>OD@)E=_>Q-&QW A4->1[H;19HU2AL^9[1ZWBJ5-'88]G1X#%
M.Y/Q^Z473]A*Q!WSZ@CQ@#.$;C'%C>3!?/"[8+N-L^GZ>@2P4=^# -ZK&<Y\
M:[_R$KJOEN-_:<ME*:7"B'8];J*8X$.J9:"CV1D CTG'O-626^OD]'GFGX1^
MG[I<A "LOA&&T;-\AY97>0B9>Y@D\W+5/UUX0Q],X&L=&WVQ;T\$&[Q5F/"L
M4:-5:RK_W:&J[_?XSWB <VWF+EP8 5Q<$<+]+W0ZQ+^/PDD6K>7=*:FUM:06
M) F'2^]T&6"HLS&A>P\10(R4!4SG>:(>3,2]L"M67/M3+Z$;.A&8[P^R; <W
M"X&[O>^?(@#]23MJ-B5,JP$>3P"M'= 0$JUHI?#H))TX-DL=?O;VF9U'@F2<
M9LR7?LFIS-!6SN_0ZL:8S-(OW,'#I;2]KV9>RZIC,GWSZ%(W L&FQ_&)Z37?
M3"^)<.A()KP)&L7+:/W4,[HOS=?L+OUPW$RM@1XJON'&QT<6L1H;ENA1UQEG
ML&0]\2Q 5X+3!>C-HB\E+#XOJX@:Y:X(.O=V%7M3GH32*TK\I#QV%7(7GFIQ
M.X2DA>H[TH49=RR3=H?-&L))VP*Z P^3/V9^XL_ .C\"4R?VW5QL-:P+0C=$
MEDTK(^4C9EM[>#RY^J0>.&KZ42 15L[^9EM(;MV GXYW[=D/Z['G\V:3)7Q\
M&^1/'QR 7CLCLRMH+19_MY4X<D(=NAT^O>;X> Y=!TN?UO3)K)>O3?D)?;6/
M/%3;X*F6D=!=_B>4WHLOLO"W=S8)T\@N:V@%[7:IM[M@U[_KYZ%F"%I,DKPU
M;BQS^LD)"G0J%7::*PUE]QOA*E!X.<&^$0=. IPAA,V4/EH%B[Z-EQXN18\Z
M%SH=MY046>XQM!S=H3-]@[:V+L>65+BH#BP134]VXR1N(F=A[]>Y>>4FRJL/
MM2%5G(-;/9SL'(OO8C -DV++] G#0<1C+K._RS;8B8SS_ []SC)EIS_38?9V
MXC52'?Z W!>JR4,W]NEQ7IK?:M5[CUF:AS('D5IFQ=7?X*2LO^M.I3Q71@"7
MZ>[4.G>)HI #9%*ZX2XF+.ZYHYZVV[8YY+<R5/%8?YM#X/P],1"S<JV!VUBB
M!Y8-(4]8,CBXLB5])<K0AHGL/78^9 @@;BD; 1B6()VF!;XNYX/,:D'RD>FR
M A?&!,':]5JL$SGY/>ANV5&;3:.D?:0JU.7#.9$]68-OUZF?YZ[KW7G@;_K@
M'0%8_+)%%2Y+L7QQR OWM^F#XT/Z!XH@,Q7P87:\+1_5U867N+UH"K4)BG7<
M1(NPWV?Q&4D'NA:!YP@ <R=UT4W@)5M]72+D:\R3L +.(>G'YA-KHAGR$L(=
M;%? V5VT5UE;9'4%J65JU:ZS9(96=<8[RSFWA+ 817 ('O&V$<:4CM'DSZ*1
M.6_"RY[W-1<%3>LJ;; 7%>5KU6]97A:G*<BVZ[M1GI,U02V8#2>A_'X#[1?7
M/:K@"$G.-2DW;U52F*_@P 3;S%,W[F;:][5%=\/R?"Z"/NRK-#9@XL?YJYED
M'3P992E5'>:F1Y2F?NB1%SC76[AZ'M*,\[*K-,5'[Q_VJC\5HQ,)=.#/LDAS
MJ<@NYLO*B63'0V9HX!\E''^M(*AIUB* ?<5Q_S^;=")QBAWAU?<<O_]E0>$3
M=KR:/&FW\9X?$11>Y373&)."WS/(IL$L$"BS(\J@)0_S725[U_6TKE\,))%Y
MG]JHRX;:DA22\=6.^\#6N#;8^<>C]I'BBY(_:X'OEV "7;H?>_5:R*<V6!]]
M(AU  /[Q>I]>8W!+*$ZX>,Q+B??B:MFW;)9CWV04E ZAZSQI%NA.Z%['B\E.
M"JL7>D2*,D*(ZJ%E<18:8M,VL]6WF:9][JA(RHFGEN?(-E\4Y8^9A9HI#YCL
M&I*.NDCD.A=8Q>N]TGGO8LYJ7\@R_G)5ZH&OT:VN 3]KVQEZAJ?Y\.KHNN@]
MISGR/207YUG=_"Z<$^+4; AR\(U1HJ(C1->:9T/-2,F;M:R%F$[8JL\O.]IS
M8S.S%F^D%F*&N'#:ZN^-6L7E7[LYBW*G#TVNBQYY:_>0HLAICPD.N?UFF.(:
MWV-;\.),>.+KP90W4=U$Q]3QP>76-' *FY,D069@8$_567LG"P\3JABR='SX
M,GN>JBIM)2#SRCEVO%":;!12,Z,-_Q5L5/+@[:?O# $!_@3BCN.U;%DX,_.^
M&<4?;"L.C>N#TS[%.PGL'VH*MN%8BG./S+O\YL&U@NK\4N_V][IXC+P;[[=.
MUXU"/:FUEPN%O(>V@QSAAX_4WY"\92/5:U8XUO92*TZ)F2;L%PJ00*"*?B&U
M[Q0)9)-'%'3DIC-Q"AI(%LO98<_+BC&+C>RK[=+3C0N"1&XY.B6,).C->TV:
MZ,03=5U>8W@OT+Q4F"JKL%VO#X"?._'(E@[R8GHXO_*DGU"LC<A3_[@L0$L<
MB,*R'C1?B[2XA;DK53I@"SFT?J-HM0VPS/YR-Q'=4RW.F_(1RK&Q^V'M94K!
MS];NUO_!RY3(1CL2^!74U2A5FR+]Y4$FGIL  B@+<4*[?^6\,)VB!(4G9I66
MY+_ILW[$T$_\^:CO5=[-=!+2"QIC@BU69$*<6#R!']GC/4%/Q<CT7D++ W)_
M/9XX_VKYB(X6]9=T2$3?JAZ2"]O<2T]H_DCX>8.1,?_"/CH"Y;OS0FJ0\NCY
M$ XVX_C!^#0[C?,W<C'IYD1=TM</!#,>CII-(8":S!<1-81/5+:3/QS3G:3Y
M)57)DZ+07D)_RT#UGR4^7<>GC4IZ?\1)/]+12C-QU#-5'FU+N[(AC?ONQE\9
MM0[IFW2!+NK'4>Z/EKX6*MI*1FK]IHIX]\IQ0&HW=I4;]>6[O>/\;E<TUE2+
MQ;GE_8_KYV6I;*@Q);E6\YO?%JR3(UQQZN/5!@!AK!%T-]:S8L%#X4&E'RI2
MTK]M#^,2*HM94+TN6*:^L:&1W'; :2>/AJ:V8FVY-C9:<1)\7V$-"1]W^%&W
M6J9N*]0ZXV"M]V[B9"5^9*<; $?;C<G@/WNSKC3ZGOAIT3E:P"LD4/Q#=PT5
ME=N6'7//XQ8Q9U#<CO5G?X(_R,_Q%^M: 6%7M[X?+:O;EC(")1]H;^8GE874
MUU751BX1CS')Y!3F^+/O-0;K:L=[%KW0&:P+R9-HI"7 7', 4Y\2!I.C(H#N
ME,8J-DY;*MR =G?P"N&VX>3.#T9%>5<IK5#9._;*+E*&\.R8)U[!,@UW12@7
M0:XKF7B&^C11T213^:PL_H.)Y^H8]FHR9 >EW(+[CO9FMF3-S#G/ZD'W7B7?
M8!"E&52(U2[4@)12?240<Y+(YCFRJ^3O>!E&/.PK>"N/9' = F<F,RQ3!HJ=
MAJ"I0H'E7?*)YUZM.(D7' HV2)3)+=B9-X^F42R8[; NNVJNV;A7U=!R5<79
MT?T]_AL9]#H"WX()#MI#SE<B9W/\.0UV+U-N?)(I7G/5_N#I"T] ,7HE]FU>
M(2!OAYW#2IMOOC2/"E6 KMME[Z65F@SE#/W#49X+HT.5:!YVWKJ2ZYZO$F%R
M,W1AUE4E.U[F+>@.>[56KJ2J+62#^&4?+0(EM$-(4?14)PX%2]@.#AC><.?>
MQA>S\&X/F1MYB'1Y)0W4-XV5F7Y.2P'*55O'!9 @C4[N)ISJ^F/AK9Z\/<XI
MB5![\4Z./PV+XQ"-(@=7_/<NYB*&6 <;5%54#^VWS=NC9>X7ZPZ@.-'RT$@@
M<'QXOO.W[<'A6EV(%\MS4FU;!!!<C:_Q^M;W,H7T"L)[_/8S**50+N8/%@]-
MW8'S]M=X#VTHC^YRGMN;TSC/9)/9#?]<>%45.3Q.%KI$MD!KK8PC)5:\DX63
M&I/TOD3OFCHD382/X&E_0]_H!2A$?<*'/<OR[/K&+]$>O2O/G_S].=<K, [R
MI3(VU-2UU'E[_PD]2LN-U^W36K%!=V(%OR;>[ER.*;4'SG(Y>(@.B-YQVD4"
M ^/-?#F6S@/2*87R-EQ1-7-4,8KZ3B_YC; M'^XMS__8=12"G[!FO*VJ=Q$=
MEB"8JI('U"?/?45T_>6*Y^1<*<509?NENYTX@@WQH8OD G/RN0O<S2O8FG:#
M_G(H36*],E+>VIND*"HJXUR"*N ?5K4EMO;-;<EY\?7KK F^&&J3DJ#5W]H[
MOXVLR"=>O7J15LRZC&[^!T '[B1R%W?9\U\6=D]CR>KYQ&4%9?0)":<@<]BC
MS#G!!<W:NB6CP:=*BXZ) ]*!Y6,R5+J%H2Y2UJHBZN.'1RSP6U3*>R6&U,07
MHX+1I,0%N].7W1_)Y:_#SP<&RJC_!F/<(IQQ:J$Q2L -5![\<H*KVIOTQT39
M]-(<MEFT,@.)DU>"UU0C&QKU8*<7P==BY/#F[6Z\G'>RM%/5PS/?HT+:C>FA
M__[$Q/_+$Q1_1-[1UMX33=89W;G[M_HS/,(5FP=& $S=@O=QR(<W-Q1&HT(N
M+J\?R,>&5.,+RR>,*%5'S!S5I=3'9HOUJ)3 (,HSR8^F/I@T$I.8$/P23D1&
M:[X\(&MF85OX5L["@BAT'F/N7P)VJTJ($,O#72MMQ#=W085=C#<P+],WS[RV
M* O'RRVQT(KH<_4^F^WK"^(_!*CPY-M-6YB@KV>.K7:G1"X1$_]!EYW7.5,-
MD@+LOK>A3VOTDLD9,B8*_^% A&=[L:OI$HNWDXK^8S#?:DQW@"/83<&D0;:?
M-E%W\O4#X>)5*4S=)@K=Y"]DOU:?VKN]<Q GP"K+F#U$9JP YY58W*57%IG/
M:JRP!SBHG/PB9<J\.7&EA!?U9A?D[;'$YDA6+&:62I$HT]7I!4P_*!?L;ZM&
MS[#,=+: E O$CM=:YOCSU1!BP;RU&F^U+N-M!3<V^F7555NQ1M9?-$/MPWA_
M@:W'#C/[7\:C-#PM=_8GC5S,\6?;TQ5.+WU3EIQKF4+>_W.0A@1@>$>/)85=
M:-6H%1-MCL1@L[HZ]._1RLRL%>K6R)X27PS3>SIM=N9*Q[&TIC'5S]&WIQEH
M[2OP=+Q:B[-@%ZI[1/F(8HMY,</F*1*:2RQ3S9OL::GS4PWD::[#RY6ZWGV$
M*AI;VTJH5H]_R*V:6-'S]H!O6"NCG0V]11I0?8QM22U_M>!RS\/IG4:\Q<DG
M*N65P'$/_VKR;>$^ SY.\[DJ[D>Y@V^L&DP+F5=Q1CK\J":V'\[OU!:SB>')
M^H!@Q$Q5TFQQTO36S^(>['@A@!G-\L[4D[PB]6<Z&E,&LIA0093-3%S!:%Y]
M:,B&>'2:B&/9DJ;H;1NOL1C93JIV4-Y.^&"!%=*.U4BTQ O6QQ6*I*^+W^3$
M//%D)&6[9S]'22F!.2O._&+5^AZSTTFIV/+9=EA@-%;V6JO_P/;]1$^PP[=Y
MK%]/&5X)$W_T.B]!<I57B:N^#V6_;(Y7[Y29QKL),//UGV^D6MPQ>6%>MB,Y
M3!43?)3$,\=W*!U>/PQ^/O<'TJVX5&FC&NB>_\A8^4C\UDLGY%R*8'5[_'RV
MS.Q?2AAV'! JDP?,]UI!XT+M01H3JXUSG2GHQ+! ?&I(6'4TQ[2-#;XTIX>%
MP8]O%MN4?2QIYT+(+F&Z*TTY)LB^\55E(J<F07[VX&,?LU@?RU@QS.CI=#[2
MJSQ+:ZK'<5JQDX'89=9L:!(O1EW229],N.QPN^/]P:>;#!N%OVN7\O^Q%"/3
MT71LOKSZ I):@IX#=?*DZFS_U5F%O]U#&;5F_W#60^_EK<$NU_#S+AS?79J%
MA<F9M-@(.%>;3N-$-9;N$/:B3S%+WQT6$?AY'^RK.T_)^IDQ#380L_3$"]5!
M^6[(.S3=[$%*X<*<;I82@TQDEDDAI+B >UBD T+"???21?"VR='*3Y:-[$?"
M>KD48<WKD^W8&@B>1R@G+N6')?(0T\>6<U]9XN?"\HUB5WT_TK-1'U"G=ZLC
MAP'D&!%N:+^=9^@@XJMP7DC_+N:]5R$\>!*M)=8^(JJ+)J,T*\T[TM>9GO-$
MWY (.DE11I1JY=:#_F$6;\%YX!PPKR^ZLUF_=A%8(ZW\;LOBW.US."PP(SKB
MI4TWHI_3T(;ET0@BM53U.\'U?/?([J$8CLRP[#E3/<P'LI9)NN=.OO1PHDR;
M4N'P"L3'F8;J/"']Z0V/5SY9NX=JKR%#\\Q7A9,'L2SJFTEVQ@%):&S#V+U/
M9%:VLDXPN_$UX"3.J\OX;WJDUNJ2QU_V\WZ,P\RZ^.MY(;(M8;C 249LN9S)
M&C>I*EZ(NXJ%79\E*Q6&$X%$D&'Z3/RX/\X9G?=:4]\WX?350TG#_G*-(9^X
M PF.&*6K(2_-G?&%E]1I KT_";,9(J^7N[S2EE!. E+4*]V3R2Q-Y;I6UK?4
M_3Z-?IEIZSXFW9GAB_:6B6%;A+;J=7:[=QC+5JB.7=@8.#\/4OOA-/JB@6JE
M^(BPOIS_N,</\Z0EV,LMUYT+QY2@A,?8[/W.8LQ%B6LA"-.#Y I.[#8H]S7O
M;&$8/\VN[\5' C:TTIQZH] EOK8338K=XNH':[\_%2;2C\3%K._A.RT]AN66
MSWHDP&=>V*A6Z@UNEL-$Z$4EMQL>) 5N5T[JJ$L*.P]28HP+FZ%;L.!%=D])
M*G!+8K.&,RXTSW-5!O*+?*<UV<_\6>D'@J48GI G%NV)YRY<.]+%>;X^&$1)
M\#H5)^P,B/-@[I5FG+D8X!;2P[(]G"9WV$7+YL):Y^IV+X\R.,F(6%T(J6EI
M>'QX>5@7[2Y-"57-NIFA6%D&>7SM3HV^2#NT85:T/.TL)A@WI5S(\'+6QXQB
MG=D^$5>IZ*#5+>__'IZ%9[&Y\G I/<1YETSB$T@M57?#AQFR5A!Y8T2NUV%C
MCV<Y*IZE%OO5490U"U>_RD?^A#>\QO/#W:."3I-HE0=?1"K5%C?\!6;5OQ]Y
MM7A6>2  '1 Q EBE/_T [[M<9G9/7C)?O#GJA>!DMB, 8AZAWVKGML9S#&TH
MM9(F*)'WF\R5Y;AO6N&_8'6N7HR>OZ@#'$E<G0@!7ZO9EQD(0-/U:_&!B\I"
MDRFAY).JWF 2*O^5=TXVOX2,0![[LO6AZUICAV6'K."FB-S]99J._<AS-A^9
MQMC S9G2!UV78JS1^A8FWQ*#]@/9";8(_>]TRF&11Z?<AKV<+I%"EC^?[B:\
M(EQZW)1ZMAP*%YQNUO'U)BAAP8OK+<W0U!-CI:\)$NG!=QOL24GFE\.8*M48
M('TM3\#B1$!J-R2!L_U=S5"BZ$[^I#6LZ)FK[^.E>2IILX"UWLWC,/29@@58
MX$][O(+6 ^,J8;BWW5XN;:QS!OL;=R'+"N9:6,@Z+XFU!F^88!%^L_XGCRNB
MECH^!E3?;\T(@-1'R77?YJ&-O6GGL] M*L;%CK/0CA%4I(/FD)1*[F_WA9"Z
M@G1K'.$E)]]RBVZF2F(OC*+1.)"8A_6/G'KZGRF5_\XGBVV]1%;57L(;6JOQ
MS$C59 (CV;)0_Y<7#K'"R'EFKM,\QYC2;=2 ?%_B1V2#UO3"U<&??H24T]P>
MGE; 4K>W3X1KBL24\DTQ80RJIS;LVI$25BN<JCHY9U*,Z1K'/RHFU[XIEUB-
MT2K[VA4NR1IZ-#ZN\G%7I@V3VH:<E"BOW*Y?;0: 2:REFG:BIU$38 5N;0N-
MJO?H99#CE6*3*9?K5\RM=2:'#.6L<**%S.N[,#A,B 8F#2-,?@,Z84JI37EW
MDPS*&WFFK7-;6G8NEE_!9TNA^UTB)T8M!JH,)^-NB[@HP<3F*EUQ_.&R?6>=
MY#KUD*NF;75 8-RRW+"K=]IYE9?)Q@+<+6V&!  #+@UY1Z)D*G*E$06->-W>
MYWJT0I::>8="[\_5Y-7B_JN3$/\ZZYGSK^D?T,N)9"<E^RO?:S7^-0G*]I )
M^5OXWX8.U#["K<K*B$@75LPWM+FHH"KWT=3OW4S]FV4]:V&BI87G%>A%=$:2
M)DM5S2JKON ><8^:5FUMN4;VQ&,%WY:6DA&:5?HZ+$NN.WF2>9$E!?['?M_X
MV<,7C"+C5-=<QTK/D^L)G1A40AHHWZ>1H]F_:KG583SQCJ6610"&Q7^VQKAG
M$,(<35:]XWT%MT[O4(DO#Y7.9BPOKKY)B\"\BSP*#6-?U[16!PJ%F' *W\^A
M9[3?C%+/9JYA1N5!AZ/>XY<^&?!T^:*0A!8^)3/X[D(R0+_F*''M-A-CJ,Q:
M^A'?VY:VSQ]&XTKSH%B4:&*[!C,??<@H(L^;WOB-<A\=*A[E<R8Q4S+$RD5N
MV?I1[#M9'1;N^3&?<9DHG'+G6+"W8=H=Q "2)ZE [,IY/,38QL9![9V.^L$V
M@%HH)OV9+#D#K3D4;E.!#DN>7F&5>-^(^DQCE*0!\Z3'K14#JC43<G!!8_MT
M;7I/HJ59KBD+#TL,;5*;QH=KRJ5,0243#^;_-O>DUJ ]!+[+0;!ZD<6E"9V)
ME50Q6_OL([7&N$V1,F"[XAE?N>,D#2WT2.FH;6R+V&R&'H>7:FC$#TIEU]-T
M!Q4;Y,6/;AC7-0M!5ZR\1BZG*XIJ<XM"N<J&1_M@$9*)6G=RT&&]WZX7982:
MMQ@;,:;OVOU!3:C-'Z]N1C%Y>:/N;%<,%&@,G.1<<7F@B4\@?"@='.MI,^_7
M?DOT- []CEX.K6'GYIJ?4LFJY]L<8!5%&PV :>$:A5S5W>3I++%/#^=NFA _
M/GA"%R':?D-@,RZ#DZWY#L4?\[T,<RCT7)H#NI18:@0+W;Q@)F528A)Y-+"0
MYJ^T+NDFI"=[(AUVPK2WUJ4VFJ40R<AB;H7^\>ZL^A#=Y&8F6YPKO'^/BI+H
MIQ>1MTZ*=1OFR,+2_M,IC,_<#4R?GIR.Y/PXBP2&86$K4H2R8S'YA<W)IYX!
M&$T##4;27[9C:MJ@D5;'/H\\;5Q^78[],HEU%]4V^DQH?U):+TUL+>*.=;,<
M+KDS>1[K72N%XI>TFVJ88I&S._;FS5.FNG '\03O!.]$F4?%:TNDR#03S-RG
MVY/?2\8<Z *<U!<M9A:2IA*&?=6&>:Z]U'YF46^%UMV7>-N67GDQ#,8YD+2%
M3A]WMS*(IX=LEK7"DLS>UIE^7V<&+LLKNOQ !H2=TS>2I0E)T<&E7^8/NA,\
MMVG''"K7=5H?B8!P2@7?=?],":&2W1X$\</S9BI@%HK4%('<I6X!#'6\O$W?
M!^"NG59MF!7<0DTV4>E/AU4H"TD$K4'>;&)H\1_/*]ZFXWWO#P(:D^B#F$*Q
M3D!!".!4=!$RDXL =I[FP@H<3Q[S>]#+UYT)S<% JT?9JP9N>K<E^\KK'KI/
MOA\-*V-*!NQJP/97UV'E-YRW*K.'1^I@[F2S1Y0$8<SQUVJ^3^=I6GG>@MIO
MBL(DHA/II83/;LSK"0,_9EI/33 /L5.AM2ZFP>O+VSHRR*8DP71K>_-UEY'#
MX1%4[JX?\>?0W,N/QQL61D)$IKW24C*H9Z0[*^(K!XMEO(K,AA6G_<5Q)1
M&CBRF]QA#@'847VV4U$@W'IW='VY7N YY+GH#XJ&,1#?%XDC@!:#Y2 _VJ[5
MK].3%3SP.3]9G)]8FB/J @.LDU,*,,\B4+@1-/Z^<>)@^<.M8M+9<:]SS.>1
M=1GL/WMC;7AO;D$WV,62( 3 8KX.;^%! .?D9;%T,-W]GE1)<NT4(IF3D:WD
MKVY8'90KU'YAJU_3.=N=8'YZX8:KJZE\'!;O>+ PXS,$9%Q%P8&9IZ13X/U
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MP";XB@"D6!% ^UL(+!6\RC@!V<Y# #!<7@3P\(V+#G@&9%)Q*P[^90?IE"M
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MP*RY)Q__=;#GU3Z4&=%X0GD'%,R/Z?$\@8I,5G$BU:[2*'1</A)9L/TAF9!
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M2*=6S&^&F\#LVTZ1@R^P'\]R 87;NP;J10UVI^1NQ2Q%SO:?G,RR/T>GF<;
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M\XR<L$#<.G1P\Y/RGE<%M\] O],L1M(_LYE%7._0.M&PO/S53R47PZJ=8]1
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M*R%FCY9Z*(:[?ST>[=>@N=7SU-3ID(4O,'\&6+Y=5*,W,V_Z\G+5@O2!OG]
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M=E[=L>$TKRR'G8[O;-$#7T7/;$2*91%N\_'Q-9BGN2<XEG)*<19"D*(%"UG
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MI20R.J\Y$VD[[\[S>/<R&@R.&QM/'@_L_/-<+46PK&CO3B6JRN;)[W;EAMH
M@1&);(AS3V,BAAXM]0OO$PRCNA9$^?[GUXU+)CSPD]*"F[[V,YIDW#Q@@2W"
M[9EI$+%=K9<BD23:P=IQU/MN[TB9^@ ?'=6998;@9POT9G;M@".>RS'V?1?K
M;2HKB%E&N+M?1NODP(F Z!O/$*FQ,O:@F46];EHZ!Q=<[*SWF&&4D@[6]X#7
M2R8EA=L1Z:&_;EK)2<_T2K"%UED]K-&7D*>TZ"BW/P:^0D>=8[\_%23]$)C%
M"5)'$?[9<WKAOW:X>\<SI9.@\B.\DMCC]0+?'?L5!7O3\;R>I!.V/5@=-V2,
M-":5W!I'EL &_YUR,20+#2[8&'V*#Y^OP0K>F<">U;&S-]$QCI=KX%P"IX#Y
MT><,)C8S+O66SW2UPM[BG"BL2Q/'=*G[%: O;5)T?Z;$]=8R?Q.]IB"ZN^$
MHZE^%,DM3/3 -"D *%Z3)7FR;C=[?OG7ZJAK2LCNG ]XH':\M$FZ4($OT1E[
MM@O<&1<08S_T5.R'F.YF&*W2?*3:)!0,#?=?*&LJ8CWW>2M_N&/0BF '+;-4
MC35E<8CVL^E]W>%.NJV27M4J21D15A:67!&Z\8 #==Z=G03:SOZDCSB]*IZ4
MUU5SBK%G).).UU4+%VS,;=DLOB5^J%+9/00J*L1AM6*L=FZ1+#Z6(GAP@+PD
M+Y6G (8V.7=&%J+P/P3C64?<WEBL*<<;5:Y&6 9R(:^4;GY$9ML7')&(!7U>
MRW[-.+SX_*,V> 3R?&W/W)JH1I3Q>'SQ1W;#:5;%+(Y*/$J8TC_=:5>QH6&B
MO(6!#%O6L@:Q] T#07VSVV\J4J5';KR2V'[,^%V4K/FLCVAYE1\'3W6/\_N5
M/YRQ7:9<KQVQN"AW(NOG:(XQI C SARMIRGO?PWQ/Q6Y'E76 '8O!+ZN#KH'
M\"(4C 86&T=6K-K@DN%Q?B,CK==(J=%K/1(<U<?*5,EX&M=:DAKV>V\:VQPU
MNH_?ZIY63G]N+IBH4$HH6'H R_49(N2J3N=N<(GCGEB)JC=]#_PPVM24S3N6
MYUL-3^\?_;,2/H1?PND>NO^>"QEE2^NJBMR^96EI8";'E^^W)<(:<AKCI$A-
MV*:UW@,'9)U=$W2*(U^F@I4U3=YR076\S[^9KHB\FS9BM1M:<UV.;I:T43'Z
MQ%3$RA,3KS.:DLYO46,IE+US[LZOXFFXXFM#] -?I/VQ&1J+.++;P50?/HZ\
M^"9L\\>%MB6HL$?GPTTEOK.CX.-GFQ3B4",J3Q.#CT^1S6P$XVP5TXHX8(';
M;MWJ_%[K8[PV,"^QCG;--%88833HIU(KLM-95K9%(67<"[+%U!?(7*JF/[9Y
M,&:@7MMP.SGG9K7-!J2S)2%^HHE)_7TA75\ZV%><*+F4_WO9",1'U12>\2E2
MP"4>W9U>IGNT4:",YJN%#J%(I.ZT9@BC<'K,8L]QI;9<',L)KRM2J<&'6P["
M$6_'UF(\EY'M31IL9T_?$\R].5Y'2)$/\7!QJ6!Y(>WT>S+ZQT#5G,3J1_\;
M!WG6W5V4I%K["G,![T%,+V41>4A_M)GB/(8H:RH2UQ+>HQ)=&S8F9:#+[4+Z
M_OQQGL''96IKAFI'\5^SHQ5!<DZIOL@OC;!8X/'G>BD%O82WB&N)3[K8J)H%
MR6N-76!=6:RKV4V  .%G(-^?CNCWUU]M;KDEV<2S6=3N,L8G$U?H-?,2WJ@;
MU-O> \2&^YH(3*'\KW>SSLW%$Z@?.PVRFY7 4:58K]9^N72#3FSF$K.,Z(LY
MM#.3FS%<50>L!P6::0?[7]_^Z=^0J#C1E/<QN/IKROM,T1&2-4CQ!"BF6B]F
M\?+7)UB!0Y]+I\M*)5?[:+RLJYX'*CE/T#XW3KE#&R[4SC]810[ D]J5+?S)
M<6A:K1](Q9.2N#YZMC![#T@E=4\D#[4UB__II7C@Q]JI[@>M@(L*W(R3[H_X
MRZ_[%QB)L>]TF^>"!NI^%(+!G,6<&.P$6L.Y,57O/;#^I\O_W_,#>(?<?N=H
MW0V]!] :>M@ZF3\["U?:-OQ9".KAWD75M9[P;BS7;,OYO:'JJX!6;J_/MNY6
M)A>49Q9#*/U--AK(?@JG6M.A=F+U)S*=V0X2-/7+L-+<.JUV!'-Y=).RV>17
MZ<*,M=X91.\,L?<2PU0^%/(1Q2DS2W)Q67_()=@QXX00P.KR%;I68M)EK)]S
MP8+3K)]CO,E/L1X+CK:26QQ>G[<ZSERR%PVN8-43MU7@OBY\MUI/J+$B6RY]
MTOZV7DT+1H(>,,7_T9TT1%=_>^T>X/8-%4\4<*,!FHXC=7#AA?+4^S#I&W,@
M=ECB.R$?^,VX-TF@_-$J'M6 %GBJF[O%%<&71[<[)5TIAI9/*#7(3K %9@0^
MOCKAZA)A5:W<7[5F4(9D]XK&5RKA+'+D=-+EEA(2=*^C+>3ERW%GRFT)R"'I
MG%\XSK,(/G!+0G*%:!B2D!Y@OL@P&^/#.:@)I?@HW%6%M_R>-]W0S6K&%LDD
MGY+R\$&J>/]O?+3_FDE\3J#+8(B0Q D?4]O*PHKN.Q]E;^XGTEQACCP&52W<
M X:@"+-PAG!(]"=:1_'BD<89P3:AA+!C\H('IN8 ^K3P]X\S "HZ*37-!5N]
MJ44@3RE-@O4_R[/'Y9S'C)W6N)=VY!^;^3XZ;^[,8RY_LF:MRGZF<-)FD%%0
M"-1U3Q!#<*Q*H98$3"^Q5I#E8'=WN7X@:='>:08(@QSE64[8>DR4[;OGB\"O
M52Z(18HHF,7HA'+19:RM3>"7)?Z.E$O0XH=*.WP:AHN!O>,7- 4.L,Z?^N;=
M"93I;G9<Q[<3X;.9(:G-,CLF> ECH?QCAP5?V]OW%B=5!U+"]Q;]#TSWF[Y=
M:YC(DU?27:<PE<XZN!1SA?D3FLC0<_;@F;81%N-*2<MU0<D$^#MA2*-UU4&:
M:R)FC61%C1^BW01QZ@G:\KN%J/V.S)]_3DLF6MZTP!W_FOE"T9F$7X%[<Z#J
M:>X6KWX/%QV+4YRG'O.HUK!4Z?,4[G.'4"5M-/JQKHAF>A9SK'!1'79XE*^/
M:06I0F!V]<1%2$Q"F-/;?=8T0N<4!UW[1;!H5G4K;(SVE)W#-!DT91M]J9%R
M5:UX3+@?V$_3=Q,BK08/65UH9OQPF4*/37C],^1B<CW*3_J3P8LBDKT_+"WX
M\.<6L(,:$19P4<&.9DI>1<:0>;101%A+AWN)FR7G?[3#2,V 2'N&[Z8L3VDX
M3*TP"^_]<#+L\&5S;IH93(*RPQ6E?0LL&H/,X_>(!:X>\?ZY;!C?XYTZS"'&
M7V[KEC9L'4;QCK:S>9P_8[GKC:6=O4U9L1F$++BTTIN/=>?$QT$([;.61E6%
M_E+6GA:(-=X"JT8G^T>AB2.8NX-.U7?#K+4U5W;4E-'E)X1Y[-/M26+.K ,Q
M.A*<3>$C!)6WK$%2W$)]W6S==),:T/[U;1[O%@)_MWX)+N*<DHFVKT%9ZW-^
M!"HZZ6T*'B\A0G[C).]V_DQ8G)3*?1\(<5A>B'JYI=FM/);7E'A0M+N-DG35
MYH^E=!>G.BG6-:BL15#7J/RT(%N<(FUDYM <G?.%%"%Y8RV%U[VL[[S"$Y9:
MJ&O1&<4C\N/T)!\'U]O[4.=Q2YOET;8KW"ILJT@ZT+=Q=&//SQ24N\O-5MUJ
MR[H>\$FTZ'J_5?L -VY<I^&]!P"+;ED^"?/-Z95M'NQKA,H*IQVXO\O,*"U<
MS/^A:=7]LN@>X%7\;$EGR2J7BC7RQ&8DG)I*E%3I[V%SOHW^E,1L)[\P!4JI
M8.O2W)W<>!1\;+MJ79?&VYDUOO$>(#V9'>5(UP6B9'5_)IP\<H<G)K?]O:%>
MP_0/-HD_6[756Y/6T/73]W3N7X8G@7E&SZ7E:QN(^\L',"W(J2:JD"5<?KE_
MB$F,&X=O(D#QEIZD%ZPN)MT%A\K^(=>:8^EY]INI/R)A[8NE(-K*'#!KX<G'
M_T L:PUZ;*:N(LGU]U3V/2 <M*99=P_P$TLWN7PK@X _9_&RWS>)G[#+JEO#
MP=KAW>=6,)5)Z&-6Y7=7)6FC-K[18LAX-+9*'*D9A)ES2+AAPOQG%RLGA+MR
M2[D(SWAIL^] _3@AW33/8$8T\X>9L3P-_^>7W_<73\H2-G42J![GW0ZB8M\]
M>B0B3QZ&TI\P+VC?N/G86VCT4YF\J@M7;Y8!WB2]/!MN,C,Q,;J"#?04^Q9W
MXHUC.I-#4"(]HQYFYY9S)Y\NI[KV/7Z_\0Z7ZD/SV%D]74-EY8UXM+N#U?37
MS31C<*1!PQ@O=EYS<]4-S_Y3$E-S3!+:(N')0FM2SU%8B0^]<1?O59*KQ8$-
M.T@6-3-J!L,M>O,F>I:.F2#CL7][8NK0@JGVE(^]O5%F-&XJZ"YO6=Q9:<@N
MW>AN*9=TN8FL8&9'<*!B_G=5%[4%EI\'TY\=8.7P.^QF6H6FJI0=$E5C=P)T
M.SKC35Z]=G^"^F$D,T=^0["&59B/BHP '?GI64D\2SR][)"0O80-HH 4S+UH
M*BO,!9&F:="6(I&A7CL"":ZV4&=>9GP$;7]%6333U#O@7ZIN&HSA;Y 5FFB$
M,4RJ*FWKKG)>Y*S*"6Y79N W%Q>I)P2EXN%LC6Z?CXH$FB_06P@(QXC"RTT+
M9K8KDJ!OM"&F=87((G9JOG/'7QU<X8]C!,FQ$AJ*1@/Q;9AY,O)T>F'SPP]%
MJ>C_N*;T?QW+16"*9C)G\(UR\(*F09M^6O3NM884?BI,8RJ/J=-0L2N(8"I7
M-D?6Q/BX(5B3XJGP=\4]I2]C8WL\KSJNCX]0R>>!M5ZY+O#W0NK7E?MWP.CJ
MR_1W[M\<WB%3G.X![/@*WUH@F(33BY<A'V&:X!/4V/=V*1G?&Y.FS,Y$0?,%
MV.C65A%PG>DWPTAKVO&55G/\LK5F9#54]F)C\D XS<T[;E%$,!3QJ?XH,JP,
M/B@'E&_\<FJ^ZAFW'^;-?SD)U*\)7W' %@<2$-7RG9=J>*!1#@Y&./M,RJ,?
MS75OZ V2%]VM&4MZ36W-E#CE+S4-S;&58PL4<<LQE4X+?X*T^]KFCF7I9:%T
M?L0V>N0Y2^%G_BYS8)82>U69)TF<DYOU+X0KJBH82P;'&T]7]U\[AW+^'J"T
M(E%]2+'B.J+4Q\\C0]YM-#;Y*[WL*-B(NL8[ACH*;.9YYA<LM[ZZA'2I=7KA
M_$ /\MU$ER0W/JX=,T5 O_PH89*>T[)%5H41DFMH'K]2"=18]-BR\@1VBS*,
M"ZL(5%<';.X#'A$D/[/_WK(\['T]67CU2I_ 9SNPM$Y4EV.JW7LU!H0/PBK(
M\O3N;D]QA%4I*G'++7I_V@']AELKYS%U+WI\25ZUTH2B^C&>0H47KT!:#]BF
M 8^.M?U6K<C0T%?.K39#P\H>G]B]\LKIJ]/E1O.OO[CE$0B;%BB&SUXF%U-E
M*-+V?FDIL8P<Z!"#72(*"880^_A*)$1_OW6[P_-R:/*'Q:FN-$8FXH,ES6WW
MW>P*,-')J3[)?\!PRG@_68 XA-EQCQ-F'"SK?I =&FZ/$'&YUK+4)X+DS>^(
M$>WE<U;"JK_1L]_2'IH>,UYI$L[5VU%":1%]IO*S]>,S7+%(:^O+E 7!B7W7
M9D%6^1\IIB"F4&/4ECF;$O79DL_D9W QN!B@S F@P/":#-5 &OUL>))&6/.!
M2+-GZ40?!<;PYOJ%G@'8 #L[IV5*9IDR=440!6IUTJVA[/N/Q"5=7MY^/.I(
M?(MY'O$[A&R!F^#NN;VN38/;=3"LM2:),I6>1"Q$=Y3W#7MROQ;FCYQRU53#
MH@S+8^ G9A<[Z,=6MN^]J6B7(?-BB51?RVJ7SVO<(G$D8M+FIE$;'[RC1+=O
M6^/M=Y39Q[,I=16_Q#-PD5-T:I.;'A65L65YW@/@[];$'=6<F+*\^@1F0 79
MI80<<D/66]>4Z9_;3+@OO]A(+X2.&C0RGMQ&BS!U27E[%"['6P8+1*U3?$+;
MLT:.>8;K27ER9.#"CP7YQ/B3_8UV"&+O6!<B=3=@Y8^W247K&: .FR1)E1+N
M&*:,9:QY9;:\)&I*J>Y_@$(#S*8L:N?\ZV&J#P#7N,SZ]EFV:%/#KUKS='W9
M]1(3[CL/TTGA:RUY20<F*2-\X>+W8-C;O=SQ\?1&#).=!;81F-"6+1*[DF#T
MZX<9Q6%O?&EQ/8U.S\U?F4<QG*U5<=*%4JE\ E?F:%E_3%5T!C^>C4^/)*K]
M'BO+!L>&46DL%O3LY20(K,B:N,7PDVBI14E7%DQ^WS)DFFAZY3^AQ=ECK'FW
MGSMG.N^'MP6<?F?T8KL!F:*O,R1JC^/L6U: P"Q?5OGTBK3!]H;"*T-![_'5
M9+/"/OWU^6VX'+.3K %FF,L"WTAKK3"[F_UWG@[AK=:%OW_<_N@H4_>&#^J4
M*W<9L>W1]0S%NW\9N6[8;BA2Z,FO@V@"D5\KE 9/EZ&/?&YU>R1@K&3K<JE%
M1(,?+C,./K%$F(UO:[9-_-**D2VSJEV\KK[Y8YP36:[+"KN*^D>JP$0G7;[E
M!_X_?+UU5%M?MRZ<EK9X<=<BQ0I%BY/2%B^DN$,I3HJ[IL6+.\4I$"! \.!6
M7$IQ=X?@#@'"Y?>^YSOCO>?>[_Z3K#'VV,G*F%G/?)ZYIQ1L9TI.GET=S.37
M:Z8P<;4A_P@@!:ZU'8WL5WVL@62"RG(QR9R%5P>>("179N/&1I;E];;7C(:A
M,3BDN3X;;2=U<AN)Q;/GDA66_(9OAC1>];MN_D)/2K#3VS,)@L++TM6FTYZ:
M*MVKUHZ&KB:5=<7REJXAN2<8Y_-R*T:A<H+;-5#VENA3<E/*_D2<8PCIU_-=
M.B 7M@RIUE8"J?0]@*'U8@@U\@%X?',/>)#6<("",P;)U@<!1DJNN^.=\T+5
MB7'^3'SC(G<^2H,A2E8"5!<#BC#[2<XW:4! C.>S_W=N)5=\X\39G7TWGX?C
M"@EKOF6:TP;N]Y.RE?3T2X"V L3U@DX,>?0+PD21;(7FSD[W2VR_%:QPK1YO
M4B@T4W+;#X$<8"0!?]P#AL$XE3['_KNM.9(?\2F+R!P%%L7D;D&WB3.(-4GV
M*__%'IFPK3Y/BU,&VE4AVCCQBRZ7-VX5.C/2UH_WPR@[K22_E0&/7F09'_N5
MK>I2=3+SM@O\QLR^!=P.>DF2ZF4@]2&] NQ#^ ,!3@U19?T@[4LNQ@>ZY3P@
M@-!W-Z'K?'L=2^^X,PEM_LY3$E CK=IDNU6K6+/33.4<$:%E$?]"-O6O<5/@
MFE3&;E>G6@&>4@'KP:36R:82J/5,G*-?)35ND2&>9V8>.E'98&;J3V"J/JD9
MA\@LX*XA2+H'\$_"W<PGMO1"#J78:[**T*7FH?Z!=PN9A5RADWNN@^+=D]11
MX3<#X"TBD&VC#3F.DWXM)S;FN)]OLW;3<V+1$27))O]/V;XK_EBW/V[!17FB
MR;]*<0FW->SZ'B3Z?MDM#=6^;?X\> 14:#V"&Q3:WNVBINWX5'2=T*&-03TL
MNM.-SUIK2TTK1K<G6E34GL/+3G4*H^ZV6%N=_))7=_&%@JDUN424EOSZ"_E+
M*D[((PVA#*93U9%2P5U;Y>PH,TZ?Z=MVS'SG&*" P70)MX0,ASJ,)M]EN#17
MC?:DVLV]L;*E^1[ Q,W$S:96HY\FGM<4<:FU<TXG?2%4&9L'1A!I>#T*.]*_
M!Q!XI/W6AMA$#T:2'KM^57@G>0]HFW)=-F98 ,_Z6^M%-J3T"[!VFE+-"IP2
M%'AM_98CD+X1&?ODEU6ZE?MS?4(ROLL$>:,(-CPW+CBOV'[@P%X%?R(\<N,/
M<VK'-<&["=4!7_+UWFIJ.&H96>5^KI0O KU5MICKO&P(-^C/^Y#.*'G'-="C
M:3/N<'$1[]9J/M$:.R8+M('@W"JIMJ?Z)@3S*@ JAM0</^VX_?U^8($Y&'.)
M?"KCL.\+@S9]_>!(6\%0=J75;!X$56RVL^)ZEQ2[MZ1],MT0E_#"L@GAE_&D
MT(XG!Z$\^D82@+2QZ6\:A=8W\6.3,IN*(KG*>(M#H;)75LX*C5Z>/X<C194N
MHWJASA!'+[3>8\(S&:0?HB!?5[)(0"GR,$J2LPN1_B8\=&KSH <&VPUXE*@1
M9 S_LC6H?F0\-6]O3$+!8*Z@]]+\5'_>6/I)7&SU;4>--\[83I=S,L.;T@YT
M*L[V=!#>G[>J?6S?GFJIAUZ<5Q!;LPV"K[DIUE]IB+Y09AMF+R6'_$!]\0CF
M%L.B]M:*D;U4G'^LPH_I:+C(-14DKW);>L%&XE\6K.J:._"G-/#AH+Q/^)\-
M?EK#CPJA#TIE2>^9^CAPG<;U'F!@?$U]JGT/B!&^*V?H;Y9RP&_*CO /83XJ
M$\!2^5GDW0X\HVYOZ2E(:C8^GQX8W5=#KI>D%Y7*GQ>G(@()YW[\4@ZD)12C
M+OO5\EH>?4(].:'NE\$C%L'0.\6O1U^2-S[RYQ-[M@;-<RBI?X(Z:Q1I+EQ0
M'1;7@Z-GRV,=TS:FS/TBV^J]@J(U/M/PK*+>>_D\5IW*1K!X-"_/LBS6.9D1
MPD7))4Z7Q16_'%!/MZT?9LN.E(,4T=0UY47D6+*QQ6L)@LZ=("T<J'DB++5/
MOXS=%C%5E7Z]W!Z'>'WB:.Y5=K)RN^C#:,OBC(]R$A]?L@P1/8D_*1"TZB4L
M9'2Y*%+/F\SU<:KXN/9DBZSJDKQH*Y'!3T^<(O%=!#O 6VW2Q2L@X <I[SD=
M6%I'+%@]QHNZ3B,"36RCGB#UPBHGK(JI*G_R8E^Y6.8]'O7W').QV+?85!UA
M59^8B-MBOW%Z <#9<6_>#T=H"?R*[!?^!+8K-ISS'&CVN[H#XYQ=)TYN[W1,
MK+MY"_"$B3G*.-!_^\_FR67_(SF*I@-RO.]]#S"6NP?(0+].58"6C4*O^Y<Z
MDXMOV\/8BP7^CVKLK[%Y%=5.[.8F_@1>KJH3KF!EZC_S"U*8'Z0OTU$X .IU
MZR*_*7;RCH._6P<W?&BY9@<_SJLT_#C!-P0;_EC$L:>M-[FUX^C$;H^A55)4
M.OPQF;GZ=^+T[BSC0R'/\2H%%NBFFYO]JFEJOZN&BUY5*_[W1&,O+[ECBQ;X
MJOB"EAPW,Y/H@,^,!2KS/%J&K(]#5+QJOD"1-'?@G^YV,DS_75Y3HBLU<W%A
M$O95*UD 4E2;B ZUF:>6A6XQXW*4$T#QP$Y=9%8[M<63DZ#^'&_KM9NC7N#R
MR^S)=0W5X>7SG.__2A(#Q#@]QR?]]&PS>M5[@7/%3"&=_\Q5 BV5NVM4N]+*
MH(<,BUFLE.%RJ"S#ZEFZR6]BRJ^I3YK]=/R&P''Z#IR3X5:=5'A2H6O&::11
M#0F0RLMIZNAH>5T_&NAVZ5U0*=+C%KV#E"P>A9=^;JI5"K?6DD\WU_6>TK,N
MSOV=SHKM-*@;-R)#VO?_*H[G]Y')AUCO\,N&I^1>KZ&BED+1B8-72JHK9]<T
M6:WD$-4[B-A!\;=CJ;27\47YN38X75P'3R 8EPS1QG_+X0S5T2 ,516>P!;9
MBU_V0^FY,ZW=5;L@Y=9PS7+=!+S8F@_HG0/.C,'ZVG@ZC;LQ';JSEVALNW^J
M-)['<: X2F<QTJQ =P+&&P8:'1QGI56*:7_'&+^N!\WZY51#Z[NBM0-UM3LM
MT:R%DN8,O9./[[I0V@JE[RQ&E^@^A=P#@!G.?.G9%ZN)H- FDKO!IIX1&3+,
M3UK<ERB+"OQ:#5#S[:"M)09;=HDM(]4Y;EK\ >:JS<N];]LC*;*$?A=&SX"!
MZBE=#=>\MZ.U>!W7.%%,TTQ29G;PNQ$0,;1U &N)8[E%S)>+Y4PT==SI-UW#
M#Y[G^I4: @8*HCTR>SEYY*5+376^WTZ3D-;=FY3/N,?8;O;?SU4^.6\Y/*).
M,N.YGI;-O+/RALK,V#52-+H+MB53V&?JSY^1O>GE%G5B3;[)S?YEFQ]*C[XH
MJ\"1/O&L(H:A:D=_[IF)8M@4+GOAQ),8*<5?7Z@JQULSL7NJ3K0V^=H8S9)F
M-AQ>4U+WW/K-FI;= XQJN*CW[G*-@OEZHZEN1>&IBUGM]L/3E<E_:@S.C?"=
M''F';XT*#CHVW=%KD&"(XK;+S)L_O5Z\O:A)8 1W^>2EC:2I*2IZ5]O;QHD=
MJOI[G[DIIW![RMAN9)\'^SJ5EP8I NPOT[9QUY:@DNE6>9W]OU7BH$G[_GM.
M<^W1OP:4V:_\DX!5K4Z8H#;R%EN&FQ20H#9A^ Z-S]^M/Y#$16K*1J>PAUF?
M-ZNX9_UF+UQ0^Y'CZJ#%YKN+55R1UB JX1K)(5 _PN4UN>3@J [R!ZVZ0A:G
MQY5<SQ>"][>[49E2@5N]*6,2=#IR*;E%.74/P$-EM* RD)>GJL_!M=7?&!Z[
M(&=RGE=YG'B>EWNCRIPY'8-77CH)<A+H1:G>_7J?%7</6 ?"M#8V*^9'WE4V
M!&OAE?!CK1,I&18P_L>._Y\+2C3C,5E9"'=.ZB:'N0"?ADX;\IDG&]23OJQ8
M817_Z\("?WO4[V>B1 7GYV7&D[= \U6L_=&S@9IGKW+>X,;)BJ[606AW])['
MF]C:6Q,D>J<7OD\O<YJYXUKJYUQ9'M?0+SPHFZ&7-56ICH\'Q[H<N*#*PJI;
MG^\D'7<Q-L3WJ^(YUBY^XL66#/)L0:PV:^M_>9G>]<PCF!DA-S59P5YFC)TT
MTG&S1-I8];?3M&ARS'SF*:FJT8]N,HN!3XUCEKHE!RS?IW[)MMT6(4BA9*P6
MU=2VXKFC3<!C,LM8;M= G>DCGD\^>?> :G%?<.IQ=4WK4>* HXE#)3%91LPZ
M5_3[I6RA0:W:X.Z?KG7/2DHF.]=*GQW,-1</13U+HLXK'@-9YB#=)#05CS0L
M4 =_;SH6@2%JF9/M![,?FE("3=9^RTH5C#8J;JT>V84_ASV#VN)VO%)AU8Q$
MO_,+D?#E,\3WR>?7\526$+-V!=4?KN3J\=E4-1*'Z7'%;#^\LC\6(%9V*%R+
M#'GBBCG^";>'+?'U(II\;^W6^O@>T+,*J;/Y4\'2J]I#)TTG?4[ZR."_IT<I
M&G%\$/ ]7+'["^R9+9W_K_"+'CMA0KU(M\<#'U'DL'K0*4EA@&(O:GFMF>=3
M]?8LO&A":18T@*&'=*;D5?4]8&].7]SCEXY.PFSNQMM AB&1H68G5/(/Q+.K
M[^:YUEK6P)GOX  .3BES]!$F ,]M_=B01>L> )[(T^]3D]7IZ \(FE68S8:X
M^ZMXI;LMF_S-6V@0IT\O/V=7CQ:OC-NLA8\VG,W>W<D+08ATK5!FR2?0SN$"
MJF FZ;/KB@COS:9<_:M(^&XEC;(H]2C5\XDHO.KH/9!QFW;)5? 2FE@<V\7;
MLZG1DM'@;W'FH[]=ESM#-A8_5B*9.XZ#RJLUXRFMLS9C6PI0>#A_2SC'$W.Y
M/NRW?2FGY/0;A4MYU8Y(QIWN7 EO.S'@W_+!=[3C;<3B!8F4R4<P:G3[&#="
MOOJY;H]7:YW!BAPWY)*CN\>[IUR+6-+V^-;E8_J8G\I0L4Q1K7#A&[VF .L%
M%]#&0%</OK, /84='.<P:&GIP844;RY3;[WL?U(KN=Q\+!1W>FQY+'H/^!:F
M_#$\4I6)BOUQ^[H;3]O:">8I+%7-^D*HHU\#]C>Q1:C8E^P CG1J89@H14!"
M&SK$<O7F.M;;YT0U\;L)6@<-&]E=S$T2/TO3CP_TYH:K5<>2:690OYGEB^&5
M6Q:]1>H5.3HJ"SM+V%I-I%MBG12SVBL#Z88$Q_T(9P>XI+)@39P*3*+J'O1M
M$=J2P X"(IV/E>TUES8ESZ>ALW\D1;N!8A?]7-B?"YL3HQ6CB3=))Z"LK)NM
MFA8:E2$JX_LDY/FS*Z1VX0=*1+? +,72BGG]19 IW76P,T-J25&!AX0=IQ>A
MUQK<,'46-[+%17'#4TV.ZTQ2QDELR9_'<G)ELEI95@D\WKV1*FONX_9D_9L7
MT2@B-4%SM+XK.(.STA$FI;_OZ@HYN0:.Y^;,[QKA)JTN=:I=IU+',3:I-H+C
M8WB?+Q-(F :$'>R_YB[;-VVHSGCI+YT8^URZ5!UTK!6^.EDWC!!7?[*^]V:*
MH5ON$E0(C/S"$[+*\-AFU9;,8MS%,^TR:9G<G'[9!;A/T%T1>$V\,0D,D\23
MI=A5CRNS<;VL&8D[R))%;WJ9DY$AQBD<2FI.,&6IU@HOF"M@Q57.6ZG6,S\>
M@!%+D0/,K'$L&YZ+<;$@2^IX#W@U?@#I=5944]7^.IK(F6@^H,+=RBWS (<%
MNS](#/4[3]M^K\8FQTC_)2A*_QS6PB,X\^*D['/PS+?9 7:<UB/R;;FQ+!,#
MU^A.7V'=J1=CW#,E*_',^\[+9A<X8H]]01N&*6-[.'9@V(_=UGW;J2FJ.=27
MBHA?;S8PAN'O28)5H3^47940#TIQ?!UQ2&+DX78B<M:(+60K&>_HT2$<YWSI
M_DV:?@'&@V:Q;G":#;\35ZU-\@@,HGYQ$G#.+(G$?]_3(S<QVW$CM8J>%M%H
MC/C<XA5A^B0JA<[&]WU/"P5%I'FA')<MAF/J> R_V.<(=&)TM=ZLV[E<3KER
MH?.*077S&K?>J:'4^D"J>_2M,$R9EF^)$AJSHN71;X:RS+[=S8Z[F"3_D(3$
MFI5.(&!\VI*R:U":)(%=LL2LH[\SZ)+KE!TJ"[K%!##T0Z<D,%?V;=85&-\D
M/W+P^].?UMR_ECHI4+CF:N$PV;&<:([-,:8UN2.,LG+][/_H":'G$U4#_.@.
M49?F=S1I#(2+[T)7:D*[0;L!5V$9@A J/7"QQ.PN"%J=U\^DR8]UEU#ZZ![@
MEEHL=/S^Q&P (SC>)NJ%Y.NB!#]]X)_]70'U8_+H!Z/>O</2@0Q(SF6AKVDG
M$D$$U:P_9_O%*!)K:^_.9H2V4K<Z=!"1+O-6T%?5%Y\,\_KPKD79Q=8H=[_O
MR.C%*\UKFWQO-['1 ),)8Y76W I#XEDGI'AF.A6MO7SBLZYW1*=;8[;.2\<Z
M&OIW460U>>4_?8:=0M()'1SWNYQGM=OO'G> %[#M-^@VQ-6!!]%(9;=/'635
MV'A$):J,LX7AWW*'<5(YFP]5;R.=.5,LJS2./KF#=*6*Q]"/&0RV(M) U6.V
MKDI7 6E<A8L"M6SQ_I@K0RN&K)\]9CN1]/CC*ZK).DT3*-C0R3-$L9^<:0A@
MM4+C.B/>&BB7>XOEHU_<0Q# .F&K8<!VD!]4T>T.T]H:7IYLB87)E5B3IT8H
M(7B8"6I%9[VCV_RYXHX6?:2/H"5'1JKVK W1%\GBP L]Q%&_0MKOBBX)NV#L
M]4AW/,<82(I0 J>HLE0DW54Z"X>)C=R^>N%47]FIG(D,-]FHA[\JP:W?/6 .
MN*OT'\$V@YPP#KQ?KR#F/M'G>)## /2S#&VJ]QQ: ']>Z4,-1423/QM++J38
M]#:ZF9?NWX?ROYS:_UQ4">%K8=G#JPLW[P&@1G%5BKCP\?HS@)HMJYNU2GJ1
M4A(7ZL 90EAV+EP9H#0R:@'^\<2=OS.OZ)GX.P$7*K;8L_-B/Z%)[FH0+HU2
MX&ON=8L9\E>O63WMLR_.2Z/5;R23,NC2/[.S2&%^*GPOP#!0!B-+A%\Y]:-'
MQS3&8U,/9G4V&$1GP^N(?^Y$N",ABIN%>?6IWF5QDCY"-@SUD?(W%;8[36F(
M5C)[%MVC@W!PME6YSJP]^[,+2TH+T_$L$-1&W33QI>%QG;EDEU1MR&O.]>D3
MSO$,Q2A7NO7%/&%M7+#=:'DO78A75/^14>=?$FMU?[%QZH$O/?2E' V,77DA
M$[M]2?QE%WD.?3?IM7X-]X V88W<<TO50V?%(L3/&R]#CM_=E'YT-@MD2,U<
MG)HM[2IEK]Q4 <?FADCVDO[.QP/#*+71$3V6I/:ZA.SE !G23@^_-)BQ-;U$
M@ *X/BK+'I9(*$#WS9Y9!$5]@4Y<,9+Z7B+%.*^8_6V?=N>P;0B)[YV<B=\Z
MB\5(2A PQRS4$93,G&Y>:3GNB*>IZ/'U@W8/G:\+I/ $X\&XL&5_?GS5JA&7
M9K%-I30N7&_/C95%P=]"K$$#!G."I7RGM-XX28LK/*J9 HGXM5((^"L9ZI'
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MEVX:;8-D'MO?JX;L4YI$\E3:01.?X<:Y2_DZ\0-?*S8^K787,TN* 'BL.Q[
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M+2=6#A$'(.F+TQ^OBG/!3JDP/78 %(.-M(]5WI1??H7(JT*HZZI_MU-[T+3
M*NF2?/)2[:MW]S6_/!M&^O=O($:70IC04]^_Z2_)=5+#L M+#\WOW'A5+:X2
M5T_VFP7I)"L"ND_1W"B<Q6.*< O$%+>$4'9WF<N&:6*"9:^1B.K8"\\MJ VR
M(3(Y6%"FVE^>L26.*2F6"5*2#,#X?ABEK'HD%V@^G.3[7MT\6:O>M/FT\?/0
M1U3F>?\OEFOUB8-[P/NY)*9 V(U7+$*$2SW$?1+4ZK[U:UQW>L[Z8M<>3-Q#
M?0]P<>H9S]S,RWR/WU09R*.*^Y1.Y9FCFMJ4>4E)=+J34[(@0B)L8/4.:2@\
M=S9M]'@>2T%+^NH<F.B&DHMNDBRQU6@F/V6X-G<\H459_H*=0YY948^X-XRM
MZ::5#-]&9G7 '7M6),CUJBG>K92YK/N.SA'5O&OI=/!V['+4)U$^_!-=X-3'
MYS SFM%@D[5S39]>&AU9"L_\R;B9H5MS=.7$)>-/9(^GR%L19_I9\OOO4K#>
MZ*VJ;V' RH*1OJ$@.T/K5\*%BW5+.K&ICT6"96 4/?<K6AOEKJ%8][C*V]=E
ML?./NKW5GXQ0/?FB,Y 91FMY4LJL><1340+"2Z;GJ'MABH,DL1KR><KHY])@
MV;[ TXT2;TP;:*RGR*F?Q49%0?0RO> S[T'JFD&_9;,$=V\6$O1O#8,?)#_H
M:+*8NWQ"J'"/9]GHS<I,3&:@K[/Z]J+0449D<WZTI2_7*WEF6=Y:$?HZI,UD
MQ4HKYGM^0^2P7EOG9RI6KM:C(2'% ;TK[[P%V4E^G2XIATHY$N+Z>X!5%!>;
MQ[A3DR;ZM.5YA@^+-?M$:N1>G 'L;C <?$P]I3%I.EKR:E,N[CW#+ ] P\"=
MN<PN75M3*@L:_D5(E'B;*/E&R4[K0</[+O5JL_D>DW24VW";/'EL;21-H]A;
M3*Y &^?)Z"XTT9&3T ES)*Z_3DQZ*NX7>*JM8C"EO2E:H9%(1L5I%P=6:JS=
M\C;T[1&R/KJ4]G4RU"VI:>ND_#IM\@QSD7G^'D  &B*; 9 ^N&0\@+@6>?&J
M-Q!_<6X6K/W(;Q@[S,R(ER]CV65WW/%:"Q[URQ+V]F5%0_ J\/##2L7Y67$^
MK*NNQSF9ZI6A3C?<NVZV;Q=LFWN+NGPU&J:HJI>.81;)^F,UUIT9IH59)T&]
M)B&^W"<AOBI>N.^JGS!VP,0O@[-_TQ81W,O\31;K-S#(#8$_6)]!8?IS0Q:?
M)JKGEN"]J@B'$$_A;L=JD6H$K.!@P*\E>ETM?+]&&X[%1Q[_*GM#[:,K<^GD
M.6W 5!0X_>K[+Z0?YQCW<M48L^Y*O'O*J_[G?/X4F*UTCJ,YXW[,.\>&OTT@
M8$?[0OV%HC_9^-\LGP9X$3H_P+(_UA/:@%[F9O,#S?"@,W']SHUSCE7:5RAC
MRTM)S:RSZ*R_L6OVSS=RP]5K/QSB5H"&5QN7@A<9C\G+G#V?P5OT/6+(4N7;
MR;[>+0(&O1@%+?(S*6;Z1/KF*D8BAK3X(V 3N?26%TF[J/-_>B!$9^'H_;M(
M#&<J-3$J:^.N\@07PKL/$FH_D)JPHHV(DO$,Z1HBF%_0G]MU('>I 7%:]8AK
MI <S_/A]R[G5?@\@OP?86*_)-L4+)Q7?Y)NB*_GFD ].J.@"OK<.G[XP3W0V
MWZ61-9B\2K;?/:_?=GVZD%'S"\P*G\>6(,83M./'!\FX2(+HN;L6)%7$/UPY
M0JV,7J G:E+=L+,X*;J9V99@I?UAG"^P?NMQ=E^E:W[]F+"KE *U]7ZJ.5ZF
MKC)Z4&9,\_E''N-EVXY6<?@5%(9+\$P9ZS-+8^P7C#D8VAA.QM:'R=/UN?P>
MH-/9'GTJV/H'MKQ$R?:CNM&7I#_&B.G+QO&)IZ*LBJ_*N[4EH6F;-U-I+^M'
MUZ/$5W_BLO]Q,LW^C'6[.X3&MYY[)42GD)QBIO,I2X9*Y%;'3Q-)%L60ZA(?
MNVTI-400G<[.37(^@40;<J][" =+&$-60*2&/<5<H78/?#@TRM3G9-G;+Z=Y
MEBJW+NAET*1\WJ=>I!,E?:#VTV.:MJ6YI!Z-L2\,LWP$&11H_;('X@W4@[37
MN3;:$F\N:0;KP'-C?!,MU"@MQ8,)1':B827;SJ.P/6C1]M_Y,63='F?/J(V
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MI.C.];4OK]>;<@'90N*"+3/H&EC/S[I3E#MY;N-YVS2ABI:[X^2,^@%TE/%
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M7P;Y:#Q? -9ZLMP!##WB/5:>L N[0/(7%N1=-G2OO@DX?-EM9N<$8$0Y[++
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M.4@2'1^_T >?G&CBW\H1""V_>&2F4<'$TKW?O'%V-&:?5C19-WU&GNU".[O
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MX*?C]+N:EY\_N=X!WMXZZ06@6!J@6G'00&$9^L"GM_,?JJAGFFEB7!*POE=
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MN4DV7JORK93WP^ ZDPW/&D#YN86]S$F!EV_R.'2M)XK(4VABY)T=M5(M*XW
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M;TZ/QKX[V%$D3K,B?EFG1EVZUVWA1$AW6WZDX0VIG['^6%26A(4_#H<JDZ0
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MX\YTP!V #5AH[8"_WU(D'$><YL#4-F@K7"C3=8ZAWI3F.*"[_;'<ME8<_V3
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MW?S)09A1,H5^)ZQ!6<]N=+-X'<\C3ZEO;:H-Y!;O /BDJY^CVGB YUI?J>\
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M9+$D1]>6KK4S*E=1*:7>HBEXE'@SRVQA?9GZ"M,D121'8L^@3:V<D\;J4A7
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M8)T:@<#TNQ"U 'U7CE*W]NA*A?3Z1F4#O;.[$0NUDK]^,.$;2BT@/M-7?%>
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MG5/+DGD4MNZ3[3OF$'.\8H(3GD)B]\O4593,<J?\?&;B'1:8F6M%+Q T1^.
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MI<E3"4OHUZ\RZ]G-O.8M-?-O\\.@.3WG_I4:+%)32+Z&WPI])Z#@;*KC^Y&
MGTG1Q]6H=Z3BW3LVUM"#),W$3^F\%C(%UA)SQ:[.V3AUS<W'5@BW 4D1EHN:
MGB5WS,]X9R*X![)A%6=+..HY79S-\E],6)OL/?)]K\9*?MT$I/>?&!;[K!J1
MZ"!SQRX,D.7:+]'1*B3H%Y^E1ZZ)!C?P@STBZQ8)[9:D"KVY'@"OQ/H/<THJ
M9,6D\V:$Q"5WJ$-O>J6*F65:G*,;-/91'D8\'OPI'MI<6(V&^OY0G*N_:I)Y
M'V/(=,D^8CMZ FV4VR,U)NTJ<\=2G8@&OI\#HJ9+(\R^@9-%R]>'5]Q75GW(
MB.'@G,.+AA"SJGH0"^LD_7R1Y40^@RH^-9I)D$I>R^K')#PUJ/8IITOB4IKS
MCOO1L.U)SK 6H:MPTA:?KKBD 1"XI3U0Q5N_L>D/AOR\PPXWL9&%WRO,X"IB
MI<MRF_6OQUI7*TI[)\%*-=>5A6E-LM6=$Q.1M/A-Y:(:&D[4"Y+)ST+MMW?U
M?^^[L0#9;30V6FMV)I*MG'O\*TNHWL\ *IU>1^#&2E.7W$E0W!)5S3=DP'0$
M4EP;LO"&YYB?>P[L=(O*R*KUJD_6!='1-:.QJV:-S=2(47M^M@'CS,,?-=BG
MZN=Q#+>_[A3O91%-'$"G<\T38(*:CVSE^?4U61:1IRXHE$R]H>.=PQ5YZK);
MNM^^=VB6@P=^&95"0!#]1Y_UDQ'=7^>\&QVO[A0W1^@"7.B'*+GT+&HA;U&B
M-C-E,[E:6H'Q8^F?:0-Z!B,7W+9:7@+0X@#TXVJ*6D?V"7U=6X<?%"3P%#Z(
MQ.4+P W#T(PW$'J9EU$BTG;%>EB49DXER)?&019WM4NG8?9_3"^VH7"+(AU?
M@>/HI:'&'('-S84@ZFR@[#\#T69D UTSVEWTFT_\&T)TJF]9''[J>W3NHS\[
MX:E"7OKSG537-&"@R&H_3Y8Q,/()6<S2?]\-T/>]6[X%MU.C+!#W6AHJ6(0^
M<76EK3LKI\57;$?C*\=]^?"]'P2A%C&LHKKN?:IO3W&.,._'(>1JRI/V&4H9
M XY2NMV,*+P] R:J/FAX:4D^1BD'X.QI+:^=^)BDB.)M+SD'>8]X7]O^[.MP
MM5!Z'/HQE6*W617DSE]J:#&H8)VAI$_%?H5;]<W/-\XX%-#\<J5-JWWNH;B\
MTAT/MM6#WV:J9BK%]?+E"T-"/ZD[KZ$'8^J0>RVMDYI>,V>XM'"]C5<[83!#
MJ6?RJW9<LB""M[KAR(^Q>_?,QF6_%S+T>,+7'3>K]T VC<S=(GQO\9<O9J>1
MPTY T4)MFL=-6-LK_#]X\H2%O/=3XKV)QA\4DVG.'M%7RO^6)./Y_TFRBAC(
MU67B??==64IU2R 6V=!PLO8]F1CWV!+^8<(4LIMN.30:&.]4086S1$^^[!*@
M,TM&B79W6=JQG]M_6EX(9C@S^6B[SU"!N9=2G"@2AGIJI:%;+\KVS_0]<AV#
M:+'2VZRL?2O:S-*K9U:"9[SQ14AR<S'-XDO97-3N P!C2''G\ 7!AG@#TD^J
M=%E_H&FB3E]W1BZ2Q?-/H- L[AK[2]IK<PPN&_-^=1]UW-,3;P^C0@>9$WT9
MTO=<V><3KV#Y"?!WI&-$D:OKK_[61LWZK:Y@TV6\?R[MBE*W^%[\];ENE%6!
M6G;_AIB1RF'ZZ0J9SO/HWQ4X396?19G'[GSL$6"Q%YY%0S"Z=7//HLA"HQ7D
M^JW8H%Y*U.8%3HN0L\K3QD-<N)EE!7XWE=]FXB;U7OJ./]E5K,($17O55%$,
M0C9C1-=T5><SIL4".=S8<UVU]D062N7'?QDO^29\&/TMR7:LJCC<]VS;"#?6
MU>RU!'ODS?@Y5]O2YF_WO*2*([OR8<M7/V9P\]#R5B7.*[V/,UE) U^0EH4=
MQP;]?,5<O&L(L[!NF&!Z$H5Q:=7YD8DY=W.J3.B\T+#HU(/>5%WP:6U%I9V=
MH'%>N?4[,NE6_N^5P!-(Q/:MHDR,]SJT06IST!L;OJ9'WV!Y64*=+!;:Y'.$
MW\GU+>WK9\_'DS1(/;W2AMNVE;U-TW%L]P*6D42DVK19DU7%$Z;X)B.69S&>
M@B+::=']JU7'%\GD>E8P!,R$<4X!FW\>V>O';Q"H5]+3-/_>GFQZ9V!B<>'/
MUXFJW07@FO:-?OH[J+UKS[=!RB_UMW$R,G[7E;+'RR7& 5^:Z"W,Q;L? #-E
M4;D,L'Z+4IYB=2T>GSR]6_3:Q%8IE<&5\6FA?8.WEH-5V%%"[KRC2-#3D>FX
M1.*S,34%M>I9Y<(S,PQ]A)JJ-2M^DL83RX*\N-?I"@R Q*]<E@ 8P2N#UP7*
M@T)Q!=")FHGE3_).2<I#CW(GQ)ZI@'/U@Y3:&4"+(4VA%$S-K3QEES!"G=S%
MA?E&%ISOX417[%XMA9.",X2B*UM<6T.I4#J3QHP+SRQG%%_K2 0QWV^=Y:T.
MYA^]<VT7:-)9^U1@DN-B0+X0+Z9+;?:E\VEA?8.B' '-P=1->F6)Y,\D'!.P
M E>P5YZC4#Q<3-=N7/[()(% &O3K'"@#94YP<?&P^,18PDQMT2W^WXWGW2+^
M9RYM\-SJGZ+1Y_\6C1H_RD?=;__%%Y+[[SX<(VV(A/7+?0I#7KJ1@L4> .%[
M!M&4@*@W+T4EOHOBQ+';T52W)BPKEWJ*Y5>7GB-S\'S)9CS,UV;$EQH,23Q(
M)Y'"VLFS0#EGQ8$;$3KJA<G6)7M\-6ESM^?XZF^? ]#^J+Y05C%2 +[F6&?Q
M?@(FN,AXZ25HWXV(C*;KK0L:(O[MV__]#&@.95)2KZ;A5D0+6'..$@[2<_>G
MZ%1S+-1QC1?OJF(HP*+S-L]9LW+';-'OW<OYYB^^KI=RLYET]4(2SUN^?P_1
M9BUH&G$ILQ^-+ ;FOVAU(W_[/,GGV$J@R'PW?PX7(;T852XJ,2+4EB6BXO#T
M""*$-\D\=EH6L:[GBVGM@G-9>V_MEY91;#+)4,D-(5JXG-H2/]R^T1*.)9SG
MV/*!W8>+S\2:]PYX1\VFC.,LCQ'=$FR?EN_%XH+[7H:0@1X /Z2];%$<ZP07
M86(U_&? 9)<U4H6--Q:G4Q?A=O?>TTR6UB_/E/1ZI=]$9A0$B&^GNXE/S0)+
M/"NL/&@3O!0? *+$*>*K^KNT$2SR]#">9"L:U>U_)ZD:.\L+TF5(X_]DNH?W
M?^,3O Z3W--DU()6?7:4QK3ZO7OF<(TA??4(Q\BRA''3M\@W38?8$*8]:X7X
M(1NC4_S4G8X!D)_13,<&(_L$)*Y4+IJZE(+VVY\G$AXUK6Q6?%@0[_@0EN]1
M 7>R57<V.SE8.T-YEB<+<2);UYO4M_V-XZX5]*N5(3V?K36^,^+>+T.B;W.^
M[QIF&9RM_B)V$],CC+CI-32K6;C[-[ LG2/^#2H0)&&3?!>$K/^]JC>.\'FG
MLL8RL,6+^4+&ZP+X,HE9T.A;K6_^3+%1VI-S_($_.K^KCB;GORK1E@QU9OA>
MHJG_=,'P8_Q;L4/BH\E7S+$^/C'E\S.]R0CZ]_T=IP,99$8_=ES;P]#E)(Q:
M8C+6H2[S ;#"4U@%N[/\VRYZ\N32.O/7;;=N Q=J_817/.UO^L!>Y&6:IY@7
M>GH:S8BJ/)/J?3]8!I:.<<[5KBK/Q626$"^?FHP<:<MA!*97?DK8G6XKB1WV
MI MLE%DPD'ZW$B^[_BD!-9<:X4765[/68%C#:2[J5<;L@'Z)OF5-TJE+D'*!
M<[U[0Y1LO_K(VB.U$*-ON3?MR??K173GR;#/Q,[T?[CJRZ]#6I#^H458NMN*
M,H10_2GSUT,FIX)?'G>OF;Q-1OIJ>)P,#L7TNU ]>9$%9P4/L%W[E?L<P^\'
M0*$1EG0%V 3N%FSVBO(U:LCU#GGLXR6CF73CS,RF:&F^F8H^Y:3Z +#X?)>(
M>Z4I$)EL'PU?$-OO2)&6X,O%-]E.=3HC21\E<N%?R8P_&]&)5 G EF.#S.]J
M#(#E(@J;IY0'^@9\TB<:&F/F1</%"LYYV  _ 3@2ZC*OF]2FI@N-*XWOH[Q,
M*'<$@!EK>D?)MG'GUP6HP/K"=&%FF?@?^S;7,]@AIC?+3>;?S&G$3'/&->K/
M9(42[*93!O9$.(L>;\SJI8$3SP.@#>(@<0T:807^3DZ.)2M8W-BX^2=:!MX6
MA-U;K'XJ[OZG,O/U(W!0AFAG/%X!,;5U_%.^^:BW/DG\I]-;UY]BTDAK@KX^
M/(#_K71V1M(&QE1>@#PC,_>ORD.0 =<6_POF8(#\Z^-!9V'0MUT#]XY</1LB
M7Z3=*K\Y%U5RDIE>HUAR[\+8%DS[.5W400KW]'LW--#;Z%@N.+U20L>B0V[Y
M'G%2F%*C6FI:Z%N:S6\W3T"'YJ>30Q(_O,3D\DEU8Y^V&KS^4(=@^?YTGKSA
MY<\4,[7F6'_+*'M\F%"41^C9G&L[@8 ]YW8K#R)@G-O]3@!NS0 ?4^94 _WS
M'SC^EU?5?S^>,?<0L7AOI5R,A"3[6SX&]6M(0"5I<T/ZZ):B3S CBP5F<;U/
MNPN*YKB-:%_,&!>XAI/RR7%YY,  G]G9\H(+II*AZ44*-'\ J+1,LH&7#PF@
M$GOCMT&+6M9'RC?Y25K&,3$ VO<<Z$42(^XWF_".2+.:J?USYO?O>ZBSV&A>
M3L1/K;<[GGWVUASDMX(/JM=4SUO=9(=]]^S,K4Z1,..M;K3)ZPT<E!/^D?D$
M9&Q@^(K.3[%/K3#34BYAWLV+Y)9-X-XFL.#G&<RUK:_(S9 DY;TO[YH#WS'/
M++KCWTSTN/4*X70Y^F!?OI:O(^^_K;S /20.OQ;LU]=FE^97T;M>U)]'5PN2
ME0B0!N92JDN@-6KC=CY]ER)9K^E&5UA3U3)E#UI&$*3([*.K./M@G)-C7H&P
ML,6%#&J6JZYS:GS8KV:TK$O8N5;1Z72/EZ&NI!P?"/BR5=(MMA-WSX#56TKW
MCVL)#&8>273VL "#0!^]$A\ [N(SB2--J'VCM&(UN2_X",(>9R9,& 6,U[BT
M\LZ?_C8T2V2#/YD ,PRVGS^% &2[8VUT!S$B?2C.'^.9]G.0]<;_35[Q8JJ%
M][V0IZ?)+KB9AOW87O_TCWD<@.EU\TA]>>+S14U')N_00W$^A&D_+38SB:QX
M=6KM5?G!GG&NO=E(M=ZG#ILI/R1P_.*0^6/ST@NEQJB<%95- Z#7-1N39R:)
MA=HRN/C>FWAMM]0-'-,I+>'A09I))X\SX9.H6;>DK#<4%KVN"AA@GF\I-=G1
MJ"01R6EGR]FR(,)+(I6JDTJO+TE?_$1L(_G78C['W:1UDDA*C6&A62P/KD@T
MA-?7O?E9HKR=<)!POP 9G.D?VG3R)HI3/]I*5[?CB+8X926^GF])^#SHCM!#
MI?76+&_P Z; 9U'K:5-=QDG[[1CS5\]\!X8=L6RHF4O,*)/.*,XK,EO:2M74
MRD[@1'M%J=>'%H88W/;"HF$@F8K97TS$$ XI=$W2^SU#Z"QAJ&>Z<GIB;#I5
MLHH%FXW^UCOM'^&K*V*C;=-#?IYUI8E2N?*=9J+,9OFR[TU!9&NY>LR:27)Q
M5$T['RJILO6^3:1?>$96\CX <&Y(U7M4TR]A<]>OA+I+]$08N;(S<T>QS+N]
M7(H46(\D+&.7XES4EW9K)#E;JHQKW!CWSAY%0[65>VK<09.T[I-.F:/#)\7B
M5AIODCH\M&POHU(=KHB_Q[)8[1[)GGQJ$P3$A*94F\<<*:85!Z>Q_OHE>2>^
M/5-WP+;>%C82*^HH@<3R%O!UM=9TM6;3K8@M/<S1=)G*6R?S;*W<<_8%,4X7
M$S7&U_O";SEC_)OA%>=#[$)_'@ 5*S--+FU*8+%>]>1*5J5CUW4Q?S,?:ECY
M;3O5:YC(^ A^=MERG? X\TS/%Y@Q]2\0ORP+DT)&FT%4"8L;L6ZJ&>+7&V2%
M"D]WF<%"]:U2_.OL,A1O.5UT 6<$?A/R^RGCO0R68_FS8+N0TG6'6R]O&Y3Y
M\O+19;S*,9/N\H+A80+%L\KE10!5$<$X<^J;OO>GRA.:O#X$Z;]Y6P #\I0R
MKS'RBZQ'[*7>H7V[>2&J_0" ZR.&"8C:'*\&*AD79.Z%W+U1+Z!A=4%9]*="
M8E/JS/\ZHL;)>H,O0<7_S!SX.3;MNNJ#??9L3*+_5A)14Q=Y49^SC]@><N_#
M.:YWK<\JF>N*_^4=C[KG^!G4)X&4]A2,>:I:7OW;8XCASM"F<NROL*6V,EE?
M$>Q@0W=*9*Q*91/S1_=79OKNBPJ:!(^/+Y9*Y?;VP$^W%-N!6Y]8HL**362B
M!7.4HJJ'V+1/=Y4="R.&&:9;K[Q2+1X Z'H1@AJY M=SJ3MYT$MEKOK>^_JR
M4B4*D+U3U-2$$OXZIUR,^!ROK!I"'25!$5?PU:1(HMS+U6?/I(5W&=US3#P5
M?.RD<^=/5)Y3O54\ 4?YH&3MA'B8I'TN4M.FU?27<TI6:!&2# G2*%KF%#)4
MO;.26U14W-S !HE+_RYT)L8C)$O,RU!H?D1X9=/9(JBT<+">CZ&\Z=!-,=QT
MP3:>_SAU0#R^Q+^W; S5<$PA^C'G&%[XK2&Q4$&](SEUW1A$MH*?@&J+;F%J
M+VQ=Z,+=\M)KY41I&;?N#JI#G4%^,5XT68D8#'GE$O^CWSQTS>DI)A:"LXL=
M5CS$U$WHL2/T9"I'0HL:9,&MB*INZK^4+7Q*P##X='BAP"3500,%I,77^!^;
MDI@-?XY6#$B\)4*B\]"KA!??!ZZ\O&#U6\S8!]3.0Q7&WKA%C3:;H<<:(J?P
MZDY=/36KQ?_E3BAE;_&<[FNHC)DTRS!05MUJ6E)'?=YFO?I%RXF6 1%W:?*U
MAOL95_%SP9(?A5-N\9+4+S3&8ZRF8[_+?RN*G0B 0X>>0&^6R7CA-LG@U)J2
MU=^])[)A>2=\8739A]1Q<2<*,NX<J*PR_D[M&>_4L!?Q/+_<G(P[+%JB9ZD#
M/]S$"-UJZ^I7)*_JP.^TRI$S_*R8,8-E;SJC$G(S',]^'42!:J-+&6E_1!UV
MST0=U^:J@S8O\_=J_\X\  +2_OB9WRRH_C@^+,\&S\MOSO]J? D0D2'>T8RY
MJK@$2GY*(,YW<W!Z^<*<R]:7Y _:ET.MI-C![ZBIADG>X G[0SYY*H<Z*YR;
MWAUM\67RDF*51:A2)"%J$JP1S'+@GEH$]R^J_W?LA 9-/-7'4P$MTA&Q^*_4
M6X!8[S3#L52G,B,-UO.!)SUJ;6&-UEZM'=D+O@2MQ/^'M:^ :JO=VDQ+@992
M*!2*2W&GN$,IQ1T27$K1D.*N*4Z#>W%W D6"2_'B[N[N[D.__]X[W[WSSZQ9
MLR9K[9S(.EGGG+SOWL^SSW[WPWL59I6>Y2'3,0:3B"=?]-720/ 5QRI2#'U'
M6J.N+DG52 '7.K#Q6%Y_%($G"C0DQW&"M^::+K^\,\[OM^,:%-W,*<Y)M2PN
MPV^5XB^WE3XKT.8*"BW^6;(H$L<9YW@=[!B8+Q@9[FG1 &T;'8[A5X[1-^#3
MUNY1/Y:_E[)5B5+>D!V<S,3MS<GWL)S1#3*L\+E-:$"I+_K8AZ7S ,!.NH\9
M$@NT=B!CF@DZT5\U%7REL8TX%=S1O'0JG'%N$8!CO&<F-6"0PL<DWZ#"VA3X
MTF"-Y!45%:H(I^,C('F%NZ.226A1?<9*]&.\0R()HCVKUJ2^C5^,?"MMMZQ(
M3!.06] 8]76FA I)V$3 ]*;F5Z>[VD20@Z]W[^9YW$<AO=OG\*@F6@+:2TD]
MB(#,S_)+J\6K_0,T:<?9[F[HN/0M'6;N T!G%!1ENZ8H7O@ H,Q%EL#9K"T+
MV5:<\SZ[T6>.BR]9=KJQ3*7Y#K;_GJ?'&@LC6O]T3T-N3V1WMLF@^/+2=J&5
MD%VCI47ZQ0+G9.>/A44!=<;#$YGZQH;:(\L\C5D]2PW@JH'TZAWOKW/<S1C@
M(_F>1VQMFH9:H:6@).U'U3>USPQY.CU.T"K!<D95QXI'6,=$$3L]B3\P'J7=
MW6G%GUK] -BX EXWU*2T!_YB2YZ]=LJN"Z$=]G3Z_9S(]N0W[LEE+2[5$6=L
M'STKJ&DY=%L5=FZ[.PV=Z*W.XO<G>?X[%^1&@"U+%VP4@X:74@^"7="-@N@[
M( 5R*]$N1H/*?U#5/T#TLY]07';%LQ 5T5L0\9^D'KUY*,4PJY'AMY\"V (&
M\LZK";-!:&*67C)Y*GM=BXXEAF.&;\PN2KD_-M3#;#:!C[-]*U9E\A/A'/N1
MMS;Q:FA-$2/-@")+9)#3?>5[BZ\'#DXFX.^@Q?(4$8;1H%;KO+O=W<XA"62U
MD1+_I.-?VWI"&^@-YKL)IX9W.DS0>=YB8\M<.*W M "F[M/?#B>8MV@%V_R?
MWH[?VU/[8S)T<I(X>@Y)7H]!&B3<VI[?@)[TCY&86: Q9)\9[IXZU0;UL3\?
MO9MGEY>R0! A11LR><Z&=6>/(#32O0P2&:LRGT3 )D,UUG2'J@VV7W%&?8Q>
M3:DCX)XNLB4IQV1N<%-#(&8K2QII%L](0D#U(^]JGWF5*1X\N=VA$/A^NN/O
MKQ@ONF9WFU<71+B64+K)[72D6XRS%U7[R&X+0[R7C$"QM,)M#BBU) +*-U+'
MV;S1&)@73==G8PHEW,$KA9)Q0+-Q/7@.]2EZ$4>$5K0A5TW_V #9F#O J)KI
M>[-PC-O'0XJ9[N*MD>D&O@RQ4;02&YM7&=AMZ']N:\.<7A)Q(OR4/^#CVM8P
M#N!KS30NO/=TX$Y=+M2N0J,BOAG49Y\<GA#E9C<<;O0<_Z#_FCYN_T#(PTU]
MZ(UO/8*<V)NQT]UJJ5-:SUAU1Y7W1+QX,6<+& (LZ1ZYB?>1Q0QU2'XJ63JR
MYI=.*6 <YM@A9'./"UDZ3^*"NT)T)=2<F9?8GY=[;Y [['@E#%]^7]*EE99E
MO'D>.R]M?#Q/+2A"\)LDQ'V"F\3P+4:]2^+Q2,VI2Z,=L246 Q9$N^[>7S+@
M-+'!2L6M)Y]0>LWC@-*)IN'%*:T_.=KN#\SFO$/<I"]31%:\Q?<0C7WRXR2;
MR0N41G]@5$ALK+#;2Q'30L']":7JD<EVBEC1VU<S6[)"(]MQ2FV2L7X_42<:
MONI-9@JT\J]%KU#"#15S!IXL8+&@DH=FU!!"Q,9T2D U1=?BB9T5[SZ*!))"
MA"TPC-<)<#O3%X=0$)RF7S?)2*X)AP) %7'W6E^%0]D>&7CN?KG(_*=?L?WK
MK^7":[T6\O(82UPR7I>7%_?:VK4;;.Z\7)#2P'C"YG/VB!L5^.,(0W*F.;SY
M-H,]O7-".[;U:Y!61H.A_-L_A9 I^?-ZWB/-CJS2S@@'KIN.%%LLGQB)5C5B
MV&C5<M7+FI7OH4C0KI]F/ !4JMX.?PJE<L3_M8K940K?J F,]IJUW*VHD"MQ
MM9D0RZFN\Q_CD5DD[9D=)VE?Z\^EC<&.";O)O$ZPYS<JYXFW737-Z]>8$,T%
MOZ)[B?U\F41CJ)!V+J>XF] D&M0BP=,[ISU<>R,DS"A5N2B06M_FD).=I*9T
MX.N^R2XM9"YUD.%)1.=QK1:Q%E01RC!&"](CPC5.@+C$X_8/#9(ZY\@Z,97N
M?@6X+CKD+O +%BC[$-N*@XK-(R.C8*Y$JK[&N#2(1V]6RLWMSO$ ()UH.CN%
MGNHXU&BD$#P PK07KJ]%KEGX9TJ^_&E2>H+X2_/2#T=9S>3O0F'*8Z?57"'<
MVGR7Z.QAH<IU6/J\EU4M(V#7I,7BCE??\8A-;UHG)T9B^B]+6MD@Y^(10#V)
M+$K24)%:Z  N!RRAG#M=#\A@5Y*P[UX_/D(+I)VUDSM>O5_Q!(V:7P.GC4<R
M.[K38>&M,<+^Y9J5-U&#ZL^B@LJ%4Z*7U-"L73D8N^+N75)<@4>3; +9GS'3
M"@NJ!1)C.;?5.97VV7DCW_GJN%WD#NGYH<2G7_*TJO'G5.72Y!=L,S:^E-9Y
MOA)&YAQJ-^JXCXI#-YL0@RO J-L0L5&AGJ[I'-#L.FLWM:.%G!.:S8&[%FW*
M,/]#.=5S)=0\M;6!O>4!H#Y.45?E?4QG?Z5'R>3V[7,W$D 2)95Z6CJ^=I_-
M4MF\\XVXK#'8 <H@"K9B;MMEI_S^DNT66;-Q""'/C'MPNE,',O3C:/F-.4*1
MT[$O+:"O$H+K.",U6F*1L#ZA6)N";.&OL6RB-!^/5$)YDL]R^NI+LW()9^&,
M@^/S' T",;9-%$DMIM84'D3ORXVK&"$4>2#<0_W#>!&2KMX6WOCX%4"6JX[B
MQE9<J6SD@(O1R\H +#2Z:B2);CQ#)@HRI*4ZDRL1UQNUMU"5HK_+SM6=NDJU
MVWM=9GEM9*?2O-1GN\U+535TL!:Z^.8E==W[<(QL*>)[G-WV/B*]=6-<3UU,
M-?_IY75=]B/R*COBX0KTM]PDH%!>P5!,N"0D>QMO?&1V6F-V +FZ=[@=RSC8
MD.\+O\V.3"]?[ 6#LNZ<?[P!;;.NMJH;+^&UD#2E;!3^":YBW"_+-%LH_TK.
M2 E\-ZTAH=]YC^7%Z_ZC\$C#&_C@/<YTZ?N\;"CM%SBNU0VK$K_5>=RDI6=S
MG>FT>^;:?C];78Z=ZJ2SD_88^<GI'<7U_FO'JW#M\F(/=N2WQGSBYE.)XM(V
M5ES9K3.SK50<$M9'O[,U%=-1LR6E3!;\R0C+)-R\)==T&ZSUB'@G/E_S'!>?
M1Q%T[_PC]:HNOPA%DRW2S[=69JN5[)Q5/.(B"0BPY&K"PH4)K494D/H C,-^
MEE@,V;MYO%'4UD!1U*2B?,3AND!Z[073B!\K?'$_<T^@N5=QG[T9M9T7O9Z*
M$_J!2/RDQ7$'7?XEGZ<T&]Q^.3J&VWD==8:3TBZV_"D\J255QD,2]3KF&AC]
M8I_2-LL-!-$+%MH>4_'7&$JURSOO(Y'1?\D\D7JK'UCED_'#'K;%<>G-6'=2
M?D'I>,MVNY-PZ6,LG+FHJ\(ECA[Q_0,M[1K?O6;Z+ET=I[-0]$(=I= K#7;W
M.0AAOY[4K O!<G$< 4H9O^I%".X/UWL0>[<'(Q]5_KB,Q/<$>FJ%,C5S:=6B
MZ+?Q:=2_:(?CC6;BLX3DU1=B**>#Z-E]W49EOQ1_I3Q*R<B5)#=R[YDE3(LT
M1.>WI\C!4,<(@ 6AK9T:6U6W:P^.+COI42FUSN<Q,C4(JYWNF@.3H]9L(C;-
M7L9%&9X0X5J)J3+MYAIE6A?@H_-(0-'B:3&XI2_)9,0:.N>UJ+H:,(>:.M++
M:FC?__9TV$I(IGI?JK:F:)[MF2+7Q>YZ=I9.V*)+4$"80E@@26>O1O*\3X:P
M:(S]M[FS>?'CA^$C3"CPE[SG)3]<4U)ETK^F&)Y<2&HE*C>]5<O*OUNQ]KD>
M-%:1OPG,+%X@V'@;05Q ED@R,URGB+EE*#,\S(TT$+41?7/MB=OC+";-$^=_
M;_,CW2I.I.T!<&=^4&BN?".WVCXJS:#\QTG^0V%0\?\V+?K%.5/O > +E<&C
M)Y3FJ)8:ZFH^V]K3:"0\:KL>_UG)H_;S(]5'Y4PF:8-^/N'XVWR=KG%?X]\7
M EITQ DG/0.!6M&$R>U9_!85*3I%02%KB:@D3]+K'J?MR&686%&?9.NU92%=
M[/K"Q2_#OA 8M] +$BCABNJR^"E[7L,PI;C0QUBUSDI(?LT1L61+V8XC6IFO
MG&\4)6HU;\96>,%(@G&R0.NU20Q][/C"1=OG'DH\=P]%Q9:*G;Z5RY#"OE1&
MJ:HH$L<7&"*4*N)'-,>,W^*F@6:I;:_+?I*%,&88!F;%Q*92#M$5><CJRD+1
MNXJFGB4+_CP*^(V:9 ?+7L)\H^,<MJ=O5N5/1E4L6*9@MY/@Q'4>L:Z\W1\+
M6SH-(Y[?%GX7)!_9/47I0O R_VNPZ<)T'>Q-]9(*AWJ@LCA.S[]JO/\;8UC8
MJG3-KO$^1HX1,,V[)AUK,5_ 9*%@9HE['\]_I4+\_IK4O^$M;!C7^-7W:)PJ
M09;]COWF;MT9V9>8!\4B6B5Z9U0VO8G4(53ZDDJ2.QH3>EB#Q5VLGP,[\P-C
M1++M.W$:A]GL]26<SW"WAF\%ALGN="Z4[_#)-I0> "V5(R</@'<OFW+>W#(J
M%HW03DF=N#*.9%PZ9:7?K5ZH>&A@KFFI-;X>A$LQ?HY\OVE,W90LVRZ6QL N
MF##>O7UUKJ7=PP']65-<)WWIYL"FR<7WZ<5$M\(C5Q/5^XZCW))($4*I_TD)
M=4NQR/1[U*4]9PA.%0-X6C<EQFI5\U=IKMUHU>A%H;VR3M^"FL7/?TA0/D%/
M,8M'E^&H".G,N!E9"3'408]TH3JC'4\5!R#!%7EF;\V?C.<F[GMR/OFK=<"[
M9OSLC&]\,T0N:>,?KXR0:6GO4K7F:FI"QU%BQ7YMHJIX,/A5#.M ;&.LYB2R
M;>X]-FLCK$J@Y;_?X:V;D-B%W3>XSZ,IM1B8Y G4R.<M%,[LCQP*H76-Y=5<
M4TU%]]D4S&-Z^I2A;<*9,\I])<GTERU7A[4TVTW?_N[4*W)-*-5UT5,[O"C1
M/0'%'E1%LK<M"^76O*+PL3XK@@B<QJF[?RJ@(A+#J'>"@Q.-L'DN@*G#-7M8
M/.: !X"#=-&)G+C4\N%HVD7,PF(33:>_KRY#I$>(A\+(7F6S\B][@6A2_])=
MJ[61=3:I%V$B[*29L^JR0,0K/M8WUBV]J*]V=LUZC[?+\DI_2)H''>E/S..[
M?P)ZQ(#VFWY5$1_)XD<0XPJ]$G"]AG4.,Q?OK8?+9'_I_.B::CY9(HD4F!^8
M5@#T":[-,=!*R.7!KTN;;\P(V;I;$L>=-"+] G4&"7WL9UQ57?\:([P#ZF8D
M/*6?R-D:59?+4U"*XW1BW[5:#S4 N]:?:F)"2^!F$K&#D8:@CZXKP<,N@X(Y
MS)O](@$-LAH&=+:2L:H;Y4,-$S%]#/W[6UHW 8ED%WYV0]HR7/4Q5Y\2>QS;
MK>09FE]V;Z!E<B5GQ>>X[*\95HKYH52?, "/\&&<NONIW,EQT.2(8E(5/[X^
MB]*<B]<9L2ZX0">N "B\(CYT@J'AY86(3.1J9>F/O9]OWW09?GOT>-<%[:%1
MN)6D.M*LF\(Q [#"X$[%*0.A:0_3A88F9N$;/!G.O&+SVIY26>DR&^LX5>Y?
M]=]<$5970U!WH&U-*)YU'2R?W'5<J+A:=J]&M.+4F(317*5Y#2N45 62J-UX
M[Q$860BSS- F\K377\"-*0 ?SJX[$WR:DSFWNF\ 9V8%_JGZ\%4M'&HW,%NA
M=^.';3U",@F<;87HFLR:D/0!3LO#GHCG!$0!8GO:>N[Z"SC1P$7K)E!&W@F?
M=N%M@%8N(I6KB#45\_84QR.#[&J3GJZX]9WGT)_W7<;>&GH<Y*WT*,GB].+2
MFMX6YB9FQ91EL03]LWSX(@I@^S"6P=F6D_36U2=;,..B$-(:NY=L[SH^B"2_
MAV9>!H8.AZV+7(^=V)NB*:53-;ZH=;V:@T9LRLLH0&I5N#U'4&_/M(3_>I9A
MW%(4U$>(/@"$U,+^:Q.9IV]NH_4T*"#QIB%@_&?;%WJ#K=H8W4@6G#45G5*M
MN.GS,;9:>X*M** EUXRS$5M'"#W)1'J1QE+MF.5+;,7"E"!=*NLLFP(_5#,D
MWA+:5\%MZV@J:0U):L/F>[=-2_T)T?F#9:GU-S@&XZ8)'YN,GU?S,K4!43Q4
M[/IZE3&_JO7ACAY?]=.#X+1;9O>R9QSGVRQ'WK?=L<SG#B)F32?2>Y.>\86I
M7ZL> "D]TN).RIF$[Y5"=NOJ[DTXHJ+J\/9B%TZFH%K"4Q:/)Q,;"1N-\/SK
M9=Q9;J>@2BG6;_Q0*5P2;I'+NP= )73\&_.0.,XW>I*8UW6O<= CP>9!(M,+
M(L?-BD@W&Q-;'Y[N5X<KDK^3O*X0"LB_R#?+^/'WEB;_,E'7%./@KFW_W"SR
M]PRN6#Z:8P$5N73"^>GMQUT<2*+NNE*I\W+W^O>UFXRT<MY3K,7NL29LMYE"
M :ZZYF U3G\*SZ\',Q,DA<T]!?4H&ANJ>FKG$_ FD5_[;9(S7YA)6*U^E^1O
MUUV(6BZP2M@L3((L.$!5@PA@V2BUML/HFSZ_+%ZBN#7RE"G\SL&Q.0Z9F4HW
MOXV"]+U]2/\].\^M7 7B 9##!#W:'G@AB[-^@BY;/B59!IW8'I!]\C&4IO97
MITGR0H+Z[8!<I;:'!-_&]RZ_?8*T6.YF_"?2JO>'5H:G)<*7,4L6MN<:9QJ6
MA-<O[:<I@4^E G2.+AJ;LAT]G^LVH@U+WKU'/>-JTCO-9Q@=]E"0T9B.=V17
MR2UAA.C-N)>LNJ#Z--+TF!B.G*V#/Y,QZ)+J"B&YAGDB=B*DB0^S2OGK+=,C
MHE??"WHSAAWAM7K0ZM7C1=1-*71>-,J$E+FME%X4EW7T,PNWS/<#/BE)E.8H
M* #:F03-6XY2"C-9N>'?VFS'6W()1&!">&=KEV^&7S]O!OA,#@_IT@9_JJS<
M;H]]WDIZ(RXKCHOE:W!8^*KRXD^26TR/,_S+)S728 X0D4RY*>;:9Y\DI.9"
MA"1PG//N[>#L-IYR,YE%9^PY4C[7@#;FQV+$E]0"B8ID=6HTI[K-H#'-M5AM
M'PMSG-_5)R0U&N4[VQZ%7>[21UK'APV5WPD0WXXVJJ['KQVU]NI1[=PP?>'+
M_,;#NN4<7<Q=:&78BKT*3J1L,PBZ90,5]W AK2EF=QH2]1*CF3+U6_TKCZ4'
MP'-X<E7(XR ML7JD/#Z]%#K(WX^?+CKB]Z-6N79;2-=;+5_9:S)=;*K)K\M6
MXYA:/W^6DF:4A,&O;FQH0C-JXN9_DD!1U"OYZAUI"HS-:]]M].U%96&)^1,@
M$F=@S@?A$X85E+)"!OO(#7/ZIH9S8AN5BZR1Z)5G&>=K,\"XJ)'2?&)I=&D<
MJ7Q".A ('X#Q374SHRX,JVZ[(Q9$SD%'FZ.HY6#''Y68K!RA8/V1V;[@?9HI
M+PFD[]<ZF7:A&AJWDF.31S]L5"CZR\Q8A&[G^E1O2IYY:+3['7V&4!7MQ@-@
M!RX#-S6I]%9*)JG"S 9]Y<P.\@-5,0:=SJ'A8F<M7]2:Y:8+6V0%GTG>0^\+
MQO*6O=ZY$* (ME:'N496_%**)<,DY'"R&3D:.:2I&-WF8TD7QU$W"/\GRN D
M:U?NNB\MD/JO9;M*R$+2,9R%G89^&L11F]P)QP1<X(1IWG>D6@7(S+-'82T-
MD#]KMC R'P!Z90^ 39IZ35>TC>)3(9TR^LJ%LY\5RN*VI+^5Q5GHGC!(F<;.
M7;2M:<\T\.#\R*&T7= )[+P/S]:!VAL1INUP%[H>H!GFJ@Z"F-2*OUM'=!]6
MH<CA"J\@!!8DQ& PV^^ZXATQUH+M5]IYJ.2P&?_/S33?&T9A'G-E<S,5%A,%
MJ6(:T_8#5M;C94?]*&Z$;NS FHGXA2G=EW4&M$<8^*Z$I3KG43:K<[ZTJU%K
M(GIC@PG[N2QF2;@&/8Q8BG0P]K85W+5Y[B,V'WN;!@=AYK&0D,S%%=B10!["
MZLV"+&DRF'FDA+D<7S]?$,TNZ7--UFY]OTRD&W-WA[R8BB&=1Z B<IA6[/C]
MC72-&"5VUN&O(_78%Q9 [8&7K9R?&3M6D.4EA1,]"B4L['>D64Q_6^2'1;M&
M.N.N=9*Q@@^X>NX@=MM'?"AO4_3WEFA[8PZ&&L=/IAR$("V$EPU5(,>N=HN=
M!"WSM\%/O:5*< [O,]W2MZ&&]3 IFH\\DN3-N'NU>OGHYU(G4IF435IG.%'J
MBF)K^8U6#BE"><Y.*L-GHDZY751OWE$;A7DSL.[VV>F,4B8"JQ/61OQ8 &A"
MWP!HYT0UNT:T7Y$'\I?SBX*(3 2<XQ8(BHQW7:ZF=>;V2N;-?B)(DU^2XHT0
M=@SA^F,P9KI@XS!3(BO/3G!7701S9T;L!LF9%>>XL__N=>/BT64.#5Q*F/-;
M75[>EP8:2*]L*8$&=NOZZH(U2->S B2KXYU0/C3FU,S-\/,MX3;Z RL/^]FH
M#!INQO@X Q-_S$5-GNA*#5)U<A1[Q,8R/^='<0D<^$RWZN%W%DCMEF1H=H)T
M7,NS)7??6Z^&_''5_MU.'2$Z[P- Y^H:[:L6E4)B@L2V)$Y#8D,1F;9?B1WL
MYFW&+&=(F M872H^U"A&<AM2?=]2=7^;FLP ?L]$%=/C;2.6R])R/<M/[,XO
M2'[;OBKL YNH&"9S[8AX+N8:K*Z,HY3A@TW^S/I#'FL6VY5<[OJS</-L#(T3
M#A$X7T\L'6Q&LBH@KA=^,)QDHBW@'\QBR"LBDS*_18N_>9^Z!+0*Y)'W20+0
M R.#<=*,Y67L;/+TP1F1J.\ZWD,H8(PIV9(".IO9TJH-/Y3%<2/R_DQ#Q%+J
MY=E_+,AUG?^?"W+=<.Z1-\.2X;?2KDV]=!FP\O^H;2FQLUN-@7&>T$)KX^\4
MT](P3#M2"*K&#;!%\?F#T)D\<DCO?YR5O!H]A80P+(T#O^9/3^'3>;SRX+"P
M6-V/E'C<K_$!,.B*UG[$XV>!N"0897+RLB8.)7;EN1Q50#/OW6S]8AH0LU*P
MW52<V\^IME^SE-A'L;7BK"MSK!3ZX0RUNHAA*8F8)/YTE'&DA-2,3?2)E]"3
M$O'+@E=MI(1-?M(5D3WFO,1(QTD>-K>%_1#XX.U7IHJP75U3N2"U81_+4'H,
M0LK[KM,^+/,^X:QQWYI,%8;SQI2<IF^=?F<S/<QO3UK-+SR5V77C9S88^/=0
M&S0.F;"T+D?:'0_)I;Y4U'SZX+G]'8"4D)OKO-.J1=U5/^Q.N3J/S! IU+]8
M<\M(^>'HVS!7G[9J2F_O=#![APK/].LZE &^Q2]P&89.SOS15*&H<FV>\?NB
MZ<.[T034%J(Y0P52M4P[1^:$1<SX-Z$!5=#^HENA42M!211$&N3-K-Z4M-EP
M8>]-KQRFB>#J!N7=]-HMVW)Y^N0<V&E<.F^+Q_"BLG]&R@HD5'!T%)N8L^E4
MZQ3 J?[3;:C,+;X8O5AUD'1.<>-CY-"L UW?B62<VGZJU818VF%HNEVV^[L)
M*Z95-AU)ZQDJ '96 7KP1;X@ZK(\Z)9Z67K?BKHVLE^$'R6Y*OI+;KAB$V^Q
MF.*1CIHPRJ@[_]>Y^>./RS;D3X0/OMI=>+B-$M+"# ?=!8HUA#(?3UP;J= /
MZU"2DO@L)]<$L4F_-)LIT*DV,9=[^R;[TK#07(^FZH@[L6A!T0/"E2BEXLB,
M"!6E'-GD7<XX!'Z96'J;Z0(IF#&;B..9_Y3@.[4$T*&C#'<12;851CX*UL-,
M5(K4QJN]T6V*?"KUQJJ)?#VJ5?A]D-308W#0EM-5E:RQ>M_<9$B5.J^V-^@)
M'(V-X\B74(]C&-ZZFTG^>C%MZ\XUSFFAV*%&V#[#WF=X4E?V6N(#$T=4OS "
MHG9$D[NTX'./:\&P.J-H$P..$?V<28M$6=.YIF.2O=Q'[FQN@2EZ>#W9:7M3
MS,)B?)+]U?")-K%]GD/)V\Y"9YY/@VI]RQX\ CGL3ZE^[[*U8WC4/4V;*ZYH
M.*LR+/Y9EW*SJ!C(4IS-/BOK/D!9I4:52Y-Q^0B&J4XZ'@!GN]!3;76>)46"
MUG0P86A0_E;JM!;H_&4+]>3O^;1[_7"X&S2P5CAQ:4Y5;+B><[RRJG(/W\ZN
M4?&]]TL^RHC@SVYD6CBQ(3^3Z;/I\O9'ME99$A]_&57K ?"S"'HCD[P\<$7I
MB?8 *(Z$[H[USS@7"$ #XN;QN"V'=>;@CY )90S)E,CFOK/$M2G[<D;Q > K
M(8+A'/#)0F9\7OY\6%PD^L@TR91TXR3; >*"L]4G#/$HO(4;.HBLSC7MDT-/
M#> O+4SECD3\.8F$.#J8EW;NA)&]X/@_AL$?R-@8)$3)4^X@">.-Y!KFI&C0
M5QIF(E/GRY\/HQ.M0:@B/ 1,"K9@JJ.2  =='D4?_<.TFMKR#RD>\,YP*J2;
M7QBN=J#>NE/**?G"ZC.KW%LVU+;1B8FV\-37U$$*%ITQ-B8_-%<&T&UM%<V7
M=]*/ F!K1R:%N,T(65EM,]^WE5L#<?B[BG8ZUY122UBR;+P ]"C-'O7T"7'>
M$1DM0D^21YRQ5S7Z & XA;PD2E8Y8F9:867TE!&2WF5\T^R)/,I%-)I$C]Z@
M<?>[?-LMU4#O(&/3,8$D-^IKC>,#0),1,W[@TDWM='-F/F)M^>CB;@YO^P'0
M<_N[XM73!=&RX\S6_ML>%C[#3:%"/1ACVK'W7^HA7@?,F0):]G-W8P)AJWPY
M=T5-UX4NJ;/%0]<GUTK("0R55F27!H%ND1O7*G?Q,W<6O?#=)KH[NJ>F]L'&
M4^IW*[!"&Z<7<N_8B4_%:7)DI5ZO?LJZKA+IC_2$97IMTK-G5HM3=5"_L KE
M_SUY1P^R) X?+C"\"4H='5W\_$1>L?X!H(7<T$%DW\S2?PM] _43!Q-*X&<P
M; Q^*9*Q>>-!'XXN><;I0'BI22TI^,+.BKG>AZW;G_L:RT=%62YJ%?YQ7)=,
MN^[G#XO(>9/@L/3\9S6XT[=?![5:VY0@RC3DC?)E6-.@E3-\D627V3?[RGTF
M0[4Q9YS#^J[)U$7M42@YTAY;A#3F60AV:<WOS J1P\P<\D89_7(<80KF";(*
M57$64\\.P9R@4^[Q#T1WL?F1JD2?CW/*(XZS!4)C.&VM=+-N6[/%_>P^)#>Q
MI\:-%TF^#[?P; @Q:1=N1=0ZX=+SKA+G9V^J1W'B3M/N/,:V_(L7>*YG^XS"
M?,VZ8;]W/1A CM^;43<]S&6:YO5#%=FX23/W1VBMV(=&SY HTEAX'59$TC/
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M7RQ_N8RY^(ENUEC%C_3F+95!G5'-9S[%A-FA7P)0<VTT"Q;:<F')M.COYSS
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M,<#4FZFM5P3FN'!M?\<P3N)@\J:/^ISRHGS#0Z39-?G6ZVE2ZM)WV:HMW?N
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MIO=]]N/GH=G-Z\IOPX^MI^(FF6P'LZT!8]%/:O$ZBD(/]\-7#.+SB-+9@:L
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M*G'V'-[@EX:\IL7?JAQ.KO ";RU21PE'W&%O'%@N'%"15T./ETF[]*'7[;A
M@U;0WXH CEM8SF_?*^NW B!SP_*3R6_?2_J?,A2_P ;VQZ'^AQ#J#7B^35P'
M'9\!.2W@T;4!%;-X76[CZZQC8Y.Y2!E233C!>K):4G3%YKV*A:/38\5Z%S1.
M;7GIV!WSVJHHRH.7<!8[O-4\4I54XF;AI.L&_7G=]"4I=]]'R:(*XL?3A[:/
M>9(?K-J8<#.LE!TZP]:-NJKW(G=#:'NV^*>G#964J]AI]*)%9Y)7)$S3VS,V
M\BI^4 T7(4=2$ECRT":IA"3U+.I)RB,+=1&PV ;'BY4=KDDSUT2AV*M:_D]]
M(ST@UL<S-S2"!,4I$^PK0ZX)3RGK6C!FO+1\:O=7-R?'_[4+-1:XZYNC6*#_
MD& #P5-_G#-,^6I1Q'%4SJ=U;Q.+[7_K6F4_(U/A)\J*4VZB?+1Q0M-BZ%G?
MZ!3)AGY%^@N*^CEAM]_5:T\N3W(F_58;1?]VZ_QQ\.\KQ7_=P8?2#!O%K@6^
M 72G5$W/<4?[D438KK]9'\IEKZGWKCW?6TF'J^G>YG=X=$E$L<MHOKIRQY[E
M%>4,=P39C9'D74A@G71.JWUR7_KBJCT^^"G; (GW<9%[LR-W W?I#"S>.3I/
M RTTA4P<;HW;B)&J=&JQB&!U?/,4Z%[>7N_>\.7X+(H!J)!Z/E)[O0Y<DH5?
M-0G.NR;Z),_'+J=.CXG$&LE,F8=6@J#6&Q+F"SE#S,$[8Y[9"+=)=67B+='Y
M5]ZTR^SW)3LZUGD+G]9$[SP,Z*R0AQCV!PE19^R-ICC!^U9(3WG,'2,[Z8-N
MCO7_EETQ/?\*JOF_;>@?=U;6L3YVK*R#MXV+TJO%>]2N6O:*(ZZ4DK^)SY;_
MC,^&01K51R"G>3B(AT8R-,FS0[>K4SV>UG&"3SZDG[F>?.PZL+[!:V7'%$7=
M=^>V<35Z$6:B,;6I+WRR-]GTN9DZ2HB>/5V>S PJ+2*2R731\QP7 S#:?M^[
M!+N(M/5#C4?X^HW?1#_BNA^&;X$!GDU"_0XQ .X+K."NH=O+T1??T?B]&*!]
M+(@"!W81;G5QWH\BQ4XM/.N<:OC\%(:DPRJ-&_H43_"A)SRYI[O2>\(.Z#O1
M6P:0W5GHO.T<RLA2388& TQ4P.9^XIUOC<@:Z1([Z49/#!!0!MUWS9 '_G_^
MW,VN.KGG+AC@FO%4S$M6[NPX98+8[N7QBG'P$I2T(=^^\L2J9H.R]29]5^,B
M1X9 S^: %,W12$,)UD69)[P9(XM'?\U;.RUVD51.CIR8*L2S:JY>Q&4=M?Z9
M91RZ_'1$>K,6*I9#H2K8?9VD[/,32>5<PVEE=U>>KVV><25N34W=1<--#;1Q
M!@FC14M<%- -RC>STK-G1'AN+RV%2PS::;SK,B^+UKV[2F!:&Q;_ITS0?/M_
M"0O_VYY[-=+:J]L;^]SA?[+(,+#R\AG//O!=.21 2R='1F59?"W)698KD*DU
MA#8IWT-=]2W0#@-R[%Q)IXV?7V60;=[2/".;&!G5/X58O)W5*VWWP+_KMY5U
M7BA=K*9BX984DZ3%OO%0F<Y5@4$V73Z,/:_H#@NBTC.'E3FJE36MR3N^'1!>
MW: 3K>O^ *2PX]Z*?DK@_(3[QNF$5<JW^UZ*-/@:QY(WUN[Z;J@0WV.$5!KG
MG:N XB2691H"YT;&(G$YY+-UVZ;0?:7*&$#R]FT%U-1M^"?F",X\1G^-O'2\
MIB.*IUY$^NPX?)*7J1E?)88!CT"R"@3I.9G^Y+@#:@%K')9_<R?*Z,54B0TI
MAII70E\#W-,9NE8K+--!L#/78LB><)"50W;KIZU#^^_JL@[S-"RX!YNZLWQ[
MKRL.N_/6!V]40I-UWS[/V)$Y*I+EM5^4I7=WY_^T1VENCKN'7^#(&%#D8=8F
M=C'W7G(T^V7Q69Y<!86?(<SK<+/6HJPN;?(^<2N+0IL+*[T&!BC_60@$O8O&
M (W(T1DZV<;QG7VBRJ24;O'ON.-IJ_YB)L%GWD+M8^D;;IPA,6=I'^NQ<] R
M$GE<.53(7%9AJ$B-4MY1-<@W^[OG_SN=5#VR8DR7%!@CTH?7THE 67J)O)>$
M"F"+E7:P=_3@-MJ E;KA8'O_Z@H&B\B7:Y)ZWA>*RUSZ84 !?2BW#:MM4<3=
MPMR;8;X6$-#)@XY5,O3K[P(=8@^@#5G#(WY"F80L++$RK^+3NW,*3S0*#.MP
M7Y8$E7#A1M_KW .=*$(UV@%B=T>_=I<5"#L]73Z^CN1)].(%0?VC&J':IS-U
ME9%S_;;%%WM2)D/EE%H4G'E:N "._V4>7)8H0E/J*/:!JU_2-?8D+_-0 .\8
M7T6 9%7D@=L$Z5FX ^J#,E<"UMBQ,RY_<@D[:;Z?G7#Z/,95[!1;AZB37#Z3
M<09,7VW,/2AFWC:1(8L-'*I;:I>ZDGQON6$HZY#9+*G2N&!'4EZPK1VQIYU:
M8$EF9)54Z@N/53ZDIB!%R?C?%1^[J&$+JKNY9SW.P4\T?T>9-"U$P%B[=/I;
M5U=<K_V/'PFZ&2AY8;V5U(!DJUNF37?OF9T-?R;9-3IMC>2OG-YPNG.#4=-S
M=SJY=4"""5KXL%C0P<YJI&OI\IO,L.-P%25N.[.*R@A6M0C.,#H\E3_,13/B
M/UA6%H4HOJY"2<)>L3 @XW;TLRUC49]0Z4;[#@'D]B9R-=W1-_>5B4A%:P&
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M4 5OJF_>]MIBP #DJ(*R[ >Z@VH4/TLGIU,@6/[B_^D9KB>ZJS8H4:A,:O[
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M[6/X8SOI1U]ZN0<?EKPBN,G_5$$,W*1#4(#,7;BVA^A\LYC8NZ3B%L5"&=A
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M#]$!J^.)CJLRNX^BRE^H"7Z<TODJ;6Y.3GCJI9R>(%'(-]] 38X0WSVW4QQ
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MI:G6C@.,7_RE%8 ^<CB&) <YQ7%[1Y"^Z?PF1#9$\]5UC96;$/L_>/ABPSQ
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M627(.\G]N!C'F&:"T&94[>$O>I)V/.]ZQ*XO;8-(W'PL5U@MN(DL7^$  MB
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M-E9HHK6QM+"L#A%FE+P@L%ZBAK9*P#,C!659UBZ:JQ:O<UUY&^J61(+E4*L
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MJ*O;F9@_M#G8.+$XSN/UM& K\?#B; Y4Y8EZ$*S$MXVX_WGW=O&?[N[,M<)
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MCTYS0UA]ZS3]UQRS8FZ.R183XAYIO;#:WFDWWY[FNO=Z+NMTYM-4WL1[?\R
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M,^!\@7_P2*CMR=)\?8VM?>Z" L.(B7";]PL+2>Z8UNAYNBF,!.H7^J3;ZOH
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MN@15&]\Q7[&*+/!_O;@QMF4,[EC4HI<(/AT*=9=Y@$2FV)\'<ZQD& $EKN:
M+_Z0TN&Z,3:O$%U4^M@7R%W;C[/TMLW'V/T$5IYH )N6Y-'8E)CR#:#/5!3M
M5VP@$>G?7;2=[!(:=9!G)?XYINC:#VF#7X[^7(1NT)@4R$<&9](=[&G5OTF4
MP&.?&EMA0YE0)#Q87Q"+;(ZT8SM9[)N]G8MGR2>!-]MF%X)NAU_K=<G35$[7
MJN6H%;:KJLN:=RI'+69?Z!BU"4(KW, AAL$U5ML-E09A<3\4\2IE_$7QIB9,
MA6&9C!AEU%C(NV3%(*V&XV3[T5R?1IJA^!=] =0!3^Z(%:^-A<K?NP%\6= B
M0/_Z=;M.ZS&$01QQ1Q#/L8 D4)%Q6Y$IB_)U#F2J-T,$ZI89(<^,O,Z;$,P$
M-XPIA](#A5G9<_,]FV>&ZPTI<CWQ;MD(Y,7=8<)+5&/U4P*8YD"NUHXBQ!R9
MO.01KZ ?HM6_M7F]Z6=4K.6D[KBP,([DH(%82T3**L):Q2?97F'Y$]B^"X<B
M I]H;KG&I=W*\ATG+D9W[1E7(^L.^H,/+)IG$JSCR"(2/S4'([C0ZNRM14@_
M:),O+$(]AGI1Q?XGCN](\\Y^K!CV0"5@)(^,TP\K$(X4('YHG8F/G=!!BT4;
M\6?\>\_>D$6^RS!L!A+L>?KT!XB.6.O(VT]#-PU 1:C&0!_>2[<LBJ3PXS(9
M?70J@J<9,I5=B]S,9(V,50%_'!'-<N.6T"HS1?)$GY6I]*8D!V&TK!WIJ\PY
M4K<,$S9^M0M93!T5LZ_@L/KT__/1SG\^KF94[>L97D'_)@UAEU_NV3\Q*!$@
MM@V/6H\KS2,)S0^3\0%(CQ-'8*31(KE>#1T+_@V>/S\Z:3E]6&:E^$PTSZ3\
M-._4,-D,F=[?*: \UFO(/52L7QM(^OTH6SE19-D8H*RLPG@Q4 S"0PF"B=%\
MW<^:D,$MSF)5"6YQ'<_J=YCZGLJQT'IEOD;I]3WZ5"LGT=V0HAM;<T?008BV
M@JMIS8G(B?BU CO*PI,]NW!QY7FFH%?2V[%LIO+G\,,RUUR0,%2PC#5O..*V
MNR0?6Q<-9?F=\G:MFAC-J;+2G+%D1YJ>O$O>7DOT6'<8?.SVKC1_I7)3#'4+
M!5WGKP3T9P7&51)1(SD>6%_LO6"AIYO4LL>\! ,CHVI'?<0PS6JD0_*:+DHH
MU.V'X%\-3H/.#VJJ?_.]$2'_24OU5.N570BR(;IN#&!#A;;KD:>>*6BL7F:]
M:]"_R5V<(84!/]9[NZ8*,2M7+]TU?7QB7[MX,#&_XT(XK).VGB$R!;!>^7O4
M8N0GC%S.RHHQVM%T1DQF,<F[HLR>7KL[)MGYG6N\VN5,&=@@TPR="HNALLF@
MGWUL'>@6?JB>*O18FAZ?NUBJX['4@6$;?3L42\723OGQD@V;FRO6K6X+MF#X
MT<G&2)%.S!8F5E=HU_84U1[UR<%M3_V:M)N^771S5TRO66H;CR 2*7F0 AA%
M]]X 'I#"_NZ4.5#]>7%PYP; #0/O'0/WM$%&U2U-J*. !PUU&3;PMN$8U@^!
ME$\%U?"CSSP1,_DC1]TSX9,+MNM7QM:6.LF26Y59I/)RR-%">/L7W6:/6%>W
M*J-ASN6&$1)(N1;;R5B^*[-9KYT<\5_UR*-(60YPP6,/^/*YXO<?SPYX;#L!
M5U8M9K0+7CF.P?5@9+B)7'T9P9/!2K[#Q&?FL0ZL[*[H]TU@M.'LK"&_K73F
M9S'?*(.<XP^?RT[(8J+5!G96 F1B0L:]-#G(2KQ$*\Z-JY/OO3A\BWQ*<?PB
M(TWO+10RN]80= :\XZ6+N#(@8]"K^;UJ-0K*QP?XWMTYK7B11<F$+.) 3K8)
M,#)>,6*UI^2%E!ZVHB@[5^@S7C7;#V=\*J*08)O;0A+XBZGHM$U#B%']ABC"
ML9 SEF6@]F>+<'75H1L &0A+>+O7+9-&5N"G5XGF.,8 -I A9Z?UMC%ZQ2SQ
MQVW*VB",POD%9X <QQ6_%G8$.W)%R_'^&%/!-<0BCF#LS_>Z 70!1;I7:3 F
ML-O< @4=([*W]3.%R #XP/U*@HL%?G-YH=7\T(;,3L.Y6>(!^R3\C>1^;1R=
M&-% YG:FE"<XEWAE]GR\:P#E%AR_^'IG2?&"A]6#A!=_JJ1/UOH&P,.UAJ.]
MQQR7M#/[9PBL4'5+\GDH,G':HZ85XO&1_4-4^*-E"<*JS]/^;GAFYZ%?C'=,
M60/B"9H_OXR>-];[:8OEF#P](!%@9V%QMHSS5N9BY.MFE&([68&L(LH29S8J
M@I7*2D^^33\')C+YY>(G?.[UV0!X572XT4LW1(MNJY.JJ\_UZ"2D0WX!XRLV
MU) NC&='3.CVGI3 TMD=S_6>0SSA;(&.4YC")4D#TO37X6PONZQOJ@%,S=%"
M^(<%'ZMC:ES<F,[O&5)?>T<80Y18Q$"M7:M>MT_)[\726=>N]7@\]GFN'07V
MJ'(O8K59D%:^5["!0UD=N5B0\OGP3V[ EMV&&E?16O2="E%T=K[1'I@%\J#0
M)! ZU57"%Q2UUQIFEKUCY&'*C4J.QI@5J.7.[3)3A@@8N:\WZ/RLZZ/P"%#V
M[F#U2=#V@OXZ-(LQI6J*AGH&2@9XZXKSMO\OXMX[K*EO6QM=@%*D1$!Z"5)$
M1$!Z;R)-1%"17E1 FH#T "&A2.\@H"@$Z4I36NB]BM*;]"0H32"A1@CAYK?W
M^?8^^]QSSO?=>\_SW#_F/RM/5K+FF/,=[YAKC'=('RITY('T6Z,FND\N;@\C
M'#VI?H@Y0,:O=X75D7;,@MDK@C N(S>B:'EYX>];?HNTY=W=61\+5._<!%FG
M[[BMOXL1:*K/7')<O%+Z8/+XPI,XG"?=\A:"VJ%UU,^&X1QX,&:+*JII^Q+_
M;8[KRX,#<*P,63I:U15^&:J+[6O-AUC9?,F=?IGE;6WQ!_:,E7WP(83"WV=V
MIA!ZNP$KGN-3[ H3>R"T6+/S)4:Z)G- D?%CYRJ#7N^SV2TB"242#C8.FD5)
M*"%7XC>TJ//IV/H "-=Y2<5;..W4(Z9L-0H3V5B2C]?+LAQ'O=(9O2,O<X&<
MAN++&A^FTID\NJ<]QC(@MH6BU+PJ\A ?\0+BL7-SBO\V]^5YI .YPL92TT<9
M,:V><P HKVU5NF=K6-S]6?J)&J"LOYTB:=V?K&)7!=GO.$E,BD?9W)\;?.S0
MW-"<4':YO%#05?'9?>G?]'Y'TS"^!KQPL19J_NW-NICR?,D=#?:,TP$M!II5
M'PUN>!3Q&H)B7<Z6%V<7<<C%Z Y.7^NG=DAA*-?LQX3[V, C=Z#@(H+Z=!V<
M/%2LYZ'A#0Z'YQ:/&:2XTTI*IC_7[L:=5%0F\V:@)2YNF5DVZ?"_$:NW?W\P
MB*%0/25Y5FHH3:E+D'",\,S-WICI>=?9Y#^.[*!)_]-5LG6J"L#;CJ;%WA'5
MSC"BTL8^<RAV>P^U%+QEI7D=KMGP69@[?<>UKZ3,J!)JC>V/\;6CW?)GJ!%J
MW5KX\>?IV#L/M,E[E/F::FB%T277IN4N\QT5Q8IUL^,3RP7I'YNLDAQDCV;#
M)DZ8W#SUI@E.&"-N2]LYRV5G&$N=]=<L$F*[I\\F).#P()*K+/IO=/0I/>+/
M ;[]_T]O?"'MVQ<Y#<&1_"D>NNV.3S<9YHY"RFH\QI#L?0J]@2.]<,HM7G%B
M!W$PB>V4Y4>VIY3A&[NLDBHMVV0-7D7LA8M(G#$ R*H :E%OL<=$@_ZDMNAS
M0,MR'78%KVZ&30C:VQSKBCHZ'HD>2H>9Y;:]7J;&RYN/$47P!78M28Q/2R..
M_"VD^M>H4N?#-+AG$IXD88Z2L-4#4F7D;:J=WNJ6I)B>"X!2H?ETX&@+GW,@
M/[O1,*"SZ3N)2MLP]XSJTDS<7/DA*M/P$@:+7RZMG.BIE]Z$L4S+G!H7HS>_
M.C^C>TDKQ<*AVBA#MDHDET[^@7PDUTS >0;6.%D3%D7S\4SN<)397,@[+L(?
MZ.[Q/I'+S0B5%54%%<:>J I8Z9F:!%IJFRTULZ?/;%CK1D.Y7B*SD,NT!!^/
M;(<T(G':_%LL%V,'.&RK<V,Z]!I^=!3>Y84]TUFNI==@/9S_I9W<K=QNZ;0-
M>"S97=(D+RA;2F.U_O/<Z+4X6MD;;KG6XH?Z>.#)"^$WU#)'F,](2&#DF?4C
MR2ZDOC+1[*H,"+GO-DL(7BFSX\9#-O;ONN_P>\E6="7\\6:(YNE7D"$;.2O!
ML*^8XW7!%NWXIGB4Q"O9$5H;?+B-S6_RY>_<8[U.5QT3JT\;5,*^8M+'\^/
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M/OW!]Z=8Q=/ HB>%*7&TS&&#*YQ%J%U&ES:1<8$IF;?9;OH<&38%#H(1$9W
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M7_RAM:KQ1=%\2J[Z;"DZ2F4Z*Z9%H@!2V6'A)B>Y>*?$VRE*:^*&+G^H)$P
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MW?&.K?T=\>::9Y8FNS@@TU(0LG8/)&=F(N+)_K-[;9OO/,OS<\/V4-860:K
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M[I6F/O)G_].L^[UH:!R'^,LMD=G_&R<)0K\/D!X[$JW&!'L_\O4A$8"UCB!
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M?S4>%! >FR;OJ]58Y*&E7W<LZV5]>V&NK!KGVKA%:R'\4EW1]F?*F#(W4>L
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MGAV%\B!#'N03#+=962#421[$J$CW#"-.'Y3/:2>JOIF*=YTB[P>>TYGO3QK
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M\I+%WJNS,M&?L>M]+C[:$798&R8 KN!8-$0JQW,M8ME%;0\WCBJ84[ &Y>$
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MG:$6X*)*B7&*I;KCN-6LMY4)4E9Z!M'3["YR>JVE?<O4FCKT%+/6K/12%B&
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MG2)6>UBZ@<)KQ\CUQ[*DXP^/M: G02^@%EDQ)N^-D\V[S5&>9;HCU>5&(40
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M1< >3+3A*(TL-3:%V#E6>DQ??] \Z2(S?DNB<%?=HV^J @?4R1L\6<3P;N*
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M#P\^])X&?](0^O3-D(\Q]26W^R!=7J!5\P*-I5]@<Z331J\Q^^NOBQIMY(:
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MY,[)!7?Y[$@&*YP6B"BN6HPRY.R234+OI<8S!0+0E?"- $QJ(P[-O2EVKQ$
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M=5PQ4%J8B1WTOP7N^[7RSO,S<KA1Z;\ 0/A[&_S:>?:?:Q&F1.QV#W+.(A"
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M\O\X<QP_2P :8T,J2"8,]&<LU/POZ#G+>-Y=$4'7V$)N*WPK +)_R,*NVH>
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MIT)<!:2B[?B;0T$@!]K^2B_GY4P]<2D^NQYK2"N=8T9;YO7A!N,\J(/]\<5
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MUC]B<'V)=WE&8T&J2*JR!4VY*$&:[D?N&UK:KU]_2WN>B3IA8;M/EEW4O\I
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MU]]CU5 .P2[VNX<S[F]9:5\)YVMD?Z6@K"SCI^QE9T=?"\ZSFYQZI+C+#Z8
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MX\*$\">CT^?\ESX_Y+,\Y.GB/!Z^5/)W\TAY%@%JP.6.Q_%R@&6"\5ERM*]
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MP1C;?J#&L=NH;590ZB)EJ>;0DS2BF[AVZQ65:S@/;%CN+-873SLK=BP\_:E
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M9LB+0'%\J%44AAFO-1D)WX;<P8<X#Q( >P)PRE23<'9F?4$:+ UUU#OEWR(
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M/"9^=2CY&Y=A? IF@646V$_1?DGVMPD6^)^2[,^"_46N&0 A!AK*>!@D &G
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M-3[-X#V]X0R1IA=$FVR?P$ LF(&_/,V9%%!-?7'6R]F!!"P#%Y& (<AK)""
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M3U![).7HZFVC@2J'R3^;V\^V;CI+]@RXZJW01++@V?1&E6[V'A<XDGPO0=,
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MFL*DCQ?<.7>X83B C2'TB!PTS5 J7YH2YEK&WIUDOH9G\*_SWU\AFM_W<12
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M$)Y8RJ78"R#ROKZ?M1UJ$K&VOXK=QOISX0]5-H,6Y/D7L_+@\*/1%\#]E1O
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MB=#(97+3^O - )X"^^(L^?622-W2>,D,Z]E_ _"AQ<F6UX-N7MG=I]ED8C>
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M@046]GHI>3/&'7&=\-#7/U] V30L3N*8M+)4/]GZ2F';;B\.I6^G[0GC$#&
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M.,>]N3"9J&^&DO6>&]YZ3<8*12*A5A$V^*K"!087]Z\JVERFB[PN8_2NQV\
MS:"="L4;0&]C$_","(CFK.F%+D6V;VIZ"0Q(6H)6O75^,%)G&$M&=5D;I,G.
M.YIII1U\!H>F"<?G,:CT'/T4AVXI5VY:?/%RNHCMJ%(^!=X]!%/MA*U0BL1O
M,(:FG65')K3Z$;\M?^G=F.Q_)":*Z2PM&Z:B53J>T*A1TWTRCN0)S7IJ4%%;
MO/907H0O($N,PLO?*[9S.@-5U-W ^&B*- FVU;7??K<Z>O](XCY.257I2M/V
M=4/1'K(7"6^754-O !4FJ1#K,-LYE<2K48G@"\W6&\"35\Y%!J\NWC 4T&7I
MM+=4?3G,IE+%H9OC#2"7S?,(?>QWO]['''CM"<1^26YSO6JZ3Q[.4!6#H2I&
M%:(AWESI^BF$F=1OC%@3R*D)QIK44=II_P^Y6(.0Z*6%A9Y)"7/SG_8IY<9G
M>-K-/BYF4&BJ9,(^ D8"=[AN '$/,5QI42#G%[KEMB)D]@H>P+=!KQ"]Y0UC
MG+T4"4;]['XZ'%PMNVEG-P JE+FD08'<7XN>#WJP'S5O+Q1%O8M]1>KA%IJS
MY_>\HRD"V@<*OF/[!O:#8;B?GG&K@:,-$=I=8E_!UAZEP/DHYJ^ES^_P86^)
MSA@X][6VTIQ26X-I#.QJN8'^&/,<4^)%*4T#YI'^"BNZ$!D"HNZQIF$;HZFS
M.X^:AR=[8AUZ+K5R-*.C/@/<JN3AL;UWZRHL2+DT?\2(.=S5WPJ(6>RTN:W^
M9N4T39IW=ZI(MFY2\D>#T\)SB<[-^( 5](J_W-.)A.(\#= "O1[WVDA'%SU*
M!!=-5:^Q.NMYG::<">_Q%5T7MDG&((#MDLNR&1\Z6) @&(V,O=1+ T*D;$WE
M:$VSW&J>7F9GT'M-:9NHV3HS%PU:N_S^R%8#%PFR?SSI:'EGCB7+TZU?XJVK
M9 813EF'N*MZK\\/%M$9>E@G514:T^OE+!GL+@G!/^L)&+'0I9L)4W&E! ]L
M<WK!P>*GP"\?C2#D61V6.)VZK"(G(>[BZ)?+$^XF@N6K!U9W+*5><GLNQ9:J
MYH-TW>%\!LS)+K77FQPD13,12/*H;::9CF-53$KK]NOQK2G7>6[QV^\]"XP/
ML10$SZ$S)-/RC$N]9O:*V1!O:.SSA!O +\.$.!$%JHPO?PK]Q*[)M\V H7W#
MWA<]Q&?CK>0E3>\8]3%AOXY&G&+[L@?:O4@#- ([6,X83 ;_47LMSZWTETVS
MX:XU[#5(7&C;5#U=-BV"O]M2!>V28V'Z%N O@T4(EJFGWR-.R'+^>[?Q8[S#
M[+_S+ZC2:\14L=S&1PCBL5%"]CHH?+@*4N0Z1!)BA V?^(&7KCHJG&B+("V[
M#>S)!;T.$DK.5_/82VJFDHK5D#*I>+)\/:TY$)T.XGW0]PVSO?I1T1M BOD%
M\/J$'[1=H07Q8YYR)SXT7<USJ'[M4XM)I0PAO!4G)J7ZN1L?,S0\=1#[<5):
M8'?4095'K;'98>R-3P&FB0-9R:.-REWS57&&NC)$V:#LM0BP:#'@0"-.Z%86
MFY= K=[O*9UQ+RRJ>SY+.?)T8)4RM7D!-HS]NWJM+NR?\N_=F?^H2.7_;_GX
M_[F!QE&,6W2.=+9:QBKT&JSYM0F\.F9)9QP%WFXU3JM,]PPJ"HN*=QON<87_
M1==K]M6&((2QL-WN.>&O7=4N\&<_'9@>^2%K@;?^F,"FKM0Q]CXX)'MY' @W
MQVT]I^G6:'R JT"&#^[-#SK/-<CY5XR&MW Z@B CRRUCK77^[O7HI68@P4N"
ML3#S.:_^'R[M?6B)'EK3X/5%,H"0:!=+^+O&$#DV-5YG\NH-VJI55=DNK]OE
M:(:8"@>_OLYAR5/.RY_"2K]6Z-^1B=(37:Y\X6!3V%0YB</#C[6#[64=<Z4$
MG3<O01T]UW@.@!&IS<,UW#W$;KVM]21LX4EW?M$S(2AWT</9H7XL._7#CTI+
MF<%\K.$3X@]X=9*;G6;0>C 9?VJ&9T6V8IQW+RCSX7NZMK.YS^9VLV50L;VT
M(D&2+P0'Z;ZD'')C(C_<O^!=Q_L:X^]Z<6@\_>M077V\=EB'Q_&PXEOEO>(L
MZU?=[S:L3DU?$YKZDQ?<*MG#0T^4<VXXM5_+SDDL[+4_7I1U7;?7!=GFI7$\
MJU><X6_H$[]O^NM.6U[L7PIXD^6OEV=S)3MJV0^7=/FBML4.S23N -XYJ5ZZ
M9.8!E4M6)]:IE\V?S=:K15_5H8G<_CA__WO/ ^6>KA5GMS0TN>GTYW ? O M
MKXK(H3GO4D@#H7[]B+^-6%66R+B?\?8'V%AUF9RV;4.U4S;WH 2J\F(U->I0
M4L+3R;RD(]G:[=>4A6C,2[Y3[_LQWA:MQ[AXV]/2BHQDY[==9$248:3ARV%U
MH5-4.A_&5D*_/4XF4O2.\X1XK_UL9P8MT8\CQ01-V(EI> K^$N:%%/6I;?S
M/B?!FV[SF'IX%7FI&0)X1T)NUR7Z/LTY^<"H9)9Q$U[6@_9I9XB5RUI[RF-O
M4)]7+]G#^L,\JTV192[O!O %U&5*-$UEVCR9&9Z4#M)UE3 9X>?KQ^=([&0
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MFP21'G6E("&ME#?CJ73#1&=NBO77ST389+R]12C>K#>$LF_E)%(;7=QNZ^&
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M8K?IC0^WTR:.9#MW13BE8.G%[^@$"DL&+&@HR"%OHKN:WH[<W'57Q$M=:(^
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ME.G$SMOJY#7AF0<&K&Q"=XE;"82QKDRUB'LV1JB[=?.GY7,+$@L!L]K2H0#
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M$CP)#" J4:)^IIEJ5D]=>#$E.PHFEZ"S-N)6DL !I.56&JL6B-L9/@AU3;_
M1WV6W38D:,^X PP0(Z5)P)2%)[K7UKU=>L:SQ;<!P)/H:G"706_#;04[.:&<
M)0),+Z\/L[[[''T2NISAHZT2WL3A$=[Y4RF_=V5:1[CCQYP%[P4?K>,.SWYR
M^];T)VEUMU7I"SGFP?%V5&E=$R,JO:A(1C[ ZF>;"N90E50%?A-"V;J"S*R@
M!=#('V55\HLKN1@Z#6O8".]+]#])>)L05O3\(B=FPP%">#2Z&IG]:[UQ,;\(
M71P= KSUWH>3F&UKMNM=(_UWC4!F;%_&FXF,F5DXH_V#N<?7S9_+D=6J4A.?
MQ9Q-)7HT=X*:>*>6M)M>?XJX(MU=\CKC;OCGL2H(K08@G$:E[;S#*R\!F.#@
M7W!7B+U@JU@TBCT!MLK&Q0WWP@SZ9FDT2XUCV&&7ZDLGP>-,B7VN >SA*<%?
MNMS>?Z8)<9=*:S\^*L8!HD_5E!#B(@M4O)*F%ZV;M;UX!Z0<2Y6/FTYV8BS/
M731(6S[7_R"8LK\"?PW5&N/[KFD*"+5Q.TKX'JQ:GMY=/.0'GK\HH6:!IBNI
M0MBD]FT%-D%I/9:L^C>O_CS?O]F++< !%@1.?H;@ ,^P*;\+B$,VKC>Q_L/D
M?,^OB2,B+*[<?YN7=G[2] H=_MMI=0"/SY=ZM'7=473?M)J(OUYQ^^D7K^J@
MU]"+]M>MW=U_Z<AZ3#T(56C(%?2?&7HIT#>B(<Q:JON>?]9=M@(':)?:HCOB
MG(,LZT-0I#L2#Z? '8LD8U5?.2<7]A"+)MKS9+$BRUZ@KN,E2R"YF")LX?Z8
M7'F(LHV-Y@Q%XF,.&?F58-JFA/;05NE.;\:"2G8(3RY* RXP'!J$ P0M*84M
MBG*^W*W1#>?S-(OWJ2$?\K69;7A8HN_1WB((NE%-P8D==/FZ^@[/)A"#_0CJ
M/4_ S)86N'^?QR=>>#,F]\!8BJ>W98==ORV=;[*!PN=4Y,W6(P//R8/(D?ZH
MKS31-6N%I0\58B/X+=6*]JV]@!_][MHD@Z)+2JOP *,N9QATOOPUJY.,S[9;
MHL094H:RW> 'G?EH"7$*!CJ;<3/P9]K7<E)\?L:R<)O(E). J?2;.BZV(JQR
MOQ=88SN*[VSJBPWE4#;\GKJAHF;=%=?UJG< [!2* ,1OO&'1*E!3KI;L<U2K
M5*)#*_L8X@!2$E <X(,]EA_R=["Z>J:]G'?-?-MCJ3,J%]Q15_$4%K\@<>M(
M;"HG?_>.7VBAF)!-$#G=IBT.T &*&%$3$V?%R%GGQ!SEMS>'31D)H>[.OIM]
M+1A.4Z&RQK#:^S3>](9LB8V/ NH(BU<QMAZH$H5<Z$-]/HB?^Y#>,C5D1(RR
MRUY>T%:2551T3Y=[P\'UH'R7@;;#N:5HD1L=5.(QNSA)HRW*KPBRB-Y!E:?&
M!*:6E<H&&$WP-XYIZ2\<BH<LNX?:5HG3ZU0\?=9(=F#$+UFNH!APZQBP8K&Y
M;;#4&1V\2#^.,16LSM$5N&R<E:$P=24B9MMMQ8\(N.G$WE/9J'YEGL9-QOG[
M"SCM8$"&[YZTF5$?:9>G\F?]?M$^#5Z@KQUUN?BJ^;:/ K&P'V75%Z3GZIO+
M:<<HW"<8LP4F;&"%P(ANAG.JO&U(A^TQ1%(Y1#\!U-(HD_BY+M,15^D;6L %
MH>[F:IGW?Q1_&NEC49_9[Q$[OZ8GP81NA4<_TFM,[KV?8O5DCL'-?\_!*V ]
MU9?'X!8Y.0T;\HB9HBY!R*2 ?XJ-[B[O_#!-PZUWR:"'78%%/,)XAU!C= R_
MT2VT9S;Z_I"TD- MYF97[)/[RI!%R(BCD2DLS1G[$/I@=OMZ'WLOYR=+>$+8
M=Y/G5-%O1N#V#Q;011U">H,;6LE.@$AE;0&\:[(_< #*68?X+9D+3K]WG;ED
M\R?0F2V/N?;SB1KCM5QX/;=#"3D :PUAZT1KP!:TV^&+98P3\2/2ELRZC.^>
MRKN?.7BO.(D7#6"XX26@-LJ:<9<"+8/27M//=O*@4G*(6@_T9?UEIIB40%&W
M;<[FR>'SEO@*B26'?+H29ZUOH'2?L"WP!\?4]]!? VB$*VEWQU?ZB-62W6=1
M*N9G*6?/H<(%I7M[W/M,#?5?UVO3!F+[UAFGCYF^E<ZJK@1$F[**UE_A:FVY
MC2OT+(V]0N,\8(>I]A$<H#3\\AAKT@2#<O-> (&_-K]5$+)D-50X_),:RG@?
MT=U7F*Y"!P?X"3P78%_U.L_^NQS#F?[FCY>0GE4HZL85BU][^A]D\01JR--V
M[29.5%I>G#='S!QO0[DGQ+,M8G?X_?G4^%C;.5%(9].'G&X^_:Y'LX,,.DDH
MTU_NS'''T%@Q/KCB_NUMQZU9IY8IEDARX@*S=M??'K[F_VGO.Z.:VKY]HXA(
M5WJ/ H+2E(Y4 >D"(F"D(T5*#+VW4*1*$1!01 +2I(9>0R^A(S5*#R!5(*$&
M"/#PCC?&/>?<>_[MW?+AG0_SVQYK_^;<>\WYFVNM.=>%[]I?. <<'8Y M]O/
M 5CWE84O^H4BBV6-#[IXG\Y%!+#X:6 #:B?#X+3INTG1_OE^M;KE!='S 7F-
M+K,W<39PG*'4W:J7E:H.6PGCAHSB;P?F&%B#BK=Q9J;WS@$P?^XS_ 7GI7\>
MP(6#P7'EDX/DRKR$&AI)]7$]D>]2C!<?6")%<T0C-+D2%!)S]V7C,?#7E4-7
M;3^W/WZ=&#/Z^-LNMY^[)3Y<WO3%XC;%!93.[M=KU1.ICS7?%Q.N4R$K'K!J
MU\@?HX3/ :0;G>> W>WL<\#<1;196/T/F@V0B;%3K90[]M<\)7\^."Y+X057
M'7'89RY[<>#[/-7.8U!M,HN;@"5U);'KC.^1OC:U?6_!?4#]JXNT7;, ;X-5
MKL@V64MY8A=,^L60D>0A.KBTM57 &RY=LJZ3?_MD*=IJ!*=Y#OB#AXQ9A-,3
M<I]1^9L%G0/D',]$0U25Y=FJ\BK"K01>^FMB*EH-S<+]Q.T*'N7Z:^C4J.76
MO?5KD2 O\P<,+8Z=6/NIEN)"%T)3U(;=<!"WZ,T$1:_"VU\/S]9/W&5.>0?<
MMF/2>49%^HQ(O40JR"OODEG/NTSI 81W]UL*Y3!-B(L$4?;XUR&*,P'$7"%(
M7R8WYNCCB:IA!S%&N"LZZK&/#Y7L6MU2@$)UP*6-NY8+,B"%3VU5D\3L1+CL
MZ+<M 41R&&J#YC\,-,F;/]]H-.5MROPN95"-0\H ^*!;IJX$9O.LZ#9)-0K,
MN*O,+Y%^8?$X]'+9@N\&J^6C2(>78=17)DZ"!8V3R8@E9%21(S6R5%[LAZWU
MA,/CEP4R_>\DJ [77!M7IE5CH>Z1]D%]6(.QX35L7KZ=_?9MKCN+S=<AYN,Z
M$>/Q)8, ;AQRP9'*0.9=@-8',/MF$D1M=K%6P)M@+6KE@"&<TF+383D-H_T^
M'VMI5HVE[&#N^;ED ('$\UO&^SPPWN(8<^"TF:Q]2WR3)]G"B89"[><=P*6@
MD4H1?ATW38\AO0LF1UX4K!_VC*>H?2M!);,5SSL<[7VKCRV,?%?]Y[XC?1+.
M&Q.GC4GCH]<?#TK8B\W4(H.=\%":VV__W':^_J:#KB'P/4(H=-_X_M"*J<["
M-LTL#ME!97_8'?] *5;"DK/(5HKL@LF-C;&Q8>GRT! +&5VU-"6GP,*KC 8T
M^\]8D3B0<'NOGK%9Q_Y1JN^CO(#P/"^5=L/BYLU+OGS5%1&0$@<'4X^88)JW
M8OW42"GDDGTX<BHB%SL>?0>=3@K@),"I>=P,T+=PG"0R2_B>P _4BK*HI:+W
M(/'W. ?L;_2YLRKO@L9LQD1)PVL;:B$[JC-J9X%N!%4\>@6243E*8-XK.;3,
M[,47#BKWGW50_]/+C/^<_+<?(_LGY'\B+_UG1$Q[7_ML#5Y5*7=$OS=WO/_F
M5\DN]O%_<CJAO[\Z<E@Q/^#WK!R$JMJA[S [NLMVZQP GSA3*.]KCC@EN< T
M<(&I]5_")/GO6X.8/>C&YW. /_0]O!;<U]\T-+0G:?NJ+>H.G&_ZSW;QT'\H
MCFWZ\L?X?."RC98SVWD QLLKT8"\(_Z?+A/^;Q#0[Z;/@NCOBF==%J'_>/%Y
M$<2RS12()>SW9&I*!'N+V)6Q6?60IBWNBC:Q%>3H?DB4V.4%,@V;&9\#VBHQ
MH%-20\_3XZPSVKS@YE7#T>;M<1_@Y/V?_3(A6WXQ2OZN%_G^:*O9'K_=W.%Z
M'.Y9.LDY(!.L=0YHUH/:ME=0FI_ .'3^?*Q?0[5_DUWI'@.AY##%TK3G (6)
M3^> @"\7(=MN'GY,5[E]LJ]R$"UU_X"R;D>4=G\(SZM-"/U:E0>=*Y!#&WKQ
MGH462YV=ZIQF4?R%Z;\>TQ\=I3[\M\_I?[6;=$]/?$$;"X.P5A7=C%B(?@'B
MY@9&B@Y$=2I7ZCT5R=-.2B[\K</<&WBQ/DN.66[P/1C05:YLJ)ND[D\2\H@-
MV2]R&D^ZNRN4QV9MN1C%NP'[/:!_MTO).6"3P>.E;.NAK/+GIKK?&>"W2E>^
M^!Y>ZC\4_P5> OV- 7ZG],5 +WX"79?L_\;[LDZ46=_[$DT?,44=K_SVF_SN
M.YP-A[]D^PO2?R6DAO]0' O_+:QZ#0T-7U()"/^MYQ"T/(MS1HL^ 8#D1Z=%
MEN%=3CLM& ?7'\^G^NL;G^7,0TDWZ'?,UB59DP:F:^?XXG]\!%R"M5PR0(-Y
MA)?!F?H<_45^WG]K=NC/_)I$R+]<Q/\/F#C_$]Y#^9OAW&\HL5S/%KRINOCD
M2U8&02!O(FUDC%51M6@>A<[^[WE04V.)RV&++/68XTL$XBN?3=V'FAY>9 )R
M; P-+A""9 ZR]"*1>W\+E4GSK]#K_]>W^?\ $^>_%[+6Z6!0K0^#I47SK*"C
M/.N%B?01,6"#5V MEJ +NL>8\2>D\5+;'P[#^9?EVR5+#KQ.9HHI\GQ6ONCW
M-+K0/%@8%P@F^(W"GFAGYRPBNOH/>GG]?P>L_O OG8;^^F)_8?H+TU^8_L+T
MSV$:_UT6[V/VFS>/#2,$/WNY];OY"TUV#]4,[.@ZX&T8CZW.W)/\7O'H.FFX
M9*IUSBY7T>B8VM7^W04$U7Y:#4$ A9I, 4(R-*DCW5@\>4?N\*D^]\[5-Y=>
M_K.5VG_)_[+<+=F@@7"4ZCTQ>+\'\,R@),4=POMD\[)Q]H.@V>8U:KY7\@+(
M5V D_MH9>WD N?UA ! 7Z8D^55M2=(,[8+N7?J8+J6YLU@;HF[7Q_.K^(=93
MI!X]$:^%"N>XJ0+LHX(A'3=4.OL8\=Q8Y3G3"H7/\TC?&P1QHM<HY%@(S@&7
MX1:"47'CZ9L!W%(.^)41JT A58)91-3A0DDA=Z>&(ZFAX931=ZZ,ZM''2-_>
M1NQWE65P#<KMC5Q$P#4-ZX:$V8E3]EHU"T I(X5<6],K1^(V66YH&_=!G1^L
MYHUVI;DCLD3R99U397[?1YC[J7%]@OV$;!T9@]7U@'=5?3CF5B<OH"I,JZ8Q
M==,ZK=]4'Q#\D&%QS43)N8=SD][-%C'TWGW T0B7CR5V4[UG.-NE$1XVR=JA
M'/'A]C=*Q+>GWL=DS^:B JZJ9=A2K=<+Y+EZN]L3(&2U)IRG<V==)!=3X8N4
MH::W,=L1/R80? G34][+"]2OYIIK+-0X'+$46M>&6)6$D(O0:!&[T.JJO*D9
MH32A(5*COF-G&([<!_51Q\NCJ)[!%C[H VQM]#4=J]1HE.NX;AI99/)(>$:A
M>T2Y!:-!^3Z84L9)R5OT=?F%E\ I[>9,G2+:'7:CO<.K?.>"\-ZY7BM:";ZW
MO03,;SGP6]^LM-J[&9LQ/W_B ;]4>L'I]F '0,=3!C"/^$J^.T2,QX@7J(OZ
MZ.?JH1U.H?-=>Q+]0XTH'ZX&%\%MG ,X9\X!&SO 9? ;2OSSXU1MM$V2%P<Z
M-F_1GT+SZ9S)"0_G)E$*U\$# ,L2T&=31"Z8J2EQ@5SJ:6*'\P!K3K^KB"]P
MA:1E,;GD7DO3+5Q0CNU3(YR1&KB!P&EPA%11@/.FE=6-;Q2\S9B\J( [9EYY
MVM43>RHACQ,4!&Z+W18K&<4;+*:!,DWU$Y.RBW>$POGC?XK^:&:;&6VAZV1]
M>PZP[>PM(]J2R_%)\K9!SAUQ'\P=4/U:<_:9;X<RR>96X R69:_AK N\YA12
M]*I1A 5(IZ_>+HX6JB2N;Z&3^57$TE!,(JAFU_TN=]6[9:$1D>K1Q8*WT_G'
MYL=,>]! N9V;%_I_4]<^O2Q9@9U@L,(Y[:C%8$W:AH$'Y2H[7 TFWI)GO>KK
M!T(ZAP(UDN< 8EPJJC. L7("@DRN$.",3GN_Q"($RSP5-'J15'\]( P!FD__
M!('[R:(J_97(JH5-DNZNO4=QLB%O HN=)Y4&,S&>"Y93]N1\J;[XA-(KD9L]
M1U8ZIS]DFF=9-XA"M5RC30NMS&0C*];*>QN?4^;G7+GQUH5W^91 "X%KQ0IM
MZ(_1*0UOIHE$)@9=EVMX[5OS#.^OY,\24?;Y\QV])Y<+H@$RA"\,$[+'C%#P
M>)T4L:POGZ,Z_NR"7X*5(68_ RQ=F6?^ZBQK57+O9'^W@ -[WT 9,=E4^ TX
MJ\_)!+Q%T^CI&+QJO'G,4:##N;W46&L$TO-JT5FB9+'+1^!#EI\8]N%H46;U
M[B97PK,8)RL+XMMQ3[VW3;U/I,X!W8H=P/U!X/+XFJO"<SN7KHF:5<N7N25#
MWME\A>.!QZF&N[ 84S;)H:#;B%"UNE'@)F]LCJ0$ON[751F$$OD#2@W&XPV\
MZ='7.&XNZ6I\D>"[M#?@+=X"O<Z/#(%73D5ZCW()D++%2TS+ 111U//,WM*^
MV.0-XS1A0WGAN>O: ()JVC.5,P*C4_T\4>YLM95AH_R]$*'/R1XD&58)3H3Z
MU>,B)]^9I#1.#);,$&6/BU3&"$P)L%(=*>D\N+ F:DVE5VX1W!K>K'-6UH.D
M#3M"]!E$L3(;O%VS%%_]6*TM"W&@3EY7CT0>R4YW9O7L8,62P8=77/=IG=JX
M4H0K A3<I8#:^E*?S#3+WRFY?S&4O[6:T%\ 90='7[@/T68F/R[Q5./2=KBT
M)F2Y;O(-SZ<<'!&+WXQDZBZY.'H[U.V@Z1SP^AS022<W2?$M$N)X6,[V\\@X
M><ARS: MN$'7I^3-,W$!Y'#$&CM13-)PF.+=;I&&,18ZQKT!OTV,HF%#.;:Q
M*XAUT=@NL?.N$N?/Z?!PG2D.N?=[17-1AXEV,(;EIJIS0-P;:(4F \?-VB<J
MK$>7*Y^+;YI([=4VYC7T^XO'IUG9C"0C?NT[M3?3VLWRAW3*LH]EI=JQ)_:'
M_K!)THA=85:6(;K<&%!7T'8_Z?.6H:>\$LTSRS_K2_I+I#<63;,\<[T ?=:>
MHD4#WE3$M]YF628HJ\@4]B.$Y[<C3'F_FD_P2>N+>.S2D5384X<=/<]?2U]H
M)%CLU10/@EB$W;UM"67D9:*3(,%C3?W18,K(8^3KF]J4TXVQ29:-MY3>*G)N
MUE:X*&MSL\Q[P+7"W@FD&NX+)I?+ -&H8/P+](#/PG8'T\K4IE6U8#84G&P"
MKV5!XU8I9??7DA9@Q %<ZY,EU7[B"XR/=R7+JFO=26]:_XC'H@*=?# ^J"H4
M%Y>POLPI_DV(IJU(?4AP"[!8$@$\",*L:<1(=3RY2WI'+.6VUTJR A2+QI'\
M+))VC0LFZ'#D/M834Z9R'4IO;@!^-#\3D9:K8^R</2:2+18>5LR7("/>&U!Q
M=B4L4C:*S H3'%\RSPC@0HC/LX5Q:!IUBH=&=>5.<ENFO_=F/@?( S^Y3!R:
M8:KPWM+I["AZK1&.9PDB"=9*JKNAC\AWMA[T2 P1358>?UY)6!Z1*O/5I/^P
M-U"\F;/W4D/CB\-U)T-&@KA^O?V=P086.5*\M8TOFM7;L3C:XBF5M=-#"=NE
M[ZU$-8SX"M/1Q3X9S\ZS:Q5LS(C@0=).@RVK=,L;.^H.4[4$K=U#I?GY83K.
M=JO',5J'%XYQLYAW$VAS-EJQNQMW;\AD+MD55+@LM7W5BUD#8X*<]-.P$8^R
MC,G6KZJC>C1(>2.0Z &+38FF#U&+IL\Y0/>K*+_DP8+:2)O>#I,R7V\L95_B
M-]K%#:U<1F4*9U_OY^J>'C;%X4^=&*A_VEZA>LC!4>P7D]U30LEJ]@WG_%V4
M=*V$_T92];MG+L]#\!*DJ%*X3B5F*.*,'B^-??GY^#6(*;3WT7 ?L8V@>=++
MV^&<5P?]"PI>T/#557F4\J2L^FQ.%.<9J'(TC/%#IO<,7NIQ8[B*.2-Y>+O6
M5]MOO5MB.@*W,LD%(10AWA<1P*'&%5+8<_>&=/GFTVRGJ>Y;L:YIZ6V-OFC'
MX'THL7\6- (BRL^V(-U)PQQ5].&DU^7A%1N)#62.YBMIN[QM>T3-'HN-ZXCM
MYZ@EOC_M$1Z.2UD\P- E@47$>-U=/7[&>\=570^D,&));R1:,>G4:1ZNG'FZ
M/+%PULO\ <* N*H_\Z-L_:&T3=" B3@MYU+)ZVT(99*H(SVN=\,XRE];?VSS
MY:<L9Q)5S,V8B*G75\QO'*%&91_4)0^UI&YV4%4*Y;S+X52^]6Y3XF9L&()@
MD1N?]*%YNNI,H1&U /IPD= LFM[@%:XJO*/_M&,IZ*L_N/F&G2]7$OP< .BE
M/XQ'LY$/^[DNO@'750Y1SSRJ+KG(GVR;WU.I#C$,>,[2XCP7-[D[)=W/\A?,
M*K^U<JUEGK@-(<RC(2]"!B51,*_+0\B:"= Q*-2DB'V7SJ@P4LYMJBST20?U
M-PS1&$H1?2_B["X&&0-J3^>O35BG2S-2M[F5?O45Q&EQ^V[WQK>E9^-)RDL9
MJ+RGEM9@F/P(G?YZB[\FOW<<$DCY"=3*H1NJ5CNRM.LB^?YC.+#['- "[LTC
M?/"E!ORQQMIU-.B*%4N4PCH%*=GQ2T3A?%S$"!1@8C@S$/<S$N@J>%(:CP"V
M+P-#G>;(^):Q-9T?AVZ87+7ES_8=(9:@Z(A(P;#\&A!:*++2?T;E?5"CNXIR
MBR'M[OWR@ \)T/<UT6H[^LY_K[B$,6"GG:<.:,QTM+L C!! V&'O>)GLBY8.
M0TH"^OMW('$W7ZH!.2_+7P%X+<Y62(/1FM2MO'GVLS>P#VMKJ5\YTXY!^"#!
MBC&?:EN)QO21UU+5M0:.J-:!3_1Y8\P>5W[LJ1N#W$HY2= JF(L71:ZESM8M
M.K[.]\W2(*^N<R5^W=VO\_3AE$D08#%0=:\;SC\: /12U([:]W-=^$@[SMH=
M86BZ+8@]A''<KOAV[#OAE/'I:+;P\_B[']^.'[!:/5QM?1<=3"&?Y;/"'.8O
M;":#)T+!7V"5)@)1]P1@_ U]+%8)!:LM#L9[5]A@ZFVX-_[N.7YVS8VCR&-C
MZA9,B1#ID5VLU Y8*<2A,"\@A;[RT,%?\=^"2^',.MTS$J:=K=D9;461H$OX
M 6^Y8.E+"\T48) LS\3V9P3"]ZZK@[4WIQ#+_2M[ZX)(M*D)VALAM]!,96+B
MIS"^-=;[,>MM'8F9=+Z$U$-6(H*='!8^JZFG]29O'TQE[D,:!QJG%8SL%E.%
MAQ>=6L[8<^! #'W[U">"3FX09B6J6&"/S@-4K2)@*B1!IK<Y+;$2"POU)70=
M?_V"5VFZ<BLXZD[1O]1S_1]J<DT^,R8FYCHS+:%J'I,='V=-P'FFD'M!R^<6
M*'_&7:YZ[5B]J/?VH2"J#R@,ZR,X(P2I4[CJF"AQ6[NVN$LU&G6D^ Q%1,)Z
M=CL2R[L?1JAVL)^]Q_.N.8:FWY1EQT'SM#E2ZJK-R@>U37JZM,<]8%VU0^%G
M5^AAA%42MZ.+)VKCA*S, YO7H?H7%/ARD5R@X>+WC>.X\"VAX'4Y21&'SWKH
M<!3PF-SG>3A3Y5+6@=F\)6EGX;Y,>-?L;5DJ3,Y6!6O]=(\#_2N^$Q>#X!TH
MRP116S/CNJGPB#OO)N@G%N$98*S3UJ!/;RNQE. MH^DRQX@G<CA(38F.P2]X
MC=#0M2JW[U[90#6!$W!FF$E4EP?UNNNZIQC<QN-+64=&6 MY8FH7C9VT5*+/
M8<V\[KNZG_[\S\]X4(N8FC#'JGS(+)K_B?B[:)IJ58+$T>)7^IH:C\LG^#A+
MQ_A'%B:,'2//-GXM7P<9"U:-'XC:],W>P<4L4MYX[TY?6S_JMNRAX5;A&25F
M_H"YBS0^/KU=AM#_$J9WV7<H[)BU<VQG2/JM]5)2GS K,E\Z=1<V27$-4GD.
M(&MUI%*B4I-077Q2D&7O!%@S#<$4GJD%!)T#3,\!)X(E>,7H4NP[_0M>)7S'
M1#/7RR31JZ+S3&9L[].]#E!IMX, I^9A>9%]U$H@#7:*!:0W1]+$37O3JR$-
M^E5Y$<\;B9G'/C:5:M"F,%)CR_<:[4KHH;O,(;OL5]HR[WY6U0Q=B(L$DKN?
MN*-$B9IB]7>E\[.I.H4(PDB^$:KBI=QIQT6E=D;!D/JWQ0UU>V[7AJ>Z8CTE
M,\A<QQ;25742'K+MZZJ-;>Y_8A_2K>)L=2?I_;!^B;'UL(#MWE?=CEGJL<JP
M$]3U>&JHAWPO\&25!#MR6,Q/?FP+N4HF=$U.G91GWUPVM\D71US4\V(A1D6^
MCB]WZYZ@3H,&8SME-^QDN0"'[UMLCGEB*[:U?,V$KSQO*VA7?2Z< U,"+Q#5
M:6VD:NP^2#4^EKZNK,*>7U*<6X7Z#GI2*<XJG2FTC:](Q6['S/+5#T/V+N+-
M&I5,D<M#SD^?(<4_0JHXB+X0$<FV^*+N%>+%,-6?YO/&BA$&8-FZ*^PVH0Z?
M[VRVWLGP^[X1DJ[Z.9U6(E]M\L26PN<[4'T<W*C0VT+@[>WH0*DH4O#APKO
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MS3 /* PL(CC(?\7IGU(./Z$W]/'B&%A;.D-S[-G$!/A-;:QE\I;V_2[_ARV
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ME,H;ZF\2\ U??441DCJUID0S_7$X\,*$@?]LX]R_)>??_P]02P,$%     @
M::1Z6&G:=E)PL0( [DL# !(   !I;6<W-C(Y,30V.5\Q,2YJ<&?LN@=05-'6
M)GK(&01I<E) ,@B2!1I$LHA(EJ0B(K3DG 4D)\F2)6=:)&<D@Y)#*SDCN9O8
M0-/]VO_^][YYKZ;FA9F:5_/J[JY5=4Z=4ZOVVGNM[_O6/HWYA5D!;FFJ:J@"
M.+@ @(/] 9AY0!D@)B0D(B0@)B(B(B$A)B6GI2 G(R-GI+E-1<O*Q,[&RL3"
MPL$ES,-Q5Y"3A857BD_POJBXN#@[CXR\M)B<\ -QL;].<$A(2,C)R!DH*!C$
M[K#<$?M_/#!= #4QWB2Q.![.70"7&@>/&@?3"[!CYTF \Q\#^,^!@XN'3T!(
M1$Q"2H9]H?X6@(N#AX>+CT= @(^/?>J/?0[@4Q/0W!%5(KRM^XKHKC.M6%!"
M'C'GHYKOH.<3<*X'KUV"24CIZ!D8F;CO\?#R\8M+2$I)R\@J/U9155/7T-33
M-S T,C9Y8?7&^JW-.UL[5S=W#T\O;Y^0CZ%AX1&148E)R2FI:9_3,_(+"HN*
M2TK+RK_5UM4W-#8UMW3W]/;U#PP.#4].3<_,PG[]GEM=6]_8W-K^L[.+.#XY
M/3N_0%Y>_8T+!\##^>?XK\9%C8T+%Q\?#Y_H;UPXN)Y_7Z#&)[@C2DBCI$OT
MROGV7;$@8MI'"7DUWTDX'SR'@UZ[3)#2<8FO<B/^AO8?D?W?"RSX_U5D_PKL
M?X]K#B#'P\%N'AXU  8NKO@?AHO.J^\Z#1=&05D\=9@ZYQ!->/&"SPB&^1L3
MW#$ ./>27'?#/'!L&ZU,2URK8G@LW+E]@@'N1,E%0R]1&&#P]0?!"8.V?][$
MW]U#!X*/&;Z0B1LX_N=UP6 +!L@=0X7QXHZ 3/]U\R]/P+_=_MOMO]W^+^!6
ME=I=])-_!3-+R57-*+_E/U\7-LFO\*:W/+G$ )_ZV%1@*'3@AJ@BW;ORI?^\
M5OLGE#PCR/BOX K.VZBJ?U[_RP_P;Z?_=OIOI_]V^F^G_W;Z/]BI:O\:<P2H
M6JHR1HD9.%"D?Y<?1:CLB0'87 .; E-DJ9 7T3??466-@8AMJ>OP2[TO&"#>
MJW.!?3C(G2L_BI=!5X46^%_4< S'CLPP .PM.L6N_/?-7N[5_O)DU3-BWOPH
MX-_V_][XBV H_Q>!,&54K&EYFB7BS!8#F%,=B^,)36 7G6(9Y3V"7D7K_P&O
M+XE<$!T7+V* @:SE0_;-IR%H^34,X!3(3S"=&,7[Y94*[3.<_Y89PSJ$X5N9
MWMQ%YZTEIF8#L0@MEZ@?"0F?=(K>PX8P /U7!5Z(&BNYY940I(1"R3 S^HU^
M&G^+PB=+5B_MS_S(- TN.-'<% KR>O)J$BTB.;I+]OG*,4QQ_02T(LD.')ZQ
MLLVBA0((I"1WQ/IG!_!<0H(]?<^J2>[!.IB1'>]6DN?MZ)X3I%B]'Q"#.ZDA
M!'!E3\9>"[A_+'E8[CI#?<#5P>4?KJ([4<];GTTSH/?Q]<,F&FO&42G ^6IF
M=\5N].<O['(ITNJJ +2ZNF/B'N,:<J,TO-.M-7_*"36^X#<U!X\N'@J_C6-X
M9EV8$%P>[^)C),#3)X*O DY<XJI=SK+6$L, RXI69]#<-JNU&\LUM<C)V?D1
MB%262LFOLBX9:?*>5K;"G.!VW.5SKXB=D ,%CA3'X8W+9R$TC<547+X;1IXS
M95,:LRF98MOVUZ7GV@\-ILZB==V+E^87NP(W"VF(V)_RN;,^[U&OOS8L\B8H
MZECI>'^,;Y83<J]#8^K,W&85&O.6^L>FN8GVYN*CJNOF:38EUN\L(=-OC!K]
MWK5&/T/J4.S+B)KIV//;7%<-HMU*/FZ6@?P99K2*?>C2H+9,RYDW*65S%I?&
M)PIC8AT_3T>I6"D,VQ#A8777S?:.$@>22VN<D7=3-T')9QNW^[RE]O=@O9;&
MX*3I)5$D7R4RJ2\C!^I8;JQ"L1 TPV4D2#@NTW5>YL;77_%Q\TV01E-QPL&S
M$5 O]1AY--=S7C=W&?+"-[?\^<[45+_Y2RE/[7.Y>PM5%82F^]"4XW#.1[6;
M0?TI<*-X"PF%CJ)14L6+0[:^U3NS,-&7<L\7\K]MV'S286&:;<QAKO Z%-K4
M>)6B7!CA4EGR2>E0H-\/ K<T1H"CSUC?SNM_#6,N?EXS6&W\"O<DZ,"B]HOM
MI"T;ZY3;[VPV+=-WJS9/8PP4N6P:0?7J>KI/Q5IW-1VN,L1U55X_^PM,^O1I
MJ7/^A6F>:=2F\X^E- 0K0?H^B3[Z9P,H?0R0^ J*1:Q&]$_^/#9;WHO;O^:G
M_+3R]J0H'(OMSJ62^(_>'6P;O6SN=Z)ZJF('&V4'B%!&1AC@G-+QAB'EU!\2
M45BFDW*;Q%4@XB=(2Q3 2=2QV\8 JW+P^!OR.1TT00ER=A%;H#H8P&S^TJCO
MBC#9O=U39S)5E\SBZ5<2TNVWZS'K[;9A/?WE24GUH3)-<P.SG?!LI!8ZS)P'
M ^!.H>Q&PJ-0\N460L6Y53L71L(DQGE-1J^)>  FQ#+2!@*]8KR# ;J4,4"?
MD?)*8$@:VRV$=4/]O7K6R>[$.Y'VP[>;G6'.^6[P7:%^G^#DHW+YMU&\U<J*
ME0=ZEA.GRK=F)!YJ<0K[U3B+%:/<^W7D5=[!LE"Z2/=2KV-SH4I'>_O0SY_
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MVXQ9_>:MMNH+ ,,O0A[=J_ (F.)82!VOOC3V6?]Z(5VM.;9^]/'00:[YX$Q
M?U0.%FKR-RWCA[_%DB::3<2%N&BI^A2!++K14_HU8>?]:P^C3=+<7/I_&[*_
MV'B#K%B-\'NVQ)9H6M1AFOLMJ\N#:%3&X?-%:0RW0&$#Z^1#.X&?]>"XCMM?
M.WW?T9U?ZC;4S4Y TY!TKUKAU;"> )Y)/Y,B"C7UYI.\Q9KI6"ASH'NXE0&_
M!$=S81T!UZEJ'RAD+9[Q70!5G<E9]/?;&KG\M,R%2>R+NJ@K(Y MXJ3;B#Y
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M7U.,#>.N3$&B6=OLN##4RB'J9)G:[RT\-_S(NO:DI+,IXN"3R1=KU4,R&L*
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MA3W2V(/\MI$ ?Z;&=X,619(TX+D:MFXH6M CV^N/.;-;-931>FFE4BI3?&%
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MI[>,$Z+Y02?+?/ *@^ 1M M^JK_H2KF%49?&7B%3_UNTM&L8D# LB/GMN<3
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MU1624F[J5\^Z_B=1BLQMF0B?\N^5$TD,6ZC/D'G'A>%>50(B6&'!(=I<G6B
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MN:.=LUVL\$8R, ZGM+0GVR/#_2=6?-8!(6^LV_A)+-V!ZUZ91P3I)\5N D3
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MQAZ(,WG'D*I>#B/LDLP#]KV2B4 M,N,G-P!2)^0?VB#Q*O/9 L<I(<UT2@;
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M^7K#&>[>9>*L#%AO65DQ_#"Z*>,673%Q5:7<JG'8ZDMYZ^KY-6)31C6;-;'
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M<B-;%(N+BRHM'WTN3':.N7<#:-FH<LV]<MZ0C,=K+V6#M>NP.>DP[K2")V'
M/0EC('/4-Y\0*!NF$FP]_A::*-JOT.R7#W5PW#J5+?<L7W\($%YK6"V5.NF'
MR_:%,-:,;XSQB=\ &"!1^AG;V#OP##X]"?RB!)F0=%_P]HI.;C/=I/^<=NMP
M>7^;8BL&^O&8B9Y/;W_A!O#KZ)7!UR]A>48*SP;X$[P,Q1-I@YYCKF)WS!(C
MZ]+'\F]M(.N;WC5$RR9/HSUV%35_X0J@X.(@;0SWWDZ%[^_!1TFS^:0_1()#
MV5'@E3TWT%C+G7)+2Q!% EB#\Z,KT9"]'K5@E=5\8ZD&-[GOV0U ^&QB Q]<
MX21ST,TKKD@6R^ =V\SPMAD,7S:,"^VZU;=T1) C5;#$A/N,,]<RGZ[KS(M5
M/#:.R-TCW%^!* J^/#ZMF >"&L<5W\TL-AN;FFOG6%8(&5K4/L%_K(0M68QJ
M8$:4B#F$S5T*";(>ZJA(H\6RC%5)3"UVP2.9O3D"*)]YS?ZN"_$XHXR@'/T%
MIR&.Z"Q[61I5CWXKJ-DQD<O'H3!WT??2XJNL=!/B!]$>?[9K<$W:E&-,D3'R
M"KVZ&HP)RK*2<AM;G1=&!@4%*9O2"E%:2VY,3DU[4\UY5EN?3"%16J &+D'"
M#^%U&R4,?<'Q[C($N*40?D@JG/^8"LX$:9NN$<L'-+QTYEP?T4&48A KT)@<
M@8?;*4Y)A<+Y"[\Z,RR8[=D!'N.<8W5RHF*O\"'8,+F/%:>?]AZXZ]"(QFS6
MA&=HY4.3F*9/Q.:K_59"%)R]A_QY>EK-4&HXV.+.[!_A;X@$__LJ#'[O%)^6
MA4ZDA,:<+" Z(.T]K"RC<OY+V$K'6[!4]?K)M^S<C0.$7B?,I_,6$RPPQ#$T
MR7,Z4C"6PFP[K;[M$6:]/$_)=Y:]J5GI>ZYJ__R5QT(3.36.1P?KLY[B43+B
M3J6=.:QN"ZQ1_N2^&)YT>.DC_B/(9;)N,)<@_C%O7M-$E2L'[:<7G7/U!RV
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M2TWA[A\LNE/ *1T[/%_"TH<W4$)GQ8=I3H3I;DV8LHY,U_D=$M0JU>YI,TT
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M2,4<Q\7_W%VJJD).8&;J6ID@^.;F3'-=[HZ>VX^9H!"4UX_8<JH-$68&LLG
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MX?\7&^*03<@11]"IO;49^R=G?>#ZA S' *P;':"3%?;#DI2ZZ \MA\^]93"
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MGY8$01+/UKMURTWOB3XTO/:RT9[UV&F4H 1,>'KW'N4"HQ+42T(=MQ#+J#%
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M-+]!R<[*+G0GVWF#SF8<"KQ-8;.!+J5&UW8HEB/NMX1^:3"/N$5P>-(''&&
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M92/COE*JHA9N,E+J1$[_=5>Z;MCH2F[MZZ_:RE)D*[+@7%,DC@6$.<-8N7#
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MFPJ1N[-> <D7VC 0H70XSM<*M7@AEB'[@)'\B&Y!]^=Q78%6\*&(9?H)6B<
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M0.=4PX@\.SD6N +N!I\Q/,<"+<Y88'D="[Q+7TF_(,7QXB4I+(!TWA/1) Z
MMD&00YC :2B"#8JJMWO7(+PR#UWN3 _STLK+#:F,7GN;J>B;>Z^ X&#0<YX6
M>"J>Z'),[[A@_+#<L"5(E=/,MXA(5534;6T';X5^5$:2(=@FE($YXY;.RO=
M" =2QALO@]+@4W/5A A*H"1/O]262I4V?.2W0]%7#>!C#V28\88P2F=C:(9/
M6+;<["2+ZX?6(1=8<<<$+L\.*H3VCNGAC&T1[F'S8/8PRO'FU8T2Z-8$]/")
M;NV?G8&>*:32O==B-T>O+"Q A.@3[G9Q8?;CAL_#^+=YCP@C[6RNU>GE4'?=
MBI!086,TMU<IU<ORY5F8UM^\Z\XP^=Y8L1:<B(,!]I+$Q!$!6IO,&BG%RC&;
M!MZYFQRV2G6!YB0.$;XM2Q-]W/AWQMHPH$^UAN&RI(]J4GVVW\\H1\B](YOH
M'MO.&;_1["GMTAA*HF(_@G_C]B:^V370PPK<KE1W2I7D+[--A%0Q,*A]7M8B
MV4OR>/Y5J'U+ESOC,N]VJ<C6@YTW-IG5U1'/K_O?#6E$X?NI-XYM5W'KL)Q+
M>Q;$M[]+N^E,)L5Z==QC(IG[$DMACO]\;MC\VLNU_GOX5W<^DDWQ,81[W3AK
MK:V_JF_5DZ8F^QV6*%7F6./ )CPK4=;T6721;,.$HV;_B-3^*W&OD-=GKF&<
MVNP$'F*!Z:9K-0]6Z9DC[K0IJ5RY$\3&B/_QZI:!-MSG!LJ[".6<O#DN^CWY
M8$W^<@SQ^4-)M,J&OIC)G:D2X)R_W(G62<=[ZU3,<EI7SJ]V;!O&59/VX^N"
M>VF*%[4:=<7]A:('?>D..M8=.YC;;K&,QSUOUL +;@_ J TZ 30?E HZ1 [&
M7(AC 3HE_[6236:QQ&)WZ(R!3>I:PMMT2S_S&>\:_+#:D)BLK#M%W&U%$8 L
MH=O4SX98X*\M5?[N&M=3Q8B)(!8@->T '[1#L$"S^E_29_SZCV=UVX>Z$="V
M*20E&C&&!?;&_I27XI=+/7Y/6;H5$*(*K8@%9' J_/QP\6<RSU^OZ4G3AI3<
MNO_G)R8&"6>_KO?M';.//-?%DS_?IDY'^+'4P<Q.>,4IIOBC4R]3X<:?RGW]
MS6>N_==S+ 4$M%K:>WNEAX-2/S [?8:&]T?[6FBJGII_I(!<\A5"&Y:]-@$A
MT"<^-UY_3>NX/]++D/0C;L1E:7?C3#?9&D0EQV!]8 @I6A=W?6S(K9>L+H$N
MDB2=BMEV*\*(H7*7O,W77:OK0QN\>;2B=G;8)Y4.X@@U1OL8WJ[9]S)U\12!
M6)M \01;U/XJBA;B(-0.X&I@?-%4F#-C.E-<VMBAQOM\S))$65G%JD;;:>?>
MK,Z8316I)%G"E"!ON>1C<1ZR@(">Y5)-XNO+>X1L+F>+^F.BH8?JMI/")"9M
MF0%=&BX/\O?XW5E/]O1F+-IW'JX9E(\WF"Z?B@Y]>GBKJE)/AS%!X<38%RS(
M5@M*I#/ME**KB9"[TYJY=4(3>8N-9T>L.J;/S##TT3O)GLVG>"VK]AX64O3I
MA&@:,T\[=\+ OD&[&_U,XF]9A3Y&"6]RXSNVLU-6(R9^%'L)\-O!JB31WW;Y
M#?G\4@MDZ10DL, 1R<9?G)3,.^5,Y1\O.9@X(!1T3/%Z"SX1_<!@EMWG]@=F
MD;UHGE'K7J> Y>@@6.%Z0A-C_93(1IEY[1@_G[&\.OKT[=JNK^<%%"#%J?G@
M;W9HZ]S.SM*\+^*Q27"\;5EBN@WG;B\)1.=)L A+DN@KY8DCZ3H!F!AKD306
MN"R+ !M-F<D3:C<U!T-"S9-N/1NL=->L# 8K$95JR3.!$+$XK3O$@@70>"E8
M(!1G7M1 IRM0G'41AB)%84J"5N;0-E4SW/ZSPP(((CO,K;IT%A/HFXV$X>D9
M4]4;D$:_BAA[L9AY[ZW&+-]Q1/-V) 3CE]B,HL "<)5CY7PL(-^_B":&(F!.
M6>%A __BAL D./0;<_H%O@#.1F&!MNC?WVVRH<1 *MR&!3Z+@L^(3'"F#?>$
M@:#?W]\X&L9/;Q&(!<RMH(=D.!36XOHSS^HO#3QS:8UXAT@Q/>,X6\/DB7O4
M/0PM])<&)P^Y:_730':YFUKSK1R6-9F/G[X"6_CX^<D63T)">1TQ>3\CRH!7
M.%-K;1+&+RW,\8O<1/Y.9%7K&:*"0Z%OZ-1$=.'RO;>ZC/"V3JS!&'I0X)#Z
M ^AB-6[(!=QL5NG<L8 1" LHB!Y0>W>>D1P+-7QFG.[MTZF*!K-%)C!UWO1,
M^SDR*64[Z) :=++Q4T0H/1]&'$5[CU,M$ S=TE/=8DSI*!9(C]Z5 %=;0>_(
MGN &"@*O<X+WQG[*"_$)C5-0"M>Q@$\ZFJ>E(/O",!<+@$%SH%E1<#S[^;_H
M7NM_]4ZYDYS>%^V-ZS(8'GUVA?+\\.>*HGG!9-!AW$/A%I8$<8<;"^AL0(>Z
M3XB/!R'?59IP/;8CNB\(@B_.H(CL7R;F1D<++79J7ELY#SA_E;^?O0B%/T>9
M8?P5,1=@E-:OLVH@"0-/U)L>("]:+RJ>G&H=JC>'BQ37WI_LVG7[\)XS[*O.
MDZB&P$(HG+,<"Z3A-#,*'_>+1A]$AI.R$H[5^IA>D!>7P3YTC#ZUUDB>'(35
M'J\/CN<SG2BKH#D3P ==?UW@US@L%=N-<5O$;1^R1;2Z]8A>LM7;$R@56O#Y
MV\FIY/?5J?)\M"-2$L0Q[Y6M0"C]!=Q>S9@#Q?Q\?KN()5"81YH*NCP "RB%
M+55'*YBDRA!8$/+L/K]3*@TRA+9]1;A>$"VAH__TB-*MBX<L ?M@N"GG#KM_
M9/:P-A:P4#P-/=X^F\70NP8TKXL3KT)QB_+[44ZY7A_2VK#[1V^O0^]ZNGC;
M_+XCW(+L$4.';2E[<"+VBJOT(!&+5E Y=@)_D/TBA]MX@:E+>V?DK:>@GZOQ
MUP&:5&=D"5E4,K+/I4 #[//I_W*>6A>IE#\H;8=*F^$6;M*8 'L?%?0=3TB(
M'-,X/V%C5/9Q80_O#7\NEVO.$O@2=/OT(^L\(W*7?>5NS3Z#]I<L]N@XVU]]
MQPHKURJ:+3^$_,LE,+%LROO[A;*R5K>:/%Y2H'6U6J5)LC%76IG_C60DZ[T5
M[5^B(_[H1W*/&O5XK./)1LUGX[EO)AMQ[I,G8D-5OA)SP1-ZP.4RB 'JF;.Z
MQK$TE%;=$K[S<-UXD_GQC1C>),*PIK>9(031INTT7DJC#!TF/(CJ\"(C"(7?
MV['3-B[N6ZE/&5=>[<1\P2]L[19I1F1[78;^8'/$ GZQ.#S^%&^]H"BD*(,0
M'Z!\N"9CZ+X\^V"',E"DGW3ME5TE:9W+&T86AYXAC_5LI3#12&4Z>:U#VDW@
M +R3CJ/"ASRO02AZ'((O2+;K$*!RFVHWB X1,1;Z.O0P395IQ]:5FDVPA]>;
M^.'(1-40LW73W?%#R.6FI)<V.276CLY>)5VJ;*Z$FGA+E'9=I>OUT(Z>JA1]
MT51KQ71U'3DO%X103W_ </Q1)^#J],\"+M)_[R$81W*A(Z7R+[S$]^D2GS[0
M4J)M^8<RH[^+$=/%_YWS((YI_:F6TH.VAJT58K1OY=X93OM\8VZD_[MKUNR+
MXW38^EN<4IW/7W>[H-4RS03=^*.I&8XVKPKC:)"I%G3]15,R+,D)=DHV#9T:
M-SUCA.45KZ(25_(/+BBAMU!<^[CU;WIV[/_OYG[[6V'*B?K?5VF3%YK'46ZJ
M/T@#8?/WN2(RC%5QXB"BU3(ZB6AXG$8S\GC;0-7=6:;?QMJ:J35!9UUXVCF#
M0LT0N9/^SH=[B*BX:.#LS;%6@&W( -_-KXI4Q-<3:[]2&LR4HV!+.VI:U9^J
M)AXEB@N5:''%7)OK6"*+T:]7B1 U1:F6BD0SN1F0"]G<!Y7/=6W=>= G7!XM
M(7&"YAFF_SJA)S1[CY'5G\I<DV <)S/WJ6A1\,[@V]D6Q'QN;F4/OZAGXOM;
MLV^0S'%H#;>5C*)DV:])ULCJ4[Y=/K-*8XK+UV9O;,-;+C><N93UZR!T@ZIF
M5SR+UJL376_>8WKYZ".%?YTA9:"!#:R#-/71AH?]"&$EU+Q:TY&N[=/-XQ7\
MS#41/*ZVO11-9'8O3HK$QK^IQGP%&#&5;H:DR+BN8H:S;/)"J/HY^,)9]B10
M1B7;+5MS$GW=-9]@0JSJ>T(&R"*92*:3YZNWRBES$RDBIXFEIJEN7$#I&%8(
M.0Z?C3<N,LS09ON-XC>\<=U4+TAXIT5[_=:WN0V>K(O0FFX16XN-@V<!T;D>
M?'_GH,B$_J?^"?58/7CH]_A)B6%Z"S/?#&?.8UI@DZ<+#,^HC$9I^+2NIF^3
MN9O:ML[_L-A;.4]M]#S7_:S$Z]@6IWBCEZ; W%F2C/(>.2#7,+MB&IZ/:/9O
M2+F2S*>H%=<3.@R/\?A"J1@EO&<29W+U7"$H6!^1.X?^QCG ZM+SDNLP@Z(&
M;MIN2$GFYL&R=?XT7;\Q1&;_46;$\^ YIHW6M<F&KVNM'K3@RC?,U/H%H]\"
M6ZMD\KP^GSM<S!T?+C?%A8[J/7[0(_@YZ+$4E8=NX (6Z)TTA$[188$1(E]I
MNU HN=,0/<I'I:HF:$J[\M[Q6"<5877TD4U4=@3EPX-YALZ3M)LHO&5/OH?*
ML2>/0NZ9N]R<O\*B9O$QXBI*=UBC+V2@FX1(]1@6*R,,3Z=!=9UW7D7I;$HX
M;>3QV,>JEK]\O%JP[BTLSWZ.L,.H*@=C5M//!(N_E'FV++ EMJ61C3GIY^GG
M54>$LJD0AM-+'#-U.HG\XOBE&QP0T_D\;]17KD#"$*LL09)A'F=*@UKI.&$7
M0-H<EPK3L-3IT<AP*@;B(]8VU3V[=_!6",=^>C#X7MTXT)3.(_'9YL A!3?D
M(5'3RPQR/F*3\0;1XO8B2UTBTMK/=(C+UR*H%);"3GC4FJ-<C^U-# 8M^!J0
M)3$]:0ID.>;,I[M-,1=I7B9VE>$PLODYV[2AD^JB>:_L$]^SGR7P"O":*!"0
M:'X,MR&JN+.?X-4"=9Z2>3\Z5_L>;$H29O\O,N+P1" %VE.%#04<+<)95GJ=
M3&.&SM4N5, &V^L9E!^K8)2;::"Z?6>6%[[IL=H_Q,_$#V4F7WJ*=T:?TM[
M C"<X8_3C1B[6@J?)X)>W6SK8M*AXK#D3)KB88Y:=5@,"S8<O35<%1XI!@]H
MN/]\_)E4S/L6725+@GKQ=L_P@N7?%K9BW04_#"<\8)"4<1H"?RCTTF?9DJ,>
M\5)^X50;Z=/MQO3P8Q2>Y DQYBR#XD;8]B%N)2& :IE5]>,Y"!T\\O[CWX0H
M ,5I 9FTAJ>N"<SLY4NSI79J8XN/ZC\EF25?O1W#2:9RSR=[+/>NI.GG.5(%
MEV>_&3+L=W1JM,V[!&SI=L5<1?1.@BN?49\NZ$Z7G[<)1\Y[N&X81W;EYU &
M5=/4!&=9OVIR,K2KDKN*^.8]K^&^LE#7*_+E)LJ1HNS:I=,J>K^\WJ\#XHP;
MTX_Q4\N2V]LTC=;I9SI_-%KGMSMP*(>+W-_/B<HXI]&'P"^LN)G=1<)7 W4=
M'PS?U6RJZWZXS;==^04+!$E)6277CKTP[-7GW(](F17HDDL"!]Z]>T1)G.)-
M;VRH/K$CJJ;'0G,*%*OL122OE2XE;&ZRO*9JJ)#J"I..M><9)LQ-2%KB>RDC
M["%J)GD)\\*%T0R_X)%%'O3)S&<OPM<Q"Z;6!UU#1/%X3IIUBSR7: '9BM,P
M^<=(R#M;+][)/,."W:S:.8*8O.$RJ<)5+/!Q7(X1L9K&U9PV*EU9=;=]C<&)
M]W(/8Y=*J1/S@P:DN']5J=C^[:9%F]OC?#,/IFUY55\21!NW8PA5$?G66S-1
M&K33K.D*M9J$E*C[E5X6&!IU'LQ%.N9.U@CZ6G)Z\*Q^[61IY?G+#VU>Z[U,
MQ/@?H^JRU&G:+/$K300L.;5OTFP_$F>U%]XSK&=KC%QLDWPQOC<86-?<_XA#
MR$8Z$1]_'"G/NE (WY&&C*W6U2!% P^+Y.D1>4R?';H'/)S+7.R.A*#UT'C;
MS;-7 1;F-\=DY&<"NQ!Y-&_,VD[>I&N I=I2+AZE[Z9_?Z0R)F6!]B_! EO^
MT/4;I=K&PA@%'>A1*_CPJD[1P_\J(YZBJPS]I..<T>?2!JV*OL%A;B9.#)WH
M*U2X1IPNXFMQ7L<LYY?*!((W*X3O_=#K^!\1 B%<R B&Y-\6V*(AHVI^^:K7
M"'=IWNM%M?M%PYYH(+M#.!'.C0E9:>R&%]R2S._*N1???'S>LBLI>>9,%[XD
M$.(#JD1,1 64FK1G;YX9\5@X6GNT\0H!=00(A2Z/410.I(H'+;9-G<G%0XE@
M15::LKE5I7%7PD4";#7F?(D<-U_CCY1R^?_X2AJNJUN3(.J6)/4SB4WU':M>
M1'6*6#1<%O2H]LV0I06M$.O:CZ< )JM*C?M9KJ_9L$6</+OA\B)E-#-:IW+$
MV7 KW%BL7?W<IM)EYWO#:$7\"Q8V7Z.5V<G*'3FJUV*NGXQ5"K8B$ \^<WL>
MWWD@R<2XJAW-X"52@W1IM"D>A%G3"QNJ?*:K_'"CR[V?7^%:6C";_9W4]+;\
MRJ::>CEQY-.%1\5<B7S'6@C'(,95]B!?6>JP%VJLF1&V971AJ?D2' 5G8^O_
M5\_K72K#,<=KQ4-G2UC@[ KL0]RNP+#N6'TZVA\&WL*QJ/5;32\@M<T*IOKM
MIH00[;,T"L<&.;."K+ SQXX_0OBRB_!T=$@U=*__9\8FYXD>M# 6B*$?NCB%
M'HJ5U3=+#( 7-K% *,9B&@[UHU3Z>4C,R$)A?Z@+>GK'(_W"X<_,K;@1-80%
M;D*>8(&RN]#U<B,Z;WH02NM0A0X2&DBK94CU#Y\IUM,)H*MYL] I'+W139W*
M\KJ*!6)3<.3,I )Z76\9&BAP;P/]X.SGT;94Z7O_%?*LD%',F;%.IIM,]Y89
M-NC)Z.45.GV3^>#-[L[8?JG4,H9/=AQ**GI<.92T"DS+;/-GXAC&_#A>W^M%
M<C3A\OGM[V.BI5:8R2OH?#./<YE. %GGWJ7"$?TP=@V^Z%>"5K#)-$(%&P8_
MK@\?]&<89W4/CY60Z'*3L1!=3V/\/,KK)6G&'DA[)5_D#I)1'J\5_X?$)L31
MR*ZK7PUO2=59)4IDHO36NXTIDNQ!?:_.ML(N#_.56=D"_)$5!5I51LY /&6(
MS)/"]XFO.83('CRE9P]F'5O'[[%;0S[% O2B*TN&UIS[S_QEM8^(Y1Z-V?11
M$0\P7N\F9G6<J9>]BN%.?35N[>#VQC(E>H:\,'%P-N#DK<,4772A@9?\J-QU
M:^::H$J6*X?GJZ$O:>;QUH3X"3[TW)F6AKP ]@;?O*YO[O",?#7)9];._++L
MX\#]@TXWMO?/]HEVW?];V4T=A WUXJ"3V2:WZK?A^XBA'X(?WE^>46$DGJRO
MYS&@R[^754@^0F?9E<-ZLT+& D-'C[,WX!G7B\.?E7! B(*JQ5/,6/->_D]W
MT[<"F.ZY)].\=S?EL0ZHXGR("<?AE<JPP-!Q*A;P!F,!&ASSYG/%0"OWSC>P
M "KYV(H;L]#E:FH/??G\'-R 3$<]-=A#8P'+Q9,QW$81@;9E34'7SC6P0%,Z
M[CV O<J*WMFV<#XA_G]F__ND H',\U475>TF&]]?)'$^8]J7?Z8A9VIU=,9=
MQFHB5<V7KYLY%MS^)",Y6#,KC"=B_=].W/._K_:V;BKZ:5/TP[BV^M]&()ST
MR?6#UX*$=BHYG"XU4H<!2$HZM-J(<Z-:NZM8M52ML? 3P\*&_EO$_20M.T>2
M'&';(HOA"Z )435U.5*^YZ_JXI\KQ_84^7?C<\F0[*W_JAM^+5JY\6M-RPQR
M[U_BDW1\<,KLQG$2[N88Z/JERG]+(>/%]K-2-8S6=S/?MG"1("'FC)O6'0 S
M^/ UA_Y(O#><:SYB]D9-:)4E#W3.5>-3M05EJ@136S>1O98!"TY'F.Q/:+ O
MWQ7V]2Y/;<0"BON"!*Q7_;D!F!%*!6D%(870!Y?VF2K%E+,.QMJHXMB^\+C+
M)D_/.A +,'%5 =XG=@[D\PVN]*,YPP\S5V+%R$KR,PF<Z7J]'B&>([L#\L>>
MFZM-3T.L=B46A+L\+UUA@MW ,2<? 17X%\%\:Q6-BI>+="53A :B,OMB'[VE
M=9K1UYM9P.O6T5C@$O2<!"A'3"WG&(B0PBF9B<8$G([VS6KK.(GPLYH\J 0#
MAJ.GA/:>CLT>?ZP>I\>,?W,G67Q-(Y 8?0VGN1R>B@[AI$G=H,K[>(LY-7"U
MG'\\5K7IF:P00WI7'1\'O"04^7BLM1X-)XW<E\U>BPQL(8BV>P@<04+!#'R[
M-BGM[&2.A5:NBW76X6\^9\C>NWKRX2R*T,645(;,BQ2N8&V_>18X=F4W[%"G
MZQ+^'-[BE*AC&Y@<+;J4Y^Z4(B:N(58UL-?TR -_F#*#;O(?D_23+X/?-3$@
M=:KX2XNZW?G&,Y_&U][)P/,%=HS T3X4;HKM"X031]:DUKGUU<%>+W=) 5>\
ML6:#$^85.5X<_^-%$E]X4EY<>8T_*,>(OHG(#VNX\K+8RN6$SY6GARUVJ4#B
M!3$HT(,H&.'9EL8ZR7=D+"B065]CT[-H]8*R@*-6+MYTR0X=6RJ.J5?#&=[D
MOZ14^I=9PGUXH3V9#!<^*NCD!H\9QEU^N+_^Z.4<>YCP1X+'[IP7/--R?$*P
M@&5>>=";Z,)C*R14"GRZGGXRG/?NZU:'B61CP%/Z--9QF5+^2<X@#N9"2K_>
M7E P_/'K-#Z;5_W:(VBMPHR:^H 3FH%+(7,N2]Z4<"/*5!#Z$'*^KK6F@@5D
M:3!GM'B32@7?8&VGE=7UX3L_L,  5< !7<]I< T=>WS!M]8E<H\VPY#1W66W
M9$;5TX_D===\B.K^USRROT9C/+@N#F^';&]_'ST2"$98TFR)S7A_;]P:JEYB
M%4J=%\2<;#Q='>>=A7]D?E8;L5"6,_I!^("@W6OZ<%57\*^3<!_!*<7[?RK;
M\;JIJEB5]-Y9[D%'?V6VD>1C6<&T^+%9-I V@CXI=VYK,ME[L&H@]G.?D+V:
M632*2K3]]*^-V9V@!R/@O4QYMIW4A4 X&ZFVF$>'1W4NE/)]Z"6JD+ONX"1P
MKKS7_286A$]2WCISQ*LS'>&%?GJ6Y]U7>LXH4>0.<G_I0>4O<GK,-+,.I7(N
M$.T7'S^B3^YH^C81(T_B-M^R,X4H;F)M'CX$LUC'\N>^$=DHG=T>#3I5?47^
M":0UZ+[W#X(&X"UEU7P:G3YT@[DI!9T')J&$33YOO_A]E;W+\_X@&PNDA?XL
M4R&SC@76LJ"+]SX$C]W" D^XSO-/_]9);UYX;]Q)Z D$2?D0.'-\A 7>:Z?_
M/&)-H%U4G ?MN36$J>7"^-^94%7X+V.*PC9_L/"HEI6Q<E(ICSY80VDKJZ(#
M ?,M'TK$7LB\^:2(M73OTV>JG&9N["G!$L>#PDH(W: &:<ETU1'>'0L.=BN5
M1/QAP=Y+M:7@%?+!]NY"4S<-3'_;F.IG6>-%>TV-"==']CDGO=V-#WUXK&8^
M6""F?(\B'WX+I9KON2_X@)C%KW4%F4&I40*E0ID^0"J5Z)Q5E?]V#V/.'RMB
M1X,%W/4?7)L8O&4]FWKCJ[?R-QL[\T #-[J:RW-1NK((J^^ ^VHS!5K1LBL8
M26-0%<'.T:3TI>60\)/E"%JXH1EP2^Q*_E$,0AIV7JL*O$AZ$@MF/F3FOA04
MG6TY0Y1$GYIKH&)M2>_2"=+PB(5PGB<W_P?G\'2?_%R"M0M[Z 7!U(#J"<,Z
MS\8\!*.@FW[4B@4.:4P%N>9,,V E<)A_?M$%A%AR 20XKJ7D+;G\1T$"['N(
M(<Q]0_#)]Y^E .HW5WUPD*$GW *#;CYCT34V_?@*M.<,[< "PMOVS2W!66C_
M,.XRX8Q3BQ4P.EX6@JG%C9G5::^]@+;  ?#\0BPPQ0@^U"LC:0JG1'.?<83E
M=[2%<9>&_ ,<.(3X@_>?V#1O3=JM\GS=&I&[C-.+ZM58 *:/0X8.X+;$3"<,
MIS=8B5;W:VKF?Q5(\BB9L>Q:[)5L_1LQ#Z7N]KSD(+BZ <G[DJ-5&2N4Q<T[
MT W@C>,8W'.N-F,5-5?(9;>Q)R,EJ?W>H7[)(D/&=<^CQ\\G&EG@6L:OIG21
MD!!8@Y+[Z]F=E=K3YZ%?[C[Z&-.-TM7*1DVU2UT<)ACHU%BX.C+RFD5I/&![
M<,2^(JJKB8I>FN<%SS2HYA-!&F(><3[?">P=!)SIAE!1BYVO]&R]1+WS^3MO
MJ,G>H[]]^X@B_VW,X8V:[)B7H9R*\?:,(#.-#$II.5'D8/B'*LK@)P/M.=4,
MO3? 38+OY:HX#6HZ&NV79]MG3(.7N)*J2.,<;\EJ<[0,5>AF:,G3B7SQ_*(N
MM$!Z/N;M$D)0(Z<9/6B[]AKN$V^+ Q<YKTAR/_@"O5Q5?(XFDHC.J7"T[$6T
M76'*Y=PD\GX"WI<ASAJ7NS0DCS/(K=GL5,=_Q+*0/^[;U<.<*=C'"EW(RVB?
M(:-#TMB&&T1=X7IHGGP%LV6Q<3-#K==?C)>9*$S/^\<XS\^G*GZIBTX<BOI=
M^%(IA!K:,U8$G6J'7M=WOH]C<H_^@7Y]V0LRW1(%YYB>B]J+_CZPJ5 P+5")
M]FG$WPQ8+21TX3I2+CQ_X[B)YM.Y3F[!HQ&B_8B@:T2N>,/>AGX+/TN^XO9Q
M,+7U)R^WH&ZCYK3E8TDNPX\#QFHA*7*+8V%G_KXD=TC[^[WE^CS[ZV)97E/U
M\D;9T\GWWFI21JY%B#;3;6W =NLJ1U\FE1X>4CREO2=D+Y7^@=I;0UJ3>)I6
M-Q%MB6S*Q'%G$OW.W ?/F\99N[CP;W%JDE[%3%W#GTT[6DM.;]^C63?!A[!R
M1=BE/-$SJT\ "Z*4N_%.S&-B/D:PJXSC;TCQ1* ,EV>CF5#,4X\;2(^GYTMW
MF93QZU=^=+_QIQQ/WOX_3^]_ETI;U/9OWU*&R6I^Q@N*_P.23OD'N%W \/@A
M=Y9?(*T.*/2(' JI\(=0KH]8Q56FF$>I^5V^WWKZV>/ +PQH0Q*'>]V7T<&P
M(\HBK;T=[&QK&!R-!\RB[G;L:$7EK(A8GD5W%(KR/!T78:/@N15_?U_)96 S
M:=5O;KD.">[0:] \VZGQWWF1X.E<4Q^RR=U_]_'#N^"V=D[7'M'F?%1 ]\&F
M3KD)2FAR8>2[=O++<;J(UQ!>8B\/36+G7\+Z?XF<<CKZ);!*DZCI5RC. _ZU
M_LJ_IVUU0] F*#E1+?&0!G&[< 1>;7G070),62U&0&MQ:VJV((/2%UTHL\?5
M#Q5WF?]P6C'&> 3+EJ-"LS/K!73X<-8,(@EFIP<9.^2B6K  0\;.T4;RF0F.
MI9$K7S]GE=.EV9X1.TW3V9D^&@(;G*1<W!M2*T\XQOS@L=;3=8KMF]56F?3E
M'3%1*O$9;F+XG-XWQB<@*D1!FG5JC;)=Q3RM!^]<@5MO>)5JS!RHO7"HFQHP
M[;8#YP(>W]V4]M"I+VLN'$POJ*QGM^U*G7FX[=Z4<=16)[EV\]K$/]\D=PO\
MVRVO\>?7_] QCJK D9T*'-G9P7%O/A?G+B]]G(SU<3(^QKV?";["<D0XG7UG
M#+J5TWS&!%.&2:)8<"V*U;% 62P66'_5R/QO44..Y,NV-.9(SL*/.\YDPJAQ
MT#</*!HU@P46XW%O6HT2\!33CR.[:UU3&#0,I761B./J0Y&PBU-31+&3)B%D
MNQ&,\;*![O7]Z<#*_RO;NF.!1%+3\_UFN,YZ!@' #0# $MY,PE^<=O^DHI\N
M>*4$"[0U(^FEL,"K.3/,1943'?G<)P4+F:E'X7:L;_83SS/E>[EF:?'@N/?]
M:L-U@58\^'J5MM3[T1LUY^ 8KK/AHLN]1L[$'Z<@&6AS!'LZO)'_J\WS6$-/
MB1?.])]32PKP6 5>\-BUS(RB^GCF%1H$Z8)B6<GE+,V,3WAZ7G5)L%(.%>:[
M+1H$MW[Z9D7<+KAHJ7ROYD"1>K=:XRZJFX/SS&E+GLTVM<#0JMZF.M."*\G&
MD;F?9BFRK_W:TOZ=045+OH9C>W6KGLE]9=A52/W3"'_9\B>:Q ++0VP;:=2Q
M"S/6UK,7]^#ZRY_+@P?C8SS*V7R/Y(*')[R%E^4B"TQ>)\#H)HJWQ+)^#/Z(
M<+=5Y>B?N\*",5J9<XS3\^$=)PY >XJ'.+.HKH[:'<:8VUT/Z;')57F%Y[O*
M0\1Z%K:"EBPS1%6TF9 ATL)M9">.(B<:!W=Z Q.D14-K!!>4Q=D#V!PG?67W
M_X."9B1_X%O5V(3NDS3@%I02"V0DGX;*+5\0>EN0>]')ZFZZ27Y%G$9EA?%L
M#%']$84[@09!]V]\PP+- IB@B2E=CE_A&WKE+A;P+,9PG::;!6((9!E6:;64
M'%*)^\$X6+=:N D]ZJ*\H.?Q+SOY._QVJ >%JXRP:LO=PC5X(_\/JO!7!ZN)
MJTDH0@7ST*;FPF,0'6@6BJ%M),U'<FR<<6<U.>W\ER\\O.GNG)H-(M_83:]8
MQ)*)X[ST1B$HYL:7Y!]RU[NSU)9L5&541#ND5*^L]=H*K:P9U^+,+3W._!(B
MQ5OK;_DASOJ\V;OXY(YGW)ZI?='^=EM?3H6L/:''[../+X/"\.Z R@_+AJ84
M&]^S-;-4,ZDE3WB_298)&Z",E[;X;DBG6G287*<74F6&I7H8JY6W>7VAE 0'
M6H+\DW&/]V$Q! L@GF.!Z6'B'%\ (,,;)KE=GA'&&4%]KT 38G)[',_D0//S
M6":-J7&K]56)11D_(I^<\1@C1<GGM",]NBS^=R5Z>H;&'4UX5OCNM)M.^MPP
MVE);6U@_LTH5(GZ_$R1,L7*CS%WZ+&VBE*VT+'X%@K]I\*8LN:S<JMSJ;G$L
M_S4UA^"7.Y5%/Q,7E..L'!%#J)<$YD;0@LB4J#=/[XO9REF_JW$<C+84\F50
MXRD;.1HW@8&&<5&^%\NJ^C9-\V*G+V/J9DP!0L:A3V7'Q28;DU*_6;-=Q#>.
MWIXKEGFX!-*\G$%Y&V%2"+>6?6Q*[9;8.8/3U6$"R@.Y+8(SRAY*5&AWL.E;
M;Y_/*H$-,I<Y%$9;B:^%2Z# \=9_3CS 9TE:_B*?<Q7=C;:4ZR8^,<2<@U>>
MC,A3>4=1[M9<'$.[HLM;+R9QS'@(-7ZH22^CUO%,(/1(7HHT"!.?9)#&B;/"
M^4]Q5C@(<^__8.\[PYK:UG6#H* @*+VC4I4FTFM I L(2&]*D295D%"#(+V#
M@" 0E"X"(KWW+H0>Z83>2:B!A'#CWF>O[=KEGK;NN?O'^3$?2.:<(V...<8W
MWO>KWS;#<?/A_=^1$D_P]8\JYCIS5UMB/[*BQ]OT_1#]YR_R?T9!O\AIV<7^
MY6>5?BQ@M\#S-AA[[WNJ981_^62+9F29=49O7P"B-17P+,A^Z\_PL1BP;OX$
MMW3H,R,N=4?:0^BS1SW4IOE1\AYT3?U2<:>1+JWF#C<A]4.+C=Y3M"^J8K08
M\M^_B=AS>B 84^F$NV? GS%:<T<>]):I^67=+GCM@_YPLV40NAC'HB'(4J9A
M?V90 G2I$AIA4Q[NGE*;J?!.(V?'ZEDSWZNQB*TFCBG0W&Z_)O/5]$Z)OM7E
M<-;')5=D<%W#01MBY%('BW7="(9SK3$&XDV]>+;BMMQ%&U#O$R#WTO.6?B9&
M%<D2+*RF>=T.2R5(+,UWE]4ZX4&.52%46N5VN$Q>4U8-8C?I<V[#5%>BI8\G
MHQQ)"O4&*^GR):7'JPV0Q>:VR!UGG1$K1&;H<\H;V9%OR%( ;%^[E.B6A/#*
M2S;H^;N:\7BFF#KBU.Q<%!I@7+)SE$[:#S1&B)8]\4L$S,"+9$2^:J-8EKG)
MK:GQ.EN)E[??.O =O[^+1W'+JD"LQ;*;4?\SZ ( 3ZH.;V!,TXA(KC,Y/O#+
MHXH08'R,?AW7JN0Z3[>@G]'<OA?IW17D"%=7/!MDHKY4U)BK4TN)N*I5&[!-
M*NGM@C>*A;Z.F"<M8580\WOXL%F #N\&.-J[^R^OUD&PS9^^$A$;\K)"382?
MZ=OSG.=!K(G)EAL)FDQU>N, N;^^X5\GIT'0M@O8HWFO'"OTVS3-_Q3PGYXR
M'2R_O>OLO[0H+$UY.4SF'TQ)+N)_MB9N_?77_MI@X7H6SQ_3_><%D?27M0*D
M#S3^T&H[6H,C/.1"7,Q/<CXE!FB(T15RDW64+@H;DZ&4+"O<G-Z9GN<LW<!A
M#//C GRHT!XM:!W5;$@,U\]TO5R6J"$1L5,)_]IR*'FZ<3XUX2C?C;TU(63+
MCMBRK7(Q9^\<;YOG=@Y_]>Z6!Z$TM[E92K?+EEMU:,7L-6,.A8YJ[;J^;L:@
MF/9*_=%=+$=5KGU=2"I\^=N#@AI;F[B:QYA.N;T(P&[!K]#U=WKZDLS?J_$!
ML-^Y']G\+NG"?[@0@=1MW(:ZJ73NRG+&40B*\9-?HNDX]>6W]N%M#JT8\3V)
MLC8H;!=@NLJY8G*XM:7'3S=ZG%YKBSV;%#<OG1R\M[<]SZBD "LA$]5TC[PM
M[5H1?Y:<1?9DR)<"/G_]1Z=#WH9(8=G#U$QV.Y;9]U&)ZDC"-QC118>[O)6\
M').145>SH]@*UW5;>K"Z0\.R+#(@LSTME!Q2"*3SI#9Y278L5>%+ CF5&B/W
MFR%&3'%LL4GC!2#Q2Q4.<W#C]OOK!N>?0E/LX!_"GC)4U+O2,&92+AU<*D3)
MM\])P&3XIT'E'=[W-C9(0$EE9<K[?5Q:"3_SDI[\QK^>8L>^86'87O1#O_H>
MM%+B?/]LM>=:I_%?D4\--!*XKR;U<\3GT0]@-B8VG9!3]LR?=,WY/-467_!O
MU-<'D#?-^ZH5\V<;.%CC,%SP1^>I^6<06L\F[/#4 TQB7_>2M\JX7OR9XN#]
M[V_)QB8R%%ZY7L_] A,E)X('DR2(KW^^HH(IP!_$,J,N .U(D$6W_#A_UHB'
M(Q]5>6U%H^M5O2C''MX N2Z04/,-["V4J]3= CL]^N"JHL+-^]*YE;D?PB<S
MY2ILG&3QQ==*[9<KH?0@GXX$CO(2C' #I+VSC:]J77Y[<*B#B]#)Q^D<5/H$
ML1?8P/ZQPCLD-'NR;?^6[>X-9\<OP. /;)>DN2Z=!+MO',82K9\Y]GX_KGK2
MSBE^F@0 %A1[<V61LG0VB8P+S?K/MV<R#&F4%?4Z.5GKO5-B%+ !E$E9Q8%Z
M=K8,I\!A_NSG55-T&$)+1]O]@N1'3?)E*J<?\&I;5HM ]4^09*%8CM8OMF:4
M3>//$S6I82' VEMSAB)QI!,ZZ6NW L68[,=3.LRI9N:GC0<0,-WJ"$-=YA>0
M.\*<EV-[ASRRR)3_.R_K?YT4_O:HX8]FV5>IA)Y87 "&"TUW],;H!Z5EO#S(
M.+==/WI%M5!>$V=;BR)Y$2"EU@VA;& I1DG -+^.S1F_WRVVLA(9X:-BI!:_
M1PC0M_(7]P5",2%6P..UGT[[1M3T)V\]^*_,HC[#U,(/^ZV3WG\0(MUB=M/5
M+!$;!%Y;M43E+]CLTV'X"Q1(!B/*^W.[RJ([ &HVM*L!TA:BAI:&-U8,KA#^
M&"WX4\'H2DJ\50C%,Y2CZZM+H#8D;R49]\T&GD5GGL36'Z3ZXEWPF)H]0RR@
M":6?NU5FC/+42M@SK&=657?[UA %&!SZGL75LA/S+N@I(CD4Z=E)V%'M[553
M%S&[DU=SNT.9XOI-Z,S+@!^[1"7UJDC1@%(/21_'>Q< Q80SQ0YN@/KRPF'+
MX0# 8^Q_S/?@CZQ^_4=Z0"L 7+ \B,K:,2O8 M)Z+;34D,I,2^*4E-*U3F0!
M)@C'3?:I<E :]&&",1EYNU0;QYA0SQR0C2)Z\+X^_H^EN4I?2\34GA%2'\/V
M6L<.YA:6!"P_,J!7)AT>NP'BW-!:OP#<2%&8V)82+ ;YP]3KZM_)$]N]ZN9A
M#V_IBWK@?R= 6N1_UHP.^ (D![7+(3)*(5\V!8S7=KLS1H##2AP%OO+(=&9"
M1,[9AV"?_//Q+TJH9=8H-*G*F?Y[%#Y<!]4(AM]'CL%H/&F*5]M?[@7T3D(8
M%XZUHLCZ L3U4-%9D!@P(OD"D)/!;9,"X5^[ .A72[X:%;H 7 /!%!$T'?7]
MD0Q+'O!H_54.H5OM-2N>=UO[R.6.-])^..(KL52$#7>EV)U_6+Z,YG\GU7PD
MOJ&#T4%Q6EOF:I:"C.AT>JZH1=[PY!O<3EVV+&1$C@1(K_:=C6J71^SV+7)'
M>CU]H$9Q18]P*(*_=$>H7YR?O\2BJBK*R<O:Y3/A&*R/7B,4;(TX ].BS#MI
M1.:MVLPG X>_]2@SWG!I"23J*:EN,[]V9!Y69QH;)J6Y^*%V>Q?/XXU!11!!
M3/%^J?P0/<"K'K*DU%FO5T[2Q#1L:#6'<7[2DABKSPKPOG;&_,U7'-[(WU8G
M9626^/)V=6R"=WGF=G=M\9]-S?<8Z@M>%G/4U<9;!E(^4-X&Z>*SC8TO02H(
MHS3BX3T-DB^5IH3O/^YF>7T#7$A[AB_+K"3:,5V)JL#>#\Z[[X76(Y_YX/\!
MR.>Z96XR92KO9WUYMCXT!#3QZ/FL<D_IFZ*))D84;%%Z,%T*"+<JKU>C[0];
M(V)Z4FWQ_0$>,,061YRY.\"5,E+@(1;-"T"/.<:490K"#%PGPVT=R_Q8O@#I
MN@@DRXYF+,LAX>@%8)_F D"C=)S?'7N&OW$!."6^ $1FD3F5""Y",0G0&V#8
M5]S<2Z[1_/T-AF?+8 8IN4^F&Z)3O/&5=>H)! +<EN(+>\=9I$M_@V"69>A
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MI(=[9;@5&@YP+N'F-D(J9F1M>BM"O*T/C@R_4T]3N,P(G,0^[RG^O(*Q7G2
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M+8GU5;M"/AY_::;"6'X=JIP4DF95K9\XXJI)DW1YV.43M9#@'X0_$2#](.)
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M.?TJ>XL?/://LC#-'RJA&?-QY#;,X[J.0=F+P._F/4:T)C9N"@$T+FO(C0&
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MK^$,U )K918SU:-OMAT2AGRE\T&6QW%!JB.+H)T[84GZ;LL4U)J<6^8*0Y<
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MMU!?E>1:)T+ZA6C#7,37$J6126\GI8 ;KQQ)KK0?%.\9TZUL4"J8\@TCB9-
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M*RV1#JL=_@?A0\OSM,U+Z)_Q*#BZ*5QJ6,J!ZKP L$PIG;NEG!9[3[*@#V7
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M226O59WYD?B6ZKL,N,]IAF:[^2D+#W@&=XNL\)[PPOQU\+)OV07 S?P< &N
M]2)IT&/@MF81GTDE!$OI*=5O>JC/OZ3& G$6!/XT0\MW3RF6^MCEV:>1N$(+
M;4\"=R7M&&QK3',-!7_$S="O5K(P@:I-1YV$HD7AV"('/T\&N36SN*_R-<_*
M7I*\2=R C-0YXV9$8U)52N[Z@T[GPLV3P G)5'VWEH^&D\BA.)H /X?8<AG!
M2"6DE(@_ET^&DMR8;V?R+A6WQXT P4=*B$!-K8WI L AE,S._(<_PZA0(F?:
MRV++@.:3B *Z<V[5\@HF70_<R:EOBI;&T[9K1.!0MZ#8=N'L7["M_LVEYINH
M#^IDS^$9#(.0[>)7?-DNKLXO@\19=H",_#5B=P(DO;G?HSR_F#M@ 2/"ZJI:
MO"L="KDN;SQO;$N0$@+T!9Q+0/W=$IG%HL%'W->YE49+C";H.*L.TO85T)/0
M60TEUDR?(<)\+9/\ %]=U\4,^B6TXBQOI:/,QO;>QUC)1^&SKWY< *(]W/\P
M _&_JM^"6E<35=W$0$A1CGV0VD1%E6=5K<<LG1ZMN^NL!N%([6L$+*;!DM$;
M'.XKGWW]Z@Q#V&%<EUJ2-NE AXM@U&*%KX_-E>8E36*4LV[:H^&2B46OYRJ/
M+3:5VW:BX@<!; OZI.Y%3$"X]42YHU"R1&AHI4]KKI3;S4 ;_#Y6X/UG@-:?
M\0\GE4\BJ!0I20"2VJ.W7X!8/4U+^HCY/W:K^OWVU ^4+=[CL=DNN,]D+>+F
M/#F(019I,<579+_+2_S>-]6(-[>L?C<>=JE.@@N_2W@O,,T5Z1RJD92G<7;?
M#ES1/R\BVS(9/5!?XK_C<SDI1\(ON#&IAOMR@QKELS*V>U&DFIQO=(;_+P[7
M%0UJ=\@H-[/J@HY#]K:Y^;_'HK=.Q\DE(IQ364Y@!]E_^CR*-Z;CVW,!:&K.
M8+8"SYL/!C IB/[IS/"JTOD19OW?/3_^:QK](BCFSQ=[7@!(Z(S4=1SP.TS)
MT&/OH?+_XFD _CZ.\%??X3KO51G<\_6*(PG/0;V8 GSSWZ=XIX)D70!^J3G[
M#_VQK@+(-0";ZKY;#G:<7>#(E&(_GF\@!U4VMF<[E^5:M&*VY=B.6L[TA^@3
M5#B20'%K [:,'-*OT_5#, 03[HV$;4UL->-.%I4B,*Z#WKNMU_0!WI#W-V-U
M9)FAKV1B<42(M%?RBPB]:93A':$67>8 #V"AD#Q?]$\[;4X![Q$3W[Y40!^=
M <L3[YNG0>9W?=50J7Y+ S\K2%2\OWK#F! (!/JAJ;%/]T+ %*4-A 6G.G1.
M[G:Q>\75?NWGAU#Y34EL!=ZL])?Y*TU\/SIMW/OA W8MML8\5"I=9'74!"SR
M1\77!6.G\DZP-<W8<"KSI<&BYZ7K310?E&MB5M5J,W:F6)-O!;.\F9'M+K;P
M!8I.V70CG1=Y];@;E141*F*)+G92#030@HTC2KS#@5]U!M:@6-D*I$RX3+P?
M>YL1-%:P)]'R/J$8]&.W<)$"P,OY9X*]-Q> M<R/N+_ <_M]-"34F\"<Z3DB
M(A=ZK--%&\0/A7!5SW47^RF8W?2Y ' :XB2/B?X%X!$]8 ,,AV!PQ$KJB QS
M]0*PI>\#'[@$:Z?GD5"/JB8W:H5P0_VVL])W")FX]?Z1FUVM.2UJ:KX-2U4/
MX[6(U3$VU+MK$>(BDC"MH3QX7U,5L%GPY5Q2/_!LI#/7=J&NOMJPLTB9.$"6
M,R:?;BNB<)&%7.X3"*PWMO"T,44]K)>WPBVZ'5],^C42>B= 9"L#R1_D?@&@
M''!DWX8)?/"P-F</&'1-7V9136DWXP@R1QPG%7Z/GU0KZ%Y5<&3+*ML:S0.M
MY9HUCSMN[^RIJC#"1*IV7";Z;\W)$L1(1"W1%=_5RZ K''UMI9%NKY2LNKYT
M ?A3O,[)W\3KS/TE7J=8\S)H;KXSDZIJ8O=VK#H-A9! )\_"[JVE0-E>F:1Q
MF,UQB2#67Q"R*09>5L*[ %R+?7@!@#3*8[&<?Z[^)DV,]3\B0Z,@&'7/0ZWS
MHBC<Z2B9[%#L(Q<61,$A_REZ#+BW"/Y96BY[J'EM[\D%H#G\ M ! RNP3-5
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MI*",7DFAF\7I>GU48H2(@8.48&11[^NY*D/B'NIA761=[$>&G:>\\&#V1_C
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MI<,1"]#M;M>[22G"E8H&_ I09+F?\S,U'W\.![  4J#B+]HM^B?.I1=]&6?
M=>=S8#Y[63IN^<@^A>+B81*7O<RHA!1D%F!>(P;STH0^)@RV+^J;=E]_1_'L
M4"ZAO)/G/2M5+S;5MGX3\Y698ZQ]9>;<;S["E*0$W2IVX):@W/"@4.\7V\>E
MB-7F&#BL5GO-OWY.GVQ2/(M(5H<SA%?:/^";++;GC'>'E'=7RM^1W0.%57I
M<)I7WF\P'+<V'YEI"09XT\'0@$:Z45VU?&7MW+FJ^PF"USXEY;VF.8VLZR%&
M7&2#"K;]8@3QC-2H[Y!U@;'-PYXU\[23]2&S:"'\RSEVBX;V!?AMP="*BYM&
MAEA#FN"C-587/Q==S?HW!ZC7^T;I5_ZK.DMX#T"P.:3)!YP_("QG.$,D'S(L
MRGV/0B*5SJ)@&3<W\B6^0M:7'+]>#;,%Z! NN'8UQ#\!DWC00'I(,P^*U.<#
M&ACJF+_Z>PM("PW8Z4;YWD-V(U1/S-  B,37#,EVS?-_6/_WL?X*)X^Y;%X<
MD)-_=';M9';A\-7>]QHSH9X!@S_GLXRB\19G(.3;WI8JN&S>5>>H;XAB=Z"@
M[%I.6LI#8#BY;S?J#74)DJL/\<4&W"C0DER)%;R)L1]Z8OS')A R?T'<+9S>
MTIIT :,!U11I7OD>.&B0-"#@8@[1Z7:.!MHANT,AU,IAS97AH.]+/"?&S*\N
MPP=.J_$L/3(W#4O^SBGK[TU3P>:$D[0*THN-,(Z:?4,#Y= )$XZI@*^\"]Y9
M^WC <\B#49ACX"Z2;M%6G'A:F4_RYNO075YA8<[P%!=/RUQVXS_I(\ROWJ]A
MEB@21S(Z)]M=TSDU669]PQ6R(='JJ%5=%V^\B57AN"6!_/5O6:YHH-)VJNF/
MH_)@@_IE$M<;DUS%5Z<N>FUE_.WA?&_Q',32FM7U^+'_V(J?0'-_)X[Z>[_]
M+0SK'R/A\ECUE"K'T8*9H<_O[C\3L%8LO2074HQ\M.AT;C&TJ[@=O%-4'?Z&
M.;TQ$@&D%[,K=\0@/LG;7\ELRO2GH9+=0ZAAN1?:M/;?YR4JUXS)BMPWQ<@R
ME984"V42YO7"?_RPKA]A"GFC@@8$&<./3S-PQ\ VYQ-+S(N.P8_FP9_F- 5?
M)4XG]9*V([Y] MZ?++\YFX3>OROU M,LFL#92!0NU]9$#COU8QH_4F0W!&E4
M)I'D_IAF(^Z[",):_/K1(,UUC'^["LK^O64LHIQRO.;(SO5\^/KX3\FMP8EA
MP3KTWK*4&?,H^Q^3%4.<['^S1_]].0'*,E+_&/__8?T_K/^$-3^%Z0V.@;U9
MZ_&_[OZ&/POLR6@LKQJWRRVO#[2H^GA+@2:22EG%1ML] K?^A@JO;B20V^Z,
MW^?H;[7Z/#DF@'#4CYPRRY]R,>2Q''6@)AV ":AOW=][425Y.$#[]#E&C'\X
MBI_QCA^C/R%C**#W!Q,G_V5]5:AFJ&)PK-Q%_B &2$J2" U8ZJ(!&XCU9:K$
MS,H9O:^$([=HU>6C ;U<13X5V9=)3R+YMP9;,!!)T$MH+AH8?CR&0@/<B.$;
M?7]@GVVAH?:U5<-%0>B:'Y7S=6VMT9E!?WGSQY$1(^_#B<[4[78Y=S@6RRM"
M3*K?7'?N:B23;+F6@/N!2Z.R =Z7L?#AQT.&>(ZQ=D>&CV(%Q&X_=DA]+?Q8
M/L48&F)F8?WMQN*$/YIL^=/F<5ME6Q'V5$V1)->>RWV]G1)__E*CW'!&_TO1
M*=&3@5/I&C7?CP7T3T(%8N4T9*@XN@%"*" 2FG=9DKL,FB9//SV#=$$+L53Z
MI*Y^8_^_^][8/\CO?(?=3XWE:1,OGJEWC=1@7R_$HX=0)X4"0\-'^MP$&U5U
MS].*JQ+ZM![NZ/@IB,7M*;G6#;7-W]RN*_H92,-DJ-S9KO]#[+$):DH-8\AU
M?-)<!E ;K4@%28^9CAW5RT/MF2CELR@QQR_BME[SO_H71$S_Y1'8TT'IUI^G
ME,T@CG2=1=M?Y+.IM,@L0H'EBO3 .9*12C;NW8HSEH2IM>\.7"SQC&C 62=:
MHK&P[+]],_8?Y:_#!_V3R81]9YD0>Q9<KSEJ6M.H.<R9TOOZ)2Y6K>/B]:A%
M^G2]U;AG8TAN>++LF#<[Q?>LNHKX8T4A@[.G?MZ1VD+XZ8<#;FGB\%&P">?1
M#!%>W2JBL\A52#Z+JOLC,_VUJ$DRXY8$(X:19^%S3*7?&N0*!"[Z,UW"#T&&
M^1@]JE.$RCV8-#(C'!)WP/T=YXG!)A0G23[S)SX11>'>^?%R7V=<3T/V]4"$
MU$H4':A[,'"2+H?;)G-:I[EI%UNVP4[O#J%R5P%83JL,]B[<6S]SV\-9AR9L
M.7]:O/^MPB?G7BTQ8IXA-* ']1:/N_#J,F*'O\2(3/7@T$J(C9;\:&I 0?^]
MBPUS9.-WO6V[-S7#T\S Y6G1T#>_&!1AFVF3%!61$Z8VGL.K+/'),+'/*,M"
MN3_TJ-<\$L?(VH#%N<#2;!BCEW^%PO/R7<> 3OOK(CWK.8**Q \YM3HYXS]H
M#V[V=1"N(_W8#(SFYU$#X=,I4<Q*3%)XY0>C,NOYCQ7V(]='*SD6$?P".5AI
M"9[6M18W::&X16J@9QQO[5DE@NH@5,9@&^5WY4/\42>#@9BR7Z3SY'$T92E;
MM6BYL&0]M47AA!U&I!.^U!#S34%RCVK!,%I/\]0"?*;>F.I;P@9XYYXJV$6J
MFFX]>0%/RX-6UA899=ZO"[_(H/<ZU/HUM;98OQ-UFYXS^;GB[%,=MV1=O&HM
M>1P*HS<?B/R$D=L%Q<J=OOS5L.*R'-VM5T^LDT*L5L:IG\EA8K25=D,,(E'O
M,=I[S3.FO*5A2TBQ@X9#'NI/U@<4U>13*SU2#P@-/(86];3.E?(Z"$.,[HBL
MR.X_&Q&K5]07ICPS,L.KCQ9)^X$&G@Y-T$B5P^>#F& DT\4YG,,4(]:1>$JV
M41_Z2%:7R\10\7F?MEZEW4;D+$6(ZM9&#G(:9C5_27MUD_:#@4B0V$N&54D2
M!!<((>O+M(VZ7?4:]$6FP>/$693\0)!6Y#ZH/6YLNI&I8:9U\N:2<2C]';AX
M&!5?/M1L#+K>W?\(L[8O;8$>=;S)][M#&F9BTG@JH05+J@Q"ON067Z+1&VLY
MRZFRD^J-C1]7*$0"SO2U+V**]QZ*"V\:H%+.WX(PD8;KESD5G8^*WSMB'%)/
M+7!YN(:GL6=7P"$!#=9YLW)+_>(B;8?/D^1SOHROJ,%?<>3X;4?.Q8<MZK]-
M7VP.G3X94_G6P$WW-4 YP)7*O)*RY[&\J)SJD)DDV=%4$T&G?=[4O-[FP"N3
MB+NIF1#N@0>\>!EVL^F>)[;@3_[3;!F:.JK7N@J'V2@!7[(U:C00)H;O"DO0
MU[]?M%*=-M93/F9V)X<X)E E(+6U'B5</-]:E5A%CSMBST\W;Q<TR/>>IQ>/
MU,DWE0W3Y5\0?WSK3Y$M_*3^I5O^9,GN2W1,7:N[Q94T8(MG#G+>1#$QDM0:
M6B#DW23LRQN[H/V%@IWC2U:56O*3I,"&L=LZ3!+/L=4EJ?DTO;:W#06Z;&>^
MC^)::33$UK;ETPVXAL$%6_%:Y4*.?L1%6@!7QH5(W8/ O>J<S6FI;\7["V'*
MMZ GL0NYE'X$<@:Q()%:T@(^!8YGU((J?>V9V-%6&$=_WU72Y%36&:NPRDQ4
M;0C]SOKQ142V$#ZSF^J>D\WN;W,[E)=!^-W,S-M:-EN=.E0B1*UDV?<U"F R
MS4^>Y5$BGW?MD@6@@9O509 -07,T +EA/.;>^$CG$%)>DEEW4-;<9[<[] PE
M^UG'<]A@-$!Q)$3S;6J<S#E;T:QR![5LA+.U8X&-P$FYD42_6_S)1YHW;\ZB
M!LLX1O\A'8;J)MWJ.;7&%&N;@MBW2Y4:\*:L>2:O^?']JJ_*2\2D/FU.WIN[
MT![;M01X0KW>RP)'0JQ\&%DR%M/@L"?C7%K3_3IC>Y8OGG;BCXK2NK=@\_5'
MD5B1)Q+K_[!-LGLD^ZK!Q;"K*&_8WX4-4RNTT*Q@RB:&K\[GN/*'U8SN[JKN
MM;0:%I(A)NCO1_A- 6*FG9H?F2"24&MNZTYY8RGA&>_*2]^@I+"$$(QF&9=_
MSZY._9E/;3B*M%Z$.IS950S8#.YMOB\-O<_;09!;,);T+=.0ID)5P]W>4FFX
MB/I"LS%H])O._02MEMX-B4I,;E755C%M ?C0]3 6WGPW=V&\[)>W?7C4_EX-
M::V)HX%;<_>/]:?LF1*DB,6@?H.N?N((/@S?/RP&*%:FN;NK>&7C:L/83/2]
M4&'-)%ZOA]C,\'QN]UT&I10I2*&.WE<-P43Q/N875[THM#",%4CVN%U_U%W!
MB!.D\:4^!FM-W^MM=/XQ(\D;Y?IO%3,WLX(.52JJ$HR/K?GZPM& I#(?QK]B
M%?^+D0<L;'QI1_@_QMHK*WQIB*<P;>RXM<+EZB>_F51BN8 &\*U/G6>_;U#;
M-WZ5X^DG^\)^OTN(T7FB:B/C%G5"2([M@[""S:K$S^_8N.YHSQSU+!5+XVG!
MLA_*QCP)N!6<J2F7@9DC\4=3RRXFNTS,A<W-23,^2 H[G_\-&L!A>*MLC+<)
M0F"E+QKBDV(\;U<8JRAD-L^;FIF>CE4(HFR[PUJ"&6F#RTU@Y6D_,ZNS<4(^
M27B:$S1+%+5TPWI$\@;9('BFXPO"K!T-6%>\X7*G"8F=[ILM#[%P]2,0[E9'
MJ'OC+[T6TUSL;*@+Y-Q?3%*T[2$1BM2PN_UHD"< ,8RM^-M9KC*KIV^L7]DX
MVZ#>-N\IK,*;GL_/3XJ1GFNE)QM*:WVE]Z,AC2=@34$?I_OG"5&YVP]Q^$5Q
M;7O>K]SM>+K H!JC;96! X5FE%<K>NDP^Y-2RB^K?,Z:(HCG)(M::M2SQVY+
MRH7:T[HH6=L=,BFD9K])H74-!:8^E5?@/S;4;I]VR.1E4G2WIQTL2,WXXB\Y
MY& K^XL+Q;N/%,S<JF9WSK<ZH5 O85* CDSYLFB]=\Y6+7+^E&WS\',60"AY
M?UP%R[ YJ()=\1#BF&4--XR+$]%G]+Z4'+#YLWUW;0I0A[T G?Z.J>*]MSTX
M=1<VP6\QE#\RTYH\+9TI/5!@""IN7AH 2?G/Z5I6.]_1I=-S*F(<I-8T*J9@
MC!:U\!/<***CZ-02R8W@RN0[J5J;?9;( ^WK/7$3?F 05??4;TJ<7? 9XHT)
MY'/.6Z@U!EXO2Q#\:2)W<(($Z'6CKX.("O8_3.>7B+ .\C3J41J5>MV7-R;8
M,@,]%/C"G?*S:N^5'QE3B*,JIKD*LF:MSC^^VR62%LT.XWNQ$._&0GR3BDX&
M<!O7I#/3*A^N"(.JH92Y)J8?L81C/1<']A1:,,<G0;G@Q3U^6W9\?:FFD1E5
MM0E>@R^\ V]J"J:?=W>+*@'NX]IW"A";N\>*VYSL4LW?)I6 ^0&[GL*;S*+:
MSC?F:7?)LKC#W>2]V;&#IS<C4YT^FYB'E_<,M&6H]IJ"NZ& HZJ.!#&<%U$B
M'WMI9_F%YX>"P_"@+$QE89V.L-+Q+_<]_ZI2P@!O1D92-,NC@2,,HU8CT#+D
MC);;-P8-;%Q+(A$^WVS O)(Z=L;';<J;!@-N<QAH(*:*^WR1]2BWXTHLD4!6
M/H+#_I83VVGERXHPMX6=/@O33I9)>#GV23'8._"UHAU-$#"X@ZJ<]E9" ['F
M2]SG!W%G&D:8PT>O8*!WQ9'QI@X$Z9A4OH/)(5.\KN%KV5E]$KWY>KY?1?(;
M0ZU,8G?-RT/M]N3Q1G87CJ[O@2*])J%;].SEL"C_H[#Z?,N:A$7&JJHJOVN'
M3_L>9K'21?$GPNM1"O?*CZ\TMMQ=2\1D1_4Y^9N%"T4?26L!SY!(FD;M7F(:
M<YP:3&:@2IDU]V8&?CTWO9',$BX^38<O3=V( S]QVZ!RA9PS:7C6747664<[
MS0BO;OR\[?;V<ZX(5^@V$Y%8 JRGC(7-DR*F1LV+$$ZVEFC\'72E_RC(DY=V
MU3M$'0US$Y8V#*1)[/L"S3&DZ<%T?L4!BN,[#7?@R9UF'10JW^4*.Z^?:'MP
M$ MJ&/#NB5V[V?4("7H*;%<0TEM/=R84WEWAW=3VE(54V#L$SP) ZG=:WF@"
MG*,B1X1N77B2\R0GDNQS_V)+D+3/^I,OE-WP8(4?VK3KXL*?1;H*L:.\>99M
M(?B;^B>2=Y2>,M8T._&J/N>=ZA))RZ*S?5^1W);7XCSWPUL.3OV^@J@_.^(I
M?R+8,)>(Z-FRL.H,'5R2CK5SU[1KO]6(?"(SV2=@6Z":2>7FY=RDW7*Q\PS4
MWA@IWSBB)2ZM"XO,,LOHV?ITF1,Q][ ;(SOP^0J=Z'K5HT[G-)'J=S((J84*
M19J>S #UJF@]@]+8%[=Z9FB EX?A+SRUT$!'"0W"0POA]3K/6B^U*0OR^8&4
MK;7-DH+N]W<:M,7B+>N1%1A3X*RN)(_ '8[U6.$2!^X5(EV]::XS+LJCF=V>
M]1^>$V(,1 X<E?KL#&1@AT.I"^\T36C[$"VL/"WT:[I3NK1!=?!.+BRR'+9N
M\"T^76G4WK?=YX%_OR/SD]O"7> AR(EO/'>G/40!_NI='MBVO2ZB*N_SO%''
M,#3%W_B^-DL]&8@-.#T]XL/8/E)CNR/)RD)040%H?_6,0@9R0[:7E"]Q)L?B
M#^FST, =Q?ES1!P:>,Q_A.2':YSYYH6E(!^>Q1>.H_ O9RVW"0\\#_J.00$0
M#]WS=F1:H_?^9=>59T'OJXLZ9DA?&5(KN3WI)HC(*@*WJP67MV=)G>#?B8_$
M;V/@E:7<CZ:0B#"*NO)#FV&A8%:5<3,[PR^OR4.%.1_!:NC@D[!BZ;8KG=U@
MDHGP'1T=ZHZ=ND_OEK"=T\G52Y-PX\-J[9[M@O)GD69LQ&='(J1(Q<2N/6K2
MES/8Z\4B[F# #1>P0>F6%Y%!7OL^.:):$ZY5;Y]OY4%HPT\>J4M_SEOGA-MA
M(C=_7@*5ANVQ#V$BI2?$R J,+@NXAVVTM+% '$^[+RU(G0BQWW3WV,RW#Y@I
ME<.;(RKZD[?!CL7N>5:<*TXE;*VK4MMCE8"#$?CDQ-Y59;1!<+$0:GTT<?/U
MPQI%\$CPX#?NT^29T)%A;]=LVR;*NLGRNZF-<?*)(2X/3W8"."CQ3EJ7)V$E
M0I5P/HD[XY7=<.5(!Z2 '7=V$-V#T9>5SM1'IIV*\LIBA,I.[.SMGH:#)3#!
MKI-IVQ\&!@,% XRZ4H<?[H<$.ZSVE>2Q#&._FB=C#6H3=]ENT\NFIXHNGE7*
M#B_5$B(PP7:2CAEJM-ZF;HI  [BX;2<NF[>-C(RE^1*2(J4>/BC>3XQT$<<I
MNHOXN"C41*-3=:'T=!6:64W-9FZ='7<K]Q'5=9A73*3$^SHXZS)A^^C$TO>(
MG+D7/9?S>TW[M,YC44^!#?YY6O'()F]0YD:UR%QIS,W<("HUM@7I,>^H%M;2
M C<&^LVZIN3/!D8R HG.V<3\-+9%#M4MK,)_6_W;H2M\]EK=;0P42$.*8 >3
M4D,=:5=+=Y=%YA@R>?:&A9<DX5[4OM4%G<O[V(@Y0GQK R8.Z_R.+-0]O \6
MF@OD+31>QY09^/<0R?EHP"+578SLL^"[:Z]S$0.WX_I1B'>B5<LIZWG\>4OI
MP4F0H ;1;-M>7*/-Z8@.U1 F;U(YM1FX_W/@HM'VZV)R6U:+M8]@AR-1;-4;
MEE$2]?"GQ@YX3+P?MP^.ND27DX;A12I6#'ABMZC[]FB\#+5&M2IKF!3BG78T
MJ_QPS4HQQT@Q)HV0"@TC*Z'[!K#(O-P-5_FRXDR.LK(HYQ;>)]GO&=33[>"Z
MQL1(W24?=D/8<55,[C,[R_$[-\4$8_*;6>,(1/)!<V+4QB&^CX;Y2S ,-JD%
M,FT_;^E5]7!R<K(0RW_5H8VG+>:9I_T&"0ZM(T^%;5\\-H\4Q=?ZYG#/[*"X
M XCU$;KG)RZJ4-?8,+J[QX\OMGGJ4!L[_O7+F25K1'_K\?)$OHTO/FRNTM.1
M7YR@[6 E7YUC.,@46RI.+T%[(BD^Q2-!\.&/&?F;"IE.&^U""Y&$3+7[P6FL
M],0PV<R"0M.-O#@;T0IHV_)FOP]&!@%S*_6]N )OPXG*" :ERO+1"B%4J^.)
M51M'><I9I//XFQJ?6Q/T'[T6/C0H+0M[*^7*%!@+5/*VW]*E"=%B67X%G&FS
M%HC%[!IEP>;;E1:-,:W/O=LO.2=W*9X<\S9SIALX-0>ZGC-$B-%E@N,Z$@0G
MHA&N:A2R^D%U<2@0-HM\D8]K=-;%#W<^C#$$D^,M0RN+[38B/3D3CK=U,S*K
M2\\ :2X,_'#WDT(C3C@ *PETQW>&1O14A(-B&2R0I92#!"+GVE2P'(GO4'![
M![D*G\B]/&^HZ:WWQ+MX]))Y&:92R$MVXZ539&PJ!%7#C0K7 [[6(:#N]KDR
MQ9 VNL_5[W0UDU7FWOBG+Q$Q?"BYD*/:5IM%JJ5R&.N6PA(*O!9[6BW'XV-Y
M5=S=0II,F];I'DR&23)<KP0 S M*-S10;)IN"B 8R(<!-/#6JUH9<9J!7SA$
M:55%?YN>+6D;==?BQD=:PH_M9C9O+I?D*8^+K]3+DF]!ME6YK4C)FV-%)='^
M>4>>-$$.Y5EBMK-/0\^BG>2+U76_U-5=IC2(.MN3]%6!+.O3A+H49;/WEF<8
M463#2"DX&@CB!P4E97N^*K3W<?:RZB>KP&]2C8G]&O#^%J^"G1DIQH8(>3Y_
M(^;S;UK,.(U5D0NR^LY*?314^^$3@:Y-UY87UX/0P Z5(QKX-%'W &!?A80W
M'VCR&Y^O8Z-"]<X_-6DC^M' 777-JQ8Z039RBI'-B)(Q9'BA-^M-HT"8,NJI
M3]ZEES(:R @]G#[B]H<<J.^"MJ<AE]>U\X)1I(T$GA!BB<P2'KAYA80H(MYD
MD2KQZZA;O473N 8M5LQXD;Q/U^Z\M-&[@BV!:=EX]_PYH2NW)$F7\@2P:'C7
M@B*!.U3FS8*KYCM+/OVP/:0I8#24$(YLD8]:,TNQ%R-\S+[^?"P'(9T_V,30
M .O*Z+Z0;I_DM#C;&EGY,+,9_F;GA@EK.-+&E]M@<[F]O/>6SDOK]&FB&QJ'
MP(7LWMMEA&?X-_".N^,[$#G?@++.1&2![1*_@+:VDD/TC7A)HCU-H9TL,>>Z
MBF)^>Y#,969Q[C?N%^6A]C?-(A7?X13/V:1< P]=^; $)1WT_#Z/.FXCO.1'
MUB?X/[X0O(>S*A\K=!@QN-NR/H7ZE UK#A_K$ G*S)ZUKA8Q*LNSOU!*V2GQ
M:[\3/[[XKM&YB05.FYA.[(@4+03G*N-::U65]5^/KGM\&ABD^'J08)A %MN
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M;'> <O?N!4@8_X6&HBE*/)\N)?<A51:(MZZN6I"C[;/UJ%M'-DE%(S#B#K!
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M3<VZZ38'UQBM+"HZ8_OL%D1)917)?+C?G>+U]9?BXXN&1KT0"$V7$CG./S/
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M%I9,=0< ^Q\*Z)#,TO31//9@ZFM>!1S$WP&ZFI$W,U4E7 L._ '"RTO$I_5
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MPLW69OW/-4"=J6XM9:^N9AW?(L;4>''J/\2M\03B\\/8=\I-)US2(&%FE-Y
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M+Y&F=<X;8BB_R!.^[2F6K]W6-A_+-Q>?C6@:)?1SG<G-G>S>BW,&SE@Q!YV
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MX'RT,W#"6Y T-#NJ[JON]BHH/?D]P4>?$35YPYG[?5RSGMP-MNSRW)J^;/#
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M99=;X'?^\ZYQYF:SRK"QH8 6ZAFH3A<Q4H=H><=M*;/R:DS$M+*4[N2#V\>
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MOANDU^]OWAFUB0]00\[UQM$JW\RV3WN2><JZJ04\3M6T-V*!C,EH\/6WG(X
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MT]^S#7+)9B_[#.91&!3 DW3P=HUN",V]+OH6YN=4(EOCC06CE1\0-S]""",
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M##64T<CM\6*T[6CQ=TS^:5Y.?\8!S%&(]34JG5!DPJ!9/FF,73^ZE _:&U)
MUZCU@!BF_1DQUH;1/=J?H=9&GU["[M^1\8F0<9L/0/ZXX3R%Z>#"O(?S7.7%
MV(M^R:99O2YP #3!B6_]89G0P-92(&2[_I4BR .=JS0C)HI*.)!Y+- Q4ZDA
MQH@YR=_N8:Z<*"L(%KE6*U!&Z9 [,(CW?(D_IHELIN?14>VO[;KF^SC>8,F,
MU52.4(2C_5OALW9L#>UU;<^H!IZ:+[:8D9(F8HW*< .7[ DB=C#!-VFLKJE7
M,YFMT1H94G)/)/?*D\,TWP+.,!F5:&_EZ5,*DEV)A>JLU#J-\A%>CJ^#2E3
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MC+"G VF TO$OR5/V<-B5\0OK9XGU1A> !>X\*,>&:Y#6#(ET.'XBL"&DOP=
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ML81<XZS?>68')VYRH5,]K</R3R;A-L@K.G'&3'6&V<-N-:(I)?= 0UD">KF
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M'UG3TAT1AQW8PNJ?D-\)&ADC5<M&?-F_2$OQ?4.CR_,<O*4EPSMX=KT<*SW
M5:N:E"(;!/>(UML!O@?4F]*Y47"/?*B+)L9@9#8%<O=7"(LFS7ZF[/B=1 D-
M@23B/VYSU#6M_=%PN74R"NTY")G"J_K9#.,?30U/&JJB,[^5NJUD?_?)([^)
M/EZEQJ[J3S4<J,Y#8S0G#0> 3G;\"Y>:N6ENHCZV3\IER?'ZQ2%PM_(XF:Y
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M6)S^+?A+A+4'G8RF+=W>HE1ES1Z#:-M=%?PZX1_ Z3D\V7*%?H%'=HN>[M!
M0_U=TKSH??%EFKE>:<[99%\;FB;-[SJ/SX7I">DO$!0- .5B;*GB[&%1P^19
M)<G@^N;Z1X@7< YP+'>IWZ!#N6W"W"MQ65-K;2.VA$BCK* !-7.7=KY POC%
M_NJ@N"/JQTA_/7N(=1M.N_C,:A!VC]K4/^2GA ]SIW3M6K9$?Z]T1!RLP53=
M^7>F<:Z.BQ00131CH&N;MX%C <5MZX<$>I_>2T#[:QQ2<EJ*':3]Y\Y-PAKZ
MLC@_)?>QOM>#-ZJO1Z_!@45=J-Q/C;ZJY0*]J:Y+FGC$CY7%7@UWO8K<<@;@
MDW?7^/,T?EQ5P9 5/2DP58&M]";R_#$  J@H7NH2=%[SP^X&C4\4WP+6E.:T
MJ&K'[FE21L1-BWS/"B?\K.(SUBO#**"TI8JV"<NN-V+H1=;D/$TQD5$?L"=7
M7,L"*##L.Q] OLR<)I:8O>DJ4F)V84TD]J;#NP.:QY7(B\-=1D:IPT/+GQ^)
M%MZPX!\8T',GO#/SM*2%DXFJUNYI(Y3NH!#K^#F$\N8NV*:;YR/>-UT7+)<"
ME:%HEBC_5Q2A_G)@PI!#VWJ:;P4K9$K4AB_Q.NVEF#SBZ_&V#2_/TR$P\^W/
M2X?33NP:MA'69-&KGEMT4N?BQ69F(*[FF/X5GN\MQ[> NM,1><848KK5H5K'
MG+_2AO@9%_&;:,[^N/S.R8*P_9Q#@<?5)$2H+C;X\B^A)D)&MQP>X/1V#1VV
M4/]F"4V6E\1.TP 6:\IMVTQ_:\08U#8H'BCG]:>#=P1Y/'$+L"V);0KQ\E]Y
M][7$8R=D,EBZ@F_4GZ4&VF0I*9U]</")027L;%@PQMD$_$E)<>NI[M-MXJ=2
M-<;71C."I^=S3A"P\6):Z+.;P1SE1P0_#)N9"-F;&9_E4;A4^=T"<!97<UI?
MIW/V],JT'\&:@31HV?FL0W^0TU!HXR[D*%#S4<P*FJH8_\3(E9!P->-DC&8G
MAPG=&%IIJE)*IOD&PS1)Y%3<6V<VN@[$_SO]<DOV[B6NL&KJ#77"3A>K6;I;
M#3/]%'(]P& FO<&LS8_!/H<RABD]7P^*(5=#GQ*&@CD*X(7/Y_S]JOSE0OLJ
MRW?<Z*HWLGZ)I[LT\%)FC](Y<MO_>+63/ :*0?ZU$KH/]=.90<8BTE)WGJA*
M\37;LD2\ *2]FA5;9GWVMS# !7P>A:\;543R6VJ[,J>D! YOG#K@;(,W1Z\L
ML+5JV+A6%$XG_X!)8/.1[=*B8!2-6N:KM->U41PI/XETU0L=K0NVRL]&[*&7
M8M.R1FO9-#O/4VF-CD=DM88&K"*_$S 3#6[CF*5F$K+,9]$(CN-^U= >I3T+
M]E$^D(]@IIBM4(CU%P=5__UR>9[5=-48D+54@UY=1@1>-)ELN@@<G.;&IJY:
M__J0D1.CL$@*51EVO#?@]_Z.:@!?L$9I E)K-%Y6E&PTJGU=GO/X1E7I%H Y
MVU@?X?"-%Q'-TB5L<V@=3<\W"8 9=#9^#Y5YGCQPGW);=/KJ]:SDN6]VEG<J
MK>ZRJ;I(4C=RIN.348[QHNEN$'7]HFD4HM"^&.LNM;^11LJ\?)[>N<);F.O;
MM/9%2Q+%'2\&?FY<]2AU<O>I[CMK'RM.M#1I"D&PW/_J=4__DX,#*F36)E.G
MC)SPZ<.[[6TO$@EY1DYJNV,!.APSEVN!3X(&4BC^?JI6.+6K6!'!A.>78!OE
MZ/8D<IB^2^R)F81M)F8[OQ\D>.)]5Q&PQ2T[3E@X8>%4@;T%O)ZXIBRRL"C)
MRB@IAIR_;FGZT-Q(,GCR0^E-^,3GO"WN#)=/LBY^?JB!>HV&YW,"SJP^AN=R
M@J82'U6VK/G\BQZ,Q[M+'2B"TEZ+,]OJ3'ZH#3]?'TJZ='-RE!!>9<,/6V-R
MI>"^ ]_3GI/UKMG.F*VT+;?WJMU)2WO50]48KNQ9FWS<0BI!2OK^C@Y7'D:[
MS1O%3(B<;;!UN;=BX?!9/5&]_Z>1<(>[[P&A/)8*;\_3B"BC/Q(NN<[,HCXG
M3F)N.&8B4B2J8G_NW91(ZT6TU/4E_J_'Y;&W)94XR1\(R4]F]REMTS>;T5/:
MR>HY&TN?.( <E=VIK.B6'P@/1="8B@^B=ETK,$"ARYN!LQU.:[(1QMD$US.@
M2-48I'-\/+B.O[Y2;;F[PM/0,0'GIBFTX6H*8)JC9<@T03U]IXR8;_(?&6#*
M<LLYQ5N98;8V_C8N5GZFI;=F^DL1+TFO:M%=D8F'XUC-84-,#MS[S5\SN7MA
M9C-[Z<$.P;E,I,!UR9<_^7@V@PMJPT_(*0C2UM6ND[2\_\X'G;KKWFT3BLXA
M[FR+GV7VY4A5_G3U7$2)[I(  CRK0=3ZJQ3] @<^;/\V_4A#8+/!\1"X*0-]
MMZVF"^9#.OT=+47_?-8*]_*)Z^@>=C?FH\:_1!<$2U_R-A;[@=*+EU>'2-3
M),-(W\\5&OV;%B*YU!"7?2QD>L;)^7VR8X1BC'INY."FX7J^:ZD48O(9+K>K
M*C[:A6#8DK_35,<8"C_ZL=@O03;56E+VB&'SB<2VI*#.:5^C,O/A\W/]$08^
MN%M=A>@G4L6!NPD O_,\XHI/OK.Y$BWRT6GTTV_#;).8XXX1_8 M.MGX]!$?
ME:;>$6TR?0V?AK]">N"K^6IGST53[@>+$4^'O5E3/I<C?%A/HG=.5_\(9FS]
M#:F^!9R**C+_]5AAP_1'R/)YWZVI*V.TWU+FL&--4AHB)_Y#-:=L88ZZ.E#6
MQO;EZY38/W1H K[("LB0FF2/6^?VP/0!O!@HXOUE4/:"UI-""\CJSQH\8!_K
MA5+9ZUW1\=.J3]B>-:E[ZQ9XQFLR)MJ4-Y>/0W 8ML,PVE"QL LT0@\O/(D7
M6DX7+,P<&9"ZRA8.F9N%_^SNX,<0Y*)]%Y[Z4XH?9E-_B3GO\::/2^,GH?L3
M4)@5:QL-.-_SBW0^6&]N2N'Z:$#!E/C-QD:.B+VL:EFA=T&BO&J7027E6"NH
M]+-@_KT?_;GN3P+0VA0$+0&\-_T_+.]6PPK;-??\9"@DZ(-YN6PW%0D_DSQA
M.N;[--4@1]CM#:*8%?!_5F+A('@ KB$2M+9-.^#V4Y^78N/X*\<#7 &GS :R
M8_5[+JM:+4HKZ%RL[DT^;YP<K'\RL*D;GV)MBED-OY8JY\JMV+6T;?4DK_WS
M4/[94T+>(@AU3TUUY8XEG?_;!;6(#[,FZOSP+NIAUS_&L>LREUO<I<4 ;QH+
M&?1*?I[%7NI"B)-$;Z*;J.E0VQ,\A<>Z_1__!WOO&=3D^[6+!D$!:8+T+AUI
MTGL3:=)!6D)3D!9#+Z$CO5<!Z;U([UUZ%>D0(/3002!1P"@!-K_W_9]]]LS>
M'\XY<_;,>\[\/]RS\N%Y9JXDZU[KNIYGW6M)89NV;E+Z$WE*O<RZL)^CY]'!
MJ2^\ WR4"K]QC(QK8= P0"LBU"_-*;58MA2.^79SV=FA@^^A!YR)CD>G(JNR
MUOUB60$8;M&:X3 '%HDQYH*;@$.L/&94722&_VJ\VO(S[9[&8"L^^]HCH4!E
MB6,IF&'=<#[.QKH2!%+=G#+)' UHRG\8W4>S\G'\7->?L;N]"^ULU4:6V3/)
MUCJK&;178K_WYN8% ,,=2!XT5A/P3^W3] VM/7;Y4K=R"=I:4RJA"=J:G@V3
M%TS+YO4EY&*#Q;FQS;(UU$/7E7BPDQ0/P1/^QM50;U-T*F-\W;$7Y5^C1-LY
M#8:%;R'@S S'.''SY!0W*4J*&F0J*%$769*EL\K2E?VJ'<PDQTG8.%3^6QOO
M^/%64)\6P)O*.QU&F6)N8:;L?*]*V9HD7ND=JV\9RK(.2<E'L:1HL1HT]ZA-
MT:]^8W+XC5VJC& B.NKA:&UM6]3;;6UKU\CGDB-3,=N2N&4_**P5>/4"+/]4
MH%NU$#1*F5B^+!N7(<CUIB??RZ7]^MOGD7.+^_0'EH_Q(("\]8B^S,:[I&0F
ML&O7X]!1C+N4C30P$C6WTYPYE5NLW%PU5<PM4M_%P_]G2$;5MPNMISH+]_3I
M^D;E"J^LYVMSYP)GI^<C)0G^;]>=NU98%[7EF@US+8G$4+L1"U:7>5,'!T&_
MR)MO5/$::HH[W@SVV+7S+1I$%N/.'JNK?EVV8V3]S)YCQT+2BSQ,][S)8"%?
MN^&>-V4O3%G%;)NVGP232)PGI(U F92UG 0HCV-Q.@/#$=SDIJO#U^6".%SS
M +FC5,D;Q[*O)4<&X$ :I'/XCR*-299CNHGL]D^VWW".:4;9=V_/ \MA_QRU
MC=GW:&G)0IC]<665MJZ]%^^2C3!_SVJH#7I@ZD2SK<4^#[&IDK+0D$*:(J[5
M_F27^(7@V'\<XC\ HD;JO,NA0K\']5:KP$T?[)T?&2K&Y7]."-3'ESB):4+(
M6ELBER(O#L];3CGH,O<].Q;V0[&H4HJXL&U5#U\(S[/IXGJ*S*[VL\VU+N_H
M_]@()DPU;*XQF@#-G5[R2?TC4\7_D:F1]RH5P3.-X=Z1SB>%0^M>=W1%ZM)"
M.IN-4?"O#;DV\8F33]U**%@3B"#_O#=*,=\^_WO)]'T&U_J_P'/9_^W+D+]W
MYWC^MI-IUW']?RA^+J!QNF=,>/^+ANAB_W/?=%W^DD]ZRMB/]SV<"77*H =#
MG==K*BC'DP^LT8KK3)_"M76^>BSHX@IM4.?VL(E'3WXC<"^Y=_@_S S7W>O7
M3?/4M8H]M-!<&1KOK57G)PZHPU++L8P?'_AMUO:NU%9;=SC3L3E1=8;_E)<Y
M*Z%XUN$;A[Y?B\A;*7\=_48VIS?^RMWBQGEQM,G*E*#<-G"9."#N:Y.5-5HQ
M_27(<=03XD0F#4Y2M.27V;$:$<Q3E)7V92#'^G;DJQ/+ 8.<M]PX?5=TK"6;
MU@S?49\@=/K41>:ZHDIS()I-%5R[@SR/]]AL5;!!/5R?'.)K1CQ['HP=( CO
M^L:%G8BB"JWUS,<^ZB0TUAT5+88WO=XZ?4MJMG.2\/P@2D9<K@&A0W2<;*9*
M[ZLUU#@6A\]/([9E_$]GYT.D?-0/_LM5"*M98Z@&K):],T^]QO2LT.<1->NC
MQZJ%;T=+U:L/Q;+D^WERJ4!Y8A$3FLN_5%Z(%WRCF [H=STWOQ13V\D22BGJ
M9*P<9)[!947^>IDUVJ\G5PT,T#!\]$O7)_!7=[!_.6-LB^L/L-A\?Q[OO,B]
MFA ?2F_]2T;68':3V[-.J-S48"+V?2=XR [^]7$,8/^L6U1F0WRV9;C#X&%X
M#NQ[8LJ9I1.QK]=^YVNN F+P "--_B"D-O.,-?M:PS#K1HR;C@(5+GDFJ+[#
MDPMY-U<M\BB=)WOU(@'\*4RB+?C!G.#8<PEJFF,=^B4M9< S0 C>F,P3\'2-
M# TBETH[=1#.V/L>4M D&6/*EUO'I_>YX955O[:0RY"-W;)QH9X"?5!T-T_E
MQ@;43W]6E,!S0<2 6:FB6*T)GQ5O^%N2^\><A/W.[-B@EN4)B##I_I"U5]Q6
M7!R9['-?+NQO9W+TT,H@7,ZP.T!;<^E<C:;M6DTJ;Q..2_][Z7I<FC\JZMB<
MM7X$=433KB@"'13+F@IS:WWZ8A'SV;OO>,P7HQ1S>@HT4@RM;1^<[P"MSEM=
MO_AS3V4J6GUT<R!*QZHR,($XC& U6&KJ8Y5]1KK1;U_-5 FJY*;B/S%414F^
MMEV/N; S9TXQ$,82.HO>68Z&9;=TKY]LV>VCO$/6->Y'6SID)D=9&9'-ZU[?
M&!ZARCWM6JT]J;)3K(FZG(1T)N-^@F<K"H@9,"1>MPQ(V^RKL5=9#Q>;?\G-
M1[]2>Q-^,>6WY*I,CG6P)(>+HDB[:LRC7SJM$5FWM<U#2%?9IFOXT+^%L[83
M!Y"\/L'(%ZU"W14:9G],9/NIA3E.!=J.Z@>,CV/ K^__\#+D]Y\8M5:41'N<
M(N5GF H]PW!<=IM=V7-Y(JC1CM*<Z(2DT[OD2[KKJF8;7+S&"]PU8P-E@$OT
MEL8P6O8.@&>YRGQMN:(I;]^_DGO=E-!>PXEL&82V#<)'X2P_F[MH("6:#%-3
MY ]D>PS,M<BQ)E>@3GZ645)U47 HG&!" C+'3+S'I:U^&O,M=AN5K8:*R R
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M)\@JG]B3@6-T)(/ENRI?35UD>4N\Y\.D%$I*YG3N+@:J<KJ&X0!LO8 LDN:
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ME?!!=VNV=\>VD6X33]@:*UA#W"1O#5?^-YXX_J^T_N^>?M:.,&&+L^8M(5S
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M%@7G\X,&YK@'OJ$SI J,D47^6O.B$*<E]8ZY2P@'XE)CA4%E]1LH#5N>>_R
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M,R[<P0TU?]2 <E>9\;29%[@XU1)@:]1H#G]+^&-ZCJ_@(,CL:NO7O8<G>@2
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MOB :ME#+Z$?7)4)"=X:#Q7V+-2_Y^^\,KGNUO^Z,2!VN";I,6'0_VT>JKP9
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M8#ZF8M[]2[J4!:A"20_#@+D9'T5O^*^<?_SQY#NS7J-S;#S3+TY1P1OV[F%
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MTVEME&5;O8(TIG-_WDC=D1QX>^^G!]J0I-9IF9.B&7(N7E9C^-)-7QQ/]0'
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M)FC@ &%@UU7Z/653VK/54E)^)OL'(!7>>G;>'? TIOL/@/CR0)+#J *&A85
MFGB^E>6 XC4M(JN?-7B,$('[S:@N_@"H-?),;1&F:;:3N1VR0&0S,5^C*/;.
MG20&4/<'0##PQE=\,=)#S6W-X*UE\YEC*!>'R,I8BRU>YL>=Z%T0290A45K$
M198I+]R4IZJ+BQN6ORPX,5F*$_1( I@-WUEY='(%MSLY1A,5C:?X$HTM+OEG
MOV2VLJNCQ;9EV1ZZ*&:/<!KHYL5?L,\F;)^Y'S[+B%Q+RFVM&XV5R[?D4KHG
M_^<!0-EZ-94\6A@17 _3?ML"9U9]>-<<NW;!T</1$]^/>'PF#?B;A 9Y/6C.
M7]R@@ZS'+[SV? (JUU9:@I-S";\P*$AE0JK5ID#XER9DX_?;W6#\G5CQA;%K
M-#M& SNG.XAWZK_,GD_.VRW54X]:ZX$6S8("]B3A'X *(#WZ; (?JHX<:&<(
M[6/D2#VZNGUGG4ZAVLP2/R;\I((N#V .</,>TST]2G'-]7L5JH$"E<'I/69S
MF>S27C(W\OO/F;OU$OZ>P3KXK!=N;(1Y3:2AS$1X2;MH"M[MD0=["Y:>8-].
M"(HR,S-MHM+BM;N1OXWC>6F6(CVF\BI>,Z*5/H_L?-\/ QZ. 7R)*+=R2*BF
M)%S+!M8Y6V(2\(J2<<_9O)^IMLWW.FSF- \-T$JK7'#;F$S_EK3@A?C^@'''
M1/X>$G.2Q-NUQ5:(WLS%9*U5_.4HHM=3@ZN*E((\U<(%3V7OZ.CP)]=.*^*+
M16.(4+(!?3Y';') T#N<&3UJRU,RSK*+G:9)N!&WL/87BYJ.+/*/E:M>;A54
M,JO=^NZ'6B:82_4*?\L"6[%L^%WF+:]U/6E8%.*SUD_AIJ,*&89/E$/V3$\N
MP-(/%=&E;^:$2)XIZ%"3L0@</OU\P>&>=-BGU83Y1I7E3=1>MM[F-G$8'!?\
MBA..)(ZDU/_LGHUMN4J!M:QI//YI@V(6TGPA?LAQK3QK$60<XPN+98W,=-)5
M8%X[4;0?K,=DW!5]</<MQECJMX6,VSU#0'7YMGZR,K1\]8X KKO/_>TL;*M!
MI^$UCI5_TZU]YF(QY"K-9XDXMC!N6*>)Y>(90E*['W?1($-IV@-\:'TS3Z5:
MU& [Q=WCEI<UKX 6?<SO.@;PN-!+APZ@Y9>8B%=[&>EK,CLR-M]>/XYV*"3C
MX%<*VVQ0!G[$'D(CQ"=H&K(L2V)@5!@P7:B8T1Y?O;. XWY?J,-C7'P+Z& N
M<7[TSF]I=.EEQ>T8_XY&"Q)D!-)+GSZP$Z<_0M0F5[:2)D*?9:&/*1>@XDHQ
M6NWA=N:^7]><6:W27&]_'"?(C@&<-8T+H-OB_I00@D-RG?ITWR1'FP]<X*N8
M8A86>]S.#=$AFJXQC0)HRZV<@2.UYC2O1]Q;N:O(]>87!US>72]V>\GP:1D4
M;+$+\UOOI:,UE_1-S1:@8 -$W?=T_6/K*)9>67R<V.^\G4,$F<3PEG(H4N/[
M5'W;ZQ7Z+)G]T:@/#\L?G*>9]!P_H;#\5Z\8'[U='TA97.=:9N<EYKCRK7S^
M334(-M[_BX:ALBJL@OC1VF5E=:C3F1_[9-;\MVC5Y 'V._=)/(B\6\"ST^6.
MB%99Q_Q *WOJZT;=,0G2^7Y@,U%<$ZME;+(&X+'_=>S""GI.HV[R^!@>!4O=
M-Z(Q! D-!NX4U#W4S@SB=_][LU:C'"*)]'D-M;XV; ZY6OHQ<664P1[IG\<^
M^$ R=RVER3PTA-@=530M\=$9/CL%XJ;Z U":80M:DDEC8[".!3)4QBJL)R5Z
MT_[#S)IC.SN1G'I3![*5%V9J9##$ZN5,UB_1%A9:+X#]M'.<6F0"!MYGE)CZ
M><$M\+Z1FGI#AZ.!"I5TE+H>.0X0Z1=/B7V'I\H%YM*@MP&7:2?(Z;>3GV1G
MK(U1WW*J"- [@XKNSH\<&@3&\8ITIEHM&?-@0E&E>UX(A<IGY],K!Y;X!>/X
MBJ]U:I9LGM5VK%M53N]/[=W3H7C_ &J=BD).U_2O<N6&M$:%R>=LAP:,7648
MEBE'3##7JC&OIR'B+YR<%_7-4ZDF7Y"I]'X,;0IJZAIBC]6NKZ:?-R4RE%29
M/E!$3%N2K?1 *<)B0[IF)[]8=4J2V /V=JMXF"+M&?M]_P!([!<"T@(YY!P#
M76H.N?X W'TXJ6.%+7J:QCE]).V5);2%HCU:9N/%/[CP?I-VZ4T4PKV_%AV
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M"GRYO<]5V8@X GY]'PX+Z9$P=Q-(OZ0;39"M2>BM ^_7^B.,=.HM6[;.>JB
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MB/0F("WTGE #A.3%F3OWSG_FSO^6]>;-O+7FL'YKY>SL\GW?_NK9AZ!_H)<
M4E5%%44 "QL L#!_ 'H.> 3<N'X=[_JU&WAX>#=OWL GI" B)" @I"6_14+!
M2,?,Q$C'P,#"QL_)<H>7E8&!2^PN[SU!86%A9DYQZ0="4OSWA85^38)U\^9-
M0@)"&B(B&J';#+>%_L<7NAT@NX$+W-C$P;H#8)-AX9!AH;L!9@R=U[#^< '_
M=F%AX^!>NXYWXR8^ :8#A!3 QL+!P<;%N78-%Q?S;0#F>P"7[!KY;4'YZ[<T
MS?#NN% (!2?DW&!]6-5!^6P4QG;_I>OKF_A4U#2T=.P<G%QWN85%1,4>B$L\
M>JR@J*2LHJKU7%M'5T_?P-S"TLK:QM;.S=W#T\O;QS?D36A8^-N(R,2D=\DI
MJ>\_I.7FY1=\*BPJ+OE270.IK:MO:.SLZN[I[?O:_VUL?&)R:OK'S.PR=&5U
M;7UC<VL;?GAT?')ZACB_^,47%H"#]:?K/^6+#,,7-BXN#B[>+[ZPL+U^=2##
MO79;\#JYO":>F<NM.T+!-R@>)N14==QDO?\,1OG2=12?BDUXF1W^B[4_</;?
M8^SU_XJS?V?L/_B:!0AQL#";AT,&R )G%URY0?A_B8=8VU@78Z-R1#_:YIF3
M)2*Y@-Q(+BS\N^+<]X^SN1@!9E6#/S0!^5SYJT7#8RF1@!RP"5P\&U4 ;FOX
M!@7F!I40/PP*?%>C@4VI-8%S0G%-<P3KF )S2WJC QA[9;H?]RU# :#05 !P
M+5Z,>W*>Z1X6:LK=H)3_JD&"F>[?%@S!#,W_D35O^JNSV$NP!YA;]-^[*LGA
MC?QA0> $N++]4_LUBG]R4(:N")")A4JQ%]E'O>)7S^7Q83]U'+BV$Q+;FOQ=
M;<6)3G\K7+L)=D<T,\%G:&HV5X4ECO:K<=X#!FB0-'GDB@CS6]&1K07J">$=
M)\CLSG3"'*ODN17+^6HT0T*T^4G%T'_L(D\F;#$BW70"<JE80TK$C9B]3NYX
MY(PU'TWHL37H+@QH*E#\#> N61QG8T=&TK_G?T3#$:M1B&<>UK?V;-RVG(;3
M.3=R#>D!C<HBM(&)IMNDID'V.@WU#1H>) QS/MBEN'7^#*<H][,_+?0QW#J4
M%^)"$ZG_O R.@ZK0?N"![$ *ZN9.'9]#MHZ5-_B*Y+&'>0U)OD4[$[O$!G#A
M/(SDPJS*0V>8X>]=2V!3QI<N+[I6T"04>&+9WQDZ_/3C2@OP:O3?J;3>NEC(
M*C&UH_)T^\ QOD9F%/,&U_5^=,(PTSNL'(7GDYPMM>/\'.-E4X?P6X*&-;F"
MK+Z.TCQO)IN=5AQ(5!HF19BOZ3^R?I6^!MX+?<#4SLDY&R1-%[GLX<2X[2G!
M&>;(5T.9]6R:5O-5?N,ALO9NV[7:K%5N5%09XMN!=AB18:?G%-43^N\-ZNI6
M=X-<#D-I^]NSB2O^P,)?@OMF)9]#OO)&0Q@GN+YB62T :T?NUA\9<?8]Z"YR
M-V6818 OI3]!^"B\ZJ!/^,H2-P:>"2[2;C\0QEK05-ZORI/\K*V9")+CKDTO
MUK<[)3.U/;OK9L_OWV NKM/!LG0EGTWP7/.70>DMT$V*&!NJ)P:8*@9P+%O;
M3%U_IZQ__=XY3IN4G\;UP7]7PVMK:[49EB)KJUO7:KA,5"P>:&M.)#VMK0\[
MG*)/]R)_)'23U67T773(N09NC8YG0Z5M)OW8Z@3$OJ 6$O=Z]R9;9A!6/^>(
MCMCK9A>G%>V)S(7.[<%7A:0)KH#5UZ^2?BX_1O"T%9SKP*1.NMT&G^(*$""-
M27IU=Y6"US:3KM]HG+N9T8"VXY;,[<P=I:8)CPR.E4=J+WNF]A6<$G39#_/A
MTX?91+,\PV:(2KMGLZ@#N<FR8X(/N,[;XXJY]Y-"K32\N#._!]B/!.-B$\L?
M_./-^E_X:VA-' REOSQ[..67D4_"?>WG!B<#?H,"X(H&8!_JK@AFAU$X:.!D
M)QC.W^)3MIWX@7!$GG:.L9J\2?!J^6K[U&[M! W@ZN]XA1U*AD/J7]W$+[+T
M]V*=7@AFZ'OCK^WS(G%FT,FGZ"%@,T6Y +]  ^WVGV3NOY!=-9D"PS#:56D@
MPPQ;*PPOSV"Q2K&](?3DRI 1[_-I>22PW"K N'@3,B9/&W8_9.XL0E]>AMV>
MB2[JR>MA^?&]?3X=5D]'MN0QH6P+_I^./1XF,B..2-!2@)9BE?>S]2U*S4\O
M2<TF&UANC3!-UA4:MGSZ8.MP^QHTE/5EBQ %3N1U'Z<H=QHIP4_^XJ,.J[9W
M:J:RHY6[K@VS??3L9X/62?D5E5=4%\J#H=5YMB#Z^W,SCI<.WS^L.$Z^)"5>
M:=LJ6#$E7/2./.A*G&G&;W0L9EQ=L"=5Y7>E!E91VDH&L+ZWY<VN*&[8ST:+
M<9!5;9*AG>0$%][MA'?DTCV A3=G3[52&2*WYT1M3U=EG._9X8+A9J01%W=/
M0AUWRE;'G?3<K05N./@-=8\F(O=B6+=)*?/;$)5VS5ML3\5OS_?Q<'A]-HYF
M81MO1-*=;NU<%+[EWSV@UH-$WKW6^ 67FX9" QR$#;"M'JI;Z7NK]?DR!7.&
MUL08JM+I#C.VYG#%&QMV=W^\9IK\WF)I50-7YA[<L\ R8'D/1[,M22EE?[+"
M0RU#AB-38:[WZ^?\Z-K 5\[< H3>R7M('[."+8,A2+G-]*@RAT1&3?J>I6:#
M<D*"*SWNB^.*$&V83AY#&G%A]K:=1PS3+:=U._9\PZ\_@,Z',J\2[R<LE-O2
M@2(KFI6HJJ",#Q<6Z+T-'K@/BNH3/AV<7..+Z?:D63D/<C6A&!7P:*-$+ CL
MI0_*=(B$L;]B4.)-I&3V@2EK" 8))C[UU0D+ASJ NE(7^$=%2OM%'H^4IYS.
M;LOA?GG\U= \_I[>"\*)1G HTG+YRJ_;H"+)+7^8J=A_G"]Y3KF$FIGG0#-^
M7IZ&)4B\7(#8F\.;N $,57OO!%%W\6]J8Z&,?/ ZF>R33SM>\6DVH0../)PS
MLOF^$Y1GF&8[Q2#CV-3F-?W#* = *O?]5\E>P8\?IQ5@!]VIF5RP-.-MP=Y4
MF#I[>4?<?E.OLYZO=8A>HW4X,F"YG,6&3@$5Y6%&*CAK8A)!Y<VZB\_%O>;G
M*J$+6CH@?+3,3"Q?H"3Y4YFV(-.+1NA;'^^/O6$G>3GZ"<T_IE]_#I<Q1)-I
MK"V9/V611&DR,8?1/;R0\197)FFX29W/IPY+F02OO Z>Q'45K/OF"%=)MT1)
MN$F'?N-"J!F446K&CHPZ3C+YW7)"B_RN_42GN?-QJ:)K?LWN'#BJJN=MUV2Q
M>N_]Q7%D7%:S;(F)3>,D9"JK>6#]VKT<Z(NGHF2+LD,M8-0M9E+P2%P1>!%C
M^?A)\@B7O$V#UXMXF=O>0R_O)[P=+@*( P8]*:<_K.L9*3Q> :4->'F<BR#>
MO_B<7"Q?K+I@<%]6H:UQHF:MH7F\8'R=M[V#Y_H+K*55W^E4NP61D;A>T72]
M9N]=?UG'D;EKKU4>&:N@JEHU7""!)G[3%3]OQM3DSB=8<_E_6>&F9[!FK#9"
M \%(W@5R&.Q+YK)CI56:6GI3O.#ZM[U$,"])9_-=R%W1Y%3S<94"*^=%HF:U
M H%N9M+--.-QM4]V_!X\?' I/XL'1QH\@._1,<4\3\>%*9(_P& \  VD.EA>
MF[#>^[*_8,K)Z:D/GI'2M88.WS2R]^T-*=NJTS38EE ?@AW>OJ/\WFSEP486
MO.1LX=94'OS(.U5QTN&VVGO6VJ:ZACJ!=XI#&J_O*9\4TX9 BX\'ANF-YNP,
M*NJ*R^[E]N1N)GPGJI+ZP&[S=8"I/2%8_P(O&L+'NKP1?4!85\>IV.3]"EP3
M?#2J;!S%X<.NYI9I_RFI(_/.N)1:R78@W70Y7_9DOKZC67/-?9J?A(X/:0*5
M(@-#83"]S4#6T1/[TPD'2'KXAS765UD202K28A86YL$]@)7\DKHQ4MJ\="N3
M8P*\S.D1N;SON)^QM\9Y+2&7F?\[.8#SN?1,C)IU)2S=<?SK'8?K2M[)PRE&
M:M%[6UF^Q6C@!DG$_G$ZF-C.A#M6'9L\\@E5KV1Q[J/DF"Q//#FAZT]Y<I,Z
M#[/>>@:RJ;V=FEU\8L_,:OM3)6!F^!,73M*(^[D,F\E.XZ?R$CN-V3G3 7,S
M>VO/$5X>)KSWGBO\*L/B14BM8N^LSLR;8\)^\\\,,YY>:E)9H7J%CJZR4KZ]
M%D^UZ4,#IFDS3M?L+_BK2HP1("-(-6220^S6[(+!!YV[H 7OKV;3%224;%E$
M#G,=*1?<VW4O4;.;IH]*Q ;O_ S)N 31;- '2)]G$XMSU(^=.'#O=#:"8]ZT
MV<<(Y$SD9"I;!\<RIOO<UO/ -6]Q,+&M\SWH=0"I2[1<?4IK?"X$(BK;HXU/
M80&4N*55ESZ:2Z5-F]Y$I.M.N)]+J4,);%_5G+_9<BHTK&&V20C<2HYBPCM3
MNOZY\I6'85LL7=[F;*+>0E=>9]=0^&"D-K^\KE%([!M2>5R-:^EJ*LV"<"9F
M_*XB4Z/-M*DLWM<$Z>$)>_DF-Y4XG7']3DI,B9OY"A^M.%%\B_-K>C*A(QDP
M[4HJ'X?H#73K7ZLVU@E>)D!(J8A%-"L4]Q79[>'-9.O=$>QRH')]B*W"EKF>
M-X;D++=I%9TX4>/3&:W)>+9D9#2GYO@DY_4*?OL*;9^F'&.!3V4WE0PGW"D<
M243&A_L%;&,GQQ2O&*@M>R!V7*E: >H*)&\8E]*N1$1I-45NGSWS4/:'L,AC
M7TULM#VYXL+.BA,F\M.91 JZ91-8V!,4LZ78PG1(^VM$?[[^T=_.")\MHC^X
MA9#LN6"/+2Z/<5.;LK0/&)O+%YH;C'XM^H)2)KS G4D05M#W=JQSX^FDY;B(
MNH26"*23Z*O*=D4&#0/)4=KPN#]MZ3PB=M@8;@6ARI/)I-_5J:U%/1>\3T@M
MSE9M/ET >)ZL9&+#\C/Y8)/S4^65.X_Y3K[KC';XPM_*N1TYN_;)-  NL9!=
MCT%OYBXMA)9\TM/ZAMCEA6W[&'@Q#O%<U2#@W'H==K41Z\\_W<H"YZ@6CE?G
M*ZB;V4\#HFA9_1PN]T'BKTXI93ZL&)N"$*S%.[K4S/83-><<D$BH0K_KEU>Z
M9C^C0PYB[;_ !,(X8:GAB^J_%IC=UC_K+5!DK(ZUIUOLI$K#Z^)S4I[>)^IY
M5^[F)I4R6KNF*/D%CRUA&I9-.*C5<4L/07RD6P=GJA'I^>RSWN@W?5=PIN%=
MCN3#3+EV7&=Y:.-!^%B_;-<PR:!P'%N<V:W[3516[$ILF9#UV8RA'(QG_K*N
M5DF_=>8+5/$XFM4=5E2T&K$]56/,_WB]?7YZH46R_311#T$B#_F@;Q';26EI
M]IJXHR.;Z ^/&C:0FI5V:0R>Y9^\/7?TA:IO4BTH@+B >T\#P 7N%%I/OY-(
M.3$CBNZR+M>6?P0/=S)OF<K8I<5,-10/%VW?%^GY/J17_7%O8[]H%T_N6D",
MB5>%/QULO;I4I8AM.H7#6D!8YWL30Z8*$%(G,SFJ6'9G?O+M.T-QT_!6*;@4
M$QU5@K>]QO1R[;L^Q@DWK,\OF'E3MA5]+\B,%Z)6F$GM?'M:,C:"3Q@E%IX]
MFE>3$.H+4OZ*TP $BHQN-O*%A]<4N0\*81'5L*X9K2;ZL&6N9I[DZ ^Y.-1$
MJB2+2"LNJHSM0^CK9IP<;JG=/M5,@Y4R:G4V3G<9>]NA;H]G3Y_,Y+>^&$..
M*!.;@1R:Y)#JOI5QS=+%WJ6*=:-EG\+HQ??S)$*:2'NOB7._9TB4VXF<5Z=6
MC='65:_&D@-\"-J90RWNQXV<"*Z@@5!28\C5?'E?O Y43=Q3F3W:+,S9^Y4U
M8T<)\XWC!CX9AIGM43LO![Z>O-VZQBS1SZ1[KTOCWOD>&: 88!X'X9CH>DN)
M,&4G>[O\-,I[) .FVD4LND(/>L746=TLN51)-N=-=]F1UC/TL=%IAJT6TE0M
ML,'8_;'Q<U]@T @>;3'BXP]OQPV=6CBJN,@[<O$LYE3/^'C=87&[_?#4H8]V
M")SLQ71[&F*LI0/K"ZN9FQJWG-R;W=_?)R5,Z"ZZJ7<4?U/*&F)EXBW9-QL7
MO [[..U[#?+1,_?&>JT*SG =O78PC9Q+/ZU,ACW8!!98X(EBGCSV:[)W\%*,
M&] 4JI87$@K:_+%*_.!.$*^-+^?;&F;R9D[=K.>PX]KS^2)5)NC-X$T:K ;E
MDRWD.2-U;V-* LQ)!WYML#MU>L0$1$'DW--JSM^-]\.Z$.(Q2Q4'C6A6G-V(
M$*'W[I1?-=Q*<X]]8?3Q T.MF%@A _[ :"OC $;CYY[!/E4+RU?R<[Q3<U3#
M_7D9?XC'@@EXPM[FO:*B.G2U&="HP4>Z\_0+!J;*I;9"6:TE.6"OV&X=4$2S
M45V@S(2PY)Z7UNAQA@37T=4'G)II\OJ?KMO1FL]?F$=/?88=Q$'HU?CHGT\)
M[QA+S*_<-[4=YC8VRG4W<;[U@)8E:TOW1);(?M8KRK%99=EVETX-\8QGA^=J
M.Y%BF='8]1'@\O5.D) 4$91GH 5D,D:M,2$BS4_@D=F+.IS/?6=!.EI-:=S-
M\&)%1*W=5^!ML^$2G^RS27^SLKF!.U6UEVPE^4#W]?CX)V\21CZ:XRPTSM]2
MFBY_6EGB':Y-3:V;L,R[]P$U8!=9^(9H,LZS?= 9#1!"X<U@HIJ.'".;(P,C
MGO>#L 2+&LD?I**K#[ZR63.Z# )":$"S#6[:D>'JH*51;_Q((7%]UA/BQ,?_
MW9RYV>A%,:X%\<DF$_:8[!<DGP4:F)4(W9@MSTEU^+GP(DHP+OD!O>YL]5X@
M\U7<\J><98LV(>/%/AZ0SYV \_S5VM$1:P9?_$F80^7;5\+*N_YRC8Z7SY5?
MV%.Y,E+*#3CBX,5.8#6XV3IX5Y4/-FO=^*G\^C$A9;@B[;ZT?3#""0VP@N+:
M=H7 QW3'JJM(UN72>0(#N,+:7/OH=EIP8Y!B=_S[OL'X>X$?LHGMNA[!OWCW
M]21N.5@7&"P8]W&;S#^VLGW]::0H* C/J.J$AC(9"J;8GBWL'*:S]6TF[2O=
M(F&$?$_I/G?-^Q*_3<+*\S$.#6A[>#52Q]2TD2UN,S%,EE7L.GVUJIY<>,B7
MU1!=$6AZZETL'!=>E,DT_>ID;K%N<>?[,-B%;E?#)?2&Y+6]-$#*P\FQ[?J)
MGIPIA[3 *LV2@V9=7!'E",)X 7339IC?O[?J36V )_ZR!0P4XV&,B0"-0]6?
M,K#Y(O@&&Q\T-H3>Z"0-U-X44@0SH=(I5'#O$JJ2/YC@+MH$EO"!(_7']HW3
M/3M7Q-/=U&F>[QN?:ZG6KCH-'<IZU9.^.7MEC<.XG9R<&M&V+-T&TX 'YKK7
M[Y&C@;VGE)78274#Y&1!]X=<,N\))ADG5X8+O$"D%WG'9#)7&=E6S>:&R;SP
M\$]4%(SV&S/T=CUECCA;8+,.W]7:BK IH3E/GSPC__7=R'6E-_L>QJQ0XO)E
MR4&3#>TOD=\DYVPK[XTK-=0F\P(_)2=E291*_1\YJ!ED=1MDIEI3KM9.436Z
M1]%H1Z_X?]!J3OH!-V:O"Q<P0V0$0$6] WMDTAESN<S7G71_JM#T"AX8%8:7
M>Y3?UY[>]:<LL4F]<)I;]7G1>J2C=C/]0.";C,=7Z;ZG+38XH.6"?8A, 71
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M4B<$-3N,,5!=6TLS^T+#M[Q[*Z]O([D$T<!.*07&@@A09 +DS.>1<^#%&32
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MH0$_S<;H"Q4WY[8IC&,)I*X9SX0.;1OV(V[BV]VR2/J)_(F_9U$-2;VRK!%
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M-1/%# ^PF[-?)V"^EZG29D:*9B>IH274F? X6D!/D>*)<Z(9JPA[/7.K\K'
MW40=O3?59JZS%W/(]G7.INM4+0NK?VP<([JMF/\E\Y#M9)ZOL5R?PMHC_W("
M^%^<H/K_M!/^\RG_^93_X5.*67FTS\*^^U"MI_]CB;O_N_(14]?Y%O.N_>SB
M]TZ3?L_7:)&%U65M-)MV, ;2-M/3=6[ONGC/1EO)LO);KLX/&;M\M3>::D[
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M'*#O&@=@K9KMI]>,;)HJN1J6N[SAX<.BK0?3N7M<-Z!E'0=H-:\2-*:V;+C
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M]_U+,IRS,*<X@.*D"0H1_4B%6Q%M6P2_?Q98 <RIJV,)4?XSV71/:L;5GLP
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MWPK!<ZF$]4R0MZYP>ROEMAYOJ*U9,%U_Z"G/>B3B@6(N)M9_6S+2!0>@:/J
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M/OR57%.5>3CRO\X)1HV?&&:AJP0DS??#SO!5JO4_1'*N!]RG6U,LFK88:E1
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M/2.SW/09.^HIN@/&]+0^F%'J+&$^NNZ'10RP[DD 2T2)Y_4*%A# __/CZ%J
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M8#-%\SXTR_2397Q^CVFO.@/C\OF]F@.C(VT(Q9K&I#5F>G0B8LQD1 84K*A
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MP4!PBSI,VD 9/;/^US(\$&NU<;[,T?*+<0OPA>HGMFE*W^>7DM9532MF_EC
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MA>S E['F\62'4\$8G93PTFVX<. :T&]=1W!WRJVDF>+/#+#OX%=%!DT'\.Y
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M)6-%JS<0O"/>K_Z\@78YV3^L032[>7)4'%E<P/PYJ^I#A:"V+P6(V;YYN5@
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M.P"">[*)L6#O.5I^>J8K*BDEKE%H<.,]WA:;.$",YF"^J15#J=#9>L5$?0?
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MY \,)#R-E%)")E8)P:B(7-1B:4ID@?S[(U5;&WTL(*=/$\*#2S[2AE\<A.X
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M\_$)F>CP6&_=>WLL9D>%#6F@W PM"MR]HHZT'5U&AU\3] SJU-7A-_4V88X
M <Y.;<-.83M"JC)GQL3=&,7W 2JAY IAK[AZ.YUSF>2)Y3P+>H:HM:9\A L@
M!>U"2 ,CP44%@D2+_E53JUT\J=<3V/W"U<A['F!N8]R5-YGZ 7*\/R0KY1@*
MI)Z]<$B*"F0@Y9XH.Z,O-3TW3SR\TDF!S^U; ^,6/A#@7[11#NYFL#:C8+]G
MFZ2R/-Y</2@Q_U*>JP=S/R8[[@8,5(J0O(8S7,TH0,W\5BI?7<'.?6>;]8S!
M@V_-'H/]/(PL"R0YL8*0$ZO=J6O1.'U.)<O&5>J+*O>_DH$G:T%4CA)Q$+_?
M66BF:.\BCZ0.P2&.<[>A\"\L+R,8E_4M3MD,3RFWI;#W[?=!6*RB-?'S_0[Y
M#GP>R?1X]L0/\"B[;TC'A25(&*&")CNU-162.7])-(3-M[#]%6D1WQ@2"^"E
M[#UKA$PDGQ?O !9-HYTJBH3?/#J J4PM4_,W^LB6]%7^H :3V +/4BA34;//
M.>&<A;-GVP]3LE,8F=4*]1.42>;WQ94%W "KP>="8?K4UO+S^"89Z7NZ".WA
M>L1*4(/J>@MC<U6+[TN7.58(RW=_^',LE\#VG>48"I#*'8!][$],+:W%?+8Q
MQ?+A&//116)FWDQ_:$C<W6 P^-4O.]]-&Q!DDB[#(>FBZ1&M//G^-KV*F^;T
MNK8I8N&H5H^FM\X\K4R JS6HR;O81Q+)EI]9@C9_$T/I/K&IV/OF(3#N=40V
M4:91 *?_RB>#@XW@VF(/G4/G\Y\Y0^1;3T05YE=]L7K%SB]*8 36*\@Z,(N-
MKA]+HC4/;VQNU))1H39_-0MPB:9/;#UE&_, #=%2A;Q!J97;(!_F6L&5U(L5
MC6LE#D!!<*R,IFG&"/&>=ACCBK%JKK$-'=MXE;40@>+SQ,4"26Q^66+!^1A2
MC^]=?B0^RA/V( G0V.QB]Z\!^T-%SE9H]AG-^J->X7)4AW[3U)_DST-^W(6Q
MZKMH#'9GG.*UIN,A8(LIO\AH?@](ZP,S]TN1&T[/GN=B477,]=L7V5Q'ZD<#
M".%NI=&1?E132<833<:Y\\V_%YZP#I!36\T!G9]K])GT,#Z3M+H'#)4B$#(E
M0!.L:8XN;]*'F]$T\#[G=J-]2[RQDQ;3P?1UA C65PEM/3^[ V2/(588;59(
M;TA<++ZC+=^$_<'$&-V(V Y"!1IL/A7S6@ 3UTJ(:[.\U-R,044\I%&EYUIM
MX>.GSY&):P3RJL]8T*K%L-^2R,#.E!(KV@-[]@1J!BJR,L&#-%WLU?H;DJ([
M@)4-D+1:XO+,,)EX*'0+FW8E 2\M[MXIP'6SF6/5/=A!F"0(_'B,O[2,)Z\Y
M0PM2]6HL]ML,48!@Q!V :Z.) _'"C][09-N$$^G6-?G=G)6\M,XG#L#\G(9+
ML9<YHR ,4(^4ZG1_!FTH#R[E&QH*[^ Y?Z)V[U<-5@\R&(=<4LZ9[OY*\(S)
ME"["."K'I7!P]D3IW6B+VGXA\Y4Y+8 XX2_1Z=#'L"1=17?2-5U*K>:YP,ZV
M[6>^835Y"*&ZH^ *LLQF#X&5B#A10\?#V1+=Z-^*U%C4DBVX/&J'!VLJ$E?"
MSZ/S=PS<[@#G'.'RU07*NW*M\1NIEEN@1S&*/69I'YH%FB!P]R W*)&A]LQA
M2?[$Z?6WIE2HYS%C\&T;_"2(X?U97[EM/E[(#:FYRQJ$9JE?4'!HP-<B7JI7
MA[^[*PE#E1]AMWYLK]ITC]-_4U3P&1'Z4<H"D@9,BSY"&!.\+G'O/VZ3]"0O
MQX@/7=(5H;P5)X_\GFXG4:78;73B4[;LF-6ZRW5VIL4\$]OT%_3C\1$>NV'[
MKK<[_6BISU-X),&)K3-UL$0[=7#D0^_!GG$\D &=M*H;9-\D7"AD$"Z??ZB3
MH-6;K;P>1ZPF+6R^5AVTF;WZ\,%^R:%]KN'9NT24T&>BZ#X"$DKEE=]@CFD,
MN<>;#H7)W#$'.UU7A&X<%<LFO:)&1H&8$%;T7YHDNH^NB&'KD[ ;.3<8255T
MZ#GX<8HIU:ZI]41D)1='6O3UT$"@?\Y/FXW652V?/ZXC>Q6&%%B[X?Z!AL%A
M-!X.G8],]C"L= DY"T(J#^H2D!M?@SM0H\!A?SX?DX"G8(H];D(ENL3(4#D
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MVS\H=UVH="[]6-+O)]L,>+%G[$N!M4%M0H).]2S?N9J<WPJ)/ A08L Q[*7
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M!./EPW%)V?MIO@*PWY\XNIIY8D8]8 8R2[19+I=PW9PQ[8-4=!SLL7.&[1V
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MOYJ-^N^D.F,.#-<(PR)4]<0Z1<VNY&1L R,*A"!+I1B@CZSG!>;T;N8S<N\
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M<;J:->[<:>'D?=G^GT2Q,^N_+"VKCP9Z-(,H5ZW=(*P0Q^''M:%IN+&5$=<
M?"EEY"W_6E+8@;!VW63&_'EG[9%=(A:M]E%%R NFR[(P/8.$=QOD;,+4'WSY
MY71^3O*Z22B6E7(HO4O +M+!"Q#@&G*I?O?[7\KU82>&?ZR)Q>R\U&#[L?V3
M3V!K"W!8,V2FH%F8FN,][IK ]\1WE-)]K' L$Y=B'[FF:3=:(2!@GB_/[T]V
M%W@'Z"DM;SE"2!7D>VFSC8-T4<*?YU&ITL@!YQ1;U?#PO(/-S%6FE0*O4SL.
MA8DJ7G$)(KYA;A4]S+Y3!.%5QOIU!A0JF]E5?(,_E58;U,)@8'6Q93A=EFF
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ME*>0V!WIMTUSYU"J"R[#UUL4 =?]T&?D-N';K51&\Z!IEL^\8_<_%7KJ\#]
M_\B]#3!Z40C)%$\2DL\?!#E:/Q >$L+:2V$:6%C(>Y?-P]&M%]".ABX28;:
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M#VVQSW3;)ZKNE*WTK\>_DOTMXHA#/S$8N4 D./OTRU>0:1!L%8SG.%TIZFM
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M\S2L)6_1$/8:*Q1Z4I]RQM2$6O[((RIU[#!L&AQ+#G?.7G]^#CLS-JAMD!.
M-RS6Q>]&)[1O>JG 6?*T:W_41#_H4SDA[4M]2>Q0<SI6L"YS(R437/EK0KM_
M-J'QK6,1TU#F@F4WGGZAJ*B[LK&:7J*R\Z/*6KND&S $P5?])\(.2Y7I2;C8
M_R3A@3^QL&D1+DCW_[O)^!^>_WZ>];?>C;834O<["?,;N^Q]8UZ/GRP>>+KP
MFD9;F?!_/QTH'</F\=.#JV6]2"+]N/.MJB&U0K#[6V)NMGF*]AHX7\OL35S1
M=W")>D:+O:OHH]XEM3*#:6KAGNJN=@JN#-HY.R;Y:%3V]+K7EVO>ZL%3G&S
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MLW]H$/6371/YRZ86$NWCA,&Z%O@8RA?KE:H=>5!-&*V^DO8T597FII19O(;
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M,;VMN@]0L9[FW$!ZD5O-63I3)\0AU%U+U(C%3BC*9;'6*JD8<@B=YHCT.I/
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M3B(^7V6X.N2X%&0XZ@%=KMU0#,?([#/&K?<:\ J1',)%(R,QYW\<511SZ==
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MF :^7QN' *2]*!B1%^3#LSE/\!AV],':V!$35\#R4C\16-M7E^X1V3-L@4,
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M]680G%!&1>*E"L;&Z*R_=#ID/I6_16B0RG)NNW4C(PYQO+8_W>8H4E;K=J0
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M<&-^R\RZ@-RDEQ%"5.:.OB#JF_WWJE-KHD9BV;@Y<"5OB:2>U8?,=I'EQ?Y
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M\X*UK6IK?.]:?[9*/V'&.O*!@"81DQE9-NJ]G(*B31EY1O130I%V'DI^Y9[
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M" #4^;YB6J<$AKX;CS<-.$#6?_4L^U%?3F*^9]C.BDL:?\QTBMK%[5_2&I^
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MQ+]X8476I9^FN[8W],YNZD,E+:%\-\WSOEMO>6,8L=XS[EH$13MQC!HP2X1
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M9M3_!4#?TD[]O0FCD\U[?6?.Z\J;9Q5VBEV2Z.(!.PXV#*F*T.3!-0"0?0V
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M(EN1]/&L(KT&F64%'19JZ@D$B:L<MCRSK:%6:')\6#CU+FA_08ISBHYU3,"
MPI',[J(XW?]LQJS*,TUK^_W4<7%^>^<BY>A>!P6%'L4(\4I4;[!_@XMQ<@W(
M](&+/XBGV>.,1PM_,F41_D>Z*DO(S"(?DD$T\MB;/LX-6GF>S;1PZ<\0_W9K
MD6#X6.[(?@\'*J$RT'K$S#;%EK,2=N/N\7%?8M;/,+>J&!"EKFK[II!E#FWM
MKHDO7DS[W>5C!W",?3S-?;5O\,N*_/1:4Y2^*-L93S."//<:\#$H'?+N\AJ
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MX*K^02#$0SK;3=UBA2<]K\:</(Q;.&(DWTYH<JD^S/-60"RXMF&49Z/4:^E
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MT@X5(&=#@F];WQ^_ 2F>2N&KLFE[8?YKP*XN*:N/!.^#V"M?WXXH5>>P4_9
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MFAN@LXREB29.U4UL_<Q9/1F>^487^H.%5<^%@X*@$8 KO%E:HO[PO@PU;JX
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M,G=JCBC2CD1U5X>FMS\CD(A%^#DV*=W(EV30J69IX2'3LX4\#'76?6Y8#.6
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M[8UQ);/G4@,\(E]. '%^&S>Z UIY"?6#D8I)?/,6KL!.)=Y.C+1#="I5QPD
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MN6?^-5=GYLY7>SUK[5KUUM[U5M7[U%NR-WH.O0J0/E;75 <P, $ X_8"T N
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M)JBG%0IZX9+7F,9!,_]2_@&)A0<:"(0ZU2'LR'[+:3<85I8M^M#M\T_)W"4
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M[P4DF[P(-45%]H]93^45Z0_Y6T1N.K<6+'_JW%V%VZK[7?C?4)VDRB$LOIN
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M"X) T\'D@3+30LUJCFM$3R?,M64&KN8>#AH6Q@<M8HV,^8T&WO6M "-NWMK
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M]>VG(FRJ#H[0> C!D;9.5X90+?)^)NR2))*^K&=O2L>+?XC^JS)F/"$CN::
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M2: ?."-OT!DL.2[GZ,@YK]U%Q][WQ>W>7J+<<?_Q&1U5NS7JH->*%SF2#SO
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M2416L7X]UQ@RKUK&XP/@X7+&O:T"J3GHQ3GC.5)K8QXR7'<#: G\R):5<>P
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MO--I5VIRWI.]XP=2J?/ /V9S6WMEXV&1GQ6!+ ];>N K6X >]'V"D Q_;)D
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M&T [S^KP@V/?<Z[?OA"L,?HCI!4/K=\-0WY SL84X149*]X ?HBB]5MFT)S
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M+T^?- B8M!UBC@[*[':2[;T&[3=R6*:WS]HIS#"'OP[-?/S(:&4T4TTN/?Q
M373HH&\K*^)H\#^+RO\CN.\_AE4<U,#"W]P ?N64!=9?:5PP"@,O44$W +FX
M!H)_M;8;LH/@X=ZHCY<QX:^*ACX7 /5708G0WU;NPQC#A<TIS+<_FT%%ACK4
MP<5$B@<'TG-4;!=3Q<-$'B)'LIP',2_9.\9)@\Q>OX&1P@G?"TD#Y:NF3@KN
M&7/%.SV-?;H7(]T ,0+,(:V&&K/129K(F,8">IV^&M4YKDVJV!5NW>*K0(DI
M+Q.#P!-B+V&_%YV+')Z4^DW1;V(FY]=YWF@KF9PSIZ;LV_X]78G^'T.)FD\7
MEA'9W5:R4W,&?=ROL);T=H?,<G6)/+/([ 9@O4U9N^X1:<L ;F[43?5/0(5D
M%R[L&D5=IF$&A1<&O.+$S_>D 5MX;[C*"4/.!FM.%-S8^OV",CW+95$"DK:S
MN4V;20-%(M2*A3J!> AC891Z?+'9ED0)35Z:TYO&6G#O:B9]&WW; 5<SSLI2
MS%W9"=R2;*98NWN,>8J;QKJM+HW'K[WB:6JW_'"+/;/E?GVI*2R>F27%"*C@
M^!..8_7:[9<8I+BLZC^@RX79Z(F<+VPARQI!EP;T.=CAANJ!<+<TZ]DY#^Z:
M+6M(US><BRF/' PITCVMN@Q\($R-I^/&/P<[-\ Y'K3I"PDY<CGA//973-L!
M,OBJ%?:#3]1$)G]5M ?KUR4=+?LGJ&));P"1,L(;R!T0CFMD??,@(W"/B'&T
M.6*L"BRH%":?MWU6$W:7_XY*\N6RJT'!Y?@3C!@S7?3!,.XHT.9;R)/3:!>Q
M4,^]K'D-S+V6]L8%MN7-P)/2DEF0N8KXDL^3^!L /0*B<FA;DA]1*KTFC%\6
M[*-**RU#2IQ00C%"LASR+.A/;AL7S.5??R"M$QA0AFV]<3%Z\>T-@/OM]2KV
M1?YJQ'*U8Z1'+=';D1(*XGGN>,R!?X08UFWK;>5/?29#1?5#^6MONNJ**CL[
M#M ,0S5S; >M,E?1TZ@?_*TX\U-,Q1A5Y%ER@Y@-:#L4.4=4YC>-NK"NP\<(
MKII3*57N$$NTJ[]8E.EB5.I!&YCF^+*.@F\WYTO5CI(L,S9"C^A@0XTRN0$=
M$/C$AE\V%H+L 4[R"[<$$?+N;? U,WO&FZ;.;ITM62^TJGX0Z(?0.5]H62#G
M.E/65G8-ZZ]$#E3GQ1-UT#;0SJERP^U)(\O;M+1*X%7&CH>XPU/T]A,<-@1Q
MZ^TZFJ;GD*E%0L#&H9F#F3'3< Y:-0=BV7='5)310:IT(/6CGT@4$>/P8CT_
M,K_3>K.?S_+I\.6AT"I#73=HSK:DT,:SW^.\W/\&D']JH9+LP. ^NAC"& P7
M!"/\N/8^\R<:@(]?*1#6CGVG#W;0DO>JMA\JF=\XF)G!5R#5BJC\;<[TK?ZK
MDZ.,G)YEH%W'Z*2Q[5BO6I1]V!D*XM<]2HG:1D]IK Y'$:Y B/L0"T#%IFIX
M@U7,-BNU)2!0Z_E:W'.Z@&[/?'L&8A0WC';*$"K? ):\,N-H_@68^TX^X+;=
M5NY_)24#25OKV5BE/8M>2O-V ^E F>SW>3?X(SVDH.U (L<QA$QQSD+#S([W
MR&LZI?HC/95]?9SF6VR_:JM=EY!#E_G71!3FZ/LW (R>'XZ\2XFI[IR&RW6J
M!JP%D7:J<4G%W8*DOP&@BW:D/)"+9^>(D-C\UZ0>A5O.9:U!#-[[LPC9 R=\
MANE#LQ_R))1Z57/3TJE@B_5=QHB&LN1E:E\ZH2/>=N$2#R(ES]7W@7E2EM_O
M?/1/3]@VO^-+[H78?WJH/[X_N[B#X>PBC))RYE6:EWRH[KR%ZQU;\_$GZ[-N
M*WJZ@H6+\6H]9TXMYT]@OS:YH?UT4P1C6,-9(^KI5<=4(L6(8>O4+1:E5/[I
M:9,XY]XR\U7'H&HJX5ZX>6X74[<>;E^XAY# DPOFQY#[SP3G&$X/A71[2/NT
MU D6GZ^Z6?MVK)2'-0QW#M!+=IP9B3^Z1Z%L4<OZ0BCCC04T5D%Y\WBE*4@-
M[?[=EPF"K_&4,'G9.E&K/WSZ &^+%F>+JSYB%I\ZA=TBJE8[XJZ]D1L_I<HS
M?55-S9WA) S'JIH-@N>@,&?'6U+\:\BS?JS9#*#5ZOV#?@4);R+]\W8-(OO%
M)RAXL]!$QH=:9>8T9C=.MN3C\]]^S)WC$X;JP]&Y#AFI+8MX1R;O(.A0#N!6
M0&MQ.N_VK(BC.XOZ@@8^:BI,RFL90E=]9;I@:DLBED)U!F7/W'WTH%Y;'$>F
M)V43#D+A::%SS^@?R8^PZ2K[CCVL_7JD''A7B4H/D*YQ4IX[\X)#'Q T3CJ9
M3 RG6 Y[&_/,>T]3\$([A)7TQ]J$&][=RRU7+ YRS%.UK8;F552Y,TU26E)F
M;+AUS_<A(,$V>U:]%1OKVF4*"_BW4BK\P[B4F7=B*2M0@<9JX,(!J\)I<1!H
MEPT7P58$TW3NE4E(0CD<'9'@RUI9.$T>V7L@#>$%3GIT:=/ $)E/4TPK+;C&
M&,&1)U-P)@\/<(%7H1U?,L>'-,L+EX&QQY\[QLAN%8*16<:>BT!2S^Z-7450
MD)NS3<6;&*][\T8*PX_3E;!Z.TY58 (A%B)Y63G8A_+W%M5>I;5MC"3*-#4_
M_(IVDMB2S7QJ"/;GER'1WO+5<'WW[[.MC4^"*<2FQ-L#/@*?/'_X__W&B[)>
M/J#\.>'!]9\B2+;%.!O\;)30+6GR=7]F]"YBG\]70DI[9PHG>ONJ3O8&X!D%
M:V4L]>K$<J-C49S6-6,/U\&&^[8E9%T/\'[T:P##,5Q%5"IQ!HF1/T.U>$@/
M9)C1T0@(H0-4<WRD3!'3,(<],N^\#XOAZA.^ <3,+A;S3<.%\R/YGNTKNAWG
M.Y[K.@%1.RV(EIGKH1F,:B&XKZ^Z<@>R^!FZ!J0Y'<1IE\ +>7)TXL>[.+U*
M_-BD=\E "C94U4R3N'B,P3T<Z$6:2B(,8N!V[@VA8;R65?J;0^-T\+K?3@C_
MN7\H&-AI?ANCF&_Z*$O*NS03!S?M78*&DZP8,* \QS;W=*=PP6@A:$;^P),R
MH!E_QWSVESDZ]VW@)-Y#GA0E^MRWO42*MUS'7334N99LL^IW]=,,O,BI"HH?
M9T5P/0W\O^EQ!AZMOR]QX$U]^+E[]!F]$@YP%%ZK@+P!1$FYY<JN<-T J,VV
M.;R;W:H3TS.8M=(-V)C8J,JUFQ[2T@80*0LUZ[P/'R(?$L.;/BGG1*+0N8@%
M_@]S$"*[RIE.C9G51+1#P+U>J+O_&PFB8Z@18 M."UDAENSTP#Y$D:_L"+0Y
MU"9Z(-RKOB?.OH!JRGOHK>ESH>2FS)LG-Y#-R:X^;C3MN>6!)?P<S H9#,G,
M<5ZL38(O8+KU(Z5YDR4K/\8-&27P<Q8+7)R#EJ(8NS\*V?XW[J@5LX)_4)I;
MF_RBBY/,37H\BM2<VK[!4K^9J7GT)-E<*X1Z48PYG% HHOFC6T_!R: ?-2JT
MVZ:#@4)$Q&5__/3QR$O=8S)(-W:>CL1UW^0&T K#C:07QFAY4; UFG,.&KI\
MWDR\K&#\?%ZN2,@F%U]TN1=E7;_$L6E&@#8O\\S6"]I/I*0P4JD#A1\\Z#95
MU'ONQ7PR+'MI,,$>2</YN+V@%>=[;E8]:(7E]4(2/GOI[[%00OBWA2<E+0]V
MG3Q]7M:-YVNO\']Z[F0*!?B[:7XJ4I;CW(_G8,]GJQ1F+X?Q8=Q65*_R4G?B
MC0-=*HS3PK+'QK'B99$OT>5^%A;,$J7U+0F0\?Z<)S+#/3NX/FYB$')\5X7!
M,W.DA@1UZ3V5H6T/Z9 ?I](>JB/92P5+LHY;)4O\E^QK4[$:JQI4GD46CKD]
MS$J>'.]"F78V\S<X-Y*1V7K-\?LT73O&#NL)&M\X+N-[CG,J4SZ0HQ)T?1/+
M+R_XK[W=A#K:6D2SA-V@D9,C#FI/N_*8<J;PWMT EICB+PV$''Q=5RW"L*-@
MXZN@WE!&,U'_ZNT4X$>X=#;8LR1QQ?D&P%,&\5SZ*$72:J "P &\(0!6/?L*
M?E95=C6 :4$$[23L0AB\W143MVX ^*3NS17^&J[$!:T8PQM L$>*1D@5F/CY
MV GZG:\KJZCX#2"  604L=RY(9:J@6++!\=.*-Y32&K[4YU[V-;_Z^J@X9%3
M_N+7TKV?NFKLGLX: YW[-U'=(+GZ&P >I/>A^>7U[U\CI<__[J;"=)!.Q_L[
MS<R_]C)&4J;-C):ZW//6PS3BV;Z+K\5P?9[""*,T.AN<OH_;("\^JL23<#>D
M];K ]Z4L#<I'GC,8@?T%]\7&I213G8\8L:Q-O+TFD;3.GEIEGU0WR:YR4<<6
M<^*%6__X:89_$S*+=[W-@JP=3D%H[N4AG)\(%S_ CL;WDNM'W5AJ%'U;[:C;
M-^/D5K9^(KU>>B7]-F"P]J>4!B."C6NROKR(1<H4+VWVSU9ITYP%YZSPU4X(
MK2]?-D6HAIVP3VPW3UT4HQ<)8Z)=>^J.I+P)K:KK:'$ZBC)&2AQAR:8W\23"
MQ-DAU+?T1'9XL\M3_K 3&,;X@->LYV6(YQ,'(@G[!\]O  XZ8\=:QF8,:-P"
MT[IZ%&].35O,9N#X15SMU2C#K4L<4W.]8&F0RJ*JB_@<6K/Y*?K:SV5CKL/H
M32V1>\ZYA6\T=L_BHW_.-=?]8<0-H),O3)3#IU15ZADLV7I\.@KGNC=4HY?@
M''(?3=F13BY[G9 G3S>]L2+;K/^G$0SA)MCZ'15R;"N('/N$,D$>20UWP.Y(
M\6?O?=-Z:'_.E#KO_$!F) 8H !I]'$AKJ$WKF1W!3*4;+5<$?2.A^\6 >V<H
M&YXV\%=9+?\'X-;P+*3WHO &,!7%>$F6\,O@/^V\_L!LOC0AN&N,PRJ0]7/
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M+1(N]>9[;$;E !X05(X'H$5J2%_1LT7XW/RNM,!U%"D(77P\#%I?@V")DO"
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M&YHU2U3M+G2#!'2)!UBBLO& D&X('B!KW(*Z#VV#[3AZ82^PAF=A)Z%,9WC
MD]&\4L$KE1[B2X*'>$#K%47K& %&?3H9!N(!UY3P@+M*)_R2N  <#[;]0HD,
M.W^%,MC&.$OY0 QWJ\/G,50@3+(=YK>D;<;9$SQ@<A37T0WE6&KIMT2*0=:P
MP+,_)C]MS&\_VX]XP#O+RVAA[)M )#=TP1 /L-:\N,N"S8C$ P1Q(^U0T04\
MX/>Q[W+5?@0C?X3GB?VCQMJH)84@LKP DKM1%Z2(AU[HP*VE0>^7(\OOC>\4
MJ/(_UHJ-6H;8'\+RV<_3CS<6'M]ZNOK1P)SF]")&RL(^3C4TMQGCUIT,"E^_
MX.5[V#3%<&<0P(?;9 :NF_C61 @'D-T:$U@,:5!*&PR,%"]-I5(*Z2AK8/O>
M6YYZ)T"N5&&XF=IB[D/]^/X$S2=B+@KX?7@A*_&V)L-G*]3!>KYVE\"/_54\
M@)17YF5X,:N1_,'^4$.1OZ7^+"LL-WY2W=T91 0<FP!4H;NC!S=E1L"FC6&_
MPX":2]AHWQC80C'A<^3$Q,U#BC,P:!]X* TB-90S@R*-')]^434Y_6-K11I(
MM]@4<SA:+C6JC%&P(T>,[Z=[ @^Z9APUX?F7/(VCPNI/%#_VC1:]K&'I%>B_
MFM^P]I<TZZ^$,%&:Z+?(W=$]B<V7^=J8!]3_9-J-?YF4W-BT:E(&ZFH/>$#
M]'$^2Q$4!&EML'Y$JO^K*TM QH%K4,$#OD5^7[0DR(W BD+\"N?-SOQ,),6R
M7E:S7S^0(V9/111K"N0<VR[9CY4[351=G)TQ/^F$3TL(1B/-X4:11NM1*M01
M#UBCPN[AA,_1 C?F+;Q-NW,5?#Y.]SA/E'^[R&D):=UQ@[5.5)=G4$)K!'"M
MB!;KP_G?2.NN?G342:?YBZS$&H[*2'5ST9QAP>Y#W;45KZ9DD_12!>\Y>"1P
MK@6[5 )KVUXJLRF&MBDZD4+?7,*3=4N8Q*8Q!A[E+3;$( >ZE?2<T:[#OJ38
M4CVOQ;$C*Y=][6<!=B[W8TCR'KJ,Z\AV!%YKO/N+47VBJ4 MI]WO84[CD%.]
M+>[P06P(4$<!U)E,Z,W6<8=,YD#^Q2OO-Q<E'Z@$71"YV^89DY\3;,).FB]+
M*K''XGA 9>[.N(6FY\G,Z7F1!Q.EP&<(N.-K5SOW.N@%XA::R;@%]BO9L;I<
M2L5?%QXKH_L^I7J]6O.@1%1]R)^GT-N'2MH<[''P6&%Z!^;IPR)A72M>XO]4
M+U=I6C]>I<&V%"(ZQ3C>53MVXFSHV5PR[[(W9BBY,""J/R(L9%-@\<RKK.)Z
MK#AD]I/@K7LVQ&(G)9&-!4-Z:\MT[O5IE2NK-(^*KCK(6Z-_5X@_\WJD%,5W
M3$-/@.HMJBWR^PTUG[J%K8<$=W<<WHTWTV\@^7:+K\9(5-7&F\8TWLS/,J]C
M4_:^6SV)D43Q3#JDH,/"^/T5DQ]/:U*#7HXM-L7W7]_3&]2S;A$F$ UI!&9A
MY =- [CIR)Y TGU2&RM$"X6V3<?^$USS_J?HTLZX[?K+E@^5Q:-*8.Z(.)D*
MLW0:Z9/U0YGQ;1"EE"4P6(K#Q3]'?:>EKB(*#Z#^X-&=&15_U.U[T/)N[DZ
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M8.TRC#%VPNM)KXJL*7R7ZXZB/-9'.:I%9-B]N[8[2Y ::<Y@]X=L_58@'\^
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MPQ2O !HMY54'\^(VI@MPW!$LQ;J[H$_EC%#1>.H& C=U%CB3?V*TW^<LB0<
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MC(P,OXB"LKPT1.*6C/1?2L@N7+A 2T/+04?'(7V9Y[+T_W CM0%,U)2?J65
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M2 -'UD4$J*:I6(]-._<"9TGY96]()5R+/;UC5%#@!&=U1ZG$?F"3E<7V<S3
M5X!T6@Q])U)G@M3WY52%!#R.EUK*5G" A@(,+T]&B3+XC<TAN9#JM0J9(JX3
M-2*%LN!)'<*U%'"SN@2QDXSRNW/N^/.>Q<#W.168%(],X<;,D,U$30L5HO=,
M[BQXB00,84K-$.29M'Z<.*JO"+8YTY/!9<,)ZKKK%PZ4]1:5GABU#1[S%Y"
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M%O)(3AQ\8K/11BA^\S_F14LO(2 ':QP;">B^[JMD/J_V1[;A\>_<B_+*B,"
MUY/_'4OO[)RFA6/"]K5+!0TB^QQ>I9I?;^=98O1E5(&%>$]D8INZ,OAKB -#
MT,OFIFN!Z;']S^.E[<HX,F"T1L7Z*CRN05">-2)MQB[>8M91\:],5;.E :9$
MNQ2H]'S7)\$B\?_H0XN^#XR:JNT7$8D G#WX:2A:KD?<U6PLUMQDS83M6_V/
MJ-):J.*;%R=ID]_@Q:JC?G:H_CEZAZR?7]_% EN@Z&@JG^!M9='ES!#%)\WH
MICEMU=$#JM%-B3=Z7RTZ83[Z6F3GB;)]!68FXY,R"0@G@MM16_08<VQ!^5>U
MK\;==I>7.&,EQ6L^DG-'1K=\)%NU9,1.$D0E059F>E]KLRG+4^&\.;N'U\P3
M02*G>439%019M>=D#:]'=TJUDT? D;I\7L";F]QID?LPZ4!?VHG)T/-Q&@-[
M:WK0->,R5BJV4I<^9O.STYLAQLW[B"K]5!'1IX0D =_2,D\D% &OG@4ZTP6\
M<,WO1;76T7SUO8_6D2_;[R<LQ!?.L$[[*4T*X?@[SK@-/Q\-"M=K&1](O,OE
M[_PJFXJ+(6I!FTF .>:\,OKZ*( RE/^BS-QQ3^KMA<)/"V<^P+[//UXBN*%@
M>Q/#I+1R6H_./35$#):0@%@2P 54J!G]"Q$ZMK"W 5N"=0>*Z3\F_D.(J9$C
MG P>,^"R:%@>(_XAY&[ID !H%?$NP9Z\B]7J/TM_J_^?4S_R#_701_A?[#/0
M6Y8SSXG8&8W]G_;RA(UA&"IEW_6$X;R47\@KE\4W'KD3+,=VKD3][I&!&G+T
M&?SX\':GMQ3!!!=%IYE"6L3'#K2F[UE!C6V0[F(T8^FY%X%]<,SW0.5,U$X'
MMV1HU4*_PY=9B]0N->L;-[:FS0I@\V6%5I-B?K+9<^LGD:GBI;%--L5\/Y2U
MY$$;EMI8&/I%-OIZ(7:YP6U2SOW>B]H&1.N5() HW])S1A^,PIKY9&<,HQ5!
M'_>G/!BBV+4I7G!C5^(-)#@TKG5*-1;&U\!"MFPI/G'@RNYX!!4>NV+-VMG-
MT<LO])0V;'*5FK WWY*&%PB!7EJCB-N3Z2$!5YJ]"WL8Z*?@ANT!EX:K]SO9
M=J3$-*1O4IO$-"C(KBU0PI;B[3,/9TB AC+@=8!NK8:%EWN6LNL-E>3;)^O/
M']$74N::TWW>%]K;[_$Y+,)93?-_GTPI^%"XD:0/Z="52*8.%K9YR8O?I_0^
M6:D!/$@ +?&B Y\PUM-TOL[C];+E]JY@G5N.+,47D>!X39%1CC))G08DWA#W
MNM2ZT>%R32.C7C3%T&T&P8(WL?YA93&HE1YJ@B!*;5A67,*IXJ799N5= <L+
MXC55JUI+=M&S1I_PR:9-./8/DJ]3>SL-Y[66-P&4ZFF6W3> =@@\IZRNQJH^
M@)KX/BGU8^G[NV^@,G"SSF$!"<@T(0&7B3)DS\++_X7H_[5U90+1BX@"C'.*
MS_XA\#NZ'A]D[O)C5-BN%9& ?T@:TZE$?SM"*'Z(,OQ&ZS^$X;^U_ZW];^U_
M:_];^]_:_];^?TK[<Y?G%EV<"JMS#OO /W^CZG\! T9J@5T&4]-KH)68D*.D
M3(8647A$AVE3?E:C?])(W^[7Z<ZLOE5.,\'=<C-\"/J7W'<B0VM#4WW,0,H<
MIC;4;4[TFP"@K-"G'"(9">6%>W2OQQ2;?FN(=-;^POT\T,<NFZ^3Z\]^9F#
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M<P&_#F]/) R2@ O"'=[N59C-X@$J1+,*GS<V5+]R%'ICRM)JKMWY98[_J([
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M!K8>;RMZ7)EP,NF T@LE\F!-&X8WR?4$.F;OSRQ9K]7O_S_LO7=<4UW6-GP
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MR%C#Z5U.R^;!'#<P?B/>4@_W3!=NM/V9CSPU*>N.3;*K 9MEID%I'#6/G@A
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MD9M/G#6/$&XW7!>M.8V_'3^I7>5EUC '=4)WQ@3(L=#=EE'<(MM1973/JV6
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MNZN FTS<RM=V>4Z6E%K<82++K;(*-'28@]CY.G!V0"DLHF^N, 5Z<)6.?G#
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ML)%!B[C^O'0,:BQ$197 ]5@GXU+,NFZ;]51L_BRHA(2>E_*\Q2M=WV3V-XS
MY38'KL5=FFYV%$.,T/E\9 G2:U]Y561@PJXPVI2W8""ULOGVXSO>/2F1J;J3
M&W=2HDU8=7MK<NK+"CG>G15Q1B-@84/&SUPN.'./*ENGM')9P'-S]M<7]UX@
MQ]8Z&3&2C9<?Q7,,T]'UUSN<O#6M21_;8,G*>"N.M@* !IEU?-SY'K[2D01
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MO9&S 24^[WK=WJ:^G=_08!?8WXG=201N"70@<$"W@4-C%W!TNLB!H[V@0@)
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M;BCK\P9G_,42.M$!WUPUV:29(&R )NS6XIJZ%6VP/>3@1;;'?+8/LKY8^//
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M0:PI1<K2M^;C_EOL]T.M:!UL%Y:S_>NC$*M0#[OHMKY[YMJ@W/XPR+MU!7D
M?RZ)YA*&YD.S>VUJQ5),4&!@QD;^]L\EF2)M,*H'/\%/S6AW#D=*?N7^Q&<\
MJ0H\5E>OEI$0YL^Y&EK7S\%Z%OHBG1=X^T[_<93;:X^%A:RLV\OG/J4CFCNT
M'O=:I"5_V-S4S9%^?4JS?M1DS[#D$:3T!WSWL%G_52K6A*Z:SFO';O8,T=06
M+#K8MCAQN78N(X,)4!+ %11- A[PDH!E<\#52X'KX]L(^X.)Z3S ;16')[-,
M%B<>R0#L#"9['F^'!-5WRV@.;S%,F=NI/OKT>3@2%F3J63!XE[,K[C2.&^$M
M [7)T(O)-*"OHQ-I<)L.3B>FE*MUYZOTV]PN[K:C%+E[MT&[#\*[K#Y+0<%+
M/M,O<2>GYTGM>+0C37_NP[=:=T5"I0/\<JVM:3+I9&O2J84#2D//WE&?5IZZ
M2UFIO\YS%HYN'MQ@<D35(0[W3^N=B;S($-Z9N>?P(1GETT?X!XKVDN';*#-;
M<+J59U7&"LJHXMX$2=@1JD+N401C.+AJ#HGV7D^TA/E7.ZJ%HM2[W,1&XECQ
MW+3(X9)[2C>[+8X5?7QQ-:3"3T/L0?AG1Q[6*;^E)H]W!#E<3*.E]?O-Z]&<
M#QF8C:;).+H]1MF #8P?\H&MT(<9W=I[;V&A-V0E 'B6UE^>P/7O\O^NT-'A
MMU*8BMOMC-A%RC*?T>$9)D@ 9Q;24[K4;$@%?^J)8*S5?+TL?21\J5]7G]6V
M=0[B(]&Q;]_L5\'(R50:$A 4IL<RC& 0]QU>8-0^(%Z0:!)20^FP_9>%H',W
M*(*K\<DXM=IHE:]/^[*3NKA/VE;R%Q.N=JMQZ"H/HWQ[7X70/.>K+?.Q9!=F
M@,N@;;!45_OM,A_/EIY(SC3F:&T>W!2XC5]+<90F1J:_>V"1U4LIE^G#M6S9
MX2ZM%NC4H3Q$(\[+.M<U$21_8=K#@03@Q'2'."/'IM@*,C^=DYG9 UF]84C,
MVM",A$76^&AA%YX_Z55M2=4N?;HI/DM'L-,H]\7;),,-8.1*^49]7/*GPK8F
MUH.7ZH?E.5UQB?6:$0[^PUF"8W,5 <K._.8^Q\NGR;\8A*TP!0X/>K)$M?HD
M=&6O7'X?-R[,?];Q/);N6''#Z,I(3S'<=Y8$8-_;50O"0JP1\[-W-=7-L9T8
MF8*7C11%>P7]VCW>-0,W)8?HK@(3I0(86<UA5(!17NP7G5KK4?W>YY_.?J9*
MFU6ZX;R,A.$],,/#T/TJZ;JSSNDO_-HX+]A/UG>1A>$U@[X1&''Y3<HG\Z8Z
M6DZI*'/WY0FOG$Q1M228>6):J]P.YQ<]::07_G1[3"53WHXP2?X2Z^.9;^D;
M%3NWM9HRPWYM+]J&3OAKZ_G;QN1!KI1,+/Z$X^D$4?23U ]==WV?KA:&"$54
M1A[1.++&6</FX.4"P;0>F@KKASG?TM6U?5U_AFKJ.'<%)?=M)_H6\WZ78[@5
M8FO!-'.A[KF\.;9G[\U;[UK<\@-6%LA@2?B2RM6-5^\R;$L2BN],GM1+<J;W
MPJ.;B9"]^*9K@"$),%4B 8D*KONP)572A5[+*INJ=[*:6JS'ZXZ]+*IKDVI@
MQ^G+F![*;_7-.J8]0!&!/Q8%+3LB8F"UQF%"WDX4P6,?.Z@-QTK??V+>MR6N
M,,7O1=3>]%Z8=@OO(!S'/XT2> <+OEV@GGZ79T/TFI<X+HX$+$A,2JX@V4V,
ML?# /8\U?&T$H^W9M R/:+M+M<H^/5L]R+02%)G>.R-]KR#9X%AH[[CPR2>R
M="MS\LQ3V3-LYTKV*>S-.^Q.F25=!/='B_021+LYCT2=&.?]^FKD3 ?O X35
M%8()>:.+$5*?< /74A"2N&=5O>'A!_8YRX7/ U^VY/(-,*T^F02!!\.Q)T!2
M87W$/VK#%5H2LQE&9/J$5ZIGD:.*PKA*MZI%8>SV/RJF;GX'];:J)I=!Q"?C
M'(+$($=;S 03F9(>=8FD?@UW/Y\;,XJX"JS1>:(6K]\G <@WJ.4SXVYG\?L>
M?0RK%2_LB1@+N3E^-/WR@T\!>YZM/+$.PF=K#J-K!/25RSMDSCTI@#\L*KO]
M</+::_L)2FA'FHL6>GX%SCY]]O.LN>W$6=UJ1+B5W*/Z=*F)3D8RA^I!UGP2
M0&=R8XK/S-3^I6 #=TR.H5Z%QYK[7$<&3*EJ#<H@<TMV(/5=+_*-4*Q]BCS/
M*X?]L<\E6^7YT(1SX!P7#+#E!RVI%)8713$Y9I\Z\NBAB!7\F=/#4J%:'6<8
M7WUAQ,:]YA<]A_D+WD],R,O?/[ 0,+311ME#?_GEQ9#+"08*!]]) Y)[$-H;
MG/%VYN1J7=KV^=VE3\.7^>-#=/Z23'I_EW]-(=.\^5Y52:4D-^RHX'%8D"LK
M_9;9B"^_Q9Q1Z("*;B V-Q!E6__2>FI.WZ1=GEVHBH/[ ]+'_M1E/H$^V<[G
MK%S6(R2 8T\:X4G']80A_7REHS(%$@=X>XO/JWWZ1K?F,Z87H@"X.+R=7),N
M+TLUK1JP$K0P"/3U=3^H91@3? W]Y8H_VYEC!]^=!69/=]V@]'4QQ#)M#223
M@ .GPA^OG<$]*WU^//)FH@]Y43UEYY[B+:H1BZQXDQ!337%Q]%/=^* #CU[6
M52H!9Q>"8C,F>S,$HQ_(Q!GV:'0H;TWX*A,:XNFB2@7B8?X8%G_5V05[ <.B
MI06+0FE%BJ=W**_%N=.&ST/I2T\0A;%)$1JS&<Y4OG/^5E0!A*35O0S0,S-W
M[C">X;W##E  R?%TD2["(QP.PT&)#F8VJ4Q!#V4V57(,JFD#LI9'BD0'Z?&H
M&@C#BK]6E@#W'OZLLJPPX=&51P\&/1HK6)&I$_F%'V\4'E(0"?*\3 W5N2)@
M/G<[JZST1OHTEWSB<CPMO"*.'5$U0/.ATV)<I'\X.=8_@NS+J+O:@PH"WWC@
MG@/U :(=YJGDFU?EKJD&KZ"N;JSZ 8N0P'(ZB0)A6%3="31SO()]6K$0,^P)
M;;(R(3C_@0L+SG9#[^W T2X&N[P2\YYLW%GZIGZ;('(X-,NYGQ&XQ?W\](AP
M"]L5GW<?/>F&3)=O[-L5%@Q3JE?A]JF5OO(A[PSBX9,7#R0_$_%,RTS?OPNE
MR+QO"?2IB$4YSMB<ICFI9;UDW?6H:,$?3KNRKR=;1BFI3[8[JX'&CE&E&&-U
M5I?CZDL*ZS9T:;L\Y-PDZDBI0OPDSE3N7GAK:-Q=D;O/&<YXN._?:\QTJ7K@
M$(ZE1M9)I3CT 4W-@-%X@HCYC0,3ENFSP)!FYWO3 H:6"66C)XLK ^VGH7%G
M&@  J.  XO=G"3S,S?/LV-='39]IC7R;5@%YF9[VUR06^;<M?$$X=$CVI,3&
MJ5B,I.W6/<#P\D>M;SFC7-039G!O:X,:)Y\@9.EY \ZW&U=-WPF*E7B<]0TU
M^K3?0X;!JKZH^@;E^_8[F<C9_/U1*D<;!!,5O[12>U0\^!(R&*)A\D=YJ?XN
M_UZ%_+/<2=-RVK;EOE:&Z3B(UXVN1WSL#Q4>+1G6,7):45!.S=R5AJE=PSY/
M&%Z744NL=#;(JN,JICBA&MXH1;9GD67O'NC74V6+6HEQY]AS,U\X901XX6_@
ME/BXE-FD%+]YO^)(35%*&&VCL/ 8+N.I9KZI/;GZMG= ^5JSQ]?G&( GU)E,
MY\-?EX3_[_(_I#!-H)C<N'G<;=,,/OA)K9B5KM,WKAFH=W^AO3)+":\J-;<+
M#H@:".;QG9O/A\XN4\BWS09>#4HV8.6GD!YJH^SJTO1SX< 7I\$2;\MQXLB"
M=.L"DPH^WMEOV->H01XP<I(^Z'F^W%F7V]&5RK1AB?O[-(O4A).L6'7K8\B#
M9JVLXR0W;E!FM.OS-F$0_E&"T988_XP69=OUAM,GI[,.DW?R*GVB,_"(ZYX?
MI'8[?FEDBVP"%DISM=OSWL74L49V:1+PW@HVYRD[25[TUF^4>!R&Z:MP.^)Z
M5:MT\PWD4X&7).WHX<998"^BJ0RP>Z79Y.3@*R?D<BD"LZ!8_/'0Y2\GND,'
M3LK:>U[YYKAR"HG7'Y'P<SF'N9 (:Y:M_?CI1-$Y168S-[=5I0%RI%3#I GY
ME,YIIO ND9>W SS/^^G\8<;\/RS(8[C(8(*9,>XL3*UJU<F\J>QC$]NWT]37
M.UJ66-3;;MO @D<>Q5(-W(/I*\?M?SX1Q$P]ZKSO51B>7)ZS7N$IE$[&V7AD
M;A\RX45??T75^8R'7Q?[CNSEG'9VW3^GK4\E8_D.WSR#ZO5]C+K_\5#MZ/&[
MR!;TR5$L+WG;Y*Y;*5W % :)Z>_3->DP-7T\YVC[(&QNORXY><K^E7BZR_\0
ML4K],:FUL@954:/22CX"YMD6)PHD-%.THM0$SM5?%*Y37CU1!JEFFY7CQM;%
M9O:-&'WC.ZY.$&B/Q-Y7&I9GZ[K-4ECPT?P5.C*O?M^',WK*AI)WR(O%F,/?
M?35S>B(=%&M5R!QF6'_&DQRX(NM:&4_UZI<M]-N::OSV83)4'^\$^@F>BZ@G
M7\H^-UQ7.,+QN.^&)<O4Z=3&P_&%5 >"8<?FI^LE*PC?36'GO7NNKJ)5WT<M
MKL*&"KQ5&OE]#L8[G'+G>9MN*IT?5)QR*=VTD,K:6-RE^/:AHWO39^9I[L7O
M\?O<D]\O5/W19IJM;%8CHK%NG>[6).5-5Q^Q<2(KOD-&&W=P\$).![63[?"G
MN\VC5RIOQ\R1LYXT0.)O4&:VW^C_+/!DHHCK!._7UJ%S>D))A/NXSV5&J_U\
M%?I/"K[=:O%3Y OILHVGLWA;.E/E=@Y7D(MAY<]'[&U,T?I8'#H5F_/L-%?:
MO!64;0!7'R3:NL>DR=4-*?J^,-+2'#(87E8&S,-K;E"J*<!F7![BF%_FZN/#
M*B(CV$0S@6)-[C!9D?V0D%JGSPBXV3O3U;756_P]A?2^)T*<1$)>FNQI^<\1
M89!)QM%UJ(]&>E"AT&]"JXOG*[7(<?@KUY$/AY0;;\BE=B )PKA$V$0E;EJ"
MBD%?@>N2';N\-[74WCW*E3?I)N0YPADU]$(P ESZSLD=2$S))M>Z#>O[BX4I
M3I J=['?K+!(B-:L7+P,[_5N:J,N(&)CKYS#5\%G^ZZ]MCH\_NW"I]%E0AIY
MV>[)5#2Z+%AS)JV1)YX1^*#QR!=#PU=CW_%M<BUWX )C"G,H?_@ <))\T%-:
M(Q9@U*0:L62"%5[H-I\C0(=Y>@3B@ 7IW*,0ZZ,P3G=(7?%S?!B.FS'/12+\
MCJ*RB#@ =O?%))MRV*&&JO4%FWV"@UU*O6%!'O\5@Z>5C4=DE2R@TN/&^&),
M"9)A1D?#:VBLJ_/:1QCGE:2'5D?"E5E'SJN-FI!_Y46>[BR%XQAF;GTH_(AW
M%"@KS3NA(FR_U<M 9A'K(S;=]9\[LGH0# D(E"[P'RF)%I#^W.M*=3V.5^B1
MR9MH:Z@D-2W9L/O08DI9P9'$(D^IMU:XAH1V'\6]AFR *Y.*1H_H')5:* FX
M7>+7T2%#$7'+_<"D7+Y8^#<V[\"RN8SUB#7ZS%PYX6(M0T[70$#MUX^U#?#O
MEN[D8&NW>GP>"^9+CK24<E-1/@DZN[_UR,+MT@/I,)\[V!H'/9X<78YKGZ;;
M,HV &VZW/%6![<07.UYX:7\<1R7#+-4D-FJ7->S["GQ>KCPY[$YY$@MC)$M6
M$#G-;!)Z6TKIQB?70#E09T?AX$'+D+U?'3?ROQP6B?#K@49IN_E/S5OQQ>*-
M<.(3&(J$C$KQ5Q&G#>E?'J 2IM9]WL!.^$ VN:P!";";P**>V0D\EM1P^.#O
M5%?C7G_,@&M&S]0(=PO#G&Q$,X>HKH_K-:)C3^=Z^<F)OA9PEF6JA4%JB&?0
M\_,C.#IOA*(?;_?;D-<(8=]1&Z5@-ZZO>-Y>[7IC\>1,O1C=+Q5N#\^YJU$"
M<91[$15ME&8*CMR%=1RWKG1EF1/,A\_',O3.%=3:L[X_30),Z/NX)*4XPV>N
M_I:6&A#XJZG]3Q;(28(]*G0-$[M\[:O*E8>>PI/BSZ$9;//S*!,:KDN%!1VB
MLC3(S*P'5V2^<B_>";]-%VX?%IS-UR(G?!'KHH&^M&)*7]]6EZ39$>50C:16
M&GK]X7!RGPR#KG?H+=8ECH:Q-;O^.)M>]W-N1_%AE7*"= YO30JD+=*?0!WW
M%P1RR\.^92:&RXK(.K*CW5TNOEE!!7Q\I4E]M2"^ '7YYF'0&7:C;Y6+Q,&O
M>5(*<IJ:)_6U=YH98X<@51GX%M7(NECEU/6+TYB;:I#35A5$17<Y!&[\#=-"
M=:!]A6()!>)XH/,>_V+XB;>E=*L.J-!!#$UMO(N2W</AR.[P5U[K%H2924NV
M;_6F0_><,)<63R&D9M"CQS0_H_):$M5PG-I5H06K(L*R'MRWX>?D(;?0KUVL
ML/;IF-:#NN(A]$7%N3&?S-$+5[RM[#="*NO=G-&IZ% 7&*X@83B0HDFU(\79
M.589X3)IU<@V<ESMH0JM*UD\+=>P<:WYN8HH)K1/Z24#1^J<;S)^[;41C15G
MIJ\<\X1N:64_)3;=P;?C3DW<:%_^&O\^?"1PXJ5+CN([B@F+Z)P#%1L'9^28
M7+C:2W6'#3!TAUILK+F_!>6>?!K>RQC.7Y_^\,+JD"8',B49ZX"Y^](DZED+
MM>XI!7N,UA=C0W<KYX#-/<+R$)T^^8*>7-T$[H?R7K)6%&=T/#]-668*S+<=
M"JMYGR8K?Y]N)7WRG_9L&@CVS3+Z-L\?;*9M')ZZVURXAU%P\2SY5J(NBMX"
M\P%WKU/JR&)B!0EP1X>:Z1US]A&N&]QZ/)5P\8Y>])'/CWD>#/>[9LL=-V%N
MY&(RJ]UK(7O6;.K@.MWP"#,^;!A3?W( "?5 (L_@7H5+*?+EI%^=GO"$(70[
M2\]O7M5][)3?4)#GUT#Y*D/\W&&R*D^GD'LIR;BFB@(-$37S=[++GU(-#_4U
M'&E]$'&#LJ>8P^9Z;C?<M$E%5K&#JL3X_=&$6/*$FFN*%]:0FOE8->\G*8=U
M\#;*SR^T=WP^JS1U]U%J#+%U@SG1.'F&;6REN##XSANV_9_FN#6M^2G7E%WH
M$M)(@#&Q7) $Y'B2@-F5.0 X2[$/AIHE >C:P=5#^EMQ[M+ZS 2%LLY27?-A
M"(WIZ?29L&,AA"E[A8,OU5H&XQNG*CELM-DB:Y LL#.+#?B^ZE6JE'[E,?\6
M\4<GSLUG7K\N5<]!>Z8..9)E< M7MN!32O/VR[?!KX)"=D<[\[EDJ*T]K6 S
M?:E'L@^/,+K)>%5I>-5*?#S9$ZK'&\B?:'W,*BM(R[8.?A58"X372#L\7Z8*
M-%./-H_A/<K7^-1M4OU;J#S3A+V;%#X\VW2PSTG"*Y/EZGT]UFQC.9?&Z5*/
MAJEZV3QM$O"!O!E%\\'H8A5S:8!RD,^::@ Z:W) ;943L6I>KO0U<7%UN>^#
M <0;N(^GK(_0DVZ+V^#5Z1CO)Y24F-)>4PU8&3FV@6O;T!1$,90J8;+T%CLK
M=/;E]X='SX:IHUXF71_P(Z.<^FS=N*=P16N9RO(@[ ->VS8W+5JJI2%W<6T]
M&L)Y7\\FMM]UIMGM<"_AHB7Y92)K6=N)SE[' RI)-KPN0_,5&P9]C&3])OKT
M*UHN#^B\98P3%5(>2_!%J_@[2E1+37C$C$A6C"[5,[6ZM8N<U+%\/FKS3&7\
MD>1G8$\\VH5O1%6SMIRM%">.&G9VG,T.GPN5TCEM=+0MYT;UN PUW:V%6\3V
MX[31P[FGQ%V+"XU3SIZ3Y]A;?@;OGZ$3>ZNZG+D3?>V^7K_8@8:BHN"\?7OW
M-4S299FZR.(#*0,[%CLP=:KGM7+,"\5#V4=B#!G(IL]>.$)18GB0_B)PB.Z5
MT#5GS1=X$T6XZ<*AH\<W$YX0[3]'%]270+%"/>[2K4<(:N8L-6?Q!M6]M\SD
MCD7NK<C*/]'0\,W5^K,D\/1*9J 2AB6X]#C#8TX^;&S8E$)5DWBTE "MZP6#
M+<HR(Q?1(_B%$2]G$@#Q2%XL7%DDM'<2R?.P2$W<4UWEH7YS(>%5&P.)-R%Q
MXFQ 8:(9LPXQV.S=5.>!+,$;,I:=6*Y<RF/!ZIH9]6X4XN_=&/K]Z9]8:"RJ
M&ZV^'="\_'FN=,1^/KS; I]. F0(1TD 7!!5Y7[>S_#]_@3'@WE[;];P-DHN
M<[18ZY:?@;="*4C 8!,2F^A0J[8^,32XN6Y'9"3K-MFH?8Y*OI ^%7G:VE1Z
M[*1^%WW7(=BQQ3/.347\_,:EQ=;LAQ0[&B;PH&XC>,,DO$C L"3TL)W-\'!2
M-F+57>P"V<LOCM\LOQ99+$'[1^2^9*>.U+\PRL4F%_ID.H@1\\\^.^$ZPLIU
MS%7Y#D$5,"*<[H /BQ7C+ /$8+ZJAHT&!PNQ54K-4 %_$D F2@(\/@9L*!!1
M0ZH7<FU2[\KD>/7;Y./F8C.A ^_TCO:X\>#UJWMTQ(*K)]U:S3C;6GCXG2*@
MT)O*T,"G3BGY&#BMRZT.@AD&0@<WR*KQ9\2<>Q4NWSN1/F$*66N(I[N-;Y+P
M15<Y!>B8IR!.^?48#C2=RWE#NS $C*1(]SA4-B'8X%52"9>XG[^2$1M3]O?@
M<DT\\L0ZQG5>VC:[$..5B: 26U.D#GQT-4=JKZ'-#<(Q$A"J'@]';_^2*U">
MT44==U2] !<*@U9]O*83D3?F>\IQ["LC$$#X,HKS=.10NFDFLH31]ROE>/=%
M%S\B_SZH;E5-0,AVRO>V[&*FLN1G9^M.T4T2P&'FA X4$Z"J<!)$B+7X-#JG
M#\2<*+#V"#C<P%5N!:MHL1ID,<#5L(F'EI\I;3<N=!YZJ,OZ3;KH5B,_)2O/
M<CR=(X[EA2T)H)J4D/Z<?%I%BX7'DG\4RZ3T5-5Q+#5(CGO&R6%U(&1H9E_'
M:\OG1_V]5GW#NAW)0SJ#G!^E$=M5);&G7J67-)B-+0EW;ND:0+.<>L+&X 9:
MZZR+;JV0R*!H^P"W5V2M>*IZ>[WS(-P,L!1\+(2?F>[^?$TM8&6>SJ#^TI0V
MZB#!+@T_<[4K._^HF19GSTS#!0O6/>)>845QCMG!E_VK;[2DT9#9YK]!2'C6
MU)? H3/B:Y_GRU?&$7E(@G_4PM8S-:([+WD"#EKC_T7F%@G8CWCVP;M[)?_>
MTIN3?31%=6X&@T>.C-J1A]6J!V,T7Y1*8?AH^.JCF/)?22R\'R#676RW:& ]
M%NH4$@?[;.U7C1=M)@&'79S0^CB\!:V#ZZPCLH0$&&WQ=;LHT#U/]ON"#['-
M8VM\31M_ P#Y9&%A.9XZF!-/[*L4[PGACHEZGN%&O!?[2HEZPB,,37Z2]EFH
M6]$XLO0![M+E3H1VMPQ7<GDLPWK8!?.G+OBP]).C7AYH "V!H['+".XEEU<]
MH2N)W/=2W!*65(L8"(LQ'N3$9[^=K\;,%MRJMTG'W] M??)^(4A>/.3STS)A
M>8YZ'QE5(PR"NF\FRMKRE"&/P=;H@TJ-M;V:KV%J(W2^+G<LK8U2\4\'UG2U
M@YA/F60-^Y!/A'R)4S$$A&,T%; ^U4LPRXK"B)O3']V2LNQ.AC0]@$:S>?J)
M3W \/5!?9C.8%U4C<SZ[B&KB*)9UK?>0 ;;1LL==L!4'K>6D[Q$0*'4<GM$U
MHRK\RK'US#N$KNCD!(?:I2#W[L$ ![E3)."9R@U50;1J]$7G$Q83X:U1* DL
M8 7[/^R]!U13T;8NO!$D(DUZ)RB(!>D= D&1)B*( @H(*""]=P@$1$"Z@(("
M$HHT*1%ITCNA2)&JM "AUX0:("0/SWWOOG/.>^.-_]UQ[W_/?_\S&',,QF*O
M%?;:<WWS^U;6GA-5(HDY"H:)O=.I_B'K>B2_7G?M3T[_K4*O.;'33^FF-GW$
M]FAO_]..=14.!*4SS/KLF8Y%T"0K&!'XS4SKG,FK)Y1W,3&8;;?A7/]35S0(
MNI!D"][OUSWEW)\:I&2+K.?_[-O()2?]@3,@X"EA_XV\P<L6L(P\?U*'W^L#
M[%/B<*I:9<4-&@:[.OXXZ8L%V?)B ,_Y &O?QBP2<$T[CP3\@I" E9KKY*,P
MK<L1K<?U7USU>UZ"AB\XM#6RPS2'ZJ]BCR<?F AMZC[R6WR_Z?A"Y&>IROEX
MQY!)Z:U47!DO> 1>L23VB\N.=5[%55_BLSBAW/2PS>E:J[]Y.)K(P-$Q^JY<
M/"!9\=.4A44Z.8J=G>A)!GY%O+9B)OT]N6=$UZ;P+K72IZ$P&%VNWQEIQ0Q]
M1[#QC3?9HFE696_RCO6@!Q@26BQX[Y, 3.318S#C%1TH!ADJLM<UZD4=$6-*
M,5OKE^8.G[V*&GQ,%(!O("9LVJJKP;?8O+.O3^W=ZA7P)7015LA'(0;YJD6^
MNH9?OZO@=.VNO W@R0>MT='/F;)MG,*OHML>4L0],3;39CP7M):N#)611N-3
MCWDD6R=*-K98KPM?==?]EKJ+_KW5L1G$5=F&JM[T^::9#_93,1A8*H9>!/;]
M=WC,YY?*/A/NC1!$62-YL_E5JAZ:"%'EOG__A/*%*[/U-[=FEO71>?^+0D$C
MQCAKBI+DQQDH*]4C)A56+V0D]!*,EV\$HCTGQ/"Y:ZUX+"G9=_?7IW8;+' \
M]A8?-H]FCA2!4<U]</;\CC?9O*=[ZWY;P=TN"*]D!BK7'#]- @001B3 'WS*
M69F/+;M#$,5B]8"3*QG*><$2]60X$1>F==D9WK&]G%R'*I7RMKJ;LQ;<-F_5
M;Z/D07QC\?%$ODE?P9DQ]DV!$6F'I=]VU@PM'L/72BDU>21T,7$W1^CQ]@$S
M($(HBAAU+Z(]IN3D =[/A7[+<!06?"KKE,1^.'T\2+F7(8Z/S3:&.S@0&<L"
M;ZCX#;6ZVU0_R'TC$-Z\'C^$)-S ;65AIA4?U356588YE=[5.[K8YMKIUPW9
M*R7J9#PZJH,UY'MO?=A.Q2%_C]L<4#8M8FP.(GKC=7*8R3;VSN0]2PO!6,#W
MP=2KVR<O/.6(;*4[WT6CX3LW)L_8[1I\1?39D?G)(O11"A=Q&ZK:"4.1@(QX
M$A#("?G7WYQ8CGGB$^J4(['/K[6DR@LD'3Q>WROI:<7:$"+]H:?^^3O%Z,C&
M/Y69M9O]X[*X-FL3SF+J^A(4B,_L#6(YRA/"[^[#/QZ\@T> [[HV\L+QND2(
MO0+ZN$^T[>=IQJ]]PZ3W%(&Z'WX?&)?,G07 UR!,5=E<(5V?HC%O8,&U8)3(
M=Q* &EX[_X*@5(./G:.G?2.%(,\=D74YR/&0G%N8HI3<I1./ZL4G!&+J5BO0
M3&M$YF=7= 35A'R8K-R;"UP^8+GR3T9#LO9$HP1Q IQ63G,!)M1IF.MTU?T]
MKR#<":_D^Z'&6&1HM;)LN+"%KW^;9L8T,F*B;RJFN 3]\@*& QF(/2@'O:E7
MS%\[:/<S<KV523\GX-X4TD40ZH7:#.!Q..CI:WA6)AUJGJW] H'I_.M+3ZJR
MOJQ)'!DF?SGQX0Y)#"H&-3JDCQ*<</RMJ6YC7MLT=DQV;XSZ383"=U]08 02
M;Z^!SE5"O# ?/1&,JXU<@YZV7N8,TZ(?+Z61\9D%O? _B\&\.<#+&CAW?OL^
M5K#,K60:[R:UZWP7JY+((9-(R9P0LQ"W1[;F[Q*Y-ZW=ZHI_I[VP.F02F)MA
M1F-/:2*W):8Q9WH^OAW*A6\::,"ZA&WT)S"]B\/H?RC2C=\*5H<^W'Y2':M
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MKDPV)VQ<NX5]Y;;+J'D*#+BEKL)42QW\FUX+>^F>5\TWFS2[,R!D5B[RJ^<
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MZW[?+U4^09DS5@A+K=<VA>[A/F?22XE-@2ON9)1T@_/'6=[CE,IQO<V%7B2
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M?.U_=LV9_\(&B9B'M])JHS*N1QM6C&P*YV@_#O[\I7U!DAM'W/?NFPL(Q[^
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MT-)8D38?5R$:?7M"KU<.U\CP1H=VV'"5/KE:G+KW4L^P'&T<[FA6K4$@<"0
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M?LZC/4])T4-<Y]G*@9,F+J/3IZ;E-1L' AC[BJL5]''LQ1G-:4IOAUJ4;<)
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M2;"7)@4[-B;K;**"0U1IBB'K ]!=KGXC]E1FGQ<>;(97.?QPW\5M!K:^\Q1
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M[L]<_R-4]0?]58!+:!<)F]'OARP=@JV;F>2;8*;0$4(ER/JO?JN[]?\"UF!
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MM\G.&T?3+B]3LW,I#C_G!PSH6B[948^ZN[#961T>W8W*,1U[Z_\IV."J;]1
M<0[%DH%#07G*U"[VTV":Y^[S><?8;4+YGVMX,<C&A&,USU54YS3P#'LAZ@FW
MW\ /6H[D9FAB"\#'B4SJ@.-_T7')"E]'A+;P6/[2?J8<ZVHB\BL@M(TN^1D0
MCOT&"#$BQMY'4"(FWA)VC7%-WD<KV_2^_F/>+%RB.(-*"V#B(YXL@*P/PW9Y
M^M=.MT%U_3@5\3;78/-%%#DDG\/@4"S]W+U&")T*EWBG])]99UR ^K4?*T[^
M2Z,OXF"3QZL#BO*0XD?VR ",K*=,(7=+M6\?5MW-1:JJ5>"(05KVW#L-VFR*
M2$_P0 ?6'.DNCJO$YLW<.RCQI?0Z)$8Y8.@4GT\0)B6CET3C-=B8\-;2J_#2
MP98GPM'FB*(+5P3"^IAV]06":V)3 X_,FUF^"LLPFX]CILUSMF;62 [T(2!]
M5J6#D70>9( &OV#I:%C6.];_,G9/G5#AI\="#U(\-U#VJ8&J?CAT+1E@\T(T
M)^07V'AD9!1_'+OI*/F>BX&JE5;3Q8RR-(_ .# "G^6$!T#KVP00?I__$77
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M.'>C*M9RYE55K.E,7AJ+.=\WWD\M)Y/HG*JG@]$YA9]_@K[5_K)8*[N8R8A
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MXB$+$+./?5I&4P*2>:DI1:X+>."^LQ4BT<#?= G"1GO.=L%.SG;1.WWQ._%
M;*/XL],>KT1?Z2I>!_93+[8D?[C>[_#J7/'SFS!]7S9 !*; -T$!^.B]<[OV
M)4X<4,=R32+('[[/OMG\%'X$H!G/"L&A![X:&YWYG^>KPTV?\O!HR=]_W"/W
M /$AD]#SA@A"O(?O[4);JO>F[//M3>Y^H=P6<^->,H,F0;99UG)NFFTCEJE%
M=_#EP(?-!+C@][=PO(_9B]C1_=*ZWXS/??V_<.7YJ- E'R> B!KA'>JLS_'L
M12"RK4>[(%!!@L']ES/\0A!U+GT=+J=E^.H:$11U/=QV+E*#)HS/)I/W$'A*
MZ OU,\NY&9V.V@>XZ\J^,GWJ(!K-?D)EF?EE^;A91AL/R^*#?$SWT\T?4,KF
M1PR#Y2JCU9ITI@""81#_O>FX3H!1,SY]0&@!!QS(ZN8DY,=C[ LUPCH$0RCX
MV=M^-XI]Z.6/HZ&FT$10!$1_ -'0G2SP^T6MXEMP@/)Q Q#5( KXL&FD$5+@
MMX.B_EJ^>F"OLC?_)F<5,[9\>"K1CD&FQSKE X@[*WD-RDSH86<.\1:1<( M
MY^A=>I,U;J;YM;!T!4^AT 7RWF?J]*1L;FTA,(682L$LU_E<UWPGQ#FTQ5^
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MRI2/3B[\"Q&$EL:RX ^Z:=80:!,8_6RXHV%=LZ ,G<S)ZYR^#>\Z8W2O!;D
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MF.5>GG_+!TN6V)WO>9X(.C=JJM[?$.U%QO5&=%()&H9T?W5_P<15.LJ+*:C
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M_5G%/84SHQ]V!$*JJNY16V;$P/*0Z4F-W@QGK7M=O]SLB;A&YI^0$1J7=LG
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M,-5Y3C3OIB2$A+CNLW0$&F)IVAGU.ZKZQM3UNJ)G[K)"3"+VP*W<[!]+WZ=
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M\:UA.X>%Q6MP_K\^$XSO_)^G^YO@ GFH&BTM+7AAJ]&ENF<UJ:M7^1[V ]H
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MY62CB,JE2=+/ !XVZZ6H-WB37W>"7D+-S*9^Q!CX(B@&\(H=Y6Z1VGMTQ%3
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M&]AWJ]./1JD+!PTUA00Z6"'<_J>'8XKKS>C2/IO'#\.F-:-YCY=6H.6E&,X
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MR_5:IYRZ!/6)]/49>O(%=#C&\@/,:[\Q6AG6V\?Z2[ ,J#7JL?(_'!\[VS'
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M,[_]?;J'B(Z.7O[DO;\,^?,P.)YJ7XB>MX;$(*Y*1+E2-3T$5RV9KY^X\EJ
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MROU>Q@YIY5(:)MHH'4&&>,14S:1#L]GQSRM0S[SW@NEBY_@H5<?WU0]?>>\
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MSBBYA]WQ:PCMLY8F2JW9%/S]B8^F*B=#KE'.WS9*G=2=<\.A,A^^N\H;'&M
M9HR7%*JM.JXZ[S?!?5:0@WZYYHI^7G"+"H2]D< WF?&"YVU-],^4/!_L?=-$
MP8>$O6[7J!P4,U:=Q6JA;F(!3"<+5\&_8W\J>ZV\Z&=34DR%/VT:F>3PQCL=
M65.6B9WKBPKP8_J.86R+E.A8./B4&'QUE\-\&A^CZ"^*Z<C& A2DGRU1+^^Q
MC.1,Y[OYLKVO*92R7B3DO-*:I_"MSY0,/UT#$KU ^-Z3\(5_LFFCEI)S1I(2
M2B<-9*OZ<5.,O@)D4?XDWF^@ ZH<@X)!AZINT)*V"_[B#8<'&!6&:V 6'["
MT<D,FA>?MEEK.;1L6'VM]W L\5KO5K19 =_6M1B,7H:X.W0= Q,-4=1?C+<P
M!#0=T6KSN4R"2C[ADY"B6$<"]%O4^;7>'?)>WGZ*3DU#\':+3(<%@RIHY"E3
M7<OY,TL?\+^VV!900DOO@'RW4ST9,D<6VY8\4%&HX;U;2@JQIU#.707AOL0F
MZCFXA_B0\Q[DA#?J,_#.R8MZPLN/_.,,K^"I6$!G%#PL2J0ZJ>UGT,Z@J()<
M4_]<$RVH)4::<PPCL((A?U,<DQ)&A07 (O6U?_D:!?Q034L\ G)IFBH&H6\6
MH;9]OQW_*OUB+*_-G'PS:*TJ4"1X&&_*,Z(9)!IRLG7LF]9D5QQ^X[S,7EF>
MV=I1B>Y]U)7=N"[CVG=_]0!]NQ3R@S;BFM<C ;C;-(7OV40JAQD55CA,^&:@
M#C^%%W7W9.BQ@ 1K.&CA=U,;=5&44>7/4:IZ>%_5=8.IY$I9\]QWOK,</172
M8+6PR-2WEFU33]PTK^;^!-B42'?&<1<8("S'L. 8REV0@@7-'LL<8@'-H Q?
MZ!XA=+?L[DI9B@CH(*2PD)QFXERW#AU&,6LZY*H^@KFGG&>D#%YV4.#L#:'Q
MFDPC?*193S+'$":]/7R*WV%^05,#NMQJ0TW*Y=N8XYL_K_:]<M6,07Y]*L&>
M0,@Z6D^DN)-:=16'4,6$WM4X2L8"HB=$84>7;8MDK8J@Y2O.I<',L'64ODES
MRT3S)(-.=^*OH95^7G5).'V>?^2ET?"E*O@4G FU.3QJZA\>C')-?]/$2_43
M+5HS\CR3;)+7L08DK)@L@K;?<#[_2*)^4K%<]J'<$/5DV!Q1?791^9Q4F>F1
M27B*:\.3J'0Z*U?X=&V(4B^[<HOOQ^691DGP#34$0LT9&"0SR- ZRA=2P_*I
MB;C949QI@GWHIK=];2H<S1-)):49(<PNK$345R2Q3ZL"K@CDD[2DMX'>;>:'
M;<N(C3ERVSM^#1K;8LU<6WX<7N2BH*&E2'4&BURYU>;@A+14:ZYZM#YF^6%(
M'YIAQ5NW318[5!'ES5'?,[^S'NF(;!HYD&';-J-&#!6_ANW0O)P\4?PP\\NP
M@<&((_['QL.8DEOO_)M2NQ#K98L+D.45N3;$!(W>EPKJA_&S/._X"/3OW&9B
M6GL8?*#;*K;IZ3-A!(((U<\?:5#,T'_5FB&/6?,C[A,;=I2VHUT,"ZUA]WLI
M_,LA+UBC*E1>X%LNA:)%=+;T.P*V\1N5'QZ6H\_.DJ&+VDZ94R.C*/$LY:]^
M.LA;R1Y/9PVFF^7Z<,(^0_D85O"19?Q(;[;>Z7/'?$THZ.Q7V1/$1A07Y>G[
MEHDD70J:J+(W"0\ZEG1I94(^!KC'(O4[&O.25XIWZH4N(TK<J?U0KT,95WS]
M5Z_16L><PR NMC4;34I#*LB1;0PAJ1_^\@GS'FTX?<.']689T(GR,?F!D6GU
MPMW66[9:VW:G_AK:O&OM6("WF?QMB&*!9GW,+#P8)Q"PIQMVEB_.G4:N1OID
M5)Y\PNK?-@KYBR.,,<_L-"[60<>B94IEHG]RT8?@&*X6PSF2D)MDFH9D_]%>
M;/)VKW7E):1^V%K-![5W:5&:#Z+W&MX)3C==+#4;M7OM="Y^)/BX:'V5FT__
M/;-+F/<!JG&JU] *<6'\4+OQ'<8Z2?J=-*=UAPB%GAE]C"IG@OMIJ,!W?M/<
MM*]4>U&OZF",E!25G3Y*(23+_";Z7<6A,C2M52'O&VHSVO&.F9TO@C7<.(V>
M44X9&=DF:Z'JNF\?-F&6YVG#Y$,DB7"G\A'R&/<];;6:MO@SU6@*5>NXR'L$
MJS>\#V([JZ3HB[S :E6-$C,]%*4;_!FP!)Z %* 9Q\$''KV#/I^)'8+W5B%F
M8BD>'U-HE>DK^< T]I].GDHU7>DO$Q?GP7)=;WZ5?7W_FVL5X6'^:^;,[%J;
MU-[T^3N3;DV#'/N;7<YBH6]9/]5;H"ZM-YWUA=YH(_4-3:+"\:FQ )<,)'U0
M7EC\+:?DPM/LTN#LU\,TV\GE&2"E\3R^V6W278'@?A[9E:.KNW+NB]7C0N>.
MQZ5/3GB7HRIL6'FJG/LK,\6OV%O%@XQ5]YC,E%*52MY<H<R^NA"#GX#NZ]<
MJ38/MP0B">OW]_.CDVB]&CR8/>D#MUVW5/."/9H:4A;GY(3:PEP7$F?+A6"4
M\!$='\HPVNX+EQV:M9/9RMGX446R'@KAH5N '$1BV&E9EVHQ58;G\]?R]LBF
MNAUM+XT>&H^,[+R$XN>UE$F&T?&N=4S,J]K^]BQC*\>2Q7.$/6->CMO;QL7*
MED<.5I_6DJ-6I"^  _-%VXR8R^5GTU8TT3W5I-.Q@I:9#W E%67[WF?.3J2:
M+" 2_&0E>K(JQDN^'L:_JB<5(=&XW(2V^XS'A:%YV"F90*^VH!:R;N>?_!1S
MZH+5,@NSS>;P;?SR(=ZJQ:MTUB"5L0D_LOSGF1<.6E<GSZ)S!<^[>18% [,#
M6^IS44D=;G9T'T'CVF4C<-TBY^QY+ #>A 5LLB;.!U<V\:,?%9G8SM\/7=\:
M4,?-!GG,M+/-%WC=7)_P8W-+%M4G'G;F"K#XF/Q"=E/C^9ODI95;"(E[<K1K
MJ_ZVT/>\*^-H@@)SOB/2>>\<CGP8&=V+BR!?<C^-O)E-BHH^I^(=?9KH#@(G
M_.GOW[?B 5OH0;?I-\G%!E[RI7=1$FE,HE!!ROM5KE&9]3!05^,Z9+KD M-6
MU'65_8B1ZEVW;.M/8.#IF7#;\IR:>^R-V;G-JI1%'@K%J/N'N*%G%Y=OTEH[
M]28_NQBBS.9[QLZZ8WG*R9+J8_:&#Z0#5ZA+!W&LD:+OES CS8V&EG%57*2[
M'C,?<:2OKFQ+6QN6O/S$:J=-7@QX(79CIL2J.)44 Z2]66%HR2X4-[D!_Q&+
M2?""D/1[Q]=HZ=&5QO'>++AG7+/H<SS^'WJL[4!OWY-2;M9U3U1R2?M1_TAN
M96)4 T?^VBIQ4)44#LQ@:VHOR_3;J/EWKTLF*ZD-8/+3J;*WNR0]:N^LK(S*
M@&<]) 7<<?1'<ZCB7E$:CKE!ASR#+X+AQG8JL\[0PJN[3V%;@EX\MVNB*?8W
M^F-DJV8TV./H->#H(_6D-3^6E9FF <1 _O9;D5E+CBC^CBLPOV*4^R6WJWKL
ML]$\U9V!0LIP]44(L8O&VL4(\93G;-M*M-QP4/SIM<MQ9,1VES;1GL$Y3K,L
M&%QSO D[H5<_J:%^I4?*G*LE(X;CC[]NR\M@7!K6M5D:2?3$(E8:IX\<;K-P
M2%A];>2P_[Z-3K^2 YZ4AQ]8P]FB*.OLS9YD[)UZGXDN"7!#<&>J,7490U/N
M0'&)!SR&;QV33VOYQDA24P(/A0VOU:X*"^ W.HD#_=VB.M';QUF0I__LG1%_
M2W\(T=D5PHS;'\:2J,7%'L_$7A%-M$70=J$$3LP+)Z[G$X5_]EG:OR63NMBV
M57P[+,#\% NXH'<7'O"ZQ,AZM)U@ 4Y8P->)X:4W**<5Q8EMNW\/S^G56&T"
MMWFP@)UME2IH8;_?G_>LG #_M*_%K-<<S;;MJH^*O&"M\%RZ>K6@6W[8.NFH
M'#5 Y8X7)!B\@ ^90"K&U!Q0]3DP5#F31=C_&"W1Q*-^>$.C#/<<+B[O(28_
MD%+ZO"&CA'P29;<L&B'%DM<*S9EM3QIF3[8O#WL4#EB\>"<&TX*PW!XT4EE,
M,Z8L._$=5#1.,TB2AUP8-I_&XZPMJS>%2M!=V\>5D2L:,8SO7V%&:EVR:><G
M58&N,Z 0[RNR7!52965[87'NE)9<KP'3T69EYV5"R<'&D %!$\&'["(K\=0^
MEC(9DOK:16@GI$=^_L ;J$7%D4ZQFATM 4#ZG6$,2?VJ?KJFBH[-][DOVO';
M[A?YW0L/=LP8_(DQR]/&E-&6%J?O@'?D\#U\$.(EL<1>V0:(S"PG-[LJO!B1
M;U%-\7*;_3Z7#%D5FWF%'6QDU18_#ES']V6D4*UV'C%B0O5T401:%%RMBX+W
M+_1Q*!H*^I:I3M8;;&H>;U#>L&EU&9(@E98NEH&\R%8'WL$7E_XU@8(N4X8W
MFUN0)U4(-W^4?YR"]P)/,I"I+(^@"$.!K&U:_+6:H-2H"]$BJCV$H69C5CUD
M5FXU;+-?BKD<SLBN>S9LZ6,!]%(6OF\1SX0N62V"A>Y5.!_/=I/ .(=H;#*7
M8 PV-!Y@OGZ3 ][T_6&3C?3QQUED7TE"#.C29H_]>5? 46X[\G6))66G@7C)
MFO2H,PZ%@+Q**6VD9/<\3[4=Y\[G+Q7VE+4U3R H#)(Y7G!($+*R6:C#GO\C
M"R;C;0277CCUP )B0??!O[6+HFA> I6QK('OISAI;\\2M#Q@Q55[IF1HR<H?
MGW-/04-LB/.'G_"* [B3P"659?8=]P"G:BMY HL+OEF&FO5.ZOS796DS4VV=
MQ-?-GSB:BO#P'K<O.H_H ?5:;-3U;+" =MYI(P+NP04*/R4D,.J+L8."U]=*
M(MK=VF^:5#$AE<I.7\5@9M/KOISUCJ5OO!P?O4,.4'<Q$7^@@4"VHYC(!\B_
M)B0X[AZ3H^ KB>%L,WO*N+2#6?LR&&CN.^UA[LD?=0]DSO,\XA5 W=VKT!\3
M;EHA8D^7]&@3?$,,Q@_RQX4Y39],%-37)+X)+_]&E,_$U,98/*HW^5VBC12M
M@ 1&5G>/UWCOY=0JZ[UD#'PTBX.;?IFZP<6[?]R$<BKA8:YM#*E3Y+(FRD>?
M'NAN%EX#ZD\*=G&8R\QP0&[T(&0K!HB3WZV45#[I[]LF#[SB_(A4C!8^H-*@
M2^W92*%[]KETQ31.P?_)F<P&:_GC@F@:9T_(A*.+CXAA^03/<3&*=Y>'N:[I
M_>\B;FJ@/)A:? 3\O)$^T^&I=[E7"6/%VCLB3MKM Q+7R;0S'FLLZ]]DK>6U
MHQG*7KZK9:JJV^B;UN#%,PO EW\A!O"YDRU/;L-<$N&X/AS:K%GDI:B5\&*,
M.8*'.;RSUZ K.B=X?/LF;T2S;A&J[07DTB">G0W"RT*DN4OKHJ%1*!PISZ-T
MY&JL>21IL%L-A,BP(^:C;R7DS1KEYM#6<LZ$.BI;)F1ZLS;8^5Y&FNIQJS!F
M;;/W=,8WF"[5$4L+3A=K*FM#''+K9],DADG1BDBV2+>*?-NC&65[%D/9&$#8
MNR'QX098VI+B>PND</5T37[X@5N+7K\KM?$+@0)9#M=-;ZJM'F\'LS'W#(TG
MK92-NL=3G@\=%AY8,HW$?/"EB1B[FHF6QJ>^A,?M3">%(*UUX4/!OOZN,E&.
MLG;EKR#BC^ZFU_X092JZ@!LC!W3J*E'>+)&-$0?Y,6+9^T_*WSST 4A<QAH=
M,B'3^D)$L "[KG%J"N>-<_U'13LT20T^3L+&6P<\M_M2!*UQ1X@#?>^LQ] X
M.G_:C=]]NRW/9OE+AL8K4A:AT46[]\1?X?N)X;1J;$5$\N K&8-Q1]<AP6-[
M.,1T;ACL+;TV$:J:%D%C:/)[@?4[**7 >9!\4CW^0RY/R9!VHQ+GEQID7HWU
M$F<LT5,N7-5Z+JNG]W@\Z:!IVYS0K.I/.G7/\J8Z9H%/4S?1FBL9GKWWC7I*
M5/$B;7^,>K_XT/$0-]V?,STKC&S:P?:]2&(0Y''>0UA59QNIE/(B2F8@WU21
M.TF5T/C3/$3#M#FHM1Z?_/NH]F,%VS%]&@=['X5<9%\O34BV<;>]O2H1M4.6
M)'+7,!QHHI_>U!PO%2\I%=.3\G.U0BI>>=NF^G_WHHS8D  V5%JG2-!0_S)G
M),O0@%T.3\7&9<X]V=,ACKX(&6Y467<MB870Z:E'/,\ORZHG>7*S%,SI0+DH
M^%UYC8K\P<&! M?^J?K/5'VVQZ; %?/(XTB\*L^J-H-VG?A]$0&<34,#ZVWO
M,LFL(K<E81O.H 1CVM;'R(":%<+5QBF>#YD&C%26IA7=)*;%V_[J:A::\CJO
MLDH^S/B49T'8P_^-4_#"=;$.'3X%/?D!WG0RBS-S^J,_F5&&-O2I:@3>N38I
M*A__1P2%[*5TCOT_(#]:"*@9,ZY=RFZ(V'=VFD+'7 5!C:Q 3M5\@V'1#.[$
MYG@LP']9:R&3PYF&@.@]F?ABK;C0]F.<K,?=H;(0NI.7XJ!H$CH72Q_.EZN.
MU#T2$, 37'8]0!"?W('NXOANJ6GF_- \FR.A(FDAZ&.QT M<+:$(CUY(Y&;V
MC2_UX[NP6>'!C.8?$M2,>J""WX^9(&*6][LAX1(<43@HK7/-\\PW/0M1CGV@
MC.M/V_7& YCEWQ'+6J0Z X)N?Y,NC!\D(VBU(17"')7CGN2$+A.&<..-]F<7
M*A"!5  N"G&P"7G=8\WW2N7=!9J6LF%%(51"%T&< X8Y_#VN1#$216)LAU]N
M7K+4H2][L "_.W&6S]3"(<6;MVY*?(TYG#)\KCG;>4A< ", A@ $Z"5ZI[6Y
M*#R02CZ-SXK ?!QNT4RF%5E%%X_;\S5EB0Y?"7AG&CEA3D>A0Y\4@IX^E"?V
MXL)G0_Y^ED25']4G9,/(4+1]&_2^H'27:_>[R-1'60UM,@O7<UW(8YPR&J4F
M*WGW8XLX=0!.(-^U44@3E_,R?/3%@WBR5QGR9#AK8%I>Q^,#$N[!Z(G3.IP5
M32Y2LI>$=%$Q=AU8P!(WDO>*R*@-<^L[1G@?Q !:U06>C%W_!1^:W%U\E<&M
MKYU4[-?;AV9I9;DVSR*OY^;V7Z#>6)2JGRH6\)3B-XU0)3C:<M0T/6[WM8<]
MN--XV?R"J@:,OIN ?HL%?*CK;COFM\4"4+1LJ"EI,A?%<M,T("()E8P)Y3;'
M G"M?M,E_ %%K#Q=W"[EF_^X2$5FWYN_*K   J<(\.:K22P (:*!S,:0+I!B
M 2,]Q5C HCUTQ>!8\SM#QU_ _@+V%["_@/UC@<60D.Z<?M-:,)E8>J)*'K,W
M874BAE_Z^G?)^(+[_\,J^Q>POX#]!>Q_$K!R*<-_+]!6J=EX6:!=-+S&Z?=/
MNWON.=GQTD&[VXKA:"5%=)1$'>:6,D:8+),%R8$%_.CZ5_"&'I3]48_J0>R+
MH'SX=(UUS;=OY'05&A9SB<8]9BS HW_#/PY:XOH[H&:^+CE(G3E^G6R&SB;A
M/U:B:?'*TV"B6=7!"5R\,-=1+YKL['+(\Y2'F*#7#@)+:S<_%)D) %Z03E'5
M][S(S" N>0 V""L\.?GWF.'4_SX.9T:=K_T)!<<"F-LTL0!8.7ASLBR9\_]E
M@U\9\B:9IFGOHW]RR!1_''JS;57A=RS;\KK1?(XA1^"@A4,F(S"<_[I16WSD
M_?; RP.3&2.H%YKRY'%R_]4R=-WI%<:5*WT'?OD5W L<KDZW6GS',>D*O*<N
M1>\!GHF]+I1L:MFQ?S6Y57RD)/<VG%3%(]22Z/F2@( H0]]T;0GOGKND4%-5
MRIOW%P)8 *^ECA_(P@X_U+YT#.\PIT[/G4ER@"C>WT7-508W(DT9[O JHW3"
MI%&1$0L8X.&OMQZ/[<^($_6<.'@+$_+R?=&'CJ6$HC90$U.I],>BY2H8_L8,
M+7E+0OON8)#;T7QBF.?/T*-.>.H99+UARJ,V@71YFNP3>DXB9NX[FI/79-RA
MF67Y+L/&T[NXLP-K _8E*HVKQ&$[IGM7S75)#V8ZW$['&A,-/[[^> $YNDQC
M1S,MJW*KZGRT'1G":,T.0 4>;-]2V@>;?1IO$- 31K]VE3XMS44YSEN'.!G[
M=WWM..QS&L$\R9Z4PL]3?9LMRV]HRU?.^3BQJL_TY_=!:U32E.]"!(5>A09+
M0^;/1XEB+Z$B>_D34;&]N4BVX%TA:1HU8T6;4EYNOLONG -JP(;TUNF#J?V>
M ZJY[?M;$F8Q"3B^!1)=0A7I'C@5N\KHHKM.[1>.T"^JGKDY'\U_Y:<F%&?\
MT$^ PG/U)@^,L !-A%GV8X(-L3?'1"IOFJ3=IT DVUQ] &/E833>V'17I2<3
M8CUGNBULMPS*8!6'1F$0BYBL&LX4Q T!+Y$!3Y=5?]'4K4+I@9B./QT,Q%F%
M_L$7/-;HBSTG5[QRB_Q].N^HQM> 9,EO2&7AWK7&35O]?Z$&^Y^2'N\HJTB,
MO;A!,S;NKNT0SB,PPA#6"#XI%AJC2>&,IM<YW6'$?T)M8,6W*?_:Q/B>!KFY
M^L1\3RT?KZ/&C\S,Y;I,,9C%@R<=*XX?]&Q^%M/-?+W5",0!?YMQ0($W50WA
M%#^'R8L7W6:69YR.T*J&RW.(HV/1#G#STXF+[4HWDC\SSY41P0O3D(1=^@'<
M"/>I6$NA>[//D97-JR&T)OQ#.-+%O6U+T.;K(5#.%(BY2,8"PLNRWY9NO;+5
MBN52_D168SUDCAB>_\T2 [ON_O[7DT7W]<M$5\NQ%W<VL8"SB3:TO#^MO,W)
M]ES/;I;?VI^? ?^<6W^T6O/ZY:Y?S\X',-27/<!C\M\D.(5@% 3T?R+)WIEL
M"JN,.$I&"YY!0)N<OSEPM+  )!FX"^25C0EJ!%V=\&(!]\T51A7AQ9XDKQ]L
M\**L#\C (_J_*7!RL8#EZ])# Y"*5S?=P)?;YAC&UNBLV#*]?89^MO]<U8!F
MI;/2GS32_RRG[#^AOQ"!R+08U_L^AHK_"9SBG\"3'SN0^?O4O3O5E''Y$[C8
M/X'GW)Q^?''BN/27:/\2[5^B_4NT?R=:9W-B(4DHT>9@UMP 61T%I.B 0))8
M590:<,S89/2'BXL&V,65ZR;J-X,@CPO_RV?^]8"1QP.EEEV>%'HJT9*5Y,0S
MBD0$ZW6/OZB9&A3GR;'4)EKC?2%@#+D?*$Y]!P?FV\5 WU!9.<7M+O91T5?R
M(^GS-2K+@BU34[)]"G%GQ%G72\M=+?#"V;6'DC33WG@S=U:4;UIB@##BWOG0
MN_953U@,A*>GOXE.;3X"MMG*TC@E)+;<%'J04KKFG\. &FYCVK:I?'N!!4"$
M)96%![SLW2[UC_#NMY[&M7R#+4-XZ K6_;2_F)G/_K)M?!Z>FIC@]QYE2';*
MACX13BDP0I5UG^[DS?V2RS.LPG5^_$F2CVX1QW20S(3.T37S$:+1U@>/0N3Y
MH\QA.Z.&71U+_&W)*>%=!D%X26B"I[6=->%''IXD6<^"8\ U?#'8(82'6)3S
MYZ^>_)]RUH#N%U_D+^Y4R)/]'P?AI!)6^M"0;$RC_+61GGH^W1J!0F(!C 77
M9GP<>/--JT>9'0Z:-^6[\?+UVTW/H[$ /-0[5%DO34#,3#=I@V_HTZ"*QP,O
M3Z7#&LCWKA4-1TKX*L/UE.#DD?>:Z$>K^IN>*VO?9L;%2J"_SF1G;A4NLVNG
M4!G):IPI4 ]O5(/;[8H1H!@L8(D)>0"IKA)!<:_J5=(W5U_-Q)V\)$'?:?ZA
M9IM^\*N%T6T<L@8O/,+14V!G3'1G,=1X)0%)'>H]T&Q4-:8UW(<!]WOP7O_$
MW&@\B*0A.<7OEI:[+S(SOWS(P/>;'6 T6#_?#XA0@.;1 DF[2KW//#V TDF4
M9[ZU"2,;49ZPQL_AO?&%L]^UFTN\\EJ6_"V[;HVZIVE4?O>DCA<;"'WY964=
M-]\L,=;\A9\\"ISGU:=9T= *;ZLRFZ>(UK[M&>0*_0Q!8 $W_&1:D$-E[DYW
MVVLKJNTUW/2=5S^2*WJ(L8V0=.;%< CF#_*DQ>A,>R@"Y7VK_&@18I.WKB5*
MH#LR";$R3EE>& >Y.OHCM\R<5@X YEXD6J'L^<;%G!_56OIA8TK;)9)\WV1"
M89FLZ0L<L\GJRB:K;\OD4;Z(S+/>I(5ISV1NBYQ]CICB1N5O8I*N[0!DPL(7
M6*_3^P"&B1)'DK!F5:ZZ%Q5/K.+%L_6!G3, #K#FEHI7T8MD3DN=G,EA8933
M4C$)!:I7FDW+)NG7E_@G%N^B$WO%.TY@P<M]@4+F>,9;O#G?W?8\#KF@;S_)
MW AAHL*E5W/%T")TA_*1M[TTM%)-9=:>%W/VBI(_SJW?^J@@?BP,7C8/?(5@
MGK9WWDZF7+ S)!!\:)KF<;QZ,G>ATV#6J&(J0E^*_[53TRQ_42-8GX%Y;&7*
MO;AO_/A<WX^_-WLP#M2JO*1SNI@ A\RVH:ASMFD$S;PTNKD]'PX-2SR+9U?:
M;AJYFW]4E,3QZ77_ST1V8=?NQZ5J;%W3>37+>",E>\:7<CEOIT7/_;+:O"IV
M;Q';_5Q$42[-$'IIFR*YOGORX@YX+>G)0*A(;8OT\S64^172<RN6R/2S_9ZB
M-#P7FS2+#.>$3Q/KN:)V(AZRO6^B(V>+0G[?T@M@0+/5(MM"%W23]3-'DY86
M#U="#/R^T*U"?60J-!*FS65/75IB^;):\OH681&OWUD@12-"JH_Z!ZR=Z"IZ
M]]^7Y^P/&<2TOW3[7F(>WG;[#2+T\T5OHCOW:08#WA9'K  =@I8IU.1D\7[J
MY^5"%9/"Z+%$F/=D:)I_T1PW+,-:>J[++>;V0!T\)G@>9H>AF6SF=75R*#$F
M](U8>I#CVW6O@2G=31P?<M;VH15_'"VC;50[U0IW]L_O6S>V +LWV7F(+R('
MU9!L2_LIRRU&TBIGW<!?AQTV:R5B&I]O#$(_QYH$D$?V]DT?'O/^\JW;]AN5
M9TPOD*EQ4JV/&=>O:/Q4#B'\O.:?S69;SX;;=J,I!3*[+_4( >Z689MQ]HC.
MV5JU4G,&'@"O?J) $7TK+_P44"ZM #7A9%V[@]KJR"-9IE_E[!CDD&= XM8%
M22^UE"&24&W4;8"DRB8^A2A^UI7KO>4;*MP0:MR)*TZV4P@6H+W4=K'EC(YO
M1NF5[JU0;T*?>MYV$8FA7!KN2D1>;,O7*%9<WH_R*R<0/;B[SQ_=5NIICABJ
M (^,\V( L1B>O*N,9=SG\/6. 9-G*<-9"5A E=Z;ED7><*.S2.'B/8EU7V/\
M9G!51-DT]_=QCFPQAI0>CL3\O5QR&9T@?I/"Z762;F (P:(Y25<13^59Z^O^
MCK6:\EAJ(M>,OLNV4M=, H1"[DJTX1Y7BD7=AUL-C<Z)X0S!]#\7%WVUI0RS
M4<5=9^R6RPK-''U^"JJA2>S\<^I*WX8GWK2<+<*2*5(0TV,[;TD7I)(%1 N^
MZV(!?3IZB9PJB0R.=G43*AS:TWVBHKO(?%J]>ZB@8Q.'I4PR=N@[/F<4/!H%
M[9)(_E#3X%:JSL>BV2K^8%\E+)O]> 7!1#Z.>MHKD=-&N2<L7L;JM$=XA/>]
M.9&_B5RW[SGO0&RN#]O>S3Q%WM#JP1=L!Z4P='P[&+=P!U50&*)2O5V@XUFO
MPO_)6.G\$,+9C') G)( 1?*J;+4-:4&\#"869_MS<+8HARN[2M<HID'N*$M*
M-JMW;OIUQNC;XWO"[+TURTSD<>^2WJLH<LT2Q1L_=%$"X.[TJ83UF..P5M?&
M@(GF!SPN)QGF=PO$V&B# ;=NN2A(X!Z7Z E$>C0$]"M&CIJ=Y/OA(X[+:UKZ
MPO>M)YB K12#5#I.9TILU"?":ZV2"/F-]S4U%?6?38R'0E7M IL\"\0>QOP0
M&Y[0U>X>+^0Q:)'G<($TB?MPC@;0^W$T($ON%IJ9M"1]@FG2DU&S6< =O0!N
MPU+(GW#M0K][HSSTI<W2RPI)& +*/9%Q5=K*/%E'LALEMY2&\9 ][*\*%4Q*
MH[43]*44(,?#X= [>WZ$7^0*Y8N'/9GK. '12[I4CR+$\:>;AVKRM829!NDC
M/IF8?M8TRJ0?X6W6A,W8T+@4UJ=#4S"[MN)<\^W@$%^Z!=QF[IPM9&O5<L3>
M.OC3\T-YHM=7@)=@K@F=LCN.8SXQ?"Z3#/?E?1TS+F7..Q?G=_:+6$#6\?/D
MKY.X;E"M(KP?QJ2_\X9Y=K81"1W<1R5W2S"GSO4T7ZAU1-_IS!]ZGC@'#XX;
MG]4IT65-T["X9&>PD7<+D$04(O0AK&,R(V?WN92%7"5">$K$%WWN*2Z9Q7[U
MNQFI,\(E3-CBN#[M^YG4.N2EUH-W0P(:+3I(LB5RUN-7.JMSL>19U>YJ-"O/
MD2Q3$4%G]TS3=%=HAW;9T2XD*V81*[$??,!!:$Z1,M869ZF.>+&O?!P1]+'/
M-]Y'03N+=+]2)/CNWKD[^VLDX#[*21OE:5<VS/J%EZ5<E(OTW8. ,2]:'V>S
MAV$N[-)*@_[Z2\!SQB30Z6VG*P \PD\$9>&Z4FQSP-80WZ?^ 4\YB:_74#*0
MY*4$U(3$:/6KV>Q^]JB@8>>ITF(!#-HGPS FQ0VC9U.;?#-A_0&<*]E;%%=G
M1255?K#5OI/N2CY#S<YC]7(R(PC"^51N7-\029&2*Y7'TM(0@\L8]8G(^:/D
MN&/_KK+)<%:+JS9*+AOEJNG=++?L:IW%41#S1OZ!!ON0KNP0@&H#[VA/O0&E
M^-4N$PC51HB&FVO%$^T'O<KWQI5T 7#\W(H;WC'PM\T\&Q]_JO&:Z=O;;)DO
ML2\459Y#-@4I(,\A-?FFA/3J0\B/WVJ/<GIP>O=*B$%T+]H/_*@1GB;(9^;V
M;6_&N*A=Z>)[&@W]^3Y$D;C&VJXV&WZ))?+*PP+D*5E7C23*TK7?[!8XIHCM
M0$YX\?V4X7YV2$N5T+4>6&J6A^IC@IENM: -U/"FY)VE $[P]Q?PMIT2\ 4[
M9_RG[<;9JCU?O\&<[ $W381UT F(=GO/\J7>XZP79Y0"-[18I&5*O-M/I4,\
M77_SX-CXN0V4 >TGR,[M<WK)0%]7<#.[I\+:BV>\JX'W-LMGF6FJNP?NL^$5
MJGT-<ZUIO+#R@2=J+!Z0SFQ;JZ8]F: Y8O'@(NH8+GC)I]CJK-RO7?CXR"6'
M@(5LS]6XSYQ$&'1C]HDCJVH389 >83W<46G#CF1);*,0'_I4'4'9-8 %T)NJ
MCP[5^KA7W/#--YW-]"C8=_Z^"[IO%HSDCPE!.#U![)>ZQ.^ &LY%;[V^3;P"
ME>5K.%!K^(BR/+6MO>39S)_HC* C(GWM8HP%T-$&)'(TSPD[S-1@ 9J'/*^B
MP+>;.4MJ>J!A4@[T4_FWF;O71;5C7]2+G5'W>*L7Y\Z_32T=2BEX\JJIUB6>
MS?PK?CT3'O"I]K46)SQ#BB07/F5+FCKCKUVZ&FOGNR!GUL_!C$BXZ6$XQDYN
M3W#.35<JOS^#B.(?V@>0YYAL3;Y(:+2JSJ7-\:8GTS15^"\'P?]_2#=BJC]E
ME[( 'N4(Y7V<J(@6?M/W(EDCV<5OM&XAZABT:%N1E]HOSP33"\+,JCG.?#JA
MG[B@:5L2DVHC-TKW!%Z0PDEL?(6C,/;<PPK:HV%?86>=HDEG%X,E(^E\[B34
MV_DNF,R3P?#D_3?-,26,5VAIS1/YOU_D*,7_UT4.95,UH[^CG_AG)J(_7)AD
M*.&)#CUQ.KOV@$?LC-)^W_#\#T5)POQGGRLK0 K\K0BTDV-^05V643S=#B9<
M=]%#!052A^MH#?7=R6Z0ODG^RX]K].M4P$,#_]P58V.NN7ZKESB_HK,SV_C-
MO\%-5K]2LHT,<>SWC1KAA_&XD81Y7#! F=\M]+W145GAJ"IGKN@S_YQ@ @R2
M(=EIO8=\G5EQ5?5:R-E1.=M@EOI^Z.WALJ<GY,!>*(/9EO:6C^/[(N'F'S2^
M$0[I#^KVBS9VZC$WFG/0\LBO^!@.AZ>82^"2V6L:X7Q\9GBS6[^S^O#7'2P
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MNPC,SM/D;@K1-+?UNB.6AJCJ#ZRX= P-@"G*=CIHF(!UV<S:\-5AXC#ZZ6@
M TJP4\#F=-K_T\5.Y\/ #;>O%<&<B\@8#74-.5.2=HUSMG@LX.<3\]7$]*PD
M^AI?$:&K'09:Y*T+?^V^Z>.SYZ9)^TK:GH@L^B+\/$!9SG&8@]W2W8H)@D28
MF]_SP>_V?4$:;3[+-0<?)#2BFO5]B[;,'BF]BE]+?E&GU-7L$AP&V%ACCOG@
M.6CKIX8,2%PBN:F\5"KP=A ]U3E$Q63_F7&FNLK'KYGH4&/%2#?=MN!)Y@Z"
ME;UW+QVXB\C&D.X]7[2^%'.-O7A;O3!]DPRUHL$B!_HU, $>5RS! H+F'XXW
M2Z\H*V1+&'?YVCJ,V=#>@5'QX9WBXUG#R;<7[C53+X$I&G<HIW_5I$[]^D@%
M8YK>%NAZ5#6;F5F3J^PKI2]46Y[<<I<DY7&.=B+>"6-2RX//^S(D6,!WG='6
M!/!F/NSH[QW0>N '%V9S,B'/Q,E[!)4_9''/U&;AKI=/3#J<2<+\(E:2[9.I
M?RY5=/KHW]0XJ_<!IS2#/PR9+Y5USP!QMNI.ZXS<>\;GU%GN/B@ W,3%!ZFD
MZ:.6EE5C[T=>"<C7CJU85/8J3=:5T=;5"B8,/^U118#U$%EJGMFHU %U&[:/
MRC:NWG?XAO@LN;IB F/ZV) '9:WX7KZ:2/;)L4,#MW,ZE=-[6>'#E>671<XC
MQ!MX6H4<]XJN<A09K,G?V*.URVOA,A3;E*0/2? (O7'YUJC?@5\HH6W-0^*Y
MASLSR!3:XQQ'H6^(VF.'ZA>BYD'C"L%L(=5IG_=Y'.^4CC]I+^$/(IZ-$24%
M]%FD3UEWD-#_LBD?7,K06^*>7!/XI<IDH>S40LWV=9@)SC;=T!(U3W.Z X[S
M&\CL2T&)L(&!FYH<\2O:X?>DH= ULPWDJ7MLN]X(M$48_=)ULT3CL#02&"I#
M.^IG 8I,LB';]XYGIW_&U^2_ 4SI5;\5\/F0),I,O ;YIL[),K>?9;SZZN=G
M_U^YC@3FNH"7#.C3T@E,A9D 9/2!HU)3IH/9PJ4D&(:D'%O  JS+[I797D%Y
M'M8E=+-Z+T<R+M#.\@1@ <_AZH(H4DQCBA9JM-_/L2%I8_GUL4#%V[W2):5/
MZ2$W<>E\7'I;=I2:ZX%W''C]ID0YL[F"GGC/,GX#F<"'VZAR8YPB+JKC)+Z%
MBO'UNY#L)[6,J[14FW^@&*6MQX/^#'0XTA<_]'&'J2"O!D%Q)>8M3)T!)+-J
MP.XK^C&%NZ#4RO2CA_P5XB>KN"?DF\!J<PHS!GL7%NCOZV&/H!^&XOQ41C(5
M=>1M!(;^1<F^!HPDBYQ1!  /V2"F56H9,;1 C@N]&LI+$VG0C\]M<U5MHVW+
MV@C;:37IVFH)WC1:=B"X?PX*V[?; (7IZU.TW1<B6/0\LFI^YD)[<Q)EGWF.
M!R_P8T-E9/=\45R*O6_ZU/YTV[(NU35\+?Q8@2U0P7D8[U6-4 ;^4FQ(LZ&E
M;]XVIV^AR1!C90UDRY&"S34JL 6 =]CW_L!0OI''.=ZA<J'ES6<L8!H?\ZP4
MA.DDP *^2/MMF<MC1D"'+ ;@GW*@8_RR#,YL7#39:^-EZ813[R 1N/M 4$.2
MY-LXXQ%!4O#Q_7,]WC[C[[#61U=)IO-JI3EVI)E0$<-PABO0G0&4\0J5'^WR
MDK//CT;WV0#Y 1PH;WKQRL^34]:6R#[PW6,L('S8IG0KM?O%\XK;Z&--+FW%
M])@/+@+>PS[]+CH54D>_LE8.M"LI%TU/>A:Z<B&>UL;&#0_#ZZR6 M&$-$?^
M^*:8CJLO9:N>,S?G<Z73FQ<M9M;8-COLIIMQ<M]. T,5DK/,N8_UJB1,3-CQ
M_68IA\3V;^$_?]7Z"EDEX84%=)/0DKM/O'EM\3.,F09"H%.LZ6:9YJQT:AXE
M\\#!MZ?UOAN^PRP68/'Y_:@ \+J52?5-2[UJW&+#6VD0TP(YHN4_7INXB74;
M'*\9Z!Z0V$V;1TB)9]N>/3#V7F?YC.]^2]PCT9ZX+PD8[8=$XO>0N")?[1C4
M)+ALP?ESF]B_,9(*!F\:>VX8CGXH:K/FK83.ZZ3&M PKPIL9>$!O31EWV2Z$
MNY]@GA.+=HI@ 2#>HQ*-:5SS2X6*O,W[HM_MJ!L^DQS4W2$9E0,A.$[KW>DI
M=HUML];'P1^?NU1')BIVW8='+;D>E\6A=4M%P]'Z1;:[RL9IH6^/)A3$Y+
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MJ:R]EZ"0(W%./SDE68L@G(NQ4=.\)P"REP"93]6:LG<?YZP6L,UJ-UG6D+W
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MS^L^<,>R'7J,#T83)F,!$-@%)&"^[ C4+,[T<Q&\]-SK 2;P  MX[X(%('7
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M.IB<S\2FF3I[3%CB0\BQ@$ON*<Y#X(^=UEL>#/,7)+S<!MC>'=;@VJ>IP<Q
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M:$B-%MLV2].&<,+Q118F I8/\/7 YHK1BE&++\A^?"7: #QS[.'G8946))6
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M=/!'*%YBCE131@0'M;KK!^TY%QGQGS;PKHR^>JFUD&7  0$HZ'H^V3GKFSO
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MY!4PW'SX"<>D85@0$BGY+PY/K4=D8US8YE21YA?WU?K0S_1JJTV ;J,_CD_
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M6'&&M4T)M?0*+5XX)P;%ZUAMO?!DZ_-)E](6S*C^8'8,&K2B$6#  )/#DKA
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MA =W\RJQL, W]FTVLLU5+Z@CPQ1PR!DE[D45%BV*G_ W 1SBU0U;.S8/QQV
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MMAOEM+='[&^#>ST%06-"U574$+G)PR$/;G_FK:<A 6YZ?-MZLT\4%5WNNSQ
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M^='X^AAL=TX;5VZ[O0K=VQ"DM#H)+1Q!=+B0XZ_7:L/+J-D*Q%9G$EU&AM>
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M"'&%-N)!+@ZB;Q%\:P_1&/X'*IA1R*73"H*XCG>(NW7;+U;@F(BY\0W6/!*
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M%3-"SD&Z8U,]6C!50N.4'MI=V4YTFK&YELT$#/AY>:?#J-CR3MQ&>'@<MIL
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MZY;U:]40(0 &SU@_M'H:,9S0V:SX ZVL&3'N+@SW-KMA+I[F_D.4#> ?I)J
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MT8G.SS;^?VCC8M?=O)DEHC$]W;!GC9,=4(Y&[6;U>K)I,%9?--/U5?]?V9;
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M*!D1)"OO:<N)J5^R_ZHTX-3Y2;9 49^E4-@A_U@#Y"V4NQ1F6CQ!26@GA#]
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M>9_GNJ^[/#=J K4 N"4G+2L-P+@& &"@_P"H:8 DX,;UZSC7L6_@X.#@XM[
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M3%E$Q=U;H$<<9="$;#JMRA/1X:OI)<?\W3VU/_ _#'F7.CK#I:(&I9:"LM?
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M5C)D#@<K O[L+@K08 ^&"9 E4WKB$V.4K0@C=TO[$-'U2NC?%4EVYK%EW&J
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MBO_O!'MYJM'U[ P]3=V"#>Y7KTV .X5-2"<S"&GY5U>>IH2S6N'E,.-FP;Z
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MS/=9/>M6^+;_9WI'B=1N-:2EU9;[ 3!<@B!!?=@0=O/]/?D0,MZ9E- 2R<0
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M=S'F'$"MY#KF#WEM @V$^+GI8"4%"_%RSCNKL,6H5!#=9/T*<7?30GN.*3J
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MO\'P"4Q:OU$GLP%>..&*H<HY;,^7((=T(V'&R+[0IX1R'8<,$1MF5J'HM_<
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M7'H"-NPG/^T#D\P3F[?984T".;706W2#6^]WPXMZWKD]\8F1'-PYZ)&I1QI
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MB#IY=21BDL#[><L:MOU'X!Y[_N\)1>GCFCJJ-[: :^!3;LUB)3EVKU3N7[^
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M:SL?P9)&^N>/PT*\$@.OC(2M6%>L2<B7K/@?'7/\AY8RU>6? .:78XD5+2>
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M5_];8Z5&U#9O?-6'72-:#8B$F_^?BD#]_,]% I@B;5JK++#-'<K?8QH:OBG
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M]Z["6.5>D#"AF$*HRW3)BC.APU>P*D&)9O?ERK+"A;*U  TG-^_X#-AI*W?
MWXLD[MR19GM#SA:_S<= <"KLRV?_AEFGF9ZXPSVL24)1)X!75)"U]Y(4J;^.
MH7@$*O[RT:]C*$R@"Q2A/"5*7QJAF:KQ1*E0^(7.]?!?*M%W4_ &-3LPJ]QS
M&9SS5\<H6-&0$?&:</T%UZVKUC[L ^').8:PE.649!BBBBJ!ZVP1%TI9(/FF
M1UJX.\?!2SE:W;?_-@TI=BR.C@AU"1.:5O\V2/ALX#+*"(OG^($OC#+B",9.
M-Y;RWQY,.25^YWLOQSFC3<)#S*C[*04Q+!_+$/?45++V^?P(IFD>+:I'QK&@
MSN_7#=H:/P#E69+\'&U\:H0PR& 4E!U]"Z;;U=-*@G >,?P''TDN[T7R$IB_
MF>>%Y)>D(SWZ=:35.J>HS0.7"RJ(^<R?G7#X09)D#K[Z_M%TQK^':EN"_Q[*
M&7FH+A%O6&AE9&T)_)GC YE:@J6 'C9-XDB-_O>&982JNJ-RG[2(:M()=GF&
MIV)X=/MY?89G87"J\C&.!Y<1DF09D%9P1:]!?^- 1HH7#9?<IL<U$M3&]%(\
M*!E*OI9T)IBWS(<GEM %(MYT"%F_( BZ_".-RIGVV^[:03#)GA?C.X%-JCXR
M\S;F'L($ <GI8\KW)X"9YR< M!5HUMVCD&#Z%--Y65U]LD.X?_.#\9X<RU2$
M,CSHM<IAQ%DQ9#/\VL*=XO)OP16^EPQ,B>=P#JV#8: 9\Z+LB9!:6MR;6)'[
M=\V3Y%G\I^E!OBC7E(B\-JMSJ<OO1O,K$FH#B"PXF_K*5_W%"S;I0.R>Z X[
M_JT'!'>1;D!#SEE9,ZHJL4/I <E"_3TCZ\Z]H> $N'\YBY@AJ&#=ZZ>8IR\9
M,<MO>&S;MKZ@KCSNQ;TZ G_ O9N#!^^98*VFU*+M/5@4ISDD)TX 3WB^QES+
M4]4LW.&/5FS$BQUI%O1M=#4G>SK87#P!Q$2UTL#Y#>7SL*EU%2_-$-O>A^3G
M[>ZPP:=5W\#/VBRJ=*Q5R\_F\^5GE"=6M GXCQ Y<H9='B_SA4VT#<.HG09
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M9L7NHEZ%B\P&WPVF8WU"IR%_UO?GF;%$.4\=[O;4JK!(Q5,W[>7_8]")C"-
M/(@MX!4U+4*C-_#RQ;H+-1K8P, T3&WPED!S6_ ME\MP!'\[LN/=YA68J;$&
MMK8!O297,OQ2?6JT+/H16:ZM!^?R-)XF/Y==[?GV[BM5(Q8:TO7)-:$;@@IA
MJ0FLQF+]*.;]<>43@,5WSHP8PJLCLH 3P)MA3KFGZ/2;-P>L1B>.(A&+56?R
M3P#U<C,PGF<6DX_\%!Y)0AL/]9!9# 2;=-3GCX:OT'CFMLE3#_3#'XF\ /FA
MYACW4W-$'"B)N,$8]]A1)!R"AK1L46?MH@10!1)6LY^@1K,VU1RJ.:QA&,6&
M8\/43>0R+!CUGM?N:U%%_-"B$,+#L.6NL,X+1VF"S42=[O[']0,%=KW7E1](
MYS[RBFYWJP%"!Z_7F%4T]A2&C)G<2MAC@PT3%-;B#Q&5? %)]Z3HL:\>\&\4
M5#;>%)7@XER _R#Z#4MQQ!8'?$[YLMZ307HI;-=_BFW^MTK\9D&J^#?M9RJ/
M1 !:.3U2?#CDT?7ZZ=&?4KQ[]YOJ%DR 4*(H)0ZI7.'H'(FX[@:6,&@FLL%I
M<=E;&N>.$X#<H^J6PQE+;?@HPPU:<#E]9@YK FG'7EAYP.7*L3=JS=+&J*<F
ME:^+=/<.?CHZ$X4#CXRIQ=JEK)  9;Q=64FPB?3$&S&D\\!1_#;UFQK:;3M[
MJ+HKL$?(;N.Q&!=(G#KK%IQLS7C8F%>J3.+PQC^[EX8<=7]V,==0540SA"Q7
MT#N8KPKD&._:&>@\WIKVHV7 ]"/A#,L;<+Z&OE:.F#WF53NW/O\<:0?4M3$^
M*3%BF7ZJ;#XFGIJ!YU_+PQ1N[^WFBFWY\*NSU=*Z_N;67O\^A5IZ@0<N)%@'
M_JD9]9$V:7TNLLB*=/OUK_U%7RP[_1/W6[T$@'@?N!]"+L!\!TJ1;D/VM(0Q
M-.79 <?#5^)FKO2<'WXP\UR6<Y67Z#+\+ALWLB!%2^#ZKM(J(8OF<?,WN;-Q
M?Y[>W+Y[[ANS[Y)$DMA1'BTX4+\XNR->P= D)??MO[9U_0%!2_'61F,JGSMF
M*^I]M&=H7M%0PL_$;ZR1->-Y<(%U^J6QUS;C+2F"84:*9L"#/D1?E'*:P69P
M3!:264.Y70?Q[8YO'7D).^Q._5^M/]H=KNLB5X2<M=+_T?] /I7KHV1;* /5
MJ)$\Q;PCN?)AG';1^6<JU]^0>QU=KV/DP7G7Z:O%<F_$TY^)AC$'FP,/^AEG
M.MFMK7ASQ]X>Y)]VA<XQ_\4"J_^10K< OR;%:X!S[^X3X% ),XB.M"\89SD!
M;('*I*?[BC.4==@[:)25N=>7)3RQ0!6,*BJFR;Y$Z>;#,1Z770M0?6W6QD1$
MG(0T6E*KB3%G52RO0Y7?,36EN7928T2'LK(RY*C<?G,ITCM8KRI2<=2<LUSP
MBK<'5, 2Q1_IRD2Z$OE1#U,0VK_S>#*=)V-#*@.4-Z%7,,,:6-M@=Z>:'B7R
MN-;#]+V+U!"4]%9?Q?09Z!TVN6R/I/M4C#QD> 80#MG35QU'<S?,-$R'YHF.
M#CV ZLVE651(62698D,.EV7%C<39#='[ AVOWIZ?GXM<&HS0M)%'\'3;E;E9
MDX[_]A^ZC>FY5M_6Q 07/XL<3W8^H)&*8P+^V,'IC-W+L' A;Q[6[1N=[+(1
MVXAG8!2&R).?\S%)R=]!;X8+H)@GGH:4\BP/+3CU.\W6/E.?,V3V?A\KH1WN
M=NH^YM!L3A<MEE1,Z_Z<K)E[,"$K&=%^ F@#B>VO'LK.2J&.(["W5$Q&$"MA
MN>^&/>I/ '/CZK,0\'!P>. #@P.QY<I&DNY#_[&JEL.=.92?3T-V ]I \4=9
MU5V>]ZF;[>173@!GR7:TUB#20^!@EUL.USV\#A0K@97?(RQM7X>*Z@)ESN1A
M]F#1<KQ^:A+M+<VT.HGR]7/* _DN1\6C3G:L<G?Q#T5 _KJH9#5\PNE70-YW
M J"$JI\ *(!^)N%6PL8C:(I"SQ?DK=-!<ZM7W/9V@ U\UTA&7GB.TBU>-08,
M7SY@6#YSE(<3$MWM@HD:2W$@V79'/]=-DE27X<(_'E;^^4)2,39HZF#0+"<6
M-CAAK]_'.F_@96M\ @AN(]B,$^_A(H@T)X +W>]KQBNW=CT</0$1<;7G>]!R
MT![C\$M).^8ZP"<D7Z6JDT>E ?^@)ZCDZ ''3Y_]U6=QS6[AN2TCEY'U13:3
MQ+,>!AUEE5C)3FC'9V\9!<R[G6_X!+Z9P?"[J,*O\]JL73PL3>DK0V/RL389
MS[]V>%O&<+5\HU^:RNN5@ZZY#R;^Z8;OGQ.<7=/,NTKWH18W<J\>,OI1[LP1
M]6]?4CC>*:PJK&G"1OBM5YG.'A97UGZH(5P_$T7[+I7:OM']',E?XL D%<P^
M(/E+!KIJZK&/0UNX]G2W=E?%?8VG+E4DT+(LS^=<2.Q4_LO)P'LZ*@]USA6(
M -R_G/G/%?PVW!]TR5YWGYK& S'2Q/2;DI7%[09^-W?F-ZMG?IFZ:D]Z_*J=
MC"15_$,;79):\6R>_7OWPP^JB]-Z/5R$"VDH;=9;X%"I%&E^;E#Y99-:DUQT
MWJF_<52Y0/?<0Y';^ZCO:V3Z&(4 J.R=6.W>/(NXBG;:M,#5CK=PL5U+TXF;
M]P<[.>4WEW&K"'P-M5_2^;*/BO'GS *M>-F=#OEIC*6QE0V/+),XBJL*2\*G
MZC<GN-,4Z>CZWP*8J(20W97W3._H0H,9E*,0E1(U)$5=]/!?$SE[U&^E&$(,
ML(*3"QNY[C=NQ"P\9W_2VDT 2,]@OQ-UZ*RY'9UAY'2=ZYXP[G]Q0_=<2%I
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MW*"M&/V=(GKC2T9ARY+ZXJ?%AN_^<'L!AB]"BO9(\K@L>,/T>++[=L6/E=M
M5F!V*/R'0IY'$PR)5J6BON;A=J183F;6*2=+<W KNVSF"<@?Z@0W<_JZ>O.&
ML,:GS0?SEFFRH[YU*!LR@R0FE,OKH;#$]ET-.7=Z?Q@(,]P8V%A#51IO,>EI
M1XQP2DK_Z#B-F#EVACP$)T.!V)O[H)"A>G!3:=HY3D[?VT>!.R1\\R/G,YUZ
M4B+^U-U-)2UT^\K__]Q='O)F_6V<37TL/NE)-.OX1<EY^YMK;3T_&9W4U%JI
M*7$E:+Z-'@85N^N+PVH7)D5G:GR<#[$G@#-T=7U%_.7F)ITM;%&1JNS>W][Z
M:6MT3_XB*J-Q5^C;%*PVZ7E:;-0_J5S 6:JNM2Z&3(=%I:ZXX3G"+-+'+DO;
M7&M,RB#+.I!4'ZI2F0$&2!RM]5R;X&RSOU)="J]1Z)Y^^QXT(U^]664+,[;:
MY@W4H1\]C:/\\33A_[.\W6X??E;J;3-N:?\"7DW;RJP^P,+MQ46&0,YR^MJS
M/Y;RI3<=$P]^YJ/\ QP"A6",,OSVCA3Z-J!ACU>I/\CRVWU0HS<+EKR45-T%
MD]23XL.DQX9"0;RQWA_9M@+,&"S3F.E]OH3/Q*\E(Q(X$CY;=KOTZ[/.Q?,X
M-Q*O#Q+8LP23LFQ;'T/+/YJ+*F27D7#"$+/WA\C("I&QTEFY?[528R0PFH5]
M@:G=7]IWWNCV:7NWM-XR/3K,,ND]1YLNTH)V8U1==Q+0+(PVR;WXPE%Z0TG[
M-NH9CG7V4TGM=:,IX[$6IY=6]CJ1VI=#MWZ<8Z&^%;%@" F08,_UJ-0PD.0=
M3'CE6?2MT8E:UV%E8)]N#^PGP6,VLT7=D/[<#./>]8C^<:M7 >$-V;>SWPM*
M!F[/).4.?>3=^MGZ?V^2;FG(3,1EG)<T;VRJ?MWCW8]9GN2]G]E\7&OE/*GR
MY'/GB3LYT;R^<K2ZIO_ELZO#POUM?^&PG(FO:CAS,HY[Y/+ N'/NYX;V:.<X
M;[IPH%*EA+$@OY*(BZL/+++U"R\CN5T9PC56\X[%PM'?UC;&.WB,9$8W4';)
MY;Z_-V8^\\B7AY-0R?>/K?AS+R,L-]FE#WG.&*=+-!E,ZQ\R;;Y;AJ9D/W^;
MR1[\@ZS:K1:3#=63X#LN/TXX<D86OC@\>G2P[]I29HQK@@%3<*P-4BSO5=*7
MA[X]K6;G-I;>-6\#)CH,#'0:'3<=A N((ZD>_\MY04S6C"]B>H)>/5Z-%\S=
M$7XN\_']\7-']:7G#Z%LF =5*;_]9+TOKN3$$]'V"3%H+K"1;;)/7;YC\?<<
M8LGZ>I[+T:O2PM* L7-'!3*^M#  .B.?29Y;IWB4L3X^Z)1'XU]*N^BP+02.
M).X30/+GYR3]> C'91^QU#"AU'D1T&&C6JVDRI*P'IRJA,X)0%:HZ 3@NWT"
MP&JG-M?PG /BE$J20"OX4X[53)3*:$N!_^@^Q%^P& OT=YE\?K&K\TX:65$X
MD\_EBWD(;,0;QA- 8H:UV#E43)F3\T70A#T][ S@5">/KOU J8\..(F_Y+7\
M2M=( &.9:FYAV >&BJJ$8Y^6_A03&M*<B+PX?S6Y?-W)J 2*Q6X9'UD$W]]5
M'#]P>^09>?D$T*%0US*3#-]*U?'/V.!.XXXL5@>=4F,W07;Y;4 X(-\)@$[A
M/[YH0TKUIN*^R&9W;4/-0ZP D:,O);;1J^I#]3SW\D'?U1_?S]%4?H#H@YNE
MZ$\ 'XKD3P"H9=#N(X@%./I3TSWYUN4OFZ<-.TNW/AA.R%G9"'9NL@;0/E9<
M2LEDX-Q&10G6!OFP#>QUC(_#G+6+WUK%I;R]54YC^I20#1!90>RCPHCLQ%:,
M1]]LU$W]SX<6Y!^N;2]A#\'+JM!!X]*SB 7GR(G%O >V__?VZVS4GI,P=<U;
M&1Y3R_ 6'-PH\NQMD_"?G+._V,:6 #R^".X>[/.@;+2HGWK<O\=A\J#AT)T%
M*WSET!7O:R2"H$D4BAP(4LVRAL'E;M]Y<_LM]>WPW9(99E]C.>SX\T&!$&:Z
MXB[E[;:TR&>+8VZAI6?GQ!5[]/?&L)"Q6T1I//6QZ^=#=I?9:ZXI<8D0WR0Y
M$L3.0-0NFP_!,5*DNU#--Q,8Y)IGT!S[WEJ_.=GSTDKW&G-71VMR56NS8V/H
M3!)LK9EGT < ;SV G0!>M(%V;756T2_IY'45)(4./^RZTFH84XR8XQ#/;V.Z
M\^YK"KQF3^@,#SRO*"--7H"*K)T5P(*/+X_U$,D[3@!-X"%C3M+AJ)/.%,5P
M M@E@] /Y\3*B;0O+^6/64[\QSL ,1UNB#Y@5C.E+;>M)/I*3\T:2V)OSG'N
M"TZ,@0+/O9[Z35G=;>[U;Y.#"O(O)Y+(:^W[T9 @,\RP+]^6'=)LX(TT&55V
MM].'S0OJLQ"V/4'Z^P+6WCLCV26,O8R,^>79:[$L/EF9AI-M(UUW7M1*__2A
M0^KN5C_>>3ZPL;MVD=$F)W"4R>:4#>""DN0;E&G!<5*Z]Y-AXFV]?,6%VZ53
MV3[IOJ#W*.5T:Q?;M'7GS'8#%DZF2-F[;=<+Q1)R[M61CPRGX&3G6&IG#U/?
M:47O&8%2V;KBGGGE)*G_G(?QW&H^ 5 +.I#UT%2^^E[X:0.Q>ELFZGB(?!-I
M?QQ!SA0FS.B:.GE^X0(L*]5&B)$8?2']:W>1?F>Y+K-")FL!<Q,$E41RVM\:
MV/EL27]H*ZT,ZF*,.GAE: '4Z89/TNVR>^@AI-I3@X<IG$\CTWHQFH-[!I+4
M2N4#6PLT^N/)[@[+DDH29U9M%NS<T0K!>V'6JWAFBV>% >#CR9*2_N8/J)?^
MMRV8U9V-%)H=6.#VJ[4CC"ZC_;G(@\[ X*_,/LE>U%"D\G;VOJ.'&?V.JG6W
M?@GO^E^X_FO3Y"Y;UVVTX/6RN6L5514NK_**KTTIZOX?]MXSK,FHRQJ.HF)!
M$*6WJ'1"D2:=B$@7D!HZ*E)#$:43B(I(!P$! >D@G="1W@F]0^B]]U!#",D'
MS[PS[\P\,W-->>:;]RL_]@_N0!+.?>Y]UCIG[;5=U_2^O-=V.@&KP9#S!,"7
M DGH D49?5J1WWWC;K"OX(G"F4(R3MT&V]8[.-/42Z^B&$WO]DJ!P494APB@
M;6;3=F>\U0:IS+/1D74!#=7";]V^Q0(08SE&W$+OMHWWM%0Y^-)JLK":ON*B
MJ=Q=]FD ;C/5%HU6S88D/HZ1VWM54OXA<D/3_5IHZD,! B"):*VMS@*A?OU;
M<$QIK*]!B&=6&3Q[UJ:";?553>*&V<C*]\ISFWRHV\?FN+! YY^EM0(/#_YP
M=R/OT(7F(0MI$89AQVYL?2=US*T#C%1#'&29,QU8]&$!-FI=<U"MC>M^=!9:
M IH;)#;JJ;_\Q?RL^,6RGM=-A-8>I*T6HO(GL*]%#75\S5?DFC?VT6;2(M#$
MZPQ"?D$I;VS4W1F1BT[W[WK(<PW]*SUW>TWAO8?W0Y34BQ2U4N>16V(R2?83
MQI.S$[*NU@*J#@+$H2_$2#)3*(7=D W >RJ.;[+6'E2:ESU>F&5/+6HF^_T>
M?@'J$FNXAJ<Y_S"&QPA<VL2&_X=WH[6%$RS5^X4JRQC5EGFV4VDM[-./ :[L
MA920EAGV(4GV=*6LC<BO,BV.8?4@%QW&OOU=4QX,"BF>%%(FZ^C2!E+L.!-.
M_94GBRW:@7]?J"H<T]=U]:3M30W+3D,3+\BG+$*;;SN4#SZV;;8EXUO;W9B9
M)MYP\[@@C?>"F;LH4]HG[;<NJ_VN4T!R<9(8#;;,91O\PY#4XOF44DFAYI%:
MZLGL8\:W&8I#D.^#MDU[P&;/7:KN"E>);:<HASA;V.!B3B;FD.D<M!8"4BX:
M$%K+$]IT^C+QR%<._^Z$?7CD9VKH34T:,\4%N=O^/E>>K0$8KTO7!(XLZVP6
ME;Z]U.H%_%?V[P'/F*^]HSM]T&+@>JP0(,P#IC'TC F!3Y,X8M_652-^X06M
M9]^B-Z>XYAWL%N-#8X&/"(!^&1RTXCI(%5F9()>R6JHAYV$A8[)\)F4#WZ<;
MU*]?3>B&GN8"SZ_6/*TF 'S$DXY=6^)9>,KXF"/&PX;M@9C]_(\+*3WRBE7V
M@PK#%W\..YWX#Y=A'R"187>"[GI,ME"A%^Z@E_L^-\0J$..O_2$ ZI00*9L)
MZ+YOJ%:3>_6#>Y+'Z@)3B8,(T&&?[):JP[?<K1Q.I\?I[FEFBQ.<^OJ,X<,7
MZ?'::Q\ET^>.UZ4Y36Y%Z/U*]V^,\GNE\'"((YDL'\99P.Z/XW^3PRNB2G-
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M;8$:=0+@<>(%6C01) #6;M3Q(TK^^I(A#^;=1\CT=2_D7Z:X6,SX*=XG9?B
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M>!-O/),Q?VJZ'"4W?,%"W-Z8'M##=R--1+PLGR;!'<T_5+-71*6&>]&JD6V
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M]6UT8;F\\5IQN>/7YTBPKU>MG MW!P' MV"^)=D7[@3WD^9!,7IWI1JSV!$
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MR_>GEB61_K^PV4#7]:%UDV8Y:^6\=8G62(YLD.#B-*2ACF. ,?I,ME8.N#_
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MI9UHI[.;;$VW)K$NB(S71L-;@63DTD(T/T#*84YJ716J6]AW?S)]C !P+"(
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M7Y7;@ZV2I8-:T8X3T 580J'Z9@$PF6,[BPMV&+478[W:=(L B XX^73"]9$
M ""2H:MH[?,$W=")#RN7EAJ]>O^VU[B?#]O(X=@_]1J?^L]YC9.>S'7ORZ$5
M5%[8<G<(B!XQ:8D<:)AJ73#VJT)*?#66O'FO3NE@=R]M[42YB,\/ZNK"$=1/
MK$>&BE *\Q>Y]H^J^OWSE&V9LG[[AF43JX"C]N?@PP<FY*9R^'YRHKE\<:/]
MJL "Z:(./.5!AN<?:@^.Q7STI<S8PE)E[_BC YKHA>/,NA8>>PK/]](R9<88
MJ(-:L=P_>[LP]$Q_PJ&;@0>.73,O1Q,O,"'D5O)?FEWT$0 ,]4LN)01 X0?X
M6@=H[?;%BK\8@PL=A1^3JI_3LCJ_)@ "7QR+DWT^UJTP8,M!4?5W-BT_$Y"G
M!_+5>F0>J\5?W(@S];/]^GE3MC&KN/)<^HY,:]<*?S^2T>/=AUIKRCZ!%03
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M0HB$BZNU"3XP*VHD$6Q3J*BU<(,LDJ-P"M89QM:.$ZQ=%/JZ;\=L86DTC.K
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ME%\VD3"Z%M&TQ7Q;A@E_IF^9@9PY8SO?6BX)1V]<SMP7I2T(Z ,F)%>YP)-
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MI=)PQ[C*GF2?S D)Q2RK-"Y46_$*RB\RKC\8]:Q=GE[$_@ON3:->W4>N??8
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M&A64H=R00F-!&[Z_7&X>C\/#D1UN'GL3\P?HBC+AC+P>\.<<N!\ <]&11MV
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M]9)R%7H/]&C;GPO-T!&<595!O4MK<6#VQ(- :C;M66>#1HV-INMJ']/([P
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M.OL-=&>!6[>[F0<GQG'WT'9)$?5@XFPK:<53[H?L;(_%HW,=?:)[&\5+XEI
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M!M=H; ^G6>*C*8*-C*_H.)SBT17@&$UU6 C["]*OB>FY K"<0\\QG\XFQ*X
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M_[A_?P<J&@28A\RIHIFQ;^N.>?G. >3Z^J$QWSX;7XU)? HVNR-%>5EAF$9
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M57>/\%(PBG8&GU&P-M!.B"OL]$FG?E5A2H92SA)+%?<I"<[=RCS;##+Q@.<
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M@!3HRAV<DQB2F#_:.T)\$3\'1.*JY[XZB*H!I^'KB'MWQ.[OB"/@HBR>0C9
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M]=9</2AP7VI@:WC7@$]7=>\5<6,4$$F1$\4*3 UBD_W7$ \SA?NECA;43Q(
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MA^SMG[;T"LR7R7.VX8OJ%C_@YP!0/Q;2WG=(R8?SXNZOOV>3XJ];D&[ EW.
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MM<["L3DI3-):+-E4];4=$IF3U_GDMU:9\&@;SFLWJR66+-SYPR;4!,Q)4O5
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MF_S\^;6-I!L"O#^><FD8Z>?F]H44XK7K5]3XG%Q+FM2(YAV,7,UI+WBQ'A?
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MP4<"/\)+9 !/XRDL?(Z]RDQ,3+Q<>T^%A0VO:1<+6-":,8^4MW OJ>NO'X]
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M7Q:V__@?#!5F!>2>QM!/4H<TN*BHB>1_U LFOQG77)58R/S4U>'J@-JK18O
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M06]F7ADXH"AA;GU)2J1!K?<X0CJM.GD@LL7)US%"Q>DK)@R@<!=C/>[[G(5
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M@*IS!T>*5N+W+'K/?;WL\!9H)VE,O-2F(#JQG!/]W#YA2QQ_ 1L.^,BJ@5V
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M%4')P^:W*9G"0-I85M '^J)@Y[1^#R,YY5[31,2N_%_E(V-#%.O3:XD88R0
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MA5-Z9O2L"^HTHO*\E0JB-BZ^O"I8^.%&#9M *A[",O\[K9OGN>GA ,9753A
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M2/P8Z[A7.F2W8LQZ@;E<XMV)?K09?RZ-G<I[;7'[FU%3IHM!^TXCCR'^Z>R
MHB+?8#F76CR+P< = /%NN#AJJ&G)]:OA!_LHF8O():?$7PH2!C"70AXT6&.
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M>I7&'9HDNSWLR>'-)G9M3^NPT2W/3Z?=>.T0<=": ;KE!K/]V<6K\TB9HI%
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MP7R_35"-CTLIG5X-\5IF KUTA(7D0-8SX8(G!76@7>85R.$-/.?MA>FQ3^&
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MGAPCLW66=48&VP5528 @E[+6/_55S&+@P-##JF9%"<JN__6*:VAW BW3U?G
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MXMP4]B*U6<'@VK$; 2Z<O.ND]V?87V/M@FO7:PW!#AE%$@)[+V[EBUJ@[OM
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MC>.55],0=]$X?G(%:>"L&Y%F5;![.@OJVEI0:F!0[/I,D$<;NE_\)5Q.JB1
MFE/_2JN=YD38''A!^'L_X:OA6W@+ZDV*!ZIMA@;!6<@] DD(X'AA?<Q9&?E\
M;5DJGOGZ;:X5:Z_ "__>8P/1S2RR"ZW'GUFW]!:EQ^03Z1U^M9%31A!8)IVO
MJ\HK_)3FI-^P?HJ2K ??>/;< M)Q$2.:MX HWLL;#S3G_)FT!8'KK2ZXK:=R
M/OT4_<L9:/E]U3\:Z3P]1*2,']7;D!DM_VN8FP K3,IUTJ+DM_Y;&:I[2MP"
M8L#%:)LM0QGGW0+:<Z'*-W? )Y:VJ.>E?_IE2;'KU ]!=RZ6RL2306LZ^7!"
MLZB7;.JK_@O4YWOUX!Y1I04%[1<\>39'4RY?TWA^VKKH4Z:ED[;")=,H=O[U
M>X#.BSSIH26E#I=W[Q]D.<9?4_J2I%W*TGH#M)3HG";D,YA8S\2\IJK0WY_(
M2G5E*99W<\"WB@R*FSGQ\VYS#)0Y" BA@;ZE,%O#X&G+JE=:2"N [;P$XHH(
M0X\[4LEKR?@TK1E'KRL6^2X,<XW.,7BGM)CH'^5\,RI_SE5=="73A7K< $UM
MX@UOY_*)F9X@["R[$#RGPCDOZ9"%SQ59($Q=$EP>@08H N3F^KD ]@TERBVD
M1Q0EX;E6\1\FU"I"]S"&Y\C2S['SQ-9JK2+]O$F3C&$#>:UUMP MRCVM6P"U
M*EAWS-AB,E3C79VN._6S4JOZA*^\W2U-8F:#M1$":VJ!5'$RS"U;5CO (&_2
MA/9E4NVC&>OSB:O3TDN!]M)5H*KEY3^U]Q1/B1]NM$7!3Q8T/?^THEJ'1&/&
MF(]9X 7;&\IS*Q6X/414[UTJZEK^U.:C]3APGM&@9^<)[N*X4S(5P=M@I8F?
M)YS/EC9[FI+)C7OB&<Z9FT@+NYTFR5Z'Z7ZFGSG8F/04+-#N0I5OC6NK[?6^
M1CF?&&1WUKMDWNLO8:J),\7M@'_;QH:17G#:UZ,UYA: #P^"'3/7),UO228R
M5'DEC^1C$J9YJG9HA0OG?VI7:>ZRO>>IX-_M7K$[9A&CVT=5EK*4C<]-KH41
M>5%_K?59/S?0FWHG]5%CS*D2O[(]@S13C!N&9Y:?- "C(&)J:II77[!I*%2K
M.O?5^@V6(2&<&]4^^V';/)X4=<HZ#'R$@[3:"F=7:X(>U=V[J3DJ.61@_O1U
M] 3W%\*4 G%1E_8(C3%3&;^-@-\_WCFO]0T51*S[P_WUC&"X2?8Q8[&_PW!)
M)FS8HYCU\+!2(+,N&O?5$/]W?WKLS?E79\RGI2RAXUMKY-NA]QE" 11:;QA-
M,%>)/!Q!MP""MA=X4GR7R:J)X#J&?C32_(FJ6K!HIAGG">>MO*826WXJ\\35
MSU26R[]!I(:ZKCB>+H[WNO*YYJ4( :2EDQ^:,G+AA3*43;GDP])]+&)#G9DC
MLR:*"JVI#=I;%O[JIJIM^JYWQ^$)=0#%AAY$V2]E+N(+MY+2\P\8)P1=3D+/
M@W/A[CT'NJ8O'OPR;N=+W,!5UK=AIA'7/]]3R[O**.H/M7+\78GBX/??G;[8
M^&*]!QET%HFX -_@-HTW2JZ/YTWRR/0,&G\C/L"]!824_&"&J1#/GJ Q89/C
MHY+KU4%?,1:+4,<$N6]>GCG \5J*(V\"<)_Z&/BP!?4EIKP4R>K.G0ZCWZMG
MR6BV._I+5BPAS2]O 7WLTRV'P:C(B(:D/Q]7I2.U$1D?H16;\NA'"H/\OD2L
MM^(6$,D.1FRU].?D?;H%K/>OH.I*3_(+M^?^LIX8?RN8JZ9G)?8+GF';\!#>
M!I=K3D;;"_LKF#:I"I.X%(D&T?^IMD7_3$@AS2^@PW5N:TOR:POR#?'D3/U"
M;V2-?,>;^D.GX[04E^X7_MCV.3CZ)$*6NV#0"E5*_;"S\82>FXO2"Z<D(I2-
MX2KY=Y>$K+\T5_?OI=#RX=ANC>JS#H[GXE1?L(JF/%:?*M=AFC[Y3M,[H>>[
MSKM/_<0EML.%8R.V@ES,)PHH#E(&%4,,KQY_:ED"(@A+&F7:P_*//OUN+/6G
M#FV"3TU#U^&RO&/^T='C=04KE5X7T?S7 LC:_&@5IHQ0-OE_4=U2 #S38PU(
MX-KO7#W#*UM4,JE\EW'#5TN$V^<AUA-J49QB\_&+F,W:K ./&](-0RP1+8_\
MH7P+W93SKL56SLX7]NRR"][[^&7#8L?46TTN<?(V/^JTF9WM,M!FC/WU_*DA
MT<*N.RC[LSFGT1+_7([YI?"I?V481"+52U$9ZF#MH3=MR_M 4GNRY-,A_2Q]
MTNX2A?1NFX   &5<B6A0O\DTWIKN*1XILG"I"?EHGZ_3@>;)+O>9-5P0K(*\
M+LVRL'OQQ00A+SC/9;>LI;:$3[(2[XN0GF-7>0E"<)SQP#@6[_8:FN?C]Q@)
M+H-_BJV:B)WMOU-?2_I<F\F>[*0BY?A81@2Z('&J+Q_]QI_CY*6&RI&R?&B/
M2MDDY)4V:&&I\R%>&UMO'<(?9 UKGE%+ZYCFU@VAZ&;5*9FZ(R#P],DU03*,
MKNZ%G\M\(DQ_AF^?=F(:2R&AI[<'+G,]M[V;IKL;CKDKE/!L0.]?Y@9Q&?V[
MTD_2C31R3\//V55!D=G+(U9V<[6I"F[R+T$2)3(BR,Y((UVUG#V%N/L-[*DU
M4IXUZ?!+PPGG >&!XH^J]36A[\S\]'*=G78Z,-=SP!2((%955U7M[R(VZ7'!
M$@2T4],_=W77PDK$_BAQ^%MOM8VTM[+W6DT!34^3);E9]V>9<P\Z"-RMQV7M
MFLO!'J(F@WX,L?;4R]173E_IP=<:%8D8C2)]$RK'/(J+ (6RZTZE:":_Z?[=
M>;CLCVGH['$):S(!M(EKL7HAIM)L_2;>.*N1#08:GKY%MX#>S^_0\#<1>$9O
M(&#)5;#4^ZW(R]'*^<'A#S*7\?NTJ;PQ_!C'[/C^5Q1)99[/?B-L_]\(&WSS
MN*I*_T33^C%I-'BM&%NAP4KA!C0\#WG-25D>:!0=W64U,Y1&AH;2F8;@&9:6
MLSMZ1KMLY9NF?7,TDKOUU6E%>E7=R6X/%MDVR2%VK7QWNF4\":^F^D]?^+:<
M,"R#9Z5N 6?ZSKM5*=H.BET/A L#253>_8\FRY<2P<]O 33U-#>.R5?9'M:N
M"3VE\)M1-"/_L3+$GGL?J?X61=R3EQ%Z/GBW(<U_Y42#Q_#:]A:0P5!"\>?C
MHL); "XH+,]3%E$2RE+Z0_B_/2C_(ZFU#0.>R)^7_LZ*S5POV:H%A^'J03Y4
MDA#9WU]'-<CHCJ(XO%1>P75.4DA4#*7M?J?ST9CJH+EV7,N-H^&FFH8BYV"2
MU+?PRR1,YCUUC7HH];:LBA2)SU_=NB0[OWKA7<NRD?9Y=B$_%_/DM+6^R[/?
MPSJY_NIZ\_\W1(MXG890@:3G;454#O9QBK+(+0 '.')2&$"9$I5<+J30\LB"
MC_O)T0L3+4I2_3H:_8^D$OM=20SQL72@S<0G=S:!^E[L@WDE<<&1CD#S]B:,
M#M"S\:)*/"NKY*H(\TL;U>)N[>AAT0=N-Z19JSE%?4H]A>!VC0SP" *\PHDB
M=1E0*Y_4",\>=#C<(SD!/JQ:CQMS96,/AN$[O'G:_\:6)^([[2I-#TV<B1"A
MBC7WY,+'G'\;,?@'3BC+$=M7;5DR9J>NK(S?4D=0J,Y:.2J%LN1Q_.&[AIIY
MS WG0<21JN&.?"E,ZY%76[,/$(= WU*Y@LMINSTAKZZX]J.@-:90\;VBE^ 4
M \$315E% ^TK<"O%R 59>.5 ]2>)\2MNQ"?PM[0.6A3I.4\, Y=(^4MU*8Y!
M=X!0TA6&QD3..*]5D]"J]\6\9DCMOG\82M1JT?F8/,0;5RJO*&U7"UJ<N)WV
M*B[V3 OXI>1 0\Q-JJ2>O&U^.Q0>K.GUN9,?D;Q]P_3!&;M\>Y/&IQ7)OC,2
M5$]P@>W'D>&\8.\@-L%_/1)&T.82V=Z(USI/AF3P?CEQ=FDP2B[2!U\? ,DB
M[2.[FPMW%<B%&14?XN6O7=X"GN963>8&HPCA5,6;KE-#;2.8D4<P4%6F88J6
MQ,3YXS!IF\/,'S\%%^HD3401,WWS(\A@9P+$5>PM0(+W_$4 <$-N%'Q ]=L=
M36>2RC\*M1?'6I@\%3Z.X.=+N.3KD @,X*[T:!Z7MI,=6<KWE(15SE^]W)E^
MJ<@50F'QP7BL, ZSP$=<8/A5]'ACL,[O/-!T-/OD!N](-^FUMMSG.51^73/E
MW,?\L5Z9FX7.VO?=&<,Z0_1(S@-K(776;%8ZM=@QJL?%,*9C::A8<(E";IN]
M6 ;0C:).2BT,-CF.!,)CF;^>YU=V9'5]B-;C@60F?)96"7L/]N -A,4J^<M!
MO7USYX,>Z?6;A''UM2IQ6^&MVB(C9M(N'H)OR*E,\]6<],>/-%9X(]T;&FI^
M5<8?'9D&+3-R,D38D6A%[X,IUT(A&6,\;3R6=LQUQNG-7P1[)E&D-#V*#J9"
M+H'$AR&3BX-WKA?CWE[;]9R<E9A (GU^PKR&AJ8S3C@#\W%57P5%CPB,O,<V
MS,L(?\+F/?Y37NE"NBFAQ]J( >M:KBQ)Y(3V!7G/9'RI.C0WG">-;)ZGWC,L
MMAL[V?HY1FY+[25IMVL'!.OK3;"]<[H48_92XP=QFJ3A&!]NF4$YS O!4CIH
M1 -_L(B*25[GM08#'LLPAK3K>S#!)(;&0;ZFO]-4$NDB*'><FA?&#E?NB"SH
ML:SA**=S^W0MPSR#5:OX=-U3Z_,FKRBWL()&^%*VW-?JU[WO7G++M>XOUS1S
M@_O$TE#-="AGB!CIZ$B(B+)1EEL0;VU4L/TDR[WOD9X8:L&92NH_LH)9>0XB
MQ5O@^P55<T+><1^I?HG@^0UO>(D#O*4;TNX@%2IA >$FHK45D]&?OW28,:I,
MYI]3IXW\<&P6@1M";EZU7>H&Q6+&7VI:,G"8?20J>4T;)$!)"8N(VT3=JX\9
MZ4FB+*-\!>HAW*ZH[D!P%5ZH6T[8X$Z3;J3F3E6J2+EU9S+&/0O9C/.3#OVC
M;0/OB6VH<Y^(W)K5H<JE=:K:)BN*A)(%Z8.T6O)^ ?>_IFD;,2,^K)O\WEJ[
MOWGN>&4$7M58;WG( SP\IK2X.$K^Z=L\P4_^5.T'C;%+9'<3/H,Z[=XKUH8&
M$A$U2&$IGN6[.8./3M5C2O>?;"9LT?ACT01Z1+83/ )_<A7\E/UIT:)X@T:-
M?)-@,^X6X#.MU?. ^%#W06H%A=G!YLDF/<JM1<([#' +\-5*0[+"L-%NQ7H]
MNLS:6VR(21D0>T)SO8^QHZC? I:X>??"16:\:M.; SYDE;4R8)2I4WSPJTR.
M.1KVQ&B2A;)FAC[7NVI7*&,8(;6GNWWX .-+V<UA+DVQY]</H^)Y"U4'#S@;
M'?*3'KDDO/,V&S&6EG*$F'=_=MA1WYCNR=%%.L\0Z2_MNCN5H8$V)RQML +,
M=FZ+[3K<TZWKF<!G-X+7WF86H0&1.[,)OD+X=MG1(EE@&E$5 9+9^K\Z;=ZU
M[GB8->][W>?=@>Y4(UX$Y$SP" 08<?X0]X\95H>$',D=2]E^M&*9"[!=A'CJ
MP))FY%KB.Z0K].:,C&.4Z==>=N2]$[0MD5&ZL4JJ@N^7,-0UC)_MFJ .]-:!
MB1]0&ELNUI@4X0V@UO&%'K;$=&P+9^PM_0L&4ZUR#&AFEZ;$,.'#.(<.PCI)
MC/3#^.OB,X:9-_FJ.3'V+8ELBN?"Q__\/9B_-EIGNPJ-F39_B-EZYYELWGQ]
M?4W@B)C.^9JE;:[[EL([^5'$/..5G8/VI;%'[+[A"]<6_81.$%O+I*E7[TE<
MP,? <"42@HYSIKJ\L7#=B 6Z;*;H10.D\_2R\:>S)C&6T_:A9LFK(,-- [)
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MX!P@Q?D(D:M+3Q<%Q[P9(HT39>I\/5:[T[&"QA"@.R5H*B =*?R%8SC3AF"
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M9Q*M9WG_4773:63(\O.TM[)GUF*:H6NF*R)Y=AH$=\0/E @@YZ54)15KFK<
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MFUYSC#&%*SP28^O?QF/":"9+B:I551(/MB&S+HVO3MPHJ7)#V(=\P2CM&5A
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MT28QA(O%^<$7=SS^GJ=!SX#[5&C -9N7E[ZB\<U61K;OR,_T8-  WY\%607
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M.*":HY,?:_YVRH2".]G'(I42.O(=N42,#.FW_B+90P-NE;A87 WX@.'K8>_
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M2&^*X>QQ*O&>E]^Z%/EJM\!QHBV3/$8J0PO:I06:X\D;#S21?4$9_N!&NCO
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M]1V6+I2/I.B3EU040S7EI%)GY?.6""ZI/S9?;2U>84&LCB)E[A1'/$(#-(9
M?.-WND]X.A%8**DD=E0='^K3!!P->-0@Q/Y%6% B/[:^$LK+0*5KA-<<"U9F
MGH@,=:UB*%UMHAH_V^.T6!0C<@M+E7U?_3C1&9Y#4FV_H@34TY&S$UQHX$R3
M4LLI89&\=YT<_76YF7 ! ='@4Y8$TG1S<QK?)=O>%2M>00-6;WD\E\/GR*@U
M:8G4PF(!*@,V3XM8F!TMB#O"Y-JN](LL5AJ?FX[9$6KLO^P??GE+#B##?_J\
M/B4$?'P/(\KUT"T>LV4T(/3@[%(Q"6HYVO?8EL\^Y 5XEBKH?&=[H<#3$ WX
M)IF !NC-H@%BA;J9.YTR),.;HH_?1+K6F9I@=YONY@SOBR&#BA=7TD&N;+UD
M('LR Z,>5'9-\V?P,:\>%/;U+_>^5B*R, A1OOEL ;PIFW/==GE[ZL0@  TX
M!ENDG&/0C(2(C>>[2/$5$&GX564%7K/J7LH:Z.ER,S)\QNRF$J. 2GH7G>SX
M0_G;/^'.]A516@&/:4-B0DY26L)[XB<=5(I+IN2,!H5%,-Y:OBJ.^QF__R(G
M:9&&00)5K]ILI<&X4S,EO.KQU$*W!UM%*H[2SUN)CZ2><8WCYBT#2>==53?T
MOA5U%DZ=&!KY10S[3<&4"I&ZR2L#::/6\9,:I"?K[SJ]OX9X,Q[GQ\>*1BCU
M/^DR:R\"JY4=548-&#H1LY:!&KZ5?>+EH(R W_'PLD=A'7G!@ME,=>J?A^E\
MP-*EN9E-43(]WSS<UO.W?T^_#G;3^O[[[K2_>R# OS-N62DI7 1M-?/83)I&
M :]ZP4MT2)1ZC@I;G\[O.LI_.8?QKPP#(4^SL>2Q;@5G".&"3J9/_>,,0Z#!
M=^_W34'%<BL$?FI=@@11A&_'V7HC9R2WD^%>X< O)$WDZ3FJ!^^-B\.Y$'0E
M8H;%^MM\#XGVMHKNV_J/@=G' \ 7 QX#GFYN9EX9<'P[%[S)Z@\O?_UD^>5!
MB&PEF;9  YXB=0PM?_(,- [K8\UUUA[MBY$AW8KK$&:JNH>T7&7EHF&1FBNS
M&])YC;[%JZ$=Y]2G?06YK#;/Z^JBW_L2L].'N*I31AFP[* X8)YRCL0SH2?5
MD;/I8> (.M'4AZ@;JPG#IB/V8-$'ENFH4;$/I>Q1]D@(1P&(8Q:62B>R<W]9
M]['-OFI2?Y''JO_J7.\3/T.\#WZ59K5WDKJ+AU\!PZP(U(\@'5X&4G4Z!3J+
MN].T=L+%\;>MNV38RC_A>,+XEFXLQ]H7F,LFV&WP^Q]QL'X-"?'%PCN*2$11
M%8QZFASY*4X(BSAEFT]62^K4A*C*"?K?^VSX\Q9]HK$S)4PM.XT^[<%EA$>1
MUF;R;>?P[CH*=C7GKP@B/^3.#(H3VBN:@FJB13FMB-[!X,8#<0STG\*@?9;S
M@Y"48R4,<2CYTIPD 5UML4=HK8$?%+&5>#_;MI]G*6-V(]%)<WH-.:8#^WL)
M&5!IZNM97!PN:,F.Z+:T2<^[YU'"<E/"9F+/[;YS6QEZ55-#?]<LF7*A >$J
MP6F"D8K/[M-7"A $/9D\3WE4^:7H]9>&"4_V5_W! YA/$.G7+^GQH1Z#_92W
M7>35&</,5>7-L/IM<A9Q+B%^M);4M)/GN1Y%K\^MK^M+UZZASPRDE3S,#L>6
MS_('2_BF:36C5:"3OQR41'RL$U/&1X+J/K^KOK<_O517[>\IMW0C/A _N?'$
MIUK*S2XR$?K(?NRHM:B18A4GF+M766^(.@,@G+F%933]'2NEV KZ"K%J?[N7
MNM'P/*34. :&^Y8H*4L)^^&GS9P2[25/L^(IQ-<.1TM!YV36=T[JTY\>$$Y\
MH31& V0G6=0\*XU.&"7RS4:JW&]2@AJ>\N89:TJP5<1)7O>T2K-X=7IF&8@A
MN<=L/Z(!_A %A^)FRY-].HU=_]OA+7M#JP:B;PW?9S!GS3E. Y4\E2.EFRAV
M\)\N,).GI$6(W=POP3[$;ZR$A7.;V[95/%][3)%&\SCCY'93/.QC[EDC[K7\
M]V5;0_,+Z,>(5N1#@F4#)GUM P14V\.B?791JV_\@[I/SSLH+;XD?LY]\=S-
MQJ&2G4V"$-ZJR<5'C+SP_#$QRC*?FY.(E Z E08PS'W<W358CW=0)[7FY+B%
M"/[6Y8I0WS'?P,"R^ACN[M<0-<_A",*[VTWIW-+%OQWL:BV\/7A\OY<G;1_Z
MQ^M$QZSZF^YB$'R4&QI@^!1CL.UAV3!J.D39"Z%_NR/!\_JH^NVU00C-3XU?
M6CI,=".+&V#$_J\3P:DCC;R;RI5&-17\6L8:1S(TX!TE.TKPCA&L5E;XIXK
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MB*RF&UA1O+Y35:UI9?-8?2!&"&!J'M]IN0@V'==?3^44F'B"Z__*\H/$]T]
M_<K@ A]=PYZS*_9HN$>T?8,JD[XR\0QLPL..,#'&@\W7MS!SX@PD3JR<A+YZ
M$],E2I D_HFNMVCC@8QAL:WHUWS8TR9D*U:![]\(S KYKQW<38M%DD1/%NU
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MV\T<#^W1%"$+LR\.V#ZT+L'O,'GD>O-\55%9 L=7A+3DNJHK;TRH%P44V<
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M,H5NCL< I'L-<=LAEPP50]<@#" SHQ'/I 7"0[_5K!.#^H !Q)0D8P"&#!C
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MKH0O5I+J'AH8A%;_Y+5ZCWO'_%A6:JC8 W(?LJY1AP' MOZDX$WB=G%?XNU
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M9U^XS.%\=I.0OL%K>O*7/*]>)KM*=YA/B7T6L!*OLH_CS!O>$YS?D6&J1"Z
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ME*-@/#-[6IN33?C+RV] B9VS\+$A'6:9Z5:3ICP.QZ%DY;\:2EV:VJ\ ]ZX
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MO5IR:CU%Q)>?)+49#>V1DLWD)LZ]_70% (LBB9&4-ED<=(HT6::W\I]?)YH
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MI-0JD&9C28$+IE*VX%V&8?#&,N3L!@K5F1="^5R;&$#T\9KGM9W?R I3HXO
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MG \H!^&-X5AA_#G &G1T B$(FS3-[=QJ0@.!;9DMPBGH"46+\=+NMUX+;-0
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M;3F5[V! \N<E2QF;7#[_YJ^_?2CTWXN_6%XL?AZ#"AD:11%\!<"KY%.:JS^
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MWC?3-48[?(IG9,,L9?U*J-/9<$22"UP+V7(SJ0TZ<C:*##T'++JAD)O,CN>
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M8X(P?=^N;NOPLZ004@0D4^5#^3/'HVO+]*;+%G'/.4!1.2M">_L-Y+OS5AP
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MS++V;5"VNET8N2-N=OP0OP$3\,Q+L]B,?(F#VI$$-=!9#\XHTM_H3\S-^!(
M$)VZR786?>U#"A<N-M<CZXA OD,B*ZH8T9K"^S(&7GO6<L!&PN@OVEX9V@*G
M+&*J^'R+@11U(X_OT6<RDKK(R-UJQ#L,PM\E]<;8,2U,/-OQ=..[:+3,-A3X
MIFVAQXY;2<,II61K+-8];6REC@C3.=2XFA"8OC1ML_AAK%-ZLWH=/H&O/[L>
MPAGG_'5ZT>!RBM^_7M7:E ]_\?E&?\\_!TR"SN[%[H_ NK!F!"4+Q#G@/7Q?
M2=?B%BZR/R21/BQN2/8JO\3[XE<WPT^%R("+MK.$N[BF4]N7A-;:&.'1&U?N
M>48S?CS3]3W6%4?/WN0)];G]E#SOK&%FWMKNXA%0"<1 $,B(<639@+$8BHZ\
M:[C^ !T]/P%)$5KXL-H^JQYEK*E49\Z8$[!=F]S6QG/,4' .V*1//>%36B-<
MA;??TCD'(&+/ ?VV(;C*O(F-!$),KK[4*32<6]A4_;3#"5@E2C*E:XMA)CPW
MJ#R#(0C^^L,Z32RM#?SNK<C[CS 6I63)C^-9!Z*G+6=*K[;JQU/_(>QL&)B0
M8 M\!$MJJB-:"J_5^?$5/CX;I^F3-M'$=A'D;<&G)&R$L.@:N"]H]\H(<F,)
MOD_;JO4ZY\FD>JZ4+0,DH@Y*Y2?U9WEMQ_VPCY_._&:EQ:Q9TO89!X@8_S*T
MM3+>#;N&L#[T:(JSEMGN:!4C72!(P;OKSP$.X%.E7/R-<\"7WHN%-EF[E(BG
MI/8V39DX!_PAL^PQ0TG(S*OP-]%:-XRP[2[T#LO2>-(-R#N;*.?@W9#6>M8)
MDF6.D37VQDFI3A1AWGP^Y=TP+13KJ(2S)[F3W:;AYL!C#SH?[$E<WZ(D9]:%
MJ]ZF@A+0'BTO9BE^M?FP4I>=-/>/!7/*CX@;:SL&<N%B+L/K-F0JM4RM4=A1
M&;&LXHR'G[_<KHAP:C@U1*P8SE*O*"."=([(MW>7:H)13K$B',WO&.7[1R9!
MGU(8ANH4K^=?Z7S]R=Y0T=#K)G_3NSW?5>=>#F0K\IC\/@%I=K%I!J6J,?D@
MBZ#"Y#[._\/1%9^<M!/KM>WJB*;ST"J+%OVM;BKT%W7N^U_4N7L'DS 7%*OL
M4!E[ZGLG8F=>DAWG<I*A1Y%+:P9OGYPJK4N9+K\R3G>L66GCBP<^",ABB>*Y
M BWQ<?#VIP9%+FFY[$1,I*DB)[Q4DGZM+)\^LQH#VK64&ATU-<W56A?QP'0_
M!+Y\9+>5X:=X]Z3TF@;P!\EL1&SMPN1.$&V1+_,JGZ%T7K-6<\6HTPL6&KJO
M>%^O=XLGVC4N7ZM%03G&$T>2,<^QUY/G[9X(,O Y\#T0U]=[$U6;3]::XU':
M6@/QW])0/G)/47NE@[U=NX#\P;A<YS^75<R5&IHQ)$R8/WG0>1]O)4Q\;(_?
M&).P1"L#'U@YV'IUW8Y:0E?_[N;:V)=L@W=6VVB$B]65C&5,&C#J0[&3.I[
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MFA2T:KR_6(XUEK\^CA^8>']7!QJ;MT,J04?6_I)=8?(W#MA0_620%6-@TTZ
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M'L\*-!C31+T?"6*$IEOJW"?*Y=ZKHM0V&+VKM$35I1;&,:B:?B4:D?L&)4!
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M!II#=E#\T6-,A EYKP2)P_&7U8^8;KHC&E*59+F7^5=R,WZUF4:0TE;[:Q_
MVZ(LC@&F].1MY@CQ&3,VTC5,ZTKH'!H^GQ#9,,_B>-L>S.4CK\,J/<"ZZ:"B
M!(2L5BH$N*08">=8OQ5BY+DK=8WMK"Q6)G"784O;2CW'NK*'<8_5/\5;"LS=
M+;*DE-]:;T)=8O.:Q);P<LA Z,XYBZLTA<I46+^54[L@/TD-76BM.P6L^_%X
M\9N,&JQ: GV1"F73F+/R5HO]TL*=2+I,L>U-H@#J\B2T8?')I>+(EL/4JJ@;
M,@$1U^W@:FI.2];+)=KRU-_XW[\#_#@=4VXY'"V^/M#;LM@^=;O'#-L=++P#
M7;0<FC3K#+FM6VS5&M8H:#U&HH:W!1X#=@]Y23XE\W!&T%RZ%7E;DK_LDS2/
MC'KU_<M 4AWY;/?H5.)HJB7MV@*)X!3R?;@0]\_AT1 Q3#?[TM3ELJZU*?/Q
MBZV6ESM#-^"5,MVK:G<<71_9MCYV<*#)JXZ:4 YO9)[84JS7!F?QID&'0VOO
M,FV3!>3%*SD=-8<BO*0*W_X5\E50#F2";NKBO.H/#6M5([^2QY-BFC@&0 ^1
MC0R=D#3PN93<W=>.2-.M+J&F;M$^Z<@*P8TUE3LR2KQ9Z1KRKE]^G_42)M)2
M\Z2H[75M^E<%,@".U7'8*:QJZE:).D.2-CJEO[X>M-M#)D+.WKR9N=E#?C?=
M?VL";#]%2;#.@?:Y?*:P3,MYJ5)F4K-R"7[YB&K91)E@W3"F_F&GN: O[X-U
M?>3CGQU>>E4GKX5*DOP%H)K,-Q230Q\EW_#3IO@&<*8_P%EC+/3P1F&96AID
MBE#Q?\2&_F\']?"!5V*.F5#T4;$;8U\HBOYC.'A_TYAB=MIGV$,]/@OZ1LG]
MY=WN-]Z6+X%KQP"8=YUQR8X,0PGK=NKFE9N40MW^;=?"%<XEUR)QBPU& LT^
M*JLT<=ZY[G>S21MFI!$.,C5A/UBH=1XF/L@F6&A:<^CWKB\ G1-UY%;R>H+Q
MF2]-3X*:,<X33\D<L?*WL) DXCQA6P\;\D-?95&/L3,F\FO2+M=AQH3W Q0<
MBT2(VC$]I$R=4EUBB>S3"C#1!%7+M,X&[[],]7'/^RV:%'>7A8,YAV_WC'.^
MQ\B;@>'7SU_UXK49,,8TA&YN62-$4'WDG:V\'>MMNKT!EX,P+X0^WEIJW.A1
MGU2.5."&T!R+THT7'?#+QD;*FNGK7.;<[4O)P9W_F<@$50A,+K!UEJU4AEMQ
M!#X-@"O/K_;(\NE^JBVHHPCBNG-G3ROBQ%)W5),J7VS2PTKO2I?,D5GJ27)G
MV(N_Y<?)3T'O**@SC]U>9E5L)1&X#H9%C-]C2YMJ=G?WV<',0>I5[,BC,]XN
M][Q7)>T=%E ,B_N<R)/&![O7_U.1AE]YV+V&L84,\93,96^OB7%8NVPO_R(U
MO7TNU4,IB*K\\U>SN49^UE_BF **ZVCT9!(CK/'6;N$=[0OWY@,!7PMXDX.[
MAZJIT*A+*V?)O*_?N]?Q^76X[),99[0N]=)2DIK2I,RCMLZ>:IDT@E7[VLY'
MDR*#:G\=]3M(P8=GYH-DZ+6%W.HY.7!"*\96!_ QVRMWKM0EW#"5X[XH<&HP
MU)E>HYM['Y6IQR))1R;-%^L%664R1E.^^)9O<VPY(# \WX:K.;X1XMZ\'A*4
M[>?FU[FWJ/B9*FI/5V>=WJF#.#P@&&)$T>#!ZT?J/0HUQ]L5VVS#/3:K;!WV
M@EJG9&2L&__,BUL;@CI/R$.'NNG@BF/UO:/<G:A&9TWNWOHH_/ !2_Y7P6.
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MW/BQB%!N_NO2M FSW?Y,B2(XZA5[J]L&W]Z_'%E2:N->1.2YEX606(T($N
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M_7Q6H'V2IM[@<8OL>:COFO[1KX_W7@K,33.J*UVZBFAV(G.&8/40[\OEA</
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MJBM=:8Z&"B*]I.94((^ O24-/GY*('#G?FHPG9B^CU;L_#S=B$5QI&VAI.=
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MV8X\U2LILCW>;72[%,;HY.>>G'[KO&_K=LM:O2"%PXI#EOGT0_/ZLD_*-SG
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M@4SSGDF5(8 @+N.SXZ-N"O#[5AH%IXK=) 1@CZJD5%&C4GP:_<O%Q:54]&)
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MCBQU$2$H9FBY/63P0Z"HYV>5/ :DB ZRCZK<PWB)W_, :=SIODX=)%2;W"H
MI:T45-<WUXW6,<GZ1(OEID!-XXZ' >.ITX?S*<FI^ZO_FH4%PZ-ZIW>VPI1A
M$R@!9 $3KPD%J_-1'KV6>+!:\:(D1Q6M>3ANQ&)Y%E[*VY]W:%.^IO026?+Y
MUT[Y_M:IVW$BO& ,$+5D28K331^>T:V,8!# L(,LI. XG3TQUQ@E/!,+PRZ:
M73Q,>=V9@5MP#,[PB)$U)<Y'&L.J^3.!O S5]"PUJK2+BC_E-T!0?!"@R%'?
MU+UJ7[58KBH[@<C2T^&\HDJ$2))*@1#'R\L2[J9<+H]L%,:C9AE0V!C"SN@W
M@XP=T$8< D%2"._-3/," (C(GF7!Q1-H%NRW+T)?V=>W9FSN!M6( 0" UZB
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MQ._W$SRWILY,JREBZP">#@MQ/.@L_+\W4&SO2LZ*W^_JR? @G .OLZ\4?F]
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MNYK3L+;P\DHT<OKSI9 @DF*Z.%8\!<E_;"^B>#VE!ZB1%GP1&RTP/K&DYCK
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M/O?V1/R.]);5E71[S$QE$6W#02P8E/>EK[2+ CWB\NO@RR8*4'41Z]&"8U'
M)4E2@55E+G5O?\AG_)F:2P';\R+%3-9>G]I_[Z#G__'(FYP@B(^NFCX$KR:3
M^4U3=G=O6?0;7&6KU ]S2#255H69A$[VX9HB8:$<;W<\D3/\>4P89(D0(E_T
MY]A_8T#%7H."0MHI]8R'/M[$-[O1?PE3\]9*/T;ZIS3;CQMO0)WP8!$]1YE+
MG=@$/[/M;3X>M8+9])<?(9%:5Q^AOQ*/5?A)LW06782T_3'7M0NGW@[/,?8
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M9!DX+K0Y!5GLN >0Y$0PEV*^0FQ/;G,ARH18?,8A\'E0HRI&Z@_O)]W4#;;
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MD:@LW+?<&(L$.><J5F38V(3 OB92!8WTR,U3 ['KKG5TE^">,J=)*JF@2&7
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M]7G-31O-ZI:MJB>E>:6\B\+!RPH_1O \A@S)8^93I# ^%1A(HJGNN# X1P0
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M2%.76=FGOK%BI>-)!L61FACH=,.VM(Y29*;FT]*JJ_U&9J2# PFX#14']EP
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M5A4"98S'!1GT%H2=6TRM7K[B)=@.OT4_*5R)8J)_Z;P2JG:'Z]Z/VR;G[:J
MU]K7(;R$.^"!ZF[GDG=)03_YA2]'E* )!!9H:*9B9&D96!ZV\>@&A@I)WP,B
MLPL@DWGW@+T?R0+W@._^_D*[5Q#.[,P]F?E"$C_8*OFKOIVJ=V[FY7+QTD8F
M;"0W5>\]HX<QG?I<'$"6&N O4.X0^S/X9E#1*M8U'J<>_-)BDZXR9G<9Q?P)
MRR\K('*U:L_M8])PY5^5FK'!Y^XBN=.SV\6:3?V8Y>O!W0VE;5_C*Y:A+W1
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M* >;,VL>QTY0_9D3$/^39G9ZZ,:%-K[FZLQ>5X;?=C<4)7;5-6WI(;<D-HC
M3#-!6\J<T*Y+"!(GGW7XMTHFV94JO??=!S\['[!6LTPSUFP5?X/]%#TA-$ (
M(0[D'XE 6"-"YHQ+"K8?0016H!75S:'WJ^I;:S\8.+ER#[#&C(Z&WP3?U_9G
M(@(!;05M")0N+E*#EPA\MZPG1)L!"SG1XL"_6[IP#*N1T)>K5UX$A'F;1$$<
MYAP,.I<71-:?=S2TJ)HLK?(2:LCVCHQUPQ1XXJQ_<"OFNS^>MYS14LO7H5K7
MO$<],=4*L#[0!MB&H 0U5'OXRX-:)[M9VD;\3Y$E])-^<)Q/?6]"-)R;/FZY
M[(*+-/X]3TD>Y+K T9.C%S>&GY]Y0R)P-\J\A\W.V5,I/ID8'>H+U=.H5E=N
MB)-OBN&SU1B3/EQZQ4C6>UR'/+Y1'G,;FX]8"-0.'S8/%GO>;<(5U8[>H2<H
MK#(1!GV;S24,5^B4UP58N'_\)CM:2,25#/K;( S=.N";+B6:S2)<X2M"33<T
M(B9\28AD%WU:CX#W^)4PZ,QUJ>QV&=J\^:&JOWK#@1?%FK67F=DWVY:4?2%:
M_/_$KI1O\[[>>_.-5FSZ/GE1Q46TS"X/E%R-GV_,RHO7YR3BU3DN-/DT^GB8
M]I4)=U_HD=.]G>+&YJIHQSNQ#+^SOS#.IP$S_R$>_S+R#+B_QW("_9)(2G5)
ME_U;=)2QDK%PL3!YAWHGKMA=AL_;OAM>89_["K5H(6RG$\<6?)&&:Y5Q-= #
M201XU4 K+I>PLU,G.F-B+76&ZI<=A22".E>%WP;0X#:7R%M85JP9O'L/]DW'
MQ*KKD_IS384E0N9&D*$;H#5-?B*@K>7CP1;WX<0M23!$,?$G5P>Y: NX.ZO&
M=WD9M9BDWTLYN(G98H(]TN3':S\<+;=M'3DZ+XZ4&W3BC=?LD'S,@MO:_2<E
M_LW<5(:[P1>]80\"($^FLFN;-;ER/%YHJJM<K,[V'NA:O)+B4&/X4*(O6$NO
MB-.)^NOJ1=1P+#\9VB120V!^:=-,JF>R1(L[ZGXY+7EF09-,,#\(31VN(/7\
MN$P:*IS&V>TDR/F"]B=BA+K^?Q+&_M?,E/\R6C%AV?#ZTK92,93*L]S'WD7[
M03_DSK(4Q %$83%?\U#CZZMLA(%"W>-S7%[66)#ZG>B^T1:3;.]@<D>5UHR9
MWCNZXHL:)1.!E]-7LE@=%YE&[*84Y,5F5JXVOP":D]Y<"-$Q0FJRUY[FU:/6
M"Z]+&C_=%7$7*A*D94/5@'BLND^$:^PT7QX+J<%G"(SHMD0TW=V6+*/:9@.'
MK)_O+7M+VH6$Z65_]OC/H866G4L0"P]7UF=GS3,NZ4BQ=4.;?X$7_ /F?8^N
MDVV"><4J&U!&8?GC_&*52@:KG_6NU-MS]G@N,1'X=-%T6N//.*)LW5YU3GE&
M_#Z]@RB74_D"_M&FQ2$?:<Q\/?-A&RH]?F2QX;CB*6IIEW+%4C8WYFG(TN,Z
M*]K9RQ] +UH";=#9H+M85Y0OLD-#./F)DX?,)0//X*_F-OQO'X=F]!4LW5DA
M HY23JN3[G&T?.]<;SGG6?5\_FC=3>EROM5:\4-#=DP-FANGJ__Y/>/,<]>(
MJ%9.F%5XFS/V7$(??6O9/,]SY!M>\<]ILB8W$:@N#Z,\B:YE,/.>',H"GM:#
MFO;TYB$(P0BD%;I\BY]S4M+YB,_ =#QYU_6Z#)VE#C@QGDP]0+DBP5W*Q#I^
M=OO6R"*2(!H;(VD\D"HRUTR7.*1AD[C4:@;W)UL99GP:@[?6::BODR3[_/%-
MWM'0F"MVA+JQ8@>Y_)9<NKKDO0^%FC5.VX\RHZ&ZJK[VDEH(Y]2U_9-T<B[E
M_1[_CZB!E4 28%G1F9=$B8V*OJG6W,V2$-LO\&6>B#\^_F' FU@:N?43(?==
MC<F761.4D_R6"'@'NCM;[X.&@MBC#0?PRZ=CH9D?R Z&,E &/1HB\ IIYQ>6
MTC\,HC@-70>J4M2^,<+4C*E[K*DW"31H]?+D0K4Q78QPBK[(Z^I&.PITQX8R
M&T;*O_;\-JQ?IY[4 OQA9SPC5"<[XT1 D %&:-3&S;9%5&1"[+).::!$X/B7
MS/KD$>]J64N>!XT>KHA\93AR=CZ-Q(@8[$ZG/W(PL#[[LLRRQHFKQL)'LLBN
M*]<,1T05<4Y8O)*_7HI=S<GX!M$ZA0^8E(]9SZM^J;[3G?50OZ)2XQ*@P8:%
MD1,LAPGA$V1_P#7Q41PS[@'.RI6*F+J/'5L-\XUX: 26I4SC$UIT%N[#M,6L
MQM@:U;N&U]VV:CZ_=;F^ZW[WV_K19V=O)A'6]);)*_81J1RNYR_0IZ1H!(YF
M'0@])0+P Q*A8+!20KD0[@R%$@%+$2(P:F35?ZX#^QEG0P2L!XA MH+_^'.8
M3X%5G\]S-X7:"1_90;H/'C\[.WGC:5G)3EJ]/^T*^=FIR>=-UT2ZI!T.W28(
M<NK0!Z9*G)I$9H&QOV/!K%!K+(\8=DJM/FG+]WW#9(6TK7378$9"NJBZCY 8
M.IMQ"1$7UK/?(R6[?.OAS,LT8SZV6XG#$^\AW&<'+<V( 2RW.K<YC,Y"=>D:
MR OSG7VM54[%";RSZK8%G7#XB_T76O&K*IY9;GYO7!E:#"6R;+D@O]JXX0H&
M"4S>X>>/TJ445G=%@3_)'7VK$IM9"8%"A#X4\WCN:Z-O>H(D@B79)X6G1EJQ
MH=*[D-TPYIH!'R:%UN: ;\]@35\2X$Z )X3-GT)-';7TX].#VSGFRH1ASU^R
M*<E_AO''[8=LB2APMZX.-B1%3F,NX)X\.?FX]^E[(B!+!"Y4Y.!@V23BJ8^P
MM+[[Y'>5IIDD?<;VH;1&G@VZ(D9RKW#<@U-Z6=59*M^413WUGNZ6./F^[Q\<
M="4,Y?)N7P%>HP1];<.OE_S<::@$3@WV4[]*""W1*M]@YRX%;^TA]#75J^2C
MD6W*L'ZA*=@B*7ZZ(H ;-_4NM4NY=ZC16/LR7Q*HSD*8'VIU@<6U5V]:/J%,
M+!;BH [1;TOIZ\((/4@2O0J7:YNN@C112ZH?0+A/VZ:NV#6'B\NO-X?=]>A7
M9CN^%X,"=TZ9W7[SRCC)VJJ*3*'KWO:AURQK$)6OUW$V(U@7GU<1-L(]%?%Z
M:C7(;'#&5-<M7!A<H.W7&U'N2! :W3VVE$88.:JL/7US<X]FY^:N-3].#_7%
MB@Z=OYCH(J'_FLWV7>, Q?/WH(95DTK"X*<Q_>QM8QE!V:XW23H16*\KPX00
M<?(F; *:$1)1QZ[TT+',7SK?X4?IHM4\_9^O@VZ9(.SF\Y4X,S^#,HESN44Z
M1^F7C2D;*M_*Y7M'MTDI7E.!"[HN<W;VEP.S+;<QC=BB=:-+K^OERP:4&\8C
ML??I*W'!V2 [-&A70*C)NT4]-Z_R2D?F<>32'K-KPE#6<M:LHFK,SUV<?KZN
M"TL=P^17D4?S7_N%-F 7M^<0NL'Q'UY/]2[;S05[82(.E6QXFG9QL@FO3J'F
M8TNWX2Y'C;RJLQ9J(A%:-8FD_J:Q$^)=7H9L"-%.XGJLHO(E_*$<C<(ZOSIV
M&!3<<L?=?F2UY3+KIT$.00V,=^_XIAF8PF6U#6N2?SK&X<VM]];O:N,LA"S8
M2N)<$]9O"#L[C#D;H6[P5\*F@KMO%IWZ/IK&QPP,;7:GGS@3@9<V/#"S[=K!
MNPY-;(2B%_)T>OPVG$[-=;%(]1*2 K)+:%Z!E+43AJW:D16G3+7[9ZATTA9=
M)UMM1XVS$X$C"9)T""8MC*QP'2_O_5I@9O5N6EI0WY,EH_D#KSVZ(@2Z-\P(
M^UF91X*1#Y S()L>PN>O,^I/Z1 7.*R^VO'9Z?+YGKK^1N[2*3S!.G#,M^NW
M87C8<U:KY.:?2Y\ES#(A6 524^/ CA&!I]%$X,[Y]5)VRA1'<N%G !D9S?&^
M.0% <42HD>7]6KS:,#)GG#CG/GXO_Z$&0-="[X=>#+J!!V&23#*5CQ>8=+F4
M'4M7Q5S:>K=/X?6;W*WAK?F=Q8Z?KK@ZJNSILYR";ZDP^9K\:N?:59-U6=D0
M1;5,@9Q<7_/;5B;R*R2[\G$$Z0%(=(4F/NWXQEHEW+U7N).\1^7ED30G& _<
MI]R?U25H&PH1VHT(0="!0&I8O_DH$5C((@*W6WU)\$<$+A<DDM"RD AH*JRU
MD[>OEI'4RMXP$<BQ"M)H^8M0*?^C& M8*X7]O$0$"*VD#1PQ].?1Y,] NVDI
MUA'8IY"QD14U13:)S3Z108'9T?LP.[S[8-Y6$VML]]S/>F;R$8DWFC@=&/<(
M-C2; 8H0S7@327\6D,<A[II<(TY/C7##FB3A..",46@9(_K.YZT+4-%[U(,G
M,#0"H@*<57>KM/B"(CSXC!\V.TDMWN=$7*(F1RN#X_R?+R_(P3BPB[V]MX9%
M\-/RLFJ[8FY?\'+0#:-9#FL5KY!G8S8O1"8*R4C.J(W3PRQK?Q"&TJCGU![
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M <4SIG>1&CI3[XN.7ER3/QJ>:K4VQVHM\YGN>1CJ_#)U693LOSRO$O(KR!Y
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M,<RV.4JS,?*<"]7NF/%".(7&;_=:I'7^4PLE/$"YW95Y>&&+!P+"S)&[#_
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MYL.1QGC@R-*P____>QTROHLG&+V]\SYM-,-GP7O&Q8_=Z%\5T24Z94F1;5N
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MZ!*,F;QL:)<P0/\V[8UOXPA5H_WY#?2(?(M_:3XT@P%^"S/:I=YU+K\OOMK
M86%ZN  3.\EQSGG I5OP3(FB2!J0I@#<Z745P"Q^_ZS"LT!<B/^, =E[L\-S
M>9_B>A""F 8'&:P^,N5.W,?>3W>N@;<FJW\EZP;0DM=&LGTAIL(](SI-.L*=
MX]R\PRZ/L=N+8!E#/)"1/'\Z-K*V-7\X>GKH URTE?@]7)H5<F#NF*[,?/N
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MUKXX?U>2N9E&Y%K3L^%%S I+_(*2P*E/)N!6"+&'>X-X,Y,5\\Y/>*'DJ;[
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M>CQZQZHCXU#XLDOQ'L<H\O&,-<2=N)NL%SL&O/O+#\7[B4'9)W5L)5B? 4@
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MCCQN6<F1V^;5&I\Y(;^^FN# X.EGE>37=T@M*'KEI9]>C/[3=?]4F(@I/7D
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M *\(F3?CN5TDPI6CIQVL/01423HYE.-\P&YA8WSL/*"T5!R@]%[4\7)1=%_
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MYL2XL;K2AQ/5*1:A[H<@?/UE%'M(_;;Y[O4(8K>L0]@-Y(V5_Z=->O^IH$F
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MQ(A1S/[D]G%?T_]F)@#6\,VWH(>1%7Y7Q(Q^39U[&)GL)=:3!V86BS*JJ5-
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M??(S0W8"Y5N=G3S).WOY/,%)CB--V@_WR=ZVLOL/E_OK!#+N>IT[(;5^P6F
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MD:;TU0/S1M[AG0S& O(4=4\JKWH%W-MO93 _FW6Z=*5)+5_C15H8*.GKOW5
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MY[=P]C^3UT%:/7<!SV/':Z[OSH5$XB$%D\TSF]*^$32ZCP7Q38HO6=_,6!6
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M>N\]A$" E%^<.;^9>=\YWYGYWN_,G)GO>__8U[77@KVNG;V?^WGN^UG/6CN
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M^AU)_W@D%8EN7[6<NN;/Y'(F4M>,+Y'&]69!DL1@E"_=.+=3"(-(4B32&%(
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M,QMJ2WYNY6AM5Y3!ZP.&>T+\=DX.%VB8HWW*O\Z%<#\UO+BHJVG DW%0A0^
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MNL,:"B$J=+,3ZTU(@!\M,':(^*\[;C0C6@*RUF!G5/$2[G\4CS?^9LU2+PG
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MNXU&GT+IIA&^"3^8[I7=AQGB@>_KRNA=!PSYT3TW'>M>0UP*)[356]4+QC*
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M9'&!WX]>FAX-U?\%A8C"O<M3S,,5N?KZ^T_*5]TA"E1^QW\O*)]9/LHW)ZS
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M'E<5M VD$KM"@BO.8C&4N&'=_'G6"PHAI=UX56ZAF^^WW^!/>ZX7PJM ?/8
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M_:N";UM?8)TD6BQB0BP?K]ME?[1JB /^L)M'W%KVD9^L L6.\4UF[=#[B8I
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MB]>2:$2J)N@O[8EY?6.R,!C>57:0J$V<,_)]=OC^').4C)R"DHF9A96-G5]
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ML^#?UD:;2[UDE#HN@O4NQ\?)ZZ*75$?A4;VU&;1I!Z+QIV7+"2)L#OWW@@U
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MX.:0$A/U_4B+ZJ,J.:"$YBA,LTPXIRK)4(><,.N^/1C,D-WJKZ@^YGXQ[?0
M6G+!P>E69"=8T?D"%AWC*; L*L]339B)BA+3?7H1(^L1 .,I\/[7MCRH*P+
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MK<PMGN4+"9'__DK->JTZKW[4T[,'*4!5"&I*,JJ 12Z*H*)K+WT6WUO*1@"
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M>KY"EDKAG^A_';QV&K1V.(/7S.:]8##1DOU A4R%T(4V++*>#G)$!JEXPX\
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M+6""^VYKT;)54_JPFMR1^;,R8KNBWTP?GW]SWA.(820]C&*,*3'=-;?1R32
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M=4\Y4'IBQ/LB<I=72^X'?E<A L!<&ZYIT42T ,?+$3W_D:Q2F$>T6EA,R80
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M*%\")^O=]=FE2\[3:,. =_U7_SQVD[C? VF0(CU,'Z@LSE::+S91_.+DVRV
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MF8")KR2OU^2U6K HT1)13!6,NP@#,1EET-NW@+/CT1UXA9M;J:X4C(UWLE:
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MNU%5IY@\.2E3Q=G%L%RZ*[=KD]EH*8W/-%-6MOU 0T4COSC*#O(:P7'YY)]
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M][JGF</'_)/'5I.SZVCZ#!7BV;(V-1-N@"JRR)546J&K:B.0-?S+^_BKY5N
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MZJS?<WZ^]G&'XHH A5+RR:<LK5TPQ-/RD'D7HE"J%W21$PM-!NUV7.\#K2'
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ME_.2%C;E.<-&#4?SM*6<FUX<"%KAL<('S>KH&<5<L9'G(-9;P$.^T)>:2:_
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M!W=_QV#0TC.PQE3YA?TR(\?+S:'?"U5/L^X!0\&%DAM*DVTX T%K]F L*($
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MD+^,K>TC9XX$FY[)ND%G)UC).W_,N[XZ_5?U"D1QD.$XE;(X%(/FK12;YGL
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MM;'I0+7\AVR^5]JCB]4L6SHN#N%=UA.1;P)?^G]CF<C6*W:M%)@*S7P%%_,
MRC-1WS;=9LWX\>-O=HFQ:@ZK0Y546U5CGBVS)5T((R><#&D--OP;Y$UG<@R[
MXH';[TTFT#%H#KQOJ$S9GDPQ7=:,$H%_%C2Y;N!9M_4_3%@";'LK?;.:HL]O
MNR9<&?%LDT.I ;:L5'H&U93@%T*/Y<TB]U<A4E=]KFM(NZ*)-UZV:$)K4XB)
M7)?=X')VG-RZ1_:[(]GVA$A'BV\J1LZQD=_^C_G=V5$._R!$6OK4\&2:W?1N
MGZ[\LN7*:IQ.DG/9TY)-94MC)CW'Z-Q1&BK6K'PIF;AIG+A?LS'1RJKF&2%9
MT9J_=5+?_PB+UNXFNC;X^GX[#D>/=E-DG$%+XZ6;>?E*@O1+7 EODCY_RZR3
M#-74>M/]DN.^G^A#!?WXUCVS2X7GEYRPA-W(.*?1W,.T+:26GA%6<"8[F:F2
M 5%QIH:&7^+OH['?F?]'0IXTJ&6I^;1^=?3B5][0FW#$\:(ALR-QQ#*Q58IZ
M?7QR][DH^3XDVTHZ3;SHU5IW&'5]+:QXM;;&\:C3L6U40,4P%4ZO^N#N+\H[
M<2$ LV\U@'UZ9YPO6(>Y_('P-S+T_GYL5EF'N0'+"/JZ8^Y5_\Z9\#Q"IS2C
M;#;E6"=^$VGRM3#-7(%UG><Z9M%@8(L2[M9X7"/+-9E+-1K'# -H5M#@::)4
MI,'9M6L;)G253W+:O5O45'[GU/0E7C['"R$1*O:^@#)]9,2"=(U9H 7+D=':
M&H&S(==A>'.@@-W>+2_.C3[M,U(LF&>U0%;&N2EK5;'C-PWPJ+%M??PV>[=L
M]/W,0+J.XMZHL4@(QPUH8&0_Q+%6?ZK;_@SGUT">2"[%!V:M$5.W\+$OCQW\
M+!&K#U^', 8(_?B9.SB?*2/>K=*=^F,YNG)_]_.&YP/8@@3!&R%A^I6>@1K!
MC.CWVC"]\6W5>4&)%\<:7,[H,+IW]VA)-;J8(YY@U>B?]+U*.6-[?/*&4%I&
MGEV:5(.C!^[W/#@S1TY0HK)E5J;&OC7O)-?,*F1U]$])C W2Q-"'2$WS _.X
M6M7[LU-42%O&MXRLHHZ4E*$#UITG')EWI"E5Q4)<''P!XXI]A5LQ3>\_VH9*
MC-1<@:"NL6M*A,1K9N]->XM_U^^_USB.X2.@Y^HUU?5VCV$%!I!*U=<)OVP3
M/BTNKE7&Q@ RD;"..!E_=$8\ %*&@)VJZ<HL1I]0_$6$]Z^XJ[\42KT80 5A
M"8^WG4U.IBDGU\>WF_MNP!$;'VY9C3_P/$(KS,6D&-FC-?JEN\_Q4N(;#=&@
MEA*Y<.SEO>_.*F"WKW_USA.>W9W,"UUI:%%=\NSKJDW(E%0,JM+[Q)WL#-BR
MQW!)L=01;JU%+ =(57;$ (2/GM0B^"NX9K-<;OZDQQ_0@R:HG8!S>X'PU%S%
M38[4T-/GS3[HA^ Q!A#$3+PE];376NM0' -0,]*8E:(=JZ@Z*M[,?A'1]"/L
MH1&+Q8.FI&)+3_UD 7[^A_MA4C OAD++");81+5&21/7&P!2(.G^9X;-+?AU
M%LZ]S,OON@]4Z?-,^YGRQ@#YQ(IX02*VAY7VK+F7:%WO""9"S\ON^=!?#WC[
M(#PH3-#@<3_Y,L%/LT+I6=^PA5AWG3EN2TL96*QZ1;+R;\KTXN7"_Y6K?/[A
M:I]K9H4U;Y%Q#&"F^JCY((,"-:&CK]7^PNB7=)\O>FVM A_9G7O!!F4M'(W,
MYT?JE)H"8W*GV]&=*A"FV[G9UG?HG0=(8_]1NZ<5?R4U'KZ>5?>>ZS+4U@C8
MSH(!:&O]V-&-MJ"2Z#L^#9>4VH9_!(D>;C%ZF'HPONM?+2>933PK\P8)S%DX
MSXP>';//EJI/J%2H@'THE_]/]!>N;FSQOB&(JYB1;2MM1T5%I_\;\P&3@T#J
MLK')H^5D!=Y;"=\)/T8[R('5/NO52_V^ZB_PKXZU*TEP\_A5S@+$5;8VI:1-
MU^'(R%4K>&'&H2$4';M\]W-X,#?$A5D92X)H$9)0?+^':"]/S+92QA"ONJP
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M' -P/T%S?(&])"+4-JKMT]2*_5T%^/_!^L->(HTP #[0Y0T>*-=*U4J_XL$
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M0S^BQV'@J+ )"R$)-7WG#*5N+?1A/F8L]\@6/9EU^/3ITT2EBZ@-K UKV?W
M+JM:46(-O5>2S)]E5K(2S:%;:2FM:!Z?\."SKEZJB>C\EEM@CV:5EP4<)-(A
M TNG6ZX\@>*KCB=# TJCU)>R6.XVJQFX=5";)[T:V0\A>L;M7;*P&\L8V0=V
MIKOM_N&0+K6JC-[AGA9'_Y38QH(@<3$Z.A',[HL!<(BX(2'+I"_FP?6+9I9]
M76B.Y.A[;VNL/$S,US6G.U>P@9XGDR:(G%#QLMI(G<^PV>/;#YQ&[_O&MB&#
M-.*U)HB]0F^9VB>91/'+,=+ETJOE/I/;^=#@YR!'SGU% -.9$3C 5BIX/D.:
M]#WZ^:-'IX)/O$$(_ Y@9[5^V)Y%+3#;,Q7FCG*-]/"@"G1_9Z9A^_E3A]6
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M<C3W=$4B:X3=TO-]7*=G#_[%)]],P$2.KL',PC38Q8I?$;NPEO'EUY9O6]U
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MD\: E$;%');0&HZ.MG:.?:.,AFE(F*XW1;2>4*17(R-?6H*H?Z1N6EL:69&
M%;R\M%)X!-X6WFS)X6F6G)9MMLMN. [DE\ +.2:@6*&%SBU+%6QA "8R8J^&
MNAJUT+L?GY_#E'Z31%*J_'<WP:]_3RV5Q2X7J<J;/[HYBAG@&P-CW@RY&,"
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M6.PW)(C^EUS>5_3(278F%.#^-$RV=7;$<CS[7O48]Q(##K,+?-D2ZKFC;A]
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MKPWCLE>A1]E=E9S=L.\4Z"<E&1]:(1K7@!K(9#F:%8-09\$[(V $2ZFNT9%
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MT$RSUNXB^KQZ4:?<:<?9,5_H^GV?7X%@M^YR*#QRFZ!!U@L-Q\M=T&G+QAJ
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M7@-N>_A[9/S0-<S7<ZEX2?8^W:=SJ97W&7)*QO#>I2@R)$VY/:Y5P> [WC7
MOP[CE2BO&)X8&N@<#60/JTJ1?ODC);S<1Z\4^A'%F6]=*KW)(*$C_@N><\Q0
M4]3A)[8SP+C50EW[OC*CJA]CC[ZK +M9X*35^'ZCV6&DS'UD0T+P52[ZNM8O
MB8GFC([;GCW@-+MQ@9H=&QN2>R/DI/R^>U1^@\EA1Z2%WK+U-\'4K_\*;6EZ
MS\5:F7%L(,EC8-:*N:5=\78_8=E;]LN+H<E^B5^Y9>AY8X<94/T0!3_-D^>
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MK74S0N=+T#T<.U78HN< E^YJ)SIJ<V62K?L?@DZG98 ' 893AWKH5_(Q%WO
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ME_RID2'(:5NC_E%;3IU1>Q.!-!(U1?IH)BL:A";ED\9FT:6A>5^YXQT:K&N
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MKX>;8F1 @_[?=33;D( %!O0L_+Z;6HL=7\^#1HL&5\ES&C_2+=>CC>^PA]<
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M]&RY37F62Y!0@RVFTKT[:Y_1ZZL)&=Q@WNDTONDDH-#<429#6%ZH3?Q,FGC
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MZB/54O],HX15X<U,ZIK9>E^S[C4V-AU[?N^SKHL3L3.HEB1QMA/W;Y6>_V_
M;Y>'_:)AY=V7NM_4]_T[;I3%54XJFU;1(S&PX*<LK6  &=TA:DMY@,U!!D=
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MV2L\TH?.D*VRI?VL748D'XJ]A.(._D1E*H)LL?5LHUY\FGRU4&E&4GLAN..
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MP$!'1U[U15X'T(DPB!D%Y#!)-%]A,;TC%0R(S<)F?E+90:8U!F41LG@?B/.
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MYMC=2C?E1V<RNVBP=S0H;A%#KA%B;$6VH\24%OQAQ:YTA=!!K=3#K4LS%G5
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MO*7OUB9)#^;J_F&-_ 3_LI*GYV:A;""@7:!X]6'F)8/E?$PD CCEMV^[V$<
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M$]8G4^?0NOF+JR$FP^:XC&-2U@^PPY$-X[;>F&N4W;8+Z,H-OKV'0\>%>I"
MOM+5$?=VE%)C["YAT?8\:\G=T^D*WF:%<EPCJZ[7G@E*TF1DT0!]K6A2H=HJ
M'SUOAF-1Q!+'YE/?*DQ%Q3XI6DRJPUT#>M)*Z*\K,=U6SD1O%9)[(SQ_[+4O
MJ_2.NM,CG6*FG/7C-4YBFBVZ"3IO$@\RKYSRA )&_":[C6 _BT#A+M>7@>L+
MXLS2-$SUS8RK4=:U@R"R?>HXJ5]2*XP!-EU\M.>T1#WF?_U!>9]T[R6&3(I[
M\I"0@+X+WF*! $8Q>(/V/-*R^>[X.(R0\:^T>6.II 0V7;Q,.WZ*@@#4I)7N
MA1PV+E0#UE8BKBAF"M=)VX12"7SJQ/LO5J=CNA$ I;TI4]7WZO%RZC6++T/,
MUZ\SZ?)DK_W%MP+H($'M9D&E0/LMV0C:_72Y]FH]=6L! C =1 !9>CJKE_A0
MK^>TZ\.;H/(_%[\/EQ7%&"&#XF@AR"+M'IYS0M*7HVPTP##17?XIW$-_0C*%
M;J#7LZC99-4-RII65YGMX"Z+\]$YE4-7FI!."2O(X.9U!C3 1TW00;-IH8\E
MHE'Q \TF)GTS]0KLVX8)R&@T<_R\)*96<KCJ1[%@,$!+(#L@GJFDZEP!#I,A
M=M";"+B,^;ZHQ(\6^#-2" :%4)\Y_Y6IC9OI*Q6J6)IG637PQR3+CRE-Q)M<
M1N4LVK5AB;"7?\X],UA\T:_$U4B <M7+1;-:<.>S#SI2NMNA&EPR6/:1.;G3
M3=0K73:.Y7]U>AW;2,N_.R&RTT9ZI^F:;4\^[49<(R:6FQCKE8UG2[\9>TV]
MWOH(J:CJ9E<\)9"-1]^D$IM,"Z@3PQE&^V5O&SNT_)I'F7&DL I4U\"'83XJ
MA)<=02/Z49WT<P]>N-N"RES;L)LU74OF1_)6GH\/VM>NQP[K9SWND(8JO)N^
M-". K-&KSAWQX<,^.=?JF0\]$@<V*-E:7!$ 3EG-7$'S9,TA[]&0C+[JT(>M
MTE!Q!I^</#2C=*<U'J9C_1.5B8,WAK^&60P*8D+TSQ+[9@ _D1\;$ Q()]&E
MM)YR6\,"2PK5X*NQ]GYQ.KD>:P^023WT*C+X]QK7ZX7UV/;A=G5C7]GRI/6D
MB)J6-S\'U<:W*12LSZQB25??^>=(JPOWC.ZX\CBH/_0A:9ZTZ4N'<JI&!T\K
MH,]0K!+B#*S_X)I](T)UZ+*3JS4F/ZV"?7R =59>Y_O(B6)59RJO\_6W+!+E
M@N*DA!?X"E CN)Q$P;V[V3WFYYO4]/"K=!S8UR:%EHF!-_5<Z"6IW)_:B6)'
MZ17>W+T)$6T:I_I"\KN_^<:FLA8!7/.\1[H+\ VJ[G'O"@PV#EZ*OQ[E#5@#
M83I*U,*3UEO4M6(<JM1(\7#I@O(E^>BXT'JQ0S=P6.7 ]D&IWCS>6$$(8%-U
M% 'L]X+N ;W/L"[XLVND)_X*CAL5J\P[T>LD-S2NVH>.<!F;+64(4.*7]+VY
M+[[J<D:S/YO=]6-W_!8\WW_X.YC&3]>:_A[#X<XV:J&+?!PE0?67P'G_8[@.
M5A<?N3T1#*(^:M7 57@=74+>*UDOR2_>*P$RE,#2CCD)Y(!UJFBHSV=NTP\:
MM5'61CWA<9AX;A26.3$/%KBK4OKJ;KX]0Y\0MHX4EAL+WFH.5S6I[U8GV6WR
M*Z"/+_/X<'@9A\+BCFG2,-#E1/,A]B)3B<=Y=05O#V(3W]G*;62T^AX9,BS*
MU>L$@C+*O G2\*=:4YPP+CH7390H#6PT_3?=.RJP3J*_K>X;*?,VBQ4VQ_^(
M7#BR>= P_%Y1#HM.S0L!^ ]=0W637>G@?ETQ0L>O1P8SNLY[\.QV=OZ3$.#_
MB7@5X$5^7S0I;O)N-)4SD^ZU?3G3C/]6"? 7\KT^O,#E."C?.'/:EJ?]I$+S
MY8**=O)<@SD! 00[K1'>H!;<(P DG@DO$37%A/9F" XYY1B5AK_'38S'@J.K
MN0C_-1N!870OVJ=3?\IWR-@8(8[+:8LUZ>5'%D:(S'-Q.L22DUEHSC+2ED(W
M]6/&FPS940K#2!UI[0K#^8MS $)9+B%=Z'1$.;^3^HN0M?;V#PFOO=Z@4T]E
M^PN<5SRPDV!I=4O+ZT!O:(]/?'7.K4+&6[UVS]4M($]>8L.K1<Y#R3M8$QOH
MI\7U(AP8@K>/MWU' )5^_>!JMX-3L3J!U WQ$3,O80CAKBDH1+^F1.YUW'=;
ME+DJ)?5F-7M-68Q72Q[@KJNFMLNRX=0J,V>]L^89K/<;6"B5LVYE/]E1$XMR
M9QUU>:P+%WAZJA_V4,;VBV,Q!*F-NSA)/JD63;8NK/>O?!_PK4K=I_)1Q9@L
MI9:'9-?I/GC^.+^H[>PIW#WED7O0YW<_Z)3RS*:$?24-Z\AO$E+U!- ^T[XO
MF"3JO^.\($496?!@[A)]JXY'_90]/G] QI9;;^*=.)TD$M+[8JF.\FP&/:LA
M'U.^79*OMJZ,O.N^1*TIS,23UNZ TT^7MTX4VK\=$M]GL'GB]T-Y9,-0PBW)
M,G<V@@O7*G"6^*ECG*#7Q46)BP:6)%N % _/7),O^<H0FQ0Y;L:5W,+-RXK5
M%4*9\J:B\0V*XI_[3#_*'_ACDM(U Y*ZAZ0HL:4P2\43O%B9,HMZGH><'_OW
M:^C5EYAJRLK6JFO#YY=$Y8G1%08D7[[%$N$A18DJ\5"7FV$CV3.TTOZ%*?6K
M2H#^MS+;2>$C*#CD#?>KJGCET -HI8N"K=G72&)EAOB Q>0=]DQLGM+#0^[L
MZD#^NA-%9N4!GF TX,/ QO3WE#6D!M*O#KLH2W5^Z'IL=KLI"GZVRYZ)YVO6
M.?^HV5PB+7#1$Z>*NW^_UE<&.?KSRS2J^F69:I^[ XC>OR#%0QE250 ^S+1B
M0%NSWDXL[HP*E[Y_1A[#-AG,H)N?DKL[+X6)+S%,8S<P0%0NYJNN#9N:9T<#
MZ4/+0RM&:&_R A<'J0\4!256;1]?*Y><Z1N.Y->E<3.64?.Q],7_M*0<_C!>
M.B9+)2$64N-,2!6=8%'7:X[^-7;!3<)WW=$PG!U-2 ]Z&5O!R5OTBFQXI&GH
M\^"YN=R]0QR,N8NC8, \^2F7,S.F*][MU^AOKX^.)T1&-66IZN8QD^RS!W(Z
M[$C48TVH\0_D\-.Z6+93TR_HH];*:+H.!<9+=6=_ ?'$DF_ZD/KKJ"E+Z143
M=(YOI T?:YM(=!SYXIFO!W(_@E(2R"14O'/"F/JQL/@DKG._=L/UY_=SIKQL
M?_%],U28Z?#)F]6Q3(,O1Q@1_%CWX\KWG*H@3!CD^12XIO1\*N2,>]DN47[0
M=;4._&SI;VZ$M1X!&,$T/\"_^[+_PRD5&:FF;& X>R;J?Y0*]PQ%4TJ?,DV^
MSFI4N&VUV*P8O2#S"@>V+&">:^Q69R1/0]UOM92[3KD57#0ZR&JX\(A8-!DZ
MLWE'L;Z3L9*B#/BH3&9/^.!#MC!XWF<OB[R:K(>T6\') J"VSQ[N)#65\ U]
MX$N@ZH-6F$W.Y(PX.;L$\#*$6&,Q6D<^QIK!3",5D*.,ILP)%QACULCT0_7?
M8QGM^8#;)67/_8*_?_]SUVB0\=4=US'.-=S]\H_[:KV%'*?-WG,AGR%SX#*-
M/C&N1QSEYU=:(@\RO5'T;PJ"[J3+3&C2Y%5#[$<,T 1)+N85(=2+V?Z<]C?6
MB4E6W =.<;CF*D3ERML5AGV-4,+@-]M":MD=6R3QE6DH8 4&/24%X.7$^2 =
MY\+!C6^N[NBVI*6QU4V&ML$X3++K;!\T/VY?/ ,W3QH^LQI>&]UPD_32_4V*
M(J\W5G/H-6KHX-:Y#JQUDEM?A_H4828]&^<65F6TSE^(\'[;$XAILWFQ&>>
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MV+X%\R!C4'95;7U5.)>WOF4(:;O^ADDQ&$5+$S:*Y7\G'#A_U7NZ8*Q$.SJ
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M5I=)1,[:PL_[WDI%AH!^^DN3AV_79A!'@=M/':'7UO-S5A_%.$V^4^P).L9
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M5(_BM)/>^Y9($TT-ZA9T'T3IM00*1%WW66]E.JEA+47%3$X[*4EWZ^ZVZCT
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M'^R<75Y5*PE4&Y$@@!SORR7EP0S$4A@E>-;H1^TO\X[HL<^E+F6IM#0YITI
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M[B)V^\G3_M:U:C<UTAI"E\>*#G%]/[S'_WQHK%R!8W<?XFPGF3A@*]*L-%)
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M0/E18(FVD ]SGXN:ZMMFIQ/ .0G1/F-18KWBJO[6->^([H,KP#"@/_?7JLT
M7.]\&YAROOV?*9OFW[;/J&N>!Z4-)UME^!?9Z+B\$5ZB0QA,*2O#B>S6$TL9
M<&(6WZAF[P&;VU=T-'F0Y?6LWNBVE?!@H%:ZTM32?U;*ELB@R2TZP LMH43>
M>'L[Y\P9RF]$%%3=:Z"QG-><-;$^#FRN"G5R]MS2,RTY"\WB:^)7DTJ[@"QJ
M2^&(#^FT(,6A[J4LG>/!#>C&X]^0I2MAJD+7HX:F'HY_[L]_IC!QE5]F)5&
MR;K 2JPWE\: TOKENTZP_,>&_,@+)\MHU\P]; 9&,6(V.#>S9">YL*RSVD>D
M41M$7:CT\2^WSY?\K>C+PF>#8,8!?@D+(]B%KZMC?KQIQ*'(&K83:J. Q=8/
M1FQPR(]3XO6H\=E#_C=:A>B1A2J,M!D"J&V"0F4CJQY:>/AJC,V6-]\\!QU.
MB[G'^<7R=G!?UM='QIR&RHV1"S.R04X/:SPQV!Y S>76U/87:ZR%@$[\IX=_
ML'H-J)Z.(@7F\X-L.>J2F,_(/(Y2<K%9X F3O.)2U.X'QFKB[4C$9=0R)VN,
MNOB5[+WTHABIE\^8[Z#!>?$"+3/FBX)!<74QZ^% [6>N LZ6XF1D9!)(4UO-
M$J3]<<A29 JF\]W3P[/ (HVYX,[8 Z3..&+K]MW6B?I._W2?3,6>?=S*Y+"U
MCT4,63R66;7)=\&_2(5TI30[)&B8&O5K@8Q)*U.G HRJ/^IYEBV\,1N&JVKB
M5*JGVR!/YFOV>6^WYXOCVABD,\^8C[8<%C.VN=]:'#UH(G7H[Q -SFO)1D-X
M/'&7X1F"#,%66AL 1D\)2#8[-[P'% 4D\C.]($P'BZRMD-YV-IVDH7WZTZL_
M>-XYDFBY0X$5R"#Q)/E?%40$X D X $>_A?9];R7(/%Y:MTX_'4HI<O3=!%D
M3A*UUQJK3_U+0LC&&8IV]U=-4AUD[&?,-(*8VA1"RC"NL"I$+2[)UT(LR1JV
M^]N;9G1$EU7<*V0P"Q1NQWN]71%9^[W!7U46"F3$Z //IP=<![653Q650Q+K
MJKMU>X,2JTF4WX6T#-4ANCE96B7EC98\S=)0C767J:($S)SH-2=>EU(,KS[%
M*R."NH8,E2+[>@P3O?&(%,<C\0$KQ/G&-.QD4A=8OTC#/.6X(')=5_G>E>NZ
MP5W(2V\/]3 >AQ(HK*SQG-%DQO>;$O<"JFPTXXT%=X!GI P9"7O9QC%Q7X^U
M1A)I&%8GSLG,EW^JD>!XC"$T33,;@CYR70;.<_1:)+P4>;P4L+M07H2%KZ9K
M9P^ARV/_6\5$=EV6 7.S1$T:^H$1/I1J]L&+PX4D&RAD]O))6)+11\Z]V7TO
MP;TMR]WAOFJR%3(RFF[5:_:<<]6NRR":PJ>9$B9U]IW+H%_[UIRJNL+EJ6C
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MCZ3:@QD-""B>?<ZCW\^MDV.SQY+7##/EGWX=.?O%ZZ!"AC-8$U>K=57T!8^
M%-PT([>_KJZ$P)^0@_$)(5[WW=+5,/;<C86@RV /GYF]]"=1ZJY-LU.5\@3Z
MH'+K^84X"/W4(U^V!YM@UZN)WD-[EI1KZ3$1:S#GM7_Y;??G1#,EX9[22RL-
M)J)MSA4I?*RT<'<(L62Z_4[2=4HL XL=U/;5:78!@JU.NOF#VZ-#'H[UQW#D
M0M$?T>?5N4DP#Q F=1V.363>9Q12?SH !M*'^%N-K,RN1/<?UOLM[QNT>&BR
M<M,VS34=[_#HK1]HQ_15!L0P6@+[JO,9(@VWL4WBUF9%87YAM\^./+'.7242
MQZ%^ S6"@=+L<10<S?]C]8&&.)-NWP0SUSFD,BZ4$8UJF3WR0#,& \D'9!H;
ME#0W/_5;X_UG*2!D['DAZ9-/B4Q[@\8AY&.362F!6]H8D2;B)=^=P3DGG,DJ
MKJ27'A5BL55"1N/Q_"C1Y/Z.13[#$?< G-<U\ZIOF3<E>;D'?S'<:,X]FB,$
MW@SQ*/#><7;B6V$;9VF5B;](#YU^VJP$D?X\DI#M)J_*P]'CIV=F1F\6% 9[
M L5D8E/?9I>"L@L7,)O1]5,C?<KB "N T<5 U*\C5"?\\%](2V1 VHOR6K#+
M-#J2C^*NH'::">/.H9"9N41+7Y-XO2L'Q<U(KU5<P9O4M#SHV(+54I#;<8?0
MBSN0HR9*[HN6KX;B-4*:'J7$JSG.C@'K>,(R84E($WG:'X-P.H*_N$>KT?J8
M?.!"+3DM@.N;9M'-FTW&2N8[<ML>Y=!Z93*L?;W6ZC%HOF[2S!&FPA%I!O:C
M54MO[L!1N*<3RY553]!^H5X$8C!HGD;+ZI I1P>7/>QPPFL JHC,W[O^P-M#
M4O'A@?L"%MR^6;XL$@9:L1AGPP.">@&[+37;0^L3?,G*=B2U,@:O(7$6;J^$
M6'K.]$8RBFB@SB;V45&U#Q\7T?)_)E\>L3/0&W_*RZ2*_H+B9A)V1]&.]];,
MB *G4KGT<-0#&W3G1-XF1-;QHR$V<1T@?>B6$'C7(Z1YY)$/MV$F<DMTJ%H5
M"*PP >?0!#N4H?DY+7(TDO=Y(DZO_)NASMUW0%(\=_1"$+!CUGKWZFD[R+Y=
M _.Z/KQN:TLN(_'<C52 'EMO3''BP1/)?Z>*S_MU0:?>*-R9'^4*NL=A@PXB
M";XN<W+8%U2Y$>J([;"/(P+N76!$7MJ17YK1 FX%++)';\BM)3&BYJ4VD9"/
M@8L:KLX<K?.59W>_3F]DK23P;+.[(A4]\?33QW;%H)OV+[WPXCC)=.I?KAP.
M;JE-MF(OK$D,"UTAAH<5![HW3/@_L]BU+VZ0/^Q<IC=&?WB4Z^SM$LAQ2C#F
MTQ61]BY/0IOVA:8^F@<W[%S[Q1UGH--RM<HW>@[,!P\4L:V>Y:B!;Y%K=*H7
MJ9P-SAU>8=]T433LK%2Y!YCX7:I:9%("G1A:<RF!NU6\F#&7=-GX"+G46 =H
M<2"5,HWI^^&P*%K%6Q XRC@R-V$C1K7P+/@-811&+WG.T8,VR3,.^AU=>.((
M1>KWPY;@'-XB:E\(=#D+-K[$ONH:G+<[N./LO_"^X__M':2.E!=Q5\;_[N64
M=B(A'>X,:FVI+6\\F2DOU)Q4+]5*5.O:[/(Z)A=3R]]81',MVI%H"@GLOLYB
M_06ZV[H+:)B5&=NK\,"KJ[#,M%5&B,T1[8?$Q Z?Q.8.A%S2W@.PM!\<Y!#?
M_PJ9?9$>XSSEQS'-^,*_TD;T?@8K*][Y:V'=N\TI;V1OYUHF6I5@E8KYGPGB
M5.&CBUM:YZH_/LX*-+3I_;+SQ3ZYFDPRYW4Z". $Q='2L#G@52\'GLO:CP4R
MUDXA-E75OQW+_-(-&OFHZ4;K[ITO!%,N9.)2#%0M.\$#>.U&IBX++:LP%_;7
M5Y.D7V>7\6Z.61W+.(J MTX\4U7]3_P-RF^Q@4 )9F$,7C_0'GSH5U:2KE)5
MOP/1[D?5[-*P*#JA<#$=S/(6#W78@$LN[<Y"V6<Q[ 3#*)\^JROR8T:W_+9C
MV^*H4OFAM@QHH#VR7 &V.B.QZNU"N@6EY_ MIF6T3[0B*9F.-:$H3C9K#&VZ
M=4ML<5I2C!I'Y1MZXEIKTL!":=LI=JF?FT%WMHR/9A6CNOM3THD[J;R9)3>.
M[@%$$U6-OO((I?>>5]#ULK"0((F\MU11D94SI,&WNPZ7(YXQ&TYM/34('H[$
MUO %[>YP(PX?*U0E1D]\H"8[J>KB ^*RC9!7!ZB2SL(X8=5U?,JDC<$C2=0^
M@FOYK ASN[A]O4INR-MK2KR;IE>S6IXKCUFU''BP;B.\-6T.F.?JDDN*E:9!
M0KMPM'D'6J&YCU(%R5I:ZO%=7S#G(]VQ'0ZDYU'Q5D\G!V\@[FN=,[1A/4AS
M=C=-'>7IW\30WS?@Z9>=]N*'AHYW?!@<(LM<W-%T*E>)'+5@1+%0%]SYQ =O
M-QS?XSQBS,GM![.TB1^R )M*^2U#N$-A).X/,(78&;88K#= D@FVR%KZP9AJ
MUU6TWK*DLW4V^6Q$<KQ)>B%XGLR:QT$4* B"T&54\?_Z3_292C[XS_1O]1EP
M32V*8V8!SIY44^LX>,WX$[A=L?;"NTM)Z1Y0/.U]RG#LX'*=>Y42IG74)$JX
MCXN"4BJUK"(N0VZ>T60J4UEMH79<HT?PR;D$\+*S"$7]*QKGLR#B:++GGM7=
M^4Y+BS&(/;O(#]$=9.]Z3J^(ZC(DAR[*I VYV?C:[K:5D[ST2V/<W!,9#DLE
MJL-MW2?"$M_87D1+1JDI@Y*#C+F15SDK"8\G@D_$G6*WI-S(8"#PW>2H]\;=
M[-U=(?G,E<W-/6#6>W&\..^L_!Z0X+DQZ,%S9C3#D+$=AV4;7[GKF04T4V=!
M4<?Q@.0.L$W/Q;^L$AT& 47_0Q<@O1!14%&:6$ *B^<S=%E8-=5"VY@RN67E
M/2#U6]-!NL0L4]/&K[?7F^"-<+OCQK;3O_Q,5NM:XC%L[ U2<ZN?GP2'AW^J
MP8N.VH,SYH!?M.WC P;!8UA[EVK!J]%1]IX6\ L?^&U3VR NMZF5@G@U#^&V
M15QQ98]M3QBI8.GD37A\'R-O!72S_&%1#>Q?Z0JM*%LU*^OPHLPF,@R#?&M.
M@+;R8Y#&.\ 1AZGV5@W Y!G;BTMD=1F@*.Y:S(A7[@0'0[>#.%.Q&#0C-C82
M4AIKQ/TJ!,>,T>%5?JUXSKO(/!%/)+Y,F^_8OSZN'.<I*_<PV-G%]=E%!\M:
M>SXSX7>9L)T7836%*?0(DV+*KI%?;B]&%+$OQV58._+L)I=.E'ZN/U5=]4K/
MK]107'4='ZLUL/?KV<BV6+)3)D4?R9FZV@:J:-JEVC7*> ^JWOC31BR>3#=1
M*($GGK21F]A<[B^>=\&NV>\!@ZWW@,77.3"\+V$$];&4=OI25-"XJ+@OC/RR
M-O35_C+T#V*-X&!?X!Z0S+,JY?S_\/7684V^[_OX$!4$%45&=\- !>D4=(R0
M&#"ZF]$M70HZ2EHZ1HWN%)'N'B'=,4I)J?'#U_OS_M3W]_W^L>UYCF/'L3WW
M?5_G?9W7==WGU?C2W+R'L3BR1G[E_L>!7QST1\RF+?5G6-<?;B1HMVA<Y'VU
M$80;@&T5LJH !K"*;[6>Y.9FWE^ZF-!-"=5\TAFT-S53W'-)DGKXGG:C:';V
M.E5L_.4+=(;\NWIM>+>MKA9Y)F!5Z(1OUBJ/)_95NI(TVG&_J>$H\JV5'U1S
MFUL^L2D?FB5+?A?G&/D(PW$,HWC8[A75E]GPM>WK0\'T5-<B-GIJM^+J2 74
MT&YPQM<+]5IK)0[,Z=M:1HN(1,?9U'VFY.H^$YPS0*;1[Q'U3UDDG.$X\OW-
M%+XR'+F9N<SKSM7$%.:Q-@^=(CE]RZZ7SS5\D>3[K\6Q:CIQV?NA&F)ETN)E
MU^M7!3,W@ 7#OISL@H$HTQN IS_G&ZK*> M5(A4PF'_),$%"N0RNH,R?VD2L
M$GF-<2@).[5[;O'F5+@D9Q%W71G6J?.TNN !Z ;@<UP$O/NKZF7,JQ":9JN:
MX)04Y_)+<-.*'&[6ENRV1KQ^(HCQB2^*,4[IH?.+P3E5(6\?3U...<KG J5[
M:/]$MK.I0V1_XN7.N5K[KP=W?:V/!W;5ZR-7^\Z9 9LQ9,G9?#_7A:TE28%5
M8-92:\I(SIZAT'?O4SPRALL[M2[%0HLSH]XD5RDH@IYQ",/[,DS/JSY58=>E
M+U0KV)RC,OF18-)W)&NU%CXBKE\LS;M>[<F=BHYTA)7[95=;9;=O>E?&=+XO
M])"C\O*I+J+I" C::E'G=_\2/@**EQCD/+$:OKI[ XB0[,V@EJ.[/H1;$M6M
M"U^@'X 86M>\H-YWPJP\8B6OCJ.PYWR>?Q>BU@W@(%:MZ#[%_31P;X5N;_T-
M(+WB=G&R(A,FK4W,/)E::>(F9M[\X+LS&H>L3=Q=OAL=CTO.:15$&/@$RN7_
M@LYQXD?3_7O/7_*R<V T#I]+;A8;GO7>[E5B85'G.V37A_Y=):-2+,J,FUBO
MSMNAS_B-H@]<C5Z+G@@#2$ CDVZ_F8X <%AS6)&KD[WTS!2AJ<R?E_C>/9.?
M'4B"_"*;LU2$&Z(VH2@1]E77(P-_(, X\7+URKI@AQ%/[8MU .;_YS0S:&Z>
MI?'0>3-[@LJ:+?E@ -?#-#U +>+#F%Y%=,B82Y.XC0Q[# E^ ("3WW:^7EI
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M8%";13#T):B*J!(S)0I=HN7E*^O%7(LE@!XCS5@SM.H=_"$X*.Q#793W9FP
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MY,C['BBC^-8UXM7^A*K<6N)! ]-XC2776XV9Y/9'@M\_3-41@NXIP;PODHO
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ME6YE1-HV5B%VO_5D>*A_I_)>>D>9ZFGMONI0J_: :! W(D6;DS;<6WZ?>=X
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MIUG6"981=W'P.WSZISW\E(D:A-WE#K\+"U\8I5YER\H-X6P?9Y^2O> _0;>
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M[[[U7X>=F//_I/!'>#JWS0]#N)![()=FY'GT*!C8YDO^KTH-=#^)0H)D?C.
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M-%5CH&G]D3.CFTC@G%(-S7DI\M"7PT7[04G6#4";\,5E/C]<7'[LG=\QQPW
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M^'R^BH:_VG?Q\TY*F[8AV<W(W&YV8@#MO1'BX59+O"A794JREIVO6I"JI>/
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MU307J#^U_X!(C' )AMJ;OSM^$E$UI\J+?IYHP>GUXD._C+S("^^,@]PC[1=
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M\"X1HP!G %/Y4II4Y.F-$@9*Q#*^QB)8+/-Z"Y845[U11:TE;8A@X'+Z0>[
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M,CTC>R,=$]T.AFD7JYXTL5C+:Y7IBJB[[]\M '5BQB=?5,1N)_:7L91I9F[
MDG5CFGN#N"9#23N56:BD,YF2*XR(B4*?6F_-21"IW_X['4Q[@ZRQA?Y]+:5O
MS;I*G^B?P>%_BU05PY1>CWGK98S3@R(5YO.R,3DTRCGG^ZO:-_<LL-R>9(?W
M0SMSP AQA72%6*^HV-*4[5?)4%:5YW\X+79-=VA^.?"Y HYYF[B.^Y#5X!+0
M*K*.*JU!?;1LN'>A<\$ZN0WY0>UP"= SO 2(\<SYH>">$3V?1P_SK^NXZ_NJ
M>C\+UWRZ\70^COE]_P#-MU,8]V1?S)WOY*#4+NX8+&EQ?7>Y?#I#B1ME %NQ
M W[X+GS"%>W[M*G(DN %J"F9I:E"*PD_-O<*E*7Y'A#/@/P*%+],6B/7W_</
M=H#W0GH)/=.J\'JHW_A2/L.:P:\PY8,_"A$6=[(M_LX-GT@ZY&$M;_8>?9]D
M'*:WN#@P,_G^_2;F[9KADDP1-0>5]&ZDSW.$DZ <@R(_X^"(C/G:\-K]+/^[
M\OF%NG*V7RF"V"Q2ZXO@W2O=O:ZDN;Q=\OOYZ4S#[E_2FE/5(NLHO]"^[7EK
MK#)AP%8J=6IXP&-1=,R2N\RS+*OO?R7,EB\!"5].5:,4J)N8D1@&R:'?%/,4
M[ZJ6Z;,E*<Y-0L9YC))JDV.ZLP?W=219!&F9956F I.3N<[8^>GP['H'Z#R(
M5.DB^7STWW\K+#*2J2(XDS11CGR(KZJ6,@B8Y^DIR[*7W8NKN*>E>)>X./W%
MD_ZHIF^F2P>ES/>Q)X]Y%*"L@0X.SF:.-*2L#Y.A+%A_-G<>G[BAQ)VI#]=J
MSLARD\L@^)#?T_?R#&K^V=.MK*<G88DNS[4I@6P[H$I[3P*"E7BG17^4A-'%
MI.-PSDB7\$JKT//[3!Y= D!5%Q7*&(4CJNQ3>YOC#K@UYA<30S41YO_8EON-
M)!6>CD.9T'SX)G+,/;.8A3Y#EC\9'M=F,B7=NOV&\I$_I%:"#[?&T6A5[A_+
MZ#\33_4F"PX[[;MTO'#?7AU9'?'>7AHH/T.BO$'XVJUZ*%/:SQP=*0\)Q,@P
M/^*R$Z$UK:-P\0S6Y91(]X8O@LZK$V7K!P[7I^B[BNJY0[[5!2J0>?H6@0/,
MUL#L@7 JCF2*VOKV2@$4SZ=50ZT$[P=.4?0F3B?1) )5@2FE4.7*0[\3FXZ:
M.16Y]$9DKM*Y8ZZ;\H[\13896YQ>T@^TO5*D((HX$:\D&Q2T^%)K(2 LLV=Y
M.,_9D%#P-?%C\*? ^(/3J*U-NPT[)9[*CF%&9!:\QO_U0^Q83=5ULIN>I?#;
M2+E4F4O 8PS\<W,)=NQE..6\NOG>D[:0%0D-*XYA\<0"G$0QZ#CY\%<I)*16
M!"%N"=:Y@FX'F"MC29[3D';CEF0)Y+-7EX!*8',A3?^8*#6=Y4IR]&._@U+4
M!H+F0(TGUF&!ZG9141WJ(/T,?Q<FNHQ@CPB$LC*]6;9>.K2 9;CX--<2XR_+
M C]R#:RY:3ZQ/H3;=2K?2<$\>:3' >R!6ZTF8$2TAJE\E:S9;Z>-!*KV>A;V
MVX^1R3\G'XYJ;4S85MTE[O7A&VOVU()1LYPG[O*,FE/=\WK)ZN!<[);7BMJ
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MV3*GRZ.+"QL.K5R+># UMCJ0EIE]'0C#)?J/_"^_>_OX?_?NK;%&[1PC?;:
MZT.0 RY]"7 AT"<(DQ@)PB!2N^]LIRV^U)&@,*1.9F9=B[=4S-]45@;M1V>#
M>S\ W)*CJL7[,:1KJ6T6;V/C0T>]]JK[!>W(5-7YN]2BPDCMILV=6W:HK(?V
MWX-L- YY//^IJ_N_2N13$@+!_?VD*E3AA;ZI-]#Z(X,=4]/^#913UM.I>Q?+
M01.H?N#4)2=!DS:<L;Q520&;-$YYC X98%C8XXE^W'#BQT I5GO@2-U?(<!"
MR5?M^\+.::$P$ <)+.OIR&@(<NEB00(3@2(P$N"8_XBSQ&,C=$7$R/8);9!O
M+4F6 \]!ST86AJ7.B:IDX<,OACR^KEI%5LIJF4V.G DLA<=A% ] A#<#B D<
MU4F)UIBRKM-@_-N1_DHW5X\Q^Z'WMO!_YJ+#[T_*G-FB3A6[3HC\\QYT^1=+
MJ3S8_>C83?G<GOC#4PID;QD?GI]:&=)K#HL\!>Y*6M;\FM[-D%$3$>7.R;^^
M=74SXD4M$SP(:R74Y4L3^;L(4CJ]E]]:R<:](H&B:(ATX)S&"2W*NP.(=$-:
MQE2S$.F\[">:+!*12RY&&GXK\4'J9H+H"()?NN<DO#2+ (80&XKVVE3*P<52
M5NNY')Z].PTH$D6G"SL@+H]97%J1B-\P5=:?"?*DJ/G #>=T/;SKY.#,"LMB
M&!0%T)+].,PE#&<DRS7?N#X,=+TA^$ODG!,0#U[HUD,^5H=@KP!M!%7J/1OL
MGN:T%QRQVS64WI%,G(O5%N*A^EH2X)*U-/QJ<W'#_8?Q;IQGA'\VTZ#:9IG%
M_8 >JBON?W/C[^S&\9T2[T/\^^MRJ:MI]%&O0V(T:M5NWO X"V0UF\=\?Z55
M;H;)?=CNFCRV$VQ_;J7.(EI_O#U=X/0F[9N'[.*[LN;KLW/T5<SCPJ9U@W.1
M2YSXR-N:HRGS5\:)RT@+N0W2^VW-^CSPXNK#] O+*PQKV=Y9$M2Y^JV 054%
M*\!"S.#U][7?/%5_(OS?=-GGW[0;,Z#]GUS[#^E:BX'O0G68>3P G5Z.O*]M
M'>*H4T']K\SXR Z;V%_[PC94 [:^Q)W&7[%<[L<;?S*H_Q7HIU'OL:_P)3.M
M[;CK(>M4IAO%)\Q(O]KKM'4N8E*^6&N24C>/SS2KY"\!5'N7@-*9]DJ?TSE#
M?$DZVLZ'KD;5#EHCFE+ID>T#EF<K1JRF\:HZJ\Y13^Z$$-&LEL[&R+!MS5X"
MM-$_K-V"1-AK)XQPCO]04Q*C=I4^NXZURK8%E6ABD1G5)_BW$&=:)C>1X0JZ
M!JSP$<NRA["$2.(-3U2 )M8#6=,';AHI!G6T*,:N;ZNVT^HZXQ&](/KQKLG^
MAJ3>)U.R!<!A^DX(Q+R"_"P7MI18(&I?UG!W\@PK4;'P7$@WSG.W_-Q-C?Q=
MXN(\R+<'R;JJXVB33>6GC2' -ZY-PDUFRD>4U[@O3<C#UO(=/N'!N+&S-7.^
M50EA>6=CQ#SHSVO2P2I1\%Z2WZB#-S/-X)9?_YQ (,5TDOYSY>,(W8.4A)TN
MJMI8L?4N?G4O[Y V<G7^[4=(KI3U"*%CRB89+8LF!;5@#PF=(*40%R<\83 Y
MC9^B#%8:,?P52%F]_^C66I-B:>:GD!(IU9/A-3LWKOAZY2F\-.G8%DH)(.V@
M"HGRT/NSF&1IH?2#=#;@-#""5:\^WIC:E\= 7D+JK)!Q*HM>X^Y4%+EJ9&MQ
M9PC-F^<9.;%^G7O6*["DM [NL <59KWOB-H7LG43)?*F)'T9$+;)OYYB_$<J
MZA]L2OU)3>F.E/2-/3(F8PC>A!*=]_.6E&1N_G[<\?GT=),1@=GDUO);.T9V
M6C":TKA6V_)%\8EO!2U6TN)KPRU$3>:VG-F;U:>5%2:AN\V<(AMR%T.H]"H#
MN(+M?P)1_D\2FL"U%?GIW&M5@@9Z";"]8*G2NO:%&WSX32+@\F /-G\# Y8K
MC2X!CZPK?HO_V'/R,%J@/KWG-'...0E9*4:$98]T5),].#R^DKV:R:_<@+74
M^*?C@=\07=0=-RX2;DCM\K*)':*CHS#T7XH(:(L(RL%<O3823<X)=R C^(FK
M:USZB@TS^-1X+O<4OX_3EKM4KOH9O AJ:]V20D>AZ^F7U"Z7C"P,2T%->4'V
M''+8HIP3)7>/SZ@B%F13!2(8F6OHG#**B$)\=R\!HGN(PBE/NE-352M^TN:Y
M]GN3H;SX)[@&)\#7LR&W0EP*TI'TNB93U FG:PU;9C:33>#[C5: DZ#:F(A0
MAO5/03U>Z(Q@]UK\# P(^0ZU5^*>:F'-,?TEH!<7)&LP@#6TV?XBBEWN6'BF
MY8@*M[HXSY#T9<B+W.89QQXJ772@H_\N=&<&[P1KH-F0P$D?*%?Z9$4CM.).
M[[:(QL9#E2F9Y; $GPK$.#5*#(Q_X2YW9<U!YU&$)XKJNPPP9_9B!"05U+MY
MGW.LLZ^PJYN P*ZVK:V;:UO=5X'46<324TXIH: H<%]U!UAO@[_VK%PAFRYD
M1@_MN_#@&#\?!C0^.VP=NBC"B&0JV<E-O"B"R;..^M[AJ:SADDCXQ.NTV;.L
M[_R9YD0;9AFBO8YPSK!8S=.1R>5@C%#$<"88I70(\HP8=-=N0;)<&%$*%5[-
M>;C &]1L.[0^<\#<Q-WSZ,1L!X8BG##<#- !/1S@)8;R!5+9XS,*1V4<BDR=
MEXJ0N7,.6S_F[N)\8P//I]]['#_-B7>GCNX!E8!3;DGM>ZF=!O&G:(D;HZ-&
MYQ.<$)U3YX:SH[)O:_BNR?KRQ#\^JT_S-7J'Q\5]Q ?W<\!=Y3-U)@A/7X7F
MC3 V1/2AV$">9,/ _H/S$E,9HO!]H]%&1_Z;!%S0Z9.RG4M @^?=G<WXI0#C
M'47V7K^Q=.?V32/_I\*U.8:W3[P,=_&;$G%ZYK']TA*8*1]QUN8%5SQ(N.&_
M;^"]>XZ28.="U8Q<<8Y%ID(RXG;;P4B)4OX/JP<C#9< KW?E:4%X9?/:*7*N
M89W08=ZQ\TK;[BE)\*Q1X$5VLN^<60.""%1"O1.H_SV2Z_ND[A1W!46QNM]-
MB$ASQ6.*"NVK%<'UV^O4<;M=#+D]$0C$.OW28$"W>]_7P&%N/7.6"X/P\S=M
M,?0T,=4@N 2O1GGX('SB^PP;6XZYU,ZY5E1+SQPQEC4,DO!*1"((<.H[<?.!
MVP># L;Z&5\JTL*/P+MK%+GTJ_1=<[ZNVT5J@9@+6Q:)=0'BRB.5FKEKY>N%
MXZ$Z#81M=*P4;^GSGP!0:T>;NI[ 7B'T'!<_TUW>S]/MIP_5="%%*:]5Z;R*
MP@][5B5T!IR(GXWG#]?=SM9_@ @2P=/2,;>W3""*'F>"[1L7NPHUN>R&MDZ!
M'=KX*877W6EV\'V%].<FUKM,NV66H!N-_@7EK]\Q-Q,%_AA)6?%DV<'[D#1A
M/ES-]#UT>!S(+K2>8LK:H_)T?56+&@TK$<>27IK%B;>.*I;PVW#VAG$LF,=4
M1'K_4<!Q \0'13I(9T.P)J*C+X/RLSCF2*:;=<*T6^9_8RN<F?#DA!76EB23
MZ:*<*K,0U"7M/L"B4-K3+L/(M^KE=3(2B]0HC5F8-RU:%N2->"1Y!<RP/JD
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MG)QHMOH1"$@WE;S-UZ/87&'Q)IR%2:N=>RO7_?B;Y5FBSR'=('=%Y$>GV4N
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MHPV%V<UCJY6[R?%9\U"DS,T5B$[@PY[2$)V3W,IZ4>+)\DBE?]Q<:BLK-,P
M7T6*F6PS4'?4:<6*;3.'/72\__:LM\B&7882$$W3A/*8T8'"V6]+<F63NX-8
M^.9>Y?:)]SCF;,NZW!&0Z.IG5)6DFAG+3[Q Z!XH]XSA-6..(E4O 6+Z%)<
MC-!+P)X$M=&NXA7HLT&2R%T"VHAK)!YLGTFSO?((:@(>$/?5[&@_O@30*?_2
MF:;D):#.N 89<M59]R4@Y>/_Z^Y?IKN6*'>U 7?QQPU=TE.&H $QDC9]]@WC
M@%8-S&VRKT8[B%C+3?CS9DHYA=*\4OW>2<F^TB-:XMU+ !3)XSH')- #:7Z6
M;&8@$Y2A-B5>,SE45<!W2"@$?ZWXK)(41P43(C\#-L[LV3R%C K,G+*[SX(U
M\RT-[[KS>NQX"_%C="ZKZ#*]9K(:Y5B<"*D@W;!\^Y*>^7E')O=4KLN4,^3V
MV^TMU$/=9XEL3^5O<K8:F,>\0 <9J'&&'5=9?F)$9Z@./&&<'2L4)K&R0#$$
M;BL!) /JI'UI:0<3(&CJ7S*^R9Q"XVQHB\^IH9 55AAD-M\0)0W;\&2^!"3E
M!EP"/K9!3A^5K"#PXR\!,I3OGHBTS">>8:W,G+!%70)"F?[N-O@9TS*D7\P(
M_4^W!^6=I*,^EO.BL.FOU 9T)CG0^8*.Y'_CKF[JN*0\"/B=3<0*=V6$UG[O
M:?I?8WY>H/G@.^21T.6!<P'U"_?]7YF9A'_?89Y"P=HQVW+TO,C_W!!U$H9^
M":#.W."I8'_^KEC#Q;K7!&Y-T,)$5:&HO,4IO&Z:::$C'X@ 0(^FC,?M ^]H
M^I]EXZF=>TG,'XN9RDN\$G=U_68@\3J[W9J=P2JR_ ,I_^:#*J]WN+WGY#,I
M"Z^PF#(>/V8_..>WWEJ\*T:XY2SL^_^1]][Q<+WMOO 2@A $T<LD042TA(AN
ME&A)1(L>1$0/HK=A2-&9( @)HT8G>B=Z[V6BFQG1RXPZ8<P<O[/W<S[G>?;>
M[W[>\WG/^YYSWH__UEH?][WNZ[J^Q7VYUY%\\)ZF(UF\1IS:N,9F>+;0X%O@
M1"*Z8?LTA$=E(O54 >Z4I'U['F[;9G=:&+>G53.>A\B))0(OPGO>T&X%WJ\W
M./2#-IT?'UIZ]&XH @ Y4#BN\,:T$G!HN5'WIU0B7]@#S^P=O$,$0C3,P"_H
M<D6/:?.(@(I%'LYLE@A@4_\E1+*LX%\R\',:_SP"Z2P4FPK^X04^93_2QE-4
M$0&T1/._8@01>+D)/938A./H'(A MSVA;9((K#M-@3'<$T0@>OKHND?KQHWR
M]^?O"R[  U$(79:_&(PM^XSB H(RRYY?^*8 ;8*XV>2_8A/=OT[FXNG@8SC>
M%K;-I4T(;;YXF&0'C!MRU567)<13_V\TMWUHK.GEHYK$7$?QS633#VY/L8QR
M;J+)=:0]25$(5PBBT5 [HHK:E1'GOZ?1B.1_*FC-Q^I>K!#&E,L^GW@=OO(T
MT\L:?>NMF--L$!?^[KOI*8@V"O/)[%&+Y\/*:X#N\!]H%B$H\;<%+V8U$YEF
M&BBJ%Y&=>(4*]^>UQ6!>79EV%/I\TKM<<9&M)LY:IU5B9HV4[2QQ"R6?L]R<
MK)].)7#6K=ZY%^&.JU#)=1 4,A72ZIM]/D\_&C>C;H6#*ZUZ;8OC(76IT_8L
M'<SE$3J9@IZ^O=U!O_U@81#Y?-]DP_=/)JP<^-Q)%12,$8WWMP5&+8:9/_OI
M'=3E%8W-'\%#&BX?#2<7;MYS3#:%N _&D9*Y2:94,8Y\B9GP>6-4_ \1<H12
MXX+FV@E<E>/"?AJ,5W%MWG*5H((2_WU!P[7\E5:>[_<K_HEP&;ZX"'_1_T8Y
M\O_TW!B-GEECY>?@FCO.O42@1U=[ZV_SZU$8Q\7^9)1(^YYWC2"HOG\!I"V<
MB?P$<H5$IV=3V]7R6ZX"C#V$FD4# 2&[\QPY6)G*G$2)26I+A'/1+5GF=_LB
M+QO#(EXI]-0=Z;?MJ4[,"PU\-E1(*9@_+S],,]"35Y-8C/W&-PE=TOUU6N::
M^^9YM2V)*A.LP-%(&-*@%D^_MZ R(+B?5)X>VU$OG]PZ_J'T<HRZ<<4$E;I<
M] D#M+ VXLD _UFA--Z?=L7 )J'39YFU1.BP#H8UETZW/$-2ZD"7G8VJTA@0
M&C'1-M\;DE-V5U=-8$4@;44IKH\.!N;"[P;;")U32RERVMYAXQQF;\'8%>O3
ML7]8H9+-?V$%BG^(HOH_!*\V/_LO9K\<#?K[*(+^+GI_HS3HWT7Q ?3O@N?D
M'RF]=/C)N.T?@O@?3:TS2-+7FP"B_>4H[H@P_>!]<IE5FU/P=QB7>E+4@N*:
M?%%[Q$_>0Z;C]/KLV:U3X<5D_\:,^NAL_[),[N4#2Q[?HO99V(?J L\%9?$V
MA><_(0FBMOKX'L>CMTR?LWM/U"7L3>8W#IT%NUMI'N.J/8UC&I5^NR:IQGGW
MO;OR/+ C8P4[Y%^,,8/HX S."XIG^!)1'8)==_CI*];6V-8<9FGI7,ZWAO 2
MV%K3T2K?JKE&2@DII$Y<'V\NYYWU*VU#S['0;AK7+E-KAS@SE>\S&@\'/]5[
M?X)ZEI-2;P*K$>,ETM_'M>3QS>2YUVOE,)S!3I-!E/9&_LGAKGLE>WGE9DY0
MH2$JM<YDL,^:(1?+>-.:UH2H5XPR!XW"PEK]9Z0N.91Q77YKBX[$5QE$[FO+
M)<<4_WLDQ>,.*'#DD.NR0TQQIG9RT>W/+KNF_^ER"W9?K+>ZP?\'(?ZWV<=<
MV%06Z?KK5-/YC?K&M;\]![^/2QKX]$9"X_S>]#A=SZHA/GE+SWBKIM8(;)TN
M_<85F^#@>:F>NU#I+GI!LZ2_('\CR;^ZH*8YQ";Z6S1&Y]B&)Y%GTD-=+""C
M]M5C0:KIU3W5EK"G4[?%YYYZFRRUD'@3@70]ZQC<NK]D><FLEO&E2$%)HREH
M95;DG5<'>[MF ]6UPY(U8IKRGVDUMP7X?%Z3-<06V.0^@OD\G+@YQ^F8FZYV
M:, F%/2N@ <7IO\G(W1)LQ;L56HT_ UF'JF<>9ITPF2G,=KUN00:*#I[9)+,
M,$_?#MM5 W\$ZT^NUMPM39K]6'J!=>UBX]$+6_Y-._.Y(Y_ =]HCP4B&"B(
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MMA#Y2;Q5P<8)#$WSD(/CPV=*Y@=S]??[SGJ:[7Q9NAO*PO&NJ"'N/\X?:Q+
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M]NII[-OK#'XK<:F_FT27TZQ1Y!\OI(<VREE/8"\D?II:H"DGY,H?#=*#+B!
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M;%%V2)OSWW;9+>3/Y&9FYWUI_^35A!JR1T4WD$O]2J_>]NBVJ8V_IRB4JZ2
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MMU>S_Z]7>R,6%\+V$?>]W\VO1/QVLN -X[BFIP<SFGOK*MSFZ.%H(@VF-^*
M5G_5L#7S]+LP^9Q-NE.!DAAYY.9XKO1//(EWIZI]A,W""" !]:*0JQC_#TP=
M@2P!!E+TYP;\9 ZCS+44Y0!NJ)Q<>6TGF.L;)B=FN]I:><5%-Y1H_BY2]D=W
M,@_=EB-Y#\C$X 6)8ZNDG6O0+W$^\E^*K!U<C@)A;B4_4O>'4/BRE3:)05Z*
MM;MI6KV=U]KN_YE6[8 5PI8'HRD*6N/#>*&F':\ZRGS-!KRN#SVX$DC)]34?
M 5<][S^%;;_T(D[@8IPB<)L"T+:1QZ[NXM2('3"\7C"73\M-C$D&FKSH@UZY
MZ19C(.98E$6DURHRI1OP7*R6R?$*P!"IWQHV6-CP#3P_,HIH3*[1 B4J:N/T
M,*?FH]L'NL+Q/]V>)6A]HUYIX_H]?#Z JV3270396).Z@.)/IS+*3VGX96YP
MGF'.],,@!M)!+Q4-VA:V=*)[6AVQ]=)RXZ+00>XE$/5V$\N%U@I(E(BT1NIH
M2'S\YSFE!\@&WCEMB)@5G?![3%13#@M<^=GOKFS>ICAJRQQ1KFM3L!M,BN)<
M6MO9]92"S3EW,,0WR#)I7P+W=T5=>_F9]^G@_&SM$X1 >0@[)JG^2TO^B+6Y
M55]WOLN-IJ_+!_R/GN.>A"M568PTR2);$\$,XU)4R^E:.RB7K[_?^8M[P;V#
M.'V2O:PA/7HSFLEX#I3\R!G@T'X[SG2K*"P03P6)\O?$\V,^%"PD^MB[2)=F
MWFOQ%;P!F0(;K=Q1%3G2]%IH:+;5&(<39*P5C:N3-L9LFSDC#RB+P:AP@5"-
M[R+*%0L[3%5F^'%YKZ^"DHW@MQ7,.!",N02=P^E\VZ&_L5ZR4 -L\F8Z++KA
MU"!BX0K\M3M[8G>QVX"]\BPKV5#86D_@@6!MB.R2'D='0TO)9Z<(OXR'K_HE
M%,_%!3!W !<H?T#W<^DRFVQ1+V)9>FS)FI**(XP'Q-M 316.Y78]8& DQ.<\
M5:DJ;RK-\<,[IURJ&Y)]?$FH\-M@6:<,]HI.CMW*CV_*EK5_FJ95&OR  3XX
MD\7."@8G(@\&G"']>FV0MMI3CUMC;=[HW,7M<8C."&8XJOH,N.28\U-&S$NZ
MWM_;/>?',Q&$$'F2\-L), U4X_!0M\2Q0JI?8/BMU&GDE9J@A$?ARM$4@!?Q
M=J882T@H9NA#05W.*7\IPONN-]]UXN/S^UMY&],5WN6PC@6J$24.-WX%D;B.
M,?3@F[?5J7:%9F< ;[?O5<"$_B5L60A9<4J50Q#,KBVA[(+L,6(0A!?#Q#0#
M4UKB&=!G\/@;Z3>AZ R8%OUS4M9N3>&S]Y\M_PH8?TI2+JBOQDGI02QK1\L/
MKO-.N-]YZ_;SZV[=J]O*?=(!#R9*]T/!EH0[2)'MQT"_\/N;">B<+@2D! \>
MA5>P.1%O- 17%IN]8#C_ZN)0SRT)\;0![H,*%->E\:X9VJGD,'OF6AUF-48W
MUW/TE)1UN=3LSS[;E:YC;=<1XG,S Q]2>[S+(B-/XHH\4(ETF]89=R,?1NCI
MW]JMH?U=+J_TD&2MIV+4CC(SX&Q[F9JE%Y*WGRVG]0-!4WHQG?,L^MAF1/SC
MX*K/5CL+93SB^#;RYPF'![ETFG\*F^#*$..1$%F[XIHTNL]")_JY112,GJR4
MM5:KZ^8MMW%.2XOT.,C]R5VX\IT5K,C[;NENK(A2HW[[\_;^7O<W&V!!3'8B
MBB!GMBGCXG7EPVB-3I/;1KYON:4.3GAI6U3#AV(2'>C&^6S'#<6C>KZX#?@]
MQVE(81!! M":;L1:T E#Z?!/-%'=S9;807L&Y,;MV])"'QI@*F*B8XOZ/0_#
MZ[E]HA\W5O!<BNG@IA[#,]IY.11(#Z@K+?@<[[#N],BUD?#Z>[S/&9"2U@8Y
M(,WK"2<)7_H_I ;1;Y*QE956B(O?__#QJRKD: C"OF]P%<JG@_7;>>/W6?E[
M?\%W^\C^5]=OZ>1D\:SNT$_5[&Z)2.NRE5:4H>O@[_S[K\:_Z@AGL_\RO<%N
MI? &/O' ?(#UC3V-S':/3R;6(,:BNZ;Y5 V:95CE>3AFKE/9L.]GSFO8.8V6
M_JF.,>@0OS<+JV[I&:PO#9OI(#\@SYFJV?>(:6!^CBK)N;P^.D#[X_ ,>':[
MA.R2T$!',6=H^^)4N,(7['!2SMX5C 'AQ1GPQ;02(8]*IG *$\VZE_' Y8V;
M@@<8)-#QZQN]/"7?KZMDHPQOKK6XXP*7#.A=N 6Q@C$HV?IXX^I&CYO2'S[]
MYNL? !0.(7>$UV\NXQ]BT)UAHO6Z@QI36KNO@%K_,=9?@.^R)XQ!A=N-9 CD
M>"E,_DEHX<<+E0$^,+$,BF;XU-&02C]-)[D06PF(X[&;L"5&OV54?GQ+-.*'
MIN+MOC:0-U/KS9TF14QC)S?G1'011=-1T$MYRY*?">7-==LY(<\:0A_J?)W:
M_UE-T)E2+-&._GGMU5,0!HQ.4:'7T_BNIV1;,"'XHW<EMC,Q2OS#S_4$T_@0
MWDF>*>(M*.)!S0KU\Q;)C18'2FQYP^)2T0NW7SR)&I;*LU$)&0F/*.5/\\[_
MWG )5L4(QB-;+SM;#&56:8)SS_5S(W_E4O+<#!=7X79"FL;K$@J5=)GF^AFM
M+>I>R/?L]0@!01]R<SIJPB N,B2@0)]S+_@M\6> U+/KJ@.72ZGDMN0V=ZT]
MXL,X<3X]J9K@$F?4CCA<U&WQ:;A?3Q"HR^1.""LFSC$@Z%'<%J'T8^9ZX;S\
M)6_@R>T+FH]56#-[<KP^APUZ=CI':S_4C[/^(J'SF:*5APHOG(_3+9O>R*'U
M]?+P8@O68I[QG9-(BF3EJV6%J%G;)!=8KF5*%V8X6\W.=%U+_B'_)&_BJ%S(
M&">T-/_@1!=>VU ID6J?- 03 2E[YW.&7J  '"V@B'M_0'Z38KZZ'W^-_][=
M(W66OF<\Q9?:O^G[3-!%-V4@(>%-PB@W[CV$:>JZ=(EPM/:2;AZ;\1K=Z,[%
MP>#6F!#Q/)RI_BE=HCU7*?^.Z].J'!.A-#.;:SA+9/(59X>'V53;TE>\$28/
M63\T^DPX+++ETC'>Q\1T)M-"9^^,@0=+%IR/)/G:7ED%1EQA?9P_0$-'M09]
MJ(WE8*?L%;N$B]O?&L^_^[Q0Z>;EP?<Y>9$XTT]0.V1O-%[ %Y$9FM<?UA;=
M6/^J_\:PC0$YN,UDJ!FY+=PUX^)TTOTZP.2'-]/)YX/SWO1CX4*MDZZ^@Z)N
M.GL;UTN1"7U[Z:RS!)=>F$-63@T]DQ6:VV_.(_G>KC3":?%"D]!C)8-KBPN=
MU!?BIO;6^B\QC%.U09)<?#JR*<=". 0_G5A:@6J_"[R^APSG@P0 C[P=R?/_
M2P>IW*'#=L]@'W9*J4ER1:9Z5H@7K<LY:V? (5WR&:!28DM]8%N<_6OX/[+G
MIF1?0)9U1F!;7!YGP*>I&B<#U*.:/_<O_J<BRWF?829X4]H/Y+58W4;NN-RG
MF7F?<)':6*:\>2>6D065Y,ILOE<<Y1"+VF G+D)B]_ON%P^[1L'CD=&L<OA-
MQG8BS1B>H6"@:%W/<V3@QIL$D@-LXPI'QP&-LK'5EJ'^(G1N&N<G?@&]SI:K
MC[RAH.?X+STE)6:.Z?2PS_.:+LXO+J2K1;'),<4&+HEPG_8RMXB^V6FM+GMU
M[6;?>2B0I"&)UVQVA.9T^H-%1@I'#YC?N17>-.MHMXQ,Z;\0+N;4\":[XC'3
M88YG!O.WA-Z;G-'<D\LPNC. Q(QVB11G0!Y%4$Y,-0>$9LVD0?WYZUG+&T82
M-2L]/OUM!Z7;H'8%DUC4AX==,LG>'GY*QRAM,M6TG-=V29IE@ ^,<_\T_@R(
M.FIUN+.R8+;J":FC%\(,N5!WP*B;*% &-&;.Z>,+WP6B0@9K2V7J0+?YE"[[
M= =S?-+ET+Q6DG>NM%3BHK(JTVH&[#R>5WFBRE+TXZ,T6%G$T%J^QY;J,/<$
M60KF]!Y&)*/+^L%XI\E,?F9T#K6F\G)JK$B?@*IAP!5]Z#I>,,]-%HGHMF5P
MGAIS.O)GGX]_NY+AW<[_XDI!.(W:H^<#-/L5FIC5*%];JFD.9>8>1;.W.]X2
MYL,EXLM3++'$JSC3;HO8"??MPIJ6)]1S%KJ_JM"(",G=A!'*3'6/SWA)7-E'
M*.PN8E=:6=;0GM'L1_L/9[,(+4Y/L&LX/2@[(]$^^1XAKTDL-) G>DK72%48
MTUBK4S<\4;$B/*(D@AGNY&9H.'V6\VS/]E$RW*KO:5IVG3+EQ*51K$&D+X3-
M7* <_E2((?5)BEE)CX%U*21#/_LUF1H*7%NTSGUN<KFQ3OUW6?;U-,]YOJ]M
M0$!Y\!((GSH+.SG).@/NE,S8ME=0.>F*FY7O/$MECA)LR J^4WK;WRO<:Y'3
M5!=I0.U$I!L9UQIG]Z_1="+[T"ECMKP'Y-)+XD@4ED^3M#8VB1 "G;/E.[[X
MP[Q:"85<!??1.K308U0S=2?WQ;$F@= 2Z_5A[[&-U%AWI75RH*WRV/,"^)AP
M,R:^A07GT9,QNKAQWTH]D#WJ]W;!=+>FBO=%]+H*9^\VG2K.PUVUCSA*L@Z5
MU 8/)E@_^R1DZQ(IS-\LG SC=,SLC71M$O$3V)V^-6\C8Z[Y5B>:_)8F!'I8
M-K!--VZ(63ZYVG/?2;H2_J0L9MK4@Y++:UN%,Z;=X%C PF#*@$"#D$>+'<L-
M7R"Q^<]GP Q\?8$=LYT1)24<"M)WRIRBG:7YP58O+\]#;U%0C!/6F52R*X)^
M0I9K?"PJRKBH>4X"[)['24 OA"LA4'>WD6()1'9LZ(SX6";HV\#U!W<=5FG?
MP[X=D[?0!G%78JD[%=QC!',S)]_TK/77)E&E:[YKO%G<+\0?*DR-JHU'8GY8
MV-<4(7%^>NS$.QD/[GE_7:IPY?;4Y@)O&_KA[B-I!6&7G9SR8_&%+O[:">6#
MD>'AJ:K@Z=Q+L*JF1+$H>#V7?]6&:U?0E7B;;AMC#/V]AF\8Z<%?$VZ@PZC-
M.0W2A"Z)AL5<:#8)5W*X?P:DY8ZW;G%"]ED*< C2-#J$0[8$S@#XM0K5K'8%
M(Z)<3'<Y C)S7VWY2PRWS1S#.-NP4+-8; A3 ;3"<,S#[T+]E76?P"FB;A3%
MMZ*5/GG0=1*UB#H#)FM'$$DA9*<M(B0:_O+/%7L_+WY_%<00MQHBM/1!N/T3
MWBG1>]$]:RACV'-15OGV!4HILM'1_XWBUG.D& X[ =L2#B2YE\PX)=(+<BLD
M$Z(\(/L^]TT?HIXD_9_2(C^J7S6B^2,[M5R]2V8^C3LY [KW%N:L;:TU?WW1
M87DJW';L*3EBAP7#IT;_76#)BIB%]J#?6+C6,'*K(J'A0_FN D@ X3X>^9NI
M?7-ZA%+U'U,YF3Z4NV0&Q$B]@^N9++4[T,GV,>2PR7%>%R(Y.>[K..L\:)JE
MM;=BUJ"D*4 >8"\XY4I#D_2NAW+$6!CV@OWIS'O9$V+%E\TQ%=4XQ?4J=C0A
M9:JQ6=$0/ED]ZZ;QW4!F:D4@76C&U/MKGYQ2DK+S), #D'[HPA^,_E^(1ID\
M@Z-$0)TU'6BSB;+2//>K@SP/>D?HBC#E3Q;10N'NY6%#V;RQMG+SMR0T6H_&
MKX/*@  C(_^CR_.SO5YN4CYJUZ*U^1Y];SLZ[_>9%#!+G!6B:MX4SFVP? OT
MKZF4&@>/S=[7T&Y;QB@:A]);CS=IYW=_<3*]$"RO3<6K<6]I"=/&74V6I\X4
M50SMO3.&U[5'S@Z,<W\.^H)176[T./\*_$@FR>A N9C<_[^SSE=*E6#(1(.N
M,9S_N)&YM%9\B=HO.3;;)G*&:N*%AC\WWU>521.XSX#[60;5DZ[E8H_[TQ=N
M3.;?X^0LEN<<N9!X/UYC_-&4T"2J*M:/"LTPX$DY]%WA7*@<4U <($SY[TD(
M+D%?0TCQ^YI,/<E\'IP!:X+E.3W-=P^O86OQ<0&+N^HD"WS0H+"JY$;ZHS='
MIZ.PM8GRI!B,F.G)N3F2@3V/^J_#EW_Z,%$<S/FSAPXN?\Q4A&::4$]$G7\?
MC#5;H,.&QB16BY<XC<QUDJ7DS7I_*4M![*1"+("U_]%,>W4YB'/DW*A5!%YC
MS!+%A^.W6(0Y5IC7"*412[41_D&<OIO6H?\VU\9PCK7]08D-HKU_W S+NTG@
MUIT(?<G%.*!*W0=,A>W)0@_>#-6\5]L8?5WHML3\M1+F&0X^%^[;'0W.__L;
M'R^<_EOU<6W)W[[^JQAY7I'4YD%L*CT#WA^,F$**8'W8<ACB3<[O[(9+/HL[
M^.=_B@Q4_J?(8 #+W>R"3*9?<)%-&11H_A+M^^+<\A5*X)7BR028"2N=$X^'
M7*AZS-1E\IOY4L8E\@1.SG"M[4T5#J/_%VW1O^T3(]3^H0R4\B5LF1<Y?'HI
MF< @_6=C.89XAYN3Y+^*SX!11E.UNS4J_U\%M55 EP$WK(.\X*<-B;L1&K=-
MKRTZY/QR^Y[V?MMU?]TZXL-W^N)!0.0?3:#'!G>T!;MZ2XF%D-6Z[;\ FU7"
MNR*'9-Q6=_R&@[;6_M+A%%&2S^NM -<UA) ;^4TCS([[>L1S<LMT_K$F(P&3
MG-R*O(G5?%EMNS7\[0RPLY+B#LAI'>K\MLJAL=B8750&^/O^^UA$HD#'EZ N
MQ Z',T"[Z(]<!ST^2DF:-#B29T#^^&3G7R>#KJU[D'42[*4FK871KZ:J5GA2
M@]._-?SW@/RGS[;RB%,B^>J+B'B\<NZ?(<H[?6(@-OS[,!!RVVI[)L#O@.GG
M_\\MT$P]3BU@X@CNW1>HXJGLP.GY.[;PX^/%-VJ)6=!38E'!WWOS=SD\J"Y1
MFTC"(H](@'W_TKI+)B8#GT8 $=M'28N9R0495G+ .%>/I#^^4@TZI;0D-<++
M,GLP,?A8"WI"9!GIGRRF!F_@[S&WDT)&PM_MOVZ8!7I$9+!EA 9H$ =/30]_
M+)AFK6[MA3VU0CO-'Q$T=8"MM7]<.;DL-87[/ZG?ZHVH\;Z06ZR^+.NVF9 R
MW P8_'>G[T_!+XSY*A+4169^;;LMV$?ITT09?<A=0LOUJIF%D6%#>Q-]V>#"
MB=S6-]#UCN>O:%E]O536*&!Z.KT^$Z[PY?JG<)ZF;W]$"F<.9X1?@G8U;UYX
MB&-?+2-R0B6F?KGS8A;>?_O<!]:2@ZAU^UTU/'?S"\]=PR]Y %DXA<B_#[Z7
M$YJTC*_^PA@</E-J](+,*A%;K[NZSNX2-K;_6326O,,6BR:MD6F3WV> IO15
MTA0H^8%.+RW UE8^E1=U=7.]P/;B8]E["<'2ODS#N/\)U:"V9MLUKCLD&V)C
MZNZ221^SLM))4;N2$<CY1^1=ND,/F]<N?N^[--6O1 X7 Z;21%;(KAW3./1;
MK^9$B'BH6X7!\KIK^!PDTZXC@GZ!>\EKH8G8BS+H) AKZ3%JC4MSJ>E%G3>O
M^2K!1W\8_RCM()=>Y0QX4:'A03. X@CN;AB_=F=;I$Z"DRZ/_/VI:>+Z(@O)
M6J,JBJT7G"WB<2$J)E-SEK7?IVV*+X0&2E>>@M_:ZF)O&0K'BQ<_N[[,^>65
M5\KT$@WA)H1.DXU0H'2G@,7CIX(;Z]IKLHU47)IV#68_Z&!^9F9]3.-;K .%
MG'MXY%!H T(8U)-\OFDML=C@JONL2:#(4[/8,P":8!+39:W8$=#"'=MDZ[7L
M5/.;\IY.?SU&!1"[Y6EPKB[G"EX7\ZP**:*F4SMZ(%_&/3_&]F2\U;>(DTF>
M%4!G H<<+F_%1#[5U[P3C#"F2^6S-^-^P;X,7XP+8\ <YAZR!,6F[T .4BSO
MCKT] Q9FY,KYVAOFAV)/9>><#179ME'OGKCNO6@9T1RI<?%9RHDI=0-SSVP8
M>%RMG8D-+/K0]LSC;;A$:&/02K@BC!Z7HX'5BVT:K4 UQNHCIL.>R@VQ<JL_
M@@:AVS.X%:<>C]V:4@Z;A;AE?+<7XG=84>+V&BL<(7*O+W!C"PM0R@HH1U@U
MHVNZUA=>RLA7P) WU1GPG!U%Y(;U^V!7CXGB*MQI* BS8S9CE669,U'1R.[%
MPP'Y,\!>4_!;$P2KV)'-WVI)S76W ,W)SR)>?0_O\(MVJH[VW'6\PZG*YA%[
MJ8L2^TTIF:]: 3<EOAJVP18U-]0#%B1P?@70[E*!5,W*QF^OM;D&OUQ/2T;V
M<TE&X@PIM3]OU+"+O,B8>3-G4E-)6+=W);-Z"F%78I#^WN4G_T3#K42I9J>2
MD8AE+>=#BQ:Y+UX.$<O?Z/?SR>MH=:RKK=7;E7QZ!M"SK2=_E/Y<AK^#>09'
M#GQ@]Z#9?+)@=L\Q3Q?0\&JWXKXH)T6VR:(0!2]_)_II[P(\B4\<2G3-9>OK
MM1%^#6+"@PA1=.4S[W0#Y\>N.F8-OBHGFWG;OR&<C+,'DRR3W"_86D,^ST6]
M/D[@G4X*=UMGA6O50YC#+NUZ9_N>B_=LK_36$3U[_[5H\4_HJ.%[[S.!W1!)
M+$LGMTB]B[7P?5K_W#0/"=9E'C\>;GAGR%-<:J9)1L GQR-$3>:/A]?ZL!W&
M_DS]9'V]=Q1\C%H4S-J1L\-TN"J=6!&XG.@A2Z+_<3AMI[_"/M^<>!DLN1V$
MS'U]+=JE.,EK.&R?; )*WW-B&^>+*[NUW)BZ,37%YSG>,9 63C47M$?K+YV!
M[%+'3+TVOLKH0*?%%:9J\72)D43N=F/Q <C%BZ[6=H9FA:_L>=3%^&C0O)IR
M%6!</+J"'MJ(?%;+G1;:@A*[U>]QDW7Y?I,/O+[[/D[;PPU-SPVMZ&8OU?7Q
MHVU+FM;Y^$*GN_+Y=)0A1&$*AT6&@E?;)3;OS_;2$K**=N_[9VC(W?1"%"N=
M&%*Z83!H9&MT_SHABY(8+BSV ->Z-"BSIVLRL8#2^L8O\[7ZR]O-]/MQOYK4
M2ZS6054:.2)Y;U>R].&U"T44QAW19T"O-X0];\F#&ZK9R7WYZS@*LU,]]I:I
MW%Y/UC/]CD2O?]CCM-Z:Z^2(:C$&)[#@>/=A<BC3?(M_NMKWG#L*D49->B16
M@5/E4QC*?=5__8=GL1A?TOOK*TTYR,$M6TR#M+R4L@)Q0&W"+5.-J;LRUD0U
MLFU-?CZYS!SWV(,^GBB(:^W*)/5;.7^ ]M- ].7/HG)<7XL!\$JX,D<GC$%)
M$E526#TN?=E]XHI;H1KG"[I\8;\2B]:$:C=ZF_%]R^/\I#W\,QH-'8;WG+6J
M8U4A:IA-/423;H'+NI=TU.'[T\Z9+\FRKSQ_<N[SK>D%'O7,,DTJ!2_-@[6Y
MY7:L.K9B*%T4HGN7]( @<"(6U,G-@V5T##+Y>%@"UPCI9=OKX_*<I[> O23R
M0ATZ:J\A'DX86;]G<+OTCG^UT#C(^%2$7!VS'>LFJ0NO.572=$KBX0!\YR<0
M$2&WL84QA0,E+C,K&9\WV"</QL6SJ2'R=C9U)D*1:>,CEX##7=H0%<QBO%!P
MJ+ AK1^K0-DO-<YPNE/+,I=-]JDL)$'^@-9D3UC7B(>-7XY-&3@ 3R[92&"E
MH^%H".UF-ONHGXO>G9EU]1_?S%F;^@;HJ-B&33@/I3?.  ;7)I!?@?D\]#OZ
M>Q4\XT<L36GC7%*6:3KZ.!,HH>SQ.#^HH#&3,,(?0R5U.)22@V-@+=]0?"L
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M+_DDR?[A[(E!J[&099/)/Y4>'@1@Y )EIRW'('J1;O"+WI-T-Z[..WS:U!$
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M,B)\"-N-@VQN0 C993A2,'7HAARLM9Z(W@2V\&[8"XL=IO[L3YD9-X*ZC\\
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MB.$+^^Q][MGGGCN^;WQCW!_YD3<9;]:[,N=\GKG6FL_LS[VM#7FS.,?"FQ@
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M^[K/Q"9[JY/ =84]_2+1; -_8U0EENT*\*@B&I^[Z%T!0CRU?XGT<,4:3II
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MD=#407(%&%+ZUS:C83O3;H>>XK#Y?]M$++/X=PDG1_W_L0%BZQ1"Y.-)N?\
M)_ET[8*H9,%7]TTS4%KD1@5FU%F#/T11?+)-. (0="J=UHW@9?'XE*1>S#U+
M@'+JGA_XB!7UMBTW(;/?:+77>U)TK@\8?1$_W\8: 3C26SUDAE'U-L?DKGXI
M.^'@UTL<2=%N2ARV6Y$]O]7)H4OIY:S2*:&Y!F+%_.EEM3Z+S*V9E"A7 DL^
M$++YPQM?@WUZBZ-YJ]#AVJQ^XH1@VA"TZE8H[\3OONZY999WMY+H7F_(GH>/
M/9YLNQ>\$;]"OWO]/1J,M@D*CZ)R?5\:F!J"7HK>5SHY;SK7'-"#QT::T\*Q
M>MYKGR2\19WKI4,A0=9/YIIT_5Z+GX&UCO$F&([)7/7$NJ_!?I<+&RZ?PE^Y
M$/@W_B1@@XQ;GIR4L0FT/UR!",=[%NZP>B4=K<^TCA\V9%NK6OU!3A,<5QK@
M37!L]?"C9"7PY=Z'YI&FQY);J>3M#J"TQO[#S^E<E>6O=_T8T5NA.('=]ONH
M_E2K$I6B@8TOF]^>%=V^=9/1W(-[W3;BU.$>X2CN-H;K!7H@]+AX-8U-R*LS
MO[M8-O9GYV+35C8[IY>!H+V2$-0YFE\?[PQ0#TZS_GSR[ V!B2@'YH!>#YZH
M__"&RM648/<5H/U\K]S&EWKO3Q,Y?X\T&P$J( &9O>7"2>S=\@4?UQD%3:$O
M9GS>3L*RV&E9QQ+1!OD6SIF=VF?$1I]^%T[[\)?-S1>FNKI:*8CR*2_NLP'$
M8.SQ\*;8D';F:3>J,)KMM)F.7Q7:/SD857T$Z8*3>-TDEZ\W"+)@3@C;'IOF
MR5;0JX(]+X4:EM>>!335=/VZQIZK;URG(A) -V&;2$1E&-:@G,V[3EEGL,[]
MY3XQ\_U[5DUAW GB0XK0^6O3O (@,@-%L-:%+\%Y9NK$A04C6\IW+V.GHOX$
MQY$@VF[@[2SO"A#2A!#DGS@1Y.!_$O1"=-&!9I W_G,41T2%<Z^'S%[__2M
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MV15/4NXMF/%$K\_Y,A=Q<Y4#W$^2*C IJJB1DL4]N2A&%]';"OT;5;.DLJ"
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M^EUDML.\7TK14JVT5[!C/5A@3G94+D!Y_>Q.@-1V!12,"5SSA?1:S,GYE3/
M<T,=XTK%UM3 H\3+2G56O>9BJ+,0&@ADAKO6ED5CU'C.*X2%_RB+8EXP>=R/
M!Z;=V_!H5AO^*F$=]7VPG*YAPO2&/VDAFFW R_^CA'RC^7EYG7>DK'D/M43
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M;\E!AD;@A]C=@'? C"]9E*%5K8\1;53=WQ]+-?@ENXSV\=BH.?:2(S>(6\/
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MK<MJ5.[X^.8XT4IL'IL%:?SXKM4YZ;:2]!5@Z/[T%6 9CY"/&<:P/@2."O>
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M\O>:\TXI".9S@(U2L^LHJU)(((E3@482^X\6#*8<3\BD11Q=F!.D>%B>3T4
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M>E$:0[DLRW*\&2 +)D_U8_>Q=0(N+/ZX8"SF^NI$'@7^O$XKBBGFQ!I9(<>
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MT)OL$P!"[< \J]E6D_("9<G/\%;V%944[&VMZM(&)8HM&:.+#X5O[QEAK2Z
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M_G7O\9P,R(PO67//HK2 .L@H\_$'-_-3YWQ0AMO3)OX4;\_"37UA;)EPI[4
MK!3V>B9_QQO\2D)M^JRA5V'="^J._!!.W8^EC)%+849J>7Q&OGW]\-7=>"'?
MKN18T9M[U@?&E *?B1S:N2G(2YZ.GJU!K;I/H-OVM*Y3$5SI43#F&ZIZZXL!
MC\1W+H/[*[J,.QR'QQJ'0?' 'T12SH2*15?"K+-9>NCMBL_2>449Z;HCH%6;
M?/IFI586C,*;CSN7O,0-E/NLN#((X&BO!;<LSI3LHRTN#\3U>MWU;L27T\1D
M.NN"2P7--9&$[\&JKQ;)?CNF/=>YG\B0-@C5!@*/\==!L6T')! <%Y&YL%DW
MLG5!*&'/L5YR@_14N\:K0FD+YEJ;Q0-]RW:/_V7@]F\YT*IQH+BFFB=\1>Q7
MA^SU<E$2H38/.2#6"Z,'ZI)=1_P_]+]&#LUQ;T=+9VR&0K]54(N0DG;;7\8L
MQG^OJRWJ\..G%6\N"@_R,N7BG2G%0Y8D:7#6C@HIA1U>RF2!W37I#PZY?F6D
M]#:JB)!R=?,RCX:8UB5\GGF;YB:9"]JS4VA#?->!<WZM=+7V>BGWQK?%>G&'
M]7FJO?KVFX[^53WUT"V=>."3RT>K7VY2;OX8T9F;U!W<=PU(V-FI?=)AAY4Z
M\*B%2PW-BM#EWV8#0[]6TY@(.%JV@\HUXETE;EDJVNE6;E.I2!OA^7AFZD(,
M2^8%0&41>P$L2Q() &*;\LR#_0R:*WRLUM;4Y#6/+MFR(V<FR42!Z=WLKX\-
MO?V,//\XTN #?CWPAY[8_^4Y_OF>Q6Y31ZPF)_Y3V#B484]=Z6^90$B2U8=P
MY7.F#@TP9K<BN,S-GX+FQ]SY!ZB*[F+6',R9S^>W6,'_)0$)DOQ/OU5T:LH:
M*[,?AS#M)KQFO1LJ(WH]1+H 6M+U4"*AI.4=7:N8?YT6I^+=Z%Z2E:D*9B#Z
MIFG1):I>.J>.92@]<O&\=?'6^*/FH9"#6LV3PSD*#_MXX+W+^PV5T,/!PZPW
M+IX!SPV@:E)ES47OTG]2&$'5QC:#%+(K;GW9S/$KWK[SG'&-)97T@!]AHLGB
M>Z[2=Z?:0%UEB,; 2?"SE X#A9$1@*XP:<64Q/H9I-0X_+;VG+@ _HQYW/?'
M]U?$BUQ2XHM!LL10I8N\>FC"+ +6%&TM+')K[.;5*7GH$4BE/./-V-^6QO(\
M'AAPH/E-4]SZNO':.W&>*/DO== ;<<IDE=+O)@=J?M D*9XI>(@%BOM3$7YB
MHWA'1_T/VMM1%2::5ZQFK#>FTI!6-EJ>GNR=VM1D9KSMST0I1VN^R;L>NHQ7
M<)DD^0O-1-\M:TZDZ-5<(3C_?1"O@UD>\\D*/QHEB9W9S_=Z>:!+L+*C,-Y1
MWW,--+1Z[(GG=J7BY0I4O5GRW:22YQ%1:43H?B<>*"_9J%,Q_(!TF_(_\O^N
M;^F)I@K/:Z87K='@'KVQL^NY/"8N$+-1/Z>3]9O5_/!A,O2O,"WMO&P74B)^
M"&F>X?C(88_+PR\%8DL]1HR:WF9,=JP\#:+6WE7E<4^?@X+-;6=\_Z"'-JTY
M5MRX-ZVWD#JN 0BF#F4FH9LLKMUIFIWO8,8T=.F*4MP[I"BU@CG>''^4(\;#
M!JU-?GQ=M.M)'(]>!R5I6OSDAW!1-Z1Y?I'U>;;AU[KJ^@$OT86KG"N'2J3,
M@Y+:8P=Z]CQB1C5?7\[Z"-6(L3N."P+*Y1/&Y(9:!N.''O#J306%Z=0+8%@U
M+G-ZG__#N.\- 1US.TF#ZBJZ"1O-K^O[+.^U 5WU9D5C.<4K?>)&4@/\,42+
MJK9#A)<'9=9W6#GIWWA \ <QDPQM4F*/_@O!E?]<[_'G_[#>XU+M4:YCF8U\
MW7L7\@FZ*64T?0E&GN+->S=.T:J-(+O<^&\_:%Q9U<Z?B=V*!W2U?44V.?0Z
MR)PX>U,Z")PQQSMI,+B!P>?U(1N]KO5II4%/$TV G9U'-"DKJ7AC.D#17,6O
MN+9G_&E#%KL9Y[WTY]VT&>E!IY.;(I>R2@HW<G[24'PJ02YT5K0X?GOI9+Q0
MP#!5R2_N6AK/<O\!$= 6?P@7F7%%VN?Z^?@YEEC;V-HI;+U\&&U2K"PLKCF@
M+(RH"%2]/7AF+"#GU.N[?UFLXWP&X?PA7.8&_OKRK,%>O8VK]1-%I_7AY$F6
M/P0,1X6SV5_[+1]$*O%GQ0,E']TXGR8\\:QIHK$1X4AXO?/!<J+^[A)],^C[
MVT^N2.=JJH1[XQ62CCR,*)944'M\BS9@.N[K*:L;U_/1;2K+)*_<B[H7M'(]
M_Y>U[E';4?V17?Y1EO11V]60.4<PG&.CQ]5$DS9+9#UZ.4<^_3IS>2%M#&4D
MU:YH5O9[-Q5.O1RC-RZ/JE*=;%Q9I;I]AT9DK9F-*>Q+EEM 5FE.DW+!--,.
MC=,*&U?!+UF>#_6.0^MM@L4L/=_;LRH9\Z>TFQ&[[N/[8K?3VK:T3Y:S]EH7
M@-HNOQ7;/O_[<3DZ+FU:N1;1[S\"%L[D:'CA5ZWE_I=.?_WOUZLA_WF]>N[?
MJRS368[2FS&#']XI_91;1A&T1,1D5-\_2WVG.N"/-KL9;4Q9P/P/=5_[43]#
MBVY[ZFSH^&YE86W;HFH7@S?C7N)JW&\E]5"Q25K7/A_^C$UM%2+ZI2)[$*[;
M<H,9F+P-;8QONQGOQVQ,JE;ZXZE(4XLWE#@4M+7O[AC+3E]*2P/OB=9/..=J
M W*]B>_O7"<M$"A6B1<AJ>"$+&A[E0XJ 11 ._$&-^U'EXWU?NMM&/WC;J)=
MA;\>93QZ.E\;$(3.\6,&$LNZ:$EX7Q@#)N$ Z1=B\'$RL"20&T--R57B_[]7
ME\3^QZM+\/_7U:4BD>(H%K+D%\FO:HQ)K5AZ.;1 WCE_G_:6:+J9IO GTHKK
MVN+LI7,JW#X&VH" :$.7B,!(O+&4E C10@'-V4B)/5N?.PQ:K-0DZGH\;JX%
M9+^:ZCVY6KP':=_'L%]2IR,Z,9PXF@!_YK=L_CN% 97*)2::5"8&%**7>2[S
M7 \:_8O1"SI+24=HC?]YU;4 "-<!\>=\_;#N+C)L2TWT3WQ9%'4!2/,ZIYQC
MEK;P!+%'@+%X2^E_^M0M7F8V_KI&0XF)-J#X:'>^YNEAGUP1!3O?E6!.:Q$2
M@/H?-M3\^\W4>?]^,S5@H6N[_@+^[P0263R6P\H/F>:JET$GC+[@,TH;(BBH
MK2CKP<3B7ZJ SJ,JB#G.>FKR.OXN:P>1/"6B-<0M[=WSZ>035&FL*BN++(^T
MJ-G\N^.-@!6,Z 40OOVQ!@<O0-K/JMWK>LRIS_PI1H>FG^] ?HSH$( 4 -3)
MR5GBQ O2QO\>8 F87F$G!N'[OY%0^O+8S.*W]-_'=$TB?4KUGNC>Z\9_XR6&
MF$K</Q#=YU#0(_:W<Q[^UOG;":+4.WP,&YK&A=0 ;R3Q?PP3FOQ'FZ:YQPZ)
MG^'>FY!;6JC^[+H9"P7+K92'\43_7!)-OQ4.-:6TIJ*E^E>778IF-P8.F&/D
MG.=,] _YB2%^K6>^R75.%9UC+5) YF3!_IA6G6KP!K/QI7\QM>C^[;.R\@-V
M8@>3*_XPG*W[&QM&'\*9_JT[_ML3"6@6WQ*Y-^$8;_9/$SWX(0MF_V[$_/W]
M[P@B9P@GOQ\QPC!&-(!Y*HE[-<WR+'&\M   *"COW/JW$" &)_/?$'FO6\!>
M_-_$,*3^(Q'6?=&&[C,A#HR*=4*RN^AFR%V37U!N>'_:9_ATM<5-VPL@&;*B
M-P79FBDO>(^GF21$3/R'LS__;[?_N.' ZS_N1R"FRY&\[C!%XFC7.=MB(R1:
M_R[/^R=:?32MI85C*S\G+34')]:*58 [&EL+G3:S%::&!>_^:* @35:=6O4!
M,\!7<F%1A.8B@ADI'\X%X<Y[#<.;7^Z>+ICMP[;0'W&SZXH2;V?C)B8_.ATV
M;(OA*4Z)K:SP]=08:50_P 2.&5Y]U,V?_TID2"9X:BH7G<("@_9EA;%@JY$+
MLYOLK$'O&$Z"7RIQ "330"*M$W>:)@\X60B['33T2DV(6?(!''W0+R 8TO5Q
M-\BE.$!^S8$1;U.!"^YI9?HZMA>2X'&6E'U]5<#+[KMT%EGRY8WX6NS;[M.^
M%W@6^L(/=N=9&PC'N+:LE/W,YSKL#!/4P(&*V(#GTU916)=NK,7HWL$\XY!E
MUZRVVM6U7._C1='O38WAZG"F8LR//F1]'.+0 81+'E*2;[G1!ANE%4]XY[OM
ML]%!$:[.7]5L&*KQ9MG3_'0R<LX&.2#^1$?S05&RZC0(#>'UB.UE)5!C'K<T
MYS25O/'Q>R:3]2/QX/1!QK"QE/YG.(L^EJV3P#SQ>%KR<_/-8NA3S)S<%2KG
MNKD&>@"0B0S<.RB@+UQ>C#ML8\;+JM3^3/M1UI#[Z'&B:!;'3)]10WD^Z#&V
MJ-%S!OO96VCD=> EJ? G2-GCT*T\G+18!\;S6N*.KR)M"4<'!W\EG@NK\Q75
M1FUGOV4!=VM(QJ(L]M.D"BY1,)/,C5!^&+6_ZH7>X[;'W\6RQ<CE7\...2</
M[S"(=CG'+\I^,^9H6+H$%?3;,(5%=3LP:7"KMU8@'-R0"TF"'Y33V6][\@9?
M8H%67AXV<B5%_JX,Z.:5^H*Y ")7L7+M+0W13O%2SYR<>R?Q^F CPV>G B%F
M6.=L^C;6;\6_CXZOKR%_<=WD<U*K/.)+2TN.??];A'2J%,&)F4X.<2D->9C0
M9;V>^9A987 =V<59=6>SZ"5+W!S)$EI^NX;D#0(798CI39/X5&X;R)J62A,M
M_AP&D&RZST=O6V?E>H92[%U;$\I2[Z+TH$TD4#0'H'MS41"<SAXB^1O'2$B_
MYGC8SZ9Z)]J3U\/VWCE;&MR_8-E&(Q62\L,,6L'%=?E,-K,)]Q.VT:X"XA1&
M;,FNI*T?FOU_](8IX-+*[?N69L0/DAB'H"*;;-*7!5^=7:+:&))N5P\L&49[
M<82H33_Q5'LZE9.7$D2P=O?_&NC)!:\!2!?9-_J%V0M #A_2K.RTKI/K]0N\
M9XE )UD;@MJ14\4TVSDTNM**Q[:)U_']!?2*MKBWY>X:(F^[-$C'"B<0-X8D
M$->>:%VFI!Q74B<T4)3.0['5NI&&MTP^;)K<IFGY3/.'89'[.B1BT Y'7G3S
M,6;'CP68VY1M3O^V%?V(B$XBX4LZ3?/W>E0H8I_5G596/WPL6[F:C%HVB3OL
M4!<AI5D>[N9R /\>FQ,'/VZM?9"MT%-=DY>HNK1T>"!0Z^\W"+-WH-!7G\&4
MNWYTIIX6-F+8%1 FKPM>1[0\;Y7$+K1XH_6:F98:/-_>FVG=W5]Z:O!80%U=
MDV\?9 P(CE!ZH]Z>)4EVYE2<%Y(WU->FZ\UD\TF9ZO)L,2U[Q?F!F7&7^LPG
MG?0EU@*UJOB,;S61M!^Q], :O>+"6#%Y'TX/=[+CY,H37&("^<*UY+\^#/\%
M4-BFY>&/*F.7'/#IGI*$1B*2*;0.5^=L;G/ 5M:7X#U&U62]U R*YWLKQ)WY
M+-/!$$63$8M2BUA8-<'(H0MR. #/&*%L&+45[D;P#BZ=>=#<D)B4E!\T<K@V
MQC8T\IP"G=R<"O0/+UOE/\35?[3.-3P<%+Z?27$BUU9-9JJ2J0]0!GR$%8",
M/AJ(/[OUY\ZR0)*!+&\XO3Y"&J>,Y@GHO8ZP]5 DCVX9*[K"GG97]+G_ZGVF
M9$J-3,G>"X!AH @F<"8ZD@'_/'"DEQ:&-5)<"NB_"E_R)>F'>:!YV^#H6=G2
M,MWE)*-=&P^9AV8"[-0!?NCG+IL>"UN]:L&8$]^]2'_6N@*:>7+6WXW'3ZOR
M/^I#PA&W,*"7;#UAU.-^=AT?89'087VVF&'T,%J3$8?H#1*.(A*MVBVV1S+M
M)\8E@X)%_F:$DI0@5"MWB/F$FA]J]EP&?2?F^Q27CUK(UPRN5\ ,NM E7.S;
ME-K5#QZG+<DE93,WYJ:NOK@L*5*4^MSBO1I][2J!# @;Y94&'E!Q11 .?$EV
M7OT[75>6Z, +0& H[>_J^N(YAZ=-[7^Z8$9'N #Z[S[-_WOU[RL5<_@I\V&;
M)2<<GZ*R?AYH1013]Z;.E?>.PS0C_SL%SO^%9J&.&CX,4CR/KF@[$+"C\UD0
MOP L"N&_K&<O@%ORO@1!X2^M O]#2C'_7YZD]+_3_@'1+?X+B%Y/2!^V^(=7
MH ^);+C_ OA;2"^Q=0'H=-@<1D#^51F_[> )2]OMNO_@%)*>$ LL%\QE>:W8
MA^958X.)V].;'0MXI^#H.3CU/*8RZU0X6JY%0=<EB\;)RNIU^G#BUX$+P#7G
M3TKBTV/"#0QO;-*(K;N!X$!B)&G!\!(-P6\3F5 3]'BVD.5Q=#_?4E3-"'F.
MV'I;#!NO"G8MRMNI5;CIR]?ZUR>G4<HY:^8/I.(L\07TST%!$RHI":WL,*+;
MQFK5PT*#;T\)72F?]^&7?E"TDG[3]'O04M2X.J#>&?_G HC7D)L(D74K<<MA
M]FZM+X>NV'AQ1=*3/ E0YO/I4]^2@<?:RZ9 /7Z%\;N/>=QIZG9"S;SE0#(I
M]3U!8PI ]SXT>$43Y!NPB!<KWUJ3[IE49U94^M.*20$QI'4W\7_L'V)*C+'#
M234_YI75]/W<W,C>[\IS6 X_FXUA%?D!?O5,7P.-!4[YF[?0]M6?7.V!,^?,
M8/G<820*JL#:Y7FU2BP+*P!K6Q8:S*M3TP]&_);YR=]8W^8Y=@W>J'^DU*N\
M*6:!;OD9D$_-WQA=KWUC@O'J(9DT,\F&"O.8+2SX;HZ+I'A6FFJ3WR-C1D-7
MB]0->T9L24*(9,GB'*YWZY9N;>+,C-NFIMX1W4==6AI&*;V=_'9+G $*P6#O
M8;T7K::OB*P\R#IY:J0H-5]/R1-\!:KV1Y.WXNX;NZ4T1\_*^]$:L=P6\7@M
M+.7+@^'$4_78V-U=N]W/=7W.XU+A_:C;] ,CT<O)NICIQTL7P&5<X:T)27GP
M%5ACJ.WP4XOM;JEDX7[55RX\<<NZUL#;94(T:I[%CP25Z^JN8W'OZ>WH.I)W
MAZ0\93MMR4\D6OGF8!I<@809SZ<N.>8 '_LM8!?FO3'6 'TQ;5T?CU=$E1OL
M!)C^,=R(X<JOD=4'^C",L$JMNQC/E0N ^]"3"H:P279]TAUKJM_?D.J9N..\
MJ_'P @B)!XX@<2J*\?(5UZ; U)M=AHWZQS^NIGY<0>HH4;:*%8\_:H@RJ(G9
M=U!84S)QSE!>6-84QBHC)'%]@64PQ^6U#-[\SXO%/P.D-8\]5 6KPF.%7G.G
M>V?8P*_@'4.7]F*^NM?=J7*XRQ^I+'@2*2MAD#:'@7,">YMBKUDWISP"!,5+
M^^^\NT+5Q[)29T^)=?Y4H%UAC;\SL3YY[064\Q8Q_Q3'KUR;0W.@E?!B31BY
M5I&,+A-$PDYAK%G2=UF!PL!/O=S;2I3ITCM[FMQ[G3SF:X9<IIA#?+KZ[DO8
M4??W&>?$]/OY]H>_)U=4Q"X I[#1T_E$ 09W<S'5"Z 54";X;4W\UQE+>1E\
M(HR$G$<1\\\(N:_?$$R7H']$Y)P/?A,I)<F_"?%K_*=ZI7\(\6?\]T+\MO4I
M3EC7D2P0I4WWZ8NQ%X%%O@Y75;_0=:@W321NNB($IYI!J!905T#0/*+[AKN=
MZ1!%0[IROE_3#M>;6[R46LEM=[;">&!Y>SV+H.W:A(G;36E.^FJMI#+2=NW^
M0[+QP%8I(B^,:P&VWEM>[O8,EK4Y-$23-+[)^"WO ?VM'G;'_>3+@@SCF KU
M.W]Z+@!J-:M"H<67$O+G3/?S!YQ:!/MC^;@9]<DHR!XL_>D!@G-9ND),L3_S
MJ#"-<U:]5>X6Z50WS'KO<SM]Y6D'?V*)?8@YZS.UNE8<B*4QC;5^_$<MVGBJ
M_]=9M&S-6:KTMBN)FBQB\]B!IUFWR-9=D=%M"L,:/_-V16O?%_P2OS59WDY@
ML]M4S.=6TY) D#W;Y)],7^97MMOLO\S;QX'W6"0FZ>99E&+"X5N[8#U,; RO
M2&WHW=5=NX! AE/T=.1S7?>?TVHL:##][VR5M3=84O.FMNJ7E8*1>VN1QH7B
MEQAO8>@I-=[Y%8!L$?R3:@$H+W9<Y7I7&'!%BSQ-++#,5L),3^GJ<_4@[XSD
MKIR96NQ$XW&'P1ZS+GO,H;C+0OGH8TT=W;IG83'5$)=Y#1JO6$__>+6MIGHW
M,'=J Q#&3? E(>^+:!7YU2>TFI(RN#-&]\-3SL9DN$0P9:Q.@SGD]C=L<>Y.
M<L73+QZ</N3O1'?HZ76\?ZU<T1VK;X9B05T:H):88=L)3F1@X1^3VXP:%H(N
MHD5^%"DTN N@DR#9G#=[JU61J3//*6I[CY=-:<A*)U".9*WM2BV$>2'$Z2MF
MZ"5*+%>&J]RR_U??H_HA_?93\VR\6,I+AP/3C\2H!N,]<G IE;,XCZ/PL</@
M4I<<+@^EF<((+>4A;+L@/:%VX@+HND6<6L.#+@ ":=\%T"=R:3T)W&U/CQ-X
M[CSMW#!5\4;1G>I.]=,&WK;MNL7.+P>2Y/A;4P=</"8:@O/=$DM6+YROJ0;0
MHE7+/5"MY:S?,-?V[D<J/XK?N?'Q]BM@D_.^$A_3H$\K&VYC^9RK$VG_5B.M
M0O]&1=7M/6;IS$<4,I>]>P &7 D1BM&%N'UT71"98+(:\V.CRA8*\TYGXSOL
M%W3BQGC,B[7'$!^(*R2T6+[([6'A[Y1UO6Q&!%)(F6R99(A^DC<JSZ<G> =@
MMA#""O=8\-)CM'<1;HP#OL6/$F#?RZ7;'ZE&V)J_7-ICQF5TU2'W\.(5T+-;
MFU=EA*H?S5_F0!I? :GY@N\ 1Z*K>&GT6Q#+%F=/=%+SQGFV9(9X>KBB@IX2
MD"=3DM,S<I#""8OJ 'V$51&V="<%&K@D?4]&G;*D2#A$GA&GW$KRP.S."X#*
M;G-!&'O;!%9H]55!L<=NIT3TJ9[_&M34^S0'.-6(1X4$4"8ABL;EAJE5D#9W
M+H -9)J3)./!B5DRE#C;*G-/\Z!O4/; 07AUX9>^^=SNQWON_4]OU%+\*4PS
M($D%T4R7E'AK\B:ARW_D0MH;)^??[9%W*R1CO\?2%M%_J&IE<@] ]G4E*9R9
M-F9M;FI=.WFL[-R5"KF3TIWSUL.!'%&KF*AS;&V1T]]"(I9.6><1A;/Z $OI
MT;A4$^<Q'<2;]'286:QDV;G!L[OZ#4B41! @$I/Y\CCL0A3J_-'QW8PNE5_C
M[U_DUUY-1;R6D1[AQH#6;9\$K;]LY0RY-2['XV/UUFI$_E[5PMK6&T?EOAO3
MD1;J-RD3.4=P Y\W<\PKE@7':[F:;C>T7I;ID.5+"Y"DB^I?.2R@<TAL;"TI
MP*L&#\H<>1C4-KP,^?66+NI=XA0VQ7R2P'4K)W0CUOS;N*/TO.R#E]2D#6E[
MMHB^Q9-K3/#I.8>I.C_5-]NMEP=]/.12;;7?4R9;_BH7H-*A$DAU)=5M;[2(
MDX/3GV=W-Z9.^(&49X?H;5:4V@=(%_]4YC3O+8^[:US#09[4J[2@%NUT14.;
M!IW?T*-(*825P=;H$._E7(-V M=;LR9<+DHW>]>F8_V+K/ZO4$+NP#;1,Z4(
M-9RV"\K#BZQV/6Y/@O@#'JY/WG0.T#M**LA2<ZE4=:Z6VZ/"'??(VBW"2KH;
MLR)IBVPLW2RHWS-]E2A:QZYO$,&$;7U<L]_#Y47&WXVT4^,_ LKO?.V^1W*%
ME5H?DG+7 KP4&MP=!.V>-VC/62CU@UVM/]-NF4MX"72F@BJU?-(#63IQZ([I
M()?NX<MN5;@2Z^;@F?M"\]VKQ?4G[3]=ZFU'*%MP93_,B" OU.V#?6B*:1H0
M&=KCSQTUX5+GWA99L^-S!]/34A)72P+_)/8M_=EJ_:5NA"!]%,L@+J_+& /O
MY/'FGSXT^-%?*-,7ZJTL*V$%HZ77@5388'B;,7B!K]/R"=]*I&::_PR*9?O3
MI >J941H\@RRH,(X'3CQELFAS^&,=KC@VW]R5&T\U3P#2#])IH96^:2#+A4W
M3(>881 ]*H^S6CYK-"T/:N.+ON5*R]W(6__4JVOZ7)T."%9G6<WGE4\RT,6H
MYPYEEMI9W3W^_='&+4=!U&1(IJ3DTH>43@T5K'\V*R(0;=/"&APW91-,(W3U
MJJE,V38[FU*OSR+D#G 8+_:CE0G693<I>8B@Q65IYYN..8!= ;JM=.4^>UU*
M'I#\IMS_;'T.;L8 )V9I<@%H#-J4=;R2>1<I0V<QX4E.>.OG&F3()+PF?1\O
M#_,*47TLMCYHB?]TDW :4G$:I?N+_F/%_U_DY7^+\(#^JIYD?$8$U/J"3:4@
MN5Y3H)<7P)CC^$'MV71]7,4%8#M^3$0WR>_!IJ(;>#WH ^P[9^AEAW 5,J]V
ME?P-F]*.43LCLYB;I9*>IJ>]J#';[3R%I-87CZJ;;_@?AX'KF!QW6$_J7[LH
M^:KJG8LL\$9,S%0ZHB3Q&8@K\.E7^=\;@[YC%5*1%T",'X_0M2OR<W17,K.?
MV1[WZKA3>"^2.D<Z1 <][_Q^]_F=*I*9^HSAI9MXC]>XN=%YW'#[J5\#*.QI
M @ 2_8R-.$F%[V78<$([#:%=UD]HEH=9ADL<GM#XWE9=:GCX#I(%I4ND;RDW
MZ&RC<1Q3N[T@.%WK=CCHPZZ_9E<.9C^Q$'[GO8,,5T8DYN]KX)@(K1? D6_Y
M8@T4GY$ /[NL?0$4Z-NQ)363*B:$:!6X>V]*(RLS%7-&:X1^YLN\(TU+SCMW
M[^O.)_N!7J3M*=(.R;J;;:"<]D$RE25&.NU\;RQ<A>XR*P2T41K/8C[%!VPK
MQ.\/DUP  Z'8X7,?\"FC1<6OV;>&&LA?7QQI#3@>2+\#9&VS8_&7)5YB0?98
M+??+,NX)-39Q\:]/*/=<\O)>D73B9/WJ=\"H4@2]<-9U3KKY.ZPZ +S=^\2B
M..16'@T\-HPO?=TK\XCC?F10>A$)+EU,MA=.5]%L\FG6PU_EQ:E1D[LTRS:I
M,FG!PT4.0F9:,*;-%LOR(FM!!/OB-%XT@XRA_>H+_4B6.=+LCG4.9A)0Q]X)
M?\F&S[D[:&:=<-MF[XP*0HBLG89)=J3C[K7W=54Y"/T@'!]O<9C\6:^#0BMD
ME]LBA3"\$1IO;YS:U]3305ZGL;?WD[(/'!30"RQW7L>MH[]1)RU51?VFC8+T
MF_?U[9T(_2&F;LC/J>&8$'+)6'P "L306I#Q\;.^)9GVW< G^\]]3LR&X\)
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M/<KJCF0&5J2KBB]A=B4DBC4F^//+O[6)!-W[_D16>1%_MS "+]-FH=Q.OC1
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M=LLS.C8_"-.7] ?!N.XG2F=V)C^D^OD80?*GB6%:E7V+LN-/*U<?>%( .XZ
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M.XN:YXYSP->2YD[[+E%_E$SHDQ02P@1Q:A1$ O0 %_+O1T]2QO\-4$L#!!0
M   ( &FD>EB/LS@^C/0  '-^ 0 1    :6UG-S8R.3$T-CE?-2YJ<&?LNG54
M7-^6+EH$38 @P5V#0]#@&BP$""2XNQ2%NR8XA7M"D.!>6!5N"1[<"BC<W=TO
MO^[3Y_8;H_N.U^^=*V/<LVI\?^VYYEYS[CWG]\T]ZG'Z<0F ^UY.40Z ] P
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MV/>AB]VU#D4=%EX6?H7-/7C\$WH:+2+'*@-"\6.CG]U AL/OJH!-V^YR+T<
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MUVR?ANY(J<,#ELF^;/-L2T_7X+_6XK$?%JGJLO:T?<[>+ ,QF-\APO_SD7]
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M0BD%$%-*#\.U43+V]-Q%ANV7-V.4/SR$VD*K<JYD*9BQ3A6T+P4%J7\6^?(
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MT% !>.409H1WI9/=.&E9.^&ZZ9@ 5?-R(/*YG1PF 7JD6684SMF,TUU?,H>
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M!47VV]AMF#T4S8O/,E&3QP_X;<)F%F]'?CPDD6S_L3/Y\C^AQIC_"13[#TN
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M"Z<&]?MLXB#<Q2H!-P'M9V)EI1P^8UW/H/#L*O0X-8:O%5H."5NYTU/I>6G
MMW6F$4*ZF/]T/Y1;_.]O71V"0AGM'[!5 T_?=*"K$(5/;\1ZFYW9QJ1$(816
MWT$1&_E?6P^HN\PL&2\W;./D,S!EM95?0QC3%7[(%?_?)A5E[2:;DMX@?>.;
MNDU/A<M832VTNLDH0R9W:4*'K'7$T4 Y!&AI8C;U^\7VA>?'M4B@3AT)0-(0
M1'(1**,157_6B00.5- F%'6LX"P)S @/=O >ZLUB-@HXA6> ^S+VK@[KX:J
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M&D9_X"!I[X"N5: [MV&RUF3':U-6%E_M;H]IM-CEG$]_O]635>3[S@%;@UJ
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M.ZBWA#9B:8@.J.*[6V(*/D<:A\GMIO=C6![P+,D/]7)?KB*!?O.@_,(/QQZ
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M7+Y05\?9]39AZ@?M9PT1K4[Q=UW6*#=9J=627@RKG<X^G153JC;IY?",$($
M8;O*+@Z\S5^K,T+3[^.B,3 0XD51GQ$?9BD^NXV?S(>9?,6<-BAHZ):A<>4M
M^:"V]#HVQ5RC$'>O1!%A'VH\A,Z""ME8]'H[>^?D_(]J&LY"AMZ'Y-N=/JD@
MLUQ6=PPC60V$9U54TE3RWB! &W_23)X4JW$<1UO]JB&)-JF+%,ZM$W_4Y6!#
MUWQ(2A]:(5"A9,[_CQ/OKXC]_:9CMG3)-U7THJ> 4S+F*$.L:C#O]+;U#7NB
MR-#QYT629N1[]2@TBB7#+%8<&.[#C1=]X8:E:9*,&_+=U"F #>^*G_KJEL40
M<[<P53PL$^53#:6@L%1DK4A)B')F_<2QN% A/(@8"9RT,!L5[8"7W]0C@8)'
MVH1OUY[_D2[HOXI^\+)5BS0NDN ?>9+.DLZ515ZW$"A*&OY19R,:LW2H;=(>
M=')$?90?VWK #O=!#4-A-!)(X*U,;.WYO7C_^YX+B8RDO7K+VA:]Q!6*!-PA
MWNA84U.%5N;%)HM>M&'2V7NQZN[#M/T8VOM;2?=^. 4Z[/L(.N3J0_V1CW(R
M6%T33*FR9,$EZX%N^N=D[$A@"Z+68CR),@4#8"2@HU3.--'K_4?:G7\5_=VR
MYAH5G8#.<<U >Z##S \]$,;4SXW_B_CUOTT_G@UI\_[DB%K8" 7%_EZ\H?6D
M$^4I&0UO@K,'IYG\##_SCTEI7" !>!-JA'<>I0@%<R,(,U$KYCFS_N7QW)($
MG%E6%.&M5G^V4]]:RP9A(Q(<^GN!TS\+_%G@W[G QE\+!$CM6\X6G.42+G/&
MR?A56+;++0H$NZI%_=A4%=X-<.$!QM6'943$R'"K;&Z<^@=#Q18J,Y31'U)
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MZ]S[7>AR;;+\(L--/R+&XW703G<@/[,C$FAT.GV<;UTLP9_<Q70-DZKF)"]
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MO#%!"\IP_:$3[,* T?)3F?M5U=XSEI@"PF^_H3]Y2W7UM<:3[,#I(]QF@?Y
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MC7Y*0G@[^O=@QD9^\^GC-[_7C<+%ND?@]G@D<#+!7%; O!@%]^]#^;YA5=]
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M]9O5]:]9*7H_C.#= N'"%2:7[T[P?K'&)GGX;'V"RX'BH$U^%*K_28_-#>I
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MGH]-EE+$%I,&];-)%[H\D+=6V9S,D9U47@HW.T^H=UY13BQ.Y!J=[M<HK$2
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MM]XTR)P2)!A4G&A$(BDM;@N!?76C0@/$>"/0@/?2%PL=C3#'\UL3(-15)L3
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MUX%%\QZ#>N89,29EC</X0I:( 8\^< I_9\'@T$(3+=W;HQPLD2";YA.\ONH
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MZ1-,@8?:7"N/BUX^^-),-'<^WUZ9G_@#I,GQ5 !5AC#:0'?FDTW=SB$=_^Q
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M($=1.ZNK<#\ 4<3S,N=- ]:[RR% &=U_:(0R3VK>_2?&M9O_IM_$__B/_I>
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M6TG'G.Z7Z)O",VKG2".Q/282E?>"%FYH4B),+D,XH^F5B?&& R 99&NH(O,
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MOI-NAGC:!2CFH1Y&ALLVG#X#JM>3W!=05/8&@@/Z@]\@7/<MC]"$^?*]U@W
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M*4@[]=UG?\T/V41-/UAGP9L0>'@-XHE7G@9J17^@$:UZ#$&_N9$-S[S'?-3
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MJ^6!_$AKG=G5\9PX'2J]Q;OO^ N?6DYCM0Z_ET:S\\RA+8__(Q#_$G4%!B4
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MM]WXXC:'."E6O*OH5A)IE[OP!PGN<Y"YFB)L-M\7A"0WI6:AN,KU[/=;NP=
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MU1H_'DA\2EK3TQO.^W%NUX.;YJU8&2/@-=4&ZQC>.=Y5XIK+;5+ZT?5Y^ -
M/A\?6S)%:QXC,_Y,7\@AC2K<::ER+4JCMB&&%&YW]?(-H*"A@_YF2M22"W%?
M2-%;;[KT^7B!TW>)0[>:ZQ!:56G7_P X><DOMT^'?3]@R8]RKHHU&<<MU;0+
MH)/ .[.HOL^K0W5543O3$9N9DB09[!)2)B'):2IM7<<\7=YBP1/\)',TQ@=T
M4=R)]\=T8-/=LLWLR&SB<FD*T6S9=#?IE-26L3X)@E^#:'M!7Q7N>&;:B1RI
M:,-[@/RUOR9$:B<6R@0&_A1OT%Q@,X52V'?I&3 ??N.2FLO<L'-LOH_+];6:
MG\^LB,O,YC\@Q5A![621DOULQ/U8MG=/-BIC7J@/QHCH.CYS]S*240=3(=UG
M5>,,T\U^FN%2%WA$*!B]G>*38//7]^./:16"\\35[$A.UPWW"SX94&&=,WX$
MQCLA#ETA^G!K@2H/')'!9A'E;^,/]BM(=2,EANI5RAA#QC:;LK_<DS(^.G9J
MWO$FXVVMCDI7P[\_H<3&<+Y@?ARPE_MVIZG9T?0>HTG*$CKE.;*[+(TH"OTX
MTYS2XD#832\MGVHK^YE3_-:Q/;YDUY(?:8=Y'GT\OYLZHT3Y'ON#^TGYXL=U
M4IZAVNPP2T9$?]6)SUZOZ4O$EP$SI4:;]^Z!I[%TU*-3:?V9XO53RTN4&Z+7
MC'UYR):>99:OT (@98-[4"*I+!-CBQ;QCM:LM$:!O0#%E(B9E%1X1!9YXU<N
M$!$.-D3DE"KJ 5!=JTU=-QOB<CG72^KO^\Y]^57FE,#Z)Y5 *,61)2="*W%M
MB:_'9&JC)=;G@W2OF3=>A^"1! ;C>:'ZXY HI[D[N*[S5@)2#CI?67A,I]Y^
M+-NZ9TNG^IL]<2A8.A_M))K?G BX= @!R< A!(ZJS05D.YID?9YN+L][@='U
M9O78(J=,01^EK,B00UH3_%GZ]4U\#+EORI\71),2NUG)9^,X+.,C7> :A()F
MWY^DS?A^6Q1_O[2Q%HT&I:CD>ZRG9G]V.Q#BY/@>R=K#1/QQA:1B)<RSQO]'
M 1_&BV/;*R)T>K0SB&J*\6K$1MK+6#:ZS*7@TCA=;?4KZ*KV;1(EJNP'=0SS
M**X51_(Y>ZXCIDA_SLTK_UQ4+F;\4"XHYO=) %KRH^2%;L6 _T[C5"KOJ'XB
MW#N8M>F$KC?%_S2Z<M/J9IL E;A,EQ:L3*&>=FX4?:TA7,^T:(S]22Q9G1 +
MG9HP6[56(WN1HA#?#*M^$K9^K_W1)>PXTSXD%QR8R=.WDSOP1%3RJ^W):;):
M$FFY;"/S]?&.NK&/>).>BQ9LN.+[X75J9*M<OD5 JMY,^8=#T?"3XF\\3C)$
MA"IE/M">-/+'FB5 T90=25P6S ;A+W[/#0985RA@<O2(0!:"LQL,J^&R$L1H
MUPT3F8_EK/&LI]3EU#D.I>JR&-W;5V^Q<*ZJ<OR(NE.KBJF5/?SC4&Q51N/E
ML6PX7'7IS$EW^71H8T:TA_.<VU7^E@<;NBSV$_$ "#\W+O>,$O=$OM,C;!&L
M#8I@ZO2[+199#23*VNM9(?OX:RV5M.]'0()N^*.7_-7A8^<0$V0-ZG>JJ1JS
MTI:3EF '%=+'P0H;K@;8U*/:?B6O0R5+U+9["^;'-@/)D4MQD2)F*Q3(\$<:
M2JK+%P%E+8&J.F-N.Y9[#@$.X'>I,ZD"V@XLJ6IK;W22/"7.5F>'F?!;:8J0
MLR93S\XEG/-CE_^HARUU)VA89X3T>6=35M@@LGMXF>0GBAHMQ!=]25L:?N^$
MO2E7%N=H !F\XWIAH/]N?V61Q"5E_]#YGAW)W;_:)?=E_[;3%=0V 0@LQ:E8
MXC>>%!G2KMLQNKC\:H<)<_TC&]XH9WIU [O/1DR^'LM:Z&W (GR[E J:J%6/
MNF7'N0++WD_/@221P'(?HUZWO<? ><_-[]S"'NPU J>IV XCHNOT3",U9<H9
M9$8.E7<!6 5S>TDZ2N[D__9QM+%V8X?ZI[NU\Y+)0_Z)'!GMF2*II-Z\2.Z(
M?_8N3'IK+?PVT4%N[X)X$S@J2XP4>W'L".0PK06&?'AW4C\XT."U?R9]1K$-
MII=;3U=[ %A5@84L>5=7Z/<L":CR5>L:L@_,"-H_/D,N9%@[4.\"QWOZ=7OJ
M"(_NE=T=U,S/.K[(X=Z*%2)E;PS'X2DCFP/2B\*_=UC6'Q6(*8YB&(DA6%\W
MA?0WB)*TT)F5B?GJU:^S @-\68_+^2E KX[%(FN/BQR5Z:3$WDRH8!!DO2=2
MWD]097"5X9F1)=R6I?\Y7BFBR:KCI'[]0<F#I_?=\[7L9T_6B:X&1C E3B=S
MIC7-2&N2QW?$J!Z;+*AY>$J[*E /#?&$HCATV@:T]P& 01?'>D^J(7/?(;IR
MLT=]!X0&"B+3]DR/$[<%AFNT)^?>X9CAG-)3>EW;$']@,OTS=4_O@[?2G7B7
MV&?X$_B\T\8DYM;6]BO!P5Q6> Y4SK1?W(>S6*?-GV*X,KRI1]CH<<&8!GW5
M+S&V^"K;M[LXJU.T8876!7,RA_G>A(4_72=^PXQD,\YEIV'@1]*:'EA-_&&%
M7D"I'VD^)''7)52)<?+*'H<\V/"4#E]X]A<RAVH)()"K+[E XLI[G4=LJ@$L
MS_6,YZ*2<*>M)ULCZ[3@5AZ14O.#/3FLS8%W2'0J^O#%UK@W6N(9)./VF<"Q
MG3HVY.+7 V \K,VM'6,;_07E\9)%965)<MNIUHK8W4BZ!_)F-A;)]30.;AG*
MT \ZFR:Q&1A8I,/.KG!1T-/)9MV9TFV;'BT1L7IL?TV5?%=1:FI\-7=R/\ZL
MB=R+OK;1O_8JMBZ;J]A,]R5<JB'-,[9R3Y",GHT-',OV[^FX6'D V%36K$)N
M$Z6TKY$HCO2BTDB)F[OPDB=]N7IR!=G1XV>PGN(7UE(\OZ02@Q@2-S2/CH[+
MK?BRKF:MQOKFN#G,T%(1?2SRRF.-ZC9IV.7N#ZHL-9VM1T)[/9!F,'V_T'RG
M5G][WH,5FC^'.<ZW6-I3>EF,@T3\)H^2C]:=@+*BB-'P2MG1TCW#^M.@1"*-
MQNO28)4UPUHK4OMVUI@5Y:D#R(N \XAVV^N2]4"#528\$+'MFI.V?O-,EF]%
MQ8L4?"[#%".VC72(O':3B!"2K.^>^/C&TL=%O:.IKK:)T$5RC;3755V,E16C
MY-HPH6=2LR=]V<HU*7T&F@?21(80Q<-V<A$7+?;-@^;E@E ZG@':$[H-&1SQ
MK3J/;!P0T &SLD$LXE:)=DE;^D-,@-OI<SR/Z(MK?2:J5K0"^WF#V8@#VU:Q
MV=1=FU@U\O[V]VJ=Z'(5;V]YD;[Y2'B/?KI^VH5H73*K=HUJ*8XMVQ;S=#]Y
M>^7*VI11JL!>EO0$Z F<4$PSO7?^1VVMH5U=LO-+C2>VV,$*HP#:NE49IAX_
MT0CI0,IVL7K!12I?T#$?6R>&#=H"O1'N\<S<LU8FV()J%/5JX\G7ZH$GUIVC
M'100A,@$?[C0P)-N]K/?T#%,72 5]GD@<"<@LJ/->DQ$TTISG%=VNM1J8:XK
M SM+ODDV9.J.Y]$*"@^=BQ]#X5+/UU=]T^/!1T4 HR -SQ^W^L@8)X:^'N;6
M#"C.+F\.C1SG^;S0(7!"V@1A]*(64;&Q''V)RNGXKZ1WO,N[E$U4H1B?_+Q+
M??Q<:QW%O/C>7\@$,=C$V"@;*:,E)ZV3[!+[#4RU&L$.:(_VF[/JK.W<:N62
MI;O,'+9=44&.Z5.Y(6("$G+C4;,3UI0IK1Y-VAM"V\89@/ZX++>*-98CT?(+
M".._2TMR[6B_<+?VN/2-\YENM88-XU';3IVG:WAF8L0_6O@^=?:F+#$.I-_,
M$5$K1ZI\E._H=1DLUUY=3R-;ZJJR86D!ZPB9D65']-575SJF'I4Z/G[VY;AQ
M 6\-Y[G*<"BT. <BAM"_M&1"9A9"Z0O4&',O)"(9V5XL4 <06PV6BONYZ^JD
M_-#2--V:/LOYJBPYIHS+F,2_PF0*%Y:.)<8"\5F1YO?!2>=S6@FJ MK4A%Q&
MEAKO+ZDAFM.>;?PO(YY.U^$#J=>=?DS^>BSDB:K3>XH?  /OPN][H \ %=IS
MIGG\>Z4VUON.!13_%UG2C?)\@OWT\'UAOEUN-@72]V/8=&R#]5U6I;48R]NJ
MJGN2W8!0@PEI7YB%WYG)3MI&^25O=Z][] /@, Q=+M1GM(<X?,QG13UMRZ2M
MA=8I:9BBKI:(ZC(:7<HF) YV?4\QZ'/3P[,*H=(L-EG28+./<'/AH5?]="*H
MXJJB\])U:G%)UDEA>/Y"MB:OIE7&_VDA+)/[VOI[Y3-XBN)NGP+':04MW'&D
M+Y1<1_6_^V8U(SO H7;] 6#<84H]4/  ,'1L,TZ\,RD]%_CC_M\[WH.F;_OI
M$A(/4ONA"==FLAP%NVU$'/UFM/X8QGP#N  8S<H0 7MEGX 8IOC.@6W GG<2
M$QN_:XQK,&P]+B/)NC#65]=H*G\SJ+YP2=>(UQ&ME7G$'YJ%%ZY)*??GM6JZ
MJYW[JXK[F?NFHSY? C"AM -LE+9B,ZI(6Z8N^? &&"_\9H#R<+5JMY6VM^%8
M+JZ50*EF<==+A^,1_I^H?NR<91SHV*P_C"G6Q2V ,#7BX$VDA#%S>SWF"[*Q
M9OKC0TD_PT&*G:+)S5=&42N*8R#@&J]4S[QL,;UI77)[#4.-FI,+3_#&EZM
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MA7]%OV0@YT'?">;NB&DE+O99TXB=/YA?WGQD.K\KD!*=E1.[Z_/K B)8BZ2
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MX!X!].$(9EM7.TNCKR3?ZK;4,-[I%$M]>J<_02<P[5#G=']OMI$O+[<^D7$
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M9%TT*Y3V!9>K@5T"4]#V NMY%XN8235U_IU40G^Q_ &#A7?F_6\1!O_)J=3
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M935JJJ"0.U36<]V7F+_78X7 /4O[!50N*[PN)@W6%M:MLD5#SN0_)UD6"^^
M !_"S4]?Q,M/&4X[.F1MW6-R&'IP>HH>5]0*!.P+^U9V#XOK3U?@S?*0)JER
MC^$\&/Z%YTZZ/7K Z&<$VWNPV*\MYP_CZ2&D]3[MQ2WR]K45^&5E=?(DUM-!
M9F27B5$2T_L:3:74NVP=V.W@BNM@H:TJ+THQI/LIDC&=/QC]-5\B@M;F#VOX
M>EMA;$J7ED(WQ&3LP,/^]2#^(L?3,@_CN(@=[[+IH>FZM_?_V?GKOYW!WJ?8
M5RUFO>Z]'NM39;VNU=WK >\-ZY?$=2=H_N7)HS_Y]I(0,_)Y.']WTEX:SK:R
M@9P3X!V5I22F'UJPTAF99G1R#7IN7KOO9'U\% )X(W>1Z,,I5"VU<N9EY!WB
M\:O@I!\F=9Z_"HZ:WP*OZT*1@!B#'['"<T,G.4H.!2. =\Z#V9*UF>LM=.1*
MXBAW1UU,$M03R% #;0_Q*%M)WNAL>W*W2W,W9>9JO^W700Q?6 ]OO0._9?H9
MGVK$88OGW!4"SVH]W_/+QK([ -IPR4O/TR51?AA-=V,8Q8AYBGCE--(0B+ZK
M:>0M=:PS+S7NY_[#B"8T/@C(UU=7D*\<7V]W>,#JQ:T=^WE5..IQH_T'#RXA
M^P2^)TJT!F#I#0O!SZNCD6+'(><%D_4^1]P"TVD#S0W-S-F+VQ@E$L&$CA'G
ME3GG9B0VAJ3CW65V%ZE:/UK'61/8WX[P 1^M>5";A;3TY;N  OP*AKU<;S9!
MC6)'%BMH56QQCX<%]81-%46YJEMAIOK1:^&U3'PUSQ1_MKV300(,OF%7@MLX
M<N'Q?6*A%X9ZN3Q9&*9N5Y=Q(8[2JZ<CJG[;O383]*'7/9HQ\HDO2OG'L(P#
M4];-\-HLWJQF>5Z@HLC&Y@SV0_\4(^>"D#8A-45(5!L/7SXKF1?HA/1PJ,(1
MU 6&OT<"9+"!4 M6N+[<^AV_+G2T,UI5"K$9GHN_[I,D)RXD*TYTZB%!9*@
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M\:&D]%OP.8FH%G.KH^?0?21G+1'XJ'$O6.&Y'*MIG:;T QQ:'-+0[7)4SVW
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MFYY)P2%..<CJ#]X=))1B4C^Y:OVT SV]F77T&9$5I0O/C?*[ 2RX2:-5(1"
M#[+N7UZ38&2  (*R\W)OB//V4(- ],5W?Y=1H G>3\U64I8X&QS)+?I<+_,K
M1N,_7#?0U^B>!%53X%CR"MIFHF6Y'O6BZ'TPOQL^'TE135V+/AO(NO!@CU-@
MXL WVZ7 O*+/Q>&T'&^N3,+CLP?0(DP1/LG3Y?W[I=WW.[(<4XM0K/CJ7ZZI
MB>F/:FD-LWY16HCG*KO@_PQ4T<5U3E,%15N<\-L%-81XD30S&M+4 GEP3Y#G
MV*\(?:OG)A,7C#L6L4>6O.,3;.HN;&*"KI(2CS/89;+"K6E2J7/.POTE<=4$
M_\Y7$GD$6&17S)O\W7ZM40X]36J_XW$.\^%L<D?3LL+GY&(\,03WG\MN&B)J
MZN7#W!^JR>26]*;;8*)5LUY^ -@+;$L^GSU?[#S34M'M=G$TC>M@K'ZQS8?C
M'ZT&!RZH"P\ "?[O'$#_ZQ?^AND*NV_*-$ #>K$!O[(S_TQ%$3@6RML7U-TL
MX#)W&OD\-E^C8P]CH;B!/23$/!%QGE)]NZYCJ0-WSEE]0W&RDZI*G78<&5L5
M$]3A2$%81+6>!^E?N!TO<#43/+.3<PK!*)UG$_GY).=%UD18>[8Z?:RK=>\0
M!) %P5N&59Y'$TT[CR>]T7@++<A2 VU92E),M+,%$1,^UU/#MRPF(+9:'JM-
MQ(I#,<IC<<GG[2L*Q#M=..:\%Z&<VY&/GL<O")=+PL-%\R-&]3CUFUJ*83:Q
M9%MJ$;LL9#+.S[+K1 L)9$_)O(?/P!JZ&';FRLU(KVH(NOB(TF?* K])$P:*
MHY5YS\]/O6EI"8^W <2.[<RW(#"N*!ML*./9C.OT5@KT#3-F.Z-[#N5/$R"
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M^]W=0D[U\:TV+61;-"K6R8N2^:<,]R,W3 D7&Y;J6S-6NBRU0YP+-3S6EF(
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MQ=Y/"R" #DEF/N*U%O*ZFT^)[7(/HT+W5(/7,1H1::+"W^15#R-=)U;M5T
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M=[+C&^U)I'Q#*O5_1LC\HZ4HR(VGK/^OYB'9\3^GH=)@]'6]]6P1 M!-E21
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M>A,(=R-7Q=0,>_7I(DZN/1<\G/O1KYVW6(Z3PG3UXOT>CS _H@^1L.=4E-V
MPY7!4EN^;@V\-TDG2GI04YHUGV2ZR+/;E!>:E,"(4DXT@"YX8#5<^';T)$SI
M!D<BVV!.4B1[_4W"Z<?\&OEGV2KCK4V$-4M*=;L&//PAWS3V^@CE^><ED[TS
MJ$[Z>M.;M9Z!,[T62.AG2-0LZS(;N=0OR80F@?JIH"^V>TT*2UO%N]GQ3#:2
M:\G#LE@,(4':IT3\63VOJG<EU,>NK*R6%9A4?3CPNZM19NLRM6)SKD.(;>%A
M%67YA9'+E^:-5.KK)HX5#)=M2X^MLE_,,S]%!0LB2CTG1>@1[R75H,"4]$D[
M/UWLCK\PV,LUYDUTWJFS5ON42$6S$(Y#628<&!YGU2[H<]XX>26>/]T<UE/M
M6M%KP8 @DQX&>__*GC T6DAU6S183Q(7$XGRF.=1$$8VH6@<113!V1WR1T9S
MN,=HLNP^].W'>5>WY^_;V7PP%H,X @6JB-M#&G%[-KG_?]E(9HVBR:Z8-S@$
M[AW]SK=#;5XD\W\?.O[E$6S)FS+U$T,:%4K*)^.@D%]KQ/](]:VDE@FZ6L'1
M\GICHS,KAR@Z;//B^'E[<+*#I,[P!W?Q1K302MSWVFU/1$2-T!>V/7E>>Q 7
M;W>5P@L RN@][-,"IDA5C:6Y+/*L)MQ<^0C(>5H;7PK+7L<XF!QT%*UZ(#DB
MV$M-B!8H,DUAJ!GJF!5NX;BWRDWN7:&<"AE(J5>/G/1$R0LPU5 -NSQH V0=
MA6KEJ[Z:^I?X5?3\E",J#\A=EEN/Q4(:DFL?W-CWKA!J94PF*]T$@P-X-^E<
M((#>S-[C4LELG(2[&;%>LK<0M/VW#F0M6Q<:GF6+SM>,S?JW9C+UWPJWED]U
MV;NE,A;ELWJ<=0JK2Y]12?BK$'0_>#V&'ZY6:J>@3>G_Y#+"> T^*0&V P^9
M.B$ @PT(8#C, /;?R^3SDVYH?"@V[8;NDJ'AJG%3I<PL;+G.Z76S'T?! 077
MH+C RZJ/@_6U!5KS"J\<V\>*TMPTT;AIU=)%"ET%HK%L9-"(](OI6:KMTS++
M.\7+7"_BWE_665.\/_!AFH_0/<H_QBEVE[N1T7*9+\ET!6/LLT( ;X%8%Z#I
M@_O-UX59/N%N_?-OD&6WP1  BB\9QDCTT')[Z7-6Z=-JHS676Z^$K5^:#Z39
M+*,S$ZIYZC@9Z3.J,'\W"-%YRS<9G\,'*J7DY/W:V03FZ4\)W_DGNQ7^^?93
M]AER#<D!E@T*>TE,G-)N=K2-G"<P8_G41Z6<-Q_ 51+*HV3.\!%JU:_E!:,:
M^6>)*_"URZ,_ZU_5MU&/-#/I!.VM/AQ[4N:34#'S,7Z_T78:&3-7I+Z79Z4_
MG34];>X#VXMJ\]VJ8EKG>=X>;:5$E[O:53&E LLUGR]<1,<Y&<@7GUO&X^-/
MJ.!SS'9%YMMFT0/,#O.W6U(2."SB'19$+[/\\=T&W/A5ZFX\"O%DQ'\1[0^.
MJTO7[+3%W\,4P<1DD:"RE/JK,;C$;;DEQY8[*4Q0XK)/:\'O9&J^%6%PPR"/
M7Z"4AP(L[_WXYG/RJB\)#02 F'56_\'HS,58:VU0+J-@6S>L)<[J]'4I7]\<
MSID*=S#=M$?12W#-JT\:NL<5[]CQ5;%S%\,9YLFP"Y$:9:<VS3.K_UH/\  "
M\&FIFG&Z/KT8M7KTW=OK-_;S5@ HTG"Y7-W19*3Y]4W7_Q0RKH2KY_2&?(+M
MN!]'L[(Q95T]_GG*\"<;"P! EKJ.&LD1-US\>*51<%GTWA8O%S?QBQO&P,Y2
MD:I$Z\-/>1TK"P^)AB6P@@C?/QV]GS0EDW\PLO_ JN^-\S631E5C0XU\7DFU
M+&J%H6Y@M8YVS$OXB(2()@R>S?'.<P-GDE1\D8F$%3TR21OGL8K1+RP&>E]J
M=FH]GF%\DK^S$8K.E#O!4ZB O<!@J[FBE:C$2,B2;O$\KDP6^?6'-OB8(9B'
M4T29DL;3YYDR8^@I+*RZ:KZ'TIA(XM)A\H(R&/1MZ,&)4[GV_^*K] \2IM@B
ME B]^[XCP]:_O1GG$, $<F)ZQ#[HKP28GPD@./E&(>=\5M$(?ZL!&+1K9UV=
MU/=VM<%'G)JQ(DVI3MK:K-K31]S#RRI71][#RP&ON8JI03;[24'FW(CEJO3;
M[ASW]4NY@YY@K^4D>3T%QNV/LK:3*M+,D5@QE61M)Z7J=,Q*S8[QJ=A-1$"O
M.\FEKVQHZU(D0?1MWI4<;7#4]3SCSMR43Z%BW?]$'# ;ANQBQN";&+<A]E<;
MFVL4&X:AB^[75@,W]WL_SUGP&1<$&[T/*GTHC=T3C1Z>WLJ1*.\4'Q17(-TO
MUJ3[.P[ U#ZCQWF,KI>Y6\H:CZ!('N_A;ZEIO V41MXJO<Z_4/6"88&RJ?_,
MO:"H%'M[-^W<=5]5)EKZ!3VL)B-()V#/40"IL9;C&*%^IY1P.Y$]8%"GJD)^
M)^D5]L#Z]-MBV^$UC2=9AQ6,Y4*R&T3PA[!U7US'5*."J(=&U/X-U=Z"8#T$
M< <">%^*<>V6"@%(\3BC_**0-<?NO/P8F-X*77=NY%O+OZQ<J[>/.='@N408
M[S$$,/;-OE\B;U2;T-["&JA=*7$J%,2LXNET-@J^[+Q5U=B]$%LC\H( GC*E
M7J.76B4^TEV/$@E]P<0_CY.ZY# $ :3TY,R0*L;D/Q1N+%9Q75AA:C0OL9D3
MYLQS?CI''%V' ; \G)E36NX[4-6>#F6<?^-S?),)+KG)Y_+$T]"^%0+$\_[\
M?NJ.I_F, EYJ>OYDN"J:OT72OSGY^.QW9.=E7"Z^E%<^NZ7H?G_6&I7]= T3
M_!ERL]?Q32R4XM&RF!X:"#T<LTL+E>>I+JJ4)H(/>J[Z8'5.*TH^WSW]^-KP
M$.-5M'!\PR/=HJ<VZ8<;FN@&:N'L:N;'-*;-.%VB',3WBQ%BGF<:61&_BR2)
MKZV".U/>L#VE"U=\0 ;6)R\L=K?2*@^X65SNVQ8E'=%N[I[ AS/O/WI?B''G
M-.8H_.W@1'9LA/8H'8&N0ER;!:&\'6E2-D#@8V!\+]%&8O7C(.W<6I Y(3<G
M59,U HPJ)](5P\DOZ0V@A&Y%\0V4MOC(<4!IR]0:T*&!HKW\ZZ2-QOZ7S#$H
M=67P70._&:SQI!B(F1JH%K-0Z*Q7ZVS(/:WQ-_-J/ M->MZ^N=-^HU.0B"5V
M$.F>% ,!4$1! )O9)4[+_5_B:SV#@AU=WX>::(@MJ%7W'O(,;QH=LKLGW;12
M0UD;>9F.."4+8D>OQ6/3D__DC@!%=V*Z<EJ7&SNRNK\=:5GCLG-';0SE+'@B
M-S]RZ%<&@[\)0E]G1'S^[%)O8B6>A-".9<^YL)B[*5MIRB3FCAFR9SCO.T?^
MDE:-9D';,*!O'EFQ3=:[>YO=ZC5B<H<;"3WQOA0'I^40P%WC3S>T\0LSVEDU
M!O% <Y*XY5XI\:C ]@'S&'BK<ZJ)"R5\T;0%P@3Q !$&%K9'95G/UC?Y[\78
M+2CS><\?BMQQG0F/L<OO>\X<K80[H1:R%(\XT[84D#NNC8VTQQ1W<%*2O5Q*
M+A9,.W&"IJ=0/ZI[2C=F@JV &D*I"5/&F<7K,(LW-ZIW-P6XPJ+4D4@003F6
M92"G8$KX>DYOJV:7D]UEJI31W^_2$68GU(P:;_3<JVO"]WZ0A_5NZ1(FNR9!
M?/%= ;+*R6Q''$O/O20P25=FQP(%<5L4BV+ZA@%M&<B!')>:H@G52Y8L8J(!
M L"P%*4<>Y)<?8TN<E_]"=6C)KT(=N.8N"U96U[KO[J _AN4[I]OO3/06WT<
M]?8/YR]][/](=?LA_?"&&'IO)P<N>:ZKAF=P64Y[=1#NM0VX.6]:E9>X]31(
MY19MWD4(99'*1AOCXQW1KU</6WW27H<HPA' +LZ=TBFE$/QZ9E^UQN]*>'+W
M<44!28BUL?IK.I(W&WZ"ZXV!$_4H**6O' T[:B<,"2[9HS0_%^^9LA:F)IE3
M$_78H[E<GV=0=H#H<R@SRJROK)9])#0%-5*:GXJ<KF3@QF)_$F+8[)W"4=U>
M8#W8>^F#%U]8-#T]]Q%&.R<&$3%=-'!NY77ZU'2&GS@@ $DX0&CXF[<D.MV*
ML] QDX#T564=(W!)#MC1X(,.K-HD=IX>N#0?W+QCXGY!P=?!AQ9QHMH# 92(
M%6L?J+>X!1[OG^)E7KT9V7;L?:R>X&P'Q8@#?W<1 (9D+S5;7*UV7DPNH. 6
MP)1_RS4FE4#M.$=M9=LW-J63-@/$^(_"I&/%&1"123#!$FF;8'H&,(6 31MF
MW%XQ6QM]B;1PU<2QG"3W9EQPBWX@DSF(W/9N#36<PZ#9 PCR5LM9.!]W1C-N
M%XPOMC*#TY>N5#HRX41$:1%+0L!&OWO2QIW%;70@5;LBP-.HAX%IJ;PHFV]!
MK8F5!7N_G#;6XQ%Z@40HSH#Z9-HDSG*RTJ5:C]ND:PIVZTCQ'HO$@I$E;PZ1
MZ5NY(O-6CCL/X49'&BTQH6Q 8=ZVIJY4*F]ZWEROC07L7K0..FQX:HI[K^<3
MW8RR8R6"S91[C=&#2HW &JF4IS5U_DNQN6<==?"EU%'*>N=GG02Z'5O*VZ!)
M# 9_BH\.J-'A>16KQGQEW 9WPL-_6 IA;^6\C2L""("J2>QD 7A-.#[$]N>B
ML8:WK2N]PS=!UU Y>8A!:S^BF/96_DPS$_N3ZU[;0?!5(!OP"ZT3!) ^<8UB
M3$S1&=+F?BD;/[*-@36%'=VS?9_IBEET%=KZ7,LHPW+8RO,1 ?@) 6&46-WJ
M/L;13/'<;*>'%4MU!V*0.OVV5Z"AT_+.VR:*E>ECO4D(X%'=D_3!QZEU$$"$
M!)0;S9]^(W^&5]_RJ?9$A!6$@8BK0>8OB3>X(WB3G842,BMQ9)U.B>+OG%9&
M W!=I8Z1_/!N#&_-&5?3-\DM7[\I  *0PV=,P[6K8FX<S"5C>NC?H_]Q$WIX
M$+[=%R)M[52%,@<YM;""]!E%?^?3_S/!K=RR!"J29ZW(\>E[[+>75W];_E0D
MT:T!*R:!D16\)(;NC1?GC*Q6/CDKM%69D'(:(SV0=(J?$,,LOF(K-4\]")HI
M&__<%-E_74AXV#*<PA'NNC%F-M/L6"_;<M_]_MT4.C!/T#&_D'[9X!@J<3RH
MOCES5O9Y^M9$#( V8(+^'=P[SC3$$SS7MZC#<^*D!W7NV0\V=X9C0P/$D'W^
MW8S\(R$FN;_C"[KRLBCJX4!KQQ85@@!0 P\I)S72(ET@ .Q(1[2Y1UAS'O(:
M33ZY+&=!-&]@UG7*WLK>[$M11%TS(;:EW*NJC=^>5:X_W&/-BN@SHV"R>9"&
M,W4@./9E4'0[GCKNRSP$@! AE1$>JT'^5R()#-SUT4E6-K#%MRHN[7==Z>X8
M-8E6BSQH=?>Q]'R+^DO?M__D2D@07[XXI3_=W_BQ+B3=)Q?1"A9=Y, J2 R)
MVS5@ 0&,""(F,=6L#=TV8J;UW1*O_4Q=(ZB5IL6Q(H9E6>/9G_-R^9H595?1
MRZW1R4DL#I>]\,X'2I/H+E1DVP[Q-'?\SLZ+/LOR[<3^ZVG_XDY+/E_7,69"
M_ZA>2BU%!,4[3@UW)D/I6ES "''9NKI('V196!.EV:+\Q,DX4GSCV,*83] D
MVHG'<V+U=D=U!1_B+K]9C4,<"XWH"?=SG(EK7IJL!N*:^XH.'5\+:H!(LLVI
MW^(-V2!(+X9=/]CJ0>0OR>U8G(FVZ'?*VSD5'%.+G)C$UUSA1EF,[.(3^UAO
M0- N2C+)6J6$-;59KFTQK-<P9Y& O\YYQ/8QC(J<*(;3T5'12:N%),N1[U7I
M\8XL\S%)'_A^,ES7,T*LO*AQC'E->X?17'%96Z[Z_S9\.R6P95%7S@FZZ3D3
M ;_[$!G%(AZ/Q.V?QT'_,3Z68RH6:W;U08KDV$1\]/QLIX_+W<Y.ZQ$8:KC9
M<*Y9GO%)CM5=^W.WCOZ\U,HJ)@=<-RP%<@B %]]:D'Y3N\0AA3_KE%B J9FB
MPY=HPEN +] 41*:YHPR"P\N>3MK5[$KE?M\8KLZJY_;LCF?Z3J_<42O:>=*R
M1DT^MKNG N?,#?B%RBOK>9IGO2\_& KL=GO223P2]R/B&=!U#U0$<RV8]^=:
M8?;28-.4NCRG;>"DB/.+7(W&(!0H"4\;8]X]41#<4&I6XIU8OQ^D_8':L:R=
MB(P_I^U(B7AK-T?/O$$]T: X.+#(KABTC3^X/HB/-!O'SY"P5,=L[[10=87W
MW**0+\)T+!UD8>M2F"0?2 7[F!Z4%SS%IE2LA-@9$?VQ3QE\/S_//)XUPB;G
M4WG!5:J#P1B""ZF]SQWM<6'XVH:<=+>GI9:"ZH)I<"HUU5.:WFB-L67W>:D#
MM(HE@QU\\958>CN@?-T'(7P'6V6<ZW%7#0B@]T%)2^'6*?Z,8;)-[O0CJNJ:
MD&<@=J?J!VT;K1-%&NE(77GO51<ZDM;YK@Z!HU<6QVI8@^?M&T"4A6Z\V,J[
MF,'W8CV>.#6M'2((.>E# /XG7IO.8A6SYI,$Y5F[;S/C<%F_D#X-=Q^P*@3?
MSS3+V=1B<^^B>3^4D=<GQ$X-T,(XN#2L'C54X-P%D>3C=M,=!/6P^W#U\F X
M!53%.G"<%;O8!F=[A$$ PJE0@958&,KAI"A= ,-$08W)JW_\(C<&#M)=B_6D
M2A+ I/S(1W"T;L3<I*XJ9;SV&_R1EWZS>/0! E "YPY+MIG]_)'YR>XK5';(
M/1_=S%CB^OEC^(\W5K$G^I$W/R*Y\1#;NKF-A8?Z,_]_9N>#JX_PR[FRPIM*
MS0"=;[L=$XJX.K(;*;KEL8+Q5' D^"B^KB]FDWPK305QJ#.AS@$WDGQC;<6.
M^EOE?.F[89XF?:L,Z[WQJ-U2ZB9,8^9R@'9M<Z$");N#O-<,YYFX=X*^M__>
MFQCN,[^R_F_MI:"477CV.'<E5!F?Z'M[^N\#7*F 8#O_-/H#;=/O[3._CZ &
MEJ)'^:L)9;V(5E0/%QIYEDJA=@P%NT=06=KT'RE+F"+!M.OU8J^YKPDZ#W6T
M#?J>LWQJ"!MO3?2N=C%B0"02>-+E@^9RTN$M47L0K91C24XW:7?\X=E"/-"D
MSMD: L !^*6\@%V(S2X;KDZW6&"M;/'@@0 P9RQY@S@+<7FI\#&B@N93W@R2
MGPQ-IKKCKW9P6:E&8)SGZHR7M'R2[_1RXGX54N]K+>A'PM_KC6,8^$C\I;T8
MS@PXZR"N.LO^XZB5PXI0$-5]^U U7P%&#/Y]T'XAE^&0M;!TCD^@LBSJ,\EX
M 2K': FJ=X69Z!K!Q:A8W=O$X?79.P0-MI77R4 ?APP#I:?Y,[I?N:14?,U?
MT2374P9@&(VRZ8<C 4V;!8JEIJDKR^/A"-<4322B]K1K?',:^W$Z>'5YKF9"
M$Q(N<C*9#<4;QYYC"W:_^Z(,T- _M!?8UYE(17,6$CJGU0N3DR>QN!FUR99U
MU!VYZQ3Y\<T@?#0,#6H*@T[XQA.G*P.'P8G;5;;B"CS,6=YIQ$V"'NP4L?/S
MW&'%)3.C><L#;J/I&1,"R@V/^$WIVE%2T@GIX'0H6;.Z\^)"([\6NU&XSQT%
M\$GO92__@."DBB23E1.?XN'Z.C#X*^HBW=4A%'MTD_R?/M<#^:#P) P$@^5*
M[R]?ED  B[C;CK#:3]S2R\K[SR7?623418B!.>IO*,7":\]^M-7VQ42\Y+P,
M[,F&LBSIB8M9*4'JP&"LGW,M4>KU)-F>49JE\KLN^(2_M-8$[!)#SP27M(#(
M,_,5U -?-+P;#/1^,#,1FD\WZ&8)*^<&T :B^%*?X WOQ]RX0P"K*TVCRN%*
M<.X#0E-XK96VCJ[A27>_CF[G1AF^)0UAEF5^3,ZG_+XS'3'27"D]GC@KT3ZU
MFV)[Q>['PV7>I@/>M%YO#K@HA/PA@/C7!FA/SD=O)$GVBX 7'.9V$G(00$="
M)F_?A]03H_/S3._4HUX(@ +W: +DQD/4HO05"E 1H)\K<XN-^@^!@Q17WBH_
MZV[1QL_1,J-20[LCSC'SMP6$U)24R]&A;'P*\/P@$\J_#XI=N4,!DO%#6?\@
MM#<( +PL]:/Z.WC70P ;J3?"]',0P!&T!3GN=Q 7NSJ"[M1+DM0;#^@0'=_!
M_-_[O07TGP_: K]"&T0@?X?V'P^&_1SU.P[Z\:3*CU%_8*$?#_X<]#LF^@?3
M;<=Z=I6#(+B>FY?YC6]G^?C/3$:/=WWI2X1Y"B5X!J>?17\T\0HU^Z#Z@N!*
M</+=N5,/>_MR,B?6P:S!.VDKXKO%5>/F63 /T+.6(N<]3DKEQW?1TS,L\1_2
MQ,[-RB*%2S.6ULNT/WV/*"(MMW(<=YZ:8^':X!QO2%CO9:[)06T@5_0Q$Q!)
M4 )8S]Y3%>IS.[)Y&O/1W*VG^#-_YWWI>>IR,D8YD_MJ=EC)*J;TPFW!C"2D
M?EZAH]LO_NK;60(1%+-S<^XZ-P-%'0*:LAJ>L40WT@A-8:],^$6D\8[)'.XN
M-Z*97G9-%&,_W')->9271A@1C[&FI+*O.KQAS%Z2-99QXNEKO7-\O3@=G[2&
MS1?YUD4 U35<?%^3:4"8HV3NW$K5#L/*N.^%*+6K\".EQQ1[%"/-%-G< PUX
M&C);#?-0#NSQU*^$=_^;KQ<C:DG[J<7WF1[=H\^&'@#X6Z\[/VR0OLKM=18'
M*7J8OR^^\[]6XE$0Z%@FUD8<"Z$QJ1'3;#UUX!_3A*'^R$?U!D##A"X1Z31$
M/KZHA0C&'^RHZ,]1*-6U=+L(82%[F9)$D^+\PK%;0X;4Y'E$L8 UC?4Y\ &8
M/,Z'YJ+W=>Z$S0SG:[BI7B3-]U\K<NG\I$2VO#WRYS<7X":JF>Z&\KF>?EZ)
M!+C6/!C (-M!:<-?(%10W*WJ$[%2'$\/MC[5K1KY^IH$*QCYDSA\"1_&CD%X
M=9;NS@S/0HPWZ<P\70)=_*P>T2#B058->BY-0VNX, ]L2VEV[XH>P.^Z4MZ(
M=4M*L HQ2&PO<?-*9"69KENS8LY"BX4M^D8?+$LB3<-R/:%)A!CX5;/!#U30
MC L00^X;J>:O1I/6#.%N3))E,</\('SP@D";E),/3+^5Z%I&7*4BR?'W^CA5
MKCNJG^S33&*FE&&'M0-[R$FHJ?4J>R]/<I\#+?+U4)*87NU1TN1%<T5%C:DX
M&JMBNRIP=N.JB/\41>'9S@8GDA3MH)+?FV+,%__%@?A>K'USGE] #_UCJ?WK
M0_$S8LBZ*.6X,'!Y5TJFN&HX?]K RJ&Y>' F2BGZG,*47CV."-YN]]UDKKH6
MG[+V3)^+B["]7E=V5KPF<E[S![KL^T'ANGT&X*S) TFW)2$O/;-(YLHP73H.
M5@^;=$>'+0.''9UX<JIA%\DJ*S+%&0>/=9\DJR.^A+/3P$D[;\WD?_<7AK)(
MF%5)S1*/J^NKP[(OF<JCN8F$9"[;W'K$=(^2&3L,E#2K*X)1:"I@XE?-26.^
MPAF.YVW7>#Y"<?!BDB;A[68,G;L&\*QY%E_0A6Q,6*\YW;S=D'XS[9@)3R[M
M*\5HN!$3GGM'1?$F[S1P F2"T^MDA]<ES?'1?^P2*]%'9<?VM\Q?EJ:WYJ_Q
M1U"AN^"WODF6VSMVS1![?I&:35>&#=V-7W;]ET%)'<D9#JI/RXN*^S,?/FD<
MV>-.&N0H&Y)FHU+_(D,-[T98TE)'02*9LRW*,L(=@;W-9).F9,$=@%%-B+^R
MQNE7@2D^6U8.1XF3FLU@S2V_K$>!K;#B7V E^-A3W_5"=^O0ND['=Y;^R:-
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M?\^K_*%&3*L\75L-NI) ($4H!KB_!'>>1+9=E"A7]OYDBJX[B2%3H)<<3-'
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M^L'EX :#BK9[3G=3OHQ2XW#O016II:C+AL4(:<X,:@>VYF LNG,6RQ4?%L4
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M=2"5$242>@N2,K0Y;[8JDX>C.4Q>/+^KG^+AIN;\M_"N\=K$56P!$O^(R/U
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ME(M2$N*TKNO3E<_9A>OR[7OZ1_1]81/9'=A5)FO6@N?]68WIJG#.PP]1\[,
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MIM!"<",#OTV&^->%V_I:;72L)UR>IF"G1>HK.M&*E46SJ=\^KEYW\P,C @*
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M8M@5*F\"LZDO@WU\VKN"6I^YZ\KV*_,N+-5<ZH_2STV)&UMZ"K\(3@M#%53
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M11H5RX@ $5.)G RK+7:JKR<)H':5.T!;7B."O9U<H+!GRZ@D3;>'GC&.N\4
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MWQM.'')R99B3NAYM 8]U'5K2R,N*46/?>0WLZ:\0G%0VKGV>=.!P.SU9653
M^&Y:P[5KJ1[:)/N.H #@=90]K"8I!F8M_Z<&O_X_7R_#7@*_'&L2_3/C9&+4
M,-3<U>+06Y,-'YQ!<GWY\DJ9[X-WBR_.G+,#^<XKKUM_PH4_U6=Y:D,=!.0
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M;[1\$&_)$1TVQ_1M#J^S><"$">"DE\@CTX=O:\3^P'1VWW87^B+="U:7Y*'
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MWC#.:>J+<K+KR[9*9))A[.H]401$8+'6ZJ. HOV0HS9ZNN:+X40]WP( KJ<
MRH&;[A?;YOYHNNYV;.7(L1C(ZKZRG4_$3)_08%)CO NQD)C%3#EOV1SH^J#K
M#!2BWEK=-D5YR9[VUFQ[08:EN_Y'4#1U=$@T00_JQ/MLJE!.W%*&<A)F<AXT
M)P6:7B5CYQ.?MSXF^,M+#<4!+K27V[RXIR]B/$:ZG5!DEI95)7VP6S;8L\Q4
MJ9":"E!!K[I=QZF3I5;%"GWU)]$8: Z;:Y=C3MYJF.YR7I#8X@H;X17!"9:9
M8^XD%6C*\=#Q&G<.!6@I?@2 %XR"26R[< DAZ.)DU -?:TU_".LJ;")?ZE.(
MYMV+?44W%BC)!CY;MJG/TH77[)*F7ZQD% >8X92FS*NU"&?J;G'@0Z'/LS'$
MMVL%V!V)#FI!X:I-B-@\7&^:Q44#%31>CIJLO)"W;^+7'F$ #,^RYP#GG";&
M-9/,T(+6,V%;,CLKC-[EFSZTZ&N"SV= ]PVQL,929%5G!WZ]0CJ[WYN?P,BW
M*WILE6@E)HZRH#&Q#\WN&5HGQ3UX3Y7\;*^TH?5-E9[,EWV)CQFD;Y*3=;?H
M-VSVI&GN2-8OI9@0J1%N,G :,>ZG-&\\;#CI@]DUOW["EY;'[9HS-6W$E!33
MU80L@:*TD>%%U@W>(]<"9&+\ALM,UK%#/Z2Q#(-173".06.2UJB3NV5\ VXQ
MC[<2E1P6QN9JQ3=\B\@2G7B3XMY=;$\.PM/::3OB7JZS9KD35#?D-CQB'8V/
M>'2O,]H2N<#;XN$J3;,:<:M=C+2T)ST6;XG*Z.==!,YW?DC1P#"PC9,9A'RQ
M.,N-58O-F!:"&?(,["J8&RO V741W-'^M/N1Y;:SC+IA-CHB+#*7)N>FJRU#
MF4\SA5P3]HR3X11%-2?9Y1)/Q530H\<2HQUP2Q0=WVY^"!2TKF)(V>E9T.W&
MH:/N ',=.^;7!&\KBVKPV@O8-[)J<1W-.;:UB-X)2FA7&!LC$]EQ)!4,3PMJ
ME8J^3=C'+S%^9S;6M_A%XCS)G^BU)TV;I#XJ(;0/$2BEK$5'GP/HG6!*CGIQ
MK' @:&!=)8+:[2#!H!)(\0(ELT:GH9>7.[5%;*[S;&K_/7E' [2.K!6A4^TI
MT7Q1EH(A,H/31)4@ZZ057?6<XJ<T[9?KD1=PK'-S1S>KQ*6EQY^8?@!$NOR#
MFO: @C^B#N[$X6%9^33R^_ N ;*T63.*H@0+G+8(5,ZXW(IQW"JPK_[ZL D9
M$)FB;+?XG5*Q[NJU'=,G1=UA4S(O<9E?C:CI@)^<@E\<!<OO.#F/IPSH0[<2
MB:JEUA.JFX7$-XJL82B.$%N5C9<1I/8^+QJ_U30D3DGQX@APC.C&;J*.FO8*
M@SGO21:0\[?:[EP%Z& CO[2-: -E.DSSRN7>B V/-1=0+\#[B&1[A07F<$%C
M_&-J[#< J)C=Q54(/1=W%WXSYJ^3J"_U^JT36;!J245Y'"DRS"3X.JSX\GON
M#,0=Q8JF)Z%,47:I[-$^7\LWI[D-",#[0CZIFZ-&CKKD]+5T@G80J^+ P%&O
MUUVWG3\9HB.<LPB!MU)L#Y&86)9SI7ZO/BO9!5_ Z,I9'X37W#(6V H9,R&F
M%_RK2HQ-@*-;B[U>?%^.F7E>O.(BM@@)BE<@1CD@UDU$6AG,O$?@)SB6VZ4O
M?RURZ1-??@FLT0Y>OSR[U"?TB!:6:=HT;_-X^61GAL.7PK-T]XI(SK,XN77A
M2T]UWG"!\T3ESP$U3$TM]Q@-3C*E'/5LJK2"3X_,&R(&&2V"?L2J L]4"4%0
M]8"GW>4VP*"X[F:%N8 ZQL4>^-YWT=\ 2TJAWX @S589N*2M"FK_]5%*D0!I
M Q%S;.83E.H--A;GA#%]\,Y=DC1M;FJ\\'Q7@KE/Z#*U"TWEDL6)UYK[>9FW
M?YMEJ1UE9:KCME_Q6]#4ALNZR\%W)Q^$L1?<B-;^%3PNA$ELMA35"+@L]2P9
M\*E0?>>#UH8GPDKT")ST;O+G14[$BCAXU:!E:DW_Z+'0FV"% 'ISCLYUA5SJ
MG0<#)']@:;.X9TGMWABY<?.(\ECE'MQ*81.]&-C3Z\ 3'/[SC9YR[$8K^4,K
MD3)N8EGHF9#B$!5JH.*C;X(T8F=:2)BGG7WI>/%K-ZQHJ 'Z6<19#G9%9^A.
MHI,J^<-R3Y/SX@.-&TU*/(;WI^S<**A-UK\J!AH.D^/NCU*6BY"CAYWM96+7
MYADB:Q9[FJUCZ8B7YL8.FU,OISWRGA!V]VXUZ.+=2D33V0(NL-F'W)"W<G "
MY%N'N"A!*A&W-IU]*A'(U,O/^6%4@QKZH@!NFE^2M<?N'4_U;_GJD)'<$95,
MK3U\0IG?^AKBJ!1+-!V$';J>>QRW\? &$GPHV<ZFL@;:;"GFF[0>=VGY*56B
M]@&+-MN?1[VIFZY/(O;(U_]81^4F_&SX":W2 S3PB!@&JTJ -VZ5/$M!.6N6
M6Y>E?GXTO3&(1LN%A+M<SB'ZL\^/A/$[7J Z/3SXCIP35#F@ '3P TAIV]BH
M4[.PTM9M6%,[IO5"8Y-UKVD#H-7@#;G->2)A8'KE0F6@3*5/'Q4M/U+5%%>)
M#G#W#H7;++B/'B8,,QCT3?')ABX'4OPHV?<K@?[4U(!"JLQCK:= LW)*\04E
MC"*6D@3U7G'A+ BF#NS*5OT24,HQ_.C<(#P,_;4>_)E>^?FPR&)FMB@CB>U9
M#]DIDJYK[Z[:A^:RV(JXMBBT*>5R%RLY8VA\*#,S]2.*-&V&G!,=OGN;QHT6
M@C2I1"IWTJ9&YC+@2"#:B&T@%#Q@_DOU;0@,,[UEXTC'1_%\$<?HW?ZLW: !
MC\WEO?O6#[:M%([;TFFBHTYBE+E$8B)%@(O2UVX!W2<5$P.)KS?8=CO#:'/!
MIS&T-SHPMW'*76'8]4P=T,)9LC756,.XK/7C%A,K=KS'G9/=5Z2VZ64 _KD7
MY?WIP1%I]1O2]6XL^<E3%L"/&^H[:]2Z_-:6'N_+JA+D@<8D9WB$1O?;8(SW
MN86TYH/TG*E>JMB 3FWJS$30HV+[@!Z/  )E.UU7&V#!JE_B@A<GJ4%&Q. 0
M21B?[ICE0+^TC*1H+L&;_-;:;EJF&;?? %);,<O5R\-T7Z"X+3MM0[5?H5@[
MM+Y@+8\F(U[.Z&2F&.Q^1/8&H0'*?MW2RN[,&=(3-B+=+P4LH0I![Q]OR@0#
M#L^//,:UINN5<1SYQZ&6>I7"7!C;:MV8'1AU!\-N,51JL[Z.&U^.+A;;N-#:
M/H58E##92"1W?3#U5[^;C-X\,^+N5O&_Z5D!0-U5E))_,IT1Z6IC4Q=&9WP3
M(R*F!!S8B>O/OI_D-&O*7MFW3+'\Q%G'(H_>3(0I=_''97_(.*^/T]F1 F<.
M&I)<3=W%R>)Q91G(LWE\UMXCYG1?NE: $F'KLVF0I7UA0A/;A9&G7KYF.%X6
MO]Y3N\W'MFZF R[2QSIFWT,O.*7ZE'U*F=H]%%?(E0M]I$4]J%EWHF'H&^QW
M_HL],-G3 Q/HN4 HY8^?<O7ZDQ9=*S!&.R&4/@" <%50'!FED7*SOAZG!][G
M5-HV*(5H?M25,6.B*;1PX8_E><@PPI*ZF:9D$PN4225Z=-"^>EMXC"H9OU_S
M(U)V!-/R)=1G:6P<UAJ\T"^2?;Z,H9 62K&8R<4;B G<]76OL-5A+[#Q5OD!
M-+*].K"Y;)!>D;7G&,D],< )RA;-Q6\&GYWG:)^$QPIPTMK;GNE"W8NR .U8
M'X+U)J36ALJ3&8.QX#&HP.G*=EID^KW//.W^PH:Z'HO(B!E?%V^?2&<N_JG^
M^J?<%*WH@<4GXBC?VS!++TO9^]R'E=M\WB M2PP/O#-UR:IL$[\P::.,X/:I
M)XO$;T:?]]M>?-^Z'YEB3HM.NDMYU%/]JW#A^^9UIAIZ<P^"#OP0A^,6Y;;$
M[L/AIZ]HZB&9&/J6]!9'ZKNB@C]D[U\T(_U7Q&E?9$N^.HPIX0R,Y;=@ '1\
MUG0X/")?;A$M6WE6E]23S8WT*_M:5:X78RQJJ;>63';8L;O8X?E9Y+F(Z)A"
M$<![4R.27@E<@Z$VYUQ7*>]%$_/!=H416N<GMG+O]38%]K3?D:I3.,S*OAS:
MX .54#:%M9.VUQO<M.@\>;JSV*0OI9Y=2#C& SJV&WR7XVIS(M[M(E.RI"(Y
MNIW#Q' 8'HNQ M &$,33]N1  #Y9)#L_[,V[ XC<.-E4/,XT:V?SOMMLM"C^
M!K@SO2$7\-&RQQ19'-6=+$ 0Q'+6T]B^?&ILPR+^_>C\QD KNI<\!AS"8\DB
MJSA(03N-LB>@^WD8GO,4%-793C7+:?]S:G:]R.A]G?7,<>I[UJ\D'V^+II.B
MX\4T7ZX+=$ E,"N6;*Y'FMNFR1* P+N:B7[/CQ:6:K7/L"G"E# !PMX/2YA]
MI%72%5X>0+R'*.J(W)G:66D.L8O\B&;EH [G%5(8[3(D##DR(NBQ@VB^/8EN
M;D^2*)5*$_!T4: @SR9Q7&&T:IA279>FL;0Z\&X5(TT2*I @T^PG7>JW(TQY
ME8B)+2H9P'8&\>E=*$'4 6-S? ?7E[E\V WF3H3>.L@PG]UW@E0WM&^5X9*>
M]X1TM,BP<8WL%1R#@<.ZB=SW:!H,;P[ZQ;\TC=<#O)N:PWUYZ\H2WQ85Q$3@
M=KHXB2&R;5,R*N?WFV.+S>VWO18^EN/U;74N#9&;7JW!T.&<E :KT;3423=V
M6B%'I)Y$Z,%:.*1=M-I\Q2@=4:+C'S4%_*C49WWM_@XP[1'_&F#ZAW@SLZU1
MIP_X:#S& @B7=I6V_1H6EKF8AFY;R.-Y_$"",2=0DW:$</<=M_9TFO&I.L.;
M_997GQ.2/#!E94/TR,3<MTL12;H-C3,. KOX<0X?$J=9TSI -[*UJ'7NX[3!
M@9)<X#,<1^+]=./D#1JN&X.X(S$FA)Q=F9'!3XY:5E:*)[['_+&8SREH;+GQ
M#KQG<F+/L]CT)1284PH<G1XR<X=N[$1$Z#/XZ2_U,>P&WH357,PR=6-A]RI0
ME,JT91.L/L;D]33IV<<//H))"B#E=5WO%_3)_2,C6,_KK>V:+VO+D*MZ4Z8F
M1,QAGY_)46++M&VZK0#E/Y]W 5C)109S":1A$C+FZ[L5F^UG'BM&_59D*1D=
MH,W0\=P-B!B-[>.+FRP:^^-9.U"*3EHN RDF-?OY\^SDA[Q\ML5]+0Z[,>)H
M,UQ=E6B!D8)0O5"&T=ZE3!&MD@^ES]7(/Z?,1!EAK@^EW5OHHQ%Z;!ZX8=O"
M_TAA2YHFE 3NX=G.]O(Q9DQ.;^.HGVV-,DF+'$7HI"5[@WHCER)F9K1S4-^[
MGV )U7(3T-=NV9HX_=B9NOII+GQP-548UZ*VZPL4-=/-6"5Z-<SB68OKHZR.
MAS1=^$QJWAUUG)9L:^$3:M+!0(4)BB$RS(X=Z;[HLZ7HP&LI>-U7._R8VBN8
M3]=)E&)#0D<8#.'F;N= >B^,W1TJ[Z7*ZF_(V3QR>/MI"0L7M(-)/8%9H&[\
MW@;N9]"MAKP<V[XTT@-YLQ;7IN]R?_FA&!7JDFOQ2.S$.;VHR):67WF4X11+
M0MV3XTSN+C_]DU#YA_>.[9-H]@/R+FVNL=:H,-8JH<80(P1WG(11<< /U1*;
M:X\<SF_!['+1(A\^\?Y*>T<FL?%=4LYTWE:*;=J?P@C9YTBRK.!7S+2B]42&
MLHLU%)PC^":QMR%;!F 5)$T[KI+X.DPH45<K!D/_RQK*OHK7:J3O*T\_LO#<
MAFE!*B]NB-2\9%B, U-K\IM*[);;A%SSP8]6N94>/D>Z/2^Q6ZTP"@+*?BR\
MAO8_?<L8ZV6N]PJK> &[<:5K,1HA33L26\/0S&-ABEV3&2PI)]8ZA=DQ8>^+
M8NE8;J)*<C'P-"-<AR-LJ6&,V#<W*&['H%BC[3<@M%V@H_[EW,MO*OWSR,7M
MNURNWP###3!@?RO^%<Y 5X0<AVQT4IR,UKF]#J>C4HAZ,,X7Q@R1V'U&XJ@P
MQF2)V)P4]D\G=+=,E TY4BTER-A]/<YC;H;@07/IBK+CW(&YX2?>+H#.JS*@
M8^2%?CL!TOO4WL&Z7E+>\<77V,7Q[YF.OH5L&,+KTKCR  JI.I3]<]U,Y%/]
MF8S>ZY10T,*P?K\ES1(C4#%TB%_\!56!B(7(AD0TH7&,-'5V/0+UW:3[O(#Y
MUP,R6'5/K=B<OL"Z=FVP,[3(Y.1GU'G<TXPOA\S)7!!%,M)4GCI-6565@4ZZ
M_B)3FYQ3@XO5&]3%@%U[M?U[0SIJWY?,U=KI*FR;)D^<?.-E9%<6SV!3@9+8
M!?P_N$B7ALG3/C?%.2UI.;T3VTA'*#^$5W:SLR]/$O3W@4>(&T-;%F61C2EC
MEL\LO3H]X2&!&Z*2B%%'HUT7)<3^<E]]67^+HAVDE T R%)(N@J8R2YT'W]
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MF(-(4]K3HF!]=0WL=5/<. LR0^H1W?3GV:Y#.ZT?\RO 9)0$*9+%I4NX/L(
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M0>?_&&=P1MP#Y$YUH,PE,PT+*MH\.D-BX#[O/RIO#DKLVBK;I: Y*)@2  I
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MEB"_]*^1X_R11=/9-62U5LE<HCX*, Y'P=HD7]?-,;6W-G7 ID;#]CYNR'(
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MJX8[QE$?MB;W): 3"5K<=R!U-M^H>LAZ49H#2KHEKLPMVB?(E2#) 7MA N%
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MT[P;\R/@H<E:;BU)(.20\[3\F%FR&_5?9:4^W_C8^OB5&,A4[%_QV!F?/D#
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M]]:<2L*JE:5RW$N^)TI^\GK9GXM!G5W9'+DI0NTL#5PEYF1(&ODXT=9:>BS
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M?Y[_2' 9<KB&(4^<'(J1](0(VO_G<_'_=_W?]7_7_U\6^K^%_P=02P,$%
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M+\91U#K,$NF-5R&_@QPC+*?5D2?X+70=*'5DC$37D!I9Z@0]6KK8;@!K42<
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MUHB8(=?9PQ&XKM<L[(EK7YL)Z"YGO3G, ]+FJFH#7M0+S;6AE;*UT!WE&*#
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MR>V@+TJ?H!((I7!O:+C)<D;I@H7QLD!\4 8[\-VFXV;JRSX+XOMG=/,H4P2
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M!L7<W3YK)+>^D=/5$6I+A??=:N'LA>!6)Q!UGC7.1)58*OD6][JX2Y<2D@T
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MTZ]'BGUZQ,MWL9)S3^F&\^'LN2T"R@F/BF7I0I,B6A,/:DV;GAL5N-P7VAA
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M^L,GT"Y72\?R+A97.*(.A3*"K K]L7=_OO4JU[!?MEJK^!/T'03FY[> #A$
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MAK2<@#P,P45;Q&#Q$=.\7Q?O;OWJI26&'GG#?C39I0V4EV3::!;VVQ77,QS
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MJYH1^.O%:G+KC>UXPX-Q*I;;(1,,/,@KL^4!C2\+Q!&(62W];!_2#=HO0?%
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M#CHT/+)CQ/F1M!(/HWAE49I_M,KT,43NE,MB)7<E>[[I;BZR91BZ5=:QPLM
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M-![BXK=]^360:]I@VOZ,R];N?J4(3F4'U?,W!QCR=E#VE=DMZR] ;P"FFS<
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M1ZOD378DG?6+[B-?HH('33"\RUWML>2='?+PC)A)X^M%4PA--THFGM?P<S$
MWRT!]P]'\%4QV3I5'[-);A_"B:BV%OEL_-VQKK-9G[$M=;?O22GM->&L.MHS
MC4P5#G9C>BIV$=2^1G=*%P$K>E]G&!;%7[IZQU!)"-?9<[_;[9K+?*1@I%DM
MMT>FO$GMF?GZ9A3)%),O(EY56BT+D:$N0#>-1"(-KI,15-_SF"XT/W/$I.O.
MTC]^/5+]$E+XLZJ?99[]%!_W#Q,#MSQ#N;[(ABS.A7S2>TP^^X0,'\_L5<=C
MSAY)P$:5EG\\: XT^K3@S#%ZQ>3)/D5R$9B#&2]+H52:SEG1RENMPWGQD9/
ME+]F0S3+,$Y,+B+P^S+MOE:7$\ER.%7Z(Z^[SP_'\SRP1+=6]I.S4G%>=L*K
M=T0+3*=7]OD73R?,KNZT4$3!;"'+, W- #%9,>(>[C)S7:*8>EDPX;E"K"K:
MX>N=ET@-)BL0;?U!@2S89MBP(D6+V!#C\1GYI#="E%M9.W.2HL:/K^=+M;YM
ME9\/J<D-0+C$BD'ZR?8KQSSKFD]EWPM@AN^E'(I-3?1?UHK]RM4,;HFUC+)%
MK_P87Q[Q5RL86-M&_]+9?U=1+)792:+I?82PJRYDCQ+FU?+?R9%AV+PZ+UX
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M2%Y0*>+$>-\CW[H!W&OF*7T?6[QH7_MDAK<__E5B/N(#*;!]C1!J_ =T!UV
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M(@-;+"I;V*&E.]!Z)@,"<:3L8>#O^(JY)@Z(S4 3%U:-J'\>U7Z\XF+PKS"
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M%L,!+&5*N\G1T$R(-QE89VQYK#3;BL]3Z,5 8ASY@@;(:'\ ;9-!"AT$F>"
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M0%2=Z]01&9P-:>DR)8];D/))]+-JCN\-DCMB2LQK\C;Q K]AJ,R8O-J1XI)
MK5DI.GP!H[C,C+6#DAQ&N&S^B@'7#/H/&5^O9L&H*'^2W2D[5J7T98.]D@7S
M &.&WB/:;N/8*,_J*\4POYSNF'0[VUP1T@X&@FW/8]_Q_+DU(X\B1L7\M:.4
M< :.Z\NT<=PR2J3D/!EO,/+/$3*7';0/Q]A"7&C\2&,Q7-F8>5UEF2E&H686
M]!R6VN2Z<EZ@P\Z6V;>Z<(J^].]-NW[G%$:(>;CL+71V=SK[" :\<%756$UT
M:TA_F;#UP28-P9*0M(#W&)HC:]9X+36YR3N::7WD<K2A.=<5J?)M0^S%.K,K
MZ&##+ZB4R/E=[)O3Y (?[Q^A<>R"60U[G<@&\_S349.?3ZV?VW["F*A.L&YT
M&3U*[KOU7NO%TZ_6<6!G*>LF;P<O%5]EE%AH59&Q (N-QU%RC5JU5)_""5VU
MQO=69,N- &^#PB#ZB^3W%QF'KZ_>YO-J"<;+E]>Q"V'A52/)P1KR(PY?Q==5
M*=%%_F0FRR6>1V2,1SM8B-R>OXJ:LQG!5JH (#/ZNC+%\^LWPT-Q$C#K?<PJ
ME.K^8,4""]N"0W^3NVCP@LS=D<<OI-]81='=K[3F['4\D5%S-=KS-=Q=#G<O
M,H.T*)W)U&\_B\M=EGEK!=SUK]JL6@31.>6-NV_1M9[Z4/.-%O&UL@2*/SUS
M!X<\'DO:)M[ ,MC5]U?,VXC(>$-%E[TL+.*R<E_0 P@YEH<&$GCN91;9Z%IB
M9@2YJZH&5BU/[$O4K%7;8H-^)68;C_(7&4=G6(<U,Z_;/FO0[M.P66!M\QA/
MPDB@*-[<W'WMK1A<*;ZSG:"0NKV^5/V020@AP5L[[XUU2ZO*8K5^:(X$74?K
M=(O*LJ+"*YN"SBXR;5A,>HD3 1>B=A6(X)58GLI4H4%?/2(J6\\LB1CA=QGY
MR!JB_?Q*T)O)KI;P3[MS40=N(TZET%&UJU:<G)GKD*TX#=FD(5_YKW0X@,*]
MA[COJNNM,]H;.."A LH[3.=SA&XZ_7+4L@2-9(:F@KQL'3C4<Z? 5W(H-R[9
M+>S;'>^/>;1P_?"9I_?E:71^5\6]*Q;C5S8X-C57VV+TBZ>#[ ]$/(ZW!>!U
MZQC+UAQY&MW4/W2 >X45_H(*.= /;I>L2L^XE;S_X]OE62ES+APP7!_!1?!-
M,0PKC ,&$5DX8"X)!R!IZ=HSJ-%E9BC1<MOB]?#\)X:?-$2Y**_U-A 0WDH<
M/"PM6H"&*X9@R'Q<F+;JZT!6-8?3'8EHTC'HZUDF6>9=CK(/:4X"+<-Y[*X#
M,T2KX(_\64)6@_Y"E7OTOB;9=^3#Y05+Y08(SN5=907'_'D@M]MG=[11CFD"
MDQQ[6:&3LZ(>XKTWZ.7PJ]G%=']T/&*=# =<O8I\>UWU_;V/@.7IEI5.XDDS
M4:T1/6M-ELC&JJ3/.J=8B6.H:\#=1==6Y%[1@59<B[#?4.^I#L-R=04.:%=%
M?5MJ/LP(NX/YO!(H=8Z,?7K=#$U<F@*3%:S>U0AC'UV.[7__3M[ILLNRDH_U
M%X!*H\H%2O"^;*M1M>0;&.J3_W&%-=C3K"BU#SU2T.: A!+GH,#/JIRJ5#*M
MG??IG&&NKV%(E5-BN*&LX*PA?VE]>I+=]_07:_XJ*_3]PRH)3%.>"[R>B/'8
M@4@,V,LUOS4YI=[5H8&$^/$UI6<4;-LUK&.1K@L[$0)7QARDF6Q2K>8$[]])
M*R4QEVAUO@]SJ"LY)^H2Q0%4OE?R11+H^6?IJE-GIF1UH_*8CW4FSOVX"!)'
M&@V0 V]J\()4VUB&2:$FL<\X[4UP8]A(DJ-+<,!E87C9:K,H2B"LT<P>$<L,
M<[C9U%HYZI!"LC62#K1)N]&?ZINUM="N&=T.<T=\M%K@$]:JKO?D?O7H^1[
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M'[V2B92/;>^_<"YHE#GLAL+!_L>/H!DT^PG?<J90&Z7""59H?W7;K!%LZ^#
M7K%X!G@8E^*1P#ZA;-CDN1C2P:A.Y5&[KTP#'8-K6EGF)2WI!)@8Y\],1 =S
M*VC4(YA\O;ATE@Q&,B_C%@4B%6H(V*U3:?I^,)2KZ);WIK'*U@ I839!OS+]
MM(Y>E=M8M[\04/SN%C<7%]?KF%S?Z2GFJ>VI(#['1XOA'LC&LA"KNKFY@9N#
M>Q*>/ N+ZL9CZEJ(LYA<UK-H:@ZG'NX;-%#.3J6SEQ?.%"J55IOR +L\$]31
MX1<4/?]V!\ ^6?69'4U'23YHTEL9?!+NV$\W67?[W,(F#RD\S? YHV:5I-J'
M0]U4%$QOZ=*5S )Q[THV^>*/L8*N<?').&I;+M/IQ;W1E_S; S>/_[3)[O$G
M9]A/8B0."K]/]ZC%_L>KS@P(O1[KZ1@P!8B  H]ZR)D,>0UMZS!/E\_6G/AV
M:S=C/0ACG(I'WO7W\9_SZ+TY[%M9-4=)L=/K$G]=&'^%IU,XA11%>&+Z/S=*
M7[^=*=4+7UX&NJ7&J^RFYS>6@,. )/>*^$P/>^-51> 5#NVQ''K/7DSB$E>T
MENR:<T'[NJ(E^%39:77P-Q)P<XIOUM;4T1$9X9'$EC;V;GVLAFIW(3"VH1P_
M$^0NG"Y;O-=.H2+5=FWBFR5CQK;T9O")L8J-P ,#!8OO"%:'#;ZIDK6JJ5\&
MW?*05?-&%Z %C/^]#>840MY=O? CG^C3P\X<KK"OVD_63*VE>2+/(M:\L?K7
M,@B\C63<YL*V>=LLI7ZFV_5Q>XJ:_73!V7&,_[TH25KBH;)6:F3]@_0H]F#>
M^,L=X(DWRUGHAM<S,PXH0=#59TX_:ROQYB#SSJ74#*0+.%ZUCGCIU^A#D..!
MOA:\OT?YWB*LBE<MS36U^+[(7SGNI'%#CO@BJ Y%'A?GM:[3LBHK/TQ>=O%Q
M"$1%\_I8<08.XMRG(RSU4/,N'.1>.#C^]!;5XH#&8[&]Q<5Q7W+&#$>FL'IM
ME:!_W?NA^<(;E"8*W_@@^&M7P\LXK:O^'C9627A\8F#Y^T:YL%[UR WLQ]0A
MJ*#4,XI=/2L'?4X8>]B&I<#Z#(-3,LTE/V<TZ.WY!;#_]-O* J:>/)A0QURC
M"6_)#=IUY?*E3^7%BZ*-6(*/HE*N&;\N13?3B:>SOE;6A/["XG=$*],EL&GR
MRKF:B4(HOUP+YN.@M.1OLMVUZ/$]&#2ANY?DN[@<33-M(RKG%.N$\XKP)QQ[
MLH<*I8S.AZ+$E5M>+&P%'EZPW"^>5E8CW80\_:,]7K)7<R5S20@6@H/54#%6
MN+!Q9NV'O(7*W?@^I.<]@=XXV_VR,1,20**D2O_'O:??RXY3A;\=;]DZRJ5(
MU /^%BM0>M'#\=/6(X!Z"BI?9= \T.G<I'\5"<?IZWS;T:[OM;(2D86:K> ]
MP !_J-@!4=[(T-1[^8<>>'BN8;6XXH7;[REKX4@[HS\F_GV]Q#TJ$LK <M*\
MMQU/+"WN;0>I#^JXUWEU_.*B1#$P+^:SZBO%4( :X#V*KHP?4FV]U5!OIH1W
M!+3K%LZ6$I_ /+'U.)CI)ZB.0/<.X%:&$.XB3R=S[VN&,YY7L#] )Q>_W;=V
M^Y,543<-N279=;NM6!B)OYF-*FP<'K,<,%RNC)8$;E)9M?ZBHK@# *T/-+K(
MG''5CDQ;- *Y+BJ*.B/!:^)>?+M4(CPZ.PF$NJ:CD2N\<4P(/Q]O[0TD&%8L
M-\EG5NLII]@R6\M<^5,>LO08DSY@<--Y4.!JSOW=LY5?E'(:-?Q7;&=?]T6;
M^_N;8G29.G&R^;M/K-="V&P80[Z$$W75GS =E[\NYX,Y@F$12&7X"Y^>$BH_
M]ES+>\W8@')F@B3[T@;J_K:3Z*+X0VO$Q7;]<0!N9,\IP&@N&OFL/J57GW<6
M:><64>\:.,VYHS.U\Y5.O?P-7-_O]BGL8#0ZV7^^M ]U*.:(T6%H@Z&4(T"$
MWVH=C+]H=EYFK%DU]DPO3YJ),?A@WHN$=RGQ_0Y_WPOBO72<V4\?[@ Z?-E%
M-W89N[K>'8LILB(/K#)9V#\T.0B9;FU3RYYWW+!.[H\YV7R>):=J6<@+*C'8
MT7"H,[Y^-L3OT"=!*7+67TO\#CE ;H@*A<M+]ND_FGI^/ECX?#VT_'FH+E'&
MN\]SWG",7UH03/T&$(UV591]#\=9$9 4X9"+,+FI%62W=A+5ZL,[6#0.*L-X
M)Y83IW5/IC=CCUY.>8A^TCF@:CU^]>!LOJ7^A"Z>E3?EO9D':XT[.+!)J%V+
MP5R&8OUKC%Z$I*DE;<07,EN?)WY\$>*GJ*1\VNKJA'][SV'E'Y</"^\10/_"
M#9Y>ZW7869E;.Z7M,R4ITJ?_(%Q%1$,QFE6I?VUE*K"?! 7JQ>.P<0<(US8-
M^/9QP>NKR]+:II''J/=S-G<S[$R6 C74>Q3D3-J+8%W?!!),U[+)GCWCH]X_
M.1D!B>E/I$9C;$S/F;\D&D,L]LBN&V!94%6^9WSU S"FI1. ;+HE'4 2P4[,
M5QXE:C6IG(]H2SXSH;E\CVQ/&D1:>O>GHP.%ZZIJ4M03AF97)!GZ:1XC)R&;
M"10=NYW[>O*Y->KJMMKBOH\#^2)(G 'OE:8?%BQ0_[1I@@B<9H5BN/)WC,^^
MT&>8,!%HJ)X.B?'D?G 'X.7+@"<O"!M00\!:+8J./],,4V/B48S4!:\*P3&E
MBYK>ZY2(;?M4MOS@ ]S"/I0TP0]GZU%(+ T[*!V!>1OSQ,_),TV115=!-!IN
MSM\01"XS B/]L;4U;N'FP>J6]:7SV:@G:U\;H<)/ \BVGM\SQJGPGU#-+R:Z
MO.$/MMLF!>X 9NI-2'*]C(\V%/OR.8[7&+;W6LM%N#(*@>>&'_;-O TX^7&*
M=]C8;Y+3ME7NT73EH3S KHD;00==SEDH:<)N&9?[*;M]>VCMX_?6*E88-[VO
M$1Q*9?VU*2J@A73]6@<"BOWU=KQ#;,LVL][^]1C39).HS-J(OX6#P0[5879F
MRS:WC.60)P;E:^ /OOIUNL KA0 .H^FV"8="B\FRV=9FP??"!S0;8HU/?838
MW'X^=\1[LQ;-$+H@F7"Z8!F(H#9GK.\VRXDV/"!7'O"_2<?PEM2F(ZO%J(:A
MS^0(\ N%AY@2NUAMIWJ13D&\7T>)PP[3<OH 9-'/K2(/PBOO &TAV054JDI2
M7'\OE!VZ3M7.F7+I#T<WA0_<=?=PAPX,(U*SF/VW)\L\.FPN]]^J_3_X"9(G
M)BQXIM:[.(!>P I=00X^F2[E-.D;&HBQ,KZTI(3A+K)8U.>YME,Q4WL*'Q8+
MMUIY^L0H%,@1]E9 N;H:+3V*H<HC!DO4*8:IV09+ W_^\Q?[-N8;!_HK:*/S
M61$Q&J*V: TEV\X'XQ;]>;M-QGD1>9WY\^+TM;[.TOX5%V=,998#T% \NO.8
M9#WQ(K93J8.T48!)E!G2'JNLOIN.H): P++2@E^,:X;O]8:&BJ4MM:&U,K?#
MX]W4TP/M-G:86,R&L%F<DA9#.NI7ZP^?A-S=0ZFL/J&E"S;75L'$JAGWGW3-
MEGWUAG[DQ!!.G1.%Z<]"Y]9KR].Q0TP3-#MO=^E-X9U%%1[ 0%>HT$7(F97)
M+#&VSMM>#;AP"C@0STV$4,K*AK:%J,2VYQL1R7N62!\5V7IGVH<HG1@MY1W,
M"S:]&53FDYN4FO(4X![^1QD#H6=O3FQ(7HJ(PBV[5YZL6]6"A#R'XR8JCV^]
M.7Z^NN*4R8E\Q]K+[]W5C8!R)?&F8=FZ%9.(>@IZ>7:4&[<$ZH2Q!C].71P&
M?0KAU.OCEN9'68JL_0YYU*&>CE'3',E:UYJ^)W[\#HXU"EBW?;A1N+\2\G1!
M/++F5(!2S*_EY,VT!R7\P^'DOJ1)8]5"&?LTJ$&PCY):8$#$I!6_Y4(/(9=O
MH?U]H2V^:-4L<2K6V%TE_N,[60"AM/M)J'U#S'>D]A2O)TY7DTM@#0X.A+W\
M2.DS$>[ NB1 5B0CZ0MNAO;9H@#YNTFV@S"/NO'GQB&W>QM7&HSKY8%4)O[%
M[)7NGBXE]_8ZD3Q(6+1C<'LI+G02X5_L_1%!H-%,4">)$OI$Z,@[W@Z1+*M]
M$#6PV8;)NF36M%4@H=8R+:L4^942?$7KEN:0CCI^!UBGA4DGY@N1)GT@?DN@
MQ(#\3C E@&3-SD<W"SG\O37Z'T:^N?GJ'O7-T0[KBYJ:HS.\VXM3TC2#SW9+
MC5(D&L\R_U?A./YW)]7?RROQHG]::Q$GG/A_*OWBW+DNW?2'5:;_B ,H7?4#
M?_U%)";3TO3T']R.N\VM;$"3$E:XRF\7<R$;V$9B)>*;-Q86?]_C]1^Z$_U-
M>D!9<F!M%"A[\"WAM8Z' NA#N-5>3B1!0V'!'WA.0W5M"U%8L9DI48/CB2%!
M9=!+;@&Q,[[_)@]D/Q0T0BP&-."IDCB1CO:BECA]37W@"J$L43>%%-HQA$:U
MYM]%3J2SL*C59UA;'XAFPJY.T?6@OY#>1:R6[>\T13[N1BM?Q>@.H&ZFXZL?
MRER*_0\#)_Q.(:56Z;OLR2MD#>&DLN'OF_RG,?K$"\W^O9E9L;,+6M!T'8C1
M/;I7%GE?X[I?DRZSKOSW XF0/?]WI^895CK$M<&WXOIV.Z_:,8T-=G06YJR<
M\7_&HS)01\Y\*]2\]%NLIBS7:WB@V>!^34Q,AD7R'R3XK-2J3/MI^@IE\M-5
MREC.7NH9>P$Q:.[_RD]S.5&F*-YZ.'O2_6%\+0'B\@[@$UJL_M<G/4Z$4MC2
M?<G,?]A=H=#9E0-2=JOU-#7_HF$*VQ(AHO2@E=S_6&+A&,RRMT(=?$QM-!&D
M&QF$YO3'#OUC^NO\3='6=KD*O .X7V&/EG<)'.IFA;)^^:>ZZG^S4VM6TA>B
M^!& 1E;.2L;)=Z56\/;73*R=0OY\Y F)C<+E%O,#(1;YW3N 2"_UU*UK*" R
M-,[->XQ+^O0.D/[1A^'_O)]=3Q4N_BZD-WS3J?0DBSO4Z^?M6K;]'<!6=?[;
M%Y4+C@MTZL1KOS# T+/K^SSBOIB4CS')S7TN?5\RJ^,/OU!Z3RD%_M-#HW<#
M<P5N5L;O?*E]B4030TGA=VYM<(C]')4Y__ ^Y[^OF@SE?_\G'M3\7KI1"XKE
M7.HAV) _^7C?"PPG90U@)YI)[2HJ%IL7')=0L)#(?/MV,'+O\!J[AU=UY9/!
M28^7HVNE]QC1Y83+_'-)*?FMWOL>E=F622%'PNG2R#W]_F^Y^W*_]6\Q\,^O
MYQ+H@SA1$>,IO\B8)]1%$.#M']Y"?\F:V[HK]4,KMSOO &+#EQ/_EM]7H9%5
MX@KS'JNZ=?Q+IG>.0[I3#/2@._G5GO:7[/[SO6XL_1F8R&N.;9D_9U*K[_]_
M6V7%'TEK 9MQ2!G)<Y1W!(+%_,^+BAOY'315O> Y;TC^)+"./PL,Y7+R>6!H
MRDC8+81@-.I^T*^!A0#_]\6__.(W!PO[\[L2':$*JP*RN'DI4<E;,>^U)T4S
MUXT?96&P(($]>8F_B'H69A-O9G3!^K<SHKBMZ_^,L?;_Q2HGI]JG^:]7Q]4,
MQ @NSPU&RWYPM[Q5>H"WC#FNJFJ3^#&[T224N>SCW[W&Y_^M]*<#,H5_CA)T
M/X[^ZS6BM@JEK*0I<4/O*9+X?_5?PS*ZO@,$<&<PK2*?Q2\2!-!,_>GB.:._
MN_CPSZ87"F<F:;]-PC=K=#?FK!KF_RHL^R^LU/WGTG_"I^I?3NH):;??VE=N
M_:K__>RKU@Q"AG;XBY*4_9^]&$FAWA1Y"> 0((;F3T?UC"WL'M3KGGW]'W_N
M9](.#^.Y6@("#^&FIJFG9NS&"0*O"FP'*(XE?D&*P/AB5+V9@X906;Y6Z</S
MK7'>RJ&-8<8.IG#3J%* F]6_"8M41GM:.NJ;!=6WX*'G!SD-7/Y^UR1U/(L"
M)0I!MVQQ?2OD>A9R4K7$\D^>2]1_4%TSNN!%F9[0?5H).]33@(H&A9%K)9#4
M'I^8$,9[)AVE7YZ6'?YCXO6G5,Z!N'P>C7SA$BHC?:VJ6TSH-HY9H*1Y^XBQ
MA?I; B@N?S%6=A#<K#U_/T+7D&RP/1M\R)0*''6?>YGQ$*E31<BPM-BT7?\N
M?N4O H,D]LA,MVC ;=[ WNRYJ OI+%[&X3AW.@1^]&I!&7%S\4>R8OJ?<N7J
MK"SK]8',T1*?X^">K^$SHWK]=2:LWS(BKA10S!-4NM_7VZ_(;^9=+!38I:;B
M>[\Y_ O[:A@+;A.V>;!;QT\TC]/(P8[>9"+_#9\GKA_\CK6,.J^6NDW=<9LV
MA 2%C;0+@;K^J^UAZ_0A:!;43IY#6/;9%0*ZRM ^+/B[W+R 7>SXAL7-;^.(
M8]+G\=]E[PW>P4"QQ"YY\WSS)MV%R&JOTG/->/ML&B/?P?UQ+Z=>).<<4L\5
M+JDZB90OU)4#J7\_UD[BH;$Y3D6GP36E4<2L4WJ;K%9?G^ R.C"15CD'N"?+
M+)<7?08D(CI0/*H-5=A!ZVC4^KZY&M[*0=7WGC7 2JJC?MH(P!-'Z@.$90]Z
MW7'%.+,T)MI3%WPL]WA8\.QIO1F@P.KPH)PH?7:+.D"=>037M^/#-#&!@44_
MO*SQ#H"UZL^GITDCBXLF%=F\^--@(/66- 76_H8*W-WZS(C:.)W'29A?;]2%
MYH89M2*K17JX1XP/45BVQP5Q5Z<B"S*Y1ILH/Z)+YY8!1?-,H[R;KAVC]F">
M/KWD.S"])<;#/I2DB7V=_ST<GOHH%A]?1D" %^7@BP81G+^?8ZW\(>-9;#_C
MP9(?J]4&2R,ENXP'_DJ.!I/E.CC4)?F3]A3D![0]1F1F:D!,<V! )2KQ-)/
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M,J4<M<[4_?K7*0%7&6-JMX6I#5=\:H+)=IDP@9VF6SDR#2/Q#J"?<2U?-'=
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MT$#$V%XZJ;8&?"=_T\H?;B_*C25PD+P(5Z\VS808*D[;&+^&AF+T;40<^ <
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M=?DE;X 1>7'S(%KXVCJ!PD4QW=IM!L8WUR)$VX9Z7=M,^7S(QWHT'-MWMA*
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M_R8%L&\C@^''K=WH:$SS-K*CS-"(1 LJL(N0T=-C8Z':T<0M)-"A[$9[2#3
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MVB?S5CB;S%LHR%"OP%+?9>Z_\G^!Y&'JH#<+B-;[M#:J;*=&+DEO/3L[-5N
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MGD6[K,4SD[R((Q+(#_]J32_@+7F^6@G>9P1.HTF8 D0TZS_5Q2B[.%'V45+
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MC#6_@"Y_9CQK(0-K5D^\S*N>W']67Q_C7]7;B)O\/MKQ;&"FU19N@4X&,6*
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M(4+;&^R*>TCV,@BW1:YO.B+"GVJY&IL:5KH8>#T?,?\4?N8JSY5WR#EB:O$
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ME)A.J?>C<3X(\=.[T>PZ]\ZI DC['#:!04$'JN/[N0/,+RIVQJ^,(_*O/WZ
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M#EO=-T%H:\RT7GS>)8I,]Q+<$*?73)DG)5GA!YL.\4X*C< .E]@:<[T>CF3
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M&3AT$[D7/.$_06LJ+I:BC+L-I^4@6J[T*G/*&[- 26=/+O66XVU"MQUZA%6
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M-1+ ]+JO+J?6_]0GV3\=!I3:X'8?&U1Y]KCFULXMP='OMES&SSH_']'L*)*
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MVK7]\22.3Z]0W NUFT>T@I&>X;CFZD4MHBQ619#KRF924A7T,/CB*>"IGQO
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MB=?%:4!>7R2=&^@BJ*F'\R"/I\TC_N3[ZZRO2BZ*:(Y2-S.P1P+L!--7P71
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M<[K$T0 _55N:RONWB7I JKF!3MKV&:(,<(VQIL_/US8T01NL2O*DIT3M7W\
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M#B)->MY%=2F5.U\N"?",>I9P+5"R0VGC5VW<YQ$/'^_T85?C"@V&4\>UNY=
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M9A ; %KS_+7AWPZ&J$]ZUW^/=].YA\_A+*,Z]-9_BJ".ZF4:OF:)KWD\\A9
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M4F5F?]"]?/% ,S>,[(!"XL@T;Z6N:I\=YU0MT4+#WT'NAV[QI.N/W!0M:FZ
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MB-1S);U_ ^1N69_,K6^R>*Z7X-U3X+#Q%&E,\*Z0#1<!"%61"(7)#-S-#I\
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M:[.($S]O"^Y5OV/!0R1\]U%$-7I8NX<_!!$ZZ?&FDPP&J8L6#Z+#\$WD_V"
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M]3R>4#:'GLA3@B\.1^%FXI>: \U,?*G\-I &/%-S%I+[MF,ATBB6[7)DZRT
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MNMV,.P?W,B+5&'@AK#P#.9$3M77,R\H5IM0.KEV#12_*QL[@$M>.&#3[(I3
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M&/*8DAQ\R.S7,(EO.CX5BCU+@LG#.66(26+0#2O&NP'H(_7Q@JW*]_%!7,]
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MV\J&H(V'\5+\6X>]KEB5UZXTXN_6\KIQFW$J#'2\Z5V@_7C.^DSZ6L"GM\]
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M+31(\J[;N%BW,C+Y>G-1:C=9 ]YD.IS^3)"9:54CV_=$H 38Q<4*]6 *:!]
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MZ$HSNDZ$=M(04H&:[0V@?OID4[V&NF;KOF 10_121N!-R(W.I;?_):1C]Y@
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M;5\WC"<J644M.U<OM@?8RBZK&JD8+/EU#:2?72<-\%II?08\2Y7;MW9 S;Y
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MY^KV<5I]ZQ_<?OY1Y9["AW=;2N8ZO5)I>QMW-[WM@?[=M"#'.^P,S1=JBV\
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ME"'__A[,'0JL=*1% N[3JV7.P\14X2I<+=O=H)M=$&I)_OU];3TK8JS3_9;
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M_S6=))^%7*CWET?P'A O_ )%>/JJHDHHO14<"6 O8-Z(%<B,*!4M#_,2C-)
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M^2@42 <R6X5>60;C ?841O:-7,QEGU]F#[&,;A53_4J+V8QR.JI9370I\)O
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MK@JMJ"CAX&0$>B"B93AKM-$WVZH9.TPNU6ZH_P4L)OI>W;N9;<GS7KBHK].
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MEZD3;T5A@KHKZ)&N-UFZBFW-.JJI:D)7*WF':/O#\NP6XYXPP"13U'V$H*E
M^9'1T54+OM!W8DS=/T5HMWDL>,QM;)S>7[P'MM ?$8TW!Z&[L.X^C$)$:(/V
MNFX<L\36R]7<S^Z>7,-QQ2VWCZ8D>M:/"ZE0F?<*P$.>=C0R#*^%PNE([L57
MOD$6^7*J&9WVSSS.JN'\KV]6.L?X/#OP41-P\DA7D)/6C"\9OB_WVC/C7F18
M>]EA:(BKR LM288Q;F96#*9Z:84S2G#]GZ?HBZ5@A 2TZE><-C..D&.?] K?
M3)\A?N'9&I%!CP[;X7]\9(QTT*.HRX_VX*TCK37B.7,V;VN8D1Q=@YR]<P?
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M EK'O,8IF(;#6F<^N//IV5SZ%-C0)XMQ;G\<$YY3,8UAC_QV"/SIU9Q;[YH
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M#^9<1>CCG>GHPXZV-<J5N5H:YO D/0SN*9QUZ>V[#CQO4S64N==D3[N70Q7
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M,"WC%,]9PS]86*'"');N(O: ?%-?O3#[E0/*Q@^_U^4BC]*MKF9I\>(>$.D
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MH+\#R#Z=3VM2J7J=5?BDHNG7:%G3TM %E>TU8#LEO;< 'HJ2599#-="OL']
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M'1T37;%7:\)1X>N %93KD(WQW?U&?BB8WA#N^MZV57+VZKGKAQCQJ/TT*>H
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M7B: 7<Z=W4XG13[B5XOI1U8UD7<W]9)70R\XV*Z2STDTM8=F F6/M6)QVQE
M&G1/1ZIBCSL_"DB_>_EGV(G54S3<IY*&D)8E]*\4 #_@2&M[VBN_(SW<W1B8
M]"%=:^1,1"'T@(.?R"Z8=23$\+'XLR;";F/FJ5-Z VND U"Y5)E;/('R!XT_
M/L$*PU;ZW\;I5B'%-4A8G"V.O5GI;AN>32L<ZPO1J#OZV3?(<CAP<#SWEZJN
M0]!BY=:Z*F9YFUL\<WZ9;415([P;&!T[\B#ZNYP90"X(8=FHWCHVN#B+DV=
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M]SOB.2G@&&^!:'&9P3S?YNR KGT8.FIG)SPFW>5P3Q&?VW[!WW&6T65:^FP
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MDHE;N9;8I-4/6R'"ZU-@HL(]E2+99TG^?QD&B-J8 1*,2A($G^L&J?6GJ=>
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MR'\+@@PO68#,YR)K?@ LHA#>T79>OS@<Y3:OQ^%)W1_]^>.]"N/<IJ))'+.
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MU6 83)'X<Z'<<.WH271>/GHZ"*E&1%*1K8^\=] 9;W\70]*3DR?1^;D 3]$
M3V!@BY61W[*>DP/5G^+SRKIV 0^R1AQIBT;XF0D]/*2GP^_Q1!7);*Q,P!0;
M#UY";_OORSBE:XE\;'9;/3#2;FS>H%PY "302Z3'>@MP"V7=&:LSX ]8>E35
M$.V):FXA3\G126(?]2T'])Y+9!!#*G%13GD^8-NBX!<WF:[CG0_;9@#J"(J<
M&P'=]'MW+LT5LWSC4X:+3&QJ%A^CB>.,U13&^_#^(R<C@#'8%(YH2Z8.X:\B
M&7P^FIFN_O&"YY/EDBQ')@=#Q8X, \<!^2V ;0EX];#K%I !->*K0I5 VD%D
MK@>*[RMJ&__ F0-U5Z-,0F*P08]%,3&=VEMA/KPY\(9W1I+ZU;81'[Z_([>P
M^.?/S%!(F"EBOZ8P?B2LE;VHGW/^@(4H1.W'4WR 7U :$F_3Y9H+ZX0ZN"\R
M*"V4+^OT\+L:3'HR)O+Z+U0C^HM3Y ?(["U >Y)?^,9%M:XA[D*E/)5B:+5/
M8F@_(,W)/Y^QQGNJP8< K??CSZ.WXM"^&H/*C?0!R[/2J]<CKBV/=IQVZN53
MW*MCC\DET];C^Z0W_85MV]P2*C!J!Q27D(@[. [[E +0G?N[81[[EQMOOI#'
M]SS@P/C,,#^BF0'KT#W(4%^5'5$P;6/8>L5&LI/VQ5>V"^!Y"^B^0I!821.\
M<DO\E6=@HR.8$<Q[,&KQ7JON5\ W\6[?/63Y'7B @#<1RU<.&CO+#\&@?&NQ
M>L3,YSJ#R?=IUIOFW)P?VUZ3PFCQ\X2B78S>OV(/;@E-DHM^3N<U[_M=P2CL
M^/R@>W\KWV>$, 4W##E6L;@%E']IN236-NE._\<) K;LG=X"MF>*)J[%5J,X
MVO7UQEUMW0,G>C]QC@E==P)4=>-GWNL?W7VK%#:O8+A"FW'#G;)-_?*$)/-/
M:C(RX((]&2;8U>N9A5N F977 GF2RBOTOQ0+3M]:CGE.0A3WE'")<;_>Z,&9
M ??7=60:"U>MJ;] '#"3L<<F[?SOO,:?Y*'CAUO5/]]"GT;4Z3)UZJ1SW-EG
M0D77P[""DJ*4JKBEEU]N%)=NK/ CT%-U,!1H[O,YKJ\SL<4RCC/'.(Y )C?@
MD(CP0=-Q73_D'M9#%?/4ZR MC;DY',\^1(+F63>UE?K/N0>$N:ZN>)NW ,:6
M]>\VD+,YX U-5<O*\#_V>HZ;0+-;P*A9E8_LZH%8%QTX6;L$+VU(0=N"K"\N
MGS6!^8S2K.<=<ASY5;A!]Z^^[,- 81[HPP> OG6,#)/LE>@MH#>_&#%]QPLC
M5#DW&8A)K!:NG? 6\*GL+;HEZ%2-4&_8-G.NJE&H;U.IA%O:@&9(-ZT]J=/O
M#L%U>;HK;,8C), S[G_[JFJW-EBE"/4!EM&(=5D,\":H%')JH,.!!N&@'V)N
M/'[= EZ+;.L'1S47YAO.&&5ZV_Y(IGTO0*M-P\H:V_8[C0E]^',5]DR*7\F_
MS9)>B(O:LLT\OI_""K_#AW7U%D"6WPVDQ"*ZDGV1%]1B#[SQG5_24'UNO_I3
MGXXE*BWJN53KB,&S&EU:P*JV[WKFDG?9E%0L3URLF(_7ELYWI0'01U$$*L5Z
M5+5?S"1_&.9\E1)\%6.>W#N" \*5WTQD3_A$I,H=/B/5-!G<_&?AROR13-*"
M01T/I49EU4R*)DOB*UF]BLTSZF*L*X\6_B;[?3AQ]2L#0''5$%>!CEE=JLJ0
MKLOOOTFR1__;\7"0-I.-7"^B$-A]P#U^Y@M2FT;V(1<UQR2+H"%,$H2$(]$K
M,1J#GF@LT4J%* )EN6X)^7RE=WP+2$3H _*O('NOJHM62;:K:#=J:Y!UQR6?
MO\>Y'Q"4JJF+7]IWF5ZS3=P)D#!CJ1#<,8D>6X-9!#A ['[BNS7IGZ!4;^WX
M'.M+JE]4J;ESBK;6C]OE:5J9\A?2M0RGZM!%;6G/)M8GW!@9]0]?_V0+UXGQ
M/&-1(K@:(<3'9)TY-%JN\A)J-7@C'BV^ZG=YUCSY[:B'8\8\;?[$2"?2M8P
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M;&AETB"!OU'TD6M<"L!MVY!;0+# "N@2?_@6$/ '$05PV+Z0IAQUG8=QOYU
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MRNN+LZ#RY^?KP%73%(J'.(7Z*V6K8KN# ]A$CBBF6*-0HKV@E58*3MEN:_(
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MJ<+HO_(DPZ*RX4WR_6)"/^2,['IX7'!> 1:!9V.EFW'.U3Q?"__K/O>/VQ7
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M=>(5<>'+I-/NPEX/OJ9,:B>GP"+N"J\+)0^])<X@%<"4F'+A,DO@6;V/4U+
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MHV[[MKQ"*<@;P=[9.Z)%W]&T._%[=(Q"GR]4B*$$\(GM-%> V<8KP-A\\W/
M_<K'6&"/KSZ!00_C_U$2[L&E=Q\_%%%A,<<((AX1SR!ED^6,EY5Z@E[3CT3<
M*?ME"-]]4A7YXQPJ*G\IIZ--K:K['LHVN-W_8HRL3/O-_'[].]0P\Z[>5/YA
MN4B2VS<V@6\ 3_YXLIF6R1?8@YXXAH48(T6,;\#X7%SR:7/,]Y_9)V3.P )P
M#='X#H36M'NM('VUJJ T?QULVWST[=6&6TRSUP6R=;>Q,K,<I *"7CR#?\#^
M*:QJ#ETJW]^[!Y1\)*31Z+;H2@X^V<ZB(_ ! 8M;)3/:HT[^P@\F0"&(9)W&
MMP!95-R&(M<>TX;^\F-<@H?C>5WP:K-;;H#I'4^Q\Q?CIV\# XUC78+\:H;%
MT/P$@0F1=YB9P+L'X?E+FV\DT]_7Z?*P<3\-K%DWS]F1=R7:98I;*[<SH\:]
MOP+H!PU7\M?&>2\4\[3SF/, S9X?!6*AO=PLV)LI6>@#&J,WAJ9U P?VZW=9
MXB6\WKH@592(,]B/*^EW]K+AYJ^F)YB^E.TA7=@<<DZCT0I%Q)".-H$&K'^H
M^71%S<QDOI?I(\>?!C&%;(/$E1--AK];;JY] 5FN7FBZ&NG6^H3&LR:?$=7^
MN,: "MY)M,@>H;W<AMF4$U:N-X/:^Y,3^BJBKEE8O@K &T"$=[F&J<8W2-YI
MBS&\;)%=_'QZL<A;6SV F@2MG 4QOG3HH$T0/M39E%R)OT=@K0W6:$QZVU@5
M7S>*]PKD<8M]--\*>3.C_Q)33JBW+W:N.W4U46G^]OWFD^ZLI[$U1*FK0*9%
MW%!WV.NFB17-^)?C7E2]L0#.]:*3XST39=<5FA8C@1C$7>IZJ:^&DHER7AKW
M,(\SK/EOH2?7S"+Q;XI6E%>!-(8FO]ZH;RB<'"_HJ5P!+%W;30MC&T;N$\_8
M99Z6%]K&W%@Q,UJ0W.<+L8P73(@ W"0K'N02#L+$]31?7 %8-5:O (PV0P4P
MNWRTN'J3K'-SPVY<*K^K"M$6;-B/?Q<LV(R] H1832%$4U(?S_IO/8S*O@+
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M)E2_D3&KD0]_HJF!XLY$.3C"HJQ]9!+1@SQJG]]VRI*X!-!,--%0P;TGN]J
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MO7*H7KMRQGL%&"]^D_9Z4NE"EL)AD$$TY(Y.+C]7C'Z+;@$NJ]>?[."!X_$
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M BSFHB^P4CZ67GZM*"[7,W1%R)J&S\-SS?)OL;;X*0XC>FQ-1E9+*YGWR2W
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MK^<K$C!'^)<3>]IF9JZ!=YG7]8H<]-(BO7)TOD;'I<B?/+]Q]  EC:F6-BH
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MLZ'V.NOJ#4:AW)#];];ZZU\W"BW/5P^GA[1+2TOVNFC8D[5E?+\P"OY>Y/P
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MRS6BULO\D$\':K_"3:B->)>#E^R6BV]O<S@W2,(13*;=WT$!CR#:,KH%HJ_
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MQ?.)QO/V.[''_S4X-;_;+8"_M<A25U,W1:9/7UMOF!#)-%N\,^&T+RKA/=W
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MLJ_%^BDZRA"Z9(>5L.18D+;7Q1TNL$@R6K\27D\=Q4QFR]^H#YAFY.X>ZZ*
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M)*XG!WG4?#]&5$X1YK8B*,.F'.TML&W[HYG424(5:=B3_DA:L"6@],N[A8
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M31NEE??@L8GGH'?&X^A-SK+I$@8D..A$56P6\I7<O;*]-(I2CI3>11)IXH8
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MU$1_4LFIIUGY ,  \(S_]XFA1-\2*\6(]!MV2MWW.AWQH3U4[?#^R?ZK]YP
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MW#QCRI&7IXT,[[%)G0[T^*?>O*Y6^?])%;3&'01)@WLNIXO+W_WE=ET#LG>
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MF]<O328T16%/MJ=M;+KGVRE3W]"^WTN04Q:7)-8'P#)-$5U1[[P\] AMC+[
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MN#YGA GW_T0)(3R;/LW< 9 W9GR1V!F;([AD?X)6,?,^6B:T7N036(09)*V
M+X>6A5,3#[>]T]?(MQ1&54*E-W@3Q[HJ.TT@@6EVI:@W".OFS Z>]V_\/#!3
M>SW-E??="/W4 !_LN"(-4I0/_/\A[[VCHHB6?M$F2\X@<1 0% 0DYR221!Q
MR4E!!"0G&>(0!"0G <D(*"B2<P;)(#DI<8:,I!GB ,-P1\\Y[]QWS[?>NVN]
M==^Z;[T_>J9[]^S:M:NK?E4UW5U[)-0]Q)14RL#[W>%->*%C?,!7A91M"[Y)
MSMF6NU^WZ_G8>&J3G>'9970I+[:4<5MF=7N*]F0_BT7@;HR_ 7G0WKDR:#75
M2Q>HB3Y?DXJ3-3:/S[NAF4>IB&+YTO81L>ZT9C7\X@WB+F]^ BMEE]O74Y%K
MX'G@.'-LPO,*AQDMB>4+.T;7*]UK0";Z%%H/:2&%BL;<FPO^M4]/!YI)[B[4
MNE2#/)&:2N>J)5M[<_/]-< 'G/C^:U&K1M!%[86^S-^O9V KF$S4G6_1?\Y(
M70-T:+E)M.F*-K]1>TLCZ-?\&Y.O7V(1EW&[,4<="M]+_=5;*VI0WN6:7_8<
MO&L@TS>OMF^^ ,X60U&OZKW('XP^FMR<$MJG69I8E!SBSZ&#/MU;:M'GG,)(
M0])Y4W@J$4^RA08+X65F4 DNA$X 6*)LX-7L]RM9_284N;<M-63?>;79E*V/
M]3Z']1C#XFC;ZZ).(6H[$\EP04\!M15R?J.0[;D-V5ZJFO1>"E.FOL=>-\_*
M'\]ZR5K>0#TXTHG[I5J7Z?"A=,S)@I":*&^$P,<V%$W53GL\C8R(W?_<DKJ=
M+>"4QTD7)VXE/2?B0\3>E;61?> 7;-F7EFHACOH"=U D:;*P_#G(OG_Z<U]C
M3*9B*.Z&F?#HI=%OA\6;ZY'LM?",%D80@;]Q03;-;\T6V9*AJI5>?]&[!"I4
M/T?5\$$=&ZW#X3>C]'Y2AZT*F-> "!QD\EDU7>PV1+?6G"RGHC;;R+97P2C3
M3W6*/IX39HU]>B-*5T"))8.U?2#]SN]0[@<Q@2&J/-_08BFW4;;P&96$>RE0
M*@W%8K&V_HM$=<31$\MW59 )TZ'( Z,7'(G/^D#]5$ZK<B0;&,7%G^J(4UF_
MTE(?^3D6I4 $?]*N?%T6Z"S,6^$N\DD:[(K"W% _S='AL(_FZCRWZLX)QES;
M)R*T1;H$Z[OD F61CK)B/^,\A^7;MG7<BXA01&;8Y&ZSR*"Y4J'O$\1@[EP!
M9'=:[SB^#'W5Q\+(ZR[\F.RL?_6PG!VYV27/VVE)6G8@U]<^P]/P5CO@_F8J
M]UO0=TJ/)+#O!9"5E7%D&7<-'&J507=^@S;LHJ>8QW;]0=< IUHP5JOGH5<,
MM=5&2Y370"(7UL]6.+5CHDU^?;'A0.-<1*T%\J#R(.".M+/^P7H/H5^EKH3^
M??@O PA-$65-+;)](\M4@<);&/*P:/L+^R.A^Y 1/,W<_##=?6VIDDK1*I0T
M/!>EK@":&Q"Q.M)3=,R45WIQ2'FY2?2[M]+?0PC-!67V9RL7-!!0)@_K)2(3
MK;'%8(2N#OEGE/1Q]!\4WR21P=FV4$9VGV?$ASBM*K8'/'S/ACFV/D_4EJT4
M_[B+_SQ1\]%R0%M-"L%?%Z7"NRPN_N>CE?+=2/EWD:@[9=59?V[_'X+C90+6
M>V/S?]_%3V-VBAT27].0(9P/5_B);UL7L--<BSQX^W+">LIJ]GC+\>WSM_8I
M)N*8S;2S8#;AJ'4,/ZKOV5A[E1@;\0R;EE'RT-$OY<.Q"AU"OR3?U2!R55!'
M/$E 4)>'.+HI%*_M6*OF0-Z(1SCF],J!UZ^9<?*I**RU)AF5W!-XJZK&SYSB
MT*HNJLO.8X/A)F@W])BETCSM;2#(/H=BVDM CW1@_T!H=%2\7\=ZB,&I$ I)
MS,TK\X9'1(H'KY [=,JL[7A+Q%$F>GYEO/.-[DN?\[.X*X>VF9H22EH[0U_M
MJ9X]025-[990UTZB<JGM)W>-P!Z#@?*61J_K,B0B7R*7',(/[M+AR^;3]T[&
M968Z$]7ZT1=ZJ+QPH.]RSI'2O>VX>8\.[V*C1:4[AS83MC:S= _1.CKGY \G
M&*[=U=C%&9%H$\'I9+K)%5>[EQ%P+).3;E]LNCG0%,P;P_[16!DT\NZ@6#Z:
MG/-A[+U<-[KF &"@7 !U9_2K*22S>S)T\[5OXGEFV1BI]9%_(/VV3):31"*4
MAJQY;O"K_" 5_P@&MS\>L3C^Q$3V7(7R\==$;;2&EG4>4K)K3[''XO;$2>;E
M?.)5=O50C?Y3VKV OC=J@<XXI_36*ZI[*?5=I3XG(J5DJ:7,7+FM_*Y!?ON=
MISW.OYG#<E**1HM?,Q*[V#LWKZ=<W,$45;#M].9'Z*$65YXUY4A_:V$LTCJ\
M)865S(F53$Z4U&\?O:IQ<C:7SCME'U$OK$_S.BU6;(/N]^T/03D[XU>-+6ZA
M;#X;;R\)(M6*1'^;O!\S&W6^/9KF>..V*Z4!WD<Y,E?^*7@XOP.D=&]%(R\2
MWZTWE"2*$, ;(^E&]J'?*6"3E@K/Y0N<HJ$\RZ=9J-O85*T<? V41UX#QS+'
MS$<'(9:'CXZO@0M4[C6@4JY<1/E6;V$E4&"'9JN=7%SSN56RV5Z- 1$^D:(D
M1H:YRI]_Q9+87P8A$?WYMV^605JUZ:<I1+Y8DDN"\U 8$2L5H1^.)G)# AK>
MF>).@V&PWI)HP+PTB.@:Q;=[8T$Z6596LV-ZN7/Y,F=CY;<POP0\(:_.->^Y
MV[;>P7#><:7#@W&Y6Z60KY9L=MZE'GX\!@8A+]9#GMHOLHL0LQY-'1E9LNAI
ML;$\0-ZNZ)E)_L)UEY6M=$3T1-FHR2G&@OCJX\J$F->AYZ+%LF?J8-]K&Z8&
M]A_I[$$K399Q-)S^@LV&O\]T^ *\:='!GTZ-+@K&\AKB]N=8BN.L<L13**L!
M]:.B&<MPW0)$ZKOXLUEP$.O%N54MOVHECBK=4^#OBQ^I?RI*W>USY<R/XE<.
M>PX9ZM)>V0/L0<Y^4CF>/H7*J7:][GFV;7[('I=QS9*2^W(J1HBE%+A+##O^
M9$VT"P_.>G6EM _+\'/C>(^.<KNV9N; 3&]?MV@[=F?H+SWH)Q^7..A:$PJT
M#<+$OCZ&4INV+H>=1$,PZ#K1_*M'S(/,'G07['X(OCX%MFGQ[8JSN;!5_L>!
M2'T@,?>-%7A,WR5&ZRI^Q848]7F9>J''8UV+ ];TQ8#I!%9Q89#6\64U#3ZO
M%B% ?QRU.I90&!A>K2"WUUB%V,@J.IMEC*^A?,QW#4C0E5Y67#[,93*N=:&!
MJ'>1:-2U-![9Z+@EF'&@PZ^!D58+4W[3:,E)=CH)2M"O'RR!NNP2JVPRADG^
M3W1MD)8=]4]9'S)+19X9-UX#8V%^5#<;@%.7'7TVTX9<E?XVP@4M%Y<5>5SU
M>TT!L)?XQP,V+M,$OL,^1)WZE^KOY.R+BR[2G?5UKLSGSPW+)S\AWM;+-:^0
MY<Y= [1H6GB59O"K2\>AG2.W"S6HS GG+_?%HXS#;$\?Q1KO")ODMQE]KT%/
MZW31.]-VX;M,*SG\*(?/$%/X2.-7L\<7J;4\WV>3/>-%RA[@C3XAEE9\= R-
M:#]\(B=]#5CPHX=?H;$^,,G\VQ7GGT*1)I:4T+4LB >FQ? \0_.V[*VEK6VI
M8U "%F%^E0ZSQ[Z .P#,ET;I*GQQ_A4=.-< KC]TF:=5PUHN@4@/K"3OT(-F
M7D;DHJVGT,]VFI],!&DI^=JFQ%\#KZ"E,MEINH*;)5O,]Q38$"?A\80D)@^X
M[A$M!7Y;CJ9Q4(O"Z1PV,3"@7F.GFO&\XEV!=K,]?=H:-3(G[5\N8HO'^X,#
MD$D^S"'P;@)U@TA12;LF]KX_]!9R&)CH"VRO <_[3&A^O"<H]<_SD#Y=)$/9
MP!?2+SEV I\BB%E$;7EY*8,[T#NTJY)AGIE"9#TK\A(3_.2/1GZ+TYCDQ4,<
M5SF>OZ2Z(>] /TSO7F/[;=B);:^E+BG(NB$VW]4O'!^T:>& T#N9[9HK"Q;=
M3]-HA\Q>]8YB?I2>SP; A\Z]7"BWF=]VT9J;]/"?GJ<K*Y;ZU']WOXVLCW?F
M!#4X=-"=CJ;?*G%9>FS.M(--YNS^HRP35FENHIXL]_IR;AMZUTLD$*>^DH#1
MK.$"TGLC4)*MNTK<,!T";;Z1>>7Q4C%4EKJ--: ]',9"Y_]CL7$MM[<E&98C
M* =>)9V_,2?/::STUIHTF8L>;ZMQ=>%9FR!2\".2T0B*CY(^>DF)?ES+ 4Y]
MQJZDN$"$N9"CD+FP#$?+OH";DRQK3.J\XUS/;CLN"SRJ;[PB)"#8C5&D\I>N
M0+I$[XD[O?IM[^CT46-U<BJAK#/R7M_8FJNTU(Y9?&=#041OH$S4S1FI@FQ]
M:D+Z9UH< *42_T_K:\"H7=="&1&*48\'06?[L0I6I<-];/OEM\'$TK9D7<+P
MFI8;7G?2T6551]""1Z]'#\2E.S[B0C&DC75>O-@A6\WAF'99^VQYS>I!/-SL
M**[M<^MA2_/J)OJ=1.XI-?@*9^M&*UBSXAI(,$^[\E.]!O)(*O5W%=<8;;"Z
M/0[=POVFH[F1RW)@ R;ZN4TE<7M:*(EK%%&N>$%M.=C*/#=]SW%O=_5FW!)W
MF-(NO1(F93V7V=JF'>$T2;G05TQOO:49<PW<%M]QOP;*H&>Q!/*)FS+E7=J"
M :;=['>GUP,>;&A\3II9O :F38.9YA,"D6Q-.-LZ_B18>W*%[EQ8KM4N[2@>
M M.*.R,N5\ L 8(?H]F)=4+;T*0QQI;'+M'\9%@#EZ-W^0)"I8@*(JX!UV0)
MD&*0V:5AA:6*BYN]EY/_NYEXVD*LY#Q>47CL$KR ]'6:0./$=*T#N6,_6B',
MNAOM,EFOE/?EP]SKVLE;=+WH3)[4K@Z5M)+1J]=%D@SP4<)LY8+C9#*("M04
M.\B5!HH<+DSZ34C]WN90@97FWV/\#%JC6CQ@3C5N#NS"J;\>S!&OAM]F"_*Y
M@;7YE_H+G0%/[M#52T/946V*A*C76MVXVFH>:S\[8]+>G_6YMH)ALK-QD-7O
M[BCK3@OV-!T729,I+\;&]O1SI_5G;T?K?,YX:D"]S/0'/9=[ECVS3N1ET5RF
MVW61I(\DN:A;8-8AI" ]]4\J2)>^)5:D>7@L0[S?O0.G-Q-#;82/[^+E^!X7
MFCU5'WN8DLQ5+%U^#R%Z#;Q FR'3PCM[6@<N/4ES(F[%*<)$H*NU"Q#OG@RA
MZ-)]04^MM)P[K.JW(!ERPDRL[+6=<]1">\(0*]#OF@4-]2MW2R1N.K%S_)_J
MQMQ\&HJS NI_'U!F]18<5Z6+"_IFR0!Q!S&@W#<?-C3GS)"&A*V%LKPS((_S
M>TDR][DEL;NY,)':U^8GSL48(3C"TURVLXVE;L+IE<9>Z?L-8V.=1KDTYZS9
MI"V]KG+,1)IO6="08+8+M:0W5?G^PKDI)5=H6M\L_N5L/F04/A.Q.ND@^$5\
M3K[%,:&U)HKP9FB.\N@CN#^33[&_-"HIE]*Y,/S@4:NEQ(A7F)XJ-PTI]6R*
MC?2HU7VI/(*&.$5:S"2I$R3?U)QA2LZMGK_QF80;!IV.)O"&TAX7UY:'7ZS1
M<KP)_U5F)3!MH?B!>KN#:TO;-8,D(/DT;S;)@NPTSOIL4&VYG_DXGG5!W0E&
M235TZWNLP@M4"D=@H0[1+1@_%/6DC=!D6S+-HX.->40SO]/UW3E@&]\<?%S6
M][V-=;*%&M[OF2D=%,XY<O1#W\2 ]W9FWFKP,6ZC8C#R*AFNGU5=U9NT,,Q9
MG4 HZ72P3^[)+HQ@B%[=NM?[1;S?5&>#L3:!LCTF.4'Y,C](;FJ8Z%V[O8/L
M,H6,-D&6TK)9YR!-\6!W!6R3K_&DW*.<%K&;=@V0!'+_@@BOQQVI3"-F#L_Y
MDKF$.1@X;"JZB.2>KUE_\K,!W'(9Q+W' YEV1+M[;#*$7[_UNH*30)&+TW[P
MC0RQW A?@CSSHEU[?C+K#6C6-;"E/^P/B<V%>^X6W!*$OSIEXCI/-)\)Y@/#
M2WGL1JS][AB#*Y656-N:$4-@I&$L?%:\.=WY'BQ*"C;9>8L45U,P@)*5S)9U
ME@MQBT;>LG> F8]SB4-?-ZC LP'P-:PN6K8LA8QVM)^30U8Q[4^QL69J$/=5
MOH4;G.T6SHO79YO#\[^I]JZ!7R73Q\5.'..[SR>G"9+F>SF>77Z2B+&>IS?L
M5F";1.M_7+!GSA*X7=/A'D$6(R.2TVV88^PO@ Q,=[E*M$%2;+!1V3S4(C[2
MI41\&1U"41_GD2F&G;G:7P,L_N8%]I>&3[)&QON8SG'BG@@?DWUO'6GAA6,B
M[ L"QYA'<C\5!$2#J^S.1)VY]V)H^J8JQ?>G</I0R?"ES)5R^NV,_0)OUR[P
M#:YJDL^\<SUMCC&';KDO3!1$9VJ<A+YG9.Y(&JS\VBN,^;Y/_#Z%@[/<7=OY
M?/S>$%.J\*VU6VX-&#:'0308H?AHRK9E1BQZOE@\_;;?)]J]5,:$I)]\ZGAR
MWGT?\PA0.-906QAII//T!&E);^JT9=,>4''*'?A^Z M+5VY-0$GYD-,**9#T
MW-4,%^=B0_P::"NQA8-BG=$V\,CP E;[8ON):)_'=M3F;H?9!6%R5$JK<8O\
MI"N,!X$2*,*;HP?/#IXK-K<K]C,#)X-WY+7_XV&.P191N)/ST&K]N]K+;/G5
MB?W2]%L-]PJE?Y@]9[T&B/?F6@VB@/#]"=(=Z3W!?&.GS=B"5(FM0;4;BF'^
MOQB_NS!LY5*+H4KO%36/W:O5V.?('=8N8?+BAF6%  !RP/)3@*@JX'8-T* 9
ML=1FW]Z>M$KD;(GL/JU27*0!U"@K\>,=-[,,>3]##OHR)-(84KZB%:?*:^]0
M/:PW./CPN0\G/8C#+PNCO_->ARC37P21^^Z>.)MI-^;N^\]%7X7Y7U6EFGH*
M-,2\C#D&WN"5\Y1TP;-MH':R\=0L1,PJQC?"1M8[7034A+-.\#W+=?.#2 XM
MHS'DLR?DAFI(Q;<OWLPX#CW8X-%W>DM3>D0E=3L"3=+Z.@I8;;L)T6QA@SG(
M$H\)'#<V-&_R#CO_.@6$X,;+]'(X'JML"H.7&NG/9\4&Y.8-K(/0(8;R<4H<
M%_'^LQ]UE=C!1-V6[)W/Z[RA%.+$M5[:G^WFK]CF+[N#E-CGVYD;$<T=&661
M 5]0!=TCL>6O"]-B-3CI>-V86%]FN4KAJ/K:T.&LL2LBEB-KXB.9H?'^XD77
MP&L?-Q])B=>N:\"SU48"L&."NHI:XU?(Y@IC>"VYX.3W-!GZ:J4->R'0637L
MI0IS0L."*RD[,.Q[18>SN4PJ)_W5[AH@HU6;YLP$M[[*8KTOQ+[BVA'BLRD^
M:,>\W!T/L P+F?QY7!5"U@-K"WF54ADDG"4\W^OJJLS36A4%($?)4+;=.7=1
MQ6TR2(J4JU@G!_8A4[7G+Z'OBQ>/%S2Y*3I(3F7NY%'*HC[EH[YOBRV:=I[-
M\GM8WQ(UZI-6;3 +(6;"J0RY(:^,/M]SZ<V104I&E!VS@",,3^O3$C)];!L<
M'P:'WPP9Q/GM-LI^LENC0W0;,?]=!,+?:9"AW5UR>V8C _;Q7*5>1SZHXZS7
M84!!:MLP0RC6L3: QE)PTZ+.CS@_GJ50Z@;D&K W5I\R'*??J,<0S]0NQ]19
M<$W-+-CYFAE5QVBFVN)QI/2!9&FO 1PZG%F(;%<%ZNEWDS?1#,1U[XAO0EDC
MTEQZ(LM8>E/;Y,;\?8@BT7*")[&WQ@1ZDP0IIF^]R>+Q@]WGH&V69F\K404@
MMM%E:"<D^$D]XJH^9-_302W[94/3% N+6Y8U!ZO'3QI?PWQ(:.>P#Z(*2FQ_
MB+MME3HF5X03\^+-VNF [OFLI2K@H][%B#R-9,^&Q]IVW>_\-/?MW>R*%[?0
M;0C^9A+1Q-?7;:Q(Q2 ,IR6DNHOYQ8Q8ZU.>B^\2\YR5TMR^1TDWB ZHXTYV
MG^D014.2COHL:?/JQN_)B?O!A^5^5)E;+$NK=>P2X<=Y]+HK;0^_45!$+$[/
M?G<8I;0;T_*2F>_$ITYC6> JXJ[<">---N^AP_GA+SLI) :-N)#(+E8:,^\D
M'+"R(G[:<.%FEM(7=E)T]=%)[F&37_8M 3(GK\8WX8<?K)E&]8@>G3RZ@Y>#
M7,KU^HJB-:VH?#OLY6:'[+G)P6 EQ8HT!A&+::MW+5/L>BX:3)>Z<"7I(45Q
ME00UMC2V'!K^6*0B"TJ]6T:QF]0%!%$;=RGZ27/1]V;FO;6S>IDA.ZQ82OR/
M[:<N.V!$D+WQ'@4_(4\NE;4^I NZE/_$C8PS$.NX-WRFO"6:48W0ZFIJ#Y=C
M]+ N-6K-'K*4^QHWZ/Z)"N\P>0$TV,H3!1PN1^3<G*F!1@:*3IV0$H4,8MXX
MV!N_CR3ZT,>!JP$+'=9'TEDH(G*[-5N4/RD'K)#CKM^?<U\0/M3$N_4TBS4F
M! >6:-&(O?#@*!@RK6=CTC,9KA5+]#AD=23G]WG;<U?#("5Y8AA><MR'LK,5
MH:XMM VLOR;3_J%DJJG%B/IVHZ'SS"E7NW7H7'/&';S^FE$VU#7P<-)Z4CP7
M^"T35X![[N#]^CS.T97I'3[>;X_1O"\8$(K?(K/7&R.']'?K_+(0DCIC-]\2
MQN7\1#3F#@DA6 \L_GM*AR@%K85HJRW%:G]G1GCF\S.&5,9;^R\-=+C8K5BS
M$L! CCS_]!ULK.'P# LK@2"T6AO2-MSS\XQ8*9CGM)>GN[A[GYNB:&.-BE)/
M>*D0:3X:J\ %,3C3KD;TS$3;KI\G9<[@.GRV,.!^(A'20=-7@;X*CP+@;6PH
M]XU)N'9NQ,F09(A!.,29XQ5^F'<@++%?O =E!YF$"S>-S7>E67"._>@UU<ID
M-Q>=HF?B^JRQZS$P[.>$A3D&9O7HE@ DWA,D17T1.&\KXQ4SJ>2'\^K[LN$P
MX66F?E:RYVL9K<C<+N;92">T0I-\Z&*F0Q=W)Y-:3\=F$O^471YNBY^.(E4+
M]>JB^K.ZZG8LKAQHB;T9</TQ<R[]O?SVFT-"PAM7\EAN$:W>CY$N/8O>:E%'
M7:(HJ%I%PL"]6:?+WA$1@(,].DAX7]OO$YW.WY>]_U_<<"47%1_UL?&_:-N^
M,)#:_GL;-"3JSI\RY131*]BXS_]A;L\26W6R\>3^=,NET/VDL(@?$IM2_?T<
MK)Y]I4[.8#8TN#[Z(3MK<E>3K$:YM]N;/@_ G? &_FHQX*ZTT1H5!:RW:+TH
ML5>D6-9"O-1CV;H5-S=UBZ7;!^<#;>_NR\VEELE.$^]N2GR3)ZE0RH*&E@8K
MVY:<YR_=LL+@#: ?)^6>^4%24$I(:-_9W'IK6R-LRW-/^LRG7DOPT0M-5F=Y
M#3QDV4K4';Q,)";<7Q4F;_E$=5$X8N2M;W_N?31"?5777W(ZO!:Q\[!I,2T.
MQXGW<AS=WH^'FGU66((K$YK1A\W^PG?E1 G6VS)>49F;U4ZJ<X4;+3:]A;V
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M[V%H$/JUV3\LS-&[SH*S38VPNQ=W\'8R=K8*TI8:++7H#S!C8O.C52\7 W+
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M<0G,UEK#WZ3Y4NH9>^%DZ6;X[SG^3!\&H]M*R/Y6-C!'O+5J1U*4SJ<X.IH
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MM+Q<J\1K9)_"^7V*X1AW$6P;<BK9/EJP97]F>&<T-T_Z:X[8-9#(V TZI6C
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ML.MG0]HV'USPETAAGSQA%$\\F2D(?JENM*1Y6?WU;GP;E6J)> (*C\=+[*2
MN\L<BD<=L6\,?>NDKW_V2+5DB?/VC6-*J YF_O=*%JT[Z-SI[+O7?TXEN7V=
M7C2ZQG3_KOCZ]&6=T*RL[;,Q(!$67637%/66IKU;G#7.Q.:JPT#N/].L9>P6
M:%&*J !Y'S@$VBM3ZS<:+^#^WE?Q_H>_28J$4D 6F-]%>?)3HCY?[;XUQF93
M'*";(B_?W*FYA'(XQ?UM0D<X#E#;<VJ6EO@8L3J8GIBUD13K(O=VW53^Y1E%
M/5==6P]>\''CW^IC0KXU\4[T4E^0*$H6$J6-/"_;]^--Y*-OCGD'E_R4,UPN
M8P=6WLU5H]U7P$=^1XMV79A(?N;.$>7I#<M_N5PO'P7P)TX;X*"(RN4" $ U
M+E+LQTR"%:SDT/6ZV;Z3'N9'QQ4\N>]SK6P^C0CW7&6>$?^!A72<OBR''B*@
M-^1M3$6F"1^>^_J2PZP] EV7K.ICBI*O'H=JGU;*HH58YG-99N4TO#U\X <B
M6@,WGZ3P]X@<?Z'ALDL! BB"E%2&SNHM/]'OL(G,C(UX$F?D0$]U\7-[;HQ1
M.JBT^.)Y:18*OU\&FU)B#(%V-S^W.*1',5*_DWQ"3+[2ZWFXD@AL<\,!"+GG
M'Z"_( (ES6;YVIOJ0]*?38L6?]D1?!F&OJ ]6@#LXDOUNXWQ]V-9<8 A;]3:
M3>V_"!7-#WQ-!YD7U>"-FSLX@%$S08\=R<LW;$:)L?)#G1BG0<RC]3A8K(P3
MI+@_$WX]X,L5F#B\:)[2&YR23"BURX&WGZKE5(+>$.U#END0]A+Q1C"S]B/=
MKHBW,2PPR@#M]2/A !#4:6.%;FK%*F0K7EU@NJ2GXWF$ $R[/[RV47X4!-RS
M$$!J]ZJ+&2WB 'K(\ -O,RT?0O+EL-Q>JMK-L&S$;74W=+5+H6AA"5M(4$(Z
M<,98<M&B&W#?+9D<0$!)! 1L43K-E*JYR:TA+FH0_IJRVE-R LX0%R_@6_G9
MVE?]- 0 2;S3K=SVT!]IZSS1TYAQM%J=;L71^)*!4LW/@2))Y_%KXTH+@L3P
MV-.D: LY5'L$;R&X$&(^U<]5)QX*?ZC_6.1:L;-?FX\KUBV0,I,/+8PX,K28
MKM-D-_V\;+E/_3WP:Z+Q1#J#]7)H<>YZ[ =1V*V:I*>+VOZ!$L\<O@?Y,\$2
M!.*'KGF!U\<2ONZOWL_\HS9KJ-_8FN6U/=8=84;.]=B784CN?,SOW0\%T>HJ
M%'N(%T3=>*/C4<JRR_.DW;_3AU9[?D<T\,OQN=2:A_\9=,VH\+?T^^T!OA>@
MXA5$]5%7V2O[WW!;(/LFZ,XHXK!%'8&BQ7X4V'RH-R^5QB<M]7;47;*#<&NZ
M7!!<T<[AI YVOJ_)SX+\+@)-;/-KK=Q,[Q!HB"K'B%NGM\_Q$NMJ*YA4=>(
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MG!,W6E1BB:BNM=KDL%ML@:NN0T.]6-5/@@8\'&V<Q\G*M[D^G&]F4[R-W1/
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MHJ51BFQ!>(4PBS7CWX^I^:P#K,)]?D'%14:',IZ+0?E.K*,%(_5J!8RD,CB
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M6(]> KS9OL:RB)LN9XA(<;-C5WT#]BI3)KVTY$05O;DL?+/_!DY(4%]69:(
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M*Q$QEKLS<(9'"(:'AVXJM1UG4^Q'NF\;7P(<."V&"G_ZO>PT'BT/ND#ZP<T
M(6+I-MR]TV[0'T%KT%6<4X4XDS9:!+#D70NLV(+BG0>-^6O5:Y\HX66Y\)\C
MC<#[[T D(3+$:"@VDPS#4%NZJ7 +W3N]VCJ:Y9<J%C&G3*POUK[*%J9F#HQA
M1P30.+[)GZRU]V,L""%WWQ &OW%!"=RTP D.,\P;\EOLO_#S[*K=27^K4375
M9(025-/&#+YUL3NU^'10RC-_7IE+^7$@<M!CR,:2+VJWY19<*-:*@9T,KIE#
M1F[>[R:M%D^;<M]336Z%J4]:G(!DER8.0#?C /+-O0^JG9&<KO)!T>"/WM8<
MY%(=&6&=%"\Y>0+8)U+=4& &N#*F+&L9Q&S:G>_$XD52,_;HT_R@UZ"\.C,?
M,T#A5_9M>2I*0H<.2Q4DK%9+.]^$J5.^50"L'G3= *;0]'D,$- 1J> P#^)I
M!)K$V(ZB=UN##U,NB]W)MW3:S8%M:%E"G4Q(4[[N9=1R*;170I9\MJ$LW[*T
MT37)]MZA0H*_/\4:45!-&@+QR*98OVCQ0+>;L(!+0*.Q-]F/7/4JPJ%2HSPF
M(4%G@X2QM<NMN^5$C@&JKQ;LAV(YA.\J;?SX\0&L\ZX0HEJNC5Z/<4.U4CF=
MR=?(%:L;RX4F]&(SMK5U5J#D:#[%ADDYG=O%A8,O7^ @S-65?7.AT^]P+6T,
M$#27]2.HE8JMO?S<;@T3MY/EV;WXK&%=HG&35!Q=(P84+>BC0[-C_G%U<DJL
MRMAW]/MC3A*!MB#WW$V7R3N$/1!'MS_7L6[X#O"Y8*#T)O\@7AC+9X@IB"I)
M585%[+X9^E#$[;IP7Y5@Z\/2H3F>M!G3/.?'O\(NU/.]IY#3Q8F064<V#OA)
MXJ;].41:>'I/G!I;II@;:'TO=9OX-T+LR46N(OXG>L5VG3$Q? Z>TP .QU-/
MXOB(FQH&<F8S&BL$9.U-YNKD<'DKY0&)*Y#PXR'&K3-Q<]Z<.?GJ?HT[3L;R
MV:&)3:J.UVIWK_/$H'OH5;F@9_1P/U;+0VPH-!3%Q%6#?AY#WW"OJ^;F+OG8
MWHVX[DS&:@PBXF659H?><Z5*15';),\2A:A#9OH-%LI+H*L5V"K*GH<9PL)&
M?]%5-5;7W_#U-6B79J\D()P,N0LWN=:_(AQ:[@I8]-DCI?C;[6D! AQSA-E%
M7NNJ[BADY_(*@CI56Z&'PIJTEL'1U-B5G@IEQ\G^FE[MA-,_L,%1=1Y 5,<R
M36:%J?@28,%QE6)[.QM\/D<YU](J^ZTW5'UY9Q4OEL9=GPUZ-%;ZZ=N8H&#I
MBBDJD@XIKA?R!0!,,K#%O0$30\BH<!Q]P8Q.<3?'>?%LQ8%%/.'L\/V^C11B
MR@#O>_JD$W5<BI WL(WH)I'E2X ,KM6 *8AX06M<TYIH/_$)+HWR5'BOJ\3<
M^U!>\3[^WA84\@W-WK7 C9',"GSV/%ZBBB&4S'7.IB:\^R5</=,1X: E^.R[
MF>L+_2<(/^>L]>M&F,@X#.VR6Z0=(XN<N9SD8*7%5H^/DU#>(+DLS;4O1<\(
M>C3.3#[UH[C*X((UZ)8O+8]*"Y2)(M3=[AFJM#,MH5X'.5X;ZORU%(>:BM)?
M)(;\QFJK>1K2GJ6:_,;)Y&R=34R6.A7,=A;.7^/[2,RBJ,X'B29N*E9LP;Y?
M8N>5D\;3:'F2>^H/'I G%7^3(^QQ%UMTZJ4?ADN@M;_E[[#4QN)T,9> J_.K
MQ%NWY[YRR7#+BW7$7W.G\_129+(&05:;83N;BV<L$T$2"5.[>D6LF>8+P]&$
M"-!>:L'2P)_T31P[BMU- _MMN=3W9,1VK!H('KKSQK1U$#1/PAT2,($ 8\%0
M:^9?L)WVY;L^%O9D'D[\UVD+B=PU@#7M45%I0K9ADESG,]6/94Y#-E]FNGT<
M5QEB]0Y2J-1V#$RG+9PF[YM-/_HZTQ8FG:L=FYM-OQ+,!:%NN>VTA?HC=S^3
MXZL_?=E>F9#4ZMU!.G>/3'>"01+.Y\V!JJ-+(^(6@D)3'F&C]!'D;"ETMGQS
MPX35KH^G5$>%COG7^5U<R#7O$O(Y,DNS#_BKAI?!U3$7W[:#P0^LH[Q5DR,:
MM4#O>;+9:.-O!MA*LR&/MQ9NCYAT!3.-5SF\[A+F='P5XN#$';X?'GN@<V,>
MIXWF>)?)= F\DI=P?.K+4*LW%Z%8HK'6+*JQX<2<?8.%O:;6Z5S=M'.9_3&E
MLJX%W[R<".F4V^M?3(#1_@R!T;$;,7>AO4L1 <DGUISB=))0.6M73&Q_=_I0
MJA?;R=ZI9_>M5[6^":\??=%>_B(9CY<HP/BU-^S'5@M3#.1.EW;Y2E&=7O]L
M.$,6?Z7@P5M;BASYT+MH3H)E$#L 7/LC#=X?@$Y!K]!'!\MBQ'$B_9SS21R1
M><1HWXM'7\['Q5]=C'J<OBTO!;Q:;[2.XL5AVWNKS[=X4B0$)TP&N0G11O2;
MBS2H6$1D)K?&&[/K\4@"_$'"#\1]_C@,8SA."V4=[06;;:])WJ9>N,MXYB6M
M^F+%P]HRB76<#:W4+=L%06?!'Z$G3M[)/1 GEXQXCSM_XU_V4=68EXU(O\TN
M<YR@",V/UU#-N 2L'"Z!D01HLJ5)1Q9H&\J$1=CG.P^3"M]*,;:C*@\95%_3
M8*?TK2) [<5> M6>+W5]9^SLO"$.<E,YN"=7\:S#LO 9Y@IGB<+9RRZ!CBO7
M?O?\UB5@>Y'5?XA;&X1_;/63;3EEYZ_$]+SW*\&"S<9><--8S<TT>7 ];7R'
M)-:Y%B+3&KI9A'ZK?B^;P6DZL>C0$J%D^38>L;K6Q'\)0+=P:^6*6*M/S@HL
MV,#/6P]*KI'_HFBQL^E<\8[O3%+?5/%JX4&_;"S$O1R6TW!U+,\W?Q@GWF-_
M75W488V/;Y\J+$1F'^F*@"3 J9WL5]^;>PX+]I[EWDVY+Q7H/53M78\=V4)!
M<''F"#HXB51"E>;SL3V&19.Q_,/?J[8A.LSZ@0Y ^/9U&[YX_)W2J!,O+)%D
M:>W3IO/'T>2V^\ECBZRM'2$"<"&T=32<RVM9<\#^M]DQHUF*K ;Y'7?+3%(F
M\/WNI_A!YV^FV)0SJ-OM1B6A@!4*1(;4FM7;CD5"*YB8:F.J8;U%@K7>:QWO
M'Y[%4S= </L8A8*9>A5T;YP",ZS38 (NF"]4G;WMVF+!^YHG65*#:>@3'Q%A
M>_MQ]I5+0'YM%^XH5?I,Z&WP$$,[71O:NV1>Z@@^4"IM_0TLGO%,\:]8<?<N
MTC2)B;OEW$YT)11(,I7_437E:4?1Z$YMI,G&H=&+FG=ZP/')!9W.?L/QVC9_
M7H8! UKM_=J;GB6/J6; "_QM Y<J]J]W5U^*5ZSIL8O=+&D?E^Z([P@J=./J
MCS6[YJPJ@S<WBD@(29#:8K&;P2"L@S$Z*XPJHV16L'EJ)B_U:;+U&I>[9QZR
MIRZ!3Q6SV%&*,$I4'3:Q'G%;/[2=%IHR&!2;8V/C()5F$B>(PW#K8'PB6U$$
MRPF^8P8@!![)64/M#W,\=0 <9,!O FJ[04#?R@#Q JMFA4NA6?^&A>R&C70[
M"1MR#OFN#-2%I\*&KLB;*&,H+U[=E*\>W1U=J;,^<E0R%OJIS?PK/$F6P*JV
M&W(#&]YE;O5Q*M*'K+1:EHR\1$,FQL$@/LPK/BR7>>5*.SUJH8+8(A0_F4$7
MGJEJLJHK\<4I->!W^WYWS:HMNV>(21Z6T'I$3@.E[D-)_$.65?]WHG/R%W]]
M4!,I5#8\<RD6Y08WPFB:CA2,I+9IN@9Z4$=J]M1QZ'[OO&_0J]S[$\'R.Y@9
M)H@C7]H\:HS1M^CC=8E+2Y3U^TI(GMEV+Q9 M3H@_I!@W^);W_YA<>@%_6%O
M(KA:AX1+()>K$">%LHZ!@'P^:B\^'!,?T-1LKCLD2M5F=.QK[UGC7#JX'^!A
M!>H6)G')Y,5 7KEY%ZMD4CY8[?/L,=**:Q$;3LZD.SK*IK2.7SS0J%X\O5+:
MD2(#.+>*3H0Y8 0P,7T(>/MB(BLF0/ 2B&X!.S<8OR5-/T#94O=8WO:XE=JW
MDBTAU3E_ZU0)396<ORU"6B[XZ>X]$LKPNLS<\/9LD,Q$"+A:-2%$IE+F$F@5
MG3+ L/;Z<8#'O0<(E<=LQN64"S_,YG6NQGB%]!;H@SQ.-?B03ML<H"D^[.EG
M6(ZLRH-'#)]E^ X-;RY8QIUZU1UT5BMAI-I;;F5U!URI,C^;WX/(#SE25<DA
M"]DII'W,WY\3V7&\RZ:X!.B=('1JX1)QI=;=+(]GR)G-ET?)%3TSJ%8I3&2X
MN25:T<)X#87W_S)\I:8SKUNI6[@V&=/E\.QQG9.)Y/ZC_0I;0DP4)8[2,\PA
M1)G3&U,E6(-LYV#F?YC&DV7R[W:O*\GHL0X",OIJRHIL#O_#43^H _IMQX/%
MB+*F)V?=.6VU4V$6GKPF<_7!P?H>XS[E3[)!(&S+]<7N1()?<X?/'1X:M6P)
MBD9> .7NY0K8HB7R+.:M&I. )WW$M9_5[:M]I2FD>;U^K1F&;\L?&@HT66%$
M]R:\5Y9,ER9$*LHW&LE?%( 1CGW<+03B!$.X^Y'\""14)O:Z8<*3.J--"%SL
M;+R%^Q)(S48O7O@C?J<:[4<J$&! $7*(\L7M["$7'VK3??-'@K)O*4P+>>(/
M_(MGIL*/^X>0#<(QV57&HZZN3?7/#PWI72M!C1^RFF3]LLFM:?$<B]@&+6'C
MX?W1(?/1N29*+BZ+I,XD*E).VWA/+TMD[DIK= M39;*<Z]*.EL[C[V8%,4K&
MUL8]:SO;.0WE,0M,&*L+?&HY]O&!3O76;XJTVYXQTI1U;'9W]TCEE4Y**/W,
ML>]7Y&^L=(Y@F;W'?#.-NN=..;,-3K]2B5P"B;K7%\$[OBRMOR^\BF"^7,19
M[A7WNMELY*H/7S]XPT;!%AZ[W4+7?KVU8Q]4VE"H6DWU:^^GAMMXNC@$,'-:
MI*1MKTUAC8:2()=55H16*^R/.CD4PNK<0,H81E104SI/P#7L6U6UYU5I"^Z)
M3'P\3U=#4S_8AFF399-"'!]9N+22;3,LD6.OPCHU"L4[G5FVB8,-H,1Z"+G]
M]_9S2QEP3$D_A!16WHN7_HKABR_)&3UJEHZL&B,*G8Z68:W85NR3Y@%$%AJR
MXEI8)^!&2V;B QQS.KY3U'^CNA]D0P**V92+1.9*MDM6Q L+]Y,%7_$1CF?S
M7&CPX"76 EJ$$<Y!0OR=T;N[H2'WEY)IZWIQI%D_FL,[3[Z9PEP>?ZM73&UW
MH-"_(]-Y#U!5@ZJX9]$TD15O!ZR_O<+8-YJ4K<;<*439R(;90C/?KX62,),4
M=@,!%CE]K*K;S$PW?Z@JD53#RG\?L^D6Q"Z'7SR&YGRF"M9K!>>["4<'W\*F
MCU05PF^),S^W%@IZO+XIV@&ZGJM(\+S'8U L?DR!$L9GBC8T/VXI=EU3D^^0
M^.9?N#;B1_$Q;Z5P9T>1 X'>:O+P6'9CLL(^=:(46[@$\FMR6'TUOZO.-[><
M(&YL-5F@W&(71(8S-"9T(HU_?:]\SI!L2K\5IE0<D!4A9[3DQF&-+6@_$=EN
M""Y(:QY[$LHF(L/KM?]7];G9MVM:;5>&8DL=\A8<^3K-V;S(7MJGNQ]\5]P$
MVO?<1>)7;H<\ $5+>FTM$@C]?FEFOCRK71-I;)!D9GY?7?X/?0$:.4JN$]%P
M,TQ"1Y20/TGF^7.>U*M0:9(>DB@GXU4$%VU%X^->\KR;[:5L>H*"&4-%89O-
MVQLA5<4#H+9TA?>%CVXUUM22W2.FK%H]96,!UEIXX?(3QQ=N3S"02+>5ZBGQ
M-=(<@P@?HN3P,%$I*:*GX98U!1CR7@ZVZILX1;16Z<EK2X%4U4])A^URE0[<
MG&S!]&-7\&TCWJ2;Q2VVB=O]5-CYD\,8Q](7C3#_&^HDG$G^)*&Q'1C>C:[$
MZ'1NK ><*5VBN9^SOJ&AGN):,?'24^KO)"%:0,!D**+ .1C\M7G4R$ GG1Y&
MK<NITDM>Y2XRQC&1;Z; -+R"GHH4WV6Y2U'L<*W'CIMUR LYS8,Q'_\/G=:,
M;,9:YSEGW>3!&.=#9CIW(=,'G")[AC?(-I)[W%74, :=+ J?T)> 04,@JV-9
M">=AZ7HLKZH^Z1]/$DZDR%%)(B-6N9O%.M&D!T]INK>1K-A0F5QO6^O4QO/2
M&'"G4OJ2WF1-TW++K"S&YU,[:D!(U<!/'*DI32+=+L,MMT0%Z[M"^P/SZ_7G
M(C-6<XPICCP)[!DIWU->$^&OJZ&@64O^*2MM"N TL3>2U* NH;&S< ,UE*L0
MA 31<8_Z$O@6_,-51VN50_,2:&Y</YM*WT3CGF#]7&Z'VV:WEV_U<4M\[$AY
M>,WK.P4I^TEFE-PP4?K,1>/)^^%1X8S?:=&CMA\;]6:SM',/RZW+Y;&!2\TF
M3R:JA>FQ.8:IUN.5<E6<T3>7DCQZM(&V)8)]:(0BAQGF;$&CB<#A'BB-4LGL
M(E25\+A<NSKY>65U,I714D+HR3U^4*\Y,P8<>APDPN@]1)!RY?*U:->MAYAP
MS@6=\J8N$"IOBS OGOL7:3JZ([C6[X* 3]]I*R%4!<WZ;P<O+X%-06A= 4GZ
MX="K!89).4&;4I42\Q*0CV]E%X-1T ^"C34^=A7@*<Y7F1QFH!O,&8F9F!W;
MDSHP^&-2(4+35R\#^G$>/EH_Q(K5![' S%?4TY0H\E_5C%$GL^5^4NBB 564
M79LRPC;G;Y&ACM#C8G/*X&G4!.&U:P0AT_-520]H-T7O$"R")!?A+S MGQA%
M5.T2W5=I[ DO 7N)G8E>G Q: VT<RB-E(-A3Y,^9?F OP_P[^Y20+W,UO;A@
M&HL*O@>UG!\20;\7]1=Y/USX YYUVP^4,1,B#6;$YFJDKLCRQ:YFG(.5.,UG
MVADP G7&_13(O-7S._3@;IV8!38,(KPG([\/-F7M@K3=4/KJ2A"ZP7?>T3Q?
MZIKW;-_EY>^ ;X_RLKIB4<'\,.W3KI:;L;T/QTI7&RVZWH3]COY]H^W 8PYY
MAU"YC4-B!&>4WVO_6:(]0[LJ]*7<KYKXW=GVOB'.*>%EG47\2"9=+"\OJ@K$
MQ1[) ^G_,Y7O./FP5^UKK21&1<ZW0NV."N'Z#0(B9--Z'8A<^:(5D]NMP#6X
MXRK"J%W[LAM-7W%T8_%T @BPI]-3O/ZW6"9>F%_<^_C/BJ_"G5V%SE@EXM_N
MNELSR>E= J1#(4)=HB^:QR$CG.VKQ&#98/+,(/6RDZ;<'N@-#$E"\!TG4:C9
M%YB%-O]YIRA8#)NU.KC_+N3C XH)M:!'@W$HG4@(B@&+L'$3"!06ZIW9\Y29
M6WH*SMD%6TZY/-;6XKV]UX.46N[2D>IH#KII%VV$^5V6AW]CB_K0!^F$4#5X
M,SAGQ:84'!,WL*MVL)L\:1PK([9IB%CR^-V6N ,-0NNO.S;Q!:%VVHP/'[6F
M38^?$*6 QF1;[R'LK#2_X>Z.E..YYF"U^EF[GQ\RO^"-9YH(BR Z/"2(7T)6
M&ZR (L1=]J,:$OY4UD8>ZJBDD2TG&$7])-!7TU7:NK(6#%BI[@!0%R.F-6P%
M>5Q&<F84GS"H3A!)QOIZB>/*6LPT%W25Q]1@-J?.Q#G81N)C3_5EUU9[I7L\
M_5<I"#[830B=4B_@1,?W?!"1,_1KL]\&GXI\J^ASC=>E"?QPIU2'WGG,48%V
MHMK%6RUS<&(MP7HOC3!^0EY'M7$4#];*A9G 37Q/GK'2L/&_9-KP6.%+T6E6
M6F+5H6Y'\=9B L5GWK\__5-6N48E&::J5DZO8'L@%X<J[X*08 UTFEHF]MSV
MX$I%/^R;/ECLM?5Q*0W)X;K.LFR,>KM:08B.?3>&EXWX?LE,;7A6EM_;VKV-
MR9:H\^MO<7\L$(MOKKSX(0Q.753>JX%3G7%M/:&U^&TFI9:PH&M=/[4/>IS/
MT_=-'O1DHE3"BF;1I$;P1#-:[DB4LL"&>=6W7/@BBSKQU7%<?/"VE?IO'+47
MKMN/0V&"41'K7[IP^]</<W$] "#(6K4$%1M91YR1P_Q0D\D.]^CK4B!5/_\;
M=>\9UF2WM8M& >F@=*0J($AH(D@GH-)%>I&N%"G2I(4:BO0F7>G2BQ"1WGN3
MWCLD!.DEH08(Y.#[KG7._M;ZOG.N_>/L_>T?,_/*,Y]G9&0^L]QCSC'N2:X^
M[C,K#;L+(LH,=A._X,K)>_M/&J#_DN574@_AT$B/NA,*;U9>-;0GG30Q:2)N
M4)*V4J\[G7?>G]O3!">L'@1"?4B+K;WTF\,&WDU/CS&8%:6_55B&Z54H.>(.
MWC<$6Y@)$/?0!: CVE$QP5>EL*%WG6H_:NP&(JUB[MZCY'%>B=)UX/^88,C(
MV<Y_?W,/?L7?83N#K_-",L_3M+%G'=*<I6:[*<0?+,Z7L%KVHHM6DZ_0V0TX
M0*75E<\[]Z6"U6+MR%]-N1G9VSGC1X^4SC(OGNLFRR?^9<I@Y#^L>![BS6*P
MZB#)BU +O1::%(82OGE4D6_+8V H_^'G[UI[-M8U"J=.26:;#TF]C:-9B)30
MJEG)IXZK0,6'E5.\#@BY5#R"83(O!#VKO^RV&%1M],!R$B-58#J8;U5?%6%S
M:W?0/VMR)MD4[-&#!5 )$W-AU J[L\%^TVK"94E'/(6%KQ+2G1/\!;UF?N2P
M:^0Y9RN./<^)B<@V(_^5[E&7.0VTU1"Z4#U^?+96DT2[K1Y@XH&DT8:$4LB3
MCU!COO46Z"A"U;2J XZA_&C/6\B5+E,ZM$Z+OD6<&X.,]S=)!-*2!4FIBE$*
M_^#E"[ZNQP(XI> '%\>F5[2\WGB>P\5P*:L=1&;LJG693E6:G3-CI6<)44;\
MC3&0J>^>8WUO<RH($7M^UT<."S#;:CW&,9Q*6$UCB%;K$!\*SL&OKZ],YOK\
M@^%KHK\@F%KM+5LBF@,+8(>J80'0<"S@6/SX_IHTG;5X;$@3WOM\VQ\$CFRI
M?ZTY#<7UL>OPA[O[B36J\E_?+?X=5IRRYV>TQ>RW/[@OB070*B?E*7M5-D&9
MT LE1K8IJ9P!53U+;A!!%?'8Y^X]Y#4>3RYP3#II7CJ??UVD<KA I!ZN$()%
M3+-6,XL1_)1S9?6=OB'\8NP]?CJ7>0A;YQ,AY0.96)=QH6;!%;GQ#\>-LI'>
MBKI49T1/LHK%0-%.K8R6BM>T2T"W^&T\TW*E:YF9G)DO/F\^[5RT?O)Y0,^^
MLL(0WK9'04(!N;V!S#$E_50K,4(JCT2KR47(AJH0X)!#>'0SZ#0Z2+C@"ME[
M<IIW;\!4&_<?JM[\O[Q"G1<)BG(B1O_T*/QTC'-T%CPO*O>AQ.R;YA ZB"#P
M!;PVN"KC:=N%9<?<PH@;Y$,M+2U%3_FP_GL'Q<MLYX@MMRN:A2X3EI:Q_>$'
MC6$%2$&-AE)R)QGA]0;&%0H?8C,A%K2\^<PNC,.>[VTBIN2UD_.P5!BNU[2@
M;M*<BAUU[L_0CJPJU:3,V/L+<[;)L!%[%H+&I,J 60>9SO%*,^3O@M9+N9UG
MJ7DFEM\=SNQQ?.=^E&BS:/2)GI;WMF>232]TIY@(H5PZA&T^YS?G<0(=\NPW
MBNA, +@G[.GC8$3[Q19*)R4*\W",R6 )UV6^[WGX)(E'FYA65:#7K8A,/;N8
M=6@7/_'F15: FRQ'\'?->8.FZ2,%BF_AGRW, D81=%M#LLA0]?I)/_HMJ.OO
M9?SXI3<-B5J'US((9+FW?M:J6HSK^FAL2 [R*K^'9G_;1FWP:S^.)&+VMMJK
MF5RP]XMJY$SH;I6WH &#_NG!V\#=UV]B)^-M$=_+P[WUIV+#::5SFM+@=,^6
M>5!3B26Z%LTDLL<KK%@ R.#$ZT@1C@5\<D$@*L[M?93>*6?V6+:S[21B ;W%
M(_)?V,9W^EINC-*^)9C:Q27HXIGXR?Q1:S@S];3DBU5^(N.MY%*A^[[MWLF"
M);L,H\?L[X.E'D_JR3*-R$-.HD^$EGLW(4G S\9AFZJ<YL?"QKB>(FV0<QQP
MT'7'#4J2%=X1WE@AQ/"7H@U?3<&G>9,)^1RZ*O#B3(&!3P\3(A90>ZWA?#Z"
MYLB\GPK%YYL>"MP][BZ-R8CQ'%IUAJDT\9[TAI902(%D 753+9C$WR+[;=2,
M%&PEU(L_Z#LS5T[(Q;[\(Y5^N&:7N\8,P-NM]-1+=;T81G ,N:O$N>#PX15M
MO -)^[#?AQA"1I:.I@V9H%6]SCJK,7L,B*:YT#,*J<*04)7UG$Q&2I&MW#/_
M47F:3 @ZIV>A_<^VT5/?G+::3DWNE&=(TJ*%+'.FW I\T1-ZJ +JZ+LI>9.\
M/NJ44-M7L>W*+@$Y$H1Y48J>DK1!R)+0"O M\$H_)(BD;[^QE 5?"RIQ/H+Z
MO&L"-]UQW12<,2A;U(UCW5YYM@J2 =U74:R1+JI 1M"SH@USOP?A#8[S7Q;(
M=[M/J2A,L(VYJI!RLR56UBJZ;&N;976M70N[5T7\5$RITY"CEOE77\^_J+)7
M6$!KQJ.MNZR08Z*3N#.MJZEKG8T5&@SO=W"I_'C9L9UE7?+R[@"KC8Y HW/6
MEXAC%KC&9K9?(M7IBUPL0+]5PT06&72M$,L"F>G# L9^ZD$?W)K,])_)\!%#
MEE?<-"0J=,VE5K6^_0E]YX) DB'XB*D!)ZZ=R1JODA-=C6!8(0#KTDRP#+2V
M?.EDG.T/EQD0&/'S][+*GF@A0UM63248QVQH33G<57)Q/^/+Z^ODM&8*D#HR
M!-W%T+6((D=.O5[],)'ES+ #7BW-MNOVOI,X%17^I0\.6BV(?$N3X@:;/1&#
M:5!YE#[2:8/1<#OY-7F/"M<$2=(7V?I1HS,\D-?KUX97P%\V/ ;F*9]PCP C
M!8($6Y\)NKV&/'O],>3?Y]')9SW2/*DBT^6=/$[RLG=#Z-AO#+QG_N)D)YO'
M1(:9:J@2P906TN8/!.\FE>N/V7L@\:DG]9Y?1THIC42Z,TBK5T(- KO2RGG"
MFB)GUBYGL0#_9$SI-V1/2<-&L%"&^EW5H>\?T+NPMZ'KI(!3'CO0(6 *M#/L
M> 68P?NS77'3M*!;D/B9;%NG?I<\4\,N$17>JKCL8<%N19RC<C6X7J@;B!@M
ML#7?7!>XLZ>I]$,1>OBY3DQ3P5S&50P2_LG QQ#)>[S"PS FXG5/!'1Q%_K.
M-![F  -:9+W2HT?1MD.0J6@WWKUU?6&@DN2.DF% (^,WJ0!$9A?1&I^P:61#
M3/P\#MB!B\\BMB]%9Q$ C*(9WLN.FXS5"DC%;V! 2DF/E8![M5Z=:RT]_+;[
M<5SDD.T(:E;NW=9"68LT#2D[SHNS2JQ/WC83C7\1A9@% "YT.8-V,2[X46[A
M/G*2(SD-_:<<GF-MTF:/@_'9UD8,<$\\^- C\/4T!'W9@>KDO%_9!T#(Z2)F
MEM&_DS6=61;WGA$TS(]%S0YNK*>#4HMP=-OX\3-I[UTB5808$5P_\/5K-6K^
M" SG:C3+*@!5^^EMS/FZD;%^WV)"K9V9A:4B /F15'?Z 3H213,GI-),Q$]F
MP[<]XZ*\5NGO$D49+P$C4Z07(O5*PP+PX& _6IO?[<P?COKJCY=B-^T>#IYC
M 57-6]'@(-6NT.LY+BQ@SA^J,B[4:,RB\G/\^V1^V7<[$N\&F(?T1KQ?]48K
MR=OK691"),8,\=@3;&^?-D6U]ME7@,*_9??X%U=.X.T_]&:3;NPL.\D!O1_W
MJ#04-_\"D4<(""8^6N6Z418+R,5SE?Z//I3?4 JRDSZJ,.(EH)*_FB=/G. #
MMU?!3FH\,IM \PYQW^$$V!+MZZ8H!3>[]XR:V68+^GP$?;!1_*@=$X9:%.W>
M$[ZL8KX/:]H9",[;EOHZ@5>$C%>D7H51/@^^V2Z33O+D37R Z]M;>'NR!:NW
M_<HKUL0'W.L[_LX2MHP_[<;K\@KE$<P1+;PDBO=$\7GX*&4498\G:] D<Y.N
M=&DQ1A.5_/51 $OPP]'IWSZEC5M6Y^[,=/S94J*+SC+TR\2H[H-0+.#]3K/Z
MNET:0W+E3T&2@+KRQ8O@Q==2_F6.=S!"XTU:V0;HM!Y^E^_;#>G/WXT/_ZIX
M<%ER.V[A<!=8$ LO3V/I.$7JI;M+>J?N.#[RV3]ZLE5')G4'&#5:B,Y%8@&O
MC7'1[YC<>V[+E74)'FNZ1,4X;Q+@JN/<7<( T<6Y:.]7S9D0TAT.9TL)QT/Z
MV6_<OF'X4KWX4G8+BNULXTV1G<M$*+5P'T]'!(B1_5F6.6#.9DR 0['?")8.
M>.VUEB5K4B_#;(=:YDR NW5R]47LTSJ^C0=]I5Y$^UG4(X<3)-\_YDCD*9S-
M+I)\DT-. 5;0&4,ON3D,,'L1XG-!#K*!&6BID@PU>'D&XU=:&I)3S>+M?/*;
M-]RF/(KOGN7K5XT W<8"UH01L1=7:E=D!J>6HF:^.T/2U&@%0V1/\6IXM;=<
MH,1E4OQBN,Y9D0WA#9P[(*NZ%7OY\OD*,G*S]JV2HN.O&OP2"\BF\,[T>'YW
M'J6\!WL<VV.F=D!$#RHVA!?S%FXX1 /'M(K>B3!Z/Q#W6J=B*Y.\0GC=P!(+
MZ#X@WGJ"=N G7=@F=6A1+<AF^%CB:I31QNB^%#-'=:,G(72AU4:-:JES4!<I
M+G9LQO;*S^Q:9_>D R.(9+\FF^#GJU::WC":7#MR^*U5QZ])Q;S!'N^K5OV\
M1EH""PAN<1@\Q (Z6#+9CB8<)+_[CC2?;>*, OK;H"31H5U9L9=U"?)(9-_^
M=W/'@?7/U]S5.\L<OF\DA8L@;PW/+W([-.=$/G6*,/Q49.%BOZ;NQSQ RLT$
M8IXZ"2LF2QF<?CSRAY_F("/K+)CW9M!%.*-*_?U0-G30)180O7RK-BJ(F^5)
M:,X!Y_ECJ!&49[PL-JS5FM=<YW*ZA:5*1?N#\_K/N-A.UZPD@-?7;>L_1'9,
M"M,1^!HGV<2N?YPJ_R51;T"(?(A+T ]Y;=S$RMA%:H$\D/?N'VYEUN-,-U/\
MU]1X0(9N]]3R;W![^0&Y>+H3XK!7&DI/J;67VL4 Z?ZO17<BYG+\Q4 AUW>E
M"9"6-0G EV?>J79?'[*7*O;6R$@"<I'E03H3O"<9CW94&P2)O8M2'_O4<G<K
MM@-BTG5^<=V.B<U[8RTN59Y4V/W;P*"'+?IIII32OM):EE?S_R1YW?_N]%^L
MOOZ/;'&W9+G;0]4_ H$OD:<9\-GRU0FV>*[R_?OKBO.JO]@=&A60L8ZVD__.
M[D=%02;;SK0#E$'NI\'3"'FJZO(4\[X6QN5_;FRL$51A;L:S_<?RT__W M4_
MDZ4^VD5UHOI*Q; Z1O% F#5PYRS4/(D.WU'&]VJDS'9,KNU_; 7]*-J0XP.J
M+=2L;3%/<K'@H'G,\X Y%__9;;$M@Y6-"*X<V']H;"19/I-3-Q_3Q])LXJT$
M-Q-(P[#3OW+G?:_'2!4:@9-GNG@9(XL-GT]O/524L1[VTV7IGERMYLHWN_GO
M7_ZCTEGD6T.KP2@&]NABWMHYC?GG&FPC$GK94IYGPL5RP#_OX2^U_W/C[3^P
M([])A88>[]ENO*YOCE$#O4XW,NBGW+7P$\^$P2R\=3.HA'W;Q%/_E65Q<-('
M5&@[7_ZU:+F7/6$KQJ+:&"WG$OL%ZM+6.UZUF3?N[?]/%1XK&"AK3.<4=G1U
MYT0 /W_^3\@#;]'KC,4E"O[@_J6 RTSP?0]?=@(CG%>0DI]7_)ZA,D?IP<?\
M&$7<TR&;?WEU-XDDDZ.N-AF?CT+;>C;7WHR@O7W7<T>[ZJ]X.\G[NE_O10R3
M+E"G.?>+L6=N/*KBRK[])PSX/Y_"_S4!G%S>B(-"A9;N[&AFO0Y?M5=&[(D0
M&"4=D7W4AI"Y&$S^&\TT@(S,CDT6.9T&KVHV%A?#,5FLGNJ*[S->EM]6 @TL
M3C?_W4/4Q6/+_OAZR]!L_C?@_/Q?D5Z,3INE2D)Z&_S<"E9<KX",KMF$/C>X
M>F,))"[YCSPB E=EO1<+D-XZ'_M'/JFMCMOR 7*TGY7!_'<F)P?X/_ZFJ3RW
M)]#]-D2^^O_#?,#>.',9&+USU?XJI[+>G:494L>UW+I(]8NK3M_OY!J6ZX4%
M.&EQY<#?7O[?]T4&AQZ8[A.)0,_P!"/X:/Y7/L--&X>3WE6(*IS\$V2O/BWO
MYOJBJ0L+R 3>U  G!F4ZG)/3\#V*3^7O+[%/0!L1UV[45&_P^GW^Y;9(UGK^
M+UE'W1!QR;]+)K4U+&@YCBBOP= -A;]+(B)X M=:WD%&J#&;?Q=H:,A]-DH9
M5#M?;<U@_JM@FYOK)W'\>3@6(*EWE/MWB9P<C>Q'T[]^W-7S[Y*BHIR^_Q_4
MVGYL%74OS1443?T79^P3/>*8HU4L(,L",\3L8WJTF_6UB*OTM^Q'B#3_^:G:
MX-A&]TU+Z#]/#8P04S?*&HF\]DTX$O)$049^^EEEY\1HTW+^V^.Y27C]&'3K
MQASHJ4(6+>:2<]V6B.O_-)&CC_X24G0S*43$*?,P<![E_D. *^0O =;E[QSZ
MFS9O1H0_$C)8_I)PGXOXIZ,XZ&^=%/[6*23B]F[:<.S?*HUA 7]T^I;CW_CH
MWR1F\_T?)%#S!8^5.BX!>9&P[I]):E3HA'__3^?C/\-[%B&/J+W)&5(N ]/D
M !(?;[JJ1CVD[G&5.L[_SNM\O_O.\03_'"EQ>^G/K"SG[(*7QRL\.-9)<;41
M%UATD: Y,Z)+$^]CCBXM,[2KG2',M2%9):;+LF:5;C\>%E0S"0H8Q5G@]3&$
M-^YD51K875@<;3 ;>5@/964+5YJ\*</<0;HMQTD:6*9/B^0\71M,(5MY)KI(
M]UG>:[JP0P5"LW5-DZ"*LJ^J&++C6]!+UG&WKFCC4-ITF:E@3KRU,J;C> )D
MXIY=W*9-/OU,]E.-50XSI#7>I):]$R_DI5MI[OWP1)%3[RT:)Q4PG9.;N<J@
M;V 7GAO"<3G"AJ=Q\NB;KW(/4+LA_G2)=V7_UWB1_ 4C;!0W8<EP/EB$]MYS
MAL(O<)?SR;8U"SU"%%O[?<[HLN/VTAU\-14K%V)@]I%(<-]YZQ(3L"[B"942
MG1C!-P6X#'E.Q0F(!NPAG]4W63TD/NYXOB'\JY2\+7TZ.G^O_)M#+8V>P&+;
M$GMP9S%&@>J6%+7)^L7PP/OY_>P@SP[/GWB+OI73WV\ AU[@]?#VFX>UC8$V
M#T7CV#X_>;&/KQRK.56UQ[RP=S_CJCH=M%*7R K* !CE5 I![VVF[L/S;:?U
M\OT.%X;+%29Q4B>R"0KK ^=>&*DR*K^^%=<1"+D?=&FHB@5D!Q=>79NBOF?1
M@8%*J)X,O!CHQKF R@9GPJ/.1EPO9@%5\$PWRR<_.F1H0+FPKX#)58F8N=R1
M%4F=53N"ZM8!9'[>\0J7%W1P8S=&*\],A]\>GE$GT(=;")+F7=Y'00DQY,B0
M2C@3FU;#_=!YOMW55-44 .E@=CII,W=A3RNY/MH0_BPRUZ9#[>>"+:CQR-#%
M9P#(F%4L=&OO/XA6(KW*&$QC;0S4ZW'/"X@!$1V62< X _>K&E7"[^2VZ&LL
MT++1<Q->W]_R>8S,[30AG894NT)K? M_6;?Z"EC..V<*2''AU!59-=;46K[9
M?QB>M1_JE'?U5$MOT$2\N@6=MNI(8T=#]CH+WOB6D4'^9:/^?OM95W263-6M
MXST%(>1"[[H:]\L,$0D\EJ_EIO#:\%8X+Y(YK5ABOX%P;?'BO+B=<Z<3TE::
MAKX K<ZH80&F3EC 4QGF\*NR BQ@]/G$-1; CYY8G>0I_*Q ^KLIQHM;.2^K
M[3X*"R#!D"+]RN#VG!KU]T.SW-Y3C=O7 1PL<&'V6PG&>B'7Y&##CH:KFNJ"
MR)7JA8-#S%PG_V"^&MVQN0S3U;\:.?]-$\'?6+ LY!]L\S<FT^T_R)NQHI&D
MY ESMN:YX,VX*8(%M*B""R.%<%&0WK<YBR8FAH80J^]1TR-!2:_.$,UV6$!'
MY!AH$U0.69G$ H@ )Q0"3E[C)96,W/&^P3H5U:HB*K65"IYL50'F>B[)9J51
M"3O=8-KH$U-&<&U'K<F#YO J4[(%<=_,41J]C*^!(5(+])R<.*/J^*-==YWD
M"7)^^) -8@'D&-%!E2<3W]@3XL%EVP!UXKN ?DFB;P5VX@[55(=;*7%+"K@]
MA 8"3C_)2OOHM\6=A]Z#5XRP@$^.[>(M)64U^MF/";& @MA#Z-IK"%$^<D3Y
MOD)G- W).Z5OE]I?MPU>-)[;9Y-5E@&!G,N:TCE-*SWBA='"4 I5.#_1_%7,
M$ML+S](:^>ZWZ7>NF441/+ZE_# VE:O(5=SD]TFYS7*+@VIRC@: DQ^"3N(3
M]\$TCASEK&\@&U^37OB]&?)<Z5&CW!;'#^7Y[OHU=?E )[W-@0K6XT_B#_D4
MWYGU:M)]!4>2)]6V&\)[U9.C=Y92*CW1=,)=UW-K*WT4O^"N-BR0_%L>%(C6
M*MF>]GN((@^LEIANC56R>C9#]K$-N =,F%V[*\$8<:(,4"?<?*K1*_2TDN=I
M)Y!_67]-EVW[%O01.AQ2C,Y:Y4M"7O2<J@#I-2R;X]E"? )[I=L5<+YQIGJ$
M^]VS$><,W1>&$"V9;EW49-RK4U)ME[:63<8O(+LEZ;PGPUP%QCW%>51L8]"2
M5;[57V3CX;PT+T']1OTN(9,\P9T?UPSH$E-:\+,1G7KBT]G%=I<JLZ?ETA_<
M^UBO7(PV_"V96="QJP?X\2_)^4^C4S/;?^B3HXGYKXYDF+_^TX;38\,"=%N5
M"_^1A^\:X6O(4<?]932K!$7!5NM!+.@47>1TI,,%<Z(;[^M3F*$L#3$NAXH#
MMQBK^:2O75^5BBFES0IS%0%&HZAZ.->#ONXK=;]^+;O_(WQ&^[UNS>C1-.FP
M_-F5)5"2PM,/M5\O]J)C-^TV3(.Q -(]'S=X8YFAYM2)G8=*3S -H?SX-^V-
MSQ\_]AY^X\N>.W:?9M*^UD[:\&-&@_+!+J954WLG&2:>]OH_NR4C-'X2;. L
M-U,DU,IFE] T3*?YEBQO)=?:\.[%K%1U9:_S+@DZQ_A52UT=BUMEN!49,;ZP
M(QYZ@ 58RG*>ZV7Y4 7:91&9HD-V$SS*MBD6)5ADG/ G)%K%*<976PKS**A5
MGA#EQG?!R'N^DB 7BZT?19B)?UE\!N)&K=P%.W:MW/-[M&C3\'-;W./3=Y??
M2<_#G6MQ6#/IO\3+BG5$Y")60I]!R%U9T"J2#XI,M\[<!7N87BUT10S23I0K
M]HGAOH\HUP96+G&+.; &)%EE<D5>C;$%<VZE(O@DP=,K!)0]FL\#?^\F3?/#
MGU;,BE[O[_LE=8$EX,*%43Z2F>RHX.MOGL6V$5;/*^T//V<E'HNQN\3XF[U+
MX7=>J=CKNC<=<<@?TI!<"(<RVV(!9-4J_?R\>Y^'"H?XEXG]%_R"]1E=<5D,
M3N95]6T6N4%5LAM7-V!W^ ;V&_8<#)1YGO7PTZR [3J?37N]J/+*+!.9@\>!
MK2?-G4U=DG"V5<W)_0W43LG(\GVQ $*:(2S @0+3XBYN?[T/'G8Y4.6P?[EB
M/E,QS!V246;34'7V0]]$0;+F*1V?ANP=3GK8FC>+ S ,+;8Z\(=;RV&[4S\N
M;TKHZ_4(L'Z@ 4+HJ$GP-A-]4N+GB6S=NS/FNP"B?/-8.M/K-C[B\,9XQ,E-
MR38ZX?ZGF\M_?9#U8W-_0NG)%D,LP+F5^[ UUD6%UG^WBV_SH"@;CR[HC"7F
M<1R&:"R5;N[DRNF)'(_DU+:"5 ECQFZHI5WF=VVHNL*DIIX8[.#./)COU_;T
M\,7AG@,[Q5-C 0Y%NK9>VPW)]Z7H"1W44[!"AVZ6E=ICYAV]#ZL<SNDX8^#C
M >;9@M^6108;N4F6EVVQ17E0)C3^!@\S5X1W:$9.0[A((V4ZX1W/$^B['+[-
M^Y5$N8\J"^7*.G.EYDF5K:-0"V;)3Z)^-YB1D6O-0XL6V\A.UD'DY>3ATFSH
MWJZ]HQ?$Y6G6:A9:P]+?J/Y$[3MFLWLYX:;?2K@9@P3[S"/ %G%>.8KTH3 R
MN\%K[N[59COU<1^1;X8K<@7&@FF7LVSO_)_N=0ILEMQZ)[&F^S[<C\1ZGC]X
M_T3USJ5ZS93KIL%O!V;(2=J=UTYWQIW;F;;$I(.4F+M?)>MGJT\,42E[T3-R
M@3*<KO%0?KGE&*#XPD+U?JD=XQC=V$<'2]E#I'CRKPWFDUZT%CQX(TINNA5%
M9JP*M4S,TXU_$E82NRK&2.8$:%N-<6AWV*@.I,<I)BD;2UQC^9;3)%:V+WT/
M\WJL:HGO>ATA.QT!G'^]$&%Y2B%A04' AE\!_<B&&ZOL[$&I2_'EZ 55SF/.
M8':'L$- +Y)3N,='%Z6S\JF)G'<Y<]GX9'# GJ1N).6SBL 9@-$[?48DVX=J
M]*!)S-%CE3CMLNS=(4>F85(=:]>@(&#8)2KF]4<;,8FYV\9O=BQN9C_R9G55
M\]<)ABGRAE7BB>KARPNX E&(]:U ,29RKR/3$(/APEQPIS[:^[M)]<$LCE12
M9WK-6*!>II-. $X-0:GIO0UI>M3&)TF#P@^/=">@9,Y?%N*RLJU _KEI*C'S
ML\?;C_7?A@W[;G'W_[7L]I^>#@W0LDCFTA::D*/(#-$C()\03ELU=N G1=NI
M3UNIKTY3;'^"26120V@>-DUT@,B_H7KB);40AFD#"T,O4T*HO_3$*:23F,_@
M YSN<',\RO@\+@7Y\3:0G#5&]D+#Q!RV0HQ.:?>3;)@H:YEP@YTG)B;;4(6E
M.6@'I >2_W(2\)H>B95\L6I'G,9$VY'Z?MZ-Z;D(I"HNJ4;=.9TET=<P8--Z
M8WP/+V:V%$"H>6M?C@,,[5@P5GF-KESE!>E,,I_N$^M2*AM_>9KR7'%DILQ;
M1U3EJ]']'SK /=/7$PX?R@X<$"'>6SYIUK,4EGZB=,P(*./4_)%%.C@2,1=[
M8 C^V%T3TV'5QKF3THNY$ZZ\<%LA#Y80Y?+JZ-M14Y8TB\2UYWEDZ_7YL%TX
MNM!C5;])F#HK>/?@44/3Y[S#^9XWJV%D3@I+/*^?;I*^>X$$OO"E9XN_P (N
M+1$DCI+#N'D0#Q8/2;>19I6$YGABYB)Y,G(#X- U*3A%?<9'POMMR:L96G&C
M 8KA7A[49R?"?5FMD6]4+?Q3DI9EZ!A$AQ]-S253E77(D>Z'Z)*!>!QW& *'
MQ[?XZ+*6V,Y\G/Z-WV'<"572VLJM5*UO=I$\(X]5IM0'E38+IYNMTBT'RQ]]
MI^JW"@&0',D1.&1^"'AZW/\=2KW##S\@W$YM4F0VU"?N^2XHDDDK/<<Z\Q7,
M!I\*C3JF0H$B'?F%)99D,Z9>_M85)E%P6 OJ!9"0:"9F[(;$[>8FD1!P>PF(
MX6_:)O5 "^=MD[TLN^<5?+WH%IZWK1LW.SG'2%>O39_.@$BD'V^)/\N .#MG
M[XC>&7^_^*X?V%LGR@JS<+++17?C3B\S3F!>6"LVCO$C,A2O=^X27%CP\GG8
MG1(SA\K)6GJ3Y;^UASBXD X^%O2ENPW*4#-X\!>PY=I14A:?U$;K?ZG2D/M(
M0:6A+3RDN#E/>EU0L_Z[C-5&EUI4\-Z8RX@!8%3;ZK)$;513;ZA%.J&7]E3<
M(\Q'B<WF]$Q$6B<SC9[KG9%%A<E2R]F@;[ ON_0VI*'U5V#J#T9NVG?4M*5/
MVEBT5&,4UY\C!QB+Q*L<Z,B[].)V3)AFKA_XJ-3]F,Z=_"[Y^!U+'W<PA6\=
M/2[R3<QKS[;OK8Q@)6D:CM ('S9?#_N:M1=253\/]/K8O2P8[\J.J,MSD6DM
M3KUIV4XXICK@5CM?7TGZR/P(69;5Q<N@G&QX.4#009QX^81>^EUQ^TC^QUZ8
MU>>(X6NNZ7M4-%8<3H"U!!GV6#T+-WI+,ZGN9TT*,+_,0W2"Z93]OH/E>+:6
MG<-$C<'SH<]J'X*-LLZ"O=UNVPYW/,73M6+E#NS*]"<K*+$QJ ZI+2SX5F#,
M.Y7WJ439W[^+D3F;N7H HS=C*(OV*.JGM,\\HG%V&1DY"\,"_$,P.]Z=]VTW
M3>Z-5^U]NDH>$BDY>;]07[&OGWI[WF@R;IP+TV^A.'$Y+J!QGJK#O<E$;TPN
MKTD "H/2CC;=*_5Y/N/&^[YW;-O]1P_<GD>?+H0,3,_([8_/&.\I3#V5F$5P
MS;;I9",R([CIU8F;.NRQ5+M.!.%M"XHZS?9I)G<$)-Q,JX&Y;V V34EU ?DW
MD,&..QE3F7IT$($%().6^3*RP0[SR!?N&WNUR9NS<DM50(%-\8K3;JT$F$(H
MK8K @JDM<0DW16V/1M C\:3>I9$6YV7_G]M> 72B4M90$;3P:K1*%S-SR\\I
M*[O(,C[+\/?FR:YF3G1GK,4;HQ''$;A3&8%?V9&=M<.9=+6^*X)R1E>"G@4W
M%I+-M AM;0+/LQK45\NX!NZ !%,A\#9"$Z54B<I 6G]P=%0MR+!&[+>E[V.4
MQ$[$3K.=HT<*^!P>5E:G;L,Q=0]>L,?(2FB3) 2,*%L&7Q44O\6[BMIRMA'?
MC] >IGO/=+Y-^L95B5B!]8X(@Q$S+.K>N5ZJ#WM=PFO(/; X/.;J_OD\0 WS
MTXKMW!\"TR;D)5?.B>"ZJ_T94FX0\]?"ENB^<4[$8Z8;U!W3?B_]D%K%[X40
M $:X29BW92J"WM!#K40V<;BMJLRFO43N-1;.?6^W] X<I'JR/SO\T4D*SQOB
M_R8-OA%*'VXE[L,>_U'M%Q=.SOP?4,W <%EX"!6<\2/>NMAO]"X96"4UP&],
M_/4NK'R2\\>(+4R:#2,RWD0,-R_F#*NV.>!(>EL3HJ!.WU ANG%+%N,LPR(7
M%Q2D,>2,5[,B#?ZV-#'XF0\B?K0 +%. WP ,\,$C9JM<.\OU@$>&'^);M)]Y
M[2T+2I5^1?)W[#WM868,[;KF;6J>XC_A'8\:UI9O#,-ABP=?D-T1S2;_P%AD
M)JO5Q_;9&GIWXFTSVACE_0HYE?S-V2/;CIMH?O RBB-<7>$;2;."QDR^MR^
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M*?/^^-L:Q0_9P<1*@MF]7];,8)^]KYE&]%!:<FG&:+=BV0_!&[4+KF%W5#Z
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MA.*,'13O.U36UYK%8$1&( )33=$1RSLI^,Z^;&GR6KN'$K8[&W%M AN^2%G
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M8W:O4I$[^<<U/]RXTHZ0ZT9FM-K2.J@2F7TC7>ZU,\Z7+M3N*1QH'?9IZL
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M(Y&NEY,B&=.73@H62:#V\_6%8Q*M=T6OG^: D0V"-MVI$]QG.GYT1J<'/#4
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MBZ23>2.%GIY+[ZVB4)_A(SYF6<8/:B!(V!P(MDO9#U]G;C<.%1WEZVYV/[^
M+[)?S3975Z1<WYN%++9(GY]'P0!Q,NN;2^:VA@KH"E3%Q>RNXS:G1/N":F^/
M'NK#NWAQJ'37F $#AJ1FH5#TPP,64$US-*4FQ ;"])1(I.O&318&I(96W]T2
M0*S-0*>X53"@V:=!J ^\S_9#.B9E3K<W&&70!KHP MFDM80!$!2JV1GP';)E
M\\%2,?;QZ$WPE=*/[ NBX[06NSG(+V2_D/U"]@O9+V2_D/U"]@O9+V3_7&2Q
M5'_6^<>:<#\:KA/C-YV.:5^NS*5'"N'K!U95@O#L%W"1Z3=.+WX7F?)7*T@M
M#+NN*V_S4+W1#ME^2/IL5/U!7\K#\BPPIR3A67WW!GK>4J1%&Z8LW(Y\<!MN
MZI'QYV<,HI#LRI<5ZMR9V"ZVS: 6[?-MAK3X?_HZ^]]#,C(_[_:O1<DI+D"Z
M/L. L_[F:$!40-FT/:+&7H28_ .XH!G;BYM,&^)T/9&)*/[?L.>$0!)-4/Z
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M ?ZG$NCC9AL$?PT&/''C(5!ZV?Z?667^=Q,36?/E20JTMOHX-^\OOZ:BBU+
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M2^RO&X/D6AG::&^Y.NQ$Z2,>'TE]I;,J"J5^]'F-$L604.VF%V=,V0OX1DP
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M@>$4;46TK$N3-K4F\F3+%SLJ/@['YYUM --UBNN&R9$FI-66)V \H1\M$E6
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MSE$Z%+?0">K-!_H$SY# +]XOWB_>+]X_C9>JEGU+JWEPAV@%>03EAK3R%,&
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M"A<4!2WQK'ERSL* ^YVUU=FSAE"')K*Y?$$+0TEY_0RC&0T=<R+$A=X9B_@
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MB?P>"T4KY1)*.-5$ZHJT;SOQZ2HHG\&^0[7E]LIKN.X7"=]O95ADZP!4"QQ
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M?]BDCVN\WQCR5&Z\/)_FGL X!T/D$,Y$5++449L=B)ST-@YSM\964PUK0_M
MN-D77P6.ROVQ0L(N\X@QR_6#'-3<T66%&9I=9;(<D,X<7L2 7? C)\5U@N%:
MNLV3%\:<TLSZH>M%BNG3V0^O:,XX>F<UPU7F#_**M2<G:9S:'MI;#,0M^[B\
M-3/Q48WV.K)\SW819-7UV)8DDL\[.^A";,$TE'*_;_NJ)B;!'!\.?9*O@ 8K
M>)]\9R"U8!<3(FVZO]8:_ZH[6>U,A9"!C0S7 "N']J @F4&ZFX4OT[/[1%;2
M?NT'MHT(ZF"0<E@Z,TG.,8.XVVZ@P+.3E*D'XUV&-P#QNDC^#C2V%SD],(9?
M%A!O(.GVP@/*@T6>SDQU^-]QE;[KCW* =) E3.^Y_05Z,VBGT-Y_>YG7AUSO
M<]MMDA,:OE1'4#64^=E\;%65(X36)<=M:.O?=3CCN@$\VB*GK!='VP&[A]=$
MA%1N7>6Q^O!EQ"-"!<"Y/:=%%=+O)O ML;JS<32[GP9I:RLUXYLG0_8I'Q8B
MJ2$VVLTE[66 B/8JE!4R0)%.>DX/5<X-P%RJ..MH_H'61C+//C",>X'X59'6
M*(CR97/H,-"^$V]A3FB_8(X;$;\ [A[Y0L/\#(50?Q=H#Q:M%$S'2Y/Y$?>-
M6;-;21QOW/AW?V/QM[_5>#07&5M/\QQ%CDFE!TH70T"W5)7!-:+96>YPPO>)
M+_+<[@[9P*D[SW"MM5^$JQY;Y5)!SS6DHXO"Y]$]NX?;>NE[\9L'-P"]=SK;
MCM&O[",0Q6LZA-5>*\4*?62?N2^7KU*6![(2?IN93?]U9G8DOD.-MST+];H4
MSU2V!"HTT&F.DM16>2<,ONJOO/VOW+7VMXKB[+XISV7H59Z%WRY28.U7#LJ<
MN^'^L&64_X<CIV=O]\J[$#:+A.?*[=!\_6>0=ZK_)5+BW.._L(Z8_HA 132(
M+H,M(S/CR_V_D^OTKM]_^^YPT@UQY4-[@;7*N"2G@A3CN0$<'](B/^@EZ]:%
MN:W<)CWU8HFGUMY:3Z;-+U("K<!F'\^QRQX'U)4 PP]R=H6$)M$GQT&8Y_OY
MI1E9XN=-+U$S73$; QVWY$"70M.:]7X]YOIE'?2/?$>-YDJ;  8.19(?5!*2
MY*R@VY:1@<=@WSJPR3YG\]0G9F-FX5DHTWU? XX]V$"F2W&+[(O!!HXI<T0(
M5>24]':7%X?31Q![T)+#+$1M*%YB^)@Q@8KEGM\CM)V.UZ,$/ CGRD)W1T>F
M2LMO\4Y&=1&#:^,!;UQYTY)#R&0GD_?W8YOX*AK=:HX_52S.]??5C7[\.//$
MI3#ECK8<ZC<IZKUF[5!EB*FC47B\94K][G2*Q=ZC*]U%[7QU>!7BF @ZZU1N
MS?O,/S5=;/]MXT+.<KCDF&EYD%A,J U8J$H 17$/3D;S8-SW)&*U^DBRN8^G
M+<:I\I2<I2Y9MM;_ =WSC^SB9-HH67*V\QB..>4#P7H,PU83KQ (#B[MLY[\
MJ/!<5.X5Y;.>UN%-90M:W0;M+FPJF4@HC22%@<U]$SEG>UL71)2.S.EKY)O$
MDCGMR\GCU#<DJZL0O:;-0B9WZX"&)Q9"%&?%]HX<A$?\=7+,O58H*"%X*$7V
MFA5S!$,>5/NU+?'J$<[<+:$#MJM?H>_S#6SG29'<K:RMC<3,Q9,= 45U7VOM
M1&,Z+B<&EG2.^#X<5WSA?LA**_N]K:W3?M5*4-YM-8_+8FHX)N9KXM+@R0T@
M9"K2#"FTYY1-]YP?S-$XR+=:T<!RIG<#:$>2#EM=">6Z#/:L,N1[DY%B?09:
M8O4WN(_"DU0T7>951UE8]=A>O75F4B6O*L0D:6]XOG==/.E0_W9U;IX7QZ:[
M4=@^O#E[LS0H.'B<ZB2PTC-LM_T&@,$%?.!"SRU=O!-6X $/P[=16Z:V K@]
MOAUI2*[!FOM8+1 YV6]@MH2#B"IED?X'9+SKDHV9'CT%D)KB ):V\<(<!5>&
M$/J(*J4??&@)K_:%JA?:[=,W8_%]Y'6Q5S0NM@7>)NZ-)((Y:_5M&"(4.D\%
MGP\LAK9'O4@M= E"2&J4MO-"QSJ%.30BAO.O4&LCSUSB=\SK-I[7/Q[>;C^0
MU''J<UDM6=)_"CF9?SO&G9\0[+5OS% YBF&Z7PR^3C'UP^34YN@C=:UZ;6W#
M>3"NEE.E%.546]$F8=XCAJ5W)KDH.Q]05E^'-@4=FY\2FJQ[@YV8&%9-NJ\+
MZJBWF)IO>:$'!(-KD]6B/Y$K83N"5/0<"UVV6B^ 08ZU<JS:R23Z%9UJ=QZG
M)T_VHPY7U4Y/U\L<R/9LQ5E9F?"ZFEB6%*9*V'TRX4F;B).C'A:*/O.\NP6[
M5WBTI3G2%SD,L5-X9:=A@#2L0VWSPAJM(\@1>9-;Q\Q4XAKPQC+$%$],#N'H
M2?AR^%BV]AGM/+:,*L^HJI9?-BQ?!SU4YL2]JVF*.JD'6Y W/U/"877VR+C;
M0HD!H;8W@)31>W<#T <.5VO%C^\LMF_RYTLO^RQ2?5X)6?ATX:O=+S!DNV-*
M8&H_"3+SN&X4N?6[=C< =E4!FKWL%B3[WLLQ)D?T=_FNEL4D+R>B'K<Z=L@<
M,LMJC3G&A,+E)%:/TSI#^E<JUHKHIR1J\]8))-:D1VG+HOT(6V=X1AVX^W/D
MN3Y1,7)!^A.+!AS/I/=.-?>\4G,V:TXCK&MPGE!VDWC;:40TX0V8"PF66(<[
M\_DG-DY6&OU !XDO[50.?MW2<\T[.VS3FDW0LB!>Z:W8/DTG%)[KL.)@3&IJ
M9V][;3,<]2FO7JO">Y/&Y.FZ?@ 0#0[$/3OI 9?& $M>4VF7;OL)^^>0'3"D
M=!2Z36&2*.R-U7GW]I?)>"]G6+!57Z2LZ&F;[#]M)_:,G)R&G,K>Q<PCP1 ^
MZB(J<EM=73Q8E4W(74Y>%*M>B0[F!-J9J[3(R;!82_W@555WVA37?WW%!MPW
M6;PUV=,;@-9Y/)S90ZYX0B.81/#MR=S@W7LXW:(&QXL5K4J.AFDIRO1]KWX@
M'\"Z9!4NCA+.@Q3";@ '2L8W@&*Z&T"AC3IQ]$FTXTDAWP%$-C338T(;8G!,
ME*XX6@R'I)1O@NUU!\I9XSBM+!_[<KG3;M=G7FCP(IC#TY"T*#< --GLJY)*
M9'327K#>R)78=Z(K*E>^-F<,.Y&OB02!AW[Z.L:( %V76-V&DDO,U1)W6U-O
M@4 :&C8^6]W=YFO4;WI4)3'SX&19.2>"Y[SXZVW5#Q=B$XWM=<I:+OF8I8\;
M_((\A@>WKE#VOIZQMN-L$A<5FS.^62SY\ CS&56DR YJIFT*.6@YM>,V*&&_
M :S+Z2)\K^XEX^PSGOEJ[UL2#$VW;J FT,YBCD:VGAP5,YYE+FJSXKG,069Y
M*Z?$GDQWL%X=34=JN!LC/RE:.9X7>_*0R=)I+*E-T3]1NQSZ:GN,RGTT'UR
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MUS^6]/DVSGSX\_C6?_SXUK\N&/._L=XP@_Y?UIO<,U^D,!BV ].J-K\!D-O
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M?QG=UBG^>#:Z5+MYR-6,C8=%3N$/EV]Y_3:@AO\V;*:M\^K;1]X WJ<K(H]
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MG/#!M),O\V:[,%8F)^)2ZHCHF<M?ONQ6@+AQQP"#YGSCEC&Y8T#4_74Y7I0
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M5W;S\3C/U//1IFA".ZW&:)AB E)+5I6KIE9K>BYX'@61$\16!!S41+X7>L#
M T8B-W)\5P26[]M]!8;1!2T$BJN+M[#$&UXD#KN>#'G(7)#=3!"!74>2,+0Y
MX:9OQRZ(6VX4]?7:;HE,AZ"@@'XE]FB1@4Q0/O ]VK>_1WMS]RBBB%J1  75
M!H'9I1$EE((2:H:V;T84Q%W66UK\=UHD%)3]0]C\XM4=23XMI#@ UINAF:JV
M9&6G^.I1'A?M$Z7P'%W0"3[9%+7^(!D,#$1 B?X=*6 W3U.8!Q2MY-]2?,DK
MV6']FN\?@RP.W\KT_*;E/$_"P:@EA0W*LAUQ'^@]\/T0U$!B6R82D# ,(J^O
M '=+PC$2(D$] ?0]FHC];)=.DHJFSX4CWTJ1[MD-H7D 4#DY3\24IEV,DVE"
M/R4/H/8LX9)E/H$@'8:^8" LA8PZQ#5#$*D]X1 >AW[@1E*$LK>RTY-JN1N6
M\%#[+P^/OKU(@NW3V);2"XEG4HE6.A#5?3,FW/9!/Z>"6B'O&Y I<!J= B==
M8L"C0I;M]YL"DD.)3%U\A>N8':,AGG)E)GH_ZSY96@6\B+;IHYM4Q/NQ!7-S
M;('ZL:0.CT!ACVQ@W%00"HR<Q'% '=.UG8CV5N(?),5^B!:Q(R2S39?0R U
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M<GO+IS8A?5@;$X5N$L4^ _3,/M/BNZP^3C/Q ,[8AY&/[2".;<3<P&8"Y./
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M2!^45I=+1D++-$G@44\*T&:YT]MJ'BNR?9IFR.K"ODX!&VFI$EOWRLG#EB*
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M?)K*<UJ(!W:JWLY5ND9*B"1E'*[ MP5(";Z$>Z"F "G!\:EM.;9T^4/=@_V
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MMZ,/KPP\-G@;IA*2PUFEY:^OB+>(MMET3$1>D?J-5[^Y;K1M-_C3[.L)BS'
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M06J\TWU5'SKK:)P( :RW)W'63YL.7W>E&\[B5GU_ZX6M/*U;]C'L'?M:J[Z
M#/.#&8.*<&X8JQ^C#M7&F0TUS@HTC/QG.9$8-G<"2I,\ 97N@A;B),WS[["R
MDWD@TOIKQ'.[U36J50C)475"L5;%XZ9))M=7&_FZM[L_^F1\.3C>,P[W?A\=
M?MC_\KOQ\>#P3_B3?#HX^ ,_'QV/CO>48:*%!OI0%&<E@#_DA:G9-TB%DF1
MF?NBS'0,K\].\OBD2,KOY4D3:_ T2/+M\^?1X3^,@X_&X?[1'T?&Z.CH - &
M37-_[A__U3CX=FB\_W:T_V7O:$"06R#(^6T1Y*FDPZ=&A!L5E9[E(+Z\ ^@_
M CY\\8>'X$O/$@(W*E*/#H^-_9>%H;U0V7J,JIL^G][@K-IX @)45NWXVR%6
M7[L+F'8M8O4PW9'-C7EA'@Z.]T&+,ZSMYX_7K0P.FQ^?6/>0O']<T&[J#@XR
M](WP9@UTX1G1A='+(PQ4:>8G,>557I0GUF/0AT.8T?BH9QQHQ(VPY[H#D7A&
M1.+]2R,2%CN99H4L\_1<"K1TQ_$)QEC>S=K]X^3B6SNY<823JPBF!<_Z0#O6
MG5WD#;3C^="._=V71CL2?L)G3!9U.8W98]"+W>Z$ XT8:,2+HA'V2R,1]LFD
MR">X0/DHXL37=K:!-MQ,&_R!-CP?VN"\--K@G*3RE*9((;B4N*9'(1&?<%+C
MZWS2@5(,E.)%40KWI5$*]P3V*T]*&LMJ=B*2$JM/3(O'$2D^PT/C2$UM?)A/
M/5"-YTXU[@?Q?C\)P OKO/;\HQ8V!2<_5]#"\P;)'PPT&B*->H:SO>6H_4;:
M00Q?$,.]ER:&GW@GNJ0A9LB<S$OGEB>Z*LNC2..Z/!Q675A5;4Y7A]G[US2I
M9EOP1JKJ$W2*,!B?L>Y^H<LF[&/5[,+X.BWX&2UUU2?]VTZ!A4'0OUG0#P:Z
M]'SHDO_BZ)(/Q*B4Q;D4CQ+A5,\U$(:!,+PHPA"\.,(0G,Q;ZI3*<#A5Q9$>
M1U*YTLSG0[L )7Z,.LT+/K:=.W;S3.BV6O@.$)MIJEN''$RDGGP026Y!><*!
M\CPCRO/R@J\#>O(OK.*68$.H<WD"R(Q?I/7GQZ! _[<SOR(F_W<^?]>588Q8
M/FTK;V, ]T!@;D[N,(?(JF=$8<(71V#"D[;;U[TJE/PX79G+*D?S%DU(7XZF
MDTFJ/M-B9GR@%1T(R4!(7A8AB5X<(8E.=/'8\B3)E)@">A(]+>3C$91=/3\V
M^D(R\J$[O_$GUKP=Z<ZB5'51S)J/6&,7?S G2'.I9J \-U,>>S#//"?*\_*4
MI(B>U V+2T5Y5"BH>*S(KMUZ:D5#OK93#Y1CH!POC'*\N+35DXB=Y-A*%&06
MW4;ED:RZ!ZI_Z?Y\TCM2BYLA].X$Y"G =J P/S>%>7')K2<1[T2:8[0++7!E
M&/L" )>=_'-:/ ;!F6LT&/"BUX#-,W -QM^F15**I&Z;K;ID?RWD.?P22!36
MM!W<1;<E-_WV%PVQZOTD&?TYB2%6_7GBYE.#Y(_&J@_!ZCU#VM[RU'YC[2#
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M1F%H='HCJ93<G7"4D-$S@]IF(^0W"7L+%40:&TBG.&V3EH"/SY/:F+[.D#4
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MP#8Y#)M?U]U$%DY\,:),;:4!82S<*RDL[C2>ILWL:S:IV_XI8S#:BX$V*4L
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MD\1I7S(\3"4L]$>P9O==KWHD/L!F/.47YX9X!^.SN*1C1H2B:</X'M#FN2%
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M&P3R>""+_> 1+':WT,5P]^TO0ABA'#V\SD !Y!=9-'$G[0B?=.F"Z'6)KGW
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M50GL?Q&/\AP.G-%!ZXE@.EW;B&E'HHP&9.K)42=V?<WDQJ.D)&<5X%2'[1)
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MOFHED2!<S+6W OTBBCTS:2XO^>6@'9M#6?% 5MKP$:PT3A9B+7%=-&YW)C5
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MAWN'WW-#336NLZ+ZF&0L+:F)QSS1GM2TJFKNTN'8WKOJH/.J@[T#7!57R>F
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M1*LD+D5-#48!5\\G<F'<OZX0_7.*GK[N'C'H8%_4_(C7<<EM[]@NIQ?T9#!
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M P_ Q"X"-2E-^2%U?B'@IGWQGW$\Q<Q&^_SM*:UD_DM%_]Z-'"C5N /N:+*
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M'V9];:YY.ZU:[$6#@= 7\?'J]KGF^RNM69C6"768Y9Q K,C #Z&MD\:[P(V
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M 1%S2M98/KJFLQ5MJ.@J+6N54V#^CF*1CLW^,',)Q?B,' JT$SB-+%$E,CM
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ME&JL$17U3'0N\ZSW]5,*&KP%?^>K4[B'OX,P1:@*<QLF2(07Q%(T#7/1+93
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MVZB.A);%B?8!_D<7L<+/.Y%G.Q;,TJ=9Y>K^[IKLE[)@[$4?H#G-!:ZET%^
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MU<6'A9&\83U2*>U(TB+'"8C!*8NGOK639G$RDX.UH[%?EV0(US=5V66IX.J
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MBKH);#0RL*^^_ECNBR_,\AWL^[_PV#]1LP.+54AU?*_!C6XZBGYST[2 PNP
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MAB1$:#,2Z*:>)^B,NJE/AM W9^:'D+%"[5'<(#$T;DM!I?DT,;JR4!=#H4E
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M?@9Y][YO3+@=IJ_UYB;]@=^@O#,2\C$)NC[!;/_*M%"EGQ#:3_BVZ(XOA)Y
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M.6,ZVV8$T^'W(Z6E@SDY)"N_I*?\]+Y-@I_TM/'[:XZA-C=1](L92R7+=&4
MH]'8.:'<Z*[<2J[J0AR,RVV2IB@'UW$A%V<P&48ZJ(3$CK]8DF%3%!,_7!XB
MU%UX0:(80!'G_!:A.:H<D=#'[D07G_<DS7TB(&<R8^B&0U *[R7,C:I:4\[C
M5@2'_(C3CV+_'SWR"PK6:CI>?M1G&HE6@[]:73PGY!!]/&;&!]\5->EYO2++
M1N#\[)0#(+F4BI$38%>B4DXD0UR&SYB/8$'*)'Q52@+5)(_<\1*!TS0(4$H7
M "TTO64$<]\T%>,LD/F.O!NK8E[:N3CZ69*0DDSY/_KY-?T42Y <O,@$[]]3
MPI,NE&@J4DT._0%5NC>HTH<'5.D!5?IO43*&-]P*F33@3*,N]H'YC#"0SH61
M\1B<+<NB!?*,XDB&D!','\(RIQ"?83L%S0PZ-+H;]IB#W:661#+*]+,0)U,Z
M<DA2HEUW,5P>GB-C^8?(L>O/D?WUH\[)I^@4&!?C(99>\!D*PU!(OD<Q//R;
M+L$X157HA--8>\%BYL0D]C1I/&CV$26(/'M7$Y=U6$8A_ [#?10_(=F*_(-2
M$:7PQENC-Z\ *]\UD=D;_L,R3+2/JKEA*"I4L(S<2*$E ?5(-7FHBI' >K1[
M6J"8^532QH%GM/BMKTA7,&//YCW5 "Q?1\+"VF)%X";ZSY]>7G9#Z(NY<@.8
M#I"1XC+S0U1(6V&LQ0Q4F47KDE1(_I/,",? X=MA;HJK9=7=<$IQQ *EEP>*
MD<L*Z.I_Q6HECA=&?R7NO#!:2[>=K<V^)JQJ7\_@<"K6ITN@;M)6%A-^4LV0
M[W<^Q3(T'SN%1F-*=$JTD]!2$(.FXLQV$@[E7QC5X$0O+*=57%IVE1*=XD<6
MA!1V-EBQJ+*B3F1%82.$*8X%L?'87DV[O+01K)O.*-IDU71>E$L_5'A6)67D
M-:6X%F@)U>;*K9XJLF:F,&JY<,^&UT*=S31'X0Y72])HCZ9%=9D=KQ3%;@O@
M;0E" !4=TDJXKD&I:-<0=%@D8Z<"%BLJ[/%1P"&U,W(DRL%YW[3#;BC3)M]>
MC)97(ATP$$&-T:^H+.DB!4<POT9Y7>A&%J/E2^<M)?45C8!%<)K]PMU_\CZW
MO#_<<N!SQ"Z=>@D^.B_\P8A]1K9E$R*W-=)YVFE/@UU@'P0;8BIV.X5^0:/G
M6F7]CIB<K%R.1]7QI(?IM)(Z&14+52.2L@JL].K;A-GH#-OL#EPO+C@A<2OV
MS5V6Y;WH;267'!Z"&E?S.>GRI*(Y)7V<I]FO^&+DG"1WCF<6>0A1YBJ"151B
M($K-7G<_[(XU9:?1KJ)M>_;=7]) <[!I)R/*L%3;S1-LSY.P]5;=#P3:(&W)
MT4:.>XMLQ.._?*Z=_>CT\3?AQ/KNVT??GWW]^-'CLV_B<U<U#?T$CW_/\U(,
M]-W9V;<6!+E9Y9L\?/!@>-7/8[F2I27X9B>*.I3*3!VR7/I0/#-9['HS"(D:
MO6(Y!"6->LO;X7D8XTB*(6,D>5BG^[5.%]P7<%>T*ATH(MBQ?>A$(?PLBPKK
M2M1P6-<#ZHG41!\6V6&1L3%<]%VT4M)WI\H]*FF[ _!AS@1]GO,7HG$$9T6C
MQ BQ"4@:^&)L<%B+A[5( S6^R;+Z9\^=F00QJ-D1Q7KBQ<HQO(I),ZH8.I[O
M^;]BIO&)JVH<5M=>KZZJ_H<G]-*5$P.1675;,<E]"P;@)9F_8DG)C=,=:^@+
M (P>T!5_*+KB[>GK4Q<M.)C4_J:"WC" Z<4YM[FC*2LKKJXH^3#-_.8Y'5R7
M*'I^:X&5A\^M8:')C?V-N4?0]LZ\T>%>P6LY$:^"4H3H\)E-03.1O):K.@U#
M \1'Z?)Q7OV*.H^O;T##K<,2$)C>,-)&;6AL2%J!"KFJ@=%8R!>!7G.\WL'8
ML/9&;(J+1)S<CA+N7C?^-XZ+TU]8&_UW/$3LC!Z.&8WE[<KUA6BW+\,]N.$W
M5_I+>5/"*E,$.[EE3@0'K*M6\=^,M!U$(;##"$=.&2JB+Y>9)=/74NQX*<DZ
MV?%P?C(],1L$ Z#%*ZWV C9DH/+*<0QJ*[F 0";GC]+7UP1G-B9)T.LE=!D*
M-H8>[RI<LEHOF2^,/>K:*0SGXS'O?G]*E"H4G)P7[<(R)%$'28=2 X6!=%VB
M,QD4K=P&78]@%P'V:)# D_^@W!U^2'=0#76!?=Y*:8+-8^E+6_=M4+L[]T8J
MGZBP7^!I]CCG?G[_W,4,?/;P3&0/!2R>X'DM!06:NO -%I1E"^JH%(:+SHBS
M@1V?H=%ULN71;<D)LSWJ9?O@HNA#"$ :MWTK3Q6S^ZKFN.,11OOD5%5=GJ<_
M4%F7V ZJPK:EE8[FIG-$>/U93\]G<[1AI +$ ^TLFI35SI[N&+/A\CW@6A\P
M>;0CMJ:47(^DL ED6P#^QH$>7LSQM D5^M=X_<J8P"W:'PDON-]3C4*^KC6R
M9$FHF V94U.?:).BYCV]'T>@JZ:A45L9D2.#++P154LR6=W&EPTX'\;-W\?:
M@LM\94=Q;D4_LYE'ZD8Y/+I-VR>$(N-!'6L3*A\)@";68'E7S&*>A7.1WUO:
M79)KXXEJ[> /1)W-,'-K]NZVP1S[/T@/,L04PHJ^%LD,?L!_\4$$,J[++I:-
M;,J,;-^<@:957^ +[)X[!$-_:##DD0!6V&63]ZQOFW6PH&3[]KFUCF*C9R\9
M=D[-_B6!898 &'BL-6-*9*.F<Q=<8\)[:$\Y'TE.C *,&8Q=4E%BOLERZQ4B
M 17FK(9Q\KP0AJ@QR8 ;VT#WPO>OT+>?O?50=KF?]JJ$L_"N)*4-Z?SU_(_A
M6<O9#7O7UWTU+X2/.H5S(QQQ$V4"-:HDQ^@PFF(_NQU:H_T/48[6.\MDE(#Z
MW#7M.P:L2S 3C/F&_HCGO2)O]%'^S8,'TNS>90-IG?1UY<&4HB<JMK&_+%=7
MX6S2X]_&VQ9W*-1$J9%P0\@F/'J0U44$;:^1!4W0-N&;Z7T'=SG@J?]8//79
M 4_]!^.I]^/L$"R0T][R^-BQ49\^?P4'UV4P7$OGD2]A!8M[J"-)F@1PZ=A
MS$T^);4Y;ZIN 7!GQ:1,D%.@Q"AU4,MY9B"\ _)FOTLP7DS8$1*",7$R84A!
MD38#V]])=<%X&J&B1UC9B"-TW;SDT@0'Y:<F1,B_Q!M>0FAV9G1DY*P<BM"'
M-4H#'8K1"$/.(''M$QQ'%V_.CS-'L)Y=Z)??,!SRA6M#>8W GG[TXO5QS%@+
M?85Y?4-?[VWJWT45H5%./7CT81+KVOAYA ,4&GO<<R/*, ;?N-IROG7R[B;N
M*YVQK""$NNEMF37KB@\8RBD64&FD?$Q=)GV*Y>:&6C^I_Y":\DNOP<RCYO3U
M-9(Z?'@ S-UN(['S[@<][-W#WL7YPL>"TI<7\_)_^H+EF1"':I?#TBMC1<BR
MM9],$-5P;6.(Y32JF.!L-5W2MGQ8DX<U.3A/AL9^9V1?[$JII.?.R_-P[@CO
M(%<,.BT9%$ITY,IWR4IVF9DYT=\ML7CC,66XZ$BPC0ZL)H',^,W@2MHC?6#;
M'^@ZH+:#P_8X; ]LCQA!QOC1)'8= ;?DTB8VST?[3),T_-*5QYTYUJ'G>WLV
M4+C CZMVSL4_ !PVKBO0U6"-C7AWEQ\W($ D#UCN.7KK#GOBL"?@QEA+4Q%6
MX,86+C%\F8F%-4X=XF"7%2RCK+?S>"!0*4_([^1ZX?QX0M<Y++O#LD,K0!3_
MTASC;JL;^6;C:M*PCH!0%.N5[6S0<DM\$:AAWU2Q#.3:W3^$L_W"*JR'.O+O
M4D>^='E!2?/M;\783P9KR2@<R*5,8U'6-_5GLYMR15B3;9ZD3J6#FF&52576
M:1#+):FX^KZ:,>_C("<+J6 CO7>DKLI+84A1G%X?CJ"Y&*H2P/;9< *&J>!(
M%;]N^EJT!X7B0_D18JMT8L  &5*/,<^>G;X]9>(8=2*7Q"6AA)*)*F_X%M6I
M<61)&=<)#$V./!_('-DP4A_4!UXL^FUP6CJZ3==&V+B+5%;JXLV72&1],*%_
MK$1-FL[:7_/Y8E#_?!8^:E;5+#MORR([>@8":]&G49K"^Y 4V7K9A_LV[5T1
M3.>+6;GD'3K/?JG*V0T1]&[**MB*B5KL#*3URZW(L(L_!#B.D.H88'%7PN?H
M)8UWQ*R<O6FRY@HL+>$>+\\%!^C!_/1<S\YSA] ENT/&D2U)^#JY;,RM ,7L
M!4-L(SG0#VQF'68I'9Q],W<0<O49G[T\!T)1+KW18C;3#B60\RCWL /I\NQ<
MR@&5"M2O^DT/6#[X6H:C8;"1'[A]R&)@9N[M[Z?9ZPIYX]ZA]7E@54MB;9L>
MSW%5,IO2IKIJYML3!C$;8V>VH/)DY/6='$+.BV)SP\D"&9<RD,Z%BW*>4>%C
MC]'N;W;-7R3+5K@:TZG[>EW8$KH.=7-?4/5),K'"!1=<GFH^PG,].S_-+ONV
MZZ%4TRCA$;;CLXOC8 RRQV???G7VX,&CW#BI1-<NIHTF[(&D17G%,[Z<Z5Z!
MA//H7.9_R<>ENMNJ^-A-B=G985?$\9J<78(J,M%:/6=O$V2HS/<^?BK:^[>4
MVIJ?;$1<>N+1CZK3\C1'7D*_EI,R8D$*0#/R1O7']$H!I3\IZ[ H2^Z44<#>
M<50(&]C:!GQ #.PF-+:T5!$JG05MI38CREU<>E3*U? :?G[QWWEV_N+I:_0X
MS4AII2[#VIF7DDRAJX4X'?YO>.IY55P%:T7/WV^:DXJH54O'#"M_F&^[A?6=
MTJ>L^ZB2K1]X$<U:[%321/3A9R4X][;<> !H>B;,/S0=_! Z3,.:VQA,E$V:
MXJJZ;FYYDN2K5I\>/EP'%B<93\3P+[1MBJ?4+6E?6__P5"GUO&L\W%\C^G;R
M*-IYC".>L"H]O<67MM4N/7OGS_V*_*6NS(XN?GYY>9QU97L;29(=\C86_:5K
M@D;4*7"@$X1MK+CFKD@5">IH>=S@GA-[G\H#Y4VQ7!B"^J6P1M+8:'%PW:J4
M/AF&\28X791Q5^SX@5[02/S,56!]PJ@(Q;);YMVL:+4U52VMA 4U!779JP(I
MUV!(HHQ)<R)@;A?+.I1UY+1N.D9EDWA49ZK<1;;H6^Q.&:_&@?2L9 G(+!#<
M_*(YB;=/Y\.3,'+?$KFJ@N40#8.SAP]"^+GM6*-Z5E9K.6+YU$Q$M]![-&<:
MUV;V+DQALX8F=V2O1&^ *S"VIM" TR5\'%Y,<*[YXZH3](J<]>8D1E\6]&:
M@0,0[C3+W'R IB[Q/74Y$$\3*.#-0;AD.>_S"!5_!;927]0QU61</>PSJ[M*
MIZ:LU_R^[,=H";-N'!27F6(0ISVQKY'R;;!LW03F)KY16ZOZ!NER96UZRQ,N
MD&*!0,U+W]&?R@8.?JWT@55P7&:,Q@]O%"L/>B.X/KM>.RO6 G<?#\"IB,BU
MZ4P V:\NP&\?3ZV_S8Z'MC?C)J&&4-IMF2=+C_HDT:9;&"W>=<N)I-BJ\OES
M&0?,_B?&[']]P.P?.-#_G16DY7^<*#6Z;\E&%IV0C<[30Q=1U;#;"LR@=!*
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MY,:24#ILP\_+C(&L!!G53=59UY[Y[!_E4\,U#SXM_707L)]Z.K)K.AB0S_W
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MQ<\O+]&24<0O"W=%G+RP<F:DBQ@9$7H(Y+;N+8)0:=)"=E+(-52N\)&.@P&
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MD3..Y[KDA<L0? !E8.>6Y?S:\+J=3 KM? 5;R,2&GRJ0 DV_\>W@BK1.J@U
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MO\ WPV4KA)YV/W::YEQX\?R+_JKI"% A%T9^M69 Z1&?['6Q!O$DK?8(L&8
M 'N_[)00RR0<<M?6VX2->](L3B@_8Q?IP"&O<]=DCQ]0?#[C,,A\X@(3DTAG
M/?R>E <69&6" 8!I0SH)WW2N$L\F3P]MO+"\*_P=8.%@?K!IY^S:<_XD>5I6
M9F'(J#-4430GSIWYI4V_495VNS%8P!GKF.(ELDO2AGGZ1-+V4!H/8<J\A.H9
M#96A$(2@HX;P^WO. 34%@UL')2X0>&@V1GI4,"7E@%T% [7&E4;[@HGV;=3
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M5-I_;L.B,F]45E$PZ<:,>T.!OSHT:F(*=MTT:IZB G E>J=KT);K$AS!]%^
M87[\)0<-M:1:VM=E]O QJ\['CL+7_9K0=]D%89AI_U)K'A:M/4WFY"C)Z+44
MF)N)N>[%4$P]6$66S#HW>98JXECI)*NRH5"=,R%T#3''CL*%.B6#+5 S3)P5
M/"]L-2_D!9P&DUA))6GZT=I^R;W94<#U[#N>C3S\N.Q@+;(?Z?^$<7<]RS/:
MFU?6!P;,5W+ %J;R4M:DB<EG 4N7#3M1F88KNKA<_$4VP\Y7[63?-:$.E,O^
MV'!\HCG*V;DR-ATDM>EPIQ!FE++*H.#)E3=SS/G8-Y]\#?H?<3;!!,\3P6(=
M46@T>HL)E5AT#Q%VT;+DB3 K-2]7M$IB0>\?I<90=P69NYCYDS? 8!S(]GH,
M*5MW&R^^S,=)6(EU20.E5W]5M&TEOEU\+\,'N>\-V=#Y$/QR=,(.8,M/.]^/
M'AS EE\,N>:?TKN8/*^31#MQ)/77%#(^_!9GU-GXC-*P';K(BZ42+:DRM/7?
MG9UE1_C2JW,"@).[2!UL'(5,1>Y0X9K3"7U#IH\+-]6\DKC:DZ0(7]?]9UHX
M?<XOSOW1%1E;*/Z R"BDU/E("P/E8\SJ+9UW#N9-#16WI3D%PV#)(D@]-(*/
M$59!S4@,W E2*3&#%CQB^-#:QAM#80K,WB-U$4)8BM77S8RD2I$?L?9G[IY&
MK.?"N%$X%-XR?*+@$G2(H(R08^JL-^G36,@PYS.\AXM=OJ>DZKC\J+<,;AAU
M)$+]#O&*^X&F\48)0R<;QYXFKSQ?+T%/<AAG""6+V<YGV>-0(MG7FT%<(3&$
M9>JN4@X[\3,)K9/)0DES?U.)VUL$A;2PT'88TWJ^.Y4Z#F%SSAX\?)A'GUD7
M5=C\!?Q'O/5^?AV6_ 65PYNE;ZP1-VP>,3\=LZ;-1PE%'>H<&VO#6WU\92%E
MB>(DR %5FN [^PM?TQHQ;<=;#PLG/(5X=[#Q'WY-4Y5G<YYN,FQ$R\+U5JO<
MH#W5+N;8X0::@= #*K003O\TZ#2]D/]JKI3)BG9(<%#)$0__4RIM+=O LP=?
M!_->7'7XH0?#^ U>3/+_D;@*,B /'^Z*9=PY<;X*)HXJYZ]"S!^FX)*L;SPH
M'HZ.AX$%CIR*T7&GC 'GLK)9L<X57$*<H>'-AE5(V$IFD*#OQDJUG [_C[UW
M;7+C.+9%_PKBA..&%-$S)BG;VX][=\20(B5NBQ*#E(_.OE]V-(#"H,5&-]R/
M&<*__E2NS*S*ZL=P2%$R)?076R2!1G=U5E8^5JZ5.$S4*S,NJA!/A/])G[R)
M^*/410@Z1DQ"Q_BO,J@57W92%WWT!Z@&FF*=5CC09F:>/C%5*FM66NGU&2;L
MDZX$$8B=7W0F,^8T*_H\Y0IA42C&0FJ6-> Y^_(J4X8(W?8[&2VFY5)P#F]D
M?1$"8K[/S\%FO7-"KRWD=J+'G3(;;^DWZB-#;.*+4'E'0QAMH'[QAK:.J*L'
M5,9RS4PUO;ET!<[D2:9J 17)UX;$4E5R3,<79YP =])B-FGG[2(P(8A$2;<>
M93N$-?\*O?M!CBDX E//S11'9>^IR]\R^!/SW(-OHGQ-C (\B'$4T7.Z!@9N
M7:,.,3Z2U(#HDJE>!&(GQ?/,.6;N-#+7)2TEBJ%J.^1$Z749$]=7TA 8I+]#
MW/*W?U0+92>-!L2C6FAV.2ESY$F34DJ[:8@7Z(2JL_8_*L9'ZDZQA7URBM*5
MD?)YT<A6B2\C[+)]WB8'8NMNA'' '@U%!2BE1'+2[=O.=?FFVW5K['I,123S
MN7R:PD("KEG<B@"_ Y]ZY  6&CSV(=:]2PM(QYDLH(L+4(@ZQVV5.&S!1(6A
MH:))B0"OE8+]JDMB#OA2D#?_5^]= )^3L_$L>50TW\;EOTR3D)>AR_[$S--+
MR!*.629(.66A>DF=@W!XF9@I+X@S#;#K80,*'I%X/TB$FEX'[CFJS0UOT'_O
MM3MVK+CVE\P\+ *\+QWY(*65E*EC6ONO>_^JS+SPUU^__MPL!9ZS<7O19T;D
M0 OOPY%&$,9?^QW"7:J7;.#PA3YMXED!;Q7^?#J6Z1MC2Y$7SV=%AW9A*B,5
M>A>)2TS+?"%V91<(_@QG:^OQ(@/$EW)^^&<&L+ C.A)"6I+^*,>O3$4C#S X
MI22[GMY8GQ6?"WD)7]]?-C1H%5>^<18J3T"9"S-9D$DL=&&C':Q5'$B?;J1F
MR@B#_!$K/NILS[&T<-1@ULR]W11D@?E;2IX#\WLN#\!E669<)L%PL(CB"&OQ
M?D1J,/:F92=I>@UR"ES*$B,B<IIZX)CS(URE?_RL\$NM/&[:7AWR  7Y\7LO
M(M<2'J_J48,:SI'6RY\ZP\F-8/QT2E'S57FAM<)Q] =-$6TB#NX<$O2V<1*:
M+^A@#2**^LC./A%IRT)KEC/($B66( AIKTF6+OD(?"WM90"4,#HEB=.N:#=R
M$?(G7URNO@L%JD?L8[[(\"0$FNU1-,*K*1A$ E]<-/X/-!M@.M03)0Y>1[43
M 1,K)CBI\00/DGP\'!G>%DTN$G^ D;6Q_#%5(9$='>[/]O2)\]W@IY17/ 5D
MA7#KCBFKD6>?.Y&"L_]NT]7DUE'4F_+\S]RZX<3G#_:M&#<NTU7LE3F/)4P*
M2E?<3X;I..[[R+@6=:=-OUK:V:*:(DODB"0"&YN?NDBR NY06V"14NSB('72
M>BD4=Y>+5"ZE+.1,)-EA'%+ZOF[WKE,I"'D$O2>_/"7B>V'BDS!_6-P:%,P"
M<[M_D"_=AD_2_]#UG T;HNE#A$(K-YKK48">N/OQ49]T_U1=FI*U"Y(^I?C3
M^KW'^6E_\25I4:!^_)VYV3_;F_U6AQ4B2,)?][5PZ+,/-,1N2)2 6]CQ? 37
M,_S!GN\ZD:Z^1FCXE0[X/?/;S:$3M^.Z)'J(6B1Y^I8T'?EI4*NX\&;_BI^&
M34B=E;@($F0,#+K)DN4A%B7/5SG00 KDGN^)3F]:.=#9$M9S&UDZ^2X&"WJY
M^F%/Y%_#=<:FE@FF&QJ *T\!"H +$7Q&[5#.%-#@JE<+^7U\8[3)=KI6M/M#
ME[OE<MXDR)+="ZMQ8!1$SACAT60X&+1(. RS8;]LHTFBO03YIQ8Z<%6CT#^9
M8&9!%@WJTQ!]P^W< BW9 &W+DC%KVF"Z=N'%<@LV+3_ 9XBZ<R\ ER1+T:V<
M<7F/,B5(>.1@S[8/&H7@&166QV&)(6P5P4%?OC%=CD'@1V.7/ =D\,-&KYFK
M5N$M!U(&06:9U\@\H^MB*VO+: LNYFP=B<$0\]$M)C,G7Y'TRK&?A)&HB8XP
MU&D+]<UCV,_<N*R(TK#3I6' 8D.LV3BJZ2CNC/-,HG.?(FQ]W'"$==H5DG:#
MA!U2DX@H:$YX&3)A)HKN 8[^VI\R$/TV<R5 J<2BJAGV'-.=#P\&7;Y\6Q]-
M29J?-1-0* G4 %'E0P(:VY)XAS;[44NQPYSC8^&9?P-:H&<[*_*TNBF:6NI(
MRAVZ4OD@U:;(JT574<=)X*%ZI-:!6L-RG=(6-H%^10R$-+KN/F2ETUX/P>>Y
M+,6C)6L:OZ1&B''5ZM=ZHGAFJM$1.7^6Z%G3['E-AU$&*2L&J'744.:2/&&:
MMD4\R@FY4[>L=+;/_^7#-Y[,9WYIA4NUT,3^.OP[L9+349$\DL]'#X><L=0Q
M!P;@3JZ6R2D%;MBM'6$W\,/4<^/WG8Y.AN;18#[SQ[X1T3?_/O")9%[Q8RT?
M^!C>8\&>5\:A9U;3T;8K*+A\^?C+4*'U:[1 O\X&^O5P@7XMT*^?8D$R!,E5
MU=7FU-5=_;:H!GPGBBE6KX:"*_IV? ":0T_)I'U<N]O!B2&TOI$"?^ICA<>:
M1BZI7YD7)<7L2/\B+] 'GI90SX664"H\LY.6:=3_27D?.(:/5><!"S8*P%&+
M@W^"Y!8=+X7_O O:OEP@][[\@V*K%2LF^+7@LJ=)S] 7HX.G\@=3=[GZ@9O6
M,K8?>0V$RMMJ!-JE'1-O?-!B?\!8^9(H_'H3A9=#OB]&SF1)GS6IOIQOED#=
M%3O!S<-8;[O@#@5UQ,PTU*?JW*!RY7UM.BR!&L.<.@^<A@]^)<EG,:^VTZJ8
M#CJJ7D$.;*3P>E"11%FD0]C*D:A?U?UJ2T-NG>AK*#T-5\4(5 12+XG!IX U
M5+S8.FHC#JA7I"TAR^+O*LRIBO]ZQT7-X"8:!+0FJY3I4!%/II4_P-AD7%MN
M<-!%U+!@!C"B:Q6'[*"N]K$FW@9*OBZJ8'-I;'C7R83>X/4+@))KTJQ (JB"
M\]U53^RV&>V6?/PB!-(%VX.8BD6U<M&^'8(I1Q<);2\M@!H10^F.Q(9 T?YU
M/AE:J#//@#I3A_+)*XG>&;=>BB[1Z?G;0K6ZV(O_20JP$T:%J.G@S\@P*KB8
MRV(N=*, 4/LX$#SGTK .2O$2[2VVLM@*W2A%T1?!LX 18K&,Q3+\3U:N0(N=
M$L"FD RS0EW.T%;FY4)[^Y_?A;'\F+5CB$5R\C0/09DQ9 ,B@6NRSS (,LY5
M"N(Q(M31!<N6:4F%=G%Y4@YEH1) _5'KM+V=-@/L0DA=VTT!ZIEBDT56&;WF
MQ8!?!IS.>J1(8F/2[S"$AKL-M4<A)]7"@MX$+M;VA-(H)+N_1L]NLW''+E)G
M6DCL?'9'V(D5D:^WG+2=.#W&/-5]:BGR)%+LC-,-3"3*'<:^DH)-"3@1*"5D
MVF%3'_%W^8% .;&J0,\OXNVW&-/PP;U_T;F@(;E[Z(_E6%19&6H_(D2)5,;^
MY[4VL]D7CB_0>F<CJ"1OE%)+HMD[GJ:Y8\5P^U)/IE_8%\A!!D-2Q+31'_&W
MB=[*3-DE,K5B!2;J,LQAH45B>E&Z5\ZX;#')E1C@>MW),D R6'HTNSY^P<29
M[&Y+76 SM&/(&:O:_TX!,!%F%$X"IIR]ZAR]HK"LL;%G=UV!D(]"U9X.ML,7
MLJ=CJ3=R(L\G?B]3L"5-.5BZ31)BZ8< OYU0<")EXD9. [8P2: .WB48_+#V
MR[E UP;4;LXDYD"V24$R3ZX[6;R;E=H##Q!*M5(0!!U]!M V>4SNQQ(^OBP%
MY^UOSE2:])&C/-+\FM\)BKOET?Y1A5+*LERFO+\GWJ%G5&USCADH0ZV)2C$<
M$NH;O0?A6</.&..ZW@(_;6G)6#YJ$Z;&?,*[A:N4HZA5#)M:M\%%N[LK=/$X
MNL\AD1[=V]KQ$$G> NO)<Q0\PVE6$(#8]_T55;:@'XH'J0L06-Q K,T+TK*^
M<"ITW7;]EEGD8H,O4A<QT$4K^EQ!T!Y$FA+@W)^MLJLCH2V])A0RKX6,(N7=
MNXOSC,!VDP4-AM[8NY'?VV'NL9A@J)")E'<=3NH1,QN@C#H%R6Z0J&?B# TT
MWG7$#-_(_42,4>PAT P.^Z_1NN@I7I[.^#!\E09V!J7LC?EIWU"H)4N.;O=@
MT2M]8U,G%<X3OL8=74D?S^T=W>P-6>$MB0C)Z<28ZQ/O0OSG@+^.T=P!F:W[
MWN[G-MR]#M/6%7B6.R<# D$?H1K<%T/9PZ@OU%6(X_\U!UO\.'8BB1UWVB4T
M"QI&"'4C<H1)<PU\.^1KBV.7:@F%Y";QA_Y \P$$.K]^HZD?,H  BO7,'#\O
M@Y(:,&'^!N?AQ'-DVMP</R%=)8PPZ%W;10O+Q:$GK==H*))-PJ^&MY:HTT1#
M:U%CG:KS+WAL1<*>+NYX=@XY2 AW\4W3]T+/LO!Q2-#C&)(0M:<6PFUJ,8/T
MIMI.CN? -TL 8B'VH/K&G*Q/TRZ'CY<^A:BG8((I-Y5"V%KRBME= F-.G\0=
M8T(*Z+V54"[AO^5.VS!99O,319ZS(-B)FAT;;:ZI5Y3OL=5=KKZ#E3S]Q^#>
M<P1'B;#8KG@KBUW?5G:"7:],$98_" N>Q]G&B1([:$!Z8@<=C"".Q:@2EFIW
MT<@83@'[]>'<+;S"Z.8Y.8S"4=@#+DCCV%$ /LPEL2<>V,A]/3ZK<P,/'1M'
M/&]@46'P,.:VM-3YL3AKAH57SN<GCN?^V>GTHI^H,F-W[BDF,&]H<K,<((')
MZIIUT2$,5"(";\47,%7.&C!8+7].+IS!9:=,,&+C(>QE5@@,Y\:#2 [#P4UC
M8BOE/^<*!N]JI?D.;.-C"NM8*1%0>1L$L50])OCFUHXL=1VI;9$),HC"8BBL
M6)T_2P1D.#&Z I8)IU._3!2SAG(*#39SZ=)ATI%YJ]^Y(CSUO/6>X]8G5=C3
MB.WK:L%.GPUV^M&"G5ZPTS\).SW@KR-?PW,BI0:R)M0(05N1SG5PW#H>I 5M
M'45U5[;@QD64T;@FG23^I+ LP@X9C%;%AC7!V50^>D_18F'*G[F2,B*NF0%0
MJ8M0Z+;+;VK..L8!;\C/&@36AU#S&6?Y4JG70B=\>]V:3,ROUF93HTY6BEK.
M1&TG$G]-))O"NZ8!V#:*TXYE3I17JQHT.'A8R)EJ ,C/<A*UY$5@;BN=%R6)
MOC..PH8\5SPE4%1:WQYM-+-G<A53@*TH*!4Q@J)5K0R-9=^9Q=!R>! S+R9#
M,"R9_G<VO<06A7+D7ZZ^LC]T-TJ7A^@Y.DHGWOD)?2"#;38J^*;!V]BXASE!
M&(<PPH=&Z\GT@$"*-U/),Q4K*E,R&VX0RHL16-C,&E*U2FT)1&7CD.#>@N=A
MC*K-I.NAC@TT-3VN&W5MB;32VPT\5H+"E6)K2*?LZ+?H.BE0-XZ6([72I;?T
MIF--Q*WC -I00%#7#H%J!.^:%'2PZM(@+"HF'[F@(M;%G<QWXP(&LP8&]<08
MN\]6,VT=B-Q5Z?(M4SQR<F%BWZ3>,"RO" S92&_I*4&%$'-;=FV#5WZ^"Y91
MM$K$V5?C3B[KX[Q7,S>Z\O9]>K?TU<0/X^D#N]2HDC&S,\9GT.I6QXY&\FIN
MNXS9_S:G9V:'Z@_'LCXY,3&NU6URL&[$^;#S/?FO<+X&GJ O'BI1T"W5OXD?
MJJL['I?^XT/OL\KR F5KI\N*XXC_9,IUH'$R8J] (LSQS"H>)C,5[ '[;!;+
MXLK[P9Z)N;NBRU/B7"MXQ;0N'!G:\70^2467/)=Y%8)]( )G%3F*./Q[4SD0
M;1GP=R%2X^CRZ%_4_@Z;V'<%=JBD']:3\:9HI6$2"((JT7UG?J);A"K5&^FY
MB9]?LP84*SJ.ANS/.&R]ZC#T"J,0B\)_<S,D:.OPA"U(PR#69O4*Z/6_<2<U
M#1$Z]F$*U(?;.F/%[1(XH%LG.GT;I?@4+6J'@Y1RS'SSAD99T0=_]#?,LZ!S
M3)J%%+JTN0\,O76OZZJ78AX5_93A3.84VACDM<3_Q4%>"'&("-.'9>W%&N5$
M AI0 ,'%'"IM0I!)!H/]/_"G>=RM%*H*9E/>X-#,+<F:M^>\VY\DEHTS:R+^
M (LD4X<&<AQ6Q>?QBS+2ZA+'2]N*WY9H2[<LUAA;W(LR\F_Y&'Z6;\C&BG,^
M:^6TJ3>;_GBB[?.7[,]__N.J]9Z)BNO.<41-A0R:)"":4'^$_=G?$M'D^4-O
M]=@'MNZ&*N;^:'C<%.TZKWS2]H0\6]U4!0W>@2_P6Q^]'X08\@_1F2#I%>;'
M1W_(_O3@3S._CJ,U7\>[>/@?#U9?YXUW':L?,.>^>EW[Q&;UVB_B,ZI>42)D
M[X0R/<HTF.UTP+Q9:A\DLAL27$C;#?CG;"7,[I&\&(HPOY+]LWB)#WCL)]*H
M+BI"2N*0.FMW<>NXSEPW%&-"7I!JT5^Z,K_E8AS_@U"-O\B)ROSAGRY7WR%7
M5MRF(8;%]N:PIZPW?,D9'Y.M7OO Q*T>/GJ033N;O_SAP8.X(3^A7?+O-(Z?
MZV%'_9TS\@O?(,O#W(6C,^&,@XAG8$6C%%Q47<SH@O2P(C];.5PWJK^E[-J;
M,B](;,'O;^'VIA,8'1Q*:HD;-0Z@3&;.!MJ2YM#*JC:^C<O5*Z"IRX!ZA7YS
M%J89[/W*'5+#;%[$I&^#;"R59=V.6G<J']"52D';,ODL?3L(Q$L-R!81E(]
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M=31R9K\PZ1:&[!1SX__"/3.>9&X3[0[P<ZHY7=!HF1E+;70<049C :Z-]66
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MLD+A/."U,9,Q?&[(8L1!FODOW#%*(\PCT%Y561##'YCR)VP24I7!;4O#-,&
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M,(W$(V;HB>2)BP./::8[,Z-&'?TMMF^W9T*0UG^OW9U&-9>YU:-I72N."L]
M!S5<AF5F8,H.9>?(P.X4AB#S+47;. =5LBA*_GJ'T(<!5"F91P!\-BF5)$,"
M@4I(9^&(^*\MXHN#Z+"/;0D]1UW.D]" &!CL)"T)<"KID%06?DQGO!I\3&7=
M-W5SK.$+C[W_+VB!4ARBE!8&4QL$Z@)TH"S\C6]ISY^O[Q2U:;?+2>!IWB*_
M>^N7G4,O,L"2#R AD^+Y0'G1HWWLWE(8W3I#/56$VCOG3 0H<O,;@LWY"+EQ
M,L4RO\TB)+A4XF=XI):C2"VLBA6'*X5M5-+^-B57VDJ7JV=\\F8FT&4K(:_"
MGI&89US$'.,Y^#=U 6YU3J]U%0T6"A>3/+&<)X'/!\NW"$^=R8S?GY89OU]X
MQN\WYK"I+$',D!C8A=LA/@2G&&*B23#:BNJ\. )C'\[1$(WX(H^/SO\HT]7U
MABL #.#8^,WK[\@?HG2PL@.3K]C"O?PC"V+OG11@_9-W/!='HH$-Z\CR<#0S
M:M$_;E';1-PF8=SP]%'/*K^+F&>-4@&SI6@(:4-&JGR,(D:X\,:MIXX,_R,R
MJN=_O#C0F>3OB>A2KJJ3K!?'DU*GX9. <SA^?K,VLLSI+/X^;PYCZ4/_VD#.
M(BI%9C0;%( 8RI93=OCV=5![=14"*D+7%C8O3;6,[LQ%F:AM\.$[<M+[),F_
MDE+$4G#Y@,=^5;1O$HEO3+\1-XW?XZ=L!#R<E+^>GO']E2SH8C8?I4[W \?:
MJ3@KSP=JU+YW8;YOUFC,J"3L+<C7 P]!OQ!KVW+43()D,>.NY3WZFN5<DT'/
MX9#G.RA=AN;OWI^42(;I_6':^87VCW @+N<F2TZ4;(J$,9NA;TE/G\#P-#JS
MW/:,4^3O(C]-&#"-0ZN)D0[JM/*:YO2RLCN&<=1DAD/&[[2?D2AXGO 8&"(S
MRU*FI#=H7@72@O' ;[ 1;_VU]?ES0IY%E2B!CMI3@\\>O6$R?HZ*MD;P,V/*
MI1*<I0-^-><7C&=![*5D4OH=@GDHL?*SY@T(&M"90B&-VFK$#.2WT+^X!+FK
M-WV;#"='QF5Y_=.,S</GI"<;,ZZ1IP'5*0+J]R>#%FCL0@A]/V(4?<G,CI2T
MA.V^B/XTKF8H-\\+.LZ=4(+-2\C?Q^H4]FJ96KALW*@H8%N[X\&32 B=3;H8
M2A*G.\I<J[4+$K^O2Q/Y_FAT);2!#>ME.TGK)T<]]7W]0>1M5=R(%*%Y$.50
M=[,'9/QAS7WG'DZ;Z7+VWJ^;GA 0,P>'_@[2HXDAWLO5ZSV2)-RQ*"S,S9W?
MS]_1.MS/@X'=&;S7+IPT4V&"[1,HFZ%VT1O'] OOON?DMHS=IMR)8Q-'+$/W
M(Q5?XY;N")PD/@'WXPB4D4>^77I51,!Y0,+.)+GQY(3->0,"^47;TD%^JGL^
M'=_YQNY#OZB'XEW+G]GU!Z&&894T  AMD"2!P,3R)P;^/FB1):S]Z&'MDGG^
M>C//)U.;GF!E5-Z[[O8G$QL73"2$%(!'UBN_A4+_NN_\3G"9>C@U3!\AE 41
M;AHI<@E_#0#J2.HM&ZY<!F)+CO#D6I>K9\+C3P<NBK1P*#2  DXV$QJDS+XI
M"57T4OD@'F?<U5K.Y'SU^)LKC1O%R^BDR[;I[6'K,Y[JNE4_,G!#<[XG^NOH
MACZ(%S6S?C1>*X0D^@U%J"G!T*_"M_PJ@^NPJ?S;0:CD-U3<0C@S*/0FG,"!
M[)=S2W,,\28BL0_9572%HJ+:/58X[+H[-@6BC2V'PDFEAVU=-C)ST9IW/067
MA OPV_@T2F!G=W"77I5R<!\*D7,97")NSYQA)<Y2$>^+EK=!M57&^,@UOW4'
M;Y(=,\J-6 GE0/?;]=J)#O/PI\_70E].1BA4QV[8F[:).S5O6\/M=B\<O%O7
M KW;YCO7R7%!LEOY!A$[&;'_R+'@-R<<+=<TS@KD%D,$YZS._Q5K50^-YAGI
MG;S-Z27;JN<^IP3):;UT_2. 3N,G69^$]1@"-6 &CKV\7$H,CV2K$,'\-T\S
MCED/!6Z<'LM?@1N#U?98%[%0H3 O>A!2ECWVI;0@G]LAR*'T2A#MP3KSYN$X
M-U\=Z+CPE^/3T6>VQ-X1[WA7YK><E>-"]$JNO0O?$JRY=24C&#*&>ZYK)6:&
M+^<,S)9;-OZPHE[EY>IJ5?4 Q]$* A%7Q.1_7=1A^O@4 578G22\YF 4)H=N
M7;?.-V\$?4WB<C;ID!<C(D;^1M\@>%!+HEA;.J=B:$!&0YS:^P(*1P) CQ+H
MHK74T1"YX#!$#>@Q&-#1] U]4E!%$W=IV<-3R]=QP"I/U5U,?(+-WQ1;E[%2
ME9SC^DHY&>R90)'.6B@"3)0_[H2O#Z11_/;- [6K)$91[SWL)M1O6^BT2(1P
MXXT7IY.VJC6!Y0@NN7?RM[&E#5@>_6P>040G887?UHF.%TL7P;-S<8,[Q1,A
M#C>:50N+OL?@OK6_G9II;#8BPC1H(W]X!'/&1X .-"3BPFHXC<WF_7N5&D$F
M]2XY\C7T5]1#$7GR$1D.%#D)H&@9\L]Y]4U7Y8Z8RA9QGN^FB?(H--S5/0=(
M7/KQ#I)V#IRH>E!3]4I'3MZ1<Q3=QTP81,-I,E\@K]8BUJU:\*<H7 6Q;?HM
M\EV%AGLTO!V"C]_733PU]);6KKNEJ&!;X%PB/=#0@.%9G</4R)4<1OX0=#Y,
M:?7@M;&"$<8+<757>QLB:43Y-:F8TX:J&2BLOZNG;XP1R/MN]_RMT%VJY3"[
M]L95&3&5P2\&<J,M[;6>%?H$DCV,_B&Z4!QS](!>:AD6!#12;%PPF6>"R?R/
M!9.Y8#)_$@76=,D;8/FRE4/)OVKN@;=]<\WMNR8GB*$*O)$H6,V27Z?(A!7Y
MX.DJ/)'$K!_#D<HH]"+P^[SDP;*FOX["+WYM&%O8$M,<)T*MS2XLD)-[! ;?
M-8<Y2#K9.6D\M <%BX;#B'Z;0F[O7;=4]D/_()&_83?,\3?W#N5\H%:\_"=W
M)CL<#OA_\M5H'Z0NG@H[/C*0')@:H7P'82B7#HI01X*F;R9S,SHGQ.*FV42$
MJ&6IUA*K$T$%#9[PZZG&Q2)I*FK>(Q)'H89#_] 6;2<<!6%.)2P@'IT/^E39
M>QY'8AJKTZ_N?"/0F1<WE0[\E#=U=X3YSO>S>E&WW2R+WMJ'1-5D]L*U_N D
M@'B>'!Y/Q^:EK3K=)%PW=XCIA2?)1J5(!%51 F75^H#7\0#,BI -L7HO!= S
MMLHIT5>TYT4#C=KTIB1B:FB&')1K$U%MQ+_])Z^^LTJ9*0/ISM9J3MP#:EL6
M /H!HIDJZPAM#/^NN& =^<Z8:E=*[7"NYOI!GT%(2K-P.2UXD]YUSQ,' C[S
MJ;1(<2?"<<]W4S^@&YDG#U&7277-,W!0,WNI3)%E_.GIQY[M1T]" R:3.A1P
MW'8 )^%C=*+RI66JFC5'7/JO>":R>P$;TE2"MQ17X&5N<A(''=X>TUK<)DP4
M9[RQ7M2-JZ%4.D1-Q:8I+ >2X?Y+]ZP6"O*.Q/:">(]05'*Y6!QU23HT6S'M
M"?\I9HY& LT+(]4N>.//=0>&CM]_C@XQF6WT^]9R9+P74,16)2-Z)FAKA8J7
M7O4=#"7P&;%\FO2U3=D4JU=KX]LH'D:*E #^LB0DW+3&F#WO;P35081!#]M9
M5)Z/%6O14\29'I[.E'0P*&/.U[JS+^HT:)2_8SUVZ+1+<7"'\2@3NND36-7O
ML ($>'T+Q7M;#@J(*EM[UD+7T!=.>R!Y.# !ACN+Y?[[K**65&>4W:!.J7.T
M@Z$C_1C=-Q?+49?:U$=N&!O]XY!7\><,YT^XVS#)2];$OQ=^X5B7%#FWID&A
M\ID?Q+Y#MY.Z?AEMPQDBX+L&LV(:/J4>IZA,-(^D2&[5/G#I\NW QNY_BPHJ
MS@QQ 1T6U6FX/_():J,%(W7F&*DON1<UDVG(3")M4L1T?/Q1C4$Z:7DET9#X
M<^GL%C$7WTJPPH06])T?7>UM>PM 82/?'K+@W(T;A5N@B#+%'Y]O /2#T,&^
M)95AK,QV]KW>X>._FT+,CCHWU\![(H+.)%FHI-I$C65MT'/7'3,JP0/&EKLM
MTJ.?G&!LZ83?[-VVIU@>E'($KN4;'-Z8-% D)I?*$[50' H_1#O6HO<0&QNR
M.+'XM6C*G3?KXX>=O$6++!GG;)C"8?-'P9:L.3(5U9/MZ(7Q=K' 5&IC;&W_
MDBA6U4/)O^<1U@NR!,9V4>W2^9!3,,PSAENG6*K%!!<3!/5M=5*87@S,$(6I
M?55#T810>1RT4*AYTPYRP=BD6D?X(C+>3L##@3%?0DX*.=!42E,P;OI'N$.X
M"?/;BTTO-IVZU71\,)U7:@E_*J62QMT4_K+KVJ<H[>JSYZ\>MY\#W =XB[?2
MIYTWY)98%#%,0?2!_A<6187%YK3-XTV&:!ZYH^\]G'3JR(J&QD-\ VW/HL,*
MU!5SRJA(?10:?)HJI(G:BD<'0L&2!R)&V #R@:3FX *%4X1 4R7(]";8$7,.
M1CY]V^2W\A-%D]2/PH\NAKX8.OC*!!](<>EH  >PO<52%DN!I80.%P5GU,I4
M8:2 Z \V@]BSJ8]'KJA+$V5Q/(LY!7/BX2/M<]$)&IMCPK%75X(;M].!.LS4
M*IB:>C2+42U&Q4)8EF#%%*W_V1/!$E=.AM-VD?M2Q'G+T\1 ZI(:+#;&CDNB
M;=19)#N0/@D*>41DKKQ:(;X'6(%0=K?*_H5@W5RB<=YJF1W>IZG=1=3:W?E+
MU[<7_:)SOEB@**MI7]"DA#J86M]BAC$O&:Z'B5%B^M^P >JT^X_"CP"U<V?9
MV_T34L]W,;;%V-YE;/FJW1>[P"(8V/AB^7?K=)AR2'=WB]H<HUTGX'8PW#"(
MN1CC8HS)V;O9UW6K_8S2AV\5%]Z,0GT3\0G,<5(97?(EMEOL:\*^E-8A3(Q,
MJ=6-<X-[F,\R&/KQ!T/_O R&_C*#H8L;/"\W&([9 $9$.85&UI!2]!7GL*3D
MUO3709(YS*CRV.IRJB[F1#<Z V$J0#?!F"<]3FGJ<#&;Q6R ^TATCEKOB(CC
M9# 'K[PF*57*ILQ9A\)' ")$20DFCUIRSAD&P!9S6\P-A]Z^[[;U+8$V9&[3
MOR52K\24'Z63CJ9<,=V9J3+P+M_PP$/:>9B9P1:.MB"R",8=NF*";"<3I0#S
MPSFDM3YS4]1F>DHU$:[K>DA%?VR(C-YOM,\V7[UX^7F6#EXUD=)"BX0R[H;A
MXF4#+1N( ?A%L[V@HHNAUHBH)F+J$\UFEK[;B)Q)(T(#;2H(*P.W4X#[3.4)
MZ .CH3T]#T3OI9(:$$WNRCP*;Z9 $1&JX#,(F(RW3/A7W2WMZK.OGKS\/&X0
MLQN7#;)LD#LWB/_;1GA2!\:,H5,A&4#AO)'Y]2+E/:"_IQ")ZE0\QOHW_W>+
MK2VV=H>MK9V/(GA^;ITW-+".47> 5/D/<&6W)$WI_PZ:$5M5U)0XA)T=4XIH
MK?V.0?HT"IGQD10 A?&"U@T9.78%#:JR5!;AO)UYJ)3"(R6/!),6<3;29@GZ
MUKS%.$#CI\.0NUVG=,R>#I))"@ SL)KNMS,:7 VBW))E30F)%54(63=U[Y>9
ME7P"Y]:VOE- X$A*3L!\1=1S W%+YKS.XP0SQD_G9_7 )]\Z^38'W5S2#V,S
M.^ETNFTRX3KY#.B"@@\S0= &'&0>B=<@/ILR;NY=7G;[#:B/A7L'H8G_=$^:
M;JSM"WFH*K^&Z<7GS[?^A10@O*+.U[KW.0/1G;1MO2D"2^94ID!AT"&L/VNV
M$>M"%RA7O).HO)O8R#(UKG0W.7.98:>,UN&,Y[:9B6MR;!LQI;7(+!D"D+\:
M4]%E^LU G!$(:F<GOP-'%[/59H$5UXSDSTEN6-U 3& 3K9G2\01Z@$ 26[(;
MG&5B"Q1^+(G<DG=O"9A"Z?5(=#82?[#B@QLS#(RD$R:8 _"E\(#Z8.=LEY:I
M[!#K#H&>'ZX31! P2V$PR5+[U."@-0:<Q[G"8*?^?6@H,+#X*1("T,,8A1G+
MGN)?B4@R3G&PG^_[O$KVX=3F8\4TUE@QYXXHG?N8K ,[\XF2C<(GM"*^(G)P
M?!"#"X*IEH+* '5!P\8+0F)!U")3S3,M;\UA>M0C"0PC</>;>&TMY2BA3(WT
MBY%82HFH!B[R)M!M6T$\>V^S]Q5HK-(951\<4WC(M/^U$MO%JO04M= O0?W_
MB=';+"0^=]S-_4E\GD9T'<M;@"J+X]AA&#J*KEO0MR0*3E0DH,NW_4&V%'31
MF'I'[/V0;T7ZD0)38OF57([(L(CVD3IT+0CV?(X$C9=C&0^0NN_ 4LQ[V@>"
M5"HS#"UZ31%E(10J9=:XG9&PIK" ,1=:V,CJ*D3:#5YAK'X:/E57PI6Y:7KF
MT7K'TIWQ>?+<O([ 33IX.^!U5A"=FSMWO/F1)@__%9-0BS $R G!:E0A57#-
M:H@G!>T9<P=%)EO^I^P^Q$.)F)9$.9,E8^0U1(!74^P84KQ(X1=_GL@C46G[
MX%_79/-Y90BTLV$Z2!:OJFFC[;(M\NN*Z^7OMS^$L:]=?7_UZN73__X.3_[L
M^3>O7UZ]>A[/SGMN(*[5,PVL70/=O_LZQ@P"'>>R#X<5,\D*I;QKQW4HI -"
M.]B$MS%A)R))85;_UAG.UFD5=^H#A)+I.F^+UDB]^K/=)^!0^%+*6U==Y]?$
MG16T8V(A+6UF4.K?4@^!G9BY,0.5'DB$5#5+W.:0SYC1F*4)$I&L;)C@BJ*#
M?7$4=XGWFQ+LJF+MQ#\%#<2@U<*EAQ+#F7T;_')XJ6?L%)_9W(@LD3/*DBA+
M6)1L^C5K)6DA(3OWLCLYUG]Q".9S:"DH3FOI+'W!Q6C4:.1H);,IZS@Q,QBZ
MO]7 93&=Q71 RF "-\0& W ;RT>D1E0')9<%F;"84?! T PG =3K!JP+"26<
M:6]\YBZO+[.!RFF&3M'OUSY:VA'3>Y 8RE8'1QPS17M 84Z47DG2I:(O4[Y$
M:4Q%U;K/%WM<[%'MT;^/ZT(R7>3N7)#VCDX%@.'<%D:KQ7;&ODP(?'<?-JRW
MV,D9V$E1C<GJF;%4JB\VTV=2WGL%3,NDY\>?]/S+,NFY3'HN3O!G&,WS43L7
M.Z<Q;ZRLV-1'L/A)$SX"/):S=#$CT([_8D0P=+'%Z!:CB[6O";1Q+%T4>17D
M+8&ND<*7_MW1-= 0!/HFZ'\85;4MX5[S:Q?F2[E,@M8E2_UMF5^?2_J()7E8
M+JJZ03,:@.<(CJ!><5!_CNVFM8N:L)K=&O-783W#%5U=+Q#T%.M8\&BF[6\/
MAH8#&"P1V8:RY)J V/Q.33M_UZ.3,VHMA^L<_<NI9^1':7BY\(^3-U.UL/CN
MH^Y6SE;&4\Q\>_ZQ^%-01:7_3F$[9"Q]R^ %].X3$,<4:H.W@SGK@:+7HS[!
M,3"Q^*368;[VUZDK*[\H.'Z[%OX9ZD;@;H:U?PH84';U-92>62DJR=+N+T<5
MI@E& .6!Q)FU$H8<* EMJLP:L<Q128VXIQ+&"YTYY/+[Z=^-X/O%\H>S!NX9
MW3;!MRI<QD8YJV/?M#UI_D0\T-C^TV@'ED9C*<"W^".D8^1M7;T[4$J.%-UL
M_L9Q(K$ JM@YXU,(0KBZAA(X/< ;'^CL:>B5!4"!Y3I?5,@/ SGL".F%+^C]
M=\<*K_L\S( <\[8+:CCR=WJD$/Y>/#=<^T3LK)<FQ)+VAK=N4X@"^#/_*MW;
MG'(R3-']5U[U-$/]Z,&C+R!12^+ ?463;K6( \(@]8<8K+"K-WW+WDMX J+Y
MBG]',*0X?YE#*6YJ;Y6KEWORD5^HH)5!8-,=$7[M<G45P6^X+57[2U TO%Z3
M5R63_>;;(%FY@?Z&WDRRU^@:@ON64Y@/DSL7$B_'OH[IG4<X\W(XG,.XN[JQ
MFTR ZS6&"/L*\Y!\&U$1I J+C5? )D&S;GE#$#[D31,1A>#$AQX JL5'_SS^
M/$M\@0Y&G@I7QL7CVR]/^DCZ'%!Q!] >7](98_]!HI4%+=YP/"G$RQ2R^AWL
M.GU\EG*\R^<%%>6&DBL?6;3[%7X'/!/DO.6=YMV$P^SV#>![-"^=K^M&A)F9
M74!45V0XOS[YX.+DP[R&)"\.2A^S 6(Q3)_ZR(E/?NSXM7,5N\^0"1 )C8VV
M4"MN:V+.'4PVV7D)-K;X. #JW5_+=XD8?GL1@YC+Q+ *]K?N*;_OQ#%,3<;R
M2-Y:Y[4,!L2DG6S9/D*IR=1[F5I-)VG/^WA_]_N8?0?3K\!D.>+BRU-,[<.[
MB9KLL^-48Y]W&UP-^<Y&(.L;5]SHJ9/*AJLP;QS>VHH'<W?8CWM;M(H #X;D
MQ#E&,M1Z( 4(IOLXFFUH S0)GE.TU&D2KK/\HT*H];HS(UJ-NZG?R,)N";$\
MDK;"K9[HR;;3CS8%1X_H:6!:,LKF_-FY.65#6J=&]2%8KT1N*V^(+4%99"@;
M'"T=C9T7\3$T^Z3;$2 ,AQ!<6&K<@2M 2@"EL40C'RAIE,< NNUQOFQD3)>&
M6.4=<XH?OJ\';I9-"%$#8BT,+=+ I:WGQ>V94FK\A+V!&1OT:0;<%V(T&);"
ME/^'>)C)54!YC0*8OAJ[-%X'"1[-C*^TV,<."O'F1_(3&K.*6I^,;.)%<:45
MPRWP(B-Q/%2YO"=^AQ?(QFX@.H LU(A1JP5-.4\TJ3E.KN=[CM(.3H#Q )/"
M&8Q[#,;W4W[MWQV?+C.IOVB@^CVZ#RH?PEEGD!;9Q5QO/-IP%U$%I4M362IF
MPG(ZN?V^H/;&(4R-VR$LR?.#UYC*LSGMG+/S.9<?R&AT:Z&3L/7ALW'C&>ZS
M/?BC%M[?OS9"Y<OMB@NA7PF;3\>\9%/Z," \9;ZJ?#I:WV(N<E=4A39(IP=&
M,ID( [<%%T)B<9P$GMU-K/,)+R6&]S'KRR)7):,II7 =YIK<]HSCAI?@0Z V
M 5%[P@K>.&."_B0B*A*90)S=$?3>YC?$+BA2H X29B6#,=SDS' [8>SXI:*"
MS@6]0>4YV49F./H$V*[H7(ZWCA/W#0]::J$K/@[Z--1JLJ4+4 JYZU/2KMQ0
MRT=B8.JLA_K*#,_#UC&-""MOQ$U>:YV%"FPH.?H[K.HJ]&GJ,673^1KFI^V
MF4DK?E#"$!_:*"TA)2QZP>) 6L84*!'[VJ!LC>0--=]\NVV(!'2RA'H20)+C
M7HMWB"PDKZ&XMS::]-Z0U\]E2ZJ-MQIR'P!%X:2)+VJ0 ?@RT79@6QR;8J/S
M\8TK#NO>^TS:)'CXJ7GH0DOEPZ?@Y8'&&_57.6\NX?IQB"BC?A:O9?CL(BE?
M[G]>P[RH=A.26SPI0E1"%R27 O6?TXZF?RSO2&(#V5\N# +[;U\C?L1:^'_Z
M@,,V.X_3%ME5WS)@^".=O N8^.?TJ7]\L(")?QDP\:>:-_UZLD/9M9]L@OB<
MMG%QH$BQZ$!<"/2@?X;Z>$'(0/SQX=\T=*$&>D6]:1"PHKPY2V1F&M?HK/;K
MDEJ#7!/U=XP#D/X??5O(V!.$C[$.9G0#/R5G7P3EP1,W2>4Z]Z$NE\N\@P8F
M".<#F).V_@A3QKQ!#3>H!_,]A!" 0 (EQSKG&\ ^&[ZM4*_"^]P@!&DW)57)
MK'U0:"LF-+ 5FRLP -/B/0W?C[1SD_/?_D3(G#@ J"ZB<= O1J(<Y6KC()"5
MCHB/F()-Z?-6,IK8#FU*[)(E?%GKYJ 0^L;MA:_+QQB%7TI+3JP_I(C4F#BR
M<'HMV#Q4?U'P1LY*Y#('QK-F&B;Q'_S2;$)N,+KK%K^@X3(O#6->XUH8AF54
MN:7E!-+H?<YK94-URO!ZC7J(Y);_% OSI6R/%!G"J8"\>T JXCO35Z$.HG%@
M:$88"6I=MI,(I%"2O: ,(R:#Z%39>+MD+50;8!MH^>CRPH[%Z;5<.&,J*=-)
MQ:N+P(&P0MQ M$^_]1E$8N!XAZ(>_?Y.*<6/INY'>D8F#(T/'CI,(^=\B[^[
MH8I$>5+O"S;$Y&4ES]#NE5F.[%D9B#=YCWON?7)1#N^-]DO8>(NCG'"4,(S@
M) L^<>\^0(EW;/BQN3/V$%FSW=![:2]7F$5M[VLP6>M36CI@6X$H!TN+Y[+F
M5P;MI4UD]D?W/+CK1KU5Q/K.Q1&A2RWU 4V76\76%Z$.Y^U:H+R6HWOMNEO:
MR(.C*7D)V-O1H(5M]6Y64,/RN0KTZ?*.A3(H^8TUM;1133F-&%2'\<@-V/:1
M@BJ<KBEB*82J'C49=[UY<\[[35<=II&,9DSW';-P^'%Y"89XW3@7:R]3AZ\;
M'+W9\*R)9VTC\%#_WOV3=HRY]P$\%YU)BBK4M& 4P8NC:,W2"8Q9/_CE8N@%
MG3;AU:<H/((29BK^3K43915L)H!KDU<8HRCT+RW3+U5GO"$*D1HH$>.L!M?3
M2?E$VJ&V9SH.$6/E.I\,B08"/C;XNR47YO^B.QVYT+_R9BCQE[D##G5.=1^
M@[$.9U[WK7A/+7,#0!TR@41% ZOKMR W?^.C4L%-Y <$"1(=P!EOS.=*BRF9
MI488V3 6Q!X8!((V"*1^/8';0JR&6N']M[M_&^:%,^(U[EQ_E)"85#8DIQ]V
MWG>J3Y+@K[*YTKR4T)7#W^[JA6CZ5U.V^:2;^C^ P'F6_U6-+LTHQ!.2AR)5
M",!@I' O34%KWPF'NPR-:^0846OEB0OZ_;EW^-9%W;G-OO(_>$UGY;9ONX;
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M<.?YD1LHF),>'Q2C6]03H2) CW>(];5 N0.,(+;V#"\(($M&3,LOA/.1B)0
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MTM7*)6KP<?CBX/(J ),"%WDD8:<OK^_Z7?H #H=%;?X7?&W7?4XD_\Z-WMT
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M?F3LVB]73^6'[51N0[%<.^WA4[+0_"8O2MQ0H5,7#+J/0\4MCOO4B$!2$%X
M\AL]7LSMFF#,?%J'T_SOER3@8R:BF/DN,*H:761,8K0</EB'1:RI%-DU/ 1
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MA#9QF#,:3QM2&]M^=$,'E!_(5=L;VOLXS:?!C!6L9?Y%1,T"WXXE8E$/;UC
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M8GGWNL'K=#M1S72\-*PY+KQ^W6$L5LJ]_VX(>[H_^TCTMY_ 'FP&KS1CHFW
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M"KC1*ZK6NB<5KV4F"=7S*)'S003;\[G#P!>(+"6!0;_L0C 1_(7I+/E:.W8
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M*+*&+3I5%!$H(G9&TS8G"0ID7)//2#V15(9^&V5UYD;\=^C>G%X:BF9,N?#
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M9?M%3$+\FG\P_4UL9QF;FMZ:\7BK*H!:<?@)]"^XA1\*[@1:8I76E%/L1VA
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M1HY&%X1 5OWX$#.%COF'/I(FNG1[$2(\WOKL57J#NO<1J^9;$Q<L)C#T8^>
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M>"ES!2DF. W5A-!&P 9A<[^7QDE"*V\(@L>D\4GIB_()FYC8L^ZG#!A@I6%
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MU'; ;SS=*QYX2J?HK0-+N#0G3M'XGGID<-%>I85%O<BUY%.!RO_U(>1_\ +
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MSM!18R[M\CPXGZL77O^A'3PT"XE<0J*G/*L<]UG,EX1XO69V15DV'BBZ<!%
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MKUP#PG??G#DK"5/<J;(UR%U]QCGR6RF-0<<LM)!*UV3&*"; 46 XO/N&3,B
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M7F(,ZT"GBIL0)7"C&RH2Y76$M9C&4LKTE^J=2+YDYD*>%Y\L/A=G$E/'L..
M-%M^%U5[$E/"Y7+4.GE=LBZCL7W,+,C_YSV+FL7JS"1@PG%P2$7;P12HCO[;
MPQ[^;,B=/R%FY]"SOQVA(61YC9R5_R7S,[< ?A;DUFL0Q; ^'E. ]1-4,.K=
M'EPT1O9%'Q 2#%R:U?*R"0]Z<=Q<TJ\'K\0XFFVIG=JL*]=51%4I<0(40-M.
MI3<*U02-8AR(F9V^IW[N7J4 G#@;R/HSR4MK#[UA60/DC4YE=A(-$8V6)M5
M"B,3/@P54XA7+J#HEY2W9L*W)#TO \D[$^P]ME  Q):M9/_81/ @G+0%4:53
M"*G"(: )6-<H+.Y*#MMVKDO[X'2P5YU;W4-;Q*@(:N^JLZ,P& L$H?R) *(C
MDB^]9#SSG=8!M7HW\7AG<0O!)DU?BMNL4N9(H\M-% YC\_MKZ3Q928A](HMR
M)5,EOL7TM(6->CDQ;XJXU_#[IQ"Q]"OM'N3I!-IO>FEI*PD+*Y\NWB-?263A
MY]0$P3S3J#P;K_ER4]9;D_CDY\%.&#U.84KNHT?BR]7AZDJYQM\I&*E8_<QJ
MIRS?R_[SMOP *2CFKX.N!7?:R$+)]\6=&,LV/GA\R8X3CK:"M,/$Y?BQ=XDM
MM28]#%A27RT[D%=\:-KKD\OV6MLQ0 !'_4.VW!E!TK17,G-MLLW-,N7[Y7 :
M1S>P-?!\Q(X/@0N!HN05V$O/J*?#LU97M%/PAN/Z1@^?-#KZ]2W4/(YQ4Q5*
M(7'<+7P25$R[L^DC8YY1UXLA1URO=IR7I+/4.<7/H1TS=-FN*0Z:*6>E!I B
M?IZ@([8 C>.:HZ8/>"-K:\J$"G$^6+Q0M E6^*(D9%9&];JC/&B]M%YA?9\W
M;/FX;Y<9!?WUAV93:1-Q.-/K36&K'IO =7_YW]E)UG [MAPMDO($RPEO(3&[
MH(W,!G:GV;[#4*</(CONLSI54_<1/7:% 3CKH?/&.CGR_*IED5D4Y:UJ.VH[
MI&)NG>UK?<NL9U##/&"OFW&WB2S"W'681FYL/F?1FHE#,'FU*]%]Y>55-VLR
MCZPT01N45EH7_#R9_:NP2U;EWJE=F,T[WIU+Y&:TLHNTWS/V;=[E:QQTG;1Q
MOCWAGPO)T,11,WEFP!,!3Z/<$:4)-(2BD9,O&U<ZTE H\XJ1\$??>'@%;_WT
M6L8L+4.1.\M)$@LD$W)]/I\HC$6ZZ./QY7<"'R4,.-4_D 55QRB))&XR<C0C
M3*E6TMML1Q:D44:SE$@OB1U.IVG2)O/0Y5+Q%JY7U11DF+EP;IK\#??NLT=S
MT^1OW#3YYS\0OB7-P.RLI_U.\2RQY82 =T" @^-T 7B-&!283?CZL**>Z;2K
MKMH/[,%!;!*4,#WP^341JX[/9*6@T7R)V/"6/ T./!COTW'T/ B/XJJZZ"H<
M7#$R5(=DK3&-BQK$J'NJR=/%:W((M<O?74"/!V,@4EKS U( X'+G&PB)2KT7
M0O8+B8L^5-5NP6JQ?#;0B0<1*BJEPL'L/<Q)@IN_*25ZS%.,TZ'AAFXP<&EO
MJ_Q[BLJ)&.QC6R?GOM=?4_C/@BK-0^5I(ED1X(?:W1*><?:C8^5,::;Q!;UQ
MZ "GKJ&VV,YL!':#<GXEN;(W<L]PF_>4@"&/9_$:NWCQX(=W;]Z_?BC;>#I'
M211=-\[U-PL@=*+RPQ$*)H84U]4]YBFQ> _ZATED<8?)J]<+P_<<<Q;@?7Q)
M/N.HLMM@H+(NZ&;85AT9=JDL(WIW5L[B\]OB:\Y30:MHG:6KE&HTR4[%;FP5
M6Y,3:2^HE,]@]\)JY1!& <U$G>OW7Z]6_<"3*U>T4"9N-NWUW,M]]%B7R1 [
M/!GL4[UAW\K4*R-7L0"O'E2G%Z=%(I+"U2*B<5:%5N+M1QJ*VL:Y,D:?%9'&
MWRF-8@-NR74 )Q+Q!H,&K-H:I:'H+(?I6VY:TLWL'QK]%'ZHA$?7)6NZ(-*4
M$2<<=?'KV+I"UL[EKF1*Q&L,/PS;D&1/9Z#BO']HH/ LR-W "M2H0MV&"\J!
M-2@A;NP,NZB"8XH:+MK1%WD[:$F'&)%%4EL>'7+$*[HI%JMV.>!2Q):[KNA0
MO+%:I94P5 5 6!N=AR,')@<T3=OD]Y5VKK+Q6=SS</&VV4KF>%/NF/NQ-+=I
M*@U62/:NPY$I:/9-13R31)>+=D/\1L.D1CCOI<KDBY[S1ILWVL&#2F)DMUZM
M.IV6&^95-*^BN(IB%<'BJ\)7<J*<3J$IIN#.U%VPORR^5TCLQO[(*%/E' Q9
MH:I:?S E,R_0>8&*/Q$9F!,MQV#DH!$O,BK(P$3_PN A,<62.!_GK;*=(K_'
MS3C+=E>YT]BE)(%.JI&-D3(3$Y:-&W;FOHEY[1JOB8(?M9)93J7>C&)8EAUX
M3380#BVOVDZKI/S7BD-"[4H;=I?5!EE]K'].U!6D?HILALO7Q9)H&;;2GJH,
M[8X ?T.C(H]=%6Y19.BKZ<*I1X#-71SODZ"BKY9#GI$#0HY9'\(Q5T!:[P2Z
M0%O-7W%,\',JU9$R%5,"HK!;5(7!O0HK-J-@P>5TDL"-Q(5M![@&+Z?)#/4>
MU--EWS)&8-GV>ZG_E!COYH:PJ TM'/XT7#^%8W(W^+B2$R'/I!RH1WQ+$GS,
M98_I,7V+A-1Q7=8;J)[0^@DVP6?"G?Q<HN?+Z< (7@W6>C?L-6G!DF?[METH
M>%2P$".S7S"]D"H$UNNIFU-.A3,PE)?A' QY1&%/#HR?=!6W$*DR1*JGOTOB
M9NA%S=&20FE.B+]6'KGT98+,*#?!_@T7EZ "I5.>SGIJQ6U.8AI,(:=K7CLE
M:G8E%2ZW@JW:7UH=]/I25&%*QN2SZ([]- ;VOV#EQ9=.7S:ZJL+<B!ZH+G)M
MTDQZL7CY]G6?YA,='KR#.!S$Q4K@D2$DUG8>@3\"FMP(RVI?V;-CFW:0%^&!
MQCD2=78L:N&]3S93.56*"-L+N5(1T @K_:>JW9&RV?\H<,>54('.'>T])Q3J
M7[8FB;*)=$T5VNIMD*"HJF@S)=XAZ9\1OX[HM+F%9(!Y*H6$=<\N99P6F*B+
MCAQ1VN1&2B^H()HQ\C9K+:$;_-YIZVTIP[0QS09^&H".I.QX,91TARI:1%8B
M  1KQ0/-WQ?6--ZDF)MX.1]S68%'H>&;S>A2N-DYJ4^O!I)Q_!F'SBKV;'SL
M.D(IT$T6R)&F*N7ZN.>DIDIR6?TT-@XF-L-L.6.)[>E?A>35W&X+:Y#JWJQU
M'E9@.!(NPFTO:U&"%,H =Q'-Y7U$[P=OQ/2HI%-C?[,C\/M&0F(:>']9";QV
M\?AYB+J;_64OFCF<AB_D\ 5N$%+TC(K *Q2@[!I"YM<'R]=TM%:=%+[JKD>A
M<$M2Z@Q>L,7J ,$)/I%>_@B@Z+#ODT! !;A.WIW,!0Z]<>BE]8HXKB,^!+^O
M"3>$E;FEZ )[D.0_Q2ZN3 3.G4*%B6LRW9@C@(6X&/14KR=<^PCQ=K5;ABG&
MNBS7C$1%3$X%\EZ(I@!"T7M(VJ<_*COO%;(VVUG4/BEN:2_,4TB#PITC.CI"
M2*<:;?Q]$RRH J9IA^'8AW I6F."E7EWR8I-9OA$9D3K:%0%@Y[N[X7(^8/U
MJ\Y=N9^E*Y>QVW*JT@JR\$X/5U[^9QV?3=0L$$X**(JM%_\."_W#XE_?EV?%
MXINP!OM]N0J[ZWL(C=T4OA_183+$A!RXTW^U5W3>)TV7BN*@0P?+'_XB;Q)S
M]**(Y41SH=^5$6&M8Z(AZ3V\Q..,A/Y-D="/9R3TC(3^_#!+J'NC!QXQLV9B
M\N[1R39$YXF2UP'OG_\3K1)\Y)-Q9/E+L5W<K'Q+*_ZP&U,?B,DJ? A>:(H4
M'1S4;GV@D59:MY/&?NTX,Z&\@XV69'A#X*W-5X9D&$.LX9LDW3_?UH@_, =A
MBLQ\6]X96 -X<=2=!^DW),;(>D<)U/%I0-B@8;/1P >.$&<NF6]J8]$@DH_K
M4HK2&'G5D?ZDPJB<5^4Y;R,/X&T#":ZC#5L.CHJ?>3SFG)T7YYR ,'QY2693
MT*\0=!,/+CG0G =[X,6'P5GG'VG7:"3V44L\?ZF^#2JF-[;6QQR^'U["ONKB
M;:3Y.]L=G =QK^_.EV[K@WCRX/1SB@/Q+YVN2$S7O\=,'V]8^ W/NRA:4C*=
M)'XI'-M?4P)'WO0O\Q'58(PPNE,]ZR&Z+#O#MX^C-R_0-%Y=LZC27#QU0$(K
MR(N-0,(5"3(]%L;V*2;<4/T/0^+FG1.-5IB48\:7S,L,'->7%2.N)>&KQ 2M
MP#_IJ'$'L9S1Y"HBG\RM\(OV4"9;?!HUD-KB+Q!K,X7Q.\C2Z6*>%^F\2&F@
MUN"(<IDY<99G=_21D5S8-WFRP8RE18+:^00,]R0&C_NRWLVF<5YUMNI6P4V\
M8.5R%Y;E5$)DOH:^2JU=Y8D5* #01:9L4_?* -X235^C<!D[9?KPHWY](\BH
MR9'/Z+QY>7L',RG<9R1Y%I=G/,?TNY_:FG()!)C#.NUT^4][ =2KZ-(]F@R*
M3)EAZF@@,Y2.RATK#69!!74[0@#YJUB*[CB)0?F([:ZLNSR-D)#)*0.4<[RZ
MCF0S&;% V(\EU1X8?1>BX=X88<X]DT[L<MVD#)5IT@*9%?"R,]O!G+V81'81
M4=%2:MG7;;=9A5]4A>,IBCY.K [MAJX?'',E<IUG,:N X^+VBTTE=R?>(A>A
MQC?<[C8W/_M;^F]P*.&?C+]O>5\,@U"A>V&[\#1+TW&NIG;DSCZY/2[,+1[0
M1>SO-LR'0(QDTY5>RWVLO7D*4K549NRR4Z#^T--[J66';,E^[C95%I)SAS;9
MUW8S>%(EA7!EWR?+X!*1:(RE?!=279P[;,(6#B;[.@,0<5]*DE)PI"'R#B.I
MXY3)$> -:[D=N %=,Y;UK9MWG-%.T5&%IJO#L+R&',,1T6X<#H<0F\)Z*#OP
M+T$2%!F48.%XR?X@AI<>+\4+_X9&N/A<\]_?\P4<K]&7LE^D94;:VJ>'J9:V
MCBHY3..0AQXI4.SV-2O+59B1<?OU08YK([ZX;G15<)FR7W;U.8$/PQ*[SFA<
MHX>GL/4)NJ(0FO<';<QM90\#*@G":""H^ P'^B,]Y:\.!_K1;)\A_A2\F73'
M<2N\GC>3N*%^$OT# \5>PQ%;IQ^LPI"[D@(D)UJFTNC.G(N&XTEHCOK+$N51
M]C;>,0CY)0F^AJM)DTT(.CMVE,+XPWZF-]KOVR4(JQFWP%59P#S%(-9-C<(;
MP?)%L/B7W$$.+D(5BX4;PCLH]X)*EI\JU/QQ\?7C+XJGCQYGSR5"CWQ)X":8
M]RD9VJLWKQGA&6EP[Y[&X$EPT7+QER=/3Q\MPBO<T'=QDU5PO<+PE B<)D2/
M 4Q7\"CZ-3M5D',#1U[= '5@2N(*5>BUZXILO-]982/)6[BXH-KFGDA2-L$S
M;YLJ[K)PCV%'7__+XV=?G3Y-!\HX\DOR$]G!\0/Z^W^>*<$*^/L,FUONR*T6
MN;I[WOSIX]$LW7ISAW^QZP:G\"5]W+!V7N-PVAXN@VZEM?< E2Q<)E&<WCB+
M^QI="UU[4[(<+?T\^.JK=@AK\V157]0,1*]7)WN*;,*12& W2)WA=35T5C;5
M7AETUHJ!T5/Q"G<0'C,9&MH#$GB*2Z"[(& XN.,//1 O"S?,!3FQ29Z(GH5V
M@7\^QD&DS]VG[\5&R'7T90N ][(*Z_V8B<^<41Z%VX@)T-P2UGV8?X1Q;"25
M%B9,\5_<_F#E@D[4"Y*WB^-4H]N)'4>6F4< B@VW/2,J7[;D,[<ASUD%?')3
MZMV<!?!;TGJA#IDH'@ZM*UYO"UYO?G'&C=>DNTAR!+3'5#_\Y)S2N_BG1BRT
MR>ACC9K"T]3CYILT+3+.(DQOIWM,N%WJSBG_ZLE'SODRF%]@_9.>"6^+"=N'
MV?J8=Q*!=F31VL5E,#0G=[\=&_%G?$=K-ZF6EJ!F2;[M39*B.*]@<%9#5:BM
M^?T=_AG8_:L"NY_,P.[?&-C])SN;'6$!TF:N&VL]$* ZLCF3O:\J4>V(=D=C
M$%:\X)0;^L?6RO%L.J19:]1$_FW.BOR1GO*W:))*DOM.E,LK(%7*]& (+%VD
M@*JWY8JS_$CIH8/)<]Z.V2%&7."2!<\T*":[#B>;#:=H;U4+*=\21QT*>,85
M ;W#33JO6R]H%%Y"V9!3Y=+,P5,C3RS\T^B 07;6;JZLOL4\JVQ<I 7\OP?J
MH8685WAE;*JB8AY_?]>%8(T*791:HY)'N$5/UV5%O-A0C\4JJ6["ZE,YB)23
M+TH55:1P+USWIBJI]S1IC571).J=*'C-%PMPM=640C;N-5Z7:0V$OC=4V9)6
M!/[$S'"?C&F:T7P(^/M>](.32D<\=YH-GVCQ6]@$<\4%G7YQ=]W2RNNIY$9"
M95.]&4GT@LB<R)=(UB G.O=]Q[GJ@$0[*%,(@+3LD\N-B %"^."I9;9<]M1[
M4>FWJY=>BTG?)RV7:G_9KOBZ!$'1>(:^?#ELB<6[78U:(X_(.L2J)JOVA']2
MC.7H#"9I2X3_/.W<#@'=L$2Y)^4[J54<BTMZE,/AXT>N$I:/%J]I^Z,+7G?M
MZ>(_82](B7%5=JM4%(+I[^FBGD:1R3/X%JSDU%?[O1!23_-.5)N^8DHF87'A
MZJZ2/%K.\615K9E'/5Y>DKIR[6!6=]26$U[4L!?!QE6(GKJ;TP4KF:PG+0+7
MSU+:#BW_;D1@ULEAB9)<V<>V)3!,Z];C/^/U41I7:G3D+^9D +2=ME5)#T7L
M\_[05COB3VB+B5/8K-H8X3[#E8<^\G2#TG+JU@=41LX<&ZNK+V;S,^+B!&.P
M8]L<B[A$-1@&0%0C+;8RGB!(?>C%^[%*V^)E>'55.._H'2&[L6HQ_82(6QA@
M/FD7_Z4L_JH4("]("4/E])1/^8FGMX5Q_;_.G*X#KS23'HO3Z@Y$S(F,,'/5
MRHTP2N8'C!=;Q0*E[(KKUA3F- \OF#5;?AV_4*ULPLLM'G_XID*_2IS;]5[5
MD5L 04<.%;W9U*6*0G,'V7/5K(EP2N2U4565.W2BC_P-*G%BV(;B+$[Q%785
M_*=:!:>=6@Y@';H,XG&B;GZ?U1ZE8F0 L.1ET3("J/G1B^#?DPWH]OCOQR_D
MV&;\5^1.JE))P6]JPFGPD:,.'D*!E?VA&RAF*,^IQ1O0,E^GI 7('#/B6K@'
MS0=6Z,CXQ+?K<VI:J_[:HGE-VHR3KE J>>$?DT/K8$R7 ]G$75WQ%,5N4!N,
MAY=Q@+2JE@(49%K]$_.1<,9=$@C,3AAWE^GI8#_%YH(Q>/F,G.J,O-N#3E*3
M]E,[L,BF0F_B,_O!BM1K46""SH&D&[22?'"M&+@/+@T*3]<*07*J!+*D.R%,
MP<-Y_5@8K2:R)3#QH/*X35VH[I,'6+7!$=GT[?04),#.">*R(CM/L0L; %=7
MTIU$=,KV])&YUFS?&@((?O^)-@./^-AY+G],J5]5LR46"-5(V9[']T<\J;2L
MF+5U&0;JP+KV,_$:,Y)90GW4L)OC):EBRU&_JV=6+//,-VA34X(LL@&\U@ZS
MT94;IZ=.*T9]0LH"!-LM#T1U\?$Z2<YX;\#Z%E<O8"LH/'&> /7_@J)@&JUL
MQ[AT:YKS(+ID!([%RH8'7YICH79(1DF>Q;RB4\Q:TOWO24WI=G9@PX;TO;S>
MQ)0XL]M-FR<2LN,"IASVK(;9]OL3YNMTH8^QLNXTB4CLUUU]5:JO?=4N[=_N
M91;^@L*B]^#-]V\?1O ^+"12.?S75V_>/G0*3QI3.)E.I7:,B< BC=7SC)UG
M 0DNC/\NS9/W8/>JQ&<S*KDDY\92?&I8YU7E&55$203S%=].X4;/Q-.6P53R
M#\J=)*GY(@U,.=@#KB-1C2BFGA:LYMGY,P+)?@9I.67C)H$>KC,'(VK!OU+Q
M**R$%9D7[\!P&-<673 F0B=U?@K[6!M2Y&U%+FI13^3\J<;VB38'?1\<\-G\
M^4B3)0YRVMU@3Y)DZM#+>[Q7J6+<%"_X+Y5,99:WH4M0>9/TGI_^RKB1)+P5
M;'P3\],T?M\3 E)*!#)WFAMWT\93 XW:8(_(I-!4GBY^G&AWM6MH72#C"C]\
MWH$2F8^4^!Z9A]).YKBOR>Z9YZC4J4,#MT"8>.G(Y#_+6=25=1_/(<]('YF6
M?/@Z+=T.V$C"72Z\K5SH(G<#:)1LCK,I3E4\)7ZFYX@L@2653\I^CYM(@T35
M798[XH7?%+<LG2:G9Z G":$*!0NVAB86C^;>DA6$#5SF.]67#R>R-M3MDE6G
M/R%OPV/PRLW IJ6F)-A?RALS_I<X^IG4E6FQ/08<@&'L;!J>D![W0K44SNOR
M0KN/Q$4RE"35NW0SU9D,Q8AP67Y(X)!P](.$;1],^@7]>^WGSS3LI1U6E]]!
M/F5Z4="D:%AXB,)6Z&(H4Q@/T;%-K>!#K"I7^9,<KC$?Q#PNB[\(VMC:_S+[
M9^EJ^L-A<X1?T0BJ+56YJU1Q@VY4#@V_6\X1TIE,H#?Q!O;53I:E/8CEC6FH
M$JHQUUQ8XJSTL.K*:_XK.DT,66U"$TQK0NL@:DUH'6""T;:?V6QG--N? ,WV
MQ8QF^\.@V?ZD@*/)GD&! TBY3+5W:HC>K$BO#,F.F"GEXZU70I3IJN'QY@W>
M@R::D.- 9-CAJPY%N5[3AC.'8KJ14S55^XAJH0Q!28P=M_Y"6IQ#*.-[=S5C
M-M'8F6(4"3;341S$GD;: 3U='W:0D)G^\+C9::8%P"@KLS068&MDP.)G<)4X
MU3.'U[R,P.'%^9T,]:")+HM&.!&/^)%3/:D>P"_,RA3!&N[CM3E-GO3H27HK
MB?#3\-SA8E*H4 L]FGF=S^M<N>I\Q$U+![IB4N-B*H\-Y2AN! 3NI(LBC@S'
M?<$9?*J=<ZZ CF7Z"VC11\PF'ZH"]%_& /_I.V=>UO.R9B^@4&J1<1HJ40KT
MPI]*)U>(-I,UY1CV_';5K]1&IX[%@63Q;+/GQ?W[+&X"*4%[_I95#G6YJ57+
MHGY.1$&<::Z8UEZY<5ZU\ZK-/&H'PW*D8_=$"Z\&7H=)C]E=FB]W93GF13HO
M4AHH8Y9206U6W3DHT'G/PYO=9+*UF^!+ W V)Q[F%7C?%=AQ=Q%#'43^/ IV
M)R50#Q(:G)!1R]"J/D,Q%*XO4P@YD*8EH,2\*.=%B469AC+&9=H25LU:.259
M!E"5+,(,QK)A#DG?4,4HF+2M*DM*S*MP7H43J_ 0;0;A+VG=753M1;AS,&P"
MHF364_0<3K8XSNML7F>3.5'$RP3/H=QC,%WH'.%.(2_%$14U:M__SIW$L1L4
MZS5C$& 1I0;I4,XJQ;Z=X"]VE'0%((N1U_%.KBCA:Z-6H*"S'9R#4D#=EC\E
M0"U!1LTV=E[[>?G44-T1'W=09M5J5<JYL)E]QWE%F5R,Y<#7"Y<&NA]-_"P]
M-*^ES#HM+UO"OY.1TB1U[%*C1M<5MX$:=,CZ"#K"./?5LJOV DM*@?HH?P[G
MQN*07=S2WCB&)Q.*LQ31_YGAT3./W6\,*[U#E#Y=9F.!>EY%U43E@*IE/2C%
M@^/#71 )B<U5W2H!D3OGHK#DO83F7TJS6LY.HWD6A:UE@ZFFAE)) 6[BQEEG
M7:T30#'"JMPR7WCG-6E65;#XN>:@\+N-50<K@I4>-8O*'<L0[8D=/)SRJJU%
M[3M"$O/%QJ0-O)!DH4DO7K[8[K7,_M%>5^"4  .;A+'%/>0D7;PY[D<6*-HO
M6ZL.'!&UIP\"BTEUD$F=PHQW[68S0>ETNB!=@$9[>TNFDD%1<15>6]WO1<:5
MJ-Y&H\[ =3F$ _<?;5,^RL(ZHMY#=!U-<NQ]AF[-(]Y96!T@S-!EB/"!%@Y3
MDWJ<S7@WN/K(9%.OH=$*0-&H>9(T,"Q]P@)=P;Q]KC[I%$*J.%-H5T0:)+YB
MD<F#)8D>Z;]'(R^WQY9)IV-D>??M\>'E7N*TJQLA9=H3"\,4LPNS ?CB9R(4
M?[AOP!CP$C5;9K_SG;KFN#ML-M$_#O4^RG[%7O\Q]T"?D0R$_W[UYFW:#AJN
M\N;[M^F5A)DP4B.$;_T-UJ6CIN66C8@26J9D+%DOYU;)Z[AWLCX@:WX2Z6=D
M)NHJ82.X;<:PWJOM;M/>L++,Q-P[)@'462C/C23A12GT_]8<"3H.]A5<LO-T
M\5]#L%HM]5XXFHD?3M^=,HNIS$9F&;GW^'"-G-9W]7,==1G7=;7A$S&I/#KR
MN,_4W-X9AT9"FW$[* _@53W80)3@UAIE9H>-KC3'*>H%, D^*W\!3Y'1C3KI
MJ+VJ/W?I3S]+8__<./E;-DY^.3=._L:-DW]^E^?5!!)$=$BV+4S,13AM_L=,
MUF;#!?FTM.15=!F"5!'MGU-YHCBA[?/K==4:Q:AP=("LAU2W#4O*NJ&7V:U:
M(MDJ^[:Y2W-T2C*XD$I4(:T (P52SP#05]T5*-&X61"<M@?K<A9;N# FA6KW
MC@XU$;WBLH;/8^G!H8P>0KS;,-,\N#QH>NFX[?=,>^/$;B7:N(XJJ:MJ33/:
MVT^,+LB(05+_H-S[J>\-KP.XA8OQZC5_SVZ@[RP2C@@E2E2 9?85Y<VG!,&F
M\MF!E!PG97P6 B<.@<)Q1S_5I +RK&%K=4UUTXMV\V)=D:.TCH*BA$6FU1H6
M*:O16E#F'QCJ4SP <'QD@HX2#!Q:JO8(OD?0!#9R!=U\->,0!O&:RI<RH;2N
M:[EY+X0H3I#/9DRCQ-6!&/%6WA6ZV69?;[E[%C@;D!I.3=/QAHIG_2UN-%%\
ME)!5H9;DMJN2C:3$Y" UK?L/IENM%<[/T-IW,(,"_I^T/]71]QS,ZOQ=6K(/
M4;UJ$82YK,,TK9F+*H0-M+7+2'!8=76[PAUJ(H<)82,Q(WI^5T\42&<3X1#[
M2YJQQ,PK]>*4Q^W#77U<V.%QVNFS.,*%"E0>8)52:JAQW\,D/:)7?AW?'/T/
MCL$VTKB>W_*6B-(5G#:((J%<84=+(>!/94HV"OC;HBV;8QIKYW*^4SB^SY#/
M8/@SO\N<Y$A(*)>.S2Q?%$F.QD1Z9<D)Q8/?RCT(>HGA=I_/*[L K)E!*1-J
M1@Q#7PWL=PBOKQ))@ZA/J-BVK4TF1^00-"$BNS!!YS !@M*)=[\!OU\X3_M>
M@W<!ECDB+-[=/C]#QU;3T@^'#KR-.;V9IX'U'&;&?<L-PO:Y (O4S0!O;3I]
ML:!FQU]!3.M$&+S!Y^Y@.7>G\2<FRX S_MR9KDQ[)&>IS_*!*1@??B7X'#$:
MA-\3+22ZFGL3@_4^8L:('(U+5\7R$G%)=77EWJ\?*)P_2"D%:U-2Q\NF(D,X
ME9"NQX2./2,9>ZT'(#\C7X)TB@(=R_!&UA555L^I1XQ\CJE\FW IAQ,8.A7Q
MG;&ZZY30XS%[&)3LLT-[8C[O6<BQ>&%44C#QJHR#C,.B\+>9YN2XD3#Q3"<J
MPTV2^34[RT=C0W*OL*!H&PDV?(;FS8N(!KHB'7AN<(.=D3B=&W>3<Y%%]JHN
MA,--M<F(,.?E-"\G&BB;&Y]Z WYDQI;/ZP/K0X%%OQY 8EYI\TIC[XA9G8>D
M0293%HLIA8FDL)5=1#B^WY^8IB:KP\]K;5YK-%!-Y/):\Q61B+!$L=_%=R^"
M89N7S[Q\1J8*& :F)>_:FW+#0@!<2<(12:2NVT\N9!6QDE5$T6#C!2)#J<H:
MF2)&C#OS+DFJ7V*(C'GUTKXN)3YW1T0MTQ,M)H@2A)#S6NV8<TR@GH_H;"+G
M$[W;JOFIK?V;]A5N+XSKL["% "3I)1EV]3XV+*D#NXIT6NKE@BXJ*JJ$4QTH
MZQ:)  /?>JI\F\.J !/X+/"P;[@V'JO[G-2;D$RH"<[5$</AM7)L0/;<(RU=
M!H9U!#B@CCKTR;<1>ZM4DZ#ZJ.S1AY>U5/D%G[KGPC?GF45EQ13_#%.@ B->
M=XC7%2LG*)Y!I]=*YYSGG88ZZ -LJ7GJL)&AC;_;>R-#ZF%2+H^5,!7-N,;;
M+/5U 9==75#NF8G*>!%EI7575><:K34VL-GZG%9KNKTKK3[<6E<T+:>*=M3G
M*+3%?4OU1VHAR-+.85Z5/?V8=<QOU>-:_!0L%\SEN"D@XH,+5?\B?<"A\XO0
M9E@78UCJU@.01+@>SIH!FCY/P%M\LC RP[FYBRX,25KK\BKN'6#CW&*2A)^)
MS-R6B8X%#;KL97U>Q\EC0S_JN+K') *H?' &4<9UQ;XCWB=OK&P*GT)J6LX#
MR?BO^^!RER;1W#,>A2OE/UOY,1Z#P-=8V+Q!NTTC-O-T\1W73^E+$1\AH)?I
M#@8BO*)#Y":>6_!_FD:5I@BW?2<R_K9MWQ>Q$%\R!H@Q=R3I)!GQ!$/CF3H,
MY453$I8PU,1($MV(NK)]15O=Q!7$;:/]A[X#V@/,!1*^7=I>I;=7-T.$R#0W
M8P'!VUOK75@*R3-/\; >"!V5[+C?K$EW!JG_JB#UIS-(_<^I[O.;/>)1]YBG
M^M(1-8VP IZA^"J*N(3TJ/F*$JN(69]L\U8%:I*CM-^M;]7/RP*$_677#A<4
M\X7S43J6!)FM[*3'[.\H5C;K:*>)O>C*K;(3>\"8YB>L66L]U5X*+':.XN$8
M]:)KKUG2,9$YXK=&*$[?%IZ=SGB-Y![%UX<006C"^JRI;32N(W[5/UX2AE>V
M!]RA.(<9 G;)RN0:1V"_:"@Q3<>:0PZ9/GW3+C]$2*Y</ \)+:KQW2\'](,C
M2VOE&H;9A:*LSC)26^>/5JTFLZ['MPP<+CTUV;RW9.9M A$&)>V>KL$3B%?+
MP3A1\EL;H7^1Q7<OV"M,4( V$H+-&XB3KBH <J'7W!]J+07LYZ-%HUU1@GX?
M#YP<Y'V7NER9JKH%_U.9F9IA>QYFEUIK$4GVE%U$PX'KM::![8:.VK TAUAY
MB5J$>TLUXO<<EE?E(/1EC>SH?H^WPK0#,<]&T]'?-CR.QJ;%Z[@/.U@'P:AS
MLID6?1'>P(Y\$I<5IGFY@+3O-"CW (%'N!"?*O6H<SV.E,U5^&%% ^1\_+D?
MMT@"82]1.E^J"V6/]*:3FHBMAP.GK4V-.6D#_)07U#;2DL5O2OK!2.9>50,_
M< #L&$BZ*JQO4[^F;=7OM4/PMK:N_\?>NS6[;239PG^%#S,1=@2TQY+=5T=\
M$6JYW<=SVL<.VSU^!HGB)BP08..RMSB__JM<F5F5A0OWUM6RB9=N2R)!H)"5
ME9>5:T6_405T>7S$.'WVZ'N/(2+/&M)@/._T"]\BON7\SF7)F4;+O_7OW#]3
M,O*X3^=V)+Z1UD^ZN]^^A+@2<H7C9B7DFIR[TBI#F*NT'D+%S.*?1.L"?O#T
M3!N-F@9I[FP.$V\/]U!9S&;T'>,%><1EB:><.BF!E%S*C/ZJ5QQ)O3!=LQ#X
M3$/AU^-_>DB7Q9^M30BAT^E(>F'YX&.SUC]6P;%9G$*T,\&8YAM_^5+@IFU@
M,<&\3@PP:,,_"38X:9=8/DKSN[:]I,Q4'%CMF'V'CB']YB-U161B#&:<L5IO
MRK?/I#;RL3!RF:G"7QST[WI4$)Q2U^$D0_0ZA/DV,X>7]S+]S@-2E.BB=LQ$
M!4,;Z;KF,B^96=LI#4TRX5=O_CWXPYFGO4*K.,K]1"7H6=6K,)S/E7,G (N$
M$$C'[1/Z3X JV!>%U\!%:)J>?3?SOY@@).!!D==*206R<!]YQ<&TZ HQR2A>
M2M[ER%,1ATXC8W=<2H ]3OLQ8C\C@J?D9L)M=#R2)@D(_;JTZT8WP+6*O.7&
M7%.?*N]X;C;_$&/@$>/P_>!2 U4 Q6@R^V8ZK4?G O%"1X0&Q*;G[W?P[S=T
M?X[CY,?_]$OZ1NV-JNK/_N5LO:,9.IE\;$N:;?#/V^W:\L1;%5 G1'K<0 >?
M6/C2D_Y\HO'*81MTT+#;DZ>K9Y8C<"RH)$OZL&9.AQI+Q.HA72R_#&AB4=SD
M=D/,I\*(*_TSRDTANK,MJ- U8D8K['&, 7IO3,)#(*^E%\_X?"X]F!^[X@/.
M.YK<; 9U(@JI 1!8D%KA]6)F_Z'=$<ZEBFA6<BA >==#&U7XS5Q[R$^=P/&2
MMVU4VQMAEICXF/'IPQ>@1D[!&JP^+_9[CHN0YH(R(SHN)_ MS8R5E^3;D7S6
M='X$$M^"C@&RLIA+"KY?G3(9&<QZL)EYH)X<U[[<C*[AU+/>;'X4HHVFLX.8
MY@GO?Z6<YO>_6=)FB&;*$JEYJZZ$J8AE@ >M#32L/SF>C=T_& AF'&3NABIO
M@2&<"&R0S6/T6>]+$PQF-U*E#6^;R./S;O8XO-E\9ZOT(5L@JZ$\8,_4N6;6
MTJF'X-(OW7+1.(ZV>"X^H4YZ")I[Q3;U=T$&4KE+,T:RBWU^U_AD+D5P<(PZ
M#>S&N->+-94(36+'Y,_IH4WPKX+D%"+*X.]0"!R-1Z9#D69:4L_DLO5&X0]J
M%/1.5%6,-3FXLO0)[5,%F*ZB8K 'F)N&8^V X")O*)5"G_\,.R>EH%!"# !.
M('KG!6S2J)9JR%VV20!96(1R.XP(@E'N6U)FBGXVO,!X7^!99(F=[O)B^*/F
MWP.H*GBWCO7+'P(L/7#Y2ZBE$4[)OU&MQL9G"X]TXUW+VV%[IB%\6+BI=430
MT;B-R L4\D=^CQRH7Z^W^37A9^_">;U?H)JF!CX[]EN3LJ"$07C6#J_8F%;)
MBU^KPKYB!M\K9O"/*V;P]XD9_&@Z1=\\=%ZB<B*:V4.-9 #A71PBP,%'GK03
M:8O3T)N@BD[VSD0^Q*ZV,X<DE2TWG?^^DW%QZJQ?<VCTE9[]F&%J!3A2+[6U
M[1P(QR21[I25JFE$BG#N1U<KAV42^\K?I.SU]^ ![NS1=W!YRR#]=J@0,6'*
M0) ZJ3!!6QZ3V$J"W_@;:"U0W;/EG,>G;M6YX_X\@P,HH>#!%CG2T^< :(<G
M6KBLK^")@@K>0["PT-^/,Y@!<-@L]J!T"8L2HPH'5]QLGN]VWB_Z2U7G;-:@
MQ8I'IMTWNY?:9X)I2^4L>1K#J1N"$K.39!I*?I!21Z3F27&N6[$$*Y;@W9\0
M7_F]?)=KR3KFZ3+U&7!S\-TR<\P,FG0X<(E>$'0*=DL.$IE4DVZH'4?>H;X2
MNY^!_37V*ALH#1)KUO'46U13BOZ;5@FO^7R9?Z'4CVA>SM$A^D7> MC>T[\-
M'6N3[:H\<KA+P^NR4?![F#,,SMVI+B>DS+8A,J\2XMWQO!WIW.\[MB2J3_87
M[.G!RO6[KU7C)XLX15\L[U1J[M+FBP/@EG<^E::SY1>NVH'3WY9=3:$U'OLZ
M1C_&. *[GY3B\JYK=F4>VJW:6!N5U%YSC([!&=083NQ/JGI<E@NHS;[UCX?)
M8?.O0<1  X0LO QSR6@S,]ABX*D"B\A(""&%G,ND?7<H3PF0\N"J$UG"MGW3
M*64@,"E2\*'&6AI9 X8/&S!\+VS)#L(@A&+I*EOX#)V3&<> *CRYG&YH@?((
MVIXI(L, =%+*?2$)%PB ;CSC),W)<L4QP'/!$U!;I7/2)X873X4; J: T9PJ
MJ5G2S%5^YW]Q$S75F@79M5'S./!X?Q>F]NBM\1NS SP7)>P"!TR^.7A[]K=!
MW$SP<8%<0-N"7.F70?FR/PL;_!Z]AV;A+OS/GL@'^I4G3FYZ'KVO3EA_9[&P
M94W7A@L-MLTGM56\'9&D=W@(^Q7MB60(H0 41V]!NQ9^$Y7^<2A#)C2[_Z+V
M;3/=!"U%'YV !!P3Z=6=/\;1'VW\ICE+?AVT[R)H!3F\M[@^E @B+JVY=S(V
ME[RH42<_Z?"@K>,/ SI?-F*&L<6V#'IA3&8["BF[X<1BD'41;S1E_)]=TSCD
M$6@3ZEQ5WQ+(/I;9+SDZIW330FN1LVD#>4G2P8<<-/7^VJX4V&9D@9\LH\7)
MX!-S*V<BJ@BR0/E 2A'X2E+BF*]AT)1,[KWH/:_^KCF-'*#!ZERQ*PQP]>F;
MH.WCZISQIV1K9#-'GN_SEW)/VIS)+$^+1YX>2) (^'$X$6YR\P+08[IZ.Y"*
M+E6)!&:I1@S)"YIT<=2 8%F23(V,7ZONVO!FIPBLB#:@5JGL@EW9[H8CA?BB
MX77O\I>N#KE1D+I1S<U[BE+M%;JR'S0+,Z&^8#CH<*>+Q:/]K/D=%_.:B0#X
M!<V(C)N@?K]NE4:(*+LXA*4EW $"4,S]7$@GDQT39AP:4H?@WZ;RWE=.55TP
MS[,3?0=-<.D%OFAJ?\QT,EN,O]J[ B\.<'+]!TJ&$:=W?L]6)##!4/E>Y$E5
MQ_,7GPETQ"7&U9$ HF+XR*WJ7&YNJ?%=V\-10 ?P/QOX?V$EP]NF)I!-*?@-
M+RQ[[;>(R;4-"CLMGT;]V8B09( UF OE:F80+7F/-R$^GMGBSSY_NG_V'K<X
M966O<MJ]F>ZH^((Y>U3(>S<Z$TGQI3"[@5)O;_'4I$1T^0FX+C_[\ON?GN._
MGG[Y*8^01F/&W4:HG!8?]!,\'LUS,F2XS=!O_-4H2B$%N[(W)&==7DK.'(W]
MX#V\_SSK"P+T1SJ#_/F[TMV/95Z8%T^XZ^2IW*M3R;G;AE-('1_RX1^YOYL+
M+^]]YU7/*:Z<F&VF5IJ)Y" AA\WV\!LF#'&;R?Q$9^:3"%Z?FS__5"<;N?Y
ML$6I0-A23TAS.4*8YLA7?+;^R.Z/0N5=#)5L!#3V=.1!1K&/-^F1GS37PN@+
MO"/M1K_LVZ8(X[3JQ_R','UIOG>0L"A$?,E%U%V?]1+=.+"S]TQ[Y0T];$)6
M(#AU^=+(>R9A"M_%GE,"/4SBBLETCT)PYP39#=.B-Q1)D^4G\;?^M1(-9-XE
M/S@?K?Y]H)CS9O,<8"@4A +JWM4RUY( ._TMT= 'FX/$*Y) \4Z.W ISH2T$
MU!>#YWS;-KD_T!.W+Q58@.7IW,>4V&U)U5!>.!3(PMQ1<"!Y'>O4.L:U;R0)
MDMC 7G1BO?NI4S(DEW)EEM[B-F\@2)SF8!+'8-XA.$"U-PHW-!1$BB,:2=PZ
MG)F_X6)EG+Y)!N?X/*('PG@,KY \OT8U8D6C^^1%#7F657.?7#RO[7J=L_$&
M"F.JBZ8 *V@Z-TJ6H*!Z),MX5);V3A,U$G)KN6;_7G.VU,!-5JO4CC8D]E?A
M;9JG#IB+[-1WUKI<,<X[$.3SEVEPDKS9X!>"W(D*_YV[WKO8OFE>FBK]?P_>
M=)YFFV>?/?M<>],(3M)*,\<8X[L;\6K0&X84,NTZE&[4]+C\+1M$Q%_Y?@@!
M7,A\X^P-9_%'DZH##_?3**;,J4&&CI68C9/ M-#6^46'HX!UT&]( =0\<*HX
M2E>V)YIUK.;[G"5^\J_O7WP*UXJ/?/^"(:?T$GB"51\EX%%K3(+L'(IR(BW'
MG\UL>I967\]3,L,;N9%N=N$U%4Y\$]W>:/&X,<"X]2%P(\P^OO\RAP-'K<AU
M&T[Y\NI7C#]7R..'A#S^:84\?C20Q]]DSC&N2GNO$H[GZ-(0<(?:N9X22VY)
MG7B8?/?'UMU0^0!91UW\F4/ ,'S\R1:G:.ON&A'>C8/7]+O9N/^N?3&$=C0Q
M;T902PPM)_-V#2KB=(C2P+WP+<FMSO+4I_4"Q/,-;0PJ9?!QW:G[C[/]DBRM
MS=N/Z2D_('/,5")=K5BC!\Y>&B 8A _#R1^2/NL(&CIE];_> LDW,P2'45*Z
M]W%71[@@JB>*F':RR.090K@\US^[3+5")<;P\YQS"5=")ZT G6N*]Q1)\ZHJ
M6@#GK_I/I-_=4E1D/Q %<Q1.+F9%\=+01ZZ]APWJ39Z5<G7JSEB@T@*3SE@M
M/)]=B$ XQX#&;=M0 <COD9*/CK*G(4]""(7'4DZVO_L,CSLJRT],XXY4WNEA
M29R@<:(4('2J;?Y-5'TAW!IH#LSX(6A-PI<H(= ^CJSB'HBTCH4&VCMN!8$2
M59='VBT@^_/O%6P:2JE)R;SI3%SQ9OYG.C4Q!4*B1*W<-XII#S6$J9-=M Y]
MYWM1FXDULZ [HRQ*9=J?.^5G^MB1Q.?IOH*FD"7)H$*%= TOD4,)C'V$O'Q_
M,++-WZ-X#2*@A%'4K(&L<+(.$Y+^QP(>9>$>@#S^1N*'-4IZEQ WYL ,3'LZ
M&3\N7%KF4:6V!:'-VTL2"052^.4X+DWGQA7[8LWSA/Q5:L'^__>.;N9F\P]'
MV5M%K:D11R&Y%JUXY=SO]>OY[#,NAD8(N/\3=77[P M,;%9@]>E$S(.1WDP2
M]#]Y2[Q6W&WI0M_("@=FWDGV.L/%M'<U"%Z'%MV%H!\&QV8NI.FI8AD"! S/
MFY8L0_\^HD3*GAJ;35MT8+ +=?-O(N*#_"GP(B'TPKK(77([G.G^?'B0G[C-
MO"&0EF32T*).AP6H'/\J/Y8!>3(-ZC:?S'?=/T7K@A:@X%_-=TB0N=P9TUIF
MD/!G6D^U1.U-:6;_]5?/M8_'O&;4+:= NVR*])?#6G^*+4KM)QLDIO$AO=8>
M!+B[2#16.!PF8C[T$OTMM]'LQD\8#[M)]^@=N TR\6@L3;U+2@XP&F"?"!5
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MBV9"$SN*\%B(G!9.:<($@SNDFD0JYX<X[&P4B04[I9JA$:<F &6K671TH'@
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M',$O@L]IY9#F:;;76A"521F;>KZIA^.6F ?VC]J]9O,J%C!,PG51S71VQBN
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M^+>Q+:W#+.]UF.4/ZS#+!QYF^?W[Q)]% T8<R@,4 *#KXN"-ADQ!_^4#20A
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M,5TV==/$]_%B(&DFI\US%>BX$M+O5!F;UDR&C+3L;8/6I$>-*<7/_L(H&&5
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M.^!6QT/5WK2HE7>L_*(E,+?Y[^_^]B,]/E<0@I87E(BB7!+E9?Z_$"_)\<H
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M/V5J-"(/*/) T+KW,9<_A:@^1'&40/VDHQ-''__CZ<VSS_^PV?J;D8C+&^R
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MHVQ'0O(:U@'5U<);!#'[S- 17EB&\ #^W9Z84O2(>D+XKBP\LPZ;F;", $\
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M2%/;<RM<6)2S<3Q (>MF<\&O/_O\Z?[9>_3KWUP )EB8P+3/98LJ,:-^/,K
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M#/R%([6KI(*FH-=B#R19RW_-UW&C*N4B\A\T@+8UO;QIQ-_(SFNT21HS=,<
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MWWHHXDQ%%W_MS6&EF@9AGXH"R5)YII43M>0S,N4[5YG'X.=/+']DW8!/V--
MO*<3M5\]AXX J>5+X-_7#7\YOB-9%?8IJ&-2DW>:FAR:U.0G3DT^?COS?J+Q
M"XB8W&K,7^6G .I2#LE49(+A+7';ST9QI[2X+)O:]-+7X,O?L/:J+A2=!YU)
M9:_&]EEV6]HI*@IGPH1H1H#&O6G*#<;P9-I(>^6URMCBT1)C;2WS_CWOQ%0.
MYIGU<5NF5"P!Y<+U.PMM: 'M5=NHG ,R0_HR."H:F<RS"RII44L'(CA%/X-N
MM1>NA=M^X2075TM/U3U4<2N'E-_"_,I/Z!?XW9%_:5CR/L]XJ,_EH:Y.UD 9
MTV/FO$E923JV,NNIE1A1$=;JM*9)V>+E@FC?@9DL:?^@<P\@D)EZ%W4UGY*/
MVK0T<4LJOCQ1\B?5A8 >PFT39H1LJP[QZ^8,$Q67RQ3R19VBEK4%%?[IO&N;
M#4NLO^C!HA+))-;=Z\J[EZ^R9NQ&[YXKE79Q&V'3.&4YR(+%-M-!5N"OBR3H
M7).WY[6V]VW=.5,7>N)IU<Z<U)"8SC9$TJ)K:":N#Q>G@*6@@K&KQ7O1@JI(
MK?DTPZP+Q6S0YGIVE]MTK%WT!Q8FJW-_H_(NFD'985EJS"- 97E_B"BJW225
MQ=<6DLN>7%QV68$Y3F9WW0>VJ0;M[G1AG>>MC_*_RAH"F- >U4;Y9TA[+,=U
MPJ5THA&OHN.\!/]2LN,*A2JK5&: 63^#:"%3,/BH2!I6 8ZP,PNI2K YRO1&
M.'C?"[S2+&^LV(ZBT&KP::!07/"7"&XQBZ:A%?*O?+VXSV38;+.1_=CX]RGR
M$N-H/H";C?IM^:X?B&$HFBRJ%ODN":Q+0<>8LU369].W+ZHJ6^AIT,R+&5/*
M+[MR88IURS4C^995G.AYM6KPE1*#OFKDAGND7(,S68?QJ1O>">O8N\7<,HVE
MD'C?9.9)ML"+UJ/,58QLHE=SR[U)[>*PRSH<&&MQ:=U*J&+/IM;:0GPQS\ 2
MYT(TRI,N V&9+?/,^DRT$"5O9&AUAJ.U]2%B_SP*H[))>P<KJ"HD9X)D^<QX
MCIRGLB!C-BM5!0NQ.JQKRJ%U'UAN.F\OWQ]KWH), =A'I_1) "+XBLV0OS8L
MY[.;KQUK[C[!!.#V[]BQ^0L-DGJAR$&>,%C<7MMN8NH[C:D/34Q]Q7+ZST+W
M\4P2M&6@^W3^^0_K_?L'V(([5WUC6_ U_"I8B+Z";_NUYA?$13Z9-5\%A]9^
MK-3[V3/DSZP;#%BG\$PUM\$3P>=VU=H(PAM!0/;V?^?DC7R69W/JBR.Y'7_7
MN.[?8Z9R;7T"A^:2^/[!UQ'?5<4PMYU$]P,*[K2H)YPQMF[N4HBT1/;3=6[H
MYHMX4<_[_'T8,43.,YZIF+[L,O5K627@W7_AR$BA%%*$!B@-Y&8,^Z1RE/_Y
M]O.Y3+VTX R4<OC"C>4%-D8)O#,+SJ.8-$+1;R;:9]38][#!=O*2O7N!99"&
M!]_L1O[S$O.@R*(E6@X*)MS(7W'5\&DB&=VZ#_1>MN=*_^1YHH\^!>V%WO^#
M3$!SNLI^3B;N=\J&]UW2P:#5.2XJD[2 H>\)M1&F4^9\IY6XB:K6  =HYA^B
M PG6,TSF%!+$MCGZD^A:#[GR:Y&01240W6?E6^2G;=7=3=R9]1Z$')L84$GX
MA&-/'LSXO)[0ES";_IK*!HC;641/+WE),9U&]-Z;L#''FXFDKK[Q'@__I,+3
M.GSKC_[0EM>"[@ZRB@O4D<-<&F4W#-6;1(YD5L-ACYKKT'NI6.IA;L=Q*.DO
M!=X7P3Y\0N*#/2=(VXWW=2\@.D"6;,7\->%7Q+:>EJP6/3.FK,@LV7_K$H.0
M) J-:J8B<09OOMD4L^M;R.GUEY)-7/ Y@G+=XHSN6)OV*J&L,!+ ZS&F%UQC
MCHZ\:->;@TB&:L%]2Q6@;&EDBEVVPEM!+JXK),W[4G8 OJ^]_?RM@F4_!Q04
M@57*;/CX/4=$@4?-ZD(VCE8]=B3AK*(/PZ%TH\!O8^&IN !&C^JZQIM-D8TD
MR0;$T[<3R#/>SMX#:7>$M<Y%/Z[_X+4;R :>>XD1^D_RVN61]XW>E>A3R29K
M':7]$ N#O0^3"BXK47W$!"I.??_^O4"EQ3I4DA8]6U&PK]-UKA":7BLKS&UJ
MNFXJX JI>V39?8Z*N%/T?6I>;*E]BD&B_4<B.GM_TJCH?X5771IX.3YXV9 '
MVFCX<6GXGR+/02:7&,?A"#5;Q(Y^X:E(\AIX%#X:V!965L@SS83/5+J*K%@5
M17@%413+"&N%7"Z8,=,5^Q%B8"5D([D[$JWG8#$123#41PIYH8I24;?@.['Y
MXW1>HT=+9[3/<SB"!7[P,OGI9? 3GAPIXCR2$>?]VSZ#2+M I,\<+YVM+ZP4
M]WK8M 'O"SE&&KJCT;,OS_/L_K&#U8=J6SVZC*KOO:K??G^O6H_)RWZ,G9WG
MV"V8CJ6?1*-=X[ 8#-B/O7YR#'CT16:7U#3\BD'P^HIG^P$,%.<:8M)TLT^)
M3+A >YY@<&R(LV]*=[B3.YATYT?@VK,F/(],PO/A)SPO6L;1UZZ&IJ':CSG1
M3.^+G=PG\SBV1F=:Z6Z;W/M+NVK"B:?.L04Y_5W/HC>]"L+/75_RCRW+Y48^
M87CF#D?[8I[BA:4\Q^JP@[/!ST5-^S_5W&HNB:JU1K(6D:Y1EA51FF1]J6*:
M5*GHXT*[>]769$7'>\'^\F])--B1OW1/:69P[.QX4T1/;)&E/JEF7+5C@G_R
MLN'7E)FWDB+8G&R>?;[/)=!:7A$1G!0-=HE!&N-.SK1+>WN]Q.,SL3L'WO-?
MLSISRJHB)D!-3*G,N^8Y97NC,-,MOVTA%S'FB6*F)99YYXUL=]4U"E>)FX+$
M7;*OPT_F$TE<0HF.+14VO:G7A;L6+,Y%,I]QR9#2=&SP::<NDA]:3@W3#3C,
M5@SH=CVR-7JMLFT6+@FWFP7&[2\P-US=#Z"JLA075^N=7+W?Y.I]:5=/I;[C
M0.0S=*;LL_U@)=[;ZMMC*#;Y>(6<E?SZE Z)1P?.MV2R4D*F)>BS))T\P#BV
MHTF*2F-W2R433UX!1(FRDPR;6513U>:1VIW7"#!T(L/ZE$DC81SP<X8)\P*3
M<TJ5!?3$?Y"7T7#9*Q>I^_"%HI%LT2#9!F#L^XOS#YB3Q;!8AI?T*SKPJ1X8
MWXIL@DQ_#) 4QRLX\4ITF*9U1;0;*0RR0*(?P/492XN43V?$5X=, S/KDI@(
M&E[F#LM@P=1EVQ_G;]X[[U(KGS>RX<F,%[));5)6*1@%V-1+Z^?S=^^$9__I
M\_O?Q+@2L#(@/TY*A0;3"I>]$-U$14:M6A-TQ'".@M[G$UX'6'YB??S\_M?W
M'Q9Y_K4^CP3VHMB=C 6RH;"46@RT<T2CT.M@2T.C%6T;04XKV317.89L1@Q
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M?NMX?M[]<M[U62:*5&H&JIZI ;-ZHW_7&W':?97[QR_G8M.QR S+R9 (L\S
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MUU3"*[1/+F-'ABA74Q:3$3NY1!%;LB/J34XEBZ@RHK4X'K9Q:.GWD6LN6Q?
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M$CXGU<19J@I?^@$=B1P\$BU6=\IQ=QC1[:S=.MQW;";\"4LY(> &;U)?JF[
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MU)#XB1_^'H3V,/)4ZK2:\-\/6=ZWI\D&N@QT'0=TN2R*>)KFCI\/(R?(_"%
M5Q X7CP,XT'*O("[B]#E)S& %!\Z@]3C %W#H1.#0 'Z18&7^_XP9(-GA:Z!
M'83QB4/7EN,]QA->O0&_L_H;E[FP+5F&,25'K5K&@N@6),M#STVBP,D\SW."
M(!LY2>RY\#>/>TD6YDD8;,/Y[32M8Z61T=DMV0W/"VUW$)ZXX3! =>I;>:1
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MW&$:D' X'0A4::3+$*(N+BIBI#5>;41UGR=@]'*IW5AK/SK 1]B&%K1U@$&
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MO9DL:K]//NMZF%CW_;CY%&VV/^9<_OT5X??:=+0\OC@05-D!0@)"[JVO3-I
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MAXCH93IJV$N!2"FQ-B4N&5GK!T6E9!6C"CG"/.*ZQ,@P+% I@Q!!VS+J[L^
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MI=R,FV;\)6[J=E",_"3IYG;<3B"&?MB\!I)HY0 #9TJA+4&5TCBJW$PAI4Q
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ML$0\JM51RU8::4(-DMA5"E=2EV8? ANA_NH=^A_?C-.&D930GR"M"31J0$M
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M_HH*1W>,'<%DYUZ9<M^.H&7*K1E;TA7EGK<_3>1*H@T"'!0@B?WK[\FLPD:
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M&&6?\[?QM@N\3X(_&M_V*?^'[!5,OP-F3^GA%>QHE;>T.KJ24?6Z-<Y.%K*
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M_?WMIW]6)\>O?__X]M/;XY--<@NV_+35GF:OO5G*=0'^0POF4,ATOYC/TFM
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M D7<I;@CU1A9YI361C$EZFUX>GX=#DX_A='Y%NN$N#Y0]?55B _.),\O0;J
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MXT[@D8U_/_A'=Q3)0T*VU=-9'5*Q2Z!P6&4)=\7F25\ X04$-J6>WF< #N=
MI>L<6JYO)DWVOXVSZ[_)9 17 3UQZON/9M)/%G^$JX!":9+<&R?-S[G)J,G.
M+J#3=+/>8 (:7BOO^B&;8N<@6?N 4WW0*CQ8O)V"N*@0+N#7P,\YIG=^#A(
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M'0K"[<B2B]:WS5%0C,4:K$QD2 0-3OB8T%(BII7%!M RNI5ROH?3^MIDX"E
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M$ER<O07L'L>2%E+8(RG4F"LKK436*0!.9C$R6A.D\[&_DUAZO=9Z8!?Q3TO
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MD(PEICHRAP@!C.5<!V2#-H@EQ1+VVG"W%@@AJ0K6T@#$-C<^3)@B0XQ$B1-
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M= K\X46WH_O23D?"E,#T@HJ/9VT+*NX?*GIM@)Y'AY2B&G$@:\@)0A$#;'3
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M2TH3OZXL1Q]\>5%4=L4E,U<X?;EFQ!&5O.B8@F5E20\?RYBU-#EO$%:)(BX
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MTN'P"6VTHH56 CHT(Q)(]*PA8> $V4 DDE3&(+6!_UN+%NR%=?]M- I?Z\$
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M0A(DB(?)2OS['!A.YKC0%^TF1TP]\ GKGOIL;M?*[I<"P 6 "P#O"0 3JCA
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MWO3F#U7!YGX33RA?H>R9@7<T_;].%[[U<_LY=FYS9!,,]9D=?+473:X4N;Q
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MT[O6.G[WMOKXZ=V+__T_[]Z\?/7AXWU<CCV_Q,I!1J^2Z7Q4A%&&J%<<<4E
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MY"K&[3H\4_*(!SB*=2S0XT"2J#:0ZA!L/5(3SZSMAJ@59G82(7U7::6CNCB
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M7?6>!W[XWQ3AXVWVIGK[%7N=M>,>?\<7A$2-O 6T2!_ZXO:#.'H:*04C6W;
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MW)90;(X-V3>X,WS=2^/03QZ4)!T, C']+(!)'^!9%+@7"T=Y94K^\*1XL70
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M[5LV3(79KY3I\G8?6K/B]Q"AQA-LV1ICLM?>MHRU+</E6O]?.+Y_PE]"@IV
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M2 :.LY;.U*..MHX?CA^T1F::,;,NCK=X^X#)T %7T9ADM$^4*''3!WR<3=+
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MZGW[-AU*%#I^_:&H_+J4&)1&>:'ZV:4,_9YVM7JM/0KKGIXU_ZDB^5LF?(#
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M"=Y$&MKQ^2N5'R)"=S&]L%DN)KRE$. ;!71HCZT:R'0]+L0*=0N&LO7FBRQ
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MFSSONX;-B@>7$)[>L9)#4XOY=*^ T<5>M:3?; +OV'AAJH[94!;G=>98&C&
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M9P'"5?%0OVKQW79I.6/U!(]9JYT PFDO0U%<1XF8J(O8:6\XW_9VG["70L1
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M39Y]6EJ2 X24N)<92' C5 @!E8_-9W@1"IH U6[TN%0_:UB"KT&L8D<63P*
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MK@^4::G=JAU(QYJRO-E\L$X.E->BA4+CN;2@R-7VP.1UQ*20OA:NNC&1WYG
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MRB6SOI%)+4+!Y].031)'A_^FYD,%EJ^8D0QKWD8]$)_?<0P/'$Z&1QRZ]#H
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M>?:#?CP?'H.:E3[G$CQDQY1+EW<P^5DMH-K7&P$#3Z_9]>8J"A^AT!,(R!/
MPM\0/W3]'>46A&\G"+B'_6SZFCA3LQL4.*573MX1*TE"NSJ&OA!3/NR7 B@9
MZU2WPX!B@H5H,$\:Z1+GE:=!VS<_CN.HR<I*R4T<F0DH;\$><&6QIP 'D2BD
M'UVN(UY'R5]QLO*B'20/FHS5Y+TCWCU248:T 4!(!:)#0&(,7]F<!".G8X:
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M]L+IQKL2I*+')'X/\ Z^//Q( >6PB#F:#$L?MC^1OWA78%[Y#?2&9>#?"KF
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M!1O,EOYQ;F)%_1K1E#F@P8?0Q9!XXNY9T_/+PNJ[;<HLZKK[S)0Y>$::Y7>
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MW76.ET X@@A'&;IHE9$$GG@@)!?)6%S'*X[I5(<<<C.'=T63KUPX,@KD$3-
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M<N1?D] W*G@3T9?F883?&*K?743E]Y'&&*H<"4BGCD\#[FC(EO,._3HA[[@
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MA>+SO"N9R^6JPS=)=GC.7_Z*O&P3KY/5NQN$1"L3)P5<-/'#'N6<RGMR6%<
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MB?!]%UW%)-T4WOD4M5(PW(^\:8M.P$Q;=L,Q/(6.CI!6MBQ/FD8Y70XG%(L
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M*M0M(W'.0F4%G_>; ;H*<ZF7Y %XCMVB_MB=FES09:,.M&H_'35S]9&-7VW
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M3-LEI$@3,H,2MX9QFFGJ"G*]N3\&"AKRUDGY4DFKQM5%8[U3;$#I[N<\=!1
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MC9G0JUI(VXD3'ZKHKD0XPI,?[V("!EV,R6&#JD&?R.-R^, 6\]N_/!1__EN
MA8O$>SO<X]L]''%+"O[Z19ODR?^P^M/,MR7%@<;,=#/PVP#CW4.<(>$92]^P
M^(>;$)ZZ4T0%B;TY$>X.7K/?OGS]>N14ADH"H2=9<\&T%O#;%X=VN(P@/#\+
MJJ#?BKF6%%M,J9415J!E6*$%HN5>[H\A1#%$))W:?C?$=B*<^2K<7=[1A4.Z
MNB";O>AM(9^(^<@/AU)^A"2WX@_O61>$4K04I1M<" (X!"OQJ.2IT!YUPA;M
MSDN%Y$Y&C7@/*4F:WR' 1V@'PLQ5'.$S.0OPGX\),X406^BHNZ=LWQ$Z<(H>
MF+EUJ2-V-G(K?M0=:#[>I)T4JO]HTLFRW @GD$MV(..55P)M:Q%\0(#G1?XU
M.<_HT&GDT /Z()]&J;3H^<%BV0+2D^/3VP!"&"A4HA.A#_HQ946/D_!0I)FV
M[M#FV=J^8$%9\(K]H"5F)_5FMP_C T)/%.Q80!(?ZC G2*N\\2\<2EE*\L<Z
M6$A G9S0L >-1T><*L7?WCV HF1VL3J)/83\%-3#X&-,$DE1#.?U=LH4)JP?
MJ@4F^?%<DD.+05IC8<Y,1I.YZ1?G5F;"CO8#.G)3N4X4_DXC/8,T[DZ+83PH
M<_X^N#LT[@FE3FZ,KP[<\F)/J=)K/DY3*:?Q*,2V,DP1 MD]L=WCH2BL$@,M
MRIFHCX<8\59OHFCFRYP:X(4@%)X\ GRG\%GY S([P!_IZC5!:(BZJ>J[P3LC
M4>%%TA#B90=7!LDE0?Y,'9?W.;//T:ST<]NI1/>=2#>Y*DE/Y,_4*?HZ8K(E
M@6<FVE>))U'K)AX?(OZS992LQ.\A(A_MLR]TGEAUN+TI/O0JQU="G-P&R>[.
M+Y@;*SX2#OW>T%#%+!X(R<%77'H]< 7K=8ZJ*<!$RL:V9901(J;W)G$C"D'U
MA/9QDE6G3U?.BIFL^73?142X3%.(5 (K)-ZLUV#;C(G.6C6#?=NP@G"\B-"!
MRN6W^#9@+EXJ\M0EK2"B*2>3BI2F\E80).GA85AXY;"0N7ON5J0BK$L]*PCL
MFO](=U)VJ6L%H7+F'A YUU$)(J^<Q)8J5I U6-%,_@<4P(5>\JN*!U.V;P7#
MJK'GI0)$CD)7,:-K72L(K8*@PR6(]F[@5R H\,E$; STJE21/:PE*YA0XB:3
M"^9'%&3IT_,/_>7:6,$*D@I7K[MHGV<I\?/ZJB>HH;@5Y&S0#I"+DP.U?&EL
M)H2"PF2BHG-(.\9%]ILH@T=%_A(&WFT8NS59O5; BCGK^D2"S,>W^"4^YIG%
MVS ^5_S9=!?AY_RNQ-#3/:^JY:R8N4(O7D%VUAS[RK)&":$ZG$10T=2//ET9
M*V: V]B>\5L@\)!:OGJ(B9B)J!25$F6H^!U>% ]Q]A\H VS%UPAD5-44SM:9
M^37PW?T9[/+=ZA7/,?@T\$2_#&NB%,:H5N\-A=LG]!J M8:H9*OK961[YADR
M6%+_'D1 >;%6\I?42P+B;0+PG35.S=61\1/^SMLF3+>YRC*"!HV'=ANZK]4S
M7E_2@G50P,"J9X%(1MR9J$C:@.6A'?U-J=>8MF7S3!*MXY=QDL0?$*Q%HE!J
MRJI.%<R3I!* J2.0* 9OWI#HA52C<U K5ERLA;CR Q=-,C>(")@<L\\W"CC*
M&E80!6<D^J\<[[";=Z)6:Q+8M(6M($4CZD/L%'4N4I'46LG\OE-?AXH[D)V,
M>.S4[[*"#GCS$R5>P,"R.EZZ(WNQ8ET(MPH<-I<'DF6L]K3J4-S\6I#S;Q&7
MJ[JC56UN.]6R8JXVB0N!D )69^1?T:.3?6) MTW'5.]&K"!=S*BG%)$:"UI!
M G/K?'23[$",ORY!*V^\(]OJ6$$872]7^FM$*F#%D)EEA#K8J88L%3!_LMWC
MZX*J^$GXY$M,G[WJG=ZMAA7S(/@X@Q>0D,N&"L!*U65+'>,/6:HU7OD^ELU3
MDJ9LG9"\))%74U<VE;5BAFK>',3&U,GO@Y2TB@@-DL55#+!6.>#^4(&WY50>
MT9P5[+B/\1L2)3LPFS;*"LJ"5I!0W_80ND[?R_N0S $^!E.JVPIBM7&]9QL6
M7 .Q&_'L-QK%>[V('?,U5&O)'E2_XH+$DXSH/2JO*O+Q&I^=A;5U4E^*84,P
MOUK468G[/(LZUS9^Y_)7S6'W$H?52U;Z:,5V4&'G=KI3<3DK"!# Q$7]I/)%
MIBYJ?G]T5NH(9T2+?J?(^P R -SWN1O"!3I<H32^;RO6RS7:)\BC*>C$!&$L
M\PXBEE#='NA4U0HRF6>6TB.KX8'<H9H5Y#7EN5=N_8;R5A $@FT9[:_5>BJ*
M63'\6H91K=Q32T-J>NB@FUMOY=20Q0E6F/BNW#W^IM,#]&G!#J)[>%UMWA*D
M7(R]&[&"=$$*P%,29&Y(UR5SR_=OX^0VS_($\2B$%E&B6R-6D(YOJ7R7$T4N
M.=<5 (SZ([1S9?/RU,T.):]X1?Z*=U[V!@-UHP/HM/*TP=^M9U4K9A2O,RQ[
M1?1J]F3-?.23_PRIWJ>#H]_@QLS/^ _FNE9QVZ:>;!H%18<ZQE^3DE;V"C ;
MDDW\(1D*&HI9L43%H[+08Y%T?FT'JUS:"F(:\_H!'@0D)@ G-I8SJMV7H;T-
M*PCO&N.U^8CANM=&U/9IP_RQ,MC; A^E6Q2  *#3T\WDYM&S8_,L?HS<0'-
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M%DG]7)VC<_X3OYL_%/#+*2#)F>XI>DR<')[W+OXE^W.,?XB^NVGJYEC04$4
M#FO!BEEJ3C/PO<BN^(PW2HC:S+'#6[."&:J# <RSX*46Z7VY6FM909Q>6VF!
M/K+3PZ?W2\D*DJB#(S'8KAJ"AVNES)^)?\:;$["IUULN]%4%Q89BEBAO.&YV
ME,%=H];9R&6L6#3T3+FGC[@"N?J^"0NPI8H59(DZ<?U[K5[*DL$#;"1^^3"M
M@1"LBA<^?E1J=.AMM:P@CCOR/.<O?T5>MHG7B7B9R\>L5J3KVXCY,TXOM5TF
M0?KB1NC*#8,MEM\"M[?@IVO"BAFO+LRF-X:JI!5$%+I0T2%*&VZD*VP'*4,]
M4+BQM-!4$5OSYLV-RL ]&H5<-UPLWKD5K"Y3[%T'Z9ZISM=;*@<KT?.::UA!
M5&%&@<PI$?CCD#G4A!NMLEODX],K)+@#<&:5]36/NTD[,'_R:S%CJV:&]M)6
MS+]&@T>MW%H5GN:@'-24\;@?EO2E?I/5/EHQ8^)S*66&&0@+94IG&1D+@O;#
M.,V3YIC#L6U:P1A-S$7[^[\H:@49@R_5 E932&C#_4K_% ,^"H%_ B\/NJ@G
MO=)[]VX%LW\\_QKCDYHZ\[\B?#]5,Z7J!=RN=:T@E$I<142Q_AFM+&@%"27J
M"A/"Z<U"?\:K3"F"M5:R@K3R/,+2XI6;) ?\\*.Y[G3N"RU5K"!KY?\U9ZFH
M-S&7_] #RDHGGTT,3H($SMU'_N7A1PJ8X05Q*R\+WH.V-$ES]&,% Y]S/)7$
M%0/H4)[74@DK!@UG8"DC-(/$JTI:043Y= .+U'I[F:=!A%*EX*LK:P4A<JPC
MP:MZWB?(]=?1G]PD@+,"+F7EX=FUKA6$:F2Z*5WJ!C1JB4&#^<8^H3V  T>O
M%#=0;=A0E[5BCFLXV:L\>XL377+9AN)6D .8G+@XX/]>0];SF 3!,HV(QF]#
M7\&\<D2#6TA2U/>#.A2JF">+P$PI0X&++U8LIUK.%<$YONG5KRIO!4%4W]".
M)&.5Y##X!4U5W2QU;2J:P$CFC$E?ZRU]6<%(&+0ZB$5=POQ!P=1ES_$VPTQ&
MC<ZA4B$K^"W<EMJ YVH92P:N?.-3570?K0"K8051Y$+,O8QHTAEXMT8DJ)4S
MOQ.NX@\2L,E@JN]#3W/_ZPJ:)Z'1G$$-._ C0XF]BZCBK+9SQK9EQ6*$)")X
M[-U"\K2%C;^%V#AN@]1S0\"VN,%R=,5NV53.BKE0W_G=I0/CL[#*_2"+$Y5G
MG?#)"EX7S_]2D=BH)2B+F3^_'E#^ C[%;_@_]BC/ @_@8G7@' V%C2\8JI:X
M^4DBLHB.A1Z?:O5%O9P52PF0>,EH='Y&4@$KAMR2P[/3DU*N8@59/<@Y"C)D
MQQIJJ"\-(CU\<JI5K2!3!3QXW^31W%C!@F,YCG;%"*F<5XZ3V/'P/:*6(KM7
MM6+F^%D@82\W'1I202M(:-2W-H;7M56S@CP-JCP/ )\:K;Y7NU8PZ %BS=!Z
M6X)/J,BME[)B\$)H1Y<<2PW%K2!G%>*A0 "$^EG38#7I5M,*(I=POW)_FG3^
MHKU;P6R5I*#UM]$6MH*4!NR.=F_(SI7-2T_4C]X-?TWB?(_''>8 P4524Q&@
M("Q$\$.8ISVDF9NX"[X;UL2J"=JT8@U4)<+;]X< ;F+JRLN=5%0+H%M-*XB\
M#L"!*_)3<.=2"I-B 2N&7,4+ZG 7MU2Q@BS-(_+J#2Z+NZB& @/W [U/(#^+
M+GWI^%;-'U+DT/09NBUQ*22 X<C7P?$UE[=BMGLEH&+Z\QE26VE;-C_K/#\B
M\BFH  U'ELQSQ46J60C]F[!B;5"O1QK9H\,<;BMK?OZJE^"?@^PMSK,GY/I!
M>+A&&4IV042\)+BT^X"R*QJ6C<4!U04[:<-6S'4A&;)74Z-WCK:P7:10(;?T
MHI;2?S;2U5C3$KL)?G_A(\5-#K=!B!*-SV>ED!7S4\GSV+C2=&6M($0."JJB
M';5G!.Q3WPJ"!V"XL@S?>I%P2&M6,(-<;R_M2I4738Z(2B@\]]G3ZF^F[\H*
M-H+G64#M4L1="%8!#[KK%&S2JP$+Q!$>,(W@/R,"%4(,=/S#AHH-,'$:<;)_
M$U;,]-BD*L2#M<@Q_6NB47K,T(T5[*-6W#X.6\TUS&\%,KXBSJ:(O;F+\*F_
MH[.FV/<]JUHQ=_7DE ]QACH&\7>N; 6I')0=LCIKTL15BE@Q; %Q[[(3+M^E
M12>K',_'V0MF&;@)-+;YQBI6D-4W%ZS5"6#+!'?KCPCYJZQ0"JBWB*ZT%<20
M]S"X<[0_<C1%[2 CB"#GN)RTC!HR+^,DB3\H1#[^HC:P]:EO!<%5^T/3?M*5
MM8(0%<INJ4)E2,)=%F?O9LR+3<43)_L>A/B4B/$B? F#5RKV4'&O)C!UJ63%
MS.*Q@*H<PB; .-:&$*$M;04Q:A16K2]"0W'SRXY']))[EKV5\,.S$N!+7E)M
M0<'=FS!/-D3WP!L;\+N+&#E06/V(L*3Q@0^(#$6W,5@IUQ'W=,12[7JK]8^<
MLETKEOD5% %P<YC1IR#]&[T2X2^U%*TM;@4Y@BT+#S4-?*:/+/U#2"0"/F1T
M 3I]&K"#Y*%*D_LFE^WQK5K!'/U;Z09O18_DI$0)+&GWM4->^I8&S!]YJ]<$
M(7V:=/&K%?/3.5]QIPH6\+\FU*A12#7EK)B3R4P6[+]OXV2+@F6M)<U=6\'F
MZB,-L)P\%5.4!:T@H7X#E#.%IP(QFX9^-_=JP J2N2<!7EF%M%=Z4ZAH;*YA
M!5&7#!T-;[H79GQ:>?^5!]21B_D\:6.%NM>V@EAJDR[L#BWI%U5%S5\S&_<G
MQ,!_^^4/WW0)NZLEK."]F!!$D*/3RX/X11>.V[VV%<3*NBE=:L9Z*?/+ZQD_
M4E%Z]81\+"Z"7,*P60%!3TZ]K5E]?1NP8KXJ&3"?4!8D9-]W=F;H6MT*<B4?
M5EAW5)T#8#7Z#=A8Q0JRQOH0_(G(CY@P'BRUB>$G(;O\#,DW>O9M')__"0A2
MH_,+G\P?9#SJ]XKE[TN)&((93-3F;M@4A#FH 2NV +@J=T-65BWB[K6->]->
MQQY1RU!_'PURD+*0'3NH>LY*'ZQ82IT\]!KM=/U:L()HM==./P<&L8851,ER
M9G=7>BM<YW6JD.L@S#,UT+"FJ/D[J>[5QWU A9\>XDCA'3BDOA7S5HL1U*=*
MN,8O[C13:\(&-'-LY(\DVPIR->&#*M(T1:T@HSG&HUL8=]\VK"&\M'D!\I\^
M-XVNK!6$%)YWW_%-EM/7>%K\^&\!WD58MF](8-NK ?-7BPH0HT5,ZU//BCD=
M^\:^^8D2+TB!V/D>\K5.K&"=_MJX;W(%Z%#-"O)6OD\L#FX(WNEW$4N:)_CH
MJ*AKKV4%<<_>&_)S\$UAOHUXBZZW]W'T"D[?< JWNTSV;<,*PFO"CRCEJH,4
M6JJ8/Z?!F2C*P@.%GQ9\ 9(XPG]Z])[!3\C_0-G*C_=@VFA55(UMTHK9+I>H
MI&LF>N;2CJCUPNQ1W0IRY:=V>IL#:AU+QL@?WM<YDG[GZ<6>P.<H[/""']2L
M%>QIQ&@7/5'9?:O6!/1OQ0KBJX\%033#)W5Y@@-V11"M(P3VWL;(E'$M6L$4
M6>O1+\JH:UWS]P/)3)U!SFUX&X(J<?,1;][B/'4C?_.!=^AA\Y8@_"L*WQ5V
MF,&-&-?H4^@++)/AK9D^XL/:#?]OL+^*_9I:7U_2$B*(KZA+/$2OW<Q5J//:
MREJQXX334YFW1?QNQ8!)$#A"-$6>_FFO*&;%\-=X\P)P&HT@W*NQ!%H+6T%*
M'<22R:4I%D)T(EQK)2M(D[V/]:M,5<[\_;))_%62W/S<!S2XH6HVU1:R@O==
M=:J@KN!@=(44,Q;:IU?S5K"K,5#R1^07 '<W/SU<=+6#_U+*3T,:LH(%@]5Y
M5# L]=LIL;-MWMQ(B3@RJ2JQ9]^62#U_1F'X[U'\$3WCY0& F40T2-1BCZ:P
M^0-RY;T%Z)VE$W[>(R_8!F0"=_!"=,,B$%<7+MFW@>/8)FDWM3<J%N6?4?#Z
M!BYMP)17Q+\3F,E!FV72$5BR9<#+/-G'#,X:G,VOX.1,#OIG3V,5*]82N)"!
MOP_^!PZR=WQU@@C7CK/<J:+Y$T)^7<M64(X^H!2KNE:T8A:+T =Z&<&FQ&<6
MN')I/(0;*]A!4K[;N<EAO2VP"26?M&8#2L>ZYI>GH.I9<6W/.D)<I@!; 42N
MAJX.J*YO U;,K4;I7WJL-JD'.U>V@M0298@H;\%GO()IW!S8U+6V^:5<P5.2
M(SGQ O3 ._DFQ8U],$U!;3'W;\**.7Z$'+0DF(2(_J#D3(JHDB*#4S<WW*%M
M6<&(FD'W,8GQ,S0[P/G#5R])Z-7)'*RM;7ZQ5]4-LC*"(%K*&HBOM<7>OPDK
MYGB^=S*-JM$\",@C&N2M1LN9-8,S_F2YCSTW?'S#0EW=>TKUW8ZUE;^D@1]@
MT4V =]&*L+K"=I RG6?:Y(_S:;HV?P@7(,TD)4:>>&\0!X$OBYMTOV\#=M;7
ML6+]\#SJ"("-PDX9=UNJF)^O$H0,M ::"5(5LF)&>(AA>^Y2BP;=Z%.C H4C
M\&<,CB77H;^,;=0*UJ@RM_7-]&95.$ 32,O-*(B7&_OP70H%UGH+Y\1M&'\T
M9SEI*&\%07!7)^@-GG_O+!\'5:9VT<5VK&O^"M#[J)<&;/!FJUT+72M:,9>%
MVG&59V]QTNAYH"MK!2'KY-6-@O^F>02Q:(B7D\^!,Q[Q00X^J/"?^'2O)0IH
MW(Z3-&P%BU:>1].-(:JQ4>Q%6++D"L2SK&)&SR:,ORUYI/XJBG(W?$+[.*GY
MRZG*6#%?A,.4J<J%67XV?UJ6B)5<"4J@;/=N=!#B7@38$2QC<;^LNR+C+L%]
M\>$3P\,E\&;T 80?/K6C=I%>K5@+ CF/;K).R!'C$P5.4R+&#M7,KQV.:_R8
MOV 9@ ,::QY=386MF*DR'U/R'GA(K>(H4"4IO/4FIO%AQ7<(*J&1-4]%,#-]
MNN!ERGZ"<DK_V65'8'[]K#"]AY_X.GZ(W]TD"[0>-.IR5JR:L3"E[3A/%079
M$P+1C8!N41PB?/=!S)[:(]N:T=DQ645,V'#OH@X!9R,;-PY(Q)*?J$&]I(]6
MS&KQO+GYZ?*$>8\H<D,6WL.1NAN 67LV8079&[0#MZ_DP+1&5(PJ=Z:*SK8Z
M5A"F23(/+C;$A5ZI.FNM9'Q7@;]!DKX%^_I#7?'9BID -5;%^T[6G4MI/ZI^
M>D3HJ,=P>&'N$]!C[PW.PQ(_7^<"N-P(K&#ZKR@"XPH "_KX+ I2DF+C';&S
M1Z]>[531FI?];8"?-[OL)DGBY"I.$D0 ?&]#5SJXNM6P8M[*^W\598$/&&.8
M^:4R'R\WO.[P>S6!-,F[?<[53U5XLH[ #5/U8GQ%7$'P)MZ:*A]G\9L5LWQ=
M(!;C4P-O->+D((@/;1;4/O6M(+@[!FB3,K9_*^:?I_?X#8XG@T!5AK@0\[%7
M(^1TJV'%C H>GW<1\_DL89]JWI^8&)1D6"39)"Y<F]1QKJ.OX5Q]&3^T^*4D
MY"I6KHNVLE:LB!;)88"P80=98ERWSL>K5LC\P2-$C*U2O 7PXA$Q/G_LI:P:
M[6%GG1NQ8M8J&B790UMXJVJ3Y/1JP J2N4F.HR,K3Y+6PE:0(CF_Z=\JBF)6
M#%\CIS +\4AIIZ$5*XCGSF7X4+_&1T<8$T]X=J)3/X\FG[2&:E:05UCW]2I<
MJ805@WY,T-X-?,9-'K-!Y:('7+T.)=.OIA5$BEAM7?+Z= )]Z]R092Q06P9$
M<#(P U.3 ESK]+<^D(]3]&"- 'Z+'P=NR"V<7JZ5OFL%K9CW1B0- :!/-:-=
MZUI!J&Y#=GQ(]JAN!;E=YP8<"C<?\9CI94U803;+2( EGRT>/<'2O44H52">
M=:MA!5&%6- HE]=+F7])8JYZ"/DI:(/5J<HKJ<GKGEI]6[!BQD;JQO7 1Y,T
M; 6+&C,1VI& 4 S#0_^5PZ/BO747:LK:04@A@M4"D<$44&IG^DASO9JR@@W"
MZ:'7$-0*F3]-83'ALT_"\2L]6<E[ZT#C/^YC-UHG(H;+'0!NW_S,4.3+T,33
MMFS%_,I(-HW;55/4"C*JBC;MJU-9T/QR99+5%?X]\(BJ_CK)7[^[4;YU&;8)
M4P[4+5D]ZEHQ5VJHJ%5&PGCP8+7A_)TJ6D%B>>)W\A,&+%B/B2%53V *?=_M
M>IFX,RM8*6C"&EXF]5)6#'ZL3Z\0>W\797@GIX%'5ODL'L3ZWJQ@9JD^&.6V
MVP@B.VT7QA5O%'90$,\:/4^[U;!B+:C?=LTYS]KJF)<"'E .>Y.<8X!BHK);
M-1:T8F[*$$7ZQ@:HO1PO'*8= \4^VL8)*CRI4&/VR!'-6<$.\?77+]V39:F=
MB(]?#-#UBF59^VA^-Q&9H!XO+'CVZ/,R]:AKGE!1[T?!CU29 1O5A?IJ5NPA
M"&0"6[S&+TCX;,5PF0BJ<155'6%-'@K#6S-^7,CV/)*7J-WL5Q2S8BXUJ6Z+
MV5"%'K$7N6HR1S1G!3L$<#60G-9;P<"G%[W::]E!G%+DIZ\C,A\"?FZJ=[(9
MT(S%Y$^?\\ R+,>>@[-BJM2F/OI6(\@*Q2*#G&E*UI'55P18B1XE:@^E&3NT
M@J6E'PT828&^1FUX0W$KR!$G[#H SWX"MK;>7N8I'FB:JL'<.E0S+E4PX?3
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M^KB\7N,843X":6.8WH9XMOQ-15H8FV;;9F/,L]/$W#O%L5<]YTDX($US)(+
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M*6OE)&^07CB^,8B*.: /<#9UMXVY9TP*=83W@DFKA<'<\4I]W.[;S/ "\!O
MB#_2+"6L\-9B!=%%D0L'-:*[?8O#[%+-K37&=/<O-E6 ;!N#PL1YC'%A&/P$
M+#K/I*YBR(WAWHGX-<<3+P5<VK:U?T)]6>PZV><F98)7\('F 4A"#&-I-T=B
MMEW )3H^8B\;,8^YY@R) RGU?))/7<LZ&! AI7"__PZ@'Z8@?8P+-],.UT5Y
MC)&XC]/0)UDONL6)RJ>=!99(QIJT7T!X>$?'YP;+G@,@/^(B9@]>"*?$6'46
M9N%^$Q/ZUB>T-L<+)WT[>:LH),=#=IH/&@.QXZ?@^H5H+77?C!K+NN7K+_44
M\[?4AR'A9UQOEWIW:JIO&7SRM:-Q"YYZI;5U3W*6\3?)A9_\<[:L/;:VTI?7
M;RH\T.NCO2@$W=E4[B:D'$. T'Z,U7Q9>L?63'-3EK2R@PJ;WXO/K2EO\RS-
MD.$0Q@<<^&1/MIIF$0PEIP=2BFF S/-A]Z1%05D1)ZT4'-TB@OH-\\<[6DND
M>]"I^IJ4+IPBO$9TZO;OV"GU-<G^";(7X">'F%-%;;KO+0_"@C?0_BK_A-NQ
MR@C,/ E;]+K6$56*L8<\BL[%[MK$04N$M02;5G5OY!3<$X[D?TK'>\$5+&;4
M^@GW@*K<>57IV72;O0.X>_?BTH*N]^'L)KS.J9F+9$5DW'+##6"X_X[_DP6=
M9&<[DKNHN3MU4M>8Q)I5W%N\%BW@PD/WRM=L)970LBJ@6-=_^D"N A1]*3>L
M>V>2.2OK0%MW8DL;]%Y*R"H I>26=!X4[9ZX2Z_ H2>%A5$UX5*&71,_7J3B
MM?-O5G')6Z#!J&?\K *U:4[NZ1*.UK$H4Q[PG<-NZ<58E(2"E@RP511$H.8-
M*PF 4:EB:RFC<"TWX>+9I93IM@HQ,>DY)J[MNW!PK>1^Y73$M54TT;\1NA[)
M=> Y'>]/E!NZBKHJ4UX0:"\4-?^T0GCI2L^D9ZJ&?77E=&4!-'$>\RIJ%<TE
M>Q@)TQ7&2Y<^=BF=PDSN552=,L3Z_7SQ"NOK%E 5_?KRW%=1&6R"%9@IZWX5
MU<<L.R/H^?M3%#%;R4I,>#V@"D==3Q"+EH5QY:!:JX6'8BTR],9>;*A6ZNH/
MG_'8H=Z,J%;BZIV=<26T7KVH5O#JWE)?0=D[&A7&6AU63E28?<V/1P^>+_'M
M.EF/UH*2G8Q4H/OPQ,X&0C\J%WZ2'/!:YO-:YG/.\C;]H[";B,E#:H*O7:LW
M3E>]D18_[+A+6EGE6.<IEA29&,?B;[2*J!H'=D^<4!-??H))JEV^<+YDL+0=
MYQ&!]I)7:7',VAGJ [DO9<M_/R1P#\+9I:[@Z^[#:_(0^_4O[LJR<HMA@5P0
M-9$D&W['6<A^+KRJ<8"M6.RBVR7X3RV7W*1(2G]^EB(ME,DVF^5GFJNE$NHD
M@XZJ74SR(7O9C6G?R^39\M T,0-W81XD\YM 6FT2MNSP4JW +ZJ/ &_>;]N"
MF152\=<_N5A@::A23+%5-7W=67C%>H8!U"^<E*G-WR)0L#U? /9XD[!N3)Q"
MN1?M #Q>)!(T?-Y9"Y&]3UFT<LO:S3P39V%7WJASKX;&"1J3*J2,0K632[I:
M!-2OSG+?7ICGF\XR<FO7=DF:04ST/[A@74*.5\W/QXZDC7&U+F0#W*LHO'0M
M[D<!9<)TKBF<_%.LR:F(164>S&Q:&7V5VG2&AA>]*?3'T(57^9<)I*7)HKQH
M_J)KCTW+V#I6>>FURB;:"2,2-+36S_E[@71,%.? !E9W1+$1)8=HK?1R725=
M61^3%, H%-#[>"TKHS=Y98H"&-<5F2 W9HIR#2M8J"F#SE-4%+#4G#:T>W2F
M^EP+#)A;)\5<H6L%@IGEG')"TK4:@4U'$4Y+FJ;HP HTA-G3JR:I.7!=J-D2
MM2:I5+""]9L_!>Q:D<"<%VA4'MDDY0VN"S9[!EJUCBLO+CFE>!R;RU8MS;4.
MHE&9.,B-J];EZI^P42,4;J<9?!6VE^,9*FYEV2*,;%F\%1?-VQR3/,Z<+,9#
M_(VXN+Z7Y2FW(@^MI07IJ)0U*FLC4JOUC!C &)$=Q#DE>H;MKC55KC55YE[Z
MQQ@)7U _U/2$/X(GR.9;7@]C9$A55BV+VZ'_VN[[M5,).PX.]Q[INK]B#"[9
M,G]4%"0[V\;2W&.2W\<8*;A>.5)JWY'B<@<^0)2<6NH,]Z24Z6FE'H!L27"I
M*C <PYPV &)T2D1H&3;!,8Q#?+KA]TAEUE"NKQT&%4<CI5M(8@UP%;G53&VQ
MC1H5W%7 <[T^L; L<ZZ^N6A<)U95+ZCBO&R\)2P<"09=E=25TJ![STZ)]=15
M0*=!#Z)HP-=K3:,/'(J"M6@T1^]A24MET>!-RXK:3_XI'E$?7+>S*]QSX=J8
MB/9,Y)%F.2LU#^Y> 9CZ*9@6/75 =8K*1.(/Z@4QA5D+0/2O!CSTCU]?\'RI
MCJ7^K[-.JWPIDSFQ[N_S(T8)>71_NX;GKN$Y(T)P3$8)3R;]G* E#B.D+N 7
MF,M])W2S3SZ!>:51\2PU6QIU?E_T^A>4&ES_<@++ /DE3'][@  G: &D5F8S
M;S'>YQ<,\'P\S/O\,@"N=NE=^!$&R/+!%,XI'3K?78 _@.NJG]+*6;3#E6'I
M8&PIUL8ZH.C'- 88+1J&:\S8;3DY\)OV^/J*X.4GS4RFY**#!**3IVM9+AJ*
M:?:][KUP70+K!4=EOTT1T;HNU02>#*V5#:\+-9U'9(I2A]>%TNE9F:+TX5)N
M;KX@=H8AQHSTWR#,NG_Y%H?9QL\0H-G9R:N<^FXBZ_+-/5D2^Q\S]_M_YX@1
M'F/$(SDQZ[?9.X"[=R^F%X75C9WR]Z]!Y6M0>>ZE)W/<H0]P;GEVVRQ0$'1+
M=LXN!WJ?MQ=@9DG-AD/B@/ZND2J88SYE+W"C6:.H F*,,WN?7R# =;E^8Q@/
M9[! F"U3M7[]B]%[W&VC171SF])VR?S1J^=&CL8[I"_6)K0YUA%/;8$+PZUF
M;L'JJ,YO@4O4/:3M6R+5^2UPB5JUS.U;'Z7)+7!Q%G'V_/IW2S)N]/DPM;C>
MU373ZX.DU^PHRZ-4S%NE/6_>HI%T5>#TG8W7C)3K,Z43;@^J@U_/0TH\KV^5
MO/.'J_"Q2?CT_<G7IV.M7":*5_KZ?*R5*S5T+%\?E-41+^Q5E*)YS"N<KT>,
MG3M"PITRW4N_UMG:KBVCLN-_BL> KYMQ[MC %.\'7U=QUO#!]5%A"Y=0R9,_
MR6/#;!729"IX50?O!L1@'V98&4PW01 6-#[&^P0>R1>=3.CN<!'.5\]"2/BH
M 4"01:LR@KG\8;1T,=XS^"&JMQS/%2]DN;803Q4"LJ+PW&Y4O+K$RA^^;% [
MQ-0(!FC+HTN!G2\ ,*L,:<!["GU<D#3%KWDE$>*@!)*Q>3+$,1$2>6FZW1/+
MEYM22VFH.X<>G2 @O7T! 0!'[)._Q8<:S$+TG\\5#[&3VL:-83!/CP1!GY$=
M>>8"3VFH&?@-8M$=]/"C?Z\;-K:T9IIG4NZWP79C7H_@=S"735+50F[O&LX5
M"'9[S0#??V"5<CB1WH]3?)7*Y(.?=;/V 0("+(OF;H.IOLZFO=_$"GF$=CE2
M*GRRDV[.[5\X/*PP@+E]F;^E81 B=>;5(P%CT;YDMC='0C,1[-;>[EM8\^_$
MB#O.),T'-K*,1'^Z^*HH8Y8[<#RAC\!S8603@(@5GCZF:0Z"NQRB$V_W#@HG
M5_$3;>;C!C+W=MWSEGLYH/E]&K:@*-5T6U6RDV[9C<PN\$%$,]HU)^"'^Q $
M-Y'W$*+.ARU\ 8<\PL.=-Z<33#Z\Z$L8@31+8I!RE"@-PVJF])](,%2[KCJ-
MV 1P6AMC960&'Y.8Z$YT_9734#?;(-OY_!UQZ5>T=,CNX+$"H^FT\HW(HF>(
M5A")(2*#)&09I=,LVPVO%WX__I*]Q1EC CM*8@?1FAG;.K1#JWU<%6<5\1Q_
M!9_D%Y:R-&JH*=GH9P]],$]O4;?0]Z+6<U'$5U;)6676&CON-*)&@N&H#0U*
M:^R224/\[,Q 26*]F"'H-!T;;5*2*@J"I]![PU7$0I!^.R7QQD=<GA(GH!3;
MR(^CF1;Q033M^5-O@RK!_]D+^]>@.0VGG\V9Y5QBMC6V=;8G[+Q&LI3<G4#2
MIGPQBR62V>V-D7"3I\B22U-T++^%<1&Y:+9 ^VH(@R:% >Q\3)OI/^'UT>UK
MIQ_.A5 MU'O\QY+O'^/B2*=ZW,>-I)F>%Q#DQ)/Q&.- %?HB^MI#CG,:6F#2
MYB_94_-\FT_50F;[%H6'DIU]B."DS5:JGQ6\0KO1>/%PED1=F3&SYJZ:<BQK
MBE@J^N);8E=B#3OL56-'#4<M^JZ9?.RKDTW$#C(M'ZU!(*MFGTZP:?E 4"-<
MS5[J1Z 6#<CX6%;W/L!01*T"-F%TK"-]).)04Z!FP^5'M>A6O1E'1IK6P7O2
M8<TV$[9B6(M&22UN5C.<0*58/F24Q)/F:-01X%L^A(P<EAI&7O1PT>C(68.\
M$.6B2S.H&'RLF.FB 5(S^FBZ_GKAD=:Q:-'NY<.F?NSQ NW+QTMTQE$#^XN&
M13J1N7/&44["A1=J&>>Y4_%/+/^9*B4A?UG>RO+!E!;]HY-CIL#0&J>.\"2@
MY]PLGZ_4%-66=W[YK[>-DE^B)*CEPR8IJ13RKZ; S!G)Q+"=%\Q Z@%3=GQC
MBJ):UK".NA7-R-E;_@./:L><!+#SO;AH&V1*W'7N1"2N:'4%%R?M<]%EL<8C
MII)ENNB:5.,A%.2P+KH,U$C!-C:K=HIZ3*YC*9O16[EA5^A?9(,GEUY<0;=,
M%_:L>[A;&^]/6AU!K"Q>0S61'F/4#.R\[R!M*N\7?WQ*TO0&[!,(GF'R$6+O
MQD,"6QV<K+)6SU^ZJAJOA[G[_O42/:#]44B('">Z%,HE#C^0I6LO%_J/- M]
M+IGC1G0)!L3#(#RPZFI<,*!+(-Q_1_R+Y%N(B\$1T?DU0;_&&1(/:&J'QQA)
M?K2V^E"2_J(=H5(),=%)7;QD.ZXBL6IZ0.N-O8I8_O1XRLN(20)F2>9%5FM)
MN%PG4L5Q_=[]DC2DNW*9:CI*+T%9=9?&.P(-ZI(13=:I)9-^ (BY<650ZMP%
M% LZFZO:D$,L8/0M\04#F@:A7"/9I17U,JP&.F_95%N')*LA4_\)?67D[I,:
MPC3[=2:IR(2"OL;7<-RRV;I2:M0(.ID7$U)4*$S?Q)NTEZLJO0KJ4D?^*@RV
MRU6$3H:4Z*Q=!::*1MLE2[ */"?:_W*JQRK<#)-( 9'*LPID%67!1:R^"D G
M$@:B_3^#UVMI^W_=D([RW!H%RR:OZPOPD]@/HY!\9EF>UWK^FSQ[)RO*?0.
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M9.QI0--7D$FF]5.[&,\]K6=5U]O MU]N/0C/^P1^>C!@>7Q41C#O]7';@S[
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M<V$G /LP#GO7=7IW9,J_*E[B>4EP8?[$SXN28<7_;^+@/LX0V:W[.UKNX*3
M_\,A^?BO (1%O!_]1Q/F1_^HI]+Z\F ]R]B^L+F6/(514Z;EOW.;7I/&KM=4
M>)DK=EQ3N0#I7Y$(\_)(4_*U_*;$/BO.1B0_V\ $-[),<*.3"<0X;A!* 4;J
M(?(.%""[O\\TJ>)P^CF)D-&!+-J',$*'*V5R]':S3O(7$$7_-TX^XU?@I;C:
M)O%.]-=9W'[F;5.X5.[CX Z)>\[^Z;:;>9(/8>I[T3^!!Q_07WCJ0;^ED8D6
M6,E-M=UVILGNH(<+M[R>CV])1)E@]_=9-]$+.(0X*RO.L&^!N7=ZS6:=XBW
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MM7^W2*1HLR4O\(X3*1AMRX@W)U]B-"I_'*"R]Z*F"(,TV>]H9.CG;^#WZ*\
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M8/%*5\V)\P0UBW(<*FHKZ@Q\IOVFP4.OTKQWZ"N<J_"4AI9,^A;I2 =<;HB
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M@6MZI ,>&_/2H\)7KO>&9V$.X@K#ST%X69YR+P_36EJ0FT39BR4G4B\6CQC
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M!)U$A,YJ2 0EJ]15PY&!0$=!4H_4=I[@:H*'CM+/2CYIA*>.,*7+X##R0VJ
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M;UIG[J.&,*A^B;UF#$5,V-$J/5_(:X).PY3'7E+CC#F/3<ED(MK2YO6'CJ*
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MJ"<KU]:XP[!X(37UW\'1^W__?U!+ P04    " !II'I81Q?7_,T*   [7P
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MTR/:N1$4_XI2W0=>\3-J+,;MQ[(!-:)]( 4[^!(,$9P(CW"_^L8P *K;4F1
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MN4S S OQ_::VJM%E.I"DMPJD:LGP+>EXP<=BT0!;3L2')J4^90;2HT[ZT/%
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MK"<YWR8A%<KH#28:E1_=4 JJE1 %<^*Z4=C/4&>-Z7A 44'3&=S3=.G]GA\
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MY79>5/Q[4FCU9*+*EIF!V@/_>S&=)FF"<AT_@8?BU,@TPGS"NH%ET_'<6;1
M8_@2QI;A7.9SS'/7&=K ,*:QRL!RK5BOPEL4*BKA*I@7T*>U<D8S ^W[%94N
M?%#D]25/)JE3F3JVO^]%6"Z)CM$6' )DCRLI)QM)RDD81M=1DD8F0J;C8BQ
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M/M^I&[+R3_E$]&3E-^]BMC(K'^U(>>WJK+P'W_\)D]7)V,)DMEUPVY.=7^#
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M8Z=ND[?33BP+:_@*W37Z>DET&^;<ICM'$E_N:>,']V=F4S^ C7N*6@KB\@H
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M(+KF@Y<TSS-*A<]0MVA2)*=*NK,GA#YE7$_':DSN2O>91M?@.$OBOLE)03$
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MN^$+4["B;:OVZTE*OO5^,Z4(D2YJDL!@)E_NK* ?"- M#F2QJ,Q_AB+>K,/
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M9&]89SP4CI"IT865<Y,?WBSTN00R=3(@II8CIMYLB)@"3XR SIG*ZQ;X>L<
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M*9BBC,*OHR %2::"+,\*3-PQ:@SCLO8^?%\XBDF%3[U&^E'_PS3Y3TTC1RR
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M;\X.S\X.3X\VR>G?@3QEU<:NPNW4E*[:U[ITT:DC[V-+G=XO,>E]@KL>C;S
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M2F)BS/"(1"[/XO3[MV N:='''<HERE>_T$EU.+!;*!A?$@#%00'<)29;SI0
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M= _?&=Z=[]X9'HZ,='Z^:W,8C[$YH!Z0#/IE@\\OL=^0O'9D<QB/^\UAW^:
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M:L^EHO'A-YD'O(VL)]=&6$[&@K4 S$?7QW02'K,W([F,_ $[H(=USR"596X
M&8D"@KM9 :K'N$@$XST8))';?2/3XHQ<-NB)H*LEJ&9?7JW-DANDN. 6K(W%
M?>?F%T[TH]8')!R"2,%*EO8 /I>PWT!=?3"SY_5\?;,(-@=JY^^.WO7CY0>[
MJ%:",\'F;X*$,.9-A"?3E.#8Y.>+!Z.8M!CY1DJ(.2ZML2M#P<#;GJIO>]I!
MGQ/6YX3U.6%]3EB'243842MN%^8<3A6$)U_3A2&L[(52T*HNA2I<B<]7[.=+
M;S7_W=RM96;=PUI^^ZC^W5=;,K'$5(YC,I5S#_V0;,!.I6\Z8BK'<6\J[S&5
M_UGDIXX;NX-0KIYW>U8,DI1%B:TEL?[,(*K+$G:F*S: FV\C3_8Z[;0S(BWZ
M:XB//;*OVY;DR9R].YXOR1J6=5V(V"4AR@CQIC*.EQ:ES.+'6F<GLD(;&!N#
M$RTI47UDY@S4;=A&%;<$C.JLJ. /OBOJ++9&O(/,%MOSMV4R)[7U&OYS&J60
M3_CT?QL5<V$E1:LP#R4L)\]BE3?[=_SE/1P&BX_,_@II>Y9%'FDXNB+6*1!\
M/']MIN\YR^)Y5CD2N#P-7X[K"B>Q2FA><>Q +<J!;P[7BWO_>,/[-W!P/16@
M?U?2S/GDE88)FR'XC:O?H?WVU*DWN]]N!<+Y '?>^=OQZ:L'1 IVCOA#;8SS
ME[M,#"!-B8G!UM:5P0&SX8SC+SIB8@">MK<Q#K Q>#+%6W#LX6IXXP)_6QJZ
M3T0]LFZ4IJ^;_*-!$'$5CYR"?9(8PD@QRKR!T*Z8(FD%Y1BY8,&ZU\;[5#3.
M4 V23"!!-?4DC&/ >(#?: W%2QDVTF';=[4:!-/Q$;A>W)Y+X'1.F9#E\1SY
MC^K%GTR:>J.R?;LROF^=23V93'J]<0^]L7&A'GOX@F.*6VR#8+'YC(/-;%"A
M(-LL@ 9ZE<8O);G-1!$I N5L)%&V(;S0(RT6W4850Y:=Q5*VJ7,:X5P4:\T)
MBLM\DBI[@]D,L9VKD$MBG$/$X0.B?H3?8$FAF-.I"48,!4IVZ<G+X<GE$,HR
M2(*C!S H\7)6U#B<35E%"[&1R>BAN22L!%11'MAC.'PFAY*/K='[**-W_%4M
M85\MB[?KVM;PNV,+3LF5A@O4^I=XR49GF8T:VX748&1R<7HYMGQ"\*/V^2\<
M^'#UZ6>XY?2<SA0GK^D8%7Y^YY-\FB2>SRTB/9W*7H:\LAKY/UH>4RP$]DR-
MX8[L9=-IOY<=L)>YR=0\#@G.'7O<&L:PK"^7!1.>Y9W AF"KLDTYE6 ]YJ8*
MH5N1?IFSOE8L"WY)@'JR"XYB:WKTL[)-9S.29_5*>D>Y8@S=S0K4N)B\*[;I
M;-;+\SYY_ETF\]BC%)B@BNH,/WG*\K?%"[X'_N7M)LB7Q\LY?: GZ<7+#4"I
MOH:LO6%NV%,[(G-T4O^O8R^FKHM<Q_;+P=8]'?LE[9TD/U6R+8MSTQZ[CF%^
M[UWNYT?=Y=Z\W;7+75][B7,G7B][ROS;E5WN^KH/#A\D<8-+.Y?''JY ]BR-
M-%+YX!XMBSR-]K!N6Q^+=$NPVBQ[D4UGTQ3G'%S)>9QJTMTDN$\D]VSPR7_C
M!JB9%1ZFQ[L$:[W%ML6W&)TU:6X;8CM8U?-Y@(HWI6,X_,D;V[F>F1V\S;F3
M/?EW6+92%O5T%HZE8HRLI<Z;K* ;'') V,FSP:^&WK$V*K:,LN7FWC76#U2#
M[Q[[_/[SZUV:\.;&:4)99FM&_[(@N[\CFO#FIK?W#U.%,IG''JIUHY_3/^!D
M<RF_).>[+(P!"%M0Y.$TAA+JB;\Z.$N@RW*<"!#&Y"4[T,7Z--\^S;=/\_V1
MTGSO=:Y_,!ID^V#?VE^S#/LK5%4[/40_,[995RJVLJP_:>S;7B5'NF/9(0->
M3 *4Q\%++C[2C$V4T0MW["0I&9($22-A_ G@> S--6JADC3+Q6D/IGTRE= 8
M/5AP^3B@B3R2Y&QZ-E*G.1>GBQ==2XGN!'C$U?-81"!<5J8W]G- $_O"XXRN
M YYHZ=4RG?OZU*'+CI&,VZUNCQ&JC$:##UJO1%V77[6P]</'/WRQZK^2DDY$
M<PGI/ZQ\])%=C+MKVN?SEB;:[/CHB"::SWM-=+@F^J$<'V:@#@_)%PF[>: +
MI'67ND'DQ+]IT(YP[#]RV#[/H0SN\"_^2V+[1XG_2_V[ZH@RR//^V+]7&]SE
MHV,/$0G_<QFK).Y'ZQZC579AM *BD.X/&"I1.C!F%FG&++T/SH-7>=1 "YQ@
M!QCJQ#W$ BH$/Y+\A#\KZ&=X@:_[*":V&)^?8B(MP&E<C?$*[@A9"5+- FTW
M?SNK@0T2"#!7OBQ-!*0MG_ ZD@0^ZR8<-0N(PJ/1B"%WBM)&1T.B@]$FA!VA
M0*#.TI6)]EM:)G@V?/](CD,VSY4N:7'[/."0\:AQU6W<%V)6%,65,)UJ"";P
M=B1T?3K.$M3C=L2L*(K>K-BGRX)XVK%'*G1W_*JK:> J@H/ @@)]/&I<X:%
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MQA8')90!2^ D1*EN;1FM)'CW[MNR5KK#$^4D^%B;> RPD'A+4GA5IY)5MS[
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MTD!%T$YXSTTWWL#*DX5_42S"4&8%):[ =Z($GDU0?_,5.%YVXW4U?9'FE%T
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M9:ZU:>&WP,!1\%G-&EL$,QE=D@U503<47G=!YP 2M*$,3:=$.9W2V4,[D99
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M^0M6;%VJAX<YKRZAU4S2/CB8''8]!O(=D$HERC-0]T)'CH[@B^)7<E0Q4#U
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M\@(ZSD-RAAI1"/L959*6Q [8:>C2B7PU8F"R2>7GK'6J1(KJV:8S%9SPG^/
MF$KVP?O,F@+$+$ACL/5-JW^;MN";0M="H1  .AP.D5!B?NVP7CJ8HZ&[A$&+
M\L5'"%]J2T\2 <=R3B 01XHJGA03[Q0/'EC3 U* S#=P7+Z*E-465KD8)8.#
MXB#NI<H24 #+8[L;#-PJZ:H#XBVA$*GQF5BOO<D\P1NLL5:X?= [:;9+E?57
M#KZN9Y*4T!% 9<*D&Y)=/U6%/',K"/=X*4*-;X<B8G'1U1H1L!FEJ/5ZXQ4\
M;D_'$5#$&C-D]_)K<^37-@@P(2D(BM*)SW-TYI*,<CUR25 6/K[PI"_H@IR2
MMW:V9&RP6K=.XTT$1^=,WQM7O/!SI(G)KQ^*_/=<(/D93&F5P7D066O9,7G7
MFL'8J+5?<W"-<#/.8F68OF'Y!0,W5>H<A"</1"[-01[ BT7C"-!DM?HJ=-,7
M\)A^1+;Q\OM.T$TS8^/!J%W. 3?F-EMP7FP@H@2DQM95@3RI/_\2*MX: U1E
MDB9M943W)1747>2 YQZ?1=85N;?LE8A%QI2R'JTY+^5^,6=@3;Y,J0U2)VG%
MO*IJB#AIK!6U:\8+F/&\HGI8/=./YZ=;;Q!ISG$&U.M9_;!!)P=^CI3UH@5%
M;.:#\ 2EL!^UW30>'+S(YYJ-!<=3;(.N"Y!'FGR"X58R28WS+>"P;%RMJZ=*
M^0-I[=\Y;!T9Z[-5F1<] N2BQ(T&G5KVUW@8"MNBG+U-VV$4;ACF>[V^#:27
MH!K%JS@>\(OV"0QJ-YF*Z882[VIS% 34";_;WTJ&&Y% X7O 7Z>I8HY FY1%
M]A"Q0 &WKQ:G%;(GZV&M:8JMC+1,ON*@1=IZ+HP01?88A8)3'P1X\&DX\^N3
M#2;WSKY]=>J"T(ZR]Q^F+OI?J;7D[%I%S:L'$<:IT[GFEW6TVS/J$DDKW4>Y
M-X,T;93[=)>BW'?5>IZU%L!>F9NJ^>-7C8^GZIK)*,C7$H#98^^])@L++SS7
MSJE8DF$!'R6F6BGQ7%E>N0#A23'_?8[J/D=U6_"Y%QEK$1GO=DEDS&QAM+GM
MQ8I+F6U7B>*>YT'>*HW/:<PDHWL5W$\TSBFU)&N0O:$RZ]&R:2^\6COAI(Z2
MD?%R40<I"O^@ITI4K]J^+ZRSO-[#.,HP5<@VBNH)4 _[,TO30)1IJ@XV"9@8
MX,JK0A!I #7"@#E $@LV*KNWUS W@5V<[1*[N%;L=VG52SH-=_Q!K+'F'TO]
M$_(ZVY8*YFS1%?;VG.>LI%)]5>/U(KT9]4U3+H7'*N RA-\X^A"KG (K92-R
MK6!>VZ=^7WI")PWV@?1%A7]>4=]E@6X2S;KP1""!#6%"5\!=ET/^  S&()'.
MLP;FXDJ_JG9G7DCKPA?H/!)18MS@Y$/OP3J\KY$:!<(?6&Z#ZQP);$[J ^-R
MJ881%=P691EJ%*&?*J$."0!4@_5EQ"-/VD(O,W,@!O@9!X(%/J%54W4%E"^.
MJ?HV?N-CGE^B<&4(- P4F*1R8,T9L$PMJ2FO%YB6O0I>@,?W+&VC6-KY+K&T
M6ZP=MRQMK8SLH]%H8D"Y.4>5=M3E=M-4-@)\RC;6,(PAT_2048/P%3RV1N=(
MQ[8)3Q:!D=S/R( &;0AH&(OW,:#B?J&02/$KOII'8NQW)M "@"I=I W/A15?
MS(&="X5MV>+<9]-#UN!9AQF;TVP?KB,[>7P&6@8E,<<J221Y%2K9TV5'O?%Y
MT\('J,.9+*0I!90 R6$N ,QA<V\ *(%(4N=<=!#@/ %F\X0@;)"G6JB)'Q):
M]GQOD_A>^V"7&-\G$LBNI?1RO5)68/3E=?$E;8:ZE<1TIBQ/R5N*N48F'#0$
MLP+K7LP;_$:@GX9&4\JKW&%\RI4[/CS#H%J[7NEL6*3.W>;YA)@\Y\I<C:4H
M3*3MLU9DJF7)9'8N!9)GKV)FU/C.9OI]I@S'_9G?K#._4_WD_YIA,0RV_%AC
M\2]J.F2*H5WPS4%4-2T2D5M;Q*;L;0P@&$O=\Q9=SE!N-<^QUP50^WA&Y-LV
MNL"GL0W<E$43!X(#,(D0DZ=^'TS8_&#"^[<]Y8]_^</[M\,T#'[Y?U!+ P04
M    " !II'I814,B$Y4"  #."   #P   '9E<F$M97@R,U\Q+FAT;=U6;4_;
M,!#^SJ^X@31M4MU7J$J254((IFF $*!M7QW;:6YS[,AV:;M?OW/:LM)I$V,(
MI%5J6L?/W3UWS_DE*T.EQSN0E8I+^H4L8-!J?/*%]0?M7M99#@G062&RW,H%
M^+#0ZMUNQ=T$30)\&NPKK&KK C<AK;F4:"8)C.IYNMNXE7B[-EK-LF#KI-L^
M0)-6:%BI<%*&I$?#W,Z9Q^_10VZ=5([1&_*3U6L7A34A0E32Z]8A7=)8.DR;
MN8)7J!?)#5;*PX6:P96MN%D#<QN"K0@;U#PPKG%B$A?#QR#1_EZ<6^Z0LDI\
MQ;5F@M<^%59;E^QUFT\Z*S$HYFLN5%([Q6:.UTL:LV52N=4RW>+\1YK$<88R
ME$F!@0E"*A.YG<Q+S#%DG6A\G^D+,8)EERSY=&KZDM"-X$^L56.[(9>@^,IM
MZ_7$53@BX?5O<S^VQM,_L 5\,%+5BAXTO%(3],1-2;B<YAH%' EAIR90/\,I
MNFJC7,]0**V*7]KZH65Z3%4^*Q"KP@0+H52 1EA'6P,/: WD"W"JH/(8$:<:
MA&M*M@+XP(.JR-[#FPO;AL%@P/K#@_WNZ"W0]*EU%5RS 7 C(\"O$8/1X6'S
MLAD>#/O#PTV#4=3)3AT%B]L42(HBX9P[44)_V()^M[_?@AF&DA"^5N*.?X&&
M&T$Y;U(C9Y^4XW!3TK-6TX#"MZ@/1/MYY?VW=? 8@3N^ Q\OS]_#V=GE_]W*
MUYRZQT7MO; M."86A74&>9:[\?W.>?E"_&WJ#]WA7^_UAMUT*[^-T[S0:LXD
M.EHPM'H3TF-:F52BKS5?)'%V^WC_.O4!B\4Z1H-AM'G&C.Z.C]+]O"Y,%,N=
MXM\8+ZC7$ZYG?.&;>T76B;>1\0[=3N(]Y@=02P,$%     @ ::1Z6%K94?1I
M"   ;#L   \   !V97)A+65X,S%?,2YH=&WM6VUOXS82_MY?P=O%%0E@.;9C
M;Z^R;X'M;@H$A[:';5#<5TH:6;Q0I$I2?KE??S.D%#NVDSC)IJF[7F"36!H.
M9ZCGF1F.Z$GA2OG^&S8I@&?XFTV<<!+>7_PG.N]W^Y.S\!$%SAJ)2:*S);-N
M*>&?;TINID+%C-=._TV4E3:.*S>N>)8)-8W9/ZK%^(U7FXE9.ZBY&SE=Q;WN
M2*AQ*514@)@6KKF0Z$5DQ?](1Z)-!B;"*ZAI4K5*<JT<B4#<[U5N' P)*L?^
M7LY+(9?QE2C!LI]ASC[KDJM6,-'.Z1)E'2Q<Q*68JEA"[F@.&MY.,R^$@\A6
M/(6X,A#-#:_&:W,/<.Y[I\.YYB)S19P+%Z4H"8HF^?9M_UUO/#FCL>\G9Q7^
MQQ7R*_62+AI:XTT?O:X9-P(?76Q++F64\LJ.4RVUB=_V_+_QW2LQ#T\NT3(;
M;]C\E*6Y6!0B$:Y=FW5+7\DB%JCPY[%G#3=[(F8P?&BNNT&3XJQ@-E'S%-^]
MT@Q2;;@36L6U0FI+H>!+K,K'B\]7ES]>?OQP=?G+S[\>]N-Z.*X\+HSMZ_GS
M'+WLL)^XL05&$/8CANUE"AV6@G$B7S)7<!<_YZE\V8>PEH\R82O)EW$N8;'^
M$-[A5/^M+5G?*O(RD77<N+%?[0BM+6V<< L>QYO/967.L#LZ_^[OK_6@FME;
M5X4B:R/O\3TNOGG?[[;KMK9@066_U]M4^$JP8P6? 3,P$S"'#)$F+/N@5,TE
M^PQ4DS"M") EZ_>B?S&=L]_ <'95X,\*:B=2VV&7*NV.5RBA;+S*R4>T[(66
MP0&@Y0=<_(P 42[9M=)S"=D4PY0'C0EHR31J4MHQ&L6%8EPM6:V<J0%MY?@,
M417!B+,2/V'A)%G.4[QDF"Z%8TX'N2T!!2E8R\V21$I^#3COFDZ+US(T!J>4
ME()H#A)(A4GK$L44#F<^:S)<G[1@MJ8?J_%S,- H(0=*8266[5A'L[EP!3IH
M*TB]@:2W0M-TAF[.<%C&DN7Z,AS)\#PRG!\R&8#E0B'<"+DK>'60"2B.M\W:
M?:%RC*V^HL._4UEGJ!,AO(:E#L)?&+ED:+PE\A"IL$JX84<#3+LQ-5J:"5+<
M(8E:H@!20B-N_736VY-R6[!<ZKEM^6)@*JPSN)]AG"X&N]'*SAKL;6O,EK5'
MY#\/^<,#0/[5+9A\^W8QZ/6_']L&W$W12G%3Y[G CR?VU(/HDG$#'JX(/Y%(
M(%@Q0-<3*6Q!(TBLQ+1!J8,^H[NIU+;&<32_T3+@MC(ZA0PO6W:",,T <1^P
M>+%("ZZFP#Y@K/Y<2Y3HG_.H/SJ!8$5_E(5/X:.@#9H*?"']C +Z&HT"K,F6
MO2?*;TV4XT3DYR:Y4()JKW@/PC0@)_S&H^Z@-USAX&4Y-.KVWHU>C4.C[OGP
MO#<:#(??#[_K#8>#)_#IA)_^^0GU"2RN+<+*ER0/8[Y#U5+*:[O_$"I;$D#\
M-C.%0DC7!A5@3)\)ZS,%2H'R>FC/N<HQZWG*@.2>$$TEM )UI\EA=%-@OD%;
MK)8BX\X;FEB1"6X$.2!"O>8SIR)-M:4:RH<0ZPLNGU>T!33(81ZC014^4Y'6
MDE,Z1+>\$:M:#$>$RFZ](,6_$B!!?& X'K)],M21<$\G7')PA-L[!6SQ;O_D
ML3?]D+(SD1&KN-6*4Y;D%AE)^Q>B&C=9"WLDHN")D,+Y/=&N:2D(>(9X\ ?^
M8J&WJT -R7C1.%35ID+R65]MIJDVF3? [X2FH+"(E,A!O ,5D9M$<)<7>(9!
M0%28#X],>UFFI0? M(L9E[6/_P1#R'/<J8@9 LCNV'&L2LD]$EKXN'L7XIF%
M S$9V;#7273M[C9AGY3+;Z2!-G+YPUT EK1;1!\L("P%VC/VRH_D>$ER9 =
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MG/.E]>ER<D;?E7W_S>3,?\OV_U!+ P04    " !II'I8AX2][E,(  !(.P
M#P   '9E<F$M97@S,5\R+FAT;>U;46_C-A)^[Z_@[>**!+ <V[&W5]D78+O-
M%L'AVL,V.-PK)8TL7BA2)2D[OE]_,Z04*XZS<9)-4W>]P":Q-!S.4-\W,QS1
ML\*5\NP;-BN 9_B;S9QP$L[._Q.=#ONCV4GXB (GC<0LT=F*6;>2\/<W)3=S
MH6+&:Z?_(LI*&\>5FU8\RX2:Q^QOU?7TC5>;B44[J+D;.5W%@_Y$J&DI5%2
MF!>NN9#HZ\B*_Y&.1)L,3(174-.L:I7D6CD2@7@XJ-PT&!)43OV]G)="KN)+
M48)E/\.2?=(E5ZU@HIW3)<HZN'81EV*N8@FYHSEH>#O-LA .(EOQ%.+*0+0T
MO)IVYA[AW)^=#N=:BLP5<2Y<E*(D*)KDV[?#=X/I[(3&GLU.*OR/*^17ZB5=
M-+3&FSYZ70MN!#ZZV)9<RBCEE9VF6FH3OQWX?]/[5V(9GERB93;=L/DI2W-^
M78A$N'9MNI:^DD4L4.&/8T\'-SLB9C1^:*[[09/BK& V4?,4W[W2#%)MN!-:
MQ;5":DNAX$NLRH?S3Y<7'R\^O+^\^.7G7_?[<3T<5QX7QG;U_'F.7O38K\ 5
M^\E@).FQ%(P3^8JY@KOX.<_CRRY_)Q-EPE:2K^)<PG5W^=_A5/^M+5G?*O(R
MD77<N*E?YPBM+6V<< L>P9M/9&W.N#\Y_>ZOK_6(FME;5X4B:R/O\6=<?',V
M[+?KUEFPH'(X&&PJ?"7 L8(O@!E8"%A"AD@3EKU7JN:2?0*J1IA6[*,V)1L.
MHG\PG;-_@^'LLL"?%=1.I+;'+E3:GZY10GEXG8T/:-D)+:,]0,L/N/@9 :)<
ML2NEEQ*R.?0":$Q 2Z91D]*.T2@N%.-JQ6KE3 UH*\=GB*H(1IR5^ E+)LER
MGN(EPW0I'',ZR-T14)""M=RL2*3D5X#S=G1:O):A,3BEI.1#<Y! *DQ:ERBF
M<#CS^9+A^J0%LS7]6(]?@H%&"3E0"BNQ8,<*FBV%*]!!6T'J#22]%9JF,W1S
M@<,REJRZRW @P_/(<+K/9 "6"X5P(^2NX=5#)J XWC:=^T+E&%M]+8=_I[+.
M4"="N(.E'L)?&+EB:+PE\A"II%RSHP&FW9@:+<T$*>Z11"U1 "FA$;=^.NOM
M2;DM6"[UTK9\,3 7UE']P3A=#':CE;T.[&UKS!UK#\A_'O+'>X#\RULP^?;M
M]6@P_'YJ&W W12O%39WG C\>V6,/H@O&#7BX(OQ$(H%@Q0!=3Z2P!8T@L1+3
M!J4.^HSNIE+;&L?1_$;+@-O*Z!0RO&S9$<(T \1]P.+Y=5IP-0?V'F/UIUJB
MQ/"41\/)$00KAI,L? H?!6W-5. +Z6<4T#LT"K F6W:>*+\U48X3D9^;Y$()
MJKWB'0C3@)SP&T_ZH\%XC8.7Y="D/W@W>34.3?JGX]/!9#0>?S_^;C >CY[
MIR-^_,<GU(]@<6T15KXD>1CS/:J64E[;W8=0V9( XK>9*11"NC:H &/Z0EB?
M*5 *E-=#>\YUCNGF*0.2>T(TE= :U+TFA]%-@?D&;;%:BHP[;VAB12:X$>2
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M_OYE8=:A<0XA648\=V!B+I=\97VZG)W0]V#/OIF=^&_0_A]02P,$%     @
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MFJ[;? H!LXYF(D(ROUT_:+5>KHM;B:'7_/JJN.FT<%=G?)OMIP+P0M!0LTS
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MO:-6>Y$PJ4WQP.;L$GNF+[GJ3G88O!<,-I\(!IG +2 E%EAFA: V$=ZUF*H
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M5$++JR$KFBT@"F+&<6CARI"&$\DT0SA$1-"?A0D1%Q306,J4,F[CRTA&1%-
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M[J;N%E0-8[ =QP9OJE@89Z=N#%[ J=V/FFX-H[B[U9&Z@=F__IZ'U*^9P<2
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M "LUDV&'G^E^#QG,<P5R0&"P)L^!_'GYXL&P@1Y)&723"4PGG0VN(XH5Q0%
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M9S<V,CDQ-#8Y7S N:G!G4$L! A0#%     @ ::1Z6/TO8%0\0 $ MMP! !$
M             ( !+N$" &EM9S<V,CDQ-#8Y7S$N:G!G4$L! A0#%     @
M::1Z6$X_,!P#]   1#L! !(              ( !F2$$ &EM9S<V,CDQ-#8Y
M7S$P+FIP9U!+ 0(4 Q0    ( &FD>EAIVG92<+$" .Y+ P 2
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M.3$T-CE?,34N:G!G4$L! A0#%     @ ::1Z6/0=^HC<50  9:4  !(
M         ( !>GD- &EM9S<V,CDQ-#8Y7S$V+FIP9U!+ 0(4 Q0    ( &FD
M>EC(68)PI_<# ,QW!0 2              "  8;/#0!I;6<W-C(Y,30V.5\Q
M-RYJ<&=02P$"% ,4    " !II'I8.G\[0FR#   <P0  $@
M@ %=QQ$ :6UG-S8R.3$T-CE?,3@N:G!G4$L! A0#%     @ ::1Z6%)2-5SP
M)0$ 1[8! !$              ( !^4H2 &EM9S<V,CDQ-#8Y7S(N:G!G4$L!
M A0#%     @ ::1Z6#9\5O')?P$ ),L! !$              ( !&'$3 &EM
M9S<V,CDQ-#8Y7S,N:G!G4$L! A0#%     @ ::1Z6$-D6:WUK0( 9PX# !$
M             ( !$/$4 &EM9S<V,CDQ-#8Y7S0N:G!G4$L! A0#%     @
M::1Z6(^S.#Z,]   <WX! !$              ( !-)\7 &EM9S<V,CDQ-#8Y
M7S4N:G!G4$L! A0#%     @ ::1Z6$84HE*HSP$ V#4" !$
M ( ![Y,8 &EM9S<V,CDQ-#8Y7S8N:G!G4$L! A0#%     @ ::1Z6%I1=T ^
MV0( F',# !$              ( !QF,: &EM9S<V,CDQ-#8Y7S<N:G!G4$L!
M A0#%     @ ::1Z6 L!-EU\H ( V @# !$              ( !,ST= &EM
M9S<V,CDQ-#8Y7S@N:G!G4$L! A0#%     @ ::1Z6+@DJQK4E   ;P0! !$
M             ( !WMT? &EM9S<V,CDQ-#8Y7SDN:G!G4$L! A0#%     @
M::1Z6$F8EM'^6P0 KCLJ !$              ( !X7(@ '9E<F$M,C R,S$R
M,S$N:'1M4$L! A0#%     @ ::1Z6&L*[805<0$ 59L5 !$
M ( !#L\D '9E<F$M,C R,S$R,S$N>'-D4$L! A0#%     @ ::1Z6$<7U_S-
M"@  .U\  !               ( !4D F '9E<F$M97@Q,%\Q,2YH=&U02P$"
M% ,4    " !II'I8X=Y4YN,K  "<0P$ $               @ %-2R8 =F5R
M82UE>#$P7S$T+FAT;5!+ 0(4 Q0    ( &FD>EB7X'.7\X\  "+ !  /
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M   /              "  2-@)P!V97)A+65X,S)?,2YH=&U02P$"% ,4
M" !II'I8)>JIL$4%  !G)   #P              @ &>92< =F5R82UE>#,R
M7S(N:'1M4$L! A0#%     @ ::1Z6.]CVG2;$@  8F$   X
M ( !$&LG '9E<F$M97@T7S,N:'1M4$L! A0#%     @ ::1Z6#4>A_QW&
M?,L   \              ( !UWTG '9E<F$M97@Y-U\Q+FAT;5!+!08
..(0 A !$(  ![EB<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>vera-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:vera="http://veratx.com/20231231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vera-20231231.xsd" xlink:type="simple"/>
    <context id="C_b150cadf-6fed-4382-b18e-37a4483af270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_539e555a-bda4-46de-a744-e41a88c96a83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_97937f19-9b0a-4f85-bf7b-949364d71662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_45e8c8b4-f505-443e-882c-c062f4a6a499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d99a19d8-325e-4a9a-aacd-082609a73db3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyThreeTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ba1ed2ab-29c6-4f44-8a57-210882c88795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">vera:CeliaLinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5886db7b-8ba3-408a-b5d3-cf86749ed8e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6af2ee58-50ae-4209-960f-c26d33ada18c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a6fea3c9-4692-4fad-ad2a-ff7a304239a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyThreeTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f3deb204-a947-4aea-a198-2bd978183c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_8c1ed1eb-4ad3-48de-bbf2-10a461092b17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_656df8a2-b22a-4441-86ea-edc39b8cabaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">vera:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ee626bdd-f836-4146-83f9-c629e739a018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_e6f5b77a-d7c2-44e0-9317-e969b8465d61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_06c1a6f1-5730-4884-a735-4b4f7cac06bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_656af685-44e8-4daf-aeaf-64e77e34538a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ed279c02-7bf7-4e6e-932b-ec6e10a522e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7049dbef-cfb0-4b5b-aeab-21592adc5141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_27ff2e6e-72bd-4173-93c6-978428eecba6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyThreeTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4204b6de-68e6-4940-9da6-ada3032391f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88fbad11-b4e4-408e-a5f8-605f139b9287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0c317a6f-636d-4344-a7db-5f93a49f62a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fad68b53-11d9-436b-9004-a5b8faf94415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="C_644f1830-26e7-4980-866c-9c896b77aefd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8ac3dbbb-9f62-4b97-afd2-60e8f5b19158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8ba166aa-651f-42ca-a136-020ed2b46e9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0a795fca-1ad9-451e-9a6e-1d3d138b141b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">vera:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_83dcf10b-9a2d-456b-b6d7-c0671495052f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="C_652b7128-53c0-4531-a4b7-ce80609438f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1d9746ec-02a4-4faa-807d-24788184f0f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_106b349b-6afb-4176-a3b0-f3279ad1790b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_12676876-59e5-4f18-b296-25ca0885c06f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cade7871-7cd4-4bc1-8f5e-7e8350a76e16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_39cdc351-ad9a-4bdc-9a2f-e68f40e8b2b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7e0be373-0021-42a8-b661-4dcf7ed20677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="C_b73d9107-896f-43a1-9a6e-d51d7847b59f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d83a4fc8-8999-4dbb-8d15-fe08a22689c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_a88ca419-8f83-4779-954c-2d82558cf7e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_98c19bb9-6dc0-4e42-9491-940aabbbe506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9c7489d8-52e2-4215-8365-cea7bd8503e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-20</instant>
        </period>
    </context>
    <context id="C_a335021c-fe71-40a4-b161-f8c7dade5c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b3e496cc-f877-412e-b2d0-1b4233183c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vera:CowenAndCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:TwoThousandTwentyTwoAtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="C_d97919f2-efef-4f37-8154-249dcc9ce087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">vera:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e95c3e40-5150-4128-b63f-a06464bb547b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9f304eef-dfa2-48ba-a1fb-90a97b78c719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyTwoElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5e13a118-4107-4dfb-bab4-6714cdfa6f1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfSpecifiedBlaFilingOrRegulatoryApprovalMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_43178910-84ec-42e6-9755-a7c57bb14391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_aa03b9e4-2af3-40b2-8a5a-57a770a088a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyOneTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">vera:LondonInterbankOfferedRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3b708e8c-5665-48f7-9c36-8c9a842be8a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_df5e40de-de67-4c81-87ff-65f4bafe12aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_80f2efae-f54f-4396-a49d-51ff68d5fa88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_763f4bc0-e8d2-4dff-a69a-bf5d94bdc0c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_88d87548-c2bd-4d90-827b-1b12287efa7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_866552c5-4fd9-48eb-ba57-9fc63a8df408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-14</startDate>
            <endDate>2022-02-14</endDate>
        </period>
    </context>
    <context id="C_2ee2de34-00df-4708-bfcd-a29d841f802c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4a52fd0c-ea66-4e45-91f2-1ab3d98bfe72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:ClassACommonStockIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_75cc6cdb-a496-4205-b05d-09f40af83bb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3ba2032-8472-4a06-af17-769f411f1c3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_83acb7dc-4dff-4e8f-926f-7ad1a9c65845">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f419ef0f-acae-4639-b7c3-1c50d6d17329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vera:CowenAndCompanyLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:TwoThousandTwentyTwoAtmFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6eaa2abb-9090-46f3-9dcd-75944c3a5636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8590b670-5825-42b7-a28a-b57150a094ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_55828b2f-49ab-4655-b54a-8c64b655d49b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a9205105-dc48-4b1b-8905-ca16af40dfee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-06</instant>
        </period>
    </context>
    <context id="C_24a4e735-d3db-4c23-bb5e-9ca013ac3681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4135b425-1776-49c1-98fa-141157b08b6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_49967e2d-722f-4392-96f6-1a63849048ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">vera:CeliaLinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c194f4a2-535c-4148-b525-7d7cf987efe3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5ea44b8b-7856-4f7e-9da8-750bd3da72e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b12037ba-e589-4ed7-b30f-5ff359e4b80b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AmplyxAndNovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4c8b4716-9f64-4262-a82a-7d6247559af1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9deafbe4-5698-4e04-a2fb-fc9f4ae865ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_e4034580-fe87-43d7-b8fa-5582e2ab5313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e02b6343-2192-4292-8c98-078fac080977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_778ecdc2-82e7-487e-8f23-1ed776e1936e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8be84990-aa18-4a2e-8a74-e8d386ecfe3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="C_ddb29d7c-a69c-4f1e-9ea5-993bbfcc10d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">vera:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8436e431-af1b-457d-91b5-f52f9019d971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b426fd92-70e4-4d90-867a-c0ba79af8b53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vera:UnvestedStockOptionsAndRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_45df6405-1d04-4fca-8db5-99ee7b1dd71e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="C_9972233c-cff0-41a9-9e4e-78f8ec9718ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cfc189ab-bacf-4a05-9ffd-a7ef871b7cc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5dc0b4e6-1ca3-4772-bc5f-e4b2611208cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91729747-ed44-43ba-b06c-0ca33c08ecef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3bd84b09-3c01-4501-bfd7-f6e21766d9ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2f5962f0-d8e3-4966-ae7c-c8b41d160a04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2b98fbe6-3c1e-4766-9160-92841f2265a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41942c9c-8370-420a-b267-bd2d98ddef61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ce276b6-c154-43a1-9f92-2f2097479a87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c93b8c94-7f03-454e-b44d-c951c33fb0a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-06</startDate>
            <endDate>2023-02-06</endDate>
        </period>
    </context>
    <context id="C_33e49389-84fd-47c2-a929-1bc794eb3c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenAndTwoThousandAndTwentyOneAmendedEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_64111eab-3827-4866-aa3a-fc5810fb7d15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ddc80ff3-7e9a-4f5e-8fc8-162ee5659dda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_aac5b93f-8d14-44a8-81ce-17fdcee51c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_76b7492e-4260-4f67-8590-2c3713b1204a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:TwoThousandAndSeventeenEipAndTwoThousandAndTwentyOneEipMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_edca4e98-4e0f-44a2-ace4-368b647169df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">vera:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3b83fa9a-deb4-4a21-b9ff-0b9830dba0d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_299bd9f5-1494-45ab-a9b2-e9efcfe185b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="C_28836329-d13e-4a50-b307-58f77fac513d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c2f7961f-3a91-49fc-8d5c-eadda8e3cd86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_27a18667-bb0a-48ea-8694-1c1986159e16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_113d6c08-ba78-41b5-9746-69bcf0dfe625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b5a8210-e301-4c4e-b003-8559739c8a43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_67ddbf76-c9a0-4921-9378-a929a1fa7f5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_89a4ab10-0f5d-46b6-bb03-b0eae339e011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AmplyxAndNovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfVariousClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5ed90599-4b8c-4161-b826-92693ffe24bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_883d50e8-64b0-42ff-91c1-09162e80e0ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_94d2afc6-a122-4a1e-804c-c6fd42dafadc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f0446608-4adf-4b9a-a12b-80d69068a5b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vera:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_caf5dab2-ce38-4cdf-9364-9103e398ebaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5f7c27af-2605-4301-ae0d-b823d5c17fb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyTwoElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2c78fe3f-f7cb-44db-809e-efe584139ec5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyOneTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">vera:LondonInterbankOfferedRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28a77420-c2ea-47f5-a8d9-5ab260bf4726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_627daa2d-be5a-4f02-9196-f41419329d3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_1d2f152f-37d4-4884-be62-4c29d7144c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_c9b98e83-50fd-4219-bcaa-dce9a91dd403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_104cfa0f-5c0c-42af-a707-85e7636b50f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_ce9554a4-9d43-44af-976d-e2f6d319f429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyTwoElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9beda916-eeba-458d-97e7-f73f38603c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:ClassACommonStockIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c9ecbd41-6232-4712-8087-88a53aeacf61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5e154e33-2372-4217-add2-91f0995fc280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_15d01a5a-3d63-4633-9f8b-b5972d8790e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ae34e80b-e684-4ceb-8100-75a5ed7d4c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vera:EmployeeStockPurchasePlanEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_be8fb598-3863-42c0-ae6e-183bbd558432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="C_9d1e9814-ee09-45d4-9d31-1141dbaf3188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6f6268ee-8510-4770-a4af-2174ce8766bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a737ba92-a0d3-4854-a286-47aa2bd6f909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fe9431d7-e239-4190-9590-1758494ffd28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vera:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="C_dc44f825-ebce-4f12-ad2f-3c428d8aa752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1ffca1f3-be18-4f89-a42d-d60b717612a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vera:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_36414961-ec1c-41e6-866e-dc6627ebdbe7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vera:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2e56d451-bf45-4d4d-ad5b-7a10597988a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0c6e0d65-dc7d-4088-be4a-b8a144d6a7dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vera:CollateralizedNoteTwoThousandTwentyOneTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">vera:LondonInterbankOfferedRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f0d79c47-62a3-4c6c-977a-e3a7e09cdea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a437c869-1510-4704-bfa5-0c8b5fb1e04f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8211428a-3da0-4229-b27d-cbfee378013c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b5bdaed-6212-482b-968a-c7919dfb3d46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AmplyxAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5b5b601c-cee7-4811-bef5-aa093f9e6050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">vera:AresTradingSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:AgreementAxis">vera:AresAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="vera:EventAxis">vera:AchievementOfSpecifiedCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_7402c574-533f-4f99-9103-cfb6bfdbe42f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cd7aa2da-6cbb-441f-945f-fb8ccbd69234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_ccf892e2-cc65-4d06-90ab-1234329305b6">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_889c5f43-63dc-4264-9bdc-f5352440eef2">0001831828</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_91a574f5-f528-4208-af93-dbe15c2bf248">P436D</ecd:TrdArrDuration>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_73d24ba4-af5c-42e1-9de1-9b315e3db229">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_a640b435-6c35-4471-99b9-67265e6c5a22">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_0892ac04-799e-4a6a-b237-002187e9d87f">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_ffda962f-9677-449a-84b9-c3faa7a8f058">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_350db3a7-4f48-43bc-a55e-518b93cd904a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_1f7633ff-0d4f-4e3b-a661-014ec32e1dc9">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_8e36a540-d4b1-49d9-b18b-5e1b28e77a8a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_ed9791b9-6fac-4767-8961-754cbff299e6">001-40407</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_82f340c4-8482-4a36-81e1-d626f99e6a72">Vera Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_43bde9a4-9572-49d4-9812-4822479c6065">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_a89c447f-3681-4fe6-a662-455d904391c3">81-2744449</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_9b8efa79-8800-4f7c-b45c-8399ee919df4">8000 Marina Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_a9eabc00-62d1-46ec-ba0d-4536a2132e4c">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_4b207383-f0e6-46db-ad90-a7bbd68246a8">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_908d12e7-2c91-4fbb-bf48-5e2148c51b55">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_0031c51b-5b66-4b16-9f06-19a9887373cd">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_6601dc59-eeb3-493a-805c-b7b3a5354723">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_1385a9c0-dc9f-4b02-8289-a475f3b0c3bc">770-0077</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_3d3ed0f0-563b-4e8d-996a-49333bbc4c88">Class A common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_5a434bf0-d413-42a5-be9c-6cbbc345e0b3">VERA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_6ecfb3ee-3d7d-4746-8406-504e2f614f6e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_61015ac9-dc41-43aa-acc4-9e558a2edff5">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_c885ebeb-8a83-4cdb-95b5-6f9ef4a5fa52">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_66e9df16-bcd9-43bf-ba6a-fa98923648ad">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_6e480967-9fe1-4312-b408-c311d8a52065">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_8e20d37a-8e51-4e3f-b830-1151fba1e642">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_3f118c02-0394-4211-b465-c039b060c755">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_2de41b35-40f3-40ca-b119-e875fc9cc5b6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_64d6c4cf-67ea-4e5d-8183-0d350d432401">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_e8f5d0bc-95ba-4ffb-82fd-18a01bdda0ac">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_4f6a47d0-135f-4ed0-9e16-1871f2e3e657">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_98163537-6968-404a-a258-10de9a252785">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_9deafbe4-5698-4e04-a2fb-fc9f4ae865ad"
      decimals="-5"
      id="F_24609b0b-eb0e-4436-abfa-b8570851f906"
      unitRef="U_USD">449200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_9c7489d8-52e2-4215-8365-cea7bd8503e3"
      decimals="INF"
      id="F_8f182822-9332-4798-be5b-c7c109fd9c58"
      unitRef="U_shares">54452029</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_83dcf10b-9a2d-456b-b6d7-c0671495052f"
      decimals="INF"
      id="F_06cf0e95-2017-4035-9712-203f469c9ee6"
      unitRef="U_shares">0</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_d2d67f6f-2db9-4024-8932-32f0e456da85">&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Portions of the Registrant&#x2019;s definitive proxy statement for its 2024 Annual Meeting of Stockholders, which the Registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the Registrant&#x2019;s fiscal year ended December 31, 2023, are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_ac88040d-5da1-4c49-8791-b6d9edebfd73">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_b5e51085-e58f-40ef-b016-19a57e3a9655">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_27a859f0-ffbe-4ea8-9677-0d5e6d271d59">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_1fd9e5c4-9216-4288-ad02-9e61024b7bec"
      unitRef="U_USD">45681000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_0a88eccf-2f68-4d26-ad44-196593ca14e0"
      unitRef="U_USD">43459000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_df510b84-d111-44d7-b910-441e1bd5fb54"
      unitRef="U_USD">115035000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_86d31e56-ed3d-4b84-b0a5-e0ef52e3872b"
      unitRef="U_USD">71194000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_7bb52a63-9750-4273-86bd-ac9fc261b968"
      unitRef="U_USD">11307000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_cc5045d0-0471-4515-97ff-d2fdfe309432"
      unitRef="U_USD">11045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_389885c3-4ff9-4bf7-8139-34df3e771c33"
      unitRef="U_USD">172023000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_91258019-d654-4d0b-b717-1d3ffa5400b6"
      unitRef="U_USD">125698000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_682d1b0e-38a0-4ec0-83c8-eae523a8baa6"
      unitRef="U_USD">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_88a85bf6-c083-4b52-b2a7-3a6a3e7cf5da"
      unitRef="U_USD">293000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_bfc822cb-cf6b-44fa-ad67-54c94fa58983"
      unitRef="U_USD">92000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_254a42aa-79e1-41e6-b35d-752a5fc361a0"
      unitRef="U_USD">51000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_7202e4ba-8fcf-4117-8978-966263a3b965"
      unitRef="U_USD">2949000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_43a2df3d-18be-477a-a635-adc27b651a59"
      unitRef="U_USD">5173000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_0de31780-88d6-4be2-9547-0f2a6380f18d"
      unitRef="U_USD">471000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ca400b9a-9bac-4a6b-be2e-24284480a4b4"
      unitRef="U_USD">162000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e5c7c4dd-4f37-45ab-865f-98b05c692477"
      unitRef="U_USD">11000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_b7528db6-38e6-4eed-a06c-1dc9f646af4c"
      unitRef="U_USD">58000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:Assets
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_1b04a008-a148-482f-960d-7b08afefcf8d"
      unitRef="U_USD">175546000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_1e005dc3-6d13-4990-84b0-e48a88215faf"
      unitRef="U_USD">131435000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_d1c93f03-7324-4660-900c-34eb3babd4f2"
      unitRef="U_USD">11118000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_79182f78-b43e-4f19-a2bb-fd05e02d5170"
      unitRef="U_USD">11991000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_b4b99b41-811f-4c75-a323-47954bf94052"
      unitRef="U_USD">2436000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ffa8cbe2-dcba-4be7-bd60-80689107c1c0"
      unitRef="U_USD">2645000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e03fdd3d-5691-4746-8f92-658901242c91"
      unitRef="U_USD">8749000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_eaf9d03b-eb11-4847-a678-d0d648d9615e"
      unitRef="U_USD">10964000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_369884c7-d00e-44be-8cda-3475673407f0"
      unitRef="U_USD">22303000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ac58032b-af2f-4a3a-8a5e-e0c1c2936e84"
      unitRef="U_USD">25600000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_81c6a8fd-b323-4195-bda0-38b5bd2fedba"
      unitRef="U_USD">49877000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_f0fdbd19-9e60-4a1c-b35a-0945f88f8280"
      unitRef="U_USD">24810000</us-gaap:LongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_748568d1-3a0f-43a3-8dd8-cc6ffd81ec37"
      unitRef="U_USD">1395000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_f066a50c-d3df-4cbd-984b-a44852d32424"
      unitRef="U_USD">3831000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <vera:AccruedLiabilitiesAndOtherLiabilitiesNonCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_9e598d5f-0716-4840-8e34-abcda95b970e"
      unitRef="U_USD">286000</vera:AccruedLiabilitiesAndOtherLiabilitiesNonCurrent>
    <vera:AccruedLiabilitiesAndOtherLiabilitiesNonCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_d9c6c665-e935-4baa-8cf0-0d73a4cd1b80"
      unitRef="U_USD">286000</vera:AccruedLiabilitiesAndOtherLiabilitiesNonCurrent>
    <us-gaap:Liabilities
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_d2a65f0c-853f-49ed-8089-04f747dc80ee"
      unitRef="U_USD">73861000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_3e415532-4899-419e-a7bc-6c6a5e266b9f"
      unitRef="U_USD">54527000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="3"
      id="F_74dca446-ef3b-490e-9302-15839d17b2a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="3"
      id="F_78f06f87-456a-48b5-a597-84d825ef1c24"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="INF"
      id="F_d56a3d58-799d-426c-94cc-319775225859"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="INF"
      id="F_07ec2406-7aa3-4c70-8196-c845ee8ba859"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="INF"
      id="F_9be670b4-5f70-4eb7-aa74-a789cb8e32dc"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="INF"
      id="F_f2a20967-c050-48c6-98b8-be6b2a2e67f2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="INF"
      id="F_a8c6c226-ffe8-492e-bdca-79473a862148"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="INF"
      id="F_d62eb141-96e3-4111-9d6d-75ccfddc8ed1"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_56dfc381-5bf6-4372-a6cc-10aac47e0ef1"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_1570f6f4-0813-4981-aded-e7a8ef423ab5"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="3"
      id="F_3da5843d-8147-4a1c-bfce-ffc5403bee0f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b"
      decimals="3"
      id="F_80b7f455-bab7-4542-bee0-69513d668ec2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="INF"
      id="F_46a2764f-9571-42de-b455-bac9aa982f33"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b"
      decimals="INF"
      id="F_0b77163d-bf7f-4a89-94f3-b5a3c32fc02d"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="INF"
      id="F_f2c3d8c1-4e80-42c0-af85-5bc0a603dff5"
      unitRef="U_shares">44452161</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="INF"
      id="F_1b805e70-6e3b-4af3-9723-e2ad3f72a6fb"
      unitRef="U_shares">44452161</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b"
      decimals="INF"
      id="F_05641d71-b973-49cd-a5e8-4da117712a3d"
      unitRef="U_shares">27800861</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b"
      decimals="INF"
      id="F_2685bf58-808e-4bbf-83e8-a21a2f2165f3"
      unitRef="U_shares">27800861</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_455b089a-0638-431a-84b8-81ef664f1ba0"
      unitRef="U_USD">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_a21b380c-71c8-45b7-9646-cf85d1c83126"
      unitRef="U_USD">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_2f89adb8-4734-444b-9719-c69b173b6630"
      unitRef="U_USD">410492000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_f21c5217-c3f1-4518-bd80-e13c8e7c3ad5"
      unitRef="U_USD">290216000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_4c8d651c-152c-44e1-a28b-483bba2d0509"
      unitRef="U_USD">251000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_23ec1dd3-5898-4aa5-bb85-88b8fa5b0c5f"
      unitRef="U_USD">-224000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_c52257ed-e934-44d1-8ce7-07b070fc372a"
      unitRef="U_USD">-309102000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_8aa99605-23f0-4000-b5f0-2d69cf215bfb"
      unitRef="U_USD">-213112000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e44f3856-68f2-4d73-80e9-3e774e1cf804"
      unitRef="U_USD">101685000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_9b0b7aa2-cabd-4359-9e97-37387a5f3542"
      unitRef="U_USD">76908000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_956ab0c9-ad15-4cb9-95f5-df41a484f642"
      unitRef="U_USD">175546000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_1fd75d54-8419-4d76-ac55-68d0fcc10158"
      unitRef="U_USD">131435000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_07568bfe-90c2-40e9-a537-5b9eee49b7bc"
      unitRef="U_USD">78225000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_5c0efb2c-336a-41fa-9008-f3892c7898c1"
      unitRef="U_USD">68993000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_447b60ea-ca8f-45de-8861-19c22cb93de1"
      unitRef="U_USD">23787000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_15124c16-4bc8-4996-b89e-f53169cc4f44"
      unitRef="U_USD">21910000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_aa84d02f-7d0c-446a-a5ff-91761b8cbe91"
      unitRef="U_USD">102012000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_dae34db1-53d1-4469-a612-e62f9ea4a3d4"
      unitRef="U_USD">90903000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_77a019ed-b942-4cdb-ab03-38453c5923ea"
      unitRef="U_USD">-102012000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_dbfb097d-26ff-4d65-9829-ceddf3ac2e4f"
      unitRef="U_USD">-90903000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_b2e13362-2899-4bed-8b72-91fdc4c69c4f"
      unitRef="U_USD">7979000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_f84c7671-93a5-4af7-9106-89a628b9edfd"
      unitRef="U_USD">1750000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_df5b999a-bab5-4d51-a848-c6a308030277"
      unitRef="U_USD">3786000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_22e58e95-f4c5-4919-ad9b-67ea00c84691"
      unitRef="U_USD">992000</us-gaap:InterestExpense>
    <us-gaap:OtherIncome
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_9ee506d6-c87b-466b-9923-0e474e5276c9"
      unitRef="U_USD">1877000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_4eb1ecf1-4e08-46d0-9595-792582fdb3e7"
      unitRef="U_USD">1899000</us-gaap:OtherIncome>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_11b3dad6-ba25-431d-be39-6929a3fef76b"
      unitRef="U_USD">-47000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_01a9dabe-a3c2-4816-907e-15a97985d0ef"
      unitRef="U_USD">-809000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_b0dfa8b5-3aed-4f20-a27a-a7a6c5d011b5"
      unitRef="U_USD">6023000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_e1eca33b-4a99-4522-a0ed-792ee5871dcc"
      unitRef="U_USD">1848000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_e094441b-9b50-4cec-ae81-8198750d0e65"
      unitRef="U_USD">-95989000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_dd75645c-5c52-41ea-b1a9-89a2249a90f7"
      unitRef="U_USD">-89055000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_b705d00b-49d3-4224-9896-d420d42094ed"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_285f6ab5-036d-4949-9cbb-3f30d54fe72e"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_eea46298-25c4-461c-a203-fcf5de407c4d"
      unitRef="U_USD">-95990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_bdad4a17-9642-453a-9b8a-111ac4d0f4d4"
      unitRef="U_USD">-89056000</us-gaap:NetIncomeLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_00ee5306-37b4-472a-bc6c-656d85e26c8b"
      unitRef="U_USD">251000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_8cf15789-bf37-4dbc-95d4-512d064d5e62"
      unitRef="U_USD">-224000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_5e1b6aaf-96f3-4d21-9d8f-a0d84bc632db"
      unitRef="U_USD">-95739000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_70fed9d9-c1bf-4e2c-b3d8-0752018851cb"
      unitRef="U_USD">-89280000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="2"
      id="F_3ee0d97e-61c4-4434-8741-a21aa24afa1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="2"
      id="F_a83bd7d7-e67e-4b60-86fc-5b88472a6c21"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="2"
      id="F_6f73cf1f-5245-4b2c-9c4e-df8d48dab030"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="2"
      id="F_0e50a5ed-bc29-4503-8f8f-c755e415dbb2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="0"
      id="F_2f8e59d9-4ddd-4272-8a74-0ef4a60ec237"
      unitRef="U_shares">42707072</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="0"
      id="F_34c3f15a-55c9-4676-ba64-b4403bfbb424"
      unitRef="U_shares">42707072</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="0"
      id="F_3e467ea2-824b-4074-9079-ad50a6974bf0"
      unitRef="U_shares">26570676</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="0"
      id="F_a98527ce-c53e-47f6-844a-142feb96555d"
      unitRef="U_shares">26570676</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_e02b6343-2192-4292-8c98-078fac080977"
      decimals="INF"
      id="F_30918cc3-fd9b-44cf-b829-680d0423e12d"
      unitRef="U_shares">20968376</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_644f1830-26e7-4980-866c-9c896b77aefd"
      decimals="-3"
      id="F_eeeb673b-b48e-4cc6-a38a-0c487d63385b"
      unitRef="U_USD">21000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_8211428a-3da0-4229-b27d-cbfee378013c"
      decimals="INF"
      id="F_27494326-4e32-4035-b563-5410486be3ea"
      unitRef="U_shares">309238</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_39cdc351-ad9a-4bdc-9a2f-e68f40e8b2b8"
      decimals="-3"
      id="F_7c46c62e-e9b8-48a2-a2fc-8ffbf16521fb"
      unitRef="U_USD">193627000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3b708e8c-5665-48f7-9c36-8c9a842be8a6"
      decimals="-3"
      id="F_89bb8742-60f8-4a2c-9e0e-600cabaa0edb"
      unitRef="U_USD">-124056000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ed90599-4b8c-4161-b826-92693ffe24bd"
      decimals="-3"
      id="F_bb636c61-b0c2-4743-91e3-1cb1599e89db"
      unitRef="U_USD">69592000</us-gaap:StockholdersEquity>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares
      contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61"
      decimals="INF"
      id="F_b6958400-33be-4b8d-98a4-ddb0c27b02b8"
      unitRef="U_shares">5742026</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
      contextRef="C_caf5dab2-ce38-4cdf-9364-9103e398ebaa"
      decimals="-3"
      id="F_c9d3cd91-c90e-439f-b3c7-6f96fa411d0f"
      unitRef="U_USD">6000</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
      contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6"
      decimals="-3"
      id="F_fb30579e-eba0-42b5-a3b5-a14c8ee46c5a"
      unitRef="U_USD">80028000</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_f79c6c2b-8f42-4e54-a1a9-d80ff06a4460"
      unitRef="U_USD">80034000</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61"
      decimals="INF"
      id="F_0b0000a7-bfcb-434a-b93f-fa007cb0e108"
      unitRef="U_shares">405140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_caf5dab2-ce38-4cdf-9364-9103e398ebaa"
      decimals="-3"
      id="F_ee1f8257-3e14-4e51-9275-7a5d94b29b4c"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6"
      decimals="-3"
      id="F_c427707c-77fc-49f5-8a8c-f7c4c6d2fae0"
      unitRef="U_USD">1791000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_b100d443-e137-4beb-b221-a6e9d0ae4a15"
      unitRef="U_USD">1792000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61"
      decimals="INF"
      id="F_b4998d8c-78f9-4720-814d-dc665b649e6f"
      unitRef="U_shares">15328</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6"
      decimals="-3"
      id="F_b46165c3-37cb-48a2-b344-61b6ec813a47"
      unitRef="U_USD">291000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_5095082b-b254-4a05-aac3-5d950b4344de"
      unitRef="U_USD">291000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61"
      decimals="INF"
      id="F_7a5f5a18-1fb7-45bc-a645-cec977c860d0"
      unitRef="U_shares">77719</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61"
      decimals="INF"
      id="F_8c4ed986-9b04-42d7-a64d-137437b8ca2b"
      unitRef="U_shares">309238</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_aac5b93f-8d14-44a8-81ce-17fdcee51c82"
      decimals="INF"
      id="F_2da0ac64-c334-40b3-a376-00653453bdb1"
      unitRef="U_shares">-309238</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity
      contextRef="C_c9ecbd41-6232-4712-8087-88a53aeacf61"
      decimals="INF"
      id="F_bb7dd076-1716-4a85-9c9a-796312f627a2"
      unitRef="U_shares">283034</vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity>
    <vera:StockIssuedDuringPeriodValueLicensingPaymentsInEquity
      contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6"
      decimals="-3"
      id="F_58c795b5-c5c9-4555-9b2f-a25e768165b5"
      unitRef="U_USD">5592000</vera:StockIssuedDuringPeriodValueLicensingPaymentsInEquity>
    <vera:StockIssuedDuringPeriodValueLicensingPaymentsInEquity
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_3a81a8a3-f2d6-4749-bb42-fa6b2337491b"
      unitRef="U_USD">5592000</vera:StockIssuedDuringPeriodValueLicensingPaymentsInEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_09b43f54-b8ec-47bd-b821-2cc4b3e695c6"
      decimals="-3"
      id="F_3374b6ff-ff62-49b5-a810-8cd05f53d754"
      unitRef="U_USD">8887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_3d37eff7-3b38-4b50-942a-10af3893cb79"
      unitRef="U_USD">8887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_67ddbf76-c9a0-4921-9378-a929a1fa7f5b"
      decimals="-3"
      id="F_e6b6861d-1cc6-466f-acf5-a8b9a0ebcb5f"
      unitRef="U_USD">-224000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_f234ac92-b417-49e6-bd9f-22f290e39ca5"
      unitRef="U_USD">-224000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_45e8c8b4-f505-443e-882c-c062f4a6a499"
      decimals="-3"
      id="F_ab719833-a8d4-4b23-8b8f-73cc26f7ae0b"
      unitRef="U_USD">-89056000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_9e222870-6914-46b5-b9ec-b14a5cfef3f0"
      unitRef="U_USD">-89056000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_1430c488-f1f9-4690-bf3a-f8f0dbf9680b"
      decimals="INF"
      id="F_8e89c0b2-480b-41cb-b4e6-66c42a22bd33"
      unitRef="U_shares">27800861</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_883d50e8-64b0-42ff-91c1-09162e80e0ef"
      decimals="-3"
      id="F_e525f961-d2d1-4cb0-8fca-249620a4fa36"
      unitRef="U_USD">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ed279c02-7bf7-4e6e-932b-ec6e10a522e9"
      decimals="-3"
      id="F_7b517f57-d0d3-4d46-b004-251f1313db34"
      unitRef="U_USD">290216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e6f5b77a-d7c2-44e0-9317-e969b8465d61"
      decimals="-3"
      id="F_71c146b2-262a-4bdc-921f-72fc7dc6ac77"
      unitRef="U_USD">-224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28836329-d13e-4a50-b307-58f77fac513d"
      decimals="-3"
      id="F_e38c1345-cafa-45bd-be87-1580ab505315"
      unitRef="U_USD">-213112000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_e8f99a54-759d-4b28-93bf-60ff6c54fb96"
      unitRef="U_USD">76908000</us-gaap:StockholdersEquity>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="0"
      id="F_1f9bc083-0c9d-4687-acce-e40603731ee3"
      unitRef="U_shares">16428572</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCostsShares>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
      contextRef="C_15d01a5a-3d63-4633-9f8b-b5972d8790e7"
      decimals="-3"
      id="F_facb44a1-0396-4c46-b407-79db8b6ce8a5"
      unitRef="U_USD">16000</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
      contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43"
      decimals="-3"
      id="F_9ce9b1fd-74b1-4b70-88dd-4cabf7b9cc48"
      unitRef="U_USD">107727000</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts>
    <vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_fe0836a5-c771-4d81-9ccb-cbe9cfea5e78"
      unitRef="U_USD">107743000</vera:IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d"
      decimals="INF"
      id="F_a434daf8-4f02-4ec7-b724-14cbaf8c31a3"
      unitRef="U_shares">111927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43"
      decimals="-3"
      id="F_b00401b3-5e58-45b8-865f-dec5bbfa4ae2"
      unitRef="U_USD">781000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_8c0a5af7-508d-4e2c-9bbe-6210ee4dec49"
      unitRef="U_USD">781000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d"
      decimals="INF"
      id="F_93f86380-8043-4358-a0fd-1d09624079e3"
      unitRef="U_shares">66321</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d"
      decimals="INF"
      id="F_bc069f43-e804-4c30-838c-b98bb6e745fd"
      unitRef="U_shares">44480</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43"
      decimals="-3"
      id="F_eb66414d-3985-407e-b930-3c6d3c5d1765"
      unitRef="U_USD">275000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_a200476c-afbe-483c-beef-2160a8e8f9b0"
      unitRef="U_USD">275000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_a335021c-fe71-40a4-b161-f8c7dade5c43"
      decimals="-3"
      id="F_5e8f4583-15b9-4430-92f6-e0c216c35df0"
      unitRef="U_USD">11493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_cb7713f7-6804-4717-96f7-6f99a18a6eed"
      unitRef="U_USD">11493000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_cfc189ab-bacf-4a05-9ffd-a7ef871b7cc4"
      decimals="-3"
      id="F_3d863d8a-471f-48f5-a5b5-a7dcd43f2877"
      unitRef="U_USD">475000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_0228bbb7-75c7-4ded-a1a9-e68d1d52ec65"
      unitRef="U_USD">475000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_98c19bb9-6dc0-4e42-9491-940aabbbe506"
      decimals="-3"
      id="F_32fca3e6-ba81-4983-8d79-6099841b6f9a"
      unitRef="U_USD">-95990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_4439e1d7-f0a5-472d-9f22-7c9cb8c68e85"
      unitRef="U_USD">-95990000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="INF"
      id="F_f529f1e7-4c1d-423b-b238-5ea50e1c48da"
      unitRef="U_shares">44452161</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_539e555a-bda4-46de-a744-e41a88c96a83"
      decimals="-3"
      id="F_b797f4bf-e05c-4487-b3db-e07a4534a2c0"
      unitRef="U_USD">44000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ba1ed2ab-29c6-4f44-8a57-210882c88795"
      decimals="-3"
      id="F_4c51c627-4c2a-4215-a20c-a6d94c524fd5"
      unitRef="U_USD">410492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a88ca419-8f83-4779-954c-2d82558cf7e7"
      decimals="-3"
      id="F_55146b34-7023-4c83-a0ab-85ae4c765195"
      unitRef="U_USD">251000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_28a77420-c2ea-47f5-a8d9-5ab260bf4726"
      decimals="-3"
      id="F_500ef725-7601-4cc2-a072-772929a501cc"
      unitRef="U_USD">-309102000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_9ea3b4ab-cb9c-407c-9ef6-1af1218305cf"
      unitRef="U_USD">101685000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_b1c03544-a706-4a43-9230-1ff91bced7c9"
      unitRef="U_USD">-95990000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_6a756b56-7925-4065-8881-9a1ef48bfd89"
      unitRef="U_USD">-89056000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_ee79ba49-6eb4-4e32-9da2-c722a62bbc6b"
      unitRef="U_USD">-4086000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:DepreciationAmortizationAndAccretionNet
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_afc4662f-8b13-46c1-abed-bc551e1a8a17"
      unitRef="U_USD">-846000</us-gaap:DepreciationAmortizationAndAccretionNet>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_10c9a97b-dbd5-415e-aa57-420f6364211c"
      unitRef="U_USD">2224000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_457100eb-cd78-44be-9ebe-2c00f21b5346"
      unitRef="U_USD">2271000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_402d7a12-3ce3-4fd7-9b9a-2d74f6ceca1a"
      unitRef="U_USD">11493000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_37a9900d-ac2a-455d-910c-ae14b87775d8"
      unitRef="U_USD">8887000</us-gaap:ShareBasedCompensation>
    <vera:IssuanceOfCommonStockForLicensingPaymentNetOfCosts
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_cbdf3eb9-ef4a-40ed-ac87-14aad6f0ba68"
      unitRef="U_USD">0</vera:IssuanceOfCommonStockForLicensingPaymentNetOfCosts>
    <vera:IssuanceOfCommonStockForLicensingPaymentNetOfCosts
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_8cfa00a3-720d-4190-8af4-1886a1f570d1"
      unitRef="U_USD">3592000</vera:IssuanceOfCommonStockForLicensingPaymentNetOfCosts>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_129ceffc-9dae-41d8-b495-3c861c788c56"
      unitRef="U_USD">-47000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_4e97284e-f873-40e7-8784-cef8c659ef29"
      unitRef="U_USD">-809000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_83b0fde0-97ad-47b9-89fa-84cd9e512629"
      unitRef="U_USD">-173000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_d5714fb0-2935-416f-9859-31d5dfc27465"
      unitRef="U_USD">8182000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_43fbfd18-c791-46f7-8b02-84914d77762e"
      unitRef="U_USD">309000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_ac3854de-345d-4182-9ad2-a589149b8213"
      unitRef="U_USD">111000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_4014b648-9988-433a-acc8-c5532b8a8f30"
      unitRef="U_USD">-873000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_18b81df4-1e24-4f7c-9d09-1634df87c2b7"
      unitRef="U_USD">10606000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_58f42eb3-0109-40c6-a326-08e69a647a0d"
      unitRef="U_USD">-2215000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_35ea50fc-378a-438b-bc53-0b23d271b882"
      unitRef="U_USD">7036000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_9cbe5f06-4360-45cc-845c-c5d1c97611cc"
      unitRef="U_USD">-2645000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_c96e9e62-f4b1-42ec-b1b1-2103cb2e569a"
      unitRef="U_USD">-2602000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_7263c2a4-0747-4d50-9ad6-ac310811df18"
      unitRef="U_USD">-92181000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_3a9af986-0354-46ea-8706-20e510f1a35b"
      unitRef="U_USD">-67596000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_3d9468dd-d33c-4013-9c52-8559508485ad"
      unitRef="U_USD">63000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_43eb23f9-cebf-43f3-95d9-4f22ff7eeb35"
      unitRef="U_USD">62000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_aeb48b86-9c02-496b-a84d-e6786bf817f8"
      unitRef="U_USD">224930000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_a234c64b-b52f-4d35-9405-4d31038033d2"
      unitRef="U_USD">148490000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_cd1d0b98-264f-4d05-834b-6f0110f2daf2"
      unitRef="U_USD">176019000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_09a862ae-6f4f-41c9-96c1-73386d6183c4"
      unitRef="U_USD">78000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <vera:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_a52d2dda-20f1-42a8-92a0-7803802aba73"
      unitRef="U_USD">9543000</vera:ProceedsFromSaleOfMarketableSecurities>
    <vera:ProceedsFromSaleOfMarketableSecurities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_a6850c59-463f-4099-93b9-0279f469b8f3"
      unitRef="U_USD">0</vera:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_8bd48052-c905-421c-99c3-cbe8eb325085"
      unitRef="U_USD">-39431000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_f194ab07-0711-42fd-88cf-36aa22845ed3"
      unitRef="U_USD">-70552000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_2654560a-8f8d-4a46-a6cb-aceebd64f214"
      unitRef="U_USD">1056000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_e834bd46-47a9-4211-9fd7-4444eda0b95e"
      unitRef="U_USD">2083000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <vera:ProceedsFromBorrowingsNetOfCosts
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_7db57ac1-69a0-4a39-99bf-7b205f408ff5"
      unitRef="U_USD">24741000</vera:ProceedsFromBorrowingsNetOfCosts>
    <vera:ProceedsFromBorrowingsNetOfCosts
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_957f32a7-3cec-4f50-96db-9211b672cb9a"
      unitRef="U_USD">19816000</vera:ProceedsFromBorrowingsNetOfCosts>
    <vera:ProceedsFromIssuanceOfCommonStockFollowOnOffering
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_18d3a8f7-3bf6-4de7-9492-bd07a0eb846a"
      unitRef="U_USD">115000000</vera:ProceedsFromIssuanceOfCommonStockFollowOnOffering>
    <vera:ProceedsFromIssuanceOfCommonStockFollowOnOffering
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_c110ab00-1240-49bb-90d7-3b7bd153258d"
      unitRef="U_USD">86131000</vera:ProceedsFromIssuanceOfCommonStockFollowOnOffering>
    <vera:PaymentsOfStockIssuanceCostsOnFollowOnOffering
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_cf8679ab-ff34-42cc-a658-58f90e226f63"
      unitRef="U_USD">7256000</vera:PaymentsOfStockIssuanceCostsOnFollowOnOffering>
    <vera:PaymentsOfStockIssuanceCostsOnFollowOnOffering
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_7f2b770f-4971-4c8b-b4ec-2f4f38e1a89f"
      unitRef="U_USD">6097000</vera:PaymentsOfStockIssuanceCostsOnFollowOnOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_b67507fc-c84d-4518-ab87-484e1d502846"
      unitRef="U_USD">133541000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_c7e34e70-63bc-4f10-bda2-6a01797a3dc3"
      unitRef="U_USD">101933000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_01672a41-6514-4b8c-98b9-c0b41b0e1fd4"
      unitRef="U_USD">1929000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_c735286c-986f-4089-865c-efa6382158dd"
      unitRef="U_USD">-36215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_101785a8-7fda-4767-975f-0ccffb00197f"
      unitRef="U_USD">43752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_5ed90599-4b8c-4161-b826-92693ffe24bd"
      decimals="-3"
      id="F_facb835d-212c-47de-a77c-85db3b623c21"
      unitRef="U_USD">79967000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_9c22652a-4164-43b3-90ae-353b162d0353"
      unitRef="U_USD">45681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ec55d594-0bbe-4907-9bc8-687c88a8ea09"
      unitRef="U_USD">43752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_80f2efae-f54f-4396-a49d-51ff68d5fa88"
      decimals="-3"
      id="F_edb23367-989e-4b47-a2a5-eadf46db72eb"
      unitRef="U_USD">45681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_88d87548-c2bd-4d90-827b-1b12287efa7b"
      decimals="-3"
      id="F_d15beecd-b507-484f-a791-56e0f5a16ef3"
      unitRef="U_USD">43459000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f0446608-4adf-4b9a-a12b-80d69068a5b3"
      decimals="-3"
      id="F_00a9c25c-e239-48ba-8389-078aa5ce016d"
      unitRef="U_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_1ffca1f3-be18-4f89-a42d-d60b717612a9"
      decimals="-3"
      id="F_d76040b4-3af8-450f-985e-0ac28473fb6a"
      unitRef="U_USD">293000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_55f98f6c-a706-4d80-a6e7-4e9776ca8379"
      unitRef="U_USD">45681000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_0b6c900f-fec1-44df-88c3-27a97f9f1840"
      unitRef="U_USD">43752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_ff75e03d-1012-481e-8ba3-e8b76779e60f"
      unitRef="U_USD">3352000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_c308643c-4699-4ab8-bcc5-b7126e2ce584"
      unitRef="U_USD">895000</us-gaap:InterestPaidNet>
    <us-gaap:OperatingLeasePayments
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_49e23c1a-7aa4-4e1d-a113-e0d0904c3a23"
      unitRef="U_USD">3000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_16bf0bdc-3703-4762-be40-adbba54a60a1"
      unitRef="U_USD">2734000</us-gaap:OperatingLeasePayments>
    <us-gaap:StockIssued1
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_b1e977ba-245a-4c76-b8f5-dad6a3ad295f"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_75cb2101-8afe-4f7c-a4f7-b28a23cb3048"
      unitRef="U_USD">2000000</us-gaap:StockIssued1>
    <us-gaap:NatureOfOperations
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_0a7ae46d-7af5-4ecd-9477-4b50ac5b08c3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. ORGANIZATION AND DESCRIPTION OF THE BUSINESS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Vera Therapeutics, Inc. (the Company) is a clinical stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases. The Company was incorporated in May 2016 in Delaware.  The Company&#x2019;s headquarters and operations are located in Brisbane, California. The Company operates in one segment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 13, 2021, the Company&#x2019;s registration statement on Form S-1 for its initial public offering (the IPO) was declared effective by the Securities and Exchange Commission (the SEC), and the shares of its Class A common stock commenced trading on the Nasdaq Global Select Market on May 14, 2021. The IPO closed on May 18, 2021. Prior to the completion of the IPO, all shares of redeemable convertible preferred stock then outstanding were converted into shares of Class A and Class B common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Liquidity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;S&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ince inception, the Company devoted substantially all of its resources to its research and development efforts, pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. The Company has incurred recurring net operating losses and has not generated positive cash flow from operations since its inception, and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;309.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;as of December 31, 2023. The Company had cash, cash equivalents and marketable securities of&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;160.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;as of December 31, 2023. The Company has funded its operations primarily through the issuance of common stock, redeemable convertible preferred stock, debt financing and convertible notes. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management believes that the Company&#x2019;s cash, cash equivalents and marketable securities as of December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months subsequent to the issuance date of these financial statements. The Company intends to raise additional capital through public or private equity offerings or debt financing or other capital sources, which may include strategic collaborations or other arrangements with third parties in order to achieve its long-term business objectives. If the Company fails to obtain necessary capital when needed on acceptable terms, or at all, it could force the Company to delay, limit, reduce or terminate its product development programs, commercialization efforts or other operations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_161a21cd-ad06-4091-950b-280a17e1e307"
      unitRef="U_USD">-309100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <vera:CashAndCashEquivalentsAndMarketableSecurities
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_99d32a74-1995-4b1d-89ea-7514e9d59070"
      unitRef="U_USD">160700000</vera:CashAndCashEquivalentsAndMarketableSecurities>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_1c1fa952-f638-4d64-b8b3-2b9fd9218ab2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the SEC regarding financial reporting. The U.S. dollar is the Company&#x2019;s functional and reporting currency.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the research contract costs and accruals, stock-based compensation expense, and the valuation allowance for deferred&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;tax &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#x2019;s current and potential future product candidates, uncertainty of market acceptance of the Company&#x2019;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash represents cash held by a financial institution as collateral for a letter of credit securing its operating lease for office and laboratory space, which is classified as a non-current asset on the balance sheets based on the maturity of the lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company holds investments in marketable securities, consisting of U.S. government securities. Marketable debt securities with stated maturities of three months or less from the date of purchase are classified as cash equivalents and those with stated maturities of greater than three months as marketable securities on the balance sheet. The Company determines the appropriate classification of marketable debt securities at the time of purchase. The Company has the ability, if necessary, to liquidate its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying balance sheets. All marketable debt securities are classified as available-for-sale and are reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss within stockholders&#x2019; equity. Interest, amortization and accretion of purchase premiums and discounts on marketable debt securities are included in other income (expense), net, in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cost of available-for-sale marketable securities sold is based on the specific identification method. Realized gains and losses on the sale of available-for-sale marketable securities are recorded in other income, net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company regularly reviews all of the marketable securities for decline in fair value to determine whether unrealized losses have resulted from credit loss or other factors. The review includes considerations for the cause of the impairment but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers. A decline of fair value below cost basis is considered an other-than-temporary impairment if the Company has the intent to sell the security or it is more likely than not that the company will be required to sell the security before recovery of the entire cost basis. Regardless of the Company&#x2019;s intent or requirement to sell the security, an impairment is considered other-than-temporary if the Company does not expect to recover the entire cost basis. In those instances, an impairment charge equal to the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;difference &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;between fair value and the cost basis is recorded in other income (expense), on the statements of operations and comprehensive loss. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment loss was recognized for the fiscal years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The amortized or accreted cost basis of the marketable securities approximates its fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred offering costs consisting of legal, accounting and filing fees relating to equity offerings. Deferred offering costs are included in other long-term assets on the Company&#x2019;s balance sheets. Upon completion of the offering, these amounts are offset against the proceeds of the offering.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases office space under operating leases and determines if the arrangement is a lease at inception. These leases contain lease and non-lease components. Non-lease components include payments for maintenance, utilities, real estate taxes, and management fees. The lease and non-lease components are combined and accounted as a single lease component. Payments made under operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;These leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is a hypothetical rate based on the Company&#x2019;s understanding of what the credit rating would be in a similar economic environment. Operating leases are included in operating lease right-of-use assets and operating lease liabilities, current and non-current, on the balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases may include one or more options to renew. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured. The lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign Currency Translations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value measurements are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; Quoted unadjusted prices for identical instruments in active markets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed in the financial statements on a recurring basis.  The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, prepaid expenses and other current assets, non-marketable equity securities, accounts payable and accrued expenses and long-term debt.  Cash, restricted cash, and marketable securities and non-marketable securities are reported at their respective fair values on the Company&#x2019;s balance sheets.  The remaining financial instruments are reported on the Company&#x2019;s balance sheets at cost, which approximate their fair value due to their short-term nature.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are highly liquid investments that are actively traded. The pricing information for the Company&#x2019;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s non-marketable equity securities (see Note 5) are measured at fair value using an option pricing valuation methodology. The option pricing methodology relies on risk-neutral valuation which calculates the value of an asset by discounting the expected value of its future payoffs at the risk-free rate of return. The fair value of the non-marketable equity securities is derived from quoted prices for similar instruments and observable inputs in active markets. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December 31, 2023, and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company held $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, in money market funds.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss consists of two components: net loss and other comprehensive loss. Other comprehensive loss refers to unrealized gains and losses that are recorded as an element of stockholders&#x2019; equity and are excluded from net loss. For the year ended December 31, 2023, other comprehensive loss consists of unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred and consist primarily of employees&#x2019; salaries and related benefits, including stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support the Company&#x2019;s operations that are directly attributable to the Company&#x2019;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs incurred in obtaining technology licenses including upfront and milestone payments incurred under the Company&#x2019;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#x2019;s research and development activities. Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research Contract Costs and Accruals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#x2019;s employees, nonemployee directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgments about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#x2019;s Class A common stock on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all stock options granted, the Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#x201c;plain vanilla&#x201d; stock option awards, as the Company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. The estimate of expected volatility is based on comparative companies&#x2019; volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company determines the fair value of its Class A common stock using the market closing price on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect tax rates expected to be in effect for the years in which the differences are expected to be reversed. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies the guidance in Topic 210, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company&#x2019;s financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_6617a6d8-a140-4e80-8b5a-ed91c13e13af">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP) and applicable rules and regulations of the SEC regarding financial reporting. The U.S. dollar is the Company&#x2019;s functional and reporting currency.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <vera:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_34b9237d-e0c5-45ed-8d53-ebbb7362623e">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;T&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;he Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.&lt;/span&gt;&lt;/p&gt;</vera:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_afc7e2da-f586-4f5e-b76a-1848121e38e7">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;preparation of the Company&#x2019;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and liabilities include the research contract costs and accruals, stock-based compensation expense, and the valuation allowance for deferred&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;tax &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_4ab9eed4-6bd4-4acf-b410-a3a487541315">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash, cash equivalents, and marketable securities to the extent recorded in the balance sheet. The Company has not experienced any losses to date related to these concentrations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#x2019;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#x2019;s current and potential future product candidates, uncertainty of market acceptance of the Company&#x2019;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. The Company relies on one supply chain for each of its product candidates. If any of the single source suppliers in any of the supply chains fails to satisfy the Company&#x2019;s requirements on a timely basis, it could suffer delays in its clinical development programs and activities, which could adversely affect operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory authorities prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_b864c9c8-883c-44ab-b3d0-fe22ef8d4792">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_d45a6b03-1634-4a1c-9595-263c9371f0d1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash represents cash held by a financial institution as collateral for a letter of credit securing its operating lease for office and laboratory space, which is classified as a non-current asset on the balance sheets based on the maturity of the lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_0f208aa4-0321-4fd0-bc21-c2d343d9f64f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company holds investments in marketable securities, consisting of U.S. government securities. Marketable debt securities with stated maturities of three months or less from the date of purchase are classified as cash equivalents and those with stated maturities of greater than three months as marketable securities on the balance sheet. The Company determines the appropriate classification of marketable debt securities at the time of purchase. The Company has the ability, if necessary, to liquidate its investments to meet its liquidity needs in the next 12 months, without significant penalty. Accordingly, those investments with contractual maturities greater than one year from the date of purchase are classified as current assets on the accompanying balance sheets. All marketable debt securities are classified as available-for-sale and are reported at estimated fair value, with unrealized gains and losses recorded in accumulated other comprehensive loss within stockholders&#x2019; equity. Interest, amortization and accretion of purchase premiums and discounts on marketable debt securities are included in other income (expense), net, in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cost of available-for-sale marketable securities sold is based on the specific identification method. Realized gains and losses on the sale of available-for-sale marketable securities are recorded in other income, net in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Company regularly reviews all of the marketable securities for decline in fair value to determine whether unrealized losses have resulted from credit loss or other factors. The review includes considerations for the cause of the impairment but is not limited to (i) the consideration of the cause of the decline, (ii) any currently recorded expected credit losses and (iii) the creditworthiness of the respective security issuers. A decline of fair value below cost basis is considered an other-than-temporary impairment if the Company has the intent to sell the security or it is more likely than not that the company will be required to sell the security before recovery of the entire cost basis. Regardless of the Company&#x2019;s intent or requirement to sell the security, an impairment is considered other-than-temporary if the Company does not expect to recover the entire cost basis. In those instances, an impairment charge equal to the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;difference &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;between fair value and the cost basis is recorded in other income (expense), on the statements of operations and comprehensive loss. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment loss was recognized for the fiscal years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The amortized or accreted cost basis of the marketable securities approximates its fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_ec8b19e9-84cf-45b7-b992-4436aeaaa875"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_2aed0c9e-099a-40c7-a3ff-ad8d1a5014b4"
      unitRef="U_USD">0</us-gaap:ImpairmentOfInvestments>
    <vera:DeferredOfferingCostsPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_750083e0-ac31-4bdb-8d92-00e900657d99">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred offering costs consisting of legal, accounting and filing fees relating to equity offerings. Deferred offering costs are included in other long-term assets on the Company&#x2019;s balance sheets. Upon completion of the offering, these amounts are offset against the proceeds of the offering.&lt;/span&gt;&lt;/p&gt;</vera:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_b62ee3ff-e676-4b08-851b-807686763215">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases office space under operating leases and determines if the arrangement is a lease at inception. These leases contain lease and non-lease components. Non-lease components include payments for maintenance, utilities, real estate taxes, and management fees. The lease and non-lease components are combined and accounted as a single lease component. Payments made under operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;These leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is a hypothetical rate based on the Company&#x2019;s understanding of what the credit rating would be in a similar economic environment. Operating leases are included in operating lease right-of-use assets and operating lease liabilities, current and non-current, on the balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Leases may include one or more options to renew. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured. The lease agreements generally do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_6882f9dc-a842-4ebb-bfcf-31aefaa5c6aa">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Foreign Currency Translations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_6bd3c13c-107c-40ee-bc4e-3f7544aa4b55">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value is defined as the exchange price to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value measurements are classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; Quoted unadjusted prices for identical instruments in active markets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013; Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions developed by the Company.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value accounting is applied to all financial assets and liabilities that are recognized or disclosed in the financial statements on a recurring basis.  The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, marketable securities, prepaid expenses and other current assets, non-marketable equity securities, accounts payable and accrued expenses and long-term debt.  Cash, restricted cash, and marketable securities and non-marketable securities are reported at their respective fair values on the Company&#x2019;s balance sheets.  The remaining financial instruments are reported on the Company&#x2019;s balance sheets at cost, which approximate their fair value due to their short-term nature.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Money market funds are highly liquid investments that are actively traded. The pricing information for the Company&#x2019;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s non-marketable equity securities (see Note 5) are measured at fair value using an option pricing valuation methodology. The option pricing methodology relies on risk-neutral valuation which calculates the value of an asset by discounting the expected value of its future payoffs at the risk-free rate of return. The fair value of the non-marketable equity securities is derived from quoted prices for similar instruments and observable inputs in active markets. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December 31, 2023, and December 31, 2022&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company held $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, in money market funds.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_763f4bc0-e8d2-4dff-a69a-bf5d94bdc0c9"
      decimals="-5"
      id="F_42ba38c1-f24f-4f59-a57e-17c0e83679ee"
      unitRef="U_USD">44700000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_0c317a6f-636d-4344-a7db-5f93a49f62a8"
      decimals="-5"
      id="F_ce2054b2-f69d-415e-83df-8379d6aa1ba7"
      unitRef="U_USD">42500000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_c156bf53-654d-4598-ac91-6e6613aebc01">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comprehensive loss consists of two components: net loss and other comprehensive loss. Other comprehensive loss refers to unrealized gains and losses that are recorded as an element of stockholders&#x2019; equity and are excluded from net loss. For the year ended December 31, 2023, other comprehensive loss consists of unrealized gains and losses on marketable securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_11e5e162-0548-4f1d-9eeb-56e0dbe6069b">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research and development costs are expensed as incurred and consist primarily of employees&#x2019; salaries and related benefits, including stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support the Company&#x2019;s operations that are directly attributable to the Company&#x2019;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs incurred in obtaining technology licenses including upfront and milestone payments incurred under the Company&#x2019;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#x2019;s research and development activities. Where contingent milestone payments are due to third parties under license or other agreements, the milestone payment obligations are recognized as expense when achievement of the contingent milestone is probable, which is generally upon achievement of the milestone.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <vera:ResearchContractsCostsAndAccrualsPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_81623283-a923-4b65-abea-706e35d740ba">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Research Contract Costs and Accruals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#x2019;s estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</vera:ResearchContractsCostsAndAccrualsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_19a00af6-0424-4eea-a1ce-40a0ada79a8f">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#x2019;s employees, nonemployee directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgments about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#x2019;s Class A common stock on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For all stock options granted, the Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#x201c;plain vanilla&#x201d; stock option awards, as the Company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination behavior. The estimate of expected volatility is based on comparative companies&#x2019; volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company determines the fair value of its Class A common stock using the market closing price on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_caf7468a-5707-4a39-8d45-86d7ffd09d03">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect tax rates expected to be in effect for the years in which the differences are expected to be reversed. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_8dd51fab-69d8-49d5-b48b-680bc4dc0e99">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class A and Class B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class A and Class B common stock on an individual or combined basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, because potentially dilutive shares are not assumed to have been issued if their effect is anti-dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <vera:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_663f5c7f-f08e-4227-ab14-1e3f1239fabc">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies the guidance in Topic 210, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security and introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The guidance is effective for annual periods beginning after December 15, 2023, with early adoption permitted. The Company does not expect that the adoption of this standard will have a material impact on its financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU will result in the required additional disclosures being included in the Company&#x2019;s financial statements upon adoption.&lt;/span&gt;&lt;/p&gt;</vera:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <vera:OtherFinancialStatementInformationTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_3a19f464-8865-4fd2-9505-2929c00c3964">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. OTHER FINANCIAL STATEMENT INFORMATION&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid clinical trial and drug manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid equity financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid software costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid recruiting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical and drug manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Related party payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued legal fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Related party payable represents amounts due to Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to manufacturing technology and know-how transfer services performed for atacicept pursuant to the license agreement between the Company and Ares (see Note 11).&lt;/span&gt;</vera:OtherFinancialStatementInformationTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_2d9716a2-592b-4641-8475-f4a166a312d5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Prepaid expenses and other current assets consist of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid clinical trial and drug manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,487&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid equity financing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid rent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;257&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;247&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid software costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Prepaid recruiting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <vera:PrepaidClinicalTrialAndDrugManufacturingCosts
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_0ce95763-c4f3-44b8-8ef2-e80b2cb9c1fc"
      unitRef="U_USD">6480000</vera:PrepaidClinicalTrialAndDrugManufacturingCosts>
    <vera:PrepaidClinicalTrialAndDrugManufacturingCosts
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_2ce4627b-5233-46d9-a108-a10a41490bac"
      unitRef="U_USD">8487000</vera:PrepaidClinicalTrialAndDrugManufacturingCosts>
    <us-gaap:PrepaidInsurance
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_ab6cd07e-2e36-43f3-8b19-a841508e4cbe"
      unitRef="U_USD">597000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_6942faea-4ff5-4147-8d93-825ca1838397"
      unitRef="U_USD">998000</us-gaap:PrepaidInsurance>
    <vera:PrepaidEquityFinancingCosts
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_53ff6ff3-d0a2-4f35-8fd2-74a4f97fa887"
      unitRef="U_USD">410000</vera:PrepaidEquityFinancingCosts>
    <vera:PrepaidEquityFinancingCosts
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ff77f860-7af2-41ed-9133-37f5dfcb8c8f"
      unitRef="U_USD">490000</vera:PrepaidEquityFinancingCosts>
    <us-gaap:PrepaidRent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_98e60549-8e19-47b7-a193-3fd45c5cfd43"
      unitRef="U_USD">257000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_8feaf5e1-4d42-404c-adcf-006c1fa87810"
      unitRef="U_USD">247000</us-gaap:PrepaidRent>
    <vera:PrepaidSoftwareCosts
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_fcf4e55f-9b3e-48cf-84cc-b00b6675825e"
      unitRef="U_USD">237000</vera:PrepaidSoftwareCosts>
    <vera:PrepaidSoftwareCosts
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_94a352ab-ab5a-4906-8c3b-f11463489bf4"
      unitRef="U_USD">104000</vera:PrepaidSoftwareCosts>
    <vera:PrepaidRecruitingFees
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_9172d596-e50c-4612-925f-a693a643d6ad"
      unitRef="U_USD">109000</vera:PrepaidRecruitingFees>
    <vera:PrepaidRecruitingFees
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_934d0a40-0bdf-47ee-ba0d-a803db2eb4b1"
      unitRef="U_USD">0</vera:PrepaidRecruitingFees>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_548f82ac-65e4-420b-9e83-b5b1fdb3079c"
      unitRef="U_USD">3217000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_b5f88010-f6d7-4694-89b2-ab496e7c95e9"
      unitRef="U_USD">719000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_2e5d00c9-6da5-43e2-8b90-a7f8bc0d34af"
      unitRef="U_USD">11307000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_823081de-f65b-4dbc-8219-dab3fdc2c4be"
      unitRef="U_USD">11045000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <vera:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_2542f035-0eed-42dc-baa1-1f42149e715a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued payroll&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued clinical and drug manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Related party payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued legal fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Accrued expenses and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vera:ScheduleOfAccruedAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_f9816849-3c4c-4e35-9c9c-8d645a6eeef7"
      unitRef="U_USD">3932000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_e9c559dc-4465-4579-9f17-0be519d5dec8"
      unitRef="U_USD">3217000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <vera:AccruedClinicalAndDrugManufacturingExpenses
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_d3bab69c-a485-44b3-8319-8625bbad535d"
      unitRef="U_USD">2213000</vera:AccruedClinicalAndDrugManufacturingExpenses>
    <vera:AccruedClinicalAndDrugManufacturingExpenses
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_f61d6287-79f7-4225-93b7-8899aac0c85f"
      unitRef="U_USD">4334000</vera:AccruedClinicalAndDrugManufacturingExpenses>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_ddc80ff3-7e9a-4f5e-8fc8-162ee5659dda"
      decimals="-3"
      id="F_5a687bab-921b-44fe-9e3a-5689690d58d7"
      unitRef="U_USD">1926000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_12676876-59e5-4f18-b296-25ca0885c06f"
      decimals="-3"
      id="F_9aa8e46b-eb08-40b8-a12e-ceaac9f4366d"
      unitRef="U_USD">2780000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_61d40d97-9ce5-466c-806c-ee8243a8bbb8"
      unitRef="U_USD">59000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_73a165d2-64c6-475f-9a3b-b2e0a85f2f63"
      unitRef="U_USD">338000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_45de3c3c-ac76-4d04-8a23-92e244cc8349"
      unitRef="U_USD">619000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_459694a0-58a8-49a0-a777-bf192014b4c2"
      unitRef="U_USD">295000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_936b0018-10ec-49cf-b86f-bc5404e208f8"
      unitRef="U_USD">8749000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_92fe98dc-4cd7-4b56-929b-ff42f0d71f63"
      unitRef="U_USD">10964000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_23fdac9f-ff36-453e-8868-05b32155b1e1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cash equivalents are classified within Level 1 in the fair value hierarchy because the Company uses quoted market prices to the extent available or alternative pricing sources to determine fair value. Marketable debt securities are classified as Level 2 because they are valued using fair value from an independent pricing service, which may use quoted market prices for identical or comparable instruments or valuations using observable market data. The Company&#x2019;s debt securities are accounted for as available-for-sale securities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unrealized gains and losses are reported as a component of other comprehensive loss. Fair value of the debt securities were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.647%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.623%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Marketable debt securities that had been in unrealized loss positions as of December 31, 2023 and December 31, 2022 were in an unrealized loss position for less than 12 months. Unrealized losses from marketable debt securities are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on evaluation of available evidence.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.975%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due after one year to two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_fda95489-5659-47df-aa41-c04af8dc94c6"
      unitRef="U_USD">115000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-5"
      id="F_f1369714-bfef-48d7-add3-a1a0af39f15b"
      unitRef="U_USD">71200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_da7b905e-1275-4a64-b6e6-f11cc5dd62a4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table presents the Company&#x2019;s financial assets measured at fair value on a recurring basis by level within the fair value hierarchy &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:33.647%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.623%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.4%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.682%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="16" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. Government bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;113,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7049dbef-cfb0-4b5b-aeab-21592adc5141"
      decimals="-3"
      id="F_8c3d16dd-064a-4efb-9016-4614b678165b"
      unitRef="U_USD">44650000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_6eaa2abb-9090-46f3-9dcd-75944c3a5636"
      decimals="-3"
      id="F_5d1af2fa-1c67-4083-b061-df5fc476ff2b"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_6eaa2abb-9090-46f3-9dcd-75944c3a5636"
      decimals="-3"
      id="F_865bf027-4e73-47f3-9daf-6b03516f99a2"
      unitRef="U_USD">0</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_7049dbef-cfb0-4b5b-aeab-21592adc5141"
      decimals="-3"
      id="F_1ad5a296-2979-4aa3-acf6-b279f7885777"
      unitRef="U_USD">44650000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2f5962f0-d8e3-4966-ae7c-c8b41d160a04"
      decimals="-3"
      id="F_bb589d33-3914-4eb2-a65b-90b6a0dc2533"
      unitRef="U_USD">63619000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_27a18667-bb0a-48ea-8694-1c1986159e16"
      decimals="-3"
      id="F_afe047a1-0905-433b-9ddf-c22dd1317bfb"
      unitRef="U_USD">70000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_27a18667-bb0a-48ea-8694-1c1986159e16"
      decimals="-3"
      id="F_0c3f69c0-abd8-48d8-9076-e7f115d1cbf2"
      unitRef="U_USD">6000</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_2f5962f0-d8e3-4966-ae7c-c8b41d160a04"
      decimals="-3"
      id="F_99fece51-f7f6-481c-9c6d-a079b9df3529"
      unitRef="U_USD">63683000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a437c869-1510-4704-bfa5-0c8b5fb1e04f"
      decimals="-3"
      id="F_f13d3459-830c-4967-a688-7c4cbbe33b20"
      unitRef="U_USD">19665000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_91729747-ed44-43ba-b06c-0ca33c08ecef"
      decimals="-3"
      id="F_2f1b8bc9-f57b-481b-97cb-7f66aa2c5f93"
      unitRef="U_USD">7000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_91729747-ed44-43ba-b06c-0ca33c08ecef"
      decimals="-3"
      id="F_7e78ddaf-3da2-4a1b-b8c7-b1d05de0ead4"
      unitRef="U_USD">14000</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_a437c869-1510-4704-bfa5-0c8b5fb1e04f"
      decimals="-3"
      id="F_429d4741-b737-4b36-bbfa-7aa11f9212d7"
      unitRef="U_USD">19658000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4c8b4716-9f64-4262-a82a-7d6247559af1"
      decimals="-3"
      id="F_0b7708dd-d288-4bd8-b9f3-d6bee3dda4fb"
      unitRef="U_USD">31500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_ee626bdd-f836-4146-83f9-c629e739a018"
      decimals="-3"
      id="F_532e4288-d371-4b2d-b380-aa2c85652541"
      unitRef="U_USD">194000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_ee626bdd-f836-4146-83f9-c629e739a018"
      decimals="-3"
      id="F_35c2d102-4696-4dfa-b47f-f15ba9a37d9f"
      unitRef="U_USD">0</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_4c8b4716-9f64-4262-a82a-7d6247559af1"
      decimals="-3"
      id="F_9e0f30ee-94de-4e7b-9ee7-0850094e1b1d"
      unitRef="U_USD">31694000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_a6f4b438-93d4-46b8-9a1f-c66bd4db2588"
      unitRef="U_USD">159434000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_3ab6031b-1e77-4b16-a89c-24b502ac1541"
      unitRef="U_USD">271000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_4ce45c5c-1f7c-4e8b-a07b-e94525e11790"
      unitRef="U_USD">20000</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_9ace1d4f-8808-4804-89c5-9a21adeae195"
      unitRef="U_USD">159685000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c194f4a2-535c-4148-b525-7d7cf987efe3"
      decimals="-3"
      id="F_c986f10a-270c-42ef-9006-5170a66c7c1f"
      unitRef="U_USD">42495000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_8436e431-af1b-457d-91b5-f52f9019d971"
      decimals="-3"
      id="F_d4e04748-51d0-4515-9e4c-2fea9d691e45"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_8436e431-af1b-457d-91b5-f52f9019d971"
      decimals="-3"
      id="F_6c88157a-3eb4-4994-8146-c986fb5b2456"
      unitRef="U_USD">0</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_c194f4a2-535c-4148-b525-7d7cf987efe3"
      decimals="-3"
      id="F_0cb6b4c8-7523-4163-87c5-7fbd01841657"
      unitRef="U_USD">42495000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_3ce276b6-c154-43a1-9f92-2f2097479a87"
      decimals="-3"
      id="F_8a84a3a6-bdd4-4dac-9afb-4f2584ee7f4b"
      unitRef="U_USD">71418000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_5ea44b8b-7856-4f7e-9da8-750bd3da72e0"
      decimals="-3"
      id="F_14291c63-1978-41a8-ac2d-6274d503338c"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_5ea44b8b-7856-4f7e-9da8-750bd3da72e0"
      decimals="-3"
      id="F_c9479f1a-ecaa-4b4b-9ad0-2aa8a53c4615"
      unitRef="U_USD">225000</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_3ce276b6-c154-43a1-9f92-2f2097479a87"
      decimals="-3"
      id="F_e40c0ad9-65f8-48ea-994d-02d7fd968e00"
      unitRef="U_USD">71194000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_265d697b-30b1-453c-ac5e-0f9c5673d5da"
      unitRef="U_USD">113913000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_4b2c5852-7f0e-4405-8a09-f2bb18831be1"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_e9f52a5b-0b9b-4d39-8bf6-26ee3b4d1145"
      unitRef="U_USD">225000</vera:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss1>
    <vera:CashEquivalentAndMarketableSecurities
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_f8140ded-744f-4963-84fb-17bb70669ed3"
      unitRef="U_USD">113689000</vera:CashEquivalentAndMarketableSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_a0ff302c-144d-4a6f-8f1c-426777100f76">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table classifies the estimated fair value of investments in available-for-sale marketable debt securities by effective contractual maturity dates &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.975%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.3%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.724%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due within one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;93,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Due after one year to two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;115,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_20122ad6-8cf6-44b5-9593-8c1c38fe3e05"
      unitRef="U_USD">93845000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <vera:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_63ba7bff-49d4-4116-9cb3-e958e0e9f458"
      unitRef="U_USD">21190000</vera:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_bb26ed4d-71dc-4e6a-96cf-582c34a6dd8b"
      unitRef="U_USD">115035000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_12a35b58-3bff-4310-90a8-36149d453517">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. NON-MARKETABLE EQUITY SECURITIES&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value of non-marketable equity securities is determined using alternative pricing sources and models utilizing market observable inputs. The Company reports the restricted equity securities as non-marketable equity securities on the balance sheet and determines current or non-current classification based on the expected duration of the restriction.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying value is measured as the total initial cost, less the cumulative net unrealized loss. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the value of non-marketable equity securities using the measurement alternative &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Initial cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cumulative net fair value loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Carrying value of non-marketable equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_fe2c2822-7592-4bac-b162-183a5a6b5204">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes the value of non-marketable equity securities using the measurement alternative &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.48%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Initial cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cumulative net fair value loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Carrying value of non-marketable equity securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
    <vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_36e3ed46-de76-470c-9f06-c231483c4d77"
      unitRef="U_USD">1759000</vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost>
    <vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_f2c3b7ee-3ca5-4515-9136-74491729e245"
      unitRef="U_USD">1759000</vera:EquitySecuritiesWithoutReadilyDeterminableFairValueInitialCost>
    <vera:EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_3aa17ed4-6871-4d60-88c9-9b65db4d212d"
      unitRef="U_USD">1748000</vera:EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss>
    <vera:EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_4b7d75e7-2070-43c5-916c-5708737e9cd6"
      unitRef="U_USD">1701000</vera:EquitySecuritiesWithoutReadilyDeterminableFairValueNetCumulativeGainLoss>
    <vera:NonmarketableEquitySecuritiesCarryingValue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_00ba5bd0-363a-4923-bc69-ceeddee09aa9"
      unitRef="U_USD">11000</vera:NonmarketableEquitySecuritiesCarryingValue>
    <vera:NonmarketableEquitySecuritiesCarryingValue
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_4fd0c14e-8636-4eff-82a5-21d0f7286272"
      unitRef="U_USD">58000</vera:NonmarketableEquitySecuritiesCarryingValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_ce901a87-933c-484b-82b2-88a9ed6320e3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. LEASES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net lease cost recognized for 2023 is summarized as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.532%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.143%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the maturities of the lease liabilities based on minimum lease commitment amount are as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2020, the Company entered into a non-cancellable sublease agreement for the leased facilities in South San Francisco, California, which ends concurrently with the original lease in September 2025.&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, under the terms of the sublease agreement, the Company is entitled to receive future annual sublease payments as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:25.119999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total sublease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The subtenant of the leased facilities in South San Francisco, California, has disclosed in public filings that there is substantial doubt regarding its ability to continue as a going concern. As tenant, the Company remains responsible for minimum lease commitments of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of December 31, 2023, on the South San Francisco facilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2021, the Company entered into a lease agreement that was amended in July 2022 for its headquarters office space in Brisbane, California. The lease term is through November 2024 with renewal options for the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company had not executed any finance leases that were yet to commence. As of December 31, 2023, the weighted-average remaining operating lease term was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years and the weighted-average discount rate was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% for operating leases recognized in the financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_3fc4209c-3653-4eb7-891d-66e3ba266cb2">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net lease cost recognized for 2023 is summarized as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.532%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.603%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.143%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,378&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sublease income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_10944205-2593-436f-bb39-8b4e9839cc97"
      unitRef="U_USD">2577000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_cf9d5a0b-f2ca-4e2f-ae2f-9de9426850a5"
      unitRef="U_USD">2378000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_10fec6f2-1e01-422d-9bd9-55aa1db14a71"
      unitRef="U_USD">1928000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_6ae7b7b0-a302-4e5e-9521-6a9d4bf96f07"
      unitRef="U_USD">1928000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_35ca71c2-d314-41cf-872d-b13445b5ae36"
      unitRef="U_USD">649000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_2582425e-c251-4d8d-8f43-a1908112395d"
      unitRef="U_USD">450000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_afe1e361-b5b1-4b53-8194-97f13038554f">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the maturities of the lease liabilities based on minimum lease commitment amount are as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total minimum lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Current portion of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_60da932a-1868-43f4-9d22-5c78aea715af"
      unitRef="U_USD">3022000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_0e221dba-fa42-4ea8-ba63-fe5bb4221603"
      unitRef="U_USD">1880000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_511b13a4-4526-43bb-9b4f-1002bd4903a6"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_c56d8fb0-a7ca-42a0-859f-0a9e7495fd13"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_796476f8-8147-4aac-92b2-971cce498e58"
      unitRef="U_USD">4902000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_4ad88924-d5db-47ac-be9b-4435873392c5"
      unitRef="U_USD">1071000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_3ba95671-5053-47d5-96ed-c0147cf15d72"
      unitRef="U_USD">3831000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_0b0a0bff-be1f-4b0a-8707-a5914715531b"
      unitRef="U_USD">2436000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_57562bf3-dd65-4442-abbe-def0ba816460"
      unitRef="U_USD">1395000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_15fb2b98-4d9f-4f49-98b6-3e78eb66e814">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, under the terms of the sublease agreement, the Company is entitled to receive future annual sublease payments as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;: &lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:3.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:25.119999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total sublease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e347691d-74ac-43c6-a944-c5b1a66ecf71"
      unitRef="U_USD">1954000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_5e1adeae-31f2-4305-80c9-57a9f9e41978"
      unitRef="U_USD">1496000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_066c1e76-6e10-4d65-a68b-eb14f5184290"
      unitRef="U_USD">3450000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_5fa0d973-c93b-4f53-9c1a-e193b9c33af2"
      unitRef="U_USD">4300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      id="F_74f8ae50-d9b1-43ea-863d-7ee4ffc91ca8">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="3"
      id="F_27eccf8a-9f5a-4a7d-bf3c-f8486cd52b58"
      unitRef="U_pure">0.091</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LongTermDebtTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_f051488d-5ddd-42a4-b687-75a2d469b724">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. NOTE PAYABLE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note payable consists of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:26.985%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.242%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Effective Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Effective Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collateralized note 2021-12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collateralized note 2022-11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collateralized note 2023-12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The carrying amount of debt approximates fair value due to its variable interest rate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2021, the Company entered into a non-revolving loan and security agreement (the Loan Agreement) with borrowing capacity of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, which was scheduled to expire in December 2022.  In November 2022, the Company entered into an amendment of the Loan Agreement.  Among other changes, the amendment extended the scheduled expiration of the Loan Agreement to December 2023 and modified the reference rate from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financial Rate (SOFR).  In conjunction with the amendment, the Company borrowed an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Loan Agreement. In December 2023, the Company borrowed the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million from the Loan Agreement. As of December 31, 2023, the Company&#x2019;s outstanding borrowing under the Loan Agreement was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In March 2023, upon achievement of a clinical data milestone, the Company elected to exercise a borrower option to extend the maturity of the outstanding loan by 12 months, from December 2026 to December 2027. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The interest-only payment period was also extended by 12 months to December 2026.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The Company is permitted to prepay the loan, subject to certain conditions. Upon the maturity date or prepayment of the loan, the Company is required to make a final payment equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the aggregate principal amount of the loan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The variable interest rate on the drawn amount is adjusted SOFR plus 825 basis points, subject to a per annum floor rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.  The Loan Agreement contains a subjective acceleration clause in the case of an event of default. If such a matter occurs and is continuing, the lender may legally demand the outstanding principal and interest immediately due and payable. There are no financial covenants associated with the Loan Agreement and the loan is secured by the Company&#x2019;s assets. The Loan Agreement is available for working capital, capital expenditures, and other general corporate purposes.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Principal installments due on the notes are as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_9e02275d-124e-4e53-ad03-f04c6c2ff9ea">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note payable consists of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:26.985%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.062%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.923%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.242%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Maturity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Effective Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Effective Interest Rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collateralized note 2021-12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.57&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collateralized note 2022-11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collateralized note 2023-12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.37&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: Debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net carrying amount of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <vera:CollateralizedDebtInstrumentMaturityDate
      contextRef="C_0c6e0d65-dc7d-4088-be4a-b8a144d6a7dc"
      id="F_19440935-5089-421e-aa42-43ad028fe500">2027</vera:CollateralizedDebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_aa03b9e4-2af3-40b2-8a5a-57a770a088a6"
      decimals="4"
      id="F_834f8427-579b-4e98-8406-92f60ce541b0"
      unitRef="U_pure">0.1473</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SecuredDebt
      contextRef="C_aa03b9e4-2af3-40b2-8a5a-57a770a088a6"
      decimals="-3"
      id="F_18042c96-d4cd-4756-8ea0-6abe512d613c"
      unitRef="U_USD">5000000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_2c78fe3f-f7cb-44db-809e-efe584139ec5"
      decimals="4"
      id="F_7950f382-c3d3-4319-8406-128ffc437dbe"
      unitRef="U_pure">0.1357</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SecuredDebt
      contextRef="C_2c78fe3f-f7cb-44db-809e-efe584139ec5"
      decimals="-3"
      id="F_27237736-f783-4a02-ab5a-1fc57214d1be"
      unitRef="U_USD">5000000</us-gaap:SecuredDebt>
    <vera:CollateralizedDebtInstrumentMaturityDate
      contextRef="C_5f7c27af-2605-4301-ae0d-b823d5c17fb3"
      id="F_7c2548ed-1e0e-40eb-b864-c323c764afee">2027</vera:CollateralizedDebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_9f304eef-dfa2-48ba-a1fb-90a97b78c719"
      decimals="4"
      id="F_c454b453-53cd-4a98-b49c-630a48b75b1b"
      unitRef="U_pure">0.1487</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SecuredDebt
      contextRef="C_9f304eef-dfa2-48ba-a1fb-90a97b78c719"
      decimals="-3"
      id="F_a7fc5b67-15e1-40c5-9e04-52f18a78e0b9"
      unitRef="U_USD">20000000</us-gaap:SecuredDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_ce9554a4-9d43-44af-976d-e2f6d319f429"
      decimals="4"
      id="F_8956f6c3-5b97-4dd1-8043-4bc820d17bf3"
      unitRef="U_pure">0.1374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SecuredDebt
      contextRef="C_ce9554a4-9d43-44af-976d-e2f6d319f429"
      decimals="-3"
      id="F_b307315d-b4ad-486e-ad08-aee8173d4496"
      unitRef="U_USD">20000000</us-gaap:SecuredDebt>
    <vera:CollateralizedDebtInstrumentMaturityDate
      contextRef="C_d99a19d8-325e-4a9a-aacd-082609a73db3"
      id="F_02c847b4-9a50-4bfb-aa0c-f967619030dc">2027</vera:CollateralizedDebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_a6fea3c9-4692-4fad-ad2a-ff7a304239a9"
      decimals="4"
      id="F_6abe1734-3666-450c-9066-7dfefbb424dd"
      unitRef="U_pure">0.1537</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:SecuredDebt
      contextRef="C_a6fea3c9-4692-4fad-ad2a-ff7a304239a9"
      decimals="-3"
      id="F_b7b5a1a0-c169-4668-bdd2-1dc275d532ad"
      unitRef="U_USD">25000000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="C_27ff2e6e-72bd-4173-93c6-978428eecba6"
      decimals="-3"
      id="F_817b5301-f4ff-4bf6-8b3b-90a8b26a051b"
      unitRef="U_USD">0</us-gaap:SecuredDebt>
    <us-gaap:NotesPayable
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_2e75dbe1-03d1-4d40-a387-a405775592d5"
      unitRef="U_USD">50000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_8b8e7fd7-f390-4ee7-a6b6-5566363888a2"
      unitRef="U_USD">25000000</us-gaap:NotesPayable>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_6f608881-d8f6-49e8-80ca-a18ae14691e3"
      unitRef="U_USD">123000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_4cba08b2-51d8-4608-a659-307052015172"
      unitRef="U_USD">190000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_294ef806-5792-4ce7-a290-b3c899a83857"
      unitRef="U_USD">49877000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_81b73d34-a725-4878-8fe4-9a48c2575392"
      unitRef="U_USD">24810000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_d97919f2-efef-4f37-8154-249dcc9ce087"
      decimals="-5"
      id="F_a947a526-136c-4862-8f6a-ab054739ddce"
      unitRef="U_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_d97919f2-efef-4f37-8154-249dcc9ce087"
      decimals="-5"
      id="F_96888a64-6246-4282-a650-acf947961d95"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="C_edca4e98-4e0f-44a2-ace4-368b647169df"
      decimals="-5"
      id="F_49b75612-9ad2-454a-b23e-de5c6474d037"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_edca4e98-4e0f-44a2-ace4-368b647169df"
      decimals="-5"
      id="F_0b4b6beb-3633-48aa-be76-8078c2a5ef15"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityFrequencyOfPayments
      contextRef="C_0a795fca-1ad9-451e-9a6e-1d3d138b141b"
      id="F_38d8a9bc-575e-4247-8ecb-7747fa7af0a5">The interest-only payment period was also extended by 12 months to December 2026.</us-gaap:LineOfCreditFacilityFrequencyOfPayments>
    <vera:LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended
      contextRef="C_edca4e98-4e0f-44a2-ace4-368b647169df"
      decimals="2"
      id="F_80b4ffb5-c60c-4611-a987-5644822c3016"
      unitRef="U_pure">0.07</vera:LineOfCreditFacilityPercentagePrepaymentOfLoanOrMaturityDateIsNotExtended>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_e95c3e40-5150-4128-b63f-a06464bb547b"
      decimals="4"
      id="F_fbc9837d-e50d-4bb5-ba4f-db243715340e"
      unitRef="U_pure">0.0825</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_3eb74c76-4bf0-4a4d-9406-9340124a7d1c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Principal installments due on the notes are as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.236%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.823%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total long-term debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_a84b18f1-5ab7-462b-9d99-70162018ce95"
      unitRef="U_USD">50000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e00a606e-1e55-40a0-80f8-dc099aa03332"
      unitRef="U_USD">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_9763371c-8cf9-4f00-8c45-02916a46ea3a">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. COMMON STOCK&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company&#x2019;s amended and restated certificate of incorporation authorized the Company to issue &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,600,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class B common stock, each with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Each share of Class A common stock entitles the holder to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Class B common stock is non-voting. Class A common stockholders and holders of Class B common stock are entitled to receive dividends, as may be declared by the board of directors. Through &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; cash dividends have been declared or paid.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2022, the Company completed a follow-on public offering pursuant to which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,742,026&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Class A common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;748,959&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class B common stock were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;210,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock. In September 2022, the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class B common stock were converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,238&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock. The shares of Class B common stock that were converted into shares of Class A common stock have been retired and cancelled, and therefore will not be available for reissuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-265408) with the Securities and Exchange Commission, which permits the offering, issuance, and sale of up to a maximum aggregate offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the Company&#x2019;s common stock, preferred stock, debt securities and warrants. Up to a maximum of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of the maximum aggregate offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;400.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million may be issued and sold pursuant to an at-the-market financing facility under a sales agreement dated June 3, 2022, between the Company and Cowen and Company, LLC (Sales Agreement). As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, all $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million remains available for issuance and sale under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2022, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283,034&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock to Novartis Pharma AG pursuant to an amendment to a license agreement between the two parties (see Note 11).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In February 2023, the Company completed a follow-on public offering pursuant to which the Company issued and sold  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,428,572&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Class A common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, including &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,142,857&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="INF"
      id="F_6907a71b-c380-4f06-afec-7040241148a3"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7402c574-533f-4f99-9103-cfb6bfdbe42f"
      decimals="INF"
      id="F_0686d66b-4f01-452e-b44a-2f4deed41d25"
      unitRef="U_shares">14600000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7402c574-533f-4f99-9103-cfb6bfdbe42f"
      decimals="3"
      id="F_34406778-529f-4209-a0bb-a154052ccd42"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_4204b6de-68e6-4940-9da6-ada3032391f5"
      decimals="3"
      id="F_fdf2c660-75ff-431d-9636-93abbaed6718"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConversionBasis
      contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d"
      id="F_155a08be-eb37-4d82-8c9e-6d2b00907988">one</us-gaap:CommonStockConversionBasis>
    <us-gaap:DividendsCash
      contextRef="C_8ba166aa-651f-42ca-a136-020ed2b46e9d"
      decimals="INF"
      id="F_fa6b0096-170a-4290-a46a-530c6dd075eb"
      unitRef="U_USD">0</us-gaap:DividendsCash>
    <us-gaap:DividendsCash
      contextRef="C_3bd84b09-3c01-4501-bfd7-f6e21766d9ca"
      decimals="INF"
      id="F_cfbeeb2a-ae63-41be-886b-e24fdb4123b6"
      unitRef="U_USD">0</us-gaap:DividendsCash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_866552c5-4fd9-48eb-ba57-9fc63a8df408"
      decimals="0"
      id="F_0e7e72f1-fdb8-42f8-9429-e30c290e0aa8"
      unitRef="U_shares">5742026</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_fe9431d7-e239-4190-9590-1758494ffd28"
      decimals="2"
      id="F_e7d81fde-1633-45af-8964-37814e9e86d4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fad68b53-11d9-436b-9004-a5b8faf94415"
      decimals="0"
      id="F_5633a347-b60b-4fbc-9537-529ff24adf68"
      unitRef="U_shares">748959</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_43178910-84ec-42e6-9755-a7c57bb14391"
      decimals="INF"
      id="F_44659264-e0d9-4f6d-b3c8-e64368a9902b"
      unitRef="U_shares">210000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_8be84990-aa18-4a2e-8a74-e8d386ecfe3d"
      decimals="INF"
      id="F_d04065c2-396a-49c0-8a8f-28d58c687968"
      unitRef="U_shares">210000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_1d2f152f-37d4-4884-be62-4c29d7144c37"
      decimals="INF"
      id="F_da474c42-6b03-4a24-9d52-11cafcea6f64"
      unitRef="U_shares">99238</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_e4034580-fe87-43d7-b8fa-5582e2ab5313"
      decimals="INF"
      id="F_9b168f3e-9f7a-476a-9f45-fab2d7f652bd"
      unitRef="U_shares">99238</us-gaap:ConversionOfStockSharesConverted1>
    <vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_b6838b73-63de-4e04-b29b-2e63dc078019"
      unitRef="U_USD">400000000</vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="C_f419ef0f-acae-4639-b7c3-1c50d6d17329"
      decimals="-5"
      id="F_d4de7fa1-9263-4b88-b3eb-08b263470dfe"
      unitRef="U_USD">150000000</vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_8feabc36-5fa4-44b7-87bb-36b34f9f49cf"
      unitRef="U_USD">400000000</vera:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vera:AvailableForIssuanceAndSaleUnderSalesAgreement
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_0ed78bc2-41e2-480d-81e3-9fd821501227"
      unitRef="U_USD">150000000</vera:AvailableForIssuanceAndSaleUnderSalesAgreement>
    <vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity
      contextRef="C_104cfa0f-5c0c-42af-a707-85e7636b50f5"
      decimals="INF"
      id="F_7b4cd367-1f05-4b84-9d1b-666666a6cc67"
      unitRef="U_shares">283034</vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_45df6405-1d04-4fca-8db5-99ee7b1dd71e"
      decimals="0"
      id="F_ca287270-92cf-41d2-8c3f-88621e2f91af"
      unitRef="U_shares">16428572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a9205105-dc48-4b1b-8905-ca16af40dfee"
      decimals="2"
      id="F_648e810b-2187-44da-bd2b-87735345eb0a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c93b8c94-7f03-454e-b44d-c951c33fb0a3"
      decimals="0"
      id="F_541fba3f-5d71-4190-a322-054d064b810e"
      unitRef="U_shares">2142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_4b56ef34-3afd-4eda-8a03-b78782f415d0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. STOCK COMPENSATION&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2021, the Company adopted the 2021 Employee Stock Purchase Plan (ESPP) and the 2021 Equity Incentive Plan (2021 EIP), each of which became effective in connection with the IPO. The Company has reserved &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;707,942&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,650,796&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock for issuance under the ESPP and 2021 EIP, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company may not grant any additional awards under the 2017 Equity Incentive Plan (2017 EIP). The 2017 EIP will continue to govern outstanding equity awards granted thereunder. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;288,775&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares available for issuance under the 2021 EIP.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2017 EIP and 2021 EIP&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the 2017 EIP and 2021 EIP was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.638%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.664%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.743%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.845%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.264%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;NUMBER OF&lt;br/&gt;OPTIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE&lt;br/&gt;PRICE PER&lt;br/&gt;SHARE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;LIFE (YEARS)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;AGGREGATE&lt;br/&gt;INTRINSIC&lt;br/&gt;VALUE (000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,821,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,291,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,762,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,611,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,762,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The aggregate intrinsic value of stock options exercised during the year ended December 31, 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The weighted-average grant date fair value of options granted during the years ended December 31, 2023 and 2022, was&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.92&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The ESPP enables eligible employees to purchase shares of the Company&#x2019;s Class A common stock at the end of each offering period at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the fair market value of the shares on the first trading day or the last trading day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first day of each fiscal year, beginning on January 1, 2022, by a number equal to the lesser of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;440,502&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the total number of shares of the Company&#x2019;s capital stock (including all classes of the Company&#x2019;s common stock) outstanding on the last day of the calendar month prior to the date of the increase, or such lower number of shares (including no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares) &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;approved by the Company&#x2019;s board of directors. As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,808&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares have been issued pursuant to the ESPP. The ESPP generally provides for six-month consecutive offering periods beginning on September 14, 2021. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. Stock-based compensation expense for the year ended December 31, 2023, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the stock-based compensation expense for stock options, restricted stock awards, and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company&#x2019;s statements of operations and comprehensive loss for the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years ended December 31, 2023 and 2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonemployees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;22.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of unrecognized stock-based compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.049%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.676%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company grants restricted stock units (RSU) pursuant to the 2021 EIP and satisfies such grants through the issuance of the Company&#x2019;s Class A common stock. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows RSU activity for the period ending &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.19%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.544%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.544999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;NUMBER OF&lt;br/&gt;SHARES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;GRANT DATE &lt;br/&gt;FAIR VALUE &lt;br/&gt;PER SHARE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the year ended December 31, 2023, the Company recognize&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;d $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;f stock-based compensation for RSUs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ae34e80b-e684-4ceb-8100-75a5ed7d4c34"
      decimals="0"
      id="F_a03497f7-5d48-4bdc-9afe-21b713fb38b6"
      unitRef="U_shares">707942</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_106b349b-6afb-4176-a3b0-f3279ad1790b"
      decimals="0"
      id="F_66d81b95-71a8-4aa8-9d32-a9f648d65864"
      unitRef="U_shares">4650796</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b73d9107-896f-43a1-9a6e-d51d7847b59f"
      decimals="INF"
      id="F_a868059f-5a1b-4194-b4c8-7efab8c2b62c"
      unitRef="U_shares">288775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_446db923-88bd-4503-ae03-a19f8737a101">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the 2017 EIP and 2021 EIP was as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.638%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.664%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.821%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.743%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.845%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.341%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.264%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;NUMBER OF&lt;br/&gt;OPTIONS&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;EXERCISE&lt;br/&gt;PRICE PER&lt;br/&gt;SHARE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;REMAINING&lt;br/&gt;CONTRACTUAL&lt;br/&gt;LIFE (YEARS)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;AGGREGATE&lt;br/&gt;INTRINSIC&lt;br/&gt;VALUE (000s)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,821,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.51&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,291,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;111,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;238,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,762,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,611,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,762,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_4135b425-1776-49c1-98fa-141157b08b6f"
      decimals="INF"
      id="F_dbdbb465-7125-42d8-9315-825def1dc24a"
      unitRef="U_shares">3821787</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <vera:ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice
      contextRef="C_4135b425-1776-49c1-98fa-141157b08b6f"
      decimals="2"
      id="F_ce97ae30-35f2-4347-9be0-ba5662eacc22"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.3</vera:ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice>
    <vera:ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm
      contextRef="C_76b7492e-4260-4f67-8590-2c3713b1204a"
      id="F_1af44e14-a067-461c-8109-711b0724961f">P8Y6M3D</vera:ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm>
    <vera:ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue
      contextRef="C_4135b425-1776-49c1-98fa-141157b08b6f"
      decimals="-3"
      id="F_f33f7eba-a1f6-45df-8106-398b0a249fc0"
      unitRef="U_USD">35872000</vera:ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"
      decimals="INF"
      id="F_1abcb711-e45a-414d-ae85-5e2f72dfcbba"
      unitRef="U_shares">2291000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"
      decimals="INF"
      id="F_2f891993-e0ed-4c5e-b64d-6b60f98004ca"
      unitRef="U_shares">111927</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"
      decimals="INF"
      id="F_9b92bb00-f21b-4d60-a7a8-554712834008"
      unitRef="U_shares">238624</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="INF"
      id="F_d009746b-fc6e-4256-bd22-90c1a7c068fe"
      unitRef="U_shares">5762236</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <vera:ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="2"
      id="F_481ddc91-807e-4291-ad16-20e85d87b735"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.42</vera:ShareBasedCompensationByShareBasedPaymentOptionsNonVestedWeightedAverageExercisePrice>
    <vera:ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm
      contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"
      id="F_d0640a75-0251-4bd1-a3da-ef7f20eb7765">P7Y7M28D</vera:ShareBasedCompensationByShareBasedPaymentArrangementOptionsNonVestedWeightedAverageRemainingContractualTerm>
    <vera:ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="-3"
      id="F_18b8d27a-e640-4cf9-ad48-8c17a6b9f84d"
      unitRef="U_USD">39197000</vera:ShareBasedCompensationByShareBasedPaymentAwardNonVestedOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="INF"
      id="F_dfea28fa-34c8-400b-a892-df24f7f908ae"
      unitRef="U_shares">2611696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="2"
      id="F_7897c37e-bb6f-43ec-94de-1c58e059b59e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"
      id="F_e273974d-56ec-4736-bc67-a65d5841d38b">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="-3"
      id="F_8047a6a6-ab7c-43a0-9881-8dc91b606c8f"
      unitRef="U_USD">20112000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="INF"
      id="F_64c783c1-ec9a-4ec8-88c0-c104280f8a64"
      unitRef="U_shares">5762236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="2"
      id="F_19da75bf-e4d3-4c77-acab-8e6cb4dc366e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_b4b0d33d-5bfa-4c4a-be6a-7148543d07fa"
      id="F_3e0960bf-f631-4a5f-8e19-8dcd3066dcce">P7Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_41942c9c-8370-420a-b267-bd2d98ddef61"
      decimals="-3"
      id="F_ba5e14aa-665f-49ee-bc77-180f1213b867"
      unitRef="U_USD">39197000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-5"
      id="F_06028e3b-119c-448d-ad89-3f73f0c894bb"
      unitRef="U_USD">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2ee2de34-00df-4708-bfcd-a29d841f802c"
      decimals="2"
      id="F_3bb58020-0e55-4572-9642-ee128e6ca3be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_33e49389-84fd-47c2-a929-1bc794eb3c19"
      decimals="2"
      id="F_018d57dc-456b-4376-a435-06ed8f951824"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">13.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a"
      decimals="2"
      id="F_39b9e1ac-f0bf-4dbb-81cc-6ab92f97f336"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <vera:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate
      contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a"
      decimals="2"
      id="F_adf254e2-f5bb-463c-b85d-ebb27f3a6b53"
      unitRef="U_pure">0.01</vera:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_f0d79c47-62a3-4c6c-977a-e3a7e09cdea5"
      decimals="2"
      id="F_1d64db7c-bfa5-4e72-88c0-7fac3a8ff24e"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <vera:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a"
      decimals="INF"
      id="F_4cf1f9d2-15d3-40a5-aeb5-3543e49f160b"
      unitRef="U_shares">440502</vera:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <vera:PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a"
      decimals="2"
      id="F_727e7a5e-3e99-41f3-9497-13af33840773"
      unitRef="U_pure">0.01</vera:PercentageOfSharesOfCompanyCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="INF"
      id="F_6354a920-f567-4a57-8f0b-2bfaf0a42137"
      unitRef="U_shares">59808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_656af685-44e8-4daf-aeaf-64e77e34538a"
      decimals="-5"
      id="F_40ebacfc-5bba-4e51-8a84-e53398b4f7ff"
      unitRef="U_USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_9196806f-5640-475b-9377-4b7b51b7787c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables summarize the stock-based compensation expense for stock options, restricted stock awards, and restricted stock units granted to employees and nonemployees and for ESPP stock-based compensation that was recorded in the Company&#x2019;s statements of operations and comprehensive loss for the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years ended December 31, 2023 and 2022 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,592&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Employees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Nonemployees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9972233c-cff0-41a9-9e4e-78f8ec9718ca"
      decimals="-3"
      id="F_503c604b-6e45-48be-9f88-3748d5b798f8"
      unitRef="U_USD">4845000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5e154e33-2372-4217-add2-91f0995fc280"
      decimals="-3"
      id="F_b85b647d-c191-401e-b1a4-611996746519"
      unitRef="U_USD">4592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c2f7961f-3a91-49fc-8d5c-eadda8e3cd86"
      decimals="-3"
      id="F_53886819-01bb-4a0d-8431-32f498d3dc52"
      unitRef="U_USD">6648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1d9746ec-02a4-4faa-807d-24788184f0f8"
      decimals="-3"
      id="F_c1fc00c2-e906-48cb-91e2-f96c572da22b"
      unitRef="U_USD">4295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_ff98f3d0-5b0c-473e-bf6c-0a6a2e55bb18"
      unitRef="U_USD">11493000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_3e60302c-36b3-46da-be19-2a287874023a"
      unitRef="U_USD">8887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dc44f825-ebce-4f12-ad2f-3c428d8aa752"
      decimals="-3"
      id="F_83643e3e-eec8-4e4a-8f8e-f85f25153083"
      unitRef="U_USD">10494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_83acb7dc-4dff-4e8f-926f-7ad1a9c65845"
      decimals="-3"
      id="F_f1977f64-4179-4dbc-b969-3e86bf406d6a"
      unitRef="U_USD">5975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_55828b2f-49ab-4655-b54a-8c64b655d49b"
      decimals="-3"
      id="F_5412eacf-cad0-444f-af51-5c8f7cef53e0"
      unitRef="U_USD">999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_113d6c08-ba78-41b5-9746-69bcf0dfe625"
      decimals="-3"
      id="F_63c9c690-c072-46dd-81fc-f7185d6c3e14"
      unitRef="U_USD">2912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_7ee8e440-54ff-428d-a84c-e92cf7f70724"
      unitRef="U_USD">11493000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_e8f8d84f-f409-4ae7-b45b-133b85a39444"
      unitRef="U_USD">8887000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_df5e40de-de67-4c81-87ff-65f4bafe12aa"
      decimals="-5"
      id="F_4cf06714-b931-44b4-939d-abd439f1cd24"
      unitRef="U_USD">22000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_b426fd92-70e4-4d90-867a-c0ba79af8b53"
      id="F_ade7cd62-18ec-428e-895c-0490e7523520">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_d25d3d7e-7808-4c93-a042-9d5490f6695a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of stock options granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023 and 2022, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.049%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.676%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:21.676%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;77.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.76&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_06c1a6f1-5730-4884-a735-4b4f7cac06bf"
      id="F_7f5e35f9-de56-4d63-95d2-ed34e612ceb6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6f6268ee-8510-4770-a4af-2174ce8766bc"
      id="F_772d5f71-0026-4d67-b085-f4d580512989">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_cd7aa2da-6cbb-441f-945f-fb8ccbd69234"
      id="F_c6f6e618-d8d6-40e4-91a8-f4c2d8fb094b">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8c1ed1eb-4ad3-48de-bbf2-10a461092b17"
      id="F_f568aa1b-78c6-4e3e-9633-f3979c0ebbfe">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="3"
      id="F_3e1aa8b7-680c-4c16-8f96-859a86d40d71"
      unitRef="U_pure">0.795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="3"
      id="F_9a4a846e-e7cb-4437-9b1b-51a35aeeb0e8"
      unitRef="U_pure">0.805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="3"
      id="F_15ed519b-2b28-4358-b30d-5a69177334c6"
      unitRef="U_pure">0.758</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="3"
      id="F_5b0207be-be2d-4ff7-bb6a-e83411d66567"
      unitRef="U_pure">0.776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="3"
      id="F_c5080289-1d69-4409-ada2-83133020c812"
      unitRef="U_pure">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="3"
      id="F_2a208c8c-dca6-4309-8db9-4c70241a5e75"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="4"
      id="F_6efa3c56-1b6a-4656-81af-8782050512ed"
      unitRef="U_pure">0.0176</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="3"
      id="F_5d828a6f-fcbf-4b92-b55f-26c4754289d0"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_55b9b727-8a2d-43d5-aaec-192a41a89e34">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table shows RSU activity for the period ending &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.19%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.72%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.544%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:23.544999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;NUMBER OF&lt;br/&gt;SHARES&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;WEIGHTED-&lt;br/&gt;AVERAGE&lt;br/&gt;GRANT DATE &lt;br/&gt;FAIR VALUE &lt;br/&gt;PER SHARE&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled and forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested balance at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_8590b670-5825-42b7-a28a-b57150a094ad"
      decimals="0"
      id="F_81e9e0ca-abda-4b6e-80fa-ae877717dffc"
      unitRef="U_shares">204000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_8590b670-5825-42b7-a28a-b57150a094ad"
      decimals="2"
      id="F_53091cad-1ab9-40e5-b023-ac481daf4c57"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662"
      decimals="0"
      id="F_a14c69ce-eee5-4eca-a7cc-1d2408f07859"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662"
      decimals="0"
      id="F_6e51ae2f-c69d-4d9c-839b-392479d56b61"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662"
      decimals="0"
      id="F_ce74bced-a3eb-4218-9af8-5e09c9adafaf"
      unitRef="U_shares">66321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662"
      decimals="2"
      id="F_44e22d07-b789-450a-944e-1b5eca1a2791"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662"
      decimals="0"
      id="F_7859a292-e138-441f-b4fd-ee96313bcc91"
      unitRef="U_shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_97937f19-9b0a-4f85-bf7b-949364d71662"
      decimals="2"
      id="F_0b891c72-fcc2-4410-aaa4-1dd55e7fa163"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c9b98e83-50fd-4219-bcaa-dce9a91dd403"
      decimals="0"
      id="F_d2e45f90-7772-47e0-b514-f6cb3b24dfcd"
      unitRef="U_shares">131679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c9b98e83-50fd-4219-bcaa-dce9a91dd403"
      decimals="2"
      id="F_e5e5292f-ee20-446f-904e-b9b14991d680"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5886db7b-8ba3-408a-b5d3-cf86749ed8e2"
      decimals="-5"
      id="F_1a75712c-4d11-457c-a887-868cecbd2cb6"
      unitRef="U_USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_b150cadf-6fed-4382-b18e-37a4483af270"
      decimals="-5"
      id="F_cd1f2a62-bb62-4275-8ef4-8a214762f9ef"
      unitRef="U_USD">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_652b7128-53c0-4531-a4b7-ce80609438f6"
      id="F_d8887b73-e481-4864-818a-bfac6cee20c0">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_3a521c5e-3cca-4894-b4b4-ecdb8f7ad96c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. EMPLOYEE BENEFIT PLANS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. The Company contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;142,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to the plan for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_da9029c7-d4c8-40c9-9fe9-0459f42e3445"
      unitRef="U_USD">142000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_26805581-a218-4139-a80c-bdb4aae48fda"
      unitRef="U_USD">95000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <vera:LicenseAndCollaborationsTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_7138a32e-0262-4796-8917-91fbd8858405">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. LICENSES AND COLLABORATIONS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Ares Trading S.A.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, the Company entered into a license agreement with Ares (the Ares Agreement), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As consideration for the Ares Agreement, the Company paid a non-refundable license issue fee to Ares in the form of shares of redeemable convertible preferred stock valued at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, resulting in Ares becoming a related party to the Company. The redeemable convertible preferred stock subsequently converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,913,501&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock in connection with the IPO.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2020, the Company paid Ares a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon delivery and initiation of the transfer of specified information and materials. The Company is obligated to pay Ares aggregate milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified BLA filing or regulatory approval milestones and up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;515.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million upon the achievement of specified commercial milestones. The non-refundable license issue fee and milestone payment were recorded to research and development expense in the period incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent to the effective date of the Ares Agreement, Ares is performing manufacturing technology and know-how transfer to the Company. The Company recorded related party expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Ares for these services during the years ended December 31, 2023 and 2022, respectively. These amounts are included in research and development expenses on the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered royalties of low double-digit to mid-teen percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed product-by-licensed product and country-by-country basis from the first commercial sale of a product in a country until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii) the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or manufacture with respect to, such country; and (iii) expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to sublicense its rights under the Ares Agreement, the Company would be obligated to pay Ares a percentage ranging from the mid-single-digit to the low double-digits of specified sublicensing income received.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Amplyx Pharmaceuticals, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In December 2021, the Company entered into an asset purchase agreement (the Amplyx Agreement) with Amplyx Pharmaceuticals, Inc. (Amplyx), a wholly owned subsidiary of Pfizer Inc. Pursuant to the terms of the Amplyx Agreement, the Company paid $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Amplyx to purchase assets relating to an anti-BKV monoclonal antibody referred to as MAU868 for the treatment of BKV infection pursuant to a License Agreement between Amplyx and Novartis International Pharmaceutical AG (Novartis). In addition, the Company recognized a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million contingent milestone obligation as an assumed liability related to the asset purchase.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; The acquisition cost of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was recorded as research and development expense in the statement of operations and comprehensive loss on the acquisition date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Amplyx asset purchase, Amplyx assigned the Exclusive License Agreement between Amplyx and Novartis (the Novartis License) and Manufacturing and Supply Agreements to the Company.  Under the Novartis License, the Company has exclusive worldwide rights from Novartis to develop, manufacture and commercialize MAU868. The Company will be solely responsible for all research, development, regulatory, manufacturing and commercialization activities of MAU868.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Amplyx Agreement, the Company is obligated to make future milestone payments to Amplyx and Novartis upon the achievement of specified development, regulatory and commercial milestones. In September 2022, the Company and Novartis entered into an amendment to the Novartis License to modify the terms of future milestone payments. Pursuant to this amendment, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;283,034&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock to Novartis in exchange for a reduction of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in contingent future development milestones, including the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million contingent milestone obligation accrued by the Company in December 2021. The value of the shares issued was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;based on the closing market value of the Company&#x2019;s Class A common stock as of the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;effective &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;date of the amendment, and as a result of the amendment the Company recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of research and development expense in the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company is obligated to make future milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;62.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Amplyx and Novartis, respectively, contingent upon the achievement of specified development, regulatory and commercial milestones. In the event that MAU868 is commercialized, the Company will be obligated to pay royalties to Amplyx and Novartis based on net sales by country and by product.&lt;/span&gt;&lt;/p&gt;</vera:LicenseAndCollaborationsTextBlock>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_f3deb204-a947-4aea-a198-2bd978183c67"
      decimals="-5"
      id="F_90a22db8-8849-47c9-8ccd-cc8b19bc60db"
      unitRef="U_USD">13100000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="C_88fbad11-b4e4-408e-a5f8-605f139b9287"
      decimals="0"
      id="F_4c7547ff-51fd-4bac-b7af-aed3a559d129"
      unitRef="U_shares">1913501</us-gaap:ConversionOfStockSharesIssued1>
    <vera:MilestonePaymentsPayable
      contextRef="C_6af2ee58-50ae-4209-960f-c26d33ada18c"
      decimals="-5"
      id="F_4919b824-8694-4cd1-a619-5d9caea80b4a"
      unitRef="U_USD">25000000</vera:MilestonePaymentsPayable>
    <vera:MilestonePaymentsPayable
      contextRef="C_5e13a118-4107-4dfb-bab4-6714cdfa6f1f"
      decimals="-5"
      id="F_0cdbb831-bb9a-48eb-894c-6c7b44c2e717"
      unitRef="U_USD">176500000</vera:MilestonePaymentsPayable>
    <vera:MilestonePaymentsPayable
      contextRef="C_5b5b601c-cee7-4811-bef5-aa093f9e6050"
      decimals="-5"
      id="F_ae15455c-5e30-4edb-9016-af4c49bf3123"
      unitRef="U_USD">515000000</vera:MilestonePaymentsPayable>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_8ac3dbbb-9f62-4b97-afd2-60e8f5b19158"
      decimals="-5"
      id="F_2886d594-a4e6-4be3-b533-750879e78d31"
      unitRef="U_USD">2800000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_3b83fa9a-deb4-4a21-b9ff-0b9830dba0d1"
      decimals="-5"
      id="F_c268ea49-be8a-47f2-a452-f980805cff13"
      unitRef="U_USD">4500000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="C_8b5bdaed-6212-482b-968a-c7919dfb3d46"
      decimals="-5"
      id="F_5e646b28-cb48-4ada-9e17-61079a6ebc72"
      unitRef="U_USD">5000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <vera:MilestonePaymentsPayable
      contextRef="C_9d1e9814-ee09-45d4-9d31-1141dbaf3188"
      decimals="-5"
      id="F_7f56b315-15cf-4092-8656-266510b5b6c3"
      unitRef="U_USD">2000000</vera:MilestonePaymentsPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8b5bdaed-6212-482b-968a-c7919dfb3d46"
      decimals="-5"
      id="F_c8afb0c7-90dd-4b1a-906f-ca4ba7950334"
      unitRef="U_USD">7000000</us-gaap:ResearchAndDevelopmentExpense>
    <vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity
      contextRef="C_104cfa0f-5c0c-42af-a707-85e7636b50f5"
      decimals="0"
      id="F_db824f9c-0f30-4163-8cc2-025a9e1826a3"
      unitRef="U_shares">283034</vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquity>
    <vera:ReductionInContingentFutureDevelopment
      contextRef="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c"
      decimals="-5"
      id="F_9ab58cf7-79bc-402a-a16b-ced5ad043f34"
      unitRef="U_USD">7000000</vera:ReductionInContingentFutureDevelopment>
    <vera:ContingentMilestoneObligationAccrued
      contextRef="C_8b5bdaed-6212-482b-968a-c7919dfb3d46"
      decimals="-5"
      id="F_cd43e11e-fa42-49e8-9db5-cecfa2b3e456"
      unitRef="U_USD">2000000</vera:ContingentMilestoneObligationAccrued>
    <vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue
      contextRef="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c"
      decimals="-5"
      id="F_2e79efa4-4b98-4044-8c88-f8bffc78b13c"
      unitRef="U_USD">5700000</vera:StockIssuedDuringPeriodSharesLicensingPaymentsInEquityValue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ddea2591-7fa7-4bf8-b377-bd8062b0dd5c"
      decimals="-5"
      id="F_a8a4f772-a688-4906-bc66-ed60e789dde6"
      unitRef="U_USD">3700000</us-gaap:ResearchAndDevelopmentExpense>
    <vera:MilestonePaymentsPayable
      contextRef="C_89a4ab10-0f5d-46b6-bb03-b0eae339e011"
      decimals="-5"
      id="F_b29e654c-861c-41cc-bf41-ad2840c41dc0"
      unitRef="U_USD">7000000</vera:MilestonePaymentsPayable>
    <vera:MilestonePaymentsPayable
      contextRef="C_b12037ba-e589-4ed7-b30f-5ff359e4b80b"
      decimals="-5"
      id="F_5ec68d7a-73eb-46ae-bf15-46c805cc24da"
      unitRef="U_USD">62000000</vera:MilestonePaymentsPayable>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_10b9e67c-1bd6-4670-89c1-00da109ba68b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For financial reporting purposes, income (loss) before provision for income taxes, includes the following components &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Provision for Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision for income taxes consisted of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.59%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.823999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.823999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the provision for income taxes computed using the U.S. statutory federal income tax rate compared to the income tax provision included in the statement of operations and comprehensive loss is as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax on U.S. statutory rate on income before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Deferred tax assets and liabilities are determined based on the differences between financial reporting and income tax bases of assets and liabilities, as well as net operating loss carryforwards and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. &lt;/span&gt;&lt;span style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s net deferred tax assets and liabilities are as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state NOL carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and other credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other DTA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total gross DTA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right of use&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other DTL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total gross DTL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company has federal and state net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;118.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal net operating loss carryforwards and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of state net operating carryforwards will begin expiring in the year &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2032&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, if not utilized. The Company also has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;109.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal net operating loss carryforwards as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; that does not expire as a result of recent tax law changes. The Company has $5&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of federal research and development tax credit carryforwards, which begin to expire in the year 2037. The Company has $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of state research and development tax credit carryforwards, which have no expiration date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Utilization of the federal and state net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to the &#x201c;change in ownership&#x201d; provisions of the Internal Revenue Code of 1986. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed an analysis to determine if such ownership changes have occurred. An analysis will be performed prior to recognizing the benefits of any losses or credits in the financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence including a history of operating losses, management has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the year ended December 31, 2023 and 2022 has been established to offset the deferred tax assets as realization of such assets is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Uncertain Tax Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has the following activity relating to the gross amount of unrecognized tax benefits &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decreases based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. None of these uncertain tax positions will impact the Company&#x2019;s effective tax rate if assessed. The Company&#x2019;s policy is to classify interest and penalties associated with unrecognized tax benefits as income tax expense. The Company had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; interest &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or penalty accruals associated with uncertain tax benefits in its balance sheet and statement of operations for the years ended December 31, 2023 and 2022. The Company files income tax returns in the U.S. and California. The Company is not currently under examination by any major tax jurisdictions nor has it been in the past. Because of net operating losses and research credit carryovers, substantially all of our tax years&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;remain &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;open to examination. Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations, or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_59f94d3e-b8f2-4366-ae1c-62d39bc83077">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For financial reporting purposes, income (loss) before provision for income taxes, includes the following components &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Loss before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_a454a3c8-156e-4d93-825d-212fd2fcfa46"
      unitRef="U_USD">-95989000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_9e2f2d15-0e5e-4d47-a008-7ff9f7773e26"
      unitRef="U_USD">-89055000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_14e8caeb-fd6f-46c6-987e-58a1cd31e10b"
      unitRef="U_USD">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_8678e79a-532e-4484-a45d-291115448d99"
      unitRef="U_USD">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_60bf09e4-3615-41e9-92a6-c5174a2da4a4"
      unitRef="U_USD">-95989000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_b234cc87-712d-41a5-9656-f16a239fca36"
      unitRef="U_USD">-89055000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_be20afd7-457f-4b20-b2fe-f59fa965ae55">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The provision for income taxes consisted of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.59%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.823999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.823999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_473c74b8-83b2-4178-9fc0-ccef86c8d9f7"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_6be9d1fc-7cb9-4b22-b691-051673a8ebf0"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_d87b44e2-27b1-46a7-94cb-09e34a7bdd05"
      unitRef="U_USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_3a4c0338-e540-4084-b381-716d2ab63c38"
      unitRef="U_USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_3b60d454-96fe-4f8d-babd-6d2d043d2bda"
      unitRef="U_USD">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_663ac063-99b2-4d9f-9b9f-789a2c6fb23e"
      unitRef="U_USD">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_73211efb-88bd-422e-9199-e8d45887ad03"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_7780dfba-c387-4b71-bc7f-d8e3415409e6"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_d5ad2101-f001-4aac-9ba0-10ef82117ae4"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_52b86013-1cc6-4d75-bbb1-283874f992e4"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_4cc0a4dc-dafd-4cad-a79a-93af25413e3d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A reconciliation of the provision for income taxes computed using the U.S. statutory federal income tax rate compared to the income tax provision included in the statement of operations and comprehensive loss is as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.459999999999997%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax on U.S. statutory rate on income before income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20,158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;489&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;State valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;710&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;231&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_a9bd4a3d-9222-4471-9773-d29607b76c3d"
      unitRef="U_USD">-20158000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_b3800540-669c-4c29-b859-08f2d5cd888c"
      unitRef="U_USD">-18702000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_3b7db8e7-d3e5-4da0-80fa-31a1d59a8aac"
      unitRef="U_USD">-489000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_6daf6ae7-54da-42e2-b8e5-26844da5ac8a"
      unitRef="U_USD">3583000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_cade7871-7cd4-4bc1-8f5e-7e8350a76e16"
      decimals="-3"
      id="F_91bdd744-d71d-4f08-9e6e-aa1f00419f22"
      unitRef="U_USD">490000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_64111eab-3827-4866-aa3a-fc5810fb7d15"
      decimals="-3"
      id="F_c07c3e3b-dbd5-4c4f-a237-d622101a43b5"
      unitRef="U_USD">-3582000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_778ecdc2-82e7-487e-8f23-1ed776e1936e"
      decimals="-3"
      id="F_09d42ccd-d93c-457f-a896-7a45014e8a24"
      unitRef="U_USD">21250000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_94d2afc6-a122-4a1e-804c-c6fd42dafadc"
      decimals="-3"
      id="F_cb1dec62-6023-4536-8aa4-6900b13f9726"
      unitRef="U_USD">19643000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_bd74061d-8f73-41bb-8594-6e2f055e662e"
      unitRef="U_USD">1598000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_c89fc6eb-7728-40fc-b512-3859b6905c95"
      unitRef="U_USD">710000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_58f96198-052a-4c60-9886-d2da499cdd26"
      unitRef="U_USD">506000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_822c0490-d376-4f67-8ca3-07af7a6a0a87"
      unitRef="U_USD">-231000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_c63b7c49-69d7-4438-8070-865361ecb58e"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_e2b3dedd-6608-400c-9b87-0307c83e008a"
      unitRef="U_USD">1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_00d6e265-7142-4470-af7e-726ebb1d24e3">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant components of the Company&#x2019;s net deferred tax assets and liabilities are as follows &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Federal and state NOL carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27,539&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and other credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;519&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other DTA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total gross DTA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;72,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Right of use&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other DTL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total gross DTL&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_dd72337a-90ff-4ff0-a60f-820f107d9e03"
      unitRef="U_USD">27539000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_658189e4-9390-4a62-85ac-d2a50f5f6b83"
      unitRef="U_USD">21945000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e6032db9-1de9-42b1-ae8a-12891db7931d"
      unitRef="U_USD">6051000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_67179538-a9b5-43e3-b252-bc8b2354d36d"
      unitRef="U_USD">3762000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_df682965-279c-42fd-aeef-bf44622f458e"
      unitRef="U_USD">25264000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_3aa2fbc9-07f2-45ef-8510-73cef045f8cb"
      unitRef="U_USD">12731000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_86028361-1df5-4568-85b1-024b5439a184"
      unitRef="U_USD">3000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ec1994ce-1a51-4739-a6eb-67c5c5134982"
      unitRef="U_USD">2000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_f524856b-c406-4155-ba8b-1e19bfdd0e20"
      unitRef="U_USD">755000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_96b03e42-dbe2-4524-b001-9744055951f6"
      unitRef="U_USD">519000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_c0f5d282-1d7d-438a-a068-24672dcf2c6a"
      unitRef="U_USD">2978000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_4af81ce4-5881-4dec-88f0-8c0ac5547e29"
      unitRef="U_USD">1430000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_8831685b-69d7-4d41-ad16-626ed689689b"
      unitRef="U_USD">8313000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_9577762d-9464-4341-8d4c-840396086c81"
      unitRef="U_USD">8583000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_9c00b8d7-fe54-4318-bcab-d89cac98e898"
      unitRef="U_USD">384000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_57c58819-9ca2-4e3a-aac0-53e6c2a24b43"
      unitRef="U_USD">402000</us-gaap:DeferredTaxAssetsOther>
    <vera:DeferredTaxAssetsLeaseLiability
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_ab7191b8-a689-44bb-aceb-3a9f5b5255e5"
      unitRef="U_USD">804000</vera:DeferredTaxAssetsLeaseLiability>
    <vera:DeferredTaxAssetsLeaseLiability
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_77853698-82a2-4b9b-bc8a-e64fbc81612b"
      unitRef="U_USD">1360000</vera:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_03d0279f-0965-4bab-a06f-5fe1ad600b2f"
      unitRef="U_USD">72091000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ec3d6e6a-efea-4164-96a3-6db2aa45474e"
      unitRef="U_USD">50734000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_481eef39-036f-45b8-9f98-276f47651d5a"
      unitRef="U_USD">71372000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_12741ee0-0292-49f3-a56f-6ceede718863"
      unitRef="U_USD">49648000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_0754491b-909e-4fa8-a7ee-1ff4518bb101"
      unitRef="U_USD">719000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ba4fe011-9c86-4006-bd0b-8be47b30aaab"
      unitRef="U_USD">1086000</us-gaap:DeferredTaxAssetsNet>
    <vera:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_d71ab86e-c72e-43fb-a778-467496378b22"
      unitRef="U_USD">619000</vera:DeferredTaxLiabilitiesRightOfUseAssets>
    <vera:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_167d432b-d596-4211-8028-af7a889ec402"
      unitRef="U_USD">1086000</vera:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_87e3869c-0a3b-4277-ad5b-690c6ee183ee"
      unitRef="U_USD">100000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_76607bcb-22af-4ce1-9018-cba3c1ca80b1"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_e6ab9e45-6774-415a-b651-41c17d9ddba5"
      unitRef="U_USD">719000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_ab61c124-fb0f-47e7-84a9-e6e027a4717c"
      unitRef="U_USD">1086000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_5230020d-4a8a-43e0-931f-339b387ade1f"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_1d443680-b573-41a9-941f-dbd788c54383"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6b5a8210-e301-4c4e-b003-8559739c8a43"
      decimals="-5"
      id="F_e83c2586-8825-4036-868d-75b883f7d7b5"
      unitRef="U_USD">118900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_24a4e735-d3db-4c23-bb5e-9ca013ac3681"
      decimals="-5"
      id="F_5ebd7dd5-2d79-4cc1-9541-b5b800b439e4"
      unitRef="U_USD">35700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_656df8a2-b22a-4441-86ea-edc39b8cabaf"
      decimals="-5"
      id="F_d7578b5f-c1e1-4234-ad62-fc1180c0732b"
      unitRef="U_USD">10200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ddb29d7c-a69c-4f1e-9ea5-993bbfcc10d6"
      decimals="-5"
      id="F_09b2337a-4f9b-46af-b757-1ed096817393"
      unitRef="U_USD">300000</us-gaap:OperatingLossCarryforwards>
    <vera:OperatingLossCarryforwardsExpirationYear
      contextRef="C_778ecdc2-82e7-487e-8f23-1ed776e1936e"
      id="F_35e2af96-4ee1-4446-af0b-c5801e390aec">2032</vera:OperatingLossCarryforwardsExpirationYear>
    <vera:OperatingLossCarryforwardsExpirationYear
      contextRef="C_cade7871-7cd4-4bc1-8f5e-7e8350a76e16"
      id="F_14035370-f4f4-4dcd-89c5-41ed4599da10">2036</vera:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_1057e7fc-37f6-478c-b1ec-b701f7174306"
      unitRef="U_USD">109000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2e56d451-bf45-4d4d-ad5b-7a10597988a0"
      decimals="-5"
      id="F_7f9b55b6-3c40-41b7-99ee-91a1583bdacd"
      unitRef="U_USD">400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_e3ba2032-8472-4a06-af17-769f411f1c3b"
      decimals="-5"
      id="F_2e0eb0f7-4198-4330-822f-0a2af860e57e"
      unitRef="U_USD">2200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-5"
      id="F_4a1de001-2d27-4f0e-ab01-d3c20b4bfd5b"
      unitRef="U_USD">71400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-5"
      id="F_f3ae8b2a-42ed-497d-a4ed-3ac7cee99dbe"
      unitRef="U_USD">49600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_fa65c08e-0f3d-47e6-a25b-5c7cd011aad5">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has the following activity relating to the gross amount of unrecognized tax benefits &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.151%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.2%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.224%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Beginning balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Decreases based on tax positions related to prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;265&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Ending balance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_10b57d5c-7214-42ef-b2f2-5c9d2ca54063"
      unitRef="U_USD">941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_5ed90599-4b8c-4161-b826-92693ffe24bd"
      decimals="-3"
      id="F_2a1b7048-f45d-4900-9e3c-08960199b91d"
      unitRef="U_USD">668000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_443d74f6-f204-450e-aada-3912cb1cfbb4"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_a8d55c30-5da0-4196-b244-d049df512a2b"
      unitRef="U_USD">19000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_1e444562-ba16-4385-bbce-42e93319dbeb"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_418293a5-4555-47f8-809d-3887bdfcb75f"
      unitRef="U_USD">11000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="-3"
      id="F_11470b04-a492-4c77-9f44-481fa887e6bd"
      unitRef="U_USD">572000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="-3"
      id="F_64e0aaee-3778-472e-b54d-b65112a05402"
      unitRef="U_USD">265000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="-3"
      id="F_4a52d649-b350-4393-89fd-35abad016588"
      unitRef="U_USD">1513000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="-3"
      id="F_033941f7-0d5a-455d-a8fe-3df872c395f5"
      unitRef="U_USD">941000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_6a85ba1a-b72c-473d-a4c6-c8fbb08ea9f5"
      decimals="INF"
      id="F_5fad7ab4-34a1-4b8a-90a4-78b542b13412"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_2b98fbe6-3c1e-4766-9160-92841f2265a3"
      decimals="INF"
      id="F_ff5620de-ec80-49e4-a8be-c3bc26d83076"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_a88832c7-153a-45c5-be6d-c35b8c0547d0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company believes that there are no actions pending which would have a material adverse effect on its results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Indemnifications&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2023, the Company did not have any material indemnification claims that were probable or reasonably possible, and consequently no related liabilities have been recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Employee Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has signed employment agreements with certain key employees pursuant to which, if their employment is terminated following a change of control of the Company, the employees are entitled to receive certain benefits, including severance and accelerated vesting of equity incentives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Development and Manufacturing Services Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company enters into development and manufacturing contracts with vendors in the conduct of our business. Contracts with these vendors may be terminated at the Company&#x2019;s option, with varying provisions regarding termination. If a contract with a specific vendor were to be terminated, the Company would be obligated to pay for the products or services that had been provided or received at the time the termination became effective,  and potentially additional compensation based upon lead time remaining between the date of notice of cancellation and the scheduled manufacturing run.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_fae65d4b-d708-4b3e-b391-07e82d7dda29">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Class A common stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,762,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,821,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,893,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,025,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_bce71323-2c74-4612-9650-1bd97b49c47c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented, because including them would have been anti-dilutive (on an as-converted basis).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.26%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Class A common stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,762,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,821,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;131,679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,893,915&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,025,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4a52fd0c-ea66-4e45-91f2-1ab3d98bfe72"
      decimals="INF"
      id="F_acde5451-74a1-437c-89bf-3f54e0577f9e"
      unitRef="U_shares">5762236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9beda916-eeba-458d-97e7-f73f38603c69"
      decimals="INF"
      id="F_135a2a27-f1c8-49fe-adf3-06998b25d8c3"
      unitRef="U_shares">3821787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_36414961-ec1c-41e6-866e-dc6627ebdbe7"
      decimals="INF"
      id="F_034d435f-5dbb-494a-8058-e20251f069c8"
      unitRef="U_shares">131679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_75cc6cdb-a496-4205-b05d-09f40af83bb9"
      decimals="INF"
      id="F_72ad5b9a-9903-47ae-8261-f535be974a87"
      unitRef="U_shares">204000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      decimals="INF"
      id="F_c0688afa-6b50-4630-aa18-06ea9d0fcd26"
      unitRef="U_shares">5893915</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a737ba92-a0d3-4854-a286-47aa2bd6f909"
      decimals="INF"
      id="F_9eea9aac-5bf1-4b24-b0e6-3c24f8b23078"
      unitRef="U_shares">4025787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_1fa6666a-0e71-4a58-800c-53df180dd7b4">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;15. RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an exclusive worldwide license to certain patents and related know-how to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. Related party transactions and balances in the current periods presented are described in Note 3 and Note 11.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_627daa2d-be5a-4f02-9196-f41419329d3c"
      id="F_8f739bf9-5914-4021-b503-1567fb39c63a">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;16. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective January 29, 2024, the Company suspended and terminated the prospectus (the ATM Prospectus) related to the sale of its Class A co&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;mmon stock in an &#x201c;at-the-market&#x201d; offering pursuant to the terms of the Sales Agreement (see Note 8). As a result, the Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus, prospectus supplement or registration statement is filed. Deferred costs of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were recognized as general and administrative expense upon termination of the ATM Prospectus.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 1, 2024, the Company completed a follow-on public offering pursuant to which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,274,194&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its Class A common stock at an offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, including the exercise in full by the underwriters of their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,209,677&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of Class A common stock. The Company received total net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;269.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and offering costs of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <vera:WriteOffOfDeferredCost
      contextRef="C_b3e496cc-f877-412e-b2d0-1b4233183c32"
      decimals="-5"
      id="F_024544fe-84c7-4642-9310-1781aa51ee4c"
      unitRef="U_USD">300000</vera:WriteOffOfDeferredCost>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_be8fb598-3863-42c0-ae6e-183bbd558432"
      decimals="INF"
      id="F_e62b858a-2318-4bb2-9af0-787e6c79cce4"
      unitRef="U_shares">9274194</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_299bd9f5-1494-45ab-a9b2-e9efcfe185b5"
      decimals="INF"
      id="F_7ab0365f-3c67-4cb8-87be-e10c825817c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d83a4fc8-8999-4dbb-8d15-fe08a22689c1"
      decimals="INF"
      id="F_d187f12d-5a24-45da-9fa4-e10c180acb0e"
      unitRef="U_shares">1209677</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_7e0be373-0021-42a8-b661-4dcf7ed20677"
      decimals="-5"
      id="F_36154202-e3a3-43f7-93b9-42efe8737672"
      unitRef="U_USD">269600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="C_7e0be373-0021-42a8-b661-4dcf7ed20677"
      decimals="-5"
      id="F_78b0df87-029a-4661-8448-27da998325c3"
      unitRef="U_USD">17300000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_7e0be373-0021-42a8-b661-4dcf7ed20677"
      decimals="-5"
      id="F_cd20f023-6774-409a-a9a9-cf65b8c8a321"
      unitRef="U_USD">700000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="C_5dc0b4e6-1ca3-4772-bc5f-e4b2611208cb"
      id="F_2a426196-484e-45e8-b04f-08cc2ed14aca">&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the quarter ended December 31, 2023, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated the contracts, instructions or written plans for the purchase or sale of the Company&#x2019;s securities set forth in the table below.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:21.12%;"&gt;&lt;/td&gt;
      &lt;td style="width:10%;"&gt;&lt;/td&gt;
      &lt;td style="width:13.84%;"&gt;&lt;/td&gt;
      &lt;td style="width:9.22%;"&gt;&lt;/td&gt;
      &lt;td style="width:9.22%;"&gt;&lt;/td&gt;
      &lt;td style="width:10.74%;"&gt;&lt;/td&gt;
      &lt;td style="width:25.86%;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Type of Trading Arrangement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-top:0.5pt solid #000000;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
      &lt;td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Name and Position&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Action&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Adoption/ Termination&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rule 10b5-1*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Non-&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Rule 10b5-1**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total Shares of Class A Common Stock to be Sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Celia Lin&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Chief Medical Officer&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;***&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Adoption&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;October 10, 2023&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;X&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Up to &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;December 19, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;****&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;* Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;** &#x201c;&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;n-Rule 10b5-1 trading arrangement&#x201d; as defined in Item 408(c) of Regulation S-K under the Exchange Act.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:11pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;***Dr&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;min-width:fit-content;"&gt;. Lin separated from Vera effective January 3, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"&gt;
      &lt;td colspan="7" style="border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;border-bottom:0.5pt solid #000000;padding-right:0.08in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;****In connection with her separation from Vera, Dr. Lin terminated this 10b5-1 Plan effective &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 19, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_8d602f56-894c-4d38-a5fc-9e86f3510aa7">Celia Lin</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_3952a794-cfed-44e3-ac2b-f9d933761b7e">Chief Medical Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_c694922e-70e4-44b3-a102-ca2fbd7d1ad7">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_681b238b-a5af-42f1-9bdc-3f400f5eeb6d">October 10, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="C_49967e2d-722f-4392-96f6-1a63849048ac"
      decimals="0"
      id="F_71d01983-f901-4660-89b9-e067dfbb3828"
      unitRef="U_shares">134401</ecd:TrdArrSecuritiesAggAvailAmt>
    <vera:TrdArrExpirationDate
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_38bbc43c-0aef-4ba8-a921-1064ab768160">December 19, 2024</vera:TrdArrExpirationDate>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_e767a0b5-acb9-4169-9405-b06191a34cb0">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:TrdArrTerminationDate
      contextRef="C_632ae0a2-bfc8-4d5e-b3e5-82196a6a9bb0"
      id="F_5ee51d4a-7c7d-48ae-bdf3-98e16a559308">January 19, 2024</ecd:TrdArrTerminationDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
